<SEC-DOCUMENT>0000875045-19-000041.txt : 20191022
<SEC-HEADER>0000875045-19-000041.hdr.sgml : 20191022
<ACCEPTANCE-DATETIME>20191022161244
ACCESSION NUMBER:		0000875045-19-000041
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		123
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191022
DATE AS OF CHANGE:		20191022

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		191161860

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-2019930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:49803BA13DBB5092B8986DAA778CAE9C,x:fd62c62ed6ec40c38483ea9faa4f54a7-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:biib="http://www.biogenidec.com/20190930" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="Fact-A720BDE589E655AFB947A19A47DA30B0-wk-Fact-A720BDE589E655AFB947A19A47DA30B0">Indefinite until commercialization</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="Fact-39DF7314CAB059E3AF0C295901DAF1A6-wk-Fact-39DF7314CAB059E3AF0C295901DAF1A6">Indefinite</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:AmendmentFlag" id="Fact-A162EC76C09152549FA91307CC0E32B6-wk-Fact-A162EC76C09152549FA91307CC0E32B6" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-BA29B3FE73D45B01BD57FE5C7AC3243A-wk-Fact-BA29B3FE73D45B01BD57FE5C7AC3243A">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-267386718B765BC68F7C40790D39F307-wk-Fact-267386718B765BC68F7C40790D39F307">Q3</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:DocumentFiscalYearFocus" id="Fact-E8833EC0FF745E31843014B77B5D26ED-wk-Fact-E8833EC0FF745E31843014B77B5D26ED">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:EntityCentralIndexKey" id="Fact-36253F93FAEF5A1A9839CC0E73339640-wk-Fact-36253F93FAEF5A1A9839CC0E73339640">0000875045</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-9BC34F91DFC05A12A7E82E01B624BC8E-wk-Fact-9BC34F91DFC05A12A7E82E01B624BC8E">0.0005</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q3" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-61EE282E8A2A5F75BF531D03B1C37FFE-wk-Fact-61EE282E8A2A5F75BF531D03B1C37FFE">0.0005</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-4326F7288FFC547A8D0616E2DAAAD145-wk-Fact-4326F7288FFC547A8D0616E2DAAAD145">0.052</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-3EE86C2A036D57DDBE9E37C5B2B437C3-wk-Fact-3EE86C2A036D57DDBE9E37C5B2B437C3">0.0405</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-CD5CED4136C2541CA702F0C580F0A182-wk-Fact-CD5CED4136C2541CA702F0C580F0A182">0.03625</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-142450F9DE9654E18013986084873980-wk-Fact-142450F9DE9654E18013986084873980">P18Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-2111C3F4F1B956A29D4A88DE030D9834-wk-Fact-2111C3F4F1B956A29D4A88DE030D9834">P23Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-D4C2BD49A7F4521CB6E8AFB4C036484C-wk-Fact-D4C2BD49A7F4521CB6E8AFB4C036484C">P28Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-A5FD42464B565034972B507687B1BE7F-wk-Fact-A5FD42464B565034972B507687B1BE7F">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-BDAB5C2C4BDE5A21B95154931F71F201-wk-Fact-BDAB5C2C4BDE5A21B95154931F71F201">P13Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-518C26F410825D8A8E8EB710325F8CFE-wk-Fact-518C26F410825D8A8E8EB710325F8CFE">P15Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-DA3ACAD0F8775332979A2D5D75AD2B81-wk-Fact-DA3ACAD0F8775332979A2D5D75AD2B81">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q3" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-56F39C19EA9C5B3883993722132C76CE-wk-Fact-56F39C19EA9C5B3883993722132C76CE">0.001</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="biib-20190930.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-10-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BG00011Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BG00011Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_PLSRMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:PLSRMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-10-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DeferredTaxAssetLiabilityTypeAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="sC0DB047ACECC58BF82C11B52A405AF74"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:18pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;</span><span><ix:nonNumeric id="d101485642e797-wk-Fact-E49BF18CD1BB5261ABF2109066216216" name="dei:DocumentType" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d101485642e815-wk-Fact-181460A3204D5502B725D9AA01122BF5" name="dei:DocumentQuarterlyReport" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;padding-left:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d101485642e825-wk-Fact-097273B468FA5B05BF1B4BEB48D9907A" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q3YTD" format="ixt:datemonthdayyearen">September 30, 2019</ix:nonNumeric></span></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">OR</span></div><div style="line-height:120%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d101485642e845-wk-Fact-5DEDB907355A59B7A4E0B528C7C489F9" name="dei:DocumentTransitionReport" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number </span><span><ix:nonNumeric id="d101485642e855-wk-Fact-79ED6F4DFD525A4698BD703D127E8344" name="dei:EntityFileNumber" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">0-19311</span></ix:nonNumeric></span></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><img src="biogenlogoa05.jpg" alt="biogenlogoa05.jpg" style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;height:30px;width:92px;"></img></div><div style="line-height:120%;text-align:center;font-size:24pt;"><span><ix:nonNumeric id="d101485642e864-wk-Fact-9270B3526E145AACAE978B4B276D5120" name="dei:EntityRegistrantName" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d101485642e886-wk-Fact-AC6580EC3275527BBD75BE7DC580E3F9" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q3YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d101485642e896-wk-Fact-5F0CA332F7915D328E488DC5C0B4F217" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q3YTD">33-0112644</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d101485642e921-wk-Fact-88B763BC8CE75A1B93ECEC1ACF66139D" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">225 Binney Street</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d101485642e926-wk-Fact-9E5BEA5AA0155FBCB679E5181DF4D3DC" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">Cambridge</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d101485642e931-wk-Fact-DEB53439F68B56EE88AEFB34C373F295" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">MA</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d101485642e936-wk-Fact-0C894F537C3D514F8BD6F9B1C35B24EB" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">02142</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d101485642e944-wk-Fact-24224EA8ED98553F92119DE1B4422509" name="dei:CityAreaCode" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">617</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">)&#160;</span><span><ix:nonNumeric id="d101485642e949-wk-Fact-9008D8114F0B5C85B7ABF1EDBEF9BCCB" name="dei:LocalPhoneNumber" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">679-2000</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant&#8217;s principal executive offices)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d101485642e1010-wk-Fact-2D41975665F1540B958DB626B2EC2CFF" name="dei:Security12bTitle" contextRef="FD2019Q3YTD">Common Stock, $0.0005 par value</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d101485642e1020-wk-Fact-F6D67E1F4CA250A1AC0ACCABD4CE1BC3" name="dei:TradingSymbol" contextRef="FD2019Q3YTD">BIIB</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">The</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d101485642e1035-wk-Fact-E0736260E3505B889AB18E77BE00E8E9" name="dei:SecurityExchangeName" contextRef="FD2019Q3YTD" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d101485642e1040-wk-Fact-9C004188B29252D0891ACA8734F8A6DD" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d101485642e1058-wk-Fact-8C326F01892352418C1040AA24A491BC" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q3YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:23%;"></td><td style="width:3%;"></td><td style="width:43%;"></td><td style="width:28%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101485642e1093-wk-Fact-962CCE0CE8D153F1AB624ABA2D517812" name="dei:EntityFilerCategory" contextRef="FD2019Q3YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">x</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d101485642e1139-wk-Fact-8CD6D69DCE685C79B4256302E70F2FBC" name="dei:EntitySmallBusiness" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d101485642e1165-wk-Fact-CDB579FA6AD351D4A2F0F5D3EB3C9448" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d101485642e1175-wk-Fact-09DEFA2E9C0C535CA5BF5F8EFC428A7B" name="dei:EntityShellCompany" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox"><span style="font-size:12pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;No&#160;</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October&#160;21, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485642e1193-wk-Fact-11BD0E492772596EB5E4C984D9AA936C" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q3SharesOutstanding" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">180,441,878</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s0C4E77289207564D858309F54C79A897"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Quarterly Period Ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE OF CONTENTS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:81%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;I&#160;&#8212; </span><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#s5F54D31813F65F5C8215D10B0FADDA74"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">FINANCIAL INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements (unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD2C290CBF08756639342651973415EFA"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Nine Months Ended September 30, 2019 and 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sD2C290CBF08756639342651973415EFA">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA8978C5D3EA15058878D8A0C36B245A4"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Nine Months Ended September 30, 2019 and 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sA8978C5D3EA15058878D8A0C36B245A4">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6840358A7C9357A3BD191C53AC24128D"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets&#160;&#8212; As of September 30, 2019 and December&#160;31, 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s6840358A7C9357A3BD191C53AC24128D">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5CF404583A95540592C8C79F8E3D01D5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the Nine Months Ended September 30, 2019 and 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s5CF404583A95540592C8C79F8E3D01D5">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s47961572DBD45117A90FC46CF613E457"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Equity &#8212; For the Three and Nine Months Ended September 30, 2019 and 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s47961572DBD45117A90FC46CF613E457">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s3205306FA0625B3FB00E628FBA166CA6"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s3205306FA0625B3FB00E628FBA166CA6">13</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sDD7E3B206A4053DEAFFA3530DB2D2796"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sDD7E3B206A4053DEAFFA3530DB2D2796">49</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s79F039A6E4645A49AAAF78BCCC2518E9"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s79F039A6E4645A49AAAF78BCCC2518E9">75</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sAA150311235A5C13B880F3323FEC8DDD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sAA150311235A5C13B880F3323FEC8DDD">77</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;II&#160;&#8212; </span><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#s37FC5D7BE054593AA8DB98320C352917"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">OTHER INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sB3E72DC025ED5E9E9C58FFFDA9739AA3"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sB3E72DC025ED5E9E9C58FFFDA9739AA3">78</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s0F62B022360552A4B807FA30BE9C10FD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s0F62B022360552A4B807FA30BE9C10FD">78</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s3586694736B45C69BA45665500856C15"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s3586694736B45C69BA45665500856C15">93</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s7D13BE9AE464534ABCCE71A5C9FC206A"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s7D13BE9AE464534ABCCE71A5C9FC206A">93</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s13242AC6C6A15948B3E92DF536E4EB10"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Signatures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s13242AC6C6A15948B3E92DF536E4EB10">95</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s269A8195871E55459885553F4CDD12EC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; "would" and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expenses; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete, including increased competition from generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our plans and investments in our core and emerging growth areas, as well as implementation of our corporate strategy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intention to commit resources relating to research and development programs and business development opportunities, as well as the potential benefits and results of, certain business development transactions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse safety events involving our marketed products or generic or biosimilar versions of our marketed products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, including anticipated investments, and activities in new or existing manufacturing facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) intent to voluntarily depart from the European Union (E.U.);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws, including the Swiss Federal Act on Tax Reform and AHV Financing, regulatory requirements, judicial decisions and accounting standards.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div></td></tr></table><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and ZINBRYTA&#174;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are registered trademarks of Biogen. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FUMADERM</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and IMRALDI</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> are trademarks of Biogen. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ENBREL&#174;, FAMPYRA</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, OCREVUS&#174;, REMICADE&#174;, SkySTAR</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and other trademarks referenced in this report are the property of their respective owners. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5F54D31813F65F5C8215D10B0FADDA74"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I FINANCIAL INFORMATION</span></div><div><a id="s8D649EFBF696536C91A7767EBF30D758"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sD2C290CBF08756639342651973415EFA"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1065-wk-Fact-3D28795085EA575193C5CA658480CEC6" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,894.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1084-wk-Fact-7BF8AC4CA5E1523582F8817F03BD95BF" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,780.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1103-wk-Fact-57FC3BF8DA6B53A78893FAD196CDD478" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,455.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1123-wk-Fact-E8E82058EC25562986B774B17A9D2FFE" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,061.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1138-wk-Fact-8935D8BBEFCE5ED286B0DE4994D83C3D" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">595.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1157-wk-Fact-084A8A14D1EB5CEC8E6948EA789D8A2A" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">511.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1176-wk-Fact-6C7B08DD49815A12A560CB733CA3B725" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,689.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1196-wk-Fact-7BBDC0B573795D11894123AF71626259" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,445.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1216-wk-Fact-DC33E683DC765E5C9A12FB403038A719" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1235-wk-Fact-F66F19EADE265DC9B1853BA2CA1992B0" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">147.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1254-wk-Fact-CEE81A8C61A050788B24277BCB2F809B" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">562.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1274-wk-Fact-0D413906F9E25B0A81CBE77DAF4D3714" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">420.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1294-wk-Fact-0CD821D5D869505598AC9AF461014C2F" name="us-gaap:Revenues" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,600.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1313-wk-Fact-4AFAB2732FEA53C9927DCFA21DE12846" name="us-gaap:Revenues" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,439.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1332-wk-Fact-670B810E65EC53F89A9FD22B4FEE157A" name="us-gaap:Revenues" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10,706.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1352-wk-Fact-C62693D4D87457C1B8DC16EDC6C6C06B" name="us-gaap:Revenues" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9,926.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1454-wk-Fact-4398076668E95D6F8BBE2DCE53C7CF6A" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">430.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1473-wk-Fact-3320419AA13155368CD89EC047078EC3" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">460.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1492-wk-Fact-A13BAD179BFC56A59DFF61EFD3C43034" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,508.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1512-wk-Fact-F0C8EDEBDD205FFBB2A0C0B7AFDFF8D7" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,327.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1532-wk-Fact-5887AC3DCAC65AA0ABB2D1224CE813C5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">540.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1551-wk-Fact-A35E1B39D0ED5612B58BEC6AE99EE416" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">507.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1570-wk-Fact-70AF7A2CFC915C15A030EF0FD4DBF312" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,588.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1590-wk-Fact-11FC0192390C5427BAC2B9380F26D781" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,985.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1610-wk-Fact-4E1D22AB81E95CD1935911458DAE07AD" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">554.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1629-wk-Fact-1E95BF05DB415E558D74F14636E615EB" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">497.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1648-wk-Fact-EED7A858F0CC55B8BE77E721769495EC" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,709.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1668-wk-Fact-B7D381D394CB54EB844F0ED37F840AFC" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,515.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1689-wk-Fact-E16816F8C6345C9F843A76FE6FE7E93D" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">283.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1708-wk-Fact-60CBEC0AE94254A1A0FFF49B4C048842" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">281.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1727-wk-Fact-12AB224A4EA35DA89408132E43CA5AB9" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">422.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1747-wk-Fact-2168DD63A96A5DB78AB338B8966E624C" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">493.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1767-wk-Fact-32CB9D4583B45F179C86FFF3B5CBFCDA" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1786-wk-Fact-C0B8925BE8DA566196A767C76EFA086C" name="biib:Collaborationprofitlosssharing" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1805-wk-Fact-6DAA978FFDB15053BB443111B1C4AB30" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">181.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1825-wk-Fact-982DE42822645CEEA7477869F0274757" name="biib:Collaborationprofitlosssharing" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">129.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101493944e1845-wk-Fact-B033055EE06F5EE3BC24B154C762FC6A" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">17.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1865-wk-Fact-877CB4507B6158C69D828BB60C807E94" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e1884-wk-Fact-526E40F32DC65027BA1F64FF315F5FE1" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">95.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e1904-wk-Fact-543AED3C148A5BF5A038840458DF783E" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101493944e1924-wk-Fact-6A3D37E1187254C09B6AC4C5616FF447" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101493944e1944-wk-Fact-039C01D7065755E1B84538DFB48BABF7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101493944e1964-wk-Fact-71EA0E01C5515EB8915D8014F3984813" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101493944e1985-wk-Fact-38997DD058735F02BF9DD1F00498AD0C" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2006-wk-Fact-76BD8F641DB759D998E8967D931DB763" name="us-gaap:RestructuringCharges" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2025-wk-Fact-B3ACF0F845035AE589F9C30358D82173" name="us-gaap:RestructuringCharges" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2044-wk-Fact-69D6550F53DA51818961C08A25CDB303" name="us-gaap:RestructuringCharges" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2064-wk-Fact-D374FD76090D58C691530FB5386AE8A9" name="us-gaap:RestructuringCharges" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2084-wk-Fact-A2D8DB9B83C9578E8F085CBC647DD123" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2103-wk-Fact-33F0DE158849587DAB1BDE595BDB71AA" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2122-wk-Fact-EE9D5CB5D2E85A1C8C8AD3ADD14680F7" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2142-wk-Fact-2CA811F753CD570B84DAA2F7964FE11D" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2162-wk-Fact-D4C10BAF17725DC08B4AE22BAF2FBC17" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,793.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2181-wk-Fact-5103BB6AC63F5559A39DE4ED0C8AD3E1" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,741.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2200-wk-Fact-EAE56E7FE4AE539DA15A94AC0F949F31" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,441.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2220-wk-Fact-B06392F1017F580D9294B1E503DCB2F0" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,481.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2240-wk-Fact-A7D9BF3F74335C15AB9305CEB006E893" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,806.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2259-wk-Fact-D5C03876FBCB508086AB9D5B6C0E7152" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,697.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2278-wk-Fact-D9BEED595D4B56DB8185C9B3B7837D0C" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,264.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2298-wk-Fact-DB015EB13B1E5FF2A8D43369F6578E5A" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,445.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101493944e2318-wk-Fact-E9D12EA36B4D5C33868828CA4F85E261" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">27.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2338-wk-Fact-2C8DF4D3F6FF5FBB8B107A909ED110C4" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2357-wk-Fact-955EC3C90AF15B78B661F5AE7D5AA578" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2377-wk-Fact-84F574B1C98951649E68D68912924040" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2397-wk-Fact-1467A4E00BE054469EAF39E1B6BDD386" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,779.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2416-wk-Fact-7E83C86AE3AE54DCB8D8BD2AC0DE19FE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,812.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2435-wk-Fact-4DAB2CDB8737537FB94F9775B622D819" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,397.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2455-wk-Fact-00604DB125C1532595C02BAB20FD2118" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,485.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2475-wk-Fact-E07E8C7734D15A648BF5E4196636D5C3" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">211.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2494-wk-Fact-5AB6392D5D7C5A8D8FB29E1A6E5AAB6F" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">369.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2513-wk-Fact-0C5377FD993951FD83D2139588B19737" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">881.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2533-wk-Fact-94D258EC9DD1534CA3AB453291E84C59" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">956.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2554-wk-Fact-F8037FB875E15271B114ACEE1F87809D" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2573-wk-Fact-BD38DF3D4A465A88A720F85630ABCE52" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2592-wk-Fact-8A0AD72840015E7AB86F0386B4EA5E19" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">66.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2612-wk-Fact-E18F08DC45E950A0925D75B8779AEDA7" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2632-wk-Fact-295C51D2551C57C38B86AB20FD5C8538" name="us-gaap:ProfitLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,545.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2651-wk-Fact-4C53D8055C3559E2AB7DBEC22965795A" name="us-gaap:ProfitLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,442.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2670-wk-Fact-3AADFF2A153C519091C711159E3B32B2" name="us-gaap:ProfitLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,448.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2690-wk-Fact-2B961E9A38315302B816B2E71D3709C5" name="us-gaap:ProfitLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,529.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2710-wk-Fact-76CE7E28B64A50EC8E3544414C30DE95" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101493944e2729-wk-Fact-ACACAE974A30595B80C03585DEEF0A84" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2749-wk-Fact-4664C7E691035BCF98EEF8686E324D37" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2769-wk-Fact-A615AFFBC8635C799414FB51461A4CD4" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2794-wk-Fact-8BCEFCADFFDD5171A80A5930F9D729B5" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,545.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2813-wk-Fact-A3394798436750ACA93FC560D5254E0D" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,444.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e2832-wk-Fact-FF611939A9605722A2FA20072DD911C0" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,448.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e2852-wk-Fact-71E4AC6E479B5D7B8F2CABF3359E1159" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,483.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e3036-wk-Fact-DABD96074566598EB3C07BFD113F2CBB" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e3055-wk-Fact-20A1825877345603B0F899B54405161B" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e3074-wk-Fact-D8BF6C918EBE556E860AB77142CAF641" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">23.38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e3094-wk-Fact-F5D9F5575D7752D2A51E550B53879B6F" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e3114-wk-Fact-0E70D06DC9FA56B989AD5945AB2BF49D" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e3133-wk-Fact-5D12A2C162AB57F889CBC8DBD9E18F6C" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e3152-wk-Fact-B947642BF82A5ECCB2AFC553ED1C071C" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">23.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e3172-wk-Fact-E7A40373C9F75A7091E8B4232C8C4FFC" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e3351-wk-Fact-F6CE5BEE80B6540FA43FF8EA2757EB66" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">184.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e3370-wk-Fact-E9DB242D33DA5FCF80E62B38AB8B3CCC" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">201.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e3389-wk-Fact-D122FB3C0DD75244A8431CFB07FAEF38" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e3409-wk-Fact-A1872F8928FF5D918E5EC1A8811DC1C1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">206.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e3430-wk-Fact-93A4BEF1889A5DEBA0656CD4B052EC65" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">184.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e3449-wk-Fact-3C339B177C795EFCA2E51E30FA1B6B01" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">201.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101493944e3468-wk-Fact-E79773D2EAB35D32A14B66C86F627853" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101493944e3488-wk-Fact-097BC21BCB8351D6BD7B65093FE992A9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">207.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA8978C5D3EA15058878D8A0C36B245A4"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e983-wk-Fact-8BCEFCADFFDD5171A80A5930F9D729B5" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,545.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1002-wk-Fact-A3394798436750ACA93FC560D5254E0D" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,444.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1021-wk-Fact-FF611939A9605722A2FA20072DD911C0" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,448.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1041-wk-Fact-71E4AC6E479B5D7B8F2CABF3359E1159" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,483.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1138-wk-Fact-76A5ED11418D5BF7BF9A34FFCC9325EC" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101485078e1157-wk-Fact-4A59616144ED5961916A9798F924343C" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1177-wk-Fact-C0F081FE8A455757A90EA6B00383AE0C" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101485078e1197-wk-Fact-86FC5B05A66C5915919CA9875A1C2F9D" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1218-wk-Fact-31BE7B6AB20E5BE88A540CDFBFD9000F" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1237-wk-Fact-43550C1C4A7256779B2A8AE9160D07F1" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1256-wk-Fact-4854F85A96D65FBD9C09F377F0FC18AA" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1276-wk-Fact-0E1620A50114582C852D80ED4660ADC0" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1296-wk-Fact-02E59A34E043562E873149A6B428D219" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1315-wk-Fact-A8BAF411A8FC5A96BA88C816664E7903" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1334-wk-Fact-7F087591389B52F9A8CF9EDF1629A84A" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1354-wk-Fact-452162AA382853D0981FBCC5B27BA815" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1374-wk-Fact-8486ADEF7E245E9393C9C0F327568A2E" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101485078e1393-wk-Fact-06BDA25FF1EC56A1AC030B0CC2AC00D7" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1413-wk-Fact-1D1E835AA5675E06818144DD02344F8A" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1433-wk-Fact-A8070A8B147351B7A1E60087626478D1" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1453-wk-Fact-F8BB5F76671B581E93281CF189441430" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1472-wk-Fact-F10E2D63CD145821BD9EE3DB76385797" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1491-wk-Fact-5A30451B7A615910ACF5E13D9696FAB5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101485078e1511-wk-Fact-3FBCA042F22C5C759162C22194715F57" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">38.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1532-wk-Fact-0258E3DA7739597FAE2A1F9A9FEA77FD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1551-wk-Fact-2E58A4FBEAF45408A246611108CA9348" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1570-wk-Fact-4BE449ABC68C5BBB868E2225D4530616" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1590-wk-Fact-61FD074FCC6D59939B8BE32C48B29249" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1610-wk-Fact-57EA0A92B874536CBB2610EC93B7E76E" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,706.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1629-wk-Fact-DCD795F4DAD25B6E96DC37AE575F740C" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,457.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1648-wk-Fact-5C95DCEFB970549F8B08FF376112D424" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,596.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1668-wk-Fact-C4957DEC8263508FA1E6B344D6F6DB03" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,552.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1689-wk-Fact-E397511F983F5E87B82187CEA0403912" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101485078e1708-wk-Fact-F28E26711D165E02B5ADDC01EAACFC8B" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101485078e1728-wk-Fact-A38D73EB5E86516EB5FF267F16BEA51B" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1749-wk-Fact-D037C53F384253EAB8D89D828F57606E" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">45.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1774-wk-Fact-60D072D8BE615BAFB48DF2F8BBAE9C28" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,706.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1793-wk-Fact-03369FE59EF75FE48A0CB365940CCD87" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,456.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101485078e1812-wk-Fact-96AB5CA8535D5A8FAE33F1ECD7878AEB" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,596.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485078e1832-wk-Fact-4517B7B13CB05F16A0A3044320A963AF" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,597.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6840358A7C9357A3BD191C53AC24128D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, <br/>2018</span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e935-wk-Fact-83A526C3A2725C42B7F158D072E0F5A4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,343.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e954-wk-Fact-F2DAE74D0C115593B118EC48C694BF5C" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,224.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e969-wk-Fact-C298836C09855D1C9A8917411E7A4AE9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,093.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e988-wk-Fact-F018E8451C8957A08F7079FFB8D59F3F" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,313.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1008-wk-Fact-8C63902DCE405F6AA706D3D9EF2C4D4D" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,933.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1027-wk-Fact-814BEE20D0EB5418B809192481DAE7B5" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,958.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1047-wk-Fact-290794FEB3A95955968569909E8535A2" name="biib:DuefromantiCD20therapeuticprograms" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">582.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1066-wk-Fact-3F53EB504B2C54C1B16CA342645AEA82" name="biib:DuefromantiCD20therapeuticprograms" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">526.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1086-wk-Fact-C0E7BED0E0A95BE78B67788E90DC38BE" name="us-gaap:InventoryNet" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">751.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1105-wk-Fact-E643FBEA510257AD9C0E842D75167864" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">929.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1125-wk-Fact-A7E031AAF153505C892B7F1564CFCEC3" name="us-gaap:OtherAssetsCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">743.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1144-wk-Fact-4AA23FD66DE850E39D1F6CD98677E785" name="us-gaap:OtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">687.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1164-wk-Fact-87D1495EE96F502D929A0C1BB41A62B0" name="us-gaap:AssetsCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,448.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1183-wk-Fact-143F2CEE2BEE562C93C5BCE7B3869174" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,640.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1203-wk-Fact-E6153FC7558757788377A9AEA4996959" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,813.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1222-wk-Fact-6C19C6ED1107532B96BEA89F99B89C76" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,375.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1243-wk-Fact-781FAF2FA25C5DE4816B81351E6F77CB" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,138.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1262-wk-Fact-EE1A2112EC8951CBB34D626AC0C45223" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,601.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1282-wk-Fact-1C37745BC3885835BF4E8A23720C16FB" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">422.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1301-wk-Fact-B6678B300D3D56C799561C33B73005B3" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1321-wk-Fact-590BC6AA99A359AE8B2D093C3E37149E" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,392.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1340-wk-Fact-6AEEA34F46DE51CAAAEFDC70DF10D84D" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,120.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1360-wk-Fact-0C60CAE51C8B53A7ABC528A464C8294A" name="us-gaap:Goodwill" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,746.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1379-wk-Fact-EDAA6B48B7F75DCC9A54B3A7C0BDDC58" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,706.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1399-wk-Fact-F66C6C9C15F65F1D8ECB69B751886781" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,284.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1418-wk-Fact-F621B0599EA35EE883AA1B7730BE2101" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,153.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1438-wk-Fact-7B852389140157A4A8260E8B14EA1983" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,238.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1457-wk-Fact-89466BD8C6B45327BD61A0ECB81E173A" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,690.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1482-wk-Fact-55BDD2060AA757EAAC872D6DB53C9927" name="us-gaap:Assets" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27,484.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1501-wk-Fact-FAAAD69603DB5E5B9F862B8B135DDC3C" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25,288.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1603-wk-Fact-308849C12114E2457E24DF18BE2C342D" name="us-gaap:NotesPayableCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,495.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1622-wk-Fact-91C66CFF1C4448F0BB2FDF190080F42A" name="us-gaap:NotesPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1637-wk-Fact-B8E9D40B043C5C97B77D88A407B5E6B2" name="us-gaap:TaxesPayableCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1656-wk-Fact-BB2A31C8517D5EBAA911970CB9A1098E" name="us-gaap:TaxesPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1677-wk-Fact-496E65744BA454AFBBE4E22A73F7762D" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">382.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1696-wk-Fact-750385800D415C4DB8129FCF499223B1" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">370.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1716-wk-Fact-C6AD992658BE523FA538C7C0C76A2090" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,429.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1735-wk-Fact-BE16E177BEB058B89BD806D640DFC45E" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,861.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1755-wk-Fact-67D828B802B951F4B20207E1DC993F54" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,432.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1774-wk-Fact-C32692E20D225EB6AFC0CD72B96858BC" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,295.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1794-wk-Fact-13E0432DB7BB567F8E6B5F5AD776202A" name="us-gaap:LongTermDebt" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,458.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1813-wk-Fact-2FF75B46492F5477BEE57B562A605D00" name="us-gaap:LongTermDebt" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1833-wk-Fact-F4AAE7F4F0BE5A7CAD3F2BB8053E81E8" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,820.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1852-wk-Fact-86191C856627546AB71D0AC817931A2E" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,636.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1872-wk-Fact-DF012A752E815C6091CBAFFD1F0FDC94" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">410.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1891-wk-Fact-F0993C1DBBD052B09206580B64849771" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1911-wk-Fact-3B76B476C9EC5341AA786EDA6E0726CC" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,370.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1930-wk-Fact-54B9F535280E5673BE39CEFF072D9B0B" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,389.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e1950-wk-Fact-8936E5CB413B571B82246DBA0028A0BA" name="us-gaap:Liabilities" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,492.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1969-wk-Fact-97E2DC9163B755A49A8C1A0F64464C48" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,257.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e1989-wk-Fact-A50F964A18F452439EBF80FA7B620812" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q3" unitRef="usd" xsi:nil="true" scale="6" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e2007-wk-Fact-C99AE73AC60C5B1B89DBABAEE47EA785" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="6" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e2109-wk-Fact-962A446B843657E6AFF4A597E0138E20" name="us-gaap:PreferredStockValue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e2128-wk-Fact-48451208FE475A3DA8BEB2C40076392C" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e2148-wk-Fact-35CE2716383B5AE3B925429C24A4ADA7" name="us-gaap:CommonStockValue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e2167-wk-Fact-B71B7AC7B2E05AAEA63770CE1A93C1D5" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e2187-wk-Fact-47619F822E3A527E8ADA394CB3C7D18D" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e2206-wk-Fact-AE65C64FBDA35AA0A9B723A96F852669" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101490761e2226-wk-Fact-D19A1A49D241536C9B103A6500E3337A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">92.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101490761e2246-wk-Fact-2AD3B15D1D55512B9C6B95F3C78B4D85" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e2267-wk-Fact-50CC37E48EF5582DAB0B2F6EACC9AEE0" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17,065.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e2286-wk-Fact-457A1B15015854AFBE5811D84B6176F2" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,257.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101490761e2306-wk-Fact-DBA2285F07C6556884D1EB21B6713F8B" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101490761e2326-wk-Fact-F543FC63AC235575A1678AF91B890C47" name="us-gaap:TreasuryStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e2347-wk-Fact-A2AF55501BAD547995BE423EF29B658C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,995.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e2366-wk-Fact-44AC8A01AD1356F5A9EB4B9A72137222" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,039.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101490761e2386-wk-Fact-3CEC36CBF1055BE6A123C365060F5F58" name="us-gaap:MinorityInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101490761e2406-wk-Fact-16C8C5F03C1C5585B1709640505A160A" name="us-gaap:MinorityInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e2427-wk-Fact-29E33AB9B71A5B1A92211499B9EFB12B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,991.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e2446-wk-Fact-B09AC96B85E159EC99ACF965755BAF33" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,031.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101490761e2471-wk-Fact-76AC70AEF6025213B3222C8ACD9EB3C8" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27,484.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101490761e2490-wk-Fact-765C507BBF6556C8B6728676B0F6AE0C" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25,288.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5CF404583A95540592C8C79F8E3D01D5"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e934-wk-Fact-3AADFF2A153C519091C711159E3B32B2" name="us-gaap:ProfitLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,448.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e953-wk-Fact-2B961E9A38315302B816B2E71D3709C5" name="us-gaap:ProfitLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,529.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and impairments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1009-wk-Fact-33452851621C5F07A9C9EBAA4EA6B82F" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">567.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1028-wk-Fact-D8242BD7C4A65758A3F6BC8039223103" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">686.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1048-wk-Fact-EE9D5CB5D2E85A1C8C8AD3ADD14680F7" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1067-wk-Fact-2CA811F753CD570B84DAA2F7964FE11D" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1087-wk-Fact-C7C799CAD1C3585C803C44325A020472" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">143.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1106-wk-Fact-CF36DCC358E25DE38562DE6E739CA7A5" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">119.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e1126-wk-Fact-71EA0E01C5515EB8915D8014F3984813" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1146-wk-Fact-38997DD058735F02BF9DD1F00498AD0C" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1167-wk-Fact-1AD545FB7F2A5371B77A378648066CCC" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">95.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1186-wk-Fact-833103A7D6915801BE746271BD22ADFD" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1206-wk-Fact-C2C2A1F795915C9D96C513797CAB67E9" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1225-wk-Fact-EF0D76A38A7F597A94CEDC0AD45CDC38" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">44.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized (gain) loss on strategic investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e1247-wk-Fact-D65DFA33112E52C9B4A4A1E59A1B9FA5" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">189.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1267-wk-Fact-55BFBC2FF16A57C28A18B33E4345147E" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">136.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on equity method investment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1288-wk-Fact-3EBF7BA106C63991434BDF1FD033605B" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">63.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1307-wk-Fact-57C41D64DF04C5CBC74FDF202E55A13F" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1327-wk-Fact-5970C35E4EF35EFA96044270222D37DF" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">87.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1346-wk-Fact-3719FFC295B6502FB9A786DDED0FBA94" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">68.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e1407-wk-Fact-C8A85D4916B452DDA086ABF9B456D6D1" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1427-wk-Fact-DF132AB08A0851B1AE109D0EC1D256C1" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">254.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1448-wk-Fact-9EA0182E264353B7986D19FBE8AD7D5E" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1467-wk-Fact-1C106B69CC91540CBDAABB2F9C6FF2F2" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e1488-wk-Fact-89128A91D27B5BD99B7DE0A8E6A2C725" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">109.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1508-wk-Fact-76206FF6BD07526E9445A05442303B4E" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1528-wk-Fact-04639F8ADC895C789F2D301BBED6EF73" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1547-wk-Fact-64494AAB60025472B47618AD3C175E9B" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">315.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other changes in operating assets and liabilities, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e1567-wk-Fact-9A24E72FB0F05ABE8F8E8F796BD85551" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1587-wk-Fact-ABC3502D7E3459D59F99356D87DB6395" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1608-wk-Fact-DDCA05B63152502A883DBF0C88CCD247" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,118.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1627-wk-Fact-8E179AC4269650B588F40F50D654A06D" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,292.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1689-wk-Fact-5E1D8F7CDC5D5971BFCC69B7E527C60C" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,867.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1708-wk-Fact-F0FE9623A9FF52ED9D5ADA61948D05C3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,994.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e1728-wk-Fact-61FC7C8C612F56CD9DD89654C0837BC3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,052.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1748-wk-Fact-AD1873A67E6A5F4F9E0A47DA13C65CC2" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,093.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration paid related to Fumapharm AG acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e1769-wk-Fact-F17A1A59D3BC5916BA007E220C849E6A" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1789-wk-Fact-B897412B83335209B78DBF38B85508A5" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,200.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition of Nightstar Therapeutics plc, net of cash acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e1810-wk-Fact-7B404276589557CBA07D97016C06503D" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">744.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1830-wk-Fact-EBE43BFC249F5845B673472EE0D16C7F" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1850-wk-Fact-21D3AA713F0EA2E9CACADF24BE08CAC6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">923.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e1869-wk-Fact-EEBD60E282A013176258DF24E6474522" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e1889-wk-Fact-AD8B3A35867756C98C0969516A36078E" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">404.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1909-wk-Fact-94A2D1C18C6E565787B5F6E902708951" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">544.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1930-wk-Fact-E65F2CF901365080AAAE43C87C12A895" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1949-wk-Fact-3F47A04D66CE5637B61EC983694A6E6A" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e1970-wk-Fact-29A1E9B40ED456059989BFB340E59E7E" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e1989-wk-Fact-AEF16EBAC64154E6BF9D7393F71EA03C" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase of Ionis Pharmaceuticals, Inc. stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e2010-wk-Fact-474692735A7D5AE8ACBA5C8F8A7AD1CD" name="us-gaap:PaymentsToAcquireOtherInvestments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e2029-wk-Fact-0E2C681D61B1567CBC1E30EF986EC73A" name="us-gaap:PaymentsToAcquireOtherInvestments" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">462.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales of strategic investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e2050-wk-Fact-EC8FCC7D36A6566A8D2479C01357C9C6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e2069-wk-Fact-79038D827FA25A978709096A05001AE0" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e2089-wk-Fact-358F039701CA547BAD90F17B83549CC5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e2109-wk-Fact-A6D835B6A23C5D56A4299F2766535328" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e2130-wk-Fact-07D1DA4D70F3553ABDD930B5BE13032E" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">237.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e2150-wk-Fact-2B1DBDB45EEF5B3099CFCD6C0B368069" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">421.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of treasury stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e2212-wk-Fact-9170BCFABB65589B94DE58BFA74AC05A" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,775.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e2232-wk-Fact-9AA1718984DF5B8E8246D63B92A57FFA" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments related to issuance of stock for share-based compensation arrangements, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e2253-wk-Fact-9B82C510C2D4588AA66EF704CF04EFD2" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e2273-wk-Fact-F2D13445A75758BBABB91342157219E5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repayment of borrowings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e2294-wk-Fact-89E1BAC77A6886A2D6D68270C6F1A263" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e2313-wk-Fact-06AB359CAE9625DC3CA58270EF4D874A" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net distribution to noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e2334-wk-Fact-24BE8658D9F858E9B1A28E023311BC55" name="us-gaap:PaymentsToMinorityShareholders" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e2353-wk-Fact-BBAE32D04BBC58D4812EF6C32641FDBE" name="us-gaap:PaymentsToMinorityShareholders" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e2374-wk-Fact-6B28D4ADED495034B79B15A73017253C" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e2393-wk-Fact-3F7161126EC35BB0B126199BFBA8E2DE" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e2413-wk-Fact-40C71F2A45F25B948951D2AD307FD3C8" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3,744.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e2433-wk-Fact-444379A4A2AB5470928C2576F560EED1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3,035.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e2454-wk-Fact-A1CC385BF227504489040649F8C25E33" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,136.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e2473-wk-Fact-58AFDCE9750D532CAF4615A0E7B7C032" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">836.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101488732e2493-wk-Fact-B3DE861386415094AAC2D8E37EE3A027" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">17.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101488732e2513-wk-Fact-C9D710FC606C53DDB68FD819DE095B24" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">23.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e2534-wk-Fact-F2DAE74D0C115593B118EC48C694BF5C" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,224.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e2553-wk-Fact-3DCF5FF7FC2B5D0889A1B757B35D3D09" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,573.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101488732e2579-wk-Fact-83A526C3A2725C42B7F158D072E0F5A4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,343.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101488732e2598-wk-Fact-4F468DFC96A355ABB0BFD7FA4C2F2FE3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,386.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s47961572DBD45117A90FC46CF613E457"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1335-wk-Fact-4DB1897C193D5053A4199A58D004705A" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1354-wk-Fact-C1BDD266FBEA5A5CAB31010DC9AC6F8E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1368-wk-Fact-31A6828F27C55C31A3A1012062CB9DF4" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">208.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1388-wk-Fact-27D5A6B1248C575EA1CC3FAE3CE42A35" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1407-wk-Fact-9E3630F78EEF5FEE923770FF345DCB53" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e1426-wk-Fact-8EDA62210500500783D0C50325720711" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">252.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1447-wk-Fact-648BC3AFD33F555AADECBB0155548354" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,182.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e1461-wk-Fact-A6C210ABBCBE5C85ACFAFEE305213781" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e1481-wk-Fact-70CA9E6A75D85E8EA9BB1DA671C20A99" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1502-wk-Fact-790D39D271FD5078B42BFE8604C22514" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,952.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e1521-wk-Fact-66CE5579DF38532497778508A28E6ACB" name="us-gaap:MinorityInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1541-wk-Fact-CD539AB29EE653758B894A0D73A565E6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,948.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1669-wk-Fact-9D8EE02555B95F9DA86B243B1A8779B0" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,545.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1724-wk-Fact-8BCEFCADFFDD5171A80A5930F9D729B5" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,545.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1743-wk-Fact-972AAEB857205ABCA7754A63F71350FD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1762-wk-Fact-295C51D2551C57C38B86AB20FD5C8538" name="us-gaap:ProfitLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,545.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1874-wk-Fact-B6CDD3BAC1C151D7A18485F5A3F03ED1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1950-wk-Fact-0258E3DA7739597FAE2A1F9A9FEA77FD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1969-wk-Fact-5EB98767A3005B6BA3A1AD4A89C90E5E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e1988-wk-Fact-8AC5B7C40AFC5741ADDC658D1984EE8A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Capital contribution by noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2177-wk-Fact-058C7C59A31752FFB35DD63324A879C2" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;font-weight:bold;"><span><ix:nonFraction id="d101507987e2196-wk-Fact-591F8F9F0BC752429B9306CC93EBD8B4" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2215-wk-Fact-7334719A4DF75EA5AC5A3612BB179E7F" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2019 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e2368-wk-Fact-8AB1700A6308512CA6108A4C1B59FFE5" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e2383-wk-Fact-4DCE57350C1D5FE48C8E834B670F9E6C" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">717.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e2404-wk-Fact-E706166A246E50A4A3964EC8D4173977" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">717.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e2444-wk-Fact-E706166A246E50A4A3964EC8D4173977" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">717.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2019 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e2501-wk-Fact-BEE64B24254756FAA4FE34B68DB5D626" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2517-wk-Fact-AAF64793156054F4B341E33669B280DD" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e2536-wk-Fact-350B28044C0158F3B1E92B6A9150EC18" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e2577-wk-Fact-7766DA95C71C57E2983C41DB828CA78B" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">662.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2597-wk-Fact-931B2B0D844B53E2B66EDD99F25435FE" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2611-wk-Fact-3490A712F30C5780926E1F6AA26714A8" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">717.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2631-wk-Fact-2BDFB5699B1F568AB743E6C21CE026CD" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2670-wk-Fact-2BDFB5699B1F568AB743E6C21CE026CD" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2726-wk-Fact-193A2BC9B0FF5AECA4A368CB1ED652C1" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2741-wk-Fact-72EDAEB7046656BDBF8F5B84F99E5829" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2760-wk-Fact-4438BBED29125EFBB26F340DBC3BA794" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2856-wk-Fact-781108C655DC5CC99AE57A39FDC6343C" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2895-wk-Fact-781108C655DC5CC99AE57A39FDC6343C" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2951-wk-Fact-54EAD90C49E15D7CB2F09EA6499A3C6B" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2966-wk-Fact-618C82F41F9454BA84963FED9B1F7DC2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e2985-wk-Fact-34FAFE47F9815381BF69ABC5AB987B50" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e3025-wk-Fact-FC7D12D12F20551691B4A0266C8D5B33" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e3081-wk-Fact-AD204A00E2935B519B8BE7817A545C8F" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e3121-wk-Fact-AD204A00E2935B519B8BE7817A545C8F" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3214-wk-Fact-224362906372580FAB28748827B330EE" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3310-wk-Fact-970839C28F2B50C5A232885A09D5E460" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3349-wk-Fact-970839C28F2B50C5A232885A09D5E460" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3371-wk-Fact-CC4EAD3DDB495DECA91DF851D5A77A08" name="us-gaap:SharesIssued" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3390-wk-Fact-5C4E8F58B2925D6F8DEC5D09D278C5CA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3404-wk-Fact-ACE49EE2E82D5033AE6D239D6DCE8F40" name="us-gaap:SharesIssued" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">205.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3424-wk-Fact-8CE223771A1F51ECB44C691CF1FD8979" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3443-wk-Fact-9573B47AB29854CE9B9E18F15E746C28" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e3462-wk-Fact-87A8BF94786F56169B1ACC6749A4C8FE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">92.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3483-wk-Fact-51D3851DCF2E5B2AA6B7AB0FF444BF05" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17,065.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e3497-wk-Fact-118AB936D3C45732B5CEF0784D36F781" name="us-gaap:SharesIssued" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e3517-wk-Fact-82C6EA1AAA685D239E476B625189F3A3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3538-wk-Fact-A2AF55501BAD547995BE423EF29B658C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,995.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e3557-wk-Fact-1D8876B1731957869AFE70032B521CC1" name="us-gaap:MinorityInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e3577-wk-Fact-29E33AB9B71A5B1A92211499B9EFB12B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,991.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4175-wk-Fact-640CE05F3EE159F4B8DA91CA166AC695" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4194-wk-Fact-BA6F1D3312C05F18A38960700E33CC05" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4208-wk-Fact-D3BDFEC3E79257F59F85C4A727DF1294" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">221.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4228-wk-Fact-5980E45B3ECB52FD83B0E414D6AE5A50" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4247-wk-Fact-5AA8653F41B750478F7DA9FB1355EDB5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e4266-wk-Fact-9D201A6242E55282985A0646AED341FB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4287-wk-Fact-2FD96C1583D65C0F99E4B96F1E23CCFD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,257.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e4301-wk-Fact-5DC1AF8E16045C7FBCA71C7ADBD7E0C3" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e4321-wk-Fact-8FCF068AA21E5675B1639DAAB3CDA1E6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4342-wk-Fact-44AC8A01AD1356F5A9EB4B9A72137222" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,039.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e4361-wk-Fact-4F348DB3C0885EACBA22A7154D42FB37" name="us-gaap:MinorityInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4381-wk-Fact-B09AC96B85E159EC99ACF965755BAF33" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,031.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4509-wk-Fact-87B56E85E8F5514884B7DA0E6FB7C373" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,448.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4564-wk-Fact-FF611939A9605722A2FA20072DD911C0" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,448.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4583-wk-Fact-A2ECB36D60F058E3948D45C8C21EECAE" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4602-wk-Fact-3AADFF2A153C519091C711159E3B32B2" name="us-gaap:ProfitLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,448.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4714-wk-Fact-E855D976E7645FE28E8294E32E091502" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4790-wk-Fact-4BE449ABC68C5BBB868E2225D4530616" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e4809-wk-Fact-E2004262817151D596898DC67BE629EA" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e4829-wk-Fact-23D720C9EF9A5C77A76E77E1DFCDC213" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">147.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Capital contribution by noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5018-wk-Fact-205D79FBA7D059F08F4090774ECEE149" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5037-wk-Fact-DE9772B0D0435724B042B1219FF18757" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5056-wk-Fact-B5B48664EC8D575FA9E9FFA7A551865F" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2019 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5209-wk-Fact-510D324B12955B8EAD22685535814769" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5224-wk-Fact-2F6D738388A958379B44B92B02FF9D56" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,627.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5245-wk-Fact-8335EEDD20175A37A9DE25E92A95A616" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,627.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5285-wk-Fact-8335EEDD20175A37A9DE25E92A95A616" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,627.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2019 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5342-wk-Fact-3821DC30956C542DA4446D5DD426373A" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5358-wk-Fact-C3C91327E47C539D8EF62B05CE17C1A0" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5377-wk-Fact-3ECF397022DD524DA353DCC4084A542E" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5418-wk-Fact-7882078D6A43591D8BB48ED60EA826D8" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,553.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5438-wk-Fact-3DF00A101904587BBCFF856168B2B98F" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5452-wk-Fact-2B4D4C1ED9FF50E99F2E3C2D3F531A97" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,627.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5472-wk-Fact-28ECDBDD7EA05C14AD813D69BDCAE900" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5511-wk-Fact-28ECDBDD7EA05C14AD813D69BDCAE900" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5664-wk-Fact-F5875C2744F050EC9C24E1D87C9CD0EE" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5679-wk-Fact-4378ACB64E0D5BA593FA0EC569E8175D" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5700-wk-Fact-FD45E4C38F2F5B4681DF318A97EE6344" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5740-wk-Fact-FD45E4C38F2F5B4681DF318A97EE6344" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5797-wk-Fact-E05FD02788A45D47BC37067FB850FEF3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5813-wk-Fact-6174981275CB50BFBCB1136224B468BE" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5832-wk-Fact-CD87922BB008598BBB34A2B6DCB668AC" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">110.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e5873-wk-Fact-F1561880AB1C52F194880CCD1A595DE2" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,036.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5893-wk-Fact-25FB1518268E547FA41946AAC16848E9" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5907-wk-Fact-DD9D4F8F2BCD5A37803F322F526F66A3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5927-wk-Fact-3D25247FC091590BA5F465588A682F8E" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e5966-wk-Fact-3D25247FC091590BA5F465588A682F8E" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6022-wk-Fact-4CCB10CA01D5543C85D4DA480E3CBEEC" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6037-wk-Fact-B54D0FC34EE158628C62C2C218E4C3F4" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6056-wk-Fact-B256372F76AC51E7808CB990AF565FB7" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6152-wk-Fact-46269E519E135F9AB903964D533B4863" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6191-wk-Fact-46269E519E135F9AB903964D533B4863" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6248-wk-Fact-56DCB67FD1D557699C17C430276DC180" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6263-wk-Fact-1F619C17BB725C04906FE6C91ECF3667" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6282-wk-Fact-45188D4ADF8F50B08797279C4E24F40E" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e6322-wk-Fact-643A87850FA15BADAD9C60992EDDF4DF" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e6378-wk-Fact-7630FD4D8FC75971B59A587F7F17E3BC" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e6418-wk-Fact-7630FD4D8FC75971B59A587F7F17E3BC" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6511-wk-Fact-64E4A81E47555B93B86D8FBAE52AA5BB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">151.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6607-wk-Fact-1AA391F5B67958DF883BA3E4EDC0D597" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">151.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6646-wk-Fact-1AA391F5B67958DF883BA3E4EDC0D597" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">151.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6667-wk-Fact-CC4EAD3DDB495DECA91DF851D5A77A08" name="us-gaap:SharesIssued" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6686-wk-Fact-5C4E8F58B2925D6F8DEC5D09D278C5CA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6700-wk-Fact-ACE49EE2E82D5033AE6D239D6DCE8F40" name="us-gaap:SharesIssued" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">205.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6720-wk-Fact-8CE223771A1F51ECB44C691CF1FD8979" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6739-wk-Fact-9573B47AB29854CE9B9E18F15E746C28" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e6758-wk-Fact-87A8BF94786F56169B1ACC6749A4C8FE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">92.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6779-wk-Fact-51D3851DCF2E5B2AA6B7AB0FF444BF05" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17,065.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e6793-wk-Fact-118AB936D3C45732B5CEF0784D36F781" name="us-gaap:SharesIssued" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e6813-wk-Fact-82C6EA1AAA685D239E476B625189F3A3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6834-wk-Fact-A2AF55501BAD547995BE423EF29B658C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,995.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d101507987e6853-wk-Fact-1D8876B1731957869AFE70032B521CC1" name="us-gaap:MinorityInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d101507987e6873-wk-Fact-29E33AB9B71A5B1A92211499B9EFB12B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,991.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.85549132947978%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7456-wk-Fact-E51C6323182B5FC3A6EB103E00DB77B8" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7475-wk-Fact-61562AE107465300BFF198C54788ABBC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7489-wk-Fact-5C5B8621389050A491B1E92CA9C22DCC" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">225.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7509-wk-Fact-58375CCABF015F62AE1AEFAE888B6E53" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7528-wk-Fact-8A4511BAFD5B5A95B03413B6D11BE0DD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e7547-wk-Fact-98C33DC28B9D5F2DBAB0B3184BC93238" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">261.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7568-wk-Fact-282DEC3F60005849887987904B177308" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,499.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e7582-wk-Fact-8CEADDBC7458518189E8E7295BA4870F" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e7602-wk-Fact-0432F42C91FA5A808696EE47577A6010" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7623-wk-Fact-F76936530B485B38961CD48EA3AEEA7E" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,260.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e7642-wk-Fact-2FD89C272F495BF8828BFFC171A64752" name="us-gaap:MinorityInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7662-wk-Fact-42ADE483BB3251C48FFAAB53DC167672" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,253.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7790-wk-Fact-A26D3704484E5397BA9ADDD934CAFDFE" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,444.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7845-wk-Fact-A3394798436750ACA93FC560D5254E0D" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,444.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e7864-wk-Fact-024FA8A2E157538AA584D37B41907406" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7884-wk-Fact-4C53D8055C3559E2AB7DBEC22965795A" name="us-gaap:ProfitLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,442.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e7996-wk-Fact-6E3CEDF358695E12B9E914F1CA53A5FF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8072-wk-Fact-2E58A4FBEAF45408A246611108CA9348" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8091-wk-Fact-F0DFA38CAF0C5B1D97BA81438DA090CF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8110-wk-Fact-608D1370C40657139D4C33E5BB2CD622" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution by noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8299-wk-Fact-323E5F0CDDEE5FA5BB637DC9CC04C09A" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8318-wk-Fact-ACFCE8E381FB57B2888342A6D52F4668" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8337-wk-Fact-18D534EB12FF505F9996530C8F3390AD" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8393-wk-Fact-5F884D20FD3050148A78633FD8B307EC" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8408-wk-Fact-DB812A2481E65909AFF9B3CBA2E6C5C6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8427-wk-Fact-0E6C1FD978545ACC980E531CD5A4507D" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8523-wk-Fact-75B4DACC04005DCFA08C26F946A49A3B" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8562-wk-Fact-75B4DACC04005DCFA08C26F946A49A3B" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8618-wk-Fact-7B4F909B5F2F5793A0721BAB900C8CAA" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8633-wk-Fact-EF43F2A8951D5B8FB8D13AD4178DE5F2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e8652-wk-Fact-C7EAACC8B2AD52D5B05D3FF9CB6233E4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e8749-wk-Fact-082523185C3F5AFE8368BF402B372E61" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e8789-wk-Fact-082523185C3F5AFE8368BF402B372E61" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8882-wk-Fact-E4B73AAEA7B45092971A9AC9B265CC7B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8922-wk-Fact-DDFC03AF46AF3CF2584B827AD9B1CC40" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e8977-wk-Fact-24D337343CEF5BE2AAC244DB803F478E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9016-wk-Fact-24D337343CEF5BE2AAC244DB803F478E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9037-wk-Fact-EACEFE8818A25323BA3CFD81656894FD" name="us-gaap:SharesIssued" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9056-wk-Fact-2269215F690C560CA4134A321A2D0D92" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9070-wk-Fact-F92BA010426D5AA29FCAA297EE15E6FA" name="us-gaap:SharesIssued" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">225.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9090-wk-Fact-66CA277143645300B289A549905DF29F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9109-wk-Fact-2CA404F5369756B792C0224B994DC944" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e9128-wk-Fact-F21626A61C08532E9B7F50AB676FB8EB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">248.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9149-wk-Fact-FF433E37989959FAAAE2A6F4E212120B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,944.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e9163-wk-Fact-3E306F47AF775673B1493E17FE6A5D3E" name="us-gaap:SharesIssued" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e9183-wk-Fact-AEA6364BFD7B5F1EA4EE6512823F7A11" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9204-wk-Fact-513B120271295CE4B9FB2CCB29CD1744" name="us-gaap:StockholdersEquity" contextRef="FI2018Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,766.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e9223-wk-Fact-1B479A781AB75A8DBFC27D42C87AC415" name="us-gaap:MinorityInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9243-wk-Fact-31E771B49E045426B9D89F8B2EB22F2F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,759.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.71098265895954%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9845-wk-Fact-67E6C07379C557679C5CD039B938981C" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9864-wk-Fact-AFF300890C5B56149EC7A6408C949257" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9878-wk-Fact-628FDE18159551DB81DCBB916428E239" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">235.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9898-wk-Fact-C967049A914B51E59ECF3C1EF5BC62D0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9917-wk-Fact-AA9DC132C178521DB8DB36B219D284FE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e9936-wk-Fact-850D8B8C51005612908926183ECBDBE6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">318.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e9957-wk-Fact-1CD1FAB9A3AA5658B2A2AFE5875474C7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,810.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e9971-wk-Fact-A54361F0E14B5D1384B3E6508578D145" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e9991-wk-Fact-800C0410E2825448A4268BF65677612B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10012-wk-Fact-9C60DE1EE2F45DB08FFE83925A33E132" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,612.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e10031-wk-Fact-FEFFC5DBBB485E22A627E15467845492" name="us-gaap:MinorityInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10051-wk-Fact-87CC3B3CE380518AA61BBFF8C334DCB5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,598.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10179-wk-Fact-6A66AD4CE9175C5F903AF19781CC064F" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,483.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10234-wk-Fact-71E4AC6E479B5D7B8F2CABF3359E1159" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,483.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10253-wk-Fact-8439350BAD56597A8A7F7690E39982A6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10272-wk-Fact-2B961E9A38315302B816B2E71D3709C5" name="us-gaap:ProfitLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,529.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10384-wk-Fact-4E00D9635B3D5A6BB6B95B57F55B0993" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10460-wk-Fact-61FD074FCC6D59939B8BE32C48B29249" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e10479-wk-Fact-C9D377A4B2CD5DEE83E192BEC8C5E415" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10499-wk-Fact-BA092162E3245744B49584C5B64CF75A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution by noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10688-wk-Fact-CD93967D392E59D5947CDD3E1EC69E04" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10707-wk-Fact-64B6B93D9AFE518EB1B77AD291369DD9" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10726-wk-Fact-C0A48F90FEEE56BF934148B6799C37E0" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e10915-wk-Fact-66ECB2986EDB5B029693209B725FC7C3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e10934-wk-Fact-A8E8AF8CF17F5B9AA720A6BD25BD4ABD" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e10954-wk-Fact-FC742150FFC65A9898AE7746E02ADF10" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e11108-wk-Fact-D4E83C15E9FC500496A238715166ED73" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e11123-wk-Fact-965EE22B3C8555B7BF3BE1D87DFA9156" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e11144-wk-Fact-DB6F8720372956F887FA506E41DB5912" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e11184-wk-Fact-DB6F8720372956F887FA506E41DB5912" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e11241-wk-Fact-FD6300FAFDED5105B5DE77393E2ED284" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11257-wk-Fact-D267A46FFD475116A694815EA773E7FE" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e11276-wk-Fact-B692AC0C447C5284B390B5F9416D261A" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">171.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e11317-wk-Fact-2B2E99A011B558E5BEF2A86B70A192E4" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,828.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11337-wk-Fact-329F72046E2A52888E180A013094E208" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11351-wk-Fact-049176E6EBF45DA1B091133E9EC76C48" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11371-wk-Fact-D005A910D3F65E059B6A912C9F9375CF" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11410-wk-Fact-D005A910D3F65E059B6A912C9F9375CF" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11466-wk-Fact-9C64F87F0ECA5CE2BF948C101CFB8C28" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11481-wk-Fact-85EF591A928D5FFD98AE842D11DDEF29" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11500-wk-Fact-DFB5692685BF527FAD879F93C68E08E3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11596-wk-Fact-FD84E25F75165A66904B79A688175405" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11635-wk-Fact-FD84E25F75165A66904B79A688175405" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11691-wk-Fact-1A9EBA5663E054B89FCE9372FE3D6E33" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11706-wk-Fact-317E3982302D5AB998A103D8D3531E4C" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e11725-wk-Fact-8C7818D7B93857B786E408DFC23E3EB5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e11822-wk-Fact-0EB86ACB9D555B2589489E9742A19F14" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e11862-wk-Fact-0EB86ACB9D555B2589489E9742A19F14" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11956-wk-Fact-BD5678E097C35B3095D4C73DB4B41E3F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e11996-wk-Fact-B3DCA5818CE19DF73595827D19E08560" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12051-wk-Fact-9F548400CF785562A855C94B904BA8E3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">128.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12090-wk-Fact-9F548400CF785562A855C94B904BA8E3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">128.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Adoption of new accounting guidance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12202-wk-Fact-5CF94D26BF525028A2250536815ABB92" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q3YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12222-wk-Fact-09A404D67EA252448F389E431FA93CF9" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q3YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">478.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12277-wk-Fact-B8E50576CA135DD497BBA962921C78E4" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">479.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12316-wk-Fact-B8E50576CA135DD497BBA962921C78E4" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">479.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12337-wk-Fact-EACEFE8818A25323BA3CFD81656894FD" name="us-gaap:SharesIssued" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12356-wk-Fact-2269215F690C560CA4134A321A2D0D92" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12370-wk-Fact-F92BA010426D5AA29FCAA297EE15E6FA" name="us-gaap:SharesIssued" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">225.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12390-wk-Fact-66CA277143645300B289A549905DF29F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12409-wk-Fact-2CA404F5369756B792C0224B994DC944" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e12428-wk-Fact-F21626A61C08532E9B7F50AB676FB8EB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">248.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12449-wk-Fact-FF433E37989959FAAAE2A6F4E212120B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,944.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e12463-wk-Fact-3E306F47AF775673B1493E17FE6A5D3E" name="us-gaap:SharesIssued" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e12483-wk-Fact-AEA6364BFD7B5F1EA4EE6512823F7A11" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12504-wk-Fact-513B120271295CE4B9FB2CCB29CD1744" name="us-gaap:StockholdersEquity" contextRef="FI2018Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,766.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101507987e12523-wk-Fact-1B479A781AB75A8DBFC27D42C87AC415" name="us-gaap:MinorityInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101507987e12543-wk-Fact-31E771B49E045426B9D89F8B2EB22F2F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,759.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3205306FA0625B3FB00E628FBA166CA6"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</span></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div><a id="s6D66D150E5335F95AA8DD243ED7DE6D7"></a></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-C8DC5FF7164C5EB98BC8DCA34E57F914-0-wk-Fact-92440B7D94115F868C1D3A2C62FA0743" continuedAt="TextSelection-C8DC5FF7164C5EB98BC8DCA34E57F914-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-C8DC5FF7164C5EB98BC8DCA34E57F914-1" continuedAt="TextSelection-C8DC5FF7164C5EB98BC8DCA34E57F914-2"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:BusinessOverviewPolicyTextBlock" id="TextSelection-A3EB42A3C0FC5A6781CA40138BDFB135-0-wk-Fact-5A7E953BE9A254E59C384C101318038B" continuedAt="TextSelection-A3EB42A3C0FC5A6781CA40138BDFB135-1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy, Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-A3EB42A3C0FC5A6781CA40138BDFB135-1"></ix:continuation>Basis of Presentation</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-F9ABB9575D2A54A9916199FE6719EB66-0-wk-Fact-10D945F8E9C95337BAD83499352ACC83" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485908e883-wk-Fact-A2BA10EC7AFA5596938BDCBCB3F6B3E1" name="us-gaap:NumberOfReportableSegments" contextRef="FD2019Q3YTD" unitRef="segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C8DC5FF7164C5EB98BC8DCA34E57F914-2" continuedAt="TextSelection-C8DC5FF7164C5EB98BC8DCA34E57F914-3"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-B95F347E2C005A6F8330D91389B756B2-0-wk-Fact-F485BF7FE8DB5BF3A0DD9B947C251772" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101485908e907-wk-Fact-5F4F73EAB6E8515AB264459AA161E2F5" name="biib:InterestInSubsidiary" contextRef="FD2019Q3YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:UseOfEstimates" id="TextSelection-F8AC6A77EBC05DCF8F155D373862AA69-0-wk-Fact-732A2AC9D3185967AED24B633D53CFF5" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Assets and Liabilities Held For Sale</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:AssetsandLiabilitiesHeldForSalePolicyTextBlock" id="TextSelection-7BD53852F84D52839FA8E8B6ADAE8BA7-0-wk-Fact-683EEBD63E9250209EAB833DA49B8505" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-9F1453D21F46562DBD1F178C102012B9-0-wk-Fact-4D8A93214F525FDFA08B0CEAF25079AF" continuedAt="TextSelection-9F1453D21F46562DBD1F178C102012B9-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-9F1453D21F46562DBD1F178C102012B9-1" continuedAt="TextSelection-9F1453D21F46562DBD1F178C102012B9-2"><ix:continuation id="TextSelection-C8DC5FF7164C5EB98BC8DCA34E57F914-3" continuedAt="TextSelection-C8DC5FF7164C5EB98BC8DCA34E57F914-4"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101485908e1025-wk-Fact-B9D751963A5C56428A0708B1A8027EC2" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">463.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101485908e1029-wk-Fact-EB17D24F1D1E581EA23B15C74C7ED6CB" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">526.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-9F1453D21F46562DBD1F178C102012B9-2"><ix:continuation id="TextSelection-C8DC5FF7164C5EB98BC8DCA34E57F914-4"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on the composition of our investment portfolio and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative and Hedging</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF70C236A3F8253238FA8778F45805664"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-80D234F22FCA5408ACD813AC13201460-0-wk-Fact-CD0670D4E97A5F24874B654FCD6F7A48" continuedAt="TextSelection-80D234F22FCA5408ACD813AC13201460-1" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="TextSelection-80D234F22FCA5408ACD813AC13201460-1" continuedAt="TextSelection-80D234F22FCA5408ACD813AC13201460-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 7, 2019, we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid-to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (formerly known as NSR-REP1), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (formerly known as NSR-RPGR), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101483402e789-wk-Fact-7E5E8DBBAE565B34A7AF24BB9456F861" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">25.50</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101483402e793-wk-Fact-D3238A1CD9355C9683943A40A4B4EF51" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">847.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101483402e797-wk-Fact-3CA598FA9D1C56D1A699E7C09C3E2705" name="us-gaap:OtherPaymentsToAcquireBusinesses" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for equity compensation, which is  attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101483402e801-wk-Fact-02406D0B4C7B577BA19CB8437EDE637F" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101483402e805-wk-Fact-93945BBBB40F5784B8B52F1B7D28591C" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recognized as a charge to selling, general and administrative expense with the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101483402e810-wk-Fact-6EFEAD92D2DB570B99C5EF06CB7EB74F" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. </span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="TextSelection-057F4220308A5B3281DDB95F4B616315-0-wk-Fact-1B569434FBF651009EF39DA797B1FFAB" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of June&#160;7, 2019:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101483402e865-wk-Fact-FDD59567C12552EE9E55E8AC6B8701AA" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101483402e880-wk-Fact-8740F5C2B07059CDB1B0D4093F297119" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101483402e900-wk-Fact-CBAA3B57AABA5FB385FF1A913131541A" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">700.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101483402e920-wk-Fact-94999C2882305AF6B77E2E7FD3098A55" name="us-gaap:Goodwill" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101483402e940-wk-Fact-324597F783FC5FF4BEF90FC41F72CA9D" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">77.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101483402e961-wk-Fact-2B403C71069256C2AB974DFB9ADB1528" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101483402e986-wk-Fact-4027A97040475C659B141F00267D1D65" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">852.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the in-process research and development (IPR&amp;D) programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101483402e998-wk-Fact-AA40ADDD487656DBB2E7888A321E795E" name="biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">12.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101483402e1002-wk-Fact-320685B0257F5776A7DDAC645D5409E0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">480.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded an additional IPR&amp;D asset related to BIIB112 of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101483402e1006-wk-Fact-1BFC840C7D285AAF922A642EEA5A6310" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for global intangible low-taxed income (GILTI). Goodwill that is tax deductible for GILTI purposes is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101483402e1013-wk-Fact-AAD835787B3A5B3C9777BC4D028CA071" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management&#8217;s analysis related to certain matters, such as preparing and submitting certain income tax and non-income tax filings and returns. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the date of acquisition. Although the final determination may result in asset and liability fair values that are different </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-80D234F22FCA5408ACD813AC13201460-2"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">than the preliminary estimates of these amounts, it is not expected that those differences will be material to our financial position.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our condensed consolidated statements of income. Subsequent to the acquisition date, our results of operations include the results of operations of NST.</span></div></ix:continuation><div><a id="sE64EA5469A8D58A9B547089D326BA1AC"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="TextSelection-43714A3A234C582FBBFDB6F954E1F9EC-0-wk-Fact-D683DB22A14C5F2B86E91C56ED55089D" continuedAt="TextSelection-43714A3A234C582FBBFDB6F954E1F9EC-1" escape="true">Divestitures</ix:nonNumeric></span></div><ix:continuation id="TextSelection-43714A3A234C582FBBFDB6F954E1F9EC-1"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM Corporation (FUJIFILM). Upon the closing of this transaction, we received approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101498098e785-wk-Fact-689EE6A35350571A87DA2F9AC691BEFE" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">881.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, which is subject to the finalization of certain working capital adjustments and may be further adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101498098e792-wk-Fact-A2B459457A495987811DA496F1828779" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2019Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">114.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction we recognized a total net loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101498098e812-wk-Fact-4EE52A55094459C6BCEAF64211C50B24" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101498098e816-wk-Fact-0FDDE334468A5B84B73FA243BD3A679D" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">95.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects a decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101498098e820-wk-Fact-62082251A99C55549B0CB0CAD7FBEA3D" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our previously recorded pre-tax loss. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101498098e824-wk-Fact-4B40B74AFA11528B9700D00D489DA14B" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our estimate of the fair value of an adverse commitment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101498098e828-wk-Fact-A2B459457A495987811DA496F1828779" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2019Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">114.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101498098e833-wk-Fact-DE53D21C5AE75E5C9034597BF3D7AAAC" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this transaction. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sold to FUJIFILM </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101498098e840-wk-Fact-3EEED51EAB3E718B7FAB8288CBBDFAD2" name="biib:InventoryrawmaterialssoldtoFUJIFILM" contextRef="I2019Q3Denmark" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the adverse commitment is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC3192FBD98785BC193BFD5144EFC5048"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-1D889E6639C65375AFDCB8FC86303457-0-wk-Fact-25F26B4037405985855F7BD422C401B7" continuedAt="TextSelection-1D889E6639C65375AFDCB8FC86303457-1" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1D889E6639C65375AFDCB8FC86303457-1" continuedAt="TextSelection-1D889E6639C65375AFDCB8FC86303457-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-0C39E7E4E5D655E5AEAE24717E6B0E0B-0-wk-Fact-E82C1AB9A0FB570BA1E9664BD3B66EAE" continuedAt="TextSelection-0C39E7E4E5D655E5AEAE24717E6B0E0B-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1343-wk-Fact-853171242B68503587FBEC4038B47293" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">842.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1362-wk-Fact-BF48983D080957E7B815FA0C3502EDB1" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">280.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1381-wk-Fact-DE3610F9879252498BCB5354554F4A19" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,122.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1401-wk-Fact-3FD9A507904A5096A01524B328058BC4" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">842.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1420-wk-Fact-09B20DB4293656E7A49617D8E5A51692" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">247.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1440-wk-Fact-9A47A99ABF9C518D854EEE334C0AACBF" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,090.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1455-wk-Fact-BF03E0D0E27A50D683F01C14953DA5DC" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">360.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1474-wk-Fact-8670B929DC3B5825A7A8F6977372C6A0" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">169.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1493-wk-Fact-880E09F7D11E5018B50A36CDA70FC1F3" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">530.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1513-wk-Fact-35A608A4A05D522AA4AD993645AC5C89" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">421.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1532-wk-Fact-4B4F7E17FB32592DA26353BFDD6F147F" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">168.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1551-wk-Fact-FB1A3358CB9D5438B04ED89CCBB61053" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">590.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1572-wk-Fact-4E38C68EBA705361B296C94BC4D0622A" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">263.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1591-wk-Fact-81845EFA29B15F8DBE92C6F78DF312AA" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1610-wk-Fact-A2DB69BE11445A48AD6560F0B7B24AA0" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">483.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1630-wk-Fact-CAACF16CA10F5AF4A6D84021D9DE462D" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">253.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1649-wk-Fact-426E1A52BF4B5A559273EFF28DB739DD" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">217.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1668-wk-Fact-EAB6C8ED01CD5C1492BFB5D2F67C839E" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">470.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1689-wk-Fact-187FEF0C8BFD55B8984A747A0DA55EB9" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1708-wk-Fact-6C7A9C768B3C582D99CCD9C6D91CC688" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1727-wk-Fact-29584C2B33B7551BB7544A63DD58E35C" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1747-wk-Fact-B1C611986C0A52ED83827AF1FC9EB313" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1766-wk-Fact-A2BD646F4AEF51CD9AB55DB5E68B9266" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1785-wk-Fact-7B5B5FF0494457E091F7A7694C59E1A4" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1806-wk-Fact-07D89EE4DCDA57DAB1C0874F24526EF8" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,465.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1825-wk-Fact-6992AC0E1F9055AE88242E66CBA624EB" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">694.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e1844-wk-Fact-D5A3B6BFBCE85F009AE119B547F30AD0" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,160.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1864-wk-Fact-5C787CD13D6552E28949D84608670793" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,516.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1883-wk-Fact-79D50D31ED295DE7BC1057EB3AC4AECD" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">656.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e1902-wk-Fact-A03F60F5FE5E5A74908718AE4203C4CC" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,172.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2168-wk-Fact-0101A37FFB15521C9E8B78CD4B283DE4" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">236.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2187-wk-Fact-97B7AE2C71565213B2ABB2D86B39A9C7" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">310.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2206-wk-Fact-8E69163ECEF656F49FB4E8DCE90D54C7" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">547.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2226-wk-Fact-81CE911D5EE555169927C917E1B90CD4" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">223.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2245-wk-Fact-59BDC4BDA2B052C79EEEB615BF72FF1B" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">243.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2264-wk-Fact-0611A1813C185C82B8BE108AFA03518F" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">467.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2529-wk-Fact-0CE237F505BF54E2918B4A0848D45484" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2548-wk-Fact-EC53E8E738ED50A7937E7F2A29F13552" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2567-wk-Fact-8F3FEFFA6A615F0EA12D47EAE96AD735" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2587-wk-Fact-00CA8CF575AC59BF8BC57FB6BE2F67CF" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2606-wk-Fact-DA1E7499B60F5D2EBB4FBA7C736ACD2A" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">123.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2625-wk-Fact-595C90A876BC54DDBDA5A34B9FB5B33B" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">123.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2646-wk-Fact-9D33FEDCCD185B2BAD82EDFB01E6AC2E" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2665-wk-Fact-056CA68F5D4E5F399D72C046C6C42658" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2684-wk-Fact-CB95F3D8829B572F900CA994795189FB" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2704-wk-Fact-0E54A9087FF85E0AB3A1F1953DAD6265" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2723-wk-Fact-C9A31662B3BF52CF9D49403F16FD995A" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2742-wk-Fact-E58A85A1D12052BB92DC8FD099184C7E" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2763-wk-Fact-2D7E70C21D81512B96E44327FBF09A5D" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2782-wk-Fact-4D6E36EC54D95EDF94F4FB08A8DAA8B9" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2801-wk-Fact-8C6F7D41B83C530BA9E925EC85F85932" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2821-wk-Fact-80F67AD0F114501797B9FC89287323A1" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2840-wk-Fact-A47955A2C5285BF38D65766E08A79083" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2859-wk-Fact-23F6ED6519555137924F15D3E995AF4C" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2880-wk-Fact-33BAEDAF2FA054F985F169557CFC4540" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2899-wk-Fact-F85E37A42298574390709C8CA5A6D4F7" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">183.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e2918-wk-Fact-3F6B7361FE9859CA88E450DF26EC5912" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">183.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2938-wk-Fact-8FD47159E3CB5EF5BB2605CCF9D4EC37" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2957-wk-Fact-2BB94E4EF8E85B18A99B70BA8422B71A" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">134.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e2976-wk-Fact-94C217E97A1C56CBAC6846AF303648B1" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">134.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e3243-wk-Fact-FA955BA425175A3085E504F9B0F79DE8" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e3262-wk-Fact-50ED3A59B4E853F3BC1801DFB2308899" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e3281-wk-Fact-BA9D024A1CB95359906FBBC4497CC6C1" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e3301-wk-Fact-788AC6E3B7B05E619C6186D3831B35FD" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e3320-wk-Fact-5F1957947E7E594881BD8C3E51E405E0" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e3339-wk-Fact-ED83FF3D46F551BEB8B3FCE7BFF08AD6" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e3365-wk-Fact-5357ACAA4D32560A86013038725C2F2E" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,702.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e3384-wk-Fact-3AC2E331ABF757469EE9C93141B67CB3" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,192.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e3403-wk-Fact-3D28795085EA575193C5CA658480CEC6" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,894.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e3423-wk-Fact-28DC9950B2AC5004A490D39C838B7D2A" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,740.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e3442-wk-Fact-41AF5FF12CF5554882698AD725EDC469" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,039.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e3462-wk-Fact-7BF8AC4CA5E1523582F8817F03BD95BF" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,780.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1D889E6639C65375AFDCB8FC86303457-2" continuedAt="TextSelection-1D889E6639C65375AFDCB8FC86303457-3"><ix:continuation id="TextSelection-0C39E7E4E5D655E5AEAE24717E6B0E0B-1"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4021-wk-Fact-B553A3FC703459E5A24F35D5BF5CAA49" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,429.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4040-wk-Fact-E95E928892A551AD9E3121E1C2890E74" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">841.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4059-wk-Fact-FA3130C4C6B8589589757B247BBF72DB" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,271.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4079-wk-Fact-11DF9D04E7325E62BD7E20AC971258F2" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,396.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4098-wk-Fact-68ECCAA634F950B3A29581EF97E1D5B8" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">766.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4118-wk-Fact-CC80D8F9D7E354E480E762CC21E2A1D5" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,163.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4133-wk-Fact-A4F5388B06AB5886A0F9E38C67736146" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,067.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4152-wk-Fact-B4F5FE0D7A4D54AFAD1EA1F49302680B" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">518.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4171-wk-Fact-2D7888FD0756554CAFB99073C65815C1" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,585.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4191-wk-Fact-661934C06E995138B72198AFAAD19A34" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,237.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4210-wk-Fact-719D7D1AE55356978E170404862E7E34" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">528.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4229-wk-Fact-E38DDE3262A55740A599A14E40B07510" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,765.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4250-wk-Fact-0212F9B4B1E75FC8961F48DD039B254A" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">772.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4269-wk-Fact-18BB70B37AA9568C9B01AF72CBDC57B8" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">647.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4288-wk-Fact-3551797135E0580FA589DF66BDD4715B" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,419.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4308-wk-Fact-8BA2A304B8C05961B0C86A7293AD02FF" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">768.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4327-wk-Fact-A26FCF387C035A6DB626AA41F4A5FAB6" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">631.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4346-wk-Fact-0FF1F9911852508B82AE4F55D4F74D78" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,399.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4367-wk-Fact-0DF0A442C0395F1FA0987AE28ED96413" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4386-wk-Fact-56AB444319265ED5928AAF1010F7540A" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4405-wk-Fact-246DFC47D1E454A0BAEB74F5F9C5DE10" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4425-wk-Fact-A84E817BAC105B07A662B42DFEAD8980" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4444-wk-Fact-F8997CC9D46C5DADBCFCEC4823ECE0BA" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4463-wk-Fact-9B39582525F65CE1924CAB87BA62070B" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4484-wk-Fact-0EB98AD7A17059D8977E10B5351C77F2" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4503-wk-Fact-134746D4AEA450C6A83018E6ABB47EC8" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4522-wk-Fact-71462306E4DE55C5BED1C2894F6D7127" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4542-wk-Fact-2DC56A94150E50038CDA73C7DD11E028" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4561-wk-Fact-AB6B97956DA65E0391373125631A655F" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4580-wk-Fact-2C903D653B0B511DACBEF29001CC49C6" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4601-wk-Fact-3453A4C80F2B5654ABAFF817C01041D1" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,269.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4620-wk-Fact-8EBFE15E72545622AC614BC706D50360" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,078.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4639-wk-Fact-E5168A2B72D355E58AB0F45E5451980A" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,347.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4659-wk-Fact-CC91069BCD7E5586ADCB4507500DFD45" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,402.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4678-wk-Fact-4AD1B5E71AD2596790DA76B503CF4704" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,997.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e4697-wk-Fact-CEB1BE2C4A9350FDA49CFE276C89704C" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,400.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4965-wk-Fact-AA1B3FE9613C5B319DE9AB65E65DAE5C" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">690.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e4984-wk-Fact-97C82ECD8F6453FAAF26E05C9FAC5D1A" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">863.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5003-wk-Fact-6CC16ABD0EEC5534B3D60F91A67DDFEE" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,553.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5023-wk-Fact-F72905555DC95202AC8A1FCD2C79F1E8" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">617.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5042-wk-Fact-78B06C4372605EF5BCEA09FBEEE1ACEA" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">636.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5061-wk-Fact-465AC814628E5CE08850F1D292A9F218" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,254.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5328-wk-Fact-50E19D7B3512570BB1E29520D4FBB83B" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5347-wk-Fact-B1D6B521158556A7AC58AD812ACAFEA5" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">360.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5366-wk-Fact-835AA356DEE75B06AF473218B6A99048" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">360.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5386-wk-Fact-41CB512F9285526A85016E92B572E256" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5405-wk-Fact-F99DB67CE5725D11992E9601AAB34B72" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">359.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5424-wk-Fact-88A446DABF1F58598AFCFA4AC4FF8085" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">359.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5445-wk-Fact-D03854B2554B5353B5B21EC490E31A8F" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5464-wk-Fact-B2EFB8511CB55386AFAD774D4A5399CB" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5483-wk-Fact-4694504C07325C468F7852A281286908" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5503-wk-Fact-49B07F27CD3C5821ACFA485D4C54080F" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5522-wk-Fact-5DE31F6F7FA25DDAB024C120716C9A11" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5541-wk-Fact-CFAD58E1F67A5A3592C93317B2AD5F69" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5562-wk-Fact-D3A2A398C8E7563F8BF445400A93C468" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5581-wk-Fact-B36F406FCA245730A6117847243FF9FB" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5600-wk-Fact-BEDAD413668D548AB54B1CE1DA568C89" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5620-wk-Fact-9E8DC5EC9840596D937DB57FB3E3DC68" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5639-wk-Fact-F2D586815CD053FABA749129356D0D60" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5658-wk-Fact-F34A0D2B65625EBA8783DFFD157024C9" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5679-wk-Fact-56878A03F07C596EA6C0EA1FAEF7AF8D" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5698-wk-Fact-808E2815B0695918A73007D37B89E59F" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">542.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e5717-wk-Fact-A48BBC17448459BD9EC5EAB74ED619BC" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">542.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5737-wk-Fact-1C5FFC9ECF4C535BB58980C978E1360B" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5756-wk-Fact-D9BEDEBA8FAE53E28199D01D3298D1D1" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">389.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e5775-wk-Fact-3A50E721E3C85267B68DBF18A1B25BDE" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">389.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6042-wk-Fact-B2618FD00F0B59A49DA7478020C06FB1" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6061-wk-Fact-A83516875A7B5AD08C6A9E2B1728B653" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6080-wk-Fact-6DA687371D4250279E8D4249780A9A59" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6100-wk-Fact-39294C6285D2595A986D6DFFE01D428D" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6119-wk-Fact-DD14899F2B585BFEBC0CDBFCF21E47B9" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6138-wk-Fact-011A83522E595928B70A8568EEE9FC68" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6165-wk-Fact-8C9DFEAEB155584281323FE51C59B585" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,959.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6184-wk-Fact-A031E24CFBC251D5A964C7CF420EDB20" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,495.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6203-wk-Fact-57FC3BF8DA6B53A78893FAD196CDD478" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,455.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6223-wk-Fact-8B685FDF878C52FBA0A1B327E625E928" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,020.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6242-wk-Fact-DB7A56B25B415E7BA00F3080A9400CCF" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,040.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6262-wk-Fact-E8E82058EC25562986B774B17A9D2FFE" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,061.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6278-wk-Fact-C61E43EB22CC5943ADC94704262F5FFB" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">28.7</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6282-wk-Fact-FD851A6E1E675851BFD061D688D340D8" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">18.4</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6294-wk-Fact-A72A49F9C1005FC59E5E1295A678F4DD" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">30.1</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6299-wk-Fact-4BF9A29C97E45C4EB52B9E7A010F1891" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">17.0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6314-wk-Fact-2652D87D583B5E548D209D8F99E75D20" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">30.7</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6318-wk-Fact-868F694D43DB5A988013194B20313923" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">19.3</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6330-wk-Fact-06567C00AE255BAF86D6DCAC34F5EF4A" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">32.4</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e6335-wk-Fact-DD0DA463314655248D36CB9003A7AE65" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">18.0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="TextSelection-6D9FD895E40E5D2C94B9B6756245BD90-0-wk-Fact-9BBAE3A3EA305CCDB7EF737D1A8A2636" escape="true"><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6482-wk-Fact-8D4A18B543235294BD95119660D23729" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6501-wk-Fact-EDED2745A4E55EF88ABC9D738954C822" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">888.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6520-wk-Fact-029B0A3DBE4351C4ACC6AA3EC03E58D4" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6540-wk-Fact-438A685C2FAD56AF9134724F56676CAC" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,051.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6555-wk-Fact-D5A32FAF0B0F587A940CD749BFC7B11D" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">480.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6574-wk-Fact-3A58C432C96F51F8B5AFDCB90641EA1D" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,149.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6593-wk-Fact-599529A53E5B57C7904E672FE276F06A" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6613-wk-Fact-68A9F33ED61754EEAD6F51D9CAD27A81" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,646.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6633-wk-Fact-D6AC319FC4175583ACA854647F19BCAE" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6653-wk-Fact-5C9D6D9F7EC25CB0ACEC1BEBB526496D" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6673-wk-Fact-C5570CD9005B559F9328489D66904433" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6693-wk-Fact-511DED385AAB5DC1BA0B086A008ACD42" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6714-wk-Fact-0ECDB2CB36AB52D98C76B44E430334AB" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">349.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6734-wk-Fact-9955D42345DD5AF78DC234D819501CCE" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,510.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6754-wk-Fact-5EFCEC7C44475C458F1694C6E433DC06" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6775-wk-Fact-337839161C2752FDACAA22D365758851" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,860.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6796-wk-Fact-92FEB920585455FCB7B5B84F3A85C890" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">129.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6816-wk-Fact-C7802013E8A95037B07A33A42B405B03" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">564.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6836-wk-Fact-BE477A46C7D55A3882BB32A4D0C85BA4" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e6857-wk-Fact-8DE18F084E4B5E8AA7C941A25FC427AC" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">709.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6883-wk-Fact-D28096BFED1753678E7D854A5FDC5CDD" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">129.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6902-wk-Fact-DE36DF9E94245B0D99932D86DDCFF1CA" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">917.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6921-wk-Fact-3AB2BBF12A55566FBAAB43073F619CBC" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e6941-wk-Fact-B910D1665CA455B7826068B86CE5F1A6" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,085.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1D889E6639C65375AFDCB8FC86303457-3" continuedAt="TextSelection-1D889E6639C65375AFDCB8FC86303457-4"><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="TextSelection-40B0449CC8A25BE49CAEC3A1C439FADB-0-wk-Fact-7AB0C86C6F9F57228C8150EB72D4BEA7" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7041-wk-Fact-8752645395D15ECEB06340FAF0BA0811" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">201.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e7060-wk-Fact-676D5EB10A3F5B0C969A0EFE9CC2CA18" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">176.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7075-wk-Fact-93E9038349A6549E86E73F0F4F359577" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">884.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e7094-wk-Fact-9790B7529BB852F99BAA6B9B78CB9C5C" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">874.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7119-wk-Fact-B910D1665CA455B7826068B86CE5F1A6" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,085.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e7138-wk-Fact-438A685C2FAD56AF9134724F56676CAC" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,051.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="TextSelection-C2934E945E3A50979753BC5105F7D6E5-0-wk-Fact-A5FB1B58ABDA517AAE72671DB6126372" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7360-wk-Fact-B4B86F47BDF1540AB016AE4FFA426E0A" name="biib:ShareOfCoPromotionProfits" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">393.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e7379-wk-Fact-EDD7FC64D769594BA686F2A1D2A5BC7D" name="biib:ShareOfCoPromotionProfits" contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">358.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7398-wk-Fact-71D19606B9155009BAAC8D2DA407F049" name="biib:ShareOfCoPromotionProfits" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,161.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e7418-wk-Fact-44A04E0F4FAF560DA2E675535E59D67D" name="biib:ShareOfCoPromotionProfits" contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,066.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7433-wk-Fact-F98145FEFE9B5AD89288DD63F6ABC6A9" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">202.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e7452-wk-Fact-28E199D3F30F5C6AB7581C161C93DEB0" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">153.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7471-wk-Fact-9B02CF57AFEB544E8C24E64802C076F4" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">528.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e7491-wk-Fact-6FA55D7DE16C528C88E45FD0B02237E5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">378.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7516-wk-Fact-8935D8BBEFCE5ED286B0DE4994D83C3D" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">595.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e7535-wk-Fact-084A8A14D1EB5CEC8E6948EA789D8A2A" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">511.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7554-wk-Fact-6C7B08DD49815A12A560CB733CA3B725" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,689.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e7574-wk-Fact-7BBDC0B573795D11894123AF71626259" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,445.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:OtherrevenuesTableTextBlock" id="TextSelection-496DF7A53C2B54F988A7CFE4E1A75B06-0-wk-Fact-91BC6C27CD6F544DB8797FD1409B1D45" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7885-wk-Fact-73A4D8F8BB8B5419A251C4694C2C38D6" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101529877e7904-wk-Fact-8F32597DF04C547A903997CAFDC3B829" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529877e7924-wk-Fact-BBAE89907F4A57E99B103B09253D17C0" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101529877e7945-wk-Fact-15BD9EAD2231570AB80EDD696AA88F4B" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7961-wk-Fact-007F8062360750B4935397733B1696A8" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e7980-wk-Fact-4FCBEA0BFDC85739AE7ACF6AA208D890" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e7999-wk-Fact-80570CCC93D455EE94682B88CBB2F344" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">89.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e8019-wk-Fact-100A1E9EF88E5AA082807EF6F1A109DD" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e8117-wk-Fact-902C56E9060E5FF9B0298198E8BD161E" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e8136-wk-Fact-02C92B55FBD059ACA7C3A3D7DC814983" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e8155-wk-Fact-13A197A7967D5F38BD3AE9BD4C8988F3" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e8175-wk-Fact-BE4BDBFB8A6F56EC92BF1261A9588E58" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e8195-wk-Fact-5761E083740451DFA00F565506F541EB" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">93.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e8214-wk-Fact-A1F23E4D29295EEB9B33E35F41B956B0" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e8233-wk-Fact-C3D691516939506A9B60FB15A3D7959F" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">462.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e8253-wk-Fact-50B60A0646AB5295ADE07664B861E04C" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">311.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e8278-wk-Fact-DC33E683DC765E5C9A12FB403038A719" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e8297-wk-Fact-F66F19EADE265DC9B1853BA2CA1992B0" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">147.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529877e8316-wk-Fact-CEE81A8C61A050788B24277BCB2F809B" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">562.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529877e8336-wk-Fact-0D413906F9E25B0A81CBE77DAF4D3714" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">420.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529877e8359-wk-Fact-52263C8BD9895E598763262AE9975163" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529877e8363-wk-Fact-EC8CFCC051075D0F8B49D175A4A2ED66" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">306.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529877e8367-wk-Fact-2DAC540F7A8A5D51A0DF2A8E391221A2" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529877e8372-wk-Fact-22B9E97BBE415CEE9D40B4847DDBCC65" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we will license certain of our manufacturing-related intellectual property to the customer. We will be eligible to receive </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529877e8379-wk-Fact-C9BE1C77D49835DAF003DF339247BCEA" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q3_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in a series of three payments. The first payment is due upon a regulatory achievement related to the customer&#8217;s product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We do not expect to recognize any amounts related to this arrangement in 2019 as we do not expect the regulatory achievement to occur until 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1D889E6639C65375AFDCB8FC86303457-4"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc., please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our manufacturing and supply agreement with Bioverativ, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div></ix:continuation><div><a id="sB379585BDEA15680AC86A29710672F54"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-623999EF47D450E591423751D554AA69-0-wk-Fact-3DF50D1EEF745415B4F7F35D3365F241" continuedAt="TextSelection-623999EF47D450E591423751D554AA69-1" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="TextSelection-623999EF47D450E591423751D554AA69-1"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-0C84CFE8C2BC54769812B88A1DD7724E-0-wk-Fact-9ED1C63A94995A96AF58119B533C18ED" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101504379e867-wk-Fact-1F5F40200E28588AA2FCBF16AC106042" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101504379e886-wk-Fact-D5D7FB84C2DD5CD591483031F4A11D0F" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">196.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101504379e901-wk-Fact-35866DFD4C3A58BBA658F07CF65E277E" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">421.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101504379e920-wk-Fact-12A69F1BE8CB5F7CB0D00610855F4030" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">606.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101504379e940-wk-Fact-86A82363F3B15C8C87E4DA100ECCC6F8" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">170.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101504379e959-wk-Fact-0BB452B01D7458349EC77AE3AA9B44DB" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101504379e984-wk-Fact-AC403B171A93561E852D40EE4C010A90" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">751.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101504379e1003-wk-Fact-492BA6EC4EA2580DB1B88690013645EE" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101504379e1105-wk-Fact-C0E7BED0E0A95BE78B67788E90DC38BE" name="us-gaap:InventoryNet" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">751.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101504379e1124-wk-Fact-E643FBEA510257AD9C0E842D75167864" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">929.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101504379e1139-wk-Fact-6B9FE764C5B25D7D9B1CA277A8CF3439" name="us-gaap:InventoryNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101504379e1158-wk-Fact-9A61F72C18CA56468209180BD8960C2D" name="us-gaap:InventoryNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101504379e1183-wk-Fact-AC403B171A93561E852D40EE4C010A90" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">751.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101504379e1202-wk-Fact-492BA6EC4EA2580DB1B88690013645EE" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019 we sold to Bioverativ hemophilia-related inventory on hand with a cost basis totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101504379e1222-wk-Fact-B43F604DFFF959C9ADFCC6E4B90A5E2B" name="biib:InventorysoldtoBioverativcost" contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_BioverativMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">173.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included the sale of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101504379e1235-wk-Fact-71E6A8218C76AB21E5A282AEE231F33B" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" contextRef="FI2019Q3_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of work in process inventory. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sold to FUJIFILM approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101504379e1242-wk-Fact-3EEED51EAB3E718B7FAB8288CBBDFAD2" name="biib:InventoryrawmaterialssoldtoFUJIFILM" contextRef="I2019Q3Denmark" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB969C23ABB535A268402FFA96EC19FD9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="TextSelection-D285D6F439165C71B9A95EB0F1AD89E4-0-wk-Fact-3D25F74F802F5CB197D20A41C7F45592" continuedAt="TextSelection-D285D6F439165C71B9A95EB0F1AD89E4-1" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="TextSelection-D285D6F439165C71B9A95EB0F1AD89E4-1" continuedAt="TextSelection-D285D6F439165C71B9A95EB0F1AD89E4-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="TextSelection-8F5D00B0DD6752E9BBD9724D5D8A05EB-0-wk-Fact-721A2063F127558ABD5746DCE1C18A69" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1132-wk-Fact-34345BAAE3115AEFBD33E989806C8EE0" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">543.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101509770e1151-wk-Fact-E47033DE082D578A869F15434BAA01E4" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">542.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1172-wk-Fact-7ED35D4B8C175C10A598208C77593113" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1191-wk-Fact-B3C0D4C2DBA855D7AC418C025A415CF4" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">543.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101509770e1210-wk-Fact-5B6B545C01B2533E9FC4914C94AB56A3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">542.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1231-wk-Fact-88689549E0475DDDA3B29927AE9305F6" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-28&#160;years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1259-wk-Fact-CF403ACEFF5B5F90A14ED63BBFA30A0A" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,005.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101509770e1278-wk-Fact-E62931DB55D2512DACDD1A592E7CEAD3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,764.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1299-wk-Fact-A047482676DF5F0885AFF6785B25D5F6" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">240.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1318-wk-Fact-E84C18AEE1B350EBAE45D714F926E713" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,005.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101509770e1337-wk-Fact-5321822A791F5C458657C6E29BFB4E9A" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,734.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1358-wk-Fact-45EFDF2ACC4B585EA7E906A0B8140958" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">270.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1388-wk-Fact-C00C75D2A9EC576280710969F59C97CD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">954.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1407-wk-Fact-79400DF27C6D5E768E0BC72A49CFDE06" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1427-wk-Fact-C00C75D2A9EC576280710969F59C97CD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">954.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1446-wk-Fact-70D53D4D0D4158028DD6435D9E451955" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1465-wk-Fact-EDA7ED89003556FDAED2B3FB2E32A0BB" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1485-wk-Fact-70D53D4D0D4158028DD6435D9E451955" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1518-wk-Fact-A37B20A528545064A2C56C8C78A8B929" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1537-wk-Fact-2A67A63BA5B15EAEA9B62E6C128828A7" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1557-wk-Fact-A37B20A528545064A2C56C8C78A8B929" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1576-wk-Fact-2660F7F3F13B5DB3BC1821AB45972688" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1595-wk-Fact-EB5BDBDB34415C1D90C25BDF572FC84A" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1615-wk-Fact-2660F7F3F13B5DB3BC1821AB45972688" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1648-wk-Fact-3AC7A49E8F3652C3854ACBF43BCA3F64" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,638.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101509770e1667-wk-Fact-2FAD57D35C275CE196141D33DBE2EBF9" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,506.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1688-wk-Fact-3372F6D1C1D757F882AA7FA40E3B7915" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,132.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1707-wk-Fact-0B08C52A28C757FC91BBE8FC25DDC0DE" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,638.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101509770e1726-wk-Fact-D783F3AE93AC5F30AE9BEA661781DE14" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,330.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1747-wk-Fact-27E8065BE85B54D0AA05EBE5C57CE1E2" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,308.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1782-wk-Fact-86BFE9DEC2FD567DBD41C889E2F6A3A4" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,206.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101509770e1801-wk-Fact-68F9B30CBAD8531B80D5079B3F7B28E1" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,813.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e1822-wk-Fact-590BC6AA99A359AE8B2D093C3E37149E" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,392.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1841-wk-Fact-9A5FEA9159CC523DB093094C791DD61C" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,727.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101509770e1860-wk-Fact-941A451F11BF5A408C2463F31C6FE6BC" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,607.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e1881-wk-Fact-6AEEA34F46DE51CAAAEFDC70DF10D84D" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,120.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairment of acquired intangible assets totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1909-wk-Fact-E16816F8C6345C9F843A76FE6FE7E93D" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">283.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1913-wk-Fact-12AB224A4EA35DA89408132E43CA5AB9" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">422.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1917-wk-Fact-60CBEC0AE94254A1A0FFF49B4C048842" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">281.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1922-wk-Fact-2168DD63A96A5DB78AB338B8966E624C" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">493.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the impact of a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1937-wk-Fact-BE0FDD374E38CC01BE4282BA5D0AF2FB" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge related to certain IPR&amp;D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis (IPF), which was discontinued during the third quarter of 2019, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the impact of impairment charges related to certain IPR&amp;D assets associated with our vixotrigine (BIIB074) program totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1952-wk-Fact-BED16A34D5A51FF910EA82BBE98C2A83" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">189.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as discussed below. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets, excluding impairment charges, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1959-wk-Fact-24F9C1D18A3A8A3A5DFC82C55F10FF06" name="biib:Amortizationofintangibleassetsexcludingimpairment" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1963-wk-Fact-995DC045F2BD4C4CE54382C590E37421" name="biib:Amortizationofintangibleassetsexcludingimpairment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">206.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1975-wk-Fact-34C9D09C72A336F5AA8182C5AE865C96" name="biib:Amortizationofintangibleassetsexcludingimpairment" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">92.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1980-wk-Fact-6471DB02EE1E45D9116C82C5CE658BCF" name="biib:Amortizationofintangibleassetsexcludingimpairment" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">303.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in amortization of acquired intangible assets, excluding impairment charges, was primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This decrease was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e1997-wk-Fact-DF84549E9D115BEDA8E7149F9B9B47EA" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q3_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">236.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D285D6F439165C71B9A95EB0F1AD89E4-2" continuedAt="TextSelection-D285D6F439165C71B9A95EB0F1AD89E4-3"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of NST on June 7, 2019, we acquired IPR&amp;D programs with an estimated fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e2011-wk-Fact-CBAA3B57AABA5FB385FF1A913131541A" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">700.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">BG00011</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns. As a result, we recognized an impairment charge of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e2025-wk-Fact-ABF5F11B8F71C4915AAB8311A08B86FD" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2019 to reduce the fair value of the IPR&amp;D intangible asset to zero. We also adjusted the value of our contingent consideration obligations related to this asset resulting in a gain of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e2029-wk-Fact-CD260BBA95FEDA7074308312D1B57B40" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in the third quarter of&#160;2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed the Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR. As a result, we recognized an impairment charge of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e2039-wk-Fact-2CAF8EF3164FD6B13822830DE3EC208C" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_PLSRMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the IPR&amp;D intangible asset to zero.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of trigeminal neuralgia (TGN) as we awaited the outcome of ongoing interactions with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy. We reassessed the fair value of the TGN program using reduced expected lifetime revenues, higher expected clinical development costs and a lower cumulative probability of success. As a result of that assessment, we recognized an impairment charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e2046-wk-Fact-0F2C8AA166B800DAA2E7830BBDE95A22" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">129.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the TGN IPR&amp;D intangible asset to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e2050-wk-Fact-A7BE37048EAD8ADCE2CB830F8E51DE86" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q3_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> at that date. We also adjusted the value of our contingent consideration obligations related to the TGN program to reflect the lower cumulative probabilities of success resulting in a gain of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e2054-wk-Fact-33A49BF626AF9F65ED7F8310CEB6C4FB" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">89.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in the third quarter of&#160;2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The IPR&amp;D impairment charges were included in amortization of acquired intangible assets and the gain resulting from the remeasurement of our contingent consideration obligation was recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. The fair values of the intangible assets and contingent consideration obligations were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. Acquired and in-licensed rights and patents also includes our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e2071-wk-Fact-737447E23DE35D9CB5A2A23A3D6BD273" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q3_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,889.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and the net book value of the TECFIDERA asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101509770e2079-wk-Fact-9F1626303250523A87F911EB4D30BAA9" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q3_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our TECFIDERA license rights, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D285D6F439165C71B9A95EB0F1AD89E4-3" continuedAt="TextSelection-D285D6F439165C71B9A95EB0F1AD89E4-4"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the second quarter of 2019. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="TextSelection-0DEF8259EDC95B4388AA4B7272E84D34-0-wk-Fact-0BB1C85167FD5689B823BC1412E5783C" continuedAt="TextSelection-0DEF8259EDC95B4388AA4B7272E84D34-1" escape="true">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0DEF8259EDC95B4388AA4B7272E84D34-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining three months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e2163-wk-Fact-F838795EC2F55A5ABD634299933E520E" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e2178-wk-Fact-7E039C0248C954A1AD1FE4CEAEDDF1E2" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">255.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e2198-wk-Fact-1A0B461ACE5C509DBEEB5742F460243A" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e2218-wk-Fact-B500BBA2CEC05A39B86AC65C34BEEDA3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e2238-wk-Fact-4F35FEDB118653F088657A02C9F98D69" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e2258-wk-Fact-6542DE796FDA5EEB894E090EA61EE687" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfGoodwillTextBlock" id="TextSelection-FEFA0A947428572E948541577A5E27BF-0-wk-Fact-300288AF5EE75DD4A61E2FE7D09F8F8F" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e2341-wk-Fact-EDAA6B48B7F75DCC9A54B3A7C0BDDC58" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,706.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase in goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e2356-wk-Fact-0342C28B22565AFCAD29B8AA8EFFE33F" name="us-gaap:GoodwillPeriodIncreaseDecrease" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101509770e2376-wk-Fact-2877ED6BF5BA52ADA1C854238A2EF7D7" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101509770e2397-wk-Fact-8FB55A2EBA335132AE57AC9C39E8EAF3" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101509770e2423-wk-Fact-0C60CAE51C8B53A7ABC528A464C8294A" name="us-gaap:Goodwill" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,746.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was related to our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative fair value of our Hiller&#248;d, Denmark manufacturing operations. In connection with the divestiture of our Hiller&#248;d, Denmark manufacturing operations, our remaining goodwill was reviewed for impairment, and based upon this review, no impairments were recognized. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101509770e2468-wk-Fact-0B1C6011A8E75CD4A379688DA1894E9C" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="FI2019Q3" unitRef="usd" decimals="-6" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-D285D6F439165C71B9A95EB0F1AD89E4-4">Other includes changes related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3C3D93B74D625440A1512A2DEE2F4752"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-311A31172B1E59319F1A430BD739E453-0-wk-Fact-446811FD9E6E50FA9744696C7D0AFF3C" continuedAt="TextSelection-311A31172B1E59319F1A430BD739E453-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-311A31172B1E59319F1A430BD739E453-1" continuedAt="TextSelection-311A31172B1E59319F1A430BD739E453-2"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-50E3108E60C35EC2B3EA2D92A00EF310-0-wk-Fact-98DBA7AEB5F25D63B7581CB36DC48AF4" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1023-wk-Fact-DBBE4E93BCA454FCBCAC870742EC86B9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,655.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1042-wk-Fact-74F8055A56DB550CA018CC5A300B04E1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1061-wk-Fact-8F58B86DB67F5BA2AD19D400BB2428A5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,655.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1081-wk-Fact-9C5FA5B9515051568CAE51DB75ED065C" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1178-wk-Fact-37BA958C3A1A55C5B52BE2519580DA77" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,702.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1197-wk-Fact-6BF8FA6C1FEA506BA6E65E4FBAF4D39C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1216-wk-Fact-299AB0CDF2AB591FB668155A44CE050C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,702.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1236-wk-Fact-55CBD3E7A2C053C7B91542A20984ADE4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1256-wk-Fact-12F116E9849C51199D1053D6A519041A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">868.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1275-wk-Fact-8C86CA739B1650189B5D778C21008EDC" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1294-wk-Fact-0922B4A905045DED84ACAB9239E7AC45" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">868.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1314-wk-Fact-D5F544CFE10E509A89F9D64642AB3BC4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1334-wk-Fact-AEA539E7A981552BA67FCD05DF9B4DBA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">337.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1353-wk-Fact-18590AC5A9F25A1FA8490B1347FA5D6E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1372-wk-Fact-07D8093C7445566D8CA54A324193D727" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">337.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1392-wk-Fact-9E27CFD0125C5A8B9815C9EAE21E044A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1412-wk-Fact-9856266B2CE75C50BF9BA6A49E88F2C1" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">336.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1431-wk-Fact-600DE8986DE853FC998CC85556FFF36E" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1450-wk-Fact-8CA6C007F7995ACCA5FFFB7C5D3ACE26" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">318.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1470-wk-Fact-4C45A1A337D4592288EDFD9C6BF01BA5" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1490-wk-Fact-CA0CB4451A205380814AF4FB71CE2431" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">161.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1509-wk-Fact-9B3D80EE7D7C5CFE84A39B8C4B6AB292" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1528-wk-Fact-FA086FB1219C5B7D902C5902A9B515C5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">161.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1548-wk-Fact-2E5C4BE87B1858A8AC73B7625B6C1E70" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1568-wk-Fact-C14C795E15EE533493C93A9CBA5A9110" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1587-wk-Fact-CDFECED3CA5953A487286F960D355C65" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1606-wk-Fact-57987BA27D8B575AB76B9A421481DDE2" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1626-wk-Fact-9017C465A07E505581FB0E07E2B3CEE0" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1651-wk-Fact-A5FFED0F3DA259058C00ACD05AA9EB5B" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,087.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1670-wk-Fact-1D60B96D816951ADA3729685825F8DBF" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1689-wk-Fact-6BC2141F5D765DD7B817E96CDB4CB75C" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,069.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1709-wk-Fact-B08B960D4E6058F58A1E09E210E9F00D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1812-wk-Fact-3865A3EA76045585B165E3B6BF5C517E" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1831-wk-Fact-95E011E445FA5366BDA634E92E96BF72" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1850-wk-Fact-F00D79AEF6815A1B8B780DF07864EC79" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1870-wk-Fact-20D88B36892C5150BA3D4A8A60F12DBD" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1885-wk-Fact-942AC04AC4AD5FF38BE8576E01D16EEF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">343.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1904-wk-Fact-FDA9FBDAA6515D7ABDAFF8FABEA4D751" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1923-wk-Fact-CEF872470A51551EBF0F6F0929F9BF5E" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1943-wk-Fact-37FC4361FDDC5848BF30192CBC417437" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">343.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1968-wk-Fact-C80F845E1D6A5B0EA9922EEE9C7023A4" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">353.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e1987-wk-Fact-917C89A7510455BB9A89FB919EFC7018" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e2006-wk-Fact-A9A85DAE5397598EAB450231BFFAB1A5" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e2026-wk-Fact-FFCE72358282515BB669EFA035DDBC77" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">343.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2261-wk-Fact-D0EC4D7C9BA052EA8BD20E6237672B60" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2280-wk-Fact-A6A1FB3CF6AC52FC9B273542D05F882D" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2299-wk-Fact-77680C2B0319538389814918A713909C" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2319-wk-Fact-F929ECFC3BB1528E96E3A447A4542982" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2416-wk-Fact-D3C5EA7A8BEB565A87795FB40E38E3B7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,459.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2435-wk-Fact-1212F702D9AD55829D1037B6F55BDF30" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2454-wk-Fact-0645F79E4F5359C19FA5BC3C18332909" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,459.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2474-wk-Fact-AF92AB4F37275569ACF9AA50DFAF013F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2494-wk-Fact-6A3935AA5789595B8CF2AE7AB558AC1F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">969.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2513-wk-Fact-5910CC94117B5F7197B0448C42D1DF1A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2532-wk-Fact-580CCFCA9DF2588F99842EFBB46F2915" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">969.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2552-wk-Fact-427BE0FC82675D81B515F031C1FFE301" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2572-wk-Fact-BEB2815C0C735A408F4306BF6BF06271" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2591-wk-Fact-15681AB034E1532E8904176B6A659B6E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2610-wk-Fact-834D4A1E68805CA39723F64836475EFA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2630-wk-Fact-1C45646B225951238DD72261EC9FE864" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2650-wk-Fact-C4FF02F86F0A5A1E88F4652456B388FE" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">615.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2669-wk-Fact-2BA37CEF10AF5D2898235B27F769E7C1" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2688-wk-Fact-B8CAF92D58E757688A630CCFBD754ADA" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">563.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2708-wk-Fact-F7E995ED2BD958EC81E48C98ED2CFCE7" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2728-wk-Fact-FECF91BD0C4A53A7A47B43DA7F420258" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2747-wk-Fact-8F791E6C4C8956AD955F9622333E0211" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2766-wk-Fact-90E3470516FD5A90BD54FEF6F8BBA1FE" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2786-wk-Fact-61C6AB5FFB5A55019968313681096F9C" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2806-wk-Fact-CC2DABE24603568FBDE8F0EF5AF1EB39" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2825-wk-Fact-D2E37CBDD40358A1AB0321A65EB20768" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2844-wk-Fact-B461F24B46975BFAB2955EDEF501F701" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2864-wk-Fact-8142E95E46EF516DA2B218B4BCF43B49" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2889-wk-Fact-3E85CBEEC48258A187A1CF19361C328A" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,102.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2908-wk-Fact-6BEDCE1103C85F2BBC0622CED20418D3" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2927-wk-Fact-C2F97441AFCB52B8833E931766DC1841" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,050.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e2947-wk-Fact-002F20AC971A54F79C5D0DB6AEF72CA3" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3050-wk-Fact-914B9564037556189F63F0C349D15F9C" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3069-wk-Fact-4B18FDA7C31552FBBE30175354697E5F" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3088-wk-Fact-5138C2E5A54D5CABA2D75437104E71AC" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3108-wk-Fact-697D13C8EBF659BDAFF92E5ED0FF77CF" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3123-wk-Fact-19CD2F1140065DE4B03B9E30209A19F8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3142-wk-Fact-C9CDFD02032F5C0483303E7438578B7B" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3161-wk-Fact-72DA51BB1BC754F2BB4C5DC89EB6AC3D" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3181-wk-Fact-256CAF67851B5F82853679AE948CB003" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3206-wk-Fact-BA070C65C5B8554EB85EC11D33433029" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">434.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3225-wk-Fact-218D4C3690E15895B86E0C0E7FF9F6EC" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3244-wk-Fact-AD05EAB238475AB6ABCC0ECA51E7A1E7" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3264-wk-Fact-B3F5D3BB2A135B05998C80E4396C4B71" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3284-wk-Fact-83CA23BEB0955D07BFF9858757F513EF" name="us-gaap:AssetImpairmentCharges" contextRef="FD2019Q3YTD" unitRef="usd" decimals="INF" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairments of our assets measured and carried at fair value during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3296-wk-Fact-60A34C303BC25130AD2419C9164D8BA0" name="us-gaap:ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" contextRef="FD2019Q3YTD" unitRef="usd" decimals="INF" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our June 2018 investment in Ionis common stock, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. For a description of our validation procedures related to prices provided by third-party pricing </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-311A31172B1E59319F1A430BD739E453-2"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">services and our option pricing valuation model, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="TextSelection-DD58FF436B4C5B2B879A13E59C008B28-0-wk-Fact-EBEAAAFF7B085EE4AEF66EBE4D14AFBC" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e3559-wk-Fact-FE042043F2EB5BA5A8DF64A243EC01BD" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,509.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e3578-wk-Fact-9E5EF7A2EE53513589D4317EBA61E1FB" name="us-gaap:NotesPayable" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,495.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3597-wk-Fact-EB913F799A9452219F75231D638BFEAC" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,489.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3617-wk-Fact-AF77AF747CDC5A4B9E6F029BD42B1D43" name="us-gaap:NotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,480.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e3632-wk-Fact-5C5F5B2D22125316B1F96FFC6AA56268" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,037.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e3651-wk-Fact-1C932B61350D5A9DB8E5D3DFCE6C47F9" name="us-gaap:NotesPayable" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">996.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3670-wk-Fact-5D8E162026845C2A911B8ED611E14538" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3690-wk-Fact-94939F3C450A5FECA6DC38B806231265" name="us-gaap:NotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">995.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e3710-wk-Fact-891E451BC9A35236A6760582E16CAADC" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,888.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e3729-wk-Fact-CF5D3F26B95F5F31BE6727CF246E37E7" name="us-gaap:NotesPayable" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,739.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3748-wk-Fact-9E117B65C6EE5B8D8483601E840562C0" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,745.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3768-wk-Fact-1C4E692B04C551FA8EEB2198DE99A7E2" name="us-gaap:NotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,737.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e3788-wk-Fact-196BFA741EB95C82A352A553A363F4A4" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,054.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e3807-wk-Fact-2B0C2AE4545E54BC9497A8D1BFDA9843" name="us-gaap:NotesPayable" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,722.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3826-wk-Fact-E0301F2E6A9E5D6DA34D9B9FC1532833" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,802.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3846-wk-Fact-9D4080C23227599BA211C36F77B5A6B0" name="us-gaap:NotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,722.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e3871-wk-Fact-79688E783E635DC4809926AB442EB9A6" name="us-gaap:DebtInstrumentFairValue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,490.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e3890-wk-Fact-6B2575A08581557881448D7AEFACAFDF" name="us-gaap:NotesPayable" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,953.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3909-wk-Fact-1D995634AADB5EDF87C6C18D7C2C327D" name="us-gaap:DebtInstrumentFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,037.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e3929-wk-Fact-C18FD1BC4BCD5A20ADC5B4E281CBD5C5" name="us-gaap:NotesPayable" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd., Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-90DFE05EA3825D6984B8F7216F6C4A06-0-wk-Fact-F5B02941F00258D5AD8B3076EC909F2C" continuedAt="TextSelection-90DFE05EA3825D6984B8F7216F6C4A06-1" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-90DFE05EA3825D6984B8F7216F6C4A06-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e4174-wk-Fact-792737EACD5855D8A3905684809D47E7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">401.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e4193-wk-Fact-1D46153B21B85ED785B165AF66531CF3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">499.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e4212-wk-Fact-19CD2F1140065DE4B03B9E30209A19F8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e4232-wk-Fact-BE5680DF9AC05C2C844CAD2283FCBA95" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">523.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101518089e4247-wk-Fact-6A3D37E1187254C09B6AC4C5616FF447" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101518089e4267-wk-Fact-039C01D7065755E1B84538DFB48BABF7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101518089e4287-wk-Fact-71EA0E01C5515EB8915D8014F3984813" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101518089e4308-wk-Fact-38997DD058735F02BF9DD1F00498AD0C" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e4329-wk-Fact-EC24C61899E55170BD6CF5397A823C15" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e4348-wk-Fact-9775B9C59FCB5743A802C11DF4DD337C" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e4367-wk-Fact-D65713B9018855EB94DEC4568CB49384" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101518089e4387-wk-Fact-4F8001E784375A628E0B3B9E46AA1ED7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e4413-wk-Fact-942AC04AC4AD5FF38BE8576E01D16EEF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">343.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e4432-wk-Fact-AE51B9D3B1C656F485FC4846BEFC8F97" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">412.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101518089e4451-wk-Fact-942AC04AC4AD5FF38BE8576E01D16EEF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">343.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101518089e4471-wk-Fact-AE51B9D3B1C656F485FC4846BEFC8F97" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">412.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518089e4499-wk-Fact-0C4BF3A9126257ACB739E3D975A76B81" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">196.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518089e4503-wk-Fact-FDFF614CA41F5767B9AA14B62D806A98" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">265.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF resulting in a reduction of our contingent consideration obligations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518089e4518-wk-Fact-CD260BBA95FEDA7074308312D1B57B40" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to lower cumulative probabilities of success related to our vixotrigine program for the potential treatment of TGN, an increase in interest rates used to revalue our contingent consideration liabilities and the passage of time. In addition, we dosed our first patient in the Phase 2b study of BG00011 for the potential treatment of IPF in September 2018 and paid an </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518089e4533-wk-Fact-DE392063FEE3FC3BC13C833F4DBF9DFC" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment to the former shareholders of Stromedix during the fourth quarter of 2018.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFE7A3775A36E55C8A4BA91E0806F0102"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="TextSelection-ACCF45B5079555B4BEB4C2D4019EABB6-0-wk-Fact-33518BD095ED545591B6548C61DFF417" continuedAt="TextSelection-ACCF45B5079555B4BEB4C2D4019EABB6-1" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-ACCF45B5079555B4BEB4C2D4019EABB6-1" continuedAt="TextSelection-ACCF45B5079555B4BEB4C2D4019EABB6-2"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-3F163F50D263530381D7C27076BBE24A-0-wk-Fact-BA9CA8B483C155D885EABA8D24911789" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e864-wk-Fact-74F3A33FF4A757F28F8A3CB2F3F002B7" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">255.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e883-wk-Fact-8C7B55659D175D15AF473686D64C6731" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">231.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e898-wk-Fact-6A41DAF3F5345E19AFA812DFEF9D5441" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">176.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e917-wk-Fact-E84099672A6C5C0993A4940FD3D07F04" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e937-wk-Fact-64F531ACF01D5057A2810B7133753F72" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,103.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e956-wk-Fact-2BBA343CCD9E5707B893B3D8004A72E0" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">279.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e976-wk-Fact-C8C34D4AD041558B934CD0366C7FD68E" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">119.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e995-wk-Fact-16877A3C66245533894D2191D39B1D0A" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">194.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1020-wk-Fact-799A91B5DE235470B756348FCD0630AF" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,655.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e1039-wk-Fact-F14D7624488E5FCA9BBC7EAD2F0FF21D" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="TextSelection-7A27AF5C7E3F597FA5C38E324C6BA767-0-wk-Fact-68833170CF405C03ADE55E359F6FB09E" continuedAt="TextSelection-7A27AF5C7E3F597FA5C38E324C6BA767-1" escape="true">The following tables summarize our marketable debt and equity securities:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7A27AF5C7E3F597FA5C38E324C6BA767-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1285-wk-Fact-0C0B43B2B0885AD197DE321833CA8537" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,655.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1304-wk-Fact-AFC36D941B6D5F0FA0853420AD9B39C7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1323-wk-Fact-8E4DA25A882C51508AA31702348AAA79" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1343-wk-Fact-72D29DB503AB59A5B0C71C6A93598A34" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,657.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1358-wk-Fact-3F37DC9732765F8BA4F85D569C1E06E4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,040.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1377-wk-Fact-74BAE31E128A539AA46FDFD4FF48B86F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101517712e1396-wk-Fact-F1318701DD975343935EB5E24521D6D8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1417-wk-Fact-7A09DD4079EF5421BAB447CD53BBF123" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,044.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1519-wk-Fact-FEAFC06AD0C65B928E13B6D134C70CA1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">435.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1538-wk-Fact-D34499D3D8895CAA8825B145F226B657" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101517712e1557-wk-Fact-C620D4EF87A654648EB580BE5975BC3D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1578-wk-Fact-60DA0AF49DDF5F0C87F463AE9EFBAC88" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">436.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1598-wk-Fact-ABA36DACDE5F5A8CAE1DF0CF6B34DA8F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">431.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1617-wk-Fact-7F0D14D3D2EA5638B4EB714F07EFCEC5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101517712e1636-wk-Fact-BF831364DD545CE08F8925856A38A27C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1657-wk-Fact-25CDA8D50DF3597CB4B23CB4A66A2063" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">432.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1759-wk-Fact-20504B60A2E250DD9E8E5C078D5DD23E" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1778-wk-Fact-DC14A680184F5B57BB6401AA23ABF31C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1797-wk-Fact-661D0619D8515281883EE8DF30A25B6A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1817-wk-Fact-C2ECC10AD131517E855548805C7538F8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1837-wk-Fact-947D1DA9F23C5C908535CD56795B85C5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">335.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1856-wk-Fact-ECFE37EE411D59D7B1682843131975C0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101517712e1875-wk-Fact-35899C4D2512560DAFD3519AE9A913F6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1896-wk-Fact-2652EEBEA90759B68B5405DFB4EE5F77" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">336.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1921-wk-Fact-21E0E8A8142E5E3DBF4A2429F11CB61E" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,899.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1940-wk-Fact-106C9EDE310F5145A5F39FF72C609BC1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101517712e1959-wk-Fact-9E4FC0C30586547C90172FC539166E6B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e1980-wk-Fact-2A4B5842D5AE518C9271AF0E1DDD5274" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,907.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e2001-wk-Fact-B186F4587D1151FC8FF2ED072E2822B5" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">218.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e2020-wk-Fact-24A1EBCBE76D5892949FFF63E9217F04" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101517712e2039-wk-Fact-AB5455A2190955F48944313A0630381F" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e2060-wk-Fact-4CF43CEABCD858E1BD04AD0374B64B9F" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">336.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2286-wk-Fact-DA9FD2C9D424517589E573ACCCF8D4BE" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,608.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2305-wk-Fact-BBDF50D9825057B588DD38CF87180C24" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101517712e2324-wk-Fact-C0C7FDE656B0596CBCF197C3B2635954" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2345-wk-Fact-2BD99D4AF6945A20B6BAEEDB3F530559" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,607.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2360-wk-Fact-2F03B4FFE9A65A9BB3A50F45AD9A1746" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">854.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2379-wk-Fact-316301EED9935592BAE82E30B20EF16E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101517712e2398-wk-Fact-18A3DECD3CDC5F7E862B45B92C0B5333" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2419-wk-Fact-5481B76E7C265C19AB26EED753914A2F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">851.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2521-wk-Fact-59811D26E8A85426B426C66D78F74724" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">706.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2540-wk-Fact-AE259A5B1687567487D82328D8735E51" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101517712e2559-wk-Fact-34DF829E7140565FA48ECB126D29C560" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2580-wk-Fact-BCE774B66CD85A39A5C04C171E156EBE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2600-wk-Fact-BA960BF8BA065EC2BAD98B2AE6268137" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">264.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2619-wk-Fact-656DBC7E52855EA5BB2226591882888B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101517712e2638-wk-Fact-FD79E103E6E05A33AC79BD7219805D64" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2659-wk-Fact-7CC4DE3C5F085B538BD3971BE702C781" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">263.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2761-wk-Fact-A8CE4214B03B5488951C7D6460B7BD29" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2780-wk-Fact-9EED7EE95E67560BA8EBBE3040CAE83B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2799-wk-Fact-4B5A8627B5B858DF93DB02DFB5CD8932" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2819-wk-Fact-1BBAF27BF2425F2E9540F4190BBF2112" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2839-wk-Fact-878FBC03DF115C49ABEE445BA3C4F310" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2858-wk-Fact-1B671E603CDC546FB2AA1489FB966978" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101517712e2877-wk-Fact-6F1772B4D17457AEBC2B866803CA6B4F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2898-wk-Fact-9A9557D2A6AD528985BC7AD9481DBEA6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2923-wk-Fact-D20DFB3CDD5B55F684D45E1A4D612B41" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,694.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2942-wk-Fact-26DF51F2A8A65AF5B0F4A183E6936E1C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101517712e2961-wk-Fact-1FBDF0CCBFC05BB09B6AF3B93C0ECD7A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e2982-wk-Fact-4A10346547B35AF7BCD523DAE511BF86" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,689.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3003-wk-Fact-16003D9B21385DC6BA5BBCB3A6D5D465" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">496.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3022-wk-Fact-C10A71651C045546802CF309A9A7445C" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101517712e3041-wk-Fact-E477E922EDE453EF9A1C3368FE3C9657" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3062-wk-Fact-1C46221FEACF515BBFC94F17166A3ABD" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">615.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-ACCF45B5079555B4BEB4C2D4019EABB6-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-6398CF9B00CF55AEBB839BE4CC39E1B4-0-wk-Fact-404DC4E418AC5952BA436F1F14A9B120" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated<br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3304-wk-Fact-2A187C5440665A2EB694A9C8D5E2CB63" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,091.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3323-wk-Fact-66B83FE47E7853C0B895AAD16FA7FEA8" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,093.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3342-wk-Fact-CCCB35C2863D5C329C4EE002FD7EC3D7" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,314.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3362-wk-Fact-E94681F8C6A75892B3F4F91A19FBAEB1" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,313.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3377-wk-Fact-9CF98AB70DB959CDB90E8A437DDF2D3D" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,686.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3396-wk-Fact-DC73F31AE29D57529D0675B8A30F357B" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,691.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3415-wk-Fact-3B4C0A7FA4CA5180A0CC064696D1A69C" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,235.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3435-wk-Fact-D255A16462E353EEAF37A022218C2D5E" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,232.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3455-wk-Fact-30936D4F6E115BA9AA3BF24C89FC0070" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3474-wk-Fact-DE974DD2E78757CD9443DE0AFEF317F3" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">122.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3493-wk-Fact-70DAE5A2D3FF50A5BEBB5AD0B714E612" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">143.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3513-wk-Fact-035DA27FC38E5F968E1F45089BC09286" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">143.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3538-wk-Fact-21E0E8A8142E5E3DBF4A2429F11CB61E" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,899.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3557-wk-Fact-246ECA4FA34252B6B298F23DE9C20A17" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,907.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3576-wk-Fact-D20DFB3CDD5B55F684D45E1A4D612B41" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,694.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3596-wk-Fact-77D2F90ACC3C57428514A1146715B58B" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,689.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101517712e3624-wk-Fact-9653D0C1C68A559C93362CB31A2F7160" name="biib:AverageMaturityOfMarketableSecurities" contextRef="FD2019Q3YTD" format="ixt-sec:durmonth">15</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101517712e3628-wk-Fact-32B2F962CA2059E9BEC9064816F732BE" name="biib:AverageMaturityOfMarketableSecurities" contextRef="FD2018Q4YTD" format="ixt-sec:durmonth">12</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="TextSelection-EA8A1F5FBAA05454AA097354EFD2AEEA-0-wk-Fact-D875D2FB394E542AAF5B51F15CD0B483" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3848-wk-Fact-0804E7D4566B58BC9F77D28AE7232BEB" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">611.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3867-wk-Fact-DECB15CC00A45B6CA2F0497AEF8BA49A" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,192.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3886-wk-Fact-5E1D8F7CDC5D5971BFCC69B7E527C60C" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,867.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3906-wk-Fact-F0FE9623A9FF52ED9D5ADA61948D05C3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,994.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3926-wk-Fact-3158E9372C71526C86CD277789BC6E2B" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3945-wk-Fact-B9552088A29C57E7B3887E7814084617" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101517712e3964-wk-Fact-9D95FE79271D5FD78C10515DF619BD19" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101517712e3984-wk-Fact-9412C533162651D8873CFA3F4077CD42" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101517712e4004-wk-Fact-6FB885F80DFE5357A5C0B93106C0EA20" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101517712e4024-wk-Fact-DEF6AF7316A05F7C8ACEDB158135BEE8" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101517712e4044-wk-Fact-62E53D30C1E75754B9C27BAB8B0937DA" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101517712e4065-wk-Fact-700DD37618FC518D94AB92519677D9F8" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101517712e4097-wk-Fact-E545C62DE0445C299609AA88BAE36E03" name="biib:StrategicInvestmentPortfolio" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">394.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101517712e4101-wk-Fact-9492B0525EBD514194E97DD535F7E843" name="biib:StrategicInvestmentPortfolio" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which is included in investments and other assets in our condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in equity securities include shares of Ionis common stock acquired in June 2018. This investment is classified as a Level 2 marketable security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effect of the holding period restrictions on our investment in Ionis common stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in our strategic investment portfolio for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflects our sale of a portion of our investment in Ionis common stock for approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101517712e4126-wk-Fact-82ED73A7DFE65022A371F7DA306B1AAC" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">382.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as our sale of our investment in a non-marketable equity security, partially offset by an increase in the fair value of our remaining investment in Ionis common stock.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our June 2018 investment in Ionis common stock, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3B742D2141415053870047D0053892A7"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="TextSelection-1252369334B9510F8FD8ECD9426A3A22-0-wk-Fact-9C402D14AC135609B28AB0D968D17CD4" continuedAt="TextSelection-1252369334B9510F8FD8ECD9426A3A22-1" escape="true">Derivative Instruments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1252369334B9510F8FD8ECD9426A3A22-1" continuedAt="TextSelection-1252369334B9510F8FD8ECD9426A3A22-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101529856e802-wk-Fact-0CB53547D9FD5DF4B518ADE276EBD490" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durmonth">1</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101529856e806-wk-Fact-66DC20EE44385192B46A7CFB9E9639D6" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durmonth">15</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101529856e810-wk-Fact-0BE67837DF085CE3A0E10723487E3AF7" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durmonth">1</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101529856e815-wk-Fact-04591DF42729556AA6FBBE368E8ACADA" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="TextSelection-DC31D04187BD5C5994561C8164E37DA4-0-wk-Fact-4EBC6EC4B25952E8A569C51B6CE1F953" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e941-wk-Fact-D1D8042B056457DF9D3CFA7FB8BD2EB3" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q3_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,943.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e960-wk-Fact-F1BA9775EB155B29BFE89D077AAB1A11" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,701.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e975-wk-Fact-9C139AF574BB5177ABDFE1190601868E" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q3_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e994-wk-Fact-57840C69919351B28F636CCC6A52D5B8" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e1014-wk-Fact-71235FF60C4B58598B2078B13E82A3F7" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q3_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e1033-wk-Fact-9669A726BD5156138BE1033028EC58AF" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e1053-wk-Fact-BB9968DA837E573C8998ECBF4B77B23F" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q3_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e1072-wk-Fact-26420E93BEC65BC8A8D59BCAE6F74DE8" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">98.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e1092-wk-Fact-35E94D9C85C75EAEBF491A6EA0BFAA55" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q3_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e1111-wk-Fact-963ABCA57FCF5D69AF07610E1C3716A4" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">92.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e1136-wk-Fact-7D2C441ED0885379B77534D587C974C8" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,096.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e1155-wk-Fact-DDD83853FCFC5D7990C9C81FE65F2017" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,239.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e1175-wk-Fact-17A4B938F4BE5770BB477EFCCA096948" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">65.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e1179-wk-Fact-20C5A1050A7D5B7F8244F367A7B1800E" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e1191-wk-Fact-17A4B938F4BE5770BB477EFCCA096948" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">65.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101529856e1196-wk-Fact-66DC20EE44385192B46A7CFB9E9639D6" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durmonth">15</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e1200-wk-Fact-9A107777D64B5C888FE47F71287F0E46" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2019Q3_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">59.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these gains are expected to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101529856e1204-wk-Fact-3C7E52F278985F47AC9C7C8D4E6A54DC" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q3YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" format="ixt-sec:durmonth">12</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-B180C810201F56068D0663A03BD619F7-0-wk-Fact-97C71D95502A5E469CE47A906AE33153" continuedAt="TextSelection-B180C810201F56068D0663A03BD619F7-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e1571-wk-Fact-CD27E87C323A558F81FF05E837C57216" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101529856e1590-wk-Fact-FA1EC17BB43E5DBE9415A2519AFB38B5" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e1621-wk-Fact-F73B839B95155BDEA97DF33649C62487" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e1640-wk-Fact-EA3831132E915AAC9479DDDA958BBCDB" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529856e1665-wk-Fact-B5C3ACEF4D235B699F5A774AF61CA5CC" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101529856e1685-wk-Fact-1765B3A840E35940AFBD08692564EC8E" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e1716-wk-Fact-A5A285AEA8E456DFAE1CA40DF287B263" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e1735-wk-Fact-38BBD7C3A5625BDF988A4528B9FEB532" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1252369334B9510F8FD8ECD9426A3A22-2" continuedAt="TextSelection-1252369334B9510F8FD8ECD9426A3A22-3"><ix:continuation id="TextSelection-B180C810201F56068D0663A03BD619F7-1" continuedAt="TextSelection-B180C810201F56068D0663A03BD619F7-2"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e2086-wk-Fact-AAF47C5EDE3458C1ACA82A85478AB3E8" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101529856e2105-wk-Fact-3272F850BF755076B76601589DBB8531" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">51.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e2136-wk-Fact-B9BCF00A004D5EADA8B2E43B558A310F" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2155-wk-Fact-13170DFBC91A5E68BB69777A8885C6A2" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529856e2180-wk-Fact-4D79C0DA81B65AFBA16F49B68575D56F" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2200-wk-Fact-1D3594444EC059E889260E0358F9D986" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101529856e2230-wk-Fact-CA4CB9CFF43052E180843E0BDCC7EC94" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2250-wk-Fact-3A90B1368361500B90813F43AB77EDDE" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-B180C810201F56068D0663A03BD619F7-2"></ix:continuation>Interest Rate Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2274-wk-Fact-745D0807F2EC531485CE603C650CA0F1" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e2278-wk-Fact-5A315878D52157DE8B6397AD350F70FB" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">675.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2282-wk-Fact-745D0807F2EC531485CE603C650CA0F1" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2286-wk-Fact-745D0807F2EC531485CE603C650CA0F1" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e2299-wk-Fact-AC69AC8A8DFE5401AB04A5DDB8C10B65" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e2303-wk-Fact-7A845FA2CB8D5BF486874BE5CE8A275F" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2307-wk-Fact-745D0807F2EC531485CE603C650CA0F1" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2322-wk-Fact-97B1DC30EE1451B589E24F434EE28586" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2326-wk-Fact-57A6C7E488D15251B4859C133413AF19" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2330-wk-Fact-41C9076F0CD05500AD40C9B1813B62B7" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e2334-wk-Fact-74188DA200735AD0A97071671FA83255" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101529856e2345-wk-Fact-2F772C16994E52D7BEC927D89BFE4958" name="us-gaap:DerivativeTermOfContract" contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" format="ixt-sec:durwordsen">one month</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e2349-wk-Fact-59EF1684015F5229A07E58FA283517B7" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e2353-wk-Fact-786F960E4FAF5F8FA5E19F2C41B19892" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e2366-wk-Fact-B5FEC877BDD557FB98611AF173B7BB07" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" contextRef="FI2019Q3_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e2370-wk-Fact-A6D066961C6F5FB1BE607CA0ACE55CEA" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-867CB7E7662D521D8902342FB602879A-0-wk-Fact-FEB2CA46121D5A2EB7513CB3838E3567" continuedAt="TextSelection-867CB7E7662D521D8902342FB602879A-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e2904-wk-Fact-031FD34B96A95AF38C0B77ABA4ECA92B" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2923-wk-Fact-A4863E0AFB0D5075A6585072B01B69B1" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e2953-wk-Fact-F0293FA72F8750DF943F090C60349118" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e2972-wk-Fact-538D64BF547D5EE9BEEA57DEA5716140" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e3002-wk-Fact-7802FC0475FD590A887FF63D17F6B9CB" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e3021-wk-Fact-EC016DAD155B57E2833BB8D6E9BB3DF4" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1252369334B9510F8FD8ECD9426A3A22-3"><ix:continuation id="TextSelection-867CB7E7662D521D8902342FB602879A-1" continuedAt="TextSelection-867CB7E7662D521D8902342FB602879A-2"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e3543-wk-Fact-B2C540D8E99E59B9B3144D782AC142D8" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e3562-wk-Fact-47AAC987E025564C8FA3D761AFB31B41" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e3592-wk-Fact-C49547DA734E5D2AB91A65F22DD384CE" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e3611-wk-Fact-EB1BC513F0A053F589F3B96AC31DD5B0" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e3641-wk-Fact-BC02ACCFF2275F15A30BEA911B34B359" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e3660-wk-Fact-32B13941C1185077AAACC1FBF8EE4987" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-867CB7E7662D521D8902342FB602879A-2"></ix:continuation>For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency forward contracts was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e3686-wk-Fact-E5EF3B2E60C952E799C24A520F1130DD" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">848.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e3690-wk-Fact-98697610D2F158D696B8206FDC9666B6" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">735.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e3702-wk-Fact-11DE7711E98F594F8F0336086106C752" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e3707-wk-Fact-104DEFB194C85C14A2AE0F620197DB6B" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recognized as a component of other income (expense), net for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e3719-wk-Fact-92AAC1C3552B50D3A6E0FB0C94B3FF63" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and  </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101529856e3723-wk-Fact-5A6AD6C9C1445C61B2E697323AC94AB1" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be materially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="TextSelection-CC1F23C0DD915ADEA7C2F65DA64C4EBA-0-wk-Fact-E3B55C5246105BAE8441D0C6CFFB7265" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e3904-wk-Fact-5F0DF5BC7D4B5D688BF3F4508E6F84B7" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">152.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e3923-wk-Fact-F735325A93A85BA9A5D50126C558308B" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e3958-wk-Fact-BF929826D689EA27D500834DF82B4D2B" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e3977-wk-Fact-3C971F5D764DD31F3BE6834E61C30E1D" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e4012-wk-Fact-08E6365C916C572AA4439F4B570BDB58" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e4031-wk-Fact-BD89134997365CCCA2AA02181614124A" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e4122-wk-Fact-AC69AC8A8DFE5401AB04A5DDB8C10B65" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e4141-wk-Fact-7A845FA2CB8D5BF486874BE5CE8A275F" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e4232-wk-Fact-3A4DF61A252A5A18894EDFD3FC42AF2D" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e4251-wk-Fact-D04248BA74355BB8B16AC0E8276895CA" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101529856e4286-wk-Fact-B9338614A5E45EA7B99C84EF107E594B" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101529856e4305-wk-Fact-9899C6D2285254179AA74C2B4A4C6909" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="sABEC67533DEE57E3A60FF81FEBD3E12A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-3A1BC886A5315D5DB290812CFEDA48A4-0-wk-Fact-8E0CAB5BFB145CBAA2C246D608702C79" continuedAt="TextSelection-3A1BC886A5315D5DB290812CFEDA48A4-1" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3A1BC886A5315D5DB290812CFEDA48A4-1" continuedAt="TextSelection-3A1BC886A5315D5DB290812CFEDA48A4-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e785-wk-Fact-DECA43AA977250CC98A44C79B06BEFF9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,555.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e789-wk-Fact-156BF1D9B7625E97AA4A26181B93CC4D" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,797.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depreciation expense totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e816-wk-Fact-F8282C313DFF540580692E7D3564DBB2" name="us-gaap:Depreciation" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e820-wk-Fact-34374FA1CF2D54C5AA590EE3666E919E" name="us-gaap:Depreciation" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">145.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e824-wk-Fact-FB354661350E5450B8FA8BA04A4FA052" name="us-gaap:Depreciation" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e828-wk-Fact-EE3542BFD4AD58F4844FA256102538E9" name="us-gaap:Depreciation" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">194.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-3A1BC886A5315D5DB290812CFEDA48A4-2"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51,000 square feet of administrative space. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e849-wk-Fact-906F0B80E8015C389D7721D13D72B4C6" name="us-gaap:ConstructionInProgressGross" contextRef="FI2019Q3_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e853-wk-Fact-02B39D4140435845BB6EEFBD8DB7C70F" name="us-gaap:ConstructionInProgressGross" contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.6</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e862-wk-Fact-3F78FC9290EA58E79E09BCB9720B862C" name="us-gaap:OtherCommitment" contextRef="FI2019Q3_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding related to the construction of this facility.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e872-wk-Fact-5BC9A91E1ED6B4E2D01EDF3DB0889D41" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">631.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of property, plant and equipment, which was primarily comprised of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e876-wk-Fact-C7079089F2365415A1DEE46F4002F0B7" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">312.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for buildings and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101518085e880-wk-Fact-F44027B7A775585BB1E8BCD1277896F4" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">287.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for machinery and equipment. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div><a id="sD7CE645EFAB05467A0190B8AA6708CCE"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-88C04D4652AE5F0A9C92DE7F3746A587-0-wk-Fact-9A8E3CB3CC905A019DFDA792144CAFC6" continuedAt="TextSelection-88C04D4652AE5F0A9C92DE7F3746A587-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="TextSelection-88C04D4652AE5F0A9C92DE7F3746A587-1" continuedAt="TextSelection-88C04D4652AE5F0A9C92DE7F3746A587-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease real estate, including laboratory and office space, and certain equipment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our leases have remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101532007e785-wk-Fact-E078D50A5B925DEDBDB14153D1B78109" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q3_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101532007e789-wk-Fact-731F4B1E48A95E13A1E02F5B3A6CDB75" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q3_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">nine years</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101532007e793-wk-Fact-D8DCE93F5BDC56E9A4FD74C96C684188" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q3_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101532007e797-wk-Fact-0DD896FE89AC5DBE91F54D3D72444140" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q3_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">six years</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101532007e804-wk-Fact-E078D50A5B925DEDBDB14153D1B78109" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q3_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101532007e808-wk-Fact-731F4B1E48A95E13A1E02F5B3A6CDB75" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q3_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">nine years</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our subleases do not include an option to renew as they are coterminous with our operating leases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All of our leases qualify as operating leases. <ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:LesseeLeaseTableTableTextBlock" id="TextSelection-2367368EEDFA5CFCA9223E680F3FB5E9-0-wk-Fact-F447C98635985CCE88C5D2DB788FC006" continuedAt="TextSelection-2367368EEDFA5CFCA9223E680F3FB5E9-1" escape="true">The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-2367368EEDFA5CFCA9223E680F3FB5E9-1"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:41%;"></td><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e918-wk-Fact-4056AE589A0455BAAA742ED5E25003B4" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">422.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1010-wk-Fact-83651E4ECE335F3AB793B926252102B5" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1035-wk-Fact-F74487B0DB6D55BEA85D2F6FF49BF5C9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">410.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1070-wk-Fact-4554B7DDB01A5621880B9264C452DFEE" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">481.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-D494D1AE78615D759397160CE8420135-0-wk-Fact-D1E2CF021190557CB369AAA32C2D16F2" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:35%;"></td><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1229-wk-Fact-A55F7385DA3252CB881CD71F34B7E17E" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1248-wk-Fact-BD7A78F5931A5F08899BF57AA98C823A" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1273-wk-Fact-DD189F2DBB395985895AAC3B5257AEDB" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1292-wk-Fact-B574C8B4397A52E4A1A1BCC48FD56A37" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101532007e1322-wk-Fact-63518F845DA751C39D5614CC6D648CF0" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101532007e1342-wk-Fact-500C48257DE157C3B0C2956E3871EE6F" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101532007e1373-wk-Fact-52E392791F12546EB71685A31C5863E9" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101532007e1393-wk-Fact-955C3DC2465250B7B607DB15EA785EC7" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1429-wk-Fact-D44DFDF858FA53589482C6EB084539B2" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1448-wk-Fact-AE2AE0AB07465F67BCCEBC0E673F5A9D" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-88C04D4652AE5F0A9C92DE7F3746A587-2"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-838E892EF7555E21BBB6EEA92FF8ED91-0-wk-Fact-221C5A6FE31F536DB278E46A4FCCE96F" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining three months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1512-wk-Fact-10851E0259FE5DE181E7F8D8698D1FAE" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1527-wk-Fact-D961F0FC704258479FB19FFD9923804E" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1547-wk-Fact-D1A7FF46A52E5F088D39663C156EEFEC" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1567-wk-Fact-45588583F71A57B1A712D5803CC2BE69" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1587-wk-Fact-9071FB4F71935006BFDCFABB1F0FFF19" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1607-wk-Fact-840C16DAB212526B9667950DD50EAF96" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1627-wk-Fact-2CB0EE1C65E659E0AB2F273DBDA4E21D" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1652-wk-Fact-D5C150BD87D659098B432BCA8B9E3FC3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">542.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1667-wk-Fact-C0769AFBA70559F7A8B29B58EEFB95F5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e1692-wk-Fact-4554B7DDB01A5621880B9264C452DFEE" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">481.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="TextSelection-8DF3E4296906554DB35A7A788EA0709D-0-wk-Fact-566F3A54C0645B03B113F98C81B31BFA" continuedAt="TextSelection-8DF3E4296906554DB35A7A788EA0709D-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e1903-wk-Fact-55302935C24F59FBA41720DC8A54EE0C" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e1922-wk-Fact-A7B07601ACF855E1A65B4A1813193A76" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e1941-wk-Fact-A029C00401C85AFD9DADF455AEA16D5A" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e1961-wk-Fact-DB9174C63C515C2CA42E6BFA1BB20B8B" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e1980-wk-Fact-89959E743E025B84AF8F9BB78363313F" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e2000-wk-Fact-7475BB6186E85FBBB0F0BF7F586372CD" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e2019-wk-Fact-FF12BFE0FD8A59A1AFECB26F3FE28A72" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">601.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101532007e2036-wk-Fact-9538B0C68BCC5CE8A85A9F274AF7F966" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101532007e2056-wk-Fact-BB1897976E86556990402A834D4B57D9" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101532007e2076-wk-Fact-BD8EF4294ED15006B4441A4BEE61B5D9" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101532007e2097-wk-Fact-D3574F69285154D981811D1DA24171EF" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101532007e2117-wk-Fact-235A3F0115815C6FA97D1F4C532702E8" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101532007e2137-wk-Fact-924E8BA3885653E58F9F4BC85E1A61FD" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101532007e2158-wk-Fact-C83C3C83363E554F9C8CB9A906C7B0D8" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">182.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e2184-wk-Fact-63379C10B0655D5C9D287644877E4A0A" name="biib:NetMinimumLeasePaymentsWithInOneYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e2203-wk-Fact-65738D33067854A4B75AE596428CB9B8" name="biib:NetMinimumLeasePaymentsWithInTwoYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e2222-wk-Fact-9C959B5CD8CD5E018DF80227B4C50813" name="biib:NetMinimumLeasePaymentsWithInThreeYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e2242-wk-Fact-335FA93877AB56C484D4AF6B830D8ADE" name="biib:NetMinimumLeasePaymentsWithInFourYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e2261-wk-Fact-688A24F1C36F5A46915040A8F082AD90" name="biib:NetMinimumLeasePaymentsWithInFiveYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e2281-wk-Fact-728F9ACF11C254ECA29E2A28EF4A94A9" name="biib:NetMinimumLeasePaymentsThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">156.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101532007e2300-wk-Fact-3A154D2169805427826C9C7DFD2EEBC6" name="biib:NetMinimumLeasePayments" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">418.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-8DF3E4296906554DB35A7A788EA0709D-1" continuedAt="TextSelection-8DF3E4296906554DB35A7A788EA0709D-2"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><ix:continuation id="TextSelection-8DF3E4296906554DB35A7A788EA0709D-2">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world.</ix:continuation> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" id="TextSelection-F8EB14FD365757A09511CCE5BD71530C-0-wk-Fact-9A86E6F3CDF953C2BE6205AF5FDE1DA6" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:83%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonNumeric id="d101532007e2364-wk-Fact-2A6B7CB14FE559B7AF74DBE518B126DA" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q3" format="ixt-sec:duryear">7.2</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e2379-wk-Fact-92F5F5641B2756E9B260997332E7F971" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q3" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock" id="TextSelection-C68049379ED850BEB09E74EC31F78A68-0-wk-Fact-9FFD81E2538F59B7A6F6958FC567F82B" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e2507-wk-Fact-862B79EF3A1E56348FB0C3C17B007550" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e2526-wk-Fact-EFFEB88FD6385EEC81B96F305BE26771" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e2546-wk-Fact-045530593E2159668159B42E00E9DF22" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101532007e2565-wk-Fact-47CD428B4C44519ABA5DF203D8BDC2DC" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101532007e2581-wk-Fact-BFF9DFC8BF0650B89F74DF3E2537734A" name="biib:DisposalGroupOperatingLeaseAssets" contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating lease assets and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101532007e2585-wk-Fact-BAE90A15236B5B6F844343135FD39108" name="biib:DisposalGroupOperatingleaseliabilities" contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating lease liabilities. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE137F049A121585CA972B75CB418E5E8"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-1F4709E1673F566784AE4B274CE1FEF9-0-wk-Fact-F1BEB16BE1D154F4890F8249639F2ED2" continuedAt="TextSelection-1F4709E1673F566784AE4B274CE1FEF9-1" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1F4709E1673F566784AE4B274CE1FEF9-1" continuedAt="TextSelection-1F4709E1673F566784AE4B274CE1FEF9-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543163e785-wk-Fact-CE3BF3C335E853D9A150555684FFD3A0" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2019 Share Repurchase Program). Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. Under our 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e789-wk-Fact-4462974FA98C8ACC47E183593F50B950" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e793-wk-Fact-9ECA67F8EC7D5CC79F43A0B162ADA392" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543163e797-wk-Fact-94F6E0F5F1CF480CE20183598CA77AAF" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">717.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543163e801-wk-Fact-F58E7D69E4ED5ACCA7A8A4C3258663A0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.6</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From October 1, 2019 through October 21, 2019, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e817-wk-Fact-DA3853A34DEC7D159737DF3F882B6B7F" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543163e821-wk-Fact-29374F4EA784B24C49CADF414D8DBE05" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="D2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">508.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2019 Share Repurchase Program.  Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543163e825-wk-Fact-F11D8348181357C98DF4441EF31A1846" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="FI2019Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.9</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our 2019 Share Repurchase Program as of October 21, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543163e832-wk-Fact-D166121B09D354B3AAD2EB054791255E" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e836-wk-Fact-FA65CEDD6C6A596CB30A8730836F494C" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543163e840-wk-Fact-DB73370AFA5F5A5FB0F6DA10BAA82DA7" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.1</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543163e855-wk-Fact-CAD41D4D47D357D980BFC744F3424D96" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e859-wk-Fact-3B2194995783505AB8AD186AEACB3EBE" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543163e863-wk-Fact-551FD2EB11605154AE2A88A336BCB221" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-66F2385BEAB5540F8F2C0ACBEAAF034F-0-wk-Fact-04386EBB607D5AF6AB1CF4F251290A71" continuedAt="TextSelection-66F2385BEAB5540F8F2C0ACBEAAF034F-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1079-wk-Fact-635B12F221A55641B6BAEFE2FA779199" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1099-wk-Fact-092D48D2B7525F9CA8D7101FD399A6C8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1119-wk-Fact-F7837A79320C5041A3BA69F8C0C11C70" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1138-wk-Fact-34AE5E0CC39252468413D61379EE8E4B" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1158-wk-Fact-883E3C0D1166531EB6FE74A9C3A5163F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">243.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1179-wk-Fact-2AD3B15D1D55512B9C6B95F3C78B4D85" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1200-wk-Fact-122F895B4884534292125E856EDA3AC8" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1219-wk-Fact-335CD73B00E05887831451E194843301" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1238-wk-Fact-D471468B4DC15A4E80B99D7D4207E1D1" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">53.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1258-wk-Fact-F793E8E1C37C51AEBDF33CA3406D5578" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1277-wk-Fact-C64EE0A719E25F2993B39598E57D1A29" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1297-wk-Fact-18D13DE3565B527F850C6DEF51EBC953" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">233.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1322-wk-Fact-08B57A371A3A5C7CBB2619E91FC06BB1" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1342-wk-Fact-94C875A83BF7581AB04688CB2440375B" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">77.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1362-wk-Fact-9C67BC4A9F1B5CB4ABF880E51F002F57" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1383-wk-Fact-2C2835DB46E552359E1F636FEA0FD17B" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1402-wk-Fact-0CDE5DA95A7A521BB91114BB8195BB80" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1422-wk-Fact-7F644F30F60752C78255FA12C7265AC3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">85.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1448-wk-Fact-C8334C6258795FDDBE1577E873E24892" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1467-wk-Fact-73ECB6C0E6915CF1B1D1A34DCBC28F40" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1486-wk-Fact-F53523D5B812595BA59B512B2E9E3D28" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1506-wk-Fact-E2D96DD5957D54019BA84D848738031D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1525-wk-Fact-578384EBE6395C20A9BDBC1C543F2FED" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1545-wk-Fact-4BE449ABC68C5BBB868E2225D4530616" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1575-wk-Fact-F4A14B1E52D25EED9649ACF032845F18" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1594-wk-Fact-3B7F17369E6753CE8E0EDC4EC540A64A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">72.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e1614-wk-Fact-D3699B1576FD5BB48D130397C57BD5E6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1633-wk-Fact-A2EDED11C2985890B99479E4C77214F2" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">29.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1653-wk-Fact-FF9E0C94C302564AB5469BCD2DC765CE" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">192.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e1674-wk-Fact-D19A1A49D241536C9B103A6500E3337A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">92.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1F4709E1673F566784AE4B274CE1FEF9-2"><ix:continuation id="TextSelection-66F2385BEAB5540F8F2C0ACBEAAF034F-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e1864-wk-Fact-E468B46E393759DE9D6935D888D8AFA7" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e1884-wk-Fact-333ECD5838155560AB3BA1B487B7B105" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">104.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e1905-wk-Fact-55C089DB35E2577298612860FD471F60" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e1924-wk-Fact-A6F5DF0591105090A22BB9564F91B8AD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e1944-wk-Fact-5FB6F2DFBA38592B9849BF170BA50968" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">175.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e1965-wk-Fact-10171AA65B5858EBBD2DD843A3C0FFE9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">318.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e1986-wk-Fact-AF4B5D3D486157C18392BD4A56AC418C" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2005-wk-Fact-1607C892D1165369AA37D209287E057D" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2024-wk-Fact-71A785022A7B5A68B393F778E848A58E" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2044-wk-Fact-77410517F4325E73A7D0935FAC46A49A" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2063-wk-Fact-55447D7198A15BE8B65D58F078C231D9" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2083-wk-Fact-746B5582208E56AC82FFC30F19A84702" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2108-wk-Fact-09F7C829E3B85067BE955E54F832A976" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2128-wk-Fact-7D0315218B6650368D04A2F4065C6140" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">104.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2148-wk-Fact-1B75927D82205839B6A4A9048D698855" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="0" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2168-wk-Fact-D6C26711256854B8B7C7720C7631DEDE" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2188-wk-Fact-ACAA34C72E7D5ED6BD0DB6560C43E86B" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">175.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2209-wk-Fact-CF2F016C0E7658B48BA40655A96561D9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">316.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2235-wk-Fact-654598FC41CA5A7C92DF0E48B3B09382" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2255-wk-Fact-60A34CA8026456B8A76B4BC76B849F48" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2274-wk-Fact-52307463D26455888E957E70A37589F2" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2294-wk-Fact-CEA8CB7B1DF551889ABE21911344AE9C" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2313-wk-Fact-7D2B10C0B17C5F5ABBC1DE18DE1AF96B" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">38.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2334-wk-Fact-BC91EE2BDFD95362A4A86405576858AC" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2359-wk-Fact-35B884AA42E4509CAB167F6D1842BE2E" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2378-wk-Fact-7A47F3A5B5B05AB3A24D8184D96F1AA5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2397-wk-Fact-B1603A059C8952F4B800C544BC9C0FAB" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2417-wk-Fact-BEC437DFFD1350C8AEA98166C8D25633" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2436-wk-Fact-854B33DE6AF353EE8D96CB514D019B02" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2456-wk-Fact-AF693D52806E5A598300D29D2AA9AD71" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2481-wk-Fact-1F9CB585DA06573A9649D13DDCC298A3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2501-wk-Fact-77C297AA58D65130A8E001050E482745" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2520-wk-Fact-A384F0C43CC15F7F957ED958AD286768" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2540-wk-Fact-29F8AE11800955B899CD474D91153F2D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2559-wk-Fact-107CDA5806A65B94A48D28F733A90A26" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">38.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2580-wk-Fact-61FD074FCC6D59939B8BE32C48B29249" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2610-wk-Fact-43A3A6CD371B56F8862DFDA11BDAEF1E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2630-wk-Fact-93A4DD0A8DEC51C9804B6E256D71E64A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e2650-wk-Fact-103140FC6C8A50B6B5CD973577A36E72" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2669-wk-Fact-C14DD62B1A5E5B8CAFD61D0A0C6283DA" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2689-wk-Fact-143CE23DBD9B5E77820DBB0D51516429" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">214.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e2710-wk-Fact-59C0EAD6DD2E5FDABB0786818BC7B05E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q3" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">248.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="TextSelection-3874991AEEB952EF8640040AD2308BD0-0-wk-Fact-D840189BE6E55884A78AE313B598706D" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:26%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e3061-wk-Fact-8BEFD7670409555F9640CB59A1DDDAD5" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e3080-wk-Fact-77DDBEC2FF3352D392504631D620E2F1" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e3101-wk-Fact-B20E5AA5FCF8517B9FAD81076FE14931" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e3120-wk-Fact-761892AC01BA559790DAC3969D88197D" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e3146-wk-Fact-DB8616DFC95B5B8682D8342D0D20045C" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3166-wk-Fact-9D85D0278A0653FEA9540BCE6FACFCE9" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e3186-wk-Fact-67DEB04F037650B0A149BE90B1CFFE03" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3206-wk-Fact-B9FAF1EA9B255B5AB3EC7691008E1DD5" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e3328-wk-Fact-154B0E00CF0E5A778019A18215B9F8BB" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e3347-wk-Fact-3F3B25882E60546CB830130809ABC7D2" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e3368-wk-Fact-61B963EA2A42509782413D0C6952F245" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e3387-wk-Fact-BA40E37D5F1F540593DC23564EB1A27F" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e3418-wk-Fact-9227FF83772C50D59311281580DDFC04" name="us-gaap:OperatingExpenses" contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e3438-wk-Fact-CDC31325484955A78828C41D9FEACF8D" name="us-gaap:OperatingExpenses" contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e3459-wk-Fact-74D2840CDEFC5682B3FEB6C3A6EA14F6" name="us-gaap:OperatingExpenses" contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3479-wk-Fact-7F3BAB48B06454F1B66864CDEF3E07C4" name="us-gaap:OperatingExpenses" contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e3509-wk-Fact-D3BA65E6E6CD55DEA450073107787B66" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3528-wk-Fact-D9FE23793A0C5FA8907CBB11D6025006" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e3548-wk-Fact-F67DE9432D9E50B69F96239AB6CDF6E0" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3567-wk-Fact-9AE5BA7AF09D52DE8F2887AE21423244" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e3597-wk-Fact-AB422335BC6D5530A0DC89E2432C4D93" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3617-wk-Fact-7DCE4320F6735667B204AD2458806451" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101543163e3637-wk-Fact-90F39731BEDB530983A53BD175614202" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3657-wk-Fact-F8E92C9BE0995E1D934825A1645A5FEF" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e3780-wk-Fact-99058D90712A51ABB959A52124124C25" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3799-wk-Fact-26BCCB8BBF9F5139B4A6031B835A0DF7" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e3819-wk-Fact-3B8F2ACCF3B5587A8280FC3961722B03" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3838-wk-Fact-E8030C24F07957A980399260F10B546B" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e3868-wk-Fact-48AFA680D78C55D3AC09B20F290F3159" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3887-wk-Fact-0BA549A4236B529FAB23C9CBD23DB478" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e3907-wk-Fact-93F401C7BDEB54F2B1037344BC2ACDB1" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543163e3926-wk-Fact-F837600B394C532DB0DEB38F5D4FFD60" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e4053-wk-Fact-B725205ABEEA58BE818E78AFEEA230AE" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e4072-wk-Fact-C7CFB9CC55E15ACFA735A4F2B4387834" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543163e4093-wk-Fact-6493EE6FF5685D3394B25E796C1EE325" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101543163e4112-wk-Fact-51981C56018C5F19B969591ECE8A0D21" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">56.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA6BD3571F3E05B88B052B17E2E26762E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-E5E351BDF7A45596A7E3D88A69DBC7A4-0-wk-Fact-75A7A1102D2154F4BF9DF2BE43433BC6" continuedAt="TextSelection-E5E351BDF7A45596A7E3D88A69DBC7A4-1" escape="true">Earnings&#160;per Share</ix:nonNumeric></span></div><ix:continuation id="TextSelection-E5E351BDF7A45596A7E3D88A69DBC7A4-1"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-30BB3C1736B356E287B074401CBBFE33-0-wk-Fact-9CA0CBC99B975BE5AD9CB011D1D61281" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1079-wk-Fact-8BCEFCADFFDD5171A80A5930F9D729B5" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,545.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1098-wk-Fact-A3394798436750ACA93FC560D5254E0D" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,444.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1117-wk-Fact-FF611939A9605722A2FA20072DD911C0" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,448.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1137-wk-Fact-71E4AC6E479B5D7B8F2CABF3359E1159" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,483.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1234-wk-Fact-F6CE5BEE80B6540FA43FF8EA2757EB66" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">184.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1253-wk-Fact-E9DB242D33DA5FCF80E62B38AB8B3CCC" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">201.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1272-wk-Fact-D122FB3C0DD75244A8431CFB07FAEF38" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1292-wk-Fact-A1872F8928FF5D918E5EC1A8811DC1C1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">206.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1394-wk-Fact-545C91A0C9A95D07ABDA3BBBD9552FC8" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1413-wk-Fact-DAC06ACAB85B50D8985F92CC7F4DE3EB" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1432-wk-Fact-9543566ABB4856E69B37E73DFE40F500" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1452-wk-Fact-D0939E94E36E540C828B3EDC84FB54EE" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1472-wk-Fact-60B06648579A52399752BF84D19F7722" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1491-wk-Fact-A440912A85E55C51B14B8F678CF94FAF" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1510-wk-Fact-0D11369804555E75A0DFE73BECC9F6FB" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1530-wk-Fact-53DA8026BB4B5B23A16AE2FF86D8C074" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1550-wk-Fact-323908F7C51E5C0B8ABF71E189ECF471" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1569-wk-Fact-6B6EEDFF745953ADB39D1492358010E0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1588-wk-Fact-668B22E025D25E6A8F5D8CF4D2BC24E1" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1608-wk-Fact-136E2CB0045752068F73CEEC96DB2C16" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1628-wk-Fact-C39C6E33ECD95D3E8430581FA7AC0C77" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1647-wk-Fact-DF137773BA225B94AC85A022F5C47CB3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1666-wk-Fact-98E5A21B225D5252BACF8F1F32533579" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1686-wk-Fact-BA76595DDA965FE3B8CC530EE56446F3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1707-wk-Fact-C8B4136A7EB65E1D90145859BD10B5B1" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1726-wk-Fact-FBE31F4FCDF15B11935CAF33D72898AA" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1745-wk-Fact-565C9C386E505E30A7B04E2D6A68288F" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1765-wk-Fact-9028B223615D51FCB60B9B58CA0F12BD" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1785-wk-Fact-93A4BEF1889A5DEBA0656CD4B052EC65" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">184.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1804-wk-Fact-3C339B177C795EFCA2E51E30FA1B6B01" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">201.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101533586e1823-wk-Fact-E79773D2EAB35D32A14B66C86F627853" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101533586e1843-wk-Fact-097BC21BCB8351D6BD7B65093FE992A9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">207.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:continuation><div><a id="s9FE8D1EF7D5F53ECA6A9D1E7966FCEE4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-BDD850B2639850D8B2ED09A7A09AF1DD-0-wk-Fact-582183C7B64E51179F0C4695C4E62C8B" continuedAt="TextSelection-BDD850B2639850D8B2ED09A7A09AF1DD-1" escape="true">Share-based Payments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BDD850B2639850D8B2ED09A7A09AF1DD-1" continuedAt="TextSelection-BDD850B2639850D8B2ED09A7A09AF1DD-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-C39BD9693E915261A43AD7C58AA26A8F-0-wk-Fact-A9F41029341A5745A64969DF826F5C15" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1000-wk-Fact-ABA058359F3B5A76955AD5C4B655339A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1019-wk-Fact-74CA9D38F7175BEDAC11208E6EAC3ADC" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1038-wk-Fact-143884E0BF805009A5D97F224B6F8052" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1058-wk-Fact-673EFCB7E5E85D319CE495DC65070143" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1073-wk-Fact-2B50999772645E229E5291EDA7AF72B1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1092-wk-Fact-65F3A1C5CDD35A479C04DEB0F845E1F3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1111-wk-Fact-D57CDB857151594E89DC7D603BE19CC5" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">116.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1131-wk-Fact-6F70496D82D85DC78B6DC6CF2EC1D406" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1151-wk-Fact-74E16BC1DB9C51A68545C932163EA52A" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1170-wk-Fact-987AF63612A753CC8B67053776B3524B" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1189-wk-Fact-D2A3EF02E5AF5D31B3E4CC6D73CD206B" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">182.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1209-wk-Fact-B674E77FD9885D4B8825DC3A19AB4A13" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">143.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101536639e1229-wk-Fact-1F8B5DF3DDD65C42A59D8CBEAB5ACC55" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101536639e1249-wk-Fact-0459486163FC5FE88E0C4371F05FB4C9" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101536639e1269-wk-Fact-B08CB46B391C57A687231ABA0D9AEF98" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101536639e1290-wk-Fact-6B97BF69070E56B6BF5D72ADB0E54005" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1311-wk-Fact-F209147987695BC0AA500F00D653DDB6" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1330-wk-Fact-AEF85C440AA2530F8E0E1E013B6112CE" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1349-wk-Fact-8B2E2E15BAB658A08B0AFD6A401BC7AE" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1369-wk-Fact-D745268D663C5E8FADDBE423A1D47AD4" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101536639e1389-wk-Fact-E92077B62C745CFF802C66578AFAEBA0" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101536639e1409-wk-Fact-0E0FDDCE0C89510CA268238FDBCFDC80" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101536639e1429-wk-Fact-C9587320B47E52CC895971EC5AC88C8E" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101536639e1450-wk-Fact-18D1A95A60C95B98B8C72EB5FCCBF6AD" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1476-wk-Fact-5AC151C5867E5A15B05FE27252A22674" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1495-wk-Fact-6578FEE51A0A582F8F06AB4456A1D66B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1514-wk-Fact-87739C66D48252BD93550D991A52317B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">145.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1534-wk-Fact-89000F788A5D57A59F2949C219006D6E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-BDD850B2639850D8B2ED09A7A09AF1DD-2"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="TextSelection-25B2063DE9C553808E88FDE10FB2D5B4-0-wk-Fact-EFADBB8D785851EABA46EFF629A5D4FA" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1763-wk-Fact-77998986CA825766801F6DD7FD25B891" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1782-wk-Fact-6E1C575A18DB5CF18ECCC55E0EC86603" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1801-wk-Fact-35212C51F5BD5022975D7F9251CDA1CD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1821-wk-Fact-80FC147CF5B158C79CCF9448EF1D0144" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1836-wk-Fact-781D3C0B06DF586C9BF97ED4179F7074" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1855-wk-Fact-0B30933B196D596C99B613757DE3D602" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1874-wk-Fact-E9B5215F4CF5530783081A1C859B0B88" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">104.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1894-wk-Fact-394078E62C8159349D0A1A688BE4703A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">96.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1914-wk-Fact-3942538699575549BCDC4DE73E2657D6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1933-wk-Fact-7469FB469948510983E89977ED165786" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101536639e1952-wk-Fact-01EAFDD463E953BB9654A4CF1D454BE4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e1973-wk-Fact-0FA867213F52583A80C5C9D2AFDC80CF" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e1993-wk-Fact-6E5BF6E7E500566FACDAD632FA66D99F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2012-wk-Fact-814BC632727E5CD680A5D9AF20D2ABFF" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2031-wk-Fact-B77F75E93925519D9B3DF42E20AEA593" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2051-wk-Fact-06B27721CF4C58BD9FB2FE53BE0B0B4A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101536639e2071-wk-Fact-9CEAFAC279265A91A3465C5D09B9972E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2091-wk-Fact-CF9F90F3B6A657EE90B9E0427A35D594" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2110-wk-Fact-9935CFACBD2C57099C6F53A878C7AE3E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2130-wk-Fact-17BAD4858D8B51BDB96BEFE06C7B327D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2150-wk-Fact-F17C663B465E53C6ABC6B0F112C3AEC6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2169-wk-Fact-E206A8CB76C155A2A0DFDD2C13F1CB5D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2188-wk-Fact-B131CC5B55945D809116FE1388C10D0A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2208-wk-Fact-856A7C5CDDB757ADBBE97AD9B8696BF3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2228-wk-Fact-FDFB1739ADA5514F839041ACB91E3D08" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2247-wk-Fact-F2636C770CF15562B0E973FBB6EB6D60" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2266-wk-Fact-35524D15DA27544FA73A9F9CB30273E6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2286-wk-Fact-9D9A4EE704FA55B6A71BCC39B884E800" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NST stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2306-wk-Fact-4B0B1A0EB02F573BB28CFAA787153B70" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2325-wk-Fact-B635FB959EF05E9F8EC03DD81F0AB1FD" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2344-wk-Fact-2D3A4507D8AE5FF8A75B4F74523BEF6F" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2364-wk-Fact-4AD3B367C47558C8876CF5DED2B1064B" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2384-wk-Fact-74E16BC1DB9C51A68545C932163EA52A" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2403-wk-Fact-987AF63612A753CC8B67053776B3524B" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2422-wk-Fact-D2A3EF02E5AF5D31B3E4CC6D73CD206B" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">182.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2442-wk-Fact-B674E77FD9885D4B8825DC3A19AB4A13" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">143.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101536639e2463-wk-Fact-1F8B5DF3DDD65C42A59D8CBEAB5ACC55" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101536639e2483-wk-Fact-0459486163FC5FE88E0C4371F05FB4C9" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101536639e2503-wk-Fact-B08CB46B391C57A687231ABA0D9AEF98" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101536639e2524-wk-Fact-6B97BF69070E56B6BF5D72ADB0E54005" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2550-wk-Fact-F209147987695BC0AA500F00D653DDB6" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2569-wk-Fact-AEF85C440AA2530F8E0E1E013B6112CE" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101536639e2588-wk-Fact-8B2E2E15BAB658A08B0AFD6A401BC7AE" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101536639e2608-wk-Fact-D745268D663C5E8FADDBE423A1D47AD4" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock option expense reflects the accelerated vesting of stock options previously granted to NST employees as a result of our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div><a id="s147969D11F805B769656BCEAD55881AA"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-A179028EC191579A87D968DC537AA4E1-0-wk-Fact-A63B00976C9A5B469A3325B66613697F" continuedAt="TextSelection-A179028EC191579A87D968DC537AA4E1-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A179028EC191579A87D968DC537AA4E1-1" continuedAt="TextSelection-A179028EC191579A87D968DC537AA4E1-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-9F3535D6213B558BBFB666590A2F64A4-0-wk-Fact-B8AD35EF9CB65FD3ADE56903FB93F5DB" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e951-wk-Fact-4A6994D6B71C5EFEB272226B4E6D2A7E" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e966-wk-Fact-8BFA64FA3C705C91A74627818736C647" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q3QTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e981-wk-Fact-47A31FD7D703533EBDD2399B060CCD2A" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e996-wk-Fact-BA868D51D6AD565ABA1549B2B982F599" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q3YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1013-wk-Fact-B6CB4F9384EA577AB96472705A91512F" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1027-wk-Fact-E5E01A6BC9105BCF9707BC2816F773C4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1041-wk-Fact-76DB83C47C8F58CB9DC01529C0AF7AF6" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1055-wk-Fact-E9B8E7015FE7548E915870F390A1369E" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1071-wk-Fact-318DA773A01D5B87831861612149DF46" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101534516e1086-wk-Fact-034B25EEB7F959B785530D12B05CA1AA" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1101-wk-Fact-6AED3382EF645E1FB16A185E36A20520" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">4.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101534516e1116-wk-Fact-9A35A4C8C6AD557EBF9CBCF17CB1C107" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1133-wk-Fact-9272A83F67BB555DA2AFEDE761AA909E" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101534516e1148-wk-Fact-CF9EDDFB02FB5035A182092785452C33" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1163-wk-Fact-C2116C082BF85A8894F800018D209899" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101534516e1178-wk-Fact-099106EC00C8524993F8BF753568A247" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1195-wk-Fact-BE4BB4EBE26E51818ED2A6024B0595DC" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1209-wk-Fact-39EC2CB180895AE19AF5C5FAAC929740" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1223-wk-Fact-947FAB6F287C593D8F037A99625071F3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1237-wk-Fact-4C2F2CA1C4C753B7859F143D1902D79E" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1253-wk-Fact-46DF25CE8A145732A92A2950B80FB462" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1267-wk-Fact-AB82E368A87F5518AF06CF142A9C82B7" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2018Q3QTD" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1281-wk-Fact-3AD5BDC9C52C5435B215316C460E3DAC" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1295-wk-Fact-8F964E02D8F05B978F243A79414595AA" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2018Q3YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1311-wk-Fact-8AF7F1DBC04C5FD6ABFBF015E513B559" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1326-wk-Fact-F5040E734EAD50568E90CB009E329616" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1340-wk-Fact-6DE31362C9F555838103674F85C8D204" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1355-wk-Fact-D4F477BCC8F15EA694267CC52792C4EA" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1371-wk-Fact-8FD5955E47065BA49D62DEFCAD2AB299" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1385-wk-Fact-91F98E5ABEC35071897E1F5CEB029A16" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1399-wk-Fact-0C56EDA7AD1F5808BCD67B549B2103B2" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1413-wk-Fact-2F24F38C6DE851018EACC20F3A1C635F" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1429-wk-Fact-D8D71667CF30BD58CE65DF487F096181" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101534516e1443-wk-Fact-C3A37E68E47A53D4CBA5DF48A946DFBB" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1458-wk-Fact-527D41FAC10ED8A983FEDF48CBA8EEDD" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101534516e1472-wk-Fact-C834C00E87E9BF745C73DF48EAF695D5" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1490-wk-Fact-B80F4A5B951F2CEE3D80DF49C93D5502" name="biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">3.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1505-wk-Fact-3C43984D4EC3991D5209DF49CD254F9D" name="biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1519-wk-Fact-6F724C135CCE13217417DF49D08A25F3" name="biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1534-wk-Fact-04CCED9F0C4ACE624C77DF49D4770CE5" name="biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1550-wk-Fact-4B41029719BC520895721907F06FD276" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1565-wk-Fact-915DF50B91CA555D86AF3146B56A93A4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1579-wk-Fact-D50AD40AF5E35E0996237365BD3022B2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1593-wk-Fact-038697C57FFD594F9BE27F4B479ADB25" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1609-wk-Fact-CD7D332C15D35B40A434815BEFC84607" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101534516e1624-wk-Fact-CDE90DF44FF35B4C9518B4EB5969EC63" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101534516e1639-wk-Fact-A3EF03E884C153BDB8D546527152C7B7" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101534516e1654-wk-Fact-C8719CEDE00D5818924AAB03E627ECD4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1671-wk-Fact-68DA5BCC5E4E57F4950C6F7B2BD5877D" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">11.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1686-wk-Fact-655A7C888E9A5EC886428E03D1A1E18B" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">20.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101534516e1701-wk-Fact-140A8775F21F54BC9DD63EDF285F06D8" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">16.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101534516e1716-wk-Fact-DCDE9D2E3DE35EBEAF4C84BD79725E49" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-A179028EC191579A87D968DC537AA4E1-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2018, the decrease in our effective tax rate was primarily due to the enactment of a new taxing regime in the country and certain cantons of Switzerland, which we refer to as Swiss Tax Reform. As a result of the impact of Swiss Tax Reform, in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded an income tax benefit of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101534516e1757-wk-Fact-D7D236741AA948C95874DF4552979A5E" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, resulting from a remeasurement of our deferred tax assets and liabilities. In addition, in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net benefit for the impact of the internal reorganization of certain intellectual property rights and a net benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101534516e1770-wk-Fact-A8EB1CEFFA938331E193DF460E9B4991" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> resulting from the finalization of tax returns in various jurisdictions related to the 2018 fiscal year. We also had a higher effective tax rate in 2018 resulting from our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2018, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of Swiss Tax Reform. This decrease was partially offset by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101534516e1785-wk-Fact-DE53D21C5AE75E5C9034597BF3D7AAAC" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense related to the divestiture of our subsidiary that owned our Hiller&#248;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Although we are recognizing a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture requires us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the internal reorganization of certain intellectual property rights, as of September 30, 2019, we recorded a deferred tax asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101534516e1795-wk-Fact-9DAC814C958E68A7266FDF440061776E" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2019Q3_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">754.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101534516e1799-wk-Fact-C2C2DE1D815220C43F65DF44423E2BA1" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="FI2019Q3_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">603.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Federal and State Uncertain Tax Positions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div></ix:continuation><div><a id="s1AED48EF895B579C96C3B9E28B9BD732"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="TextSelection-654EFF0C4B3E5E8D8594725C1F0B11DF-0-wk-Fact-23236C586E585529A35E7B6C1336740E" continuedAt="TextSelection-654EFF0C4B3E5E8D8594725C1F0B11DF-1" escape="true">Other Consolidated Financial Statement Detail</ix:nonNumeric></span></div><ix:continuation id="TextSelection-654EFF0C4B3E5E8D8594725C1F0B11DF-1" continuedAt="TextSelection-654EFF0C4B3E5E8D8594725C1F0B11DF-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="TextSelection-1C79B6F5234D50FEAFDC6B2C5605FB21-0-wk-Fact-F5AAFD9900F659B593A00AC13CFC7479" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e1000-wk-Fact-AC69ED6D87DB56EB9F937E400DC25A79" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1019-wk-Fact-232F654D865C52BD816B4BBDD2742B19" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e1038-wk-Fact-317D0FA1071550369E079EAE2CCA7A44" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">90.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1058-wk-Fact-F8C14051A8275AFE8C4E902BE47B4D72" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101538747e1073-wk-Fact-BE6A17A9C60058B5BBB2C1E727E959CE" name="us-gaap:InterestExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101538747e1093-wk-Fact-1B02DE9A9A865BF7BB82747792A1338D" name="us-gaap:InterestExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101538747e1113-wk-Fact-CF7DB68D8F1052428FB71537BCAF862A" name="us-gaap:InterestExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">141.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101538747e1134-wk-Fact-12AA386232E65BB19563813890083D36" name="us-gaap:InterestExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">151.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101538747e1155-wk-Fact-549EA97F600B511FAF77B71D21C12F33" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1175-wk-Fact-1B3BFA171E64588DABAD643E55F66FB9" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">141.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e1194-wk-Fact-58D07A5924545B3F837D6F393083D0CF" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">198.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1214-wk-Fact-1870778514715E99A0E624A144F2FF7D" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101538747e1234-wk-Fact-2DB4BEB185D05043B97FA67A703262E7" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1254-wk-Fact-B0D41692FEFF5B26AD356976B80B246B" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101538747e1273-wk-Fact-A5DBDCE0B64B50A8AC5D51A7BD4DC742" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101538747e1294-wk-Fact-FA06420214515D18B218B780C0561FA4" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">13.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101538747e1315-wk-Fact-D66A8A0AA9C7590B8EC6B43024565762" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101538747e1335-wk-Fact-64F097572C235991B3664C6DE980FD1C" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101538747e1355-wk-Fact-0A794B06EA2C5F7081196027C39E8119" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101538747e1376-wk-Fact-F37ADCA6FBF552F9869D9048D2BAC99D" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101538747e1402-wk-Fact-E9D12EA36B4D5C33868828CA4F85E261" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">27.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1422-wk-Fact-2C8DF4D3F6FF5FBB8B107A909ED110C4" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e1441-wk-Fact-955EC3C90AF15B78B661F5AE7D5AA578" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1461-wk-Fact-84F574B1C98951649E68D68912924040" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-654EFF0C4B3E5E8D8594725C1F0B11DF-2"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:GainLossOnInvestmentsTextBlock" id="TextSelection-EAF2CCDB7EB854B895377B94E6E58C75-0-wk-Fact-DC89261CE4CC53BE96A99D70C324C9D1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101538747e1690-wk-Fact-4F0A0E53EF0653E8BFBF1FA8974E60EC" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1710-wk-Fact-9B0B34237D4657F584CA1C640CAC565F" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">141.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e1729-wk-Fact-95D515F0048B55E381F3BF8BADAB4777" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1749-wk-Fact-20E7CF25749E58CC917B9D2C24776D46" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">139.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e1769-wk-Fact-B004330B14945A15ADE1A1036C838E15" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1788-wk-Fact-1D694515CB5451069B7946745A629D11" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e1807-wk-Fact-56AF3C182A95503C804E6A4741EA881B" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">46.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d101538747e1827-wk-Fact-F56B0EFC65A059EC9CD1654ABA059ADD" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d101538747e1848-wk-Fact-2A998132A2EB5F2AB0BC8648B0E98380" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1868-wk-Fact-DA7B2270E3A55AA28CDC611D81AE4DB2" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">141.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e1887-wk-Fact-060DF082EACD59D1B9A99F90CA86211B" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e1907-wk-Fact-573D5DEE45A754718AC18B7A4832D260" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">140.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-77F0EC83DF595DFE8577AB98768C4905-0-wk-Fact-8726A81E2B8050DB8B8AA4F1C0067CF5" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e2004-wk-Fact-93E9038349A6549E86E73F0F4F359577" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">884.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e2023-wk-Fact-9790B7529BB852F99BAA6B9B78CB9C5C" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">874.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e2038-wk-Fact-CFFC95FE8E8A5AA1B626B842D127F929" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">259.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e2057-wk-Fact-7ED29700BF3D51FDAB4704488F8FABBB" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">320.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e2077-wk-Fact-AFFBC6A9C702595BB81D4BC2EB914D92" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">222.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e2096-wk-Fact-76010EECC7325A02A135B1CFC6B17490" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">224.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e2116-wk-Fact-A903322B46A45634B3E4C8BFDDED7290" name="biib:Collaborationexpensesaccrual" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">188.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e2135-wk-Fact-55817F4886FE5A3094654C927E60D28A" name="biib:Collaborationexpensesaccrual" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e2155-wk-Fact-F1BDB2B6F6745908AD67332BF552BCCC" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">147.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e2174-wk-Fact-AA2E6A97539C59D8B1C886EB6579CB0D" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">444.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e2194-wk-Fact-199AB922B2F4502EB81981AACC08E84B" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e2213-wk-Fact-801E712D75355E3DB04035A001F3259B" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e2233-wk-Fact-6B40452BA2825C20ADB291B3CFBB9690" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">677.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e2252-wk-Fact-9649755958F75469B852C8B2232263A2" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">609.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101538747e2277-wk-Fact-C6AD992658BE523FA538C7C0C76A2090" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,429.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101538747e2296-wk-Fact-BE16E177BEB058B89BD806D640DFC45E" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,861.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101538747e2322-wk-Fact-3B76B476C9EC5341AA786EDA6E0726CC" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,370.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101538747e2326-wk-Fact-54B9F535280E5673BE39CEFF072D9B0B" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,389.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and included accrued income taxes totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101538747e2338-wk-Fact-A152938A51CF57F294149D28EDD64EA8" name="us-gaap:AccruedIncomeTaxesNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">801.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101538747e2343-wk-Fact-45EF85BCECE25A5FA02106B4D4D6F044" name="us-gaap:AccruedIncomeTaxesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">791.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></ix:continuation><div><a id="s5FF7CB1DDEFB51F6BE3A912F7F5CF222"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-0-wk-Fact-4E9144A498E054759A483D2A3A25EC9D" continuedAt="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-1" escape="true">Collaborative and Other Relationships</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-1" continuedAt="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, MISSION AD1 and MISSION AD2, designed to assess the efficacy and safety of elenbecestat in patients with mild cognitive impairment and mild AD. As a result of this decision, in the third quarter of 2019, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e808-wk-Fact-F603D8390785954FA5B7DF4FC3E05906" name="us-gaap:LossOnContractTermination" contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our share of the termination of various clinical trials and research and development contracts incurred under the BAN2401 and Elenbecestat Collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for early AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-2" continuedAt="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-3"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial. </span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="TextSelection-F21BA2255B6B5D1081E0E068CCF3AB62-0-wk-Fact-80EA990B1873598B8804C9CB6BFFE5EB" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1046-wk-Fact-7B73F5DB58AF517889FEE22BE3321663" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">168.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1065-wk-Fact-934B46BE70B9570E98CA8356A42ED4B5" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1084-wk-Fact-611C1922CB775553AEBB25F630E8F6AB" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">305.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1104-wk-Fact-3644C864F3245BE58C2615E4611B5AFE" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">176.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1124-wk-Fact-AB0AB14933D655AEB7CB6965ABFF28DD" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">84.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1143-wk-Fact-015B1529CD465838B48DF9519A18770D" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1162-wk-Fact-8F26F1374421540F855D9D049C250BC7" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">152.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1182-wk-Fact-ED75C03850455951A03F6A31A56C166E" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. On October 22, 2019, we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1205-wk-Fact-A20A9201DBA65E798200BDA5CE4810DD" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred and, beginning January 1, 2019, is reimbursing us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1209-wk-Fact-C75D5BE58E7954D29497C1EEA45BB805" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1216-wk-Fact-D6F0F74ECA5554F59E1028D87F85B0D0" name="us-gaap:LossOnContractTermination" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the expected </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1220-wk-Fact-C75D5BE58E7954D29497C1EEA45BB805" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-3" continuedAt="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-4"><ix:nonNumeric contextRef="FD2019Q3YTD" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="TextSelection-A70B00E5FFE15F628D0B87A9264FF276-0-wk-Fact-2FAEA637E15E5525B3D3C57C1F904331" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1437-wk-Fact-C45858AA40815D0D957B3CDEA86993D3" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1456-wk-Fact-387EC15DBDEC54DA90765784F4BFB660" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1475-wk-Fact-8457EA2A37BF53F38DD4C1F1A26BF747" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">170.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1495-wk-Fact-0DBEE02C8D1955FBAADFD2646430615B" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">204.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1515-wk-Fact-7629DC3CA69159E8BB2B825840670686" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1534-wk-Fact-869F1BB9F79D50C29F045335A63D97B3" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1553-wk-Fact-F821504C0EDC5226B32210F8467D382C" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">93.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1573-wk-Fact-FD94DFF7EF45538894D50CF15D1524E3" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">183.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1675-wk-Fact-B72A7ADD40045615AC11FCDE308B10EE" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1694-wk-Fact-592E67D4FCFB5855A91D6A37D36B9A8D" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1713-wk-Fact-B8CBC22F72AD57D29C37DF894F9CC926" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1733-wk-Fact-D07F2679CDE957D5BF9857B3626CDA79" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1753-wk-Fact-2ACB150FBC5750C1B70DCB2B635245FE" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1772-wk-Fact-B57F6AD0986755EA9E2836A9F48BF0FC" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d101543847e1791-wk-Fact-3D1A2FDC06EE5B7A9540BD306F2FAEBB" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1811-wk-Fact-966AE8BF05495327B7C93C7BE529B4EE" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1840-wk-Fact-443F6836C1E95321B10A41228EB42BD0" name="biib:AdditionalMilestonePayment" contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1847-wk-Fact-669699FA3E4B5ADFBBCD0175083A7BF1" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1851-wk-Fact-09D27EB3FC1F5583B66FFD1CEF40C1EF" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our condensed consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1855-wk-Fact-83FE42844D2D5D6D9AD2EC92B3D55533" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1868-wk-Fact-97B1DC30EE1451B589E24F434EE28586" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1872-wk-Fact-57A6C7E488D15251B4859C133413AF19" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1876-wk-Fact-41C9076F0CD05500AD40C9B1813B62B7" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1880-wk-Fact-74188DA200735AD0A97071671FA83255" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1889-wk-Fact-57A6C7E488D15251B4859C133413AF19" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-4" continuedAt="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-5"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">basis differences are amortized over their economic life. The total basis difference was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1902-wk-Fact-4ADB0647375A576683A472EF7E0A8666" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">675</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1906-wk-Fact-D851BC4B1C335CC3B74482A13BFCF67E" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to inventory, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1910-wk-Fact-3BEDE1E9E4BC51E88C84676A8C5581DD" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">615</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to developed technology and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1914-wk-Fact-88117E4C0E605DF2BBCD0A9D1BD20CC9" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to IPR&amp;D. A deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1918-wk-Fact-75D5E2EA582B5853ADD771B13BF6AE88" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101543847e1923-wk-Fact-D0B56147375C57EAB203DAD4E080DDA6" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" format="ixt-sec:duryear">1.5</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d101543847e1927-wk-Fact-12C935CFC7AB57C8BF3EE69A1F29D59E" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized losses on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1945-wk-Fact-5694131C618657188A5FC2186907BAC8" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1949-wk-Fact-676B308204A75A92841F894217824D62" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These losses reflect our share of losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1953-wk-Fact-E5852F6168BE5BA58B14D3B407F5DB2D" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1958-wk-Fact-5F87E498E0D855B49F991DEAF5A9A0E7" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1962-wk-Fact-29FAD35FFD335207BD199E86B88BF5C1" name="us-gaap:AdjustmentForAmortization" contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1966-wk-Fact-07D0FCC880BE5388B970E346B41D0DAA" name="us-gaap:AdjustmentForAmortization" contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">57.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1982-wk-Fact-614A26BF9CAA5234A94F21D03DD8B343" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">687.3</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1986-wk-Fact-21F8693027075A7C89C073D8E7A70F10" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">572.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e1990-wk-Fact-64EA025950885D3A83542D028249601B" name="us-gaap:EquityMethodInvestments" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e1995-wk-Fact-4B8BA2A26F295EA8B4A73205911DE0E9" name="us-gaap:EquityMethodInvestments" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">680.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e2008-wk-Fact-84CEB4A8EA4E59ABB78813A74FC4E419" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e2020-wk-Fact-0D1BCCD91F2A5BA397E75404BD9F30C6" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e2024-wk-Fact-204F715EB1E05D2E8869EA3F6855ABAC" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">181.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d101543847e2029-wk-Fact-84CEB4A8EA4E59ABB78813A74FC4E419" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e2033-wk-Fact-6B7A94489A0457E88CA91367EA0E88F0" name="biib:Collaborationprofitlosssharing" contextRef="FD2018Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e2037-wk-Fact-1BA41E4C34FB57CC96448CF19C880800" name="biib:Collaborationprofitlosssharing" contextRef="FD2018Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e2055-wk-Fact-C2E0730DB89853288C1399A328D3976C" name="us-gaap:Revenues" contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e2059-wk-Fact-4FE0583E44AC5A58B3454C36859D621D" name="us-gaap:Revenues" contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">89.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e2063-wk-Fact-E6F4B4172899582E85224D6FDF55563A" name="us-gaap:Revenues" contextRef="FD2018Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101543847e2068-wk-Fact-4A63DD97BE2D507993CD98E5B245B34F" name="us-gaap:Revenues" contextRef="FD2018Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations on August 1, 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><ix:continuation id="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-5" continuedAt="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-6"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis and our other significant collaboration arrangements, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-6"> Form 10-K.</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><a id="s54104CA9136A5FAFBE2C82BB08DFF17B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="TextSelection-9DC7D8892C215C19B8FC57EE48E08379-0-wk-Fact-81BC8636C2F75220A6F8D4BC4C459F01" continuedAt="TextSelection-9DC7D8892C215C19B8FC57EE48E08379-1" escape="true">Investments in Variable Interest Entities</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9DC7D8892C215C19B8FC57EE48E08379-1"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound.  </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our collaboration and license agreement with Neurimmune (the Neurimmune Agreement), the royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, range from the high single digits to sub-teens.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimbursed Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101542224e839-wk-Fact-DBC793BD60245A08B229FEA9A0B1A6CF" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101542224e843-wk-Fact-15C578FB0A225420AEFF662EE7B1CF18" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read Note 20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></ix:continuation><div><a id="s3FE96619292D53BDB5B08A4410A5AE78"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-0-wk-Fact-FE4CEBF7F10E5198810F9B7BB6E8BE6B" continuedAt="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-1" escape="true">Litigation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-1" continuedAt="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-2"><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-2" continuedAt="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-3"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH&#160;(Fresenius Kabi)&#160;commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen commercializes in Europe, infringes the French counterpart of European Patent No. 3 148 510&#160;(the &#8216;510 Patent), which was issued in June 2018 and expires in May 2035. No hearing on the merits has been scheduled.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of the Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. A hearing in the proceeding in Germany has been set for March 2020. No hearing on the merits has been scheduled.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss in the above matters cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the &#8216;510 Patent. Fresenius Kabi counterclaimed for infringement, damages and injunctive relief. In July 2019 the United Kingdom Patents Court entered a consent order in which it declared that the U.K. counterpart of the '510 Patent is invalid, ordered the patent revoked and dismissed Fresenius Kabi's counterclaims.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &#8216;510 Patent. In September 2019 the parties entered an Agreement to Discontinue Proceedings wherein Fresenius Kabi declared the Dutch counterpart of the '510 Patent invalid and surrendered it in full. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the U.K. counterpart of the '667 Patent, and in August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. A hearing has been set for May 2020 in the Dutch matter and October 2020 in the U.K. matter.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-3" continuedAt="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-4"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case was filed under seal in January 2014 and unsealed in April 2018 after the U.S. government declined to intervene. The case alleged agreements with pharmacy benefit managers in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. In September 2019 the court dismissed the action on the U.S. government's motion.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers were defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In June 2019 the U.S. Court of Appeals for the First Circuit affirmed the judgment dismissing the complaint with prejudice.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dismissed Shareholder Derivative Litigation</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On January 13, 2017, Mary Ann Mullaney, a Biogen shareholder, filed a complaint in the U.S. District Court for the District of Delaware asserting derivative claims on behalf of Biogen against certain of the company&#8217;s current and former directors and officers alleging that those individuals (i) breached their fiduciary duties by failing to oversee the company&#8217;s operations, (ii) breached their fiduciary duties and Section 14(a) of the Securities Exchange Act of 1934, as amended, and (iii) were unjustly enriched.&#160;The complaint sought unspecified damages, interest, attorneys&#8217; fees and other costs.&#160;The parties filed a Joint Stipulation for Voluntary Dismissal and Proposed Order, which the court granted on August 6, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial date has been set in the Delaware action against Banner Life Sciences LLC for March 2020. A trial date has been set for December 2019 in the other Delaware actions and a trial date has been set for February 2020 in the West Virginia action against Mylan Pharmaceuticals Inc.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals Inc. filed a petition with the U.S. Patent Trial and Appeal Board (PTAB) seeking </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. On February 6, 2019, the PTAB instituted </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 Patent (the "Mylan IPR"). Thereafter, the PTAB </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-4" continuedAt="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-5"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">granted the petition of Sawai USA, Inc. and Sawai Pharmaceutical Co. Ltd. and joined them as petitioners in the Mylan IPR. A hearing has been scheduled for November 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the European Patent Office (EPO) revoked our European patent number 2 137 537 (the '537 Patent), which includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for March 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for June 2020. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &#8216;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &#8216;127 Patent) (&#8220;Administration of agents to treat inflammation&#8221;).  The Polish &#8216;263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish &#8216;263 Patent expires in February 2023. No hearing on the merits has been set in this matter.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which also concerns administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed in September 2019 and our appeal as to the German action is pending. No date for a hearing on the merits has been set in the Italian action.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We are cooperating with the </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-5"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">investigation and have participated in preliminary discussions with the government regarding potential resolution of aspects of the matter. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also received subpoenas and other requests from the U.S. government for documents and information relating to Biogen's co-pay assistance programs. We cooperated with the investigation and have received no communication from the government in this matter since December 2017.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d101544328e943-wk-Fact-259FC5E41D445CB6B510A8BB339F4FF6" name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDD7E3B206A4053DEAFFA3530DB2D2796"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy (PSP), Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.  </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the E.U. For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. Additionally, a significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">future sales of our existing products. Our products may also face increased competitive pressures from the introduction of generic versions, prodrugs of existing therapies, biosimilars of existing products, other products approved under abbreviated regulatory pathways and other technologies. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures as well as the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the competition and pricing risks that could negatively impact our product sales, please read Item 3.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Quantitative and Qualitative Disclosures About Market Risk </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Brexit</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. electorate voted in a referendum to voluntarily depart from the E.U., known as Brexit. In March 2017 the U.K. government formally notified the European Council of its intention to leave the E.U. and began to negotiate the terms of the future relationship between the U.K. and the E.U. upon exit, which is expected to occur in October 2019.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The potential impact on our results of operations and liquidity resulting from Brexit remains unclear. The actual effects of Brexit will depend upon many factors and significant uncertainty remains with respect to the ultimate resolution of the Brexit negotiations. The final outcome of these negotiations may impact certain of our research, commercial and general business operations in the U.K. and the E.U., including the approval and supply of our products. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and consolidated results of operations from these developments remains unknown. We do not, however, expect Brexit to have a material impact on our consolidated results of operations as 3.3% and 3.4% of our total product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and 3.2% and 3.3% for the prior year comparative periods, respectively, were derived from U.K. sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have implemented measures to meet E.U. legal and regulatory requirements and continue to modify our business operations to prepare for the U.K.'s separation from the E.U. However, we cannot predict the direction Brexit-related developments will take nor the impact of those developments on our European operations and the economies of the markets where we operate. Therefore, we will continue to monitor developments in this area and assess any potential impact on our business and results of operations.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA413B7F9E6A55FA8A63D4024F43FED7F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</span></div><div style="line-height:120%;text-align:justify;"><img src="financialhighlights.jpg" alt="financialhighlights.jpg" style="height:426px;width:317px;"></img></div><div><a id="s3C5357228666547882ED585A590450B4"></a></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.39</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 17.3% over </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our net income and diluted earnings per share attributable to Biogen Inc. for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3,600.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">third</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 4.7% over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3,439.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2,894.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">third</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 4.1% over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2,780.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a 36.2% increase in revenues from our biosimilar products and a 17.0% increase in revenues from SPINRAZA. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$595.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">third</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 16.4% over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$511.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">due to a 37.3% increase in royalty revenues on sales of OCREVUS.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$109.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">third</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of 25.5% from </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$147.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily due to lower revenues from our contract manufacturing agreements. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses were </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1,793.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">third</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">3.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1,741.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">11.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in selling, general and administrative expense, a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">6.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in research and development expense and a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">34.2%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in net (gain) loss on fair value remeasurement of contingent consideration. The increase to cost and expenses was partially offset by a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">6.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in cost of sales. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. was favorably impacted by a decrease in our effective tax rate to 11.9% for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">third</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from 20.4% for the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due in part to an internal reorganization of certain intellectual property rights and the impact of the enactment of a new taxing regime in the country and certain cantons of Switzerland, which we refer to as Swiss Tax Reform.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Condition, Liquidity and Capital Resources:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities totaled approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$6.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$4.9 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We repurchased and retired approximately 3.1 million shares of our common stock at a cost of approximately $717.9 million during the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">third</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of 2019 under a program authorized by our Board of Directors in March 2019 to repurchase up to $5.0 billion of our common stock (2019 Share Repurchase Program).</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions, Divestitures, Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. In connection with this agreement, we made an upfront payment of $74.0 million to Skyhawk.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Skyhawk, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 7, 2019, we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added two mid-to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (formerly known as NSR-REP1), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (formerly known as NSR-RPGR), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa (XLRP), which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.50</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled $847.6 million. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM Corporation (FUJIFILM). Upon the closing of this transaction, we received approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$881.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, which is subject to the finalization of certain working capital adjustments and may be further adjusted based on </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other contractual terms. In addition, we sold to FUJIFILM $41.8 million of raw materials.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Key Developments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB098 (diroximel fumarate)</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2019 we and Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of RMS. The NDA has been assigned a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019. In October 2019 the FDA issued a tentative approval for diroximel fumarate. If approved, we intend to market diroximel fumarate under the brand name VUMERITY, which has been conditionally accepted by the FDA and will be confirmed upon final approval.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab (AB mAb)</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 22, 2019, we and Eisai Co., Ltd. (Eisai) announced that we plan to pursue regulatory approval for aducanumab in the U.S. and that the Phase 3 EMERGE study met its primary endpoint showing a significant reduction in clinical decline. We believe that results from a subset of patients in the Phase 3 ENGAGE study who received sufficient exposure to high dose aducanumab support the findings from EMERGE. The decision to file is based on a new analysis, conducted by Biogen in close consultation with the FDA, of a larger dataset from the Phase 3 EMERGE and ENGAGE trials that were discontinued in March 2019 following a futility analysis.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Elenbecestat</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, MISSION AD1 and MISSION AD2, designed to assess the efficacy and safety of elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, in patients with mild cognitive impairment and mild AD. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Share Repurchase Program</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">common stock. Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></div></div><div><a id="sA5CA135CD08855768E07E2E67DE2EA1C"></a></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</span></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,702.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,740.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,959.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,020.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,192.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,495.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,040.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,894.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">80.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,780.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,455.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">79.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,061.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">595.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">511.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,689.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,445.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">109.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">562.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">420.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,600.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,439.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10,706.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,926.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</span></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,122.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,090.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,271.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,163.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">530.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">590.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,585.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">483.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">470.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,419.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,399.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,160.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">74.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,347.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">75.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,400.4</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">547.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,553.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,254.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">115.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">123.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">360.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">132.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">183.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">542.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">389.1</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,894.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,780.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,455.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,061.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s9B874DF013555EF4ADE2BF441E9ABC01"></a></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;"><img src="tecfidera.jpg" alt="tecfidera.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, U.S. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA revenues were consistent with price increases, offset by a decrease in unit sales volume of 4% and higher rates in discounts and allowances. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of 1.4% in U.S. TECFIDERA revenues was primarily due to price increases, partially offset by a decrease in unit sales volume of 3% and higher rates in discounts and allowances. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of 13.1% and 9.8%, respectively, in rest of world TECFIDERA revenues were primarily due to increases in unit sales volumes of 10% and 13%, respectively, primarily related to our European and Japanese markets, partially offset by pricing reductions in certain European countries. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate an increase in TECFIDERA demand on a global basis in 2019, compared to 2018, notwithstanding increasing competition from additional treatments for MS. We expect volume growth in our international markets to exceed volume </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">declines in the U.S. We also expect price reductions in certain European countries.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, related to TECFIDERA. These parties have, or are seeking, regulatory approval of Abbreviated New Drug Applications for generic versions of TECFIDERA or NDAs filed under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. If we are unsuccessful in these patent infringement actions, generic versions of TECFIDERA or other bioequivalent products could be introduced into the market prior to our patents&#8217; expiry dates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</span></div><div style="line-height:120%;text-align:left;"><img src="interferon.jpg" alt="interferon.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases of 14.5% and 13.8%, respectively, in U.S. Interferon revenues were primarily due to decreases in Interferon unit sales volumes of 11% and 12%, respectively, which were primarily attributable to patients transitioning to other MS therapies and price decreases. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of 0.7% in rest of world Interferon revenues was primarily due to an increase in Interferon unit sales volumes of 13%, partially offset by pricing reductions in certain European countries.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease of 2.0% in rest of world Interferon revenues was primarily due to pricing reductions in certain European countries, partially offset by an increase in Interferon unit sales volumes of 15%.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that Interferon revenues will continue to decline in both the U.S. and international markets in 2019, compared to 2018, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;"><img src="tysabri.jpg" alt="tysabri.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of 4.0% in U.S. TYSABRI revenues was primarily due to price increases, partially offset by higher rates in discounts and allowances and a decrease in unit sales volumes of 1%.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of 0.5% in U.S. TYSABRI revenues was primarily due to price increases, partially offset by a decrease in unit sales volumes of 4%.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of 1.6% and 2.5%, respectively, in rest of world TYSABRI revenues were primarily due to increases in unit sales volumes of 14% and 7%, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate TYSABRI demand to be stable on a global basis in 2019, compared to 2018, with expected volume declines in the U.S. due to increasing competition from additional treatments for MS, including OCREVUS, to be offset by volume growth in our international markets.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;text-align:left;"><img src="spinraza.jpg" alt="spinraza.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of 5.7% and 11.8%, respectively, in U.S. SPINRAZA revenues were primarily due to increases in unit sales volumes of 6% and 12%, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of 27.3% and 35.6%, respectively, in rest of world SPINRAZA revenues were primarily due to increases in unit sales volumes of 71% and 68%, respectively, partially offset by the unfavorable impact of foreign currency exchange of $9.2 million and $36.3 million, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world SPINRAZA revenues were favorably impacted by approximately $14.0 million as we reached a price reimbursement agreement in France, which resulted in the recognition of additional revenues in relation to sales for the period from August 2017, the date upon which we began to sell SPINRAZA in France, until December 2018 as we had a change in the estimated amount of revenues for which we determined that a significant reversal was not probable. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the rate at which SPINRAZA revenues will grow will moderate in 2019, compared to 2018, primarily due to a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We face competition from a new gene therapy product, which was approved in the U.S. in May 2019 </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">for the treatment of SMA. Additionally, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market. Future sales of SPINRAZA may be adversely affected by the commercialization of these competing products.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BENEPALI, IMRALDI and FLIXABI</span></div><div style="line-height:120%;"><img src="biosimilars.jpg" alt="biosimilars.jpg" style="height:333px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of 36.2% and 39.4%, respectively, in biosimilar revenues were primarily due to the launch of IMRALDI in the fourth quarter of 2018, partially offset by the unfavorable impact of foreign currency exchange of $6.5 million and $23.7 million, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2019 we expect strong revenue growth for our biosimilar business, primarily driven by the continued launch of IMRALDI.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5991B778E5935447B753EC24EFBFFEED"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;"><img src="anticd20.jpg" alt="anticd20.jpg" style="height:346px;width:317px;"></img></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables provide a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,189.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,112.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">141.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">157.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,048.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">955.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">393.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">358.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,581.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,350.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">473.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">499.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,108.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,850.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,161.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,066.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues, net was primarily due to increased net sales of RITUXAN in the U.S. of 6.1%. This increase in net sales of RITUXAN in the U.S. reflects an increase in unit sales volume of 2% and lower discounts and allowances.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues, net was primarily due to increased net sales of RITUXAN in the U.S. of 6.4%. This increase in net sales of RITUXAN in the U.S. reflects an increase in unit sales volume of 3% and selling price increases, partially offset by higher discounts and allowances. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in U.S.&#160;product revenues, net also reflects increases in GAZYVA unit sales volume of 20% and 13%, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in collaboration costs and expenses was primarily due to lower cost of sales on RITUXAN.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in collaboration costs and expenses was primarily due to lower selling and marketing costs on RITUXAN and lower Branded Pharmaceutical Drug Fee expenses for RITUXAN and GAZYVA.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are aware of anti-CD20 molecules, including biosimilar products, in development that if successfully developed and approved, may compete with RITUXAN. In 2018 the FDA approved a rituximab biosimilar in the U.S. A biosimilar of RITUXAN could come to market in the U.S. in the fourth quarter of 2019, which may adversely affect the pre-tax profits of our collaboration arrangements with Genentech, which would, in turn, adversely affect our co-promotion profits in the U.S. in future years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs consist of royalty revenues on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in other revenues from anti-CD20 therapeutic programs were primarily due to sales growth of OCREVUS. Royalty revenues recognized on sales of OCREVUS for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$187.8 million and $482.1 million, respectively, compared to $136.8 million and $326.5 million, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">OCREVUS royalty revenues are based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></div></div><div><a id="s6DE4ABEC9D0E5769851BC102DF4F7AE6"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">89.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">96.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">88.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">472.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">84.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">347.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">109.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">562.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">420.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships primarily include revenues from our technical development services and manufacturing agreements with Samsung Bioepis and royalty revenues on biosimilar products from Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations on August 1, 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized $12.9 million and $89.9 million, respectively, in revenues related to the services described above provided to Samsung Bioepis, compared to $48.1 million and $80.7 million, respectively, in the prior year comparative periods. Revenue recognized related to these services totaled $96.4 million for the year ended&#160;December&#160;31, 2018.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborative and other relationships, including revenues recognized under our technical development services and manufacturing agreements with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</span></div><div style="line-height:120%;"><img src="otherrevenues.jpg" alt="otherrevenues.jpg" style="height:333px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">amounts earned under contract manufacturing agreements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in other royalty and corporate revenues was primarily due to the reduction in royalty revenues due to the expiration of certain of our patents, partially offset by higher contract manufacturing revenues.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other royalty and corporate revenues was primarily due to $306.9 million in revenues recognized under the manufacturing and supply agreement with Bioverativ Inc. (Bioverativ) entered into in connection with the spin-off of our hemophilia business, compared to $131.1 million recognized in the prior year comparative period. The increase in Bioverativ revenues over the prior year comparative period was due to sales of hemophilia inventory on hand. The increase in corporate revenues was partially offset by the reduction in royalty revenues due to the expiration of certain of our patents.</span></div><div><a id="s314A589F19B9598D97502CD762FF49AE"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</span></div><div style="line-height:120%;text-align:left;"><img src="reservesfordisandallow.jpg" alt="reservesfordisandallow.jpg" style="height:352px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues were 24.4% and 23.5%, respectively, compared to 22.7% and 23.4%, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounts were relatively consistent. </span></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </span></div><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in contractual adjustments were primarily due to higher managed care rebates and governmental rebates in the U.S. as well as higher governmental rebates and allowances in the rest of world, due in part to increases in SPINRAZA sales volumes worldwide.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenues are recognized, resulting in a reduction to product sales. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserves were relatively consistent.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenue reserves, please read Note 4, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div><a id="sDE06B3C1C9AA5F6584CC1E9A6413BF7A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">430.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">460.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,508.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,327.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">540.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">507.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,588.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,985.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(20.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">554.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">497.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,709.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,515.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">283.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">422.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">493.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">60.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">181.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">129.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">95.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(57.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(87.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(66.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(91.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(83.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,793.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,741.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,441.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,481.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</span></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="sBDCACECC8E835696BECA8FFEBCFE3360"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div style="line-height:120%;"><img src="costofsales.jpg" alt="costofsales.jpg" style="height:293px;width:317px;"></img></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in product cost of sales was primarily due to lower cost of sales from contract manufacturing agreements and a decrease in inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons, partially offset by an increase in sales of our biosimilar products. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily due to our sale to Bioverativ of hemophilia-related inventory on hand with a cost basis totaling $173.5 million in the first quarter of 2019, pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, an increase in sales of our biosimilar products and an increase in inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons, partially offset by lower cost of sales from our contract manufacturing agreements, except Bioverativ, as noted above.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in royalty cost of sales were primarily due to a decrease in royalties payable on sales of TYSABRI resulting from the expiration of certain third party royalties, partially offset by increased royalties payable on higher sales of SPINRAZA and IMRALDI.</span></div><div><a id="s801A88978A9E5A15960224FF440CEB49"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;"><img src="rdpercentofrev.jpg" alt="rdpercentofrev.jpg" style="height:366px;width:317px;"></img></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;"><img src="rd.jpg" alt="rd.jpg" style="height:766px;width:317px;"></img></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represent costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily due to increases in costs incurred in connection with our early and late stage programs, partially offset by a decrease in costs incurred in connection with milestones and upfront expenses and research and discovery.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in research and development expense was primarily due to a decrease in milestone and upfront expenses and a decrease in research and discovery. These decreases were partially offset by increases in costs incurred in connection with our early and late stage programs.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Milestone and upfront expenses for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflected the recognition of a $38.5 million charge to research and development expense upon entering into our collaboration and research development services agreement with Skyhawk. The decrease compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was primarily due to the prior year recognition of a $486.2 million net charge to research and development expense related to the closing of a 10-year exclusive agreement with Ionis to </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases (the 2018 Ionis Agreement).</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Early Stage Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in spending related to our early stage programs were primarily due to an increase in costs associated with: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our decision in September 2019 to discontinue the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis (IPF);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB092 (gosuranemab) in PSP and AD pursuant to our license agreement with Bristol-Myers Squibb Company; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB054 (&#945;-synuclein mAb) in Parkinson's disease; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB104 in cognitive impairment associated with schizophrenia (CIAS); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB110 (ActRIIA/B ligand trap) in SMA.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These increases were partially offset by a decrease in costs associated with: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the development of vixotrigine (BIIB074) in trigeminal neuralgia (TGN);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB067 (tofersen) in ALS, which was advanced to a late stage program in the first quarter of 2019;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our decision in December 2018 to discontinue development of BIIB087, an investigational AAV-based gene therapy for the treatment of X-linked retinoschisis, and BIIB088, an investigational AAV-based gene therapy for the treatment of XLRP, upon the termination of our collaboration agreement with Applied Genetic Technologies Corporation; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BAN2401 (A&#946; mAb) in early AD pursuant to our collaboration arrangement with Eisai, which was advanced to a late stage program in the first quarter of 2019.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Late Stage Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in spending associated with our late stage programs were primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of the termination costs related to the discontinuation of the global Phase 3 trials of elenbecestat in AD;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BAN2401 in early AD pursuant to our collaboration arrangement with Eisai, which was advanced to a late stage program in the first quarter of 2019;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tofersen in ALS, which was advanced to a late stage program in the first quarter of 2019; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB093 (glibenclamide IV) in large hemispheric infarction (LHI), which was advanced to a late stage program in the third quarter of 2018. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These increases were partially offset by a decrease in spending related to the discontinuation of the global Phase 3 trials of aducanumab, net of Eisai reimbursement. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab. On October 22, 2019, we and Eisai announced that, based on a new analysis, conducted by Biogen in close consultation with the FDA, of a larger dataset from the Phase 3 EMERGE and ENGAGE trials that were discontinued in March 2019 following the futility analysis, we plan to pursue regulatory approval for aducanumab in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 Eisai initiated a global Phase 3 trial for the development of BAN2401 in early AD. Under our collaboration arrangement, Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, MISSION AD1 and MISSION AD2, designed to assess the efficacy and safety of elenbecestat in patients with mild cognitive impairment and mild AD. As a result of this decision, in the third quarter of 2019, we accrued approximately $48.0 million related to our share of the termination of various clinical trials and research and development contracts incurred under the collaboration arrangement with Eisai.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</span></div><div style="line-height:120%;"><img src="sga.jpg" alt="sga.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in selling, general and administrative expense were primarily due to an increase in corporate giving, an increase in commercialization costs, primarily related to SPINRAZA, as we continued to expand into new international markets, an increase in incentive compensation and an increase in legal and patent fees. These increases were partially offset by a decrease in operational spending associated with our pre-commercialization costs related to our AD programs following the discontinuation of the global Phase 3 trials of aducanumab in March 2019. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expense for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflects an increase due to acquisition related charges incurred in connection with our acquisition of NST totaling $33.4 million, including $18.4 million of stock-based compensation expense associated with the accelerated vesting of stock options previously granted to NST employees for post-combination services performed, partially offset by a decrease in operational spend on ZINBRYTA subsequent to the voluntary worldwide withdrawal of ZINBRYTA for RMS, which we and AbbVie Inc. announced in March 2018. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><a id="s85D18EB6E19757338B11B6148A14E191"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization and Impairment of Acquired Intangible Assets</span></div><div style="line-height:120%;"><img src="amortacquiredintangible.jpg" alt="amortacquiredintangible.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the second quarter of 2019. The results of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA analyses were impacted by changes in the estimated timing and impact of other alternative MS formulations, including OCREVUS. The outcome of this most recent analysis resulted in a net overall decrease in our expected rate of amortization for acquired intangible assets, which was primarily related to higher expected lifetime revenues of TYSABRI. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended September 30, 2019, reflects the impact of a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$215.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge related to certain in-process research and development (IPR&amp;D) assets associated with the Phase 2b study of BG00011 for the potential treatment of IPF, which was discontinued in the third quarter of 2019, as discussed below.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended September 30, 2018, reflects the impact of impairment charges related to certain IPR&amp;D assets associated with our vixotrigine program totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$189.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets, excluding impairment charges, totaled approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$206.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended September 30, 2019, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$303.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in amortization of acquired intangible assets, excluding impairment charges, was primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This decrease was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma            A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D related to Business Combinations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">BG00011</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns. As a result, we recognized an impairment charge of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$215.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2019 to reduce the fair value of the IPR&amp;D </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">intangible asset to zero. We also adjusted the value of our contingent consideration obligations related to this asset resulting in a gain of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$61.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in the third quarter of&#160;2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed the Phase 2b study of vixotrigine for the potential treatment of PLSR. The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR. As a result, we recognized an impairment charge of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the IPR&amp;D intangible asset to zero.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN as we awaited the outcome of ongoing interactions with the FDA regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy. We reassessed the fair value of the TGN program using reduced expected lifetime revenues, higher expected clinical development costs and a lower cumulative probability of success. As a result of that assessment, we recognized an impairment charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$129.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the TGN IPR&amp;D intangible asset to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> at that date. We also adjusted the value of our contingent consideration obligations related to the TGN program to reflect the lower cumulative probabilities of success resulting in a gain of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$89.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in the third quarter of&#160;2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon many variables, including estimates of future revenues and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates and prioritization of these items may result in a significant change to our valuation of our IPR&amp;D assets.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For example, the TGN program has experienced numerous delays in development in the periods since we acquired the TGN program and the fair value of this asset is not significantly in excess of carrying value. In addition, we are currently testing vixotrigine in another mid-stage clinical trial, in a different neuropathic pain indication, for which we also have an IPR&amp;D asset. Data from that trial may affect the economic value of vixotrigine and the IPR&amp;D assets for one or both programs could be impaired if assumptions used in determining their fair value change.  </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the amortization and impairment of our acquired intangible assets, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="s6CE2DFF5E5345B72A810F9D815DFA675"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</span></div><div style="line-height:120%;"><img src="collabprofitshare.jpg" alt="collabprofitshare.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing primarily includes our partner's </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$181.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$131.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. The increases in profit-sharing expense were primarily due to increased collaboration profits resulting from increased biosimilar sales.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><a id="s08849B9A38545096BD94785439DE138A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss on Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;"><img src="lossondivestiture.jpg" alt="lossondivestiture.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 1, 2019, we completed the sale of all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. Upon the closing of this transaction, we received approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$881.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, which is subject to the finalization of certain working capital adjustments and may be further adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$114.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction we recognized a total net loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$160.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$95.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects a decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our previously recorded pre-tax loss. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$114.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this transaction. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the adverse commitment is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div><a id="s9C7EE2ADC93F57A1B4D7926E533A8E33"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div style="line-height:120%;"><img src="gainlossfvcontconsider.jpg" alt="gainlossfvcontconsider.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of our BG00011 program for the potential treatment of IPF, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to lower cumulative probabilities of success related to our vixotrigine program for the potential treatment of TGN, an increase in interest rates used to revalue our contingent consideration liabilities and the passage of time. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our IPR&amp;D intangible assets related to our discontinued BG00011 program for the potential treatment of IPF and our vixotrigine program for the potential treatment of TGN, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div><a id="s0F9311E3BC9C5C0781817B57A29B9A93"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></div><div style="line-height:120%;"><img src="acquiredinprocessrd.jpg" alt="acquiredinprocessrd.jpg" style="height:293px;width:317px;"></img></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB110 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we acquired BIIB110 and ALG-802 from AliveGen Inc. (AliveGen). BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. In connection with the closing of this transaction, we made an upfront payment of $27.5 million to AliveGen, which was recorded as acquired IPR&amp;D in our condensed consolidated statements of income as BIIB110 has not yet reached technological feasibility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB104 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we acquired BIIB104 from Pfizer Inc. (Pfizer). BIIB104 is a first-in-class, Phase 2b AMPA receptor potentiator for CIAS. In connection with the closing of this transaction, we made an upfront payment of $75.0 million to Pfizer, which was recorded as acquired IPR&amp;D in our condensed consolidated statements of income as BIIB104 has not yet reached technological feasibility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB100 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired BIIB100 from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. In connection with the closing of this transaction, we made an upfront payment of $10.0 million to Karyopharm, which was recorded as acquired IPR&amp;D in our condensed consolidated statements of income as BIIB100 has not yet reached technological feasibility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions of BIIB110, BIIB104 and BIIB100, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div><a id="sA7A2A3307F145DEDBC672D49BE5DDE24"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</span></div><div style="line-height:120%;"><img src="otherincomeexp.jpg" alt="otherincomeexp.jpg" style="height:266px;width:317px;"></img></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net losses totaling $4.1 million recognized on our investments related to our holdings in equity and debt securities, compared to net gains totaling $141.1 million in the prior year comparative period. The net losses recognized during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflects a decrease in the fair value in our investment in Ionis common stock from June 30, 2019, partially offset by a gain recognized on our sale of a portion of our investment in Ionis common stock during the third quarter of 2019 reflecting an increase in fair value of the shares sold from June 30, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from our sale of a portion of our investment in Ionis common stock during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled approximately $168.7 million and $382.0 million, respectively. The original cost basis upon acquisition in June 2018 for the shares sold during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled approximately $138.9 million and $312.5 million, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net gains totaling $198.9 million recognized on our investments related to our holdings in equity and debt securities, compared to net gains totaling $132.0 million in the prior year comparative period. The net gains recognized during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflect an increase in the fair value in our investment in Ionis common stock from December 31, 2018, partially offset by the net loss recognized on our sale of a portion of our investment in Ionis common stock during the second quarter of 2019 and third quarter of 2019 reflecting a decrease in fair value of the shares sold from March 31, 2019. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflects an increase in the fair value of an investment in a non-marketable equity security from December 31, 2018, that was realized for a net gain of approximately $87.7 million upon sale in the second quarter of 2019. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="sD05C8C5EFDD650D7B9D4A724AF607AC0"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</span></div><div style="line-height:120%;"><img src="taxprovision.jpg" alt="taxprovision.jpg" style="height:350px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2018, the decrease in our effective tax rate was primarily due to Swiss Tax Reform. As a result of the impact of Swiss Tax Reform, in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded an income tax benefit of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, resulting from a remeasurement of our deferred tax assets and liabilities. In addition, in the  </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net benefit for the impact of the internal reorganization of certain intellectual property rights and a net benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> resulting from the finalization of tax returns in various jurisdictions related to the 2018 fiscal year. We also had a higher effective tax rate in 2018 resulting from our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2018, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of Swiss Tax Reform. This decrease was partially offset </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense related to the divestiture of our subsidiary that owned our Hiller&#248;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Although we are recognizing a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture requires us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the internal reorganization of certain intellectual property rights, as of September 30, 2019, we recorded a deferred tax asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$754.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$603.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160; </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our uncertain tax positions and income tax rate reconciliation for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 15, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="sBEA6EFE6F777580DA262D67925DA985D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity in Loss of Investee, Net of Tax</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;"><img src="equitylossofinvestee.jpg" alt="equitylossofinvestee.jpg" style="height:266px;width:317px;"></img></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately 49.9%.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, losses reflect our share of losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$57.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><a id="s12AE9E35A82C540EBD169D36DE4355CC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,343.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,224.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,093.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,313.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,813.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,375.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,251.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,913.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,495.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,458.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(24.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,953.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,448.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,640.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,432.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,295.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,016.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,345.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s1F2CACD8EB9956189A3943BDB19F834B"></a></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$5.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net cash flows provided by operating activities, net of</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$788.5 million in total payments for income taxes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million upfront payment </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">made to Skyhawk upon entering into a collaboration and research and development services agreement; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$45.0 million upfront payment made to C4 Therapeutics (C4T) upon entering into a collaborative research and license agreement; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3.8 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">$923.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in proceeds received on the divestiture of our Hiller&#248;d, Denmark manufacturing operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$744.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment made for our acquisition of NST, net of cash acquired;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$476.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in proceeds received on sales of strategic investments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$404.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for purchases of property, plant and equipment; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the final contingent payment made to former shareholders of Fumapharm AG and holders of their rights.</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$4.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net cash flows provided by operating activities, net of:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$698.8 million in total payments for income taxes; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million upfront payment </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">made to Ionis upon the closing of the 2018 Ionis Agreement and a $162.1 million charge reflecting the premium paid for the purchase of Ionis common stock; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.2 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$544.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for purchases of property, plant and equipment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$462.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment made to Ionis reflecting the fair value of the Ionis common stock purchased upon the closing of the 2018 Ionis Agreement; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$112.5 million in upfront payments made for our acquisitions of BIIB100, BIIB104 and BIIB110.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned from our operations. We expect to continue funding our current and planned operating requirements principally through our cash flows from </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read Item 3. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. Under our 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$717.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From October 1, 2019 through October 21, 2019, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$508.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2019 Share Repurchase Program. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.9 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our 2019 Share Repurchase Program as of October 21, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had cash, cash equivalents and marketable securities totaling approximately $6.3 billion compared to approximately $4.9 billion as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The net increase in cash, cash equivalents and marketable securities at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to cash flows from operations, cash received upon the divestiture of our Hiller&#248;d, Denmark manufacturing operations and proceeds from sales of strategic investments, partially offset by cash used for share repurchases, cash used for our acquisition of NST, net purchases of property, plant and equipment, contingent payments made to former shareholders of Fumapharm AG and holders of their rights, net purchases of marketable securities and upfront payments made to Skyhawk and C4T.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets in our condensed consolidated balance sheet as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and December 31, 2018, includes the carrying value of our investment in Samsung Bioepis of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$572.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. Investments and other assets, as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and December 31, 2018, also includes the fair value of our investment in Ionis common stock of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$318.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$563.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which is subject to certain holding period restrictions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">included in this report. For additional information on our collaboration arrangements with Skyhawk and Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Ionis and C4T, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These Senior Notes were issued at a discount and are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair and carrying values of our outstanding borrowings as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital is defined as current assets less current liabilities. The change in working capital at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects an increase in total current assets of approximately $807.3 million and an increase in total current liabilities of approximately $1.1 billion.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net increase in total current assets was primarily driven by an increase in net cash, cash equivalents and marketable securities, as described above, offset by a decrease in inventory resulting from our sale of hemophilia-related inventory to Bioverativ.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net increase in current liabilities was primarily due to the reclassification of $1.5 billion of our Senior Notes to current liabilities from notes payable, as the Senior Notes are due within one year. This increase was partially offset by a reduction in accrued expenses and other. The net decrease in accrued expenses and other was primarily related to a decrease in the accrual of contingent payments related to FUMADERM and TECFIDERA, a decrease in the accrual for construction in progress and the $45.0 million upfront payment made to C4T, which was accrued as of December 31, 2018.</span></div></div></div><div><a id="s918DFA0C45565F3A8EB89E90E43DF296"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,118.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,292.3</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(237.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(421.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(43.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,744.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,035.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s03B29774916F5011B0E2A343809A2140"></a></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in operating assets and liabilities which reflect timing differences between the receipt </span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net cash flows provided by operating activities increased primarily due to higher net income, the changes in working capital, as discussed above, the $375.0 million upfront payment made to Ionis upon the closing of the 2018 Ionis Agreement and a $162.1 million charge reflecting the premium paid for the purchase of Ionis common stock in the prior year comparative period. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows used in investing activities was primarily due to a decrease in net proceeds related to marketable securities and the cash used for our acquisition of NST. These amounts were partially offset by a decrease in contingent payments made to former shareholders of Fumapharm AG and holders of their rights, the proceeds received upon the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the proceeds received on our sales of strategic investments and the $462.9 million payment made to Ionis reflecting the fair value of the Ionis common stock purchased upon the closing of the 2018 Ionis Agreement in the prior year comparative period.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in financing activities was primarily due to the increase in cash used for share repurchases. </span></div><div><a id="s63E92C98AD68510A95A346AB7357DE10"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been no material changes in our contractual obligations since </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Payments</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation plc, full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11% and 15%, which are recognized as cost of sales in our condensed consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd. (Convergence), Stromedix, Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $0.7 billion in remaining milestones related to these acquisitions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments to third parties of up to approximately $6.3 billion, including approximately $0.9 billion in development milestones, approximately $1.7 billion in regulatory milestones and approximately $3.7 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval or commercial milestones.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately $172.0 million of milestone payments during the remainder of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $37.0 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately $466.0 million in cancellable future commitments based on existing CRO contracts as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately $128.0 million of liabilities associated with uncertain tax positions.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of both </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, included in other long-term liabilities we have accrued income tax liabilities of $697.0 million under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to a $87.0 million carryforward of taxes paid in relation to the company's 2017 tax return. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">accrue interest.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div><a id="s7AA3FF1C4FF95F10BBDF896621098C31"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - New Accounting Pronouncements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="s15E497B77D0452BB889BD01539237322"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Assets and Liabilities Held For Sale</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of our critical accounting estimates, please read Part&#160;II, Item&#160;7. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our 2018 Form&#160;10-K. Except as discussed above, there have been no material changes to these critical accounting estimates since our 2018 Form&#160;10-K.</span></div><div><a id="s79F039A6E4645A49AAAF78BCCC2518E9"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Asia and Central and South America. In addition, we recognize our share of pre-tax co-</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">promotion profits on RITUXAN in Canada. As a result, our condensed consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 9, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of foreign currency exchange rate changes on revenues and net </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $284.0 million and $290.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Hedge Program</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of exercising our option to increase our ownership percentage in Samsung Bioepis to approximately 49.9%. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one month</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement would result in a hypothetical decrease in fair value of approximately $50.0 million and $64.0 million, respectively. The estimated fair value was determined by measuring the impact of the </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">hypothetical spot rate movement on outstanding forward contracts.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $27.0 million and $19.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of certain drugs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways.&#160;Generic versions of drugs, biosimilars and other products approved under abbreviated regulatory pathways are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we receive for branded products and the volume of branded products that we sell, which will negatively impact our revenues.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">receivable and greater collection risk in certain countries. </span></div><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</span></div><div><a id="sAA150311235A5C13B880F3323FEC8DDD"></a></div><div style="line-height:120%;padding-top:16px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="line-height:120%;padding-top:10px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><a id="s37FC5D7BE054593AA8DB98320C352917"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Part&#160;II&#160;&#8212; OTHER INFORMATION</span></div><div><a id="sB3E72DC025ED5E9E9C58FFFDA9739AA3"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal proceedings as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our unaudited condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div><a id="s0F62B022360552A4B807FA30BE9C10FD"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our products. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. Additionally, a significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenues and results of operations or could cause a decline in our stock price: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition or changes in, or implementation of, reimbursement policies and practices of payors and other third parties; or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA has been approved by, among others, the FDA, the European Commission and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in certain markets. In addition to risks associated with new product launches and the other factors described in these </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others in the SMA community, which may be impacted by pricing and reimbursement decisions relating to SPINRAZA;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of a new gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA, and other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within certain SMA markets, which may impact our ability to develop additional relationships with the associated medical and scientific community; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers to treat patients with SMA.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenues and results of operations or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors' reimbursement policies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may not only limit the revenues from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, increasingly seek ways to reduce their costs. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients. Such measures include more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients&#8217; use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Payors also increasingly seek price discounts or rebates in connection with the placement of our products on their formularies or those they manage and control costs by imposing restrictions on access to or usage of our products, such as by requiring prior authorization or step therapy. Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Ultimately, additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. Under the Hatch-Waxman </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Act, a manufacturer may file an Abbreviated New Drug Application, seeking approval of a generic copy of an approved innovator product, or a NDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, which may be for a new or improved version of the original innovator product. The manufacturers are allowed to rely on the safety and efficacy data of the innovator&#8217;s product, may not need to conduct clinical trials, can market a competing version of a product after the expiration or loss of patent exclusivity or the expiration or loss of regulatory exclusivity and often charge significantly lower prices. Upon the expiration or loss of patent protection or the expiration or loss of regulatory exclusivity for a product, especially a small molecule product, the major portion of revenues for that product may be dramatically reduced in a very short period of time. If we cannot prevent others from exploiting our inventions, we will not derive the expected benefit from them. Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties, which could result in financial, legal, business or reputational harm to us.  </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenues for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon the successful development of additional indications for our existing products as well as the successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung BioLogics or licenses or acquisitions from third parties. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of uncertainty and risk. Only a small number of research and development programs result in the commercialization of a product. Furthermore, the development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining regulatory approval from the FDA and other regulatory agencies that have limited experience with the development of such therapies. In addition, clinical trial data are subject to differing interpretations and, even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, may limit the scope of the approval or may deny approval altogether. Consequently, it may be difficult to predict the time and cost of product development of novel approaches for the treatment of diseases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing and research and development and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways.&#160;Generic versions of drugs, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we receive for branded products and the volume of branded products that we sell, which will negatively impact our revenues.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, including TECFIDERA, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under other abbreviated regulatory pathways, which would be significantly less costly than our products to bring to market and would be offered for sale at lower prices, and could result in a significant percentage of the sales of our products being lost to such biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under other abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the off-label use by physicians of therapies indicated for other conditions to treat MS patients; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract and maintain new and current patients to our therapies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or generic or biosimilars of our MS products, or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products or generic or biosimilars of our MS products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the SMA market, we face competition from a gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA. Future sales of SPINRAZA may be adversely affected by the commercialization of this competing product.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives, external opportunities, which may include the acquisition, partnering and in-licensing </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of products, technologies and companies or the entry into strategic alliances and collaborations, or the disposition of certain of our assets or operations. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement. Furthermore, if we decide to dispose of certain of our assets or operations, we are not certain that we will be able to identify a suitable counterparty or if we will be able to reach agreement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may fail to initiate or complete transactions for many reasons and we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data to operate our business. Our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data. A breakdown, invasion, corruption, destruction or breach of our technology systems and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products, or generic or biosimilar versions of our marketed products, may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges or other adverse impacts on our results of operations. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy or liver injury in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators, joint venture partners and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships, including joint venture partners, for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships, including joint venture partners, subjects us to a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators, joint venture partners or third parties devote to our programs, products or product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators, joint venture partners or other third parties, and the underlying agreement with our collaborators, joint venture partners or other third parties may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third parties fail to perform; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators, joint venture partners or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships, joint ventures and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators, joint venture partners or other third parties to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators, joint venture partners or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any improper conduct or actions on the part of our collaborators, joint venture partners or other third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, and could adversely impact our ability to conduct business, our operating results and our reputation.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, or revenues from products could decline and/or we may not realize the anticipated benefits of the collaboration arrangements and/or joint ventures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues and may continue to adversely affect our revenues and results of operations in the future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the European Medicines Agency's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Further, certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we partner or collaborate with or acquire in emerging markets.&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates that may adversely impact our revenues, net income and value of certain of our investments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">diverse data privacy and protection requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effects of the implementation of the U.K.'s decision to voluntarily depart from the E.U., known as Brexit;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of tariffs or embargoes and other trade restrictions, including the recent tariffs imposed by the U.S. and China and the possibility of additional tariffs or other trade restrictions relating to trade between the two countries.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization in recent years. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. Further, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe we currently have sufficient large-scale manufacturing capacity to meet our near-term manufacturing requirements. However, due to the long lead times necessary for the expansion of manufacturing capacity, in 2015 we made the decision to expand our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required. In addition, we have made and expect to make significant investments in connection with the building of this manufacturing facility with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with current Good Manufacturing Practices (cGMP).</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures, cyber-attacks and numerous other factors.   </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilars, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to a number of risks, including:</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. In addition, following the divestiture of our Hiller&#248;d, Denmark manufacturing operations, we are dependent on FUJIFILM for the manufacture of biosimilar products. If Samsung Bioepis, FUJIFILM or other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties, we may be unable to meet higher than anticipated demand. In addition, following the divestiture of our Hiller&#248;d, Denmark manufacturing operations, we are dependent on FUJIFILM for the manufacture of biosimilar products. FUJIFILM may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Legal and Regulatory Requirements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Any improper conduct or actions on the part of Samsung Bioepis or our joint venture partner, Samsung BioLogics, could damage our reputation and be distracting to management. In particular, Samsung BioLogics is currently subject to an ongoing criminal investigation, which may impact the operations of Samsung Bioepis and its business or divert the attention of the Samsung Bioepis management team from its ongoing operations and business.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilar products, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">failure to meet certain contractual commitments, including, for example, the minimum batch production commitment guarantees we have provided as part of the transaction with FUJIFILM.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates (including withholding taxes) in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws either prospectively or retrospectively (including by regulation). Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from 35% to 21%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries to immediate U.S. taxation as global intangible low-taxed income, includes base erosion prevention measures on non-U.S. earnings and the reduced effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Swiss Federal Act on Tax Reform and AHV Financing (TRAF) will result in significant changes to the Swiss cantonal income tax system. These changes include the elimination of historic favorable cantonal tax regimes, the introduction of a patent box regime and the introduction of a research and development super deduction. The TRAF also provides for transitional rules to lessen the immediate impact of the elimination of the favorable cantonal tax regimes. These changes will become effective on January 1, 2020. In response to the TRAF, each canton must enact cantonal tax reform to comply with the framework provided by the TRAF and are also expected to lower the statutory tax rate to compensate for the elimination of the historic favorable cantonal tax regimes. We will account for the impact of the TRAF and the specific cantonal tax reform changes in the period in which each canton in which we </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">operate enacts the cantonal tax reform. Zug, a canton in which we operate, enacted cantonal tax reform in the third quarter of 2019 and we expect Solothurn, another canton in which we operate, to enact cantonal tax reform within the next six months. Upon the enactment of Zug cantonal tax reform, we were required to remeasure our Swiss deferred tax assets and liabilities, to account for the elimination of the historic favorable cantonal tax regimes, the impact of the transitional rules and the change in the statutory cantonal tax rate. Further remeasurement of our Swiss deferred tax assets and liabilities could have a significant impact on our income tax provision in the period of enactment.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could negatively impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate an owned or leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes share repurchase programs, including, most recently, our 2019 Share Repurchase Program. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of shares. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our 2019 Share Repurchase Program could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption in the past, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3586694736B45C69BA45665500856C15"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2019 Share Repurchase Program during the third quarter of 2019:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($ in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">378,467</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">237.94</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">378,467</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,000.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">August 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,000.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,700,000</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">232.52</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,700,000</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,372.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,078,467</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">233.19</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. Under our 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$717.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized our 2018 Share Repurchase Program, which was a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock that was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From October 1, 2019 through October 21, 2019, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$508.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2019 Share Repurchase Program. As of October 21, 2019, we have repurchased and retired approximately 9.3 million shares of our common stock at a cost of approximately $2.1 billion under our 2019 Share Repurchase Program. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.9 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our 2019 Share Repurchase program as of October 21, 2019. </span></div><div><a id="s7D13BE9AE464534ABCCE71A5C9FC206A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93</span></div></div><hr style="page-break-after:always"></hr><div><a id="s70E0FEB747C1515E94AEC9F3327F19AD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT&#160;INDEX&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Exhibit</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1*+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019930xex101.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annual Retainer Summary for Board of Directors (effective as of January 1, 2020).</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019930xex311.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019930xex312.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019930xex321.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30, 2019, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cover page from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, formatted in Inline XBRL.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">94</span></div></div><hr style="page-break-after:always"></hr><div><a id="s13242AC6C6A15948B3E92DF536E4EB10"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s0C4E77289207564D858309F54C79A897"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;padding-left:492px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:27.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIOGEN INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Jeffrey D. Capello</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(principal financial officer)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October&#160;22, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>biib-2019930xex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="scb1d9ffdf2174a2ab06baafc9946aa81"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit 10.1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Non-Employee Director Compensation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The following is a summary of the retainers payable to non-employee directors effective January 1, 2020:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.2109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:87%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#aec2e4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Retainers</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#aec2e4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Annual Board Retainer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$125,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Annual Retainers (in addition to Annual Board Retainer):</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Independent Chairman of the Board</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$75,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Audit Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$30,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Compensation and Management Development Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$30,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Corporate Governance Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$30,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Audit Committee Member (other than Chair)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Compensation and Management Development Committee Member (other than Chair)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Corporate Governance Committee Member (other than Chair)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>biib-2019930xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB87C32D1724D5D14BBBB358DABDD3B6B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: October&#160;22, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>biib-2019930xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEBF5A0A2AAAE59808F5D237FD5F3DD7D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Jeffrey D. Capello, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: October 22, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer and Chief Accounting Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>biib-2019930xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2799131509B355368E3CEC24BECDA1D1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2019 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: October 22, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: October&#160;22, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer and Chief Accounting Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>biib-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20190930" xmlns:biib="http://www.biogenidec.com/20190930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2429403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2329301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2106100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetails" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails">
        <link:definition>2406402 - Disclosure - Business Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetailsTextual" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual">
        <link:definition>2406403 - Disclosure - Business Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2134100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails">
        <link:definition>2434402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2434403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables">
        <link:definition>2334301 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement">
        <link:definition>1005000 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2123100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2423402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2323301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestitureOfDenmarkManufacturingOperationsDetails" roleURI="http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails">
        <link:definition>2419404 - Disclosure - Divestiture of Denmark Manufacturing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetailsTextual" roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual">
        <link:definition>2414401 - Disclosure - Divestitures (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestitures" roleURI="http://www.biogenidec.com/role/DivestituresDivestitures">
        <link:definition>2114100 - Disclosure - Divestitures Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2130100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2430402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2330301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2129100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2121100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2421402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2421403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2421404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2421405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2321301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2122100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2422402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2422403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2422404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2422405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2422406 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2322301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2132100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2432402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2432403 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2332301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2120100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2420402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2320301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2119100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2419402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual">
        <link:definition>2419403 - Disclosure - Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2319301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2135100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2435401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.biogenidec.com/role/Leases">
        <link:definition>2128100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.biogenidec.com/role/LeasesDetails">
        <link:definition>2428402 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetailsTextual" roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual">
        <link:definition>2428403 - Disclosure - Leases (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.biogenidec.com/role/LeasesTables">
        <link:definition>2328301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2136100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2436401 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2133100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2433403 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails">
        <link:definition>2418406 - Disclosure - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2424401 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2429404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails2" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2">
        <link:definition>2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesByProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails">
        <link:definition>2418402 - Disclosure - Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual">
        <link:definition>2418407 - Disclosure - Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesFromAntiCd20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails">
        <link:definition>2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenues" roleURI="http://www.biogenidec.com/role/RevenuesRevenues">
        <link:definition>2118100 - Disclosure - Revenues Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2318301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2131100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2431402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2431403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2331301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2429402 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables">
        <link:definition>2306301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramMember" name="A2016ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2018ShareRepurchaseProgramMember" name="A2018ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2019ShareRepurchaseProgramMember" name="A2019ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AcquisitionsAbstract" name="AcquisitionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AducanumabMember" name="AducanumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Amortizationofintangibleassetsexcludingimpairment" name="Amortizationofintangibleassetsexcludingimpairment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock" name="AssetsandLiabilitiesHeldForSalePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BG00011Member" name="BG00011Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB111Member" name="BIIB111Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB112Member" name="BIIB112Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BioverativMember" name="BioverativMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Collaborationprofitlosssharing" name="Collaborationprofitlosssharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredTaxAssetLiabilityTypeAxis" name="DeferredTaxAssetLiabilityTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredTaxAssetLiabilityTypeDomain" name="DeferredTaxAssetLiabilityTypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredtaxliabilityMember" name="DeferredtaxliabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DenmarkManufacturingOperationsMember" name="DenmarkManufacturingOperationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityAxis" name="DerivativeMaturityAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityDomain" name="DerivativeMaturityDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_DisposalGroupOperatingLeaseAssets" name="DisposalGroupOperatingLeaseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_DisposalGroupOperatingleaseliabilities" name="DisposalGroupOperatingleaseliabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DivestituresAbstract" name="DivestituresAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DuefromantiCD20therapeuticprograms" name="DuefromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_E2609andBAN2401Member" name="E2609andBAN2401Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" name="EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" name="EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveTaxRateReconciliationGILTItax" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Expenseincurredbythecollaboration" name="Expenseincurredbythecollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expensereflectedwithinstatementsofincome" name="Expensereflectedwithinstatementsofincome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" name="FairValueIndefiniteLivedIntangibleAssetsDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IMRALDIMember" name="IMRALDIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InterferonMember" name="InterferonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InventoryAbstract" name="InventoryAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InventoryrawmaterialssoldtoFUJIFILM" name="InventoryrawmaterialssoldtoFUJIFILM" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InventorysoldtoBioverativcost" name="InventorysoldtoBioverativcost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentInVariableInterestEntitiesTextualAbstract" name="InvestmentInVariableInterestEntitiesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LesseeLeaseTableTableTextBlock" name="LesseeLeaseTableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_LongtermoperatingleaseliabilitiesMember" name="LongtermoperatingleaseliabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MSProductRevenuesMember" name="MSProductRevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NetMinimumLeasePayments" name="NetMinimumLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsThereafter" name="NetMinimumLeasePaymentsThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFiveYear" name="NetMinimumLeasePaymentsWithInFiveYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFourYear" name="NetMinimumLeasePaymentsWithInFourYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInOneYear" name="NetMinimumLeasePaymentsWithInOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInThreeYear" name="NetMinimumLeasePaymentsWithInThreeYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInTwoYear" name="NetMinimumLeasePaymentsWithInTwoYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_NightstarMember" name="NightstarMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OperatingleaseassetsMember" name="OperatingleaseassetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" name="OperatingleasesupplementalcashflowdisclosureTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" name="OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OthercorporaterevenuesMember" name="OthercorporaterevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherrevenuesAbstract" name="OtherrevenuesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesTableTextBlock" name="OtherrevenuesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PLSRMember" name="PLSRMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinCashMember" name="PerformanceStockUnitsSettledinCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinStockMember" name="PerformanceStockUnitsSettledinStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PostacquisitionequitycompensationMember" name="PostacquisitionequitycompensationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetAxis" name="ResearchanddevelopmentassetAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetDomain" name="ResearchanddevelopmentassetDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReserveforCashDiscountsMember" name="ReserveforCashDiscountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_Revenuesfromanticd20therapeuticprogramsMember" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShorttermderivativeMember" name="ShorttermderivativeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SkyhawkTherapeuticsMember" name="SkyhawkTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnSwitzerlandMember" name="SolothurnSwitzerlandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TGNMember" name="TGNMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_WorkinprocessMember" name="WorkinprocessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>biib-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20190930.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20190930.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20190930.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20190930.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20190930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20190930.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20190930.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20190930.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20190930.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails" xlink:href="biib-20190930.xsd#DivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20190930.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20190930.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20190930.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20190930.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20190930.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20190930.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20190930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20190930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20190930.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20190930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20190930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20190930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20190930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20190930.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20190930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20190930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20190930.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20190930.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20190930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20190930.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20190930.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:href="biib-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetails" xlink:href="biib-20190930.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:href="biib-20190930.xsd#LeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesTables" xlink:href="biib-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20190930.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20190930.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20190930.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20190930.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20190930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190930.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20190930.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20190930.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20190930.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20190930.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20190930.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20190930.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20190930.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20190930.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20190930.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20190930.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20190930.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20190930.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20190930.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20190930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20190930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_a8f468a7-4768-419d-6f6c-e490a7380ed7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_NotesPayableCurrent_a8f468a7-4768-419d-6f6c-e490a7380ed7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_aec86b81-11aa-859e-2a56-c42f4bdc8086" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_aec86b81-11aa-859e-2a56-c42f4bdc8086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_ddaee229-3900-8fa8-8854-f625b0f95697" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_ddaee229-3900-8fa8-8854-f625b0f95697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_93dd97fc-33af-32aa-9307-74029660459f" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_93dd97fc-33af-32aa-9307-74029660459f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_cda04db3-0cc7-8cee-c106-c75d14634c49" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_cda04db3-0cc7-8cee-c106-c75d14634c49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_a6b73ecd-af5e-680a-3d1b-b936aa25dafa" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_a6b73ecd-af5e-680a-3d1b-b936aa25dafa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_5ec10448-76c0-1b5e-f8b1-23925c84050e" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_5ec10448-76c0-1b5e-f8b1-23925c84050e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6933b079-472c-4409-d821-646ed2de772d" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6933b079-472c-4409-d821-646ed2de772d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2d3aea93-0685-7648-d025-abd4b91cbb46" xlink:type="locator" />
    <link:calculationArc order="15" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2d3aea93-0685-7648-d025-abd4b91cbb46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c609427e-97a7-37ff-0264-613508cb64bd" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c609427e-97a7-37ff-0264-613508cb64bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6abb14d9-7978-302d-af6b-dbfc88f76bf2" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6abb14d9-7978-302d-af6b-dbfc88f76bf2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6d7a72cc-b15d-447c-3b26-c3564dc5b0b1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6d7a72cc-b15d-447c-3b26-c3564dc5b0b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8644689e-88a2-9828-8c4d-126d8957ca8f" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8644689e-88a2-9828-8c4d-126d8957ca8f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_483713d8-e500-be9d-d173-6b5e26416fef" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_483713d8-e500-be9d-d173-6b5e26416fef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_c4ba6750-a0ad-e402-704f-a43919d1eea3" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_c4ba6750-a0ad-e402-704f-a43919d1eea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_e7dfe01f-f85d-50a3-e5ae-55f159760a1f" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_e7dfe01f-f85d-50a3-e5ae-55f159760a1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_D51BA798FEA557FFA3BBFA31F3C50BDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ACA458F274095BA08751233EFFC82CE6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_D51BA798FEA557FFA3BBFA31F3C50BDF" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ACA458F274095BA08751233EFFC82CE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F23144165595500BACB355194B00E114" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_D51BA798FEA557FFA3BBFA31F3C50BDF" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F23144165595500BACB355194B00E114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_E618D67F17AB588B8C92F77AC72FD6D1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_D51BA798FEA557FFA3BBFA31F3C50BDF" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_E618D67F17AB588B8C92F77AC72FD6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F24627BBFDA65445974B6B6ABB7022BB" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_D51BA798FEA557FFA3BBFA31F3C50BDF" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F24627BBFDA65445974B6B6ABB7022BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F6557CA5F2665B2581E9FD9F8B0415E8" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_D51BA798FEA557FFA3BBFA31F3C50BDF" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F6557CA5F2665B2581E9FD9F8B0415E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3BFEAE22E35E5544B1B459719676913A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3C4E277B516A564D9DCABC555510A6E0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3BFEAE22E35E5544B1B459719676913A" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_3C4E277B516A564D9DCABC555510A6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BC789925AE955F5F9DE1DF90D026D558" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3C4E277B516A564D9DCABC555510A6E0" xlink:to="loc_us-gaap_NetIncomeLoss_BC789925AE955F5F9DE1DF90D026D558" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3C4E277B516A564D9DCABC555510A6E0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ACA458F274095BA08751233EFFC82CE6" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3C4E277B516A564D9DCABC555510A6E0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F23144165595500BACB355194B00E114" xlink:type="arc" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3C4E277B516A564D9DCABC555510A6E0" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_E618D67F17AB588B8C92F77AC72FD6D1" xlink:type="arc" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3C4E277B516A564D9DCABC555510A6E0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F24627BBFDA65445974B6B6ABB7022BB" xlink:type="arc" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3C4E277B516A564D9DCABC555510A6E0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F6557CA5F2665B2581E9FD9F8B0415E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_58F0F551C9C65471986C790355CC186A" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3BFEAE22E35E5544B1B459719676913A" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_58F0F551C9C65471986C790355CC186A" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_b15190d2-1e17-e470-df7e-3ace9efbe89b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_b15190d2-1e17-e470-df7e-3ace9efbe89b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_84473586-4524-2f93-3b08-f625b0e9dad0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_biib_Collaborationprofitlosssharing_84473586-4524-2f93-3b08-f625b0e9dad0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86dec120-3352-31c8-fc61-55992f948bdd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86dec120-3352-31c8-fc61-55992f948bdd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68628FAB5FEA5D7A947A292E759C3AD3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6B0616F328925560B17B210DDBF7A8F9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68628FAB5FEA5D7A947A292E759C3AD3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6B0616F328925560B17B210DDBF7A8F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E029AE01FB658D991ED59E1E830058A" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68628FAB5FEA5D7A947A292E759C3AD3" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E029AE01FB658D991ED59E1E830058A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A7AAC830C3FE52BEB467EE2768AB438D" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E029AE01FB658D991ED59E1E830058A" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A7AAC830C3FE52BEB467EE2768AB438D" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_3C10E75D1459508A9A36B9E9B6B9CBCB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_946A42CC84A9592BB94158B3CC1E48AC" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_3C10E75D1459508A9A36B9E9B6B9CBCB" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_946A42CC84A9592BB94158B3CC1E48AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2FE8C068FBFB54839372C55F3DA0E87F" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_3C10E75D1459508A9A36B9E9B6B9CBCB" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2FE8C068FBFB54839372C55F3DA0E87F" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1A32F0F765195480B0203961F963509F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DEFC5C59483A5531B9C4C3D928A858DF" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1A32F0F765195480B0203961F963509F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DEFC5C59483A5531B9C4C3D928A858DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B02DCC195CA577CAA155C164C57AC74" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1A32F0F765195480B0203961F963509F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B02DCC195CA577CAA155C164C57AC74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_E1B42B1761CA5A8D815112BF61872F85" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1A32F0F765195480B0203961F963509F" xlink:to="loc_us-gaap_AvailableForSaleSecurities_E1B42B1761CA5A8D815112BF61872F85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4A2927605A8E5E5183D177290037B8B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2FEE009640AF58DAA2FF8774E663A1E4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4A2927605A8E5E5183D177290037B8B9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2FEE009640AF58DAA2FF8774E663A1E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_56D805179F4B53AEBE0120698FB4780F" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4A2927605A8E5E5183D177290037B8B9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_56D805179F4B53AEBE0120698FB4780F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F6468505EC965CE5BACC509560FA7A73" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4A2927605A8E5E5183D177290037B8B9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F6468505EC965CE5BACC509560FA7A73" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4A2927605A8E5E5183D177290037B8B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B8BA2EFDD6CF525C8F57511AF5D40EC4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4A2927605A8E5E5183D177290037B8B9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B8BA2EFDD6CF525C8F57511AF5D40EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6C52847B6DFF534C9891E2183DE9E7D5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4A2927605A8E5E5183D177290037B8B9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6C52847B6DFF534C9891E2183DE9E7D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_A9E1C6FF74FB515F80C83C370DBC8F49" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4A2927605A8E5E5183D177290037B8B9" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_A9E1C6FF74FB515F80C83C370DBC8F49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_E1B42B1761CA5A8D815112BF61872F85" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_422E9E4D88D45289B8F819AAA5B75121" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_E1B42B1761CA5A8D815112BF61872F85" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_422E9E4D88D45289B8F819AAA5B75121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_526763D816ED5D82BE1085B8C356EF60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_E1B42B1761CA5A8D815112BF61872F85" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_526763D816ED5D82BE1085B8C356EF60" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_C01F7FE3700E509A941EDA4420FF2F29" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_E1B42B1761CA5A8D815112BF61872F85" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_C01F7FE3700E509A941EDA4420FF2F29" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:type="locator" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_9907E6A761385A948FDD0C63015FFDAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_53CF553F4BA65A0D85E7E8EE81DB0F74" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_9907E6A761385A948FDD0C63015FFDAE" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_53CF553F4BA65A0D85E7E8EE81DB0F74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_54D8BAF5C54F571B938D86AAFC8B0ABC" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_9907E6A761385A948FDD0C63015FFDAE" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_54D8BAF5C54F571B938D86AAFC8B0ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9BF66FDE847257ED926598DCCD9D8ACD" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_9907E6A761385A948FDD0C63015FFDAE" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9BF66FDE847257ED926598DCCD9D8ACD" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_8d3a9604-12a6-9f8a-2166-f625b1186579" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_8d3a9604-12a6-9f8a-2166-f625b1186579" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_1b3378b2-4516-3e25-8b78-2fea6fcc17f4" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_8d3a9604-12a6-9f8a-2166-f625b1186579" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_1b3378b2-4516-3e25-8b78-2fea6fcc17f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_c8e43ccd-2663-8a3a-34ae-f625b157f11e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e71cbb67-0324-15b7-66dc-376e90f3ca60" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_c8e43ccd-2663-8a3a-34ae-f625b157f11e" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e71cbb67-0324-15b7-66dc-376e90f3ca60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_9457929d-79a2-8c41-ff57-afe7f61ce807" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_c8e43ccd-2663-8a3a-34ae-f625b157f11e" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_9457929d-79a2-8c41-ff57-afe7f61ce807" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f67e4a70-063a-7e63-7c03-f625b0ca3e13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1f2c68db-a374-1412-5f1f-4edca1431bbb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f67e4a70-063a-7e63-7c03-f625b0ca3e13" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1f2c68db-a374-1412-5f1f-4edca1431bbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_d4de5958-df21-732d-46e4-0fb9b9ce81e1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f67e4a70-063a-7e63-7c03-f625b0ca3e13" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_d4de5958-df21-732d-46e4-0fb9b9ce81e1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_ee837b39-c135-31a6-5f3f-f625b0ab8a62" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_ee837b39-c135-31a6-5f3f-f625b0ab8a62" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2e5128aa-6caf-7804-0014-2a8148a0b9de" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_ee837b39-c135-31a6-5f3f-f625b0ab8a62" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2e5128aa-6caf-7804-0014-2a8148a0b9de" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_828e5d61-3893-c6ba-834e-f625b0ab217a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_828e5d61-3893-c6ba-834e-f625b0ab217a" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_59c79d0c-ed63-b2bc-685a-f7e81a18ac39" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_828e5d61-3893-c6ba-834e-f625b0ab217a" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_59c79d0c-ed63-b2bc-685a-f7e81a18ac39" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e87c6669-8f1b-0b93-4ac0-f625b0f97077" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_832fb73d-9886-a0dd-5905-8e2ec54304d6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e87c6669-8f1b-0b93-4ac0-f625b0f97077" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_832fb73d-9886-a0dd-5905-8e2ec54304d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_12928cf4-7bc8-1112-408f-6e02bd1f135d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e87c6669-8f1b-0b93-4ac0-f625b0f97077" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_12928cf4-7bc8-1112-408f-6e02bd1f135d" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4644c36b-2591-5821-1391-f625b166fb31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4644c36b-2591-5821-1391-f625b166fb31" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1614e10d-239d-dd27-f21f-6bf70cc45577" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4644c36b-2591-5821-1391-f625b166fb31" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1614e10d-239d-dd27-f21f-6bf70cc45577" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f58cdd58-ff91-98c1-35e0-767a98cb995c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f58cdd58-ff91-98c1-35e0-767a98cb995c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_68d18bc3-7cf2-23ef-d8d0-e5d483687134" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_68d18bc3-7cf2-23ef-d8d0-e5d483687134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C084CA3580C95D94BFB574B8925D5659" xlink:type="locator" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_349B5FE75DA55DBF87738AD20A2AB3B2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_C084CA3580C95D94BFB574B8925D5659" xlink:to="loc_biib_ShareOfCoPromotionProfits_349B5FE75DA55DBF87738AD20A2AB3B2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf6f1c09-722a-be71-e903-4b475ab6ba01" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf6f1c09-722a-be71-e903-4b475ab6ba01" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_640a7486-1200-5e33-ad60-f625b09bace1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_640a7486-1200-5e33-ad60-f625b09bace1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>biib-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20190930.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20190930.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20190930.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20190930.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20190930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20190930.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20190930.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20190930.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20190930.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails" xlink:href="biib-20190930.xsd#DivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20190930.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20190930.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20190930.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20190930.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20190930.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20190930.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20190930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20190930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20190930.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20190930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20190930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20190930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20190930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20190930.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20190930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20190930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20190930.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20190930.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20190930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20190930.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20190930.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:href="biib-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetails" xlink:href="biib-20190930.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:href="biib-20190930.xsd#LeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesTables" xlink:href="biib-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20190930.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20190930.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20190930.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20190930.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20190930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190930.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20190930.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20190930.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20190930.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20190930.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20190930.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20190930.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20190930.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20190930.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20190930.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20190930.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20190930.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20190930.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20190930.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20190930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20190930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:to="loc_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_F3CC4C69B9B051C1A3A044E7CDD7A27E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_F3CC4C69B9B051C1A3A044E7CDD7A27E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E6E0AD1BDB025150A173AEB5E324E611" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_E6E0AD1BDB025150A173AEB5E324E611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E6E0AD1BDB025150A173AEB5E324E611" xlink:to="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E6E0AD1BDB025150A173AEB5E324E611" xlink:to="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69E3437BCC685A4A89CE4BB09AFF016A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69E3437BCC685A4A89CE4BB09AFF016A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_FBF75FF1DF385D4092216D272C8CF354" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_FBF75FF1DF385D4092216D272C8CF354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E15AB3C602E552A39B5E99C3E0A84083" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E15AB3C602E552A39B5E99C3E0A84083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_955DB22F529156CD88A426178DC9564B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_955DB22F529156CD88A426178DC9564B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5A0A027A557E56B197E760986F6C6A40" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5A0A027A557E56B197E760986F6C6A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04D4ACC4BB4A57C99A3C9C706B3B10ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04D4ACC4BB4A57C99A3C9C706B3B10ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8114D4079FA45862B6426CADE30AAFB9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8114D4079FA45862B6426CADE30AAFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DC9B1E44558B55D381FA7B7990974F90" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DC9B1E44558B55D381FA7B7990974F90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_252EDC2CD25C575B9ED4859C0CEF1AC3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_252EDC2CD25C575B9ED4859C0CEF1AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D289ED2D064D5BB89FD7100D13D0E470" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D289ED2D064D5BB89FD7100D13D0E470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A9C55CA582E51B18673507F83D107BC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A9C55CA582E51B18673507F83D107BC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A259D60E66B2B48C0DD282AF2961FD43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A259D60E66B2B48C0DD282AF2961FD43" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_568B9DC2566FA61D444882AF2961A392" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A259D60E66B2B48C0DD282AF2961FD43" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_568B9DC2566FA61D444882AF2961A392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C8C4CC904B707CB5A9A182AF2961BE3F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_568B9DC2566FA61D444882AF2961A392" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C8C4CC904B707CB5A9A182AF2961BE3F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C8C4CC904B707CB5A9A182AF2961BE3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_568B9DC2566FA61D444882AF2961A392" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C8C4CC904B707CB5A9A182AF2961BE3F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_20B6A80AFDF698B5470F82AF296122B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C8C4CC904B707CB5A9A182AF2961BE3F" xlink:to="loc_biib_NightstarMember_20B6A80AFDF698B5470F82AF296122B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_ACBFFD15425ADAB943F482AF29635658" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_Goodwill_ACBFFD15425ADAB943F482AF29635658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_783A12A29E1D5B5C9D6DCA4AE7D5F165" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:to="loc_biib_PostacquisitionequitycompensationMember_783A12A29E1D5B5C9D6DCA4AE7D5F165" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_F96E615D5B2557A390A88FAE3B472665" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_F96E615D5B2557A390A88FAE3B472665" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_F96E615D5B2557A390A88FAE3B472665" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_9CB58A60A85157F5B5F57818BF62634C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_F96E615D5B2557A390A88FAE3B472665" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_9CB58A60A85157F5B5F57818BF62634C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_9C62B1C9C57C5BFBB074A6714EC6504F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_9CB58A60A85157F5B5F57818BF62634C" xlink:to="loc_biib_BIIB111Member_9C62B1C9C57C5BFBB074A6714EC6504F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_CB3CBE862C1B512BA879F55B20AE7865" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_9CB58A60A85157F5B5F57818BF62634C" xlink:to="loc_biib_BIIB112Member_CB3CBE862C1B512BA879F55B20AE7865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_34433F7F544E5A918CBDCF18EF022A27" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_34433F7F544E5A918CBDCF18EF022A27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_34433F7F544E5A918CBDCF18EF022A27" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77E277434A52584C8F1809F1F4380BCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_34433F7F544E5A918CBDCF18EF022A27" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77E277434A52584C8F1809F1F4380BCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B41C6D8908FE5F52928FBBB261D2554E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77E277434A52584C8F1809F1F4380BCA" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B41C6D8908FE5F52928FBBB261D2554E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_82DBA9DB6D475AEF933D169D734E49A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77E277434A52584C8F1809F1F4380BCA" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_82DBA9DB6D475AEF933D169D734E49A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_74A870E7DEA65B00B058CDA4C71604C8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_74A870E7DEA65B00B058CDA4C71604C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_74A870E7DEA65B00B058CDA4C71604C8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CF82A651E535C5EAF87D7079E2D204C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_74A870E7DEA65B00B058CDA4C71604C8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CF82A651E535C5EAF87D7079E2D204C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_578882998E79555BB7306D06D127E54B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CF82A651E535C5EAF87D7079E2D204C" xlink:to="loc_biib_NightstarMember_578882998E79555BB7306D06D127E54B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_CC7061E1A030507DBA2AF4D07DDB961A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_CC7061E1A030507DBA2AF4D07DDB961A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0FE12A4EA78F566A9B18F9375C71EDE7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0FE12A4EA78F566A9B18F9375C71EDE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_05E0C6E5BBFB5C4A90E1E5C7E266870C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_05E0C6E5BBFB5C4A90E1E5C7E266870C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_A94BA2B22F8851EF93037B2B7D20979D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_A94BA2B22F8851EF93037B2B7D20979D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_8AF14143AC01520EAB152B095487F02C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_8AF14143AC01520EAB152B095487F02C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1A79604345C45568AB0D1311466262B1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1A79604345C45568AB0D1311466262B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_58C954A16EA855DFBAA49FA60F65C435" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_58C954A16EA855DFBAA49FA60F65C435" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D4D107A53885091FB660DF1A982C9E48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D4D107A53885091FB660DF1A982C9E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D198F8446A12F8F6FD61DF1A982CFE95_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D4D107A53885091FB660DF1A982C9E48" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D198F8446A12F8F6FD61DF1A982CFE95_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D198F8446A12F8F6FD61DF1A982CFE95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D4D107A53885091FB660DF1A982C9E48" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D198F8446A12F8F6FD61DF1A982CFE95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D198F8446A12F8F6FD61DF1A982CFE95" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D198F8446A12F8F6FD61DF1A982CFE95" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7F4B0A08807983AE2C15DF1A982DDB13" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7F4B0A08807983AE2C15DF1A982DDB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7F4B0A08807983AE2C15DF1A982DDB13" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7F4B0A08807983AE2C15DF1A982DDB13" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D" xlink:to="loc_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D" xlink:to="loc_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D" xlink:to="loc_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EF1177428310339BE525DF1A982E8137" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:to="loc_srt_ProductOrServiceAxis_EF1177428310339BE525DF1A982E8137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_6DC8A0571B27BACF003BDF1A982E3757_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_EF1177428310339BE525DF1A982E8137" xlink:to="loc_srt_ProductsAndServicesDomain_6DC8A0571B27BACF003BDF1A982E3757_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_6DC8A0571B27BACF003BDF1A982E3757" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_EF1177428310339BE525DF1A982E8137" xlink:to="loc_srt_ProductsAndServicesDomain_6DC8A0571B27BACF003BDF1A982E3757" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6DC8A0571B27BACF003BDF1A982E3757" xlink:to="loc_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6DC8A0571B27BACF003BDF1A982E3757" xlink:to="loc_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0995F8D10AF259EBA7166B502D287EE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0995F8D10AF259EBA7166B502D287EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0995F8D10AF259EBA7166B502D287EE8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0995F8D10AF259EBA7166B502D287EE8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_AD39219053965DF2BAEA12C41D74A86A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:to="loc_us-gaap_InventoriesMember_AD39219053965DF2BAEA12C41D74A86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_D541F32AE8025C08AF073481AE1463C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_D541F32AE8025C08AF073481AE1463C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_FBCE8CABF061576FA15921B72595F3C3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_FBCE8CABF061576FA15921B72595F3C3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_AB98DC4E3C02593FA8D73D15EDB47DAC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:to="loc_biib_DeferredtaxliabilityMember_AB98DC4E3C02593FA8D73D15EDB47DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_48D085810BD55A90B661CBE8497C37F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:to="loc_us-gaap_TypeOfArrangementAxis_48D085810BD55A90B661CBE8497C37F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55113CDFF2D9B053135E0B174C496F29_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_48D085810BD55A90B661CBE8497C37F0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55113CDFF2D9B053135E0B174C496F29_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A288EC7D218F5F7AA115FBDF95393EEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_48D085810BD55A90B661CBE8497C37F0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A288EC7D218F5F7AA115FBDF95393EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9D19024021DC591B86884D2A93D57477" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A288EC7D218F5F7AA115FBDF95393EEB" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9D19024021DC591B86884D2A93D57477" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F747FCB4BF25551C82DE04AEE760D30A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F747FCB4BF25551C82DE04AEE760D30A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0CB680C8810ED75EA6B60B174C4A939C_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F747FCB4BF25551C82DE04AEE760D30A" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0CB680C8810ED75EA6B60B174C4A939C_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_51663E2F1B065674AEA4CD605DE1CFF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F747FCB4BF25551C82DE04AEE760D30A" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_51663E2F1B065674AEA4CD605DE1CFF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_506D132F58BC59F09CF649D31EB00302" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_51663E2F1B065674AEA4CD605DE1CFF4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_506D132F58BC59F09CF649D31EB00302" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5C0898A4AD7C536EB0AFD8884E50F034" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5C0898A4AD7C536EB0AFD8884E50F034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B011F405222B5181944EE14F52A6EE2E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B011F405222B5181944EE14F52A6EE2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3EADA035CC9C587A9B80BD36F9C0F618" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3EADA035CC9C587A9B80BD36F9C0F618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_91DB26CEE8165A0F9CF6477FD09EA1DF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_91DB26CEE8165A0F9CF6477FD09EA1DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2B882307CCA75301B6FBFD4B86533E5E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2B882307CCA75301B6FBFD4B86533E5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_500268FDE1695497BA3B96B7F74D4F68" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_500268FDE1695497BA3B96B7F74D4F68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5A819FD934E954E3A86F5F16642C1F7A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5A819FD934E954E3A86F5F16642C1F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_0F4E11C38AA554F8842C6220C5840A60" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_AdjustmentForAmortization_0F4E11C38AA554F8842C6220C5840A60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_47166B90C3CB5094960300DD9E5D44D6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_EquityMethodInvestments_47166B90C3CB5094960300DD9E5D44D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_865225D24C1058D1AB991C005F3C2D48" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_865225D24C1058D1AB991C005F3C2D48" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_E0240B1C2DCC5C9994D8E8143C7799AA" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_biib_Collaborationprofitlosssharing_E0240B1C2DCC5C9994D8E8143C7799AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_898B82CDC44A5E19B1C15A1CD7377565" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_Revenues_898B82CDC44A5E19B1C15A1CD7377565" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:to="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:to="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:to="loc_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:to="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:to="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_F7A678F9DE8CA693C233827AE1F0A39A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_F7A678F9DE8CA693C233827AE1F0A39A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_FFEC62C22331F8BA8810827AE1F1281C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockholdersEquity_FFEC62C22331F8BA8810827AE1F1281C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3BBE7515E9C0AF3F81F8827AE1F13596" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_MinorityInterest_3BBE7515E9C0AF3F81F8827AE1F13596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CFAE566DEDFB486127A8827E4B31CC3C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5E1A54FA75195FCAFDF5827E4B31707E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_CFAE566DEDFB486127A8827E4B31CC3C" xlink:to="loc_us-gaap_StatementTable_5E1A54FA75195FCAFDF5827E4B31707E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_61F10796F94E44412598827E4B31B192" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5E1A54FA75195FCAFDF5827E4B31707E" xlink:to="loc_srt_ProductOrServiceAxis_61F10796F94E44412598827E4B31B192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_61F10796F94E44412598827E4B31B192" xlink:to="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_61F10796F94E44412598827E4B31B192" xlink:to="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C7EBB795CDE14531CD15827E4B3112E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC" xlink:to="loc_us-gaap_ProductMember_C7EBB795CDE14531CD15827E4B3112E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_04ACDDB5797E06988ECC827E4B3131B4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_04ACDDB5797E06988ECC827E4B3131B4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:to="loc_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:to="loc_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:to="loc_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:to="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:to="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="loc_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="loc_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="loc_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="loc_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_04C1B0192880F801D90DDF1A99901E69" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="loc_currency_CAD_04C1B0192880F801D90DDF1A99901E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:to="loc_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:to="loc_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:to="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:to="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:to="loc_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:to="loc_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:to="loc_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:to="loc_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:to="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:to="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:to="loc_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:to="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:to="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:to="loc_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:to="loc_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:to="loc_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5E1A3173B126E79077B982865B260FED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5E1A3173B126E79077B982865B260FED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D059FABDBE96266B161482865B275F32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5E1A3173B126E79077B982865B260FED" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D059FABDBE96266B161482865B275F32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B48558E4BA9D3557167E82865B272312_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D059FABDBE96266B161482865B275F32" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B48558E4BA9D3557167E82865B272312_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B48558E4BA9D3557167E82865B272312" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D059FABDBE96266B161482865B275F32" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B48558E4BA9D3557167E82865B272312" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_CD1D621760D8D6C527B582865B276C40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B48558E4BA9D3557167E82865B272312" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_CD1D621760D8D6C527B582865B276C40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_61FD64935BDEF7D0FAC082865B28C19B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_61FD64935BDEF7D0FAC082865B28C19B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9311596B8A4338724A0A82865B291F09" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9311596B8A4338724A0A82865B291F09" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_ED0B4A9C69B1F92E49078288CB056AB3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_ED0B4A9C69B1F92E49078288CB056AB3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_5AD726ECBD845922BED48335B99730D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_5AD726ECBD845922BED48335B99730D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_A85E8DBB079454ADA1C412BF57A01F45" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_A85E8DBB079454ADA1C412BF57A01F45" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_852AAF8DEFBD52DF94EE593C1F0030CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:to="loc_biib_MarketStockUnitsMember_852AAF8DEFBD52DF94EE593C1F0030CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_3C8A315391A85B4AB96B681A12F4640D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_3C8A315391A85B4AB96B681A12F4640D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:to="loc_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_36E9B003257D56DDB7A9F6B659135BE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:to="loc_us-gaap_NetIncomeLoss_36E9B003257D56DDB7A9F6B659135BE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6EE397471960562FA234FCB535C3B880" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6EE397471960562FA234FCB535C3B880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69575BF5B4985E3382883FAC9399AB3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6EE397471960562FA234FCB535C3B880" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69575BF5B4985E3382883FAC9399AB3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6EE397471960562FA234FCB535C3B880" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FA17303862F5F65A2EFCD90C77D3AC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FA17303862F5F65A2EFCD90C77D3AC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6D8D1AC57C50581283967ADB9A5116F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6D8D1AC57C50581283967ADB9A5116F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF8B7A06A3F65D9588EE607AFED0EA4E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6EE397471960562FA234FCB535C3B880" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF8B7A06A3F65D9588EE607AFED0EA4E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D890BF111B17557398E36F013A2E25B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_D890BF111B17557398E36F013A2E25B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_FA6DCABFDC395DA2A23926BA570E310C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_FA6DCABFDC395DA2A23926BA570E310C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_BDB8801E011F51D192294020286EA1DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_BDB8801E011F51D192294020286EA1DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_828BACFBE631515DA039FFEE7DBB453E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_828BACFBE631515DA039FFEE7DBB453E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_828BACFBE631515DA039FFEE7DBB453E" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_96F7DCA9C90E52979EC17FC4CD55192F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_828BACFBE631515DA039FFEE7DBB453E" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_96F7DCA9C90E52979EC17FC4CD55192F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_A3A35709FB4853178B8B8A1AE05EB2B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_96F7DCA9C90E52979EC17FC4CD55192F" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_A3A35709FB4853178B8B8A1AE05EB2B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_DF8E77075DB45027A08B5A14DBA12490" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_DF8E77075DB45027A08B5A14DBA12490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8F92CA17D906548D918A63FF91D7F031" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8F92CA17D906548D918A63FF91D7F031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_391169FADE1C50E4A7947F4728316565" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_391169FADE1C50E4A7947F4728316565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E59E4622CB96553EB652C4218E3F0665" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E59E4622CB96553EB652C4218E3F0665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE78D0BC1FCF5522AB7C4853C11527A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE78D0BC1FCF5522AB7C4853C11527A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6579E70E0744534DACC9A272755E2243" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6579E70E0744534DACC9A272755E2243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EE5492F63A065861AF0C4288105FE7D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EE5492F63A065861AF0C4288105FE7D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89A50B63D0365E268AC83C65C498A109" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89A50B63D0365E268AC83C65C498A109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3068933C8F1B5A08911F36B34D6A4190" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3068933C8F1B5A08911F36B34D6A4190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C797279B7C4153B98958FFDE1B27623E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C797279B7C4153B98958FFDE1B27623E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FEEF2898E715B659DBB0074CE0E44FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FEEF2898E715B659DBB0074CE0E44FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_F8074931DF21553CBC162B54410E5283" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_F8074931DF21553CBC162B54410E5283" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:to="loc_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F1F8C8C66C315B729A92B4B70D3A61C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:to="loc_us-gaap_DebtInstrumentAxis_F1F8C8C66C315B729A92B4B70D3A61C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F1F8C8C66C315B729A92B4B70D3A61C3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F1F8C8C66C315B729A92B4B70D3A61C3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FB8D6AC745D45F76955AE76A418475A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FB8D6AC745D45F76955AE76A418475A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6A3B83BDEB0C5D74821E6A5B94BF07CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6A3B83BDEB0C5D74821E6A5B94BF07CA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_16DD21E268BC56F3821B8AE800EF3503" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_16DD21E268BC56F3821B8AE800EF3503" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1F83379E76335E1B99AA554A6980B9D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1F83379E76335E1B99AA554A6980B9D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_B2B8F2B0F5115E0EA94ABCAEBEDD9DAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_B2B8F2B0F5115E0EA94ABCAEBEDD9DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_7D8F54B6D42D5452A6514307350AEE6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:to="loc_us-gaap_NotesPayable_7D8F54B6D42D5452A6514307350AEE6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_C7091C12AEAA5254B6C18D4FF6A418F4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:to="loc_us-gaap_DebtInstrumentFairValue_C7091C12AEAA5254B6C18D4FF6A418F4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9390CE76AA624E310E2DF1A9A82E075" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9390CE76AA624E310E2DF1A9A82E075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_098C05418BF76CECCB18DF1A9A6011D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_098C05418BF76CECCB18DF1A9A6011D5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_098C05418BF76CECCB18DF1A9A6011D5" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BG00011Member" xlink:label="loc_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:to="loc_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B6CE01DB2EFB7641C7E7DF1A9A608443" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_098C05418BF76CECCB18DF1A9A6011D5" xlink:to="loc_us-gaap_DebtInstrumentAxis_B6CE01DB2EFB7641C7E7DF1A9A608443" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B6CE01DB2EFB7641C7E7DF1A9A608443" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B6CE01DB2EFB7641C7E7DF1A9A608443" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_34257117F5D0C9CE3F79DF1A9A602D3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_34257117F5D0C9CE3F79DF1A9A602D3D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D39C3E76600D69C392E0DF1A9A602B22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D39C3E76600D69C392E0DF1A9A602B22" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_90C0E1DFF2A80488498BDF1A9A609620" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_90C0E1DFF2A80488498BDF1A9A609620" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_C50031BE5DB013AE2E94DF1A9A60B92E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_C50031BE5DB013AE2E94DF1A9A60B92E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" xlink:label="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1755771D1E9912656797DF1A9A60AC71" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1755771D1E9912656797DF1A9A60AC71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DF11438448B39AD586CDDF3966975EDF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DF11438448B39AD586CDDF3966975EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15108D2C2047BF361CAADF1A9A60F10F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15108D2C2047BF361CAADF1A9A60F10F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:to="loc_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_F26B1FB4C5AB52C9A742C7619776FEEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:to="loc_us-gaap_CommercialPaperMember_F26B1FB4C5AB52C9A742C7619776FEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_85C303F06FA157C496DDCDADE895A8F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_85C303F06FA157C496DDCDADE895A8F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2905EAC9B5675514B800CE0ACEFCC00C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2905EAC9B5675514B800CE0ACEFCC00C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_223E0213AB7B59DA9A28B49C51FFEF0B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:to="loc_us-gaap_DebtSecuritiesMember_223E0213AB7B59DA9A28B49C51FFEF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_122DB266C11D586282D6D63FD1C8CF9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_122DB266C11D586282D6D63FD1C8CF9B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DDF2E6029C8D5597919B643C0CB186F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DDF2E6029C8D5597919B643C0CB186F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DDF2E6029C8D5597919B643C0CB186F0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_02547506A104560286ABF5F45AC14AA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DDF2E6029C8D5597919B643C0CB186F0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_02547506A104560286ABF5F45AC14AA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_05507BF3498D58458C6086AD989BB116" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_02547506A104560286ABF5F45AC14AA1" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_05507BF3498D58458C6086AD989BB116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1BDE7789085E530F97A84F63B85C3FE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_02547506A104560286ABF5F45AC14AA1" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1BDE7789085E530F97A84F63B85C3FE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E10D656D0F145AC4881FFE4E13E84961" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E10D656D0F145AC4881FFE4E13E84961" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E10D656D0F145AC4881FFE4E13E84961" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E10D656D0F145AC4881FFE4E13E84961" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_C7FE1DFA5A875380BB73EBDEC1334F84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_C7FE1DFA5A875380BB73EBDEC1334F84" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_51FF0D8FC5FC538E9FEED2424B3D96D8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_51FF0D8FC5FC538E9FEED2424B3D96D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_CDEEA905AC42574FB9ED1AA3784C10D1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_CDEEA905AC42574FB9ED1AA3784C10D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_463588DF84DD5B10B1524F86D5D53A6D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_463588DF84DD5B10B1524F86D5D53A6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E7A1865F4AA75E8CBFA5460E2C3414CE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E7A1865F4AA75E8CBFA5460E2C3414CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_814AE542D8EC5040B90F8D2D5D88FC12" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_814AE542D8EC5040B90F8D2D5D88FC12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_D121B6B96CA05D39B66E00AAE9736A51" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_us-gaap_EquitySecuritiesMember_D121B6B96CA05D39B66E00AAE9736A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3A3756B97BA15A9089E406762193358B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3A3756B97BA15A9089E406762193358B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01E8E3663C915125A4AA07BB3B6E3953" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01E8E3663C915125A4AA07BB3B6E3953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7EB304079B09565C963914E9BB5F506C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7EB304079B09565C963914E9BB5F506C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A574E6694E7B5399B4B4717A3B1D7327" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A574E6694E7B5399B4B4717A3B1D7327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_A8AED37EE7905C88AD2041CFA7F0BEA3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_A8AED37EE7905C88AD2041CFA7F0BEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E6C9FC6B46745926B96EECB764C7C840" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E6C9FC6B46745926B96EECB764C7C840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AE9E454631195BC19C85A4FF55EE5E7C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AE9E454631195BC19C85A4FF55EE5E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_FC7BDF9A08E053BF9E9CDE593CEA9486" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleSecurities_FC7BDF9A08E053BF9E9CDE593CEA9486" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_729266F37B54592AA3804F3425DB4208" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_729266F37B54592AA3804F3425DB4208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_729266F37B54592AA3804F3425DB4208" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4B0B94DA87FD597BB568C65B45DC991F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_729266F37B54592AA3804F3425DB4208" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4B0B94DA87FD597BB568C65B45DC991F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_7E391DFFFAB05CF0A0A2D737888DB4A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B0B94DA87FD597BB568C65B45DC991F" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_7E391DFFFAB05CF0A0A2D737888DB4A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_A51C15C05CDE5EA4A20F536BBA733145" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B0B94DA87FD597BB568C65B45DC991F" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_A51C15C05CDE5EA4A20F536BBA733145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_7AE5176172ED5840B8936B038421D3E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:to="loc_biib_IonisPharmaceuticalsMember_7AE5176172ED5840B8936B038421D3E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:to="loc_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_08D1268846AF5D2194AF0B440B4DCC6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:to="loc_biib_StrategicInvestmentsMember_08D1268846AF5D2194AF0B440B4DCC6C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_5B404AE4ADCF5DA6BC491B3362A1E81B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:to="loc_biib_StrategicInvestmentPortfolio_5B404AE4ADCF5DA6BC491B3362A1E81B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E17FB95B5D815C58A2771B3EA6B993A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E17FB95B5D815C58A2771B3EA6B993A0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DeferredTaxAssetLiabilityTypeAxis" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:to="loc_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1340747FFEC608872F46DF1A9853E7CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1340747FFEC608872F46DF1A9853E7CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_026B8AE814ABDB10E9C3DF1A9853DF7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1340747FFEC608872F46DF1A9853E7CA" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_026B8AE814ABDB10E9C3DF1A9853DF7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_026B8AE814ABDB10E9C3DF1A9853DF7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1340747FFEC608872F46DF1A9853E7CA" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_026B8AE814ABDB10E9C3DF1A9853DF7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_E5C5C39A4602F978FF0BDF1A98535C81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_026B8AE814ABDB10E9C3DF1A9853DF7C" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_E5C5C39A4602F978FF0BDF1A98535C81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:to="loc_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:to="loc_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_59184D75928501D1FA24DF1A9B2108B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_59184D75928501D1FA24DF1A9B2108B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_59184D75928501D1FA24DF1A9B2108B9" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_59184D75928501D1FA24DF1A9B2108B9" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BG00011Member" xlink:label="loc_biib_BG00011Member_AEF98AFC7AF410B43222DF1A9B25107D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75" xlink:to="loc_biib_BG00011Member_AEF98AFC7AF410B43222DF1A9B25107D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PLSRMember" xlink:label="loc_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75" xlink:to="loc_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75" xlink:to="loc_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1CA15B3C76E4B13D2FB6DF1A9B259319" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1CA15B3C76E4B13D2FB6DF1A9B259319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A70EC0D5878163213D27DF1A9B25C347_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1CA15B3C76E4B13D2FB6DF1A9B259319" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A70EC0D5878163213D27DF1A9B25C347_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A70EC0D5878163213D27DF1A9B25C347" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1CA15B3C76E4B13D2FB6DF1A9B259319" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A70EC0D5878163213D27DF1A9B25C347" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_E7D80F561C60145FDC8FDF1A9B251A88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A70EC0D5878163213D27DF1A9B25C347" xlink:to="loc_biib_NightstarMember_E7D80F561C60145FDC8FDF1A9B251A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_623B93C97D929DF207C4DF1A9B25086B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_623B93C97D929DF207C4DF1A9B25086B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:to="loc_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:to="loc_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8EE78429860872DEFCFBDF1A9B259F32" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_srt_ProductOrServiceAxis_8EE78429860872DEFCFBDF1A9B259F32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8EE78429860872DEFCFBDF1A9B259F32" xlink:to="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8EE78429860872DEFCFBDF1A9B259F32" xlink:to="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A" xlink:to="loc_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A" xlink:to="loc_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A" xlink:to="loc_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_91C2FEF90762F947B553DF1A9B2D248D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_srt_RangeAxis_91C2FEF90762F947B553DF1A9B2D248D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_085587D257929598563EDF1A9B2D17CD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_91C2FEF90762F947B553DF1A9B2D248D" xlink:to="loc_srt_RangeMember_085587D257929598563EDF1A9B2D17CD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_085587D257929598563EDF1A9B2D17CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_91C2FEF90762F947B553DF1A9B2D248D" xlink:to="loc_srt_RangeMember_085587D257929598563EDF1A9B2D17CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_68F16B6A3E5E0AA9DB02DF1A9B2DF159" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_085587D257929598563EDF1A9B2D17CD" xlink:to="loc_srt_MinimumMember_68F16B6A3E5E0AA9DB02DF1A9B2DF159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_39F49E9F5E1BFB6CF74ADF1A9B2DF9AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_085587D257929598563EDF1A9B2D17CD" xlink:to="loc_srt_MaximumMember_39F49E9F5E1BFB6CF74ADF1A9B2DF9AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DABAAD0CD365E9058388DF1A9B31E915" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DABAAD0CD365E9058388DF1A9B31E915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ECF3A22C61BF1DFD46C7DF1A9B3180A9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ECF3A22C61BF1DFD46C7DF1A9B3180A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Amortizationofintangibleassetsexcludingimpairment" xlink:label="loc_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:to="loc_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BDFF87AC229FF585C8DDDF1A9B31906D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BDFF87AC229FF585C8DDDF1A9B31906D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:to="loc_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:to="loc_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:to="loc_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:to="loc_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_AC51DA1567B95A11987460B9653C6E3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:to="loc_biib_BioverativMember_AC51DA1567B95A11987460B9653C6E3F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_3334E338259F580BB85A862AD022FFEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:to="loc_biib_InventorysoldtoBioverativcost_3334E338259F580BB85A862AD022FFEA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C260651F7A0A894EC15182AF287EF435" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_StatementTable_C260651F7A0A894EC15182AF287EF435" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_83367A1711D38905958F82AF287E7429" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C260651F7A0A894EC15182AF287EF435" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_83367A1711D38905958F82AF287E7429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_83367A1711D38905958F82AF287E7429" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_83367A1711D38905958F82AF287E7429" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342" xlink:to="loc_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_B6C6C3B53DBD1566D56F82AF287F1294" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_B6C6C3B53DBD1566D56F82AF287F1294" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_45E2A4CD264E6E7947D582AF287F9128" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C260651F7A0A894EC15182AF287EF435" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_45E2A4CD264E6E7947D582AF287F9128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_45E2A4CD264E6E7947D582AF287F9128" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_45E2A4CD264E6E7947D582AF287F9128" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_204162A11FBB62CA61FA82AF2881ED65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_204162A11FBB62CA61FA82AF2881ED65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F95E5FD24BF12965078182AF28818009" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F95E5FD24BF12965078182AF28818009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6F2A2297C33A467239BC82AF2881C7E8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6F2A2297C33A467239BC82AF2881C7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_051C137D3A0DD17104CD82AF2881EDF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_051C137D3A0DD17104CD82AF2881EDF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_E079B88591449918776682AF28824A96" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_E079B88591449918776682AF28824A96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_FA86E4822BACEA4C3E9682AF28825D26" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseLiability_FA86E4822BACEA4C3E9682AF28825D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166" xlink:type="locator" />
    <link:definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8" xlink:type="locator" />
    <link:definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB" xlink:type="locator" />
    <link:definitionArc order="41" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EBF3EE1D876484631C46DF1A98B51B55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EBF3EE1D876484631C46DF1A98B51B55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_49F6D321831BF66E46BBDF1A98B5DEB4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EBF3EE1D876484631C46DF1A98B51B55" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_49F6D321831BF66E46BBDF1A98B5DEB4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_49F6D321831BF66E46BBDF1A98B5DEB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EBF3EE1D876484631C46DF1A98B51B55" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_49F6D321831BF66E46BBDF1A98B5DEB4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_07D291638DBD73CD127DDF1A98B595E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_49F6D321831BF66E46BBDF1A98B5DEB4" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_07D291638DBD73CD127DDF1A98B595E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_4F5C5C29F62C12D33488DF1A98B5C518" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:to="loc_srt_RangeAxis_4F5C5C29F62C12D33488DF1A98B5C518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_EA6237F8EB9F7638EA2DDF1A98B57331_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4F5C5C29F62C12D33488DF1A98B5C518" xlink:to="loc_srt_RangeMember_EA6237F8EB9F7638EA2DDF1A98B57331_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_EA6237F8EB9F7638EA2DDF1A98B57331" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4F5C5C29F62C12D33488DF1A98B5C518" xlink:to="loc_srt_RangeMember_EA6237F8EB9F7638EA2DDF1A98B57331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4446B59A1745044AB0DCDF1A98B8C806" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_EA6237F8EB9F7638EA2DDF1A98B57331" xlink:to="loc_srt_MinimumMember_4446B59A1745044AB0DCDF1A98B8C806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_13475F1475E5BD14F1B4DF1A98B8BFD3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_EA6237F8EB9F7638EA2DDF1A98B57331" xlink:to="loc_srt_MaximumMember_13475F1475E5BD14F1B4DF1A98B8BFD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:to="loc_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_BA2F0EEFAB16505C9B079DCAC8C738A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_4BA5EFB1768954C39C3B9CC9832B930A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_BA2F0EEFAB16505C9B079DCAC8C738A1" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_4BA5EFB1768954C39C3B9CC9832B930A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4AE170F75B6B561194B8F3136AEC1293" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4BA5EFB1768954C39C3B9CC9832B930A" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4AE170F75B6B561194B8F3136AEC1293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4AE170F75B6B561194B8F3136AEC1293" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7D3E11C804D150E1B0D48B4D9A4B032E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4AE170F75B6B561194B8F3136AEC1293" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7D3E11C804D150E1B0D48B4D9A4B032E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_E66D0BC3FB665E53B23D9293EA4A71E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7D3E11C804D150E1B0D48B4D9A4B032E" xlink:to="loc_country_BR_E66D0BC3FB665E53B23D9293EA4A71E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_3AF463C66A5D5B3B804B78E27A25C997" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_BA2F0EEFAB16505C9B079DCAC8C738A1" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_3AF463C66A5D5B3B804B78E27A25C997" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_930305EE6B871E40274ADF1A9844A304" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7E2CD66AB5C0390895DCDF1A9842C0B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_930305EE6B871E40274ADF1A9844A304" xlink:to="loc_us-gaap_StatementTable_7E2CD66AB5C0390895DCDF1A9842C0B3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_19FEFBB3BCDEC4CF3EE7DF1A9842AB52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7E2CD66AB5C0390895DCDF1A9842C0B3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_19FEFBB3BCDEC4CF3EE7DF1A9842AB52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BADF5D96E0858281E76FDF1A98438059_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_19FEFBB3BCDEC4CF3EE7DF1A9842AB52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BADF5D96E0858281E76FDF1A98438059_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BADF5D96E0858281E76FDF1A98438059" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_19FEFBB3BCDEC4CF3EE7DF1A9842AB52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BADF5D96E0858281E76FDF1A98438059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3A4489C1401C72C14DFFDF1A98434AA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BADF5D96E0858281E76FDF1A98438059" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_3A4489C1401C72C14DFFDF1A98434AA9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_02C51DAD0A4D35994078DF1A9BC706F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_02C51DAD0A4D35994078DF1A9BC706F5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_93D260BBE741DC0AA32EDF1A9BBF58CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_93D260BBE741DC0AA32EDF1A9BBF58CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58C54C6971F188D3EB50DF1A9BBF27F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_93D260BBE741DC0AA32EDF1A9BBF58CC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58C54C6971F188D3EB50DF1A9BBF27F7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58C54C6971F188D3EB50DF1A9BBF27F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_93D260BBE741DC0AA32EDF1A9BBF58CC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58C54C6971F188D3EB50DF1A9BBF27F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_A5AB34F2F9388532515FDF1A9BBFCE7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58C54C6971F188D3EB50DF1A9BBF27F7" xlink:to="loc_us-gaap_CollaborativeArrangementMember_A5AB34F2F9388532515FDF1A9BBFCE7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1FF2ABAD6310A117FBF8DF1A9BC31694" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:to="loc_srt_ProductOrServiceAxis_1FF2ABAD6310A117FBF8DF1A9BC31694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1FF2ABAD6310A117FBF8DF1A9BC31694" xlink:to="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1FF2ABAD6310A117FBF8DF1A9BC31694" xlink:to="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC" xlink:to="loc_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC" xlink:to="loc_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_F7C8B5EF6E6C52013879DF1A9BC38E3F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_F7C8B5EF6E6C52013879DF1A9BC38E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_5952F32A2B9D2B330A70DF1A9BC745DB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:to="loc_srt_MajorCustomersAxis_5952F32A2B9D2B330A70DF1A9BC745DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B37BCA098E1A3A7F6A22DF1A9BC79F06_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_5952F32A2B9D2B330A70DF1A9BC745DB" xlink:to="loc_srt_NameOfMajorCustomerDomain_B37BCA098E1A3A7F6A22DF1A9BC79F06_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B37BCA098E1A3A7F6A22DF1A9BC79F06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_5952F32A2B9D2B330A70DF1A9BC745DB" xlink:to="loc_srt_NameOfMajorCustomerDomain_B37BCA098E1A3A7F6A22DF1A9BC79F06" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B37BCA098E1A3A7F6A22DF1A9BC79F06" xlink:to="loc_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_26160D44F470A90CDEE3DF1A9BC7436C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B37BCA098E1A3A7F6A22DF1A9BC79F06" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_26160D44F470A90CDEE3DF1A9BC7436C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2303525C1F3C22C6E2D0DF1A9BC78856" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_02C51DAD0A4D35994078DF1A9BC706F5" xlink:to="loc_us-gaap_Revenues_2303525C1F3C22C6E2D0DF1A9BC78856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_02C51DAD0A4D35994078DF1A9BC706F5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_704C876007D2247C5EC9DF3E7AEF6293" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_704C876007D2247C5EC9DF3E7AEF6293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2E1A3E48DA4AC49DDF76DF3E7AF0433F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_704C876007D2247C5EC9DF3E7AEF6293" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2E1A3E48DA4AC49DDF76DF3E7AF0433F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2E1A3E48DA4AC49DDF76DF3E7AF0433F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_704C876007D2247C5EC9DF3E7AEF6293" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2E1A3E48DA4AC49DDF76DF3E7AF0433F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_4F7206AAED39F7767F74DF3E7B9D9DAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2E1A3E48DA4AC49DDF76DF3E7AF0433F" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_4F7206AAED39F7767F74DF3E7B9D9DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:to="loc_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:to="loc_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:to="loc_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:to="loc_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:to="loc_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7885CE082F0A598C97BB58F9CE3F53F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7885CE082F0A598C97BB58F9CE3F53F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7885CE082F0A598C97BB58F9CE3F53F8" xlink:to="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_78F4DABD489056FF9780B90AAFFA4FFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7885CE082F0A598C97BB58F9CE3F53F8" xlink:to="loc_us-gaap_EquityComponentDomain_78F4DABD489056FF9780B90AAFFA4FFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A47067CCD675A98818C39EFFAB4F5C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_78F4DABD489056FF9780B90AAFFA4FFE" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A47067CCD675A98818C39EFFAB4F5C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_DE1FD97E356A5C718E518E0C60924103" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_78F4DABD489056FF9780B90AAFFA4FFE" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_DE1FD97E356A5C718E518E0C60924103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E5667DD113245E779BD04D5B0E1129FA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_78F4DABD489056FF9780B90AAFFA4FFE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E5667DD113245E779BD04D5B0E1129FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_97FDEEE752B25357A6293EFF1DD08251" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_97FDEEE752B25357A6293EFF1DD08251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_22E2EFFE80E05AE9A20E151E87F7707A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_22E2EFFE80E05AE9A20E151E87F7707A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5C59F7BEF2A553FCAD81B9D12E862F43" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5C59F7BEF2A553FCAD81B9D12E862F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F9B843488FC45D818AC883AD279FC2C7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_Revenues_F9B843488FC45D818AC883AD279FC2C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4B883AD9F9AC5FE49C7DA221148B03C7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_OperatingExpenses_4B883AD9F9AC5FE49C7DA221148B03C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0097C8D00248594095A103A39A292E93" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_NetIncomeLoss_0097C8D00248594095A103A39A292E93" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_30C7B7D4147E5E6AB7DB0D0F83CF8EBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:to="loc_biib_ReserveforCashDiscountsMember_30C7B7D4147E5E6AB7DB0D0F83CF8EBB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_8B9DF22A811C549DB917C2A0051EAFD0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:to="loc_biib_ContractualAdjustmentsMember_8B9DF22A811C549DB917C2A0051EAFD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_52119BB649D2596592C82C08D1CF7D53" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_52119BB649D2596592C82C08D1CF7D53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_F8A30071368B5B2095BE39D7ABA656F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_F8A30071368B5B2095BE39D7ABA656F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_58E89CEE697E554993799E90546FAE23" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_58E89CEE697E554993799E90546FAE23" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_B17511584A56539C8075346C3219C0CE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_B17511584A56539C8075346C3219C0CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_80D46F881F4650DBA97C491B782AFCB0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_80D46F881F4650DBA97C491B782AFCB0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_E1E8BF5C3D9154819E20700B6DCECF6A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_E1E8BF5C3D9154819E20700B6DCECF6A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3F1D699297B55AA3B2ABA8E2AD5501A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E6C40FE23701578AAAE9FF662E9D34F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3F1D699297B55AA3B2ABA8E2AD5501A4" xlink:to="loc_us-gaap_StatementTable_E6C40FE23701578AAAE9FF662E9D34F0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_51E47B3715C05991811B5C0F1F548FBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E6C40FE23701578AAAE9FF662E9D34F0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_51E47B3715C05991811B5C0F1F548FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_51E47B3715C05991811B5C0F1F548FBB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2F15974D337E5A68A7E38D9A213169E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_51E47B3715C05991811B5C0F1F548FBB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2F15974D337E5A68A7E38D9A213169E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_CC736C14669053B7BCB601C087AAA1BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2F15974D337E5A68A7E38D9A213169E4" xlink:to="loc_us-gaap_AccountsReceivableMember_CC736C14669053B7BCB601C087AAA1BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_A5FEBB4C59DE5F22B62F54561B7F1403" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2F15974D337E5A68A7E38D9A213169E4" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_A5FEBB4C59DE5F22B62F54561B7F1403" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8D9BB48DE62D5DCD94617758480981D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3F1D699297B55AA3B2ABA8E2AD5501A4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8D9BB48DE62D5DCD94617758480981D9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5C0B8ED26F6E595DACDC30E6F82B9DB9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_AA52D862DFE55B078A90640DE84361F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5C0B8ED26F6E595DACDC30E6F82B9DB9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_AA52D862DFE55B078A90640DE84361F9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_DBBC4FD31EF15898906169E4E92BD7B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_AA52D862DFE55B078A90640DE84361F9" xlink:to="loc_srt_ProductOrServiceAxis_DBBC4FD31EF15898906169E4E92BD7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_DBBC4FD31EF15898906169E4E92BD7B8" xlink:to="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_DBBC4FD31EF15898906169E4E92BD7B8" xlink:to="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_4C5A86E27C7F5608A2CDDE2AD05E32DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_TecfideraMember_4C5A86E27C7F5608A2CDDE2AD05E32DB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_A84573BFCAEE51ECA08329EC2458DDE8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_InterferonMember_A84573BFCAEE51ECA08329EC2458DDE8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_1CE09247ABC958B193026A3AF23CF54C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_TysabriProductMember_1CE09247ABC958B193026A3AF23CF54C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_4F4E7AFCF84E54D48AA79B9DBEA6F1B8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_FAMPYRAMember_4F4E7AFCF84E54D48AA79B9DBEA6F1B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_A2D1A0B71FDA5B9F8F366AC85E4E194D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_ZINBRYTAMember_A2D1A0B71FDA5B9F8F366AC85E4E194D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_A76B3B3C132A5CA88379A7500E1D3901" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_MSProductRevenuesMember_A76B3B3C132A5CA88379A7500E1D3901" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_9D49C9D9B103553183642E73B1A093BF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_SPINRAZAMember_9D49C9D9B103553183642E73B1A093BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_2A309F1B60C7584584C3B22746F5B4DF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_BENEPALIMember_2A309F1B60C7584584C3B22746F5B4DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_4F299C33E1C35D6195A81309F0D090DE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_IMRALDIMember_4F299C33E1C35D6195A81309F0D090DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_594BE6E7F38E500FBDDFAFABF3051C72" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_FLIXABIMember_594BE6E7F38E500FBDDFAFABF3051C72" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_24AD8154BF3851E6B432BDDA60EB369C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_BiosimilarsMember_24AD8154BF3851E6B432BDDA60EB369C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_D369ED1CE58E5670B693B6303087F9EF" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_FUMADERMMember_D369ED1CE58E5670B693B6303087F9EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_97BB6B36FE905C2E854BC4E81DD36F0C" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_us-gaap_ProductMember_97BB6B36FE905C2E854BC4E81DD36F0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_AA52D862DFE55B078A90640DE84361F9" xlink:to="loc_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:to="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:to="loc_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_4ADF66EACEBF5D9DB46420C74C7E88F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:to="loc_country_US_4ADF66EACEBF5D9DB46420C74C7E88F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_6A4F8F8BD8905B0CB54B88D17E642A04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:to="loc_us-gaap_NonUsMember_6A4F8F8BD8905B0CB54B88D17E642A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B87C1A002C7657F2981FCBE9CD5492F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5C0B8ED26F6E595DACDC30E6F82B9DB9" xlink:to="loc_us-gaap_Revenues_B87C1A002C7657F2981FCBE9CD5492F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:to="loc_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:to="loc_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:to="loc_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_CD064B0727EE571BBC820EACBA91DA9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_CD064B0727EE571BBC820EACBA91DA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7BF462678EDD5BBE8FDCA166B26AC0D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:to="loc_srt_MajorCustomersAxis_7BF462678EDD5BBE8FDCA166B26AC0D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7BF462678EDD5BBE8FDCA166B26AC0D5" xlink:to="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_F1A0C971902F568E8A6721749B5EFD56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7BF462678EDD5BBE8FDCA166B26AC0D5" xlink:to="loc_srt_NameOfMajorCustomerDomain_F1A0C971902F568E8A6721749B5EFD56" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_6803B75A8494565B9820AF53ED0C1336" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_F1A0C971902F568E8A6721749B5EFD56" xlink:to="loc_biib_DistributorOneMember_6803B75A8494565B9820AF53ED0C1336" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_E30383FDFA4C562DB12C86A083885A17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_F1A0C971902F568E8A6721749B5EFD56" xlink:to="loc_biib_DistributorTwoMember_E30383FDFA4C562DB12C86A083885A17" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_787C6A27F1FB55AD80DFF1F36BB7C31E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_F1A0C971902F568E8A6721749B5EFD56" xlink:to="loc_biib_BioverativMember_787C6A27F1FB55AD80DFF1F36BB7C31E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_FD62419268085294B9AB0E466CB98395" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:to="loc_us-gaap_Revenues_FD62419268085294B9AB0E466CB98395" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D783F67B1625560F852978016A2235C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D783F67B1625560F852978016A2235C8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_043319A628D75FE6AB7CDDD501001383" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_69A96AAE195C55ADA63E72B23EA8B75A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_043319A628D75FE6AB7CDDD501001383" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_69A96AAE195C55ADA63E72B23EA8B75A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F59B41DD505D53DCBC13861722646E54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_69A96AAE195C55ADA63E72B23EA8B75A" xlink:to="loc_srt_ProductOrServiceAxis_F59B41DD505D53DCBC13861722646E54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AD0F83F004ED6CDE50C30B174E1F3FC9_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_F59B41DD505D53DCBC13861722646E54" xlink:to="loc_srt_ProductsAndServicesDomain_AD0F83F004ED6CDE50C30B174E1F3FC9_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907C1A1C3D3A561792DA749196E911F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_F59B41DD505D53DCBC13861722646E54" xlink:to="loc_srt_ProductsAndServicesDomain_907C1A1C3D3A561792DA749196E911F5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_23C819B37FD75FA597D502593691E931" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_907C1A1C3D3A561792DA749196E911F5" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_23C819B37FD75FA597D502593691E931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_83ECE4D70C775445B0ABB5763DB22131" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_69A96AAE195C55ADA63E72B23EA8B75A" xlink:to="loc_srt_MajorCustomersAxis_83ECE4D70C775445B0ABB5763DB22131" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_83ECE4D70C775445B0ABB5763DB22131" xlink:to="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_62E3149C39595E4BA1CBF6181E2955F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_83ECE4D70C775445B0ABB5763DB22131" xlink:to="loc_srt_NameOfMajorCustomerDomain_62E3149C39595E4BA1CBF6181E2955F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_DFDF877A368A5B2EA28AC5D53C51E65D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_62E3149C39595E4BA1CBF6181E2955F3" xlink:to="loc_biib_RocheGroupGenentechMember_DFDF877A368A5B2EA28AC5D53C51E65D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_5CF0741D88C85CF6992D412469E0D2BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_043319A628D75FE6AB7CDDD501001383" xlink:to="loc_biib_ShareOfCoPromotionProfits_5CF0741D88C85CF6992D412469E0D2BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_6434B0FB69ED52DCBD9B13169B742AB3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_043319A628D75FE6AB7CDDD501001383" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_6434B0FB69ED52DCBD9B13169B742AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_22EC9AFFE2AC510191F03BBB7FF75067" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_043319A628D75FE6AB7CDDD501001383" xlink:to="loc_us-gaap_Revenues_22EC9AFFE2AC510191F03BBB7FF75067" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5A31F395208C3772A20E8365F8395D9F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2C627D7404B43C13624E8365F837B10F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5A31F395208C3772A20E8365F8395D9F" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2C627D7404B43C13624E8365F837B10F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A3555831E11586CB25BC8365F837C9B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2C627D7404B43C13624E8365F837B10F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A3555831E11586CB25BC8365F837C9B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A3555831E11586CB25BC8365F837C9B1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A3555831E11586CB25BC8365F837C9B1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_793531F73066410230E58365F838C39B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_793531F73066410230E58365F838C39B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F3BA59A50F882B39611C8365F838B783" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F3BA59A50F882B39611C8365F838B783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_D363C8C64F7CAE06A7DB8365F838BA72" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108" xlink:to="loc_us-gaap_ParentMember_D363C8C64F7CAE06A7DB8365F838BA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5A31F395208C3772A20E8365F8395D9F" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8352912AF6FB7775A1A28365F83903D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8352912AF6FB7775A1A28365F83903D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6DA37E34B001CE8016FE8365F839D7D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6DA37E34B001CE8016FE8365F839D7D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_375DCF08DEC73B7092328365F83A4CF7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_375DCF08DEC73B7092328365F83A4CF7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_4FEE1766516BC3B18EE78365F83A852D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_4FEE1766516BC3B18EE78365F83A852D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_8D42368629B75E9293925A2C432939DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:to="loc_biib_NightstarMember_8D42368629B75E9293925A2C432939DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:to="loc_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_83C5D6286BF45DFBA8483C927D50D06B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_MarketStockUnitsMember_83C5D6286BF45DFBA8483C927D50D06B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_8E0E544DECC25187918EFF30D2647181" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_8E0E544DECC25187918EFF30D2647181" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_F816DD50BA7B599EBB7FA2B82439194C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_CashSettledPerformanceSharesMember_F816DD50BA7B599EBB7FA2B82439194C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_D0341733D424595AB280CE6ED5C9E54F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_us-gaap_PerformanceSharesMember_D0341733D424595AB280CE6ED5C9E54F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_B35379F9E5E1542EB2D0171ACADC5A29" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_B35379F9E5E1542EB2D0171ACADC5A29" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_5EE107411D0C53159A39D9FEE2AC8F40" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_5EE107411D0C53159A39D9FEE2AC8F40" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_FF7EC0C9A2A251719D2DCCF5AAC078B2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_FF7EC0C9A2A251719D2DCCF5AAC078B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BCECFE3C16675E7AA6952AA57A57573F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BCECFE3C16675E7AA6952AA57A57573F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E33431D013025C3CAFC08FA17D6C4505" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E33431D013025C3CAFC08FA17D6C4505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_19D6C1C9BE1B5AB6B44EE394FF2FF84F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_19D6C1C9BE1B5AB6B44EE394FF2FF84F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55211FCD2D41581B9A291654068076EB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55211FCD2D41581B9A291654068076EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_D191404F0B065A1D927958BC3121A835" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_D191404F0B065A1D927958BC3121A835" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_FE94E5E4634951AAA06876B855539696" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_FE94E5E4634951AAA06876B855539696" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:to="loc_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9C7BBBB2CCC444E4D4E2DF1A98A9080B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9C7BBBB2CCC444E4D4E2DF1A98A9080B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9C7BBBB2CCC444E4D4E2DF1A98A9080B" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9C7BBBB2CCC444E4D4E2DF1A98A9080B" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_9B4AA217FE7D46FB4634DF1A98AA1CA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4" xlink:to="loc_biib_A2019ShareRepurchaseProgramMember_9B4AA217FE7D46FB4634DF1A98AA1CA9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_FC0782E0938F3A90CE5EDF1A98AA8084" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_FC0782E0938F3A90CE5EDF1A98AA8084" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_4C1ACA9EA61ACFF1BEE7DF1A98AA149E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_4C1ACA9EA61ACFF1BEE7DF1A98AA149E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_730B124876887307FCFEDF1A98AA8468" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_730B124876887307FCFEDF1A98AA8468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AC07634DDB685D75FEA6DF1A98AA5D58" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AC07634DDB685D75FEA6DF1A98AA5D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EBA4BA65B0105582BF1DCAE0207A97CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6750B441EC105253894B1BAA6C733A06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_EBA4BA65B0105582BF1DCAE0207A97CB" xlink:to="loc_us-gaap_StatementTable_6750B441EC105253894B1BAA6C733A06" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_2066B18D19C65391ACBA3C64F4879B50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6750B441EC105253894B1BAA6C733A06" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_2066B18D19C65391ACBA3C64F4879B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_674A1DA3C6B22AB088270B174E71A77D_8D2386A9B971548BBF674E0309999D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_2066B18D19C65391ACBA3C64F4879B50" xlink:to="loc_us-gaap_AccountingGuidanceMember_674A1DA3C6B22AB088270B174E71A77D_8D2386A9B971548BBF674E0309999D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_B47EE5EAFC5F54179666C5F6D322201E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_2066B18D19C65391ACBA3C64F4879B50" xlink:to="loc_us-gaap_AccountingGuidanceMember_B47EE5EAFC5F54179666C5F6D322201E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B7BD648C8C8555D5998BBA78B96CC8EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_B47EE5EAFC5F54179666C5F6D322201E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_B7BD648C8C8555D5998BBA78B96CC8EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_294E049EEEBA57688FC4433E5343FF13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EBA4BA65B0105582BF1DCAE0207A97CB" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_294E049EEEBA57688FC4433E5343FF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BFAC42727BE357C6B3A3649A7EAD5328" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EBA4BA65B0105582BF1DCAE0207A97CB" xlink:to="loc_us-gaap_OperatingLeaseLiability_BFAC42727BE357C6B3A3649A7EAD5328" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>biib-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_FD57DFCF3355A42E0A51DF18C3643DEE_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_FD57DFCF3355A42E0A51DF18C3643DEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_FD57DFCF3355A42E0A51DF18C3643DEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FD57DFCF3355A42E0A51DF18C3643DEE" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_FD57DFCF3355A42E0A51DF18C3643DEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:to="lab_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:to="lab_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0EA17FD66EE58DAF24ECDF18C3684561_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0EA17FD66EE58DAF24ECDF18C3684561" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0EA17FD66EE58DAF24ECDF18C3684561_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0EA17FD66EE58DAF24ECDF18C3684561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0EA17FD66EE58DAF24ECDF18C3684561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0EA17FD66EE58DAF24ECDF18C3684561" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0EA17FD66EE58DAF24ECDF18C3684561" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_836F9ECA9088C721D7F3DF18C36CE266_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_836F9ECA9088C721D7F3DF18C36CE266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_836F9ECA9088C721D7F3DF18C36CE266_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_836F9ECA9088C721D7F3DF18C36CE266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_836F9ECA9088C721D7F3DF18C36CE266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_836F9ECA9088C721D7F3DF18C36CE266" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_836F9ECA9088C721D7F3DF18C36CE266" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_62D07A2B6ED78FC3E017DF18C36C7CD2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_62D07A2B6ED78FC3E017DF18C36C7CD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_62D07A2B6ED78FC3E017DF18C36C7CD2_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_62D07A2B6ED78FC3E017DF18C36C7CD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_62D07A2B6ED78FC3E017DF18C36C7CD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_62D07A2B6ED78FC3E017DF18C36C7CD2" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_62D07A2B6ED78FC3E017DF18C36C7CD2" xlink:type="arc" />
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_3C85AAD167B83E3F5B59DF18C36C6524_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_3C85AAD167B83E3F5B59DF18C36C6524" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_3C85AAD167B83E3F5B59DF18C36C6524_label_en-US" xlink:label="lab_us-gaap_InventoryNet_3C85AAD167B83E3F5B59DF18C36C6524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_3C85AAD167B83E3F5B59DF18C36C6524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_3C85AAD167B83E3F5B59DF18C36C6524" xlink:to="lab_us-gaap_InventoryNet_3C85AAD167B83E3F5B59DF18C36C6524" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_B685C71E5467D6ECD215DF18C36C8EDA_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_B685C71E5467D6ECD215DF18C36C8EDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_B685C71E5467D6ECD215DF18C36C8EDA_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_B685C71E5467D6ECD215DF18C36C8EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_B685C71E5467D6ECD215DF18C36C8EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_B685C71E5467D6ECD215DF18C36C8EDA" xlink:to="lab_us-gaap_OtherAssetsCurrent_B685C71E5467D6ECD215DF18C36C8EDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_0007BC9998594CB3D2CCDF18C3748A95_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_0007BC9998594CB3D2CCDF18C3748A95" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_0007BC9998594CB3D2CCDF18C3748A95_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_0007BC9998594CB3D2CCDF18C3748A95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0007BC9998594CB3D2CCDF18C3748A95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_0007BC9998594CB3D2CCDF18C3748A95" xlink:to="lab_us-gaap_AssetsCurrent_0007BC9998594CB3D2CCDF18C3748A95" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_51AC97AFBCEB5F30A5D9DF18C3744896_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_51AC97AFBCEB5F30A5D9DF18C3744896" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_51AC97AFBCEB5F30A5D9DF18C3744896_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_51AC97AFBCEB5F30A5D9DF18C3744896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_51AC97AFBCEB5F30A5D9DF18C3744896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_51AC97AFBCEB5F30A5D9DF18C3744896" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_51AC97AFBCEB5F30A5D9DF18C3744896" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2367889CB88A1D85C3D5DF18C374130D_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2367889CB88A1D85C3D5DF18C374130D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2367889CB88A1D85C3D5DF18C374130D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2367889CB88A1D85C3D5DF18C374130D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2367889CB88A1D85C3D5DF18C374130D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2367889CB88A1D85C3D5DF18C374130D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_2367889CB88A1D85C3D5DF18C374130D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_BB45E4C219EE47B043EEDF18C374AA28_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_BB45E4C219EE47B043EEDF18C374AA28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_BB45E4C219EE47B043EEDF18C374AA28_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_BB45E4C219EE47B043EEDF18C374AA28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_BB45E4C219EE47B043EEDF18C374AA28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_BB45E4C219EE47B043EEDF18C374AA28" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_BB45E4C219EE47B043EEDF18C374AA28" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_EC33D47F795E17D47678DF18C3749DD8_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_EC33D47F795E17D47678DF18C3749DD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_EC33D47F795E17D47678DF18C3749DD8_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_EC33D47F795E17D47678DF18C3749DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_EC33D47F795E17D47678DF18C3749DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_EC33D47F795E17D47678DF18C3749DD8" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_EC33D47F795E17D47678DF18C3749DD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_7F963C87ED63583A4E5FDF18C3740614_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill_7F963C87ED63583A4E5FDF18C3740614" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_7F963C87ED63583A4E5FDF18C3740614_label_en-US" xlink:label="lab_us-gaap_Goodwill_7F963C87ED63583A4E5FDF18C3740614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_7F963C87ED63583A4E5FDF18C3740614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_7F963C87ED63583A4E5FDF18C3740614" xlink:to="lab_us-gaap_Goodwill_7F963C87ED63583A4E5FDF18C3740614" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8B44CB6B3A59063E350DDF18C374731D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8B44CB6B3A59063E350DDF18C374731D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8B44CB6B3A59063E350DDF18C374731D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8B44CB6B3A59063E350DDF18C374731D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8B44CB6B3A59063E350DDF18C374731D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8B44CB6B3A59063E350DDF18C374731D" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8B44CB6B3A59063E350DDF18C374731D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1F8C65B3E7757C3887C0DF18C374FA5F_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_1F8C65B3E7757C3887C0DF18C374FA5F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1F8C65B3E7757C3887C0DF18C374FA5F_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_1F8C65B3E7757C3887C0DF18C374FA5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1F8C65B3E7757C3887C0DF18C374FA5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_1F8C65B3E7757C3887C0DF18C374FA5F" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_1F8C65B3E7757C3887C0DF18C374FA5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_4EA1CBAA726AEA9D3E75DF18C374D276_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_4EA1CBAA726AEA9D3E75DF18C374D276" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_4EA1CBAA726AEA9D3E75DF18C374D276_label_en-US" xlink:label="lab_us-gaap_Assets_4EA1CBAA726AEA9D3E75DF18C374D276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_4EA1CBAA726AEA9D3E75DF18C374D276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_4EA1CBAA726AEA9D3E75DF18C374D276" xlink:to="lab_us-gaap_Assets_4EA1CBAA726AEA9D3E75DF18C374D276" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_8EDC4D520B9F385CB176DF18C731B6C3_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_8EDC4D520B9F385CB176DF18C731B6C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_8EDC4D520B9F385CB176DF18C731B6C3_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_8EDC4D520B9F385CB176DF18C731B6C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_8EDC4D520B9F385CB176DF18C731B6C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_8EDC4D520B9F385CB176DF18C731B6C3" xlink:to="lab_us-gaap_NotesPayableCurrent_8EDC4D520B9F385CB176DF18C731B6C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_4218A761C0E19903D1BFDF18C37481A4_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_4218A761C0E19903D1BFDF18C37481A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_4218A761C0E19903D1BFDF18C37481A4_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_4218A761C0E19903D1BFDF18C37481A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_4218A761C0E19903D1BFDF18C37481A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_4218A761C0E19903D1BFDF18C37481A4" xlink:to="lab_us-gaap_TaxesPayableCurrent_4218A761C0E19903D1BFDF18C37481A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_298A0D2BF1DCF2D099CADF18C374B329_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_298A0D2BF1DCF2D099CADF18C374B329" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_298A0D2BF1DCF2D099CADF18C374B329_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_298A0D2BF1DCF2D099CADF18C374B329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_298A0D2BF1DCF2D099CADF18C374B329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_298A0D2BF1DCF2D099CADF18C374B329" xlink:to="lab_us-gaap_AccountsPayableCurrent_298A0D2BF1DCF2D099CADF18C374B329" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_721CDF607F09DA6AE134DF18C3782398_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_721CDF607F09DA6AE134DF18C3782398" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_721CDF607F09DA6AE134DF18C3782398_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_721CDF607F09DA6AE134DF18C3782398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_721CDF607F09DA6AE134DF18C3782398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_721CDF607F09DA6AE134DF18C3782398" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_721CDF607F09DA6AE134DF18C3782398" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_56D16EE7B54CC178D97EDF18C378BA4D_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_56D16EE7B54CC178D97EDF18C378BA4D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_56D16EE7B54CC178D97EDF18C378BA4D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_56D16EE7B54CC178D97EDF18C378BA4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_56D16EE7B54CC178D97EDF18C378BA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_56D16EE7B54CC178D97EDF18C378BA4D" xlink:to="lab_us-gaap_LiabilitiesCurrent_56D16EE7B54CC178D97EDF18C378BA4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_ED88BB0D7E22AB3204FBDF18C378ABC7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_ED88BB0D7E22AB3204FBDF18C378ABC7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_ED88BB0D7E22AB3204FBDF18C378ABC7_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_ED88BB0D7E22AB3204FBDF18C378ABC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_ED88BB0D7E22AB3204FBDF18C378ABC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_ED88BB0D7E22AB3204FBDF18C378ABC7" xlink:to="lab_us-gaap_LongTermDebt_ED88BB0D7E22AB3204FBDF18C378ABC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_B0989AF452384B9EC911DF18C3783795_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_B0989AF452384B9EC911DF18C3783795" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_B0989AF452384B9EC911DF18C3783795_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_B0989AF452384B9EC911DF18C3783795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_B0989AF452384B9EC911DF18C3783795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_B0989AF452384B9EC911DF18C3783795" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_B0989AF452384B9EC911DF18C3783795" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1571FE2192CFC4503765DF18C3789D3C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1571FE2192CFC4503765DF18C3789D3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1571FE2192CFC4503765DF18C3789D3C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1571FE2192CFC4503765DF18C3789D3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1571FE2192CFC4503765DF18C3789D3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1571FE2192CFC4503765DF18C3789D3C" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1571FE2192CFC4503765DF18C3789D3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3F0989B51103347C242EDF18C3781002_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_3F0989B51103347C242EDF18C3781002" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3F0989B51103347C242EDF18C3781002_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_3F0989B51103347C242EDF18C3781002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3F0989B51103347C242EDF18C3781002" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_3F0989B51103347C242EDF18C3781002" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_3F0989B51103347C242EDF18C3781002" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_55035C36F3510DFB7CAADF18C3796C9F_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_55035C36F3510DFB7CAADF18C3796C9F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_55035C36F3510DFB7CAADF18C3796C9F_label_en-US" xlink:label="lab_us-gaap_Liabilities_55035C36F3510DFB7CAADF18C3796C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_55035C36F3510DFB7CAADF18C3796C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_55035C36F3510DFB7CAADF18C3796C9F" xlink:to="lab_us-gaap_Liabilities_55035C36F3510DFB7CAADF18C3796C9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_125F4EF6523340B5154CDF18C3797457_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_125F4EF6523340B5154CDF18C3797457" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_125F4EF6523340B5154CDF18C3797457_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_125F4EF6523340B5154CDF18C3797457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_125F4EF6523340B5154CDF18C3797457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_125F4EF6523340B5154CDF18C3797457" xlink:to="lab_us-gaap_CommitmentsAndContingencies_125F4EF6523340B5154CDF18C3797457" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:to="lab_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_197CA9AC1CECE1FE04F0DF18C37927F1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_197CA9AC1CECE1FE04F0DF18C37927F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_197CA9AC1CECE1FE04F0DF18C37927F1_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_197CA9AC1CECE1FE04F0DF18C37927F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_197CA9AC1CECE1FE04F0DF18C37927F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_197CA9AC1CECE1FE04F0DF18C37927F1" xlink:to="lab_us-gaap_PreferredStockValue_197CA9AC1CECE1FE04F0DF18C37927F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_06470510F759F133C705DF18C37A957A_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_06470510F759F133C705DF18C37A957A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_06470510F759F133C705DF18C37A957A_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_06470510F759F133C705DF18C37A957A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_06470510F759F133C705DF18C37A957A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_06470510F759F133C705DF18C37A957A" xlink:to="lab_us-gaap_CommonStockValue_06470510F759F133C705DF18C37A957A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_A6BE975B7F3456C154D5DF18C37A1DB8_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_A6BE975B7F3456C154D5DF18C37A1DB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_A6BE975B7F3456C154D5DF18C37A1DB8_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_A6BE975B7F3456C154D5DF18C37A1DB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_A6BE975B7F3456C154D5DF18C37A1DB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_A6BE975B7F3456C154D5DF18C37A1DB8" xlink:to="lab_us-gaap_AdditionalPaidInCapital_A6BE975B7F3456C154D5DF18C37A1DB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_271EBB5AF87D575088F5DF18C37ABB75_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_271EBB5AF87D575088F5DF18C37ABB75" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_271EBB5AF87D575088F5DF18C37ABB75_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_271EBB5AF87D575088F5DF18C37ABB75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_271EBB5AF87D575088F5DF18C37ABB75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_271EBB5AF87D575088F5DF18C37ABB75" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_271EBB5AF87D575088F5DF18C37ABB75" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_33DB8EBAF7EAC9657AC3DF18C37A3032_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_33DB8EBAF7EAC9657AC3DF18C37A3032" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_33DB8EBAF7EAC9657AC3DF18C37A3032_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_33DB8EBAF7EAC9657AC3DF18C37A3032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33DB8EBAF7EAC9657AC3DF18C37A3032" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33DB8EBAF7EAC9657AC3DF18C37A3032" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_33DB8EBAF7EAC9657AC3DF18C37A3032" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_2E16D469F37117E891FCDF18C37BF037_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_2E16D469F37117E891FCDF18C37BF037" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_2E16D469F37117E891FCDF18C37BF037_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_2E16D469F37117E891FCDF18C37BF037" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_2E16D469F37117E891FCDF18C37BF037" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_2E16D469F37117E891FCDF18C37BF037" xlink:to="lab_us-gaap_TreasuryStockValue_2E16D469F37117E891FCDF18C37BF037" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_D58035CB5564CA21F92ADF18C37B26AE_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_D58035CB5564CA21F92ADF18C37B26AE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_D58035CB5564CA21F92ADF18C37B26AE_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_D58035CB5564CA21F92ADF18C37B26AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_D58035CB5564CA21F92ADF18C37B26AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_D58035CB5564CA21F92ADF18C37B26AE" xlink:to="lab_us-gaap_StockholdersEquity_D58035CB5564CA21F92ADF18C37B26AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_D89CE4C882513938F2AFDF18C37B4A2C_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_D89CE4C882513938F2AFDF18C37B4A2C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_D89CE4C882513938F2AFDF18C37B4A2C_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_D89CE4C882513938F2AFDF18C37B4A2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_D89CE4C882513938F2AFDF18C37B4A2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_D89CE4C882513938F2AFDF18C37B4A2C" xlink:to="lab_us-gaap_MinorityInterest_D89CE4C882513938F2AFDF18C37B4A2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B8E6B95411154E1365F5DF18C37B383A_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B8E6B95411154E1365F5DF18C37B383A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B8E6B95411154E1365F5DF18C37B383A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B8E6B95411154E1365F5DF18C37B383A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B8E6B95411154E1365F5DF18C37B383A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B8E6B95411154E1365F5DF18C37B383A" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B8E6B95411154E1365F5DF18C37B383A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_F540299CF5A1CEB677C2DF18C37BA2B6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_F540299CF5A1CEB677C2DF18C37BA2B6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_F540299CF5A1CEB677C2DF18C37BA2B6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_F540299CF5A1CEB677C2DF18C37BA2B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_F540299CF5A1CEB677C2DF18C37BA2B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_F540299CF5A1CEB677C2DF18C37BA2B6" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_F540299CF5A1CEB677C2DF18C37BA2B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BEDD295F3C98A420EC5BF625FA08908A_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BE07720B337055769079CD9FE4FF12A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BE07720B337055769079CD9FE4FF12A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BE07720B337055769079CD9FE4FF12A6" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BE07720B337055769079CD9FE4FF12A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_ACF4E15A05FD5B0A844F966C88576DBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_ACF4E15A05FD5B0A844F966C88576DBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_ACF4E15A05FD5B0A844F966C88576DBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_ACF4E15A05FD5B0A844F966C88576DBF" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_ACF4E15A05FD5B0A844F966C88576DBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_D948CE33D7A827EFDB77827AE1EC7263_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_D948CE33D7A827EFDB77827AE1EC7263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_D948CE33D7A827EFDB77827AE1EC7263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_D948CE33D7A827EFDB77827AE1EC7263" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_D948CE33D7A827EFDB77827AE1EC7263" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC_label_en-US" xlink:label="lab_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:to="lab_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D_terseLabel_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D_label_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:to="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:label id="lab_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014_label_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:to="lab_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F" xlink:to="lab_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:type="arc" />
    <link:label id="lab_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29_terseLabel_en-US" xlink:label="lab_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29_label_en-US" xlink:label="lab_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29_documentation_en-US" xlink:label="lab_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29" xlink:to="lab_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29" xlink:type="arc" />
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD" xlink:to="lab_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="lab_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1" xlink:to="lab_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB" xlink:to="lab_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B" xlink:to="lab_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5" xlink:to="lab_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB" xlink:to="lab_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D_label_en-US" xlink:label="lab_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D" xlink:to="lab_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="lab_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_F7A678F9DE8CA693C233827AE1F0A39A_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_F7A678F9DE8CA693C233827AE1F0A39A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_F7A678F9DE8CA693C233827AE1F0A39A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_F7A678F9DE8CA693C233827AE1F0A39A" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_F7A678F9DE8CA693C233827AE1F0A39A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C_label_en-US" xlink:label="lab_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C" xlink:to="lab_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_FFEC62C22331F8BA8810827AE1F1281C_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_FFEC62C22331F8BA8810827AE1F1281C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_FFEC62C22331F8BA8810827AE1F1281C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_FFEC62C22331F8BA8810827AE1F1281C" xlink:to="lab_us-gaap_StockholdersEquity_FFEC62C22331F8BA8810827AE1F1281C" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_3BBE7515E9C0AF3F81F8827AE1F13596_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_3BBE7515E9C0AF3F81F8827AE1F13596" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3BBE7515E9C0AF3F81F8827AE1F13596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_3BBE7515E9C0AF3F81F8827AE1F13596" xlink:to="lab_us-gaap_MinorityInterest_3BBE7515E9C0AF3F81F8827AE1F13596" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3" xlink:to="lab_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interest, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154" xlink:to="lab_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, decrease from distributions to noncontrolling interest holders</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of new accounting guidance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56" xlink:to="lab_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38962C10458059BED8EF827AE1F412FD_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38962C10458059BED8EF827AE1F412FD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38962C10458059BED8EF827AE1F412FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38962C10458059BED8EF827AE1F412FD" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38962C10458059BED8EF827AE1F412FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_6F0E8419F50FD2FC0516827AE1F4E0E3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6F0E8419F50FD2FC0516827AE1F4E0E3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6F0E8419F50FD2FC0516827AE1F4E0E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_6F0E8419F50FD2FC0516827AE1F4E0E3" xlink:to="lab_us-gaap_StockholdersEquity_6F0E8419F50FD2FC0516827AE1F4E0E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_2145AD8FEB69D44CB991827AE1F435D2_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_2145AD8FEB69D44CB991827AE1F435D2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_2145AD8FEB69D44CB991827AE1F435D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_2145AD8FEB69D44CB991827AE1F435D2" xlink:to="lab_us-gaap_MinorityInterest_2145AD8FEB69D44CB991827AE1F435D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_D5657DDE802F00ACDD2F827AE1F551D1_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_D5657DDE802F00ACDD2F827AE1F551D1" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_D5657DDE802F00ACDD2F827AE1F551D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_D5657DDE802F00ACDD2F827AE1F551D1" xlink:to="lab_us-gaap_SharesIssued_D5657DDE802F00ACDD2F827AE1F551D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8BB6F0FDBA56BB9C1FBBF625F90E828E_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_63F3D129D4D856B9B663A97EC72B3918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_63F3D129D4D856B9B663A97EC72B3918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_63F3D129D4D856B9B663A97EC72B3918" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_63F3D129D4D856B9B663A97EC72B3918" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_55D1AF38F5E858A6A22D4ADF4EAA06B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_55D1AF38F5E858A6A22D4ADF4EAA06B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_55D1AF38F5E858A6A22D4ADF4EAA06B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_55D1AF38F5E858A6A22D4ADF4EAA06B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_55D1AF38F5E858A6A22D4ADF4EAA06B0" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_55D1AF38F5E858A6A22D4ADF4EAA06B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECC7FE7648594FA0B2F2F625F9AA0CCE_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_952FEA6D8C4A55F3974905C79C2BF9A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_952FEA6D8C4A55F3974905C79C2BF9A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_952FEA6D8C4A55F3974905C79C2BF9A3" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_952FEA6D8C4A55F3974905C79C2BF9A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9045D08ECFD6578799B1DC607C11AA1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9045D08ECFD6578799B1DC607C11AA1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9045D08ECFD6578799B1DC607C11AA1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9045D08ECFD6578799B1DC607C11AA1A" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9045D08ECFD6578799B1DC607C11AA1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_4982A10AB8BA5594B7C6A5E4F667B8EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_4982A10AB8BA5594B7C6A5E4F667B8EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_4982A10AB8BA5594B7C6A5E4F667B8EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_4982A10AB8BA5594B7C6A5E4F667B8EF" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_4982A10AB8BA5594B7C6A5E4F667B8EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_839C3F60233750158DAD25D0ED478EFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_839C3F60233750158DAD25D0ED478EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_839C3F60233750158DAD25D0ED478EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_839C3F60233750158DAD25D0ED478EFE" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_839C3F60233750158DAD25D0ED478EFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_501228286090569FA1B72BC5D809EC40" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_501228286090569FA1B72BC5D809EC40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_501228286090569FA1B72BC5D809EC40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_501228286090569FA1B72BC5D809EC40" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_501228286090569FA1B72BC5D809EC40" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_D4C75513BE0A5124B89C56320EF010F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_D4C75513BE0A5124B89C56320EF010F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_D4C75513BE0A5124B89C56320EF010F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_D4C75513BE0A5124B89C56320EF010F4" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_D4C75513BE0A5124B89C56320EF010F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_E9468C1ED210FD0077FF0B174D0C5886_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_9BF16201D10F5ACBB1607016F9FDE82B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9BF16201D10F5ACBB1607016F9FDE82B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_9BF16201D10F5ACBB1607016F9FDE82B" xlink:to="lab_us-gaap_EquityAbstract_9BF16201D10F5ACBB1607016F9FDE82B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:to="lab_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_93A1814C1FD9F599D91B0B174D0EC934_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69E3437BCC685A4A89CE4BB09AFF016A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_93A1814C1FD9F599D91B0B174D0EC934_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69E3437BCC685A4A89CE4BB09AFF016A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69E3437BCC685A4A89CE4BB09AFF016A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69E3437BCC685A4A89CE4BB09AFF016A" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69E3437BCC685A4A89CE4BB09AFF016A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5420DF1CAB8F1B5E7A940B174D0ECDD2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_FBF75FF1DF385D4092216D272C8CF354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5420DF1CAB8F1B5E7A940B174D0ECDD2_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_FBF75FF1DF385D4092216D272C8CF354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_FBF75FF1DF385D4092216D272C8CF354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_FBF75FF1DF385D4092216D272C8CF354" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_FBF75FF1DF385D4092216D272C8CF354" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_449A11954160AB0AA1C80B174D0EF0DA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E15AB3C602E552A39B5E99C3E0A84083" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_449A11954160AB0AA1C80B174D0EF0DA_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E15AB3C602E552A39B5E99C3E0A84083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E15AB3C602E552A39B5E99C3E0A84083" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E15AB3C602E552A39B5E99C3E0A84083" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E15AB3C602E552A39B5E99C3E0A84083" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_955DB22F529156CD88A426178DC9564B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_955DB22F529156CD88A426178DC9564B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_955DB22F529156CD88A426178DC9564B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_955DB22F529156CD88A426178DC9564B" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_955DB22F529156CD88A426178DC9564B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_5A0A027A557E56B197E760986F6C6A40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_5A0A027A557E56B197E760986F6C6A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5A0A027A557E56B197E760986F6C6A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5A0A027A557E56B197E760986F6C6A40" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_5A0A027A557E56B197E760986F6C6A40" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71F0E21B9289464ACDD10B174D0F440F_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04D4ACC4BB4A57C99A3C9C706B3B10ED" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04D4ACC4BB4A57C99A3C9C706B3B10ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04D4ACC4BB4A57C99A3C9C706B3B10ED" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04D4ACC4BB4A57C99A3C9C706B3B10ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F_verboseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8114D4079FA45862B6426CADE30AAFB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of new accounting principle in period of adoption</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8114D4079FA45862B6426CADE30AAFB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8114D4079FA45862B6426CADE30AAFB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8114D4079FA45862B6426CADE30AAFB9" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8114D4079FA45862B6426CADE30AAFB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C6EBF545D38BF8AD3640B174D0FF918_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EF8ADCF260CC588791CE5CAD1BB8D6C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EF8ADCF260CC588791CE5CAD1BB8D6C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EF8ADCF260CC588791CE5CAD1BB8D6C5" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EF8ADCF260CC588791CE5CAD1BB8D6C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DC9B1E44558B55D381FA7B7990974F90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DC9B1E44558B55D381FA7B7990974F90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DC9B1E44558B55D381FA7B7990974F90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DC9B1E44558B55D381FA7B7990974F90" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DC9B1E44558B55D381FA7B7990974F90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_252EDC2CD25C575B9ED4859C0CEF1AC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_252EDC2CD25C575B9ED4859C0CEF1AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_252EDC2CD25C575B9ED4859C0CEF1AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_252EDC2CD25C575B9ED4859C0CEF1AC3" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_252EDC2CD25C575B9ED4859C0CEF1AC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8A53AFB9AE271205147B0B174D10FC08_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_FBEEF01A11705D8990D9D492E31AAB3B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_FBEEF01A11705D8990D9D492E31AAB3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_FBEEF01A11705D8990D9D492E31AAB3B" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_FBEEF01A11705D8990D9D492E31AAB3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_7DB39F836D8FD52B3B5CF625FA17EC5C_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_95290ABE8A5F591B965F1012B1D11674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_95290ABE8A5F591B965F1012B1D11674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_95290ABE8A5F591B965F1012B1D11674" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_95290ABE8A5F591B965F1012B1D11674" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9150E3837B645E218DCCEC6B99A578E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9150E3837B645E218DCCEC6B99A578E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9150E3837B645E218DCCEC6B99A578E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9150E3837B645E218DCCEC6B99A578E1" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9150E3837B645E218DCCEC6B99A578E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:to="lab_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:to="lab_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:type="arc" />
    <link:label id="lab_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB" xlink:to="lab_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:to="lab_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5" xlink:type="arc" />
    <link:label id="lab_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12_label_en-US" xlink:label="lab_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:to="lab_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="lab_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:type="arc" />
    <link:label id="lab_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F_verboseLabel_en-US" xlink:label="lab_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F_label_en-US" xlink:label="lab_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F" xlink:to="lab_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F" xlink:type="arc" />
    <link:label id="lab_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15_terseLabel_en-US" xlink:label="lab_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15_label_en-US" xlink:label="lab_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15" xlink:to="lab_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15" xlink:type="arc" />
    <link:label id="lab_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89_terseLabel_en-US" xlink:label="lab_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89_label_en-US" xlink:label="lab_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89" xlink:to="lab_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89" xlink:type="arc" />
    <link:label id="lab_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0_terseLabel_en-US" xlink:label="lab_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0_label_en-US" xlink:label="lab_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0" xlink:to="lab_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0" xlink:type="arc" />
    <link:label id="lab_currency_CAD_04C1B0192880F801D90DDF1A99901E69_verboseLabel_en-US" xlink:label="lab_currency_CAD_04C1B0192880F801D90DDF1A99901E69" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_04C1B0192880F801D90DDF1A99901E69_label_en-US" xlink:label="lab_currency_CAD_04C1B0192880F801D90DDF1A99901E69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_04C1B0192880F801D90DDF1A99901E69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_04C1B0192880F801D90DDF1A99901E69" xlink:to="lab_currency_CAD_04C1B0192880F801D90DDF1A99901E69" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4_label_en-US" xlink:label="lab_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4" xlink:to="lab_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC" xlink:to="lab_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:to="lab_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F" xlink:to="lab_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE" xlink:to="lab_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763" xlink:to="lab_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B" xlink:to="lab_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876" xlink:to="lab_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:to="lab_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:to="lab_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898" xlink:to="lab_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC_label_en-US" xlink:label="lab_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:to="lab_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB_terseLabel_en-US" xlink:label="lab_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB_label_en-US" xlink:label="lab_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:to="lab_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71_label_en-US" xlink:label="lab_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71" xlink:to="lab_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5_label_en-US" xlink:label="lab_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5" xlink:to="lab_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D" xlink:type="arc" />
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E_negatedLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on reclassification of cash flow hedges, effective portion</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6" xlink:to="lab_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining duration of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02" xlink:to="lab_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedges</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583" xlink:type="arc" />
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_82D7F0C9614F953C192DF625F94C31F5_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_CCAE1DA16FF159919911933B8D908085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CCAE1DA16FF159919911933B8D908085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CCAE1DA16FF159919911933B8D908085" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_CCAE1DA16FF159919911933B8D908085" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_16BBA7AAE755516789F903DA720F3607" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_16BBA7AAE755516789F903DA720F3607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_16BBA7AAE755516789F903DA720F3607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_16BBA7AAE755516789F903DA720F3607" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_16BBA7AAE755516789F903DA720F3607" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:to="lab_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_F26B1FB4C5AB52C9A742C7619776FEEC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_F26B1FB4C5AB52C9A742C7619776FEEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_F26B1FB4C5AB52C9A742C7619776FEEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_F26B1FB4C5AB52C9A742C7619776FEEC" xlink:to="lab_us-gaap_CommercialPaperMember_F26B1FB4C5AB52C9A742C7619776FEEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_85C303F06FA157C496DDCDADE895A8F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_85C303F06FA157C496DDCDADE895A8F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_85C303F06FA157C496DDCDADE895A8F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_85C303F06FA157C496DDCDADE895A8F4" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_85C303F06FA157C496DDCDADE895A8F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_2905EAC9B5675514B800CE0ACEFCC00C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_2905EAC9B5675514B800CE0ACEFCC00C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2905EAC9B5675514B800CE0ACEFCC00C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_2905EAC9B5675514B800CE0ACEFCC00C" xlink:to="lab_us-gaap_MoneyMarketFundsMember_2905EAC9B5675514B800CE0ACEFCC00C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_223E0213AB7B59DA9A28B49C51FFEF0B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_223E0213AB7B59DA9A28B49C51FFEF0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_223E0213AB7B59DA9A28B49C51FFEF0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_223E0213AB7B59DA9A28B49C51FFEF0B" xlink:to="lab_us-gaap_DebtSecuritiesMember_223E0213AB7B59DA9A28B49C51FFEF0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_122DB266C11D586282D6D63FD1C8CF9B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_122DB266C11D586282D6D63FD1C8CF9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_122DB266C11D586282D6D63FD1C8CF9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_122DB266C11D586282D6D63FD1C8CF9B" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_122DB266C11D586282D6D63FD1C8CF9B" xlink:type="arc" />
    <link:label id="lab_biib_DivestituresAbstract_7FA72CB87037B2A0CB3182ADAA34FF68_label_en-US" xlink:label="lab_biib_DivestituresAbstract_7FA72CB87037B2A0CB3182ADAA34FF68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_7FA72CB87037B2A0CB3182ADAA34FF68_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract_7FA72CB87037B2A0CB3182ADAA34FF68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_7FA72CB87037B2A0CB3182ADAA34FF68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract_7FA72CB87037B2A0CB3182ADAA34FF68" xlink:to="lab_biib_DivestituresAbstract_7FA72CB87037B2A0CB3182ADAA34FF68" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:type="arc" />
    <link:label id="lab_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99_terseLabel_en-US" xlink:label="lab_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99_label_en-US" xlink:label="lab_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process [Member]</link:label>
    <link:label id="lab_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99_documentation_en-US" xlink:label="lab_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99" xlink:to="lab_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:type="arc" />
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0_terseLabel_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0_label_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0_documentation_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0" xlink:to="lab_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory work-in-process sold to FUJIFILM</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E" xlink:type="arc" />
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E_terseLabel_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E_label_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E_documentation_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E" xlink:to="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_B640C59AB7B8BB68332A0B174D4ABB47_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:to="lab_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:type="arc" />
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267_terseLabel_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_6E2CFCEDEC395831833E542A64E76B61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of operating leases</link:label>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267_label_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_6E2CFCEDEC395831833E542A64E76B61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Lease Table [Table Text Block]</link:label>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267_documentation_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_6E2CFCEDEC395831833E542A64E76B61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee Lease Table [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_LesseeLeaseTableTableTextBlock" xlink:label="loc_biib_LesseeLeaseTableTableTextBlock_6E2CFCEDEC395831833E542A64E76B61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LesseeLeaseTableTableTextBlock_6E2CFCEDEC395831833E542A64E76B61" xlink:to="lab_biib_LesseeLeaseTableTableTextBlock_6E2CFCEDEC395831833E542A64E76B61" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_460AA497EEEC55A48AA8D620AAA2CEC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_460AA497EEEC55A48AA8D620AAA2CEC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_460AA497EEEC55A48AA8D620AAA2CEC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_460AA497EEEC55A48AA8D620AAA2CEC4" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_460AA497EEEC55A48AA8D620AAA2CEC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7C4475D2DD3A554DA079BA4E6C12B1C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7C4475D2DD3A554DA079BA4E6C12B1C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7C4475D2DD3A554DA079BA4E6C12B1C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7C4475D2DD3A554DA079BA4E6C12B1C7" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7C4475D2DD3A554DA079BA4E6C12B1C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2675550A509859108BB3CA870D42EDCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2675550A509859108BB3CA870D42EDCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2675550A509859108BB3CA870D42EDCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2675550A509859108BB3CA870D42EDCA" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2675550A509859108BB3CA870D42EDCA" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD_terseLabel_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_E3C3DD54A6CF5A4B9C7F252428509E23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate</link:label>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD_label_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_E3C3DD54A6CF5A4B9C7F252428509E23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD_documentation_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_E3C3DD54A6CF5A4B9C7F252428509E23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:label="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_E3C3DD54A6CF5A4B9C7F252428509E23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_E3C3DD54A6CF5A4B9C7F252428509E23" xlink:to="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_E3C3DD54A6CF5A4B9C7F252428509E23" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78_terseLabel_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_2F01837FC10E56E79C6D52A863ECA489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure</link:label>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78_label_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_2F01837FC10E56E79C6D52A863ECA489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78_documentation_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_2F01837FC10E56E79C6D52A863ECA489" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:label="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_2F01837FC10E56E79C6D52A863ECA489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_2F01837FC10E56E79C6D52A863ECA489" xlink:to="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_2F01837FC10E56E79C6D52A863ECA489" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_85C6221FF06B764A6C14F625F8EE0BCA_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_895871D2BA845B9AB5C77FE2C0B5BAF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_895871D2BA845B9AB5C77FE2C0B5BAF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_895871D2BA845B9AB5C77FE2C0B5BAF2" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_895871D2BA845B9AB5C77FE2C0B5BAF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:to="lab_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6556D19F630D04DEA74CF625F8EE5015_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6A3B83BDEB0C5D74821E6A5B94BF07CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6556D19F630D04DEA74CF625F8EE5015_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6A3B83BDEB0C5D74821E6A5B94BF07CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6556D19F630D04DEA74CF625F8EE5015_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6A3B83BDEB0C5D74821E6A5B94BF07CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6A3B83BDEB0C5D74821E6A5B94BF07CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6A3B83BDEB0C5D74821E6A5B94BF07CA" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6A3B83BDEB0C5D74821E6A5B94BF07CA" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A58BB25EC7E3A9C64F9DF625F8EE2F0B_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_16DD21E268BC56F3821B8AE800EF3503" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A58BB25EC7E3A9C64F9DF625F8EE2F0B_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_16DD21E268BC56F3821B8AE800EF3503" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A58BB25EC7E3A9C64F9DF625F8EE2F0B_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_16DD21E268BC56F3821B8AE800EF3503" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_16DD21E268BC56F3821B8AE800EF3503" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_16DD21E268BC56F3821B8AE800EF3503" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_16DD21E268BC56F3821B8AE800EF3503" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_66023A34561B18E5FC21F625F8EE45E9_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1F83379E76335E1B99AA554A6980B9D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_66023A34561B18E5FC21F625F8EE45E9_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1F83379E76335E1B99AA554A6980B9D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_66023A34561B18E5FC21F625F8EE45E9_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1F83379E76335E1B99AA554A6980B9D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1F83379E76335E1B99AA554A6980B9D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1F83379E76335E1B99AA554A6980B9D1" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1F83379E76335E1B99AA554A6980B9D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:to="lab_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_B2B8F2B0F5115E0EA94ABCAEBEDD9DAC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_B2B8F2B0F5115E0EA94ABCAEBEDD9DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_B2B8F2B0F5115E0EA94ABCAEBEDD9DAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_B2B8F2B0F5115E0EA94ABCAEBEDD9DAC" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_B2B8F2B0F5115E0EA94ABCAEBEDD9DAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_7D8F54B6D42D5452A6514307350AEE6B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50_label_en-US" xlink:label="lab_us-gaap_NotesPayable_7D8F54B6D42D5452A6514307350AEE6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_7D8F54B6D42D5452A6514307350AEE6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_7D8F54B6D42D5452A6514307350AEE6B" xlink:to="lab_us-gaap_NotesPayable_7D8F54B6D42D5452A6514307350AEE6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_C7091C12AEAA5254B6C18D4FF6A418F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_C7091C12AEAA5254B6C18D4FF6A418F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_C7091C12AEAA5254B6C18D4FF6A418F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_C7091C12AEAA5254B6C18D4FF6A418F4" xlink:to="lab_us-gaap_DebtInstrumentFairValue_C7091C12AEAA5254B6C18D4FF6A418F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2A3B85B985F781D1FD7AF625FA27B272_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C2E58BC2F9075123B51BFDF058C365CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C2E58BC2F9075123B51BFDF058C365CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C2E58BC2F9075123B51BFDF058C365CF" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C2E58BC2F9075123B51BFDF058C365CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E00FC47E60DE52E0865F2163FFC4E2E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E00FC47E60DE52E0865F2163FFC4E2E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E00FC47E60DE52E0865F2163FFC4E2E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E00FC47E60DE52E0865F2163FFC4E2E5" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E00FC47E60DE52E0865F2163FFC4E2E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AD31CAA7C55BECE28987F625F8EEDF0E_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8C09591251E5FD184FDE6D39AC3EA4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8C09591251E5FD184FDE6D39AC3EA4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8C09591251E5FD184FDE6D39AC3EA4B" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8C09591251E5FD184FDE6D39AC3EA4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ACE872C2A5045429936655D0BC93397B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ACE872C2A5045429936655D0BC93397B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ACE872C2A5045429936655D0BC93397B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ACE872C2A5045429936655D0BC93397B" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ACE872C2A5045429936655D0BC93397B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_A60BE7B1967A5DFF9701E6396E18AD58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_A60BE7B1967A5DFF9701E6396E18AD58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_A60BE7B1967A5DFF9701E6396E18AD58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_A60BE7B1967A5DFF9701E6396E18AD58" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_A60BE7B1967A5DFF9701E6396E18AD58" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_C7281D8D6CFC56628248F625F8916F23_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_323FA93E20B65C698D63AF17B48B0A7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_323FA93E20B65C698D63AF17B48B0A7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_323FA93E20B65C698D63AF17B48B0A7B" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_323FA93E20B65C698D63AF17B48B0A7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_AFB6039C3E145E53A5930A6606E58DEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_AFB6039C3E145E53A5930A6606E58DEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_AFB6039C3E145E53A5930A6606E58DEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_AFB6039C3E145E53A5930A6606E58DEB" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_AFB6039C3E145E53A5930A6606E58DEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4974649005941E87DAD7F625FA27627D_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_AB246CDA0EC75853B36AD79548DB6237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_AB246CDA0EC75853B36AD79548DB6237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AB246CDA0EC75853B36AD79548DB6237" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_AB246CDA0EC75853B36AD79548DB6237" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AE62F8513D15524E8A45C662CFABBFD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AE62F8513D15524E8A45C662CFABBFD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AE62F8513D15524E8A45C662CFABBFD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AE62F8513D15524E8A45C662CFABBFD2" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AE62F8513D15524E8A45C662CFABBFD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74626955C1645DE598EC21A600728169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74626955C1645DE598EC21A600728169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74626955C1645DE598EC21A600728169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74626955C1645DE598EC21A600728169" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74626955C1645DE598EC21A600728169" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_B4E1855E9B0956049CED7BD6BD20C591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_B4E1855E9B0956049CED7BD6BD20C591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_B4E1855E9B0956049CED7BD6BD20C591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_B4E1855E9B0956049CED7BD6BD20C591" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_B4E1855E9B0956049CED7BD6BD20C591" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_B4BA7161E1AF2D69E736F625F7FAC5EE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0FD62E475AD05F49BDCFEAA3DEBCDA79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0FD62E475AD05F49BDCFEAA3DEBCDA79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0FD62E475AD05F49BDCFEAA3DEBCDA79" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0FD62E475AD05F49BDCFEAA3DEBCDA79" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_27C4D3F9D5515126A7009EF3D81CEC56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_27C4D3F9D5515126A7009EF3D81CEC56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_27C4D3F9D5515126A7009EF3D81CEC56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_27C4D3F9D5515126A7009EF3D81CEC56" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_27C4D3F9D5515126A7009EF3D81CEC56" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A7636F768C00F90384EAF625F8917D1D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7EA5642EE9435EF3BFF4425AFFCCE59F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A7636F768C00F90384EAF625F8917D1D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7EA5642EE9435EF3BFF4425AFFCCE59F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7EA5642EE9435EF3BFF4425AFFCCE59F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7EA5642EE9435EF3BFF4425AFFCCE59F" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7EA5642EE9435EF3BFF4425AFFCCE59F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_008CA42BF9995995BAA282E2B0CD6065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_008CA42BF9995995BAA282E2B0CD6065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_008CA42BF9995995BAA282E2B0CD6065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_008CA42BF9995995BAA282E2B0CD6065" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_008CA42BF9995995BAA282E2B0CD6065" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_01220D3096655810B2557723AD36904A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_01220D3096655810B2557723AD36904A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_01220D3096655810B2557723AD36904A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_01220D3096655810B2557723AD36904A" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_01220D3096655810B2557723AD36904A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_D40F01B88FE079F27B09F625F7EE8708_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4275735833CA5406A5F20C6A80A191C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4275735833CA5406A5F20C6A80A191C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4275735833CA5406A5F20C6A80A191C4" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4275735833CA5406A5F20C6A80A191C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B181A4E6CFC45B50A037981CE5A9717C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B181A4E6CFC45B50A037981CE5A9717C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B181A4E6CFC45B50A037981CE5A9717C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B181A4E6CFC45B50A037981CE5A9717C" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B181A4E6CFC45B50A037981CE5A9717C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_B7BD648C8C8555D5998BBA78B96CC8EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_B7BD648C8C8555D5998BBA78B96CC8EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B7BD648C8C8555D5998BBA78B96CC8EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_B7BD648C8C8555D5998BBA78B96CC8EB" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_B7BD648C8C8555D5998BBA78B96CC8EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_BFAC42727BE357C6B3A3649A7EAD5328" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_BFAC42727BE357C6B3A3649A7EAD5328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BFAC42727BE357C6B3A3649A7EAD5328" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_BFAC42727BE357C6B3A3649A7EAD5328" xlink:to="lab_us-gaap_OperatingLeaseLiability_BFAC42727BE357C6B3A3649A7EAD5328" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_66EF4F69B42456A383A58F1447822ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_66EF4F69B42456A383A58F1447822ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_66EF4F69B42456A383A58F1447822ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_66EF4F69B42456A383A58F1447822ACF" xlink:to="lab_us-gaap_NumberOfReportableSegments_66EF4F69B42456A383A58F1447822ACF" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_F5F4E4D822585AC69A24E01FB4683842" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_F5F4E4D822585AC69A24E01FB4683842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_F5F4E4D822585AC69A24E01FB4683842" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_F5F4E4D822585AC69A24E01FB4683842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_F5F4E4D822585AC69A24E01FB4683842" xlink:to="lab_biib_InterestInSubsidiary_F5F4E4D822585AC69A24E01FB4683842" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_CFF3F137479B52D799F9DB2FF680DB9B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_CFF3F137479B52D799F9DB2FF680DB9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_CFF3F137479B52D799F9DB2FF680DB9B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_CFF3F137479B52D799F9DB2FF680DB9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_CFF3F137479B52D799F9DB2FF680DB9B" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_CFF3F137479B52D799F9DB2FF680DB9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_064AF59A029B50CDACF3B63825809031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_064AF59A029B50CDACF3B63825809031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_064AF59A029B50CDACF3B63825809031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_064AF59A029B50CDACF3B63825809031" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_064AF59A029B50CDACF3B63825809031" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_AB027AAC4D2B55DC9B38B0C5BCA02220" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_AB027AAC4D2B55DC9B38B0C5BCA02220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_AB027AAC4D2B55DC9B38B0C5BCA02220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_AB027AAC4D2B55DC9B38B0C5BCA02220" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_AB027AAC4D2B55DC9B38B0C5BCA02220" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_917E89F9955F557ABC4507255AAC09CC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_917E89F9955F557ABC4507255AAC09CC_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:type="arc" />
    <link:label id="lab_biib_NightstarMember_C59737DBB14908D8B04707255AACCFAD_terseLabel_en-US" xlink:label="lab_biib_NightstarMember_8D42368629B75E9293925A2C432939DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_C59737DBB14908D8B04707255AACCFAD_label_en-US" xlink:label="lab_biib_NightstarMember_8D42368629B75E9293925A2C432939DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_C59737DBB14908D8B04707255AACCFAD_documentation_en-US" xlink:label="lab_biib_NightstarMember_8D42368629B75E9293925A2C432939DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_8D42368629B75E9293925A2C432939DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember_8D42368629B75E9293925A2C432939DC" xlink:to="lab_biib_NightstarMember_8D42368629B75E9293925A2C432939DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:to="lab_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_1565AAC5E50546A3F8E707255AACDEEA_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_83C5D6286BF45DFBA8483C927D50D06B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_1565AAC5E50546A3F8E707255AACDEEA_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_83C5D6286BF45DFBA8483C927D50D06B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_1565AAC5E50546A3F8E707255AACDEEA_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_83C5D6286BF45DFBA8483C927D50D06B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_83C5D6286BF45DFBA8483C927D50D06B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_83C5D6286BF45DFBA8483C927D50D06B" xlink:to="lab_biib_MarketStockUnitsMember_83C5D6286BF45DFBA8483C927D50D06B" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_8BB5062B8EB27477417607255AAC53FD_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_8E0E544DECC25187918EFF30D2647181" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_8BB5062B8EB27477417607255AAC53FD_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_8E0E544DECC25187918EFF30D2647181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_8BB5062B8EB27477417607255AAC53FD_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_8E0E544DECC25187918EFF30D2647181" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_8E0E544DECC25187918EFF30D2647181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_8E0E544DECC25187918EFF30D2647181" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_8E0E544DECC25187918EFF30D2647181" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_F816DD50BA7B599EBB7FA2B82439194C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_F816DD50BA7B599EBB7FA2B82439194C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_F816DD50BA7B599EBB7FA2B82439194C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_F816DD50BA7B599EBB7FA2B82439194C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_F816DD50BA7B599EBB7FA2B82439194C" xlink:to="lab_biib_CashSettledPerformanceSharesMember_F816DD50BA7B599EBB7FA2B82439194C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_D0341733D424595AB280CE6ED5C9E54F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_D0341733D424595AB280CE6ED5C9E54F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_D0341733D424595AB280CE6ED5C9E54F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_D0341733D424595AB280CE6ED5C9E54F" xlink:to="lab_us-gaap_PerformanceSharesMember_D0341733D424595AB280CE6ED5C9E54F" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_62D3EF5CE4B4AE47D42F07255AACC049_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_B35379F9E5E1542EB2D0171ACADC5A29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_62D3EF5CE4B4AE47D42F07255AACC049_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_B35379F9E5E1542EB2D0171ACADC5A29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_62D3EF5CE4B4AE47D42F07255AACC049_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_B35379F9E5E1542EB2D0171ACADC5A29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_B35379F9E5E1542EB2D0171ACADC5A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember_B35379F9E5E1542EB2D0171ACADC5A29" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember_B35379F9E5E1542EB2D0171ACADC5A29" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_5EE107411D0C53159A39D9FEE2AC8F40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_5EE107411D0C53159A39D9FEE2AC8F40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_5EE107411D0C53159A39D9FEE2AC8F40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_5EE107411D0C53159A39D9FEE2AC8F40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember_5EE107411D0C53159A39D9FEE2AC8F40" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember_5EE107411D0C53159A39D9FEE2AC8F40" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_FF7EC0C9A2A251719D2DCCF5AAC078B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_FF7EC0C9A2A251719D2DCCF5AAC078B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_FF7EC0C9A2A251719D2DCCF5AAC078B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_FF7EC0C9A2A251719D2DCCF5AAC078B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_FF7EC0C9A2A251719D2DCCF5AAC078B2" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_FF7EC0C9A2A251719D2DCCF5AAC078B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_BCECFE3C16675E7AA6952AA57A57573F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NST stock option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_BCECFE3C16675E7AA6952AA57A57573F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BCECFE3C16675E7AA6952AA57A57573F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_BCECFE3C16675E7AA6952AA57A57573F" xlink:to="lab_us-gaap_EmployeeStockOptionMember_BCECFE3C16675E7AA6952AA57A57573F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3EC8851D703EB4CDB88F07255AAC4DAE_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3EC8851D703EB4CDB88F07255AAC4DAE_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0A1427BC0E649CA13CEA07255AAC850B_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_E33431D013025C3CAFC08FA17D6C4505" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E33431D013025C3CAFC08FA17D6C4505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_E33431D013025C3CAFC08FA17D6C4505" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_E33431D013025C3CAFC08FA17D6C4505" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_2B2754BD6B359768E77507255AAC7CB4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_19D6C1C9BE1B5AB6B44EE394FF2FF84F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of post-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_2B2754BD6B359768E77507255AAC7CB4_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_19D6C1C9BE1B5AB6B44EE394FF2FF84F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_19D6C1C9BE1B5AB6B44EE394FF2FF84F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_19D6C1C9BE1B5AB6B44EE394FF2FF84F" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_19D6C1C9BE1B5AB6B44EE394FF2FF84F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55211FCD2D41581B9A291654068076EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55211FCD2D41581B9A291654068076EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55211FCD2D41581B9A291654068076EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55211FCD2D41581B9A291654068076EB" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55211FCD2D41581B9A291654068076EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5B5B47710242C2D7FD9D07255AAC98AB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_D191404F0B065A1D927958BC3121A835" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5B5B47710242C2D7FD9D07255AAC98AB_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_D191404F0B065A1D927958BC3121A835" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_D191404F0B065A1D927958BC3121A835" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_D191404F0B065A1D927958BC3121A835" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_D191404F0B065A1D927958BC3121A835" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3D64A997BBFBF6D3264E07255AACAE6E_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_FE94E5E4634951AAA06876B855539696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3D64A997BBFBF6D3264E07255AACAE6E_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_FE94E5E4634951AAA06876B855539696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3D64A997BBFBF6D3264E07255AACAE6E_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_FE94E5E4634951AAA06876B855539696" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_FE94E5E4634951AAA06876B855539696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_FE94E5E4634951AAA06876B855539696" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_FE94E5E4634951AAA06876B855539696" xlink:type="arc" />
    <link:label id="lab_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB_label_en-US" xlink:label="lab_biib_InventoryAbstract_88F3D545C38758729E59F8A8BAA7D539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:label id="lab_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB_documentation_en-US" xlink:label="lab_biib_InventoryAbstract_88F3D545C38758729E59F8A8BAA7D539" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_InventoryAbstract" xlink:label="loc_biib_InventoryAbstract_88F3D545C38758729E59F8A8BAA7D539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryAbstract_88F3D545C38758729E59F8A8BAA7D539" xlink:to="lab_biib_InventoryAbstract_88F3D545C38758729E59F8A8BAA7D539" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:to="lab_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_F1B62765F245116C615D0B174DFF6C4F_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_F1B62765F245116C615D0B174DFF6C4F_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:to="lab_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:to="lab_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:type="arc" />
    <link:label id="lab_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE_terseLabel_en-US" xlink:label="lab_biib_BioverativMember_AC51DA1567B95A11987460B9653C6E3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE_label_en-US" xlink:label="lab_biib_BioverativMember_AC51DA1567B95A11987460B9653C6E3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE_documentation_en-US" xlink:label="lab_biib_BioverativMember_AC51DA1567B95A11987460B9653C6E3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_AC51DA1567B95A11987460B9653C6E3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember_AC51DA1567B95A11987460B9653C6E3F" xlink:to="lab_biib_BioverativMember_AC51DA1567B95A11987460B9653C6E3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:to="lab_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:type="arc" />
    <link:label id="lab_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A_terseLabel_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_3334E338259F580BB85A862AD022FFEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:label id="lab_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A_label_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_3334E338259F580BB85A862AD022FFEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:label id="lab_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A_documentation_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_3334E338259F580BB85A862AD022FFEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_3334E338259F580BB85A862AD022FFEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventorysoldtoBioverativcost_3334E338259F580BB85A862AD022FFEA" xlink:to="lab_biib_InventorysoldtoBioverativcost_3334E338259F580BB85A862AD022FFEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:to="lab_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_BCEDF9FAB61B5B36B32857AE4B04C8D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_BCEDF9FAB61B5B36B32857AE4B04C8D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_BCEDF9FAB61B5B36B32857AE4B04C8D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_BCEDF9FAB61B5B36B32857AE4B04C8D7" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_BCEDF9FAB61B5B36B32857AE4B04C8D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_BD33E3F5765455BAB925F9FEBF202348" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_BD33E3F5765455BAB925F9FEBF202348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_BD33E3F5765455BAB925F9FEBF202348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_BD33E3F5765455BAB925F9FEBF202348" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_BD33E3F5765455BAB925F9FEBF202348" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_C84BF6C6CA5350CBB1C6E86964EB154C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_C84BF6C6CA5350CBB1C6E86964EB154C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_C84BF6C6CA5350CBB1C6E86964EB154C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_C84BF6C6CA5350CBB1C6E86964EB154C" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_C84BF6C6CA5350CBB1C6E86964EB154C" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_CBF807994308547B89B21F8EEEFA9262" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_CBF807994308547B89B21F8EEEFA9262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_CBF807994308547B89B21F8EEEFA9262" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_CBF807994308547B89B21F8EEEFA9262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_CBF807994308547B89B21F8EEEFA9262" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_CBF807994308547B89B21F8EEEFA9262" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_64D4FAA5471CEBFB6A5BF625F9D94B3C_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_9739A2D227A75FBABDACDD3AB50C94A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_9739A2D227A75FBABDACDD3AB50C94A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_9739A2D227A75FBABDACDD3AB50C94A7" xlink:to="lab_us-gaap_InventoryNet_9739A2D227A75FBABDACDD3AB50C94A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_02B2F24D3405512483158F6140B0792C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_02B2F24D3405512483158F6140B0792C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_02B2F24D3405512483158F6140B0792C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_02B2F24D3405512483158F6140B0792C" xlink:to="lab_us-gaap_InventoryNoncurrent_02B2F24D3405512483158F6140B0792C" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_4C7E9BF73ACE528AB07E1C3B8AB52035" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_4C7E9BF73ACE528AB07E1C3B8AB52035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_4C7E9BF73ACE528AB07E1C3B8AB52035" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_4C7E9BF73ACE528AB07E1C3B8AB52035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_4C7E9BF73ACE528AB07E1C3B8AB52035" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_4C7E9BF73ACE528AB07E1C3B8AB52035" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_8AA11A1404915897AD9AE58FFBB481B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_8AA11A1404915897AD9AE58FFBB481B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_8AA11A1404915897AD9AE58FFBB481B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_8AA11A1404915897AD9AE58FFBB481B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_8AA11A1404915897AD9AE58FFBB481B7" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_8AA11A1404915897AD9AE58FFBB481B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_20525F1AB82E2508418F0B174E0FBC64_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_D53277E21484506198B152E791E04F7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_D53277E21484506198B152E791E04F7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_D53277E21484506198B152E791E04F7D" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_D53277E21484506198B152E791E04F7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_E91E9B3DB13452947A280B174E0FACC8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_E91E9B3DB13452947A280B174E0FACC8_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:to="lab_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:to="lab_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_372DD6272618074397AE0B174E1067F7_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_CD064B0727EE571BBC820EACBA91DA9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_372DD6272618074397AE0B174E1067F7_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_CD064B0727EE571BBC820EACBA91DA9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_CD064B0727EE571BBC820EACBA91DA9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_CD064B0727EE571BBC820EACBA91DA9B" xlink:to="lab_us-gaap_ProductAndServiceOtherMember_CD064B0727EE571BBC820EACBA91DA9B" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_6803B75A8494565B9820AF53ED0C1336" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5_label_en-US" xlink:label="lab_biib_DistributorOneMember_6803B75A8494565B9820AF53ED0C1336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_6803B75A8494565B9820AF53ED0C1336" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_6803B75A8494565B9820AF53ED0C1336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_6803B75A8494565B9820AF53ED0C1336" xlink:to="lab_biib_DistributorOneMember_6803B75A8494565B9820AF53ED0C1336" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_E30383FDFA4C562DB12C86A083885A17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14_label_en-US" xlink:label="lab_biib_DistributorTwoMember_E30383FDFA4C562DB12C86A083885A17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_E30383FDFA4C562DB12C86A083885A17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_E30383FDFA4C562DB12C86A083885A17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_E30383FDFA4C562DB12C86A083885A17" xlink:to="lab_biib_DistributorTwoMember_E30383FDFA4C562DB12C86A083885A17" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9E8ED4BA179205678AF80B174E120ED2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9E8ED4BA179205678AF80B174E120ED2_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A_netLabel_en-US" xlink:label="lab_us-gaap_Revenues_FD62419268085294B9AB0E466CB98395" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A_label_en-US" xlink:label="lab_us-gaap_Revenues_FD62419268085294B9AB0E466CB98395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_FD62419268085294B9AB0E466CB98395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_FD62419268085294B9AB0E466CB98395" xlink:to="lab_us-gaap_Revenues_FD62419268085294B9AB0E466CB98395" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D783F67B1625560F852978016A2235C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D783F67B1625560F852978016A2235C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D783F67B1625560F852978016A2235C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D783F67B1625560F852978016A2235C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D783F67B1625560F852978016A2235C8" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D783F67B1625560F852978016A2235C8" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_4BA151B0A4CF992C65380B174E2A4720_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract_BEEF29D50BDA53F8BAFCF5E863C1067C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_BEEF29D50BDA53F8BAFCF5E863C1067C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_BEEF29D50BDA53F8BAFCF5E863C1067C" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract_BEEF29D50BDA53F8BAFCF5E863C1067C" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:type="arc" />
    <link:label id="lab_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_30C7B7D4147E5E6AB7DB0D0F83CF8EBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_30C7B7D4147E5E6AB7DB0D0F83CF8EBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_30C7B7D4147E5E6AB7DB0D0F83CF8EBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_30C7B7D4147E5E6AB7DB0D0F83CF8EBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember_30C7B7D4147E5E6AB7DB0D0F83CF8EBB" xlink:to="lab_biib_ReserveforCashDiscountsMember_30C7B7D4147E5E6AB7DB0D0F83CF8EBB" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_8B9DF22A811C549DB917C2A0051EAFD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_8B9DF22A811C549DB917C2A0051EAFD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_8B9DF22A811C549DB917C2A0051EAFD0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_8B9DF22A811C549DB917C2A0051EAFD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_8B9DF22A811C549DB917C2A0051EAFD0" xlink:to="lab_biib_ContractualAdjustmentsMember_8B9DF22A811C549DB917C2A0051EAFD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_52119BB649D2596592C82C08D1CF7D53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_52119BB649D2596592C82C08D1CF7D53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_52119BB649D2596592C82C08D1CF7D53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_52119BB649D2596592C82C08D1CF7D53" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_52119BB649D2596592C82C08D1CF7D53" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_F8A30071368B5B2095BE39D7ABA656F1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_F8A30071368B5B2095BE39D7ABA656F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_F8A30071368B5B2095BE39D7ABA656F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_F8A30071368B5B2095BE39D7ABA656F1" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_F8A30071368B5B2095BE39D7ABA656F1" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_58E89CEE697E554993799E90546FAE23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_58E89CEE697E554993799E90546FAE23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_58E89CEE697E554993799E90546FAE23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_58E89CEE697E554993799E90546FAE23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_58E89CEE697E554993799E90546FAE23" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_58E89CEE697E554993799E90546FAE23" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_B17511584A56539C8075346C3219C0CE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_B17511584A56539C8075346C3219C0CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_B17511584A56539C8075346C3219C0CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_B17511584A56539C8075346C3219C0CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_B17511584A56539C8075346C3219C0CE" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_B17511584A56539C8075346C3219C0CE" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_80D46F881F4650DBA97C491B782AFCB0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_80D46F881F4650DBA97C491B782AFCB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_80D46F881F4650DBA97C491B782AFCB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_80D46F881F4650DBA97C491B782AFCB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_80D46F881F4650DBA97C491B782AFCB0" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_80D46F881F4650DBA97C491B782AFCB0" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_E1E8BF5C3D9154819E20700B6DCECF6A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_E1E8BF5C3D9154819E20700B6DCECF6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_E1E8BF5C3D9154819E20700B6DCECF6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_E1E8BF5C3D9154819E20700B6DCECF6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_E1E8BF5C3D9154819E20700B6DCECF6A" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_E1E8BF5C3D9154819E20700B6DCECF6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_48CE93976C03FA2FB21D0B174E2DFE79_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_A12F86E6AE5256618D43A12310E0E1C5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_A12F86E6AE5256618D43A12310E0E1C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_A12F86E6AE5256618D43A12310E0E1C5" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_A12F86E6AE5256618D43A12310E0E1C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_CE24D17F1268545E322CDF1A9CFA1C83_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_CE24D17F1268545E322CDF1A9CFA1C83" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_CE24D17F1268545E322CDF1A9CFA1C83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_CE24D17F1268545E322CDF1A9CFA1C83" xlink:to="lab_us-gaap_ProfitLoss_CE24D17F1268545E322CDF1A9CFA1C83" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_F47DA73E27BAEC0FA4FFDF1A9CFAF1FF_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_F47DA73E27BAEC0FA4FFDF1A9CFAF1FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_F47DA73E27BAEC0FA4FFDF1A9CFAF1FF_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_F47DA73E27BAEC0FA4FFDF1A9CFAF1FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_F47DA73E27BAEC0FA4FFDF1A9CFAF1FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_F47DA73E27BAEC0FA4FFDF1A9CFAF1FF" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_F47DA73E27BAEC0FA4FFDF1A9CFAF1FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_FBA94168A5DCE942618CDF1A9CFAE74C_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_FBA94168A5DCE942618CDF1A9CFAE74C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_FBA94168A5DCE942618CDF1A9CFAE74C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_FBA94168A5DCE942618CDF1A9CFAE74C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_FBA94168A5DCE942618CDF1A9CFAE74C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_FBA94168A5DCE942618CDF1A9CFAE74C" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_FBA94168A5DCE942618CDF1A9CFAE74C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_A5E63BE669BDE8A1082BDF1A9CFAD956_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A5E63BE669BDE8A1082BDF1A9CFAD956" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_A5E63BE669BDE8A1082BDF1A9CFAD956_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A5E63BE669BDE8A1082BDF1A9CFAD956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A5E63BE669BDE8A1082BDF1A9CFAD956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_A5E63BE669BDE8A1082BDF1A9CFAD956" xlink:to="lab_us-gaap_ShareBasedCompensation_A5E63BE669BDE8A1082BDF1A9CFAD956" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_889F623B4CB7B317D191DF1A9CFA16DC_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_889F623B4CB7B317D191DF1A9CFA16DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_889F623B4CB7B317D191DF1A9CFA16DC_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_889F623B4CB7B317D191DF1A9CFA16DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_889F623B4CB7B317D191DF1A9CFA16DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_889F623B4CB7B317D191DF1A9CFA16DC" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_889F623B4CB7B317D191DF1A9CFA16DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_9BFD069FFBA7900F8992DF1A9CFA9B9A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_9BFD069FFBA7900F8992DF1A9CFA9B9A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_9BFD069FFBA7900F8992DF1A9CFA9B9A_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_9BFD069FFBA7900F8992DF1A9CFA9B9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_9BFD069FFBA7900F8992DF1A9CFA9B9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_9BFD069FFBA7900F8992DF1A9CFA9B9A" xlink:to="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_9BFD069FFBA7900F8992DF1A9CFA9B9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_987054CE5E61C8B23626DF1A9CFA6C11_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_987054CE5E61C8B23626DF1A9CFA6C11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_987054CE5E61C8B23626DF1A9CFA6C11_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_987054CE5E61C8B23626DF1A9CFA6C11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_987054CE5E61C8B23626DF1A9CFA6C11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_987054CE5E61C8B23626DF1A9CFA6C11" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_987054CE5E61C8B23626DF1A9CFA6C11" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_99263D32138E07A10E44DF1A9CFA2285_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_99263D32138E07A10E44DF1A9CFA2285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_99263D32138E07A10E44DF1A9CFA2285_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_99263D32138E07A10E44DF1A9CFA2285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_99263D32138E07A10E44DF1A9CFA2285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_99263D32138E07A10E44DF1A9CFA2285" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_99263D32138E07A10E44DF1A9CFA2285" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_CFA0FCABF6FD38C82A5ADF1FD2F07360_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_CFA0FCABF6FD38C82A5ADF1FD2F07360" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_CFA0FCABF6FD38C82A5ADF1FD2F07360_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_CFA0FCABF6FD38C82A5ADF1FD2F07360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_CFA0FCABF6FD38C82A5ADF1FD2F07360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_CFA0FCABF6FD38C82A5ADF1FD2F07360" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_CFA0FCABF6FD38C82A5ADF1FD2F07360" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_C2E65AE498928955F0D3DF1A9CFA6631_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_C2E65AE498928955F0D3DF1A9CFA6631" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_C2E65AE498928955F0D3DF1A9CFA6631_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_C2E65AE498928955F0D3DF1A9CFA6631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_C2E65AE498928955F0D3DF1A9CFA6631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_C2E65AE498928955F0D3DF1A9CFA6631" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_C2E65AE498928955F0D3DF1A9CFA6631" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6E4D03B49597CB3CBB59DF1A9CFA3FB2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6E4D03B49597CB3CBB59DF1A9CFA3FB2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6E4D03B49597CB3CBB59DF1A9CFA3FB2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6E4D03B49597CB3CBB59DF1A9CFA3FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6E4D03B49597CB3CBB59DF1A9CFA3FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6E4D03B49597CB3CBB59DF1A9CFA3FB2" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6E4D03B49597CB3CBB59DF1A9CFA3FB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_16863A50D935B9F436EADF1A9CFA7A3D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_16863A50D935B9F436EADF1A9CFA7A3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_16863A50D935B9F436EADF1A9CFA7A3D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_16863A50D935B9F436EADF1A9CFA7A3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_16863A50D935B9F436EADF1A9CFA7A3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_16863A50D935B9F436EADF1A9CFA7A3D" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_16863A50D935B9F436EADF1A9CFA7A3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_30595066846E9D8320CBDF1A9CFA5A06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_30595066846E9D8320CBDF1A9CFA5A06" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_30595066846E9D8320CBDF1A9CFA5A06_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_30595066846E9D8320CBDF1A9CFA5A06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_30595066846E9D8320CBDF1A9CFA5A06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_30595066846E9D8320CBDF1A9CFA5A06" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_30595066846E9D8320CBDF1A9CFA5A06" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E45DBA90B6AD3520200CDF1A9CFA9EA5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E45DBA90B6AD3520200CDF1A9CFA9EA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E45DBA90B6AD3520200CDF1A9CFA9EA5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E45DBA90B6AD3520200CDF1A9CFA9EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E45DBA90B6AD3520200CDF1A9CFA9EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E45DBA90B6AD3520200CDF1A9CFA9EA5" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E45DBA90B6AD3520200CDF1A9CFA9EA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_013F2968F14586FA69A0DF1A9CFAC9E6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_013F2968F14586FA69A0DF1A9CFAC9E6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_013F2968F14586FA69A0DF1A9CFAC9E6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_013F2968F14586FA69A0DF1A9CFAC9E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_013F2968F14586FA69A0DF1A9CFAC9E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_013F2968F14586FA69A0DF1A9CFAC9E6" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_013F2968F14586FA69A0DF1A9CFAC9E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_857BFE03D3509AAB24A4DF1A9CFA58B2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_857BFE03D3509AAB24A4DF1A9CFA58B2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_857BFE03D3509AAB24A4DF1A9CFA58B2_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_857BFE03D3509AAB24A4DF1A9CFA58B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_857BFE03D3509AAB24A4DF1A9CFA58B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_857BFE03D3509AAB24A4DF1A9CFA58B2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_857BFE03D3509AAB24A4DF1A9CFA58B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E23429DB5FEC8DA8159ADF1A9CFA21CC_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E23429DB5FEC8DA8159ADF1A9CFA21CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E23429DB5FEC8DA8159ADF1A9CFA21CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E23429DB5FEC8DA8159ADF1A9CFA21CC" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E23429DB5FEC8DA8159ADF1A9CFA21CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9042D23839696FC98E78DF1A9CFA88F2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9042D23839696FC98E78DF1A9CFA88F2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9042D23839696FC98E78DF1A9CFA88F2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9042D23839696FC98E78DF1A9CFA88F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9042D23839696FC98E78DF1A9CFA88F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9042D23839696FC98E78DF1A9CFA88F2" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9042D23839696FC98E78DF1A9CFA88F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_252EA8F5E6DCFE52EA2EDF1A9CFA2158_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_252EA8F5E6DCFE52EA2EDF1A9CFA2158" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration paid related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_252EA8F5E6DCFE52EA2EDF1A9CFA2158_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_252EA8F5E6DCFE52EA2EDF1A9CFA2158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_252EA8F5E6DCFE52EA2EDF1A9CFA2158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_252EA8F5E6DCFE52EA2EDF1A9CFA2158" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_252EA8F5E6DCFE52EA2EDF1A9CFA2158" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_AA718AC43721E4CA4D58DF1A9CFACB5E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_AA718AC43721E4CA4D58DF1A9CFACB5E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Nightstar Therapeutics plc, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_AA718AC43721E4CA4D58DF1A9CFACB5E_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_AA718AC43721E4CA4D58DF1A9CFACB5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_AA718AC43721E4CA4D58DF1A9CFACB5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_AA718AC43721E4CA4D58DF1A9CFACB5E" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_AA718AC43721E4CA4D58DF1A9CFACB5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5E6EFC957E2A1F0DDFBDF24BDA88D4C_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5E6EFC957E2A1F0DDFBDF24BDA88D4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5E6EFC957E2A1F0DDFBDF24BDA88D4C_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5E6EFC957E2A1F0DDFBDF24BDA88D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5E6EFC957E2A1F0DDFBDF24BDA88D4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5E6EFC957E2A1F0DDFBDF24BDA88D4C" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5E6EFC957E2A1F0DDFBDF24BDA88D4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C77FB96C936AFE522EFEDF1A9CFA858D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C77FB96C936AFE522EFEDF1A9CFA858D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C77FB96C936AFE522EFEDF1A9CFA858D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C77FB96C936AFE522EFEDF1A9CFA858D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C77FB96C936AFE522EFEDF1A9CFA858D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C77FB96C936AFE522EFEDF1A9CFA858D" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C77FB96C936AFE522EFEDF1A9CFA858D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_D872EE1A6FB733979F41DF1A9CFA1688_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_D872EE1A6FB733979F41DF1A9CFA1688" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_D872EE1A6FB733979F41DF1A9CFA1688_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_D872EE1A6FB733979F41DF1A9CFA1688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_D872EE1A6FB733979F41DF1A9CFA1688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_D872EE1A6FB733979F41DF1A9CFA1688" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_D872EE1A6FB733979F41DF1A9CFA1688" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_53611C9A09C91EBF6793DF1A9CFA36E3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_53611C9A09C91EBF6793DF1A9CFA36E3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_53611C9A09C91EBF6793DF1A9CFA36E3_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_53611C9A09C91EBF6793DF1A9CFA36E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_53611C9A09C91EBF6793DF1A9CFA36E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_53611C9A09C91EBF6793DF1A9CFA36E3" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_53611C9A09C91EBF6793DF1A9CFA36E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_C1846160F1906EC6CC09DF1A9CFAD48D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments_C1846160F1906EC6CC09DF1A9CFAD48D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of Ionis Pharmaceuticals, Inc. stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_C1846160F1906EC6CC09DF1A9CFAD48D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments_C1846160F1906EC6CC09DF1A9CFAD48D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_C1846160F1906EC6CC09DF1A9CFAD48D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments_C1846160F1906EC6CC09DF1A9CFAD48D" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments_C1846160F1906EC6CC09DF1A9CFAD48D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E8F65CA988AF2D7BFCADDF1A9CFA3895_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E8F65CA988AF2D7BFCADDF1A9CFA3895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E8F65CA988AF2D7BFCADDF1A9CFA3895_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E8F65CA988AF2D7BFCADDF1A9CFA3895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E8F65CA988AF2D7BFCADDF1A9CFA3895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E8F65CA988AF2D7BFCADDF1A9CFA3895" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E8F65CA988AF2D7BFCADDF1A9CFA3895" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBB2785FF4A4646E40B5DF1A9CFA16E9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBB2785FF4A4646E40B5DF1A9CFA16E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBB2785FF4A4646E40B5DF1A9CFA16E9_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBB2785FF4A4646E40B5DF1A9CFA16E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBB2785FF4A4646E40B5DF1A9CFA16E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBB2785FF4A4646E40B5DF1A9CFA16E9" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBB2785FF4A4646E40B5DF1A9CFA16E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7EA5EBC65826196F4B7CDF1A9CFAF49C_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7EA5EBC65826196F4B7CDF1A9CFAF49C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7EA5EBC65826196F4B7CDF1A9CFAF49C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7EA5EBC65826196F4B7CDF1A9CFAF49C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7EA5EBC65826196F4B7CDF1A9CFAF49C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7EA5EBC65826196F4B7CDF1A9CFAF49C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7EA5EBC65826196F4B7CDF1A9CFAF49C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A984C807F11F103922F7DF1A9CFA747E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A984C807F11F103922F7DF1A9CFA747E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A984C807F11F103922F7DF1A9CFA747E_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A984C807F11F103922F7DF1A9CFA747E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A984C807F11F103922F7DF1A9CFA747E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A984C807F11F103922F7DF1A9CFA747E" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A984C807F11F103922F7DF1A9CFA747E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0CBBD88D3AAAF2849374DF1A9CFAA9B0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0CBBD88D3AAAF2849374DF1A9CFAA9B0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0CBBD88D3AAAF2849374DF1A9CFAA9B0_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0CBBD88D3AAAF2849374DF1A9CFAA9B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0CBBD88D3AAAF2849374DF1A9CFAA9B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0CBBD88D3AAAF2849374DF1A9CFAA9B0" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0CBBD88D3AAAF2849374DF1A9CFAA9B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_22153B4F7AC578458BB0DF1A9CFAA13F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_22153B4F7AC578458BB0DF1A9CFAA13F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_22153B4F7AC578458BB0DF1A9CFAA13F_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_22153B4F7AC578458BB0DF1A9CFAA13F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_22153B4F7AC578458BB0DF1A9CFAA13F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_22153B4F7AC578458BB0DF1A9CFAA13F" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_22153B4F7AC578458BB0DF1A9CFAA13F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_0DD09BE1ACA84020BED7DF1A9CFAFCFF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_0DD09BE1ACA84020BED7DF1A9CFAFCFF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_0DD09BE1ACA84020BED7DF1A9CFAFCFF_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_0DD09BE1ACA84020BED7DF1A9CFAFCFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_0DD09BE1ACA84020BED7DF1A9CFAFCFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_0DD09BE1ACA84020BED7DF1A9CFAFCFF" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_0DD09BE1ACA84020BED7DF1A9CFAFCFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0B34567E527FB4A5EE43DF1A9CFABB5D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0B34567E527FB4A5EE43DF1A9CFABB5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0B34567E527FB4A5EE43DF1A9CFABB5D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0B34567E527FB4A5EE43DF1A9CFABB5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0B34567E527FB4A5EE43DF1A9CFABB5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0B34567E527FB4A5EE43DF1A9CFABB5D" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0B34567E527FB4A5EE43DF1A9CFABB5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_80E3CF00EE49D058ADC2DF1A9CFA17CC_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_80E3CF00EE49D058ADC2DF1A9CFA17CC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_80E3CF00EE49D058ADC2DF1A9CFA17CC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_80E3CF00EE49D058ADC2DF1A9CFA17CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80E3CF00EE49D058ADC2DF1A9CFA17CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80E3CF00EE49D058ADC2DF1A9CFA17CC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_80E3CF00EE49D058ADC2DF1A9CFA17CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BAB991D20197338C8B2ADF1A9CFA869C_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BAB991D20197338C8B2ADF1A9CFA869C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BAB991D20197338C8B2ADF1A9CFA869C_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BAB991D20197338C8B2ADF1A9CFA869C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BAB991D20197338C8B2ADF1A9CFA869C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BAB991D20197338C8B2ADF1A9CFA869C" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BAB991D20197338C8B2ADF1A9CFA869C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_344F3A5C935793A1255DDF1A9CFA19AB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_344F3A5C935793A1255DDF1A9CFA19AB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_344F3A5C935793A1255DDF1A9CFA19AB_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_344F3A5C935793A1255DDF1A9CFA19AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_344F3A5C935793A1255DDF1A9CFA19AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_344F3A5C935793A1255DDF1A9CFA19AB" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_344F3A5C935793A1255DDF1A9CFA19AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D413350CD77F8F1B5C92DF1A9CFA85D4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D413350CD77F8F1B5C92DF1A9CFA85D4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D413350CD77F8F1B5C92DF1A9CFA85D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D413350CD77F8F1B5C92DF1A9CFA85D4" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D413350CD77F8F1B5C92DF1A9CFA85D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_138350BEDB6C5DD145F4DF1A9CFA663E_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_138350BEDB6C5DD145F4DF1A9CFA663E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_138350BEDB6C5DD145F4DF1A9CFA663E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_138350BEDB6C5DD145F4DF1A9CFA663E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_138350BEDB6C5DD145F4DF1A9CFA663E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_CC736C14669053B7BCB601C087AAA1BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_CC736C14669053B7BCB601C087AAA1BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_CC736C14669053B7BCB601C087AAA1BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_CC736C14669053B7BCB601C087AAA1BA" xlink:to="lab_us-gaap_AccountsReceivableMember_CC736C14669053B7BCB601C087AAA1BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_A5FEBB4C59DE5F22B62F54561B7F1403" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_A5FEBB4C59DE5F22B62F54561B7F1403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_A5FEBB4C59DE5F22B62F54561B7F1403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_A5FEBB4C59DE5F22B62F54561B7F1403" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_A5FEBB4C59DE5F22B62F54561B7F1403" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_8D9BB48DE62D5DCD94617758480981D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8D9BB48DE62D5DCD94617758480981D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_8D9BB48DE62D5DCD94617758480981D9" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_8D9BB48DE62D5DCD94617758480981D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6E8FA2DBE01853224EC71B1B924FF019_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A78DE17E8C425D2B823518410622E6FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A78DE17E8C425D2B823518410622E6FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A78DE17E8C425D2B823518410622E6FE" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A78DE17E8C425D2B823518410622E6FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1D5AE64D266D5BE73C6E1B1B924F8799_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1D5AE64D266D5BE73C6E1B1B924F8799_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:to="lab_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_7AE5176172ED5840B8936B038421D3E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_7AE5176172ED5840B8936B038421D3E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_7AE5176172ED5840B8936B038421D3E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_7AE5176172ED5840B8936B038421D3E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_7AE5176172ED5840B8936B038421D3E9" xlink:to="lab_biib_IonisPharmaceuticalsMember_7AE5176172ED5840B8936B038421D3E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:to="lab_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_08D1268846AF5D2194AF0B440B4DCC6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_08D1268846AF5D2194AF0B440B4DCC6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_08D1268846AF5D2194AF0B440B4DCC6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_08D1268846AF5D2194AF0B440B4DCC6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_08D1268846AF5D2194AF0B440B4DCC6C" xlink:to="lab_biib_StrategicInvestmentsMember_08D1268846AF5D2194AF0B440B4DCC6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_A78E3B7A156B2E350C1C1B1B924FE230_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_A78E3B7A156B2E350C1C1B1B924FE230_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_5B404AE4ADCF5DA6BC491B3362A1E81B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_5B404AE4ADCF5DA6BC491B3362A1E81B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_5B404AE4ADCF5DA6BC491B3362A1E81B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_5B404AE4ADCF5DA6BC491B3362A1E81B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_5B404AE4ADCF5DA6BC491B3362A1E81B" xlink:to="lab_biib_StrategicInvestmentPortfolio_5B404AE4ADCF5DA6BC491B3362A1E81B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_72868187DFB75B03B323ADBF4E0B72F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_72868187DFB75B03B323ADBF4E0B72F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_72868187DFB75B03B323ADBF4E0B72F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_72868187DFB75B03B323ADBF4E0B72F4" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_72868187DFB75B03B323ADBF4E0B72F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_30230DA344065307A52E640A9D9AE676" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_30230DA344065307A52E640A9D9AE676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_30230DA344065307A52E640A9D9AE676" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_30230DA344065307A52E640A9D9AE676" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_30230DA344065307A52E640A9D9AE676" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9390CE76AA624E310E2DF1A9A82E075_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9390CE76AA624E310E2DF1A9A82E075" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9390CE76AA624E310E2DF1A9A82E075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9390CE76AA624E310E2DF1A9A82E075" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9390CE76AA624E310E2DF1A9A82E075" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9D03ABF8224E9AB342B8DF1A9A825304_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9D03ABF8224E9AB342B8DF1A9A825304" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9D03ABF8224E9AB342B8DF1A9A825304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9D03ABF8224E9AB342B8DF1A9A825304" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9D03ABF8224E9AB342B8DF1A9A825304" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5579194CB4C0551CBD6ED69B25937B22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5579194CB4C0551CBD6ED69B25937B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5579194CB4C0551CBD6ED69B25937B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5579194CB4C0551CBD6ED69B25937B22" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5579194CB4C0551CBD6ED69B25937B22" xlink:type="arc" />
    <link:label id="lab_biib_AcquisitionsAbstract_87D053635598CA538D1682AF2960D825_label_en-US" xlink:label="lab_biib_AcquisitionsAbstract_87D053635598CA538D1682AF2960D825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_87D053635598CA538D1682AF2960D825_documentation_en-US" xlink:label="lab_biib_AcquisitionsAbstract_87D053635598CA538D1682AF2960D825" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_87D053635598CA538D1682AF2960D825" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquisitionsAbstract_87D053635598CA538D1682AF2960D825" xlink:to="lab_biib_AcquisitionsAbstract_87D053635598CA538D1682AF2960D825" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_ACBFFD15425ADAB943F482AF29635658_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_ACBFFD15425ADAB943F482AF29635658" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_ACBFFD15425ADAB943F482AF29635658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_ACBFFD15425ADAB943F482AF29635658" xlink:to="lab_us-gaap_Goodwill_ACBFFD15425ADAB943F482AF29635658" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7F31FB1C4BA3D5E90BC6E01944A0B431_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7F31FB1C4BA3D5E90BC6E01944A0B431" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7F31FB1C4BA3D5E90BC6E01944A0B431_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7F31FB1C4BA3D5E90BC6E01944A0B431" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7F31FB1C4BA3D5E90BC6E01944A0B431" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7F31FB1C4BA3D5E90BC6E01944A0B431" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7F31FB1C4BA3D5E90BC6E01944A0B431" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:to="lab_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_5FDDDF5A049703257F78E01944A074DA_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_5FDDDF5A049703257F78E01944A074DA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5FDDDF5A049703257F78E01944A074DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_5FDDDF5A049703257F78E01944A074DA" xlink:to="lab_us-gaap_Goodwill_5FDDDF5A049703257F78E01944A074DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_9D2BBEC7A785EC098418E01ADB79EEDF_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease_9D2BBEC7A785EC098418E01ADB79EEDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_9D2BBEC7A785EC098418E01ADB79EEDF_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease_9D2BBEC7A785EC098418E01ADB79EEDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9D2BBEC7A785EC098418E01ADB79EEDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9D2BBEC7A785EC098418E01ADB79EEDF" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease_9D2BBEC7A785EC098418E01ADB79EEDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_A33E0F758506CF5FF155E02108897704_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_A33E0F758506CF5FF155E02108897704" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_A33E0F758506CF5FF155E02108897704_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_A33E0F758506CF5FF155E02108897704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_A33E0F758506CF5FF155E02108897704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_A33E0F758506CF5FF155E02108897704" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_A33E0F758506CF5FF155E02108897704" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_15078AC1B06F3A6ECE58E01944A10CB2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_15078AC1B06F3A6ECE58E01944A10CB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_15078AC1B06F3A6ECE58E01944A10CB2_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_15078AC1B06F3A6ECE58E01944A10CB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_15078AC1B06F3A6ECE58E01944A10CB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_15078AC1B06F3A6ECE58E01944A10CB2" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_15078AC1B06F3A6ECE58E01944A10CB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_5E230072C3D23C004839E01944A153F2_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_5E230072C3D23C004839E01944A153F2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5E230072C3D23C004839E01944A153F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_5E230072C3D23C004839E01944A153F2" xlink:to="lab_us-gaap_Goodwill_5E230072C3D23C004839E01944A153F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81" xlink:to="lab_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE_label_en-US" xlink:label="lab_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE_documentation_en-US" xlink:label="lab_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE" xlink:to="lab_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE" xlink:type="arc" />
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1_terseLabel_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1_label_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1_documentation_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1" xlink:to="lab_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1" xlink:type="arc" />
    <link:label id="lab_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A" xlink:to="lab_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A" xlink:type="arc" />
    <link:label id="lab_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab</link:label>
    <link:label id="lab_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62_label_en-US" xlink:label="lab_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62_documentation_en-US" xlink:label="lab_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62" xlink:to="lab_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:type="arc" />
    <link:label id="lab_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984" xlink:to="lab_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984" xlink:type="arc" />
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF" xlink:type="arc" />
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on research and development contracts terminated with Eisai</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85" xlink:to="lab_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payment to Skyhawk</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C" xlink:to="lab_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C" xlink:type="arc" />
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_FA1636403FF158C2950C1485CE27B678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_FA1636403FF158C2950C1485CE27B678" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_FA1636403FF158C2950C1485CE27B678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_FA1636403FF158C2950C1485CE27B678" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_FA1636403FF158C2950C1485CE27B678" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0_terseLabel_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_B6ACDCE92F8453D89670C111409AD926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual)</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0_label_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_B6ACDCE92F8453D89670C111409AD926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0_documentation_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_B6ACDCE92F8453D89670C111409AD926" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_B6ACDCE92F8453D89670C111409AD926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_B6ACDCE92F8453D89670C111409AD926" xlink:to="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_B6ACDCE92F8453D89670C111409AD926" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5A61FF6741C355C6A018818B707C927D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5A61FF6741C355C6A018818B707C927D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5A61FF6741C355C6A018818B707C927D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5A61FF6741C355C6A018818B707C927D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5A61FF6741C355C6A018818B707C927D" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5A61FF6741C355C6A018818B707C927D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D1C5D05F53BC5C4089118C7BE014E2F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D1C5D05F53BC5C4089118C7BE014E2F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D1C5D05F53BC5C4089118C7BE014E2F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D1C5D05F53BC5C4089118C7BE014E2F4" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D1C5D05F53BC5C4089118C7BE014E2F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA" xlink:type="arc" />
    <link:label id="lab_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A_terseLabel_en-US" xlink:label="lab_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A_label_en-US" xlink:label="lab_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating Lease Assets</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A_documentation_en-US" xlink:label="lab_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating Lease Assets</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A" xlink:to="lab_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A" xlink:type="arc" />
    <link:label id="lab_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07_terseLabel_en-US" xlink:label="lab_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07_label_en-US" xlink:label="lab_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating lease liabilities</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07_documentation_en-US" xlink:label="lab_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating lease liabilities</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07" xlink:to="lab_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_73B7657657685549B8E940ABD095A9CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_73B7657657685549B8E940ABD095A9CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_73B7657657685549B8E940ABD095A9CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_73B7657657685549B8E940ABD095A9CF" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_73B7657657685549B8E940ABD095A9CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FE8389BE43825B62A483262E4BAF8383" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FE8389BE43825B62A483262E4BAF8383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FE8389BE43825B62A483262E4BAF8383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FE8389BE43825B62A483262E4BAF8383" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FE8389BE43825B62A483262E4BAF8383" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_910E5E136E0C576BA6D60E1721E0DC6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_910E5E136E0C576BA6D60E1721E0DC6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_910E5E136E0C576BA6D60E1721E0DC6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_910E5E136E0C576BA6D60E1721E0DC6D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_910E5E136E0C576BA6D60E1721E0DC6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_33588A082EE457EC89C60A622708E7EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_33588A082EE457EC89C60A622708E7EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_33588A082EE457EC89C60A622708E7EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_33588A082EE457EC89C60A622708E7EE" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_33588A082EE457EC89C60A622708E7EE" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4E8F00D8D1FC56D786A883878CA09092" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4E8F00D8D1FC56D786A883878CA09092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4E8F00D8D1FC56D786A883878CA09092" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4E8F00D8D1FC56D786A883878CA09092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4E8F00D8D1FC56D786A883878CA09092" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4E8F00D8D1FC56D786A883878CA09092" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_ACD843703156547CAEDDC8913CF2108A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_ACD843703156547CAEDDC8913CF2108A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_ACD843703156547CAEDDC8913CF2108A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_ACD843703156547CAEDDC8913CF2108A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_ACD843703156547CAEDDC8913CF2108A" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_ACD843703156547CAEDDC8913CF2108A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_31E9E7BBC6D65B29BBB5E13851D215D7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_31E9E7BBC6D65B29BBB5E13851D215D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_31E9E7BBC6D65B29BBB5E13851D215D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_31E9E7BBC6D65B29BBB5E13851D215D7" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_31E9E7BBC6D65B29BBB5E13851D215D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_78809A97D8F157F7AF399E340E1D99E9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_78809A97D8F157F7AF399E340E1D99E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_78809A97D8F157F7AF399E340E1D99E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_78809A97D8F157F7AF399E340E1D99E9" xlink:to="lab_us-gaap_AvailableForSaleSecurities_78809A97D8F157F7AF399E340E1D99E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475_label_en-US" xlink:label="lab_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475" xlink:to="lab_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:to="lab_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:to="lab_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E" xlink:to="lab_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F_label_en-US" xlink:label="lab_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F" xlink:to="lab_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F" xlink:to="lab_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual commitments for the construction of the facility</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A" xlink:to="lab_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42A8C2F6025A5167A762C14E1D5EB48E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42A8C2F6025A5167A762C14E1D5EB48E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42A8C2F6025A5167A762C14E1D5EB48E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42A8C2F6025A5167A762C14E1D5EB48E" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42A8C2F6025A5167A762C14E1D5EB48E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_E0C2C2FB48935F6CBF5475A77FEC35F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_E0C2C2FB48935F6CBF5475A77FEC35F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_E0C2C2FB48935F6CBF5475A77FEC35F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_E0C2C2FB48935F6CBF5475A77FEC35F0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_E0C2C2FB48935F6CBF5475A77FEC35F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_701674729F025A6FBA8360AF9A15EA5F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_701674729F025A6FBA8360AF9A15EA5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_701674729F025A6FBA8360AF9A15EA5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_701674729F025A6FBA8360AF9A15EA5F" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_701674729F025A6FBA8360AF9A15EA5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_32CCB05B253D5EA3BE3148C99FE50082" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_32CCB05B253D5EA3BE3148C99FE50082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_32CCB05B253D5EA3BE3148C99FE50082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_32CCB05B253D5EA3BE3148C99FE50082" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_32CCB05B253D5EA3BE3148C99FE50082" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09_label_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DeferredTaxAssetLiabilityTypeAxis" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:to="lab_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Domain]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B_label_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Domain]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:to="lab_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13_terseLabel_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual Property</link:label>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13_label_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13" xlink:to="lab_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E" xlink:to="lab_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62" xlink:to="lab_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense on disposal group</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset recorded on transfer of intellectual property</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability recorded on transfer of intellectual property</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:to="lab_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:to="lab_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:type="arc" />
    <link:label id="lab_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048_terseLabel_en-US" xlink:label="lab_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BG00011</link:label>
    <link:label id="lab_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048_label_en-US" xlink:label="lab_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BG00011 [Member]</link:label>
    <link:label id="lab_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048_documentation_en-US" xlink:label="lab_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BG00011</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_BG00011Member" xlink:label="loc_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048" xlink:to="lab_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630" xlink:to="lab_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630" xlink:type="arc" />
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49_terseLabel_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, changes in valuation inputs</link:label>
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49_label_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" xlink:label="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49" xlink:to="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15108D2C2047BF361CAADF1A9A60F10F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15108D2C2047BF361CAADF1A9A60F10F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15108D2C2047BF361CAADF1A9A60F10F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15108D2C2047BF361CAADF1A9A60F10F" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15108D2C2047BF361CAADF1A9A60F10F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:type="arc" />
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84_terseLabel_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_783A12A29E1D5B5C9D6DCA4AE7D5F165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84_label_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_783A12A29E1D5B5C9D6DCA4AE7D5F165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84_documentation_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_783A12A29E1D5B5C9D6DCA4AE7D5F165" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_783A12A29E1D5B5C9D6DCA4AE7D5F165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PostacquisitionequitycompensationMember_783A12A29E1D5B5C9D6DCA4AE7D5F165" xlink:to="lab_biib_PostacquisitionequitycompensationMember_783A12A29E1D5B5C9D6DCA4AE7D5F165" xlink:type="arc" />
    <link:label id="lab_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member_9C62B1C9C57C5BFBB074A6714EC6504F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88_label_en-US" xlink:label="lab_biib_BIIB111Member_9C62B1C9C57C5BFBB074A6714EC6504F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88_documentation_en-US" xlink:label="lab_biib_BIIB111Member_9C62B1C9C57C5BFBB074A6714EC6504F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_9C62B1C9C57C5BFBB074A6714EC6504F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member_9C62B1C9C57C5BFBB074A6714EC6504F" xlink:to="lab_biib_BIIB111Member_9C62B1C9C57C5BFBB074A6714EC6504F" xlink:type="arc" />
    <link:label id="lab_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member_CB3CBE862C1B512BA879F55B20AE7865" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4_label_en-US" xlink:label="lab_biib_BIIB112Member_CB3CBE862C1B512BA879F55B20AE7865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4_documentation_en-US" xlink:label="lab_biib_BIIB112Member_CB3CBE862C1B512BA879F55B20AE7865" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_CB3CBE862C1B512BA879F55B20AE7865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member_CB3CBE862C1B512BA879F55B20AE7865" xlink:to="lab_biib_BIIB112Member_CB3CBE862C1B512BA879F55B20AE7865" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97485E9D64527F96CA960B174E5D6DAA_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B41C6D8908FE5F52928FBBB261D2554E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B41C6D8908FE5F52928FBBB261D2554E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B41C6D8908FE5F52928FBBB261D2554E" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B41C6D8908FE5F52928FBBB261D2554E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_CC7061E1A030507DBA2AF4D07DDB961A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_CC7061E1A030507DBA2AF4D07DDB961A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_CC7061E1A030507DBA2AF4D07DDB961A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_CC7061E1A030507DBA2AF4D07DDB961A" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_CC7061E1A030507DBA2AF4D07DDB961A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_0FE12A4EA78F566A9B18F9375C71EDE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_0FE12A4EA78F566A9B18F9375C71EDE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0FE12A4EA78F566A9B18F9375C71EDE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_0FE12A4EA78F566A9B18F9375C71EDE7" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_0FE12A4EA78F566A9B18F9375C71EDE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses_05E0C6E5BBFB5C4A90E1E5C7E266870C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for pre-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses_05E0C6E5BBFB5C4A90E1E5C7E266870C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_05E0C6E5BBFB5C4A90E1E5C7E266870C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses_05E0C6E5BBFB5C4A90E1E5C7E266870C" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses_05E0C6E5BBFB5C4A90E1E5C7E266870C" xlink:type="arc" />
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C_terseLabel_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_8AF14143AC01520EAB152B095487F02C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, in-process research and development, discount rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C_label_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_8AF14143AC01520EAB152B095487F02C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C_documentation_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_8AF14143AC01520EAB152B095487F02C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_8AF14143AC01520EAB152B095487F02C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_8AF14143AC01520EAB152B095487F02C" xlink:to="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_8AF14143AC01520EAB152B095487F02C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_58C954A16EA855DFBAA49FA60F65C435" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_58C954A16EA855DFBAA49FA60F65C435" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_58C954A16EA855DFBAA49FA60F65C435" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_58C954A16EA855DFBAA49FA60F65C435" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_58C954A16EA855DFBAA49FA60F65C435" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:type="arc" />
    <link:label id="lab_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E_terseLabel_en-US" xlink:label="lab_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PLSR [Member]</link:label>
    <link:label id="lab_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E_label_en-US" xlink:label="lab_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PLSR [Member]</link:label>
    <link:label id="lab_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E_documentation_en-US" xlink:label="lab_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PLSR</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_PLSRMember" xlink:label="loc_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E" xlink:to="lab_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E" xlink:type="arc" />
    <link:label id="lab_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE_terseLabel_en-US" xlink:label="lab_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE_label_en-US" xlink:label="lab_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE_documentation_en-US" xlink:label="lab_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE" xlink:to="lab_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71" xlink:to="lab_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76" xlink:to="lab_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021_label_en-US" xlink:label="lab_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021_documentation_en-US" xlink:label="lab_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021" xlink:to="lab_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A_label_en-US" xlink:label="lab_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A" xlink:to="lab_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1_label_en-US" xlink:label="lab_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1_documentation_en-US" xlink:label="lab_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1" xlink:to="lab_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_68F16B6A3E5E0AA9DB02DF1A9B2DF159_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember_68F16B6A3E5E0AA9DB02DF1A9B2DF159" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_68F16B6A3E5E0AA9DB02DF1A9B2DF159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_68F16B6A3E5E0AA9DB02DF1A9B2DF159" xlink:to="lab_srt_MinimumMember_68F16B6A3E5E0AA9DB02DF1A9B2DF159" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_39F49E9F5E1BFB6CF74ADF1A9B2DF9AD_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember_39F49E9F5E1BFB6CF74ADF1A9B2DF9AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_39F49E9F5E1BFB6CF74ADF1A9B2DF9AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_39F49E9F5E1BFB6CF74ADF1A9B2DF9AD" xlink:to="lab_srt_MaximumMember_39F49E9F5E1BFB6CF74ADF1A9B2DF9AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ECF3A22C61BF1DFD46C7DF1A9B3180A9_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ECF3A22C61BF1DFD46C7DF1A9B3180A9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ECF3A22C61BF1DFD46C7DF1A9B3180A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ECF3A22C61BF1DFD46C7DF1A9B3180A9" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ECF3A22C61BF1DFD46C7DF1A9B3180A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C" xlink:type="arc" />
    <link:label id="lab_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B_terseLabel_en-US" xlink:label="lab_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, excluding impairment</link:label>
    <link:label id="lab_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B_label_en-US" xlink:label="lab_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, excluding impairment</link:label>
    <link:label id="lab_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B_documentation_en-US" xlink:label="lab_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, excluding impairment</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Amortizationofintangibleassetsexcludingimpairment" xlink:label="loc_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B" xlink:to="lab_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8107D842E78C81DD6F3EDF1A9B3185A8_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8107D842E78C81DD6F3EDF1A9B3185A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Textual) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8107D842E78C81DD6F3EDF1A9B3185A8_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8107D842E78C81DD6F3EDF1A9B3185A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8107D842E78C81DD6F3EDF1A9B3185A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8107D842E78C81DD6F3EDF1A9B3185A8" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8107D842E78C81DD6F3EDF1A9B3185A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5AF310C7D520601CBE14DF1A9B316AB9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5AF310C7D520601CBE14DF1A9B316AB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5AF310C7D520601CBE14DF1A9B316AB9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5AF310C7D520601CBE14DF1A9B316AB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5AF310C7D520601CBE14DF1A9B316AB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5AF310C7D520601CBE14DF1A9B316AB9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5AF310C7D520601CBE14DF1A9B316AB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_586DAC2DD3EB60C9F6B3DF1A9B316C39_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_586DAC2DD3EB60C9F6B3DF1A9B316C39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_586DAC2DD3EB60C9F6B3DF1A9B316C39_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_586DAC2DD3EB60C9F6B3DF1A9B316C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_586DAC2DD3EB60C9F6B3DF1A9B316C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_586DAC2DD3EB60C9F6B3DF1A9B316C39" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_586DAC2DD3EB60C9F6B3DF1A9B316C39" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B70C196B4B0B6E9EA09BDF1A9B3189D7_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B70C196B4B0B6E9EA09BDF1A9B3189D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B70C196B4B0B6E9EA09BDF1A9B3189D7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B70C196B4B0B6E9EA09BDF1A9B3189D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B70C196B4B0B6E9EA09BDF1A9B3189D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B70C196B4B0B6E9EA09BDF1A9B3189D7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B70C196B4B0B6E9EA09BDF1A9B3189D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C26EDA21AE9D50D28954DF1A9B31096F_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C26EDA21AE9D50D28954DF1A9B31096F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C26EDA21AE9D50D28954DF1A9B31096F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C26EDA21AE9D50D28954DF1A9B31096F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C26EDA21AE9D50D28954DF1A9B31096F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C26EDA21AE9D50D28954DF1A9B31096F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C26EDA21AE9D50D28954DF1A9B31096F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_287D338AAB1DDA2E3F34DF1A9B315357_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_287D338AAB1DDA2E3F34DF1A9B315357" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_287D338AAB1DDA2E3F34DF1A9B315357_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_287D338AAB1DDA2E3F34DF1A9B315357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_287D338AAB1DDA2E3F34DF1A9B315357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_287D338AAB1DDA2E3F34DF1A9B315357" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_287D338AAB1DDA2E3F34DF1A9B315357" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5DB4DD205C7947600B1BDF1A9B318A07_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5DB4DD205C7947600B1BDF1A9B318A07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5DB4DD205C7947600B1BDF1A9B318A07_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5DB4DD205C7947600B1BDF1A9B318A07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5DB4DD205C7947600B1BDF1A9B318A07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5DB4DD205C7947600B1BDF1A9B318A07" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5DB4DD205C7947600B1BDF1A9B318A07" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_42A6C45DDCFF20FE5E80DF1A9844ACEE_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_42A6C45DDCFF20FE5E80DF1A9844ACEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_42A6C45DDCFF20FE5E80DF1A9844ACEE_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_42A6C45DDCFF20FE5E80DF1A9844ACEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_42A6C45DDCFF20FE5E80DF1A9844ACEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_42A6C45DDCFF20FE5E80DF1A9844ACEE" xlink:to="lab_us-gaap_InvestmentIncomeInterest_42A6C45DDCFF20FE5E80DF1A9844ACEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_662B851D55E1827EAA12DF1A98444B63_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_662B851D55E1827EAA12DF1A98444B63" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_662B851D55E1827EAA12DF1A98444B63_label_en-US" xlink:label="lab_us-gaap_InterestExpense_662B851D55E1827EAA12DF1A98444B63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_662B851D55E1827EAA12DF1A98444B63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_662B851D55E1827EAA12DF1A98444B63" xlink:to="lab_us-gaap_InterestExpense_662B851D55E1827EAA12DF1A98444B63" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_722D4695A5AE844A2507DF1A98443E7E_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_722D4695A5AE844A2507DF1A98443E7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_722D4695A5AE844A2507DF1A98443E7E_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_722D4695A5AE844A2507DF1A98443E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_722D4695A5AE844A2507DF1A98443E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses_722D4695A5AE844A2507DF1A98443E7E" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses_722D4695A5AE844A2507DF1A98443E7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0964F12D5065B1DB7D58DF1A98446278_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0964F12D5065B1DB7D58DF1A98446278" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0964F12D5065B1DB7D58DF1A98446278_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0964F12D5065B1DB7D58DF1A98446278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0964F12D5065B1DB7D58DF1A98446278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0964F12D5065B1DB7D58DF1A98446278" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0964F12D5065B1DB7D58DF1A98446278" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9B9DAC6741784EC8D478DF1A98441079_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_9B9DAC6741784EC8D478DF1A98441079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9B9DAC6741784EC8D478DF1A98441079_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_9B9DAC6741784EC8D478DF1A98441079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9B9DAC6741784EC8D478DF1A98441079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_9B9DAC6741784EC8D478DF1A98441079" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_9B9DAC6741784EC8D478DF1A98441079" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_FFD4E4532A7715B1F370DF1A98444BF8_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_FFD4E4532A7715B1F370DF1A98444BF8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_FFD4E4532A7715B1F370DF1A98444BF8_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_FFD4E4532A7715B1F370DF1A98444BF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_FFD4E4532A7715B1F370DF1A98444BF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_FFD4E4532A7715B1F370DF1A98444BF8" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_FFD4E4532A7715B1F370DF1A98444BF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_FD6B634CAC2242764BBBDF1A9844768B_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_FD6B634CAC2242764BBBDF1A9844768B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_FD6B634CAC2242764BBBDF1A9844768B_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_FD6B634CAC2242764BBBDF1A9844768B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_FD6B634CAC2242764BBBDF1A9844768B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_FD6B634CAC2242764BBBDF1A9844768B" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_FD6B634CAC2242764BBBDF1A9844768B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_88041E5AC7EB2A53C977DF1A9844E704_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_88041E5AC7EB2A53C977DF1A9844E704" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Net gains (losses) recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_88041E5AC7EB2A53C977DF1A9844E704_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_88041E5AC7EB2A53C977DF1A9844E704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_88041E5AC7EB2A53C977DF1A9844E704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_88041E5AC7EB2A53C977DF1A9844E704" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_88041E5AC7EB2A53C977DF1A9844E704" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0F24E923E710DA283B1BDF1A98446BDB_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0F24E923E710DA283B1BDF1A98446BDB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period on equity securities held as of September 30, 2019</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0F24E923E710DA283B1BDF1A98446BDB_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0F24E923E710DA283B1BDF1A98446BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0F24E923E710DA283B1BDF1A98446BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0F24E923E710DA283B1BDF1A98446BDB" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0F24E923E710DA283B1BDF1A98446BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_676D197ED5D5DC93CAD7DF1A984471ED_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_676D197ED5D5DC93CAD7DF1A984471ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_676D197ED5D5DC93CAD7DF1A984471ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_676D197ED5D5DC93CAD7DF1A984471ED" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_676D197ED5D5DC93CAD7DF1A984471ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4BBF0E7C7CE59CBDF9AADF1A98444B9E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4BBF0E7C7CE59CBDF9AADF1A98444B9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4BBF0E7C7CE59CBDF9AADF1A98444B9E_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4BBF0E7C7CE59CBDF9AADF1A98444B9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4BBF0E7C7CE59CBDF9AADF1A98444B9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4BBF0E7C7CE59CBDF9AADF1A98444B9E" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4BBF0E7C7CE59CBDF9AADF1A98444B9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_45C6E2852CD8827A4C14DF1A9844E639_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_45C6E2852CD8827A4C14DF1A9844E639" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_45C6E2852CD8827A4C14DF1A9844E639_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_45C6E2852CD8827A4C14DF1A9844E639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_45C6E2852CD8827A4C14DF1A9844E639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_45C6E2852CD8827A4C14DF1A9844E639" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_45C6E2852CD8827A4C14DF1A9844E639" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE" xlink:to="lab_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7CDB59488D62C9E50177DF1A984495EC_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7CDB59488D62C9E50177DF1A984495EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7CDB59488D62C9E50177DF1A984495EC_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7CDB59488D62C9E50177DF1A984495EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7CDB59488D62C9E50177DF1A984495EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7CDB59488D62C9E50177DF1A984495EC" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7CDB59488D62C9E50177DF1A984495EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_F62AA923CD7E9548D44EDF1A9844B295_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_F62AA923CD7E9548D44EDF1A9844B295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_F62AA923CD7E9548D44EDF1A9844B295_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_F62AA923CD7E9548D44EDF1A9844B295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_F62AA923CD7E9548D44EDF1A9844B295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_F62AA923CD7E9548D44EDF1A9844B295" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_F62AA923CD7E9548D44EDF1A9844B295" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_EE108CF6C6DBEA2FC0C3DF1A9844C659_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_EE108CF6C6DBEA2FC0C3DF1A9844C659" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_EE108CF6C6DBEA2FC0C3DF1A9844C659_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_EE108CF6C6DBEA2FC0C3DF1A9844C659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_EE108CF6C6DBEA2FC0C3DF1A9844C659" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_EE108CF6C6DBEA2FC0C3DF1A9844C659" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_EE108CF6C6DBEA2FC0C3DF1A9844C659" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_D5F1DF23D0806175CD83DF1A9844227B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_D5F1DF23D0806175CD83DF1A9844227B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_D5F1DF23D0806175CD83DF1A9844227B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_D5F1DF23D0806175CD83DF1A9844227B" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_D5F1DF23D0806175CD83DF1A9844227B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_F21C260993948A492182170B39226C78_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract_F6BE7ABC3AC8509581EA64B48E58525D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_F6BE7ABC3AC8509581EA64B48E58525D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_F6BE7ABC3AC8509581EA64B48E58525D" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract_F6BE7ABC3AC8509581EA64B48E58525D" xlink:type="arc" />
    <link:label id="lab_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A_terseLabel_en-US" xlink:label="lab_biib_InterferonMember_A84573BFCAEE51ECA08329EC2458DDE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A_label_en-US" xlink:label="lab_biib_InterferonMember_A84573BFCAEE51ECA08329EC2458DDE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A_documentation_en-US" xlink:label="lab_biib_InterferonMember_A84573BFCAEE51ECA08329EC2458DDE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_A84573BFCAEE51ECA08329EC2458DDE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember_A84573BFCAEE51ECA08329EC2458DDE8" xlink:to="lab_biib_InterferonMember_A84573BFCAEE51ECA08329EC2458DDE8" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_4F4E7AFCF84E54D48AA79B9DBEA6F1B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8_label_en-US" xlink:label="lab_biib_FAMPYRAMember_4F4E7AFCF84E54D48AA79B9DBEA6F1B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_4F4E7AFCF84E54D48AA79B9DBEA6F1B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_4F4E7AFCF84E54D48AA79B9DBEA6F1B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_4F4E7AFCF84E54D48AA79B9DBEA6F1B8" xlink:to="lab_biib_FAMPYRAMember_4F4E7AFCF84E54D48AA79B9DBEA6F1B8" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_A2D1A0B71FDA5B9F8F366AC85E4E194D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_A2D1A0B71FDA5B9F8F366AC85E4E194D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_A2D1A0B71FDA5B9F8F366AC85E4E194D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_A2D1A0B71FDA5B9F8F366AC85E4E194D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_A2D1A0B71FDA5B9F8F366AC85E4E194D" xlink:to="lab_biib_ZINBRYTAMember_A2D1A0B71FDA5B9F8F366AC85E4E194D" xlink:type="arc" />
    <link:label id="lab_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember_A76B3B3C132A5CA88379A7500E1D3901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember_A76B3B3C132A5CA88379A7500E1D3901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember_A76B3B3C132A5CA88379A7500E1D3901" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_A76B3B3C132A5CA88379A7500E1D3901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember_A76B3B3C132A5CA88379A7500E1D3901" xlink:to="lab_biib_MSProductRevenuesMember_A76B3B3C132A5CA88379A7500E1D3901" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_9D49C9D9B103553183642E73B1A093BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6_label_en-US" xlink:label="lab_biib_SPINRAZAMember_9D49C9D9B103553183642E73B1A093BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_9D49C9D9B103553183642E73B1A093BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_9D49C9D9B103553183642E73B1A093BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_9D49C9D9B103553183642E73B1A093BF" xlink:to="lab_biib_SPINRAZAMember_9D49C9D9B103553183642E73B1A093BF" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_2A309F1B60C7584584C3B22746F5B4DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8_label_en-US" xlink:label="lab_biib_BENEPALIMember_2A309F1B60C7584584C3B22746F5B4DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_2A309F1B60C7584584C3B22746F5B4DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_2A309F1B60C7584584C3B22746F5B4DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_2A309F1B60C7584584C3B22746F5B4DF" xlink:to="lab_biib_BENEPALIMember_2A309F1B60C7584584C3B22746F5B4DF" xlink:type="arc" />
    <link:label id="lab_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember_4F299C33E1C35D6195A81309F0D090DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14_label_en-US" xlink:label="lab_biib_IMRALDIMember_4F299C33E1C35D6195A81309F0D090DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14_documentation_en-US" xlink:label="lab_biib_IMRALDIMember_4F299C33E1C35D6195A81309F0D090DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_4F299C33E1C35D6195A81309F0D090DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember_4F299C33E1C35D6195A81309F0D090DE" xlink:to="lab_biib_IMRALDIMember_4F299C33E1C35D6195A81309F0D090DE" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_594BE6E7F38E500FBDDFAFABF3051C72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92_label_en-US" xlink:label="lab_biib_FLIXABIMember_594BE6E7F38E500FBDDFAFABF3051C72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_594BE6E7F38E500FBDDFAFABF3051C72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_594BE6E7F38E500FBDDFAFABF3051C72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_594BE6E7F38E500FBDDFAFABF3051C72" xlink:to="lab_biib_FLIXABIMember_594BE6E7F38E500FBDDFAFABF3051C72" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_24AD8154BF3851E6B432BDDA60EB369C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762_label_en-US" xlink:label="lab_biib_BiosimilarsMember_24AD8154BF3851E6B432BDDA60EB369C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_24AD8154BF3851E6B432BDDA60EB369C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_24AD8154BF3851E6B432BDDA60EB369C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_24AD8154BF3851E6B432BDDA60EB369C" xlink:to="lab_biib_BiosimilarsMember_24AD8154BF3851E6B432BDDA60EB369C" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_D369ED1CE58E5670B693B6303087F9EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684_label_en-US" xlink:label="lab_biib_FUMADERMMember_D369ED1CE58E5670B693B6303087F9EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_D369ED1CE58E5670B693B6303087F9EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_D369ED1CE58E5670B693B6303087F9EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_D369ED1CE58E5670B693B6303087F9EF" xlink:to="lab_biib_FUMADERMMember_D369ED1CE58E5670B693B6303087F9EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_537E2492F7B6BAE7D6B9170B392892B8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_97BB6B36FE905C2E854BC4E81DD36F0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_537E2492F7B6BAE7D6B9170B392892B8_label_en-US" xlink:label="lab_us-gaap_ProductMember_97BB6B36FE905C2E854BC4E81DD36F0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_97BB6B36FE905C2E854BC4E81DD36F0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_97BB6B36FE905C2E854BC4E81DD36F0C" xlink:to="lab_us-gaap_ProductMember_97BB6B36FE905C2E854BC4E81DD36F0C" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:to="lab_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:to="lab_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:type="arc" />
    <link:label id="lab_country_US_D70DCD898CA8A1E24985170B39291327_terseLabel_en-US" xlink:label="lab_country_US_4ADF66EACEBF5D9DB46420C74C7E88F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_D70DCD898CA8A1E24985170B39291327_label_en-US" xlink:label="lab_country_US_4ADF66EACEBF5D9DB46420C74C7E88F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_4ADF66EACEBF5D9DB46420C74C7E88F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_4ADF66EACEBF5D9DB46420C74C7E88F6" xlink:to="lab_country_US_4ADF66EACEBF5D9DB46420C74C7E88F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_6A4F8F8BD8905B0CB54B88D17E642A04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F_label_en-US" xlink:label="lab_us-gaap_NonUsMember_6A4F8F8BD8905B0CB54B88D17E642A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_6A4F8F8BD8905B0CB54B88D17E642A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_6A4F8F8BD8905B0CB54B88D17E642A04" xlink:to="lab_us-gaap_NonUsMember_6A4F8F8BD8905B0CB54B88D17E642A04" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_806ADA7C70FAA1269203170B3929D0CD_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_B87C1A002C7657F2981FCBE9CD5492F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B87C1A002C7657F2981FCBE9CD5492F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_B87C1A002C7657F2981FCBE9CD5492F3" xlink:to="lab_us-gaap_Revenues_B87C1A002C7657F2981FCBE9CD5492F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_C7FE1DFA5A875380BB73EBDEC1334F84" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_C7FE1DFA5A875380BB73EBDEC1334F84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_C7FE1DFA5A875380BB73EBDEC1334F84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_C7FE1DFA5A875380BB73EBDEC1334F84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_C7FE1DFA5A875380BB73EBDEC1334F84" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_C7FE1DFA5A875380BB73EBDEC1334F84" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_51FF0D8FC5FC538E9FEED2424B3D96D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_51FF0D8FC5FC538E9FEED2424B3D96D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_51FF0D8FC5FC538E9FEED2424B3D96D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_51FF0D8FC5FC538E9FEED2424B3D96D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_51FF0D8FC5FC538E9FEED2424B3D96D8" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_51FF0D8FC5FC538E9FEED2424B3D96D8" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_CDEEA905AC42574FB9ED1AA3784C10D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_CDEEA905AC42574FB9ED1AA3784C10D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_CDEEA905AC42574FB9ED1AA3784C10D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_CDEEA905AC42574FB9ED1AA3784C10D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_CDEEA905AC42574FB9ED1AA3784C10D1" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_CDEEA905AC42574FB9ED1AA3784C10D1" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_463588DF84DD5B10B1524F86D5D53A6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_463588DF84DD5B10B1524F86D5D53A6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_463588DF84DD5B10B1524F86D5D53A6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_463588DF84DD5B10B1524F86D5D53A6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_463588DF84DD5B10B1524F86D5D53A6D" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_463588DF84DD5B10B1524F86D5D53A6D" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E7A1865F4AA75E8CBFA5460E2C3414CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E7A1865F4AA75E8CBFA5460E2C3414CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E7A1865F4AA75E8CBFA5460E2C3414CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E7A1865F4AA75E8CBFA5460E2C3414CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E7A1865F4AA75E8CBFA5460E2C3414CE" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E7A1865F4AA75E8CBFA5460E2C3414CE" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_814AE542D8EC5040B90F8D2D5D88FC12" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_814AE542D8EC5040B90F8D2D5D88FC12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_814AE542D8EC5040B90F8D2D5D88FC12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_814AE542D8EC5040B90F8D2D5D88FC12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_814AE542D8EC5040B90F8D2D5D88FC12" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_814AE542D8EC5040B90F8D2D5D88FC12" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_D121B6B96CA05D39B66E00AAE9736A51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_D121B6B96CA05D39B66E00AAE9736A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_D121B6B96CA05D39B66E00AAE9736A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_D121B6B96CA05D39B66E00AAE9736A51" xlink:to="lab_us-gaap_EquitySecuritiesMember_D121B6B96CA05D39B66E00AAE9736A51" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01E8E3663C915125A4AA07BB3B6E3953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01E8E3663C915125A4AA07BB3B6E3953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01E8E3663C915125A4AA07BB3B6E3953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01E8E3663C915125A4AA07BB3B6E3953" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01E8E3663C915125A4AA07BB3B6E3953" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7EB304079B09565C963914E9BB5F506C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7EB304079B09565C963914E9BB5F506C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7EB304079B09565C963914E9BB5F506C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7EB304079B09565C963914E9BB5F506C" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7EB304079B09565C963914E9BB5F506C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A574E6694E7B5399B4B4717A3B1D7327" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A574E6694E7B5399B4B4717A3B1D7327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A574E6694E7B5399B4B4717A3B1D7327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A574E6694E7B5399B4B4717A3B1D7327" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A574E6694E7B5399B4B4717A3B1D7327" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_A8AED37EE7905C88AD2041CFA7F0BEA3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_A8AED37EE7905C88AD2041CFA7F0BEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_A8AED37EE7905C88AD2041CFA7F0BEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_A8AED37EE7905C88AD2041CFA7F0BEA3" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_A8AED37EE7905C88AD2041CFA7F0BEA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E6C9FC6B46745926B96EECB764C7C840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E6C9FC6B46745926B96EECB764C7C840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E6C9FC6B46745926B96EECB764C7C840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E6C9FC6B46745926B96EECB764C7C840" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E6C9FC6B46745926B96EECB764C7C840" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AE9E454631195BC19C85A4FF55EE5E7C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AE9E454631195BC19C85A4FF55EE5E7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AE9E454631195BC19C85A4FF55EE5E7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AE9E454631195BC19C85A4FF55EE5E7C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AE9E454631195BC19C85A4FF55EE5E7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_6AC24401085E257F79AE1ACA0D61A7C3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_FC7BDF9A08E053BF9E9CDE593CEA9486" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_FC7BDF9A08E053BF9E9CDE593CEA9486" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_FC7BDF9A08E053BF9E9CDE593CEA9486" xlink:to="lab_us-gaap_AvailableForSaleSecurities_FC7BDF9A08E053BF9E9CDE593CEA9486" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_44F663C75D6A557FBE65F9A4ED35715C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_44F663C75D6A557FBE65F9A4ED35715C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_44F663C75D6A557FBE65F9A4ED35715C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_44F663C75D6A557FBE65F9A4ED35715C" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_44F663C75D6A557FBE65F9A4ED35715C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_E641489912A755B58AA8F0624EC37955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_E641489912A755B58AA8F0624EC37955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_E641489912A755B58AA8F0624EC37955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_E641489912A755B58AA8F0624EC37955" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_E641489912A755B58AA8F0624EC37955" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_BB36AB789EC5549C817FCF4D0255DB72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_BB36AB789EC5549C817FCF4D0255DB72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_BB36AB789EC5549C817FCF4D0255DB72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_BB36AB789EC5549C817FCF4D0255DB72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_BB36AB789EC5549C817FCF4D0255DB72" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_BB36AB789EC5549C817FCF4D0255DB72" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_6325DE38CD455AB8A60368DA35E742BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_6325DE38CD455AB8A60368DA35E742BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_6325DE38CD455AB8A60368DA35E742BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_6325DE38CD455AB8A60368DA35E742BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_6325DE38CD455AB8A60368DA35E742BA" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_6325DE38CD455AB8A60368DA35E742BA" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_E04C4B0B8A3C5549B7A07F9E4CFE299A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_E04C4B0B8A3C5549B7A07F9E4CFE299A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_E04C4B0B8A3C5549B7A07F9E4CFE299A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_E04C4B0B8A3C5549B7A07F9E4CFE299A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_E04C4B0B8A3C5549B7A07F9E4CFE299A" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_E04C4B0B8A3C5549B7A07F9E4CFE299A" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_C64282DFC97C5DDD977C455D2E37F03D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_C64282DFC97C5DDD977C455D2E37F03D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_C64282DFC97C5DDD977C455D2E37F03D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_C64282DFC97C5DDD977C455D2E37F03D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock_C64282DFC97C5DDD977C455D2E37F03D" xlink:to="lab_biib_OtherrevenuesTableTextBlock_C64282DFC97C5DDD977C455D2E37F03D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0C73EBFEA80E542C8DE19B50EF395CD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0C73EBFEA80E542C8DE19B50EF395CD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0C73EBFEA80E542C8DE19B50EF395CD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0C73EBFEA80E542C8DE19B50EF395CD7" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0C73EBFEA80E542C8DE19B50EF395CD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="lab_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:type="arc" />
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_AE6B604B1D4A630419C0827E4B319013_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_AE6B604B1D4A630419C0827E4B319013" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_AE6B604B1D4A630419C0827E4B319013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_AE6B604B1D4A630419C0827E4B319013" xlink:to="lab_us-gaap_Revenues_AE6B604B1D4A630419C0827E4B319013" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_B9CB46E1BD9576DEF60B827E4B310B25_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_B9CB46E1BD9576DEF60B827E4B310B25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_B9CB46E1BD9576DEF60B827E4B310B25_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_B9CB46E1BD9576DEF60B827E4B310B25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_B9CB46E1BD9576DEF60B827E4B310B25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_B9CB46E1BD9576DEF60B827E4B310B25" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_B9CB46E1BD9576DEF60B827E4B310B25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2F3F889198F85D90A72A827E4B31B291_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2F3F889198F85D90A72A827E4B31B291" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2F3F889198F85D90A72A827E4B31B291_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2F3F889198F85D90A72A827E4B31B291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2F3F889198F85D90A72A827E4B31B291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2F3F889198F85D90A72A827E4B31B291" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2F3F889198F85D90A72A827E4B31B291" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_19BBAD0B25D030C3CFCC827E4B317658_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_19BBAD0B25D030C3CFCC827E4B317658" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_19BBAD0B25D030C3CFCC827E4B317658_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_19BBAD0B25D030C3CFCC827E4B317658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_19BBAD0B25D030C3CFCC827E4B317658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_19BBAD0B25D030C3CFCC827E4B317658" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_19BBAD0B25D030C3CFCC827E4B317658" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B" xlink:to="lab_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0C658078007D32589C80827E4B31890F_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0C658078007D32589C80827E4B31890F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0C658078007D32589C80827E4B31890F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0C658078007D32589C80827E4B31890F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0C658078007D32589C80827E4B31890F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0C658078007D32589C80827E4B31890F" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0C658078007D32589C80827E4B31890F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_66F6BA4BDD5087374D71827E4B3142F5_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_66F6BA4BDD5087374D71827E4B3142F5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_66F6BA4BDD5087374D71827E4B3142F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_66F6BA4BDD5087374D71827E4B3142F5" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_66F6BA4BDD5087374D71827E4B3142F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_EEDC631B246DDFB556AA827E4B312AC0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_EEDC631B246DDFB556AA827E4B312AC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_EEDC631B246DDFB556AA827E4B312AC0_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_EEDC631B246DDFB556AA827E4B312AC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_EEDC631B246DDFB556AA827E4B312AC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_EEDC631B246DDFB556AA827E4B312AC0" xlink:to="lab_us-gaap_RestructuringCharges_EEDC631B246DDFB556AA827E4B312AC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_96214B99580CC363A3F5827E4B3101E7_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_96214B99580CC363A3F5827E4B3101E7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_96214B99580CC363A3F5827E4B3101E7_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_96214B99580CC363A3F5827E4B3101E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_96214B99580CC363A3F5827E4B3101E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_96214B99580CC363A3F5827E4B3101E7" xlink:to="lab_us-gaap_CostsAndExpenses_96214B99580CC363A3F5827E4B3101E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_92449DE80A37240D571F827E4B319715_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_92449DE80A37240D571F827E4B319715" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_92449DE80A37240D571F827E4B319715_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_92449DE80A37240D571F827E4B319715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_92449DE80A37240D571F827E4B319715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_92449DE80A37240D571F827E4B319715" xlink:to="lab_us-gaap_OperatingIncomeLoss_92449DE80A37240D571F827E4B319715" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_B8A4200337466E8C1BB8827E4B310B4E_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_B8A4200337466E8C1BB8827E4B310B4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B8A4200337466E8C1BB8827E4B310B4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_B8A4200337466E8C1BB8827E4B310B4E" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_B8A4200337466E8C1BB8827E4B310B4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6C5E4DBF8F5DBC636E87827E4B31CBD0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6C5E4DBF8F5DBC636E87827E4B31CBD0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6C5E4DBF8F5DBC636E87827E4B31CBD0_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6C5E4DBF8F5DBC636E87827E4B31CBD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6C5E4DBF8F5DBC636E87827E4B31CBD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6C5E4DBF8F5DBC636E87827E4B31CBD0" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6C5E4DBF8F5DBC636E87827E4B31CBD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_D6A514849ACBE70C5F33827E4B313F2B_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_D6A514849ACBE70C5F33827E4B313F2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D6A514849ACBE70C5F33827E4B313F2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_D6A514849ACBE70C5F33827E4B313F2B" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_D6A514849ACBE70C5F33827E4B313F2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_E3412A1529A943A8F402827E4B31F879_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_E3412A1529A943A8F402827E4B31F879" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_E3412A1529A943A8F402827E4B31F879_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_E3412A1529A943A8F402827E4B31F879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_E3412A1529A943A8F402827E4B31F879" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_E3412A1529A943A8F402827E4B31F879" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_E3412A1529A943A8F402827E4B31F879" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_CBE9127D84D98FC15A52827E4B31B6E9_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_CBE9127D84D98FC15A52827E4B31B6E9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_CBE9127D84D98FC15A52827E4B31B6E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_CBE9127D84D98FC15A52827E4B31B6E9" xlink:to="lab_us-gaap_ProfitLoss_CBE9127D84D98FC15A52827E4B31B6E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9EC70D7E4734F0490281827E4B31179D_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9EC70D7E4734F0490281827E4B31179D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9EC70D7E4734F0490281827E4B31179D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9EC70D7E4734F0490281827E4B31179D" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9EC70D7E4734F0490281827E4B31179D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_EB0E339760D32D1FE284827E4B31B605_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_EB0E339760D32D1FE284827E4B31B605" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EB0E339760D32D1FE284827E4B31B605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_EB0E339760D32D1FE284827E4B31B605" xlink:to="lab_us-gaap_NetIncomeLoss_EB0E339760D32D1FE284827E4B31B605" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848" xlink:to="lab_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3830D114EBE7E9D91796827E4B318CA5_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_3830D114EBE7E9D91796827E4B318CA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3830D114EBE7E9D91796827E4B318CA5_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_3830D114EBE7E9D91796827E4B318CA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_3830D114EBE7E9D91796827E4B318CA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_3830D114EBE7E9D91796827E4B318CA5" xlink:to="lab_us-gaap_EarningsPerShareBasic_3830D114EBE7E9D91796827E4B318CA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_E5302888479D4CE421A0827E4B3110F4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_E5302888479D4CE421A0827E4B3110F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_E5302888479D4CE421A0827E4B3110F4_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_E5302888479D4CE421A0827E4B3110F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_E5302888479D4CE421A0827E4B3110F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_E5302888479D4CE421A0827E4B3110F4" xlink:to="lab_us-gaap_EarningsPerShareDiluted_E5302888479D4CE421A0827E4B3110F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_101C8DFAC852735C91E1827E4B315C7B_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_101C8DFAC852735C91E1827E4B315C7B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_101C8DFAC852735C91E1827E4B315C7B_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_101C8DFAC852735C91E1827E4B315C7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_101C8DFAC852735C91E1827E4B315C7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_101C8DFAC852735C91E1827E4B315C7B" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_101C8DFAC852735C91E1827E4B315C7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C29CDC9402869C6EB0D8827E4B31FC50_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C29CDC9402869C6EB0D8827E4B31FC50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C29CDC9402869C6EB0D8827E4B31FC50_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C29CDC9402869C6EB0D8827E4B31FC50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C29CDC9402869C6EB0D8827E4B31FC50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C29CDC9402869C6EB0D8827E4B31FC50" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C29CDC9402869C6EB0D8827E4B31FC50" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5377459470F859F9A4D87098AE6E8E0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5377459470F859F9A4D87098AE6E8E0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5377459470F859F9A4D87098AE6E8E0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5377459470F859F9A4D87098AE6E8E0C" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5377459470F859F9A4D87098AE6E8E0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_5AD726ECBD845922BED48335B99730D0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_5AD726ECBD845922BED48335B99730D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_5AD726ECBD845922BED48335B99730D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_5AD726ECBD845922BED48335B99730D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_5AD726ECBD845922BED48335B99730D0" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_5AD726ECBD845922BED48335B99730D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:to="lab_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69575BF5B4985E3382883FAC9399AB3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69575BF5B4985E3382883FAC9399AB3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69575BF5B4985E3382883FAC9399AB3C" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69575BF5B4985E3382883FAC9399AB3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FA17303862F5F65A2EFCD90C77D3AC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FA17303862F5F65A2EFCD90C77D3AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FA17303862F5F65A2EFCD90C77D3AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FA17303862F5F65A2EFCD90C77D3AC8" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FA17303862F5F65A2EFCD90C77D3AC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6D8D1AC57C50581283967ADB9A5116F0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6D8D1AC57C50581283967ADB9A5116F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6D8D1AC57C50581283967ADB9A5116F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6D8D1AC57C50581283967ADB9A5116F0" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6D8D1AC57C50581283967ADB9A5116F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF8B7A06A3F65D9588EE607AFED0EA4E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF8B7A06A3F65D9588EE607AFED0EA4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF8B7A06A3F65D9588EE607AFED0EA4E" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF8B7A06A3F65D9588EE607AFED0EA4E" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5_label_en-US" xlink:label="lab_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="lab_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_7E303BA12292E06178051A8B31975164_terseLabel_en-US" xlink:label="lab_dei_DocumentType_FB735381D7AE553EB8B8A94F0DEE181C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_7E303BA12292E06178051A8B31975164_label_en-US" xlink:label="lab_dei_DocumentType_FB735381D7AE553EB8B8A94F0DEE181C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FB735381D7AE553EB8B8A94F0DEE181C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_FB735381D7AE553EB8B8A94F0DEE181C" xlink:to="lab_dei_DocumentType_FB735381D7AE553EB8B8A94F0DEE181C" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_4A3961AD2F087A133D9A1A8B3197806B_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_758787AD23F451F18A727B65DD628F94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_4A3961AD2F087A133D9A1A8B3197806B_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_758787AD23F451F18A727B65DD628F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_758787AD23F451F18A727B65DD628F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_758787AD23F451F18A727B65DD628F94" xlink:to="lab_dei_DocumentQuarterlyReport_758787AD23F451F18A727B65DD628F94" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_4C8D627708EFB95A18CB1A8B31975733_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_A5817F8502625105A660F5EC40F13D0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_4C8D627708EFB95A18CB1A8B31975733_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_A5817F8502625105A660F5EC40F13D0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_A5817F8502625105A660F5EC40F13D0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_A5817F8502625105A660F5EC40F13D0B" xlink:to="lab_dei_DocumentPeriodEndDate_A5817F8502625105A660F5EC40F13D0B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_9300D37270521FF9425F1A8B31976801_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_6AF35006BD4F588BB5F8EE03DC962A84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_9300D37270521FF9425F1A8B31976801_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_6AF35006BD4F588BB5F8EE03DC962A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_6AF35006BD4F588BB5F8EE03DC962A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_6AF35006BD4F588BB5F8EE03DC962A84" xlink:to="lab_dei_DocumentTransitionReport_6AF35006BD4F588BB5F8EE03DC962A84" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_D37C363615D23E34583E1A8B31973862_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_856D16636D8852F18A35973C1BF29AE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_D37C363615D23E34583E1A8B31973862_label_en-US" xlink:label="lab_dei_EntityFileNumber_856D16636D8852F18A35973C1BF29AE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_856D16636D8852F18A35973C1BF29AE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_856D16636D8852F18A35973C1BF29AE8" xlink:to="lab_dei_EntityFileNumber_856D16636D8852F18A35973C1BF29AE8" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_B4CEB1130623FEBBAC341A8B31978E50_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_8B5E3999D1E957FD92602D96F4A2FAE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_B4CEB1130623FEBBAC341A8B31978E50_label_en-US" xlink:label="lab_dei_EntityRegistrantName_8B5E3999D1E957FD92602D96F4A2FAE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_8B5E3999D1E957FD92602D96F4A2FAE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_8B5E3999D1E957FD92602D96F4A2FAE9" xlink:to="lab_dei_EntityRegistrantName_8B5E3999D1E957FD92602D96F4A2FAE9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_DCE00533299F5546B3431A8B3197FD1B_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_BD69E34555AF57EBB8BB219017B88F59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_DCE00533299F5546B3431A8B3197FD1B_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_BD69E34555AF57EBB8BB219017B88F59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_BD69E34555AF57EBB8BB219017B88F59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_BD69E34555AF57EBB8BB219017B88F59" xlink:to="lab_dei_EntityCentralIndexKey_BD69E34555AF57EBB8BB219017B88F59" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_C5DEB0FB0B42718211181A8B31979305_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D769C780FC9354A4B808540D796AF6CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_C5DEB0FB0B42718211181A8B31979305_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D769C780FC9354A4B808540D796AF6CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D769C780FC9354A4B808540D796AF6CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_D769C780FC9354A4B808540D796AF6CF" xlink:to="lab_dei_CurrentFiscalYearEndDate_D769C780FC9354A4B808540D796AF6CF" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_2796CA1629204807A2041A8B31977259_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_E5647D46B94855A3982C2E4FFCB80BDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2796CA1629204807A2041A8B31977259_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_E5647D46B94855A3982C2E4FFCB80BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_E5647D46B94855A3982C2E4FFCB80BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_E5647D46B94855A3982C2E4FFCB80BDB" xlink:to="lab_dei_DocumentFiscalYearFocus_E5647D46B94855A3982C2E4FFCB80BDB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6957BBCB1BEE601657B21A8B3197D9FC_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_51F187B4CAA65A9C9924F34EEECEFC5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6957BBCB1BEE601657B21A8B3197D9FC_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_51F187B4CAA65A9C9924F34EEECEFC5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_51F187B4CAA65A9C9924F34EEECEFC5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_51F187B4CAA65A9C9924F34EEECEFC5F" xlink:to="lab_dei_DocumentFiscalPeriodFocus_51F187B4CAA65A9C9924F34EEECEFC5F" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C8C46B8774826E9673DE1A8B3197BBF2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_4F5BBC888F0E5D19B3FFBCAFB401FA7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C8C46B8774826E9673DE1A8B3197BBF2_label_en-US" xlink:label="lab_dei_AmendmentFlag_4F5BBC888F0E5D19B3FFBCAFB401FA7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4F5BBC888F0E5D19B3FFBCAFB401FA7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_4F5BBC888F0E5D19B3FFBCAFB401FA7C" xlink:to="lab_dei_AmendmentFlag_4F5BBC888F0E5D19B3FFBCAFB401FA7C" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_EBAC3D548524FD01534B1A8B31975513_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_EB6B3361A7FA522191B0376615E5760E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_EBAC3D548524FD01534B1A8B31975513_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_EB6B3361A7FA522191B0376615E5760E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_EB6B3361A7FA522191B0376615E5760E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_EB6B3361A7FA522191B0376615E5760E" xlink:to="lab_dei_EntityIncorporationStateCountryCode_EB6B3361A7FA522191B0376615E5760E" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_D86AD68FB58FB268E0E41A8B31972A14_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_F0AAE50B688C5464A504920098EB9265" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_D86AD68FB58FB268E0E41A8B31972A14_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_F0AAE50B688C5464A504920098EB9265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_F0AAE50B688C5464A504920098EB9265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_F0AAE50B688C5464A504920098EB9265" xlink:to="lab_dei_EntityTaxIdentificationNumber_F0AAE50B688C5464A504920098EB9265" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_958B9394A305FD4899881A8B3197D7CF_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_21B2A96E5FAB56BAA00E42BBB7CF8559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_958B9394A305FD4899881A8B3197D7CF_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_21B2A96E5FAB56BAA00E42BBB7CF8559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_21B2A96E5FAB56BAA00E42BBB7CF8559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_21B2A96E5FAB56BAA00E42BBB7CF8559" xlink:to="lab_dei_EntityAddressAddressLine1_21B2A96E5FAB56BAA00E42BBB7CF8559" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_47666A9C181DD41ED2A91A8B319728AB_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_88A2DC54B85A5F7983973BC69B0EBA71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_47666A9C181DD41ED2A91A8B319728AB_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_88A2DC54B85A5F7983973BC69B0EBA71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_88A2DC54B85A5F7983973BC69B0EBA71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_88A2DC54B85A5F7983973BC69B0EBA71" xlink:to="lab_dei_EntityAddressCityOrTown_88A2DC54B85A5F7983973BC69B0EBA71" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_1E5EBD14933D7DDD85581A8B31970B8E_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_3E16CFFECA03510EB242874A39607BF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1E5EBD14933D7DDD85581A8B31970B8E_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_3E16CFFECA03510EB242874A39607BF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_3E16CFFECA03510EB242874A39607BF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_3E16CFFECA03510EB242874A39607BF8" xlink:to="lab_dei_EntityAddressStateOrProvince_3E16CFFECA03510EB242874A39607BF8" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_DEEC1A963E3EE1C605081A8B3197BCCF_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_57CA0C8A277C56428620A7CCA8CFE4D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_DEEC1A963E3EE1C605081A8B3197BCCF_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_57CA0C8A277C56428620A7CCA8CFE4D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_57CA0C8A277C56428620A7CCA8CFE4D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_57CA0C8A277C56428620A7CCA8CFE4D8" xlink:to="lab_dei_EntityAddressPostalZipCode_57CA0C8A277C56428620A7CCA8CFE4D8" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_2153D7974F5C7AACCFA71A8B3197E22F_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_D5008D1976D45D4C9BE7712C3D5225A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_2153D7974F5C7AACCFA71A8B3197E22F_label_en-US" xlink:label="lab_dei_CityAreaCode_D5008D1976D45D4C9BE7712C3D5225A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_D5008D1976D45D4C9BE7712C3D5225A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_D5008D1976D45D4C9BE7712C3D5225A5" xlink:to="lab_dei_CityAreaCode_D5008D1976D45D4C9BE7712C3D5225A5" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_35B140C1A6775EB2BE021A8B31978B5A_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_E44AAC198282526E9AD22CA5B1A6132F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_35B140C1A6775EB2BE021A8B31978B5A_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_E44AAC198282526E9AD22CA5B1A6132F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_E44AAC198282526E9AD22CA5B1A6132F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_E44AAC198282526E9AD22CA5B1A6132F" xlink:to="lab_dei_LocalPhoneNumber_E44AAC198282526E9AD22CA5B1A6132F" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_C36ED970E146750146A91A8B3197C90C_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_A0A07F369A335E429DD36D9360A528E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_C36ED970E146750146A91A8B3197C90C_label_en-US" xlink:label="lab_dei_Security12bTitle_A0A07F369A335E429DD36D9360A528E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_A0A07F369A335E429DD36D9360A528E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_A0A07F369A335E429DD36D9360A528E5" xlink:to="lab_dei_Security12bTitle_A0A07F369A335E429DD36D9360A528E5" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_98F226DE26D004D8AB991A8B3197CEF2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_7EFE454214E45D498F6DF1BA969DDA7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_98F226DE26D004D8AB991A8B3197CEF2_label_en-US" xlink:label="lab_dei_TradingSymbol_7EFE454214E45D498F6DF1BA969DDA7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7EFE454214E45D498F6DF1BA969DDA7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_7EFE454214E45D498F6DF1BA969DDA7F" xlink:to="lab_dei_TradingSymbol_7EFE454214E45D498F6DF1BA969DDA7F" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_EA2F1424BA3533D4F5871A8B31970A89_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_CAD360C00D6F563F8AD73407B56F4B85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_EA2F1424BA3533D4F5871A8B31970A89_label_en-US" xlink:label="lab_dei_SecurityExchangeName_CAD360C00D6F563F8AD73407B56F4B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_CAD360C00D6F563F8AD73407B56F4B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_CAD360C00D6F563F8AD73407B56F4B85" xlink:to="lab_dei_SecurityExchangeName_CAD360C00D6F563F8AD73407B56F4B85" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_1726CFCF84EEDA949FBB1A8B31979CEA_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_510843B8142C5644AB816F12E57829B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1726CFCF84EEDA949FBB1A8B31979CEA_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_510843B8142C5644AB816F12E57829B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_510843B8142C5644AB816F12E57829B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_510843B8142C5644AB816F12E57829B5" xlink:to="lab_dei_EntityCurrentReportingStatus_510843B8142C5644AB816F12E57829B5" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_A13D6109578D5A16050B1A8B3197CDD3_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_0E1A3BE12C645F4880CE7CAA33E96C85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_A13D6109578D5A16050B1A8B3197CDD3_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_0E1A3BE12C645F4880CE7CAA33E96C85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_0E1A3BE12C645F4880CE7CAA33E96C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_0E1A3BE12C645F4880CE7CAA33E96C85" xlink:to="lab_dei_EntityInteractiveDataCurrent_0E1A3BE12C645F4880CE7CAA33E96C85" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_8C11F5DC978278511CE21A8B31972755_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_3910278EE0775491A322A8962874A072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_8C11F5DC978278511CE21A8B31972755_label_en-US" xlink:label="lab_dei_EntityFilerCategory_3910278EE0775491A322A8962874A072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_3910278EE0775491A322A8962874A072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_3910278EE0775491A322A8962874A072" xlink:to="lab_dei_EntityFilerCategory_3910278EE0775491A322A8962874A072" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_F3170D4E00B3665716B01A8B31978798_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_14D6BAC021235B458348D7E9C4FDDF2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_F3170D4E00B3665716B01A8B31978798_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_14D6BAC021235B458348D7E9C4FDDF2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_14D6BAC021235B458348D7E9C4FDDF2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_14D6BAC021235B458348D7E9C4FDDF2E" xlink:to="lab_dei_EntitySmallBusiness_14D6BAC021235B458348D7E9C4FDDF2E" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_CA05675345A624E1172D1A8B31979103_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_EAF77E45B3615F829D40B31F99A4A638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_CA05675345A624E1172D1A8B31979103_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_EAF77E45B3615F829D40B31F99A4A638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_EAF77E45B3615F829D40B31F99A4A638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_EAF77E45B3615F829D40B31F99A4A638" xlink:to="lab_dei_EntityEmergingGrowthCompany_EAF77E45B3615F829D40B31F99A4A638" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_BCDBAA421B16BB587AE91A8B319767F9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_50D4F2E69BF75D7D8D5C0FED53F7FE13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_BCDBAA421B16BB587AE91A8B319767F9_label_en-US" xlink:label="lab_dei_EntityShellCompany_50D4F2E69BF75D7D8D5C0FED53F7FE13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_50D4F2E69BF75D7D8D5C0FED53F7FE13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_50D4F2E69BF75D7D8D5C0FED53F7FE13" xlink:to="lab_dei_EntityShellCompany_50D4F2E69BF75D7D8D5C0FED53F7FE13" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_123A190734ED9CD3173D1A8B31970D54_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D6557F9188F55A2C8AEF102A67E7F9E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_123A190734ED9CD3173D1A8B31970D54_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D6557F9188F55A2C8AEF102A67E7F9E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D6557F9188F55A2C8AEF102A67E7F9E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_D6557F9188F55A2C8AEF102A67E7F9E6" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_D6557F9188F55A2C8AEF102A67E7F9E6" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesAbstract_B27431C4BFC16532A6A8DF1A9BBF8355_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_B27431C4BFC16532A6A8DF1A9BBF8355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_B27431C4BFC16532A6A8DF1A9BBF8355_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_B27431C4BFC16532A6A8DF1A9BBF8355" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_B27431C4BFC16532A6A8DF1A9BBF8355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract_B27431C4BFC16532A6A8DF1A9BBF8355" xlink:to="lab_biib_OtherrevenuesAbstract_B27431C4BFC16532A6A8DF1A9BBF8355" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073" xlink:to="lab_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073" xlink:type="arc" />
    <link:label id="lab_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F" xlink:to="lab_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E_terseLabel_en-US" xlink:label="lab_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E_label_en-US" xlink:label="lab_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E_documentation_en-US" xlink:label="lab_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E" xlink:to="lab_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues related to amendment of contract manufacturing agreement</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_793531F73066410230E58365F838C39B_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_793531F73066410230E58365F838C39B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_793531F73066410230E58365F838C39B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_793531F73066410230E58365F838C39B" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_793531F73066410230E58365F838C39B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_D363C8C64F7CAE06A7DB8365F838BA72_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_D363C8C64F7CAE06A7DB8365F838BA72" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_D363C8C64F7CAE06A7DB8365F838BA72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_D363C8C64F7CAE06A7DB8365F838BA72" xlink:to="lab_us-gaap_ParentMember_D363C8C64F7CAE06A7DB8365F838BA72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6DA37E34B001CE8016FE8365F839D7D3_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6DA37E34B001CE8016FE8365F839D7D3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6DA37E34B001CE8016FE8365F839D7D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6DA37E34B001CE8016FE8365F839D7D3" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6DA37E34B001CE8016FE8365F839D7D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A0894DA2185D56FEA2B917B4184D8570" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A0894DA2185D56FEA2B917B4184D8570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A0894DA2185D56FEA2B917B4184D8570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A0894DA2185D56FEA2B917B4184D8570" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A0894DA2185D56FEA2B917B4184D8570" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A444A0F5BDD2F76931141512B93F064B_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_DD90A985CB8B5A0E81383D5035A0D6B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_DD90A985CB8B5A0E81383D5035A0D6B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_DD90A985CB8B5A0E81383D5035A0D6B0" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_DD90A985CB8B5A0E81383D5035A0D6B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_43F7616A4C8D53DF921FDE893F9AB594" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_43F7616A4C8D53DF921FDE893F9AB594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_43F7616A4C8D53DF921FDE893F9AB594" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_43F7616A4C8D53DF921FDE893F9AB594" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_43F7616A4C8D53DF921FDE893F9AB594" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_5DAEB8AF9FEB55479225E4D4FC8187C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_5DAEB8AF9FEB55479225E4D4FC8187C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_5DAEB8AF9FEB55479225E4D4FC8187C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_5DAEB8AF9FEB55479225E4D4FC8187C8" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_5DAEB8AF9FEB55479225E4D4FC8187C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15E99504BA63564C8B9580843D7AE2A4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15E99504BA63564C8B9580843D7AE2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15E99504BA63564C8B9580843D7AE2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15E99504BA63564C8B9580843D7AE2A4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15E99504BA63564C8B9580843D7AE2A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1027752A98175D5EB7AEB244AA66276F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1027752A98175D5EB7AEB244AA66276F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1027752A98175D5EB7AEB244AA66276F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1027752A98175D5EB7AEB244AA66276F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1027752A98175D5EB7AEB244AA66276F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_68689E8C3E6816A84A021512B940C0CE_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5033A7FBED12509AA988CD824F17397D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5033A7FBED12509AA988CD824F17397D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5033A7FBED12509AA988CD824F17397D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5033A7FBED12509AA988CD824F17397D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_6BF8598A16B951C8A837E7D038B222F3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_6BF8598A16B951C8A837E7D038B222F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6BF8598A16B951C8A837E7D038B222F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6BF8598A16B951C8A837E7D038B222F3" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_6BF8598A16B951C8A837E7D038B222F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7EB530C4FA7055BB9EE3509440651AF4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7EB530C4FA7055BB9EE3509440651AF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7EB530C4FA7055BB9EE3509440651AF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7EB530C4FA7055BB9EE3509440651AF4" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7EB530C4FA7055BB9EE3509440651AF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ECFCE7FD441857329908E5FF3512BC40" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ECFCE7FD441857329908E5FF3512BC40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ECFCE7FD441857329908E5FF3512BC40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ECFCE7FD441857329908E5FF3512BC40" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ECFCE7FD441857329908E5FF3512BC40" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_CD29C88BDB895531890983C945984EBD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_CD29C88BDB895531890983C945984EBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_CD29C88BDB895531890983C945984EBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_CD29C88BDB895531890983C945984EBD" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_CD29C88BDB895531890983C945984EBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_D890BF111B17557398E36F013A2E25B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_D890BF111B17557398E36F013A2E25B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D890BF111B17557398E36F013A2E25B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_D890BF111B17557398E36F013A2E25B9" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_D890BF111B17557398E36F013A2E25B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_FA6DCABFDC395DA2A23926BA570E310C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_FA6DCABFDC395DA2A23926BA570E310C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_FA6DCABFDC395DA2A23926BA570E310C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_FA6DCABFDC395DA2A23926BA570E310C" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_FA6DCABFDC395DA2A23926BA570E310C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_BDB8801E011F51D192294020286EA1DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_BDB8801E011F51D192294020286EA1DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_BDB8801E011F51D192294020286EA1DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_BDB8801E011F51D192294020286EA1DD" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_BDB8801E011F51D192294020286EA1DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_DF8E77075DB45027A08B5A14DBA12490" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_DF8E77075DB45027A08B5A14DBA12490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_DF8E77075DB45027A08B5A14DBA12490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_DF8E77075DB45027A08B5A14DBA12490" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_DF8E77075DB45027A08B5A14DBA12490" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_8F92CA17D906548D918A63FF91D7F031" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_8F92CA17D906548D918A63FF91D7F031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8F92CA17D906548D918A63FF91D7F031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_8F92CA17D906548D918A63FF91D7F031" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_8F92CA17D906548D918A63FF91D7F031" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_391169FADE1C50E4A7947F4728316565" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_391169FADE1C50E4A7947F4728316565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_391169FADE1C50E4A7947F4728316565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_391169FADE1C50E4A7947F4728316565" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_391169FADE1C50E4A7947F4728316565" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E59E4622CB96553EB652C4218E3F0665" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E59E4622CB96553EB652C4218E3F0665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E59E4622CB96553EB652C4218E3F0665" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E59E4622CB96553EB652C4218E3F0665" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E59E4622CB96553EB652C4218E3F0665" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE78D0BC1FCF5522AB7C4853C11527A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE78D0BC1FCF5522AB7C4853C11527A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE78D0BC1FCF5522AB7C4853C11527A0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE78D0BC1FCF5522AB7C4853C11527A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_6579E70E0744534DACC9A272755E2243" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_6579E70E0744534DACC9A272755E2243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6579E70E0744534DACC9A272755E2243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_6579E70E0744534DACC9A272755E2243" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_6579E70E0744534DACC9A272755E2243" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EE5492F63A065861AF0C4288105FE7D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EE5492F63A065861AF0C4288105FE7D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EE5492F63A065861AF0C4288105FE7D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EE5492F63A065861AF0C4288105FE7D1" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EE5492F63A065861AF0C4288105FE7D1" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89A50B63D0365E268AC83C65C498A109" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89A50B63D0365E268AC83C65C498A109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89A50B63D0365E268AC83C65C498A109" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89A50B63D0365E268AC83C65C498A109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89A50B63D0365E268AC83C65C498A109" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89A50B63D0365E268AC83C65C498A109" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_3068933C8F1B5A08911F36B34D6A4190" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_3068933C8F1B5A08911F36B34D6A4190" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3068933C8F1B5A08911F36B34D6A4190" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3068933C8F1B5A08911F36B34D6A4190" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_3068933C8F1B5A08911F36B34D6A4190" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C797279B7C4153B98958FFDE1B27623E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C797279B7C4153B98958FFDE1B27623E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C797279B7C4153B98958FFDE1B27623E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C797279B7C4153B98958FFDE1B27623E" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C797279B7C4153B98958FFDE1B27623E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7FEEF2898E715B659DBB0074CE0E44FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FEEF2898E715B659DBB0074CE0E44FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FEEF2898E715B659DBB0074CE0E44FC" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7FEEF2898E715B659DBB0074CE0E44FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_F8074931DF21553CBC162B54410E5283" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_F8074931DF21553CBC162B54410E5283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_F8074931DF21553CBC162B54410E5283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_F8074931DF21553CBC162B54410E5283" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_F8074931DF21553CBC162B54410E5283" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_AD39219053965DF2BAEA12C41D74A86A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_AD39219053965DF2BAEA12C41D74A86A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_AD39219053965DF2BAEA12C41D74A86A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_AD39219053965DF2BAEA12C41D74A86A" xlink:to="lab_us-gaap_InventoriesMember_AD39219053965DF2BAEA12C41D74A86A" xlink:type="arc" />
    <link:label id="lab_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_AB98DC4E3C02593FA8D73D15EDB47DAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307_label_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_AB98DC4E3C02593FA8D73D15EDB47DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_AB98DC4E3C02593FA8D73D15EDB47DAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_AB98DC4E3C02593FA8D73D15EDB47DAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilityMember_AB98DC4E3C02593FA8D73D15EDB47DAC" xlink:to="lab_biib_DeferredtaxliabilityMember_AB98DC4E3C02593FA8D73D15EDB47DAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_F0617AAEE9BADC23D2D30B174C4B0B5C_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_B011F405222B5181944EE14F52A6EE2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B011F405222B5181944EE14F52A6EE2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B011F405222B5181944EE14F52A6EE2E" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_B011F405222B5181944EE14F52A6EE2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_91DB26CEE8165A0F9CF6477FD09EA1DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_91DB26CEE8165A0F9CF6477FD09EA1DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_91DB26CEE8165A0F9CF6477FD09EA1DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_91DB26CEE8165A0F9CF6477FD09EA1DF" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_91DB26CEE8165A0F9CF6477FD09EA1DF" xlink:type="arc" />
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2B882307CCA75301B6FBFD4B86533E5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2B882307CCA75301B6FBFD4B86533E5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2B882307CCA75301B6FBFD4B86533E5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2B882307CCA75301B6FBFD4B86533E5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2B882307CCA75301B6FBFD4B86533E5E" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2B882307CCA75301B6FBFD4B86533E5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_500268FDE1695497BA3B96B7F74D4F68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_500268FDE1695497BA3B96B7F74D4F68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_500268FDE1695497BA3B96B7F74D4F68" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_500268FDE1695497BA3B96B7F74D4F68" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_044D86DEE1016FB33F790B174C4C6C26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5A819FD934E954E3A86F5F16642C1F7A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Our share of Samsung Bioepis gains (losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5A819FD934E954E3A86F5F16642C1F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5A819FD934E954E3A86F5F16642C1F7A" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5A819FD934E954E3A86F5F16642C1F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_0F4E11C38AA554F8842C6220C5840A60" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_0F4E11C38AA554F8842C6220C5840A60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_0F4E11C38AA554F8842C6220C5840A60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_0F4E11C38AA554F8842C6220C5840A60" xlink:to="lab_us-gaap_AdjustmentForAmortization_0F4E11C38AA554F8842C6220C5840A60" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_47166B90C3CB5094960300DD9E5D44D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_47166B90C3CB5094960300DD9E5D44D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_47166B90C3CB5094960300DD9E5D44D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_47166B90C3CB5094960300DD9E5D44D6" xlink:to="lab_us-gaap_EquityMethodInvestments_47166B90C3CB5094960300DD9E5D44D6" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_865225D24C1058D1AB991C005F3C2D48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_865225D24C1058D1AB991C005F3C2D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_865225D24C1058D1AB991C005F3C2D48" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_865225D24C1058D1AB991C005F3C2D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_865225D24C1058D1AB991C005F3C2D48" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_865225D24C1058D1AB991C005F3C2D48" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_BE73644AFE9856A7B1669CA1F5366A6C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_BE73644AFE9856A7B1669CA1F5366A6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_BE73644AFE9856A7B1669CA1F5366A6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_BE73644AFE9856A7B1669CA1F5366A6C" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_BE73644AFE9856A7B1669CA1F5366A6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0EA2A41AC9B7553E9C05B35F6ED86A3D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0EA2A41AC9B7553E9C05B35F6ED86A3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0EA2A41AC9B7553E9C05B35F6ED86A3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_0EA2A41AC9B7553E9C05B35F6ED86A3D" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0EA2A41AC9B7553E9C05B35F6ED86A3D" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_15039A4FCDDA52A398EA22FEA4B1D260" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_15039A4FCDDA52A398EA22FEA4B1D260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_15039A4FCDDA52A398EA22FEA4B1D260" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_15039A4FCDDA52A398EA22FEA4B1D260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_15039A4FCDDA52A398EA22FEA4B1D260" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_15039A4FCDDA52A398EA22FEA4B1D260" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_105FBEC927B95A01875A32B39D6E97D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_105FBEC927B95A01875A32B39D6E97D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_105FBEC927B95A01875A32B39D6E97D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_105FBEC927B95A01875A32B39D6E97D7" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_105FBEC927B95A01875A32B39D6E97D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_2AB3910BDF9C5A7AA38F30F7C98E2E21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_2AB3910BDF9C5A7AA38F30F7C98E2E21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2AB3910BDF9C5A7AA38F30F7C98E2E21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_2AB3910BDF9C5A7AA38F30F7C98E2E21" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_2AB3910BDF9C5A7AA38F30F7C98E2E21" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_0B57CE25927E5DC9ABB42865BABFDF3B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_0B57CE25927E5DC9ABB42865BABFDF3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_0B57CE25927E5DC9ABB42865BABFDF3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_0B57CE25927E5DC9ABB42865BABFDF3B" xlink:to="lab_us-gaap_UseOfEstimates_0B57CE25927E5DC9ABB42865BABFDF3B" xlink:type="arc" />
    <link:label id="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C_terseLabel_en-US" xlink:label="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_7219B19F2C7C5389B2E6AB2ADA6625AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities held for sale</link:label>
    <link:label id="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C_label_en-US" xlink:label="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_7219B19F2C7C5389B2E6AB2ADA6625AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Held For Sale [Policy Text Block]</link:label>
    <link:label id="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C_documentation_en-US" xlink:label="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_7219B19F2C7C5389B2E6AB2ADA6625AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Held For Sale [Policy Text Block]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock" xlink:label="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_7219B19F2C7C5389B2E6AB2ADA6625AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_7219B19F2C7C5389B2E6AB2ADA6625AF" xlink:to="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_7219B19F2C7C5389B2E6AB2ADA6625AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EBF3B282725F5C32832091E545B25230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EBF3B282725F5C32832091E545B25230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EBF3B282725F5C32832091E545B25230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EBF3B282725F5C32832091E545B25230" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EBF3B282725F5C32832091E545B25230" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_6D1E7C68718A56EEACF9FA9DDE529C80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_6D1E7C68718A56EEACF9FA9DDE529C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6D1E7C68718A56EEACF9FA9DDE529C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_6D1E7C68718A56EEACF9FA9DDE529C80" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_6D1E7C68718A56EEACF9FA9DDE529C80" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_DFDF877A368A5B2EA28AC5D53C51E65D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_DFDF877A368A5B2EA28AC5D53C51E65D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_DFDF877A368A5B2EA28AC5D53C51E65D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_DFDF877A368A5B2EA28AC5D53C51E65D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_DFDF877A368A5B2EA28AC5D53C51E65D" xlink:to="lab_biib_RocheGroupGenentechMember_DFDF877A368A5B2EA28AC5D53C51E65D" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_5CF0741D88C85CF6992D412469E0D2BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_5CF0741D88C85CF6992D412469E0D2BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_5CF0741D88C85CF6992D412469E0D2BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_5CF0741D88C85CF6992D412469E0D2BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_5CF0741D88C85CF6992D412469E0D2BF" xlink:to="lab_biib_ShareOfCoPromotionProfits_5CF0741D88C85CF6992D412469E0D2BF" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_6434B0FB69ED52DCBD9B13169B742AB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_6434B0FB69ED52DCBD9B13169B742AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_6434B0FB69ED52DCBD9B13169B742AB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_6434B0FB69ED52DCBD9B13169B742AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_6434B0FB69ED52DCBD9B13169B742AB3" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_6434B0FB69ED52DCBD9B13169B742AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_74BCD82AB1EB061302CB0B174E210D2E_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_22EC9AFFE2AC510191F03BBB7FF75067" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_22EC9AFFE2AC510191F03BBB7FF75067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_22EC9AFFE2AC510191F03BBB7FF75067" xlink:to="lab_us-gaap_Revenues_22EC9AFFE2AC510191F03BBB7FF75067" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_267A1B7229A057998FF0B7FCB9FAEE2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_267A1B7229A057998FF0B7FCB9FAEE2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_267A1B7229A057998FF0B7FCB9FAEE2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_267A1B7229A057998FF0B7FCB9FAEE2F" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_267A1B7229A057998FF0B7FCB9FAEE2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration expected to be received for sale of Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum batch production for Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2" xlink:to="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected costs to sell disposal group</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA73C965D0715EDEA33DA3D0DB5B952B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA73C965D0715EDEA33DA3D0DB5B952B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA73C965D0715EDEA33DA3D0DB5B952B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA73C965D0715EDEA33DA3D0DB5B952B" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA73C965D0715EDEA33DA3D0DB5B952B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock_D6CDDFF881B151DD9E6ABF17E3CECBCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock_D6CDDFF881B151DD9E6ABF17E3CECBCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_D6CDDFF881B151DD9E6ABF17E3CECBCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock_D6CDDFF881B151DD9E6ABF17E3CECBCB" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock_D6CDDFF881B151DD9E6ABF17E3CECBCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4281F3C335A95727B0A89112A67D3342" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4281F3C335A95727B0A89112A67D3342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4281F3C335A95727B0A89112A67D3342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4281F3C335A95727B0A89112A67D3342" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4281F3C335A95727B0A89112A67D3342" xlink:type="arc" />
    <link:label id="lab_country_BR_0D94758BE592352CB5740B87D975BFA8_terseLabel_en-US" xlink:label="lab_country_BR_E66D0BC3FB665E53B23D9293EA4A71E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_0D94758BE592352CB5740B87D975BFA8_label_en-US" xlink:label="lab_country_BR_E66D0BC3FB665E53B23D9293EA4A71E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_E66D0BC3FB665E53B23D9293EA4A71E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR_E66D0BC3FB665E53B23D9293EA4A71E3" xlink:to="lab_country_BR_E66D0BC3FB665E53B23D9293EA4A71E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_3AF463C66A5D5B3B804B78E27A25C997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil tax assessment, including interest and penalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_3AF463C66A5D5B3B804B78E27A25C997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_3AF463C66A5D5B3B804B78E27A25C997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_3AF463C66A5D5B3B804B78E27A25C997" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_3AF463C66A5D5B3B804B78E27A25C997" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_B8FC4262394F5CC5A52BA205BD5EFA42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_B8FC4262394F5CC5A52BA205BD5EFA42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_B8FC4262394F5CC5A52BA205BD5EFA42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent_B8FC4262394F5CC5A52BA205BD5EFA42" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent_B8FC4262394F5CC5A52BA205BD5EFA42" xlink:type="arc" />
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_5DC37E0DEF6156DE861B5484BACFA0FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_5DC37E0DEF6156DE861B5484BACFA0FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_5DC37E0DEF6156DE861B5484BACFA0FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_5DC37E0DEF6156DE861B5484BACFA0FA" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_5DC37E0DEF6156DE861B5484BACFA0FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_97FDEEE752B25357A6293EFF1DD08251" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_97FDEEE752B25357A6293EFF1DD08251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_97FDEEE752B25357A6293EFF1DD08251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_97FDEEE752B25357A6293EFF1DD08251" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_97FDEEE752B25357A6293EFF1DD08251" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5372F8F065816E865A381756F1C8B896_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_22E2EFFE80E05AE9A20E151E87F7707A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_22E2EFFE80E05AE9A20E151E87F7707A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_22E2EFFE80E05AE9A20E151E87F7707A" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_22E2EFFE80E05AE9A20E151E87F7707A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_7341E87BDAD9A711916C1756F1C842F8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Revenues_F9B843488FC45D818AC883AD279FC2C7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F9B843488FC45D818AC883AD279FC2C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_F9B843488FC45D818AC883AD279FC2C7" xlink:to="lab_us-gaap_Revenues_F9B843488FC45D818AC883AD279FC2C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_4B883AD9F9AC5FE49C7DA221148B03C7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_4B883AD9F9AC5FE49C7DA221148B03C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4B883AD9F9AC5FE49C7DA221148B03C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_4B883AD9F9AC5FE49C7DA221148B03C7" xlink:to="lab_us-gaap_OperatingExpenses_4B883AD9F9AC5FE49C7DA221148B03C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_232F9A4014FA5387BCCA48F01EB0068D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_232F9A4014FA5387BCCA48F01EB0068D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_232F9A4014FA5387BCCA48F01EB0068D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_232F9A4014FA5387BCCA48F01EB0068D" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_232F9A4014FA5387BCCA48F01EB0068D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8BF7706211575B21A52C2990DF88B0AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8BF7706211575B21A52C2990DF88B0AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8BF7706211575B21A52C2990DF88B0AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8BF7706211575B21A52C2990DF88B0AD" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8BF7706211575B21A52C2990DF88B0AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C04BA8B504A65E3F87421CC7907722D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C04BA8B504A65E3F87421CC7907722D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C04BA8B504A65E3F87421CC7907722D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C04BA8B504A65E3F87421CC7907722D4" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C04BA8B504A65E3F87421CC7907722D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_698E3B301A0E57EBAB3FA9146A039E14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_698E3B301A0E57EBAB3FA9146A039E14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_698E3B301A0E57EBAB3FA9146A039E14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_698E3B301A0E57EBAB3FA9146A039E14" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_698E3B301A0E57EBAB3FA9146A039E14" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C211C27E3324DBDAF05DDF1A985E100A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C211C27E3324DBDAF05DDF1A985E100A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C211C27E3324DBDAF05DDF1A985E100A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C211C27E3324DBDAF05DDF1A985E100A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C211C27E3324DBDAF05DDF1A985E100A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C211C27E3324DBDAF05DDF1A985E100A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C211C27E3324DBDAF05DDF1A985E100A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ED8AE33A6073098FAC92DF1A985E7D22_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ED8AE33A6073098FAC92DF1A985E7D22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ED8AE33A6073098FAC92DF1A985E7D22_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ED8AE33A6073098FAC92DF1A985E7D22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ED8AE33A6073098FAC92DF1A985E7D22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ED8AE33A6073098FAC92DF1A985E7D22" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ED8AE33A6073098FAC92DF1A985E7D22" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3747B649B889D4BA1CDFDF1A985EC529_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3747B649B889D4BA1CDFDF1A985EC529" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3747B649B889D4BA1CDFDF1A985EC529_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3747B649B889D4BA1CDFDF1A985EC529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3747B649B889D4BA1CDFDF1A985EC529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3747B649B889D4BA1CDFDF1A985EC529" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3747B649B889D4BA1CDFDF1A985EC529" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_258BA25EAF9DF77E21A8DF1A985EFAE4_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_258BA25EAF9DF77E21A8DF1A985EFAE4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_258BA25EAF9DF77E21A8DF1A985EFAE4_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_258BA25EAF9DF77E21A8DF1A985EFAE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_258BA25EAF9DF77E21A8DF1A985EFAE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_258BA25EAF9DF77E21A8DF1A985EFAE4" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_258BA25EAF9DF77E21A8DF1A985EFAE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_54E1BCC7C43BC4CD80C1DF1A985E9CF5_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_54E1BCC7C43BC4CD80C1DF1A985E9CF5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_54E1BCC7C43BC4CD80C1DF1A985E9CF5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_54E1BCC7C43BC4CD80C1DF1A985E9CF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_54E1BCC7C43BC4CD80C1DF1A985E9CF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_54E1BCC7C43BC4CD80C1DF1A985E9CF5" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_54E1BCC7C43BC4CD80C1DF1A985E9CF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_3EEAF6A7958872595143DF1A985E4CB5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_3EEAF6A7958872595143DF1A985E4CB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark assets held for sale</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_3EEAF6A7958872595143DF1A985E4CB5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_3EEAF6A7958872595143DF1A985E4CB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_3EEAF6A7958872595143DF1A985E4CB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_3EEAF6A7958872595143DF1A985E4CB5" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_3EEAF6A7958872595143DF1A985E4CB5" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal reorganization of certain intellectual property rights</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7E0B6783D8E474A0592BDF73F6D42BEC_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7E0B6783D8E474A0592BDF73F6D42BEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US tax reform</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7E0B6783D8E474A0592BDF73F6D42BEC_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7E0B6783D8E474A0592BDF73F6D42BEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7E0B6783D8E474A0592BDF73F6D42BEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7E0B6783D8E474A0592BDF73F6D42BEC" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7E0B6783D8E474A0592BDF73F6D42BEC" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss tax reform</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6FB54716CEA3C7809C8DF1A985E7DD0_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6FB54716CEA3C7809C8DF1A985E7DD0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6FB54716CEA3C7809C8DF1A985E7DD0_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6FB54716CEA3C7809C8DF1A985E7DD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6FB54716CEA3C7809C8DF1A985E7DD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6FB54716CEA3C7809C8DF1A985E7DD0" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6FB54716CEA3C7809C8DF1A985E7DD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_566B7F2DB51883E6F1E9DF1A985E4646_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_566B7F2DB51883E6F1E9DF1A985E4646" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_566B7F2DB51883E6F1E9DF1A985E4646_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_566B7F2DB51883E6F1E9DF1A985E4646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_566B7F2DB51883E6F1E9DF1A985E4646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_566B7F2DB51883E6F1E9DF1A985E4646" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_566B7F2DB51883E6F1E9DF1A985E4646" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2E2B24A418DCD0CF61D3DF1A986286B2_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2E2B24A418DCD0CF61D3DF1A986286B2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2E2B24A418DCD0CF61D3DF1A986286B2_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2E2B24A418DCD0CF61D3DF1A986286B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2E2B24A418DCD0CF61D3DF1A986286B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2E2B24A418DCD0CF61D3DF1A986286B2" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2E2B24A418DCD0CF61D3DF1A986286B2" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324_terseLabel_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324_label_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:label id="lab_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324_documentation_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324" xlink:to="lab_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324" xlink:type="arc" />
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D_terseLabel_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D_label_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D_documentation_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D" xlink:to="lab_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_FA86E4822BACEA4C3E9682AF28825D26_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_FA86E4822BACEA4C3E9682AF28825D26" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_FA86E4822BACEA4C3E9682AF28825D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_FA86E4822BACEA4C3E9682AF28825D26" xlink:to="lab_us-gaap_OperatingLeaseLiability_FA86E4822BACEA4C3E9682AF28825D26" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08" xlink:to="lab_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Income Statement, Sublease Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D" xlink:to="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_DFFC36121CB925B44DC682AF28832ADD_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_DFFC36121CB925B44DC682AF28832ADD" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net lease cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_DFFC36121CB925B44DC682AF28832ADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_DFFC36121CB925B44DC682AF28832ADD" xlink:to="lab_us-gaap_OperatingLeaseCost_DFFC36121CB925B44DC682AF28832ADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 940 - Minimum lease payments, 2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2019</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2020</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2021</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2022</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2023</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, thereafter</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income total</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments 2019</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In One Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in one year.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2020</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Two Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in two year.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2021</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Three Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in three year.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2022</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Four Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in four year.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2023</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Five Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in five year.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments thereafter.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7" xlink:to="lab_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments total</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0_label_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments total.</link:label>
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0" xlink:to="lab_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term in years</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8" xlink:to="lab_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_35D631DC66D6538FA3D1BABB72166E95" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_35D631DC66D6538FA3D1BABB72166E95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_35D631DC66D6538FA3D1BABB72166E95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_35D631DC66D6538FA3D1BABB72166E95" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_35D631DC66D6538FA3D1BABB72166E95" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_E1514AD6E76E54B0974FABB3978E01D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_E1514AD6E76E54B0974FABB3978E01D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_E1514AD6E76E54B0974FABB3978E01D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_E1514AD6E76E54B0974FABB3978E01D3" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_E1514AD6E76E54B0974FABB3978E01D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B" xlink:to="lab_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:to="lab_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_730B124876887307FCFEDF1A98AA8468_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_730B124876887307FCFEDF1A98AA8468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_730B124876887307FCFEDF1A98AA8468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_730B124876887307FCFEDF1A98AA8468" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_730B124876887307FCFEDF1A98AA8468" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AC07634DDB685D75FEA6DF1A98AA5D58_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AC07634DDB685D75FEA6DF1A98AA5D58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AC07634DDB685D75FEA6DF1A98AA5D58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AC07634DDB685D75FEA6DF1A98AA5D58" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AC07634DDB685D75FEA6DF1A98AA5D58" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>biib-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20190930.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20190930.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20190930.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20190930.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20190930.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20190930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20190930.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20190930.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20190930.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20190930.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20190930.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails" xlink:href="biib-20190930.xsd#DivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20190930.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20190930.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20190930.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20190930.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20190930.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20190930.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20190930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20190930.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20190930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20190930.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20190930.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20190930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20190930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20190930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20190930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20190930.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20190930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20190930.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20190930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20190930.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20190930.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20190930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20190930.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20190930.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:href="biib-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetails" xlink:href="biib-20190930.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:href="biib-20190930.xsd#LeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesTables" xlink:href="biib-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20190930.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20190930.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20190930.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20190930.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20190930.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20190930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190930.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20190930.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20190930.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20190930.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20190930.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20190930.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20190930.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20190930.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20190930.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20190930.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20190930.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20190930.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20190930.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20190930.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20190930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20190930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9BF16201D10F5ACBB1607016F9FDE82B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9BF16201D10F5ACBB1607016F9FDE82B" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_DD6C76B0936353C0A24B583C24EDA1CA" xlink:to="loc_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_F3CC4C69B9B051C1A3A044E7CDD7A27E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_177D22C6590150C19C6392DF2B215FC9" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_F3CC4C69B9B051C1A3A044E7CDD7A27E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E6E0AD1BDB025150A173AEB5E324E611" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_E6E0AD1BDB025150A173AEB5E324E611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E6E0AD1BDB025150A173AEB5E324E611" xlink:to="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69E3437BCC685A4A89CE4BB09AFF016A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69E3437BCC685A4A89CE4BB09AFF016A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_FBF75FF1DF385D4092216D272C8CF354" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_FBF75FF1DF385D4092216D272C8CF354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E15AB3C602E552A39B5E99C3E0A84083" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E15AB3C602E552A39B5E99C3E0A84083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_955DB22F529156CD88A426178DC9564B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_955DB22F529156CD88A426178DC9564B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5A0A027A557E56B197E760986F6C6A40" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98C7D48423E35AAAB885DAEE13CABF89" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5A0A027A557E56B197E760986F6C6A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EFBF5F2A977758A58FC33A55E6F548DA" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04D4ACC4BB4A57C99A3C9C706B3B10ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04D4ACC4BB4A57C99A3C9C706B3B10ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8114D4079FA45862B6426CADE30AAFB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8114D4079FA45862B6426CADE30AAFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EF8ADCF260CC588791CE5CAD1BB8D6C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EF8ADCF260CC588791CE5CAD1BB8D6C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DC9B1E44558B55D381FA7B7990974F90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DC9B1E44558B55D381FA7B7990974F90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_252EDC2CD25C575B9ED4859C0CEF1AC3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_252EDC2CD25C575B9ED4859C0CEF1AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D289ED2D064D5BB89FD7100D13D0E470" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D289ED2D064D5BB89FD7100D13D0E470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_FBEEF01A11705D8990D9D492E31AAB3B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_FBEEF01A11705D8990D9D492E31AAB3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A9C55CA582E51B18673507F83D107BC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_93D902F1C1BB5826B165CCEBAAA87B23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A9C55CA582E51B18673507F83D107BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_38BD08407204541A9D29DB0BF1C369F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74626955C1645DE598EC21A600728169" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_38BD08407204541A9D29DB0BF1C369F6" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74626955C1645DE598EC21A600728169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_B4E1855E9B0956049CED7BD6BD20C591" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_38BD08407204541A9D29DB0BF1C369F6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_B4E1855E9B0956049CED7BD6BD20C591" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_323FA93E20B65C698D63AF17B48B0A7B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_AFB6039C3E145E53A5930A6606E58DEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_323FA93E20B65C698D63AF17B48B0A7B" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_AFB6039C3E145E53A5930A6606E58DEB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_87D053635598CA538D1682AF2960D825" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A259D60E66B2B48C0DD282AF2961FD43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_87D053635598CA538D1682AF2960D825" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A259D60E66B2B48C0DD282AF2961FD43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_568B9DC2566FA61D444882AF2961A392" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A259D60E66B2B48C0DD282AF2961FD43" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_568B9DC2566FA61D444882AF2961A392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C8C4CC904B707CB5A9A182AF2961BE3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_568B9DC2566FA61D444882AF2961A392" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C8C4CC904B707CB5A9A182AF2961BE3F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_20B6A80AFDF698B5470F82AF296122B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C8C4CC904B707CB5A9A182AF2961BE3F" xlink:to="loc_biib_NightstarMember_20B6A80AFDF698B5470F82AF296122B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A259D60E66B2B48C0DD282AF2961FD43" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6F831092922396F04BCB82AF29622056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_AAC9CB7ADBF7163736CE82AF2962E1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FD65960BA15033317BD882AF2962A128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_ACBFFD15425ADAB943F482AF29635658" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_Goodwill_ACBFFD15425ADAB943F482AF29635658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D52D382A10904574C3B582AF29638CC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_85A39466E0570C03020382AF2963A9A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ACE0EBC20D90E78BDEB382AF2962F551" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4E7EFF7C506DE0DF0F6482AF296354E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_23EF952BB29B575CA1198073A609321A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_23EF952BB29B575CA1198073A609321A" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_B576CE1EE95450B2A0754DE8D91B10A5" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_783A12A29E1D5B5C9D6DCA4AE7D5F165" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_A90CE3BC8F04586E84D75CB32FB8D679" xlink:to="loc_biib_PostacquisitionequitycompensationMember_783A12A29E1D5B5C9D6DCA4AE7D5F165" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_F96E615D5B2557A390A88FAE3B472665" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_F96E615D5B2557A390A88FAE3B472665" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_9CB58A60A85157F5B5F57818BF62634C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_F96E615D5B2557A390A88FAE3B472665" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_9CB58A60A85157F5B5F57818BF62634C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_9C62B1C9C57C5BFBB074A6714EC6504F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_9CB58A60A85157F5B5F57818BF62634C" xlink:to="loc_biib_BIIB111Member_9C62B1C9C57C5BFBB074A6714EC6504F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_CB3CBE862C1B512BA879F55B20AE7865" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_9CB58A60A85157F5B5F57818BF62634C" xlink:to="loc_biib_BIIB112Member_CB3CBE862C1B512BA879F55B20AE7865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_34433F7F544E5A918CBDCF18EF022A27" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_34433F7F544E5A918CBDCF18EF022A27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77E277434A52584C8F1809F1F4380BCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_34433F7F544E5A918CBDCF18EF022A27" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77E277434A52584C8F1809F1F4380BCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B41C6D8908FE5F52928FBBB261D2554E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77E277434A52584C8F1809F1F4380BCA" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_B41C6D8908FE5F52928FBBB261D2554E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_82DBA9DB6D475AEF933D169D734E49A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77E277434A52584C8F1809F1F4380BCA" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_82DBA9DB6D475AEF933D169D734E49A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_74A870E7DEA65B00B058CDA4C71604C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_74A870E7DEA65B00B058CDA4C71604C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CF82A651E535C5EAF87D7079E2D204C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_74A870E7DEA65B00B058CDA4C71604C8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CF82A651E535C5EAF87D7079E2D204C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_578882998E79555BB7306D06D127E54B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CF82A651E535C5EAF87D7079E2D204C" xlink:to="loc_biib_NightstarMember_578882998E79555BB7306D06D127E54B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AC364CA6B9265393A42774807130A97C" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_CC7061E1A030507DBA2AF4D07DDB961A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_CC7061E1A030507DBA2AF4D07DDB961A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0FE12A4EA78F566A9B18F9375C71EDE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0FE12A4EA78F566A9B18F9375C71EDE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_05E0C6E5BBFB5C4A90E1E5C7E266870C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_05E0C6E5BBFB5C4A90E1E5C7E266870C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_A94BA2B22F8851EF93037B2B7D20979D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_A94BA2B22F8851EF93037B2B7D20979D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_8AF14143AC01520EAB152B095487F02C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_8AF14143AC01520EAB152B095487F02C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1A79604345C45568AB0D1311466262B1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1A79604345C45568AB0D1311466262B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_58C954A16EA855DFBAA49FA60F65C435" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564309400C605DA599E78B1ADCE139A3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_58C954A16EA855DFBAA49FA60F65C435" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7D5B9F15F26B54028523A9E3C4845C0B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_D4C75513BE0A5124B89C56320EF010F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7D5B9F15F26B54028523A9E3C4845C0B" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_D4C75513BE0A5124B89C56320EF010F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7738DF83DBAEE1A0424FDF1A982A3AD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7738DF83DBAEE1A0424FDF1A982A3AD6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D4D107A53885091FB660DF1A982C9E48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D4D107A53885091FB660DF1A982C9E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D198F8446A12F8F6FD61DF1A982CFE95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D4D107A53885091FB660DF1A982C9E48" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D198F8446A12F8F6FD61DF1A982CFE95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D198F8446A12F8F6FD61DF1A982CFE95" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E238A3A924DBDB18E4B0DF1A982C5D4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D198F8446A12F8F6FD61DF1A982CFE95" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F831FA97E1C7AF815866DF1A982D23C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7F4B0A08807983AE2C15DF1A982DDB13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7F4B0A08807983AE2C15DF1A982DDB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7F4B0A08807983AE2C15DF1A982DDB13" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D" xlink:to="loc_us-gaap_CollaborativeArrangementMember_99C3C99950E8DF8256F9DF1A982EAC81" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D" xlink:to="loc_biib_EisaiMember_28288ADE8AB062250247DF1A982E73EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3033553B523DF6753E6FDF1A982D9D8D" xlink:to="loc_biib_SkyhawkTherapeuticsMember_6E454830ACFAB63B0B45DF1A982E89C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EF1177428310339BE525DF1A982E8137" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:to="loc_srt_ProductOrServiceAxis_EF1177428310339BE525DF1A982E8137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_6DC8A0571B27BACF003BDF1A982E3757" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_EF1177428310339BE525DF1A982E8137" xlink:to="loc_srt_ProductsAndServicesDomain_6DC8A0571B27BACF003BDF1A982E3757" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6DC8A0571B27BACF003BDF1A982E3757" xlink:to="loc_biib_E2609andBAN2401Member_3D3BC39387C485D1508CDF1A982FEB8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6DC8A0571B27BACF003BDF1A982E3757" xlink:to="loc_biib_AducanumabMember_F4C1DF1B880528A4EEA0DF1A982F9B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74B632A8BF586A28D6BFDF1A982C3C63" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_biib_Expenseincurredbythecollaboration_F600870793D1F87F155CDF1A982FE984" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_F857BC9E666FACF4886ADF1A982FD2CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_F0FB4E169618E4CD6F79DF1A982F83F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_us-gaap_LossOnContractTermination_BDFB68811978BC860814DF1A982F5D85" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_biib_AdditionalMilestonePayment_E65E188E2CDC9DE43461DF1A982FEB3C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F8E3E2DE7B449CA88790DF1A982F6421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_70A0B3033594004EC69ADF1A982F54CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927A876DA28B516CCF82DF1A982F2CAC" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_DC5DDEDDA71D6C8C3380DF1A982F78E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6F3CCB309FBD5009BD80C3A8102F4F35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6F3CCB309FBD5009BD80C3A8102F4F35" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0995F8D10AF259EBA7166B502D287EE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0995F8D10AF259EBA7166B502D287EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0995F8D10AF259EBA7166B502D287EE8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_AD39219053965DF2BAEA12C41D74A86A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:to="loc_us-gaap_InventoriesMember_AD39219053965DF2BAEA12C41D74A86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_D541F32AE8025C08AF073481AE1463C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_D541F32AE8025C08AF073481AE1463C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_FBCE8CABF061576FA15921B72595F3C3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_FBCE8CABF061576FA15921B72595F3C3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_AB98DC4E3C02593FA8D73D15EDB47DAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B87782E6F4FB5319B7AB8D64BB6D173B" xlink:to="loc_biib_DeferredtaxliabilityMember_AB98DC4E3C02593FA8D73D15EDB47DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_48D085810BD55A90B661CBE8497C37F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:to="loc_us-gaap_TypeOfArrangementAxis_48D085810BD55A90B661CBE8497C37F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A288EC7D218F5F7AA115FBDF95393EEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_48D085810BD55A90B661CBE8497C37F0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A288EC7D218F5F7AA115FBDF95393EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9D19024021DC591B86884D2A93D57477" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A288EC7D218F5F7AA115FBDF95393EEB" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9D19024021DC591B86884D2A93D57477" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F747FCB4BF25551C82DE04AEE760D30A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F747FCB4BF25551C82DE04AEE760D30A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_51663E2F1B065674AEA4CD605DE1CFF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F747FCB4BF25551C82DE04AEE760D30A" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_51663E2F1B065674AEA4CD605DE1CFF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_506D132F58BC59F09CF649D31EB00302" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_51663E2F1B065674AEA4CD605DE1CFF4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_506D132F58BC59F09CF649D31EB00302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_E0BF38BD95D554A1A847778FA96C2D93" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5C0898A4AD7C536EB0AFD8884E50F034" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5C0898A4AD7C536EB0AFD8884E50F034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B011F405222B5181944EE14F52A6EE2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_B011F405222B5181944EE14F52A6EE2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3EADA035CC9C587A9B80BD36F9C0F618" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3EADA035CC9C587A9B80BD36F9C0F618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_91DB26CEE8165A0F9CF6477FD09EA1DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_91DB26CEE8165A0F9CF6477FD09EA1DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2B882307CCA75301B6FBFD4B86533E5E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2B882307CCA75301B6FBFD4B86533E5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_500268FDE1695497BA3B96B7F74D4F68" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_500268FDE1695497BA3B96B7F74D4F68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5A819FD934E954E3A86F5F16642C1F7A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5A819FD934E954E3A86F5F16642C1F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_0F4E11C38AA554F8842C6220C5840A60" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_AdjustmentForAmortization_0F4E11C38AA554F8842C6220C5840A60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_47166B90C3CB5094960300DD9E5D44D6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_EquityMethodInvestments_47166B90C3CB5094960300DD9E5D44D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_865225D24C1058D1AB991C005F3C2D48" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_865225D24C1058D1AB991C005F3C2D48" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_E0240B1C2DCC5C9994D8E8143C7799AA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_biib_Collaborationprofitlosssharing_E0240B1C2DCC5C9994D8E8143C7799AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_898B82CDC44A5E19B1C15A1CD7377565" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CE2EDC625FD2567AB230DAEF56D1C1FC" xlink:to="loc_us-gaap_Revenues_898B82CDC44A5E19B1C15A1CD7377565" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37075E733A965BF5A26BB148C9A9915F" xlink:type="locator" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_4C7E9BF73ACE528AB07E1C3B8AB52035" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37075E733A965BF5A26BB148C9A9915F" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_4C7E9BF73ACE528AB07E1C3B8AB52035" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_8AA11A1404915897AD9AE58FFBB481B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37075E733A965BF5A26BB148C9A9915F" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_8AA11A1404915897AD9AE58FFBB481B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_FD57DFCF3355A42E0A51DF18C3643DEE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FD57DFCF3355A42E0A51DF18C3643DEE" xlink:to="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0EA17FD66EE58DAF24ECDF18C3684561" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0EA17FD66EE58DAF24ECDF18C3684561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_836F9ECA9088C721D7F3DF18C36CE266" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_836F9ECA9088C721D7F3DF18C36CE266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_62D07A2B6ED78FC3E017DF18C36C7CD2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_62D07A2B6ED78FC3E017DF18C36C7CD2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_C2446459AC9C96D55BA7DF18C36CF86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_3C85AAD167B83E3F5B59DF18C36C6524" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:to="loc_us-gaap_InventoryNet_3C85AAD167B83E3F5B59DF18C36C6524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_B685C71E5467D6ECD215DF18C36C8EDA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:to="loc_us-gaap_OtherAssetsCurrent_B685C71E5467D6ECD215DF18C36C8EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0007BC9998594CB3D2CCDF18C3748A95" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9CB6546DEBA8455867E5DF18C3682C7C" xlink:to="loc_us-gaap_AssetsCurrent_0007BC9998594CB3D2CCDF18C3748A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_51AC97AFBCEB5F30A5D9DF18C3744896" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_51AC97AFBCEB5F30A5D9DF18C3744896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2367889CB88A1D85C3D5DF18C374130D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2367889CB88A1D85C3D5DF18C374130D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_BB45E4C219EE47B043EEDF18C374AA28" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_BB45E4C219EE47B043EEDF18C374AA28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_EC33D47F795E17D47678DF18C3749DD8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_EC33D47F795E17D47678DF18C3749DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_7F963C87ED63583A4E5FDF18C3740614" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:to="loc_us-gaap_Goodwill_7F963C87ED63583A4E5FDF18C3740614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8B44CB6B3A59063E350DDF18C374731D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_8B44CB6B3A59063E350DDF18C374731D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1F8C65B3E7757C3887C0DF18C374FA5F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1F8C65B3E7757C3887C0DF18C374FA5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_4EA1CBAA726AEA9D3E75DF18C374D276" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40FEE73FFDE57B0DA100DF18C3682AB9" xlink:to="loc_us-gaap_Assets_4EA1CBAA726AEA9D3E75DF18C374D276" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FD57DFCF3355A42E0A51DF18C3643DEE" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_8EDC4D520B9F385CB176DF18C731B6C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:to="loc_us-gaap_NotesPayableCurrent_8EDC4D520B9F385CB176DF18C731B6C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_4218A761C0E19903D1BFDF18C37481A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:to="loc_us-gaap_TaxesPayableCurrent_4218A761C0E19903D1BFDF18C37481A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_298A0D2BF1DCF2D099CADF18C374B329" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:to="loc_us-gaap_AccountsPayableCurrent_298A0D2BF1DCF2D099CADF18C374B329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_721CDF607F09DA6AE134DF18C3782398" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_721CDF607F09DA6AE134DF18C3782398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_56D16EE7B54CC178D97EDF18C378BA4D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DDA9F7639D34B7157CECDF18C37452A2" xlink:to="loc_us-gaap_LiabilitiesCurrent_56D16EE7B54CC178D97EDF18C378BA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_ED88BB0D7E22AB3204FBDF18C378ABC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:to="loc_us-gaap_LongTermDebt_ED88BB0D7E22AB3204FBDF18C378ABC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_B0989AF452384B9EC911DF18C3783795" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_B0989AF452384B9EC911DF18C3783795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1571FE2192CFC4503765DF18C3789D3C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1571FE2192CFC4503765DF18C3789D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3F0989B51103347C242EDF18C3781002" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3F0989B51103347C242EDF18C3781002" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_55035C36F3510DFB7CAADF18C3796C9F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:to="loc_us-gaap_Liabilities_55035C36F3510DFB7CAADF18C3796C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_125F4EF6523340B5154CDF18C3797457" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:to="loc_us-gaap_CommitmentsAndContingencies_125F4EF6523340B5154CDF18C3797457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939" xlink:to="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_197CA9AC1CECE1FE04F0DF18C37927F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:to="loc_us-gaap_PreferredStockValue_197CA9AC1CECE1FE04F0DF18C37927F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_06470510F759F133C705DF18C37A957A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:to="loc_us-gaap_CommonStockValue_06470510F759F133C705DF18C37A957A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_A6BE975B7F3456C154D5DF18C37A1DB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:to="loc_us-gaap_AdditionalPaidInCapital_A6BE975B7F3456C154D5DF18C37A1DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_271EBB5AF87D575088F5DF18C37ABB75" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_271EBB5AF87D575088F5DF18C37ABB75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33DB8EBAF7EAC9657AC3DF18C37A3032" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33DB8EBAF7EAC9657AC3DF18C37A3032" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_2E16D469F37117E891FCDF18C37BF037" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:to="loc_us-gaap_TreasuryStockValue_2E16D469F37117E891FCDF18C37BF037" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_D58035CB5564CA21F92ADF18C37B26AE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BDEBD068C546192335BCDF18C3796872" xlink:to="loc_us-gaap_StockholdersEquity_D58035CB5564CA21F92ADF18C37B26AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_D89CE4C882513938F2AFDF18C37B4A2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939" xlink:to="loc_us-gaap_MinorityInterest_D89CE4C882513938F2AFDF18C37B4A2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B8E6B95411154E1365F5DF18C37B383A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AE7357826683104B9B12DF18C3797939" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B8E6B95411154E1365F5DF18C37B383A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_F540299CF5A1CEB677C2DF18C37BA2B6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CAE2BA5367295916A1D2DF18C3747A56" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_F540299CF5A1CEB677C2DF18C37BA2B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_D5ABA1F892565FAB872E61B778EDD6CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_BE73644AFE9856A7B1669CA1F5366A6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D5ABA1F892565FAB872E61B778EDD6CB" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_BE73644AFE9856A7B1669CA1F5366A6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0EA2A41AC9B7553E9C05B35F6ED86A3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D5ABA1F892565FAB872E61B778EDD6CB" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0EA2A41AC9B7553E9C05B35F6ED86A3D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_D948CE33D7A827EFDB77827AE1EC7263" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_D948CE33D7A827EFDB77827AE1EC7263" xlink:to="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_7A866EE30D6A8F96E0EB827AE1EC410D" xlink:to="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_10575945F64F0957F0C2827AE1ED16BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_34017EE22C2B122B98D4827AE1ECD014" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_779F157D99B0705AAA42827AE1ED594F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_19CF610EDC999D56A81B827AE1EDC136" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:to="loc_biib_A2019ShareRepurchaseProgramMember_F381CA8E686FAD4C9564827AE1EEBD29" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_E589074D68D626A9B4EF827AE1EED1E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_D91ED5BD087AE3D5559B827AE1EDB2A7" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_E1EA1E53D10F10F4169A827AE1EEC2FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61BB7A0A7A06B0564543827AE1EE7360" xlink:to="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_PreferredStockMember_368BCBF53107166F9AE5827AE1EF74E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_CommonStockMember_A620D7F4AB25957E0B7A827AE1EFCDEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_283E19A340C16A226B39827AE1EF5DE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A1E58DF85E2035CC6C62827AE1EF0A96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_RetainedEarningsMember_4A616F92F6F7BC3F38A3827AE1F02B1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_TreasuryStockMember_0FD250CAC60085D7C228827AE1F07BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2B05318F623608D7C398827AE1F05FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A37D300C370756EAE5FF827AE1EE8656" xlink:to="loc_us-gaap_ParentMember_C6DC477382E07A8663DD827AE1F0A54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_433E4356E04A8AE5A638827AE1EC1EEC" xlink:to="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_F7A678F9DE8CA693C233827AE1F0A39A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_F7A678F9DE8CA693C233827AE1F0A39A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_SharesIssued_9AFD86AE288B8A9E8484827AE1F1356C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_FFEC62C22331F8BA8810827AE1F1281C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockholdersEquity_FFEC62C22331F8BA8810827AE1F1281C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3BBE7515E9C0AF3F81F8827AE1F13596" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_MinorityInterest_3BBE7515E9C0AF3F81F8827AE1F13596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_NetIncomeLoss_63BF5922D57C76B77D8A827AE1F17CB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3B11948D6D31360876B1827AE1F10017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_ProfitLoss_43815057D418C7856311827AE1F1A154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8EC8F863AA6B015C2924827AE1F2B474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0130BBFD4FBB57CBD51C827AE1F21C75" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_05ACD347062035CF864A827AE1F2896E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_E4391552C473FE9966B5827AE1F2FE2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_01E06560705F15C9B841827AE1F247D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_9969EF6025F340AF643B827AE1F29D6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_4F30D4BF23DF1D169BB3827AE1F3B6C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ECF105CC713659454C17827AE1F3B068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63BE80F1946FA0433EB6827AE1F3576B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_EC469688AEB55E2C9C1F827AE1F39E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_875E187A36F400F423C4827AE1F337EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7A99ACC01EE30D96ED1E827AE1F4527B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5794C9991E52E4541F29827AE1F46287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockholdersEquityOther_5BF42E11C72077F73551827AE1F48C56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38962C10458059BED8EF827AE1F412FD" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38962C10458059BED8EF827AE1F412FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6F0E8419F50FD2FC0516827AE1F4E0E3" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_StockholdersEquity_6F0E8419F50FD2FC0516827AE1F4E0E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_2145AD8FEB69D44CB991827AE1F435D2" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_MinorityInterest_2145AD8FEB69D44CB991827AE1F435D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_D5657DDE802F00ACDD2F827AE1F551D1" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9124CD493A447A960FB6827AE1F02CFE" xlink:to="loc_us-gaap_SharesIssued_D5657DDE802F00ACDD2F827AE1F551D1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_CE24D17F1268545E322CDF1A9CFA1C83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6" xlink:to="loc_us-gaap_ProfitLoss_CE24D17F1268545E322CDF1A9CFA1C83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A411653EF8A8DF2B630ADF1A9CFAF1A6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_F47DA73E27BAEC0FA4FFDF1A9CFAF1FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_F47DA73E27BAEC0FA4FFDF1A9CFAF1FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_FBA94168A5DCE942618CDF1A9CFAE74C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_FBA94168A5DCE942618CDF1A9CFAE74C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A5E63BE669BDE8A1082BDF1A9CFAD956" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_ShareBasedCompensation_A5E63BE669BDE8A1082BDF1A9CFAD956" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_889F623B4CB7B317D191DF1A9CFA16DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_889F623B4CB7B317D191DF1A9CFA16DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_9BFD069FFBA7900F8992DF1A9CFA9B9A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_9BFD069FFBA7900F8992DF1A9CFA9B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_987054CE5E61C8B23626DF1A9CFA6C11" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_987054CE5E61C8B23626DF1A9CFA6C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_99263D32138E07A10E44DF1A9CFA2285" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_99263D32138E07A10E44DF1A9CFA2285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_CFA0FCABF6FD38C82A5ADF1FD2F07360" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_CFA0FCABF6FD38C82A5ADF1FD2F07360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_C2E65AE498928955F0D3DF1A9CFA6631" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_C2E65AE498928955F0D3DF1A9CFA6631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6E4D03B49597CB3CBB59DF1A9CFA3FB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6E4D03B49597CB3CBB59DF1A9CFA3FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_16863A50D935B9F436EADF1A9CFA7A3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_16863A50D935B9F436EADF1A9CFA7A3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_30595066846E9D8320CBDF1A9CFA5A06" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_30595066846E9D8320CBDF1A9CFA5A06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E45DBA90B6AD3520200CDF1A9CFA9EA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E45DBA90B6AD3520200CDF1A9CFA9EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_013F2968F14586FA69A0DF1A9CFAC9E6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27F7CD6166C83167C563DF1A9CFA47AF" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_013F2968F14586FA69A0DF1A9CFAC9E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_857BFE03D3509AAB24A4DF1A9CFA58B2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F291F707F56E43ED0946DF1A9CFAC06A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_857BFE03D3509AAB24A4DF1A9CFA58B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E23429DB5FEC8DA8159ADF1A9CFA21CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E23429DB5FEC8DA8159ADF1A9CFA21CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9042D23839696FC98E78DF1A9CFA88F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9042D23839696FC98E78DF1A9CFA88F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_252EA8F5E6DCFE52EA2EDF1A9CFA2158" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_252EA8F5E6DCFE52EA2EDF1A9CFA2158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_AA718AC43721E4CA4D58DF1A9CFACB5E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_AA718AC43721E4CA4D58DF1A9CFACB5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5E6EFC957E2A1F0DDFBDF24BDA88D4C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5E6EFC957E2A1F0DDFBDF24BDA88D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C77FB96C936AFE522EFEDF1A9CFA858D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C77FB96C936AFE522EFEDF1A9CFA858D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_D872EE1A6FB733979F41DF1A9CFA1688" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_D872EE1A6FB733979F41DF1A9CFA1688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_53611C9A09C91EBF6793DF1A9CFA36E3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_53611C9A09C91EBF6793DF1A9CFA36E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_C1846160F1906EC6CC09DF1A9CFAD48D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_C1846160F1906EC6CC09DF1A9CFAD48D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E8F65CA988AF2D7BFCADDF1A9CFA3895" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E8F65CA988AF2D7BFCADDF1A9CFA3895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBB2785FF4A4646E40B5DF1A9CFA16E9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EBB2785FF4A4646E40B5DF1A9CFA16E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7EA5EBC65826196F4B7CDF1A9CFAF49C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C5B1790E38A18AD6C1C9DF1A9CFA68ED" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7EA5EBC65826196F4B7CDF1A9CFAF49C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A984C807F11F103922F7DF1A9CFA747E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A984C807F11F103922F7DF1A9CFA747E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0CBBD88D3AAAF2849374DF1A9CFAA9B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0CBBD88D3AAAF2849374DF1A9CFAA9B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_22153B4F7AC578458BB0DF1A9CFAA13F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_22153B4F7AC578458BB0DF1A9CFAA13F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_0DD09BE1ACA84020BED7DF1A9CFAFCFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_0DD09BE1ACA84020BED7DF1A9CFAFCFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0B34567E527FB4A5EE43DF1A9CFABB5D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0B34567E527FB4A5EE43DF1A9CFABB5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80E3CF00EE49D058ADC2DF1A9CFA17CC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6CE169DCC10B529BB76DF1A9CFA49B1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80E3CF00EE49D058ADC2DF1A9CFA17CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BAB991D20197338C8B2ADF1A9CFA869C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BAB991D20197338C8B2ADF1A9CFA869C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_344F3A5C935793A1255DDF1A9CFA19AB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_344F3A5C935793A1255DDF1A9CFA19AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D413350CD77F8F1B5C92DF1A9CFA85D4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D413350CD77F8F1B5C92DF1A9CFA85D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_138350BEDB6C5DD145F4DF1A9CFA663E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AE227EAE1B407F821077DF1A9CFAFB84" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_138350BEDB6C5DD145F4DF1A9CFA663E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_DD90A985CB8B5A0E81383D5035A0D6B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2CDC6954342751269FDC504741EF19B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_DD90A985CB8B5A0E81383D5035A0D6B0" xlink:to="loc_us-gaap_NetIncomeLoss_2CDC6954342751269FDC504741EF19B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_DD90A985CB8B5A0E81383D5035A0D6B0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_43F7616A4C8D53DF921FDE893F9AB594" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_43F7616A4C8D53DF921FDE893F9AB594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_5DAEB8AF9FEB55479225E4D4FC8187C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_5DAEB8AF9FEB55479225E4D4FC8187C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_92E80D0104C655F0A2D39D8404169B50" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_92E80D0104C655F0A2D39D8404169B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15E99504BA63564C8B9580843D7AE2A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_15E99504BA63564C8B9580843D7AE2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1027752A98175D5EB7AEB244AA66276F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1027752A98175D5EB7AEB244AA66276F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5033A7FBED12509AA988CD824F17397D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5033A7FBED12509AA988CD824F17397D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6BF8598A16B951C8A837E7D038B222F3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6BF8598A16B951C8A837E7D038B222F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7EB530C4FA7055BB9EE3509440651AF4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7EB530C4FA7055BB9EE3509440651AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ECFCE7FD441857329908E5FF3512BC40" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0D9AFA6689E55EF4941E0B6E3C5F881B" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ECFCE7FD441857329908E5FF3512BC40" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5E1A54FA75195FCAFDF5827E4B31707E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_StatementTable_5E1A54FA75195FCAFDF5827E4B31707E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_61F10796F94E44412598827E4B31B192" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5E1A54FA75195FCAFDF5827E4B31707E" xlink:to="loc_srt_ProductOrServiceAxis_61F10796F94E44412598827E4B31B192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_61F10796F94E44412598827E4B31B192" xlink:to="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C7EBB795CDE14531CD15827E4B3112E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC" xlink:to="loc_us-gaap_ProductMember_C7EBB795CDE14531CD15827E4B3112E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_E6250EDACEE45F356654827E4B317848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_04ACDDB5797E06988ECC827E4B3131B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3FF3A03A22AC3EEA50EA827E4B3170FC" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_04ACDDB5797E06988ECC827E4B3131B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CFAE566DEDFB486127A8827E4B31CC3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5E1A54FA75195FCAFDF5827E4B31707E" xlink:to="loc_us-gaap_StatementLineItems_CFAE566DEDFB486127A8827E4B31CC3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_AE6B604B1D4A630419C0827E4B319013" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_Revenues_AE6B604B1D4A630419C0827E4B319013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_B9CB46E1BD9576DEF60B827E4B310B25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_B9CB46E1BD9576DEF60B827E4B310B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2F3F889198F85D90A72A827E4B31B291" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2F3F889198F85D90A72A827E4B31B291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_19BBAD0B25D030C3CFCC827E4B317658" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_19BBAD0B25D030C3CFCC827E4B317658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_E258440099E6E2314A98827E4B311DCD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_E258440099E6E2314A98827E4B311DCD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="loc_biib_Collaborationprofitlosssharing_A7FB575BF98F61F9C514827E4B31761B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0C658078007D32589C80827E4B31890F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_0C658078007D32589C80827E4B31890F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_66F6BA4BDD5087374D71827E4B3142F5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_66F6BA4BDD5087374D71827E4B3142F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_EEDC631B246DDFB556AA827E4B312AC0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="loc_us-gaap_RestructuringCharges_EEDC631B246DDFB556AA827E4B312AC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_C9037F952D66B569F0C2827E4B31CD57" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_C9037F952D66B569F0C2827E4B31CD57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_96214B99580CC363A3F5827E4B3101E7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FE9FA856135B07F783A9827E4B313523" xlink:to="loc_us-gaap_CostsAndExpenses_96214B99580CC363A3F5827E4B3101E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_92449DE80A37240D571F827E4B319715" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_OperatingIncomeLoss_92449DE80A37240D571F827E4B319715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B8A4200337466E8C1BB8827E4B310B4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_B8A4200337466E8C1BB8827E4B310B4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6C5E4DBF8F5DBC636E87827E4B31CBD0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6C5E4DBF8F5DBC636E87827E4B31CBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D6A514849ACBE70C5F33827E4B313F2B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_D6A514849ACBE70C5F33827E4B313F2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_E3412A1529A943A8F402827E4B31F879" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_E3412A1529A943A8F402827E4B31F879" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_CBE9127D84D98FC15A52827E4B31B6E9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_ProfitLoss_CBE9127D84D98FC15A52827E4B31B6E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9EC70D7E4734F0490281827E4B31179D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9EC70D7E4734F0490281827E4B31179D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EB0E339760D32D1FE284827E4B31B605" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_NetIncomeLoss_EB0E339760D32D1FE284827E4B31B605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_3830D114EBE7E9D91796827E4B318CA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848" xlink:to="loc_us-gaap_EarningsPerShareBasic_3830D114EBE7E9D91796827E4B318CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_E5302888479D4CE421A0827E4B3110F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_947B67FF9F36EE3AED8E827E4B31A848" xlink:to="loc_us-gaap_EarningsPerShareDiluted_E5302888479D4CE421A0827E4B3110F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75B6D61980A7DA942670827E4B222F13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_101C8DFAC852735C91E1827E4B315C7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_101C8DFAC852735C91E1827E4B315C7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C29CDC9402869C6EB0D8827E4B31FC50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7C086E01A3BF226E336E827E4B311FC9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C29CDC9402869C6EB0D8827E4B31FC50" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_63CF8FDC17595EBAA4A6A699B6B37AEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_DocumentType_63CF8FDC17595EBAA4A6A699B6B37AEB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_B52AE5F063345A818BF12F2E8750788B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_DocumentQuarterlyReport_B52AE5F063345A818BF12F2E8750788B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_AF5B4A286FF158EDBE3D51B456CD40D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_DocumentPeriodEndDate_AF5B4A286FF158EDBE3D51B456CD40D7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_D98C0D9F37D15056ADE31276C1638F1A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_DocumentTransitionReport_D98C0D9F37D15056ADE31276C1638F1A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_4AF9E3866F505E35AF505826BA5FEE3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityFileNumber_4AF9E3866F505E35AF505826BA5FEE3E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_6E201EA531B959CAB59C76DE5B8753AB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityRegistrantName_6E201EA531B959CAB59C76DE5B8753AB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_18C9F4C4ABC45FAA8E3DD943FC450745" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityCentralIndexKey_18C9F4C4ABC45FAA8E3DD943FC450745" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_27A57C7DD6C6527CBE31989AC1D12DF3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_CurrentFiscalYearEndDate_27A57C7DD6C6527CBE31989AC1D12DF3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_218FCCAB3026505EB186BB76E6511603" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_DocumentFiscalYearFocus_218FCCAB3026505EB186BB76E6511603" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_F685ED53506C564FA994F12DECA6C0ED" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_DocumentFiscalPeriodFocus_F685ED53506C564FA994F12DECA6C0ED" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2509392003F257868B317D860EBD8F42" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_AmendmentFlag_2509392003F257868B317D860EBD8F42" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_BFD63390EFC15F49BB068449D234AB8E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityIncorporationStateCountryCode_BFD63390EFC15F49BB068449D234AB8E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_D4A46CAA7F2B58D2B8F48D7F3B3DD8E9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityTaxIdentificationNumber_D4A46CAA7F2B58D2B8F48D7F3B3DD8E9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_334146B2DF6559F487DBC29A7445F196" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityAddressAddressLine1_334146B2DF6559F487DBC29A7445F196" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_B463BC17DF2957D0B7F093E33721F2FE" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityAddressCityOrTown_B463BC17DF2957D0B7F093E33721F2FE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_5008D404006859EBB3A38209E6AF1F27" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityAddressStateOrProvince_5008D404006859EBB3A38209E6AF1F27" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_F28A20F89E3E551786D578153E054887" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityAddressPostalZipCode_F28A20F89E3E551786D578153E054887" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_A4B4560CB6A75BFD832E16541F15AE80" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_CityAreaCode_A4B4560CB6A75BFD832E16541F15AE80" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_BA0F695199DC5928B37B425AEC24C63D" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_LocalPhoneNumber_BA0F695199DC5928B37B425AEC24C63D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_5FECCB64E835516BAFB2598DBA21B96F" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_Security12bTitle_5FECCB64E835516BAFB2598DBA21B96F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_5B91E085B07F5FDEA8D8CEBE83A0DD17" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_TradingSymbol_5B91E085B07F5FDEA8D8CEBE83A0DD17" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_F86EB16DCA5757CBA4809081DBCFB988" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_SecurityExchangeName_F86EB16DCA5757CBA4809081DBCFB988" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_050016FCC6AC582097C664E64B69BDFC" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityCurrentReportingStatus_050016FCC6AC582097C664E64B69BDFC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_2F576D14965C5C11BF2F7538F887F648" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityInteractiveDataCurrent_2F576D14965C5C11BF2F7538F887F648" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_BB35B1AB97AF5B7C9DF73D55094A522A" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityFilerCategory_BB35B1AB97AF5B7C9DF73D55094A522A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_6B2C9FABC29E5AE69A69C858A601AB8A" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntitySmallBusiness_6B2C9FABC29E5AE69A69C858A601AB8A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_D3B52A5A7EDA51699C1F237686836FF9" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityEmergingGrowthCompany_D3B52A5A7EDA51699C1F237686836FF9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_D6892ECC161D557FA983662D1CF0DB35" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityShellCompany_D6892ECC161D557FA983662D1CF0DB35" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3BA90F072A8A5DFDBACED074AFA03D85" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_BE7C0D00B2025D54AB02ED9CB05A126B" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3BA90F072A8A5DFDBACED074AFA03D85" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_BD20A9B2B5E5569795154B0AC86E5C6A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5579194CB4C0551CBD6ED69B25937B22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_BD20A9B2B5E5569795154B0AC86E5C6A" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5579194CB4C0551CBD6ED69B25937B22" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_55DE2F68389C39586A1CDF1A99886942" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_55DE2F68389C39586A1CDF1A99886942" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_C0421AD21795CF68CB89DF1A998863B0" xlink:to="loc_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_01925E2A4AE9DD624952DF1A9988EDFD" xlink:to="loc_biib_ShorttermderivativeMember_A2ADBE439DD507949204DF1A998813BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_539A2DC2FF7F4BEA7CBEDF1A99887B58" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_B487836C2D5F77AB8DBEDF1A9988E040" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_E63631E078BC264E6463DF1A9988FF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1E22AEA122F0E53E937EDF1A9988876C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B501D5F6B581759A43DADF1A9988DD50" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5A31AC511CF4D9BE151EDF1A998832C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_D7852FD0E924904C32D1DF1A99880B12" xlink:to="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="loc_currency_EUR_0FE4298F1B759EAB14F2DF1A998C219F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="loc_currency_GBP_1A0D003C286BA80BBB69DF1A9990CD15" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="loc_currency_CHF_E6976D5FD7774BEC527DDF1A9990FF89" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="loc_currency_JPY_0B4623FD6DF83F4378A2DF1A999064A0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_04C1B0192880F801D90DDF1A99901E69" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_DA8B4AA55DD99FC0848CDF1A998C96D9" xlink:to="loc_currency_CAD_04C1B0192880F801D90DDF1A99901E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_BA5399F16708617E5321DF1A999089F5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:to="loc_us-gaap_SalesMember_FA11BDC8BDB9AA201968DF1A999070A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:to="loc_us-gaap_OperatingExpenseMember_22802A4F10B4B23B5E15DF1A9990C4FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74EE1468DC90E9627AA1DF1A99909293" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_435C89211AB31088DBA4DF1A9990799B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_808E14D09ECF0F1E6D85DF1A99904A4A" xlink:to="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:to="loc_biib_CashflowsrevenueMember_C37435A192888883C539DF1A9994773F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:to="loc_biib_CashflowsoperatingexpensesMember_EA2C7F4680FDF4F76177DF1A99942ECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_99758FA276495AF8644FDF1A99906998" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_75222C3F21EEE5689610DF1A99945763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4EE53A4F3D41D0FB2DE3DF1A9994113F" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:to="loc_us-gaap_ForeignExchangeContractMember_C1C0C2C5F44DDB4801D4DF1A9994BF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9C994F4A34D819945D27DF1A9994E86A" xlink:to="loc_us-gaap_InterestRateSwapMember_EF3989802E91DD7C7B7EDF1A99946876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E9616B9CCE810049A1CEDF1A9994920B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_05D91ED6977672632595DF1A9994CDE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_6A71E9F20E28F7B85040DF1A99945F82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_DE9B89DD95C8D344E981DF1A9994A79D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39AC55948E681C26D093DF1A999489A3" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0B6935D2869D9E0E67CFDF1A9994454D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_072E344A0EBFA69C600FDF1A99946EA1" xlink:to="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_111279F2D3522FE2E187DF1A9994C7D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_B317572950DF8DE14302DF1A9994FD0C" xlink:to="loc_us-gaap_NondesignatedMember_43DC0E6D53A2B218A999DF1A9999C898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_974D8317B8841C70B2D1DF1A999957AC" xlink:to="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:to="loc_srt_MinimumMember_9844CF0606A2B52D4239DF1A999D1A71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9F46ED15FE55F908B533DF1A999D9EEB" xlink:to="loc_srt_MaximumMember_BA513B3AED325088E8F1DF1A999D96B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_84A12B3086073787480FDF1A9988AE0D" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_F8D00FF8A4E55AED4921DF1A999D013D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_844941934C4CCB8362B0DF1A999D0C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_F1FB097DDC6503145CAEDF1A999D984C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_A9EF46BB12A343F4B6CBDF1A999D49FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_E8C32586D302BE3B1D09DF1A999DF6F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeNotionalAmount_35CB0FEB1FFA962F712DDFC67E7D6CB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_A43B5029A8A54F2B40F3DF1A999D974E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_23997C06625B141EE001DF1A999DA1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B415E40A4C40D8594F03DF1A999D055F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeTermOfContract_7B23FDE5977CA0BEE04EDF1A999DFF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_D8B9828D980FE61CEE11DF1A999DEBE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_2C03F0589E0B661FABB7DF1A999D1CCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_CBE653BA119A902A7744DF1A999DB583" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_5969B51980F47245567ADF1A999D74C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D5E5A621938DCC4988F5DF1A999DDA5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A4163BD162BD68A3DFC8DF1A999D5A49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_B54EE69DB24BD80089C1DF1A999D91C2" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A4F1045FF3AEF623D0B2DF1A99A17DCD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_952FEA6D8C4A55F3974905C79C2BF9A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9045D08ECFD6578799B1DC607C11AA1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_952FEA6D8C4A55F3974905C79C2BF9A3" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9045D08ECFD6578799B1DC607C11AA1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_4982A10AB8BA5594B7C6A5E4F667B8EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_952FEA6D8C4A55F3974905C79C2BF9A3" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_4982A10AB8BA5594B7C6A5E4F667B8EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_839C3F60233750158DAD25D0ED478EFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_952FEA6D8C4A55F3974905C79C2BF9A3" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_839C3F60233750158DAD25D0ED478EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_501228286090569FA1B72BC5D809EC40" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_952FEA6D8C4A55F3974905C79C2BF9A3" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_501228286090569FA1B72BC5D809EC40" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_7FA72CB87037B2A0CB3182ADAA34FF68" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_7FA72CB87037B2A0CB3182ADAA34FF68" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_60C6C2619BAA58905FDF82ADAA35D0B4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_E8483659C25181B0BC9582ADAA35EF6B" xlink:to="loc_biib_WorkinprocessMember_B86F5ECE5EA5C9BDDBD382ADAA359A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5A62586F388E94CF432882ADAA364565" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D766733EA0892F034D4882ADAA36BE27" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_2BB5D7431BE53381698482ADAA369EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6202BE2CCC5320500B8782ADAA34EBFC" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1DF4F84D4D415BD4D082ADAA37851E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F4F3FAE07E6E226F84BD82ADAA363C33" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_96ABAA21DE5FB5D7E1EE82ADC25D465E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_8235BF208DD2292180EF82865B26C565" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5E1A3173B126E79077B982865B260FED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_8235BF208DD2292180EF82865B26C565" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5E1A3173B126E79077B982865B260FED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D059FABDBE96266B161482865B275F32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5E1A3173B126E79077B982865B260FED" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D059FABDBE96266B161482865B275F32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B48558E4BA9D3557167E82865B272312" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D059FABDBE96266B161482865B275F32" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B48558E4BA9D3557167E82865B272312" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_CD1D621760D8D6C527B582865B276C40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B48558E4BA9D3557167E82865B272312" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_CD1D621760D8D6C527B582865B276C40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5E1A3173B126E79077B982865B260FED" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_F0D11D45A91BBA15F1BA82865B280673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_D0859929A14011DAE7B082865B28469E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_3AF2EFE29B406EB5D66F82865B28A3D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_61FD64935BDEF7D0FAC082865B28C19B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_61FD64935BDEF7D0FAC082865B28C19B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_C9098115291ED06D3C8F82865B289FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9311596B8A4338724A0A82865B291F09" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9311596B8A4338724A0A82865B291F09" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_ED0B4A9C69B1F92E49078288CB056AB3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7DC2F59CBEA0B534DAE282865B28ED3E" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_ED0B4A9C69B1F92E49078288CB056AB3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_88ED9FDB0382574B85D59D231C57D296" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_44F663C75D6A557FBE65F9A4ED35715C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_88ED9FDB0382574B85D59D231C57D296" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_44F663C75D6A557FBE65F9A4ED35715C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_46F6E2667B0B5E0F8DD1185667D7CE05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_E1514AD6E76E54B0974FABB3978E01D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46F6E2667B0B5E0F8DD1185667D7CE05" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_E1514AD6E76E54B0974FABB3978E01D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_07E01F4713BC5BC78ECFDF8D7FB6F4A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_07E01F4713BC5BC78ECFDF8D7FB6F4A3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8536A8B03A8B58D1BB7598E7A6FAC4CC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_5AD726ECBD845922BED48335B99730D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_5AD726ECBD845922BED48335B99730D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_A85E8DBB079454ADA1C412BF57A01F45" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_A85E8DBB079454ADA1C412BF57A01F45" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_852AAF8DEFBD52DF94EE593C1F0030CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:to="loc_biib_MarketStockUnitsMember_852AAF8DEFBD52DF94EE593C1F0030CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_3C8A315391A85B4AB96B681A12F4640D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52A8B3B1FFB45730B501DC53D29D218E" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_3C8A315391A85B4AB96B681A12F4640D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_160147F04A325709B552672CBD2BD066" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3360FB2F765E59E6B8B7D6C05F85CDAB" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:to="loc_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_36E9B003257D56DDB7A9F6B659135BE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_3605209020615B5E956DE1B7F9D340D7" xlink:to="loc_us-gaap_NetIncomeLoss_36E9B003257D56DDB7A9F6B659135BE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6EE397471960562FA234FCB535C3B880" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_8BC55D28F25052FD976591513A52795D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6EE397471960562FA234FCB535C3B880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69575BF5B4985E3382883FAC9399AB3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6EE397471960562FA234FCB535C3B880" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69575BF5B4985E3382883FAC9399AB3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6EE397471960562FA234FCB535C3B880" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FA17303862F5F65A2EFCD90C77D3AC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FA17303862F5F65A2EFCD90C77D3AC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6D8D1AC57C50581283967ADB9A5116F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_1D6DB371A7005E318AB89DBEE0E210F7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6D8D1AC57C50581283967ADB9A5116F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF8B7A06A3F65D9588EE607AFED0EA4E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6EE397471960562FA234FCB535C3B880" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF8B7A06A3F65D9588EE607AFED0EA4E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E9AB6AC0552556E9970511EBABACE782" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A0894DA2185D56FEA2B917B4184D8570" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E9AB6AC0552556E9970511EBABACE782" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A0894DA2185D56FEA2B917B4184D8570" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_06094140C7295E048F446D051FBCACE3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_698E3B301A0E57EBAB3FA9146A039E14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_06094140C7295E048F446D051FBCACE3" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_698E3B301A0E57EBAB3FA9146A039E14" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CCFE88FF3D3651029D7B99C63EAE1D8C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_CD29C88BDB895531890983C945984EBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CCFE88FF3D3651029D7B99C63EAE1D8C" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_CD29C88BDB895531890983C945984EBD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_F833E5BA82F75C619D13D4BB7B9D5837" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F833E5BA82F75C619D13D4BB7B9D5837" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8FE115A350985CA79A295725C4A0BDA3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D890BF111B17557398E36F013A2E25B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_D890BF111B17557398E36F013A2E25B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_FA6DCABFDC395DA2A23926BA570E310C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_FA6DCABFDC395DA2A23926BA570E310C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_BDB8801E011F51D192294020286EA1DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C5C9EF13A4FF5728AA66C9FCC591D0EA" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_BDB8801E011F51D192294020286EA1DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_828BACFBE631515DA039FFEE7DBB453E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_828BACFBE631515DA039FFEE7DBB453E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_96F7DCA9C90E52979EC17FC4CD55192F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_828BACFBE631515DA039FFEE7DBB453E" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_96F7DCA9C90E52979EC17FC4CD55192F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_A3A35709FB4853178B8B8A1AE05EB2B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_96F7DCA9C90E52979EC17FC4CD55192F" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_A3A35709FB4853178B8B8A1AE05EB2B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_F65C8863FC4A554DA33B32526B04EEAD" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_DF8E77075DB45027A08B5A14DBA12490" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_DF8E77075DB45027A08B5A14DBA12490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8F92CA17D906548D918A63FF91D7F031" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8F92CA17D906548D918A63FF91D7F031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_391169FADE1C50E4A7947F4728316565" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32FF6AE7F4CA56A7BF0E6200F737103F" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_391169FADE1C50E4A7947F4728316565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DCBF586D32E15FD4B06A533B8043CE32" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C65F4AAF7ADC564A9C2BFA6330EC0782" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E59E4622CB96553EB652C4218E3F0665" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E59E4622CB96553EB652C4218E3F0665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE78D0BC1FCF5522AB7C4853C11527A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE78D0BC1FCF5522AB7C4853C11527A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6579E70E0744534DACC9A272755E2243" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6579E70E0744534DACC9A272755E2243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EE5492F63A065861AF0C4288105FE7D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EE5492F63A065861AF0C4288105FE7D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89A50B63D0365E268AC83C65C498A109" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89A50B63D0365E268AC83C65C498A109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3068933C8F1B5A08911F36B34D6A4190" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9AD50900193B561FA73993300C9C1C28" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3068933C8F1B5A08911F36B34D6A4190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_C1F9C37095545F6FBEFF724E964D81F2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C797279B7C4153B98958FFDE1B27623E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_C797279B7C4153B98958FFDE1B27623E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FEEF2898E715B659DBB0074CE0E44FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7FEEF2898E715B659DBB0074CE0E44FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_F8074931DF21553CBC162B54410E5283" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_61AD5298420452189F1F7FB9B0D576F6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_F8074931DF21553CBC162B54410E5283" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_895871D2BA845B9AB5C77FE2C0B5BAF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_895871D2BA845B9AB5C77FE2C0B5BAF2" xlink:to="loc_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F1F8C8C66C315B729A92B4B70D3A61C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:to="loc_us-gaap_DebtInstrumentAxis_F1F8C8C66C315B729A92B4B70D3A61C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F1F8C8C66C315B729A92B4B70D3A61C3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FB8D6AC745D45F76955AE76A418475A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FB8D6AC745D45F76955AE76A418475A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6A3B83BDEB0C5D74821E6A5B94BF07CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6A3B83BDEB0C5D74821E6A5B94BF07CA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_16DD21E268BC56F3821B8AE800EF3503" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_16DD21E268BC56F3821B8AE800EF3503" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1F83379E76335E1B99AA554A6980B9D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74E12A8F25A058AFAEB76C5F064D95BF" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1F83379E76335E1B99AA554A6980B9D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5E4548CDB9FC5C79AF863839CFD51A04" xlink:to="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_B2B8F2B0F5115E0EA94ABCAEBEDD9DAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_B2B8F2B0F5115E0EA94ABCAEBEDD9DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_7D8F54B6D42D5452A6514307350AEE6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:to="loc_us-gaap_NotesPayable_7D8F54B6D42D5452A6514307350AEE6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_C7091C12AEAA5254B6C18D4FF6A418F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D2FA21C8ADFF5033A05982A8577C27ED" xlink:to="loc_us-gaap_DebtInstrumentFairValue_C7091C12AEAA5254B6C18D4FF6A418F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_430F9A9B32B8A6A51123DF1A9A71D92D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_430F9A9B32B8A6A51123DF1A9A71D92D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_BA2FEF6C1F9541817370DF1A9A71BF64" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF2C802C2EF72A132B66DF1A9A71C3D9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_BB9BE4E4347B3E5BCF73DF1A9A71F9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_898734896DD4F95F02BEDF1A9A718CBC" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_605475C267B9024EA522DF1A9A817769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9390CE76AA624E310E2DF1A9A82E075" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9390CE76AA624E310E2DF1A9A82E075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9426B3F3174F96B9021ADF1A9A823FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9D03ABF8224E9AB342B8DF1A9A825304" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_351476D23B6C355F1328DF1A9A8177AC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9D03ABF8224E9AB342B8DF1A9A825304" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_99166A6FA1656FB582FCDF1A9A60CA25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_098C05418BF76CECCB18DF1A9A6011D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99166A6FA1656FB582FCDF1A9A60CA25" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_098C05418BF76CECCB18DF1A9A6011D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_098C05418BF76CECCB18DF1A9A6011D5" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_D4B4A20E9213DB2256A9DF3967D71663" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BG00011Member" xlink:label="loc_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_7D3C6C5E22E08B8AEDFDDF3967E72AA0" xlink:to="loc_biib_BG00011Member_71B875DDEBC7A356E68BDF39685D7048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B6CE01DB2EFB7641C7E7DF1A9A608443" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_098C05418BF76CECCB18DF1A9A6011D5" xlink:to="loc_us-gaap_DebtInstrumentAxis_B6CE01DB2EFB7641C7E7DF1A9A608443" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B6CE01DB2EFB7641C7E7DF1A9A608443" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_34257117F5D0C9CE3F79DF1A9A602D3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_34257117F5D0C9CE3F79DF1A9A602D3D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D39C3E76600D69C392E0DF1A9A602B22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D39C3E76600D69C392E0DF1A9A602B22" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_90C0E1DFF2A80488498BDF1A9A609620" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_90C0E1DFF2A80488498BDF1A9A609620" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_C50031BE5DB013AE2E94DF1A9A60B92E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2671790BEE00BBFCDC40DF1A9A606A59" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_C50031BE5DB013AE2E94DF1A9A60B92E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:type="locator" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_098C05418BF76CECCB18DF1A9A6011D5" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_AssetImpairmentCharges_30BFC918BC7BE65B725DDF1A9A60D630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" xlink:label="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_E7023CE0004108D9073CDF1A9A60FA49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1755771D1E9912656797DF1A9A60AC71" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1755771D1E9912656797DF1A9A60AC71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3608380C88FF057C8CDF1A9A606C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DF11438448B39AD586CDDF3966975EDF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DF11438448B39AD586CDDF3966975EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15108D2C2047BF361CAADF1A9A60F10F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FD07AD80507219B2BF1BDF1A9A60D071" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15108D2C2047BF361CAADF1A9A60F10F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0D67681CBE96502881B6821595431ACD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_232F9A4014FA5387BCCA48F01EB0068D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0D67681CBE96502881B6821595431ACD" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_232F9A4014FA5387BCCA48F01EB0068D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8BF7706211575B21A52C2990DF88B0AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0D67681CBE96502881B6821595431ACD" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8BF7706211575B21A52C2990DF88B0AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C04BA8B504A65E3F87421CC7907722D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0D67681CBE96502881B6821595431ACD" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C04BA8B504A65E3F87421CC7907722D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FE68165A174554F18635D2E37F03D8A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_A60BE7B1967A5DFF9701E6396E18AD58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FE68165A174554F18635D2E37F03D8A5" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_A60BE7B1967A5DFF9701E6396E18AD58" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_790F708B24A952A58CE1E624599FFE7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_790F708B24A952A58CE1E624599FFE7C" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:to="loc_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1F17E30FAA645FBF8D388D46A6CF9F22" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_F26B1FB4C5AB52C9A742C7619776FEEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:to="loc_us-gaap_CommercialPaperMember_F26B1FB4C5AB52C9A742C7619776FEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_85C303F06FA157C496DDCDADE895A8F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_85C303F06FA157C496DDCDADE895A8F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2905EAC9B5675514B800CE0ACEFCC00C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2905EAC9B5675514B800CE0ACEFCC00C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_223E0213AB7B59DA9A28B49C51FFEF0B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_40E2531F07CB5331BAB9209428DEC7A0" xlink:to="loc_us-gaap_DebtSecuritiesMember_223E0213AB7B59DA9A28B49C51FFEF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9C2627227C8D58C487525B25DE986A79" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_50E2A69852F7505A8C460EA1F4948CD6" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_122DB266C11D586282D6D63FD1C8CF9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2C5E65C87BA65914B7CEE03F994AEB27" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_122DB266C11D586282D6D63FD1C8CF9B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2F421FB37D685D4C8E23B637375ED169" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2F421FB37D685D4C8E23B637375ED169" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DDF2E6029C8D5597919B643C0CB186F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DDF2E6029C8D5597919B643C0CB186F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_02547506A104560286ABF5F45AC14AA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DDF2E6029C8D5597919B643C0CB186F0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_02547506A104560286ABF5F45AC14AA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_05507BF3498D58458C6086AD989BB116" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_02547506A104560286ABF5F45AC14AA1" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_05507BF3498D58458C6086AD989BB116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1BDE7789085E530F97A84F63B85C3FE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_02547506A104560286ABF5F45AC14AA1" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1BDE7789085E530F97A84F63B85C3FE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E10D656D0F145AC4881FFE4E13E84961" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E10D656D0F145AC4881FFE4E13E84961" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E10D656D0F145AC4881FFE4E13E84961" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_C7FE1DFA5A875380BB73EBDEC1334F84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_C7FE1DFA5A875380BB73EBDEC1334F84" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_51FF0D8FC5FC538E9FEED2424B3D96D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_51FF0D8FC5FC538E9FEED2424B3D96D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_CDEEA905AC42574FB9ED1AA3784C10D1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_CDEEA905AC42574FB9ED1AA3784C10D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_463588DF84DD5B10B1524F86D5D53A6D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_463588DF84DD5B10B1524F86D5D53A6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E7A1865F4AA75E8CBFA5460E2C3414CE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E7A1865F4AA75E8CBFA5460E2C3414CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_814AE542D8EC5040B90F8D2D5D88FC12" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_814AE542D8EC5040B90F8D2D5D88FC12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_D121B6B96CA05D39B66E00AAE9736A51" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C97CCC4B7E3B5F4BADB87BCC2D946B6C" xlink:to="loc_us-gaap_EquitySecuritiesMember_D121B6B96CA05D39B66E00AAE9736A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_A90F46110FFC5388A0543B414AE5EF4B" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3A3756B97BA15A9089E406762193358B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3A3756B97BA15A9089E406762193358B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01E8E3663C915125A4AA07BB3B6E3953" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01E8E3663C915125A4AA07BB3B6E3953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7EB304079B09565C963914E9BB5F506C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7EB304079B09565C963914E9BB5F506C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A574E6694E7B5399B4B4717A3B1D7327" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A574E6694E7B5399B4B4717A3B1D7327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_A8AED37EE7905C88AD2041CFA7F0BEA3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_A8AED37EE7905C88AD2041CFA7F0BEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E6C9FC6B46745926B96EECB764C7C840" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E6C9FC6B46745926B96EECB764C7C840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AE9E454631195BC19C85A4FF55EE5E7C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_AE9E454631195BC19C85A4FF55EE5E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_FC7BDF9A08E053BF9E9CDE593CEA9486" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0EBFA2C6E312542CB27D3B8B8FCA038C" xlink:to="loc_us-gaap_AvailableForSaleSecurities_FC7BDF9A08E053BF9E9CDE593CEA9486" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2BE65AE0CCDC50EEABEC10D3101940D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2BE65AE0CCDC50EEABEC10D3101940D4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_73B7657657685549B8E940ABD095A9CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_73B7657657685549B8E940ABD095A9CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FE8389BE43825B62A483262E4BAF8383" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FE8389BE43825B62A483262E4BAF8383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_910E5E136E0C576BA6D60E1721E0DC6D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_910E5E136E0C576BA6D60E1721E0DC6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_33588A082EE457EC89C60A622708E7EE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_33588A082EE457EC89C60A622708E7EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4E8F00D8D1FC56D786A883878CA09092" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4E8F00D8D1FC56D786A883878CA09092" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_ACD843703156547CAEDDC8913CF2108A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_ACD843703156547CAEDDC8913CF2108A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_31E9E7BBC6D65B29BBB5E13851D215D7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_31E9E7BBC6D65B29BBB5E13851D215D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_78809A97D8F157F7AF399E340E1D99E9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_061588F21CF1558F9EF9E3CA6C54A0FA" xlink:to="loc_us-gaap_AvailableForSaleSecurities_78809A97D8F157F7AF399E340E1D99E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3463B5B592A65276A1DADC79010549AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7EA5642EE9435EF3BFF4425AFFCCE59F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3463B5B592A65276A1DADC79010549AC" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7EA5642EE9435EF3BFF4425AFFCCE59F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_008CA42BF9995995BAA282E2B0CD6065" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3463B5B592A65276A1DADC79010549AC" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_008CA42BF9995995BAA282E2B0CD6065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_01220D3096655810B2557723AD36904A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3463B5B592A65276A1DADC79010549AC" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_01220D3096655810B2557723AD36904A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_63F3D129D4D856B9B663A97EC72B3918" xlink:type="locator" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_55D1AF38F5E858A6A22D4ADF4EAA06B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_63F3D129D4D856B9B663A97EC72B3918" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_55D1AF38F5E858A6A22D4ADF4EAA06B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A78DE17E8C425D2B823518410622E6FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_A78DE17E8C425D2B823518410622E6FE" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_729266F37B54592AA3804F3425DB4208" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_729266F37B54592AA3804F3425DB4208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4B0B94DA87FD597BB568C65B45DC991F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_729266F37B54592AA3804F3425DB4208" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4B0B94DA87FD597BB568C65B45DC991F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_7E391DFFFAB05CF0A0A2D737888DB4A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B0B94DA87FD597BB568C65B45DC991F" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_7E391DFFFAB05CF0A0A2D737888DB4A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_A51C15C05CDE5EA4A20F536BBA733145" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B0B94DA87FD597BB568C65B45DC991F" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_A51C15C05CDE5EA4A20F536BBA733145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7D50E6402265520CAC5B9C2FE494EF26" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_7AE5176172ED5840B8936B038421D3E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8054C70F3FF85BE6BF4704F63AC3DD2B" xlink:to="loc_biib_IonisPharmaceuticalsMember_7AE5176172ED5840B8936B038421D3E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:to="loc_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_600CF899CE81518FA4D46748CCDF0C6A" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_08D1268846AF5D2194AF0B440B4DCC6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_BDF79CA4616C59798C85CA90BE484C05" xlink:to="loc_biib_StrategicInvestmentsMember_08D1268846AF5D2194AF0B440B4DCC6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_534612134ABB5F5AB2309A0D6FE74AEB" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_5B404AE4ADCF5DA6BC491B3362A1E81B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:to="loc_biib_StrategicInvestmentPortfolio_5B404AE4ADCF5DA6BC491B3362A1E81B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E17FB95B5D815C58A2771B3EA6B993A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A202514DC03D51E1BBFD9F9A35F60DD0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_E17FB95B5D815C58A2771B3EA6B993A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D3CEAA3B39253B7B04825114432BC0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42A8C2F6025A5167A762C14E1D5EB48E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D3CEAA3B39253B7B04825114432BC0C" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42A8C2F6025A5167A762C14E1D5EB48E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_E0C2C2FB48935F6CBF5475A77FEC35F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D3CEAA3B39253B7B04825114432BC0C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_E0C2C2FB48935F6CBF5475A77FEC35F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_701674729F025A6FBA8360AF9A15EA5F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D3CEAA3B39253B7B04825114432BC0C" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_701674729F025A6FBA8360AF9A15EA5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_32CCB05B253D5EA3BE3148C99FE50082" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D3CEAA3B39253B7B04825114432BC0C" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_32CCB05B253D5EA3BE3148C99FE50082" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CCAE1DA16FF159919911933B8D908085" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_16BBA7AAE755516789F903DA720F3607" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CCAE1DA16FF159919911933B8D908085" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_16BBA7AAE755516789F903DA720F3607" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9813D0F59F884BA42C44DF1A985E6C4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9813D0F59F884BA42C44DF1A985E6C4D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C211C27E3324DBDAF05DDF1A985E100A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C211C27E3324DBDAF05DDF1A985E100A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ED8AE33A6073098FAC92DF1A985E7D22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ED8AE33A6073098FAC92DF1A985E7D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3747B649B889D4BA1CDFDF1A985EC529" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3747B649B889D4BA1CDFDF1A985EC529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_258BA25EAF9DF77E21A8DF1A985EFAE4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_258BA25EAF9DF77E21A8DF1A985EFAE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_54E1BCC7C43BC4CD80C1DF1A985E9CF5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_54E1BCC7C43BC4CD80C1DF1A985E9CF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_3EEAF6A7958872595143DF1A985E4CB5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_3EEAF6A7958872595143DF1A985E4CB5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_6CB93735740F957CF672DF1A985EA7E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_CD365EC50C3E591E107FDF1A985E062F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7E0B6783D8E474A0592BDF73F6D42BEC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7E0B6783D8E474A0592BDF73F6D42BEC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_826A95BC3E54C0A12353DF9E8B6C42DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6FB54716CEA3C7809C8DF1A985E7DD0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6FB54716CEA3C7809C8DF1A985E7DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_566B7F2DB51883E6F1E9DF1A985E4646" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_566B7F2DB51883E6F1E9DF1A985E4646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2E2B24A418DCD0CF61D3DF1A986286B2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_26FDD9D5EA5D3D968A31DF1A985EA08C" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2E2B24A418DCD0CF61D3DF1A986286B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_80746FC57205159CC75BDF1A98530995" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80746FC57205159CC75BDF1A98530995" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DeferredTaxAssetLiabilityTypeAxis" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_BEB0FA3AEE3618D6135CDF1A9853FC09" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_F378C176CE511B9F7255DF1A9853405B" xlink:to="loc_us-gaap_IntellectualPropertyMember_425B10E049032C5A9C14DF1A9853BE13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1340747FFEC608872F46DF1A9853E7CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1340747FFEC608872F46DF1A9853E7CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_026B8AE814ABDB10E9C3DF1A9853DF7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1340747FFEC608872F46DF1A9853E7CA" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_026B8AE814ABDB10E9C3DF1A9853DF7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_E5C5C39A4602F978FF0BDF1A98535C81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_026B8AE814ABDB10E9C3DF1A9853DF7C" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_E5C5C39A4602F978FF0BDF1A98535C81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6EA388800CAF5947CB47DF1A98536886" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:to="loc_us-gaap_ForeignCountryMember_7F1E6872B9DCDDC3D588DF1A9857553E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9A60F7AF022D981ED927DF1A985384C7" xlink:to="loc_us-gaap_DomesticCountryMember_B46D4583B7D9FDB7EFA2DF46627ACB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8D27B110FB639B76D1B3DF1A98533914" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97E9BA74F18377A1149EDF45528698B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6A7D4360B7088E6378E2DF1A9857D2BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_C857C977640C685A699DDF1A98574814" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_73695AB0899906BD85E3DF1A98576628" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3413F5D1104B9C52DEFBDF1A9857BCE8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_AA3B655E990C56D4B66C41EB8BB500AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D1C5D05F53BC5C4089118C7BE014E2F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AA3B655E990C56D4B66C41EB8BB500AE" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D1C5D05F53BC5C4089118C7BE014E2F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C2E58BC2F9075123B51BFDF058C365CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E00FC47E60DE52E0865F2163FFC4E2E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C2E58BC2F9075123B51BFDF058C365CF" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E00FC47E60DE52E0865F2163FFC4E2E5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F6ECCFEBF4737503B6C4DF1A9B216CC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F6ECCFEBF4737503B6C4DF1A9B216CC1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_59184D75928501D1FA24DF1A9B2108B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_59184D75928501D1FA24DF1A9B2108B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_59184D75928501D1FA24DF1A9B2108B9" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BG00011Member" xlink:label="loc_biib_BG00011Member_AEF98AFC7AF410B43222DF1A9B25107D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75" xlink:to="loc_biib_BG00011Member_AEF98AFC7AF410B43222DF1A9B25107D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PLSRMember" xlink:label="loc_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75" xlink:to="loc_biib_PLSRMember_8AED134B685E757E170BDF1A9B25A16E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6FFF945E530F0C63B438DF1A9B217E75" xlink:to="loc_biib_TGNMember_FFB916CFB6DC3A41A861DF1A9B253EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1CA15B3C76E4B13D2FB6DF1A9B259319" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1CA15B3C76E4B13D2FB6DF1A9B259319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A70EC0D5878163213D27DF1A9B25C347" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1CA15B3C76E4B13D2FB6DF1A9B259319" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A70EC0D5878163213D27DF1A9B25C347" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_E7D80F561C60145FDC8FDF1A9B251A88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A70EC0D5878163213D27DF1A9B25C347" xlink:to="loc_biib_NightstarMember_E7D80F561C60145FDC8FDF1A9B251A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DC56EDC46C5301721D71DF1A9B25B84A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_F1650D6C6D8CB6A25C48DF1A9B25C1AE" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_F7483400048230EBBCA0DF1A9B25F44F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F02E8F706AB177A0C91EDF1A9B2539C1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_BBA5E8D350DBCA934FFEDF1A9B257269" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:to="loc_biib_OutLicensedPatentsMember_71EAFE34191442EB4C7FDF1A9B25AD71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_B7D4C171B791785E2835DF1A9B2565EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65F12C1B01B58BDA7D16DF1A9B2599C3" xlink:to="loc_biib_InLicensedPatentsMember_82264109879D2876FDA8DF1A9B25EB76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8EE78429860872DEFCFBDF1A9B259F32" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_srt_ProductOrServiceAxis_8EE78429860872DEFCFBDF1A9B259F32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8EE78429860872DEFCFBDF1A9B259F32" xlink:to="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A" xlink:to="loc_biib_AVONEXMember_7B8C58508648AE9C33DDDF1A9B29D021" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A" xlink:to="loc_biib_TysabriProductMember_F4B28795A1BE8D5EA999DF1A9B29E17A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_77BF1444A78179D31177DF1A9B297D7A" xlink:to="loc_biib_TecfideraMember_2B9F9C310B001EAC6BCBDF1A9B29B7B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_91C2FEF90762F947B553DF1A9B2D248D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_srt_RangeAxis_91C2FEF90762F947B553DF1A9B2D248D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_085587D257929598563EDF1A9B2D17CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_91C2FEF90762F947B553DF1A9B2D248D" xlink:to="loc_srt_RangeMember_085587D257929598563EDF1A9B2D17CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_68F16B6A3E5E0AA9DB02DF1A9B2DF159" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_085587D257929598563EDF1A9B2D17CD" xlink:to="loc_srt_MinimumMember_68F16B6A3E5E0AA9DB02DF1A9B2DF159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_39F49E9F5E1BFB6CF74ADF1A9B2DF9AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_085587D257929598563EDF1A9B2D17CD" xlink:to="loc_srt_MaximumMember_39F49E9F5E1BFB6CF74ADF1A9B2DF9AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_53ADAAF511FDA26C5D5EDF1A9B21BAB5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07E71E99410D05383E93DF1A9B2D2738" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5B905FB25BBC08BD172CDF1A9B2D5F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_BEB8764C9FCEF1FE9346DF1A9B31F668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2B34D218B1C7017D3FE4DF1A9B314304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DABAAD0CD365E9058388DF1A9B31E915" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DABAAD0CD365E9058388DF1A9B31E915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64DACB5BBDDE53BFB324DF1A9B312A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_D4E63C582E37E3D5B940DF1A9B313679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81319829894F043CDBE7DF1A9B310AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ECF3A22C61BF1DFD46C7DF1A9B3180A9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0DB00FEED932A72F8BB2DF1A9B2D7142" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ECF3A22C61BF1DFD46C7DF1A9B3180A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_92B542E5325340A4B362DF1A9B31A16C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Amortizationofintangibleassetsexcludingimpairment" xlink:label="loc_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:to="loc_biib_Amortizationofintangibleassetsexcludingimpairment_4FB2E677B806CEBD36D9DF1A9B314B4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BDFF87AC229FF585C8DDDF1A9B31906D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FC60B2F3FB78A31E3030DF1A9B2D6CEF" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BDFF87AC229FF585C8DDDF1A9B31906D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8107D842E78C81DD6F3EDF1A9B3185A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F6ECCFEBF4737503B6C4DF1A9B216CC1" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8107D842E78C81DD6F3EDF1A9B3185A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5AF310C7D520601CBE14DF1A9B316AB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F6ECCFEBF4737503B6C4DF1A9B216CC1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5AF310C7D520601CBE14DF1A9B316AB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_586DAC2DD3EB60C9F6B3DF1A9B316C39" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F6ECCFEBF4737503B6C4DF1A9B216CC1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_586DAC2DD3EB60C9F6B3DF1A9B316C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B70C196B4B0B6E9EA09BDF1A9B3189D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F6ECCFEBF4737503B6C4DF1A9B216CC1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_B70C196B4B0B6E9EA09BDF1A9B3189D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C26EDA21AE9D50D28954DF1A9B31096F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F6ECCFEBF4737503B6C4DF1A9B216CC1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C26EDA21AE9D50D28954DF1A9B31096F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_287D338AAB1DDA2E3F34DF1A9B315357" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F6ECCFEBF4737503B6C4DF1A9B216CC1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_287D338AAB1DDA2E3F34DF1A9B315357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5DB4DD205C7947600B1BDF1A9B318A07" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F6ECCFEBF4737503B6C4DF1A9B216CC1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5DB4DD205C7947600B1BDF1A9B318A07" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_BDF44AD1AA87274F35A3E019449E91EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7F31FB1C4BA3D5E90BC6E01944A0B431" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_BDF44AD1AA87274F35A3E019449E91EA" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7F31FB1C4BA3D5E90BC6E01944A0B431" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_BDF44AD1AA87274F35A3E019449E91EA" xlink:to="loc_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5FDDDF5A049703257F78E01944A074DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:to="loc_us-gaap_Goodwill_5FDDDF5A049703257F78E01944A074DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9D2BBEC7A785EC098418E01ADB79EEDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9D2BBEC7A785EC098418E01ADB79EEDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_A33E0F758506CF5FF155E02108897704" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_A33E0F758506CF5FF155E02108897704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_15078AC1B06F3A6ECE58E01944A10CB2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_15078AC1B06F3A6ECE58E01944A10CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5E230072C3D23C004839E01944A153F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5C0AC21448E34349B691E01944A0ADBC" xlink:to="loc_us-gaap_Goodwill_5E230072C3D23C004839E01944A153F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_BF56746BD7395599BAC79EFEAA09F53D" xlink:type="locator" />
    <link:loc xlink:href="biib-20190930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_CFF3F137479B52D799F9DB2FF680DB9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_BF56746BD7395599BAC79EFEAA09F53D" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_CFF3F137479B52D799F9DB2FF680DB9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_064AF59A029B50CDACF3B63825809031" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_BF56746BD7395599BAC79EFEAA09F53D" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_064AF59A029B50CDACF3B63825809031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_AB027AAC4D2B55DC9B38B0C5BCA02220" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_BF56746BD7395599BAC79EFEAA09F53D" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_AB027AAC4D2B55DC9B38B0C5BCA02220" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_781F192F721154808D25DF37217992A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_267A1B7229A057998FF0B7FCB9FAEE2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_781F192F721154808D25DF37217992A8" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_267A1B7229A057998FF0B7FCB9FAEE2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_BF287D672EF651CB9F04DB7172F74B11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_BF287D672EF651CB9F04DB7172F74B11" xlink:to="loc_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_BCEDF9FAB61B5B36B32857AE4B04C8D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_BCEDF9FAB61B5B36B32857AE4B04C8D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_BD33E3F5765455BAB925F9FEBF202348" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_BD33E3F5765455BAB925F9FEBF202348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_C84BF6C6CA5350CBB1C6E86964EB154C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_C84BF6C6CA5350CBB1C6E86964EB154C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_CBF807994308547B89B21F8EEEFA9262" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_703C0E7315FF540B9BE0EE9D2EB091E6" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_CBF807994308547B89B21F8EEEFA9262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_9739A2D227A75FBABDACDD3AB50C94A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_BF287D672EF651CB9F04DB7172F74B11" xlink:to="loc_us-gaap_InventoryNet_9739A2D227A75FBABDACDD3AB50C94A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_02B2F24D3405512483158F6140B0792C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_BF287D672EF651CB9F04DB7172F74B11" xlink:to="loc_us-gaap_InventoryNoncurrent_02B2F24D3405512483158F6140B0792C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_InventoryAbstract" xlink:label="loc_biib_InventoryAbstract_88F3D545C38758729E59F8A8BAA7D539" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InventoryAbstract_88F3D545C38758729E59F8A8BAA7D539" xlink:to="loc_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:to="loc_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2AFA83B995645A2EBB90F9C9C1ED9A88" xlink:to="loc_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_AC51DA1567B95A11987460B9653C6E3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_701EA91CAF6C5ED1AE0D102CCDB6E28E" xlink:to="loc_biib_BioverativMember_AC51DA1567B95A11987460B9653C6E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_0D604CCD19215353B27FE73F96D051AF" xlink:to="loc_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_3334E338259F580BB85A862AD022FFEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_94ECED311FE05136AB826E01FB69EFF0" xlink:to="loc_biib_InventorysoldtoBioverativcost_3334E338259F580BB85A862AD022FFEA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_95290ABE8A5F591B965F1012B1D11674" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9150E3837B645E218DCCEC6B99A578E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_95290ABE8A5F591B965F1012B1D11674" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9150E3837B645E218DCCEC6B99A578E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_17D6DF453B3D598AA57ACEDA175CBA19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_35D631DC66D6538FA3D1BABB72166E95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_17D6DF453B3D598AA57ACEDA175CBA19" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_35D631DC66D6538FA3D1BABB72166E95" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_FA1636403FF158C2950C1485CE27B678" xlink:type="locator" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_B6ACDCE92F8453D89670C111409AD926" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_FA1636403FF158C2950C1485CE27B678" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_B6ACDCE92F8453D89670C111409AD926" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5A61FF6741C355C6A018818B707C927D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_B6ACDCE92F8453D89670C111409AD926" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5A61FF6741C355C6A018818B707C927D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_A97D3E78B5C15C99B4656B01F4B07932" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6D1E7C68718A56EEACF9FA9DDE529C80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_A97D3E78B5C15C99B4656B01F4B07932" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_6D1E7C68718A56EEACF9FA9DDE529C80" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_DB1EB7C8436EB87516CF82AF287EEA28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C260651F7A0A894EC15182AF287EF435" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_DB1EB7C8436EB87516CF82AF287EEA28" xlink:to="loc_us-gaap_StatementTable_C260651F7A0A894EC15182AF287EF435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_83367A1711D38905958F82AF287E7429" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C260651F7A0A894EC15182AF287EF435" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_83367A1711D38905958F82AF287E7429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_83367A1711D38905958F82AF287E7429" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342" xlink:to="loc_biib_OperatingleaseassetsMember_2144F31A319EC7BEBDB482AF287FE324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_B6C6C3B53DBD1566D56F82AF287F1294" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_B6C6C3B53DBD1566D56F82AF287F1294" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4DE06E9CBC1594AADCF682AF287F3342" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_18C3FF098A67FF00783582AF287F4C6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_45E2A4CD264E6E7947D582AF287F9128" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C260651F7A0A894EC15182AF287EF435" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_45E2A4CD264E6E7947D582AF287F9128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_45E2A4CD264E6E7947D582AF287F9128" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_204162A11FBB62CA61FA82AF2881ED65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_204162A11FBB62CA61FA82AF2881ED65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F95E5FD24BF12965078182AF28818009" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F95E5FD24BF12965078182AF28818009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6F2A2297C33A467239BC82AF2881C7E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1AB8DFBFBC77E123E48A82AF287F43AF" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6F2A2297C33A467239BC82AF2881C7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C260651F7A0A894EC15182AF287EF435" xlink:to="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_051C137D3A0DD17104CD82AF2881EDF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_051C137D3A0DD17104CD82AF2881EDF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_C4684F8443262770AB2082AF2882A02A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_E079B88591449918776682AF28824A96" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_E079B88591449918776682AF28824A96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_FA86E4822BACEA4C3E9682AF28825D26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseLiability_FA86E4822BACEA4C3E9682AF28825D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseCost_D28480DEB353D48AC4F782AF28822C08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_6FE037FDDA67E0787A8A82AF2882F47D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_DFFC36121CB925B44DC682AF28832ADD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseCost_DFFC36121CB925B44DC682AF28832ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_772CBDCCC475500308C082AF2883FFB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_DC2030062D4BB8E6523882AF2883174F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48427F95E09A2ADA210282AF288392FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5DF29C8F6ED87E23DBE782AF28836504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD2083D46B401FCE608482AF2883FCDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_130A6ECC51F8C3CA732582AF2884E091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CB6EC218C403EA761FCD82AF2884CAE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4A5CA9F85CF47BBF956082AF2884282E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4E9D92A7697DD437CC4982AF28842311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00EF36874A3AE3ECE40882AF2884EEC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CD7F520E8B2200D8596482AF2884A022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_FCAC896185A11617DBFF82AF28849747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_715B564CCDD62C16027182AF2885F817" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A731960BE14A57D0EE6582AF2885E706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_B5334DFFFF80BAB21A9582AF2885ED4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0955F3A842A9FA71E11382AF2885354D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1CA3D02FE43B65F8273F82AF2885129B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_B9CDCC3CB769BC679C8E82AF28859C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_C649E6E337EEC1E8643E82AF288641AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_28C013196A9C70DBCB6382AF288673B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_D8DB0824D5E282C63A7482AF28862515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_8DADF8B4AF16F2881E3E82AF2886BB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_6DF84E3BD5FBD137BDB482AF2886FC88" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_D3AB82858E76960D218982AF2886594F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_EF974B8F805E8897EE7F82AF2887BA37" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_4E4BE6FAD83CB93540E182AF28878711" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_F749006F9BF2EC9D295182AF2887DDA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4AE2A3D3DFE7E5488BE582AF288780CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_699DB2B3EF1242C683A082AF2887D8A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_biib_NetMinimumLeasePayments_3F53BAB9911842CB734382AF288806B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_CF09A2C1AF144FC9D03D82AF288892FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166" xlink:type="locator" />
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081713915E411CC7B71282AF28886166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8" xlink:type="locator" />
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_OperatingLeasePayments_143E10BF763B0F7B0F5E82AF288843A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB" xlink:type="locator" />
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88BC4C2A7AD69B0BED0882AF288149BA" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7460E5C40F61752E671182AF288854FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_EC1D37EDB29F2D6D1753DF1A98B57FB9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EC1D37EDB29F2D6D1753DF1A98B57FB9" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EBF3EE1D876484631C46DF1A98B51B55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EBF3EE1D876484631C46DF1A98B51B55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_49F6D321831BF66E46BBDF1A98B5DEB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EBF3EE1D876484631C46DF1A98B51B55" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_49F6D321831BF66E46BBDF1A98B5DEB4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_07D291638DBD73CD127DDF1A98B595E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_49F6D321831BF66E46BBDF1A98B5DEB4" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_07D291638DBD73CD127DDF1A98B595E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_4F5C5C29F62C12D33488DF1A98B5C518" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:to="loc_srt_RangeAxis_4F5C5C29F62C12D33488DF1A98B5C518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_EA6237F8EB9F7638EA2DDF1A98B57331" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4F5C5C29F62C12D33488DF1A98B5C518" xlink:to="loc_srt_RangeMember_EA6237F8EB9F7638EA2DDF1A98B57331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4446B59A1745044AB0DCDF1A98B8C806" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_EA6237F8EB9F7638EA2DDF1A98B57331" xlink:to="loc_srt_MinimumMember_4446B59A1745044AB0DCDF1A98B8C806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_13475F1475E5BD14F1B4DF1A98B8BFD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_EA6237F8EB9F7638EA2DDF1A98B57331" xlink:to="loc_srt_MaximumMember_13475F1475E5BD14F1B4DF1A98B8BFD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9EF622EB6B3BD1197908DF1A98B50405" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5F41A0EEB5DC8302F131DF1A98B8DF7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8654F5DB8329D780DFD1DF1A98B953CA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:to="loc_biib_DisposalGroupOperatingLeaseAssets_9952C9AF6BC08BFB50A8DF1A98B9D48A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_36924893EDFA695DAFF3DF1A98B88ED5" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_FF62A70AB37DAA527A43DF1A98B94A07" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:type="locator" />
    <link:loc xlink:href="biib-20190930.xsd#biib_LesseeLeaseTableTableTextBlock" xlink:label="loc_biib_LesseeLeaseTableTableTextBlock_6E2CFCEDEC395831833E542A64E76B61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:to="loc_biib_LesseeLeaseTableTableTextBlock_6E2CFCEDEC395831833E542A64E76B61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_460AA497EEEC55A48AA8D620AAA2CEC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_460AA497EEEC55A48AA8D620AAA2CEC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7C4475D2DD3A554DA079BA4E6C12B1C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7C4475D2DD3A554DA079BA4E6C12B1C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2675550A509859108BB3CA870D42EDCA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2675550A509859108BB3CA870D42EDCA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:label="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_E3C3DD54A6CF5A4B9C7F252428509E23" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:to="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_E3C3DD54A6CF5A4B9C7F252428509E23" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:label="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_2F01837FC10E56E79C6D52A863ECA489" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FDF11508A9005D689D357BFE19A632A3" xlink:to="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_2F01837FC10E56E79C6D52A863ECA489" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4275735833CA5406A5F20C6A80A191C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B181A4E6CFC45B50A037981CE5A9717C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4275735833CA5406A5F20C6A80A191C4" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B181A4E6CFC45B50A037981CE5A9717C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_5FE9E1633ACA55BD82F22DE22D8EE07C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_B55CD1B12A97504D84C9CF5664EBE063" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_5FE9E1633ACA55BD82F22DE22D8EE07C" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_B55CD1B12A97504D84C9CF5664EBE063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_36216175B43859DA9F75E64E65E5E3C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_B55CD1B12A97504D84C9CF5664EBE063" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_36216175B43859DA9F75E64E65E5E3C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_D62C3E8F77B559478B67B5F7D07623BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_36216175B43859DA9F75E64E65E5E3C8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_D62C3E8F77B559478B67B5F7D07623BB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_9EF2E156CD18540BA13332CFE2DEA4B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_D62C3E8F77B559478B67B5F7D07623BB" xlink:to="loc_country_BR_9EF2E156CD18540BA13332CFE2DEA4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_ABCED7F0D50B553CA9E6C930A2504CF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_B55CD1B12A97504D84C9CF5664EBE063" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_ABCED7F0D50B553CA9E6C930A2504CF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_722CA757AF135454883C8596A8F0849C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ABCED7F0D50B553CA9E6C930A2504CF1" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_722CA757AF135454883C8596A8F0849C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BE07720B337055769079CD9FE4FF12A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_ACF4E15A05FD5B0A844F966C88576DBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BE07720B337055769079CD9FE4FF12A6" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_ACF4E15A05FD5B0A844F966C88576DBF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56FF23A09E130A4CF20DDF1A9842CF20" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7E2CD66AB5C0390895DCDF1A9842C0B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56FF23A09E130A4CF20DDF1A9842CF20" xlink:to="loc_us-gaap_StatementTable_7E2CD66AB5C0390895DCDF1A9842C0B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_19FEFBB3BCDEC4CF3EE7DF1A9842AB52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7E2CD66AB5C0390895DCDF1A9842C0B3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_19FEFBB3BCDEC4CF3EE7DF1A9842AB52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BADF5D96E0858281E76FDF1A98438059" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_19FEFBB3BCDEC4CF3EE7DF1A9842AB52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BADF5D96E0858281E76FDF1A98438059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3A4489C1401C72C14DFFDF1A98434AA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BADF5D96E0858281E76FDF1A98438059" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_3A4489C1401C72C14DFFDF1A98434AA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_930305EE6B871E40274ADF1A9844A304" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7E2CD66AB5C0390895DCDF1A9842C0B3" xlink:to="loc_us-gaap_StatementLineItems_930305EE6B871E40274ADF1A9844A304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56FF23A09E130A4CF20DDF1A9842CF20" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_42A6C45DDCFF20FE5E80DF1A9844ACEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:to="loc_us-gaap_InvestmentIncomeInterest_42A6C45DDCFF20FE5E80DF1A9844ACEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_662B851D55E1827EAA12DF1A98444B63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:to="loc_us-gaap_InterestExpense_662B851D55E1827EAA12DF1A98444B63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_722D4695A5AE844A2507DF1A98443E7E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_722D4695A5AE844A2507DF1A98443E7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0964F12D5065B1DB7D58DF1A98446278" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0964F12D5065B1DB7D58DF1A98446278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9B9DAC6741784EC8D478DF1A98441079" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9B9DAC6741784EC8D478DF1A98441079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_FFD4E4532A7715B1F370DF1A98444BF8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_11FDC448FB9405E85AECDF1A9844E721" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_FFD4E4532A7715B1F370DF1A98444BF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56FF23A09E130A4CF20DDF1A9842CF20" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_FD6B634CAC2242764BBBDF1A9844768B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_FD6B634CAC2242764BBBDF1A9844768B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_88041E5AC7EB2A53C977DF1A9844E704" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_88041E5AC7EB2A53C977DF1A9844E704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0F24E923E710DA283B1BDF1A98446BDB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_0FCAB5F98EDD95C25678DF1A9844CBDB" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0F24E923E710DA283B1BDF1A98446BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56FF23A09E130A4CF20DDF1A9842CF20" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_676D197ED5D5DC93CAD7DF1A984471ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_676D197ED5D5DC93CAD7DF1A984471ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4BBF0E7C7CE59CBDF9AADF1A98444B9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4BBF0E7C7CE59CBDF9AADF1A98444B9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_45C6E2852CD8827A4C14DF1A9844E639" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_45C6E2852CD8827A4C14DF1A9844E639" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:to="loc_biib_Collaborationexpensesaccrual_232595F532E9A61C8495DF1A9844A9FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7CDB59488D62C9E50177DF1A984495EC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7CDB59488D62C9E50177DF1A984495EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_F62AA923CD7E9548D44EDF1A9844B295" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_F62AA923CD7E9548D44EDF1A9844B295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_EE108CF6C6DBEA2FC0C3DF1A9844C659" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_EE108CF6C6DBEA2FC0C3DF1A9844C659" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_D5F1DF23D0806175CD83DF1A9844227B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_E38F23DB1A2E24391A92DF1A9844DF9D" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_D5F1DF23D0806175CD83DF1A9844227B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C15EAC29BCC25745BAA41B980D12AD5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA73C965D0715EDEA33DA3D0DB5B952B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C15EAC29BCC25745BAA41B980D12AD5E" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA73C965D0715EDEA33DA3D0DB5B952B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_D6CDDFF881B151DD9E6ABF17E3CECBCB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C15EAC29BCC25745BAA41B980D12AD5E" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_D6CDDFF881B151DD9E6ABF17E3CECBCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4281F3C335A95727B0A89112A67D3342" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C15EAC29BCC25745BAA41B980D12AD5E" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4281F3C335A95727B0A89112A67D3342" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A783F53A13065E2F96BD197230F7CC38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_D49E764C4F1A54B78C1703A329CFFD51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A783F53A13065E2F96BD197230F7CC38" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_D49E764C4F1A54B78C1703A329CFFD51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_B8FC4262394F5CC5A52BA205BD5EFA42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A783F53A13065E2F96BD197230F7CC38" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_B8FC4262394F5CC5A52BA205BD5EFA42" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_B27431C4BFC16532A6A8DF1A9BBF8355" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_B27431C4BFC16532A6A8DF1A9BBF8355" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_93D260BBE741DC0AA32EDF1A9BBF58CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_93D260BBE741DC0AA32EDF1A9BBF58CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58C54C6971F188D3EB50DF1A9BBF27F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_93D260BBE741DC0AA32EDF1A9BBF58CC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58C54C6971F188D3EB50DF1A9BBF27F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_A5AB34F2F9388532515FDF1A9BBFCE7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58C54C6971F188D3EB50DF1A9BBF27F7" xlink:to="loc_us-gaap_CollaborativeArrangementMember_A5AB34F2F9388532515FDF1A9BBFCE7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1FF2ABAD6310A117FBF8DF1A9BC31694" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:to="loc_srt_ProductOrServiceAxis_1FF2ABAD6310A117FBF8DF1A9BC31694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1FF2ABAD6310A117FBF8DF1A9BC31694" xlink:to="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC" xlink:to="loc_us-gaap_RoyaltyMember_86A6634245C930D1AF85DF1A9BC32073" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC" xlink:to="loc_biib_OthercorporaterevenuesMember_E1ABDE118C926547F76BDF1A9BC3A67F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_F7C8B5EF6E6C52013879DF1A9BC38E3F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67C2458A47A5BBF27490DF1A9BC361BC" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_F7C8B5EF6E6C52013879DF1A9BC38E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_5952F32A2B9D2B330A70DF1A9BC745DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:to="loc_srt_MajorCustomersAxis_5952F32A2B9D2B330A70DF1A9BC745DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B37BCA098E1A3A7F6A22DF1A9BC79F06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_5952F32A2B9D2B330A70DF1A9BC745DB" xlink:to="loc_srt_NameOfMajorCustomerDomain_B37BCA098E1A3A7F6A22DF1A9BC79F06" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B37BCA098E1A3A7F6A22DF1A9BC79F06" xlink:to="loc_biib_AbbVieMember_04B19EA638DFBF8F5EA3DF1A9BC71D6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_26160D44F470A90CDEE3DF1A9BC7436C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B37BCA098E1A3A7F6A22DF1A9BC79F06" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_26160D44F470A90CDEE3DF1A9BC7436C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_02C51DAD0A4D35994078DF1A9BC706F5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_21FC8F678B768700578FDF1A9BBFC32E" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_02C51DAD0A4D35994078DF1A9BC706F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2303525C1F3C22C6E2D0DF1A9BC78856" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_02C51DAD0A4D35994078DF1A9BC706F5" xlink:to="loc_us-gaap_Revenues_2303525C1F3C22C6E2D0DF1A9BC78856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_02C51DAD0A4D35994078DF1A9BC706F5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4602CA9B72D3D51418E4DF3391F48D9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_879AE0556A18814C8866DF1A993C74FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_879AE0556A18814C8866DF1A993C74FD" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_704C876007D2247C5EC9DF3E7AEF6293" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_704C876007D2247C5EC9DF3E7AEF6293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2E1A3E48DA4AC49DDF76DF3E7AF0433F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_704C876007D2247C5EC9DF3E7AEF6293" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2E1A3E48DA4AC49DDF76DF3E7AF0433F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_4F7206AAED39F7767F74DF3E7B9D9DAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2E1A3E48DA4AC49DDF76DF3E7AF0433F" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_4F7206AAED39F7767F74DF3E7B9D9DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A9D27B3B7881AE467287DF1A993C5078" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:to="loc_us-gaap_BuildingMember_E9ADAC7CD90C2E767381DF1A993C4475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADAB4C7C80A8ED3CB9FCDF1A993C1E83" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_2AF956A3D58CA7F000CCDF1A993C6CC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:to="loc_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_E968E36452CA71CC488FDF1A993C5CDD" xlink:to="loc_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_6F906FBB2E42A4CE8021DF1A993C557F" xlink:to="loc_biib_SolothurnSwitzerlandMember_872EB9DDDC09570A0F02DF1A993CCA4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_781D65A25C27E5E13F7BDF1A993C7E9A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_17B857353A109C4EC91DDF1A993CA94D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_Depreciation_0ED4CB51E0B01959144BDF1A9944B91F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_ConstructionInProgressGross_6DC92BF7D917C9FF9298DF1A9944CE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_OtherCommitment_913B82A1DA75A61AD5B1DF1A9944E17A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97D51D2DC8B068105666DF1A993CF3A3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C805DAEA9E570ACB3EE5DF1A994466BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0FD62E475AD05F49BDCFEAA3DEBCDA79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_27C4D3F9D5515126A7009EF3D81CEC56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0FD62E475AD05F49BDCFEAA3DEBCDA79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_27C4D3F9D5515126A7009EF3D81CEC56" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_5DC37E0DEF6156DE861B5484BACFA0FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_5DC37E0DEF6156DE861B5484BACFA0FA" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7885CE082F0A598C97BB58F9CE3F53F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7885CE082F0A598C97BB58F9CE3F53F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_78F4DABD489056FF9780B90AAFFA4FFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7885CE082F0A598C97BB58F9CE3F53F8" xlink:to="loc_us-gaap_EquityComponentDomain_78F4DABD489056FF9780B90AAFFA4FFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A47067CCD675A98818C39EFFAB4F5C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_78F4DABD489056FF9780B90AAFFA4FFE" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A47067CCD675A98818C39EFFAB4F5C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_DE1FD97E356A5C718E518E0C60924103" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_78F4DABD489056FF9780B90AAFFA4FFE" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_DE1FD97E356A5C718E518E0C60924103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E5667DD113245E779BD04D5B0E1129FA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_78F4DABD489056FF9780B90AAFFA4FFE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_E5667DD113245E779BD04D5B0E1129FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7C1F9EA072B9552DBCD0B6E0C7BFAA80" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_97FDEEE752B25357A6293EFF1DD08251" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3BF2E2155F4351318D4395B5B52293BE" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_97FDEEE752B25357A6293EFF1DD08251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1E31ED9AF7CB54989B7FDE48851A1D9A" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_22E2EFFE80E05AE9A20E151E87F7707A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_22E2EFFE80E05AE9A20E151E87F7707A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5C59F7BEF2A553FCAD81B9D12E862F43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5C59F7BEF2A553FCAD81B9D12E862F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F9B843488FC45D818AC883AD279FC2C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_Revenues_F9B843488FC45D818AC883AD279FC2C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4B883AD9F9AC5FE49C7DA221148B03C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_OperatingExpenses_4B883AD9F9AC5FE49C7DA221148B03C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0097C8D00248594095A103A39A292E93" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8FCC54EA11BA53B0B79E90A5FA6D2397" xlink:to="loc_us-gaap_NetIncomeLoss_0097C8D00248594095A103A39A292E93" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_BEEF29D50BDA53F8BAFCF5E863C1067C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_BEEF29D50BDA53F8BAFCF5E863C1067C" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_36DFB423FC89512DA1C23948B79AB3A8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_30C7B7D4147E5E6AB7DB0D0F83CF8EBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:to="loc_biib_ReserveforCashDiscountsMember_30C7B7D4147E5E6AB7DB0D0F83CF8EBB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_8B9DF22A811C549DB917C2A0051EAFD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:to="loc_biib_ContractualAdjustmentsMember_8B9DF22A811C549DB917C2A0051EAFD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_52119BB649D2596592C82C08D1CF7D53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_E6B1F879FFBC52879E1F925201B3BD40" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_52119BB649D2596592C82C08D1CF7D53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_86CEA5002AC55E37BC9ECD0C4913C68D" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_F8A30071368B5B2095BE39D7ABA656F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_F8A30071368B5B2095BE39D7ABA656F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_58E89CEE697E554993799E90546FAE23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_58E89CEE697E554993799E90546FAE23" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_B17511584A56539C8075346C3219C0CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_B17511584A56539C8075346C3219C0CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_80D46F881F4650DBA97C491B782AFCB0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_80D46F881F4650DBA97C491B782AFCB0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_E1E8BF5C3D9154819E20700B6DCECF6A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_E1E8BF5C3D9154819E20700B6DCECF6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_A12F86E6AE5256618D43A12310E0E1C5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_F55315D77F2F59F08EA5FE75EDDB55F8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_A12F86E6AE5256618D43A12310E0E1C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_8D86E9FFC6FA5E6881225E8008247CE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E6C40FE23701578AAAE9FF662E9D34F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_8D86E9FFC6FA5E6881225E8008247CE2" xlink:to="loc_us-gaap_StatementTable_E6C40FE23701578AAAE9FF662E9D34F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_51E47B3715C05991811B5C0F1F548FBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E6C40FE23701578AAAE9FF662E9D34F0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_51E47B3715C05991811B5C0F1F548FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2F15974D337E5A68A7E38D9A213169E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_51E47B3715C05991811B5C0F1F548FBB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2F15974D337E5A68A7E38D9A213169E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_CC736C14669053B7BCB601C087AAA1BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2F15974D337E5A68A7E38D9A213169E4" xlink:to="loc_us-gaap_AccountsReceivableMember_CC736C14669053B7BCB601C087AAA1BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_A5FEBB4C59DE5F22B62F54561B7F1403" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2F15974D337E5A68A7E38D9A213169E4" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_A5FEBB4C59DE5F22B62F54561B7F1403" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3F1D699297B55AA3B2ABA8E2AD5501A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E6C40FE23701578AAAE9FF662E9D34F0" xlink:to="loc_us-gaap_StatementLineItems_3F1D699297B55AA3B2ABA8E2AD5501A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8D9BB48DE62D5DCD94617758480981D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3F1D699297B55AA3B2ABA8E2AD5501A4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8D9BB48DE62D5DCD94617758480981D9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_F6BE7ABC3AC8509581EA64B48E58525D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_AA52D862DFE55B078A90640DE84361F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_F6BE7ABC3AC8509581EA64B48E58525D" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_AA52D862DFE55B078A90640DE84361F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_DBBC4FD31EF15898906169E4E92BD7B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_AA52D862DFE55B078A90640DE84361F9" xlink:to="loc_srt_ProductOrServiceAxis_DBBC4FD31EF15898906169E4E92BD7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_DBBC4FD31EF15898906169E4E92BD7B8" xlink:to="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_4C5A86E27C7F5608A2CDDE2AD05E32DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_TecfideraMember_4C5A86E27C7F5608A2CDDE2AD05E32DB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_A84573BFCAEE51ECA08329EC2458DDE8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_InterferonMember_A84573BFCAEE51ECA08329EC2458DDE8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_1CE09247ABC958B193026A3AF23CF54C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_TysabriProductMember_1CE09247ABC958B193026A3AF23CF54C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_4F4E7AFCF84E54D48AA79B9DBEA6F1B8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_FAMPYRAMember_4F4E7AFCF84E54D48AA79B9DBEA6F1B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_A2D1A0B71FDA5B9F8F366AC85E4E194D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_ZINBRYTAMember_A2D1A0B71FDA5B9F8F366AC85E4E194D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_A76B3B3C132A5CA88379A7500E1D3901" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_MSProductRevenuesMember_A76B3B3C132A5CA88379A7500E1D3901" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_9D49C9D9B103553183642E73B1A093BF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_SPINRAZAMember_9D49C9D9B103553183642E73B1A093BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_2A309F1B60C7584584C3B22746F5B4DF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_BENEPALIMember_2A309F1B60C7584584C3B22746F5B4DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_4F299C33E1C35D6195A81309F0D090DE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_IMRALDIMember_4F299C33E1C35D6195A81309F0D090DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_594BE6E7F38E500FBDDFAFABF3051C72" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_FLIXABIMember_594BE6E7F38E500FBDDFAFABF3051C72" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_24AD8154BF3851E6B432BDDA60EB369C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_BiosimilarsMember_24AD8154BF3851E6B432BDDA60EB369C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_D369ED1CE58E5670B693B6303087F9EF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_biib_FUMADERMMember_D369ED1CE58E5670B693B6303087F9EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_97BB6B36FE905C2E854BC4E81DD36F0C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95721B46BB0F57CFB1D0C6F16E5367FA" xlink:to="loc_us-gaap_ProductMember_97BB6B36FE905C2E854BC4E81DD36F0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_AA52D862DFE55B078A90640DE84361F9" xlink:to="loc_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2365CD34D06D56A2B894283E19DC0A07" xlink:to="loc_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_4ADF66EACEBF5D9DB46420C74C7E88F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:to="loc_country_US_4ADF66EACEBF5D9DB46420C74C7E88F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_6A4F8F8BD8905B0CB54B88D17E642A04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_63797800617F5DCD85E41482BCE16C9B" xlink:to="loc_us-gaap_NonUsMember_6A4F8F8BD8905B0CB54B88D17E642A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5C0B8ED26F6E595DACDC30E6F82B9DB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_AA52D862DFE55B078A90640DE84361F9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5C0B8ED26F6E595DACDC30E6F82B9DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B87C1A002C7657F2981FCBE9CD5492F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5C0B8ED26F6E595DACDC30E6F82B9DB9" xlink:to="loc_us-gaap_Revenues_B87C1A002C7657F2981FCBE9CD5492F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_D53277E21484506198B152E791E04F7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_D53277E21484506198B152E791E04F7D" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:to="loc_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4339CE044454590F85B9F0A42E84BD62" xlink:to="loc_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_CD064B0727EE571BBC820EACBA91DA9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E57637D6D67950CF8102B3D35C2DE53A" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_CD064B0727EE571BBC820EACBA91DA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7BF462678EDD5BBE8FDCA166B26AC0D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:to="loc_srt_MajorCustomersAxis_7BF462678EDD5BBE8FDCA166B26AC0D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_F1A0C971902F568E8A6721749B5EFD56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7BF462678EDD5BBE8FDCA166B26AC0D5" xlink:to="loc_srt_NameOfMajorCustomerDomain_F1A0C971902F568E8A6721749B5EFD56" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_6803B75A8494565B9820AF53ED0C1336" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_F1A0C971902F568E8A6721749B5EFD56" xlink:to="loc_biib_DistributorOneMember_6803B75A8494565B9820AF53ED0C1336" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_E30383FDFA4C562DB12C86A083885A17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_F1A0C971902F568E8A6721749B5EFD56" xlink:to="loc_biib_DistributorTwoMember_E30383FDFA4C562DB12C86A083885A17" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_787C6A27F1FB55AD80DFF1F36BB7C31E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_F1A0C971902F568E8A6721749B5EFD56" xlink:to="loc_biib_BioverativMember_787C6A27F1FB55AD80DFF1F36BB7C31E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EE08E97C2883517593076DB77AAEEB13" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_FD62419268085294B9AB0E466CB98395" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:to="loc_us-gaap_Revenues_FD62419268085294B9AB0E466CB98395" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D783F67B1625560F852978016A2235C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_69F986D1B7745AEFAF50CF97D3E41D41" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D783F67B1625560F852978016A2235C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A3B34227BFEB56DC95DF78AD082E3FFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_69A96AAE195C55ADA63E72B23EA8B75A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A3B34227BFEB56DC95DF78AD082E3FFA" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_69A96AAE195C55ADA63E72B23EA8B75A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F59B41DD505D53DCBC13861722646E54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_69A96AAE195C55ADA63E72B23EA8B75A" xlink:to="loc_srt_ProductOrServiceAxis_F59B41DD505D53DCBC13861722646E54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907C1A1C3D3A561792DA749196E911F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_F59B41DD505D53DCBC13861722646E54" xlink:to="loc_srt_ProductsAndServicesDomain_907C1A1C3D3A561792DA749196E911F5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_23C819B37FD75FA597D502593691E931" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_907C1A1C3D3A561792DA749196E911F5" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_23C819B37FD75FA597D502593691E931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_83ECE4D70C775445B0ABB5763DB22131" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_69A96AAE195C55ADA63E72B23EA8B75A" xlink:to="loc_srt_MajorCustomersAxis_83ECE4D70C775445B0ABB5763DB22131" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_62E3149C39595E4BA1CBF6181E2955F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_83ECE4D70C775445B0ABB5763DB22131" xlink:to="loc_srt_NameOfMajorCustomerDomain_62E3149C39595E4BA1CBF6181E2955F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_DFDF877A368A5B2EA28AC5D53C51E65D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_62E3149C39595E4BA1CBF6181E2955F3" xlink:to="loc_biib_RocheGroupGenentechMember_DFDF877A368A5B2EA28AC5D53C51E65D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_043319A628D75FE6AB7CDDD501001383" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_69A96AAE195C55ADA63E72B23EA8B75A" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_043319A628D75FE6AB7CDDD501001383" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_5CF0741D88C85CF6992D412469E0D2BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_043319A628D75FE6AB7CDDD501001383" xlink:to="loc_biib_ShareOfCoPromotionProfits_5CF0741D88C85CF6992D412469E0D2BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_6434B0FB69ED52DCBD9B13169B742AB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_043319A628D75FE6AB7CDDD501001383" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_6434B0FB69ED52DCBD9B13169B742AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_22EC9AFFE2AC510191F03BBB7FF75067" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_043319A628D75FE6AB7CDDD501001383" xlink:to="loc_us-gaap_Revenues_22EC9AFFE2AC510191F03BBB7FF75067" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_27F3AA63E4C85982AD5175809030E860" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5377459470F859F9A4D87098AE6E8E0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_27F3AA63E4C85982AD5175809030E860" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5377459470F859F9A4D87098AE6E8E0C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_448EC6E89E335221A1D0E3054F00E5A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_E641489912A755B58AA8F0624EC37955" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_448EC6E89E335221A1D0E3054F00E5A2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_E641489912A755B58AA8F0624EC37955" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_BB36AB789EC5549C817FCF4D0255DB72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_448EC6E89E335221A1D0E3054F00E5A2" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_BB36AB789EC5549C817FCF4D0255DB72" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_6325DE38CD455AB8A60368DA35E742BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_448EC6E89E335221A1D0E3054F00E5A2" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_6325DE38CD455AB8A60368DA35E742BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_E04C4B0B8A3C5549B7A07F9E4CFE299A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_448EC6E89E335221A1D0E3054F00E5A2" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_E04C4B0B8A3C5549B7A07F9E4CFE299A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_C64282DFC97C5DDD977C455D2E37F03D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_448EC6E89E335221A1D0E3054F00E5A2" xlink:to="loc_biib_OtherrevenuesTableTextBlock_C64282DFC97C5DDD977C455D2E37F03D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8C09591251E5FD184FDE6D39AC3EA4B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ACE872C2A5045429936655D0BC93397B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A8C09591251E5FD184FDE6D39AC3EA4B" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ACE872C2A5045429936655D0BC93397B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6BF6526D8572C8FD5F358365F837CB86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2C627D7404B43C13624E8365F837B10F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6BF6526D8572C8FD5F358365F837CB86" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2C627D7404B43C13624E8365F837B10F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A3555831E11586CB25BC8365F837C9B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2C627D7404B43C13624E8365F837B10F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A3555831E11586CB25BC8365F837C9B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A3555831E11586CB25BC8365F837C9B1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_793531F73066410230E58365F838C39B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_793531F73066410230E58365F838C39B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F3BA59A50F882B39611C8365F838B783" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F3BA59A50F882B39611C8365F838B783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_D363C8C64F7CAE06A7DB8365F838BA72" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80415894E1B19077734F8365F838E108" xlink:to="loc_us-gaap_ParentMember_D363C8C64F7CAE06A7DB8365F838BA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5A31F395208C3772A20E8365F8395D9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2C627D7404B43C13624E8365F837B10F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5A31F395208C3772A20E8365F8395D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5A31F395208C3772A20E8365F8395D9F" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8352912AF6FB7775A1A28365F83903D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8352912AF6FB7775A1A28365F83903D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6DA37E34B001CE8016FE8365F839D7D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6DA37E34B001CE8016FE8365F839D7D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_375DCF08DEC73B7092328365F83A4CF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_375DCF08DEC73B7092328365F83A4CF7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_4FEE1766516BC3B18EE78365F83A852D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_4FEE1766516BC3B18EE78365F83A852D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_E320F74D7C7B9A611E238365F83966FF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_19C2D9ADADD800CC68CB8365F83A17D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C54255AAE1615F5CBC6A6FB54FB19EE9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C54255AAE1615F5CBC6A6FB54FB19EE9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A5598317934D5B639176606452370EAB" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_8D42368629B75E9293925A2C432939DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12DA2974A7BA506983794036203A313D" xlink:to="loc_biib_NightstarMember_8D42368629B75E9293925A2C432939DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:to="loc_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_AC4E6555CCAA5A56A6C1EE4170220F6A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_83C5D6286BF45DFBA8483C927D50D06B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_MarketStockUnitsMember_83C5D6286BF45DFBA8483C927D50D06B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_8E0E544DECC25187918EFF30D2647181" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_8E0E544DECC25187918EFF30D2647181" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_F816DD50BA7B599EBB7FA2B82439194C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_CashSettledPerformanceSharesMember_F816DD50BA7B599EBB7FA2B82439194C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_D0341733D424595AB280CE6ED5C9E54F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_us-gaap_PerformanceSharesMember_D0341733D424595AB280CE6ED5C9E54F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_B35379F9E5E1542EB2D0171ACADC5A29" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_B35379F9E5E1542EB2D0171ACADC5A29" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_5EE107411D0C53159A39D9FEE2AC8F40" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_5EE107411D0C53159A39D9FEE2AC8F40" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_FF7EC0C9A2A251719D2DCCF5AAC078B2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_FF7EC0C9A2A251719D2DCCF5AAC078B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BCECFE3C16675E7AA6952AA57A57573F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D0117387C7A56DC9B10243376FCC658" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BCECFE3C16675E7AA6952AA57A57573F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85EABF5DF9FD5EA18C5B1F06D51B660E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BA8783FC02FE5314B55661B9EC7FB973" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E33431D013025C3CAFC08FA17D6C4505" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E33431D013025C3CAFC08FA17D6C4505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_19D6C1C9BE1B5AB6B44EE394FF2FF84F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_19D6C1C9BE1B5AB6B44EE394FF2FF84F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55211FCD2D41581B9A291654068076EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_55211FCD2D41581B9A291654068076EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_D191404F0B065A1D927958BC3121A835" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_D191404F0B065A1D927958BC3121A835" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_FE94E5E4634951AAA06876B855539696" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_93309C5E5C675C95B13087A845F76642" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_FE94E5E4634951AAA06876B855539696" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AA7B3044B8845071BC4CFAC9FA82B6C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_72868187DFB75B03B323ADBF4E0B72F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AA7B3044B8845071BC4CFAC9FA82B6C1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_72868187DFB75B03B323ADBF4E0B72F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_30230DA344065307A52E640A9D9AE676" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AA7B3044B8845071BC4CFAC9FA82B6C1" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_30230DA344065307A52E640A9D9AE676" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_CAA95EB5D41CB13DDB85DF1A98A92530" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_CAA95EB5D41CB13DDB85DF1A98A92530" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0D050E7B1F3A0FFFBC50DF40BBBD2BF6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C9102FE514858D9FE845DF40BBBD3DE1" xlink:to="loc_us-gaap_SubsequentEventMember_8B1D1513CB669AC2B75EDF410C116E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9C7BBBB2CCC444E4D4E2DF1A98A9080B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9C7BBBB2CCC444E4D4E2DF1A98A9080B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9C7BBBB2CCC444E4D4E2DF1A98A9080B" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_9B4AA217FE7D46FB4634DF1A98AA1CA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4" xlink:to="loc_biib_A2019ShareRepurchaseProgramMember_9B4AA217FE7D46FB4634DF1A98AA1CA9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_FC0782E0938F3A90CE5EDF1A98AA8084" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_FC0782E0938F3A90CE5EDF1A98AA8084" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_4C1ACA9EA61ACFF1BEE7DF1A98AA149E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8EB48864723E17370589DF1A98AA9DC4" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_4C1ACA9EA61ACFF1BEE7DF1A98AA149E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2EA081272BECB33AC07CDF1A98A99E57" xlink:to="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_685A09A4A95C195FC4C7DF1A98AA1DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_730B124876887307FCFEDF1A98AA8468" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_730B124876887307FCFEDF1A98AA8468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AC07634DDB685D75FEA6DF1A98AA5D58" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AC07634DDB685D75FEA6DF1A98AA5D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_DDB8AA7B9793B3308F28DF1A98AAC1F8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_876166DAFC739135A823DF1A98AA1AF7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended">
    <link:loc xlink:href="biib-20190930.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_0BBCC7E9214B5A6989901A4BBC77D80C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0C73EBFEA80E542C8DE19B50EF395CD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_0BBCC7E9214B5A6989901A4BBC77D80C" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0C73EBFEA80E542C8DE19B50EF395CD7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_AB246CDA0EC75853B36AD79548DB6237" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AE62F8513D15524E8A45C662CFABBFD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AB246CDA0EC75853B36AD79548DB6237" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AE62F8513D15524E8A45C662CFABBFD2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_50FEBED867CF5778ADD67204F451F08D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6750B441EC105253894B1BAA6C733A06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50FEBED867CF5778ADD67204F451F08D" xlink:to="loc_us-gaap_StatementTable_6750B441EC105253894B1BAA6C733A06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_2066B18D19C65391ACBA3C64F4879B50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6750B441EC105253894B1BAA6C733A06" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_2066B18D19C65391ACBA3C64F4879B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_B47EE5EAFC5F54179666C5F6D322201E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_2066B18D19C65391ACBA3C64F4879B50" xlink:to="loc_us-gaap_AccountingGuidanceMember_B47EE5EAFC5F54179666C5F6D322201E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B7BD648C8C8555D5998BBA78B96CC8EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_B47EE5EAFC5F54179666C5F6D322201E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_B7BD648C8C8555D5998BBA78B96CC8EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EBA4BA65B0105582BF1DCAE0207A97CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6750B441EC105253894B1BAA6C733A06" xlink:to="loc_us-gaap_StatementLineItems_EBA4BA65B0105582BF1DCAE0207A97CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_294E049EEEBA57688FC4433E5343FF13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EBA4BA65B0105582BF1DCAE0207A97CB" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_294E049EEEBA57688FC4433E5343FF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BFAC42727BE357C6B3A3649A7EAD5328" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EBA4BA65B0105582BF1DCAE0207A97CB" xlink:to="loc_us-gaap_OperatingLeaseLiability_BFAC42727BE357C6B3A3649A7EAD5328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_66EF4F69B42456A383A58F1447822ACF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50FEBED867CF5778ADD67204F451F08D" xlink:to="loc_us-gaap_NumberOfReportableSegments_66EF4F69B42456A383A58F1447822ACF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_F5F4E4D822585AC69A24E01FB4683842" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50FEBED867CF5778ADD67204F451F08D" xlink:to="loc_biib_InterestInSubsidiary_F5F4E4D822585AC69A24E01FB4683842" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6C95BD1FBFDF5374AB66FB352072E75D" xlink:type="locator" />
    <link:loc xlink:href="biib-20190930.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_15039A4FCDDA52A398EA22FEA4B1D260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6C95BD1FBFDF5374AB66FB352072E75D" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_15039A4FCDDA52A398EA22FEA4B1D260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_105FBEC927B95A01875A32B39D6E97D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6C95BD1FBFDF5374AB66FB352072E75D" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_105FBEC927B95A01875A32B39D6E97D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2AB3910BDF9C5A7AA38F30F7C98E2E21" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6C95BD1FBFDF5374AB66FB352072E75D" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_2AB3910BDF9C5A7AA38F30F7C98E2E21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_0B57CE25927E5DC9ABB42865BABFDF3B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6C95BD1FBFDF5374AB66FB352072E75D" xlink:to="loc_us-gaap_UseOfEstimates_0B57CE25927E5DC9ABB42865BABFDF3B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190930.xsd#biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock" xlink:label="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_7219B19F2C7C5389B2E6AB2ADA6625AF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6C95BD1FBFDF5374AB66FB352072E75D" xlink:to="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_7219B19F2C7C5389B2E6AB2ADA6625AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EBF3B282725F5C32832091E545B25230" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6C95BD1FBFDF5374AB66FB352072E75D" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EBF3B282725F5C32832091E545B25230" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biogenlogoa05.jpg
<TEXT>
begin 644 biogenlogoa05.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _+_ ,0V3>&_'&L:>PVM8WT]N1C&TI(R
M]/PK7TC4]H7FM/\ :_\ #A\%?M+^)H=NV*^G6_C./O\ G*'8_P#?9<?A7&Z;
MJ6%ZU^N4VJU"%1=4G]Z/RVHG2K2IOHVON.\MM9PGWJ;=ZU\GWJYB+5L+UIES
MJ^5ZUE[#4T]MH6M8U7<#S7)ZU?[MU6M1U/.>:YS5;[.:[Z%*QQUJAFZM<Y)K
MGK^7)K1U&YR36-=RY->M2B>;4D59WYK$\:^+[;P1H$U]<'.T;8HP?FE?LH_S
MP,T[Q?XQLO"%EYUU)\[#]W$OWY3[#^O2O#O&?B2\\=ZQ]JNOEC3(AA!^6%?0
M>I/<]_R ,17Y%9;BHT7-W>QSM]<W'B#6+B^NFWW%U(9'/N?3V'3Z"M+3;'&.
M*DM=,P>E:]AIO/2O*C!WNST92Z$NEVG2NDTJVZ53TVQZ?+70:9:=*[:<3EJ2
M.Z^ 6@MJ_P 3M(4)N6&;[0W^R$&[/Y@?B:^K*\S_ &<OA<W@_1&U2]C,=_J"
M (C##0Q=0#[MP3]!7IE?QOXQ<24,USSV>%?-"C'DNMG*[<FO*^GG:ZT9]]P_
M@Y4,->>\G?Y=/\QR#FK4"5! N:NVR5^5P1[T2Y:1UJV472J5G'6M8Q?=XKMI
MQ-8FA80]*]&^ MCY_P 1K!L?+"LCG_OA@/U(K@M/ASBO6_V;M)\S7[V[(^6W
M@$?T+-_@IKZGAVA[3,*,5_,G]VOZ&_2Y[)1117[D2>8_M=?M,6/[(OP,U/QU
MJ6EWFKVFFS00M:VTBQR/YLJQ@@MQP6R?I7Q[_P 1#G@W_HG?B;_P.@_PKV+_
M (+6?\H]O%7_ %^Z?_Z5Q5^(-?K7 W">6YEE\L1BX-R4VMVM$HOH_,_+.-.*
M,PR['QH86:47%/9/5MKJO(_5S_B(<\&_]$[\3?\ @=!_A1_Q$.>#?^B=^)O_
M  .@_P *_*.BOLO^(=Y'_P ^W_X%+_,^1_U^SK_GXO\ P&/^1^KG_$0YX-_Z
M)WXF_P# Z#_"C_B(<\&_]$[\3?\ @=!_A7Y1T4?\0[R/_GV__ I?YA_K]G7_
M #\7_@,?\C]7/^(ASP;_ -$[\3?^!T'^%'_$0YX-_P"B=^)O_ Z#_"ORCHH_
MXAWD?_/M_P#@4O\ ,/\ 7[.O^?B_\!C_ )'ZN?\ $0YX-_Z)WXF_\#H/\*U-
M-_X.$OAE*8OMG@OQW!NQYODK:2[/IF9=WXXK\CZ*4O#K)'M3:_[>?^8X^(&<
MK>:?_;J_R/VD\(_\%T?@1XD=5O+GQ9X?#8R;_2#(%^OV=Y>GMFO</A5^W-\(
M/C9/%#X:^(GA>^N[@[8K26[%K=2'T6&;9(?P6OYZZ*\S%>%V6S7[BI.+^37W
M63_$]+#>)680?[Z$9+YI_?=K\#^FRBOP1_95_P""E?Q5_9/U&UCTK7KC7/#L
M) DT+5I&N+,IW$>3NA/)(,9 SC(8<']?/V)_V]O!?[;O@R2ZT&9M-\0:>BMJ
MFB7+#[39D\;U/22(G@.H[@$*>*_-^(N"\=E2]K+WZ?\ ,NG^)=/Q7G<_0LAX
MPP6:/V4?<J?ROKZ/K^#\CW*BBBOCSZP*X/\ ::^.]G^S+\"_$'CJ^L+G4[/P
M]#'+):P.$DE#2I'@%N!@N#SZ5WE?._\ P5A_Y1Z_$O\ Z\K?_P!*X*[\JP\*
M^-HT:GPRG%/T;29PYI7G1P=6M3^*,9->J3:/G?\ XB'/!O\ T3OQ-_X'0?X4
M?\1#G@W_ *)WXF_\#H/\*_*.BOWW_B'>1_\ /M_^!2_S/PS_ %^SK_GXO_ 8
M_P"1^KG_ !$.>#?^B=^)O_ Z#_"OM3]F7X[V?[37P+\/^.K&PN=,L_$,,DL=
MK.X>2(+*\>"5X.2A/'K7\Y]?O)_P2>_Y1Z_#3_KRN/\ TKGKXGCSA;+LLP4*
MV#@U)S2=VWI9OJ_(^RX)XFS#,<9.CBY)Q46UHEK=+HO,^B****_*3]/"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X[_ ."H7@-K35O#?BN)
M/W<T;:7<,.S*3)%^8,O_ 'R/P^6[2_P.M?I)^U1\*6^,OP,UW1X8]]^L7VJQ
MXR?/C^90/][!3Z.:_,&&]:-MK95AP0>U?IG"^)5?!^S>\';Y/5?JOD?GO$F'
M='%^T6TE?Y[/_/YG4)J>T=:CGU3*GFL-=1XZTR74>.M?0^QU/!]H7;[4<CK6
M+?WF<TV[O\*>?S-<UKWC&&S#+&&GD]ONC\?\*Z:=.QSSJ%S4+M45F9E55Y))
MQBN \8_%*.U5X=-433=#*P_=K]/7^7UJOXCU*\UUCYTA\O/$:\*/\?QK"FTG
MVK24FE9$1BKZG,:G'<:O>-<74CS3/U9SD_Y]JACT?GI73G2?:E32*YO9ZW-_
M::6,.VTK!Z5IV6F;>U:<&D\]*],^!'[+7BKX]:H(]$T]ELD<+/J%P#':P>N6
MQ\Q_V5!;V[UEB*]##4G6Q$E&*W;=D53C.K)0IJ[?1'G>C:-)=W$<,,3RS2L$
M1$7<SL3@  =23VKZN^$'[".N^%O#=OXH\262^<O[V/3/O2VR]1)*O3/?;G*\
M9YR!]%?LY?L9^%_V>;>.\5!K'B+;A]1G0?NB1@B%.0@Z\\L<\G' ]8EEK\+X
MV\1I8RC/+\I;A"2LY[2?^'LGWW?D?;93PRJ=JV+UET71>O=_AZGRO0!DUZ_\
M1_@S#K,DEYI2QV]TQ+/#]V.4^W]T_I].M>476GS:9>/#<120S1G#(XPPK^9L
M5@ZE"5I;='T/HY4W'<6 5?M8ZJP)6E:1U%-#B7+**MBPBZ50LHNE;-A%TKT*
M43:)I:?#TKW_ .!&@?V1X*6X9<27\AE_X"/E7^1/XUXOX+\.R>)-<M;*'[UP
MX4G'W1U)_ 9/X5],65G'I]G#;PKMBA01HOH ,"OTC@? .566*EM%67J]_N7Y
MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
M?A%T>]3)4:G<GF.U!_NX!:3!R%VCC>"-\SS*C@,-/%XAVC%??V2\V]$8Y;E]
M;'8F.%H*\I/_ (=OR2U9R_['?_!+WXF?MBVD6KZ?:V_AWPG(Q4:UJ@9(Y\'#
M>1&!OFP01D83((+@@BOM[P#_ ,&]_P .M+LHO^$F\;>,-:NUP7-@MOI\#GTV
M,DS8Z_QYK[XT[3K?2-/M[2TMX;6UM8UBAAB0)'"BC"JJCA5    X %6*_!,T
M\0LUQ51NA+V4.BC:_P VU>_I9>1^X99P'E>&II5H^TEU;O;Y):6];OS/A7Q/
M_P &_P#\(=3M6_LOQ%X\TNX"X5FN[:XBSZE3 "?P85\F_M6_\$2/B1\!='N-
M:\*W4/Q#T.U4O,EE;-!J4"CDL;?+;P!_SS9FZ_*!S7[.45SY?Q[G&&FI3J>T
MCU4DG?Y[K[SHQW ^4XB#C&GR/HXZ6^6S^X_F39=AP?E*\$'M17Z2?\%L_P#@
MGS8^$K>3XQ>#=/CM+6XN!'XHLX%VHDDC )>JO0;G(23'5G1L99S7YMU^]9'G
M5#-,)'%T.NC75-;I_P!:JS/P_.LHK9;BI86MTU3Z-=&OZT>@5]4?\$I_VZKC
M]D+XX0Z9K%T__"!^+)DMM4C9ODL93\L=V!VVY ?'5">I517RO175F67T<=AI
MX7$*\9*W^37FGJCER_'5L'B(XF@[2B[_ / ?D]F?TU)(LJ*RL&5AD$'@BG5\
ME_\ !&_]J23]HK]DVTTO4KCSO$/@%TT:[+-F2:W"9M93WYC!CR>2T#'O7UI7
M\KYGE]3 XJIA*N\';U[/YK4_IO+<=3QF%ABJ6TE?T[KY/0\H_;=_:!_X9@_9
M9\8>,XV7[=IMEY6GAN=UW,PBAXYR!(ZL1Z*>G6OY[]1U"XU;4)[NZFEN+JZD
M:6665BSRNQRS,3R22223W-?KE_P<#^,)=*_9<\)Z/%(R+J_B1990/^6B0V\Q
MVGVW.A^JCTK\B*_;?#' 1I99+$_:J2>OE'1+[[_>?C7B1CI5,QCA_LPBOO>K
M?W6"BBBOTD_/3Z8_X)H?\$_+S]N'XH3OJ,EQI_@?PZR2:O=Q\27#,<K:Q'L[
M@$EN0BC/4J#^V?PP^%/AOX+>#;7P]X4T:PT'1K,8BM;2+8N< %F/5G.!EF)8
MGDDUXI_P2D^#UK\'?V%/ L<,:K=>(K,:_>2A=K3/=8D0G_=A,2?1!7T97\V\
M:<05LPQ\Z7-^ZIMJ*Z::.3[M_@M#^AN#\AHX#!0JV_>32<GUUULO)?B]0HHH
MKXT^N/.?VE_V5_!G[6GP\F\.^,=*BO(BK&TO$ 6[TV0C_60R8RK<#(Y5@,,"
M.*_"/]K;]F#7/V0?CEJW@K7&%P]IB>RO$39'J-J^?+F49.,X((R=K*PR<9K^
MB*OSG_X.&/A=;7?PP\ ^-5A5;S3]4ET2648W21SQ-,BGN0IMW([#>WK7Z-X=
MY]6P^/C@)N].I?3M*UTUVOL^]_(_/^/LCHU\%+'15JE.VO=7LT_3==OF?E71
M117[\?A9]"_\$Q?VJ[C]E/\ :MT*_FN3#X;\12IH^MQLV(_(E8!9CZ&*3:^>
MNT.H^\:_>>OYDZ_HM_98\<2_$O\ 9F^'OB"XD\RZUGPYI]W<,3DF5[>,R<X&
M?F+5^+^*F6PA4HXZ"UE>+\[:K]5\D?L'AGF$Y4ZN"EM&TEY7T?Z/[SOZ\9_;
MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
M!5K]@73_ -J[X-7WB+1=/CC^(7A>V:YL9HD_>:I @+/9OC[V1DQYY5\ $!FS
M^)%?LW"_$E+.,+[:"Y91TE'L^Z\GT^:Z'Y'Q)P_5RG$^QD^:,M8ONO/S77Y/
MJ%%%%?2'SI^UG_!$GXXR_%O]BNSTF\G:;4/ U_+HQ+'YFM\++ ?]T+(8Q[0_
MB?L"ORK_ .#>#QNUG\3/B1X;,A\O4-,M=25"> 8)7C) ]_M S]!Z"OU4K^9>
M-<$L+G->$=FU)?\ ;R3?XMG]'<'8QXG**,Y;I<K_ .W79?A8****^5/I@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ^4?^"UG_*/;Q5_U^Z?_P"E<5?B#7[??\%K/^4>WBK_ *_=/_\ 2N*O
MQ!K]^\+_ /D4S_Z^2_\ 28GX7XD_\C6/^!?G(****_1C\_"BBB@ HHHH ***
M* "M'PEK%EH.OV]UJ&DVNN6<;9DLKB:6%)AZ;HF5Q^!K.HJ914E9_P"149-.
MZ/TD_8A_X*O? CX+QQZ=/\(H_AM-,HADU;2 -4\P<<S2.!<[1Z9E/YU^CGPA
M^-_A'X]^%5UOP;XATOQ%IK':TMG,',+==LB_>C;'.UP#[5_-_76_!3X[^+OV
M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
MF;DGZMWDO6[]#]!R/Q Q&$M1Q,%*G_=2BUZ)6B_2R]3^C^BOE7_@G!_P4ST7
M]MC0FT75(8=#^(.EV_FWEBI_T?4$!P9[<DYP.-R'E=PY8?-7U57XEF&7XC U
MY8;$QY9+^KKNGW/V7 9A0QM!8C#2YHO^K/LPKYW_ ."L/_*/7XE_]>5O_P"E
M<%?1%?.__!6'_E'K\2_^O*W_ /2N"NG(?^1GA_\ KY#_ -*1SYW_ ,B[$?X)
M_P#I+/P;HHHK^KC^7PK]Y/\ @D]_RCU^&G_7E<?^E<]?@W7[R?\ !)[_ )1Z
M_#3_ *\KC_TKGK\R\4_^1;2_Z^+_ -)D?HWAG_R,:G^!_P#I43Z(K\M?^#A+
MXW->^+_ _P .[>;]S86TFOWR Y5I)&:&#/H55)SCTE'J*_4JOP=_X*P^/Y/B
M'^W[\0IS(TD.EW<6E0J>D8MX8XF ^LBNWU8U\1X;X%5\W]K+:G%R^;M%?FW\
MC[3Q"QCHY5[*.]227RW?Y)?,^=:***_H0_!0K^@3_@G]^SM'^S#^R9X0\,-#
MY.J-:+J&K$C#->S@22@^NS(C!_NQK7XE_L3_  U3XO?M<?#KP[-'YUKJ&O6I
MNH\9WP1R"28?]^T?Z=:_H<K\?\5,PDE1P,7H[R?Y+]3]8\,< FZV-ENK17YO
M] HHHK\;/UP**** ,/XE?#[3?BQ\/=:\,ZS#]HTK7[*6PNDP,F.12I(ST89R
M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
MA"=%_P"@1I?_ ("I_A6I17E>TGW9Z?LX=D9?_"$Z+_T"-+_\!4_PK)\6? [P
M3X\LOLVN>#_"^L6^,>5>Z5!<)^3*175454:U2+YHR:?J*5&G)6E%->A\3_M1
M_P#!#_X8_%[3+B\\#*_P_P#$6"T8@+3Z;.WI)"QRF>F8BH&2=K=*_)_X_P#[
M/OBK]F3XF7GA/QAIKZ;JUGAU(.Z&ZB.=LL3]'C;!P1T((.&! _HXKYP_X*=?
ML9V?[7O[..I1VMFC^,?#,,FH:#.J_O7D5<O;9ZE95&W!X#[&_AK]#X2XZQ6&
MKQPV/FYTI.UWJXWZWW:[I[+;L_@>*N"L-B*$L1@8*%2.MEHI>5MD^S6[W[K\
M(J***_?#\--KX;_$76OA'X\TGQ-X?OIM-UK1;A;JTN8SS&Z^HZ%2,@J<A@2#
MD$BOW^_8R_:?TW]K[]GS0_&FGK';W%TGV?4[-&W?8+V, 2Q>N,D,N>2CH3UQ
M7\\]??W_  0&_: F\)_'3Q!\.[J;_B7^+;$W]FA/W;RV&2%_WH3(3U_U*U^>
M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>amortacquiredintangible.jpg
<TEXT>
begin 644 amortacquiredintangible.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M%'M /Q5U;]N+]J#P7X4O/&VL7_PHU^Q\<>'OVSG\*V$7P^\1:?8_"2']F/\
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M5KIT^E:=KUU<:O-;6TUE:VC3W\'T\"& 8=" 1]",U^(/_!2?_E))_P $*?\
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M4+3P7J_Q&\170M!\4/BIJ.AGQ+XE\+2:IX(\(MX$\,W1TZ:A\'O@=^U#\/\
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M -!%?B'_ ,%)_P#E))_P0I_[.M_:@_\ 6.?B#7[>1_ZN/_<7_P!!% #Z***
M"BBB@ HHHH **** "BBB@ HHHH *X3XF_P#(A^)O^O!?_2F"N[KA/B;_ ,B'
MXF_Z\%_]*8*\G/\ _D19U_V*<Q_]0ZPX[KU7YGQ&W4_4_P Z2E;J?J?YTE?R
M*(**** "O=_@-_R'-=_[!%O_ .EK5X17N_P&_P"0YKO_ &"+?_TM:OJ^!O\
MDK,D_P"PFK_ZB8@:VEZ?JCZ:NO\ CVN/^N$W_HMJ_.U>@^@_E7Z)77_'M<?]
M<)O_ $6U?G:O0?0?RK[GQ=_BY!_AS7_WF"%HHHK\; **** .[^&7_(^>&_\
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MGV4<MS<WLJ6EG"EO;))=WLUS>7+K#&BF:ZN)[B0C=++(Y9C^0GB;Q%X?TO\
M;-\<Z%XX;PE\0;O4/C1\+K7PEXCUW]I']IOPQ'\+KCQ'X:\"KX?^$VJ^'?!?
MP)U']G3PKXCOM0M%\3^!/ASX@^*&F>(?B7-XNTP>(H6U+Q1I-]K/[$CI^)_F
M?U]1V/% 'X@_\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_ -!%?A__
M ,%+8DG_ ."D'_!"J-S(%/[5W[3I)BEE@<%/V//'[KB6%XY%^91N"N RY1@R
M,RG]C+UO"&DO#;:IKC:=</!',D-YXLU:VE:)BR+(L<NK(Q0NCJ& P2K '(-9
M5J]'#P]I7K4J%.ZCSUJD:<+O9<TVHW?17 [>BO//[6^'W_0UVW_A::C_ /+B
MC^UOA]_T-=M_X6FH_P#RXKD_M7*_^AE@/_"O#_\ RSS_ #[,#T.BO//[6^'W
M_0UVW_A::C_\N*/[6^'W_0UVW_A::C_\N*/[5RO_ *&6 _\ "O#_ /RSS_/L
MP/0Z*\\_M;X??]#7;?\ A9ZC_P#+BNAM=)T6]MX;NSN[^ZM;A!)!<6_B/6Y8
M9HVZ/'(FILCJ>S*2#ZUO0QN#Q,G'#8K#8B45S2C1KTJLHQNES.,)2:5VE=JU
MW;<#HJ*Y^;1M'MP&GNM0@5CM5IO$>MQ!FP3M!?5%!. 3@<X!-5_L/AW_ *"5
MQ_X5.K__ "VK:52G%VE4A%]I3BG]S=^J^\#J**Y?[#X=_P"@E<?^%3J__P M
MJ/L/AW_H)7'_ (5.K_\ RVJ?;4?^?M+_ ,&1_P _-?>!U%%<O]A\._\ 02N/
M_"IU?_Y;4?8?#O\ T$KC_P *G5__ );4>VH_\_:7_@R/^?FOO ZBN$^)O_(A
M^)O^O!?_ $I@K;AT;1[A2\%SJ$Z@[2T/B/6Y%#8!VDIJC '!!P3G!![UQ_Q%
MT:RM?!'B*>)]1,D=B"HFUC5[F(G[1 ,/!<WTL$@_V9(V7.#C(!'FYZU+(<Y<
M6FGE.8M----?4ZVJ:T8UNO5?F?'#=3]3_.DI3P3]325_(P@HHHH *]W^ W_(
M<UW_ +!%O_Z6M7A%>V?!&R@OM9UN.=KE532K=A]FO;VR8DWA&&>RN+=W7@$(
M[,@/S!0W-?5\#?\ )69)_P!A-7_U$Q UM+T_5'U+=?\ 'M<?]<)O_1;5^=J]
M!]!_*OOBYT#3UMYR'U7(AE(SKVND<1MU!U(@CU!!!Z$8KX''0?05]SXN_P 7
M(/\ #FO_ +S!"T445^-@%%%% '=_#+_D?/#?_7W<?^D%W7V[7P[\.84N/&_A
MZ&0RA)+J<,89YK:48LKIALGMY(IHSE1DQR*2,J25)!^U+/3[:P\S[.UV?-V[
M_M6H7]]]S=MV?;;FX\K[QW>7LW\;]VU<?OOA-_R(\P_[&];_ -0LO O4445^
MI@%%%% !1110 50U6[:PTS4;U$MI'M+&\ND2\NFLK1VM[:694N;Q;>[:TMV,
M8$]R+6Y-O$7F%O,4$3WZHZI%<3:;J$-JBR74MC=QVZ-J%UI*O/);RI"C:I90
M7-YIRM(RJ;^UMKBYLP?M,$$LT21L ?A1?^//AK\2/C3%#H_Q4^&2_#7XL_&/
MX.?$GQS\'M!_:UT6+PIXU^)^CO\ #K?JS>'[S]C+4?B*[KXJ\(>'))/"'AGX
MW>#O"'Q,N_"NEZCKVG:+'XN\5:==_O(.GXG\>3D]!R3R>,9Z<5^+Z:I;>#OC
MMI'P\@\3>*M=U/PMXU^'&B^)X(?^"@W_  4%^(4N@>)-5L_">NZEX<\2Z'I7
MP#\2?#B[O+(:W%-#X9\9>-]'M_$/A>[T+4_&4?A/3_$UQ:Z?^T _J>Y/<^O\
MN@Z#B@#\0?\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]"_C@<>*-.."<>';,X'4X
MO-0X'N>U?GI_P4G_ .4DG_!"G_LZW]J#_P!8Y^(-?H9\<!GQ1IH]?#UF."0?
M^/S4.XY'U'-?GGB?_P DM4_[#\%_Z7,#\KK7]KOQ)=_ME>)_V9/^$.\!:?IW
MA[PEJFJ:=I?B/XC7'A'XX>/I],MQJ<?C7X9>#/$OAG3_  5X]^'NKPR)H^GV
MN@>-[G7K(6VK>+?$%WHUGH^I^&[3!\;?M?\ Q<^$.C?%B7XK_![X=KXF^'W[
M/GA;]HN?2/AY\2?$_B+1_AYX;\2?$?3?A_>^&_C?K-WX(6^L;_PM87>M?$5O
M$OPYT3Q%;_$+P3\//B2? 7A*6]T/1IO$/K?B/]E#2/$_QRM?C3JGQ5^+%S!H
MT5OK7A+X;W^KZ!K?@GP7\3-/U35]5T/Q_P"&_P"W/#E_XBM;#P]?ZS=:WI/P
MS?7G^'B^)VEU"[T:ZT*YG\+-PW@C]B"/PWX)\3>!?%?[0OQ7^)MEXE\3^$/B
M3/XF\1^#/@=HOQ"?XS^!?&'A[QOX8^,GB/QMX?\ AS%>_$;Q9I^K^&-'LUT/
MXB6?B3P!'X>M8/#6G^$=.T&QTO3M/_$XU,C_ -GDZ=/E5# QQ%)QQOM)U8U4
M\7.%6,N2-Z5U.'*DVX^QJOEES4K?@M79+==%\U>]WN[:VY'0/VU=?\6?!GQ5
M\6?#VI_LLR>#? OQ+UGP'XF_: U;XG?$G3?V<IK'2/#_ (?OO[5\/6:>";GX
MN:AJTGC+Q OPSU/1KFQ@TW0M;TS4?$</B+Q'I4NGZ1<^R:O^TU=Z7^RAX&_:
M1N/!&GZ)JWCW0/@U=6WA+Q5XRATOPCX0UCXT>*/"?A#2=1\=_$:+1Y4T?X:^
M&;WQ9:>(?$?C,>'TO(_"D*RMHFGZQ=FQL[>C_LSZWX=USQ'\0/#W[2/QOT/X
MR^-O$>F^(O'?Q5T^P^$$?_":G1/".D^!M TOQ!\+'^&DGPHNK7PWX>T:U7P[
MK!\,MXST[5)]0U"Z\5ZI:7\^DG2T#]FC2/"'PWM_A#X/^)GQ-\-_#G3_ (4I
M\--*\.PGX>ZTMEJLWC;5O&^N_$VZN/$W@+68-?\ %OC"XUK4/#WB[PSKNG7O
MPIU7PE=7>AVW@#38;IWCRK3R>3I.E3A%+%T*E2/-B[SPRB_K-"4G3CO-Q]C6
MIPIRJ4XN7U;!3BZ>(-+]%KYM+;NW>VNZZ[O2U_X!_&RZ^*FI?&'P9KX\!R>.
MO@3X_P!%\!>,]1^%GB/4O%/PYUN7Q/X$\/\ Q#\/ZMX8U+6K2TUFRF&DZ])H
M_B?PQJIO[WPQXGT74K ZQJD$D$L?ZU?#K_D1O#'_ &";?^35^6OP0^!_ACX&
M:#K&CZ!?7FLZCXGUNUU_Q/X@O=&\(>&/[2O--T'2?"NA:=I'A#X?>'?"?@3P
M7X5\,>&=#TW1/#/A+PEX<TW2M,MX[R]G.HZWJ^LZMJ'ZE?#K_D1O#'_8)M_Y
M-7Z#X8O#OB+-7A4U0_LJ*C>ZYI1K8-59Q4O>C"I652=.,K.-.48M)II)[+U?
MZ'G?Q[ .A:#D XUF3&0#C_0+D=P:_*7XQ?M66_PO^.OPG^ >A_#'5OB+XN^(
MUNNMZA#I_C+X=^#M2L/"]QIWQ%FM;OP-H?CG7=#NOBIXBMM0^'.IC7O#GAZ:
MTCT+3+O1TNM8/B3Q5X3\/ZO^K?QZ_P"0%H7_ &&7_P#2"YK\BOVJ_P!D>^_:
MAU?X?VVJ_$V+1/A]H&IWUSXE\':G\,_ WC6_M)+CP=XZ\-+XO^#_ (MUVQ76
M_A=\3I'\66 /BD2Z[9Z/-X=\-^,?#6EZ5XQ\+V,^J>7QO' OC7'+,.58?ZE0
M7--5VHU/J$/92<,.O:U.6=FJ:G2C.5E.I&-TQ/?5[:6?7^KL[35/VB-=\.?$
M30/#/BSX%^-O#_@?QQ\0/'OPN^'7CK^W/#6K>)O&?B_P!X)\;>/YKNW^#%C
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M\S[?9VEKC;Y7V:_EO=^=V_?YEA9>7MPNW'F;]QSLVC=^^^$W_(CS#_L;UO\
MU"R\"]1117ZF 4444 %%%% !1110 4444 ?B!_P4G_Y22?\ !"G_ +.M_:@_
M]8Y^(-?H9\;_ /D:=-_[%ZS_ /2S4*_//_@I/_RDD_X(4_\ 9UO[4'_K'/Q!
MK]#/C?\ \C3IO_8O6?\ Z6:A7YYXG_\ )+5/^P_!?^ES \:HHHK^<@"BBB@!
M5ZCZC^=?<?PZ_P"1&\,?]@FW_DU?#B]1]1_.ON/X=?\ (C>&/^P3;_R:OU3P
MF_Y'68_]BN7_ *EX8?1>K_*)YY\>O^0%H7_89?\ ](+FOEZOJ'X]?\@+0O\
ML,O_ .D%S7R]7C>)'_)68[_KQ@?_ %$I""BBBOA "BBB@#ZJ^!'_ "+&J_\
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M?_1YG@O_ ,-Q\?\ _P"=!7X#_8&??]"3./\ PV8W_P"4>?Y]F!^K5%?E&/\
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MFMM3>XF4_#;X]X6(V<T8;*?"60\NX'( ]"3Q7A7_  _#_P""4?\ T>9X+_\
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MGS_V=R>T]C"?)S\D^7FMS<LK7Y79'ZMT5^4O_#\/_@E'_P!'F>"__#<?'_\
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MASCN"/?UYIWEKZ#_ +Y7_P")I_\ G_/Y&DR,9R,>N>.>G- #=B^@_P"^5_\
MB:<!C_\ 4!_("EHH **** "BBB@ HHHH **** "BBB@ HHHH _(']HCXT_&Q
M]>_X*!^-/#7QKU7X/VW["7P[\(^*?AGX'L]&\%7G@[XEZC=? Z;XVZAXG^+\
M7B#P[KOBOQ#X,\<:W//\%=%TOPKK/@N;2)O"'BO4M N[SQK/8W^D])XH^*WQ
MI\(_M(_L]^*IOB)\2W^$WQB^+UOX \6PZC9_ [4/@!X)N?$'@GQOIVE?LYCP
M_P"&1=?M#6GQXT?XGZ!H_P!I^)6M+9>";74Y-;\/>*]0TVU;3?!EO]=?'_\
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MT%C_ &KK5]B34-9U);"TL].BOM5N[RY@TZSL]/AECL[6W@C /3J*** /SO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biosimilars.jpg
<TEXT>
begin 644 biosimilars.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M9!Q70T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !G%&0>ASW_ ]#7YD_P#!4_Q1XW\.
M? +3(_ WQ8LOAQ>:CXDNUU70H?C#!^SYXQ^)6EV?AK6+E/"W@'XS7>E:M;^%
M_$.EZN=*\87FC@Z)/XP\-^'];T/_ (2;1+%[^6?Y)\:?&G5-2T"Q_:97Q_XE
M\6?#WX1_LZ?#;QCJ7PO\6?MP>.?@1\:M5NO!WQ(^.6G>,-1@^&7[.\>F_"+X
MT>)/B;>>'?#_ (?^&GCK6[S4/AA\>&\-6'A[P0Z:5XBOO$[@'[V9'3/)Z#UQ
MUI RM]U@>G0@]>G3U[5^(_CO]KGQ?K__  4(^$?@&3Q/\?\ X->%?[2_:E^#
M&@>%=1^"/QBTSX>>*)?#?P[\/WL/QX\5ZOK7P_M_AQXQL[/Q[9W+_#N^D\57
MW@[PC\.]$D\8:WJ6G1_%*[BTKW/]E+Q?;67CSX@>//#7[1'C3XB?LF:-\,/"
MFB77Q5^.WQ2L/$VG_%CXU6WBN]MO$7Q<^%-_K<]G!X4^%\VG30>&M1O_  \F
M@?!WQSXMU#31\'_#5AH?A6YUWQ8 ?J-_G_/YBBOQ?UK]KGQ1KO\ P4I^!G@"
M_O?V@OA_X,7Q-^TM\%]'^&=W\&OC?H/@#XBCPMX-\)W?_"X/$OB.;X>Q^!_%
M5M=^.;*^M/AMK-EXIU'PSX.^'>G#QI?ZA82_%*>#3/V@!R,^O/((/X@\CZ'F
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YC^,_[67PP
M^!7QF_9;^!7C2S\6W'C3]KOQWXX^'?PLGT'1[*_T&SU[X?\ P[U7XFZY)XOU
M"YU>PN-'TZ3P[H]W%I]Q8V&L37.IM%;2VUO TEW']-@A@&'0@$?0C-?B#_P4
MG_Y22?\ !"G_ +.M_:@_]8Y^(-?MY'_JX_\ <7_T$4 /HHHH **** "BBB@
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M=95(PJU8PC.7Z T445^0'[V%%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_0MZO\ ^!/A_P#^7=']J:A_T+>K_P#@3X?_ /EW0!MT5B?VIJ'_ $+>K_\
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M;+&^TR[$%S$LT0NM.U.VL]1L+@(X$UG?VEM>6T@:&Y@BF1XU /Q/_P""D_\
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M%JU5A\7AN3$1I4JTJ?)BZ&'J-JG7I2YHP</?LI<RDD4445XY[P4444 %%%%
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M_9?^!OB;7M/OYM8USX=Z%J.HRZ7H=S%ITEU.DID:SC1YE2 X!15D<!2"&(;
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M_P")<'C/XDVL>F-J-HGB[4-1N?#]F_AHW,\4USV7B3]ESX%:C\0O"=M^UO\
M&;QK\9/B#\2=.M/A5\$M#\5#1/@QXM\1+\-M:@^/CW&BGX'P_#KQ=X[^(WAR
M_P#A[;_$'5?%R7T&F>%8?#\]]H&@^$6US6O^$@_DZO?^"KUY?_LFZU\&_B'X
M+^+GQ9\8Z>GA.#X-^)M9^'O[.UWX\\$FW\*?#_3/$NH>+O$&D7WAO3SJ]O+H
M7BGPQX7\6:3;W?C;_A!;K1=#\2:G<W?VZ9?IKXP?\%S/ ?B_XN_L^?&/1O@7
M^T#+XK^'7Q"G\2Z[XG/P_P#@$/&MOX 3X:?'/P9I_@0:PWCI+H_9O$?Q/M]?
M?P\FH/H#0W%UJTMU<:M:6<45TN#<54ASRS3*:3Y*,W"I+,>9*M5=)Q]S+IIS
MI)>UJI-J-*49)MMQ6-;Q PM*K*G'(.(*\8U,3356E#*/9R^KT*5>,U[3-Z<U
M#$2J/#X=RBG*O2J0FH149R_I'TS]F+X*_LK?L]_$#PN_Q7^*GPS_ &<_^$D_
M:A^,/[1%_P"+]>U[6(]<\ _&/2/B=J7B/2=3^(_CO4_$WC+X;:+\-4\7V'B'
M2/%'P]UOP_XJU/4? UAJ7B2^UO6/$?BZZU[N_P!G/]GKPYX'\5^$_C6/B3XQ
M^+1TCX*0_"+X0ZC!\,?AWX!T;3_@MKU]X,\5V45\OPW\(>&3XVU"Z;P?X8N=
M'U36%M]%\-V;:NO@SPIX6E\5>*I-8_EC_:U_X+=^-/CUX/@\*>!]*\5VOA_3
M$^(3Z_X0^+/AOPR=.^(&N3>"CIOPPU:RNO 'B>=?['\*>)=5U'Q/#HGB>U%O
M?>-=%\(:Q>)!:>&DCU'W;X&_\%\(O /P8^%'@7QAI'Q//B?P9\.O!?A+6SX/
MT+P%-X:-]X:\/:?HC-I,WB36QKDL3Q6$+7$FH .]\;MX +1K<#:GP/BZF*J8
M;^V,EA&$.>.*G5QZPU7^'[D)++W44TYOW9TH:0E)-KE;YZGB1A:>$I8E<.<2
M5)U)N$L)3HY2\31UJ)2J1>;QIN#C3C/FIU*B2JTXNU3GA#^P3^WX_P#H%:]_
MX*+O_P")K\V?^"O^KI=?\$U_VN(1I^L0E_AE$HEN-,N(8%SXN\,',DS@*@XX
MSU&3VP>I_P""9_[:NG?MS?!OQM\2].M?%MM#X6^)M]X%=/&5CX<L=0:6U\*^
M%O$!>VB\-7=W9M9%-?4+)/(MT9Q.K)Y2Q,<O_@L0 /\ @FE^UW@#_DF,7;_J
M;_"]>#+!2R[/*6"G7H8F6'QV&@Z^&=25"I^\I2YJ;JTZ51QM*WOTX.Z>G4^I
MAF$<UX>JYA'#8G!K%9=BJBPN,C2CB:/[FJN2M&A5KTE/2_N59QLU[Q_ E\%O
MCQ\3_P!GKQJ?&_PM\0C1M4DB-CJNG7^GV&N^&?$NFI,;F#3/%'AK5X+K2=<L
MK._6'5-/6[M_/TW5+:WOK"XMIED,O6:1^UU^T;HK7=Q;_%#4;[5I]=UOQ19>
M)=?\/>"?$GB[POXF\26-EINO^(? /BS7_#&H^(/AOJ^K66G:=!<7/@#4/#4=
MN-/T^738;"XL+.:#YRD_UDG^^W_H1IE?I7L:,WS3I4Y2E&,92E",FTD[)MIW
M2N_O/RJ->M"*C"M5A&+<HQC4G%*4N6[2323?+%W757W/:(_VAOC'#\/D^&$'
MC6>#PG%H%KX0C-OHGAB#Q8O@FRUQ/$UGX#_X6-%HB?$8^!+3Q%%%K5KX./BO
M_A'X+^&%H[!8(8K=-O7?VJ/CMXGUWPWXCU_QI9:KJGA76O$?BC3C<^!?AU_9
MNH>,/%^B_P#".^*?''BW0H?",6A>._'?B'1A'9:KXU\:Z;K_ (FN1;VUQ_::
M7D"7%?/E%/V-&]_8TKWD[^SA>\URS>V\XI*3^TE9W0>WKVM[:K9*"2]I.R5-
M\U-6OM"7O07V7K&S/=/$7[1WQ4\6_#SPQ\+O$=UX(U;PAX)\&VG@#P?'<_";
MX5+XB\+^$[.Y%ZNFZ#XT@\&P^,-+N+N^#:AJ^L6FN1ZWKNH37&H:YJ6HWMQ-
M._[H?\&U=XMG^T;^TG(UO>W._P"!_A ;+&TDNG7'Q$E;+I$,HA_O=  Q_AP?
MYNZ_I/\ ^#:  _M(?M*Y&?\ BQW@[_U8LM>9G<(0R?'J$(P3A"348J*<GB*3
M;=DKMO5O=GK9#.<\ZR]U)SFU4<4Y2<FHQHU%&*;;M%*R26B2LK']>/B[78W\
M*^)5&EZ\,^'];&?['NL<Z7=CDD #KQZG [YK_+=\(>+/$_@37M$\7^"]?U7P
MMXIT"5+W1?$&B7/V74],NFM)+626VE*2Q.D]I<W-G=VMU#<V-_8W-S8:A:W=
MA=7-M-_J>^,0/^$4\2\#_D7];[#_ *!5Y7^5#'_JHO\ KE%_Z+6O$X12<,P3
M2:;PZ::NFFJZ::>C36Z/H.-6U/*VFTTL8TT[--2PC336J:=FFGHT?5?BC]M+
M]HKQCXS\3>-=?\9Z5J4OBW3K#1]7\'ZEX#\ ZY\+SI.DZG/KFE6%G\+_ !'X
M:UGP/9C3->O-0UZQU"+1CK46L:IJMZVJ.=1NTEQ]._:[_:-TS4-<UB'XGW]Y
MK>O>*[WQV^OZUX>\%>(=?\/^-]1TBQ\/WOB_P%K6O>&-1U'X:>(IM TK1]$C
MU+X>W'AF2TTS1-!M;%;4:%H[6/S?17UJPV'2Y50HV24;>SA:R226VR27W+L?
M%/$XAOF>(K7NY7]K._,VVW?FW;;;>]V^YZ]?_'CXJ:E\/Q\,;KQ):CPBVCZ%
MX;ODM/"O@S3?$NN^%_"^IC6O#'A/Q3X]TWP[:>/?%GA/P[JZ0ZGHWAOQ+XFU
M72+.^M-/N!:.^EZ:;3I+#]J7XXZ5?^)]5TOQ7H^FZKXJ\2:UXPN-5T_X=?#"
MSU3PYXJ\1Z)!X;U_Q!\-]2@\%I>_"C5=8T"VMM)OKGX93^$B]K;V[Q+#=P17
M*?/M%5[&B[ITJ;3;;7LXZN5N9O35RY8W>[Y5?9$JM63356JFDDG[2=THWY4M
M=%'FE9+1<TK;N_Z0_P#!(.1;7_@I+^R5((I9$A\=>(PL-K"TTI4?"WQ\BK%"
MGS,$&,@?=C5FZ+7^B=I^H+>JX6TU"V\I8\_;K*6TW[@W^K\T#>5V_.%SMRN>
MM?YV_P#P1^_Y26?LD?\ 8^^)?_56_$"O]%=  BX 'RKT^E?"<6?[]A_^P2/_
M *>K'Z'P7_R+\5_V&S_]1\*.HHHKY8^Q"BBB@ HHHH **** "BBB@#\0/^"D
M_P#RDD_X(4_]G6_M0?\ K'/Q!K\0/^#CPD?MQ_#?!(_XQ@\$=_\ JHWQ2K]O
M_P#@I/\ \I)/^"%/_9UO[4'_ *QS\0:_$#_@X[X_;D^&IXX_9A\#_>^[_P E
M&^*77V]?:OHN%_\ D:+_ +!ZWYP/F>+?^1//_L(H?G(_ C[%?_V>-7^R7?\
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MPM8V-IM?M<?%GX'?$_X'?!.R^&'C7Q7<7/@OXH?'*P\+_"K7/!&A^&(?A?\
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M_?L/_P!@D?\ T]6/T?@S_<,5_P!AM3_U'PHZBBBOEC[$**** "BBB@ HHHH
M**** /Q _P""D_\ RDC_ ."%/_9UO[4'_K'/Q!K\/_\ @X\_Y/C^&W7_ )-@
M\$=01_S4;XI^M?U%_MN_\$]/A/\ MV3?!75?'OQ(_:$^$/C']GWQ=XE\;_"S
MXB_LV_%J^^#OQ"\-:]XM\,/X.UV:U\5:=I.J7T,=]X=FN=,?[']DG%K>7MN;
MAK>\N(9/S5^)G_!MK^R?\:=>M?%7QA_:\_X*>?%3Q/9:5!H-GXB^(/[:FO>+
M-:M=$M;J[O;72+?4M:\%W=U#IMO>:A?74-FDBP1W%Y=3*@>:1F]/*<?#+L7]
M9G3E4C[.=/E@TG>7+K=Z:6/*SG+IYI@GA:=2-*3JTZG/-.2M!NZM'6[OH?Q/
M[V*>668QEBYC+,8RY3RRYC)V%S'^[+E=QC_=D[/EJH+*R4,%L;%0Z['"V=LH
M=-P;8X6(!TW -L;*[@&QD C^R?\ XA5_^"?'_1<?^"@7_B5D_P#\P-(?^#5C
M_@GP 3_PO'_@H%P"?^3K)^PS_P!"#7U'^MN&_P"@2O\ ^!T_Z[_T]/D/]2L2
M]\;A_P#P74\OZ^2^7\;8M+0(T0M+01.RN\0M;<1.ZY"N\8C",ZY.UV4LO8BI
M3'&Q8M'&Q9/+8M&A+1\GRF)4EH\D_NSE.3\O)K^I7X$_\&UO[#/Q)\7_ +4&
MA:Y\;_V[EL_@]^T3=?"SPO\ V=^U+<0S_P#"/0?!/X(?$#_B<2?\(/-]KU,Z
M[\0]=(N-EL5TTZ=;-"YM_M$WT7_Q"K_\$^/^BX_\% O_ !*R?_Y@:/\ 6[#_
M /0'7_\ !E/RO_7DOD+@K%?]!N'7I3J?UW_IZ?QQ0(D;1)&B1QHRA(XT6.-!
MNSA$0*JC))PH R2>I-?Z._\ P2D./^"<W[''!_Y(3X-['_GE<^WO7Y2C_@U8
M_P""? .1\<?^"@0(Y!'[5EQD'U_Y$&OICPC_ ,$*?AU\/_#6B^"_ G_!1C_@
ML'X,\'^&["'2O#OA;PQ_P4$\=:)X?T+2[?=]GT[2-)L/"\-EI]C &80VUM%'
M#&"0B@5XV<YW2S2A2I4Z%2DZ=7VC<Y1DFN24;+EUO=_<>YD605LHQ%:M4Q%*
MJJE'V2C",HM/GA._O:6]UK[CYS_X.8>?V</V;^O_ "7[5.H(_P":5^+_ %'L
M:_C5]. <$D9 .TD%25ST)4LI(P2K,N<$@_W%?%'_ (-[/@#\<-,TS1?C1^W/
M_P %7OBSH^B:B^KZ-I7Q%_;J\6>+]/TG59+2:P?4].M-;\(WD%G?O8W%Q9M=
M0(DQM9YH"_ERNI\3_P"(5?\ X)\?]%Q_X*!?^)63_P#S UT95Q!1R_!T\+/#
MU:DH2J2<XR@D^>;E9)ZZ)_?]YSYOPS7S+'5<7#%4J4:D:45"<)N2]G",&VUI
MK9M?+Y?QQ[WQC>V!T&XXXZ<9QQ07<XR[''(RQX/J.>*_L<_XA5_^"?'_ $7'
M_@H%_P")63__ # U\W:7_P &V/[#5Y^USXT^!\OQN_;N_P"$2\/_ +.?PS^*
MEB4_:DN!K7_"1^+OBE\7?!NJFYN_^$'/FZ8=,\#Z,;*V^S1B"Z%_(9IC<;8?
M1_UMPW_0)7_\#I_UW_IZ>7_J7BO^@W#_ /@NH?RYEF.<L3G@Y).0.@/KBDR>
MF>!T'IGK7]CW_$*O_P $^/\ HN/_  4"_P#$K)__ )@:/^(5?_@GQ_T7'_@H
M%_XE9/\ _,#1_K;AO^@2O_X'3_KO_3T/]2\5_P!!N'_\%U/Z[_T].W_X-K/^
M3._C3P?^3E];Z G_ )I;\+_05]^_\%B#G_@FE^UWP?\ DF,78_\ 0W^%_:OC
MSX8?\&^GP)^".BWWAOX-?MV_\%8_A1X>U35)-<U+0OAY^W=XM\(Z3?ZU+:6E
MA+JUY8:+X1M+:XU&2QL+&S>\EC:=K:SMH6<QP1JO1>-/^"$7PS^)'A?6?!'Q
M#_X*)?\ !7_QSX,\16HL?$'A/Q9_P4!\<Z]X=URR6>&Y%GJVD:CX6GLK^V%Q
M;P3^1<PR1^;#&^W*@U\M7QT*N:?V@J<HP^LTJ_LVTY6IN#<;[7?([/;4^OH9
M?.CE#RUU(.H\)5P_M$GR<U2G."E9ZV3E=K>R/X49/]9)_OM_Z$:97]CQ_P"#
M5C_@GP22?CC_ ,% B3R2?VK+C)/J?^*!H_XA5_\ @GQ_T7'_ (*!?^)63_\
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M1W<*R;6DL[N]T^[39>:;?7NGW%K=S>B4 %%%% !1110 4444 %%%% !1110
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M/M:T+QAH^ML=!EL-4M-1T;6-*UN\BM_KRB@#\G-1_8*\=?$/]G_P_P#"B_\
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M>,WMN-375= \+>+? ^N7WGZ5]MM[/[%XGTTV]]);74YNK>&6TG_-W3O^"?\
M\4M5^#/[/'PW^*GCK]FKXNW7[.'@.Z^$_A[PE\1OV;?$_CC]GWQGX.?PG\./
M">E^,O%WP@\3?&V[N%^-OARQ\%:[::#XZL_%4VBZ?X9^('C;PK;>%+=/$%SK
M$/ZO44 >,?L\_"%_@+\%OAW\('\8:[X\;P%X=@T+_A)_$+2_;;Y8[BYN4M[2
MVN+[5)],\/Z1'<KHGA31)]6U>?0/"NF:+HDVL:M)I[:C<^ST44 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[Q1?0:7X)MW@\01_&&*6U;1=-T"YTZV\%E-&9GA/_@EO-X1\;? ;4X_CI?\
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MX ^H!X.1R,]>_P!>]+3478BKG.U57/3.T 9QSC./6G4 %%%% !1110 4444
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MI>G:D$CC&H6%G>A(KB.[B07=M%<;8[J$"*YC7S-J7$0$<R@2H KBOS7\2?\
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>reservesfordisandallow.jpg
<TEXT>
begin 644 reservesfordisandallow.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %@ 3T# 2(  A$! Q$!_\0
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M^*&\#R1^#(_J;QY\#]+\=_%3P7\4[G7]2T^]\&?"#XY?"*VTBTM;&6QOM/\
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MJ&J/=W3:E>VYCNKYKB=KJ:8RR%@#\7O$7[9O[6EIX0\7^+=(\5_!)(3\)/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_"0:0-0O;J2WB#7@6 SM!="  ]/HKY3\#_MM_LQ?$/P5XP^(_ASXHV:> ?
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M')]:SP^$JXKG]G4PL.3EO]9QV"P=^:]N3ZWB*'M+6?-[/F4-.:W-&^N,Q]#
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MG&_"G_L.ZC_ZC.O5_08O0?0?RK^?/]DG_DXWX4_]AW4?_49UZOZ#%Z#Z#^5
M"T444 %%%% !1110 445%/,EO#+/(',<,;ROY<4L\FR-2[;(8$DFE?:IVQQ1
MO(YPD:,Y52 2T5\Y7'QW\7K(][8_LS_'W4_"L9D)\2Q6GPLTZ[E@27:+ZW\
M:[\4])^);VQB_>_9)_"5KXA;[D.@32D)7O\ IFH0:MIUCJEK'>Q6^H6EO>01
M:CI]_I.H117,2RI'>Z7JEO::EIUVBN%N+*_M;>[M90\-Q#%*CHH!^)/_  4N
M\_\ X>/_ /!"S[+Y'G_\-6?M/^7]I\SR?^3._B!NW^5^\SLW;,<;]N[Y-U?M
M$G_"3;$Q_86-JXQ_:F.@Z9YQZ9Y]>:_&+_@I/_RDD_X(4_\ 9UO[4'_K'/Q!
MK]O(_P#5Q_[B_P#H(H PO^*F_P"H'_Y4Z/\ BIO^H'_Y4ZZ"B@#G_P#BIO\
MJ!_^5.C_ (J;_J!_^5.N@HH Y_\ XJ;_ *@?_E3H_P"*F_Z@?_E3KH** .?_
M .*F_P"H'_Y4Z/\ BIO^H'_Y4ZZ"B@#G_P#BIO\ J!_^5.C_ (J;_J!_^5.N
M@HH Y_\ XJ;_ *@?_E3H_P"*F_Z@?_E3KH** .?_ .*F_P"H'_Y4Z^>/VL?[
M>_X9V^*OVO\ LC[/_P (VOF_9_M_G;?[4T[_ %?F_NMV['W^*^IZ^</VNO\
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MYK/_ '_\/?\ R]H_M2^_Z%S6?^__ (>_^7M &S16-_:E]_T+FL_]_P#P]_\
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M3-JDJ2JED)*,5!9"PVL4;&5+*2K%2-RDJ<J2*>W4_4_SI* $P/0<\'@=/2C
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M&2XN)!%&TAC@@A!EFF<*5BBC!DED*H@+,!0!\67/PZT#X>?&;Q3J>A_M5?\
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MVMX8TBAAB18XXT5$4* *O44 ?B!_P4G_ .4DG_!"G_LZW]J#_P!8Y^(-:_\
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MXQY(R@MW.T<1[!W]/N7W+3[_ /@:_J3_ ,*%^$V<?\(L,^G]LZWG_P!.- ^
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M?\([;^"_&FMZEXEM=/M?O'QQXT\1^&+_ .&MKX?^'VN>-;7QK\0;+PEXEO\
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M\-ZSH_B'Q)//KO@\7R7DWASX?+X\\::7JWANS^]5.X9Z<D<^JDJ?U!P>XYH
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M/^,E8/XI^'GQ,T7XN:E;)<ZC:>"_&WA&SETR'1OT" P ,DX &3U.!C)]SU-
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MBL=?X3XG?\$RO"WQA^-6K?%'XA?$J[\2:3J'COQIXOL[/4O!.FWGQ)T;P_\
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M%?B_X]U'X;^#M/A\9?\ "--IT/B.Y\4VMCIL^C7S6ETE]JJ:5$DNKZ)XKL-
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MDP/?\S_C2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO7/$7PX\-_"KPG>Z3:06J> ('BMIK0 ^W:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,9__61_
M*DP/?\S_ (TM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tysabri.jpg
<TEXT>
begin 644 tysabri.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M%'M /Q5U;]N+]J#P7X4O/&VL7_PHU^Q\<>'OVSG\*V$7P^\1:?8_"2']F/\
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MM1L=6TK4($N;#4M,O+;4+"]MI,^7<6E[9RS6US"^#LE@EDC;!VL:_GP_8O\
MAKI'PTU_]KKPSXX^"GQ4L_V?;))-)\8^+=:_9^\8^#_VFM/N;/1OV<AI?PBU
MSQ9^SO>ZIK/[56G>*+>Z\7W_ (K\2?#GPGJ-NB^'=6\0^)O&'CN#XTZX;3[;
M_8.^+6D^!OV,_P!ESX9VWPZ^*/AOQQ9:3I?P&T?P%XR^!_QA^$-IH?CWP_\
M"_QE\0].T/5AXL^&^CGPQX @\.^#+C2!X\TS1M3\%:1J4NF>&[:ZEUJXLM(D
M /TKMO$.A7NL:MX>L]9TJ[U[0;72K[6]$MM1L[C5](L]=^WC1+O4],AG>^T^
MVU@Z7J0TJ>[MX8M1.GWPLGG-I<>7AZQ\1_A]X>\*Q>.M>\<^#]%\%3BS:'Q=
MJ_B?0M-\+RKJ,RV^GF/Q#>ZA!H[B^N'2"S*WI%U,ZQ0&21@I_%?X ^ ?C7X0
M^,/[6VO?ME_ '7]#\'_%+]FO]F_6?C=\4?A5X]^)OQ<U'XF_$S2OBO\ M 3Z
MUX5\'Z%\'_A;H?Q!U[PWI_A_Q7I'@=/ OAIK^X\#?!SPWX-TCQ38:SI_C?5K
ME.<^&6FO)^R1^P-K^E_#?X@:=J_[+MC>_"[Q/\)OBQ^Q7^T7XB\&:+=>*OAR
MNC27D_PHTCP)I'Q%L]0\(:+;)HWP_P#B-X#\$^-? ^GKKGB?X9ZO=>'(?&3^
M(/#X!^]]UJVF66EW&MWFHV-KH]K8R:G<ZK<W=O!IMOIT,!NI;^>_FD2TALHK
M96N)+N69+>. &9Y5B!<4?#/BGPUXUT/3_$_@_P 0Z'XJ\-ZM$\VEZ_X;U?3M
M=T34H4ED@>6PU;2;F\T^]B2:*2)I+:YE198Y(V8.C*/R[^"VDW'@#]BSPM^S
MU\>O@I\5/B'JVA^ ])\>ZSX5MO@5<^./#/AWPAXQ^/OBF]^&_AN+PU;3ZAX(
MU_7/@'HEOX5UKQ+\ ?"FO>,/%OAGP=X4TW3=#T?Q?%)H8UGU+_@G9X0\5>$?
M"O[0!\0:-JO]G^+_ -H?6O'7A[X@ZQ\)-3_9ZN/BO:Z[\-/AA9ZKXMM_@!K%
MI8ZC\+K+2]=T?4/!*+<V.F3_ ! O/"]]\3KJP-[XONM3U0 _1"DW+NVY&[&<
M=\?Y_IZT-PK$$*0#@GD#CJ1W ZFOP\T7XV>,- _X*DZ]X8\2?&G7O'/AWQC;
MW/P]\#Z)\-?B?X8U/PAX%U,2?$J[TSP!\9OV9M4TC3_%NCW7A=O"NJ:SK/Q5
M\ ZQK>OW<9\)^(_%/B/PI\.O$\FC:> ?N)D'H<]OQ]*3<N=NX9],C/0'IUZ$
M'Z$'O7YY_L:_$+4M%TS]JZP^,/[0/_"RI?AU^U%XKT,^/O&VN>%=#L=-T.[^
M&GP0U>/3-)TZPDL?#_@[P;IWB?Q=J%AX8T")YAIT5[;6FH:MKNNW5[K&I_,O
MQS^(?Q'\+?M)>#=6^"OQSU#5[;X@?$CXW_#"7Q7XC^/UGXR^'.B?%6P^"/QH
MMO#OP#\1?LL:%X>LM%\$>#_A-\0/!GAOQWXJ^-.GQZK\2M#C\,ZM9^/UUSPM
MXDUK5=- /VEW+@G<N  2<C !Z$\\ ]C2@@\@@C)&0<\@X(X[@\'T-?SQZ5\7
MOCU'9Z_X1\#^)OCGIGAC4/V=_P!G3XC?%V^^)?[3/P@\9_$2[\1ZY^T7X*\)
M^-;SX(_%4?$GQ%\./AKJ/[1/PMO/B1I?PCQXY^'7@WQ7K^A:/??!WPG\-G\K
MQ9-]M?LN_&C7[OPK^U5X4UKQEJ_A'1O"7Q<\8>#/V>9OCE\4] \:?$;2K73?
MV=_ WQ(\:>%?$?C3_A(?%T_BO4/A7XYU'QO>:M#=>+OB+XF\%>';&?0?&7B&
M34_">KZ5H8!^H=%?E5^P=XEU7PGXZ'P=\5:S>_$#Q-XI_9S^&?QI7XB:/^V7
M\:_VN_"]WIJWL7A.[.K2_%N[.E^!M:\7Z[J-]XE\,ZS\.=/T[PG\2=#M-<CM
M=.TZ+P!;?;OU5H **** "BBB@ HHHH **** "BBB@#Y@^-/[6GPR^!'QG_97
M^!7C.P\7W?C+]K[X@>./AO\ "ZZ\/Z5IE]H&G:]\/_AMK7Q2UNX\9WU[K>F7
MFDZ7+X>T*ZM=.GTK3M>NKC5YK:VFLK6T:>_@^G@0P##H0"/H1FOQ!_X*3_\
M*23_ ((4_P#9UO[4'_K'/Q!K]O(_]7'_ +B_^@B@!]%%% !1110 4444 %%%
M% !1110 4444 %<9\0_'F@_#'P9X@\>>)VO5T'PU9"_U-M/M'O[T6YN(+8?9
M[2-D>=_-N(_D5@=NYNV#V=?,?[9?_)L7QA_[%=/_ $\:77JY'@Z.8YWD^7XC
MG5#'9KE^#K^SDHU/8XK%T:%3DDU)1GR3ERR<9)2LVGL>9G6,JY?D^;8^@H.O
M@LMQV+HJHG*FZN'PU6K3YXIQ<H<\%S)2BVKI-;GE?_#Q3]G!20+CQP#T./!=
MX#P3QQ= XSDX]23W-12?\%#OV:I9()97\:2RVKO);2R>"+F22WDDB>"1X'>Y
M+1,\,LD+M&5+12/&Q*,P/X.MU/U/\Z2OZJ7@AP2TGSYWJD_]_P /Y?\ 4#_6
MO=G\S_\ $8^,/Y<G_P#"&OY?]1OE^/K?]Z?^'BW[.7_/SXY_\(V\_P#DJD_X
M>*_LX][GQR<<C/@R\..W!-UW'!]1D=Z_!>BG_P 0/X)_GSO_ ,+\/_\ ,/E^
M?=A_Q&/C#^7)_P#PAK^7_4;Y?CZW_>C_ (>*_LXXQ]H\<8&,#_A#+S QTP/M
M6!CM]!Z"O9?@O^U#\+/CQK.M:%X!E\0O?Z%IEOJ]^-9T&?28?LEU>&QC:&:6
M:032^>/GC !"?,2>E?S95^F7_!,3_DI?Q._[$71O_4B:OE^-/";A7(.%\XS?
M 2S5XO T*-2A[?&4:E+FGB\-1ESPCA*<I+DJ2M:<;2L]=4_I.$/$[B;.^),I
MRK&K+%A<;7JTZSH82M3J\L,-6JKDG+%U(Q?/2C=N$M&UN[G[2.Z1JSNRHB*6
M=W8*JJH+,S,2 JJH)))  !).!7SX^J?LMS>.-0^)DNO_  .F\?:OX2@\":GX
MQEUWP/-XAU#P9;WMWJ,/AB[U:2\>[N-"6]O[NX_LV25K5WG<21N@1%]RUK_D
M$:I_V#K_ /\ 22:OY-EBBVI^ZB^XG_+).Z@_W:_.?#CP^PO',,XEB<RQ&7O+
M)8",%0P].O[58Q8MR<O:5(<O)]67+:_-SN]K*_WWB!QUB>#)Y3'#Y?0QW]HQ
MQLI^VKSH^R^J2P:2CR4Y\W/]9E>]K<JM>Y^_MC\%_P#@G=HVE>(]%\-_#_\
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M_?0$T]KS3=1O[&Y,MK>7,4O\U/EQ?\\HO^_4?_Q-'EQ?\\HO^_4?_P 31_Q
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MH W,CW_(_P"%&1[_ )'_  K#_P"$8\._] 33/_ .#_XBC_A&/#O_ $!-,_\
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MM.NK7?/X?NY88-:TZ;[1]DU;3&??>:3<7T,"37#0PR?U/:U_R"-4_P"P=?\
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MOY.5^ZG^XG_H K^J;6AXD31]5>:XT%(DTS46D?R=0 55LIR6):[VJJXRS'H
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MUK_2[\6?\BOXC_[ .L_^FVZK_-$C_P!5%_URB_\ 1:U^(_1/_A<=?]?.'/\
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MW.?NGYI_Q&#,O=_XPZ5YTZ-2"_MCWI0Q'\)QC_9O-)R2<G%)RA!J<U&'O/\
M<I_V/?V1)/!]GX&?X.?#5M L/$-[XMM3Y"C7$\4:IIMEHFJ^(7\6C41XOGUC
M5M TS3O#NK:A<:_+<ZIX=T^Q\/ZA)<Z-9VUC%VA_9]_9N*SPCX6?"U;*X^$U
MA\"9=)30-!30S\'=*U&[U;3?ALN@JBZ)'X0L=1OKN[M-'BT]+>":9FC"@(%_
MG_?X1:G'#_:\WBOP5;^#&T:RUN'Q]-?ZVOAF>#4=<U'PW:6*VZ^'G\3QZT=<
MT?5[.YTF;P['<64.EWVI7)33(!=R<\OP\\3?\)S<?#V:&QM?$%G=WEO?27.H
M01Z-96NGV$NKWNMW.L#?;+X?M]$ADUPZJ@>*72 EU DCRQ0O=/P0RRK[7DXU
MB_84ZE6MS9)R>RA04'B/:<^:QY)X;VE+ZS3E:IAO:T57A3=6GS1/QDS"G[/G
MX0?[ZI3ITN7..?VLZSDJ'L^3+)<\<0X5/JU2-Z>(]G4=&514JEOZ2OA=\-OA
M)\%?#4OA'X7>'?"_@O0;G5+O7;^ST9X4EU;7;^*VM[S7-;U"YNKG5-=UJZM;
M*PLYM7UF^O\ 47LK"PLC<_9+&T@A]3CD25%DC=)(W 9'1E=&!Z%64E6'N"1[
MU_*AXE\-_P#"-7EG FNZ!XAM[ZR2_M[_ $"YOGC5#/-;O;:AI^KZ=H^N:/J$
M4D#.;'5]*LYIK26UU"U%Q8W<%P_]"7[*FOZ/:?LY?!N"YOX8ID\":0KQL)"5
M*^<I!VH0"&4CKVST()^.XZ\-Z/!V4X#-:.>2S2..QOU2-*66O N'[FM5<VY8
MS$3YXNBX2I2I0E%WYFG%Q/K."_$&KQ9FF-RRKD\<ME@\&\6ZL<P6-4[5J%%0
M2CA*$>62K<\:L:DXR27*FI*1]05\C_M ?L9_"W]H[QEX*\6^.M8^(UE!X<^V
M:?XH\)>%?B%XJ\-^"_BCX5N_"GCWPHWA+Q]X;TS4X--O],>Q^(WB6WOK_3(=
M+U[6=$U&]\(ZUJU_X4OIM)7QS_@H%\4O$OA/P#X!O/AWXXU[PS?WGC>ZM-0N
MO#.K7VD7-U9)X;U*<6]S+;-"\MNMR()A$Q*^:J.!N3(_.;PKX^_:W\;:3KFN
M>&?B9\6-3T[P_$'O94\=ZA!)<S"6S22PTB"YU&&;6-3MXKZWO+BPTY+BXAM'
M1V7SI[2"YGAOPNQG$60T,_\ [<RO+<)7KU<.HX[VL'"I3Q#PT5*HDJ5ZE1)0
M7-=MJ.X^(?$C"Y!G=?(_[&S+,,30HTJ[E@W2ES0J8>.(;C3=ZEJ=-MS?+9*+
M>UC]>H_V#_V1K+XZ>!_VCM$^ 'PH\,?%OP#=_$;5=)\4^%_AYX(T&^O_ !%\
M46TJ3Q3XKUV\T_P[#J6K>*FETVXGT_7YM034+*?7_$\_G2RZ]?._57W[*_PI
MU#X6^*_A-/!XACT3Q7\5/%GQM?7+/Q#=Z=XRT'XJ>*/BU?\ QLMO&OACQ/IZ
M6U]H^L^$?']W;ZAX/F19TTK3])TO1+N/4]*AN;6[_%:Z^(O[6=EX<7Q9<_%#
MXI1Z+_9VF:S(_P#PL6234[31-:G2VT;7=0\/Q:R_B#3M"U>>6&+3=8OM+M]/
MO&N+1HK@QWEF\[+WXD_M7Z7JNAZ)K?Q5^)_AS4O$>B0^(M)@\4?$:7PVDFC7
M#7J6UY>7&MZO8V^E&Y?3KM;>UU:6RO962,+;9N+<2>^O!'&ROR\5Y!+EE5C+
MEE5DU*A"-2O%I7M*C3G&=6+UIPE&4U&,DSQ'XQX2-N;AG/(WC2DG)4DG&O-T
MZ,DW9.-::E"E):5)QE&#DTT?L]X8_9;\/^#]/L(= ^)OQHL-<E\;>-_B-XZ\
M7Q^.K8^(_BUXV\<?#J_^&D^N?$PG0/["UI/#.BR>'K[P+H.DZ%H'A;P=JG@/
MP&NBZ'!H_AJWT>;%_9?_ &2--_99LK[2/#OQL^.WQ(T&^M)?-T?XN:]\/O$A
MF\17VI'5=<\>ZMX@\/?#+P?XQ\6?$#Q-=O*WB3Q=XU\2^)=4U@29NG9XK9X/
MQM\1?%S]I[PMJ6GZ1JWQA^([7^JZ?IFJZ;#I'Q*E\0I?6&LLZZ3-:W&@:MJ5
MO,VH[-UI;I*;F=)()$A,=S;O+=\4_$K]J_P9!!=>(_BI\3[*WGO[K2&FM_B2
M=7CL];L8HY[[0=4;1=;U$:1KUE#*DMUHNJ?8]2BC+,;8B*;RW'P/Q\WAU'BG
M(9/%*4L*HNLWB5!)S=!+6LH)WDZ?-RJS=KZ2_&7!159RX:SN*PSBL2W[%+#N
M;M!5WM1<GI%5.5R::C=VO_1[7YZ?\%6_^4>?[4W_ &3J+_U*?#E._8$^)_B#
MQ7\+/%E_\0_&NN>)=5M_B#=V=I>^)=4OM7O(-.'AOP]-':PSW)F>.U%S+<RK
M"K!!++*^ SDG'_X*HZ[I-]_P3Y_:E@M+Z&:9OAS$5C4.&.?%?AI!C<B@G<RC
M .><] 2/C\ER>KP_XH<.Y-7K4\16R_C'AVA4K4E*-.I)YG@*EX*:4DK32M))
MW1]5G.;4\]\-L^S:C1J4*6.X4SVM"C5<95*<5EV,C:;@W%OW&[IVL?PE/]]O
M]YOYFFU]1_LF?L]6?[27Q1N/!6HZ_K&CZ=I>D/KM]8^$M$M_$_CWQ!;'4;72
MC9>#?#UWJ6E6]_/ITM_%K&OW4ES.=*\/VEY=QZ=?2,HA/ OP=^$>MZQ\3-$\
M6>/?BSI,?PPTOQ=XGU[Q7I/PJT33=#L/"GARWT^STY]?\,>//&7A_P =Z#XS
MU[QCJFE^!(O!,NEW5S;^)]6L;2+4KRUCO+^+_2NOQ!EF&Q.+P52K7EB<OP^#
MQ&+I4<'BZSITL;.=/#<LJ5&<:M2K*FXPHTG.K.3C&$)2YE'_ #LP^0YEB<-@
M\9"G1CAL=7Q.'PU2KBL+1]I4PD:<\0W&K6A*G3I1J*4ZM10I0492G.$>5R^7
M**^B=!^&/PKUSX.:Q\0[GQK\0?"_B#2=9\%>"(T\1^$_")^'>K?$7Q9=&ZO]
M%T_7='\6:AXQ;P_X/\&VFL>-O$VNGPD]W8Z79Z;9+I,^I>(])MI(?B5\)O 6
M@?#[3OB9\-/B'XC\;>%Y?BCXB^$5S<>+? =OX$FUG7?#OARR\3R^*_ T=IXI
M\3C6O!5Q87L$%Y%JITCQ/X8OK[0K;7M.277H([;6.=X"6(6%OB8U7BYX%.6"
MQBH_6:=&GB'3>(]A]77-2JQE3DZO+5:G"FY5*=2$,Y9/C8T'B;8>5)86&,M'
M&81U?J]2M/#JHL/[;V[Y:M.4:D53<J:<)U(QA4IRE\^5_0/_ ,&\_P#R<%^T
M)_V1KPM_ZGCU^3=A^S[H.L_ /Q9\9=&\5>.II/!'A[0-8U_4M3^%TVC?!ZY\
M2ZWXHT?PY+\(?#GQ(O/$7]J:S\4M+@UNWU@P)X2C\.:O;Z?KEOIVH+!I\&K7
MWZM?\&^=]::?\?OVA)KR=((O^%->%AO?)!QX^V\;02?FD0<#OGH"1^:^+^8X
M3'^%W':PM24Y8&GAL%BHSHUJ,J6)CF.55G2<:U.FV_9UZ4U**<6IQLV]#]$\
M)\!BL#XF<$/$TXP6,JU\9AI0JT:T:N'G@,SI*HI4:E11_>4:L'&34TX.\4K-
M_P!7?BS_ )%?Q'_V =9_]-MU7^:)'_JHO^N47_HM:_TG_%/B70I/#/B-$U*
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M0;2+_2]7M#Y5TT]CJ6DZC9ZGI&IPV6JV$ZW5E$K?Z3WBS_D5_$?_ & =9_\
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M>>)HU*U.E*C"K5R_+:TX0J>U]JXRJX2;52M[>K]8K?QL0Y)UZE1PIN'Z"_\
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MD9X_9S\'<X(P?^$]^)=?O?T;O^3F8?\ [$V:_P#I-$_#?I#?\FZQ'_8VRO\
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M4J-')%(C:$5=)$9D=6!#*Q!&#7R__P 0NO[!XP!^T%_P41    _X:ZU3@#@
M?\43T X%?TET5AA,RS'+_:?4,?C<#[7D]K]3Q=?#>U]GS<GM/85(<_)S2Y.:
M_+S2M;F=]L5E^ QS@\;@<'C'2YO9/%8:AB/9\[BY^S]M"?)S.$.;EMS<L;WL
MC^;3_B%U_8/_ .C@_P#@HC_XEUJG_P Q-?-O[7__  ;F_L<? W]FCXR_%GP5
M^T!^WX_BKP+X+O->T)=;_:MU;4=*-_!>V$*?;K)?"5F;B#R[B4-']HCR2IW
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M X:G15;$5(4Z;JSCCZDHTU*?O24)-).T6]#^E"BBBOPT_:0HKR'Q_P#%W3?
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M&F^+? GCGQY?>&_$G[4.J>(]:\?MXDT;QI\;=:^#_B?PI'=^+_$ND2:'X?\
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MQFM3\,])T[]L*3X+Z+9_#MK?Q=X.\2_MDV_C>+QAJ/Q \:3>-KM/B-HW@?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tecfidera.jpg
<TEXT>
begin 644 tecfidera.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MM(LGRK6QL;:"V@CR=D42C)(R=B@ HHHH **** "BBB@ HHHH **** "BBB@
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M(_\ 5Q_[B_\ H(H R/\ A)/#W_0<TG_P86O_ ,=H_P"$D\/?]!S2?_!A:_\
MQVMJB@#%_P"$D\/?]!S2?_!A:_\ QVC_ (23P]_T'-)_\&%K_P#':VJ* ,7_
M (23P]_T'-)_\&%K_P#':/\ A)/#W_0<TG_P86O_ ,=K:HH Q?\ A)/#W_0<
MTG_P86O_ ,=H_P"$D\/?]!S2?_!A:_\ QVMJB@#%_P"$D\/?]!S2?_!A:_\
MQVC_ (23P]_T'-)_\&%K_P#':VJ* ,7_ (23P]_T'-)_\&%K_P#':/\ A)/#
MW_0<TG_P86O_ ,=K:HH Q?\ A)/#W_0<TG_P86O_ ,=KY7_;;\9^$=*_94^-
M>I:EXFT.QT^R\)1S7EY<:C;+!;0G7-'B$DK([LJF66.,$*<NZCO7V%7YZ?\
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MGV__ #\VW_@1#_\ '*_ 7)]3^9HR?4_F:_J;_5#_ *F/_EI_]\G\T_ZWR_Z
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M++77='TGX>V-U:MX"FTJ:UOM9G_6(=/3MZ=/Z>GM7XA>/OA:?%7[2FJZU9^
M_$?V/XC_ !S^ _QB;XR:_P#L8?&O5_V@_AK_ ,(U8_"^ZM_AYX%^,T6G)X0\
M.^#OL_A^71;K5]3U#1+?X6:/XL^)GAK7O!GBZZ?5+N]_;T# Q]?Y]/IZ>V*
M/Q!_X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@BOQ#_P""D_\
MRDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(H ?1110 4444 %%%% !1110 4
M444 %%%% !7YZ?\ !5O_ )1Y_M3?]DZB_P#4I\.5^A=?GI_P5;_Y1Y_M3?\
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M:#QW;W43ZQ'X;U%!H\D,D]RS 'W]_;LO_0"U[_P"MO\ Y.H_MV7_ * 6O?\
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M_P#DZOS]_P""J&J277_!/G]J6)M*U6U!^',1,UU;P10KGQ7X:7EENY6XW;B
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M^MC^HKQ3K4K^&?$:_P!B:XF= UL[GM+95&W2[MN3]N/)Q@#'+$ =:_S88_\
M51?]<HO_ $6M?Z7?BS_D5_$?_8!UG_TVW5?YHL2MY$+X;80D0?:VPRK!'*T0
M?&PRK$Z2M$&\Q8I(Y2HC=&/XE]$]KV/'7_7WARW_ (#GFG]=C]A^E"G[?@K3
M_EWQ%_Z5D(ZBHXYH9MWDS0S;" _E2QR["<X#[&;:3@\-@\'CB@30F0PB:$S
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M[8D$M'R?W;93D_+R<_T#_P#!O(B1_'_]H*.)$BC7X,^%@L<:+&BC_A/7.%1
MJJ,DG  Y)/4FOA/%WAY8'PWS_$K&2J?V;PYE641?)B56Q.&P>8T*>'CB93QU
M7"RM]9=>I.&"ABJF)IPG'%4L-*IA)_;^%.?O&^(>0X>6%4/[0XAS+-9>_AW2
MP^)Q>7UJE>6'C#!4\3&_U?V%.$L9+#4\-4E&6&J8A0Q4/ZM/%7_(L^(N ?\
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M *$F4?\ AMP7E_TX\D?R:?&#_@W"_8S\#?$G]E;PGHG[0/[?YTOXR?&_Q/\
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M (F?&SP7XM\'^)['5/ /@F6YL=332H4\,>*]=U/Q!X8TK6OM3QOXZOO"5_\
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MAK7AW5TEL=5TR*";2[_4OEBV_8[_ &D_%MK^U#H/Q8^.?P8NO#7[2OBOP?\
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MG;37FI3:7X?TA+I=$\*:%+JFK2^'_"NFZ+H<FKZJ^G'4+GV6@ HHHH ****
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M5OO%FL7CR70_4&B@#\SOB'_P3P'Q B\7:1>_$^&+PO\ %'PO^W#\-/B98?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>equitylossofinvestee.jpg
<TEXT>
begin 644 equitylossofinvestee.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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M?:VOQ#N?#$_A3QCI,^@^*8='O?D7PC0/^"IOP>U'5-&G\0^ OC!X#\&W=O\
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M_M0?^L<_$&OV\C_U<?\ N+_Z"* 'T444 %%%% !1110 4444 %%%% !1110
M5FZQJUEH6F7FK:@[QV5C%YUP\<3S2*A=4RL48+N=SKPH)QST%:5<)\3?^1#\
M3?\ 7@O_ *4P5PYIB:F#RS,<91475PN!Q>)I*:<H.I0P]2K!3BG%N/-%<R4H
MMJZ33U&M6EW:,;_A<O@;_G\U#_P57O\ \;H_X7+X%_Y_-0_\%5[_ /&Z^/&*
MJ69RBHI+.TC^7&J+DLTDH20Q1JH)DE$<GE(&D\J3;L;\9_#O[8_[2'A72?C?
MH_Q9OY]-^-=S\3?A;X$^'GPUOOV=+^?2/!=W\3/$O[.W@#4O$OPD\8>#O'6M
M^%/VDOAOX*U/XR6MW:Z)>>(;#QGJ&M^)_ACK?C#5_"7A7XBW6C:!^*8'Q"XM
MS#VJH0R3FI.@G">%Q?M)^WJJBI0C#$S;A3;4JU27+"G%QU<YPC)I)VT>]MUY
M>2[_ )G]+?\ PN7P-_S^:A_X*KW_ .-T?\+E\#?\_FH?^"J]_P#C=?SX77[1
MOQW35_"7P%TZ]^+E_P#&'7_BE\2=*UTW/P ^"-A\=/"_@?P-\(O WQ/TCP^N
MDQ^/[W]DG5M<\;)X]T[6M%^,4GB#3? 5E\/M-US1K[PE+\4-+D9_9?&?Q]^(
M6G?L26OQG\&ZE!XG^*UW_P (YX.L?M/PKN_#GB/Q%\16^+=K\,O%_@KPQ\$=
M1\1ZK;2?'E'LO%.@>$?A/=^,;OPCK/Q;TVTL)/$2?#V[&HQ[3X[XOIO#)K(G
M];KT:%%QPV-LUB)U*=&O)RKQ4</4E1JNG-OFJ0ISJ4Z<Z:<@M?H_O73Y:;_I
MN?M5_P +E\#?\_FH?^"J]_\ C=='X:\=^'?%ES<VFC3W,LUI EQ,)[.>V41/
M)Y2E6F10Q+\%5R0.3Q7XS_LF?%?QC\3=%^*FF^.Y_%ZZ_P##?XH2>$+?2_BK
M\.-$^$'QOT_PY=^#_#/B#1;WXM?#?PHS^#-&N_$5Y?Z[JG@#6_!TAT7QC\.E
MT'6[B&RUW^V;.#]*/@-_R'-=_P"P1;_^EK5W9'QUQ#C>(\#DV.AE?LJ]9TZT
M\-A\1&3C]5J8B$J4ZF(=E*T&G*EK%O1730TM=[I=T^JTV7<^H:***_920HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q _X*3_\I)/^"%/_ &=;
M^U!_ZQS\0:_;R/\ U<?^XO\ Z"*_$/\ X*3_ /*23_@A3_V=;^U!_P"L<_$&
MOV\C_P!7'_N+_P"@B@!]%%% !1110 4444 %%%% !1110 4444 %<)\3?^1#
M\3?]>"_^E,%=W7"?$W_D0_$W_7@O_I3!7DY__P B+.O^Q3F/_J'6''=>J_,^
M(G ;<&"LIW!E95=64Y#*Z.&1T8$JZ.K(ZDJZLI(/S%X4_8S_ &8_!5M\2['P
M]\(/#EKIWQ9 M_%VFSW.MWEA#HR1>&#;^%_!\%QJKM\/?"UAJ7@[P[XBTO1/
M LOA^#2O$VEZ=K>F/:7.B^'1HOT\W4_4_P Z2OY+I8C$4%.-&O6HQJ<GM%2J
M3IJ;IR4Z;ER25W3FE*#>L9:QLQ'@ _9>^""^&!X63PGJT<0\92_$0^*X_B)\
M4(_BFWC^?15\,3^-9/C-'XU7XN2>)I_"B)X1FU)_&S&3PBD?A9HO[ BBTZ.=
MOV8O@.VC1^'%^'5C!X<M_!/ACX?6'AZSU[QA8:+H_AWP7XTU#XC>%KG0+"Q\
M1VT?A_QGHOCO5+WQ7;?$[138_$Z?6I5N[[QC=M#"$]XHJWC<8[7Q>)=IJHOW
M]72<7>,_C^.+5U+XD]4T%_\ +[O^&/._AQ\*/ 7PGT_5]/\  VC7=@WB+58M
M<\3:SK7B/Q5XT\5^*M9M]-M-&M-3\4>,_'&N>)/%GB"ZL-&L+'1],&J:S<V^
MDZ5:0Z=I4%E:*86^N_@-_P AS7?^P1;_ /I:U>$5[O\  ;_D.:[_ -@BW_\
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M/_\ 06L_^_G_ -:OZE$;U%8/_"4>'_\ H+6?_?S_ .M1_P )1X?_ .@M9_\
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MW&&>8KA[)I9C@Z6'JUHXG#T5#$QJ2I<M:4E)M4JM&?,K*SY[;W3 ]R_X6EX
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ML9)1E-S3C%N\:<95ZRI8>U9NR\_ZLNS\_33=Z/\ <[_A:7@#_H8X/_ ;4O\
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MU1]08'O^9_QHP/?\S_C2T5_4HA,#W_,_XT8'O^9_QI:* $P/?\S_ (T8'O\
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MX-^-WPY\$?LL?&CXN?L^>+O%/P^^'^D?&/PY#H_AGX)^&?#?QOOKWXN?"/\
M9_L/#OQE^(GP2\#ZI?0:GX@TK4/ OQ8^ /\ PD]IIVE^+KSX?>+_  ]XA\5^
M"_"OAZY\3:A" ?T"6EW:W]K;WME<P7EG>00W5I=VLT=Q;7-M<1K-!<6\\+/%
M/!/$Z2PS1.\<L;K)&S(RL;%?*O[$OPT\:?"#]EOX/_#SQ]9_V/XC\/\ AZ^!
M\+?;;741X"T/5?$FNZ[X2^&:WVGRW&FW2_##PAJN@_#U9M*N;O2G7PR/[+O+
MO3Q;7,OU50 5PGQ-_P"1#\3?]>"_^E,%=W7"?$W_ )$/Q-_UX+_Z4P5Y.?\
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MPV/P)_X1'_@N&?\ FVO_ ();_P#B7?[5O_T-='_"(_\ !<+_ *-K_P""6_\
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M#\=O^%@?\%WO^C8?^"77_B8?[3W_ -"E1_PL#_@N]_T;#_P2Z_\ $P_VGO\
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M=[-;12RV.HS,\$<LN$ )_P#A87@+['XUU#_A-?"7V#X;7=U8?$2\/B/1EM?
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M7B2X\"ZC.GBBTT7X;^%_$D?A/1/$/C+2])U#6+KQ3K]AH5F^@:'%J&H>6_\
M!0KX7_#W0OA%X6LO!_[.OC[XC^,S\>?#/Q:\*6WPH^%7B?XD_P#",^+IOV@O
MAE\5/B[\0=1M='2ZTOP[XGUO1K#Q3?:=XDU&.WU>XN;C7-'\+WMO<:Q>V.H
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M?>)=4E9;J^USQ?K5IJE[J.L70GO]>U^?4]3U":2[NIIG^0/V7/!OQ(\2Z?\
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MFCSKYU^T-X%^$$?@/XH>,/'?P@UGXH)XM\/> ?#7CGP[X+\$:]\0/%7C_0O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>sga.jpg
<TEXT>
begin 644 sga.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /,OC5\1?^%0_![XK?%<:0?$'_"L_AMX\^(/]A"]_LTZU_PA7A35_$_]DC4/
MLM]]A.I?V5]B%Y]BN_LIG\_[-<>7Y+_#?P>_X*+^"-9^'-G\1?C%XN_9\FL_
M$5H=4\,V/[(GQ+^(_P"V!=V.DZ!X2T7Q?\2K_P ?6W@GX+:+J7@VQ^'&F>*?
M"UUXEU>;3;W1-+L-?TFYUG4=)N-7T6QU+[M^+OP\LOBY\*OB7\*M2U&ZTC3_
M (E_#_QI\/[[5;&*&>]TVS\:>&=4\,W6H6<-Q_H\MU90:I)<V\4_[F2:)$E^
M0M7SO\2OV1/^$IC^&>I?#OXK>)O@_P",_AY\*_%GP,F\5^&_#/@S77\1?"KQ
M]8^![?Q7I-WHWB33+O3K'Q%#J7PZ\)^(O"'B>U\S_A&]:T^:.^TCQ)H.H:AH
M5R >O^!/VB/A+\3_ !9XY\&_#_Q)=>+M4^'$.AS>+[_0_#?BB^\+:>_B;PEX
M4\?>&[2S\:0Z,WA+7=2\0>"/&_A?Q9HNEZ!K.IZEJ7A_6+35+:U>TD25OB'P
M/_P59^"_BK3OAQXNUSP5\4?A_P##WQY\*?V@/B?>:MXL^&_Q.3QAX4LOV?OB
M[X ^&'B>ZUCX>:7X!O\ 7E\#0V'C>3QIKWQ,_=^$?"&CZ/<6^M7BW*ZB=,^S
M/@#^SSX/_9TT7Q=X:\$76H-X<\1>(O"NL:9I=^4E/AW3?!GP:^$WP4T#0K>]
M!:[U.&W\-_"+1+N:_P!1=[^YOKZ]$C>4L('S-H'_  3T\.Z1H7C+PK-\4/$N
MH>'-9^"O[5?P \(6K>'M"MK_ ,'?#K]J7QIX9\>ZM:SZC#,W_"2ZSX(U[1;^
MW\/ZK>6>G/J6CZC;6NO6]UJ.F-JVH@'TMI7[4?P1UOXIO\'M)\6W5_XN76KG
MPK#>VWA3QC)X#O?&MEX3'CR_\ :9\4AH'_"M=4^(6G^"M_BJ_P# NG>*[GQ3
M9Z%!>7T^EHMAJ"VOB_QA_:$_:-\ ?M)>#O@_X4^$/P5\2^ /&?PV^)?Q7L/&
MFO?&GQYX<\9VWACX+W?PBTWXA:?<>!M-^!?B;0WU^[O_ (N6'_"%PP^.VT[4
M[71[N37+[0)[J"W7EOAC_P $X_A%\+OV@S\>=(C\)WM^/$^J?$58]2^#/PFO
M/'B?$CQ!X(3P-K^K0_&J\\.7?Q,LO"]W;F_\06/A/3=6L;C2=>U?4K&V\32>
M!98?!,'U)XZ^".D^.OBCX-^*5UK>HV-_X-^$?QO^$EII=K;VDEE>:;\;M3^$
M>IZKJT\TO[^.^T1_A)IL6G01?Z-<)JU\UU\T%M0!\W_##_@I#^SGXY^$?@KX
MF:_J_B#P?J7BCP=^SUXCN/!S> ?BAK6HRZA^TIII'PTT_P  R6W@*VNOBUHW
MB/Q?9Z[X \.^+OA_INLZ'KOBW1+K18)8-4E@L7]4/[:_[-D.I^,]-U'X@R:%
M#X"TCQ_K'B#Q#XC\(>./#W@ED^$Z!OBMIF@>/-8\-6?@SQ=XD^&,OF6/Q \+
M>$]<UKQ%X4U2SU72M5TR'4M%UFUT_P TT7]@OP=HUU\%;F/QUXDG_P"%+?#3
M]DWX:Z5%+IFCA-9L?V3?$GBSQ)X:U/4, _9[SQ3<^*YX=:BM,0V*6-M)IQ$C
M/7C]U_P22_9TU/4_C=;ZK8^')O"/QDTWXWP2067P<^#5E\3-$U/]H+7K[Q5X
M[O+KXW3^#;_X@>+-.TOQ%JFJ7?@W0=>N&T^WTO4[OPMXX;X@^%H]/T>Q /OS
MX7_&[X??%[2_$6I>$+W7K:;PAJHT7Q;X>\:^"_&?PV\:>%=2DT?3_$5I;^)?
M WQ"T#PSXNT-=2\/ZKINNZ3/J.C06VJZ1?6]_I\US"SE/%F_;P_9JM[2YN-2
M\3^--#NH/$7PT\,VV@>(O@U\9?#OB[6=0^,VHZ[H_P )[CPYX-UOP#8>*_$6
MC_$/6_#6NZ'X4UO1M&O-,U/6M-N-*2X2^,4$EG]G?]D;PE\ / 'Q"\(:)<^&
M]+U7XGZC=ZCXG\1_"/X5?#?]GY;>9_#5OX4TZXT'1_A;HNGI9ZII>GVYU&UU
M[6-1\0:S!KMW=7%A>:=HT6E>']*^:?A)_P $N/ 'PJ\2Z+XOC^(%U?\ B'2]
M6_9YO[Z\T;X9?#;P+_PE2_LV^*OB;XC\(:MXS;PEI=G>^*_'7BD?$[4X_B+\
M0/$%]J.L>(-1LX=3T^#08)Y-*0 ]*^-'_!1_X"_#/X/:[\3/"UUKGQ"UNR^&
M_BOXBZ9X'M?!OQ+T>_M+7PGXOU+X=:A8?%"\/@'4Y/@?,OQ%T/Q!X!D/Q4T_
MPW<1>,/#?B30$M)M1\/ZQ!9>H_'W]J&3X#?%3]G_ ,(:KX';6/A_\6=3\7:?
M\0/B/%XB2Q/P?L].UCX=>"_!WB75?#LFD7"ZWX7\1?$GXH>#_!OB'5QK>C+X
M)CUJS\17T=_HT.JS:;X%XQ_X)P:+X@TKXCZ!H'QL\=>#M(^-NF?%3PU\9K33
MO#WA#4SXS\*>/OC[\8OVAO#NF6-SJUG<2^%M1\$^*/CAX[\-6^LZ:\TOB+P7
MJTUEJ-G:Z];Z/XCT;[.^(7P1\'_$_P 2Z9K'C2$ZSH=O\,OB[\*M;\(7<2-H
MWB7PQ\8[CX?R>(X-3E1X[Q#%;^ K>SMTM9(]T>J74K.D]O:R* ?+O@W_ (*!
M> ;W2XO$7Q*M-,^'.B2ZEJ_AM+"WN?''C;QC)XJ?]K3QI^R=X&TVV\/>'?AN
M]O>V_CKQ=X7L4L!9ZO/K=AK^N1:!/H,MA!%XCO/2;W]NO]F;3]%\.:]=^-]=
MBM/$%CXQU:]M1\,OBG+K?@'1?AUXKG\"?$#7_C#X>A\%R:Y\%_#W@?QI;77A
M?Q9KOQ4T_P (Z5H>LV6HVU[=HFF:C-:>'?#/_@FWX3^'7A;X7>')?B_\0_&-
MQ\,M0^'FHIXD\4V/A^X\1^*[SX>_M6:]^U7;7_B>[L[:TCN]7USQ%KLWA_7M
M2@MH);NR1]:$2ZK<S5SGQ%_X)4_!KXB^*Y?&.L:EH.L:QK7B#XSR>)9O'WP8
M^$'Q<BF\&_&;XS>(OC;J.@^%+/XF^'/$VF^#/$/AOQ'XJU_2M%\96-AJ"W_A
M_6+VS\5>&]?N+;0+K0@#Z8_:>_:E/[-NN?L^Q7/@N/Q/X2^+/Q=LO 'Q \4G
MQ(-%_P"%4>#M1TBZA@^)+:>VC:G'XGTZQ\;7_@K0M=TUM0\/II?AS7]6\7_V
MI<)X=;2=2\PT/_@H)X'/QD_:8^'GC3PW=>&?"/P0\2_![P1\/O%>AR>)/B#X
MO^.OC;XCS_%?0?$7AGP9\*/"/@V]\52ZGX-\<?!SQSX6AM-#D\4W>M1>&?%'
MB&[M] T;P_=S'WOX[?LV^#?CYI.F>'?$U]?:;H%CX4^*'@V?2])@LTBNM(^*
M'PZU/X=7R))+&WV*XT2QU%=4T:2V3=!J5G:2E0L2E?FO3?\ @G;I/AD>#-?\
M(_&KQ]IGQ0^''A?X V7@_P")&KZ/X8\2:E<>./@MIW[1FE>)O'_CC3+VWM[3
MQEJ/QQL_VHOBNWQ0L&N-%+W^M?VOX8U/0M4AM;NU /6D_;Z_94FU#PUIUK\2
M[B]?Q-H/@+Q1'>V7@3XC7>C^&_#_ ,2_'WC'X5>$]6^(6M0>$GTOX8VL_P 3
MO /BOX>ZS_PL2Z\,2^%?&6DS>'_%,6CZ@1$/"= _X*F?!O4M4T:;Q!X%^+_@
M/P=>6_[8:ZOK/B[X3?%>U\4Z9>?L?_&?X>?"?Q;?V?P^T_X?W_B/6O!5U:>-
M-3\7^(O&]I&NC_#BV\,:AH'BYK?7;?5K?2.MM?\ @G?X)M/!?Q-\)#XC^-;R
MX^+/@WX9:!XP\2ZE9>'IM9U+Q/X'_:'^,O[2_B/QU)%9V>G:3'JGC[XA_&WQ
M2=2T>QT^QT'0M*M].L="LX8X64ZME^PKIT&O_$F^O?BEXBO] \7^&?VRO"GA
M;07\->';6X\$:7^VY\0/"'Q:^*2C6[9DG\3OI'Q%\/ZKJWA"34[.UEL=&\0'
MP_J<VIKI%G?R@'O_ (>_:9^#WBSXG77PF\,:_K/B'Q-931V-SJVB^!O'FI_#
MJ'6Y/!>E?$9/"[?%FS\-3?# >+&\!:[HOBY?#!\6C6WT+5+.\CLG\TQI'XE_
M:@^"GA+XH67P?UKQ7>1^-+F^\&:3?"P\)>,]9\+>&-;^)%\=,^'/A[QSX]T?
MP_?^!O ?B/X@Z@$L_!.@>,/$6BZOXFN+K38M+M)VUC1AJ'@?A#]A31O"?QR^
M'OQEM_B->AOAWHOAC3;.RT?X?> /"/BWQ'!X9^$2?!ZS\)^./BCX6TS3/&/C
MWX3-8+_PFUO\.?&;>(38?$*#2]7L/%$>C:%HOAVRB\:_\$^/A+XQ_:BC_:?F
MB\+?\)!JGB3X5>,_%5MXA^#WPH\>>);KQ9\%H=.MO E_X*^)'C7PSK'C'X:6
MLEKH?AZ'Q)8>&I6FNI_#VF:SX4O_  3XCEUC6M6 .RT;_@H'^RGKV@ZUXFT[
MXBZF-"T;PSJ'BVWU+4/AQ\4-)M_%FDZ3\0++X3ZM'\.CJ7@RV?XF:OI?Q0U;
M0OAWJ'A[X?IXEU^T\:>)/#'AR731J?B/1;>]XWPM_P %%O@GJ$7Q#N_%]OXN
M\)6WA#XL_$OX>Z/8V_P]^+'B;Q;JGACX2>$?A=XF^(/Q+\5^ ]*^'(\8_#3P
MKX)N/BAI&D>-M0\8Z-9:1X3N)-(.J:RESXATZS.1<_\ !.WP;)X)^%7A.#XG
M>-=-U#X-?#[Q;X5\#^*;#3?#9U33O%>L?M _!?\ :2\*>/Y[2^L[_2;J_P#!
MOQ!^!_AE8]"N[2;1?$.C7NKZ?JZCSXY$\W\<?\$J/ /Q'O'\6>._'>G^//B1
MJ_BGXL:YXG\3_$?X&_!?XDZ%<Z=\;M*^$=EXXT[PSX \<^'M=\-^$=2TF\^#
M7A:^^'WB.W_M.^T"%]0TGQ5;^/\ 3KV[CN0#Z3\4_MM?"^P^+WPM^#G@H7OC
M[6_'GQHTKX/:[K^EZ5XL@\">%M1U7X&^/_CH@L?B.GA6\^'/BWQ3:>&/">@7
M.H>!-)\6IKUAHWC+3M=O!!%;FTG^S <@'U /YU\(Z+^PUHOAKXH>%_%?AWXE
M^)-(^&?@WXUI^T-X=^#-IX:\&P>'M.^*-W\)/$GP=\07%OK]II=IK5MX0U30
M_$=WX@LO!EBEGIWA_P 5W%]-IEP/#+Z/X6T'[N P /0 ?E0 M%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?$'_  4"-T_P"CM;;XNZ%\'!
M??$OX8V]UK7C/6O'?@SX>>+;%/%5M>7WPO\ B-\3OAP]OXJ^%/@[XE6UK)X4
MO?'MI?VEK8:A?:5I&H0ZW9ZY+X9US\M;G]O;XI_"7X;^"/!OPFT'1=#T>T\8
M?M5:?JOQ \6?'KX<_'WX27>O?!@_"?6_"'@'X-?'?]H+XM?LR0^-_A)XHC^*
M6KR3W=YJFI?%;P%IWPU^(/@#PSX.OSX*O=8\/_T0W5I;7UM/9WMO#=VEU#);
MW-K<Q1SV]Q!,C1RP7$$JO%-#*C,DD4J/'(A*NK*2*S6\-^'WT^PTE]#TA]+T
MN6RFTS36TVR:PTZ;37633Y;"R,'V:SDL)$5[*2VBB>T=0]NT;#- 'XZ>*?VR
M?VA-?^)%U\./#WC7X3>$O'&O?$OP#\%+?X#Z7X;G\:_%KP_:_%S]CWX>_&?5
MOC+H?B!?%FE6WBK2O@?X[\6:I?7$]EX2F\'>(?!>@:EIVLZQI'B&\TZXTGYU
M^&G_  4$_:@\/^#/V/\ P;:^(_ GQBU;5_V8_P!F/QUXC^('B77?@CX1/QY^
M*'Q-\;:WX$^)?P[DU+QO\?\ P7KNC:]\)UT&W\,^)KWX6>"_C+XT_P"%M^(-
M*/C;PEH=O<V_AKQ#^_NA_#[P=X;U_P 5>*=&T*TM/$/C77G\2^(]68S75[?:
MQ+X:\)^$9IX9KN6=M.MY_#_@;PK97&G:8;/3;B32(;Z:TDU"6YNIM6+PQX<@
M>SEAT'1HI=/O]0U6PDBTNPCDLM3U9IWU34;-X[=6M;_4GNKEM0O8#'=7K3S&
MZEE,KE@#\5_$O[87[7MOX3\9>+-&\9?!NWMY/A-_P42^+OAK3]1^$>O7<N@V
MO[ W[17_  K[1O#>H7-O\4+$>(!\8O"'B#1+3Q3J(@T2?P3J>BW6H^&TU)]6
M,5CQND?ME?&SX2^*_CAJ?AC7?"_Q@U#5/VB?VF[K1_V5[RWUS4/C&G@[1/V5
MKKX[>%/&?AKQ$?%<M[:> =/\<>#].^'BV]C\.V\)W-KXY6#2]4C\<BPTG4/W
MF_LC2C'Y1TW3S&8+^V*&RM=GV?595GU.#9Y.WR=0F59KZ+'EWDJB2Y65P&"Q
MZ3ID5Z-1BT^RCU 6G]GB^CM+>.\%CYWVG[$+I(UG%I]H_P!(^S"00>?^_P#+
M\WYZ /Q+^!O[:W[5OQHC^'GA?3=;^#5E=>/_ (Y?#+P.?B6L?PJ\<16&C>,?
MV=?VA/C'X]T6S\$_ W]HOXQ:':7OAG4OA5X6?X>ZKXL\?:-KFL^&_%17Q?X1
M6ZT>74/$'M?_  4SUCP>GA"XLT^*_ASP;\7-(^&?CCQ)X#\.?$7]IOXG_LP>
M#8+)898KWXH>$-9\ ::MM\0_C%X"URQT"#PAX8U;58[?3;?6+A[FZ\+6WB%=
M7O\ ]1+/0]&TY$BL-)TVRBCO[K5$CM+"TMHTU*]^T?;-01(845;Z[^U7)NKQ
M0+FX-Q/YTK^;)NDU'1]*U?[)_:NFV&I"PO(-1L1?V=M>"SO[8L;>^M!<Q2BV
MO("S&&[@$=Q%N/ERKDY /P1UKXI:OK>H^)/&\_Q'^*>F_M;Z?\7OV*K+]EGX
M6>//%VN_#[Q?XJ^"WQ#\$_LS:GXCL];^!FC:Q8>$?$%AX^U'Q%^T5%^T)JW_
M  C'B2W\#:YX5\3JVL:9;_![PO?:5^K_ ,<?B;\#-5_9K^)OQ!\5_M#V'PR^
M"6CVWB33?'/QP\"?$?2?#J^&+3P3XUF\(^.]%T_X@V7]HMH.OIXBT/6?AEJK
M:!)%XWTKQ#/J&B>&+G2O'<&F7%G](RZ5ILVH6NJS6%G+J=C#<6UEJ,EM!)?V
MEO>&(W<%K>/&;FW@NS! ;J&&5([@PQ&97*+C$LO _A#3O#L_A*U\.:.OAFYN
M]5O[K0YK"WO-,N[[6];O/$FKWEW:7J7$-W<ZEK^H7NL7L]RDLEQJ5S->2,T[
MEZ /P=\$>+_ VN:SX'L/%WQ>NO!_["/Q(^.WQ-O(O"ES^TSJ&J3?"Z]\._ C
MP4OPJ^'GQE^+6B?$W4]=^%UG\6_%5I\5?C3I/P>U#XD?9/#^OZ?X$T#4HK3Q
M3K.K^#;#9B^.1\+>%O\ @G#XS^,?[6VL^%(Y?VA_$FDZ-X4^(7Q.\+^ !\4?
MV?XW_:JT+X4?&OXJKK;Z+XT^(1\3?"K1_A1?"]\5:K=>$9?$-Y#XPOM-U+QU
M?6&M:=^X>F_#WP'H^E7^A:3X+\)Z9HNJRQSZGI&G>&]$L=+U&:(1+%+?Z?:V
M$-G>21B&$1O<P2N@BBVD>6FU?$'P_P# OBRXAN_%'@WPIXCNK>T:P@N=?\.:
M+K5Q#8O+Y[V<4^IV-W+':O-^]:W1UA:7]X4+\T ?B7XD\>>.M)_;)TW0O#?C
M!_&GQNUG]M'P-;V^O>'?VB&U?3(OV3/$6EZ5K'B?X3:E^RU8Z_-=Z"/ GPIN
M=3\2:KXEU?X=V_@*[NHM&^-.D_%N_P#'7B6R\(1>[?MM_MS>//V>_C5X8\&^
M K[P[J4/A[3_ ($Z_P"-/ /B+2/".B7_ (HT3XO_ !HF^&FI7&A>)_$_Q2T/
MQEXB?2M!M=2U."R^$OPD\9)X2UC38KOQWX@FLM8L_#,7ZM0Z+I%O?_VK!I>G
M0ZG]@BTK^T(K*UCOO[,@D,T&G?:TB6X^P0RDRPV7F_98I"9$B5_FI;O1M)O[
MJWOKW3-/N[VTAN+:UN[JRMKBYMK>\,+7<%O/-%)+!#=-;VYN8HG2.X,$)F5S
M%'M /Q5U;]N+]J#P7X4O/&VL7_PHU^Q\<>'OVSG\*V$7P^\1:?8_"2']F/\
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M5KIT^E:=KUU<:O-;6TUE:VC3W\'T\"& 8=" 1]",U^(/_!2?_E))_P $*?\
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MB_\ BZ/MUE_S^6O_ ($1?_%U4_L+1?\ H$Z9_P""^S_^,4?V%HO_ $"=,_\
M!?9__&* +?VZR_Y_+7_P(B_^+H^W67_/Y:_^!$7_ ,753^PM%_Z!.F?^"^S_
M /C%']A:+_T"=,_\%]G_ /&* +?VZR_Y_+7_ ,"(O_BZ/MUE_P _EK_X$1?_
M !=5/["T7_H$Z9_X+[/_ .,4?V%HO_0)TS_P7V?_ ,8H M_;K+_G\M?_  (B
M_P#BZ/MUE_S^6O\ X$1?_%U4_L+1?^@3IG_@OL__ (Q1_86B_P#0)TS_ ,%]
MG_\ &* +?VZR_P"?RU_\"(O_ (NC[=9?\_EK_P"!$7_Q=5/["T7_ *!.F?\
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M_P#XFC^WX_\ H%:]_P""B[_^)K=P/0?D*,#T'Y"@#"_M^/\ Z!6O?^"B[_\
MB:/[?C_Z!6O?^"B[_P#B:W<#T'Y"C ]!^0H PO[?C_Z!6O?^"B[_ /B:/[?C
M_P"@5KW_ (*+O_XFMW ]!^0HP/0?D* ,+^WX_P#H%:]_X*+O_P")H_M^/_H%
M:]_X*+O_ .)K=P/0?D*,#T'Y"@#"_M^/_H%:]_X*+O\ ^)KB_B+K$=SX)\10
M#3]7A,EBJB2YTVX@@7_2(#F25UV(/=B!VZD5ZC@>@_(5PGQ- '@/Q-@ ?Z .
MW_3S!7DY_P#\B+.O^Q3F/_J'6&MUZH^)#U/U-)2MU/U/\Z2OY%$%%%% !7M?
MP3O5LM9UMVMKVYWZ5;J%LK66Z=<7A.YUB!*J<X#' )!'7KXI7N_P&_Y#FN_]
M@BW_ /2UJ^KX&_Y*S)/^PFK_ .HF)&MI>GZH]]N->C-O<#^R]=&8)1DZ1= #
M]VW4E>![U\%#H/H*_1&Z ^S7' _U$W8?\\VK\[EZ#Z#^5?<^+O\ %R#_  YK
M_P"\P0M%%%?C8!1110!VOPZF%OXV\/S&.:41W4Y,=O$TTS9LKI<1Q)EG(SDA
M1D*">@-?:EEJ"WWF;;6_MO+V9^VV<MKOW[O]7YH&_;M^?;]W*Y^\*^,?AE_R
M/GAO_K[N/_2"[K[=P!T %?OOA-_R(\P_[&];_P!0LO ****_4P"BBB@ HHHH
M *0]#CDX.!^'OQ^=+2'(!(Z@''U[=.?RH _,U?AA\:]%_:4^)_B&/PS^T>O@
MKQ;\7?!WBC1=0^$OQ$_9U\!_"2X\/P^&_!FDZI>>+/ VN>+'^(6N:J+_ $C5
M&\=Z]-9+XA\9Z4EA:Z7801Z9I5FOZ9C_ !Z_7_./:OSEO/'_ ,=&_:*\>>'O
M$VJ_M2Z!X0TSXG^$+#X>P_"GX _#G7?@OK_P_O="\(RS-XB\>>+? ?BKQP=1
M7Q))XJM/B!K5GKGA[3-+TM[#_A$$@-A=:K+^C0_'J>OU_EZ>W6@#\0/^"D__
M "DD_P""%/\ V=;^U!_ZQS\0:_;R/_5Q_P"XO_H(K\0_^"D__*23_@A3_P!G
M6_M0?^L<_$&OV\C_ -7'_N+_ .@B@!]%%% !1110 4444 %%%% !1110 444
M4 %<)\3?^1#\3?\ 7@O_ *4P5W=<)\3?^1#\3?\ 7@O_ *4P5Y.?_P#(BSK_
M +%.8_\ J'6''=>J_,^(VZGZG^=)2MU/U/\ .DK^11!1110 5[O\!O\ D.:[
M_P!@BW_]+6KPBO=_@-_R'-=_[!%O_P"EK5]7P-_R5F2?]A-7_P!1,0-;2]/U
M1]-77_'M<?\ 7";_ -%M7YVKT'T'\J_1*Z_X]KC_ *X3?^BVK\[5Z#Z#^5?<
M^+O\7(/\.:_^\P0M%%%?C8!1110!W?PR_P"1\\-_]?=Q_P"D%W7V[7Q%\,O^
M1\\-_P#7W<?^D%W7V[7[[X3?\B/,/^QO6_\ 4++P"BBBOU, HHHH **** "J
MM]:1WUG=V4H1HKNVN+:17C65&CN(7A</$_R2*5D(9&^5QE6X)JU10!^7FG?L
M,2>&?$^EW'AKX%?L<))HFLZ9J^B?$N33?BSIFN:1=Z5>6]]INH)\+[6]U'3;
MJ^T^YMXKB)(?BYIMI+- NQ;2*3RH?TTTJ"^M=,T^WU2^34]3@LK:+4=2CLTT
M^._ODA1;N]CL(YKA+*.YG$DT=HMQ<"V1Q#]HGV>:]^B@#\//^"E@E/\ P4@_
MX(5"!HUD_P"&K_VG,-*K.@7_ (8]\?\ F95'C8L8]X3YP-^TME<@_M#&GB81
MI_I&A_<7_ETU(]AW%]7XQ?\ !2?_ )22?\$*?^SK?VH/_6.?B#7Z,?&C4M0L
MO$VGI:ZA?6L1\/V;LEM>W5O&6^UZ@"Y2&6-"Q4 %B,D* 3@"O XESZ'#F62S
M*IAI8J,:]&A[*%14FW6;2ESN$UI;;EUON-6ZNQ]#[/$W_/QH?_@'J?\ \G4;
M/$W_ #\:'_X!ZG_\G5^1\'[7GA2[^-6O_!&S_P"%OWVI^%M.U.3Q'X_T_P '
M^,+_ .$VA^)=%S-K'@75?'5F9K73_$VF6'E7%[<W5K%X7AU&YMO"S^(5\53Q
M:._.:#^V=)K7PO\ $GQ=N?A-^T]X=\)Z+HG@?6=#@U[2/ 1\1_$*7XC:GH6E
M^#_#_@G0?#WQJ\17">)]4E\4>&KJ31_'4O@4V&GZY97=_<6X2\2U^(_XB;-<
MC?#F*C[14'#FQM*#FL3+EH<BE03DZC3Y5%-VLVDM6[+OTOMMM_P7Z*_4_9/9
MXF_Y^-#_ / /4_\ Y.HV>)O^?C0__ /4_P#Y.K\G=1_:AA\,?!;Q=\<OB%X>
M^,?PU\-^$+?5KB;PWXI3P[JGCOQ&-/,5OIMMX*T;X=_$;Q[HOBG4/%VK2CP_
MX/TRR\3I?ZMKB36MW;Z7;0R7J]%XC_:"L_#OP8M/CBA^(GB+PQJGA3P%XLT/
M0/"\9U'QOX@A^)DWA:U\%Z+H^BWGB+3-*EU_5[[QEH-C]FN_$-EIEK///)<Z
MQ'9VTEW6?_$4U>-N'\1)3K_5H2CCJ4H3K^X_91G'#N$IVG%V4GI.+]59=_P]
M/\WZV\S]0-GB;_GXT/\ \ ]3_P#DZE\OQ/\ \_&A?^ FI?\ R?7YO_#CXH^)
MOB#X=7Q#>>&/BE\.#)J-[8P:'\0[[PU%K5W;V31QC6;)_ /Q!^(?AVZT6\F:
M>WL;J+Q$UT\]E>QW-C:^5&9OT.^'TLLW@KPU+-))-*^E6[/+-(\LKM@Y9Y)&
M9W8]V9B3ZU]%PQQK3XDQV*P,<OG@YX7#O$2G+$T\1&5JM.DX+V=.*WJ7YE*2
MLK>8-6MY_P"2?ZFEY?B?_GXT+_P%U+_Y/H\OQ/\ \_&A?^ NI?\ R?3]=\2:
M)X:@@N=<OEL(+F8P02-#<S>9,(VE*!;:&9@1&C-EE"\8SD@'F/\ A:WP_P#^
MABB_\ -5_P#D&OIL3G.48.K*AB\URW"UXJ+E1Q..PM"K%22E%RIU:L9I2BU*
M+:U336C%9]OZ_IHZ3R_$_P#S\:%_X"ZE_P#)]'E^)_\ GXT+_P !=2_^3ZYO
M_A:WP_\ ^ABB_P# #5?_ )!H_P"%K?#_ /Z&*+_P U7_ .0:P_UCX>_Z'N3?
M^'3 _P#R\=GV?]?\.OO.D\OQ/_S\:%_X"ZE_\GT>7XG_ .?C0O\ P%U+_P"3
MZYO_ (6M\/\ _H8HO_ #5?\ Y!H_X6M\/_\ H8HO_ #5?_D&C_6/A[_H>Y-_
MX=,#_P#+PL^S_K_AU]YTGE^)_P#GXT+_ ,!=2_\ D^N+^(B:\/!/B(WD^DM;
M?81YJVUM>I,5^T0<1O+>21J<XY9&&,C'.1W.A^(M&\2VLMYHEZM];0SFVEE6
M&XA"3K''*8]MS#"Y(CEC;<JE?FP&R"!SWQ-_Y$/Q-_UX+_Z4P5.<5Z&)X=S>
MOAJU+$4*F49C*G6H5(5:52/U.LN:%2FY0DKIJ\6U= MUZH^(SU.?4TE*W4_4
M_P Z2OY*$%%%% !7M?P374&UG6QI[V<<O]E6^\WD4\J%/MAP$$$T+*^[))+,
M",#&<FO%*]W^ W_(<UW_ +!%O_Z6M7U? W_)69)_V$U?_43$C6TO3]4>^7$?
MB7[/<;KC0\>1-G%KJ.<>6W3-\1GWQQ7P6.@QZ"OT2NO^/:X_ZX3?^BVK\[5Z
M#Z#^5?<^+O\ %R#_  YK_P"\P0M%%%?C8!1110!VOPZ%P?&WA\6K0K<?:I_*
M:X5WA!^Q76?,2-XW8;=P 5U.[!)P"#]IV*ZHOF_VC)829V>3]BBN8L?>W^9]
MHGGSGY-FS;C#;LY&/C+X9?\ (^>&_P#K[N/_ $@NZ^W:_??";_D1YA_V-ZW_
M *A9> 4445^I@%%%% !1110 4444 %%%% 'X@?\ !2?_ )22?\$*?^SK?VH/
M_6.?B#7Z&?'#GQ1IW_8NV?O_ ,OFH=N]?GG_ ,%)_P#E))_P0I_[.M_:@_\
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M-34G[LIQFH-\RC&2C4IBMU_K]?NMZGA7B+]L#79_VF[7X:?#2S\%^./A[8>
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M+]^11@L,YZU^N/[(/_!1/]C3]O1_'\?[)?QOT;XQO\+AX9/CP:3X:\>^'O\
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MDTZ4^(O WB2S-C?+!>B.SBO&A^S7EK++],>6OH/^^5_^)I])D8SD8]<\?G0
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MEG-*&4YP0<<'!!P?0XZ4 1I$ #D#)>1NBGAI&8<X[@CW]>:=Y:^@_P"^5_\
MB:?_ )_S^1I,C&<C'KGCGIS0 W8OH/\ OE?_ (FG 8__ % ?R I:* "BBB@
MHHHH **** "BBB@ HHHH **** /R!_:(^-/QL?7O^"@?C3PU\:]5^#]M^PE\
M._"/BGX9^![/1O!5YX.^)>HW7P.F^-NH>)_B_%X@\.Z[XK\0^#/'&MSS_!71
M=+\*ZSX+FTB;PAXKU+0+N\\:SV-_I/2>*/BM\:?"/[2/[/?BJ;XB?$M_A-\8
MOB];^ /%L.HV?P.U#X >";GQ!X)\;Z=I7[.8\/\ AD77[0UI\>-'^)^@:/\
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MX7Z+JNHR^%[WPG^P/B73?%7C<?"C7_ /Q!/AK0M,\9Z3XR\5QV^C6U_%\1O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>rd.jpg
<TEXT>
begin 644 rd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +^ 3T# 2(  A$! Q$!_\0
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M71>+/!\/@[XI_$;P)I6FQ?#[XK^)/&6H^%_A1X0^%WB?XA?$CQ;X!TOX=_\
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MC/PCXN\8?$M=&\)^$/!/P[\::OTGQF^)6E>%?V5OVE;OP]^UCXB\#? OX?\
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M2&EC9DD.G"V+H2K$@XKHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HI#G!V@$X. > 3C@$]AFORML?VF?C]H_[>FO_";XE:QI_@3X6ZK90:'\
M)?"6H?"'4]5\ ?$:ZOI?'4GA;4--_:=\/>)]2M?"/Q9\57/A/4+6Y^'_ ,1/
M"6BZ:UOX:U[PMX2T'7]?LK7Q?KH!^J=%?'G[(OQ,^,_Q!M_VA=/^.5UX#N/%
MWPT_:)\2_#VPM?AMI>LVGA;1O#D'PW^%'C+2]!M;_7ICKOBNZT2?QKJ%A?\
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MQ7I7C_Q=-XB^&FC7?B3PSI#^%?BQHWAOXV^&)M3\/>(?$9O]'\;Z?9Z-^CU
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M10 4444 ?1?[)/\ R<;\*?\ L.ZC_P"HSKU?T&+T'T'\J_GS_9)_Y.-^%/\
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M_29&\1^)==B\/Z)X6L-!\9>,- \0:SK=_>7-G) FE:?<6CV]P\AND6QU%K4
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M0?RK]"KK_CVN/^N$W_HMJ_/5>@^@_E0 M%%% !1110!W'PU_Y'OPW_U^3_\
MIOO*^V*^)_AK_P CWX;_ .OR?_TWWE?;% !1110 4444 %%%% !1110 4444
M ?B!_P %)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$5^(?_!2?_E))
M_P $*?\ LZW]J#_UCGX@U^WD?^KC_P!Q?_010 ^BBB@ HHHH **** "BBB@
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MQ!K]O(_]7'_N+_Z"*_$/_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\
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MAK;HH Q/M/B'_H$:5_X/;G_Y0T?:?$/_ $"-*_\ ![<__*&MNB@#$^T^(?\
MH$:5_P"#VY_^4-'VGQ#_ - C2O\ P>W/_P H:VZ* ,3[3XA_Z!&E?^#VY_\
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M "(OB3_KP'_I5;5W=<)\3/\ D1?$G_7@/_2JVH ^*VZGZG^=)2MU/U/\Z2@
MHHHH *]R^!?_ "'-<_[!-M_Z7UX;7N7P+_Y#FN?]@FV_]+Z /I>Z_P"/:X_Z
MX3?^BVK\]5Z#Z#^5?H5=?\>UQ_UPF_\ 1;5^>J]!]!_*@!:*** "BBB@#N/A
MK_R/?AO_ *_)_P#TWWE?;%?$_P -?^1[\-_]?D__ *;[ROMB@ HHHH ****
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M_P"%%+_Y/S_/LP]I#^>'_@2_S\U]YJ5[E\"_^0YKG_8)MO\ TOKYY_MS1/\
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MVD?%35OB?;:IIZSV'ANR.B&VT!=.\)W3&72-(V+)!-]S#_']30!^('_!2?\
MY22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\ 017XA_\ !2?_ )22?\$*?^SK
M?VH/_6.?B#7[>1_ZN/\ W%_]!% #Z*** "BBB@ HHHH **** "BBB@ HHHH
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MXI2=*IDN:*,K+6#T:E"7+.-K2BKJ_J9)"4,VP*E%Q;G)JZMHZ4_\MMU:S/V
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MI(_:6/7[8(@-AKPPBC!T#5@>@ZC[)P?:OQ?_ ."D_P#RDD_X(4_]G6_M0?\
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M;_Y$K<P/0?D*,#T'Y"@##_X2"V_Y\-=_\$.K?_(E'_"06W_/AKO_ ((=6_\
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MSU#Q-KFL?!.YB-I_PCR^ +S7/%.H)=SGQ'<:3+X;CMX(_ D?B^-/%</[E?\
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M$889'1F1U(9&92"?Z$E  & !P/Y5_HW]"G_DW7$W?_7;%_\ JAX?Z'W?"?\
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MR>,;GPO\']%ET>R@U5=%\<^(_!GB[Q%XEA\0^(+&;7;SPG9:=HOAS06U-X-
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M0 4444 %%%% !1110 4444 %?/7[5O\ R;S\4_\ L7%_].FG5]"U\]?M6_\
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M]B]!]!_*OP3_ &5/^3A?A=_V&]0_]1K7:_>Q>@^@_E7\^>+G_(^RW_L3T_\
MU.QQ_7'T?O\ DELW_P"RAQ'_ *K,J%HHHK\I/WD**** "BBB@ HHHH ****
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MM^*Y]-^J/AEX'_:$\$_L<:'^S5\-OALWAG]H&W^%P\2>']4\:++X8^'?PO\
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M &??ZA-8K^C/]@:'_P! ;2O_  6V7_QB@#0^U6W_ #\0?]_H_P#XJC[5;?\
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M'G@;X9Z!JMA>Z/XET[PM;0R>));FSU/XI:PKIJ?B75WL+'1;;2OF'7O"6F^
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M&,Y&/7/'YTN0,9(&>GO]*_&P"BC(SC(SZ=_RI"0,9(&>!D]3Z#UH [SX9?\
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MB@#\0/\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!KL/V_O^2Q>'>W_ !;;1N0,D?\
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M:A->0^$M.L8VM-4GLHQ;Q:EJ\ZJT4:,K.)+B0E\@D$*1A17QM_P4G_Y22?\
M!"G_ +.M_:@_]8Y^(-?H7\<#CQ1IQ]/#MF>.3Q>:AV[U\CQMGN<\.Y'/,LBS
M/'91CXXK#45C,OQ-7"8E4JTI*K35:C.%10J))3BI6E97N<.8Y7EV;X9X/-,#
MA<PPDIPJ/#8RA3Q%%U*;;A-TZL91YH-MQE:ZN['QG_PH'X;?\^.M?^#^[_\
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MIC^1=0A#/:S[+=O)NX!)&9[679<0B2,RQH)$W:P^EKE,*CK0\/L4JCBXN?\
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M06_G>4$4@%4";5(!4 @&DFO[RY79<ZA>72*V\)=7MQ<HK@%=X2>615<*2NX
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M.O@\)5J5Y9GEU/V>)K./MXSE%8F=*%.G#$UHTGAJE53CAL+B9X58GZW2H?\
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M7)9MQW_^"Y_QC^*OP:^"?P1UCX4^/_$WP^U36/C!?Z5JE_X8O8[*YO\ 34\
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M8#XU_P#26+Q?_P"(5_!7_P";JOHC]G+_ ((6?MO_ +)OB+Q'XK^ _P#P6/\
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M'IU&,]<#H%_XA@/C7_TEB\7_ /B%?P5_^;JC_B:+P^_Z%?%W_AORCR_ZGO\
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M[5=+M]=T0ZOX>UN"*?[#KNAW=MJNC:K8S7VEW]NT\$5Y]OL-2L[, ]FHHHH
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MH4YSDTDDN:3;LDDKZ)(:[I&CR2,J(BL[NQ"JB*"S,S' "J 22>  2:^)=/\
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MB'Q%#%>^.M534=:\4:M[%\5_^"<OQ.\5^*_VCO$/@;XD:=X0L/C/9?&#X7>
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MLM29=/O+59#<6M\RVD\<=PPC/YOW/[-7Q%^'G_!/O]LKX2KX3\(/XT^*=O\
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MT_QC\1=-LO%&E?%"6"*;X!I\*;SP=\/;/7O@'X?\;?#OQ-I6H:?X4T:'Q'X
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M):));( HHHI@%%%% !00#_GD=N#U!P>HYHHH **** "DP#_7T/;D=^/6EHH
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MOS/ZUP-2=7!8.K4DY5*F%P]2<FDG*<Z,)2DTDDFY-NR26NB2#I7R5\!_VO\
MP;\>] /C;2OAU\:/AY\-[GP-IOQ&T3XF_&+P%!\./ OB/PCK$=G>:5JNCZQJ
MWB">;R[_ $B^M]<A74['3"FD,;JX,+KY)^M#R,?Y_P ^W?H:_"SX1?L0?M*_
M#_\ 95L_V>-&^#OP:\%Z]I.@? &#Q=XOU7]I[Q_\<=*^+-Y\&]<T*;7K3PAX
M;^,'P0\6^&?V>M5\26=OK>O>$_$VA>#O%EAX1ULZ5I\/AF":ST;Q1X8YSJ/V
M"\9?&CX9^!O FK?$;6O%^B2^%]*\':QX[2ZTC4M/UBYUKPWHNB:EX@N;SPU9
M6%W+/XD>XTS2;Z;3H-'6[?46@:.T\P@X['1O%?A[7]/T?4M,U:PN+;7HII-*
MQ=VPEO&M4=[ZWBA$S.]WIQCFCU*U0-/I\T$\-VD,D$JK^.'P\_X)I?$3P[X2
M\;:7XLN/AOXC\02? ;]NKX9_"_5M5\1ZWXMOO!.M?M1?&;6/B)X-2+Q#J7@3
MP_)';Z'X<U5= \3>)](\-Z+>Q74>H1^'O#]MH^JW-D_T/^RO\'_$>E_M&_'S
MQ5J&G36WPK\$ZG/H_P )[6_\)>)?"P@^+/Q0T?P?J/[6>J>'QXITO3/^$A\%
MZCXV^'WA35?"/C3PQ:C0M1USQM\6[/3M1U&W:24@'VK\0OCA\(/A1X>^(7BK
MXB_$CP=X2T+X4>$Y_'/Q'N]6U[3XY_!WA."VDNCKFN:9%/+JMI9W$43C3LV+
M3:M<&.STJ*]O)X+>3HM-^(O@#6;OPY8:3XW\(:I?>,-#_P"$G\)V>G>)M#OK
MKQ/X<\M9O[?\/6]K?S3:WHGE,LO]K:6EWI_ED.;G:0:_(OXK_P#!.SXK?$3X
MA?M,PZ'IGP-\*?#SX]^!?VG-"U76/$L]K\4M7UO7/CKX"O\ 0O#VKZ;I7B3X
M)VWQ'^%.JZ/XVL/!WBCQO;Z5\?\ QU\-=6T[P^UIX1^&>@WNH:(_@*C\2/V+
M_P!I/QA\6/!?QD'A'X3^";+X>^.?V=_B9I/A#X4>,].TV_T?PK\'=(\-V'CC
MX,65IHWP%\"ZM\3->\0C3_&$/@CQMKGQ3\!>$+/POXCT'P%'\._"9T/4_$/B
M$ _6<?&CX1G5/$VBCXF^ 6U7P7ITVK^,;%?%_A]I_">F6^HRZ1->^)\:@8_#
M]O'JD%QI[-K$ED1>6]Q;E?,@E5.].K:8NGPZLVHV(TNXCM9H-1:\MA8S0WK1
M+9RQ7AE%M)%=M/ +61)62X,T0A:0RIN_EG_9S_9#^.GQ2^''ASX?0>!/$'A#
MQKX$L_V>O'/BG5ETS7?@E\./$L?P$\,?$KP9X?\ @3XUB^*W[%FDV5Y\9=+U
MCXV:I\4KCXCZAX#_ &GK/Q)J?PS\,Z-XR\9Z!+IGA'Q5=_K)\0OV9/&O@K_@
MF]J/[.>@:!#XT\901:5'%X8O-7UKXE:+/<:_\>]*\<7^@7.J:;X0^'NHZKX'
MT*QU.[L9(- \!>#K#1_!^FR6/ASPEHNCZ;I^D6X!^C-MX[\$WMEH^HV?B_PO
M=:?X@G:VT&^MO$.CSV>M7"ZI;Z(T&D745Z\&IS+K%W:Z28K&2XD&IW$&GE?M
MDT<+1O\ $#P+'HNM>)'\9^$T\/>'-1N=(\0:Z_B31%T?0]5L[B"TO--UC5&O
MA8:7?VMU<V]M<V5_<6]U!<3PPRQ)++&K?E5X<_X)W^+==^(/C+X@^*]+^$OP
MD'B_3/VKKKP5X:^%=Q=^(K7]G'QK\:?AS^R=\+_!GC;X77-WX,\"Z;=^,';X
M"^-/BMXM\16&@>#Y=*\<^-Q::+%J=W<Z[XLU#Y#^//[)/QP^%'A?X=>+;+X1
M_!/P0]AJO[//@'4_#?P>\(>._C!\'[*'X#_#+]INTU+XX_$SP?IG[._C[4;O
M4?'EQ\3= \ >#]/U/X#_ !7N_!D.G^'M0UWQ[I_B6#PKXJ\$@'[]Z+\7OA7X
MBTE->T'XC^!M7T26RU?4X=6L/%>A7&G3:7H,LD.L:I#=I?\ DRZ7ISQ.UWJ:
M.;"*';<&Y^SR1ROJQ?$+P'/::%?0^-/"<UEXH6P?PU=Q>)-$DM?$":K>6^G:
M8VAW"7[0ZNNHZA=6MC8-ISW(O+RX@M;8RSS1QM^+/PH_8M^(WB/X$^-_$?@C
MX;>$_ 7BCQ/X!_94^$/@+0OCG;6VM_$ ?"3]E?Q3>Z'XBT:Y\0^-/@Q=0^!K
MGXG:%H5KXO\ A7XJU?X(1W_AUM9\):KXH^$OA34_"^G:#X=HZ?\ \$M?BM)\
M.OBIX5\2S_"GQ!J>O? S]O7P-\+Y?$/B36?&$_@+QC^T]\0_A/\ $+X7W,/B
M2]^'.@RV3^#+_P &ZW<ZUXR\-^&M U+2/$)LM9\(:' ]Y*UJ ?MK=_$#P+8:
M.?$-[XS\*6>@KK#^'FUNZ\2:+;Z0NO1ZB^D/HK:G-?)8C5DU6.336TPW'VY=
M0C>R-N+E&B'7U^./QE_X)[>,-<UKXI:EX \%?":XT;Q#\=])^*'@+PY'XMT_
MP#:^&+34_P!EWX>? GQQJDWA[Q%\ ?CI\(M?U'7M8\-ZW_;_ (;\:_"OQ-9Z
MUX:N[37=,\0Z%XL@EL]0_4SX1^'?%'A'X5?#3PIXWOO#.I^,_#/@#P;X?\6Z
MEX+T+_A%_!^H>)M%\.:;INNWOA7PUN?_ (1[PY=:G:W4VAZ)YC_V5ICVMB&Q
M   #T*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH XSQ)\.? 'C*\@U#Q9X+\+^);ZUMOL5M>:[H>FZI<P6GFO/\ 9H9KVWFD
MC@\Z227RE8)YCN^W<Q)YP_ KX+$$'X3_  \((((/@_0<$$8(/^@]".#7JU%=
ME/,<PHPC3I8_&4J<%:%.GBJ\(15[VC",U&*OK9):ZGG5LGRG$59UJ^5Y?7K5
M'S5*M;!8:I4F[)7G.=.4I.R2NV]%;8@M;6VL;6VLK*WAM+.S@AM;6UMXTAM[
M:VMXUA@@@BC"I%##$B1Q1HH1$554!0!4]%%<C;;;;;;;;;=VV]6VWJVWNST$
ME%*,4E%)))))))6226B26B2T2"BBBD,*,?Y_S_*BB@ HHHH 3 _SV]AZ#@<#
MBEHHH *0@'K_ ($?0CD?A2T4 '^?SZT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?#G[4/[6'B#X!>,_#_AC2
M/!VC>(K?6?"_]ORW>I:OJ.G303?VM>Z=]FCBL[.Y22+9:K+YC.K[W9=NT GY
MF?\ X*3>-421_P#A5WA4[$=P/^$GUSDJI8#_ )!??%8__!1__DK7@7_LG/\
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MRE\/W/BKXH_&O3+/5K\)=1P?HY0 4444 %%%% !1110 4444 %%%% !1110
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MTT:'XE>"/!*>)-3\7Z;)\+=:TR]U?XO?$Y?#OBRUF:TN=8]@M_V"?B=X3M_
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MGX>\-Z==>(+B26P^SM<?;5[ US9W=LNW=<6T\"[\[-TL3QC=@$[<M\V 3C.
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M>!_BUX/TO6=5AO=)L?!?A_\ 9=\6>'O$$<MIX/\ %OAOPPWAY/!8!^J/@O\
M:4^ /Q$\*:MXY\%?&+X<^(?!^@^//$/PPUGQ)9^+]"31],^('A;Q+>^$=:\)
MWE]<WT$%OK,/B#3[FSL;61U;6X&L]4T,ZEI&I:=?W?I7_"8^$O\ A((_"?\
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M2Z78_$OPIXT^!?CDSZ)8:+;Q>+? GQ4\4/'XZ\.>(]7U2&_]OU7]F'XGZ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>otherincomeexp.jpg
<TEXT>
begin 644 otherincomeexp.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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M?:VOQ#N?#$_A3QCI,^@^*8='O?D7PC0/^"IOP>U'5-&G\0^ OC!X#\&W=O\
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M:N_:=!$44DTGS_L>>/T!$<2O(P4L&<JIV(&<X521^T<?B"V\M/\ 0-=^XO\
MS =6]!_TZ4 =!16%_P )!;?\^&N_^"'5O_D2C_A(+;_GPUW_ ,$.K?\ R)0!
MNT5A?\)!;?\ /AKO_@AU;_Y$H_X2"V_Y\-=_\$.K?_(E &[16%_PD%M_SX:[
M_P""'5O_ )$H_P"$@MO^?#7?_!#JW_R)0!Y+\>O^0%H7_89?_P!(+FOY\OV]
MOAOXMU;X\? _QS\/O@]XI^)GC4VC^&--TSQ%\(/ ?QF^ OCB/1?!OQV\0Z=X
M,\4ZCJ>N:!XV_9]URSUW7$GU;XG66NZ)X8DT76=%\8I9>,O%GPGTG0X?W]^-
MNI17VB:*D=OJ$)35W<F]TZ]LE(^Q3KA'NH(D=LMG8A+;0S$8!-?-WK[@ \]0
M&# 'U 958 Y 95;&5!'\\<<8Z>7\:X[$0A&H_J>'I.$VU%JK@:<+NVZ3:=GV
M]UPFH5(-.U_ZZI_H?G9X4O?!/A?]OWXP:MH?PN^-^FO\2_@IH7@SQ;\3'^!W
MQYO/"GBCXK>'OBU\1_%%_"?B_J?A.7PV^@:-X'O=)B\&:KINNV'@"QBN;71/
M!*V.HW<FG2>%?#70_!%S\//VI_AIX+^$'[4O@#PA>?M6^"?COX,CTS]ESXB6
M_B:_\%>'K;]F&XO/&FCV/[0OA*WTSXE>)I/'/@?Q/K7B_0M5?QE\6=>M['7_
M !G:>%/&6KQVUOJ/[$4A /! (/4$=:^-AFLH-24*LI>RP5/W\1SP<L#.G.E4
ME!TK2DHTU3@I75.$II74K(3L[V]%?;:_WI6_.Y\?? /Q;XRT31M2T#QGH'QM
MU;PGXI^+/C/0_@CXJ\6_"6+PS\0T^&&E_"O1_&,_BCXX:=X.\.^#5\"I>^-;
M'Q_X4^&_BKQ-X*\)>,O&P7P'8ZOH$/B76]/O]1\X_88N/!?A[6OVE? G@?X6
M?&'X:>%=7^/GB#XG^!H_B'\#/C9\-=*USP=JOPM^!WAFYUW_ (2KXJ^%]+?7
M_%>M>-="\576MQ:UK6H>/-:O8-4\4:REW%<R:G+^A& .@ Y)Z=SU/U/<TM<\
M\;&4,7!4736*C2C*-.HH4E*E54XU72C34)5&HJ+:Y$G.M*$8JKR0+_E;\OT6
MS]3ZJ^!'_(L:K_V'IO\ TWZ=79_$W_D0_$W_ %X+_P"E,%>=_!74X;+PYJ<<
MEMJ4Q;6Y7#6>F7U[& ;"P7#26T$J*X*DE&8.%*MC# GKOB+K,%SX)\10)::M
M$TEB 'N='U*VA4_:(#F2>:V2*,?[3NHSQG) /] Y/_R;E_\ 9/YE_P"F,4@6
MC7JCXY;J?J?YTE*>I^II*_F\04444 %>[_ ;_D.:[_V"+?\ ]+6KPBO:_@E>
MQV6LZW))#>3!]*@0+9V5U>N"+S.72UBE9%(. [A5)! .1BOJ^!O^2LR3_L)J
M_AA,2-;2]/U1]6T5A?\ "06W_/AKO_@AU;_Y$H_X2"V_Y\-=_P#!#JW_ ,B5
M_4HC=HK"_P"$@MO^?#7?_!#JW_R)1_PD%M_SX:[_ ."'5O\ Y$H W:*PO^$@
MMO\ GPUW_P $.K?_ ")1_P )!;?\^&N_^"'5O_D2@#=HK"_X2"V_Y\-=_P#!
M#JW_ ,B5>LM0BOO,\N"_@\K9G[;87=CNW[L>7]JAB\S&T[]F[9E=V-PR 7Z*
M** "BBB@ HHHH *BG\T0RF#R_.\N3RO.WB+S=C>7YIC^?R]^W?L^;9G;\V*E
MI&X!.,X!X/0\=* /S#\>?M 'P=\0+/PUK/[7'BZV\8W'Q)_X0#4M"\)?LXZ!
MK7P5\(ZU;1_"U-1?Q;JE[H-]XKM/!NCZS\;OA'X4\0^*D^,L,>F>*/'FG:'=
MWNF:A9:_%H'Z7:6-273;!=8DLIM76SMEU2;38;BWTZ74%A1;R6PM[J>ZNK>S
MDN!(]M!<75U/#"4BENKB1&F?\8O$H^#_ (C_ &Q/C!I^OW'[.'PY\167QK^#
M>D:CX:\>:E\9]>\8_$;^R7^$GQ$\.^*-$MO#WQ3\+_"OPW=>-/&6@>&X=2\*
M:9X1U1?$VO\ PQ\$ZG\8AXJO-,T?1=)_:L8QQZG^9S^.>I[GF@#\0?\ @I/_
M ,I)/^"%/_9UO[4'_K'/Q!K]NXP/+CX'W%[#^Z*_$3_@I/\ \I)/^"%/_9UO
M[4'_ *QS\0:_;R/_ %<?^XO_ *"* '8'H/R%&!Z#\A2T4 )@>@_(48'H/R%+
M10 F!Z#\A1@>@_(4M% 'A'QZ &A:%@ ?\3F3_P!(+FOEZOJ'X]?\@+0O^PR_
M_I!<U\O5_-7B1_R5F._Z\8'_ -1*0!1117P@!1110!]5? D ^&-5R ?^)]+_
M .F_3Z[+XF@#P'XFP /] ';_ *>8*XWX$?\ (L:K_P!AZ;_TWZ=79_$W_D0_
M$W_7@O\ Z4P5_2&3_P#)N7_V3^9?^H^*''=>J_,^(VZGZG^=)2MU/U/\Z2OY
MO$%%%% !7N_P&_Y#FN_]@BW_ /2UJ\(KW?X#?\AS7?\ L$6__I:U?5\#?\E9
MDG_835_]1,0-;2]/U1]08'H/R%&!Z#\A2T5_4HA,#T'Y"C ]!^0I:* $P/0?
MD*,#T'Y"EHH 3 ]!^0I< = !110 4444 %%%% !1110 56O;RUT^SN[^]N8;
M.SLK:>[N[NX=8X+:VMHGGN+B:1R%2*"&-Y9'8A51&8D &K-9.O3I;:)K%S),
M+>.WTO49GG-U=60A2*RGD:4WEE#<7EJ(U4N;FT@FN8 OG00RS(D; 'XH?$#X
MFMJ/[4%_8Z%^T'X1N?$WB[XW? WQ+\*_B)#^VEJ'ACPGX ^#FH6/PMOM6^%.
MI?LFV?BBWT?QWKWC?2?^$IAT-8_!7B>P^)#?$KP]XJUGX@^#+W0=(@\+_N(.
MG7/7^?0\G)'0G/)%?AAX2\9ZAI/Q0\!^']8^**MJ$OB?X=3/I@_;W_;E\5_:
MK7Q'+X=UG2H_[&UC]G*Q\,^(1JNDZO83IHVO:QINE:JEXNG:[>Z9;SWLEO\
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MZ!6O?]^=/_\ EA1_KMPK_P!#K"??4\O^G?G^#[ >H_V7JG_0RZG_ . 6A?\
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M\'_U0XG_ .A)F'_@E_Y^:^\+>GWK^NOY]F>.45['_P *.\8_\_.A?^!MW_\
M*^C_ (4=XQ_Y^="_\#;O_P"5]'^J'$__ $),P_\ !+_S\U]X6]/O7]=?S[,\
M<KVOX)6]Q<ZSK:V^H7&GLNE6[&2WBLY6<&\(V,+RVND"@Y8%%1\GEB!BJ_\
MPH[QC_S\Z%_X&W?_ ,KZ]-^&/P^USP=J6IW>JRZ=)%>6$5M$+*XGF<2)<F5B
MXEMH $VG (9CNXV@<U])PAPUG^"XERG%8K*<90P]&O4E5K5*7+"G%X:O!.3O
MHG*<4GWD@Z/T[^:_K_ACT6YTO4Q;SD^)-38"&4D&ST, _NVX)&E X/?!!]"#
MS7P2.@^@K]%9D,D,L:XW/%(@SP,LI49Z\9//!KY-'P.\8@ ?:="X _Y?;O\
M^5]?8>)N39IFM3)7EV!Q&,5".8JLZ$.?V?M7@/9\VNG/[.?+WY6(\=HKV/\
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MN(J.5&'L^2GRU:LXQC%4H*/+%-**BFHZ"O?^OE^A^.W_  L#_@N]_P!&P_\
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M;S1I+RW;\F-.\+?&#Q/^S_\ \$[M7\/>"OVKOV>?$_[,7P8UKX4^+OB'X'^
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MPQCA(H(HXT'"J!6A110 P1QKG:B+D8.%49!Z@X'3VIRJJC"J%'HH 'Y"EHH
M****  @'&0#@Y&>Q]1Z'DTA53G(!R,'(!R/0^HY/!]:6B@!%55&%4*.N%  S
MZX%(R(^-RJV.FY0<?3(-.HH ;L08(5<J,*=H^4>@XX'L*=110 4$ C! (/4'
MD'\*** # R#@9'0]QGKCZTT(BDE552>I"@$_4@<TZB@!" P(8!@>H(!![\@\
M=>:;Y<>-NQ-N<[=JXSTSC&,XXSUI]% !TZ4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>interferon.jpg
<TEXT>
begin 644 interferon.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M%'M /Q5U;]N+]J#P7X4O/&VL7_PHU^Q\<>'OVSG\*V$7P^\1:?8_"2']F/\
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MK_T;^QY=_'GX8?LX?LY?!GXC?LU^+/#'BK3;^+X1>,7U;XA?"S7]*T?0M/\
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MG^,O@+XVU_4];C^$?CCX;_#;P#XRT[X._&SQ#I?P[\:0^+_$?@J;4/!'@]_
M7AOQ;X6ZWP1^RM\5= \(ZW?^.O@A\5OBQX<O_P!H/7_B#X;\#^)_VM5MOVGM
M(\-^+/@EIWP[\0W'Q&^+NC^,-*\+?&6QDU^S71O#?@OQ=\8+J\\"_##2_#<-
MKXM\4OX>\/> ?#P!^J^N?&7X=^%_A8/C/XIUJ\\*?#[^QM'UM]1\6>&O%7A?
M68(/$%Q8V.A:;>>"]=T.P\<6/B?5]4U/3=$T_P &W?AN'Q==>(+^T\/PZ&^M
M7$5@[OA5\8OAW\:M#U7Q!\.==GU>ST#Q)J?@[Q)8:GH/B3PCXF\*^+-'AL;O
M4?#/B[P;XRT?P]XN\)>(+:PU32M3;1_$>AZ9?R:3JNE:M#!+INIV%W<?)_PY
ML?VM?AU\"])^&7B/X>CXJ^+O#WPXTC5I?&-]\=;>*]U2\UWXH^)K?4?A+IGC
M;6='/C'5/B)\)O@RWAY_#WQ@\76.GZ/\2O&5CI[ZYKGA^]O-9\2V&[^PU\(?
MB+\)/"WQ@7QWIOB31++X@?&>_P#'_@_2/B/X_L/BW\:+;0KKX?\ P^\+WDOQ
M@^*>EWFJV7C#Q+<:_P"%=57PW&OB'QA+X3^'-OX-\'CQ9>V>B66D:$ ?<!(
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M8?\ OU'_ /$U^D_\2_8;_HJ:W_AGAY?]3/U_K;\]_P"(YXC_ *)JC_X=I_\
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M1B#_ &^^AO-PC\KRK$6?EXW;]V+JY\S=E<?<V[3][=Q_.E^QP5/[3GPB*1+
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MRQ?P\\;WM\2\[?;%%?%/_#;_ (&_Z$?QE_X&>'O_ )+H_P"&W_ W_0C^,O\
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M7^EBX0J67^WPV7_,-+R_Z?\ K^'F?YW_ .M\/^@"?_A2O_E'K_2U_>[R9O\
MGC-_WZD_^)H\F;_GC-_WZD_^)K\$?[?U_P#Z#^O?^#S5O_DRC^W]?_Z#^O?^
M#S5O_DRG_JA4_P"@^'_A-+R_Z?\ K^'F'^M\/^@"?_A2O_E'K_2U_>[R9O\
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M)77V\.[?#_\ ;HT)KUM-76SI&/[0&D-J*/IZZD;?[$;Y&M!.9U,8Y?PO\1?
MWC=]:C\&_&CP5XLD\-Q"?Q#'X9U[P/K[Z% SW,8FUE=(O+UM+B+V=VGFWXMX
M]UK<C=F"78 >P45YDWBOP\OABW\:M\4O#J^#KOR/LWBMK_PD/#5Q]JNUL+8P
M:^9AI$PN+YELX#'>L)KMA:Q[IR(ZZB:SU&W@DNI_$[PV\,3SS32Z?I,<44,:
M&22621X52..-%9WD=E1$!=F"@D '2T5Q>B7*^)=*LM=\/>.+/7=%U*$7.G:O
MHT>@:II=_;LS*)[+4+ 7%G=PEE91+;SRQEE90V5(&K_9FK_]#%/_ ."S3/\
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M9X.?\G-X1_[#L5_ZK,<?U=^+/^17\1_]@'6?_3;=5_FB1_ZJ+_KE%_Z+6O\
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MFM+<N8D /Q._X*3_ /*23_@A3_V=;^U!_P"L<_$&OV[09B4<\Q@<'!^Z.A.
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MI0BFY)*S?DOB[AA<M\^RI<\(5(WQV'7-3JM1ISC^\]Z%23Y825XS>D6VU?\
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MG.\JL7**E32<TVDXWE&_'_L5>'_LOBW]J3QGX(\):E\/_@!\0_BOX2UWX/\
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M?YKL?^JB_P"N4?\ Z M?Z7?BS_D5_$?_ & =9_\ 3;=5_FB1_P"JB_ZY1?\
MHM:_$_HG_P +CK_KYPY_Z3G9^P?2B_C\%?\ 7OB+\\B'T445_8!_*(4444 ?
MH!_P2QE2#_@H+^R_*XD*KXVU[(BAEGD.[X<>-T&V*!))7^9AG8C;5RS856(_
MO(L-0MK]6^SK=CRECW_:=/O['[X.W9]MMK?S?NG=Y>_9QOV[ES_!W_P2K_Y2
M$?LO?]CMX@_]5MXYK^])/N+_ +J_R%?PC]*;_DM\B_[)7#_^K?-S^V?HS?\
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MFB1_ZJ+_ *Y1?^BUK_2Z\6$?\(OXCZ_\@'6>Q_Z!MU[5_FBQ_P"JB_ZY1_\
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M110 4444 %%%% !1110!\.?&3]MG3?A;XG^+-AHOPG\=?$GP;^S=X:T/Q?\
MM+^.O#-_X7L+3X7:+KWAZ?QH+72=!U_5+#7/B/XE\._#V&/XE>+O#_AF&&72
M_!-_I4FE7?B#Q5JEEX2FU[G]KMM.^/'@KX1ZI\(_%MEX7^)/BR^\#^ _B1%X
MG^'VJ?\ "1ZM9>"M<\=Q>+K?X=:/XDU#Q[!\(-4TWPWK.D:;\39M.%L?$%M
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M54O@ 'Q0G[=_@=?A#^T_\:+[X:_%S1?#/[,GBY/#&K:1XA\+P>&_&/C"RNO
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MS>ZE%-^^N+>ZT[P-=Z5!':9E2]OK::3_ $>.:O&--_;H_9VBDDT_QWX^\/\
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MG\&-J.V+'Q[G:COC_2O">,[5;&>V>N#7Z\U&\44F/,CCDQG&]%?&<9QN!QG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>otherrevenues.jpg
<TEXT>
begin 644 otherrevenues.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M9!Q70T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJV?@CQ!\,?$D^J+8:#X@_;5>54D$' R#U''0XXSZX[T +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'S'\9_VLOAA\"OC-^RW\"O&EGXMN
M/&G[7?COQQ\._A9/H.CV5_H-GKWP_P#AWJOQ-UR3Q?J%SJ]A<:/ITGAW1[N+
M3[BQL-8FN=3:*VEMK>!I+N/Z;!# ,.A (^A&:_$'_@I/_P I)/\ @A3_ -G6
M_M0?^L<_$&OV\C_U<?\ N+_Z"* 'T444 %%%% !1110 4444 %%%% !1110
M51U+4K+2+&YU+4KA;6QM$\RXN'5V6)"RH&*QJ[GYF4856.3TJ]7"?$W_ )$/
MQ-_UX+_Z4P5PYGB9X++<PQE*,)5,)@<7B:<:B;A*="A4JPC-1E&3@Y02DHRB
MVKVDGJ-*[2[NQ4N/B7\.KJ&2WN==LKB"52DL,UA?312(>J21R6+QR(<#*LK*
M< XX%2CXH^ !T\16X_[==1SUSR?L>3D\G/4YSG)KXI;J?J?YTE?AO_$6,_\
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M]9WOE;?-^RW$-QY>_=LW^4[;=VUMN[&=IQT- %VBBB@ HHHH **** "BBB@
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MO_@59?\ RNK?HH P/[$G_P"@]KO_ (%67_RNH_L2?_H/:[_X%67_ ,KJWZ*
M,#^Q)_\ H/:[_P"!5E_\KJ/[$G_Z#VN_^!5E_P#*ZM^B@# _L2?_ *#VN_\
M@59?_*ZC^Q)_^@]KO_@59?\ RNK?HH P/[$G_P"@]KO_ (%67_RNH_L2?_H/
M:[_X%67_ ,KJWZ* ,#^Q)_\ H/:[_P"!5E_\KJXOXB:5+;^"O$,S:OJ]PL=D
M&,%Q<6K0R?OX1MD6.RB=EYSA9%.0.:]3KA/B;_R(?B;_ *\%_P#2F"O)S_\
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MZN/_ '%_]!%?B'_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$4
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M0*/MNO\ _0"@_P#!S%_\@5OT4 8'VW7_ /H!0?\ @YB_^0*/MNO_ /0"@_\
M!S%_\@5OT4 8'VW7_P#H!0?^#F+_ .0*XOXB76LR>"O$*7.D0V\#6($DRZI%
M.8U\^$[A$+.,R<@#:'4\YS7J=<)\3?\ D0_$W_7@O_I3!7DY_P#\B+.O^Q3F
M/_J'6''=>J_,^(VZGZG^=)2MU/U/\Z2OY%$%%%% !7M7P3FO8=9UHV-FEZ[:
M7;AT>[2T$:?;&(8,\,V_+<;0HQU)KQ6O=_@-_P AS7?^P1;_ /I:U?5\#?\
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M@?\ !2?_ )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!%?B'_P4G_Y22?\
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M#?\ )69)_P!A-7_U$Q UM+T_5'TU=?\ 'M<?]<)O_1;5^=J]!]!_*OT2NO\
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M /"JCY?].O7\/,#[F77] 4!1K6D    ?VE9= ,#_ );=@,4?\)#H'_0<T?\
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MP"<*I. 3T%<[\"8XSX8U7]W'_P AZ;^!1_S#].]!79_$U$'@/Q*0B@BP&"%
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MHHHK\; **** .V^'$\%MXW\/SW,T5O!%=3M)-/(D,4:FQNE!>21E1 6(4%F
M)( Y(%?:UIJ.GW_F?8;ZSO?*V^;]DNH+GR]^[9YGDN^S?M;;NQNVMC.#7Q=\
M,@#X[\. @$&[N,@@$?\ 'A=]C7VX%5<[55<]< #/UQ7[[X3?\B+,/^QO6_\
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M[_X?^+_$/@'XA>$/'7AQ]$\8^!_&/A;2M'U_5]#UO2M+O?$-C>2#P]XB\/\
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MWBBZ\)PKX.'AJWO;#(M_A_I^LZI\69=#\&>*-.^&5_\ "_X.Z7#+X4_9/O/
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MU<-"K3A"$\)@\/[.2JI2<E+#2E=:6DDM;GVM1117QQ^B!1110 4444 %%%%
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M0^$?AU\';+7/$:_$CX?ZS9>%]0U?3]$%YJ^HZKKH!]CZY_P48_9Y\$_&&_\
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M*TCX=?VMI]S;:EX-T3Q=8^!-571=.\FUG_@GY\3K[2-$^!F@_$O0/#/P9/[
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M/TCP!H'@_P"(EQX4O;[Q'=WOPJUGQW;Z]XBU*XB\8W6@6GA[P]H !Z)\+O\
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M110 4444 %%%% !1110 4A56QN56QTR <?3-+10 SRX_^>:?]\K_ (4\  8
M  Z < ?A112LELDOD 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>rdpercentofrev.jpg
<TEXT>
begin 644 rdpercentofrev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %N 3T# 2(  A$! Q$!_\0
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MPW9V7C2+1CX2U[4M?\$>-_"_BW1M+\/ZSJFHZCX?UBTU2VM7M)4E?XA\#_\
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MA;\/?C!J?Q>TBVL_!_CC9J.BZ/>?#_5=5N_AQX:NO#>H_O+HW@#P-X=EOIM
M\'>%=$FU.W:TU*;1_#FBZ7+J%JS%VMKV2PL;=[NW9V9F@N&DB9F8E"2<RZEX
M'\&ZQ8:9I>K>%/#6IZ;HH T?3]1T'2+ZQTH"#[*HTVTN[.:WL MMFW46D<(6
M ^2 (_EH _ W]NSXVZIJOQN\:>/OAQ\5_"&H> _ GP)^$WB;P=)>_M(>)?AI
MXPEO[SQIXXUO7/B)^P7X*\&:JOPY_:I^('B?PO'-X*OM#^)EYIOAW4OB7X7\
M%_#"P\1:OH>M>,O#$7]"=K.+FV@N%CFB6>*.98KB*2"XB651(L<\$H62":,,
M$EAD57BD5HV *D5CV_A/PQ:0Z+;VOAW0K:#PWN_X1Z&WTC3H(M"WQM$_]C11
M6R1Z47B=XW.GK;%D9D.5)%=!0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %'3K17'_$+[3_ ,('XT-GJGB'1+L>$O$AM=8\(Z._B'Q5I5P-$OO(
MU+PUH$=EJ+ZWX@T^79>:+I"Z??-J>IPVMBMI<M.() #K$ECD#,CJP1WC8J0=
MKQMM=#C/S*WRLO4-\I /%/R,9Z#&>>,#W!P1[YZ=Z_FT_9$\;>!M,_9[_;?\
M%^-OC3>>!O!%GXC\7ZGXB_:F\)?';XH^#?#7BSQ#J7COQUH,_@WQ*G[0%Y?:
MA\!OCQ\09[&SN?%MG\/?&NM?$/5-"\3Z*+SQ5X(\=:=X=9_T"^#OQ^^'GQ%_
MX)[_  ?\(_#?]I/P7IWQ:^)'[(MUX+\!>,_#?BD^.M;T7XM>!?V;](U?QA=Q
MQ>%9M?US4?&/PPEN[7Q-XGT"$3>+;-X@38R:I)#$X!^H^]<$_-QU!1PWMA2H
M8Y[8!S@XZ&@NH .&P?1')'U4*67\0*_ESU;Q-K&N^%O&^G?!EO 'PR^!&N6'
M[).C^,;K1OCYX^^,?[+MA\:-/^*GQ UWQMJG[1'QBL7T"]TGX?\ Q*^%WAM/
M#OQ@@T&YL_'NLZOXE^"4OQ\E\/:EXSN]%MNZTC0O /CWX5_#.W^-_P 2_P!F
M?PKX2\!_$C]KWP_X9N_BUHWQ/^,/['?BV>]7X-ZUX9N?V6]8D\>_"^UU3P=X
M;T&[UKP7X7TGQEX[N?% \2S?&;1_A'H_B'0O"_VC1@#^E0D 9.<?0D_0*!DG
MV S[4 AAD9_$%3^((!'X@5^,GQS^..J_$;]DSX"^&=/M= ^$VIFX_9!US]K_
M .&5[KWBGP_9?L__  1^+7AGQ->Z7'\27TK^PO'.B?"^7QIX3T/1/%NFW>I>
M"]0U'X?V'BGP]XXUGPAH\GBB\LOK7_@GYJ=M>?!/Q!I>CVNB3>$_"OQ>^)GA
MGP7XO\#ZMXZU+X2_$;PQ9:M;7EIXT^#-E\0/$'B_5?#'PRN+W4=1T#1O".C>
M,O&'@?P[JOAW7;'X?>)M6\%KHD] 'W/1110 4444 %%%% !1144\23PS0N"R
M2Q21.H=XR5D1D8"2-DD0E6(#HRNI.Y65@" #S^[^+WPIL/%<?@6^^)GP^LO&
MTLT5O%X0N_&OAFV\4R3S!3#"GAZ?5(]9>:4,ICB6R,C[AM4Y&?10<\_Y_P ^
MU?C=\24^/5O\5]:^%_@+]F/P59?"3P=\7_!L<^FR_L[6'B'PE\4_A_XSUSX
M^$]%TR3Q[?-<:1++)I7B+]I;XG_$OQOI>CI<_"X_#SP!X<\4>;/KI/CO]@M*
MTVRT;3-/TC3;=;33M+L[;3]/M5:1DMK*SA2WM+=&E9Y-D,$<<:!V8JJA<\4
M?,WQS_:Z^''P"^,G[*WP,\6:-XSU7QM^U_\ $/QM\-?A=-X=T_1KC0-,USP!
M\-]:^*.NWGC74=3U[2KO2=)?P]H=U;:?-H^F^(+VYUB:UMI;"WLVGOX/H@:K
MJS ,/#MS@@$?\3+2NA&?^?JOQ@_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\
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M%GQM\?UMY_%7P5\4>!?$>@:B]EX-\(>*_#WAH'X)^$(=+^'/QDT[Q_XKN/'
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M0P&9V9F(&2S$GDFG'XX>#"P8V6NEAT8Z?9EA]#_:&17R=17G_P#$3N*?^?F
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M)X9_[!P_]'35R/QT_P"10LO^P_9?^D>HUUWPT_Y$3PS_ -@X?^CIJY'XZ?\
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M!K+3K24NH!4 RF/#'<A(4CO_ (:?\B)X9_[!P_\ 1TU<C\=/^10LO^P_9?\
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MAU7QSH^EW%P]Z-*L_$^J>%?#<-C?77B;QIX>\#W^O>%[3QYK_A32[:35]/\
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M!\3_ !3_ .1^\0_]=K+_ --EE7G]>@?%/_D?O$/_ %VLO_3995Y_7\C\0_\
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MR3+J69XU9ME,<OI?5:N)IX2'L9PQ>)=2I[:K&\'&-HW?,VK'Z/?\+7\ \_\
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MFA7-QX>U]]>\./9Z>_AOQ##XATG5;7Q!X<-A9C0=:@O])2VABLXU'VW\#/\
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M&9'C)XOQ/\0L54CFM:$:F(XSXCKSC!8/ -0C.KF4I**E*4N5.UY2=KR=_O\
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M.MB*EU-WG/\ 0W3K#3]#@^Q:'I^GZ)9)\J6>B6-GH]HJJ-JJMKIL-K;@!0
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M** "D)P"?0$]S^@!)_ $^@I:JWUJM[97=FXC9+NVN+9UF1Y(F2XA>%A)''+
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MGAG_ +!P_P#1TU<C\=/^10LO^P_9?^D>HU/\/_&O@VP\&>'K.]\6^%[6Z@L
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MS1]2T_5;197@-UIM[;7]N)HPIDB,]K+-$)4#H7C+[U#*64!AG0K^G "BBB@
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M6@W'B#1(/"-E9Z=X3:RU2>SDNQ=^%["PL[/PYJ$LLNHZ#;01PZ3=V:#%>\T
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M?BOKG_!4?X@:7K'BRST3X1>%O&FF:WX/?Q]\#_$FFZI\0?#/@?QKH>E_M2?
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M/B:[\/\ P;^$]UI4^G?MQZSX!DUSXA>,=+U&33OV$?C-?> _&8\:6%MX+O\
M^S;OXF>'7TI_#$&BS:C)X1\1#4&UZ/6--$-G$ ?KY17X]Q_\%-_&VN>./&\?
MA3]GSQ5=_#3PBGB/P_-XAU#P[\1XA:^(M _9BC_:-D\5:MX\M_"/_"H(?!PN
M[JQ^'C>&+7QC-\1+A+@>/K.P?2&&A+R_B7]MK]KS7[_X%>%O#OA7X+?#OQ?X
MT^)O[#?BWQ,EQJ_BKQOH-S\"OVLM ^-QN_!4US+H&C7NG?$/PSXH^#&K6EUK
M^EK+H>IZ7J>BSZ;+IMXNHVTP!^UE%?GE^V3^V;XV_9X\9?#[X=?#?X0Z]\3O
M%/BSX;_%7XOW\MIX5^)OBC3H/"_PGU'P'HTOA>.#X5^#?&>J:3K_ (SUGX@Z
M58VGB[Q%;6'@;P5:6UQJWB.:^%SI^FS^2>*_^"CWBGPUXE^-'A:?X9>&M+U?
MX5?#_P"&'Q4L;'QCXS'AA]=\,_&[7_@YH'@WP]J5VD6JV6@>,_AK>^/O$ _:
M M89=;LO %A?? _7+3^U-.^->F+H@!^M%%?C'X\_X*5?&CP-XO\ $?P77X 6
MGC/XP_#C6_C-)XVOOAS8_&'XC?#O7/#OPG\+_ 7QEIEEX9?P/\.M?\5>&_$7
MC6R_:'\(>']6U+QK9Q>#_A=K>BZ[>>(=6UW3[[0(;SV6U_;B^)\WQ3:SN_A#
MX=TKX21_M!_#S]G5Y]5\77UG\5HO%7Q2_92^'?[1^B:E?>'TTNZ\'Z99^%=8
M\9OX \76UQXED\P"3Q)IM[';Z.]CKP!^F]%?C%_P\Q^*FF>#]$T[Q-\%K+3_
M (V>//'GPJ\->'_ASHOA?]H3Q/K/@/0_B?X'^+OCJY\3>*_"NF_"8:Q\6?"W
MA>/X)^-?"_AWQ_\ L\:QX\\"_%GQ';[M*U3P7I=E>W(_3']G3XJ:Y\:_@QX(
M^)GB;P)K'PU\0>([354UCP7KL=[#J&D:CH?B#5_#ETXAU2PTG6(=.U671VUK
M18M;TC1]=CT;4K"/7-'TK5TO=/M@#VRBBB@ HHHH **** "BBB@ HHHH ***
M* "N!^(_A?4?%WA^/2M,DM(KA-2M;LM>22Q1>5#%<(X#0PSL7)E7:-@4@'+#
M SWU%<>/P-#,L%B<!B>=X?%TI4:JIRY)\DM^65GROSLP/DS_ (4;XP_Y_- _
M\#;[_P"5E>[?#CPQJ'A+PZVDZG):2W)U&[NPUG)++#Y4XA"#=+# ^\>6VX;,
M#C#'MWM%?.Y+P5DF0XWZ_@(XI8CV-2A>M7=2')4<)2]WECK>"L[Z;>H%%%%?
M7 <)J'PO^'.JIXDCU+P-X4O4\8^+/"_CSQ4+G0M.F_X2+QMX(7PFO@[Q;K)>
M G4/$?A8> _!0\/ZS<F34-(_X1/PZ;"X@.CV)@\_C_98_9JC'Q%"? +X.!?B
MZTK?%%3\-_"#)\0//U3^W9QXN1M(*:XLVOE_$$J7PE237Y9===3K$LE\_O=%
M 'SW>?LF_LQ:CX>\$>$]0_9]^#>H>&OAM?:CJ?@+0K[X;^$KS2_"6H:Q<P7N
MM7NA6=SI4L-C<ZW?VMIJ&MRHI;6=1L[/4-5^V7MI;3Q7;O\ 9=_9OO\ Q)XK
M\8WWP'^$5WXK\<C6U\8^([GX>^%IM;\3#Q-X;U/P=XE&MZD^F&[U#_A(_"NL
MZKX>\0&XE<ZWI&H75EJANX9F6O=Z* /+=9^"'P<\0^.M%^)^N_"WP!K'Q&\-
MZ+/X<T#QSJ7A'0KWQ9H^@W%OJ-I+I&G:_<6,FJ6MA]DUC6;6.VBN52WMM:UF
MWMQ%#J^I)=;?AOX:?#WP?<Z;>>%/!'A7PY=Z/X)\.?#;2KG1-"T[3)].^'WA
M"6[F\*^"K*6TMXGMO"WAR:_OI=$T.%DT[3)+NY>T@B::0MV]% '@>F_LK?LT
MZ/?ZYJFE? /X/:;J7B;4+G5?$%_8_#KPK:7FLZA>>*/#/C>ZNM0N+?2XY;F2
MX\9^#?"OBZ82,8Y/$_A_2M?9/[5M([H:?BS]G#X >.VG?QK\%?A;XL>Z\7W?
MC^Y;Q'X%\-ZRUSXVU#0--\*ZAXIN&U#3IVGUS4/#.CZ3X?O]0D+3WVBZ98:9
M=M-9V=O%'[310!YQXN^#_P *_'W@RQ^'?C?X=>"O%G@33'T.33?"'B'PUI.K
M^'=.E\->3_PCTMAI-]:S6=E-H@@A72IK6.*6P2,);/&A96Y-OV8OV<WUCP'X
M@;X$_"(ZY\+H5M_AQJH^'?A07W@:WCU:XUZWM_"LXTK?H=O9Z[=W6MZ?!8&&
M'3=8N)M4T]+6_E>X;W.B@#R#7/V?O@;XFT#QUX5\0?"'X;ZQX<^)WBY?B!\0
M]$U'P9X?NM-\:^.X['0M-A\:^)K66P:/6/%UO8^%_#=K;>);P2:W;0Z!HR6]
M]%_9MF88;O\ 9V^ M]X5O/ UU\&?A?-X,O\ PIX>\#7?A1O OAH>'IO!WA+6
MK_Q+X5\,MHZ::NGKHOAGQ'JFH^(/#UC';I#HNN7EQJ^FBVU&5KFO9:* /F&Z
M_8V_9MOO%WA3Q9?_  D\"W\?@+P?X;\&> O"=[X.\(W'@KP-8>$_%U_XWT/4
MO"'A^303%X?UNTUZ_-P+[3IX8C]CL)1:B\M4NCZG+\&?A+.H6;X:>!I5$/Q.
MMP)/#&D./(^-.L?\)#\78?FM3^[^)NNDZSX[3IXIU/\ T[6?M=Q^\KTNB@#P
MQOV8OV='\3MXU?X%_"5O%[>$?^$";Q,WP^\+G7#X,_X1I_!G_"-'4SIGVPZ1
M_P (?))X2^R>=M'A>1_#V?['9K(ZGB+]G_X'^+=&U+P]XE^$GP[US1-8T#P)
MX7U/3-3\(Z)=V=[X>^%VI:GK/PUT>:&6T8&P\ :QK.K:KX,@4J/#.I:E>WNC
M&SN;F65O7Z* /+OB?\$?@[\:[31K#XO_  N^'_Q.LO#NHOJNA6OCWPCH7BNW
MTG4)H1;7-SI\6MV-ZEJ]Y:C[)?+$%BO[3_1+Z.XMOW5<7\2?V6?@;\4O#U_X
M=\1?#_PW;1:EJ^HZU=:KI/A_P]!KCWFO^(O"WB3Q@O\ :%[I&H;K?QW<>#=
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M-*L=$T+1=-M5VVVGZ5I.F06MAI]E;K\L-M:V\4,8SM09.=ZB@ HHHH ****
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M_P"%_P#QN^)G@G2CX5\:^&O"MO\ #G1=*^&'AKPK'KMSK'Q'U#PY%\0XK?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>costofsales.jpg
<TEXT>
begin 644 costofsales.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M%'M /Q5U;]N+]J#P7X4O/&VL7_PHU^Q\<>'OVSG\*V$7P^\1:?8_"2']F/\
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M9^/9_&/AN'P5=17-P;2VEMO%DFIKX?GBN+I6MH)(M1=);A6@C+3*4'X5Z?\
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M+_\ P4G_ .4DG_!"G_LZW]J#_P!8Y^(-?MW&!Y<? ^XO8?W10!B_\)!!_P!
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M:O"LK8>CB50IX?%RQ,H5)356$:,L3!RJX-4I2QT$VL-&7-.5N;E_I0_X;M^
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M%/@OX?ZCK?ACQY;_ +3WQ L/&EEX9B;QEHWA[P+X5?7/%EKKGCK7/##G5/$
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M_MK2/^@IIW_@=:?_ !ZC^VM(_P"@IIW_ ('6G_QZI_[.T_\ Y\;/_P !H/\
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M_P 3B3_Q2ESU/_+_ *1_\L*3_A2WQ._Z%2Y_\#](_P#EA7H/[<WQ2^-/P?\
M@A?>,?@KI%U+?VNIE/&'B_3/AW>?&#6/ASX76QNI;7Q-IWPIT[7?#^H>,5U'
MQ,NB>$]1FM9]5/A:QUY]>?PUK9BC^P_,WQ<_;=\=^"]!\2^/-,\??#9=&\$_
M [0?BUX \.Z5\$?B;J^G?MC:SIMWXV'QC\,>!-9U_5K3Q/\ !Z3X9GP>GA'7
MO"6H0:M\0_AAXPU&[\0?%9)O!6FV]I?^5A?I.>)>,I4:U#(N")1K5IT8Q^I\
M02G&I"5&*C-4\ZFH2J.JG&+?-&DIXBK&GA8.L?C'_$OW"'_0UXD_\*LJ]?\
MH4>7XVWL>L?\*6^)W_0J7/\ X'Z1_P#+"C_A2WQ._P"A4N?_  /TC_Y85VWB
MOXD_'OPQ\<_ OA6P\2_"KQ='\3/%WC$Z-\!;#PEJUGX@\%_ /1O!WB:]T'X]
M>/?BW'J]UK&BW:^.=.\)^&?%NGW?@#_A"=0OO&H\!_#7^WO%^@3ZY?ZOP/\
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M/_6.?B#7[>1_ZN/_ '%_]!%?B'_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\
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M8>I5C5G0P^'<8O#X;"P5-0PT&DX2ES.;YK-1B4445Z1]<%%%% !1110 4A.
M3UP"<>N/KQ2U5OHYYK.[AMI7AN);:>.":.2.&2*:2%TBE266UOHXGCD9761[
M.[1&4,UM<*#"X!\ 7O[7VJW7[0GCCX06WC']E/P%%X!^(_A#P)/X7^*GQS.D
M_&7Q9:>(M"\*:]%XB\.^!=*M9+*WB\0MXBO-$\$:3<W][?:MJ6BRG5#IEU=2
M:18_H2/PZGI['^?K[U^96F^'?CYH&OZ1;:EJO[??BG7-,O;2_FM6U;]@R_\
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MD0Z7\2M3E^#^I_$?QFFLZ9H7QNM?V-/$O[4^F_"[5/VF]3M[=;7Q1X9C\5_
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M>$^N1Y@WO_:];_U"R\04445^I@%%%% !1110 4444 )@9S@9Z9QSCTS2T44
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M\EQJ^J:@R6:67]%/[-VBV\WP(^%4DL^KQ2-X-THO'%K&L6J*Q$I(%O%>11Q
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MG?'W[.^@?#+Q!K=G\,?#U]>^-/&.F^,/ DOB72=;T]+:\?R_@Q<:Y:_$34?
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MI(>R]7^43SSX]?\ ("T+_L,O_P"D%S7X??MB_&KXU_"3XN_"'4-%\6:SX)^
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M/B1NI^I_G24K9R?E;J?X6]?I2<_W6_[Y;_"OYO$%%'/]UO\ OEO\*.?[K?\
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MTVG&UFF[K41^&?\ PXE^&7_21#_@L!_XL(^(7_S/4?\ #B7X9?\ 21#_ (+
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MQ;XFGCTO0M%TS4_&W@SPWI\,5MJFKZWXF\5Z/8V>G)ID6NZUHGT?7R)^T?\
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M?BAXJU:+P39^);30-2>WT70='N-:OO%5UIFNZAI$8\+^'?$7B/2/L#XFZ?\
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M4R++''(%<!T1@5&E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>taxprovision.jpg
<TEXT>
begin 644 taxprovision.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %> 3T# 2(  A$! Q$!_\0
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M6?@SXJT[X;^+]=\$_%'P!\/?'GPH_:!^)][JWBOX;_$X>,?"EE^S[\7OA_\
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M#]3\4>#OV>?$EQX-/@#XHZWJ,VH?M*Z81\--/\ 26W@.VNOBWHWB/QA9Z[X
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MVD:Z/\.;?PQJ'A_Q8T.NP:M;Z3V%K_P3P\$6G@OXF^$1\1O&UY<?%CP;\,M
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MX.3PA/9+\5O#7@SXN:3\-?&_B/P%X?\ B1^TM\4?V9/!D%D(98K[XF^#=9\
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M_P#9UO[4'_K'/Q!K]O(_]7'_ +B_^@B@!]%%% !1110 4444 %%%% !1110
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MI6M_"JW\4:?XR\7ZE<WECX#U/XE^#M,\)O>ZQ\.-2TO]]EZ<^_\ ,]NP]!U
MP#R* /P]_P""EIF'_!2#_@A48$CDE_X:N_:=VI-(T497_ACSQ^'S(D4S*1'N
M* 1,&<*I*J2R_M+'-XC\M/\ B7Z)]Q?^8S?^@_Z@5?B]_P %)_\ E))_P0I_
M[.M_:@_]8Y^(-?MY'_JX_P#<7_T$4 8_G>(_^@=HG_@YO_\ Y14>=XC_ .@=
MHG_@YO\ _P"45;=% &)YWB/_ *!VB?\ @YO_ /Y14>=XC_Z!VB?^#F__ /E%
M6W10!B>=XC_Z!VB?^#F__P#E%1YWB/\ Z!VB?^#F_P#_ )15MT4 8GG>(_\
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M_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(H ?1110 4444 %%%%
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M?T9FG_)NI?\ 9-X'_P!1<.'V_P#M[]3Y.HHHK^:R0HHHH *]P^ __(RZQ_V
MS_Z7VE>'U[A\!_\ D9=8_P"P&?\ TOM*^JX(_P"2KR7_ +"I?^F*P'U11117
M]3 %%%% !1110 4C8VMG.,'.!DXQV'.3[8I:0YP<=<''U[4 ?B;XJ_:!T_X<
M_ME?%7P]X>\;_'CP]X4E^(G@^\\6Z/H6I_L[7GAVX\>7'CO]DOX0>+=-T;P#
MXI^ ?B7XKZ5H/B&U_:(^%&JWU[:_%#2]6^(::/XQO? VAVFH1:1KOB3]L@<C
M\3^A/'0<#L<<CDU^(7QV\ ?$ZU_:P\4?'NS^"_Q@\9_%;P+\4_AII?P@\2>#
M/V<_V<_$OPI/P&BM? T_C>TU_P :>*-'M_CYJGBF"T_X65 VK:#X]T>]T7Q'
M>^%;?P!IZ>'HO$-O?_M/X?U5M=T+1M;?2]6T-M7TNPU-M%U^UBL=<T@WUK%<
M_P!F:S90SW4-IJMCYOV;4+:*YN(H+N*6..:5%#L ?BO_ ,%)_P#E))_P0I_[
M.M_:@_\ 6.?B#7[>1_ZN/_<7_P!!%?B'_P %)_\ E))_P0I_[.M_:@_]8Y^(
M-?MY'_JX_P#<7_T$4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^)_B
MG_R/WB'_ *[67_ILLJ\_KT#XI_\ (_>(?^NUE_Z;+*O/Z_D?B'_D?YY_V.,S
M_P#4VN-[_*/Y(****\<04J]1]1_.DI5ZCZC^= X[KU7YGV]\-/\ D1/#/_8.
M'_HZ:N1^.G_(H67_ &'[+_TCU&NN^&G_ "(GAG_L'#_T=-7(_'3_ )%"R_[#
M]E_Z1ZC7]*9I_P FZE_V3>!_]1<./[?_ &]^I\G4445_-9(4444 %>X? ?\
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M#6?_  G/$/\ \JZ/[=L?^>&L_P#A.>(?_E70!LT5C?V[8_\ /#6?_"<\0_\
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MSP\X2=!5Y_5TODMK]?)]U_3;O;5?TN>%?C /$VOZ?H?]@&S^WO.OVG^T_/\
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M0?\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"*_$/_@I/_P I)/\
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M=8_[ 9_]+[2O#Z]P^ __ ",NL?\ 8#/_ *7VE?5<$?\ )5Y+_P!A4O\ TQ6
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M4F2DXR46HR<7RR<>91DU[LG'FCS).S<>:/,M.97N>._\+Z^&)P?[8U'D _\
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M;:7XHT'4_ NL:Y!XXDN_&%U\5)_B5J[S?V-J6G272ZE^P5_P5WU>QN=-O_\
M@N/<SV=Y'Y5Q#_P[1_947S(]P;;N7Q%D?,H/'I7$_P##L?\ X*D_])L[C_Q6
MO^RQ_P#-'6W&W"V<\18BC]0GED,+'"TZ<_KD\1"O&O"O5J<]%TL/6C&/LYJ%
MW:34ZD6K.+1_7Y;GVI6;JFCZ9K<-M!JMG%>PV>HV.JVT<N<17^G3>?:3C!&0
MCY#QG*2HS1R*R,17Q[_P['_X*D_])L[C_P 5K_LL?_-'7B'QW_8G_P""I_P8
MT+P'K,/_  62?Q&?&GQN^"/P@DMYO^"=/[+NF#38/B_\2O#_ ,/Y_$"2Q:O>
M&YF\/QZV=5AT]TBAU"2V6TEN;9)3.GP^'\,N*\)7I8G"YAEF&Q%&:G1KT,=C
MZ5:E-;3IU*>!C.$EK9QDG][MG5HTJ].=&O2IUJ-2+C4I581J4YQ>\9PFI1E%
M]5)-'ZADDDDG))))/4DG))/<D\D]S5A+R\BC,45W=Q1$,#%%<SQQ$-G<#&DB
MH0V3N!7#9.<Y-?$*_P#!,C_@J2RJW_#[*X&Y0<?\.U_V6.XS_P!#'3O^'8__
M  5)_P"DV=Q_XK7_ &6/_FCK'_B%/$?7$Y-_X4XS_P"=_K_3TT/T7^%C,?'G
MAM"[E(Y=0\M"S%(R^EWQ<QJ3M0N0"Y4 L0"V2!7VKCIUX]S^OK^/7O7X1Z7_
M ,$V_P#@JOHM_;ZGIW_!;FXM[VU+M!,/^":W[*[;#)$\+G:WB/!S'(Z\^N:[
M/_AAS_@L'_TG,N?_ !6?^RG_ /-%7ZCP/P]CN&\LQ.#Q]3"U*M;'U<5%X2I5
MJ4U3GA\+22DZM&A)3YZ,VTHM<KB^:[:0?:7Q29E\>^(PK,H>6R5P&(#K_9MB
MVUP#AEW*K;6R,JIQE01Y]7QWJG_!-O\ X*KZS?W&IZC_ ,%N+BXO;ID:>;_A
MVK^RNN\QQ)"AVKXCP,1QHO'7&>IK/_X=C_\ !4G_ *39W'_BM?\ 98_^:.OS
M[-?#/B#'9IF6-HXC*8TL9F&,Q5)5,3BHU%3Q&(J58*HHX&45-0FE)1E)*2LI
M26H/_+\OU/LZXMX+NWGM+J))[6ZAEMKF"0 I-;W$;0SQ,""-LD3NA.#C.1R!
M7FWPR^'%O\/K76T\Z.[O-4U6=H[I<EDT2T=TT>U<D B<1/)<7H&5-S)@,PB5
MC\\-_P $R/\ @J2JLW_#[*X.U2<?\.U_V6.PS_T,=>)_ C]B?_@J?\9] \=:
MW-_P63?PZW@WXW?'#X0I;1?\$Z?V7=3748/@]\3O$?P[@\0/++J]FUM-XABT
M%=7FT]$EATZ6Z:SAN;F.%9Y.O!\%\>8#)<XX>PF;971RC/ZN75LUPD<5B^3%
M3RJK4KX.[>7WA&%:JZDU#E]K*E0]HVJ44O,Q&3Y=B\SR[.,1AH5,PRFGC*6
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M& <#('I]/;I7S5^RK\+_ -HCX2?#.Z\+?M-_M1/^UQ\1I?%>M:O;?%.3X*>
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MW7*$8MJZ3LW:Z3W ****Z0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^(;6PM;V6[N-":]1[1=8AA?33<JUN+HS*R#\.M"_X)^?&#XK_#C4[+6OA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>acquiredinprocessrd.jpg
<TEXT>
begin 644 acquiredinprocessrd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M%'M /Q5U;]N+]J#P7X4O/&VL7_PHU^Q\<>'OVSG\*V$7P^\1:?8_"2']F/\
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M5KIT^E:=KUU<:O-;6TUE:VC3W\'T\"& 8=" 1]",U^(/_!2?_E))_P $*?\
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M*HY12497BHRNUJ[=]/ZT9^AW_"W/ /\ T&G_ /!9JG_R'1_PMSP#_P!!I_\
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M[>1_ZN/_ '%_]!%?B'_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\
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MS#)5"%7+L0BLP_:2/Q%IOEI\NJ?<7_F Z[Z#_J&T ;]%8?\ PD6F_P!W5/\
MP0Z[_P#*VC_A(M-_NZI_X(==_P#E;0!N45A_\)%IO]W5/_!#KO\ \K:/^$BT
MW^[JG_@AUW_Y6T ;E%8?_"1:;_=U3_P0Z[_\K:/^$BTW^[JG_@AUW_Y6T ;E
M%8?_  D6F_W=4_\ !#KO_P K:/\ A(M-_NZI_P""'7?_ )6T ;E%8?\ PD6F
M_P!W5/\ P0Z[_P#*VC_A(M-_NZI_X(==_P#E;0!N45A_\)%IO]W5/_!#KO\
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M *^[C_T@NZ^W:^(OAE_R/GAO_K[N/_2"[K[=K]]\)O\ D1YA_P!C>M_ZA9>
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M!^A_^#B__P#E'6Y10!A^=XE_Z!^A_P#@XO\ _P"4='G>)?\ H'Z'_P"#B_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @NO^/:X_ZX3?\
MHMJ_.U>@^@_E7Z)77_'M<?\ 7";_ -%M7YVKT'T'\J_$_%W^+D'^'-?_ 'F
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M4G_0<U[_ ,#H?_D.C^PI/^@YKW_@=#_\AT =!17/_P!A2?\ 0<U[_P #H?\
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M !$0?\$;?^CW/!W_ (;;X\?_ #J* /VGHK\6/^(B#_@C;_T>YX._\-M\>/\
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M#!XB\)ZM>Z7?:0OB;P9KWDR7_ACQ/9V.HWD%IK.F/'/Y%S<V-VMWIMW>6-R
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>lossondivestiture.jpg
<TEXT>
begin 644 lossondivestiture.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MXH67P?UKQ7>1^-+F^\&:3?"P\)>,]9\+>&-;^)%\=,^'/A[QSX]T?P_?^!O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\P?&G]K3X9? CXS_LK_ KQG8>+[OQE^U]\0/''
MPW^%UUX?TK3+[0-.U[X?_#;6OBEK=QXSOKW6],O-)TN7P]H5U:Z=/I6G:]=7
M&KS6UM-96MHT]_!]/ A@&'0@$?0C-?B#_P %)_\ E))_P0I_[.M_:@_]8Y^(
M-?MY'_JX_P#<7_T$4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#@I/\ \I)/^"%/_9UO[4'_ *QS\0:_;R/_ %<?^XO_ *"* 'T444 %%%%
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MW0UUWQ=XQ\5:AJ>NZ[J%MH>BZ/H>G+/<QV&D:+I=AI.CV&GV%LEO7UU\!O\
MD.:[_P!@BW_]+6KUN#YTJG&>3SHQ<:<L3-J+A"FE+ZE6Y^6G3;A"'M.9TX)R
M<:?+&4I23DS^:UMEMZQ[Z_YGU#1117]/$A1110 4444 %%%% !1110 4444
M%%%% !1110 45RT_CCP9;>((?"=QXL\-0>*;A%>W\-S:]I,7B"='4,C0Z))>
M+JDH=2&4QVC!E(*D@BNI_P ^G\Z /P\_X*6Q)/\ \%(/^"%4;F0*?VKOVG23
M%++ X*?L>>/W7$L+QR+\RC<%<!ERC!D9E/[2Q^'].\M/GU7[B_\ ,?U[T'_4
M2K\7O^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(H Q_\ A'].
M_OZK_P"#_7O_ )94?\(_IW]_5?\ P?Z]_P#+*MNB@#$_X1_3O[^J_P#@_P!>
M_P#EE1_PC^G?W]5_\'^O?_+*MNB@#$_X1_3O[^J_^#_7O_EE1_PC^G?W]5_\
M'^O?_+*MNB@#$_X1_3O[^J_^#_7O_EE1_P (_IW]_5?_  ?Z]_\ +*MNB@#$
M_P"$?T[^_JO_ (/]>_\ EE1_PC^G?W]5_P#!_KW_ ,LJVZ* ,3_A']._OZK_
M .#_ %[_ .65'_"/Z=_?U7_P?Z]_\LJVZ* ,3_A']._OZK_X/]>_^65<5\1=
M&LK7P1XBGB?43)'8@J)M8U>YB)^T0##P7-]+!(/]F2-ES@XR 1ZA7"?$W_D0
M_$W_ %X+_P"E,%>3G_\ R(LZ_P"Q3F/_ *AUAK=>J_,^(SP3]324K=3]3_.D
MK^11!1110 5[9\$;*"^UG6XYVN55-*MV'V:]O;)B3>$89[*XMW=> 0CLR _,
M%#<UXG7N_P !O^0YKO\ V"+?_P!+6KZO@;_DK,D_[":O_J)B!K:7I^J/H;_A
M']._OZK_ .#_ %[_ .65'_"/Z=_?U7_P?Z]_\LJVZ*_J41B?\(_IW]_5?_!_
MKW_RRH_X1_3O[^J_^#_7O_EE6W10!B?\(_IW]_5?_!_KW_RRH_X1_3O[^J_^
M#_7O_EE6W10!B?\ "/Z=_?U7_P '^O?_ "RJ[9Z?;6'F?9VNSYNW?]JU"_OO
MN;MNS[;<W'E?>.[R]F_C?NVKB]10 4444 %%%% !1110 5%/&LT,L3>9MEBD
MC;RI98)-KH5/ES0O'-$^"=DL4B21MAXW5U#"6D;.#@X.#@],''7H>GT/TH _
M%OXD:]KFF?&+7?A1X1_8P^%EYX1\'?%SPAI?B"?Q#^SMXC\57?Q'\%>-==_9
M^\&^%+C1OB>PT[PM_P )GXIG^(?QV^)&K>/ENO'-O\-?"_P,$'Q-TW3M0\27
MNNZ;^RVE:;::/IFGZ381R16.F6=MI]E'+<W-[*EI9PI;VR27=[-<WERZPQHI
MFNKB>XD(W2RR.68_D)XF\1>']+_;-\<Z%XX;PE\0;O4/C1\+K7PEXCUW]I']
MIOPQ'\+KCQ'X:\"KX?\ A-JOAWP7\"=1_9T\*^([[4+1?$_@3X<^(/BAIGB'
MXES>+M,'B*%M2\4:3?:S^Q(Z?B?YG]?4=CQ0!^(/_!2?_E))_P $*?\ LZW]
MJ#_UCGX@U^WD?^KC_P!Q?_017XA_\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_
M *N/_<7_ -!% #Z*** "BBB@ HHHH **** "BBB@ HHHH *X3XF_\B'XF_Z\
M%_\ 2F"N[KA/B;_R(?B;_KP7_P!*8*\G/_\ D19U_P!BG,?_ %#K#CNO5?F?
M$;=3]3_.DI6ZGZG^=)7\BB"BBB@ KW?X#?\ (<UW_L$6_P#Z6M7A%>[_  &_
MY#FN_P#8(M__ $M:OJ^!O^2LR3_L)J_^HF(&MI>GZH^H:***_J404444 %%%
M% !1110 4444 %%%% !1110 50U6[:PTS4;U$MI'M+&\ND2\NFLK1VM[:694
MN;Q;>[:TMV,8$]R+6Y-O$7F%O,4$3WZHZI%<3:;J$-JBR74MC=QVZ-J%UI*O
M/);RI"C:I907-YIRM(RJ;^UMKBYLP?M,$$LT21L ?A1?^//AK\2/C3%#H_Q4
M^&2_#7XL_&/X.?$GQS\'M!_:UT6+PIXU^)^CO\.M^K-X?O/V,M1^(KNOBKPA
MX<DD\(>&?C=X.\(?$R[\*Z7J.O:=HL?B[Q5IUW^\@Z?B?QY.3T')/)XQGIQ7
MXOIJEMX.^.VD?#R#Q-XJUW4_"WC7X<:+XG@A_P""@W_!07XA2Z!XDU6S\)Z[
MJ7ASQ+H>E? /Q)\.+N\LAK<4T/AGQEXWT>W\0^%[O0M3\91^$]/\37%KI_[0
M#^I[D]SZ_P N@Z#B@#\0?^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[
MB_\ H(K\0_\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"* 'T444
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M] 32O_ "V_\ C='_  C7A[_H":5_X 6W_P ;K;HK^I1&)_PC7A[_ * FE?\
M@!;?_&Z/^$:\/?\ 0$TK_P  +;_XW6W10!B?\(UX>_Z FE?^ %M_\;H_X1KP
M]_T!-*_\ +;_ .-UMT4 8G_"->'O^@)I7_@!;?\ QNKMGIFG:=YGV"QM+/SM
MOF_9K>*#S-F[9O\ +5=VW>VW.<;CCJ:O44 %%%% !1110 4444 %%%% !111
M0!^('_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1_P"KC_W%_P#017XA_P#!2?\
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MRPV>KZS8Z?=/;1W"07,NR1H7+QK(%P?E+QNH/JIK\9/^"D__ "DD_P""%/\
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MK47+:HWHD[I:Z.Y;2_K^%O\ ,["25(@"^_!.!LCDD.<9Y$:.1]2 *A^V0?\
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M? I%TN]:]^(GB/4]997']IW5Y8W;6UM]GB,V!I'_  4[_P""/^F7OP;U>_\
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M\-9\?_\ YTE?9W[(G_!0[]CG]O!_'R?LG_&K3/B\WPP'AH^.AIWA7X@^&O[
M'C#^V_\ A'#,?'/A'PL+S^T_^$<UG9_9AOOL_P!A?[9]G\VW\X ^TJ*** "B
MBB@ HHHH **** "BBB@ HHHH *1AE6 ZD$#\12Y'KUZ>]&1G&1G&<=\>N/2@
M#YF_9\^&_B[P%XS_ &KM8\3Z?#96'Q2_:5O?B-X+EBO[*];4O"4WP,^ _@F.
M_FBM)II-.E/B+P-XDLS87ZP7HCLX[PPBUO+667Z9HI,C&<C'KGC\Z %HHHH
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M?$MFMAK>BW<EW#;:A:)<07:PRRV-Q:7<86XMH)5:"YA</&N'QD'YXT/]@_\
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M67]N==\(^&/$]YX6U#Q#H.EZS?>"/$0\7>$;O4;.*ZG\.>)QH6N^&!KNCR2
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>spinraza.jpg
<TEXT>
begin 644 spinraza.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M%'M /Q5U;]N+]J#P7X4O/&VL7_PHU^Q\<>'OVSG\*V$7P^\1:?8_"2']F/\
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MTE_#FAW=O83Z3IVOWESJ\MK:R6%O:M-?0?0PU;56 8>'+O! (_XF.D=",_\
M/[7XP?\ !2?_ )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!% &'_:FK?\
M0N7?_@QTC_Y-H_M35O\ H7+O_P &.D?_ ";6_10!@?VIJW_0N7?_ (,=(_\
MDVC^U-6_Z%R[_P#!CI'_ ,FUOT4 8']J:M_T+EW_ .#'2/\ Y-H_M35O^A<N
M_P#P8Z1_\FUOT4 8']J:M_T+EW_X,=(_^3:/[4U;_H7+O_P8Z1_\FUOT4 8'
M]J:M_P!"Y=_^#'2/_DVC^U-6_P"A<N__  8Z1_\ )M;]% &!_:FK?]"Y=_\
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M'BW6EV%O =%'F2Q:O+<R(/M]ERD+:3;K(?9IHQC/S9P#[W7C7[0?_)&O'_\
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MV_F^[/V[PSE*62XURDY/^U*BO)MNWU3":7;>F_WL6BBBOWP_1@HHHH ****
M"D.<''7!Q]>U+56^NELK.[O'BNITM;:XN6ALK::\O)5@A>9HK2TMU>>YN9 A
M2WMX4:6>9DBC5G=00#\IM9MM5O?VM_B3_P )MH'Q/T.\N?BQ\);OP7??#G]E
M?X-^)?!_CWP5X)TCPI=^$-=\5?$SQA\-O%/Q1U75_ OBW4?&%IK/BRUUW1])
M^'MC=6K> IM*FM;[69_UB'3T[>G3^GI[5^(7C[X6GQ5^TIJNM6?@/Q']C^(_
MQS^ _P 8F^,FO_L8?&O5_P!H/X:_\(U8_"^ZM_AYX%^,T6G)X0\.^#OL_A^7
M1;K5]3U#1+?X6:/XL^)GAK7O!GBZZ?5+N]_;T# Q]?Y]/IZ>V* /Q!_X*3_\
MI)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^XO\ Z"*_$/\ X*3_ /*23_@A3_V=
M;^U!_P"L<_$&OV\C_P!7'_N+_P"@B@!]%%% !1110 4444 %%%% !1110 44
M44 %>-?M!_\ )&O'_P#V!!_Z7V5>RUXU^T'_ ,D:\?\ _8$'_I?95\[Q?_R2
M?$__ &3^<_\ JNQ!YF=?\B;-O^Q9C_\ U%JGY&MU/U/\Z2E;J?J?YTE?YPG\
MM!1110 5]C?L9_\ (X^,O^Q9T_\ ].YKXYK[&_8S_P"1Q\9?]BSI_P#Z=S7Z
M)X3?\G$X8_[#,1_Z@8L^FX-_Y*?)_P#L(J_^HN(/T&U'_D'WW_7G=?\ HAZ_
MG_\ B'X\T#X7^!O$OQ"\4F]'A[PGIL>IZI_9T-O/?/#+?66F6\5LE[>:=81R
M3W^H6<#7>IZEIFCZ=%))J6M:IIFD6=]J%M_0!J/_ "#[[_KSNO\ T0]?@EXI
MTC4M>\.:KHVD:\?#&I:A:I!::Z?#^B^+(;%Q<032K?>%_$*G1?$6E7]O%-I>
MLZ+?O:IJ6D7U]:P:AIEY);:E:?KWTB/8O&\$+$?P.;./;WE.'[GVV3>U]^G3
MK5(>YS>_"C6G'>-*HTH/[CQ.Y'B.'_:_PN;'>TUDOW?/@.?6,9R7NWUC"<EN
MH2?NOY?LOVN;9_A=X!\=ZS\*?$GA;Q)\1I]:&@>#?%/C[X4>'O#[Z+X;TB/7
M/$/CRX^,U]XL?X9VGPXT>RN=.T^X\3W%^E_-XMU33_"-IX<GU*YCE/0>.OVE
M[CP%X.T?Q_JGP4^)?_"*2>#M/\;>+[V]USX6:)?>$[&^OYK%_#^BZ9?>.)3\
M6?'-G% VMGPO\-+O5H=5\-7FA:GX>UO6-0\3:!H=_P"!_"?]A&\^%OAGX>ZM
MI^N_".;XK> ?$NO^)=/TFY^$=Y)^SO9GQ?X(T?P)XLTO2_AA:>,;76;"^UV#
MPUX=\9:AXUL_$-MJUWXYTW[;)HR6-Q/&_7>(_P!CG7-4^$_ASX+6?CKX:WO@
MW2O#.HZ5;ZCXM^!.F:GXL^%WBS7-=\5:]JWQ*_9OU/0_%VAQ_"OQ'82^)X;#
MP#I-Z==T_P"&]IX4\)2Z!J=PMCJ6GZK^,UJ/!D<73C1Q-&>&6/G]8<Z><QOA
M)UL4I0PO)5FW'#8>.#="56<JM>M5K3J3J0HQPU7X.I3R)5X*%6FZ2Q$O:N4<
M:DZ+G535&TYNU*FJ$H.<W.I.<Y.4E35*I[3HG[0VF>)/BU??#'0O!NLZK8:=
MXD\5^$+KQM;>+/AVNS6?!#WMAXIU9/AG<>)H/BE-\--&\3:=?>!;OXHP>&Y=
M"3QO;2:6+ Z.!XCK,^*/[1H^'7Q/\/\ PNLO!FAZ_J6N:'X9UI]4\2_'/X4_
M!ZW23Q;XH\1>&=(T3P]I7Q!N4U?QWK['PMK&IW&F>&H7DA@&FV(:34-5M8AR
MGA_]E"'PWX_T?5=-USP;#X"T'X\^(?VD+",?#M'^-DWC[Q2OB2?7/#6H?%Z3
M7VMI?A[?ZQXLUW4;V"V\)VOB+4-&NU\"W-ZGAY)+JYO_ !"^!'Q3^)GA.]\-
M>)OB!\&Y;CX@?"*3X1_%_74^ "W.KRV-[=:_)JNM?"C4+WQU)J/A\7=KKS'3
M?"7Q$O/'_ACPSXDL;3QMH\9U5]0T_4.#V7#'UV@XUJ,L%]4IPJJLLUA-8B52
M2>(JJC&4ZE:G0CSU:&'G0PTJLJ=.BY)U+<_)E/MZ7+4@Z'L(1J>T^N1E[5R=
MZL^1-RG&FN:=.DX47-QC#F3E;]&?@"NWXT>!%R3MU>_7)4H3MT;55R4;YD)Q
MDHV&0Y5@&!%?KFO0?0?RK\A?V=X4M_B_\.K>-IFCM[V:VC>XF:YN'CM_#VHP
M1O<W+@27-PR1JUQ<R /<3%YG 9R!^O2]!]!_*OZ5^CQ;_53.;.Z_UCQ%FU:_
M_"7E/2[M]Y^K>&7_ ")<=;;^U*G_ *B83U_,6BBBOWX_2 HHHH **** "LG7
MUW:'K"_9VN\Z5J(^RI8KJ;W.;*<?9TTYYK9+]IL^4MDUQ MV6%NTT0D,BZU(
MWW6^A]NWK0!^%?A3X /X4^*/@%#\ ?"^W3O$_P .=5'B+1O^"<'@/PU96/VF
M7P[KC36_BMOVEKJ_\-7GAXW9L]2UBWT+5)O"^LZ9?26UEJSZ6D=U^Z@_J>V.
MY_SGOUK\:I]-\%6O[87Q@G\4>%O@!9>(=1^/W@"^TB_^)_[)WQC^/'Q,UBV7
MP7\,K#2];\*_'ZUO]$\&^"+/[3I\FF^$_"EE8ZSIOPCU'2)=:U/5[Q==.D:1
M^RH_#J>@QW/Z^I[GF@#\/?\ @I8)3_P4A_X(4B QK)_PU?\ M.<RJS($_P"&
M/?'_ )ORHR,6\K?L&X#?MW?+D5^T$:>*/+3]]H/W%_Y8:EZ#_IZK\8_^"D__
M "DD_P""%/\ V=;^U!_ZQS\0:_;M"1$I! (C!!;H#M')]O7VH P]GBC_ )[:
M#_WXU+_Y+I OB<])] /TAU(_RNZ_)+5_VAOCGX1_X*!:OX;\:?$+Q%:?!W6[
M.\\&?##3O!^D_##QA^S_ *AXAO(=3T_PKX7^(NK6]W%\9?AM\:IO&>F:U8:Q
MK>K/+X!A;3M.T%[:VT_58IX.4^&W[4/Q(_9%\"^+=:_:Z\1?&WQ5X^U3]GKP
M9\7?"EI\1/B;\!?&7@;5M3E\8>!_A=J]A;WGP6^''A6V^%<][\6_BYX&L-7O
M-1U;XE_#_3?A]J=OXJTGQW<Q>%O%T%F ?LP1XF'6?0!SCF'4>HZC_C[ZBE">
M*#R)M!(]1!J7_P EU^'WPZ_:2\6_&G]CCXT^/[;]KWQMX[^)GP<_:O\ B]\*
M- U?]GG4/A'X8@^(/BSQK\6(/ '[/_PNO?[9^&OCBRTWX>7FM>-O"6D^&-9M
MK*3Q,/!Z6?B#7M>\2:M!J$MW^O&B^$_BSX4^"'ASP78_$NT\:_%[1?"7AOP]
M>_%KXF^'(;^W\0^)[<:?8^(/''B'PEX&E\#V=W)>-_:6KV_AW1;OPQ8RSFRT
MQ[_3K4SWB 'I.SQ1_P ]M!_[\:E_\ET;/%'_ #VT'_OQJ7_R77S?^PUXZ\=?
M$K]DKX#>-_B9XEN?&7C[Q!X TZ[\6>*[O2=(T*Z\1ZU%=W]E=ZU/HV@6.FZ)
MI<NHFT6Y>PTFQMM/M3)Y5I$L*J3]84 <_L\4?\]M!_[\:E_\ET;/%'_/;0?^
M_&I?_)==!5*ZU+3[*>PM;R]M;6YU6YDL],M[BXBAGU&[ALKO49;6PBD=9+RY
MBT^POK^6WMEEFCLK.[NW1;>VFD0 S-GBC_GMH/\ WXU+_P"2Z-GBC_GMH/\
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M'%'^O?!/_17<-?\ A[RW_P":0_UBR#_H=Y3_ .'#"?\ RWS_ #[,^@*^'/\
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MFH?TG:_*\&AZS/$0)(=*U*5"0& >.RG="5/! 902#P1P>*_BA7]M3X_E$/\
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M$NN^#+74_&'AJQ\(Z=XP^'7]L^"M U[3/!\OCZVL[F73=-O-9N=/]K\#Z?\
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M8/$,MGJVM();>[:SNY/"VMQ1PZ/:ZMJ$<=A=WDUE':P!YOZ./^"Y'/P4^">
M?^2OW_8_]"!XB]O>OY,?BO\ "S6/B'K'A.\L+OPOI\>ASW;QZY>:/J\?CCPE
M<7&C>(+,:UX)\1Z'K.E3R79O-0TNY30M88:+#J&EP:G=#4K1[[1[CR^.,%E.
M)XTQCS*EAU3>"HWK5*4)252.!A[*[]G*<[-+E@Y0NTE>?\&IQ\04,'5S[$?6
MX4^1T*?[R5-2::PT.3:+E*SV5UJK7>D)?2<G[97QBM]=BT>_^(/QDTVQN]8U
M;P[I?BF^=8_#NKZ_H>GZOJ>HZ98"*YG\0LC6>@ZR^CZO/X>@T3Q)-IEU;Z!J
M.H.UB;^E9?MJ?&F[:XMI/%?Q[L=6.B6/B31M O(+8ZYXET'4=5M-$M]1TJSL
M]5NXK![?4[^PAUS3?%%UX=U+PS;WEO?^(+;3[(S30>!0>'_BQ<_$6Z\3^((?
MAGJFA:;<Z]%X&BBUOQQ;ZAX7TR\TZXM+*Z.BCPN-(O/%FL?Z/8>*/$4NLR&P
MT*XU#2/"%KIUFUQ;:SE^%O"/Q>CB\2W_ (T/PFO_ !7X@T_3K.\UJSN/'6LZ
M;J.FVU].]WX'&AZAHV@?\(IX';3]0U5-/DT:^UK6DUB^EU[7T\1W\\\C?'K*
MLA45?"9?S*EAF[.$DZLZSY^7]RI.$*/(L3)Q4O:WCAJ,:4_;P\3ZGE]KNCA;
MJ%*Z3B[RE-\UO<3M&G95G92Y[JE3C!JJOJ_1OVNOC#JNCZ_K%Y\4_B9X:7PE
M?ZYIGBVP\1ZK!;7GAR^\.6%MJNL)?2Z;/JNFW5M:Z5>6NI1W^E7]_:7-G.C1
M.+E9[6&OX:_:^^-7B.]_LZ3Q]\8?#5_/HL/B;2[3Q1=V=C/K/AJ>Y@LUUFR7
M3[_5EMS!=7=C!J>BZLVF^(=&?4=-&IZ5;B]C(^=_!7@/7?!VCIH%I!X'M?#V
MK>(M>O\ 6O"EA9>()_#GAGPYJOA=+"/PWX'M]1F5KR*Y\3VPUSQ NNV^FZ3?
MPZ[XFBT[2M,DFL@U7X>?"^\\+:ZWB'5Y-*:[L?"H\$:%::1JGC;7+>RT ZM9
MZO.JWWCO4M3U/3+#S=+TJUT3PCIDLFD>';.WN@^J:]=WB7=IG/+.'U''.-##
M-Q4983EPU*3;UBX-->ZU4C[_ #/$1]DTXU9/EJU)EA,M2KVITKJSHVI0=[[Q
MMT:E=.[JKDMRS=E.?]A?_!&KQKXN\<_L]_$?4O&7B35_$^H6OQGU*QMKW6;H
MW=Q!9KX'\$W"VL<A52L"SSS2A,$"25V_BKZ7_P""D_\ R8Y^T;_V(B?^I'H-
M?(/_  1!X_9M^)^0?^2XZIV/_0@^!/:OK[_@I-S^PY^T: #_ ,B(G8_]#'H/
MM7[WE$(4_#F,(1C"$>'\>HQA%1C%>RQ.BBDDEZ(_1\#&,>&%&*48K+<4DHI)
M)<E;1):(_C$?[[?[S?S--I[@[VX/WF['U--P?0_D:_G8_,A**7!]#^1HP?0_
MD: $K]N_^"&__);?CA_V2KPW_P"IF]?B+@^A_(U^W7_!#C(^-OQPR#_R2KPW
MV/\ T.;U]5P1_P E5DW_ &$5/_4:N>QD'_(XP/\ U\G_ .F:A_25XE_Y%W7?
M^P-JO_ION*_S^$_U<?\ USC_ /0%K_0&\2D?\(]KO7_D#:KV/_0/N/:O\_I
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M3-\0_P#S(4C?\&R_[%X4D?M/_P#!2G@$_P#)YOB'L/\ L4*_HTHKF_LW+O\
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M%W )Y@#F/B]^VQHGPG\8_$>PG^&_BKQ!\-?@,_@2/]H;XL6>L^$],T?X7O\
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MHNOZ=%:W%[H>OZ)K-EINN:!K$%I?Z??-I>M:;87S:=J.G:BD#6.H6=Q/Z/0
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MQ'D^+?AU?"S^)3X0CG^S:\=8E\1+H+^+CID7A0:,?%\DH\%QR>.O-306MO\
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M.>$+ZV\2>(;W2M'E2\(!]'T5\M^*OVO?@WHGBK3? _AWQ+IOCSQ=+\1/A+X
M\0:'X6U&WO)_"1^,AT.X\(:]KET$>PCT[4=&\2:)X@TR&*[:ZUW1;Y=0TA;F
MUAN)H:7PG_;(^#GQQ^,6L?";X4Z[8^.8M%^%]E\3;GQKX?U&WO/#<]E?>/\
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M&7]H+QUX[TO1X?%<K0:!>^+?C'J%EI'@5]6GGT[2M$TU;[Q9K%X\ET/U!HH
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>financialhighlights.jpg
<TEXT>
begin 644 financialhighlights.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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M)-0BT+Q;X!UWQCX9T'2/B#X1UA]*OQ8>)_!=[KFCSI%#-]J6"^T^6[\SUO\
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MJ?$/XP?"WX5W^N:/I7B^'P)X=/Q4^&^L_%?1+J+XDQ>$K_X=ZUXG'@*U\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\9WGA_Q)XNUC3W\2Z/H6JZEI&G:RL2W]II]]=6L$Z0S.A_;;_A&=)_YYW?\
MX-=7_P#D^@#?HK _X1G2?^>=W_X-=7_^3Z/^$9TG_GG=_P#@UU?_ .3Z -^B
ML#_A&=)_YYW?_@UU?_Y/H_X1G2?^>=W_ .#75_\ Y/H WZ*P/^$9TG_GG=_^
M#75__D^C_A&=)_YYW?\ X-=7_P#D^@#?HK _X1G2?^>=W_X-=7_^3Z/^$9TG
M_GG=_P#@UU?_ .3Z -^BL#_A&=)_YYW?_@UU?_Y/H_X1G2?^>=W_ .#75_\
MY/H WZ*P/^$9TG_GG=_^#75__D^C_A&=)_YYW?\ X-=7_P#D^@#?HK _X1G2
M?^>=W_X-=7_^3Z/^$9TG_GG=_P#@UU?_ .3Z -^BL#_A&=)_YYW?_@UU?_Y/
MH_X1G2?^>=W_ .#75_\ Y/H WZ*P/^$9TG_GG=_^#75__D^C_A&=)_YYW?\
MX-=7_P#D^@#?HK _X1G2?^>=W_X-=7_^3Z/^$9TG_GG=_P#@UU?_ .3Z -^B
ML#_A&=)_YYW?_@UU?_Y/J_8Z9::=YOV59E\[9O\ -N[RYSLW;=OVJXGV??;.
MS;NXW9PN #0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P[\?\
M_*Q!^SA_VB;_ &DO_6I/A#7[B5^'?C__ )6(/V</^T3?[27_ *U)\(:_<2@
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M34E"HX4W5HR:<Z%;V</;4)4ZG)#FY44445\V?0A1110 4444 %%%% !1110
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MVC6&EPZ1X8OM8A\07VAZ59V$%O9:=IM]K5M:ZG>VME;P1W=Y:6D]P)'M8#&
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M /RSH_L&R_Y^-:_\*+7_ /Y9UM44 8O]@V7_ #\:U_X46O\ _P LZ/[!LO\
MGXUK_P *+7__ )9UM44 8O\ 8-E_S\:U_P"%%K__ ,LZ/[!LO^?C6O\ PHM?
M_P#EG6U10!B_V#9?\_&M?^%%K_\ \LZ/[!LO^?C6O_"BU_\ ^6=;5% &+_8-
ME_S\:U_X46O_ /RSH_L&R_Y^-:_\*+7_ /Y9UM44 8O]@V7_ #\:U_X46O\
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MV@_'7C#X2_ WQ+\9_C/\.OA=\6O%/[3WC;X3_$O7]$\*^$OVF/&'PI^$&A_
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M%6;PO"@EWQ^&G?P^L@T=WLFU?A;\#?@W\$++5].^#WPM\ _#"PUZ\AO]9M/
MGA31?"]OJ5S:QRPV37<6CV=HLT6GP32VVFVQ'V33+:22VT^"U@=HR >J4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 444WS$W;=Z;LXV[ANSZ8SG- #J**/Z]* "BBB@ HHHH
M*** 0>001SR.>AP?R/!]Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW_ASQ+\(?AOKV@ZGX<\#^$-0T?5O!N@7^G7?A?X9WVK:I\.=!FM;FQDB;2O
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MB37M*ETT:=]EFL]=\0Z/I.NZVDL;OJVL:9IVI:A)<7MA:3P\QX#_ &/OV<_
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M2!U\276BZ7<:P;R:QMWCBL?V<_@'IOCK2OB?IWP7^%UC\1="T6Q\.Z-XXM/
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M?P(/T- !1110 4444 %%("& *D$'H000?H1Q2T %%%% !1110 44$@8R0,G
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M=8BTS2?BUX[U+5?B/XI\,:1XT/[0WC[]G3Q%I%AK7@3P-XAG^&.BV>K> _\
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7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>anticd20.jpg
<TEXT>
begin 644 anticd20.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %: 3T# 2(  A$! Q$!_\0
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MJS\&?%6G?#?Q?KO@GXH^ /A[X\^%'[0/Q/O=6\5_#?XG#QCX4LOV??B]\/\
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MX.3PA/9+\5O#7@SXMZ3\-?&_B+P%X?\ B1^TM\4?V9/!<%F(98KWXF^#=:\
M:?':_$#XS>!-<L= A\'^&M4U15TNWUBX>>Y\+VOB(:MJ'ZD6FC:18(L=CIFG
MV<:7MSJ21VME:VZ+J-[YYO+]4AB15O;LW5R;J[4"XN#/,9I'\V3<^_TG3-5^
MR?VGIUCJ'V&[AU"R%]:6]V+.^MBQM[VU%Q'(+>\@+,8;J$)<1;CY<BY.0#\#
M]:^)^JZUJ?B3QK/\1/BGIG[75C\7OV*[/]E;X6^/O%NO?#_QEXH^"GQ!\$_L
MS:GXDL]9^!^C:Q8^$=?T[QUJ/B']HJ']HG5AX9\1VG@C7?"WBA9=7TRW^$/A
M2^TK]7_CE\3O@5JW[-/Q-^(7BW]H:Q^&?P0T>V\2:;XZ^-_@3XCZ7X<'AFU\
M$>-I_"/CK1-/^(%C_:$FAZ^OB/0M8^&6J_\ "/R1>-],\0W&H:'X7N=+\=Q:
M9<6?TG)IFG37UKJDMC:2ZE90W%O9W\EO"][:6]V8FNH+:[9#<00W1@@-S%%*
MD=P88C,KF-,8MCX)\)Z;X>E\*6GA[24\.7%WJE_<Z++8P7>G75]K6M7?B/5[
MNZM;Q+B*ZN=2UZ_O=7O)KE99+C4;F:[D9IG+T ?@OX&\7^ M=U?P39>+?B])
MX0_8/^(_QV^)EXOA&;]IF]U8_"N^\._ CP7'\*?AY\9_BOH?Q,U35_A;9_%K
MQ59_%7XT:7\'K_XC_P!G^'_$5CX"T#48[;Q9K&K>$;/:C^.:>$_"W_!-_P 9
M_&7]K?6?"*R?M#>)=,T3PG\1OBAX8^'_ /PL[]GU'_:JT+X4?&OXK1Z[+HOC
M7X@MXC^%6D?">\^W>+M6O?"4GB&\@\77NFZAX\OK+6M/_<K3O 7@C2-+OM$T
MKP?X6TW1]3E2;4=*T_P[HUEIM_-$L:Q2WUA:V,-I=R1K#"(WN896011!2/+3
M:NO>!/!7BF>*Z\2^$?#'B"Y@M6L8;C7/#^CZQ/%9O+Y[VD<VI65U*ELTW[UH
M%<1-)^\*%^: /Q&\2>.O'&E?ME:;H7AGQC_PFGQOUC]L_P #10>(/#O[0\NK
M64/[)?B+3-*UGQ/\)M3_ &7++7);C08/ OPIN=3\1:GXFU;P!;_#Z]NHM$^,
M^D?%B_\ B#XEL_"$7NW[;G[<GC[]GSXU^&/!O@*_\.W\7A_3O@3XA\9> /$>
MD>$=$OO%>A_%WXT3?#35+C0/$GB;XFZ/XT\32:1H%KJ.IQV7PE^$_BN+P=J^
MG0WOCOQ'<66LVGABW_5V+1]*@OO[3@TVPAU$6,6F?;XK.VCO?[-@D,L.G_:D
MB6?[##*QEBL_,^S1RDR)$K_-2W6DZ7>W,%[>:=8W5W:PW%O;75S:6\]Q;P79
MA:Z@@FFB>6&&Y-O ;B*)D2<PQ&57\J/: ?BEJW[<'[4/@SPK>>-M6U'X5>(+
M'QSX=_;/?PO8Q_#SQ!86/PC@_9B_;"\'_ K3_B7XOU&Q\;SWOCCPOIGPL\=W
MGQ)^*6BVMIX5^R1^ ;M]$UW2].GU.^?Z<_8U\>:IXNT/]N+6/%?Q^T7QUH^B
M?M%76EZ/\;_"4FEZ-X-L?"VG?LB?LTW5WXF\)0ZSK'C3P5HFFZ)K%QXAUG49
M;*]U#P0?$\&O:K-9)'<:I9+^BBZ;IZ^7MLK1?*6\6/;:P*8UU"437RH5C!1;
MR4"6[";1<R //YC#-16VCZ39V+:7:Z9I]MIKP+:MI\%E:PV+6JVR6:VQM(HE
MMS;K:1I;+"8S$+=%@"B)50 '\[6C_$SX:ZUI_B3Q1^SO^T7XCU3]DK5];_9:
M\$_&#7[O]I[5/'_Q#\>> =4^,AC^+G[6>HS?\+$U/QM\%?A[XIT.?P]\-/$7
MQ,@/P]O/''A'Q1XX^(\FD>%_"?@GX=>*]9Z/XT?$O0?"'[*/[2ESH/[5?B#P
M%\#? 7[4WA[3_P!E_71\9M.T[_A:GA;3-._9WUSQG\/=!^*7BNYN_&OC/X6_
M#WXP:G\7M)M;/P?XX\O4=%T>\^'^JZK=_#CPU<^&]1_>?1O /@?P[+?3Z!X/
M\+:)-J=NUIJ4VD>'=&TN6_M68NUM>R6%C;O=V[.S,T-PTD3,S$H23F74?!'@
M[5[#3-+U7PIX;U+3=% &CZ?J&@Z3?6.E!8/LJC3;2[LYK>P"VV;=5M(X0L!\
MD 1_+0!^!?[=GQMU/5?C=XT\?_#CXK^#]0\!^ _@3\)_$W@V2^_:0\2?#3QA
M+?W?C3QQKFN?$3]@KP5X,U5?AS^U1\0?$_A>*;P3?:'\3+S3?#NI?$OPOX+^
M&%CXBU?0]:\9>&(OZ%+2<7-M!<+'-$L\4<RQ7,3P7$2RJ)%BG@E D@FC#!)H
M9%#Q2*T; %2*R+?PIX8M(=%M[7P]H=M!X<W_ /"/PV^D:=!%H7F1M%)_8T45
MLD>E%XG:-SIZVQ9&*-E216_0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445%.S+#*R+([+&
M[*D(C,K,JE@L0E*Q>8Q&V/S2(]Y7>=N: &0W=K</<I#/#*]G/]FNECD1FMK@
MPPW'D3A23%-Y%Q!-Y4@63R9X9=OERQLUC_/I_.OYQ_V']3\)>!O%/[:/A[QQ
MXW\8^'/AQ'=6FH?%']K1[[XZ?L_>/]"U;3M#_9TT^3PW^T+H_P 3SJ/A?1?C
M?XXC\1:UYOQ&\%Z[:>-M/&D?$.6PT_X;^&=;^&DZ?:'["7[0WPXD_8!_9S\)
M?#7XE>%M5^)=QX(MO@1X#TNYU+4M>F@^.>E?"OQGX^\.> _%%S>)J%]8:O!X
M8\'WFOZA+XONH);C3-/FFOK^XO;VW%Z ?K-N&"?FP!G[K'N1P,9)R. ,DC!Z
M$$KN'OU(Z'J!GTZ>_3D#.2*_EJTO3]:A^ OB;P[X5T[2;[X@>-/V>/A/;_M&
M>-_!WA'X\:%XF^!_Q?M/CG\%9/%>C?MV7UWXKU.+]H33/$&HZE\2-8^,E];>
M%?!'QH3X->&OBCH.@V_ACX2?$.V\1^$O1?"(L(O!=OKGQ!L_V:_%_P  _!_[
M6/C54\'+9_$KX4_L!?%.Q\=? 'P9;^%-=^%<4G@SXPZ?X,N/A'?Z#K4NI>#/
M&>G^,OACXV^./C+X@ZW\./&D?Q1D\,>$_#H!_2AD8SSC&>AS],8SGMC&<\8S
M2@Y]>#CD$?SZCW'%?AE+XM^**_\ !.[P?\$]=U3Q!<?&*RT;X3_$#XG^%M2T
M_P",-EXITK]BSQ5^U=>:!=7^JO80W7Q+GLM,_9^T:[TGQ;X9GUB'XP7O@[1/
M$>F:TOAWQ1J']HVOV/\ \$]IM)C\'?&31_!VD?#R3X;:1\9;L> _B%\&_"GB
M[X<_!KXF66I> ? NHZ]K/PS^&GB?Q?XWTCP=HWA_Q+-JG@_5S\,]>N?ACXI\
M4:)K7BS2H[7Q5JWC.RM@#]!J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M1O"<.C^'IO"FG:+<>'-$DL?X8_\ A?7QS_Z+5\7O_#G^.O\ Y?T?\+Z^.?\
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ME_U*?)_>SZ__ .%Q>!?^?W4__!-=?_%T?\+B\"_\_NI_^":Z_P#BZ^0**/\
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MC253_P 7)D;E9%8=44].JJ>J@CY'CV_^J&>6M?ZO0W_[#<*?=>&?_)=</?\
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MM_X.221^W1\-2.H_9=\"D?4?$?XK5^C>%O\ R5=+_L!Q?Y4S\J\9/^2*K_\
M8QR__P!.3/S^B_9C^$-[^PW:_M :!??$#QKXXT_Q';R?$;Q#X%USX>:WX?\
MA' L4::UX-^(7PIO-3TOX@:5I6B64MGJI^)4=U);WFLZWHC?9;?P/>RWUGW.
ME?L>_!3QQIWP:\6^%5^*_A_PY\1/'?Q.\,Z3X<NOB=\&/B3XR^*>D^"O@Q?_
M !4\#:;I^J>"M(M_"7P)^-GQ;U_3X/AYH'P@^(4WB/5S=:R=9\.VOB!/#MW;
M:Q\OZ3^V'\8]"^#NG?!O1Y/!>G6>E:A;&Q\>6W@#P;_PLZ+PK:6-E:6_@"3Q
ME+HDFH7?A8/IUF+DWQNM8U+0X$\%:GJ5YX+W:&U'5/VK/'^HG38+?P5\!] T
M2#QW<?$[Q'X1\-_!#P9IG@KXC>/+K0=9\+S>(/B5X5GCU#3/$S0Z!XC\1Z?I
M&D6J:)X>\,-K^K:CX2T?0-8N(M2M_P!W>$SQNLEB81YL7C9T:GMZDG##U:7+
M0A.')&FW"=I0]QQ@ERQA2G)UU_."QW#B6';PE2:C@LOIXBDL-2@JF*H5U/$U
M(5/:3J*-2ES0G>493<E*<ZU.*P[^C-<_98^&?A'Q)\'_ /A*? /QBT34/CQ\
M-M6\2^$/@/XV^-7P9^$7B/P3XJ\'_$G5_!/C>S^)OQL^)?AG0]'\.Z$?#^G:
M7XP\#Z=K'PWT3Q?J=SXD@T/Q-!I5MID5]K_S?\0_AC\*?A%^U#\2/A9XY\0_
M$6;X2_#;QYXUT*ZUG3_#UAI/Q'U[2/#EG?W6@6$5CKUO!HNA:CXFOX]+T67Q
M;?:;=:#IVE7S^/+/0M4TEK'2;E;C]J;QSJ,]Q::WX(^!GB+P0_A[0O#&G?";
MQ!\']"U/X6>&]+\-ZQKOB+2I/"N@&]AU_0M8?7_%7BC6->U^#Q;+K7C.^\1Z
MPWC:]\1P7$,%J_3OVKOB1:_$NT^+^L>'/@_XT^(=I\1K_P")Z^(/''PE\-:\
MTVNW'A"P\%:/HTVGPMIFG#P-X(TS2M+U#X>>";:VMM$\%^(]-L->TF,7=I"B
M[4*&;4W4=6<:L987$0C".)G"7M9SC+"\LJD:\:<J%+FH3JM5:DIOZQ5J8MSC
M3PW/B,3DE6-)4*<J,UC,+4E.IA:4X>QA3<,9S0HU,.ZL<36<<1&E>C2A37U:
MA2P7).IBX/VB?AAX1^&FI_"B?POIOC/P?=_$/X6Z-\0_$OPI^(NKZ9XA\;_"
MN_U;Q'XAT[1-)UK6],\/>$&N[3QGX2TK0OB3X9M];\)>&_%&G^&O%6FQ:WIK
M+-I]_??Z '_!)S_E&_\ L:?]D'\&_P#HNZK_ #N/B5\2K[XJ^*V\6ZMX7\$^
M&]:OY;BXURX\%Z3KFFGQ-J^H:C/J-_XC\37'B+Q1XMU36O$E[/<,EWJ]SJ8E
MN(4B66-Y$:9_]$?_ ().?\HW_P!C3_L@_@W_ -%W5?G/BI"K#AK*(UY2E569
M>^Y/F:;P^):AS.4Y24(M0C*<YU)1BI59SJ.4G^K>#$Z-3BG/)X>*C1>4>XHQ
MY$[8K QE-P481A*I-2J3A3A"E"4Y0HPA24(+\J?^#G#_ )-M_9K_ .S@-5_]
M55XOK^9'X&?LCQ_%OX%?%_X[:]\2(? ?AOX<&32K!T\!>-_'.FCQ!:ZAX!6X
ME^(VJ>#-*U5OAWX4O-/\<VT>B:S<6FI7^HW=AK^L+I?_  B_@[Q-?1_TW?\
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M%KL/A>\N;GUSQ)_P3^U;1_C3X2^"]OK_ ,6-.U#Q)X@^+.AQ>(?'_P"SO?\
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M_@LC_P HR?VP?^R7Q?\ J7>&*_GW.O\ DYO_ '<>5?\ I[!G]/9%_P FB?\
MV2N:_P#J-C#_ #EI/]9)_OM_Z$:93Y/]9)_OM_Z$:97]-1V7HOR/Y#"BBBF
M5_2]_P &R7_)R?[2_P#V0OP=_P"K(FK^:&OZ7O\ @V2_Y.3_ &E_^R%^#O\
MU9$U?(\>?\DAGG_8/0_]3<*?=>&?_)=</?\ 857_ /4+%']CGC3_ )%'Q1_V
M+NN_^FF\K_*"C_U47_7*+_T6M?ZOOC3_ )%'Q1_V+NN_^FF\K_*"C_U47_7*
M+_T6M? >#7\/B'_'E?\ Z3F!^E^/?\3A;_!G7_I65CZ***_;3^>@HHHH _2_
M_@CI_P I,OV1?^Q_\2_^JJ^(=?Z-Z?<7_=7^0K_.0_X(Z?\ *3+]D7_L?_$O
M_JJOB'7^C>GW%_W5_D*_G?Q?_P"1_EW_ &)Z7_J;C3^H_ O_ ))O-?\ L>UO
M_5=EHZBBBOR<_;0HHHH **** "BBB@ HHHH _#;_ (*TZ/\ &?PS^TI_P2O_
M &F?AC^S7\=OVF_"O[,7[0_QP\8?%/P=^SSX<\.^*?B%8^'_ !O^SMXF^'6B
M7MAI/BGQ7X,T:9)/$&N0"1K[Q!IT"V]O<XG-R;:WN/Y]O^"LUK^VS^WO^T=X
M1^,7PG_X)3_\%&/#'AS0/@WX<^'5YI_Q$^%GPPTS6Y=9T?Q7XTUZYN[:W\.?
M&+Q38OICVOB2SB@EEU&*Z>XANA)9Q1I%)+_>@RJWWE5L=-P!Q^8--\F+_GE'
M_P!\+_A7K9-G6.R'&K,,NE3AB8TZE).K256')4MS^Y)I7T5GT/%S_(,NXER^
M669I"K4PDJM*LXT:LJ,_:46W!\\=;)MW6S/\O#_AA?\ X*3_ /2,K]MO_P -
M[X/_ /F]H/["_P#P4G )/_!,K]MO Y/_ !;WP?\ _-[7^H?Y,7_/*/\ [X7_
M  I&AB((\J/D$?<7N/I7UW_$4N+O^@C!?^$-+R\_)_?Y'PO_ !!S@G_H&S#_
M ,.%;_+^KORM_EF>'_V2/V__ !5>>*]/\._\$Y_VRM8O? WB>3P9XNM;#P)X
M/FF\/^*(="T#Q-)HFI+_ ,)VODWRZ!XH\/ZKL4R(;/5K.19"794Z7_AA?_@I
M/_TC*_;;_P##>^#_ /YO:_TFO@W\'[SX9>)_VAM?O]5L-5B^-'QTN_BWIMO;
M6DT$FB6-S\)OA%\.O[)O7G9DNKP7GPWO-2:YM@D#6VI6L.WSH)F;W7R8O^>4
M?_?"_P"%'_$4N+O^@C!?^$-+R\_)_?Y!_P 0<X)_Z!LP_P##A6_R_J_H?Y>2
M?L,_\%)U=&_X=E?MMG:RMC_A7O@_L0?^A]K^LK]B?_@H-\>?V:?V3O@!\!O&
M?_!'S_@K%K/BSX5?#30/!GB'4_"_P6^!%UX=O=4TD7"SW&C76J_M'Z3J5S82
M+)&T4M[I6G7!)=7M$"AG_I#\F+_GE'_WPO\ A1Y,7_/*/_OA?\*\3/>,<\XC
MPU'"YG5P]2C0K>W@J.&A1E[14Y4[N46VURSEIW:['T?#? G#_"N*KXS**6)I
MUL1A_JU5U\5.O%TO:4ZME&:M&7/3B^9:VNMMOXZ_^"OOQV_:L_X*#_"3X1^
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MHO;?%SN-25I[IV?0_P O)_V&/^"D[,S#_@F5^VW\S$_\D]\']R3_ -#[3?\
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MG;GGCC/44A8  G=@]@K,?^^0"P]\CCH>:^5_COX,^&_AG0/C3\5?'GQQ\0?
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MQ/O[6ZLO)\)2NMNES]IN8[*34/[-CN]T+,I_4FOG3]IW]ISX6?LI_#JQ\?\
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M ^%OAKQK\6OBA\/_ (A?%7X36%_K&MZG\,[/Q1X#\(VFE:1XJBU#]S++X]_
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M8S2^([33?&OB.&UT+4+>+2M(U*1TOX?LUY+9A9'CV_B+^T%X3^'/ACX<ZT=
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>collabprofitshare.jpg
<TEXT>
begin 644 collabprofitshare.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MXH67P?UKQ7>1^-+F^\&:3?"P\)>,]9\+>&-;^)%\=,^'/A[QSX]T?P_?^!O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH *X3XF_\B'XF_P"O!?\ TI@KNZX3XF_\B'XF_P"O!?\
MTI@KR<__ .1%G7_8IS'_ -0ZPX[KU7YGQ&W4_4_SI*5NI^I_G25_(H@HHHH
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M_$&OV\C_ -7'_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\
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MT1/Y-N6MX?/!\[R;=C;P[_+@)A5"?MZOB+X8\>._#8   NYP !@ "PNP  .
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M:]_X*+O_ .)H_M^/_H%:]_X*+O\ ^)K=P/0?D*,#T'Y"@#"_M^/_ *!6O?\
M@HN__B:/[?C_ .@5KW_@HN__ (FMW ]!^0HP/0?D* ,+^WX_^@5KW_@HN_\
MXFC^WX_^@5KW_@HN_P#XFMW ]!^0HP/0?D* ,+^WX_\ H%:]_P""B[_^)KB_
MB+K$=SX)\10#3]7A,EBJB2YTVX@@7_2(#F25UV(/=B!VZD5ZC@>@_(5PGQ-
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MY#FN_P#8(M__ $M:O"*]W^ W_(<UW_L$6_\ Z6M7U? W_)69)_V$U?\ U$Q
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MU*.S33X[^^2%%N[V.PCFN$LH[F<231VBW%P+9'$/VB?9YKWZ* /Q _X*3_\
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MK=3]3_.DK^11!1110 5[O\!O^0YKO_8(M_\ TM:O"*]W^ W_ "'-=_[!%O\
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M,>7V-*<(2I4H2BI!?^ON75/I\M=K:.::1YKB>61U>2:XFEDD081Y)96=Y$7
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M\B/,/^QO6_\ 4++P"BBBOU, HHHH **** "BBB@ HHHH _$#_@I/_P I)/\
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M0V,CH<C@'!P1GD$9P3SUINQ3U /_  %?_B:?10 SRU]!_P!\K_\ $TC1J58
M#)! ^5>X_P!VI,CUZ]/>C(SC(SC..^/7'I0!\R?L^_#3Q;X#\9_M7:QXHT^&
MRL/BC^TM>_$?P7+'?6-ZVI>$Y_@9\!_!,=_-%:RS2:=*?$7@;Q)9FQOE@O1'
M9Q7C0_9KRUEE^F/+7T'_ 'RO_P 33Z3(QG(QZYX_.@!OEKZ#_OE?_B:7:/\
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MD8]<\<].: &[%]!_WRO_ ,33@,?_ *@/Y 4M% !1110 4444 %%%% !1110
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MK&VCCM[2RL[>&VMX8TBAC1%"C:H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gainlossfvcontconsider.jpg
<TEXT>
begin 644 gainlossfvcontconsider.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M%'M /Q5U;]N+]J#P7X4O/&VL7_PHU^Q\<>'OVSG\*V$7P^\1:?8_"2']F/\
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M5KIT^E:=KUU<:O-;6TUE:VC3W\'T\"& 8=" 1]",U^(/_!2?_E))_P $*?\
MLZW]J#_UCGX@U^D'QBUS6M-\2:?!IVKZG80-H-I*T-G?75K$TAN[]6D,<,J*
M79412Q!)55&< 5X/$>>TN',MEF5;#U,3"->C0]E3G&$KUFTI<TDU:-M5U ^G
MZ*^!_P#A+/%/_0R:]_X-]0_^2*/^$L\4_P#0R:]_X-]0_P#DBO@/^(N8#_H3
M8S_PIH>7]WS?W>8_FOQ_R_JS\K_?%%? _P#PEGBG_H9->_\ !OJ'_P D4?\
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M5RW$XF=&%&;JTZU*$&JU.%5)1E%R]U3L]=6M-Q'WQ17P/_PEGBG_ *&37O\
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M,F-NI.F@ >I)  Y-?!0Z#Z"ON?%W^+D'^'-?_>8(6BBBOQL HHHH [OX9?\
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M^9\1MU/U/\Z2E;J?J?YTE?S>(**** "O=_@-_P AS7?^P1;_ /I:U>$5[O\
M ;_D.:[_ -@BW_\ 2UJ^KX&_Y*S)/^PFK_ZB8@:VEZ?JCZ:NO^/:X_ZX3?\
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M\#VMJ^B>+_V8OAA;?"/1?B3^S5\6?'WCCXX7;>+/&7CFXT#]EWQ1;^#5UO\
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MIM(\0Z??Z'8MJ>J1^#^)/ 'QC\9?#3XF^"=6^&NB>#O'-GX)_8HU9O@[X4\
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MF'_8WK?^H67@%%%%?J8!1110 4444 %%%% !1110!^('_!2?_E))_P $*?\
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M0UN4.EWIUS>2-)]@L,LLD.IV*JFW: AB=MP9O,P0J^Q^3XC_ .@EHG_@DO\
M_P":"OZDX+A"IPGE$)QC.$\'*$X3BI1E&4ZD91E&2:E&2;4HM--.S[ 9(^'W
M@D$$>%]'!!R"+.,$'U! !!QQQVJ _#/X?-/'=-X-\/-=16\MG%='3+8W,5G/
M+!//:1W!3SDM9Y[6UFFME<0RS6UM+(C201,F[Y/B/_H):)_X)+__ .:"CR?$
M?_02T3_P27__ ,T%>U_8V3K_ )E67?\ A%AO_E77KWU[L#(_X5YX'_Z%;1>N
M?^/*+KZ].OOUH_X5YX'QC_A%M%QTQ]BBQ@=!C&.*U_)\1_\ 02T3_P $E_\
M_-!1Y/B/_H):)_X)+_\ ^:"E_8N3_P#0IRW_ ,(<-Y?].O)!=]S#;X:?#]YX
M+I_!WAY[JV6Y2VNGTRV:YMDO%B6\2WN&0S0)>+! MVL3HMRL$*SB011A=O2O
M#/A_0I9I]'TBPTV:>-8II+2!(7EB5MZHY7JH;Y@#T/-+Y/B/_H):)_X)+_\
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M\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\ 010 ^BBB@ HHHH **** /"/CU_R
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M_P"&L^/_ /\ .DH_XB%O^"/'_1Z/AG_PUGQ__P#G24 ?LS=?\>UQ_P!<)O\
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M6PUO1;N2[AMM0M$N(+M899;&XM+N,+<6T$JM!<PN'C7#XR#\\:'^P?\ L?\
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MP>'-+ALI=9U=K:"Q_M76K[$FH:SJ2V%I9Z=%?:K=WES!IUG9Z?#+'9VMO!&
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MQ5K'BSPSXA\,V6B:+J^K1Z#I.M^"=,O;ZVO],O\ 5],O_P TO%WQT_:<\3?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6640740224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 2,091.6<span></span>
</td>
<td class="nump">$ 2,314.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">2,093.5<span></span>
</td>
<td class="nump">2,313.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">1,686.0<span></span>
</td>
<td class="nump">1,235.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">1,691.7<span></span>
</td>
<td class="nump">1,232.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">121.9<span></span>
</td>
<td class="nump">143.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">122.2<span></span>
</td>
<td class="nump">143.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">3,899.5<span></span>
</td>
<td class="nump">3,694.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 3,907.4<span></span>
</td>
<td class="nump">$ 3,689.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6867601744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 65.7<span></span>
</td>
<td class="num">$ (27.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="num">(10.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="num">$ (14.2)<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">848.4<span></span>
</td>
<td class="nump">735.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 848.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">152.2<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">2,096.3<span></span>
</td>
<td class="nump">2,239.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,096.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,239.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Remaining duration of Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">45.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
<td class="nump">79.8<span></span>
</td>
<td class="num">(51.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,943.7<span></span>
</td>
<td class="nump">1,701.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,943.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,701.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">60.9<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">36.9<span></span>
</td>
<td class="nump">131.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="nump">98.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020 | Interest rate swap | Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 59.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6876413088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition (Details Textual) - Nightstar - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 847.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Payments for pre-combination equity compensation</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate', window );">Fair value, in-process research and development, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill', window );">Deferred tax liabilities, goodwill</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember', window );">Post-acquisition equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Indefinite Lived Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=117412053&amp;loc=d3e9972-128506<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=117412053&amp;loc=d3e9979-128506<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855217616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>90.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>81.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(45.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(49.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(141.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(151.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>141.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>198.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>132.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(13.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(11.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(27.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>115.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>132.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>141.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>197.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>139.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>46.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>141.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>150.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>140.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>884.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>259.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>320.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>222.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>224.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>188.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>147.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>444.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>125.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>677.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>609.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,429.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,861.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6875697632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,085.8<span></span>
</td>
<td class="nump">$ 1,051.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">201.6<span></span>
</td>
<td class="nump">176.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 884.2<span></span>
</td>
<td class="nump">$ 874.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6736464656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>842.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,122.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>842.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>247.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,090.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>360.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>530.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>421.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>168.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>590.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>263.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>483.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>253.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>217.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>470.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,465.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>694.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,160.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,516.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>656.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,172.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>236.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>310.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>547.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>223.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>243.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>467.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>115.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>115.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>123.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>123.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>183.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>183.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>134.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>134.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,702.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,192.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,894.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,740.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,039.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,780.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,429.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>841.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,271.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,396.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>766.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,163.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,067.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>518.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,585.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>528.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,765.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>772.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>647.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,419.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>768.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>631.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,399.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>71.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>71.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,269.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,078.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,347.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,402.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,997.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,400.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>690.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>863.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,553.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>617.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>636.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,254.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>360.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>360.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>359.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>359.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>132.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>132.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>389.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>389.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,959.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,495.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8,455.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,020.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,040.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8,061.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>127.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>888.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>480.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,149.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,646.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(46.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(42.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(349.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1,510.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1,860.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(129.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(564.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(15.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(709.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>129.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>917.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>39.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,085.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>201.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>176.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>884.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,085.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>393.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>358.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,161.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,066.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>202.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>153.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>528.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>378.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>595.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>511.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,689.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,445.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>48.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>89.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>80.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>93.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>91.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>462.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>311.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>109.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>147.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>562.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>420.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855184624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text">Share-based Payments<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>65.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>116.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>83.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>182.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(29.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(21.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>145.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>112.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>37.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>104.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>96.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NST stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>182.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock option expense reflects the accelerated vesting of stock options previously granted to NST employees as a result of our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855087888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text">Investments in Variable Interest Entities<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound.  </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our collaboration and license agreement with Neurimmune (the Neurimmune Agreement), the royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, range from the high single digits to sub-teens.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimbursed Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$23.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$28.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read Note 20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841750784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,943.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,701.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>60.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>131.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>98.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>92.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,096.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,239.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>79.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(51.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>22.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>45.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>152.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>65.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6854718368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>159.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>196.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>421.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>606.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>170.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>751.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>751.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>929.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>751.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_C=A'UOW<']8^.KH&K@UUVH+U!+ P04    " "3@59/F5R<(Q &  "<)P
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MYUWP.-/"5P&8NX *SKS@B99L:P"8P.8@<.P%#[4D7P5@ CN$P,D7/-<R\U4
M)L<JA+-//-?2=Q]A NX3SC[Q7$O??80)N$\X^\1SG?GN(TSHTP!GGWBN,]]]
MA FX3SC[Q'.=^>XC3,A]G'WBN<Z8^P 3<A]GGWBN,^8^P(3<Q]DGGNN<N<\Q
M016<?>*YSOW]!6$"_\F$LT\\U[F_OP!,Z)]?XNQ+GNO<?\< )JB"LR]YKG-_
M%P.8H K.ON2YSKTW>3-B<H=IQF^8-,O$8NY_RB0WK4BMVH/KVKIHJ\^-:QEO
M1J?.\,'U/LD_^-!6?BO:0]ETT8LVMB%R;<M>:Z/LC-(/=BY'V\E.%Y7:F_YT
M;L_;H9T;+HP^C:UJ,O7+Z[]02P,$%     @ DX%63]<RXC^Y!0  ?AP  !@
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6R-F=UNXS80A5_%\/W*XI](!DZ
M6';1 BT0;-'V6DF8Q%C;<B4EV;Y]*5GQ2G-&SN8BL96/0QZ2FCF4EN]E]:U^
M":&9?=_O#O7U_*5ICE>+1?WP$O9%G93'<(C_>2JK?='$K]7SHCY6H7CL&NUW
M"YFFV6)?; _SFV5W[:ZZ69:OS6Y["'?5K'[=[XOJOU78E>_7<S'_N/!U^_S2
MM!<6-\MC\1S^#,U?Q[LJ?EN<HSQN]^%0;\O#K I/U_-;<;51NFW0$7]OPWL]
M^#QKI=R7Y;?VRV^/U_.T'5'8A8>F#5'$/V\A#[M=&RF.X]\^Z/S<9]MP^/DC
M^B^=^"CFOJA#7N[^V3XV+]=S-Y\]AJ?B===\+=]_#;T@,Y_UZG\/;V$7\78D
ML8^'<E=WOV</KW53[OLH<2C[XOOI[_;0_7WOXW\TXQO(OH$\-XA]7VJ@^@;J
M1P-]L8'N&^B?[<'T#0SI87'2WDWFNFB*FV55OL^JTWXX%NVV$U<F+M=#>[%;
MG>Y_<3[K>/7MQMCEXJV-TR.K$R*'B!LC:T3$F5C$_L^#D-P@5A*:RW$'.1+&
MDS%\&F1S,<AHF(J=*]6UUX/V64KFZH1D'7+H$)6E:2*(G!-FAYA65!#&$JE-
MLR0CLI#S7@ZQD33-2M-=##64-K&"AFUO<&K([*].B!D,4RLR??F)<4,F2Q.Z
MVY 2)G6)(O/"8$K:0;21KHS5E:$NTLTJ@VZ,3A--E#%4:A.ZY$@)XQS%-@SF
MG9E:<<LJLZB,C'EE<<Q&)X8H0TI[FY DLD9*V-33I=TPF!$FD;PRQRISJ(R,
M>>6@&^D4G>:<HP2L&5):RH3F'H;R:DJ79W5YU$52P<I#+_'VH;D4(6WIJJX1
M$E$[72Z&DGY*E4CY"I2B+BA!*73T1< FRWMLF&-(AEDSD;RAZC<7 XU%3915
M@:(<%250E+%TCG,.<S%UI(,?054R;;(,,B2'>9$8/_R9T,U6\ELA4;>GNB7T
MFM*AY3TT7(&,BL0X E<2(9\(_S,*>1,@T 58Z@)ZYL(^S'MDE%SP+OP\T(8)
M)(0<1!J+XLN_T"A*4%&:2>$QA\%^Y3@M:$5<,YS1D;-4(,?%7#3A3P1O4 0Z
M%$L=BF <@TOAMLDY+HLU#S8H<D9F&LHYPVFMS>0:\E9%H%>QU*L(= Y?XK8#
M@8S!B%48L@R#*0G^E,&4GS(K@G<K NV*I7:E9\QHXUE:U 5C,5R\8:AA83BC
M/-RB&X;3VIG)[<E[%H&FQ5+3(A@_(@0N'F(J Z>U9C"'[F;38\-)]69J[7C?
M(M"X6&I<!#H)"78C[ZF+]9VQ0!GXEHN!Q@=6WK1(-"V6FA:)5D.8>%O3'<EQ
M6DLPF@P7TX0#<0RG3+1E4T=RWL%(=#"6.IB>N53G)&,QH$JO/P^T80+IR8.!
MY-V)1'="\\.J9[)/5XWAXG) F6,X?M604WIT*!DKY-V)5'"0=U,[F[<"$JV
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MW7U&YKL9+@9#0ZOC>.EQ+S>OY3]02P,$%     @ DX%63\)2#_S;!   *A@
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M9L!K]GD-1?ZN^(EH^NZ+<2VQWG\XL(4))JP PHH/M%&$LVM\>?Y(,C6"R2J
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M>T"V)[\ L$+:HVC)C@!9T516&E"R&PILI/_28/=/5^GQ,4#9\-Q)I+P%>=%
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MW*[P!$I%(I3Q8^:D2\H(7)_?V-^GVK&6B_#P9-5W68>NH ^4U-"(085G.WZ
MN9Y;2N;B/\$5%(9')9BCLLJGE52##U;/+"A%B]=IER;MXW2393-L&\!G %\
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M5%)#9R5VQ$"=T_O=\92&^!CP+&&TJS,)E5P07X+QI<II$@2!@M(%!N&W*SR
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M_0=;# 6U"\</_FRF,9L,A_W\@]CRC8L_4$L#!!0    ( ).!5D]@D#4%M@$
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MZVRBE6TIFRIJI59:I6K[S-IC&P6,"WB=_GT'[#A68_4%F.&<,Q>&;#3VQ;4
MGKQJU;F<MM[W1\9<V8(6[L;TT.%-;:P6'DW;,-=;$%4D:<5XDAR8%K*C119]
M9UMD9O!*=G"VQ U:"_OG!,J,.=W1-\>S;%H?'*S(>M' =_ _^K-%BRTJE=30
M.6DZ8J'.Z</N>$H#/@)^2AC=ZDQ")1=C7H+QI<II$A("!:4/"@*W*SR"4D$(
MT_@]:](E9""NSV_J3[%VK.4B'#P:]4M6OLWI/245U&)0_MF,GV&NYY:2N?BO
M< 6%\) )QBB-<G$EY>"\T;,*IJ+%Z[3++N[C=+/G,VV;P&<"7PCW,0Z; L7,
M/PDOBLR:D=BI][T(3[P[<NQ-&9RQ%?$.DW?HO1:[Y)"Q:Q":,:<)P]>8!<%0
M?0G!MT*<^ <ZWZ;O-S/<1_I^34\/VP+IID :!=+_EO@1P].[?X*P54\UV"9.
MDR.E&;HXR2OO,K /\1'9.WR:]F_"-K)SY&(\OFSL?VV,!TPEN<$1:O&#+8:"
MVH?C'9[M-&:3X4T__R"V?./B+U!+ P04    " "3@59/16V 3[8!  #2 P
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M;_W93&,V&0[[^0>QY1L7OP!02P,$%     @ DX%63QD.$X"S 0  T@,  !D
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M;\/WFPKW$;[_0^%AFR#=)$@C0?K?$K=B;O]*PE8]U6";.$V.E&;HXB2OO,O
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M:&5E=#$Y+GAM;'U386_;(!#]*X@?4!*2M5ED6VHZ39NT25&G;9^)?;91@?,
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M#VQV%%0^F'=HVW'-1L>;;GI!;'[&^5]02P,$%     @ DX%63_D<)#FP 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL?5-AC],P#/TK47[
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M8-MIS2;'8S^_(+8\X_(W4$L#!!0    ( ).!5D\]//[]M0$  -(#   9
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MG8A/O#UQ[$T9G:D5Z0[%>_3>"GZ\S]@M$DTQYS&&+V*V<P1#]CD%7TMQYO_
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MF:QSP*#4=KLW>SG.ES'0HIM&)YGG=_874$L#!!0    ( ).!5D^9-[Q4LP$
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M7#"_>-M,:S8Y3O?S"R++,R[_ 5!+ P04    " "3@59/N?6QE? !  !E!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6QU5-N.FS 0_17D#UAS36@$
M2)NMJE9JI6BKML\.#!>MC:EMPO;O:QN64N)]B3WC,^?,#)G))BY>9 N@O%=&
M>YFC5JGAA+$L6V!$/O !>OU2<\&(TJ9HL!P$D,H&,8I#WS]@1KH>%9GU7421
M\5'1KH>+\.3(&!%_SD#YE*, O3F>NZ95QH&+;" -? ?U8[@(;>&5I>H8]++C
MO2>@SM%C<#JG!F\!/SN8Y.;NF4JNG+\8XTN5(]\D!!1*91B(/F[P!)0:(IW&
M[X43K9(F<'M_8_]D:]>U7(F$)TY_=95J<Y0BKX*:C%0]\^DS+/4DR%N*_PHW
MH!IN,M$:):?2_GKE*!5G"XM.A9'7^>QZ>T[S2Y(L8>Z < D(UX#4ZN!9R&;^
MD2A29()/GIA[/Q#SB8-3J'M3&J=MA7W3R4OMO161?\SPS1 MF/.,"3>88$5@
MS;Y*A"Z)<W@7'KK#(V>&D0V/MN%QY":(G02Q)8C_*S'=E>C"?'"+)$Z1Y)X@
M\'<B+LP[G3PX10X.@G GXL*\TZZC4^1X1Y F.XU[2!3$;HW4J9$Z"/8B+LQA
M)X(W?W,&HK$#+KV2C[U=+AOOND,>0SLF_^#S OI&1-/UTKMRI8?-CD3-N0*=
MBO^@OURK=]YJ4*B5N1[U7<R3/QN*#\M2P^MF+?X"4$L#!!0    ( ).!5D_^
M-"<YMP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;&U3VVZ<
M,!#]%<L?$"^&)-L5(&535:G42*M4;9^],( 57XAMEN3O:QM":<*+[1F?<^;B
M<3YJ\VP[ (=>I5"VP)US_8$06W4@F;W2/2A_TV@CF?.F:8GM#; ZDJ0@=+>[
M(9)QA<L\^DZFS/7@!%=P,L@.4C+S=@2AQP(G^-WQQ-O.!0<I\YZU\!/<K_YD
MO$46E9I+4)9KA0PT!;Y+#L<LX"/@-X?1KLXH5'+6^CD8W^L"[T)"(*!R08'Y
M[0+W($00\FF\S)IX"1F(Z_.[^K=8NZ_ES"S<:_&'UZXK\!ZC&AHV"/>DQP>8
MZ[G&:"[^!UQ >'C(Q,>HM+!Q1=5@G9:SBD]%LM=IYRKNXW23TIFV3: S@2Z$
M?8Q#ID Q\Z_,L3(W>D1FZGW/PA,G!^I[4P5G;$6\\\E;[[V4:7*;DTL0FC''
M"4-7F&1!$*^^A*!;(8[T$YUNT]/-#--(3]?T[&9;(-L4R*) ]E^)^P\E;F&^
M? A"5CV58-HX3195>E!QDE?>96#OXB.2?_!IVA^9:;FRZ*R=?]G8_T9K!SZ5
MW94?H<Y_L,40T+APO/5G,XW99#C=SS^(+-^X_ M02P,$%     @ DX%63P8@
M M[1 0  G 0  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL=53KCIP@
M%'X5P@,LBH[=3M1D9YNF3=IDLDVWOQD]7K(@%G#<OGT!76NG](]P#M_E' 3R
M6:H7W0$8]"KXH O<&3,>"=%5!X+I.SG"8%<:J00S-E0MT:,"5GN2X(1&448$
MZP=<YCYW5F4N)\/[ <X*Z4D(IGZ=@,NYP#%^2SSU;6=<@I3YR%KX!N;[>%8V
M(IM*W0L8="\'I* I\$-\/&4.[P'//<QZ-T>NDXN4+R[X7!<X<@4!A\HX!6:'
M*SP"YT[(EO%SU<2;I2/NYV_J'WWOMI<+T_ H^8^^-EV![S&JH6$3-T]R_@1K
M/P>,UN:_P!6XA;M*K$<EN?9?5$W:2+&JV%($>UW&?O#CO*QD\4H+$^A*H!OA
MWON0Q<A7_H$95N9*SD@M>S\R]XOC([5[4[FDWPJ_9HO7-GLM$QKEY.J$5LQI
MP= =)MX0Q*IO%C1D<:+_T&F8G@0K3#P]V=/3]V&!-"B0>H'TKQ;CFQ9#F/]4
M>0B:' ("R8U)").&3;*@2180.-R8A##9C0G9G0X!JO7W0J-*3H._D[OL=O4>
MJ#]=?^#+O?W*5-L/&EVDL6?4GZ1&2@.VE.C.-MS9IV(+.#3&3=_9N5HNS!(8
M.:YO =D>I/(W4$L#!!0    ( ).!5D^ZIQ40TP$  )P$   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;'54ZV[;(!1^%<0#% ?'21;9EII6U29M4M1I
MVV]B'U]4,![@N'O[ 78]+Z5_#.?P7<[!0#I*]:(; (->!>]TAAMC^B,ANFA
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M!RN,/3U>TY,/!+9!@:T7V/[7XN&FQ1#F4]@D"9HD[P7BZ,8DA/E@)W=!DUU
M@-Z8A##QC0E9G0X!JO;W0J-"#IV_DZOL<O7NJ3]=_^#3O?W&5-UV&EVDL6?4
MGZ1*2@.VE.C.-MS8IV().%3&3?=VKJ8+,P5&]O-;0)8'*?\+4$L#!!0    (
M ).!5D]%+=]SVP$   $%   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;&U4ZXZ<(!1^%<(#+%['[41-=K9IVJ1-)MMT^YO1XR4+8H$9MV]?0,=:RQ_A
M'+[+.0CDDY!OJ@/0Z)VS016XTWH\$J*J#CA5#V*$P:PT0G*J32A;HD8)M'8D
MSD@4! ?":3_@,G>YLRQS<=6L'^ LD;IR3N7O$S Q%3C$]\1+WW;:)DB9C[2%
M[Z!_C&=I(K*JU#V'0?5B0!*: C^%QU-F\0[PVL.D-G-D.[D(\6:#+W6! UL0
M,*BT5:!FN,$S,&:%3!F_%DV\6EKB=GY7_^1Z-[U<J()GP7[VM>X*_(A1#0V]
M,OTBIL^P])-BM#3_%6[ #-Q68CPJP93[HNJJM."+BBF%T_=Y[ <W3HO^G>8G
M1 LAVA'(;.0J_T@U+7,I)B3GO1^I_<7A,3)[4]FDVPJW9HI7)GLKXSC)R<T*
M+9C3C(DVF'!%$*.^6D0^BU/T'SWRTV-OA;&CQUMZFOH%$J] X@22?UI,=RWZ
M, >_2>HU23T"V<[$AWGTFQR\)@>/P(>=B0>3!'Z3S&N2>03"G8D/L_^I9',$
M.<C673Z%*G$=W,7?9-?[_12Y(_P7/C\.WZAL^T&AB]#F(KCCV@BAP902/)A=
M[<Q[M 8,&FVGF9G+^5;.@1;C\N"0]=4K_P!02P,$%     @ DX%63[U/%,[<
M 0   04  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL;51M;YLP$/XK
MEG] 30B$+ *DIE6U29L4==KVV8'C1;4QLTWH_OUL0QBC_A+[CN?ESO$Y'85\
M4PV 1N^<=2K#C=;]B1!5-,"I>A ]=.9+)22GVH2R)JJ70$M'XHR$07 @G+8=
MSE.7N\@\%8-F;0<7B=3 .95_SL#$F.$=OB=>V[K1-D'RM*<U? ?]H[]($Y%%
MI6PY=*H5'9)09?AQ=SHG%N\ /UL8U6J/;"=7(=YL\*7,<& + @:%M@K4+#=X
M L:LD"GC]ZR)%TM+7._OZB^N=]/+E2IX$NQ76^HFPT>,2JCHP/2K&#_#W$^,
MT=S\5[@!,W!;B?$H!%/N%Q6#TH+/*J843M^GM>W<.L[Z=YJ?$,Z$<$,@DY&K
M_)EJFJ=2C$A.9]]3^Q?O3J$YF\(FW5&X;Z9X9;*W?!_M4W*S0C/F/&'"%6:W
M((A17RQ"G\4Y_$ /_?2]M\*]H^_7]/CH%XB\ I$3B/YK,=JTZ,/$?I/8:Q)[
M! X;$Q\F\9L<O"8'C\!Q8^+#?/*;)%Z3Y*- '&Q,?)CMG2"K*\A!UF[X%"K$
MT+G!7V67^7X,W17^!Y\>AV]4UFVGT%5H,PCNNE9":#"E! _F5!OS'BT!@TK;
M;6+V<IK**="BGQ\<LKQZ^5]02P,$%     @ DX%63\Q,B9[Y 0  RP4  !D
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M]@^OE-* 367S8/^/VG;6><&A-&ZZMW,U]I=Q860WM4XZ]^_\-U!+ P04
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MAR4N"\YZAP^GVV'])_)7D=K]2@?-9IMO:GN$BE[+,/<+=-5"(V8S8((9YH9
M2GVR"&P6F^".'N;!6XNM#1.^Q>QLF,B>2&BM-30"T;P.WUO4.F!2@VD-)@H6
MR>[N,9X]C<B:1G271IC'BS0&3#)/(_,?WMGVV&H36VR2A<V B6<V[U@D5HO$
M8I$N+&R8S&Z26DU2BT!N%\BL MGGQ[[-[H\]">TFN=4D__Q0M_F=21PD"Q,T
MN[@4^-DT1>%4[-*:ACR+3GWW,3 7_P8?FO8/S,]-*YP#DZI]F$M^8DR"2L5[
M4&=>JW=B6A X23U-U9P/W7)82-:-#P&:7J/R/U!+ P04    " "3@59/7J'E
MA$L"  "!!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R-5=F.FS 4
M_17$>_&"61(1I"91U4JM-)JJ[;.3. $-8&H[8?KWM0V#"#CMO.#MW'/NN7C)
M.BY>9,&8\E[KJI$;OU"J70,@CP6KJ0QXRQJ]<N:BIDH/Q07(5C!ZLD%U!3"$
M,:AIV?AY9N>>1)[QJZK*ACT)3U[KFHH_6U;Q;N,C_VWBN;P4RDR /&OIA7UG
MZD?[)/0(C"RGLF:-+'GC"7;>^!_1>H^P";"(GR7KY*3O&2L'SE_,X,MIXT.3
M$:O841D*JIL;V[&J,DPZC]\#J3]JFL!I_XW]DS6OS1RH9#M>_2I/JMCXJ>^=
MV)E>*_7,N\]L,!3YWN#^*[NQ2L--)EKCR"MIO][Q*A6O!Q:=2DU?^[9L;-OU
M*U$TA+D#\!" QP!$_AD0#@'A>P/($$!F :"W8FNSIXKFF>"=)_K?VU*SB]":
MZ.H?S:0MMEW3Y9%Z]I83"#-P,T0#9MMC\ 2#[Q&[)8) =(_9+S%HH@1TEF.J
MV)DJM@3AG0AV$X1.@M 2D&D&:.9DVV-BBVDL)DI(',S-N& P#H@['>),ARS2
M(3!T$T1.@NC]!8F=!+$C S+[M?'"*8))D+IE$J=,XI")9C(])IW()$'D%DF=
M(JE#))Z)])AH*O)H"ZZ<(JO_[Z#=:N%$8X+8+8.@^U1"AYMD?NC@PLZ')'F@
M\^#T(X=..M=!2T?!@XV*W$<788?.:JZ#%ULMC7 PW]%@<K69Q^D;%9>RD=Z!
M*WU+VKOLS+EBFA(&NCB%?@_'0<7.RG03W1?]H] /%&^'!P^,KV[^%U!+ P04
M    " "3@59/D3)JQ<0"  #,"@  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6R55NUNFS 4?17$ P"^?*9*(K69IDW:I*K3MM]NXB2H@)GM)-W;SS:$
M4KB>TC_!-N>><Z_C@^_RPL6+/#*FO->Z:N3*/RK5WH6AW!Y9367 6];H-WLN
M:JKT5!Q"V0I&=S:HKD*(HBRL:=GXZZ5=>Q3K)3^IJFS8H_#DJ:ZI^/O *GY9
M^<2_+CR5AZ,R"^%ZV=(#^\'4S_91Z%DXL.S*FC6RY(TGV'[EWY.[#20FP")^
ME>PB1V//E/+,^8N9?-VM_,ADQ"JV58:"ZL>9;5A5&2:=QY^>U!\T3>!X?&7_
M;(O7Q3Q3R3:\^EWNU''E%[ZW8WMZJM03OWQA?4&I[_75?V-G5FFXR41K;'DE
M[:^W/4G%ZYY%IU+3U^Y9-O9YZ?FO87@ ] $P!&CM_P7$?4#\%F!W,^PRLZ5^
MHHJNEX)?/-']6RTUAX+<Q7HSMV;1[IU]IZN5>O6\3DBT#,^&J,<\=!@88=)B
M@(2:?M  3.,!9O$)(>\U-@@F(KA(C!826X+X'0'@! E*D%B"Y%V6,,FRPRPL
MIK$82(,45TE1E111B2?[W6&RD4J1Y$&&RV2H3(;()!.9#E.,9!*72(Z*Y(A(
M.MDQ#.,0*5"18DX091.1#I./*LFC"!=9H"(+),M\LET=)AV)Q(Y_GD2XU:*9
M2I8X&!QF);<?<H)Z\9X 4FHQ-3S,C@8I E>NN!])/*\V=C#@AB3)!ZK%W48P
MN\VJ36?5YH'C T=PNQ',;PL'!6XFDG^@6MPJY!:O]*#Q.4X*AUD([A:"V 4<
M%(![ :+;JP7<#$!NJ+8'C3\-X$P5=PP@C@''U02X%^ #EQ/@9@#L>IJ>Y!XT
MOCD@"Z9"X:@WJ)DXV#9*>EM^:FP/-UH=6K5[L+W%&[SK\[Y3<2@;Z3USI3L4
MVT?L.5=,)Q,%^H@==6LY3"JV5V:8Z['H^JMNHGC;]X[AT,"N_P%02P,$%
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MR#9K;@5-1]#:W'C"]MHU_0]02P,$%     @ DX%63RRKV5'7"   V3H  !D
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M070Q'<#R</5A,1@L (-E<FKQ/6<+_([%]YS-\3N6F@\E'9EF+Z"NGP2FJ]M
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M4RJ(3!]$<@$=Y?%E&C1D+]1C(9_9L(</ T'[\7P23X>DY3]02P,$%     @
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M2!?9EMI4U29M4M1IVV]B7\=6P7A XN[M!]BQG)16_6.XEW/./1<#V2#DBVH
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MCZ/FM;_DV>/YPSY_JMM?6ZLL^RN*_8>Z. W7+U?G.Z#W_P-02P,$%     @
MDX%63Z W4S$E @  &@8  !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&UL
M=57;CILP$/T5Q'NY.%PC@K39JFJE5EIMM>VS0R8!K8VI[83MW]<VA!)P7N(+
M9\XY,V2&HF?\7=0 TOF@I!4[MY:RV_J^J&J@6'BL@U8].3%.L51'?O9%QP$?
M31 E/@J"Q*>X:=VR,'<OO"S819*FA1?NB NEF/_= V']S@W=V\5K<ZZEOO#+
MHL-G^ GRK7OAZN1/+,>&0BL:UCH<3COW*=SNPT '&,2O!GHQVSLZE0-C[_KP
M[;AS ^T("%124V"U7.$9"-%,RL>?D=2=-'7@?']C_V*25\D<L(!G1GXW1UGO
MW,QUCG#"%R)?6?\5QH1BUQFS_PY7( JNG2B-BA%A?IWJ(B2C(XNR0O''L#:M
M6?N1_Q9F#T!C )H"T)#+(&2<?\82EP5GO<.'XG=8O^-PBU1M*GUI2F&>*?-"
MW5[+.(T*_ZJ)1LQ^P* 9)IP0OF*?))!-8H]6X=%,XHY@8_6X,02;&0&*<CM!
M9"6(#$%TEV2\2'+ I ;3&DQ@EXBM$O'*XP;%=H+$2I!8/"8+CP,FFWF,TR#Q
M'A0SM>JD%IUTH9.N=,(0>8E=)K/*9!:9;"&3K60^);GWH&JY529?R63+HN5K
ME<VCDJGY8FV2P))-ONR2 93<O9TH\9:]XL]:DP(_FZ$DG(I=6C,19[?3X'M"
MIK7_PX>I^0/S<],*Y\"D&A"FC4^,25!V D_](VLUJ*<#@9/4VU3M^3"MAH-D
MW3B)_>ES4/X#4$L#!!0    ( ).!5D\EHV+5" 8  *@G   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4W+GAM;)5:[5+C1A!\%9<?P-9^KRB@*L =25521=U5
MDM\"!+C.MAQ)P.7M(\D+T6I[UZ/[<?Z@9]0[TK3:LSI_K^H?S4M9MHN?N^V^
MN5B^M.WA;+UN'E[*7=&LJD.Y[_[R5-6[HNT^UL_KYE"7Q>,0M-NN>9;I]:[8
M[)>7Y\-W=_7E>?7:;C?[\JY>-*^[75'_>U5NJ_>+)5M^?/%M\_S2]E^L+\\/
MQ7/YO6S_/-S5W:?U9Y;'S:[<-YMJOZC+IXOE+^SLUHH^8$#\M2G?F]'[1;^4
M^ZKZT7_X[?%BF?6,RFWYT/8IBN[EK;PNM]L^4\?C'Y=T^7G,/G#\_B/[UV'Q
MW6+NBZ:\KK9_;Q[;EXNE72X>RZ?B==M^J]Y_+=V"U'+A5O][^59N.WC/I#O&
M0[5MAO\7#Z]-6^U<EH[*KOAY?-WLA]=WE_\C# =P%\ _ YA,!@@7(*@!T@5(
M:H!R 8H:H%V I@88%V F >MC=8?3=5.TQ>5Y7;TOZN,5=RCZ"YN=F>Z">.B_
M',[_\+?NC#7=MV^7RF;GZ[<^D<-<'3%\A.$^XCI$2,9\S$V(8=GD2%]"C,I]
MR%< L9-#W2+,_Y3774$^J\)A5?B00'@)!$X@8 (Q))!> CDIZQ&C!\Q^P(@\
M,ZL)[ ; M,U7$3H2TI& CL()%$R@Z 71,($&#/2D($>,':V4::56=E*0$&8R
MM8HLQT V!K Q$S8F.(P0>C5!W80HS=3H''ID+"1C 9G)FJ\L* T+R(0HK5=Y
M-OK',+$<$LL!L4D[7N7!(;D>79M'7@ 4K1'+L$YE 1DV[?LK!_(*D%FSRJ=2
M%.(4RWCL&F(1Z61A4^19) 76&<8)Y]Z!QFSSE<WP:74+#$.X7.D(-RQA#&A8
M'E1<A%TBQ:B0[OX0BIC,6'"=@&PRRZ<"\,7!S!C&^/0^ 0Z9Y]-+X1; %!?1
M4F%Y9:&^@HM3AJ52(JQ!")-"1KL%RS53X-Q%[H ,"S;3=,EG6&49DMGI79"%
M"LI-UXM\6A> DRI?Q5:%M98!L<UCJ\*JR')Z83@6,QZ*65@8'HJ4U3:H"X#E
M.H]=P!Q+&6>@+)%+CD<LTPS/Q+'B<(IK<B#EW9>G-T(>"@G764S?.>YJ#EQ3
M'DN!^Y#/\$T<]R&G."<'&A<EFY8D!?&)X&[F%-/$PRYE=GH[N $H-78S/AW<
MR9QBFQPH69<4Q">"]8!3;)(#)8FD(/Y/#JPJ@F*11"@7X 0!5/P$":PI8H8]
M$EA3!,4>.5"JM$F(3R3R<X[BA42H3 &1%,0G@C5)4)R& R6)I" ^$:QL CF,
MR$U'8&43,QR&P)HD* [#@9+E2$%\(EB-!/(5L7[!.B)F^ J)%4!2?(4#I<J1
MA/A$<.]+Y"=L) 7N?3G#3TC<M9+B)^3IKDU"?"*1\0MR$GDD!>XW.<-)2-QO
MDN(D)'$( W")*8S$[2LIED*"00P+?3" *2UB]RR)VUA23(6D#6, C#B-D5@@
M),5H2-) !J&B$QF%Q491[(9"$YGNY\ETR EP*E/9*J(9"LN.FF$Y%)8=1;$<
M:OY$!H3$)S(*ZYFBN!!U6L^2$)\(UC-%<2$J'&2<+%(8DBA29%(=&A.=Q9:'
MA5+-,"8**YNB&!-%''T@7&+TH;"VJ5#;=$R!%%8@-<.B:*P:FF)1-&WT 6")
MT8?&FJ%#JZ*S2&4UU@P]PZIHW-J:8E4T9?2A9XT^-&YP'3:XSF(KPGVHYVP9
M1?:,2)M&IT<?28A/!'>SIO@4??IG1A+B$\$]K"G^1)\>>B0A/A&L!)KB1?3I
MH4<2XF_D83TQ%!=B3O_D24)\(EA'S SO8;".&(KW,*?''4F(3P2KD:$8#4/:
M^KD!,']/QR>$]<A0#(<!&RR($-A@21#"ZF:0RXCX9X/5S<QP&2:RC4UQ&>:T
M+B4A/A&L2P9YB]B./%84,\-;6*P%EN(M[&DM2$)\(E@++/(4$5MBL1;8&9["
MXBZV%$]AP[W4H!PIR)'(>O2X4?\,VQ]%_;S9-XO[JFVKW?!\T5-5M667KK,B
MR\5+63Q^?MB63VW_MN^I^OCLV/%#6QW<<W'KSX?S+O\#4$L#!!0    ( ).!
M5D]N=>;(R0(   <+   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;)56
MT8Z;,!#\%<0'@&W F%,2J9>J:J56.EW5Z[,O<1)T@"EVDNO?US8$$5@J[B5@
M,SN>]=B;75UE\Z9.0FCOO2PJM?9/6M</8:AV)U%R%<A:5.;+038EUV;8'$-5
M-X+O75!9A 0A&I8\K_S-RLT]-9N5/.LBK\13XZES6?+F[Z,HY'7M8_\V\9P?
M3]I.A)M5S8_BI]"_ZJ?&C,*>99^7HE*YK+Q&'-;^)_RP)<@&.,1++JYJ\.[9
M5%ZE?+.#;_NUCZPB48B=MA3</"YB*XK",AD=?SI2OU_3!@[?;^Q?7/(FF5>N
MQ%86O_.]/JU]YGM[<>#G0C_+ZU?1)93X7I?]=W$1A8%;)6:-G2R4^_5V9Z5E
MV;$8*25_;Y]YY9[7]@N]A<$!I L@?0"._QL0=0'1*"!LE;E4/W/--ZM&7KVF
M=:OF]E#@A\ALYLY.NKUSWTRVRLQ>-A2EJ_!BB3K,8XLA PRY1VRG"(Q0CPF-
M@EX& 6401Q#=R6 P00021(X@OB/(1GFT&.HPE<,D61(%R2@9"!;1 >Q.3@S*
MB:=R,!K):3%LL Z-,Q2,=G\+P%"4!A26DX!R$D .A@DH2$"7^Y."!"F@8'2*
M'M-)ICA!63"R<0O 8I;-^<- .6S!<6' .ED21",Y$(RA8&9W,E!.!NQ.!!-@
M!-]CM-PA/%,*\ */.M!=NO8XLG%%@' (!?&,)+@L8++ IPXT7"K+Z,0G$);,
M'1L,EQD,U!D\EQ-<&G#\ :?@ZXRA^SQQ*IDZP!B;.@7@TC@)9NH#A@L$IDN<
MHL!24398JI,$XM*Y.X7ADH.AFC-G-UPF,/N 5_#5QM#=GGB531(F*(F#R?_L
M%(<9(G-_!@2N%00M\*H#T3L/")D<GSG<^%*$@X[$MH@_>'/,*^6]2FV:&]>"
M'*34PG"BP!S)D^E*^T$A#MJ^IN:]:5NS=J!EW;6=8=_[;OX!4$L#!!0    (
M ).!5D_E7F[YL@(  &H)   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM
M;(U6:X^B,!3]*X3OPYL"1DT&']E-=A,SD]W]7+4J&:!L6W7VWV\?#(-MX\@'
MH>6<<^^YO=A.KYB\T1-"S'EOZI;.W!-CW<3WZ>Z$&D@]W*&6OSE@TD#&A^3H
MTXX@N)>DIO:C( !^ ZO6G4_EW(;,I_C,ZJI%&^+0<]- \J]$-;[.W-#]F'BI
MCB<F)OSYM(-'](K8KVY#^,@?5/95@UI:X=8AZ#!SG\/)NA!X"?A=H2L=/3O"
MR1;C-S'XOI^Y@4@(U6C'A +DMPM:H+H60CR-O[VF.X04Q/'SA_I:>N=>MI"B
M!:[_5'MVFKFYZ^S1 9YK]H*OWU#O)W6=WOP/=$$UAXM,>(P=KJG\=79GRG#3
MJ_!4&OBN[E4K[U?U!GS0[(2H)T0#@<>^1XA[0OQ)2.X2DIZ0/$I(>T+Z:$J@
M)P M@J^*):N_A S.IP1?':+ZIX.B3<,)X.N[$Y-R.>4[O@"4SU[F( 13_R*$
M>DRI,-$(D^:WD)4)"0>$SQ,8LHAL692108]N RQ,1!@$MYBEB4D++<\O ZWO
MBMQ8B:T%C24_OBEH9A=(K *)%$C&"<2AMB(* R2F59C,T]9D:8+RS"N"T:7)
MKDP& %ZL%<@$%:&7%N/+;C>UVDT-NR#4G)0*DXY":DN_2(VDGG*>E5:1+W56
M7R+6)N(I"NR&@=4P,-<W3^T"F54@>[S#<JM ;BFY]J&4"I./;"9!J/?"(C>*
MD83:![6T*!6%IW^8MGB%WM)K$Y5&L0?LY@NK^<(T'VEK7!9&-\5)K'?3PD19
M4EXJ5':O1*N'XJWO*RGK_NA_OT'D*'=MZNSPN66B9T:SP\'@.1+[AC9?AI-E
M:)E?\8.$VO<_Y=4IY"<DQZJESA8SOEO)/>6 ,4,\]<#C+7+B!Y]A4*,#$X\9
M?R9J^U<#AKO^9.,/QZOY?U!+ P04    " "3@59/2VO2PB8#  "Q#0  &0
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M<  9&L(4'YPI1B>&ZI)(.9<*8X8#SM (I@1106S;H2(6N*8'0X8CRI 83E"
M2ML-4$GGW&!D\71)&*=HM520V(:H+HFX:X($1J  "%2.C2 PL@1?'L7"D0D!
MU) H%I0C2D:!E;AM@2QF>I)FS UAW@B46ME!+"A'&,$P%+G,8-((1!H[B 7-
MFYX82:ZPRD$M@:DE4()E![&@R9.R<^RMH&E8S*))H,_M8 (*E&8Y\C2!D27B
M!R(8@T8 T- (I@A1DI.-/<JF<R>T:XTP: 0 #8U?"A!&S2"1(WXE9HQ$C+'C
M5]+TZ8D^H;#*D39*S"L)4BP2OY*F6$H*4B( F=#2%<$2TT^B1,M5"#HJ0?E
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MHU#31,Y9WPSZA:"M:71HZ+;Y7U!+ P04    " "3@59/J7E71AD'   C+
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M=J=4(S,6FK'<C*%F+&M&F#EY+)XL&Q1ML9$(&HF8D4C1]1;=8R2ZVT@,C<3
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MYY6KW=3MSH*C2PZWB]2]5LW7J/Y>=.>!W4657_JSSL7MP'7S+U!+ P04
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MSRM39QY]J?MG9[+MY<?!/%?-U[C^7G3GWKH?57[NS_1-+@<+Y_\#4$L#!!0
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MD+RJ,5$'@P-D&6.CT"3P0L,7B&ODC6!98U#6&'AFQC!!!!)$@"_&^BTCJ\_
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MG8[E>5GO1^H+P4_-7LMO-WR+_U!+ P04    " "3@59/KCD["4$#   D#0
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M'289^YMZD2'*!E%;5 >B8W<3<YYM(A02[\I,1:"H"!!E++A59 WS"7G&=&8
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MS%Q(S$30QEZVPO;&M_@/4$L#!!0    ( ).!5D^6 ZGO2@0  $<4   9
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;)68VXZC1A"&7P5QO]#=G+HMV])@
MC!(ID48;);EF[/9!R\$+>+QY^W :+U05N^Q<C WS577]??I[>OTHRB_51>O:
M^):E>;4Q+W5]6]EV=;CH+*FLXJ;SYB^GHLR2NGDLSW9U*W5R[(*RU!:,^7:6
M7'-SN^[>O9;;=7&OTVNN7TNCNF=94OX7ZK1X;$QN?KSX?#U?ZO:%O5W?DK/^
M2]=_WU[+YLE^9CE>,YU7UR(W2GW:F"]\%0NO#>B(?Z[Z48V^&ZV4MZ+XTC[\
M?MR8K*U(I_I0MRF2YN-=[W2:MIF:.KX.2<UGFVW@^/M']K@3WXAY2RJ]*])_
MK\?ZLC&E:1SU*;FG]>?B\9L>!'FF,:C_0[_KM,';2IHV#D5:=;^-P[VJBVS(
MTI22)=_ZSVO>?3Z&_!]A=( 8 L0S@'L_#'"& .=[@/O# '<(<)>VX T!WM(6
M_"' !P%VWUE=[T=)G6S79?$PRGX"W9)VGO*5WXSOH7W9#6?WMV8 JN;M^U8J
MMK;?VT0#$_:,&#&>G"(11OB3L)L"GE4(JHI0H' Q;6"'"4^!&GZ:9/_S)#%&
M.&.T%(?L4*=+X$PZ=*8O7#*!VR5P)PF D+!G_([).\9AE@>ZK(>"$21\T&4X
MCV(6&-L]AB2W7#;ZF='GD?H\0I\#]/6,'#7YR?5@8;N>\B84G!1$)NXVY0.-
M%.9Q2]#"?%*83P@#[80^(<SB0!>&VI(!%1&4DA;0O_=1'W%G1E5 J@H(56"F
MA0&E"JY@##'(1&2B $@B(.Z,)L=$E"1%223*96!VA1(WX\!:=B0$54D\3SD8
MS3V12%J2+5AEBE2HB&$#JS]4N$T16& M[C#%N8=F(T$YP@(M[C'EJ!$TT<49
M;5B,V&"#F10SGL>)SH'#/T!@+@)!.X)JURJ< 12F4%?O*:SIH#EUI)>^<$&H
M4U"=0"VY<%/<#=!XXC(HC,CC(P<AJ$]COYK*HGV5.TB68NBDXN"EIJ J!_D9
M.60.'@L/F>R>S,;FC(/3EL]=-*?5W'+GM*MR;*N*P6,#QS;'F43&&BWDXH&;
MB&>-;3HSI=.^R;%Q*@9/!!S;G? 4'(YH&183F"/8R#RG==/.R+$U*@8-GV.W
M$D+ E1\MPV(2<V<W"-K\.'8_HK^Q(7$IH?]%R["8P(3/9W=^VM(X]C3%X%&$
M$T;D!GB>+,)B G-==^ZL(6C'$@S5'0@X3P9HTA*>WHNHF*"X\.;V)$&;I"!,
M$AX@!/8K/PB@CT3+L)C"F)K;3 3M?@*[GV*H;NQ'PA4*'6H6<C'%27_VWP=!
M.YS #N?*N:E&&XGX!2,1M)&()48B\,8O)3KR1\NPF,("O*O9HSN-3)?G[D:J
M,@[%/:];S:.WSUNO%]'>B8#W(5_M./$^XJM]?Z?U/7U_Q?9G4IZO>66\%75=
M9-U]R:DH:MU4WQP)3..BD^/S(=6GNOT:--_+_FJK?ZB+VW!M9S_O#K?_ U!+
M P04    " "3@59/K,$F0] !  !D!   &0   'AL+W=O<FMS:&5E=',O<VAE
M970X,"YX;6Q]5-N.FS 4_!7D#\#<=@,1(.VRJEJIE:*MNGUVX!#0VIC:3MC^
M?6U#$ 7:E]CG,#.>\27IP,6[; "4\\%H)S/4*-4?,99E XQ(E_?0Z2\U%XPH
M78H+EKT 4ED2HSCPO$?,2-NA/+6]D\A3?E6T[> D''EEC(C?ST#YD"$?W1NO
M[:51IH'SM"<7^ [J1W\2NL*S2M4RZ&3+.T= G:$G_UA$!F\!;RT,<C%W3)(S
MY^^F^%)ER#.&@$*IC +1PPT*H-0(:1N_)DTT+VF(R_E=_9/-KK.<B82"TY]M
MI9H,Q<BIH"97JE[Y\!FF/ _(F<)_A1M0#3=.]!HEI]+^.N55*LXF%6V%D8]Q
M;#L[#I/^G;9/""9",!/\Z+^$<"*$*P(>G=FH+T21/!5\<,1X6#TQ=\(_AGHS
M2].T>V>_Z;12=V]YXAU2?#-"$^9YQ 0+3/ WHM@B?,^;,5@[F&T$NS8"*Q N
MEXC_(1#N"H16(%HZ"!Y6.4;,H\5T(R8\>&ZR"K,'BQ,WVK<3[=J)-G82+U[9
MB3;KQ)[OKC:_V*(.B;\Q@Q?G;=[?-R(N;2>=,U?ZZM@#KCE7H!4]5U_J1C_Y
MN:!0*S,]Z+D8+_Y8*-Y/;QK/?RSY'U!+ P04    " "3@59/T)NEZY8#  "V
M#P  &0   'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6R55VUOFS 0_BN('P ^
M\YHJB=2\-)NT2=6F;9]IXB2H@#-PDN[?SX!+P3[:M!\*=IZ[>^Y\/'#3*R^?
MJR-CPGK)LZ*:V4<A3G>N6VV/+$\JAY]8(7_9\S)/A%R6![<ZE2S9-49YYE)"
M0C=/TL*>3YN]QW(^Y6>1I05[+*WJG.=)^6_!,GZ=V6"_;OQ(#T=1;[CSZ2DY
ML)],_#H]EG+E=EYV:<Z**N6%5;+]S+Z'NPWU:X,&\3MEUZIW;]6I/''^7"^^
M[F8VJ1FQC&U%[2*1EPM;LBRK/4D>?Y53NXM9&_;O7[T_-,G+9)Z2BBUY]B?=
MB>/,CFUKQ_;).1,_^/4+4PD%MJ6R_\8N+)/PFHF,L>59U?RWMN=*\%QYD53R
MY*6]ID5SO2K_KV:X 54&M#.0L=\S\)2!]V;@OVO@*P/_5H- &02W4@J507AK
MA$@91)J!VU:W.:Y5(I+YM.17JVP[[I34C0UWD6R(;;W9G'_SFSRQ2NY>YA,R
MF;J7VI'"+%H,[6&"> A9FQ#H$*XDT+&@&(L%-<SI,,#21$21QG-E8@(-LOXP
MT(.) $*&F,V[@0;I>FC1O<;>[Q<=".[ 1QWXC0-OX&"DX 'J($ 8:)588QA/
MJQ:&\7$B(4HD1!P$6O^UF*C!% W&U_IOB4 "G$:$TH@0&B'N($8=Q+>?R 1U
M,$$81%HA6DS<RQ+"V-%0JQ85]E"A[TQ([P^TDS8M/!(XVEEO)D:-(1JI$1!<
M; B29*RK#3&RC'V=S I!>=0)=%DR41!0)]0R4["@'S(>R6Q$1@');$03 -7
M>Z"WMQ#@N@*(L%"BU]<SDI5?+D2OW >H(1U<I<!'Z&B]MU2@?J!H1$$ US)
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MK*W"10V.D</\!LGR(RC_ E!+ P04    " "3@59/Y!RH.(6^  #=(0, %
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M >+E0I2(-PQ<T7A^2ZH37/T!KY$Y"N6K=X$**MZWBP!:FLO1*(TX#Y[#B2Z
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M:0L='*W9"'M!ZUW?6(R1CV7!!5[M;9]JR -C#Y" 8^T(T'G0.CB>QNPR; G
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MKCS3>G]Q>7MQW#%,73G-<0A+=#1GH:KQ2,\:,S/>OFZ,[&#D< 9DYT M# (
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M[RXN/WAG,7!D09=HJ4^/)<F"C-&K.!4-C6C,,ITK))N $Z==?CZ=]CJSH@G
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MC-;\8Z\_1$.(_04YZ.&+27?/Y%>$";M#1(! I'P3NJ@F/!L-+:\^_S6<8)4
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MT3)R'P7+1J0;=;VKBIU:0#)I,;Z=S&#P?FA'?4[/V1(\A+]XL#>&/'MW6$Y
MX8&XZ'5.]C.%)3V&6+54S,Z2ZZ@A@<KH  1$8XZ&'T4YIKVK< Z%GHO".QE8
M'H((D?T\I#9&WK-RUA9A F(Y*NL4\ ,J.UN98ZK:IO+[&LK-@KI.\+B2S(<4
MADR%$J0J,FPJ4-\0I"&N@(JKF+KVRJM"9U5(.J3<3[HNV,ANLVAY5!5J:K_M
M.6!XSS4\*P%F'P^6(XPTRT,[I" 0<Q0#3GU@0F25 GD@<D'LBMY(OTJ8*V?7
MN.+?+JF)CR<E=U5G2=3#8>"K?P^2V&2FZ,S?S$Z34?5\*E/\3*IHA:M'8&Q4
M/6QRK]V+:^]HW',SO&JGV/'^;(E/.[9ZZAK6JO?9%L=V[#7L5W27K[Q5OI['
MJ;] "#%0(,-%OB))>.NUKBYOKH^97W,/3N(R1O3P%;-EM%<D<().N$/#,Y8C
MC):;.%1&RB*EVNSVL*'CN%Z#(,<V"]A!C]-7H<>BG7 )A+65W6344CM#4X$M
MXN*+Z_* 5<+'@C6%:T=!#MM['_I>Z_;]QV-Q2_I/?JA(*<ZSA< MQ=%]S$2M
MP:=3(P&0#/4.$7YQ3]\F^;UW:H'.$5# V]-C]'""4*16=!G@G5LSKS85%D@H
MK=X/5QQ^BU=>K/%6? ,2\B*B1\H1(T?*IHUBN\]J-EVCD SJ(I +KC4?(+F]
M&>M8UKE,-K A6E]BWSA3V;)!(&R79$:- 6J?*DZ1),.?"-06Y&TA!UG0I"K
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M2>?X\%XQ6L>XTMYQ#G[12%H>"N:8.PQ>H_:F;HD8%-CC=;B@80J89H7WH\*
MAUVLT6?GHCV6.&82%"E28W"P#:IM\@:IFHG>A=<@U5-M^!#Q P= ]2LI2 MV
M%B,#,9QSN\ ,D">RMB)I$!>Q<J,P!0 +*]1:YYXS-;&#ZGY"837YANGE$+O,
M$Q47L78# UNHJ@,;8G:-'^,:8X5S9R&@6-XB5617W=<D#C.F-2)Q,0SX0[!5
MJ3T$$V21"D:F8C':NO6G@VOT6U7-@T,X2XJS!0=%&KG=A5I1AE*U+$!\@@X0
M?G1&'1:"N4,YCAV?8>K4T9L'.R/#B#FUS.UF9P"B"W.,V9L8[^GU1_)KST.#
M"?W:-[\./(;)A5^'\*D#FTRB3 %96A"^2*B/44F1"\?)^--!0QJY5,*$JB>C
M.FS#S$$]B@3Z2:@!<U GW3'FV$?&:W#O8CN?,]"BV@/]K0ICI74]%-"E-9Z1
MXY\#*%L#RFHS@Z4ZYNXP*;?O]L$4=G2&:FDM^T;I^Z4[N&PV_*<S-N("!#4;
M8MG1D2GR]E!4L5LLG=-L'HNZVS."?VJ EUXGKHC%-W4*]2QYW]#H$"P+]G,6
ML^8%?L,/MQ'2U':I2]"64H__U:.EZ@.!!$)P2:4VK, =2W209"GK.*CE+D5A
MU91O;'CLK55.MS[6JJXL)!)\QG5$R?>LT%*=_?'G<9X9//%297-/0\ER-#]B
M18MNMA3T_"0A#,>L6)'6N%'05D JGE7!RGKX(81-3A8/ZG:VH-XY2^QO.<,?
M:@AT6&:-\,3(9Z:YAL NE\USB,Z?\A@W[BH)V?7#51@# ?\'=LO*:>_8N['$
M0&:^GPS>]P6KI_)TWWWZ<Q37/3DX%HGV)RY(4*A#T!Z/..U213)5??:AMF;H
M3UHI+)=B[1-,BH6!4_C[/7JP(B)RZZTI(7NH9]R_/H#(<8^E? K1NL!7%E@D
MQFIF,)A8X5GN7]9TI!Z)\R*&D/<PQ&K0LSNW2C":2EJ81#LQL!/.7U>H,ULB
MD$8 =ZJ?],<6UH;S!Y,/"#7M[E2PC*8$O@(?P!4]M#;HTIRGGZH'>N3-"MOL
M_GVVCTEF,,1 \2(@"'^J1CL8<9A@L2-^:K_(QW^!@S/ICF@OS#2+GSSWT Q'
M,^?0N']7'YK9>&:AG[A_'7!H^N.NM;_N7XV'9DS8!R.D_A%A_C0>&L('TI&3
M]A]['IF1!1#C_*&(<-3N$>[.$8^)\%Q&78?@]SDR_2%ERYH]+GRPUZ$9=F=6
M&*H./:5/U7B'@Z%SGG5/\A@! A/4,*&2%\0ED7=4G,#NR]/Q(QP4LE7PO64T
M,!+7L+:6T8(J+U@J\$9'3-^SJ!EB8/T= L*H#+MJ*RW?\.F+!N]:J7'AA"N@
M)TN73':!HXO5>]H-);0UVN6Z[K1LK:P37*B+. (YN!#P(_% +?KRF->WHAZ.
MB[<:+IPT]IC FZ6ZI/K6;,LZ7@:K?50HBA<A'ETU<(RZQJ RK"OUSY29AZ[2
M11+JTMH49.E3N[P>\2)8DMAK"=8;OFDTFC=5_&E88K79S8M<M2QM[X92!D@@
MM>\CNX U@BDC39W4U65_Q45[BW1LEPW7)T5Q$1.7I!D.$;]U<&Q4&G6N+$G_
MM\R5L%;H3 V6_ZS_IM^9=;O?0Y\1AHSBQG"VMAD$5MXF:Q(*Q:/N3  E%5P8
M_#:="=(?@AXAC."X/]JGR3Z! R+VTHS2&>$O H:;$>#PL-,=[34RQ(%CZ*9>
M>S) *"%$'QSQO]3\J-/?:Y+#$8+7C88$-S?I]ZG)*>.[T-]#2QX=SKIRJ\Y&
M R62#B9T8\%GE,A8X1"D@DDJ04UGT3M#JV-US$_;=@$D0<Y(8N(M*,A NWNF
M3)<IMWQ&^VW*_YA#TPRU\&J'S1(;SARQX9,E-NP.ZJ/5@P8>,9H4DQ&+8:/L
MRKO)DG@=+,-O<JGHOX]I"3D"M> $_(C1%REP'VSV_7K^BZ3B$ZGT^O0B_-(M
M!F%C. PF@A([Q=+I]CX44.FUS<M.W8_OK*H)*[ANL+P-6^ZK2_[M,,P6*'#?
M& 5=0T/Y*RLP@U\7A>>='FB=.7C8[1'7&<Z8#[%H" >NCX"G9T;VL@2<UFA"
M>56M*:/EM,9C!BV;]2C/2.&>U8(]MOH,D&8/KV@ 9LT.!M1C,!GW[UK&3H%/
M);;>]HXPP;N8;C"V*U<5J:ZTUVJK&3IMOV@#O[G2*2M.*YV";%NP#DD5KBHB
MJIYHZK\>-JWS_(0M2V"O7L#] S5*J0=LE%6!BA4!><\,K"U$^B0V(MW>0R[%
ME[:Y[#O5-8OO[D@]WMKX_I0NCHGL:28X_%39F@*69,F:.G=*H8F/?@-:AL]Q
M7NA)?.8^3G_C?3PD!LOQV-B!?RJ^:\?^WK[_2*$GMAOI-U_U4C IUQRB\F*,
MY0/OF]R8%Q$OM&$VD#:/0V1""@$\FO8L' 9S_RDT(57&B2INNY6GD<7J>][2
MD*LS><J> RW&6#I %=:'3GLFA0$'?\[J[8W1@1L<"57=[*KDZQ9Z$R,'<5&0
MZ52?,+$5TB 5H9MUO:6_3<L5\7196UM"6]26Z3V$KS<AF9Q9555\N#;1O#,:
MT27>'R 7^H0V/4KOP&B"A.10/58+/@WA-&>682\*MJH *-9<1OCX7A?S7?L3
MU$MN'N(DX^NJ:*?H]5!XZ,V&EA'*V/W9E'E;RDBQ9"AW1G8LEKJIU,%M4_K;
M'M-K(Z<KSH@@1NKG886BNP8N=0>%B?VZH1@)J6@R:F(D)8AN[( [+D5NL$2@
MZG3*O7S,J +/CJ!TCX&%"URT*BW5^2N->V_WE,1 P8#>$Q+RYXBK+N$'-/72
MQY?LB[15ZEI#MH(.5G1%JG/!9([?(.[MQS@Z4:B]/<+;'GH( MOJDK2*'R&A
M5MN^54?# 4:KH<FZU27\W>$ Y4B[[>$ @YM141>0X>$ '5('6,A59]A#45;&
MS^S>!C"@B8>"MO2&KJ69'+<&&R)FXD]G;%A@=.!63T O!^U9%Q>LR1C?IIJE
M"[W\_1Y#.V-R/RKMK3ZI!$?BZ=K/OF)HA4 F?G."Z4X+]G!8PAEC3A!BP<A9
MZ>D(JV7@]%H#>FQ*9O]F>ID02 )NFFP/<KVITVZ?8!WD$:1$+ 8R_:WHA?TM
M.)96EP)P\(/A?O2"]4+(3,6P#F-2VN@+RA@_A%Z&LS'C O<G3"]3@0%A)X]E
MN+11R#]HS@K\1Y6K/0%1Y>0&@8 L\>#6C29S7?J^IC-5!;R*[]D7@-,7@0[-
MMTZ!1.'YC2AD+[0^FM-A DVK/K,C+W+. E?5>[&J( HP6$BC.^M)U9#NC%7I
M?GO0&\IG@QY&9.'[_AW)=*H)92NS(NP00WE,93/&,SP16&B#"KK OUBWQ+1B
MO]1'%(T>P6[T2)?'GWTAQ(H%K^%=BEG9]*D($HG QP36^\!LT+-VNS:&N<Z^
M0&J.F\+6&RDEBPH$]-5?KJ&!:@LO@F IDJ5UJ$@:+M#XQGG8DE5)I"%,^?AN
MER_):+N:I[)80E$TS%W_,3#15[NG@RRB)Y#L6!>'-WPZ9L/PI#VC"CG7[D2.
M/+Z6N(Y3GVMNP*OZ,9GED;K6Z9>Q^D50H7M=NM1N-*RP#<AWL G*12BV_%YP
M=66PN&&LPVR34%>H-1T:P(X!3+D R3N>C!T,CX(%5=7N_2V ZECHW3$S;?.T
M>X5.R@*R9:R=A[$%F4#(&Q'=+<8C9*Q;$J1%AG@K ,V>L4H1J L]>UXD7MM#
M2S*&"*I2QZQD/)$;&\\$@3JOMFQ>LA:=@K&?M02>JB+?I&OPQNQ<<%6GU&#]
ME;VP=B"V<=Y*E+SMPBWZN7WML[-&JKW6HE&IR:+=@6!KV0B,>EX22I*KU-+3
M^69+=OR SH<WHGFI-CY!0FDY\%YLADT=BE-GEW_:<LSB?AH91 HX[O:6X[!*
M"1NPAI+UD=KAA_0*=40F/=0^8X697%@LBM"G$9('VGN,T=2&B6X6/["<)K"3
M69Q0GJIYE"QQ DJOB<_D;&(-6 +BQER'S-RY6&#ZY YO!\?0QOZ;;%$T5=?.
M8]\]X#3:98A.&_AU&P8K8I^8V%UT#&&4+H>'<D-TTQ2GZ-T'$:'K;#E !A/K
MS0+!I_=4'%3,.ZIC\2;QQ)9L&8OW.8+6@=_D\U6X6&U/"#%N6<\ GA/;ZIY-
MB70KPQ?M<5,=5,&I7<;Z3UWT46K9LK?OW'&",7(1 P;3OE/3U=01MGHJ-^XW
M\]%MC1'?M2=7&\@-A>^:SW_'F)FBG=8*AVNP!U<_1:/])5C>XV*>F@KC>Z%Z
MUC0)(PT0^("UZ<56YWN>Z6"]$]VG_>);XXNZ7\5SQ'#P[10!)_J?Z3HU)*'*
ML*#$Q0]B5K!VP!7L@:Q!4\2.*H?M6U5-EKBE2:'"\*X^-+. ]JU6*'4JTY7,
MTWS^J^#76YZ@.UFTA5HTMXXT.3YP\%1^?@V;="^A]*G.9R)_2,XX]VY;RLUN
MHB7)5;0@9-]BP>H"X%V)A5C%=D,G#&''\G0T832,"\?#DL3!FB(F9BQSJ\YU
M#V=94!;IHUJ-\597E.?1F!A.QO+P,RO(D)+7'X",9<9Y5%#ZT$B@:^>PJRFQ
M'*M[;I3*M["90J8%+A@X)8%F* HPC6,O_)B=H\)$3CI0\ #[@8=66<-75!VH
ME:CP743" SWLT]F%ZLS.&SGN%)5"2[ME!^.#-0'?20[R[)HLF.S)XI1<(JJL
M@O2JEV4>("'16HNP:F%Q,)LLGT;=NDX%WJ-59 ]N743*T"]L.'[K@,VKJEG[
M+3B.V;K4%!? F*MOLLF:O:F44'^-=2S@H@KA/#S#8\&$]("5ZI&>&1=314T&
M>A7@/4EWC^54:^ZW+[&2Q2:P8>3A_[QL%NO8Q4OKJRQ^5",[I?S_!D_>>0Y2
M*IHW9L.!*O;;Q?*P;U \A!W=0 -+;XS&:LPU'7@W3V&*>PEWLD?F?ZS(,_3^
MX(-PB =V"TO71U_<#*WT9W[D+T.X-IC/8W![UYOUM?%MCQ5CL^&8["C]=I^"
M MD<)57D')91QH@Y@(F4 5$.8@](B#0K$>.,@0!=:,+Q[JA(TZ00#C2Q+"@'
MLW670W\)[(HR#3USAC((E1EB*Z%KP20UFSN!HI%8:3L:S5QX>EY=X7!)4$Q^
MKFE:W2UMA<9G:N<<O.3<D>;H/F>C:CAS":R0?/:D\LK]8NKB,,*+QL.E\$0)
MB690EH3D\2"54D8>5]<DG=.+JT1QXJ:&T1O%@.($#<P2&10X*AN&''P#!2 +
M"$K-MOQ;P2T-.9AU9&(/5B&VB5Q3K4/L/C8[G;SF&MZ3/[I2Q(.(P'8RP^&,
MO<9L?%ZA,R*F/+G^?FQ=BIO\.K!45Z[$R=<^;-0G34\70I:AS6FK6[/N^1WO
M7ZJD:F.UKOA(5PS$7#7R=+6FY/^SON!4(?3Y?2I?)&1WGBH#-+H%*Q]B@S;^
MK#*X_S=<S0G'H[;(]^HLYY26>5*[G'UQ5Z)=OWG!E>_T0AFKKE%IV:4&?I'D
MJ< M16/;N](G?V.=*YBCMNMBC#D?5U,")&4#64219(SDS+IMJ6&1Q6K3\4$\
MR,E"+UP$LQ+<>'TN4=8\= /5ZM_?(VA@9@E<?%WPC39Q VGYIH+1AZ@4V]%I
M*O>A(\ .#8OE)T$%(S(@8!62J;)#E";K^5F6A/.<#3RN1NN& G8J I3J%_%P
M,4'[08KXJU9!1:ZQ:+MXBOX<&Q&^*4J398.F9>YX-V$DR'[8 ZH*4IR)70RE
MW:8GB3B,*9><C+:> A,E9P"9L;4LXA,TXFIKE$(1N,E^B_K+CLE(QXZ1I"*J
MNGJOB):CF$.I6+ZP+2TJ8NH41"&.MI)5TQD&:W\9H  C=1PU5M-.,FX8JW[7
MTOX.#O)"IFQ<D\2L@CJN!0SC73!/<HRVH*R+(AOPO5\1%U8[M0HUN*S"?Y=4
M\:F-/@\X5Z"HB,,#XU31;EJJ$4CX!P2!:=?)Y>V7^+R*(KC$Y(SQDRHK8IB@
M"J@5_XJIT5LW?N)Q8K.E%Y^P1.Q#N$'_#Z(3(=_%8-I"O5W6F9WS.OJ>K _.
M9\-99_:]I(-RF6(=CFC7LRI!*7T$T=P)W6VSLT(*1C'V%0;S3D88 C$7GG 3
MY[ =?P1I#I;\";%=V0MLL-5(,B_M5]$KJ TUK"\A.RO,GQ&58HF1=FP3=ZL<
MI6+'!E <6+U-L*8=NR:F99\D,BDV+E@GQ6MX'ZGY=<Q\;- SEG['M!<KYXBW
MO]&.>8_>';[T"K:> I],-U3!U+*/'JS$=?[%U?EAKX!7B%\;8]_1P,:??07=
MGEWF%3)( 8=6K0IM"C$2KD3(C-FN?\XXW(2S)4%>3@,"UOWJ(<+&,&![8=4F
M'D86Q<'^M@1@-G]J;RX*3Z]HR3E(M\:UKSJ_._:ERKOV8GW9ULEHE<^<55;:
MV;D6Q:YX=X\/UO@:6C\5F]*Y,A@S3JSC$[C%F(GH_N!^6>IY<3_[::05'[UW
M(_GAN\JM/_+Z'+2FP5;V?:_G1"M_JCSV%-W6MQY[F5G@?XGFGX5HAB-G]_=^
M;TJQ_3N)9NQ SOPSE0-_-A[>7OY\[M!$!*0ZEHGD1Y8>^5;:+>& H)X2BBTO
M0HWH)T'8[9+T6^J K,(5U=Z<<$NX7"53OZ--4%3!7JY%T:@-Y(>$ZKAJB!@Z
M&NTZ_))=#G@/H8\@GJ=#-'ZZ5_)@9)LX7G8I?W2%NU[7ON_%>F+2<%V1S!'"
M"YB0M2G:U=+6;U"ASI5J1]8LN/"D)>D\LU:=E6KA'(.'<!5HBM-8+#IRQK;^
M^VYX"(R9",WB"JG!EG"=-I(,2Q0KT516)S5@CH>D3 I=&U^6C@L0.$F&8Y:*
M5ZK8,F8FA\#X*5LEE-(F.\=%U,.SJ,:1L!)."P(S@_T3L.4^Y1$*Z?XJT,@Z
MFM5;9:=09@^@PN_V[11S3MWB]?I*<U)1,>S@'2YNA<7I)P:\JZ,E9L@J44B7
MF^V-6*P98_;415.D.KH [ 1 !<&VK>OQM!;T@&2N,=V.,SM(O')6+^NG3]<T
M&7E+5]+S5JPOJ5J]%XZ,B_P..OUB&-V5+I& @'HF3YOKV31^>UA3]9%\K]B)
M^7:COPWTMZ[5UH[]];@0>T65[R6B,2^X2E3'J9AM?^,Q4%A#WU*"830:E6ZU
M]F0VL2_6E]VBST;X<.:C#->ZKNMP5$Q.Z9$PNU>QY?&PJ,OW*,GKI9=>O +Z
MSI.HC;$SV=^#9(6-O_,7?%!0",3",'G("0&^M\+R/"?I@G+_0JX-F19@GN_4
MZV@TKNS!C01!6[)ZA3TB5FBQ"AH%$I-@)X'$87_99S()L]TX%)1$TQK9C50B
MQV"&1="[7HH #?!00/7PM QTV-Q@TV?=4G,8CD) $7D:M!EXT:1MY1LT%'GI
MQE\P68UZ50WX5FFRQX ??T9$A6!=%_QIF#$V=\@(&/N\C@+=LIV4SY ( $P8
M,<Y( 8O$V<Q]L+CM$!*,U0XS;8@K5KX;6/%!]A5?,"TZPXSOBD.R,,;QVQK<
M\@_.IG\R>/V?X(K/[_,4<^=-64_CN'#"]X'XQ )HC]<D%-'#^3P-ER&*GF07
M1.\+-U-'@E;U -B%F@E@99_/?[AX=W'Y0=*1;&>+MCO"JMHP*!S$6<^$[;J[
M)G?!2<T[&O3Z5HNH"RCVD4I V712*&>]1E2R*$BV;F__ZE#TQ9OW$KLI1?;S
MIPVWNSSP!6'799PK<BYF@2W'B@DAEE6,L:*EL ^N!Z"4&&M]T>6UXN9)83;^
M&NZ*/=ZHON@":@;YQ>1"QWQ#<D9SQSN3CJ1EQ7_Q>=QLC**/-SJP \0UK$I@
MG)<^(]C#XC*H52*<G50G>AK1?FAD=&(6Z%O]E@62W&5&+HX%:YAI^$V/L@A%
M! >17U7K9*VSL#8TX;.^)LF=ZA63 $3A>JGH(CJZAE="3^$U%MGN/U6JHUIJ
MDUZG%ECB^C@Q?Q$SYB-<4T8A+8X6N#?SK]@0"=Q4J_!N2Q)6Z?$]-+V7JW:%
M7NNT,C8)K5RMK!)R@$''/[GM*O6AYN,C;TC&:PO66H-/%$;H*,:-"L8$ [)L
MB(JFEBXU-E[34\->5X/%-ST'\YGV)'1YQPX:IXX<%JK1]VIQC[O3Y<5*?:/:
M+%N39Z5M(WB+Z[JZZ:@=$K8CHC@%JQ4%%TBB(X?@N!)9'W$_QHCH<*/.O]C!
M]GF[-29XF59OQM&,M/LM;N!8408K4JT>A>JU^@2S0L8],QVT!3 T)6).X,YA
M-^M\+0_I\)RZ@E"2# M<CC I7K\^5!^A,PG1=]I5Y:$FJ,<0).\$Y0XJ#@6$
MW^?:4.,)HU6H,?6&4UAEIM_"K&"[AHB3>PF<\B<3+C3&O;F2RB@F2FT/VO\<
MJ2!K5IKDP!M[\7T.Y(R\1:TS'M*"U,K!-@3Q@H\2>H9F_J(;"ZT0G]<,O$W;
MI#![:[>+5L+:-+\:,47A;M1NH!R5OBK:1>6Z<"^LQ>=E_U!-5$?>=$*&E2D#
M2DR8%B=< &#2H^\X*>/(&W=1RU [53%[H'0D\S'#I_9'A#C1Z@\HM+75'\HQ
M&#*<ZH@CB%N]*8,KX<&HH7WLF^QEHQ&9;\1Z-F2PG>&8TTI&8SY(A-V$0[DV
M!:32PA$OG!$=\Z9.V://I<#J->(S?SU/PN4]'/(/IVWGI4*JWA>"),3'3 /F
MQI"/N*H/@=%@[1]LCFI\\GW\%" 4' I5@O]2)7QPB$7Q257ME6,T:NY?$B?V
M O?YLM=(8'V8W">P4:57W"%AZ9/O@0=O0'Y?\UDT"!>4.Z[3OFS%H5AOM#BC
M$EPAMN "U9MW?)-S>\@=:+5+T:"O!B(S8Z,SQ<51+K@V^+OIAX7JQ%5LL<]H
M2!,W,-^1@^(Y"LK<JHZSNM/,T\8[A>-%)N0>LOC_U<$=';QON;,J;BO+R[+K
M46L'_[LISPQ]6OUI@_*L$%,I\/1:(V%2P.\'$@?IU.#4W\2"9?XV!+8.BC2L
M>9X]Q)+#Z-9-US&L^88,M!CI/[<V1G [-3!#B[HI#@/-[=CF,>MSC<^ C@?#
M)L0-G\($.). -Y1KQJ/"QB&VB353$P'<W#X7T<1WLY#JH'[>[T4Z?:;#I6!I
M95RLVC'B#0KA_!/+A.T>21?')"/W,V/4%<R"DQZBK:_K;)K/+V!3<@N@R/()
MZ((2-N0A!0.G/N_;'&F_->E;QK!GKL&H.[7"//?<;R"78J[%3"\;7\YT]0H(
MW-YDQ#)I<4'(WB)<FRS4+SYQ ROHN^[$3>M/G&W*-%<'#YZBZA4A['6LZCM2
ML1159ZK^K0/H9VJ1_S/I![VN%0=F_R)5?\A7E#8Q_L<PTO'+MW6ZU[;6=]2T
MK?5O';"M9+IYX;X.K+4\;%^GGNNJ;8I+O*2 Y#T"@JWP_(."G;7JC,'6\ZT)
M1"JJM26,7!WM2-EV&E=*8Z:2L(J8J1SX"5W<0A>-S;A!':BY6V^6'Z_*08(.
M$ H/UQWDG9SV]0IVD F!GGL31,%=F)&+WNU"A_'=HBRY$ONFSBI/16\70VB[
MPC=XY+6&"K)V2!HP2_JM08\4;,P1'0[,KPS8^VEG2/J< 7+*X!H]O)![/0Q9
MH0I&:/D985_] :KX*MXT*:7?'HB PL-O329L-QB3&:%49&7*Y@5<4F5I%9R[
MW5U01-T 8TF'!"^A)H*&JIY9\PHVB0$D: N9]-G6R G++4*C8%#-F4K,;<WZ
M/)'_I>T#:7O"\-UC!5,Z%#!E"]EZ,-8+/AG)URVL/8LT7D6)-O.1##1_&>M:
M=Z<WGT'MZ1#;/^GVB"3JZOOHRK7PC)[#'T"S0L53@QTS\*H>O:9;&;D>-XQZ
M3(;A%YS,%E<J&DVM2KAH,&L-IM09(<R^UOG$"*I1UZI76OQWA#-\UKEL]7BX
MW9E5>=B>R!@%Y/KS.67"8=#S80$X'U=>2*K?&QJ^.*5?]_"9^"]<P.(U5^\"
M45M5@62PWV6^M_FI"K6X'(Q?A29-?(G,,[51^%TR%6D(8@X^;#%;EX&2*"",
MQ+PJK^@S(R4-X/WRV$HH8!I#@9 J!*>"<!84RD(%7(* )4A/ JY T K5D^L*
M##X2)_[WC.G@:WOF/=0,PBX,/K:J%S<.9A=78]Y<XC&.\ :BQH2++$P%3)IN
M8\2Q(.Y6LM[X242!(UC(A83JVB>NU!--QJ!2<\ 3TG#!+L%PE>/I".R'6#\@
MG[F_6LCY^8U OS_FZX ".'XB)JC0Q@H0#;J$X*)#D%BCX4A5RAQR7>,A_,95
M* ;MX11K-+P-HG@=1MQVR:H>Y<0*T2PMBH5H&Y:]M#<=D@L/<Z]Z,Z3#?A<I
MYUR[@VGY*&#-*HYR0RJ*"O:@X!Y0R>)MH#%XE8*$P4:[22Q<!R=(XH$!)2;;
M.C:51PA)Q&=K*/^J8@P5CYC_@'+(,DIQ ]9S"B(J5*K6KN&]54M@BE*Y*\J'
M?B3_#ID$I<P6>1N8Q"ANO9X:<2_ZM!<SV@MTHZ(A33'_P,G;(L5+-<PR2V2H
M"UM577'K\V#A(PIE1N5\V-TO(?T^S.E$[[,DL%KHS"6;+<WOA(&&5?7#/9[Q
M3JT\JOK37-6Z9W]X9M<Q/Y=XW!WW=6J][]1!-T 4+KKK/R+FH8I;-(4S<(Y<
MG[VP8\9=HGHG^P0H#(BZ9GC0>\B4IVBTO<GG['P>8K5[TEYZA"N,U2K&H#B8
M2-':%>10D19?I:T!"[%2,G-&']X<LOBJWF0J,8KJ1AZB3,OJV80J[ Z0!5I7
MFX2PM*8L:(NVV)_QGWT6)0\:2K0ONQXP:A/\0T5?ANR5[O7ZNX-O=A)F$?G5
M*0!<][*8XE[W(JO@N5A<B=1?ILPA+4,?Y:0]>/H =Y2B25 I&GJS,9$<B&^*
M16\L%JZ8_, ;<>TIE)F0G*\J'NI3^0L\*$@J>]\$K1X1"ZG^V,"@T'S-RR1R
MTDOP.E9Y04WPO.E&I#HR,'$\'[@*'V]NY3EUJ18OH?[8$N[^A8[M$1_<(SZZ
M1W)XC^3X?C$E!&H  6UG<_$HX/<E$FGS=M23$.6B[;FI?F:G)E278%"^(AU"
MPHUP).Z9J?GI6P8/[3IUIN<F9U)OJN@DV=0)"J*$AF(5/:"5UR490-!CR OV
MDUMS/E'!$GC+J>Q:6ZC36ZSQZTGA72R"5<"%PA\Y4QP;=PD7E,_',,Y3JVH
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M+T&M+U5S,B7''0O#^XO+VPNRE_ M-2:P#:(@(@JT(ZYM>\2X;)Y@$&;K\=;
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M]X@2#@G,,JB^3_A$% =FQ^NA"3/"NZ$M" 7?K)0#)EKLA5'PE5@IE:! HJ#
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MW>7%7T[?7)2JA(D5G(*D5'-M08MYEE[(6J"(B@J9@:%_]7!W&(R?4ZQ)C,O
M&\R> <N&@\W9VDI^U?6@.'1:>6^^*)5CQ&XR,G:QX1]K1<1I2=:V=/UZ#8_5
M-DL4UNR#7)>V*4-Z$WD8!\,FG,/EWU=B<$@#/*@3-1IE,N"DL"*/Z$U[M4RB
M;:-^E,1:7'351ZQJ"V65"Y06JLY2G1QW&(.>E=SVS*JS;#6]4::"FW"-3N8H
MT.7H.!Q9^W)*5R/;D-$F53 .<&QP8%N ?)90V-[6;&WD7#TWU;&9_%Z-'HYZ
M_6*<[G1F?5*QTOK NQZ@U!AA*O5$]VP\VOEKB>/<,@REQ(75X_+ X>>H2&?3
M(KE36:D7DMD[QXW[\EQ7O B*=6=4?1>\@O(U!\2SG9:E="6%VP8E--/7F.?_
MAB9LG60RSU=?O662WU-Z9T:W%WY<MD()UG.!-K_8&97&_*'WK3PX$GD-:C[5
M 2LN'L4]&GO6KM,5%6MAZ1.5-ARI?]VZ-7O$(!;,[!;88=6">"K'ET^=A;=8
MWU#5_/9V:[_0JUV&+#(B&SSV9[B)R.VDT^?.A>2?_6(C7M*^;3CIC W/?:KG
M=$U+).8J]8!EZ'M4?6FK2J#Z@A%KG!9?DM54]!1GRBP0&Z&82$9J3>Z22GTO
M'>]C ,=CO48C]DT^_P3_G+ZOSVS0*3@EZWME.RWSZ7&MYZK&7Z7CG'>F%=@>
M-#M$Y(N"0&CTGK6++*IV2!206!"<Q ]PZ[B>J)ZF1F]0?0HO5D%*>:);5B;$
MC9\%C!4N0+"V7+/4V@0&:O7%4&*!NZ UM. G4YX_]69.<5B<?VS:I>L=F#JM
MF$741:NTM<6<++T,.*S)"L5KH-1"$PIK5N>:TQ8_T:7#@6OE0 D*Z$H"L:!8
M]?>H^S5J0Q;=K[:VO87MZ12H,/DY->9%&^5/C+Z^@;(@&05S1G6<GRQ*78B6
M$UV%80KY!@.AU)O.?#I6@"P7@H[OJBZ)O4X=Y=98?YM8>C8+L$^58==2X_\W
M5&S9]8Q#HZI!)\N]MM4*?[11I>U\BX0K!RI"1O03#^F4*H#?APR$"$+0218$
MB#90"W[+BX_'S0*XTB&.-O4FOWWLD/:6O"R$WY0/T!-A[&4K"!\O@&I<J^*I
M)9@-YXQ8UWWSK:; %I#[5+O,,#6  \SJU],&9>GH:T8G\(#$*CTR\[/&S@(0
M >"H.,B<X(;T096EPD.UV/,^5P-PE1\Z60TWL^)U4G?=YIC,%U?^XJO-SQJY
M5CW#4AP*^+4RN[)(:FYOMF^ZPU="1^B*/_MDK>M]JTG\:7+1OL0DN=< $U68
MEV!5-7O)W=UNVC<Q<A[UBZ4(C_K36I63'0MK_QO5& :&P#"=65PR7O'F-(ET
M*1S.=6A%;.Y<&'-(RB:/G;O%E*S6M6%@#(=0=_,9\"9+<--4K(BP^EME#=2:
MPF\2-4/Q)]NRY;&9N^S<+XOG6("UN]C/;AVP0/@VA];VF/IA58'7=MO>WMK.
MZP4N%Q6NRU"YNTK?X%$Y4[GVBRT.URP+T&Z>>>9M[X.?P:";=#OK81'SC3</
MEC=>/?*H3:"]'Z[E?@SN&44) Q4P@M269]@DPKTO@W21A'-T'P"5/O'.VMOI
M:]0-RR^_@25=A($KQ>_;?<XV8.4BM;UVN&[5NP^\]L;$C]]8E[N%)W8EPWK%
ML/4O15PH/(O$% LCQL@K!>"M7  *]XDAZ1*1 L4AATFV>+7.)8(/Y[!"/<T7
M6PFFA=[E2<98-7I'K*5L<WKN-Q\-6FVO%1Z+5,A; 4^2:M1FQS6P]$?4U99A
MRH+.(TIIHN0A-UL$/T,;X;&S_UP&7A?"5GJ+BA3=TBN%=WR%ZZW\1#]X2W_M
M(Q:M122B-9!K )E7Q/T_'MMOBBXC% 5?Q(@ ]S,UT'(?_<%"H3*X62PZ-M%F
MR0JASQ9=1TK46#P +PP(4%=E>RQ ,FSCM18N*6(!]@)781%8,0P\P++.2Y#M
MHI4 O8>;@/Q-<<)#2Q5TQBMT2^@K6-4=24G?97I>O#04M&^[]I0$"!N+,KXJ
MF"*-@I"$4:]  13.Q_CJ&*D0;8T,9R\RQP9($A,>-@N4K0C00A,7XXQ2 314
M)Y]3%3. ;3BGO$9NCZKD_)_HR/#IO).9X: SCKC5IT&M*V7JF.@"V!6)6532
M@Y$)A$+I:%@!N;96(D>B;2*!@0Z"R"#!_(C.0]&)"0JFZ'[M>(4[!U]4?MLK
MGHYUB12Q)H#1D; 9PMWQ1Y@CB+9YEBX>$$#9>[^>_^*UW >.6<^EO$1[;PD;
M1PXX!75$OX+$2@PFP0@,X$($(92I:B'O$C)%W)S>*%_'+48'161D]][#MTN\
MU,4E +]?P16'3!:.PCU?84"<,M.VI!C">5A3RDC9?U 5??+YC[ V(JAB:S(T
M!ZF >,-YGM"!4P>! X'?8=S# T-2!PEN"';"S\)=(*N/E1.I>J8WZG79?$$<
M;?PS_LT/.25]":B/;B,3<TMYTE@*G<?SP<?8X<&H ZW#V1;')R\C#!V-"7AU
M$#HK[&:PS%>28FCA)I3VWM[98$5!0<E6[R2;4/2&%[:S)=Z(8QB;;68\W7"L
MOSRF?!:G/]*VRY\_I)B&"E0J(0!6V,(O:"8Y@^.>F9U7NZ!.%,[Z+2A/Z8/W
M6?(8/\3+8.4&+L_LYQ;4(EPX&(+A+L,/*0F[*$I2-FW=8E!0A+N #QRA%Y#Z
M112E<C1I)&Y49.WB.]-[T1F[P'@<W[OI7'<N.^J8O0VY (VL*JS?AW#E1\[-
MA,_QRU&1O"OI5R*$W-Z)?:A.?_=O_5'_9[C25LLX08RM>U8;>!#%OM\35/Y>
M76/XH#H!VFFJU@P_X;:VUH$(>&=5(GR_>^ Q.CU8SI.!$?B?EKL+PA^%IV&,
M4HA6M0NWDKS:4* G05>23S[_D6.3&E@;(MX2/HNOT;QP,)\C^O:/,.=EO);5
M3&5#2.U^C+\&58^V/G?^V#G><W=*9$XOD<0A$9PVO;>;"=PIQ#[;/0UE1_!)
M0&#+W)+C*25L@([HBKWT*D(0IU<UNQ_,O#A0D.2O-K<ID8HB0?#B<>USD)/7
M(84REAB-O1K,K;1IR=[V-YT_=YZYR^73CI_^XM_G7#/Y@8LEI(4=?POB7.EF
MJ]GA,GZ5)9&;+;#3<Z&SMU;&^I7%Y,A&$T9%NK%VJ6%TS@[Q]HB>@4HS[U)(
MLN==OEH5J.E]L Q@X:Z!+C FX.KRK$;6>3Z?:[S"JIE>M3C1[_6]\7C"XL0/
M^%NC(%&0^0K2A)$)!J.V0%8$7PE)I/DP&LY;8J[678?\]7"6N8L[FGW[+^:-
M=<S";(H"$+0X^LPYVBWK(#YWR*]]T*WQ-VXTBZ+]KAX'-<AW'$=?:.HR#]&B
M\3,=[T]YZ-WZZX*:HO9W!,S[_V_O6Y_;QK%\_Q76W,P=>8OVB!3U2M?=*L5Q
MTIX;.U[;Z=[9J?U 2[2CB21J12EN=_4??W$>>!$ 1=GNV=U;^R&.S0<  @<'
MY_D[_R&>V.9+^<4T T);O1"4GA=0+/UQMEO-\V]P>-\50EV^EY^!T">Y8=UE
M7'?8'SMQ).3<E'JV-H_2JZTN@[R45U4^_;H#6P,;%WADN+\!;U7%IE+B-_$
MPUP,)KMYJ<N5HN[+\.(?\H70]DY))Y],&1X!\<87^:.Y5I7:K)5T)6)2RZ:
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M*A]7$JJB/A]QPSX6*WFUYVOJ@W:F&S$7 )8#8^#IT\$Y*UCLCX(O;K].X0F
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M9OA*LC!H&8-SP(,':LUU\7U>/-I*64-#\DA1/%&ES^'J2>Z(WP7?2"*84+A
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M4-(C"XUPFV/I4;:_AQF@0DXH!4*V1;DL9]((!TL-FY#,Y=_G&\Q;7$G4:KK
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M]2*9\V4BEX_LL&W1"HN^4^!R.HCCH03/!Q*T!(BLH<0.NP9$O18>+$^\BM/
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M"4/*L?5@&1/4VRG;&M0N[N&(C%(IG9X\$2BRA$F#['DF)*IW'=!$)S'^P/>
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M&119N+0VG@$7^5VYON>X=9TVR*S%6+4.'S#776$B^Z(E@:I=MPE2I8_^G(M
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M@-H:* /H/-^F9%CH)5WUBQ.56RGUWYZ^YH_?3'QIEQ!U2.5ROA #AQ0\#DR
M:><V'(:VOM^43 S.>U6T!/0S\?;4(HAUOMFN?)RGN<";0SN; J,-]A6&\YB-
M R_\%LG%U)7VG,EL46JM33MM=W4HIO9E*5D6XGYC2M9E^5T5]0JE9$E<?B#!
M\'@;HQ5*K.>D);E:K'+T]U+(<Q&XH7>N^?#S;J,AR>MOV@=M,P.J!3T+^O6F
M1=4!8._R2G0DK2^>\_#<BE+>$X=-*.OZ@Z8E0.XN,95* :U#M(LW3;/O554U
MBN]>1/"S0 RU\Y4V9*I?X*%@DF@02,4,('/N&6$+=,']C02TB1:=6U6P?\HW
M<P;080']#$AG_IRX8IM*FEH.)=O:+=S-2V-:P8*8K^!UK*J=XT%+)UPA*U?M
M5I;%^+L<@D((*7@(SOX55[F84LNBCN\V^:]SQVY,5Y7&6%64/C!71<'42!!.
MM%B1 *F;^7-5;?_Y_P%02P,$%     @ DX%63]6SWG9X @  O@T   T   !X
M;"]S='EL97,N>&ULU9?=;ILP%,=?Q7*FJ96F ,F2M"L@;94J3=JF2LW%[BH'
M#%CR!S,F2WJYM]EK[4EF8P()6](EBZ9Q$X[/L?_G9WP@![]0:XH?,HP56#'*
MBP!F2N5O'*>(,LQ0,10YYCJ2",F0TD.9.D4N,8H+LXA19^2Z4X<APF'H\Y+=
M,56 2)1<!7#6N(!=?RMB',#'BY=?2J%N7@![';P:#-RA^WAYTXU<U*%+"*S.
M^SB WO0U=/Y<>*]L1W2R1[2EVT,S/89FZ![:9U=Z=J3T0>VN^-6QXH?5N_+7
MS\C_^/9][_FWL=_?\YEKQ)VZW$(_$;RMNC&T#IT=,0R6B ;P%E&RD,2L2A C
M=&W=(^.(!!42*%WNFLXSGN+)ACT[,D]"K<,(%[+*;3/8WT4]O1/8C P@H;0!
M'$'K"/T<*84EO].#:G+E_"4$:GN^SC5A*M':&TU@NZ"ZZ"0+(6,LFS0>W+A"
MG^+$X$B29N:J1.Z8H%*":2,F*!4<50R;%;6A92-,Z8-Y37Q.=K17";!SS)&X
M$!B*C:EW79OMJ=DSVU:SVMNRXY-T04Z60KTK]79X-3:E@^\E3LBJ&J^2!D"K
MHSRGZ[>4I)QANYEG$WHG)@Q]M,D#,B')D]8SI1)I!Y80++%4)-KV?)4HG^.5
MVI33*CF5>=1#YG/?YQ1S+!'=AM:U_S_?Y7],/)[]/7+U5ND"GY'1_.'W '+2
M!\AI'R![49-7?8"\[@'D[ QOS8.03MUE;+4R.XU,XP6+DE!%>(V;D3C&EL=T
MD@'\9-I8NM-.M/V,EE=HH3^F=O3UVA@GJ*3JWFRQ"@:PM3\8<&_:S)HW$@%L
M[8\X)B6K.FJG_6(+?P)02P,$%     @ DX%63V]+9@(#!@  XC8   \   !X
M;"]W;W)K8F]O:RYX;6S%FUN/VC@4@/^*Q5-7VBZ0*ZTZE::E[8[4;M$PZNO*
M)&:PZMBL[<R4_OK:H0QV:X[VY< 3Q.3RX9CS'1^'5X]*?UTI]95\ZX0T5Z.-
MM=N7X[%I-JRCYB^U9=)]LE:ZH]9MZONQV6I&6[-AS'9BG$TFU;BC7(Y>OSJ<
M:Z''X8:RK+%<2=?H&[YP]FB.G_M-0MT.#^R.KJY&DQ&AO57ON;!,SZEE'[3J
MMUS>7XVF([+FVMBEO_:P9\<E[_AWU@Y;9J,>_U::?U?24K%LM!)B.,I_,!SD
MKF">6KXP;7D3[6CIZI8ZUJM1-7$G?."&K[C@=G<U&MX+-G+?8AQ\C:$?#J_[
M3GRI_T\WJO6:-VRNFKYCTN[[43/AKR[-AF_-B$C:L:O16_7 -%G0>^:QW55N
MVOU7L*YSCEQ$O^3N WW33CTC)H]LF32L)>Z=48*WCJ,E2X_C#@T@,P RNR#D
MOUD F0.0^44@WU!!9<-( %D D,4%(:.>+ '(\I*W.P\@*P"RNB1D$4#6 &2-
M"[GLNX[J'5%KLN3WDKO#J+3DNFE4+RT/(&< Y P7\KKYKW?7'-H#HA< T0M<
MHKG3E['<]IH9$FZ$,7L"!>T)+N M>V"R=W"'-R$8:!-DG=Q(QV.5WH5 D#FF
MR.JX<<F#O/<7)=?&.+D3*EOR0:GVD0L14D+JF"*[XSWEFGRAHF?D$Z/&#35_
M0'17(6E,D:WQGDNG!TX%N9'&ZOXW.$@64V1;S)GF#]1GG*?H($M,D37A$N:M
MRTQW?Y*%\*'7C[YW+MYM_7%D$6)"GI@BB^*C&W5Q%(&$,$4V@N\@&X402 93
M9!N\HUJZ&8LA[D:2Y8;J,'7/( UDR!H88)ZOJ,]"%G3WZ\#/(!-DZ"9H5,?(
M'?T6C:L,G$8@R^"SW;A;&.5KQ]"VM"$F9(,,?28A!%TIO0]J/F+LP6_W.X>8
MD!4R9"MXUQL[##K"I=.7YM1[UBF7Q;E2!ODA0_;#1Y=9W@_-(1'DA S9"6!6
M'DW",L@)V?DF#X9MJ1N.3.P(=[,>ZY!IB G)(D.6Q5,N_.S.#S_S1P@&>2-#
M]L93+IPBRR%OY,C>@)/BL%210PK)D15R(BL^=&>("5DE1[9*,CM.WG.P.H4L
ME72:G,2$I)(C2V6?B":Q((GDR!)QL;GO>C&D#(<LHMMJMF'2N"X-,2&SY,AF
M^3U53?8D9)4<VRI#SOHFREF3D)!3<F2GA,EK$@[R2H[L%3"+C=*' I),@2P9
M,(N-,2')%,B2@9.QL-A<0)(ID"7SIC=<,F-(4"TES^;,4BZBH5E DBF0)0-2
MDKL0$UP$099,5-\]XK%OMJ<BZDS(.06R<YX2V]6.++1J^\:F[SADG +9.+?,
M,.UZD[BCR9R;86%AGT]>"Q'.50O(.@6R=4#,.!A!WBG.-9=9:]61:S?1>OYV
MGDW(G0N<=!NF&05DH.(L!CI.O!*#LH344YYK>03Z;9>0=<ISK9.D.P\R38F^
M8O(K6K+W(,V4V'.98_SVWIXSZ13^E7RBLE_3)JSCE9!F2O0"&3#-CA?;P=5V
M9,_ F&$&5$*F*9%-<[(:L!^E(29DFA+9-"!F?-,ATY3(IH$QHYL.F:9$-@V,
M&3YE44'"J9"%<Z($E CM%62="KN@!F*&=;\*,E!UF8+:'C/Z"560A2KL17L0
M,WI,";)0=8G%^R?,Z"<$6:A"ME :\ZDUQ 2?^D*VT*DRZL_?4(@)6:A"MA#\
MV,&S$!.R4(5LH4.U-Q4H(>U4R-KYA2N5 ->0;^IS+/R["=BVU\WF9!?6D&MJ
M9-> %?,HB->0:VIDU]RR1E!CAK+?4*U2O?5SBI_X(2;DFAK9-:G"?NJ.0Z*I
MD463KNRG*"'/U,B> 2G)-,2$/%,C>R9>@4AU(OA8,;)>DG3)* G9I4:V"[Q0
M$B9H-22;^J+K.6&"-H.<,[OH>D[8FS/(.S/T/[1 F%%O0MZ9G:'*=O+AJ4B/
M,\@[,V3O'!^>2@:A&>2;V>";\;"S>?VJ96LN6?N/.Z]Q[0T5S4(3_^+/-,V*
MTC_EN>Z%>.O:/LN/BOKVX1R'OY>]_@%02P,$%     @ DX%63YOUMHB7 @
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MWIZOMP=Z>[[> >@=^'H'H'?@ZQV WH&O=P!Z![[> >@=5GA7B5Y6\O4.0._
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M 5!+ 0(4 Q0    ( ).!5D\?(\\#P    !,"   +              "  0
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ).!5D\GZ(<.@@   +$    0
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M965T,RYX;6Q02P$"% ,4    " "3@59/PE(/_-L$   J&   &
M    @ '@%0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MDX%63_2-N73) 0  : 0  !@              ( !\1H  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ).!5D\ZAQR8/@4  $,:   8
M          "  ? <  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " "3@59/*13[*^(*  #K1@  &               @ %D(@  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ DX%63X'UE$NU 0  T@,
M !@              ( !?"T  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( ).!5D].X<2$M0$  -(#   8              "  6<O  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "3@59/D$T"S[8!
M  #2 P  &0              @ %2,0  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( ).!5D]@D#4%M@$  -(#   9              "
M 3\S  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ DX%6
M3SS\&F&U 0  T@,  !D              ( !+#4  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " "3@59/16V 3[8!  #2 P  &0
M        @ $8-P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( ).!5D\9#A. LP$  -(#   9              "  04Y  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ DX%63Y"NL*^U 0  T@,
M !D              ( ![SH  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " "3@59/=M->F[4!  #2 P  &0              @ ';/
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ).!5D^ZFJ.$
MM@$  -(#   9              "  <<^  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ DX%63W\!9$.T 0  T@,  !D
M ( !M$   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "3
M@59/@FXTS[0!  #2 P  &0              @ &?0@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ).!5D]P&L)5LP$  -(#   9
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M970R-"YX;6Q02P$"% ,4    " "3@59//3S^_;4!  #2 P  &0
M    @ $;3@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M ).!5D_$Q,A#M0$  -(#   9              "  0=0  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ DX%63]N3_@WT 0  RP4  !D
M             ( !\U$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " "3@59/F3>\5+,!  #2 P  &0              @ $>5   >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ).!5D^Y];&5\ $
M &4%   9              "  0A6  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ DX%63_XT)SFW 0  T@,  !D              ( !
M+U@  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "3@59/
M!B "WM$!  "<!   &0              @ $=6@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ).!5D^ZIQ40TP$  )P$   9
M      "  25<  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ DX%63T4MWW/; 0   04  !D              ( !+UX  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "3@59/O4\4SMP!   !!0
M&0              @ %!8   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( ).!5D_,3(F>^0$  ,L%   9              "  51B  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ DX%63]!J(EO%
M 0  -P0  !D              ( !A&0  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " "3@59/Q2^V_+<!  #2 P  &0
M@ & 9@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ).!
M5D^09Q/=P@$  #<$   9              "  6YH  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ DX%63P..1D.T 0  T@,  !D
M         ( !9VH  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    " "3@59/?"X:,=(!  ";!   &0              @ %2;   >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ).!5D]2UQG3PP$  #<$
M   9              "  5MN  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ DX%63T;HV%PL @  F08  !D              ( !57
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "3@59/7J'E
MA$L"  "!!P  &0              @ &X<@  >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+ 0(4 Q0    ( ).!5D^1,FK%Q (  ,P*   9
M  "  3IU  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
MDX%63[.;)F*Q @  @@D  !D              ( !-7@  'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " "3@59/+*O94=<(  #9.@  &0
M            @ $=>P  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( ).!5D^J.&B=60,  .$.   9              "  2N$  !X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ DX%63T-IK?7J 0
M,@4  !D              ( !NX<  'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " "3@59/TD'?6; "   P"0  &0              @ '<
MB0  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ).!5D\T
M!L55, ,  !P-   9              "  <.,  !X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ DX%63\KWP47; @  %@L  !D
M     ( !*I   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ).!5D^@-U,Q)0(  !H&   9              "
M <V@  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ DX%6
M3R6C8M4(!@  J"<  !D              ( !*:,  'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    " "3@59/;G7FR,D"   '"P  &0
M        @ %HJ0  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( ).!5D_E7F[YL@(  &H)   9              "  6BL  !X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ DX%63TMKTL(F P  L0T
M !D              ( !4:\  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    " "3@59/;N,]$5,"   @"   &0              @ &NL@
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ).!5D^Z"P7U
MJ00  $T9   9              "  3BU  !X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ DX%63Y-FA$YH @  O0<  !D
M ( !&+H  'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "3
M@59/';"4N6 "   Z!P  &0              @ &WO   >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( ).!5D_)D<"6U@$  &\$   9
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M970V.2YX;6Q02P$"% ,4    " "3@59/[A)Z<!T"  #V!@  &0
M    @ 'VTP  >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (
M ).!5D\&WV&/-@,  &$-   9              "  4K6  !X;"]W;W)K<VAE
M971S+W-H965T-S$N>&UL4$L! A0#%     @ DX%63VOAK398!@  9"@  !D
M             ( !M]D  'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"
M% ,4    " "3@59/2_1N9MT#  #H$0  &0              @ %&X   >&PO
M=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( ).!5D_F 8SN, ,
M /P-   9              "  5KD  !X;"]W;W)K<VAE971S+W-H965T-S0N
M>&UL4$L! A0#%     @ DX%63ZXY.PE! P  ) T  !D              ( !
MP><  'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " "3@59/
MS#7'6?T#   L$P  &0              @ $YZP  >&PO=V]R:W-H965T<R]S
M:&5E=#<V+GAM;%!+ 0(4 Q0    ( ).!5D\R#Z:F-@,  ((/   9
M      "  6WO  !X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%
M  @ DX%63Q3$1H6\ @  _0D  !D              ( !VO(  'AL+W=O<FMS
M:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " "3@59/E@.I[TH$  !'%
M&0              @ '-]0  >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+
M 0(4 Q0    ( ).!5D^LP29#T $  &0$   9              "  4[Z  !X
M;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ DX%63]";I>N6
M P  M@\  !D              ( !5?P  'AL+W=O<FMS:&5E=',O<VAE970X
M,2YX;6Q02P$"% ,4    " "3@59/>5>3=(@$  !0%@  &0
M@ $B  $ >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( ).!
M5D]4.D0-L@$  -,#   9              "  >$$ 0!X;"]W;W)K<VAE971S
M+W-H965T.#,N>&UL4$L! A0#%     @ DX%63T:(GJS) 0  % 0  !D
M         ( !R@8! 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4
M    " "3@59/Y!RH.(6^  #=(0, %               @ '*" $ >&PO<VAA
M<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "3@59/U;/>=G@"  "^#0  #0
M            @ &!QP$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ).!5D]O
M2V8" P8  .(V   /              "  23* 0!X;"]W;W)K8F]O:RYX;6Q0
M2P$"% ,4    " "3@59/F_6VB)<"   A,@  &@              @ %4T $
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "3@59/I@Y<
MJS "  "Z,   $P              @ $CTP$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     70!= 'T9  "$U0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855119984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>65.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>116.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>83.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>182.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(29.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(21.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>145.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>112.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>37.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>104.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>96.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NST stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>182.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6851789584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and Goodwill<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:21%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>543.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(542.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>543.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(542.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-28&#160;years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,005.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2,764.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>240.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,005.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2,734.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>270.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>954.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>954.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,638.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1,506.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,132.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,638.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,330.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,308.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8,206.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4,813.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,392.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,727.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,607.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,120.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairment of acquired intangible assets totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$283.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$422.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$281.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$493.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the impact of a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$215.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge related to certain IPR&amp;D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis (IPF), which was discontinued during the third quarter of 2019, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the impact of impairment charges related to certain IPR&amp;D assets associated with our vixotrigine (BIIB074) program totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$189.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as discussed below. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets, excluding impairment charges, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$68.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$206.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$92.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$303.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in amortization of acquired intangible assets, excluding impairment charges, was primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This decrease was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$236.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of NST on June 7, 2019, we acquired IPR&amp;D programs with an estimated fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$700.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">BG00011</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns. As a result, we recognized an impairment charge of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$215.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2019 to reduce the fair value of the IPR&amp;D intangible asset to zero. We also adjusted the value of our contingent consideration obligations related to this asset resulting in a gain of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$61.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in the third quarter of&#160;2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed the Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR. As a result, we recognized an impairment charge of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the IPR&amp;D intangible asset to zero.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of trigeminal neuralgia (TGN) as we awaited the outcome of ongoing interactions with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy. We reassessed the fair value of the TGN program using reduced expected lifetime revenues, higher expected clinical development costs and a lower cumulative probability of success. As a result of that assessment, we recognized an impairment charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$129.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the TGN IPR&amp;D intangible asset to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> at that date. We also adjusted the value of our contingent consideration obligations related to the TGN program to reflect the lower cumulative probabilities of success resulting in a gain of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$89.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in the third quarter of&#160;2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The IPR&amp;D impairment charges were included in amortization of acquired intangible assets and the gain resulting from the remeasurement of our contingent consideration obligation was recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. The fair values of the intangible assets and contingent consideration obligations were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. Acquired and in-licensed rights and patents also includes our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,889.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and the net book value of the TECFIDERA asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our TECFIDERA license rights, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the second quarter of 2019. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining three months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>65.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>255.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>210.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,706.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase in goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>112.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(69.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,746.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was related to our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative fair value of our Hiller&#248;d, Denmark manufacturing operations. In connection with the divestiture of our Hiller&#248;d, Denmark manufacturing operations, our remaining goodwill was reviewed for impairment, and based upon this review, no impairments were recognized. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</span></div>Other includes changes related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855090384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,555.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,797.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depreciation expense totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$145.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$64.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$194.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51,000 square feet of administrative space. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.6 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$63.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding related to the construction of this facility.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$631.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of property, plant and equipment, which was primarily comprised of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$312.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for buildings and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$287.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for machinery and equipment. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6844297120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 47.8<span></span>
</td>
<td class="nump">$ 40.4<span></span>
</td>
<td class="nump">$ 151.8<span></span>
</td>
<td class="nump">$ 128.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
<td class="nump">182.0<span></span>
</td>
<td class="nump">143.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="num">(9.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">47.9<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
<td class="nump">174.2<span></span>
</td>
<td class="nump">133.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">24.8<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">37.9<span></span>
</td>
<td class="nump">29.9<span></span>
</td>
<td class="nump">104.4<span></span>
</td>
<td class="nump">96.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | NST stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6863703920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,448.8<span></span>
</td>
<td class="nump">$ 3,529.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairments</a></td>
<td class="nump">567.6<span></span>
</td>
<td class="nump">686.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">143.9<span></span>
</td>
<td class="nump">119.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="nump">66.3<span></span>
</td>
<td class="nump">91.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">95.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">28.4<span></span>
</td>
<td class="num">(44.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Unrealized (gain) loss on strategic investments</a></td>
<td class="nump">189.8<span></span>
</td>
<td class="nump">136.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss on equity method investment</a></td>
<td class="nump">63.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">87.4<span></span>
</td>
<td class="nump">68.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2.4)<span></span>
</td>
<td class="num">(254.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(47.3)<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">109.1<span></span>
</td>
<td class="num">(100.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">64.6<span></span>
</td>
<td class="nump">315.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(61.0)<span></span>
</td>
<td class="num">(81.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">5,118.4<span></span>
</td>
<td class="nump">4,292.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">3,867.6<span></span>
</td>
<td class="nump">7,994.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(4,052.1)<span></span>
</td>
<td class="num">(6,093.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration paid related to Fumapharm AG acquisition</a></td>
<td class="num">(300.0)<span></span>
</td>
<td class="num">(1,200.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Nightstar Therapeutics plc, net of cash acquired</a></td>
<td class="num">(744.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from Sale of Property, Plant, and Equipment</a></td>
<td class="nump">923.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(404.1)<span></span>
</td>
<td class="num">(544.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(112.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchase of Ionis Pharmaceuticals, Inc. stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(462.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">476.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(237.9)<span></span>
</td>
<td class="num">(421.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(3,775.2)<span></span>
</td>
<td class="num">(3,000.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(16.9)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-term Debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Net distribution to noncontrolling interest</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="num">(36.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">43.8<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(3,744.0)<span></span>
</td>
<td class="num">(3,035.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">1,136.5<span></span>
</td>
<td class="nump">836.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,224.6<span></span>
</td>
<td class="nump">1,573.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 2,343.9<span></span>
</td>
<td class="nump">$ 2,386.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6874363152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (240,400,000)<span></span>
</td>
<td class="num">$ (318,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">$ (92,300,000)<span></span>
</td>
<td class="num">$ (248,300,000)<span></span>
</td>
<td class="num">(92,300,000)<span></span>
</td>
<td class="num">(318,400,000)<span></span>
</td>
<td class="num">$ (316,900,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,700,000<span></span>
</td>
<td class="nump">11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,600,000)<span></span>
</td>
<td class="nump">56,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">160,600,000<span></span>
</td>
<td class="nump">13,300,000<span></span>
</td>
<td class="nump">147,700,000<span></span>
</td>
<td class="nump">68,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(92,300,000)<span></span>
</td>
<td class="num">(248,300,000)<span></span>
</td>
<td class="num">(92,300,000)<span></span>
</td>
<td class="num">(248,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">160,600,000<span></span>
</td>
<td class="nump">13,300,000<span></span>
</td>
<td class="nump">148,100,000<span></span>
</td>
<td class="nump">68,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000,000.0)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="num">(1,900,000)<span></span>
</td>
<td class="num">(4,000,000.0)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
<td class="num">(7,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300,000<span></span>
</td>
<td class="num">(1,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="num">(1,900,000)<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="num">(1,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,700,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">72,800,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">34,700,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,800,000<span></span>
</td>
<td class="nump">58,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,700,000)<span></span>
</td>
<td class="nump">50,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,100,000<span></span>
</td>
<td class="nump">109,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">72,800,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">72,800,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">50,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,600,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">50,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,300,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(29,800,000)<span></span>
</td>
<td class="num">(36,600,000)<span></span>
</td>
<td class="num">(31,300,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(29,800,000)<span></span>
</td>
<td class="num">(36,600,000)<span></span>
</td>
<td class="num">(29,800,000)<span></span>
</td>
<td class="num">(36,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(243,300,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(192,000,000.0)<span></span>
</td>
<td class="num">(214,300,000)<span></span>
</td>
<td class="num">(243,300,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,300,000<span></span>
</td>
<td class="num">(38,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,300,000<span></span>
</td>
<td class="num">(38,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (192,000,000.0)<span></span>
</td>
<td class="num">$ (214,300,000)<span></span>
</td>
<td class="num">$ (192,000,000.0)<span></span>
</td>
<td class="num">$ (214,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6857187600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
<td class="nump">$ 9,926.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">430.0<span></span>
</td>
<td class="nump">460.8<span></span>
</td>
<td class="nump">1,508.3<span></span>
</td>
<td class="nump">1,327.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">540.4<span></span>
</td>
<td class="nump">507.9<span></span>
</td>
<td class="nump">1,588.9<span></span>
</td>
<td class="nump">1,985.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">554.5<span></span>
</td>
<td class="nump">497.7<span></span>
</td>
<td class="nump">1,709.8<span></span>
</td>
<td class="nump">1,515.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">283.9<span></span>
</td>
<td class="nump">281.9<span></span>
</td>
<td class="nump">422.2<span></span>
</td>
<td class="nump">493.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">60.2<span></span>
</td>
<td class="nump">47.5<span></span>
</td>
<td class="nump">181.8<span></span>
</td>
<td class="nump">129.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="num">(17.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(57.8)<span></span>
</td>
<td class="num">(87.9)<span></span>
</td>
<td class="num">(66.3)<span></span>
</td>
<td class="num">(91.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">1,793.8<span></span>
</td>
<td class="nump">1,741.4<span></span>
</td>
<td class="nump">5,441.7<span></span>
</td>
<td class="nump">5,481.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,806.3<span></span>
</td>
<td class="nump">1,697.6<span></span>
</td>
<td class="nump">5,264.9<span></span>
</td>
<td class="nump">4,445.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(27.3)<span></span>
</td>
<td class="nump">115.1<span></span>
</td>
<td class="nump">132.6<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">1,779.0<span></span>
</td>
<td class="nump">1,812.7<span></span>
</td>
<td class="nump">5,397.5<span></span>
</td>
<td class="nump">4,485.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">211.3<span></span>
</td>
<td class="nump">369.8<span></span>
</td>
<td class="nump">881.9<span></span>
</td>
<td class="nump">956.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">66.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,545.9<span></span>
</td>
<td class="nump">1,442.9<span></span>
</td>
<td class="nump">4,448.8<span></span>
</td>
<td class="nump">3,529.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">45.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 1,444.4<span></span>
</td>
<td class="nump">$ 4,448.8<span></span>
</td>
<td class="nump">$ 3,483.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 23.38<span></span>
</td>
<td class="nump">$ 16.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 8.39<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="nump">$ 23.35<span></span>
</td>
<td class="nump">$ 16.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">201.4<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">206.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
<td class="nump">190.5<span></span>
</td>
<td class="nump">207.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,894.7<span></span>
</td>
<td class="nump">$ 2,780.1<span></span>
</td>
<td class="nump">$ 8,455.0<span></span>
</td>
<td class="nump">$ 8,061.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">595.8<span></span>
</td>
<td class="nump">511.7<span></span>
</td>
<td class="nump">1,689.6<span></span>
</td>
<td class="nump">1,445.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 109.6<span></span>
</td>
<td class="nump">$ 147.2<span></span>
</td>
<td class="nump">$ 562.0<span></span>
</td>
<td class="nump">$ 420.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6861956176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (63.5)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="nump">$ 21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">66.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">60.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.5<span></span>
</td>
<td class="nump">181.8<span></span>
</td>
<td class="nump">129.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
<td class="nump">$ 9,926.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="nump">$ 21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of basis differences</a></td>
<td class="nump">21.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="nump">572.8<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 572.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 687.3<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">60.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.7<span></span>
</td>
<td class="nump">$ 181.6<span></span>
</td>
<td class="nump">$ 131.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.1<span></span>
</td>
<td class="nump">$ 89.9<span></span>
</td>
<td class="nump">$ 80.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember', window );">Deferred tax liability | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6642397024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="nump">$ 66.3<span></span>
</td>
<td class="nump">$ 91.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">$ (81.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(20.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">401.3<span></span>
</td>
<td class="nump">412.0<span></span>
</td>
<td class="nump">499.9<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">523.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 343.5<span></span>
</td>
<td class="nump">$ 409.8<span></span>
</td>
<td class="nump">$ 412.0<span></span>
</td>
<td class="nump">$ 343.5<span></span>
</td>
<td class="nump">$ 412.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6871583504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
<td class="nump">$ 9,926.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">28.70%<span></span>
</td>
<td class="nump">30.70%<span></span>
</td>
<td class="nump">30.10%<span></span>
</td>
<td class="nump">32.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">18.40%<span></span>
</td>
<td class="nump">19.30%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 109.6<span></span>
</td>
<td class="nump">$ 147.2<span></span>
</td>
<td class="nump">$ 562.0<span></span>
</td>
<td class="nump">$ 420.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other | Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 65.6<span></span>
</td>
<td class="nump">$ 36.5<span></span>
</td>
<td class="nump">$ 306.9<span></span>
</td>
<td class="nump">$ 131.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6874074144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 57.8<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="nump">$ 66.3<span></span>
</td>
<td class="nump">$ 91.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">8,206.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,206.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,727.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,813.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,813.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,607.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,392.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,392.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">283.9<span></span>
</td>
<td class="nump">281.9<span></span>
</td>
<td class="nump">422.2<span></span>
</td>
<td class="nump">493.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Amortizationofintangibleassetsexcludingimpairment', window );">Amortization of intangible assets, excluding impairment</a></td>
<td class="nump">68.0<span></span>
</td>
<td class="nump">92.6<span></span>
</td>
<td class="nump">206.3<span></span>
</td>
<td class="nump">303.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets and Goodwill (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining three months)</a></td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(542.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (542.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(542.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">240.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,764.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,764.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,734.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">236.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,638.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,638.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,638.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,132.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,132.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,506.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,506.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,330.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">1,889.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,889.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">45.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">954.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 954.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">189.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BG00011Member', window );">BG00011</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">61.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BG00011Member', window );">BG00011 | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 215.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_PLSRMember', window );">PLSR [Member] | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN [Member] | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Amortizationofintangibleassetsexcludingimpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of intangible assets, excluding impairment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Amortizationofintangibleassetsexcludingimpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BG00011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BG00011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_PLSRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_PLSRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6861711424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6858523280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LesseeLeaseTableTableTextBlock', window );">Schedule of operating leases</a></td>
<td class="text">The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:<div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:41%;"/><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>422.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>70.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>410.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>481.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Operating lease cost</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:35%;"/><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>62.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(19.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>46.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating lease liability maturity</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining three months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>80.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>71.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>70.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>67.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>148.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>61.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>481.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Minimum lease payments</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>80.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(26.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(25.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(58.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(182.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>418.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div>Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock', window );">Operating lease weighted average remaining term and discount rate</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:83%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock', window );">Operating lease supplemental cash flow disclosure</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>70.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LesseeLeaseTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Lease Table [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LesseeLeaseTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease supplemental cash flow disclosure [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted average remaining term and discount rate [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855111600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:21%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>543.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(542.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>543.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(542.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-28&#160;years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,005.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2,764.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>240.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,005.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2,734.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>270.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>954.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>954.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,638.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1,506.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,132.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,638.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,330.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,308.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8,206.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4,813.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,392.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,727.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,607.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,120.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:<div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining three months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>65.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>255.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>210.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,706.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase in goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>112.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(69.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,746.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>647</ContextCount>
  <ElementCount>485</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>147</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Divestitures Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestitures</Role>
      <ShortName>Divestitures Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Revenues Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenues</Role>
      <ShortName>Revenues Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2129100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2130100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2132100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2133100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2135100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2136100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables</Role>
      <ShortName>Summary of separately identifiable assets acquired and liabilities assumed (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesRevenues</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2323301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2329301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2330301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2332301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2334301 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Business Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetails</Role>
      <ShortName>Business Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Business Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual</Role>
      <ShortName>Business Acquisition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - Divestitures (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDetailsTextual</Role>
      <ShortName>Divestitures (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresDivestitures</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesByProductDetails</Role>
      <ShortName>Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherRevenuesDetails</Role>
      <ShortName>Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesDetailsTextual</Role>
      <ShortName>Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetailsTextual</Role>
      <ShortName>Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Divestiture of Denmark Manufacturing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails</Role>
      <ShortName>Divestiture of Denmark Manufacturing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2421404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2421405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2422406 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2423402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2424401 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/LeasesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesDetailsTextual</Role>
      <ShortName>Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/LeasesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2429402 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2429403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2429404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2430402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2431403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2432402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2432403 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2433403 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2434403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2435401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-2019930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2436401 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="biib-2019930x10q.htm">biib-2019930x10q.htm</File>
    <File>biib-20190930.xsd</File>
    <File>biib-20190930_cal.xml</File>
    <File>biib-20190930_def.xml</File>
    <File>biib-20190930_lab.xml</File>
    <File>biib-20190930_pre.xml</File>
    <File>biib-2019930xex101.htm</File>
    <File>biib-2019930xex311.htm</File>
    <File>biib-2019930xex312.htm</File>
    <File>biib-2019930xex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>acquiredinprocessrd.jpg</File>
    <File>amortacquiredintangible.jpg</File>
    <File>anticd20.jpg</File>
    <File>biogenlogoa05.jpg</File>
    <File>biosimilars.jpg</File>
    <File>collabprofitshare.jpg</File>
    <File>costofsales.jpg</File>
    <File>equitylossofinvestee.jpg</File>
    <File>financialhighlights.jpg</File>
    <File>gainlossfvcontconsider.jpg</File>
    <File>interferon.jpg</File>
    <File>lossondivestiture.jpg</File>
    <File>otherincomeexp.jpg</File>
    <File>otherrevenues.jpg</File>
    <File>rd.jpg</File>
    <File>rdpercentofrev.jpg</File>
    <File>reservesfordisandallow.jpg</File>
    <File>sga.jpg</File>
    <File>spinraza.jpg</File>
    <File>taxprovision.jpg</File>
    <File>tecfidera.jpg</File>
    <File>tysabri.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855116864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>159.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>196.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>421.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>606.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>170.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>751.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>751.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>929.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>751.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019 we sold to Bioverativ hemophilia-related inventory on hand with a cost basis totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$173.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included the sale of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of work in process inventory. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sold to FUJIFILM approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855119984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text">Derivative Instruments<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,943.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,701.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>60.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>131.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>98.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>92.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,096.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,239.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$65.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$27.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$65.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$59.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these gains are expected to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>79.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(51.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$675.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one month</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$8.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$7.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>22.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>45.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency forward contracts was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$848.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$735.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recognized as a component of other income (expense), net for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and  </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be materially different if the derivative assets and liabilities were offset.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>152.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>65.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6846512400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets', window );">Denmark assets held for sale</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization', window );">Internal reorganization of certain intellectual property rights</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">US tax reform</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent', window );">Swiss tax reform</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">11.90%<span></span>
</td>
<td class="nump">20.40%<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
<td class="nump">21.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6875649904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>2019 Share Repurchase Program</div></th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2016 Share Repurchase Program</div></th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>Accounting Standards Update 2016-01 </div>
<div>Accumulated Other Comprehensive Income</div>
</th>
<th class="th">
<div>Accounting Standards Update 2016-16 </div>
<div>Retained earnings</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 12,598.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 97.8<span></span>
</td>
<td class="num">$ (318.4)<span></span>
</td>
<td class="nump">$ 15,810.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(235.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">12,612.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">3,483.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,483.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="nump">45.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,529.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">68.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest, decrease from distributions to noncontrolling interest holders</a></td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (171.2)<span></span>
</td>
<td class="num">$ (2,828.8)<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">33.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">33.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(39.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(39.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">128.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Adoption of new accounting guidance</a></td>
<td class="nump">479.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 478.4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">13,759.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">47.8<span></span>
</td>
<td class="num">(248.3)<span></span>
</td>
<td class="nump">16,944.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">13,766.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(225.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2018</a></td>
<td class="nump">12,253.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(261.6)<span></span>
</td>
<td class="nump">15,499.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(225.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2018</a></td>
<td class="nump">12,260.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,444.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,444.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,442.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">40.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">13,759.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">47.8<span></span>
</td>
<td class="num">(248.3)<span></span>
</td>
<td class="nump">16,944.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">13,766.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(225.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">13,031.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
<td class="nump">16,257.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(221.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">13,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">4,448.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,448.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,448.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">148.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">147.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,627.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,627.8)<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (74.8)<span></span>
</td>
<td class="num">$ (1,553.0)<span></span>
</td>
<td class="num">$ (1,627.8)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (110.5)<span></span>
</td>
<td class="num">$ (2,036.9)<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(50.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">13,991.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(92.3)<span></span>
</td>
<td class="nump">17,065.2<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">13,995.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(205.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2019</a></td>
<td class="nump">12,948.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(252.9)<span></span>
</td>
<td class="nump">16,182.8<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(208.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2019</a></td>
<td class="nump">12,952.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,545.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,545.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,545.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">160.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">160.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (717.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (717.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (55.1)<span></span>
</td>
<td class="num">$ (662.8)<span></span>
</td>
<td class="num">$ (717.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">47.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">13,991.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (92.3)<span></span>
</td>
<td class="nump">$ 17,065.2<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">13,995.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(205.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6840414208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">$ (27.3)<span></span>
</td>
<td class="nump">$ 115.1<span></span>
</td>
<td class="nump">$ 132.6<span></span>
</td>
<td class="nump">$ 39.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">211.3<span></span>
</td>
<td class="nump">369.8<span></span>
</td>
<td class="nump">881.9<span></span>
</td>
<td class="nump">956.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(3,600.1)<span></span>
</td>
<td class="num">(3,439.0)<span></span>
</td>
<td class="num">(10,706.6)<span></span>
</td>
<td class="num">(9,926.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,545.9<span></span>
</td>
<td class="nump">1,444.4<span></span>
</td>
<td class="nump">4,448.8<span></span>
</td>
<td class="nump">3,483.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">37.1<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="nump">85.6<span></span>
</td>
<td class="num">(56.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(35.2)<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(79.8)<span></span>
</td>
<td class="num">(51.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6858501008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 1,444.4<span></span>
</td>
<td class="nump">$ 4,448.8<span></span>
</td>
<td class="nump">$ 3,483.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">59.1<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">109.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">79.4<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
<td class="num">(38.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">160.6<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
<td class="nump">148.1<span></span>
</td>
<td class="nump">68.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">1,706.5<span></span>
</td>
<td class="nump">1,457.7<span></span>
</td>
<td class="nump">4,596.9<span></span>
</td>
<td class="nump">3,552.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">45.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 1,706.5<span></span>
</td>
<td class="nump">$ 1,456.2<span></span>
</td>
<td class="nump">$ 4,596.5<span></span>
</td>
<td class="nump">$ 3,597.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6645671200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">$ 23.1<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInVariableInterestEntitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6873401904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
<td class="nump">$ 9,926.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">35.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">93.1<span></span>
</td>
<td class="nump">91.9<span></span>
</td>
<td class="nump">462.4<span></span>
</td>
<td class="nump">311.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenues related to amendment of contract manufacturing agreement</a></td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">147.2<span></span>
</td>
<td class="nump">562.0<span></span>
</td>
<td class="nump">420.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="nump">$ 48.1<span></span>
</td>
<td class="nump">$ 89.9<span></span>
</td>
<td class="nump">$ 80.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855366160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Divestiture of Denmark Manufacturing Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryrawmaterialssoldtoFUJIFILM', window );">Inventory raw materials sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember', window );">Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory work-in-process sold to FUJIFILM</a></td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryrawmaterialssoldtoFUJIFILM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials sold to FUJIFILM</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryrawmaterialssoldtoFUJIFILM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841816848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 5,953.5<span></span>
</td>
<td class="nump">$ 5,936.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">6,490.7<span></span>
</td>
<td class="nump">6,037.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,509.9<span></span>
</td>
<td class="nump">1,489.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,495.3<span></span>
</td>
<td class="nump">1,480.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,037.8<span></span>
</td>
<td class="nump">1,000.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">996.3<span></span>
</td>
<td class="nump">995.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,888.8<span></span>
</td>
<td class="nump">1,745.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,739.1<span></span>
</td>
<td class="nump">1,737.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">2,054.2<span></span>
</td>
<td class="nump">1,802.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,722.8<span></span>
</td>
<td class="nump">$ 1,722.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6868997904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 3,899.5<span></span>
</td>
<td class="nump">$ 3,694.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">3,907.4<span></span>
</td>
<td class="nump">3,689.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">3,907.4<span></span>
</td>
<td class="nump">3,689.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,655.9<span></span>
</td>
<td class="nump">1,608.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,657.4<span></span>
</td>
<td class="nump">1,607.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,040.4<span></span>
</td>
<td class="nump">854.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,044.8<span></span>
</td>
<td class="nump">851.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">435.6<span></span>
</td>
<td class="nump">706.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">436.0<span></span>
</td>
<td class="nump">705.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">431.8<span></span>
</td>
<td class="nump">264.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">432.2<span></span>
</td>
<td class="nump">263.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">335.7<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">336.9<span></span>
</td>
<td class="nump">260.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">218.8<span></span>
</td>
<td class="nump">496.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">120.7<span></span>
</td>
<td class="nump">127.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">$ 336.7<span></span>
</td>
<td class="nump">$ 615.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6860756032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">$ 476.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">394.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">$ 382.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6861887248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
<td class="nump">$ 9,926.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">393.2<span></span>
</td>
<td class="nump">358.0<span></span>
</td>
<td class="nump">1,161.2<span></span>
</td>
<td class="nump">1,066.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">202.6<span></span>
</td>
<td class="nump">153.7<span></span>
</td>
<td class="nump">528.4<span></span>
</td>
<td class="nump">378.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 595.8<span></span>
</td>
<td class="nump">$ 511.7<span></span>
</td>
<td class="nump">$ 1,689.6<span></span>
</td>
<td class="nump">$ 1,445.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6862912048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="num">$ (17.7)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 95.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryrawmaterialssoldtoFUJIFILM', window );">Inventory raw materials sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration expected to be received for sale of Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 881.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Future minimum batch production for Denmark Manufacturing Operations</a></td>
<td class="nump">114.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</a></td>
<td class="nump">$ 17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Expected costs to sell disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryrawmaterialssoldtoFUJIFILM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials sold to FUJIFILM</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryrawmaterialssoldtoFUJIFILM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6843079136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>168.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>305.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>176.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>84.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>152.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>88.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>170.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>204.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>93.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>183.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855109680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings&#160;per Share<div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,545.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,444.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,448.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,483.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>184.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>201.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>190.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>206.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>184.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>190.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>207.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6736505808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text">Collaborative and Other Relationships<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, MISSION AD1 and MISSION AD2, designed to assess the efficacy and safety of elenbecestat in patients with mild cognitive impairment and mild AD. As a result of this decision, in the third quarter of 2019, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$48.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our share of the termination of various clinical trials and research and development contracts incurred under the BAN2401 and Elenbecestat Collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for early AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>168.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>305.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>176.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>84.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>152.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>88.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. On October 22, 2019, we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred and, beginning January 1, 2019, is reimbursing us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the expected </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>170.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>204.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>93.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>183.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$74.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$38.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our condensed consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$35.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">basis differences are amortized over their economic life. The total basis difference was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$675 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$115 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to inventory, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$615 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to developed technology and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$170 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to IPR&amp;D. A deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$225 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized losses on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$21.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$66.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These losses reflect our share of losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$9.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$21.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$57.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>687.3 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$572.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$680.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$181.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$47.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$131.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$12.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$89.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$48.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$80.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations on August 1, 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis and our other significant collaboration arrangements, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span> Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6861613952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of separately identifiable assets acquired and liabilities assumed (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AcquisitionsAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of June&#160;7, 2019:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>112.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(77.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>852.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AcquisitionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AcquisitionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855052544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease real estate, including laboratory and office space, and certain equipment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our leases have remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one year</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>nine years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one year</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>six years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one year</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>nine years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our subleases do not include an option to renew as they are coterminous with our operating leases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All of our leases qualify as operating leases. The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:41%;"/><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>422.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>70.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>410.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>481.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:35%;"/><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>62.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(19.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>46.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining three months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>80.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>71.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>70.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>67.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>148.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>61.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>481.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>80.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(26.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(25.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(58.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(182.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>418.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:83%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>70.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating lease assets and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating lease liabilities. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6843175456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestitures</a></td>
<td class="text">Divestitures<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM Corporation (FUJIFILM). Upon the closing of this transaction, we received approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$881.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, which is subject to the finalization of certain working capital adjustments and may be further adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$114.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction we recognized a total net loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$160.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$95.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects a decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$17.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our previously recorded pre-tax loss. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$11.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our estimate of the fair value of an adverse commitment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$114.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$64.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this transaction. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sold to FUJIFILM </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the adverse commitment is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6734059504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,655.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,655.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,702.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,702.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>868.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>868.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>337.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>337.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>336.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>318.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>161.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>161.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,087.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,069.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>353.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>563.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,102.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,050.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>434.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairments of our assets measured and carried at fair value during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our June 2018 investment in Ionis common stock, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. For a description of our validation procedures related to prices provided by third-party pricing </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">services and our option pricing valuation model, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,509.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,495.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,489.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,480.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,037.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>996.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,000.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>995.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,888.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,739.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,745.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,737.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,054.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,722.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,802.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,722.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,490.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,953.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,037.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd., Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>499.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>523.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(57.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(87.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(66.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(91.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(20.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>412.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>412.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$196.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$265.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF resulting in a reduction of our contingent consideration obligations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$61.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to lower cumulative probabilities of success related to our vixotrigine program for the potential treatment of TGN, an increase in interest rates used to revalue our contingent consideration liabilities and the passage of time. In addition, we dosed our first patient in the Phase 2b study of BG00011 for the potential treatment of IPF in September 2018 and paid an </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$81.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment to the former shareholders of Stromedix during the fourth quarter of 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6740350112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,545.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,444.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,448.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,483.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>184.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>201.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>190.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>206.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>184.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>190.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>207.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841870416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>255.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>231.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>176.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,103.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>119.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>194.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,655.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,655.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,657.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,040.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,044.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>435.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>436.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>431.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>432.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>335.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>336.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,899.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,907.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>218.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>120.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>336.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,608.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,607.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>854.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>851.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>706.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>263.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>496.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>127.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated<br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,091.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,093.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,314.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,313.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,686.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,691.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,235.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,232.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>121.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>122.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,899.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,907.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>611.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,192.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,867.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,994.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6861259952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 159.3<span></span>
</td>
<td class="nump">$ 196.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">421.7<span></span>
</td>
<td class="nump">606.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">170.8<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">751.8<span></span>
</td>
<td class="nump">936.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">751.8<span></span>
</td>
<td class="nump">929.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841602640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">5,706.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Increase in goodwill</a></td>
<td class="nump">112.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="num">(69.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">$ 5,746.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855281856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6668777280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 47.8<span></span>
</td>
<td class="nump">$ 40.4<span></span>
</td>
<td class="nump">$ 151.8<span></span>
</td>
<td class="nump">$ 128.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
<td class="nump">182.0<span></span>
</td>
<td class="nump">143.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="num">(9.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">47.9<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
<td class="nump">174.2<span></span>
</td>
<td class="nump">133.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
<td class="num">(29.1)<span></span>
</td>
<td class="num">(21.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">65.2<span></span>
</td>
<td class="nump">60.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">34.2<span></span>
</td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">116.8<span></span>
</td>
<td class="nump">83.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 39.8<span></span>
</td>
<td class="nump">$ 39.2<span></span>
</td>
<td class="nump">$ 145.1<span></span>
</td>
<td class="nump">$ 112.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6862774720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Oct. 21, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,441,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-2019930x10q.htm": {
   "axisCustom": 4,
   "axisStandard": 35,
   "contextCount": 647,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20190930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20190930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-2019930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20190930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20190930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20190930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 744,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 13,
    "http://www.biogenidec.com/20190930": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 20
   },
   "keyCustom": 59,
   "keyStandard": 426,
   "memberCustom": 67,
   "memberStandard": 72,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20190930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Divestitures Divestitures",
     "role": "http://www.biogenidec.com/role/DivestituresDivestitures",
     "shortName": "Divestitures Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118100 - Disclosure - Revenues Revenues",
     "role": "http://www.biogenidec.com/role/RevenuesRevenues",
     "shortName": "Revenues Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119100 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120100 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121100 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122100 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123100 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment",
     "shortName": "Property, Plant and Equipment Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128100 - Disclosure - Leases",
     "role": "http://www.biogenidec.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129100 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130100 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsPerShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131100 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/ShareBasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132100 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133100 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134100 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135100 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136100 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)",
     "role": "http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables",
     "shortName": "Summary of separately identifiable assets acquired and liabilities assumed (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318301 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319301 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320301 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322301 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323301 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:LesseeLeaseTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328301 - Disclosure - Leases (Tables)",
     "role": "http://www.biogenidec.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:LesseeLeaseTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330301 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsPerShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331301 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332301 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334301 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Business Acquisition (Details)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
     "shortName": "Business Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Business Acquisition (Details Textual)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
     "shortName": "Business Acquisition (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414401 - Disclosure - Divestitures (Details Textual)",
     "role": "http://www.biogenidec.com/role/DivestituresDetailsTextual",
     "shortName": "Divestitures (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418402 - Disclosure - Revenues by Product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesByProductDetails",
     "shortName": "Revenues by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1",
     "shortName": "Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "lang": null,
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2",
     "shortName": "Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails",
     "shortName": "Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418406 - Disclosure - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/OtherRevenuesDetails",
     "shortName": "Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Revenues (Details Textual)",
     "role": "http://www.biogenidec.com/role/RevenuesDetailsTextual",
     "shortName": "Revenues (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD_srt_MajorCustomersAxis_biib_DistributorOneMember",
      "decimals": "INF",
      "lang": null,
      "name": "biib:EntityWidePercentageOfRevenueFromMajorDistributors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419402 - Disclosure - Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q1QTD_srt_MajorCustomersAxis_biib_BioverativMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InventorysoldtoBioverativcost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419403 - Disclosure - Inventory (Details Textual)",
     "role": "http://www.biogenidec.com/role/InventoryDetailsTextual",
     "shortName": "Inventory (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q1QTD_srt_MajorCustomersAxis_biib_BioverativMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InventorysoldtoBioverativcost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "I2019Q3Denmark",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InventoryrawmaterialssoldtoFUJIFILM",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419404 - Disclosure - Divestiture of Denmark Manufacturing Operations (Details)",
     "role": "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails",
     "shortName": "Divestiture of Denmark Manufacturing Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420402 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421402 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421403 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421404 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421405 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422402 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422403 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422404 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422405 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422406 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423402 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424401 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428402 - Disclosure - Leases (Details)",
     "role": "http://www.biogenidec.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2017Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2017Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3_srt_RangeAxis_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428403 - Disclosure - Leases (Details Textual)",
     "role": "http://www.biogenidec.com/role/LeasesDetailsTextual",
     "shortName": "Leases (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3_srt_RangeAxis_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429402 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember",
      "decimals": "-8",
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "I2018Q1ASUadoptiondate",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430402 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsPerShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431402 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431403 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432402 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432403 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433403 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "biib:PercentageoffuturedevelopmentcostsrelatedtoEisai",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "biib:PercentageoffuturedevelopmentcostsrelatedtoEisai",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435401 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436401 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Acquisitions",
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019930x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 147,
   "tag": {
    "biib_A2016ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2016 Share Repurchase Program [Member]",
        "label": "2016 Share Repurchase Program [Member]",
        "terseLabel": "2016 Share Repurchase Program"
       }
      }
     },
     "localname": "A2016ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 Share Repurchase Program [Member]",
        "label": "2018 Share Repurchase Program [Member]",
        "terseLabel": "2018 Share Repurchase Program"
       }
      }
     },
     "localname": "A2018ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2019 Share Repurchase Program [Member]",
        "label": "2019 Share Repurchase Program [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "A2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AVONEXMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AVONEX",
        "label": "AVONEX [Member]",
        "terseLabel": "AVONEX"
       }
      }
     },
     "localname": "AVONEXMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AbbVieMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AbbVie",
        "label": "AbbVie [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbVieMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acquisitions [Abstract]",
        "label": "Acquisitions [Abstract]"
       }
      }
     },
     "localname": "AcquisitionsAbstract",
     "nsuri": "http://www.biogenidec.com/20190930",
     "xbrltype": "stringItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment to Skyhawk"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AducanumabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aducanumab [Member]",
        "label": "Aducanumab [Member]",
        "terseLabel": "Aducanumab"
       }
      }
     },
     "localname": "AducanumabMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Amortizationofintangibleassetsexcludingimpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization of intangible assets, excluding impairment",
        "label": "Amortization of intangible assets, excluding impairment",
        "terseLabel": "Amortization of intangible assets, excluding impairment"
       }
      }
     },
     "localname": "Amortizationofintangibleassetsexcludingimpairment",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets and Liabilities Held For Sale [Policy Text Block]",
        "label": "Assets and Liabilities Held For Sale [Policy Text Block]",
        "terseLabel": "Assets and liabilities held for sale"
       }
      }
     },
     "localname": "AssetsandLiabilitiesHeldForSalePolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BG00011Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BG00011",
        "label": "BG00011 [Member]",
        "terseLabel": "BG00011"
       }
      }
     },
     "localname": "BG00011Member",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_Biogenshareofcopromotionprofitsorlosses": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen share of co-promotion profits or losses",
        "label": "Biogen share of co-promotion profits or losses",
        "terseLabel": "Biogen share of co-promotion profits or losses"
       }
      }
     },
     "localname": "Biogenshareofcopromotionprofitsorlosses",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BioverativMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bioverativ [Member]",
        "label": "Bioverativ [Member]",
        "terseLabel": "Bioverativ"
       }
      }
     },
     "localname": "BioverativMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashSettledPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash settled performance shares [Member]",
        "label": "Cash settled performance shares [Member]",
        "terseLabel": "Cash settled performance shares"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxAssetLiabilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Asset/Liability Type [Axis]",
        "label": "Deferred Tax Asset/Liability Type [Axis]",
        "terseLabel": "Deferred Tax Asset/Liability Type [Axis]"
       }
      }
     },
     "localname": "DeferredTaxAssetLiabilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DeferredTaxAssetLiabilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Deferred Tax Asset/Liability Type [Axis]",
        "label": "Deferred Tax Asset/Liability Type [Domain]",
        "terseLabel": "Deferred Tax Asset/Liability Type [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetLiabilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredtaxliabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax liability [Member]",
        "label": "Deferred tax liability [Member]",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredtaxliabilityMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenmarkManufacturingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denmark Manufacturing Operations [Member]",
        "label": "Denmark Manufacturing Operations [Member]",
        "terseLabel": "Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DenmarkManufacturingOperationsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DisposalGroupOperatingLeaseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Operating Lease Assets",
        "label": "Disposal Group, Operating Lease Assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DisposalGroupOperatingLeaseAssets",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DisposalGroupOperatingleaseliabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Operating lease liabilities",
        "label": "Disposal Group, Operating lease liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DisposalGroupOperatingleaseliabilities",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DivestituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]"
       }
      }
     },
     "localname": "DivestituresAbstract",
     "nsuri": "http://www.biogenidec.com/20190930",
     "xbrltype": "stringItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent",
        "terseLabel": "Swiss tax reform"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "label": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "terseLabel": "Internal reorganization of certain intellectual property rights"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "label": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "terseLabel": "Fair value, in-process research and development, discount rate"
       }
      }
     },
     "localname": "FairValueIndefiniteLivedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In-licensed patents.",
        "label": "In Licensed Patents [Member]",
        "terseLabel": "Acquired and in-licensed rights and patents"
       }
      }
     },
     "localname": "InLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IndefiniteLivedIntangibleAssetsUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indefinite lived intangible assets useful life.",
        "label": "Indefinite Lived Intangible Assets Useful Life",
        "terseLabel": "Indefinite lived intangible assets useful life"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsUsefulLife",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InventoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory [Abstract]",
        "label": "Inventory [Abstract]"
       }
      }
     },
     "localname": "InventoryAbstract",
     "nsuri": "http://www.biogenidec.com/20190930",
     "xbrltype": "stringItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InventoryrawmaterialssoldtoFUJIFILM": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory raw materials sold to FUJIFILM",
        "label": "Inventory raw materials sold to FUJIFILM",
        "terseLabel": "Inventory raw materials sold to FUJIFILM"
       }
      }
     },
     "localname": "InventoryrawmaterialssoldtoFUJIFILM",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InventorysoldtoBioverativcost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory sold to Bioverativ, cost",
        "label": "Inventory sold to Bioverativ, cost",
        "terseLabel": "Inventory sold to Bioverativ, cost"
       }
      }
     },
     "localname": "InventorysoldtoBioverativcost",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInVariableInterestEntitiesTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in Variable Interest Entities.",
        "label": "Investment in Variable Interest Entities (Textual) [Abstract]",
        "terseLabel": "Investment in Variable Interest Entities (Textual)"
       }
      }
     },
     "localname": "InvestmentInVariableInterestEntitiesTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20190930",
     "xbrltype": "stringItemType"
    },
    "biib_IonisPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ionis Pharmaceuticals [Member]",
        "label": "Ionis Pharmaceuticals [Member]",
        "terseLabel": "Ionis Pharmaceuticals"
       }
      }
     },
     "localname": "IonisPharmaceuticalsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LesseeLeaseTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee Lease Table [Table Text Block]",
        "label": "Lessee Lease Table [Table Text Block]",
        "terseLabel": "Schedule of operating leases"
       }
      }
     },
     "localname": "LesseeLeaseTableTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_LongtermoperatingleaseliabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term operating lease liabilities [Member]",
        "label": "Long-term operating lease liabilities [Member]",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "LongtermoperatingleaseliabilitiesMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NetMinimumLeasePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments total.",
        "label": "Net Minimum Lease Payments",
        "totalLabel": "ASC 840 - Net minimum lease payments total"
       }
      }
     },
     "localname": "NetMinimumLeasePayments",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments thereafter.",
        "label": "Net Minimum Lease Payments Thereafter",
        "totalLabel": "ASC 840 - Net minimum lease payments, thereafter"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsThereafter",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInFiveYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in five year.",
        "label": "Net Minimum Lease Payments With In Five Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2023"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInFiveYear",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInFourYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in four year.",
        "label": "Net Minimum Lease Payments With In Four Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2022"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInFourYear",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in one year.",
        "label": "Net Minimum Lease Payments With In One Year",
        "totalLabel": "ASC 840 - Net minimum lease payments 2019"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInOneYear",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInThreeYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in three year.",
        "label": "Net Minimum Lease Payments With In Three Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2021"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInThreeYear",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInTwoYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in two year.",
        "label": "Net Minimum Lease Payments With In Two Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2020"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInTwoYear",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NightstarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nightstar [Member]",
        "label": "Nightstar [Member]",
        "terseLabel": "Nightstar"
       }
      }
     },
     "localname": "NightstarMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Noncontrollinginterestincreasedecreaseother": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncontrolling interest, increase (decrease) other",
        "label": "Noncontrolling interest, increase (decrease) other",
        "terseLabel": "Noncontrolling interest, increase (decrease) other"
       }
      }
     },
     "localname": "Noncontrollinginterestincreasedecreaseother",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OperatingleaseassetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating lease assets [Member]",
        "label": "Operating lease assets [Member]",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingleaseassetsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating lease supplemental cash flow disclosure [Table Text Block]",
        "label": "Operating lease supplemental cash flow disclosure [Table Text Block]",
        "terseLabel": "Operating lease supplemental cash flow disclosure"
       }
      }
     },
     "localname": "OperatingleasesupplementalcashflowdisclosureTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating lease weighted average remaining term and discount rate [Table Text Block]",
        "label": "Operating lease weighted average remaining term and discount rate [Table Text Block]",
        "terseLabel": "Operating lease weighted average remaining term and discount rate"
       }
      }
     },
     "localname": "OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20190930",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Out-licensed patents"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PLSRMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "PLSR",
        "label": "PLSR [Member]",
        "terseLabel": "PLSR [Member]"
       }
      }
     },
     "localname": "PLSRMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PostacquisitionequitycompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Post-acquisition equity compensation [Member]",
        "label": "Post-acquisition equity compensation [Member]",
        "terseLabel": "Post-acquisition equity compensation"
       }
      }
     },
     "localname": "PostacquisitionequitycompensationMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20190930",
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "label": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "terseLabel": "2.900% Senior Notes due 2020"
       }
      }
     },
     "localname": "SeniorNotesTwoPointNinePercentDueTwentyTwentyMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SkyhawkTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Skyhawk Therapeutics [Member]",
        "label": "Skyhawk Therapeutics [Member]",
        "terseLabel": "Skyhawk Therapeutics"
       }
      }
     },
     "localname": "SkyhawkTherapeuticsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StockOptionsAndEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock options and employee stock purchase plan.",
        "label": "Stock options and employee stock purchase plan [Member]",
        "verboseLabel": "Stock options and employee stock purchase plan"
       }
      }
     },
     "localname": "StockOptionsAndEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN [Member]"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TecfideraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TecfideraMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "negatedLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_WorkinprocessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Work-in-process",
        "label": "Work-in-process [Member]",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "WorkinprocessMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20190930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r175",
      "r276",
      "r280",
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r173",
      "r276",
      "r278",
      "r477",
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r174",
      "r276",
      "r279",
      "r479",
      "r487",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingGuidanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Previous accounting guidance and the new accounting guidance.",
        "label": "Accounting Guidance [Domain]",
        "terseLabel": "Accounting Guidance [Domain]"
       }
      }
     },
     "localname": "AccountingGuidanceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "Accounting Standards Update 2016-01"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201616Member": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.",
        "label": "Accounting Standards Update 2016-16 [Member]",
        "terseLabel": "Accounting Standards Update 2016-16"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201616Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r24",
      "r44",
      "r176",
      "r177",
      "r277"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r40",
      "r443",
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r86",
      "r91",
      "r92",
      "r284",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r58",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r91",
      "r99",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r91",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r91",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r88",
      "r91",
      "r92",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r81",
      "r91",
      "r92",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r130",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedTerseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r287",
      "r293",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r130",
      "r226",
      "r233"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r191",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r130",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r169",
      "r441",
      "r463"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r77"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r182",
      "r208"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Marketable equity securities, fair value",
        "totalLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable equity securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Marketable equity securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "totalLabel": "Marketable equity securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r186",
      "r189",
      "r458"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r186",
      "r188",
      "r457"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r179",
      "r183",
      "r208"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r181",
      "r208"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r181",
      "r208"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "verboseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r288",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r366",
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r332",
      "r333",
      "r336"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r332",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r332",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and Equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r300",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred Tax Liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r326",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Fair value of post-combination equity compensation"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r22",
      "r56",
      "r132"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r32",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r341",
      "r342",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r69",
      "r254",
      "r451",
      "r471"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r95",
      "r97",
      "r98"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r97",
      "r348",
      "r349",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r97",
      "r347",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r350",
      "r359",
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r450",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.",
        "label": "Construction Payable",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r282",
      "r285",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "verboseLabel": "Cumulative effect of new accounting principle in period of adoption"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r36",
      "r38",
      "r39",
      "r442",
      "r444",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior Notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r67",
      "r136",
      "r264",
      "r267",
      "r268",
      "r269",
      "r408",
      "r409",
      "r411",
      "r460"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r134",
      "r313",
      "r318"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": {
     "auth_ref": [
      "r300",
      "r301",
      "r310"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Assets, Net, Noncurrent",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r299",
      "r311",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Deferred tax asset recorded on transfer of intellectual property"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": {
     "auth_ref": [
      "r299",
      "r311",
      "r312",
      "r338",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill",
        "terseLabel": "Deferred tax liabilities, goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r300",
      "r301",
      "r302"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Liabilities, Net, Noncurrent",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r299",
      "r311",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Deferred tax liability recorded on transfer of intellectual property"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r130",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r130",
      "r166"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and impairments"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r78",
      "r79",
      "r368",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r78",
      "r79",
      "r368",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r367",
      "r369",
      "r376",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r365",
      "r367",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r373",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "terseLabel": "Gain (loss) on reclassification of cash flow hedges, effective portion"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r374",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Gain (loss) recognized in net income, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Remaining duration of Net Investment Hedges"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax": {
     "auth_ref": [
      "r2",
      "r4",
      "r6",
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r13",
      "r17",
      "r303",
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Tax expense on disposal group"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration expected to be received for sale of Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Inventory work-in-process sold to FUJIFILM"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Expected costs to sell disposal group"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment held for sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "auth_ref": [
      "r130",
      "r239",
      "r244"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r21",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Divestitures"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r104",
      "r143",
      "r146",
      "r148",
      "r149",
      "r150",
      "r153",
      "r454",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r104",
      "r143",
      "r146",
      "r148",
      "r149",
      "r150",
      "r153",
      "r454",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "negatedTerseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r138",
      "r304",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r304",
      "r305",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r304",
      "r305",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "US tax reform"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r304",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent",
        "terseLabel": "Denmark assets held for sale"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r304",
      "r305",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r304",
      "r305",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r304",
      "r305",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "verboseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r304",
      "r305",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r304",
      "r305",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r304",
      "r305",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "NST stock option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r57",
      "r170",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "verboseLabel": "Net gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedLabel": "Less: Net gains (losses) recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "totalLabel": "Unrealized gains (losses) recognized during the period on equity securities held as of September 30, 2019"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r33",
      "r37",
      "r197",
      "r449",
      "r462",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r388",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r282",
      "r283",
      "r285",
      "r389",
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r391",
      "r392",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r282",
      "r283",
      "r285",
      "r389",
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r282",
      "r283",
      "r285",
      "r389",
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r282",
      "r283",
      "r285",
      "r389",
      "r435"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r393",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "terseLabel": "Contingent consideration impairment",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payments",
        "terseLabel": "Future payment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r396",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r366",
      "r371",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life, (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r227",
      "r229",
      "r232",
      "r236",
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r232",
      "r440"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r227",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign tax authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r401",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r282",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePayments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions",
        "terseLabel": "ASC 840 - Sublease income total"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsThereafter",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter",
        "terseLabel": "ASC 840 - Sublease income, thereafter"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFiveYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years",
        "terseLabel": "ASC 840 - Sublease income, 2023"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFourYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years",
        "terseLabel": "ASC 840 - Sublease income, 2022"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInOneYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months",
        "terseLabel": "ASC 840 - Sublease income, 2019"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInThreeYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years",
        "terseLabel": "ASC 840 - Sublease income, 2021"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInTwoYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years",
        "terseLabel": "ASC 840 - Sublease income, 2020"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r367",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net gains (losses) of other income (expense) related to foreign currency forward contracts"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r219",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Increase in goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedLabel": "Elimination of goodwill allocated to Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r365",
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r102",
      "r130",
      "r167",
      "r199",
      "r452",
      "r473"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in loss of investee, net of tax",
        "negatedTerseLabel": "Our share of Samsung Bioepis gains (losses)"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "negatedLabel": "Loss on equity method investment",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.",
        "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax",
        "negatedTerseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r16",
      "r18",
      "r19",
      "r20",
      "r247",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r168",
      "r319"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "negatedTerseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "terseLabel": "Unrealized (gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r147",
      "r152"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r228",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r228",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r225",
      "r230"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Including Goodwill) [Abstract]",
        "verboseLabel": "Intangible Assets and Goodwill (Textual) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual Property"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r100",
      "r165",
      "r407",
      "r410",
      "r455"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r50",
      "r215"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r23",
      "r74",
      "r214"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, current",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Components of inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory, Noncurrent"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r52",
      "r215"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r51",
      "r215"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r108",
      "r164"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating lease liability maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "ASC 842 - Minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "ASC 842 - Minimum lease payments, thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "ASC 842 - Minimum lease payments, 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "ASC 842 - Minimum lease payments, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "ASC 842 - Minimum lease payments, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "ASC 842 - Minimum lease payments, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "ASC 842 - Minimum lease payments, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "ASC 842 - Minimum lease payments 2019 (remaining three months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, Renewal Term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r49",
      "r447",
      "r469"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r39",
      "r259",
      "r444",
      "r465"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r254",
      "r255",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Brazil tax assessment, including interest and penalties"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Loss on research and development contracts terminated with Eisai"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r73",
      "r446",
      "r468"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interest, decrease from distributions to noncontrolling interest holders"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r127",
      "r128",
      "r131"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r93",
      "r96",
      "r103",
      "r131",
      "r152",
      "r453",
      "r474"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r93",
      "r96",
      "r352",
      "r357"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) attributable to noncontrolling interests, net of tax",
        "verboseLabel": "Net income (loss) attributable to noncontrolling interest, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r39",
      "r444",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r422",
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "netLabel": "Net lease cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r420",
      "r423"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r426",
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r425",
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "ASC 840 - Minimum lease payments total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInOneYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "ASC 840 - Minimum lease payments, 2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFiveYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "ASC 940 - Minimum lease payments, 2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFourYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "ASC 840 - Minimum lease payments, 2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInThreeYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "ASC 840 - Minimum lease payments, 2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInTwoYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "ASC 840 - Minimum lease payments, 2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsThereafter",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "ASC 840 - Minimum lease payments, thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of revenue recognized for the period under subleasing arrangements.",
        "label": "Operating Leases, Income Statement, Sublease Revenue",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "OperatingLeasesIncomeStatementSubleaseRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Contractual commitments for the construction of the facility"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r83",
      "r84",
      "r89"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r91",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r80",
      "r406"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r94",
      "r97",
      "r99",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r94",
      "r97",
      "r347",
      "r348",
      "r354"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r366",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r28",
      "r64"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expenses and other",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Payments for pre-combination equity compensation"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r116",
      "r120",
      "r139"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r112",
      "r117",
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r118",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Total transaction value"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Nightstar Therapeutics plc, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchase of Ionis Pharmaceuticals, Inc. stock"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Contingent consideration paid related to Fumapharm AG acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Net distribution to noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r121",
      "r124",
      "r139"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r112",
      "r113",
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity": {
     "auth_ref": [
      "r114",
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity securities classified as available-for-sale securities.",
        "label": "Proceeds from Sale of Available-for-sale Securities, Equity",
        "terseLabel": "Proceeds from sales of strategic investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from Sale of Property, Plant, and Equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r93",
      "r96",
      "r126",
      "r169",
      "r172",
      "r347",
      "r351",
      "r353",
      "r357",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r34",
      "r35",
      "r243",
      "r470"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r34",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to prospectively adopted accounting guidance.",
        "label": "Prospective Adoption of New Accounting Pronouncements [Axis]",
        "terseLabel": "Prospective Adoption of New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "ProspectiveAdoptionOfNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r41",
      "r445",
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Future minimum batch production for Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Gain (loss) on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r91",
      "r92",
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayments of Long-term Debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r298",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r130",
      "r251",
      "r252",
      "r253"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r46",
      "r270",
      "r467"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenues related to amendment of contract manufacturing agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r101",
      "r162",
      "r163",
      "r171"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "negatedTerseLabel": "Product revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r424",
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r187",
      "r190",
      "r192",
      "r193",
      "r194",
      "r196",
      "r456",
      "r459"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r367",
      "r376",
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r287",
      "r292",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r287",
      "r292",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r227",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Minimum lease payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r31",
      "r53",
      "r54",
      "r55"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r70",
      "r135",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r107",
      "r213"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in fair value from changes in the inputs, assumptions, or model used to calculate the fair value of the contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.",
        "label": "Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions",
        "terseLabel": "Fair value measurements, changes in valuation inputs"
       }
      }
     },
     "localname": "ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r286",
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "negatedPeriodEndLabel": "Ending balance, shares",
        "negatedPeriodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r72",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r43",
      "r263",
      "r270",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r43",
      "r263",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r263",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "negatedTerseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r42",
      "r43",
      "r263",
      "r270",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r42",
      "r43",
      "r263",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r43",
      "r47",
      "r48",
      "r178"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r345",
      "r346",
      "r356"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "terseLabel": "Adoption of new accounting guidance"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r71",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r43",
      "r263",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r43",
      "r263",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r71",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r263",
      "r270",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r282",
      "r448",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r145",
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r144",
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3444-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5558-128473"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9972-128506"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9979-128506"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b),(c),(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77891322&loc=d3e41620-112719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77914019&loc=d3e50824-112756"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r491": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r492": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r493": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r494": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r495": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6842189888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 21, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,775.2<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2019ShareRepurchaseProgramMember', window );">2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 717.9<span></span>
</td>
<td class="nump">$ 1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900.0<span></span>
</td>
<td class="nump">$ 2,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember', window );">2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember', window );">2016 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 508.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6845736400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="nump">$ 48.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.9<span></span>
</td>
<td class="nump">$ 305.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">84.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
<td class="nump">152.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember', window );">Skyhawk Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment to Skyhawk</a></td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
<td class="nump">170.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.1<span></span>
</td>
<td class="nump">93.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6842106864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 30.5<span></span>
</td>
<td class="nump">$ 26.0<span></span>
</td>
<td class="nump">$ 90.8<span></span>
</td>
<td class="nump">$ 81.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(45.8)<span></span>
</td>
<td class="num">(49.0)<span></span>
</td>
<td class="num">(141.4)<span></span>
</td>
<td class="num">(151.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">141.1<span></span>
</td>
<td class="nump">198.9<span></span>
</td>
<td class="nump">132.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(4.2)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
<td class="num">(13.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(3.7)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(27.3)<span></span>
</td>
<td class="nump">115.1<span></span>
</td>
<td class="nump">132.6<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(4.6)<span></span>
</td>
<td class="nump">141.2<span></span>
</td>
<td class="nump">197.3<span></span>
</td>
<td class="nump">139.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) recognized during the period on equity securities sold during the period</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">46.8<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities held as of September 30, 2019</a></td>
<td class="num">(9.0)<span></span>
</td>
<td class="nump">$ 141.2<span></span>
</td>
<td class="nump">150.5<span></span>
</td>
<td class="nump">$ 140.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,085.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,085.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,051.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expenses</a></td>
<td class="nump">259.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">222.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">188.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">147.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Construction in progress</a></td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">677.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">677.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">2,429.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,429.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,861.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 884.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 884.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855119984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 7, 2019, we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid-to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (formerly known as NSR-REP1), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (formerly known as NSR-RPGR), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$25.50</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$847.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for equity compensation, which is  attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$26.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$18.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recognized as a charge to selling, general and administrative expense with the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$7.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of June&#160;7, 2019:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>112.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(77.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>852.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the in-process research and development (IPR&amp;D) programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$480.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded an additional IPR&amp;D asset related to BIIB112 of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$220.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for global intangible low-taxed income (GILTI). Goodwill that is tax deductible for GILTI purposes is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$35.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management&#8217;s analysis related to certain matters, such as preparing and submitting certain income tax and non-income tax filings and returns. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the date of acquisition. Although the final determination may result in asset and liability fair values that are different </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">than the preliminary estimates of these amounts, it is not expected that those differences will be material to our financial position.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our condensed consolidated statements of income. Subsequent to the acquisition date, our results of operations include the results of operations of NST.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6869174048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,051.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,646.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(42.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,860.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(709.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,085.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">127.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">480.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(349.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(129.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">129.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">888.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,149.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(46.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,510.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(564.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">917.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">34.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(15.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 39.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6861017712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Acquisition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,746.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,706.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred Tax Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 852.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6861578992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,555.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,555.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,797.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">$ 64.8<span></span>
</td>
<td class="nump">145.4<span></span>
</td>
<td class="nump">$ 194.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments for the construction of the facility</a></td>
<td class="nump">$ 63.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 631.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6862579264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions', window );">Fair value measurements, changes in valuation inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 196,000,000.0<span></span>
</td>
<td class="nump">$ 265,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">57,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,900,000<span></span>
</td>
<td class="nump">66,300,000<span></span>
</td>
<td class="nump">$ 91,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Future payment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 81,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BG00011Member', window );">BG00011</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 61,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in fair value from changes in the inputs, assumptions, or model used to calculate the fair value of the contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(4)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116651436&amp;loc=d3e122625-111746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BG00011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BG00011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6666577600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 611.8<span></span>
</td>
<td class="nump">$ 1,192.0<span></span>
</td>
<td class="nump">$ 3,867.6<span></span>
</td>
<td class="nump">$ 7,994.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.7)<span></span>
</td>
<td class="num">$ (10.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6842916208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss tax reform</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2018, the decrease in our effective tax rate was primarily due to the enactment of a new taxing regime in the country and certain cantons of Switzerland, which we refer to as Swiss Tax Reform. As a result of the impact of Swiss Tax Reform, in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded an income tax benefit of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$54.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, resulting from a remeasurement of our deferred tax assets and liabilities. In addition, in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net benefit for the impact of the internal reorganization of certain intellectual property rights and a net benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> resulting from the finalization of tax returns in various jurisdictions related to the 2018 fiscal year. We also had a higher effective tax rate in 2018 resulting from our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2018, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of Swiss Tax Reform. This decrease was partially offset by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$64.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense related to the divestiture of our subsidiary that owned our Hiller&#248;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Although we are recognizing a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture requires us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the internal reorganization of certain intellectual property rights, as of September 30, 2019, we recorded a deferred tax asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$754.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$603.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Federal and State Uncertain Tax Positions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6852493632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text">Litigation<div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH&#160;(Fresenius Kabi)&#160;commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen commercializes in Europe, infringes the French counterpart of European Patent No. 3 148 510&#160;(the &#8216;510 Patent), which was issued in June 2018 and expires in May 2035. No hearing on the merits has been scheduled.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of the Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. A hearing in the proceeding in Germany has been set for March 2020. No hearing on the merits has been scheduled.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss in the above matters cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the &#8216;510 Patent. Fresenius Kabi counterclaimed for infringement, damages and injunctive relief. In July 2019 the United Kingdom Patents Court entered a consent order in which it declared that the U.K. counterpart of the '510 Patent is invalid, ordered the patent revoked and dismissed Fresenius Kabi's counterclaims.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &#8216;510 Patent. In September 2019 the parties entered an Agreement to Discontinue Proceedings wherein Fresenius Kabi declared the Dutch counterpart of the '510 Patent invalid and surrendered it in full. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the U.K. counterpart of the '667 Patent, and in August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. A hearing has been set for May 2020 in the Dutch matter and October 2020 in the U.K. matter.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case was filed under seal in January 2014 and unsealed in April 2018 after the U.S. government declined to intervene. The case alleged agreements with pharmacy benefit managers in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. In September 2019 the court dismissed the action on the U.S. government's motion.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers were defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In June 2019 the U.S. Court of Appeals for the First Circuit affirmed the judgment dismissing the complaint with prejudice.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dismissed Shareholder Derivative Litigation</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On January 13, 2017, Mary Ann Mullaney, a Biogen shareholder, filed a complaint in the U.S. District Court for the District of Delaware asserting derivative claims on behalf of Biogen against certain of the company&#8217;s current and former directors and officers alleging that those individuals (i) breached their fiduciary duties by failing to oversee the company&#8217;s operations, (ii) breached their fiduciary duties and Section 14(a) of the Securities Exchange Act of 1934, as amended, and (iii) were unjustly enriched.&#160;The complaint sought unspecified damages, interest, attorneys&#8217; fees and other costs.&#160;The parties filed a Joint Stipulation for Voluntary Dismissal and Proposed Order, which the court granted on August 6, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial date has been set in the Delaware action against Banner Life Sciences LLC for March 2020. A trial date has been set for December 2019 in the other Delaware actions and a trial date has been set for February 2020 in the West Virginia action against Mylan Pharmaceuticals Inc.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals Inc. filed a petition with the U.S. Patent Trial and Appeal Board (PTAB) seeking </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. On February 6, 2019, the PTAB instituted </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 Patent (the "Mylan IPR"). Thereafter, the PTAB </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">granted the petition of Sawai USA, Inc. and Sawai Pharmaceutical Co. Ltd. and joined them as petitioners in the Mylan IPR. A hearing has been scheduled for November 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the European Patent Office (EPO) revoked our European patent number 2 137 537 (the '537 Patent), which includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for March 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for June 2020. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &#8216;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &#8216;127 Patent) (&#8220;Administration of agents to treat inflammation&#8221;).  The Polish &#8216;263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish &#8216;263 Patent expires in February 2023. No hearing on the merits has been set in this matter.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which also concerns administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed in September 2019 and our appeal as to the German action is pending. No date for a hearing on the merits has been set in the Italian action.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We are cooperating with the </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">investigation and have participated in preliminary discussions with the government regarding potential resolution of aspects of the matter. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also received subpoenas and other requests from the U.S. government for documents and information relating to Biogen's co-pay assistance programs. We cooperated with the investigation and have received no communication from the government in this matter since December 2017.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6872683696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
<td class="nump">$ 9,926.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,122.4<span></span>
</td>
<td class="nump">1,090.0<span></span>
</td>
<td class="nump">3,271.4<span></span>
</td>
<td class="nump">3,163.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">842.0<span></span>
</td>
<td class="nump">842.1<span></span>
</td>
<td class="nump">2,429.5<span></span>
</td>
<td class="nump">2,396.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">280.4<span></span>
</td>
<td class="nump">247.9<span></span>
</td>
<td class="nump">841.9<span></span>
</td>
<td class="nump">766.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">530.0<span></span>
</td>
<td class="nump">590.1<span></span>
</td>
<td class="nump">1,585.3<span></span>
</td>
<td class="nump">1,765.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">360.3<span></span>
</td>
<td class="nump">421.5<span></span>
</td>
<td class="nump">1,067.3<span></span>
</td>
<td class="nump">1,237.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">169.7<span></span>
</td>
<td class="nump">168.6<span></span>
</td>
<td class="nump">518.0<span></span>
</td>
<td class="nump">528.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">483.6<span></span>
</td>
<td class="nump">470.2<span></span>
</td>
<td class="nump">1,419.3<span></span>
</td>
<td class="nump">1,399.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">263.0<span></span>
</td>
<td class="nump">253.0<span></span>
</td>
<td class="nump">772.3<span></span>
</td>
<td class="nump">768.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">220.6<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
<td class="nump">647.0<span></span>
</td>
<td class="nump">631.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">71.2<span></span>
</td>
<td class="nump">69.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">71.2<span></span>
</td>
<td class="nump">69.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,160.2<span></span>
</td>
<td class="nump">2,172.8<span></span>
</td>
<td class="nump">6,347.2<span></span>
</td>
<td class="nump">6,400.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,465.3<span></span>
</td>
<td class="nump">1,516.6<span></span>
</td>
<td class="nump">4,269.1<span></span>
</td>
<td class="nump">4,402.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">694.9<span></span>
</td>
<td class="nump">656.2<span></span>
</td>
<td class="nump">2,078.1<span></span>
</td>
<td class="nump">1,997.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">547.1<span></span>
</td>
<td class="nump">467.7<span></span>
</td>
<td class="nump">1,553.8<span></span>
</td>
<td class="nump">1,254.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">236.7<span></span>
</td>
<td class="nump">223.9<span></span>
</td>
<td class="nump">690.6<span></span>
</td>
<td class="nump">617.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">310.4<span></span>
</td>
<td class="nump">243.8<span></span>
</td>
<td class="nump">863.2<span></span>
</td>
<td class="nump">636.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">115.9<span></span>
</td>
<td class="nump">123.4<span></span>
</td>
<td class="nump">360.2<span></span>
</td>
<td class="nump">359.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">115.9<span></span>
</td>
<td class="nump">123.4<span></span>
</td>
<td class="nump">360.2<span></span>
</td>
<td class="nump">359.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">49.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">132.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">49.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">132.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">49.9<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">49.9<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">183.6<span></span>
</td>
<td class="nump">134.8<span></span>
</td>
<td class="nump">542.4<span></span>
</td>
<td class="nump">389.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">183.6<span></span>
</td>
<td class="nump">134.8<span></span>
</td>
<td class="nump">542.4<span></span>
</td>
<td class="nump">389.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,894.7<span></span>
</td>
<td class="nump">2,780.1<span></span>
</td>
<td class="nump">8,455.0<span></span>
</td>
<td class="nump">8,061.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,702.0<span></span>
</td>
<td class="nump">1,740.5<span></span>
</td>
<td class="nump">4,959.7<span></span>
</td>
<td class="nump">5,020.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,192.7<span></span>
</td>
<td class="nump">$ 1,039.6<span></span>
</td>
<td class="nump">$ 3,495.3<span></span>
</td>
<td class="nump">$ 3,040.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6860717408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 422.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 481.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855184192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,655.8<span></span>
</td>
<td class="nump">$ 705.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">255.9<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">176.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">1,103.2<span></span>
</td>
<td class="nump">279.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 119.8<span></span>
</td>
<td class="nump">$ 194.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6668841296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">15 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>biib-2019930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20190930"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20190930.xsd" xlink:type="simple"/>
    <context id="FD2019Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="I2019Q3SharesOutstanding">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-10-21</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q3Denmark">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_MajorCustomersAxis_biib_BioverativMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BG00011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BG00011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_PLSRMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:PLSRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q3_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-21</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DeferredTaxAssetLiabilityTypeAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="KRW">
        <measure>iso4217:KRW</measure>
    </unit>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="FD2019Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      id="Fact-A720BDE589E655AFB947A19A47DA30B0-wk-Fact-A720BDE589E655AFB947A19A47DA30B0">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="FD2019Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact-39DF7314CAB059E3AF0C295901DAF1A6-wk-Fact-39DF7314CAB059E3AF0C295901DAF1A6">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <dei:AmendmentFlag
      contextRef="FD2019Q3YTD"
      id="Fact-A162EC76C09152549FA91307CC0E32B6-wk-Fact-A162EC76C09152549FA91307CC0E32B6">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q3YTD"
      id="Fact-BA29B3FE73D45B01BD57FE5C7AC3243A-wk-Fact-BA29B3FE73D45B01BD57FE5C7AC3243A">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q3YTD"
      id="Fact-267386718B765BC68F7C40790D39F307-wk-Fact-267386718B765BC68F7C40790D39F307">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q3YTD"
      id="Fact-E8833EC0FF745E31843014B77B5D26ED-wk-Fact-E8833EC0FF745E31843014B77B5D26ED">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q3YTD"
      id="Fact-36253F93FAEF5A1A9839CC0E73339640-wk-Fact-36253F93FAEF5A1A9839CC0E73339640">0000875045</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-9BC34F91DFC05A12A7E82E01B624BC8E-wk-Fact-9BC34F91DFC05A12A7E82E01B624BC8E"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-61EE282E8A2A5F75BF531D03B1C37FFE-wk-Fact-61EE282E8A2A5F75BF531D03B1C37FFE"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="INF"
      id="Fact-4326F7288FFC547A8D0616E2DAAAD145-wk-Fact-4326F7288FFC547A8D0616E2DAAAD145"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="INF"
      id="Fact-3EE86C2A036D57DDBE9E37C5B2B437C3-wk-Fact-3EE86C2A036D57DDBE9E37C5B2B437C3"
      unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="INF"
      id="Fact-CD5CED4136C2541CA702F0C580F0A182-wk-Fact-CD5CED4136C2541CA702F0C580F0A182"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      id="Fact-142450F9DE9654E18013986084873980-wk-Fact-142450F9DE9654E18013986084873980">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      id="Fact-2111C3F4F1B956A29D4A88DE030D9834-wk-Fact-2111C3F4F1B956A29D4A88DE030D9834">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact-D4C2BD49A7F4521CB6E8AFB4C036484C-wk-Fact-D4C2BD49A7F4521CB6E8AFB4C036484C">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      id="Fact-A5FD42464B565034972B507687B1BE7F-wk-Fact-A5FD42464B565034972B507687B1BE7F">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      id="Fact-BDAB5C2C4BDE5A21B95154931F71F201-wk-Fact-BDAB5C2C4BDE5A21B95154931F71F201">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact-518C26F410825D8A8E8EB710325F8CFE-wk-Fact-518C26F410825D8A8E8EB710325F8CFE">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-DA3ACAD0F8775332979A2D5D75AD2B81-wk-Fact-DA3ACAD0F8775332979A2D5D75AD2B81"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-56F39C19EA9C5B3883993722132C76CE-wk-Fact-56F39C19EA9C5B3883993722132C76CE"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <dei:DocumentType
      contextRef="FD2019Q3YTD"
      id="d101485642e797-wk-Fact-E49BF18CD1BB5261ABF2109066216216">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2019Q3YTD"
      id="d101485642e815-wk-Fact-181460A3204D5502B725D9AA01122BF5">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q3YTD"
      id="d101485642e825-wk-Fact-097273B468FA5B05BF1B4BEB48D9907A">2019-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q3YTD"
      id="d101485642e845-wk-Fact-5DEDB907355A59B7A4E0B528C7C489F9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q3YTD"
      id="d101485642e855-wk-Fact-79ED6F4DFD525A4698BD703D127E8344">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q3YTD"
      id="d101485642e864-wk-Fact-9270B3526E145AACAE978B4B276D5120">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q3YTD"
      id="d101485642e886-wk-Fact-AC6580EC3275527BBD75BE7DC580E3F9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q3YTD"
      id="d101485642e896-wk-Fact-5F0CA332F7915D328E488DC5C0B4F217">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q3YTD"
      id="d101485642e921-wk-Fact-88B763BC8CE75A1B93ECEC1ACF66139D">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q3YTD"
      id="d101485642e926-wk-Fact-9E5BEA5AA0155FBCB679E5181DF4D3DC">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q3YTD"
      id="d101485642e931-wk-Fact-DEB53439F68B56EE88AEFB34C373F295">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q3YTD"
      id="d101485642e936-wk-Fact-0C894F537C3D514F8BD6F9B1C35B24EB">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q3YTD"
      id="d101485642e944-wk-Fact-24224EA8ED98553F92119DE1B4422509">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q3YTD"
      id="d101485642e949-wk-Fact-9008D8114F0B5C85B7ABF1EDBEF9BCCB">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q3YTD"
      id="d101485642e1010-wk-Fact-2D41975665F1540B958DB626B2EC2CFF">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q3YTD"
      id="d101485642e1020-wk-Fact-F6D67E1F4CA250A1AC0ACCABD4CE1BC3">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q3YTD"
      id="d101485642e1035-wk-Fact-E0736260E3505B889AB18E77BE00E8E9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q3YTD"
      id="d101485642e1040-wk-Fact-9C004188B29252D0891ACA8734F8A6DD">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q3YTD"
      id="d101485642e1058-wk-Fact-8C326F01892352418C1040AA24A491BC">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q3YTD"
      id="d101485642e1093-wk-Fact-962CCE0CE8D153F1AB624ABA2D517812">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q3YTD"
      id="d101485642e1139-wk-Fact-8CD6D69DCE685C79B4256302E70F2FBC">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q3YTD"
      id="d101485642e1165-wk-Fact-CDB579FA6AD351D4A2F0F5D3EB3C9448">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q3YTD"
      id="d101485642e1175-wk-Fact-09DEFA2E9C0C535CA5BF5F8EFC428A7B">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q3SharesOutstanding"
      decimals="INF"
      id="d101485642e1193-wk-Fact-11BD0E492772596EB5E4C984D9AA936C"
      unitRef="shares">180441878</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d101493944e1065-wk-Fact-3D28795085EA575193C5CA658480CEC6"
      unitRef="usd">2894700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d101493944e1084-wk-Fact-7BF8AC4CA5E1523582F8817F03BD95BF"
      unitRef="usd">2780100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d101493944e1103-wk-Fact-57FC3BF8DA6B53A78893FAD196CDD478"
      unitRef="usd">8455000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d101493944e1123-wk-Fact-E8E82058EC25562986B774B17A9D2FFE"
      unitRef="usd">8061100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d101493944e1138-wk-Fact-8935D8BBEFCE5ED286B0DE4994D83C3D"
      unitRef="usd">595800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d101493944e1157-wk-Fact-084A8A14D1EB5CEC8E6948EA789D8A2A"
      unitRef="usd">511700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d101493944e1176-wk-Fact-6C7B08DD49815A12A560CB733CA3B725"
      unitRef="usd">1689600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d101493944e1196-wk-Fact-7BBDC0B573795D11894123AF71626259"
      unitRef="usd">1445300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101493944e1216-wk-Fact-DC33E683DC765E5C9A12FB403038A719"
      unitRef="usd">109600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101493944e1235-wk-Fact-F66F19EADE265DC9B1853BA2CA1992B0"
      unitRef="usd">147200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101493944e1254-wk-Fact-CEE81A8C61A050788B24277BCB2F809B"
      unitRef="usd">562000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101493944e1274-wk-Fact-0D413906F9E25B0A81CBE77DAF4D3714"
      unitRef="usd">420200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e1294-wk-Fact-0CD821D5D869505598AC9AF461014C2F"
      unitRef="usd">3600100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e1313-wk-Fact-4AFAB2732FEA53C9927DCFA21DE12846"
      unitRef="usd">3439000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e1332-wk-Fact-670B810E65EC53F89A9FD22B4FEE157A"
      unitRef="usd">10706600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e1352-wk-Fact-C62693D4D87457C1B8DC16EDC6C6C06B"
      unitRef="usd">9926600000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e1454-wk-Fact-4398076668E95D6F8BBE2DCE53C7CF6A"
      unitRef="usd">430000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e1473-wk-Fact-3320419AA13155368CD89EC047078EC3"
      unitRef="usd">460800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e1492-wk-Fact-A13BAD179BFC56A59DFF61EFD3C43034"
      unitRef="usd">1508300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e1512-wk-Fact-F0C8EDEBDD205FFBB2A0C0B7AFDFF8D7"
      unitRef="usd">1327800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e1532-wk-Fact-5887AC3DCAC65AA0ABB2D1224CE813C5"
      unitRef="usd">540400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e1551-wk-Fact-A35E1B39D0ED5612B58BEC6AE99EE416"
      unitRef="usd">507900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e1570-wk-Fact-70AF7A2CFC915C15A030EF0FD4DBF312"
      unitRef="usd">1588900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e1590-wk-Fact-11FC0192390C5427BAC2B9380F26D781"
      unitRef="usd">1985600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e1610-wk-Fact-4E1D22AB81E95CD1935911458DAE07AD"
      unitRef="usd">554500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e1629-wk-Fact-1E95BF05DB415E558D74F14636E615EB"
      unitRef="usd">497700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e1648-wk-Fact-EED7A858F0CC55B8BE77E721769495EC"
      unitRef="usd">1709800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e1668-wk-Fact-B7D381D394CB54EB844F0ED37F840AFC"
      unitRef="usd">1515200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e1689-wk-Fact-E16816F8C6345C9F843A76FE6FE7E93D"
      unitRef="usd">283900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e1708-wk-Fact-60CBEC0AE94254A1A0FFF49B4C048842"
      unitRef="usd">281900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e1727-wk-Fact-12AB224A4EA35DA89408132E43CA5AB9"
      unitRef="usd">422200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e1747-wk-Fact-2168DD63A96A5DB78AB338B8966E624C"
      unitRef="usd">493200000</us-gaap:AmortizationOfIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e1767-wk-Fact-32CB9D4583B45F179C86FFF3B5CBFCDA"
      unitRef="usd">60200000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e1786-wk-Fact-C0B8925BE8DA566196A767C76EFA086C"
      unitRef="usd">47500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e1805-wk-Fact-6DAA978FFDB15053BB443111B1C4AB30"
      unitRef="usd">181800000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e1825-wk-Fact-982DE42822645CEEA7477869F0274757"
      unitRef="usd">129200000</biib:Collaborationprofitlosssharing>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e1845-wk-Fact-B033055EE06F5EE3BC24B154C762FC6A"
      unitRef="usd">-17700000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e1865-wk-Fact-877CB4507B6158C69D828BB60C807E94"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e1884-wk-Fact-526E40F32DC65027BA1F64FF315F5FE1"
      unitRef="usd">95500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e1904-wk-Fact-543AED3C148A5BF5A038840458DF783E"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e1924-wk-Fact-6A3D37E1187254C09B6AC4C5616FF447"
      unitRef="usd">57800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e1944-wk-Fact-039C01D7065755E1B84538DFB48BABF7"
      unitRef="usd">87900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e1964-wk-Fact-71EA0E01C5515EB8915D8014F3984813"
      unitRef="usd">66300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e1985-wk-Fact-38997DD058735F02BF9DD1F00498AD0C"
      unitRef="usd">91600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2006-wk-Fact-76BD8F641DB759D998E8967D931DB763"
      unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2025-wk-Fact-B3ACF0F845035AE589F9C30358D82173"
      unitRef="usd">6000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2044-wk-Fact-69D6550F53DA51818961C08A25CDB303"
      unitRef="usd">1500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2064-wk-Fact-D374FD76090D58C691530FB5386AE8A9"
      unitRef="usd">9200000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2084-wk-Fact-A2D8DB9B83C9578E8F085CBC647DD123"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2103-wk-Fact-33F0DE158849587DAB1BDE595BDB71AA"
      unitRef="usd">27500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2122-wk-Fact-EE9D5CB5D2E85A1C8C8AD3ADD14680F7"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2142-wk-Fact-2CA811F753CD570B84DAA2F7964FE11D"
      unitRef="usd">112500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2162-wk-Fact-D4C10BAF17725DC08B4AE22BAF2FBC17"
      unitRef="usd">1793800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2181-wk-Fact-5103BB6AC63F5559A39DE4ED0C8AD3E1"
      unitRef="usd">1741400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2200-wk-Fact-EAE56E7FE4AE539DA15A94AC0F949F31"
      unitRef="usd">5441700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2220-wk-Fact-B06392F1017F580D9294B1E503DCB2F0"
      unitRef="usd">5481100000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2240-wk-Fact-A7D9BF3F74335C15AB9305CEB006E893"
      unitRef="usd">1806300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2259-wk-Fact-D5C03876FBCB508086AB9D5B6C0E7152"
      unitRef="usd">1697600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2278-wk-Fact-D9BEED595D4B56DB8185C9B3B7837D0C"
      unitRef="usd">5264900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2298-wk-Fact-DB015EB13B1E5FF2A8D43369F6578E5A"
      unitRef="usd">4445500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2318-wk-Fact-E9D12EA36B4D5C33868828CA4F85E261"
      unitRef="usd">-27300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2338-wk-Fact-2C8DF4D3F6FF5FBB8B107A909ED110C4"
      unitRef="usd">115100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2357-wk-Fact-955EC3C90AF15B78B661F5AE7D5AA578"
      unitRef="usd">132600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2377-wk-Fact-84F574B1C98951649E68D68912924040"
      unitRef="usd">39600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2397-wk-Fact-1467A4E00BE054469EAF39E1B6BDD386"
      unitRef="usd">1779000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2416-wk-Fact-7E83C86AE3AE54DCB8D8BD2AC0DE19FE"
      unitRef="usd">1812700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2435-wk-Fact-4DAB2CDB8737537FB94F9775B622D819"
      unitRef="usd">5397500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2455-wk-Fact-00604DB125C1532595C02BAB20FD2118"
      unitRef="usd">4485100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2475-wk-Fact-E07E8C7734D15A648BF5E4196636D5C3"
      unitRef="usd">211300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2494-wk-Fact-5AB6392D5D7C5A8D8FB29E1A6E5AAB6F"
      unitRef="usd">369800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2513-wk-Fact-0C5377FD993951FD83D2139588B19737"
      unitRef="usd">881900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2533-wk-Fact-94D258EC9DD1534CA3AB453291E84C59"
      unitRef="usd">956000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2554-wk-Fact-F8037FB875E15271B114ACEE1F87809D"
      unitRef="usd">-21800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2573-wk-Fact-BD38DF3D4A465A88A720F85630ABCE52"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2592-wk-Fact-8A0AD72840015E7AB86F0386B4EA5E19"
      unitRef="usd">-66800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2612-wk-Fact-E18F08DC45E950A0925D75B8779AEDA7"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2632-wk-Fact-295C51D2551C57C38B86AB20FD5C8538"
      unitRef="usd">1545900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2651-wk-Fact-4C53D8055C3559E2AB7DBEC22965795A"
      unitRef="usd">1442900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2670-wk-Fact-3AADFF2A153C519091C711159E3B32B2"
      unitRef="usd">4448800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2690-wk-Fact-2B961E9A38315302B816B2E71D3709C5"
      unitRef="usd">3529100000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2710-wk-Fact-76CE7E28B64A50EC8E3544414C30DE95"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2729-wk-Fact-ACACAE974A30595B80C03585DEEF0A84"
      unitRef="usd">-1500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2749-wk-Fact-4664C7E691035BCF98EEF8686E324D37"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2769-wk-Fact-A615AFFBC8635C799414FB51461A4CD4"
      unitRef="usd">45200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e2794-wk-Fact-8BCEFCADFFDD5171A80A5930F9D729B5"
      unitRef="usd">1545900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e2813-wk-Fact-A3394798436750ACA93FC560D5254E0D"
      unitRef="usd">1444400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e2832-wk-Fact-FF611939A9605722A2FA20072DD911C0"
      unitRef="usd">4448800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e2852-wk-Fact-71E4AC6E479B5D7B8F2CABF3359E1159"
      unitRef="usd">3483900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d101493944e3036-wk-Fact-DABD96074566598EB3C07BFD113F2CBB"
      unitRef="usdPerShare">8.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d101493944e3055-wk-Fact-20A1825877345603B0F899B54405161B"
      unitRef="usdPerShare">7.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d101493944e3074-wk-Fact-D8BF6C918EBE556E860AB77142CAF641"
      unitRef="usdPerShare">23.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d101493944e3094-wk-Fact-F5D9F5575D7752D2A51E550B53879B6F"
      unitRef="usdPerShare">16.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d101493944e3114-wk-Fact-0E70D06DC9FA56B989AD5945AB2BF49D"
      unitRef="usdPerShare">8.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d101493944e3133-wk-Fact-5D12A2C162AB57F889CBC8DBD9E18F6C"
      unitRef="usdPerShare">7.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d101493944e3152-wk-Fact-B947642BF82A5ECCB2AFC553ED1C071C"
      unitRef="usdPerShare">23.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d101493944e3172-wk-Fact-E7A40373C9F75A7091E8B4232C8C4FFC"
      unitRef="usdPerShare">16.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e3351-wk-Fact-F6CE5BEE80B6540FA43FF8EA2757EB66"
      unitRef="shares">184000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e3370-wk-Fact-E9DB242D33DA5FCF80E62B38AB8B3CCC"
      unitRef="shares">201400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e3389-wk-Fact-D122FB3C0DD75244A8431CFB07FAEF38"
      unitRef="shares">190300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e3409-wk-Fact-A1872F8928FF5D918E5EC1A8811DC1C1"
      unitRef="shares">206600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101493944e3430-wk-Fact-93A4BEF1889A5DEBA0656CD4B052EC65"
      unitRef="shares">184200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101493944e3449-wk-Fact-3C339B177C795EFCA2E51E30FA1B6B01"
      unitRef="shares">201900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101493944e3468-wk-Fact-E79773D2EAB35D32A14B66C86F627853"
      unitRef="shares">190500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101493944e3488-wk-Fact-097BC21BCB8351D6BD7B65093FE992A9"
      unitRef="shares">207000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101485078e983-wk-Fact-8BCEFCADFFDD5171A80A5930F9D729B5"
      unitRef="usd">1545900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101485078e1002-wk-Fact-A3394798436750ACA93FC560D5254E0D"
      unitRef="usd">1444400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101485078e1021-wk-Fact-FF611939A9605722A2FA20072DD911C0"
      unitRef="usd">4448800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101485078e1041-wk-Fact-71E4AC6E479B5D7B8F2CABF3359E1159"
      unitRef="usd">3483900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101485078e1138-wk-Fact-76A5ED11418D5BF7BF9A34FFCC9325EC"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101485078e1157-wk-Fact-4A59616144ED5961916A9798F924343C"
      unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101485078e1177-wk-Fact-C0F081FE8A455757A90EA6B00383AE0C"
      unitRef="usd">10300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101485078e1197-wk-Fact-86FC5B05A66C5915919CA9875A1C2F9D"
      unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101485078e1218-wk-Fact-31BE7B6AB20E5BE88A540CDFBFD9000F"
      unitRef="usd">59100000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101485078e1237-wk-Fact-43550C1C4A7256779B2A8AE9160D07F1"
      unitRef="usd">5200000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101485078e1256-wk-Fact-4854F85A96D65FBD9C09F377F0FC18AA"
      unitRef="usd">38100000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101485078e1276-wk-Fact-0E1620A50114582C852D80ED4660ADC0"
      unitRef="usd">109000000.0</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101485078e1296-wk-Fact-02E59A34E043562E873149A6B428D219"
      unitRef="usd">21200000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101485078e1315-wk-Fact-A8BAF411A8FC5A96BA88C816664E7903"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101485078e1334-wk-Fact-7F087591389B52F9A8CF9EDF1629A84A"
      unitRef="usd">46900000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101485078e1354-wk-Fact-452162AA382853D0981FBCC5B27BA815"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101485078e1374-wk-Fact-8486ADEF7E245E9393C9C0F327568A2E"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101485078e1393-wk-Fact-06BDA25FF1EC56A1AC030B0CC2AC00D7"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101485078e1413-wk-Fact-1D1E835AA5675E06818144DD02344F8A"
      unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101485078e1433-wk-Fact-A8070A8B147351B7A1E60087626478D1"
      unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101485078e1453-wk-Fact-F8BB5F76671B581E93281CF189441430"
      unitRef="usd">79400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101485078e1472-wk-Fact-F10E2D63CD145821BD9EE3DB76385797"
      unitRef="usd">8500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101485078e1491-wk-Fact-5A30451B7A615910ACF5E13D9696FAB5"
      unitRef="usd">51300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101485078e1511-wk-Fact-3FBCA042F22C5C759162C22194715F57"
      unitRef="usd">-38800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101485078e1532-wk-Fact-0258E3DA7739597FAE2A1F9A9FEA77FD"
      unitRef="usd">160600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101485078e1551-wk-Fact-2E58A4FBEAF45408A246611108CA9348"
      unitRef="usd">13300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101485078e1570-wk-Fact-4BE449ABC68C5BBB868E2225D4530616"
      unitRef="usd">148100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101485078e1590-wk-Fact-61FD074FCC6D59939B8BE32C48B29249"
      unitRef="usd">68600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101485078e1610-wk-Fact-57EA0A92B874536CBB2610EC93B7E76E"
      unitRef="usd">1706500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101485078e1629-wk-Fact-DCD795F4DAD25B6E96DC37AE575F740C"
      unitRef="usd">1457700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101485078e1648-wk-Fact-5C95DCEFB970549F8B08FF376112D424"
      unitRef="usd">4596900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101485078e1668-wk-Fact-C4957DEC8263508FA1E6B344D6F6DB03"
      unitRef="usd">3552500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101485078e1689-wk-Fact-E397511F983F5E87B82187CEA0403912"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101485078e1708-wk-Fact-F28E26711D165E02B5ADDC01EAACFC8B"
      unitRef="usd">1500000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101485078e1728-wk-Fact-A38D73EB5E86516EB5FF267F16BEA51B"
      unitRef="usd">400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101485078e1749-wk-Fact-D037C53F384253EAB8D89D828F57606E"
      unitRef="usd">-45200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101485078e1774-wk-Fact-60D072D8BE615BAFB48DF2F8BBAE9C28"
      unitRef="usd">1706500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101485078e1793-wk-Fact-03369FE59EF75FE48A0CB365940CCD87"
      unitRef="usd">1456200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101485078e1812-wk-Fact-96AB5CA8535D5A8FAE33F1ECD7878AEB"
      unitRef="usd">4596500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101485078e1832-wk-Fact-4517B7B13CB05F16A0A3044320A963AF"
      unitRef="usd">3597700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e935-wk-Fact-83A526C3A2725C42B7F158D072E0F5A4"
      unitRef="usd">2343900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e954-wk-Fact-F2DAE74D0C115593B118EC48C694BF5C"
      unitRef="usd">1224600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e969-wk-Fact-C298836C09855D1C9A8917411E7A4AE9"
      unitRef="usd">2093500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e988-wk-Fact-F018E8451C8957A08F7079FFB8D59F3F"
      unitRef="usd">2313400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1008-wk-Fact-8C63902DCE405F6AA706D3D9EF2C4D4D"
      unitRef="usd">1933500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1027-wk-Fact-814BEE20D0EB5418B809192481DAE7B5"
      unitRef="usd">1958500000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1047-wk-Fact-290794FEB3A95955968569909E8535A2"
      unitRef="usd">582300000</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1066-wk-Fact-3F53EB504B2C54C1B16CA342645AEA82"
      unitRef="usd">526900000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1086-wk-Fact-C0E7BED0E0A95BE78B67788E90DC38BE"
      unitRef="usd">751800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1105-wk-Fact-E643FBEA510257AD9C0E842D75167864"
      unitRef="usd">929900000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1125-wk-Fact-A7E031AAF153505C892B7F1564CFCEC3"
      unitRef="usd">743200000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1144-wk-Fact-4AA23FD66DE850E39D1F6CD98677E785"
      unitRef="usd">687600000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1164-wk-Fact-87D1495EE96F502D929A0C1BB41A62B0"
      unitRef="usd">8448200000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1183-wk-Fact-143F2CEE2BEE562C93C5BCE7B3869174"
      unitRef="usd">7640900000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1203-wk-Fact-E6153FC7558757788377A9AEA4996959"
      unitRef="usd">1813900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1222-wk-Fact-6C19C6ED1107532B96BEA89F99B89C76"
      unitRef="usd">1375900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1243-wk-Fact-781FAF2FA25C5DE4816B81351E6F77CB"
      unitRef="usd">3138100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1262-wk-Fact-EE1A2112EC8951CBB34D626AC0C45223"
      unitRef="usd">3601200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1282-wk-Fact-1C37745BC3885835BF4E8A23720C16FB"
      unitRef="usd">422000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1301-wk-Fact-B6678B300D3D56C799561C33B73005B3"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1321-wk-Fact-590BC6AA99A359AE8B2D093C3E37149E"
      unitRef="usd">3392400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1340-wk-Fact-6AEEA34F46DE51CAAAEFDC70DF10D84D"
      unitRef="usd">3120000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1360-wk-Fact-0C60CAE51C8B53A7ABC528A464C8294A"
      unitRef="usd">5746100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1379-wk-Fact-EDAA6B48B7F75DCC9A54B3A7C0BDDC58"
      unitRef="usd">5706400000</us-gaap:Goodwill>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1399-wk-Fact-F66C6C9C15F65F1D8ECB69B751886781"
      unitRef="usd">3284500000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1418-wk-Fact-F621B0599EA35EE883AA1B7730BE2101"
      unitRef="usd">2153900000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1438-wk-Fact-7B852389140157A4A8260E8B14EA1983"
      unitRef="usd">1238800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1457-wk-Fact-89466BD8C6B45327BD61A0ECB81E173A"
      unitRef="usd">1690600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1482-wk-Fact-55BDD2060AA757EAAC872D6DB53C9927"
      unitRef="usd">27484000000.0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1501-wk-Fact-FAAAD69603DB5E5B9F862B8B135DDC3C"
      unitRef="usd">25288900000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1603-wk-Fact-308849C12114E2457E24DF18BE2C342D"
      unitRef="usd">1495300000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1622-wk-Fact-91C66CFF1C4448F0BB2FDF190080F42A"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1637-wk-Fact-B8E9D40B043C5C97B77D88A407B5E6B2"
      unitRef="usd">125600000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1656-wk-Fact-BB2A31C8517D5EBAA911970CB9A1098E"
      unitRef="usd">63500000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1677-wk-Fact-496E65744BA454AFBBE4E22A73F7762D"
      unitRef="usd">382200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1696-wk-Fact-750385800D415C4DB8129FCF499223B1"
      unitRef="usd">370500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1716-wk-Fact-C6AD992658BE523FA538C7C0C76A2090"
      unitRef="usd">2429100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1735-wk-Fact-BE16E177BEB058B89BD806D640DFC45E"
      unitRef="usd">2861200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1755-wk-Fact-67D828B802B951F4B20207E1DC993F54"
      unitRef="usd">4432200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1774-wk-Fact-C32692E20D225EB6AFC0CD72B96858BC"
      unitRef="usd">3295200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1794-wk-Fact-13E0432DB7BB567F8E6B5F5AD776202A"
      unitRef="usd">4458200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1813-wk-Fact-2FF75B46492F5477BEE57B562A605D00"
      unitRef="usd">5936500000</us-gaap:LongTermDebt>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1833-wk-Fact-F4AAE7F4F0BE5A7CAD3F2BB8053E81E8"
      unitRef="usd">2820400000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1852-wk-Fact-86191C856627546AB71D0AC817931A2E"
      unitRef="usd">1636200000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1872-wk-Fact-DF012A752E815C6091CBAFFD1F0FDC94"
      unitRef="usd">410500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1891-wk-Fact-F0993C1DBBD052B09206580B64849771"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1911-wk-Fact-3B76B476C9EC5341AA786EDA6E0726CC"
      unitRef="usd">1370900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1930-wk-Fact-54B9F535280E5673BE39CEFF072D9B0B"
      unitRef="usd">1389400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e1950-wk-Fact-8936E5CB413B571B82246DBA0028A0BA"
      unitRef="usd">13492200000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e1969-wk-Fact-97E2DC9163B755A49A8C1A0F64464C48"
      unitRef="usd">12257300000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q3"
      id="d101490761e1989-wk-Fact-A50F964A18F452439EBF80FA7B620812"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d101490761e2007-wk-Fact-C99AE73AC60C5B1B89DBABAEE47EA785"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e2109-wk-Fact-962A446B843657E6AFF4A597E0138E20"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e2128-wk-Fact-48451208FE475A3DA8BEB2C40076392C"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e2148-wk-Fact-35CE2716383B5AE3B925429C24A4ADA7"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e2167-wk-Fact-B71B7AC7B2E05AAEA63770CE1A93C1D5"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e2187-wk-Fact-47619F822E3A527E8ADA394CB3C7D18D"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e2206-wk-Fact-AE65C64FBDA35AA0A9B723A96F852669"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e2226-wk-Fact-D19A1A49D241536C9B103A6500E3337A"
      unitRef="usd">-92300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e2246-wk-Fact-2AD3B15D1D55512B9C6B95F3C78B4D85"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e2267-wk-Fact-50CC37E48EF5582DAB0B2F6EACC9AEE0"
      unitRef="usd">17065200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e2286-wk-Fact-457A1B15015854AFBE5811D84B6176F2"
      unitRef="usd">16257000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e2306-wk-Fact-DBA2285F07C6556884D1EB21B6713F8B"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e2326-wk-Fact-F543FC63AC235575A1678AF91B890C47"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e2347-wk-Fact-A2AF55501BAD547995BE423EF29B658C"
      unitRef="usd">13995900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e2366-wk-Fact-44AC8A01AD1356F5A9EB4B9A72137222"
      unitRef="usd">13039600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e2386-wk-Fact-3CEC36CBF1055BE6A123C365060F5F58"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e2406-wk-Fact-16C8C5F03C1C5585B1709640505A160A"
      unitRef="usd">-8000000.0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e2427-wk-Fact-29E33AB9B71A5B1A92211499B9EFB12B"
      unitRef="usd">13991800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e2446-wk-Fact-B09AC96B85E159EC99ACF965755BAF33"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101490761e2471-wk-Fact-76AC70AEF6025213B3222C8ACD9EB3C8"
      unitRef="usd">27484000000.0</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101490761e2490-wk-Fact-765C507BBF6556C8B6728676B0F6AE0C"
      unitRef="usd">25288900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e934-wk-Fact-3AADFF2A153C519091C711159E3B32B2"
      unitRef="usd">4448800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e953-wk-Fact-2B961E9A38315302B816B2E71D3709C5"
      unitRef="usd">3529100000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1009-wk-Fact-33452851621C5F07A9C9EBAA4EA6B82F"
      unitRef="usd">567600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1028-wk-Fact-D8242BD7C4A65758A3F6BC8039223103"
      unitRef="usd">686900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1048-wk-Fact-EE9D5CB5D2E85A1C8C8AD3ADD14680F7"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1067-wk-Fact-2CA811F753CD570B84DAA2F7964FE11D"
      unitRef="usd">112500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1087-wk-Fact-C7C799CAD1C3585C803C44325A020472"
      unitRef="usd">143900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1106-wk-Fact-CF36DCC358E25DE38562DE6E739CA7A5"
      unitRef="usd">119000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1126-wk-Fact-71EA0E01C5515EB8915D8014F3984813"
      unitRef="usd">66300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1146-wk-Fact-38997DD058735F02BF9DD1F00498AD0C"
      unitRef="usd">91600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1167-wk-Fact-1AD545FB7F2A5371B77A378648066CCC"
      unitRef="usd">-95500000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1186-wk-Fact-833103A7D6915801BE746271BD22ADFD"
      unitRef="usd">0</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1206-wk-Fact-C2C2A1F795915C9D96C513797CAB67E9"
      unitRef="usd">28400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1225-wk-Fact-EF0D76A38A7F597A94CEDC0AD45CDC38"
      unitRef="usd">-44800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1247-wk-Fact-D65DFA33112E52C9B4A4A1E59A1B9FA5"
      unitRef="usd">189800000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1267-wk-Fact-55BFBC2FF16A57C28A18B33E4345147E"
      unitRef="usd">136900000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1288-wk-Fact-3EBF7BA106C63991434BDF1FD033605B"
      unitRef="usd">-63500000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1307-wk-Fact-57C41D64DF04C5CBC74FDF202E55A13F"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1327-wk-Fact-5970C35E4EF35EFA96044270222D37DF"
      unitRef="usd">-87400000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1346-wk-Fact-3719FFC295B6502FB9A786DDED0FBA94"
      unitRef="usd">-68700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1407-wk-Fact-C8A85D4916B452DDA086ABF9B456D6D1"
      unitRef="usd">2400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1427-wk-Fact-DF132AB08A0851B1AE109D0EC1D256C1"
      unitRef="usd">254000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1448-wk-Fact-9EA0182E264353B7986D19FBE8AD7D5E"
      unitRef="usd">-47300000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1467-wk-Fact-1C106B69CC91540CBDAABB2F9C6FF2F2"
      unitRef="usd">31900000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1488-wk-Fact-89128A91D27B5BD99B7DE0A8E6A2C725"
      unitRef="usd">-109100000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1508-wk-Fact-76206FF6BD07526E9445A05442303B4E"
      unitRef="usd">100700000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1528-wk-Fact-04639F8ADC895C789F2D301BBED6EF73"
      unitRef="usd">64600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1547-wk-Fact-64494AAB60025472B47618AD3C175E9B"
      unitRef="usd">315600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1567-wk-Fact-9A24E72FB0F05ABE8F8E8F796BD85551"
      unitRef="usd">61000000.0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1587-wk-Fact-ABC3502D7E3459D59F99356D87DB6395"
      unitRef="usd">81000000.0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1608-wk-Fact-DDCA05B63152502A883DBF0C88CCD247"
      unitRef="usd">5118400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1627-wk-Fact-8E179AC4269650B588F40F50D654A06D"
      unitRef="usd">4292300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1689-wk-Fact-5E1D8F7CDC5D5971BFCC69B7E527C60C"
      unitRef="usd">3867600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1708-wk-Fact-F0FE9623A9FF52ED9D5ADA61948D05C3"
      unitRef="usd">7994700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1728-wk-Fact-61FC7C8C612F56CD9DD89654C0837BC3"
      unitRef="usd">4052100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1748-wk-Fact-AD1873A67E6A5F4F9E0A47DA13C65CC2"
      unitRef="usd">6093800000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1769-wk-Fact-F17A1A59D3BC5916BA007E220C849E6A"
      unitRef="usd">300000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1789-wk-Fact-B897412B83335209B78DBF38B85508A5"
      unitRef="usd">1200000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1810-wk-Fact-7B404276589557CBA07D97016C06503D"
      unitRef="usd">744400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1830-wk-Fact-EBE43BFC249F5845B673472EE0D16C7F"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1850-wk-Fact-21D3AA713F0EA2E9CACADF24BE08CAC6"
      unitRef="usd">923700000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1869-wk-Fact-EEBD60E282A013176258DF24E6474522"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1889-wk-Fact-AD8B3A35867756C98C0969516A36078E"
      unitRef="usd">404100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1909-wk-Fact-94A2D1C18C6E565787B5F6E902708951"
      unitRef="usd">544700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1930-wk-Fact-E65F2CF901365080AAAE43C87C12A895"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1949-wk-Fact-3F47A04D66CE5637B61EC983694A6E6A"
      unitRef="usd">112500000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e1970-wk-Fact-29A1E9B40ED456059989BFB340E59E7E"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e1989-wk-Fact-AEF16EBAC64154E6BF9D7393F71EA03C"
      unitRef="usd">3000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2010-wk-Fact-474692735A7D5AE8ACBA5C8F8A7AD1CD"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2029-wk-Fact-0E2C681D61B1567CBC1E30EF986EC73A"
      unitRef="usd">462900000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2050-wk-Fact-EC8FCC7D36A6566A8D2479C01357C9C6"
      unitRef="usd">476000000.0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2069-wk-Fact-79038D827FA25A978709096A05001AE0"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2089-wk-Fact-358F039701CA547BAD90F17B83549CC5"
      unitRef="usd">4600000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2109-wk-Fact-A6D835B6A23C5D56A4299F2766535328"
      unitRef="usd">-1200000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2130-wk-Fact-07D1DA4D70F3553ABDD930B5BE13032E"
      unitRef="usd">-237900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2150-wk-Fact-2B1DBDB45EEF5B3099CFCD6C0B368069"
      unitRef="usd">-421000000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2212-wk-Fact-9170BCFABB65589B94DE58BFA74AC05A"
      unitRef="usd">3775200000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2232-wk-Fact-9AA1718984DF5B8E8246D63B92A57FFA"
      unitRef="usd">3000000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2253-wk-Fact-9B82C510C2D4588AA66EF704CF04EFD2"
      unitRef="usd">16900000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2273-wk-Fact-F2D13445A75758BBABB91342157219E5"
      unitRef="usd">6700000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2294-wk-Fact-89E1BAC77A6886A2D6D68270C6F1A263"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2313-wk-Fact-06AB359CAE9625DC3CA58270EF4D874A"
      unitRef="usd">3200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2334-wk-Fact-24BE8658D9F858E9B1A28E023311BC55"
      unitRef="usd">-4300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2353-wk-Fact-BBAE32D04BBC58D4812EF6C32641FDBE"
      unitRef="usd">36900000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2374-wk-Fact-6B28D4ADED495034B79B15A73017253C"
      unitRef="usd">43800000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2393-wk-Fact-3F7161126EC35BB0B126199BFBA8E2DE"
      unitRef="usd">11800000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2413-wk-Fact-40C71F2A45F25B948951D2AD307FD3C8"
      unitRef="usd">-3744000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2433-wk-Fact-444379A4A2AB5470928C2576F560EED1"
      unitRef="usd">-3035000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2454-wk-Fact-A1CC385BF227504489040649F8C25E33"
      unitRef="usd">1136500000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2473-wk-Fact-58AFDCE9750D532CAF4615A0E7B7C032"
      unitRef="usd">836300000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101488732e2493-wk-Fact-B3DE861386415094AAC2D8E37EE3A027"
      unitRef="usd">-17200000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101488732e2513-wk-Fact-C9D710FC606C53DDB68FD819DE095B24"
      unitRef="usd">-23400000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101488732e2534-wk-Fact-F2DAE74D0C115593B118EC48C694BF5C"
      unitRef="usd">1224600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-5"
      id="d101488732e2553-wk-Fact-3DCF5FF7FC2B5D0889A1B757B35D3D09"
      unitRef="usd">1573800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101488732e2579-wk-Fact-83A526C3A2725C42B7F158D072E0F5A4"
      unitRef="usd">2343900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q3"
      decimals="-5"
      id="d101488732e2598-wk-Fact-4F468DFC96A355ABB0BFD7FA4C2F2FE3"
      unitRef="usd">2386700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e1335-wk-Fact-4DB1897C193D5053A4199A58D004705A"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e1354-wk-Fact-C1BDD266FBEA5A5CAB31010DC9AC6F8E"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e1368-wk-Fact-31A6828F27C55C31A3A1012062CB9DF4"
      unitRef="shares">208600000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e1388-wk-Fact-27D5A6B1248C575EA1CC3FAE3CE42A35"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e1407-wk-Fact-9E3630F78EEF5FEE923770FF345DCB53"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e1426-wk-Fact-8EDA62210500500783D0C50325720711"
      unitRef="usd">-252900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e1447-wk-Fact-648BC3AFD33F555AADECBB0155548354"
      unitRef="usd">16182800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e1461-wk-Fact-A6C210ABBCBE5C85ACFAFEE305213781"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e1481-wk-Fact-70CA9E6A75D85E8EA9BB1DA671C20A99"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-5"
      id="d101507987e1502-wk-Fact-790D39D271FD5078B42BFE8604C22514"
      unitRef="usd">12952900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e1521-wk-Fact-66CE5579DF38532497778508A28E6ACB"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-5"
      id="d101507987e1541-wk-Fact-CD539AB29EE653758B894A0D73A565E6"
      unitRef="usd">12948800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e1669-wk-Fact-9D8EE02555B95F9DA86B243B1A8779B0"
      unitRef="usd">1545900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e1724-wk-Fact-8BCEFCADFFDD5171A80A5930F9D729B5"
      unitRef="usd">1545900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e1743-wk-Fact-972AAEB857205ABCA7754A63F71350FD"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e1762-wk-Fact-295C51D2551C57C38B86AB20FD5C8538"
      unitRef="usd">1545900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e1874-wk-Fact-B6CDD3BAC1C151D7A18485F5A3F03ED1"
      unitRef="usd">160600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e1950-wk-Fact-0258E3DA7739597FAE2A1F9A9FEA77FD"
      unitRef="usd">160600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e1969-wk-Fact-5EB98767A3005B6BA3A1AD4A89C90E5E"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e1988-wk-Fact-8AC5B7C40AFC5741ADDC658D1984EE8A"
      unitRef="usd">160600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d101507987e2177-wk-Fact-058C7C59A31752FFB35DD63324A879C2"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e2196-wk-Fact-591F8F9F0BC752429B9306CC93EBD8B4"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e2215-wk-Fact-7334719A4DF75EA5AC5A3612BB179E7F"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e2368-wk-Fact-8AB1700A6308512CA6108A4C1B59FFE5"
      unitRef="shares">3100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e2383-wk-Fact-4DCE57350C1D5FE48C8E834B670F9E6C"
      unitRef="usd">717900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e2404-wk-Fact-E706166A246E50A4A3964EC8D4173977"
      unitRef="usd">717900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e2444-wk-Fact-E706166A246E50A4A3964EC8D4173977"
      unitRef="usd">717900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e2501-wk-Fact-BEE64B24254756FAA4FE34B68DB5D626"
      unitRef="shares">3100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e2517-wk-Fact-AAF64793156054F4B341E33669B280DD"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e2536-wk-Fact-350B28044C0158F3B1E92B6A9150EC18"
      unitRef="usd">55100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e2577-wk-Fact-7766DA95C71C57E2983C41DB828CA78B"
      unitRef="usd">662800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e2597-wk-Fact-931B2B0D844B53E2B66EDD99F25435FE"
      unitRef="shares">3100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e2611-wk-Fact-3490A712F30C5780926E1F6AA26714A8"
      unitRef="usd">717900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e2631-wk-Fact-2BDFB5699B1F568AB743E6C21CE026CD"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e2670-wk-Fact-2BDFB5699B1F568AB743E6C21CE026CD"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e2726-wk-Fact-193A2BC9B0FF5AECA4A368CB1ED652C1"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e2741-wk-Fact-72EDAEB7046656BDBF8F5B84F99E5829"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e2760-wk-Fact-4438BBED29125EFBB26F340DBC3BA794"
      unitRef="usd">7300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e2856-wk-Fact-781108C655DC5CC99AE57A39FDC6343C"
      unitRef="usd">7300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e2895-wk-Fact-781108C655DC5CC99AE57A39FDC6343C"
      unitRef="usd">7300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e2951-wk-Fact-54EAD90C49E15D7CB2F09EA6499A3C6B"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e2966-wk-Fact-618C82F41F9454BA84963FED9B1F7DC2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e2985-wk-Fact-34FAFE47F9815381BF69ABC5AB987B50"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e3025-wk-Fact-FC7D12D12F20551691B4A0266C8D5B33"
      unitRef="usd">700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e3081-wk-Fact-AD204A00E2935B519B8BE7817A545C8F"
      unitRef="usd">700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e3121-wk-Fact-AD204A00E2935B519B8BE7817A545C8F"
      unitRef="usd">700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e3214-wk-Fact-224362906372580FAB28748827B330EE"
      unitRef="usd">47800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e3310-wk-Fact-970839C28F2B50C5A232885A09D5E460"
      unitRef="usd">47800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101507987e3349-wk-Fact-970839C28F2B50C5A232885A09D5E460"
      unitRef="usd">47800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesIssued
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e3371-wk-Fact-CC4EAD3DDB495DECA91DF851D5A77A08"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e3390-wk-Fact-5C4E8F58B2925D6F8DEC5D09D278C5CA"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e3404-wk-Fact-ACE49EE2E82D5033AE6D239D6DCE8F40"
      unitRef="shares">205700000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e3424-wk-Fact-8CE223771A1F51ECB44C691CF1FD8979"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e3443-wk-Fact-9573B47AB29854CE9B9E18F15E746C28"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e3462-wk-Fact-87A8BF94786F56169B1ACC6749A4C8FE"
      unitRef="usd">-92300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e3483-wk-Fact-51D3851DCF2E5B2AA6B7AB0FF444BF05"
      unitRef="usd">17065200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e3497-wk-Fact-118AB936D3C45732B5CEF0784D36F781"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e3517-wk-Fact-82C6EA1AAA685D239E476B625189F3A3"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101507987e3538-wk-Fact-A2AF55501BAD547995BE423EF29B658C"
      unitRef="usd">13995900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e3557-wk-Fact-1D8876B1731957869AFE70032B521CC1"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101507987e3577-wk-Fact-29E33AB9B71A5B1A92211499B9EFB12B"
      unitRef="usd">13991800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e4175-wk-Fact-640CE05F3EE159F4B8DA91CA166AC695"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e4194-wk-Fact-BA6F1D3312C05F18A38960700E33CC05"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e4208-wk-Fact-D3BDFEC3E79257F59F85C4A727DF1294"
      unitRef="shares">221000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e4228-wk-Fact-5980E45B3ECB52FD83B0E414D6AE5A50"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e4247-wk-Fact-5AA8653F41B750478F7DA9FB1355EDB5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e4266-wk-Fact-9D201A6242E55282985A0646AED341FB"
      unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e4287-wk-Fact-2FD96C1583D65C0F99E4B96F1E23CCFD"
      unitRef="usd">16257000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e4301-wk-Fact-5DC1AF8E16045C7FBCA71C7ADBD7E0C3"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e4321-wk-Fact-8FCF068AA21E5675B1639DAAB3CDA1E6"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101507987e4342-wk-Fact-44AC8A01AD1356F5A9EB4B9A72137222"
      unitRef="usd">13039600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e4361-wk-Fact-4F348DB3C0885EACBA22A7154D42FB37"
      unitRef="usd">-8000000.0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101507987e4381-wk-Fact-B09AC96B85E159EC99ACF965755BAF33"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e4509-wk-Fact-87B56E85E8F5514884B7DA0E6FB7C373"
      unitRef="usd">4448800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e4564-wk-Fact-FF611939A9605722A2FA20072DD911C0"
      unitRef="usd">4448800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e4583-wk-Fact-A2ECB36D60F058E3948D45C8C21EECAE"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e4602-wk-Fact-3AADFF2A153C519091C711159E3B32B2"
      unitRef="usd">4448800000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e4714-wk-Fact-E855D976E7645FE28E8294E32E091502"
      unitRef="usd">148100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e4790-wk-Fact-4BE449ABC68C5BBB868E2225D4530616"
      unitRef="usd">148100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e4809-wk-Fact-E2004262817151D596898DC67BE629EA"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e4829-wk-Fact-23D720C9EF9A5C77A76E77E1DFCDC213"
      unitRef="usd">147700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d101507987e5018-wk-Fact-205D79FBA7D059F08F4090774ECEE149"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e5037-wk-Fact-DE9772B0D0435724B042B1219FF18757"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e5056-wk-Fact-B5B48664EC8D575FA9E9FFA7A551865F"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e5209-wk-Fact-510D324B12955B8EAD22685535814769"
      unitRef="shares">7000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e5224-wk-Fact-2F6D738388A958379B44B92B02FF9D56"
      unitRef="usd">1627800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e5245-wk-Fact-8335EEDD20175A37A9DE25E92A95A616"
      unitRef="usd">1627800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e5285-wk-Fact-8335EEDD20175A37A9DE25E92A95A616"
      unitRef="usd">1627800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e5342-wk-Fact-3821DC30956C542DA4446D5DD426373A"
      unitRef="shares">7000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e5358-wk-Fact-C3C91327E47C539D8EF62B05CE17C1A0"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e5377-wk-Fact-3ECF397022DD524DA353DCC4084A542E"
      unitRef="usd">74800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e5418-wk-Fact-7882078D6A43591D8BB48ED60EA826D8"
      unitRef="usd">1553000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e5438-wk-Fact-3DF00A101904587BBCFF856168B2B98F"
      unitRef="shares">7000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e5452-wk-Fact-2B4D4C1ED9FF50E99F2E3C2D3F531A97"
      unitRef="usd">1627800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e5472-wk-Fact-28ECDBDD7EA05C14AD813D69BDCAE900"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e5511-wk-Fact-28ECDBDD7EA05C14AD813D69BDCAE900"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e5664-wk-Fact-F5875C2744F050EC9C24E1D87C9CD0EE"
      unitRef="shares">8900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e5679-wk-Fact-4378ACB64E0D5BA593FA0EC569E8175D"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e5700-wk-Fact-FD45E4C38F2F5B4681DF318A97EE6344"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e5740-wk-Fact-FD45E4C38F2F5B4681DF318A97EE6344"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e5797-wk-Fact-E05FD02788A45D47BC37067FB850FEF3"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e5813-wk-Fact-6174981275CB50BFBCB1136224B468BE"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e5832-wk-Fact-CD87922BB008598BBB34A2B6DCB668AC"
      unitRef="usd">110500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e5873-wk-Fact-F1561880AB1C52F194880CCD1A595DE2"
      unitRef="usd">2036900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e5893-wk-Fact-25FB1518268E547FA41946AAC16848E9"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e5907-wk-Fact-DD9D4F8F2BCD5A37803F322F526F66A3"
      unitRef="usd">2147400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e5927-wk-Fact-3D25247FC091590BA5F465588A682F8E"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e5966-wk-Fact-3D25247FC091590BA5F465588A682F8E"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e6022-wk-Fact-4CCB10CA01D5543C85D4DA480E3CBEEC"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e6037-wk-Fact-B54D0FC34EE158628C62C2C218E4C3F4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e6056-wk-Fact-B256372F76AC51E7808CB990AF565FB7"
      unitRef="usd">33500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e6152-wk-Fact-46269E519E135F9AB903964D533B4863"
      unitRef="usd">33500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e6191-wk-Fact-46269E519E135F9AB903964D533B4863"
      unitRef="usd">33500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e6248-wk-Fact-56DCB67FD1D557699C17C430276DC180"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e6263-wk-Fact-1F619C17BB725C04906FE6C91ECF3667"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e6282-wk-Fact-45188D4ADF8F50B08797279C4E24F40E"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e6322-wk-Fact-643A87850FA15BADAD9C60992EDDF4DF"
      unitRef="usd">50700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e6378-wk-Fact-7630FD4D8FC75971B59A587F7F17E3BC"
      unitRef="usd">50700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e6418-wk-Fact-7630FD4D8FC75971B59A587F7F17E3BC"
      unitRef="usd">50700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e6511-wk-Fact-64E4A81E47555B93B86D8FBAE52AA5BB"
      unitRef="usd">151800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e6607-wk-Fact-1AA391F5B67958DF883BA3E4EDC0D597"
      unitRef="usd">151800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101507987e6646-wk-Fact-1AA391F5B67958DF883BA3E4EDC0D597"
      unitRef="usd">151800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesIssued
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e6667-wk-Fact-CC4EAD3DDB495DECA91DF851D5A77A08"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e6686-wk-Fact-5C4E8F58B2925D6F8DEC5D09D278C5CA"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e6700-wk-Fact-ACE49EE2E82D5033AE6D239D6DCE8F40"
      unitRef="shares">205700000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e6720-wk-Fact-8CE223771A1F51ECB44C691CF1FD8979"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e6739-wk-Fact-9573B47AB29854CE9B9E18F15E746C28"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e6758-wk-Fact-87A8BF94786F56169B1ACC6749A4C8FE"
      unitRef="usd">-92300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e6779-wk-Fact-51D3851DCF2E5B2AA6B7AB0FF444BF05"
      unitRef="usd">17065200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e6793-wk-Fact-118AB936D3C45732B5CEF0784D36F781"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e6813-wk-Fact-82C6EA1AAA685D239E476B625189F3A3"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101507987e6834-wk-Fact-A2AF55501BAD547995BE423EF29B658C"
      unitRef="usd">13995900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e6853-wk-Fact-1D8876B1731957869AFE70032B521CC1"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101507987e6873-wk-Fact-29E33AB9B71A5B1A92211499B9EFB12B"
      unitRef="usd">13991800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e7456-wk-Fact-E51C6323182B5FC3A6EB103E00DB77B8"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e7475-wk-Fact-61562AE107465300BFF198C54788ABBC"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e7489-wk-Fact-5C5B8621389050A491B1E92CA9C22DCC"
      unitRef="shares">225200000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e7509-wk-Fact-58375CCABF015F62AE1AEFAE888B6E53"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e7528-wk-Fact-8A4511BAFD5B5A95B03413B6D11BE0DD"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e7547-wk-Fact-98C33DC28B9D5F2DBAB0B3184BC93238"
      unitRef="usd">-261600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e7568-wk-Fact-282DEC3F60005849887987904B177308"
      unitRef="usd">15499500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e7582-wk-Fact-8CEADDBC7458518189E8E7295BA4870F"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e7602-wk-Fact-0432F42C91FA5A808696EE47577A6010"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2"
      decimals="-5"
      id="d101507987e7623-wk-Fact-F76936530B485B38961CD48EA3AEEA7E"
      unitRef="usd">12260900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e7642-wk-Fact-2FD89C272F495BF8828BFFC171A64752"
      unitRef="usd">-7200000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2"
      decimals="-5"
      id="d101507987e7662-wk-Fact-42ADE483BB3251C48FFAAB53DC167672"
      unitRef="usd">12253700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e7790-wk-Fact-A26D3704484E5397BA9ADDD934CAFDFE"
      unitRef="usd">1444400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e7845-wk-Fact-A3394798436750ACA93FC560D5254E0D"
      unitRef="usd">1444400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e7864-wk-Fact-024FA8A2E157538AA584D37B41907406"
      unitRef="usd">-1500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e7884-wk-Fact-4C53D8055C3559E2AB7DBEC22965795A"
      unitRef="usd">1442900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e7996-wk-Fact-6E3CEDF358695E12B9E914F1CA53A5FF"
      unitRef="usd">13300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e8072-wk-Fact-2E58A4FBEAF45408A246611108CA9348"
      unitRef="usd">13300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e8091-wk-Fact-F0DFA38CAF0C5B1D97BA81438DA090CF"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e8110-wk-Fact-608D1370C40657139D4C33E5BB2CD622"
      unitRef="usd">13300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d101507987e8299-wk-Fact-323E5F0CDDEE5FA5BB637DC9CC04C09A"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e8318-wk-Fact-ACFCE8E381FB57B2888342A6D52F4668"
      unitRef="usd">1900000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e8337-wk-Fact-18D534EB12FF505F9996530C8F3390AD"
      unitRef="usd">1900000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e8393-wk-Fact-5F884D20FD3050148A78633FD8B307EC"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e8408-wk-Fact-DB812A2481E65909AFF9B3CBA2E6C5C6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e8427-wk-Fact-0E6C1FD978545ACC980E531CD5A4507D"
      unitRef="usd">8700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e8523-wk-Fact-75B4DACC04005DCFA08C26F946A49A3B"
      unitRef="usd">8700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e8562-wk-Fact-75B4DACC04005DCFA08C26F946A49A3B"
      unitRef="usd">8700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e8618-wk-Fact-7B4F909B5F2F5793A0721BAB900C8CAA"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e8633-wk-Fact-EF43F2A8951D5B8FB8D13AD4178DE5F2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e8652-wk-Fact-C7EAACC8B2AD52D5B05D3FF9CB6233E4"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e8749-wk-Fact-082523185C3F5AFE8368BF402B372E61"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e8789-wk-Fact-082523185C3F5AFE8368BF402B372E61"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e8882-wk-Fact-E4B73AAEA7B45092971A9AC9B265CC7B"
      unitRef="usd">40200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e8922-wk-Fact-DDFC03AF46AF3CF2584B827AD9B1CC40"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e8977-wk-Fact-24D337343CEF5BE2AAC244DB803F478E"
      unitRef="usd">40400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101507987e9016-wk-Fact-24D337343CEF5BE2AAC244DB803F478E"
      unitRef="usd">40400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesIssued
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e9037-wk-Fact-EACEFE8818A25323BA3CFD81656894FD"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e9056-wk-Fact-2269215F690C560CA4134A321A2D0D92"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e9070-wk-Fact-F92BA010426D5AA29FCAA297EE15E6FA"
      unitRef="shares">225200000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e9090-wk-Fact-66CA277143645300B289A549905DF29F"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e9109-wk-Fact-2CA404F5369756B792C0224B994DC944"
      unitRef="usd">47800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e9128-wk-Fact-F21626A61C08532E9B7F50AB676FB8EB"
      unitRef="usd">-248300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e9149-wk-Fact-FF433E37989959FAAAE2A6F4E212120B"
      unitRef="usd">16944100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e9163-wk-Fact-3E306F47AF775673B1493E17FE6A5D3E"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e9183-wk-Fact-AEA6364BFD7B5F1EA4EE6512823F7A11"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q3"
      decimals="-5"
      id="d101507987e9204-wk-Fact-513B120271295CE4B9FB2CCB29CD1744"
      unitRef="usd">13766600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e9223-wk-Fact-1B479A781AB75A8DBFC27D42C87AC415"
      unitRef="usd">-6800000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3"
      decimals="-5"
      id="d101507987e9243-wk-Fact-31E771B49E045426B9D89F8B2EB22F2F"
      unitRef="usd">13759800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e9845-wk-Fact-67E6C07379C557679C5CD039B938981C"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e9864-wk-Fact-AFF300890C5B56149EC7A6408C949257"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e9878-wk-Fact-628FDE18159551DB81DCBB916428E239"
      unitRef="shares">235300000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e9898-wk-Fact-C967049A914B51E59ECF3C1EF5BC62D0"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e9917-wk-Fact-AA9DC132C178521DB8DB36B219D284FE"
      unitRef="usd">97800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e9936-wk-Fact-850D8B8C51005612908926183ECBDBE6"
      unitRef="usd">-318400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e9957-wk-Fact-1CD1FAB9A3AA5658B2A2AFE5875474C7"
      unitRef="usd">15810400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e9971-wk-Fact-A54361F0E14B5D1384B3E6508578D145"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e9991-wk-Fact-800C0410E2825448A4268BF65677612B"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-5"
      id="d101507987e10012-wk-Fact-9C60DE1EE2F45DB08FFE83925A33E132"
      unitRef="usd">12612800000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e10031-wk-Fact-FEFFC5DBBB485E22A627E15467845492"
      unitRef="usd">-14700000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4"
      decimals="-5"
      id="d101507987e10051-wk-Fact-87CC3B3CE380518AA61BBFF8C334DCB5"
      unitRef="usd">12598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e10179-wk-Fact-6A66AD4CE9175C5F903AF19781CC064F"
      unitRef="usd">3483900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e10234-wk-Fact-71E4AC6E479B5D7B8F2CABF3359E1159"
      unitRef="usd">3483900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e10253-wk-Fact-8439350BAD56597A8A7F7690E39982A6"
      unitRef="usd">45200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e10272-wk-Fact-2B961E9A38315302B816B2E71D3709C5"
      unitRef="usd">3529100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e10384-wk-Fact-4E00D9635B3D5A6BB6B95B57F55B0993"
      unitRef="usd">68600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e10460-wk-Fact-61FD074FCC6D59939B8BE32C48B29249"
      unitRef="usd">68600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e10479-wk-Fact-C9D377A4B2CD5DEE83E192BEC8C5E415"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e10499-wk-Fact-BA092162E3245744B49584C5B64CF75A"
      unitRef="usd">68300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d101507987e10688-wk-Fact-CD93967D392E59D5947CDD3E1EC69E04"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e10707-wk-Fact-64B6B93D9AFE518EB1B77AD291369DD9"
      unitRef="usd">13000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e10726-wk-Fact-C0A48F90FEEE56BF934148B6799C37E0"
      unitRef="usd">13000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d101507987e10915-wk-Fact-66ECB2986EDB5B029693209B725FC7C3"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e10934-wk-Fact-A8E8AF8CF17F5B9AA720A6BD25BD4ABD"
      unitRef="usd">-50000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e10954-wk-Fact-FC742150FFC65A9898AE7746E02ADF10"
      unitRef="usd">50000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e11108-wk-Fact-D4E83C15E9FC500496A238715166ED73"
      unitRef="shares">10500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e11123-wk-Fact-965EE22B3C8555B7BF3BE1D87DFA9156"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e11144-wk-Fact-DB6F8720372956F887FA506E41DB5912"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e11184-wk-Fact-DB6F8720372956F887FA506E41DB5912"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e11241-wk-Fact-FD6300FAFDED5105B5DE77393E2ED284"
      unitRef="shares">10500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e11257-wk-Fact-D267A46FFD475116A694815EA773E7FE"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e11276-wk-Fact-B692AC0C447C5284B390B5F9416D261A"
      unitRef="usd">171200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e11317-wk-Fact-2B2E99A011B558E5BEF2A86B70A192E4"
      unitRef="usd">2828800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e11337-wk-Fact-329F72046E2A52888E180A013094E208"
      unitRef="shares">10500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e11351-wk-Fact-049176E6EBF45DA1B091133E9EC76C48"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e11371-wk-Fact-D005A910D3F65E059B6A912C9F9375CF"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101507987e11410-wk-Fact-D005A910D3F65E059B6A912C9F9375CF"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e11466-wk-Fact-9C64F87F0ECA5CE2BF948C101CFB8C28"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e11481-wk-Fact-85EF591A928D5FFD98AE842D11DDEF29"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e11500-wk-Fact-DFB5692685BF527FAD879F93C68E08E3"
      unitRef="usd">33300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e11596-wk-Fact-FD84E25F75165A66904B79A688175405"
      unitRef="usd">33300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e11635-wk-Fact-FD84E25F75165A66904B79A688175405"
      unitRef="usd">33300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e11691-wk-Fact-1A9EBA5663E054B89FCE9372FE3D6E33"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e11706-wk-Fact-317E3982302D5AB998A103D8D3531E4C"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e11725-wk-Fact-8C7818D7B93857B786E408DFC23E3EB5"
      unitRef="usd">39900000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e11822-wk-Fact-0EB86ACB9D555B2589489E9742A19F14"
      unitRef="usd">39900000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e11862-wk-Fact-0EB86ACB9D555B2589489E9742A19F14"
      unitRef="usd">39900000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e11956-wk-Fact-BD5678E097C35B3095D4C73DB4B41E3F"
      unitRef="usd">127800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e11996-wk-Fact-B3DCA5818CE19DF73595827D19E08560"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e12051-wk-Fact-9F548400CF785562A855C94B904BA8E3"
      unitRef="usd">128000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e12090-wk-Fact-9F548400CF785562A855C94B904BA8E3"
      unitRef="usd">128000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q3YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e12202-wk-Fact-5CF94D26BF525028A2250536815ABB92"
      unitRef="usd">1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q3YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e12222-wk-Fact-09A404D67EA252448F389E431FA93CF9"
      unitRef="usd">478400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e12277-wk-Fact-B8E50576CA135DD497BBA962921C78E4"
      unitRef="usd">479900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101507987e12316-wk-Fact-B8E50576CA135DD497BBA962921C78E4"
      unitRef="usd">479900000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e12337-wk-Fact-EACEFE8818A25323BA3CFD81656894FD"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d101507987e12356-wk-Fact-2269215F690C560CA4134A321A2D0D92"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e12370-wk-Fact-F92BA010426D5AA29FCAA297EE15E6FA"
      unitRef="shares">225200000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d101507987e12390-wk-Fact-66CA277143645300B289A549905DF29F"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d101507987e12409-wk-Fact-2CA404F5369756B792C0224B994DC944"
      unitRef="usd">47800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101507987e12428-wk-Fact-F21626A61C08532E9B7F50AB676FB8EB"
      unitRef="usd">-248300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d101507987e12449-wk-Fact-FF433E37989959FAAAE2A6F4E212120B"
      unitRef="usd">16944100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e12463-wk-Fact-3E306F47AF775673B1493E17FE6A5D3E"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d101507987e12483-wk-Fact-AEA6364BFD7B5F1EA4EE6512823F7A11"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q3"
      decimals="-5"
      id="d101507987e12504-wk-Fact-513B120271295CE4B9FB2CCB29CD1744"
      unitRef="usd">13766600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d101507987e12523-wk-Fact-1B479A781AB75A8DBFC27D42C87AC415"
      unitRef="usd">-6800000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3"
      decimals="-5"
      id="d101507987e12543-wk-Fact-31E771B49E045426B9D89F8B2EB22F2F"
      unitRef="usd">13759800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-C8DC5FF7164C5EB98BC8DCA34E57F914-0-wk-Fact-92440B7D94115F868C1D3A2C62FA0743">Summary of Significant Accounting Policies&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy, Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K. Our accounting policies are described in the &#x201c;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x201d; in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Assets and Liabilities Held For Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-10, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-20, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Narrow-Scope Improvement for Lessors&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and ASU No. 2019-01, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Codification Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$463.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a corresponding operating lease liability of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$526.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the adoption of the new leasing standards, please read Note 11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on the composition of our investment portfolio and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 the FASB issued ASU No. 2018-16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative and Hedging&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-A3EB42A3C0FC5A6781CA40138BDFB135-0-wk-Fact-5A7E953BE9A254E59C384C101318038B">&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy, Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-F9ABB9575D2A54A9916199FE6719EB66-0-wk-Fact-10D945F8E9C95337BAD83499352ACC83">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K. Our accounting policies are described in the &#x201c;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x201d; in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="FD2019Q3YTD"
      decimals="0"
      id="d101485908e883-wk-Fact-A2BA10EC7AFA5596938BDCBCB3F6B3E1"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-B95F347E2C005A6F8330D91389B756B2-0-wk-Fact-F485BF7FE8DB5BF3A0DD9B947C251772">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d101485908e907-wk-Fact-5F4F73EAB6E8515AB264459AA161E2F5"
      unitRef="number">1</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q3YTD"
      id="TextSelection-F8AC6A77EBC05DCF8F155D373862AA69-0-wk-Fact-732A2AC9D3185967AED24B633D53CFF5">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <biib:AssetsandLiabilitiesHeldForSalePolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-7BD53852F84D52839FA8E8B6ADAE8BA7-0-wk-Fact-683EEBD63E9250209EAB833DA49B8505">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.&lt;/span&gt;&lt;/div&gt;</biib:AssetsandLiabilitiesHeldForSalePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-9F1453D21F46562DBD1F178C102012B9-0-wk-Fact-4D8A93214F525FDFA08B0CEAF25079AF">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-10, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-20, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Narrow-Scope Improvement for Lessors&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and ASU No. 2019-01, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Codification Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$463.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a corresponding operating lease liability of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$526.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the adoption of the new leasing standards, please read Note 11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on the composition of our investment portfolio and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 the FASB issued ASU No. 2018-16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative and Hedging&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d101485908e1025-wk-Fact-B9D751963A5C56428A0708B1A8027EC2"
      unitRef="usd">463000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d101485908e1029-wk-Fact-EB17D24F1D1E581EA23B15C74C7ED6CB"
      unitRef="usd">526000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-80D234F22FCA5408ACD813AC13201460-0-wk-Fact-CD0670D4E97A5F24874B654FCD6F7A48">Acquisitions&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquisition of Nightstar Therapeutics plc&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On June 7, 2019, we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid-to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (formerly known as NSR-REP1), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (formerly known as NSR-RPGR), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of this acquisition, we paid NST shareholders &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$25.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for each issued and outstanding NST share, which totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$847.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for equity compensation, which is  attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$26.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$18.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recognized as a charge to selling, general and administrative expense with the remaining &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$7.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of June&#160;7, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;700.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;112.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(77.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;852.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our estimate of the fair value of the in-process research and development (IPR&amp;amp;D) programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$480.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have recorded an additional IPR&amp;amp;D asset related to BIIB112 of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$220.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for global intangible low-taxed income (GILTI). Goodwill that is tax deductible for GILTI purposes is approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$35.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management&#x2019;s analysis related to certain matters, such as preparing and submitting certain income tax and non-income tax filings and returns. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the date of acquisition. Although the final determination may result in asset and liability fair values that are different &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;than the preliminary estimates of these amounts, it is not expected that those differences will be material to our financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our condensed consolidated statements of income. Subsequent to the acquisition date, our results of operations include the results of operations of NST.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="2"
      id="d101483402e789-wk-Fact-7E5E8DBBAE565B34A7AF24BB9456F861"
      unitRef="usdPerShare">25.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e793-wk-Fact-D3238A1CD9355C9683943A40A4B4EF51"
      unitRef="usd">847600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e797-wk-Fact-3CA598FA9D1C56D1A699E7C09C3E2705"
      unitRef="usd">4600000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember"
      decimals="-5"
      id="d101483402e801-wk-Fact-02406D0B4C7B577BA19CB8437EDE637F"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d101483402e805-wk-Fact-93945BBBB40F5784B8B52F1B7D28591C"
      unitRef="usd">18400000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d101483402e810-wk-Fact-6EFEAD92D2DB570B99C5EF06CB7EB74F"
      unitRef="usd">7800000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-057F4220308A5B3281DDB95F4B616315-0-wk-Fact-1B569434FBF651009EF39DA797B1FFAB">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of June&#160;7, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;700.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;112.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(77.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;852.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e865-wk-Fact-FDD59567C12552EE9E55E8AC6B8701AA"
      unitRef="usd">107800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e880-wk-Fact-8740F5C2B07059CDB1B0D4093F297119"
      unitRef="usd">7500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e900-wk-Fact-CBAA3B57AABA5FB385FF1A913131541A"
      unitRef="usd">700000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e920-wk-Fact-94999C2882305AF6B77E2E7FD3098A55"
      unitRef="usd">112600000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e940-wk-Fact-324597F783FC5FF4BEF90FC41F72CA9D"
      unitRef="usd">77000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e961-wk-Fact-2B403C71069256C2AB974DFB9ADB1528"
      unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e986-wk-Fact-4027A97040475C659B141F00267D1D65"
      unitRef="usd">852200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="3"
      id="d101483402e998-wk-Fact-AA40ADDD487656DBB2E7888A321E795E"
      unitRef="number">0.125</biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e1002-wk-Fact-320685B0257F5776A7DDAC645D5409E0"
      unitRef="usd">480000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e1006-wk-Fact-1BFC840C7D285AAF922A642EEA5A6310"
      unitRef="usd">220000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101483402e1013-wk-Fact-AAD835787B3A5B3C9777BC4D028CA071"
      unitRef="usd">35000000.0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-43714A3A234C582FBBFDB6F954E1F9EC-0-wk-Fact-D683DB22A14C5F2B86E91C56ED55089D">Divestitures&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM Corporation (FUJIFILM). Upon the closing of this transaction, we received approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$881.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash, which is subject to the finalization of certain working capital adjustments and may be further adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of this transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$114.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#xf8;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#xf8;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this transaction we recognized a total net loss of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$160.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our condensed consolidated statements of income. This loss included a pre-tax loss of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$95.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflects a decrease of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$17.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our previously recorded pre-tax loss. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#xf8;d, Denmark manufacturing operations of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$11.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and our estimate of the fair value of an adverse commitment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$114.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with the guarantee of future minimum batch production at the Hiller&#xf8;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$64.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we sold to FUJIFILM &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$41.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of raw materials that were remaining at the Hiller&#xf8;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our estimate of the fair value of the adverse commitment is a Level 3 measurement and is based on forecasted batch production at the Hiller&#xf8;d facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101498098e785-wk-Fact-689EE6A35350571A87DA2F9AC691BEFE"
      unitRef="usd">881900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2019Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101498098e792-wk-Fact-A2B459457A495987811DA496F1828779"
      unitRef="usd">114000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101498098e812-wk-Fact-4EE52A55094459C6BCEAF64211C50B24"
      unitRef="usd">160200000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101498098e816-wk-Fact-0FDDE334468A5B84B73FA243BD3A679D"
      unitRef="usd">95500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101498098e820-wk-Fact-62082251A99C55549B0CB0CAD7FBEA3D"
      unitRef="usd">17700000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101498098e824-wk-Fact-4B40B74AFA11528B9700D00D489DA14B"
      unitRef="usd">11200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2019Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101498098e828-wk-Fact-A2B459457A495987811DA496F1828779"
      unitRef="usd">114000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101498098e833-wk-Fact-DE53D21C5AE75E5C9034597BF3D7AAAC"
      unitRef="usd">64700000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <biib:InventoryrawmaterialssoldtoFUJIFILM
      contextRef="I2019Q3Denmark"
      decimals="-5"
      id="d101498098e840-wk-Fact-3EEED51EAB3E718B7FAB8288CBBDFAD2"
      unitRef="usd">41800000</biib:InventoryrawmaterialssoldtoFUJIFILM>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-1D889E6639C65375AFDCB8FC86303457-0-wk-Fact-25F26B4037405985855F7BD422C401B7">Revenues&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;842.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;280.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,122.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;842.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;247.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,090.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;360.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;530.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;421.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;168.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;590.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;263.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;483.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;253.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;217.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;470.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,465.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;694.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,160.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,516.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;656.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,172.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;236.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;310.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;547.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;223.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;243.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;467.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;115.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;115.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;123.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;123.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;18.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;18.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;183.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;183.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;134.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;134.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,702.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,192.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,894.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,740.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,039.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,780.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,429.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;841.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,271.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,396.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;766.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,163.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,067.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;518.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,585.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,237.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;528.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,765.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;772.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;647.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,419.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;768.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;631.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,399.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;71.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;71.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ZINBRYTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,269.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,078.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,347.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,402.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,997.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,400.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;690.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;863.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,553.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;617.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;636.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,254.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;360.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;360.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;359.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;359.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;132.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;132.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,959.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,495.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8,455.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,020.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,040.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,061.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.4%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.4%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;127.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;888.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;480.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,149.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;16.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,646.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(46.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(349.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1,510.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1,860.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(129.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(564.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(15.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(709.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;129.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;917.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;39.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,085.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;201.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;176.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;884.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,085.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;393.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;358.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,161.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,066.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;202.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;528.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;378.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;595.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;511.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,689.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,445.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2018 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;12.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;89.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;93.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;91.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;462.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;311.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;109.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;147.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;562.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;420.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$65.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$306.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$36.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$131.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we will license certain of our manufacturing-related intellectual property to the customer. We will be eligible to receive &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$500.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in a series of three payments. The first payment is due upon a regulatory achievement related to the customer&#x2019;s product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We do not expect to recognize any amounts related to this arrangement in 2019 as we do not expect the regulatory achievement to occur until 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc., please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our manufacturing and supply agreement with Bioverativ, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-0C39E7E4E5D655E5AEAE24717E6B0E0B-0-wk-Fact-E82C1AB9A0FB570BA1E9664BD3B66EAE">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;842.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;280.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,122.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;842.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;247.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,090.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;360.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;530.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;421.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;168.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;590.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;263.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;483.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;253.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;217.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;470.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,465.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;694.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,160.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,516.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;656.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,172.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;236.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;310.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;547.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;223.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;243.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;467.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;115.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;115.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;123.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;123.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;18.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;18.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;183.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;183.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;134.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;134.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,702.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,192.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,894.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,740.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,039.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,780.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,429.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;841.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,271.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,396.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;766.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,163.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,067.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;518.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,585.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,237.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;528.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,765.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;772.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;647.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,419.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;768.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;631.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,399.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;71.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;71.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ZINBRYTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,269.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,078.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,347.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,402.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,997.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,400.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;690.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;863.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,553.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;617.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;636.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,254.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;360.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;360.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;359.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;359.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;132.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;132.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,959.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,495.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8,455.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,020.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,040.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,061.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e1343-wk-Fact-853171242B68503587FBEC4038B47293"
      unitRef="usd">842000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e1362-wk-Fact-BF48983D080957E7B815FA0C3502EDB1"
      unitRef="usd">280400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d101529877e1381-wk-Fact-DE3610F9879252498BCB5354554F4A19"
      unitRef="usd">1122400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e1401-wk-Fact-3FD9A507904A5096A01524B328058BC4"
      unitRef="usd">842100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e1420-wk-Fact-09B20DB4293656E7A49617D8E5A51692"
      unitRef="usd">247900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d101529877e1440-wk-Fact-9A47A99ABF9C518D854EEE334C0AACBF"
      unitRef="usd">1090000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e1455-wk-Fact-BF03E0D0E27A50D683F01C14953DA5DC"
      unitRef="usd">360300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e1474-wk-Fact-8670B929DC3B5825A7A8F6977372C6A0"
      unitRef="usd">169700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d101529877e1493-wk-Fact-880E09F7D11E5018B50A36CDA70FC1F3"
      unitRef="usd">530000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e1513-wk-Fact-35A608A4A05D522AA4AD993645AC5C89"
      unitRef="usd">421500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e1532-wk-Fact-4B4F7E17FB32592DA26353BFDD6F147F"
      unitRef="usd">168600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d101529877e1551-wk-Fact-FB1A3358CB9D5438B04ED89CCBB61053"
      unitRef="usd">590100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e1572-wk-Fact-4E38C68EBA705361B296C94BC4D0622A"
      unitRef="usd">263000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e1591-wk-Fact-81845EFA29B15F8DBE92C6F78DF312AA"
      unitRef="usd">220600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d101529877e1610-wk-Fact-A2DB69BE11445A48AD6560F0B7B24AA0"
      unitRef="usd">483600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e1630-wk-Fact-CAACF16CA10F5AF4A6D84021D9DE462D"
      unitRef="usd">253000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e1649-wk-Fact-426E1A52BF4B5A559273EFF28DB739DD"
      unitRef="usd">217200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d101529877e1668-wk-Fact-EAB6C8ED01CD5C1492BFB5D2F67C839E"
      unitRef="usd">470200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e1689-wk-Fact-187FEF0C8BFD55B8984A747A0DA55EB9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e1708-wk-Fact-6C7A9C768B3C582D99CCD9C6D91CC688"
      unitRef="usd">24200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d101529877e1727-wk-Fact-29584C2B33B7551BB7544A63DD58E35C"
      unitRef="usd">24200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e1747-wk-Fact-B1C611986C0A52ED83827AF1FC9EB313"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e1766-wk-Fact-A2BD646F4AEF51CD9AB55DB5E68B9266"
      unitRef="usd">22500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d101529877e1785-wk-Fact-7B5B5FF0494457E091F7A7694C59E1A4"
      unitRef="usd">22500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e1806-wk-Fact-07D89EE4DCDA57DAB1C0874F24526EF8"
      unitRef="usd">1465300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e1825-wk-Fact-6992AC0E1F9055AE88242E66CBA624EB"
      unitRef="usd">694900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d101529877e1844-wk-Fact-D5A3B6BFBCE85F009AE119B547F30AD0"
      unitRef="usd">2160200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e1864-wk-Fact-5C787CD13D6552E28949D84608670793"
      unitRef="usd">1516600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e1883-wk-Fact-79D50D31ED295DE7BC1057EB3AC4AECD"
      unitRef="usd">656200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d101529877e1902-wk-Fact-A03F60F5FE5E5A74908718AE4203C4CC"
      unitRef="usd">2172800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e2168-wk-Fact-0101A37FFB15521C9E8B78CD4B283DE4"
      unitRef="usd">236700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e2187-wk-Fact-97B7AE2C71565213B2ABB2D86B39A9C7"
      unitRef="usd">310400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d101529877e2206-wk-Fact-8E69163ECEF656F49FB4E8DCE90D54C7"
      unitRef="usd">547100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e2226-wk-Fact-81CE911D5EE555169927C917E1B90CD4"
      unitRef="usd">223900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e2245-wk-Fact-59BDC4BDA2B052C79EEEB615BF72FF1B"
      unitRef="usd">243800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d101529877e2264-wk-Fact-0611A1813C185C82B8BE108AFA03518F"
      unitRef="usd">467700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e2529-wk-Fact-0CE237F505BF54E2918B4A0848D45484"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e2548-wk-Fact-EC53E8E738ED50A7937E7F2A29F13552"
      unitRef="usd">115900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d101529877e2567-wk-Fact-8F3FEFFA6A615F0EA12D47EAE96AD735"
      unitRef="usd">115900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e2587-wk-Fact-00CA8CF575AC59BF8BC57FB6BE2F67CF"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e2606-wk-Fact-DA1E7499B60F5D2EBB4FBA7C736ACD2A"
      unitRef="usd">123400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d101529877e2625-wk-Fact-595C90A876BC54DDBDA5A34B9FB5B33B"
      unitRef="usd">123400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e2646-wk-Fact-9D33FEDCCD185B2BAD82EDFB01E6AC2E"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e2665-wk-Fact-056CA68F5D4E5F399D72C046C6C42658"
      unitRef="usd">49300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d101529877e2684-wk-Fact-CB95F3D8829B572F900CA994795189FB"
      unitRef="usd">49300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e2704-wk-Fact-0E54A9087FF85E0AB3A1F1953DAD6265"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e2723-wk-Fact-C9A31662B3BF52CF9D49403F16FD995A"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d101529877e2742-wk-Fact-E58A85A1D12052BB92DC8FD099184C7E"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e2763-wk-Fact-2D7E70C21D81512B96E44327FBF09A5D"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e2782-wk-Fact-4D6E36EC54D95EDF94F4FB08A8DAA8B9"
      unitRef="usd">18400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d101529877e2801-wk-Fact-8C6F7D41B83C530BA9E925EC85F85932"
      unitRef="usd">18400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e2821-wk-Fact-80F67AD0F114501797B9FC89287323A1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e2840-wk-Fact-A47955A2C5285BF38D65766E08A79083"
      unitRef="usd">11400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d101529877e2859-wk-Fact-23F6ED6519555137924F15D3E995AF4C"
      unitRef="usd">11400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e2880-wk-Fact-33BAEDAF2FA054F985F169557CFC4540"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e2899-wk-Fact-F85E37A42298574390709C8CA5A6D4F7"
      unitRef="usd">183600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d101529877e2918-wk-Fact-3F6B7361FE9859CA88E450DF26EC5912"
      unitRef="usd">183600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e2938-wk-Fact-8FD47159E3CB5EF5BB2605CCF9D4EC37"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e2957-wk-Fact-2BB94E4EF8E85B18A99B70BA8422B71A"
      unitRef="usd">134800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d101529877e2976-wk-Fact-94C217E97A1C56CBAC6846AF303648B1"
      unitRef="usd">134800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e3243-wk-Fact-FA955BA425175A3085E504F9B0F79DE8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e3262-wk-Fact-50ED3A59B4E853F3BC1801DFB2308899"
      unitRef="usd">3800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d101529877e3281-wk-Fact-BA9D024A1CB95359906FBBC4497CC6C1"
      unitRef="usd">3800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e3301-wk-Fact-788AC6E3B7B05E619C6186D3831B35FD"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e3320-wk-Fact-5F1957947E7E594881BD8C3E51E405E0"
      unitRef="usd">4800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d101529877e3339-wk-Fact-ED83FF3D46F551BEB8B3FCE7BFF08AD6"
      unitRef="usd">4800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e3365-wk-Fact-5357ACAA4D32560A86013038725C2F2E"
      unitRef="usd">1702000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e3384-wk-Fact-3AC2E331ABF757469EE9C93141B67CB3"
      unitRef="usd">1192700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d101529877e3403-wk-Fact-3D28795085EA575193C5CA658480CEC6"
      unitRef="usd">2894700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e3423-wk-Fact-28DC9950B2AC5004A490D39C838B7D2A"
      unitRef="usd">1740500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e3442-wk-Fact-41AF5FF12CF5554882698AD725EDC469"
      unitRef="usd">1039600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d101529877e3462-wk-Fact-7BF8AC4CA5E1523582F8817F03BD95BF"
      unitRef="usd">2780100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4021-wk-Fact-B553A3FC703459E5A24F35D5BF5CAA49"
      unitRef="usd">2429500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4040-wk-Fact-E95E928892A551AD9E3121E1C2890E74"
      unitRef="usd">841900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d101529877e4059-wk-Fact-FA3130C4C6B8589589757B247BBF72DB"
      unitRef="usd">3271400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4079-wk-Fact-11DF9D04E7325E62BD7E20AC971258F2"
      unitRef="usd">2396800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4098-wk-Fact-68ECCAA634F950B3A29581EF97E1D5B8"
      unitRef="usd">766900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d101529877e4118-wk-Fact-CC80D8F9D7E354E480E762CC21E2A1D5"
      unitRef="usd">3163700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4133-wk-Fact-A4F5388B06AB5886A0F9E38C67736146"
      unitRef="usd">1067300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4152-wk-Fact-B4F5FE0D7A4D54AFAD1EA1F49302680B"
      unitRef="usd">518000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d101529877e4171-wk-Fact-2D7888FD0756554CAFB99073C65815C1"
      unitRef="usd">1585300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4191-wk-Fact-661934C06E995138B72198AFAAD19A34"
      unitRef="usd">1237500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4210-wk-Fact-719D7D1AE55356978E170404862E7E34"
      unitRef="usd">528400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d101529877e4229-wk-Fact-E38DDE3262A55740A599A14E40B07510"
      unitRef="usd">1765900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4250-wk-Fact-0212F9B4B1E75FC8961F48DD039B254A"
      unitRef="usd">772300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4269-wk-Fact-18BB70B37AA9568C9B01AF72CBDC57B8"
      unitRef="usd">647000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d101529877e4288-wk-Fact-3551797135E0580FA589DF66BDD4715B"
      unitRef="usd">1419300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4308-wk-Fact-8BA2A304B8C05961B0C86A7293AD02FF"
      unitRef="usd">768200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4327-wk-Fact-A26FCF387C035A6DB626AA41F4A5FAB6"
      unitRef="usd">631300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d101529877e4346-wk-Fact-0FF1F9911852508B82AE4F55D4F74D78"
      unitRef="usd">1399500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4367-wk-Fact-0DF0A442C0395F1FA0987AE28ED96413"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4386-wk-Fact-56AB444319265ED5928AAF1010F7540A"
      unitRef="usd">71200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d101529877e4405-wk-Fact-246DFC47D1E454A0BAEB74F5F9C5DE10"
      unitRef="usd">71200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4425-wk-Fact-A84E817BAC105B07A662B42DFEAD8980"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4444-wk-Fact-F8997CC9D46C5DADBCFCEC4823ECE0BA"
      unitRef="usd">69900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d101529877e4463-wk-Fact-9B39582525F65CE1924CAB87BA62070B"
      unitRef="usd">69900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4484-wk-Fact-0EB98AD7A17059D8977E10B5351C77F2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4503-wk-Fact-134746D4AEA450C6A83018E6ABB47EC8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember"
      decimals="-5"
      id="d101529877e4522-wk-Fact-71462306E4DE55C5BED1C2894F6D7127"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4542-wk-Fact-2DC56A94150E50038CDA73C7DD11E028"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4561-wk-Fact-AB6B97956DA65E0391373125631A655F"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember"
      decimals="-5"
      id="d101529877e4580-wk-Fact-2C903D653B0B511DACBEF29001CC49C6"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4601-wk-Fact-3453A4C80F2B5654ABAFF817C01041D1"
      unitRef="usd">4269100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4620-wk-Fact-8EBFE15E72545622AC614BC706D50360"
      unitRef="usd">2078100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d101529877e4639-wk-Fact-E5168A2B72D355E58AB0F45E5451980A"
      unitRef="usd">6347200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4659-wk-Fact-CC91069BCD7E5586ADCB4507500DFD45"
      unitRef="usd">4402500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4678-wk-Fact-4AD1B5E71AD2596790DA76B503CF4704"
      unitRef="usd">1997900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d101529877e4697-wk-Fact-CEB1BE2C4A9350FDA49CFE276C89704C"
      unitRef="usd">6400400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e4965-wk-Fact-AA1B3FE9613C5B319DE9AB65E65DAE5C"
      unitRef="usd">690600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e4984-wk-Fact-97C82ECD8F6453FAAF26E05C9FAC5D1A"
      unitRef="usd">863200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d101529877e5003-wk-Fact-6CC16ABD0EEC5534B3D60F91A67DDFEE"
      unitRef="usd">1553800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e5023-wk-Fact-F72905555DC95202AC8A1FCD2C79F1E8"
      unitRef="usd">617800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e5042-wk-Fact-78B06C4372605EF5BCEA09FBEEE1ACEA"
      unitRef="usd">636500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d101529877e5061-wk-Fact-465AC814628E5CE08850F1D292A9F218"
      unitRef="usd">1254300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e5328-wk-Fact-50E19D7B3512570BB1E29520D4FBB83B"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e5347-wk-Fact-B1D6B521158556A7AC58AD812ACAFEA5"
      unitRef="usd">360200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d101529877e5366-wk-Fact-835AA356DEE75B06AF473218B6A99048"
      unitRef="usd">360200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e5386-wk-Fact-41CB512F9285526A85016E92B572E256"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e5405-wk-Fact-F99DB67CE5725D11992E9601AAB34B72"
      unitRef="usd">359900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d101529877e5424-wk-Fact-88A446DABF1F58598AFCFA4AC4FF8085"
      unitRef="usd">359900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e5445-wk-Fact-D03854B2554B5353B5B21EC490E31A8F"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e5464-wk-Fact-B2EFB8511CB55386AFAD774D4A5399CB"
      unitRef="usd">132300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d101529877e5483-wk-Fact-4694504C07325C468F7852A281286908"
      unitRef="usd">132300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e5503-wk-Fact-49B07F27CD3C5821ACFA485D4C54080F"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e5522-wk-Fact-5DE31F6F7FA25DDAB024C120716C9A11"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d101529877e5541-wk-Fact-CFAD58E1F67A5A3592C93317B2AD5F69"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e5562-wk-Fact-D3A2A398C8E7563F8BF445400A93C468"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e5581-wk-Fact-B36F406FCA245730A6117847243FF9FB"
      unitRef="usd">49900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d101529877e5600-wk-Fact-BEDAD413668D548AB54B1CE1DA568C89"
      unitRef="usd">49900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e5620-wk-Fact-9E8DC5EC9840596D937DB57FB3E3DC68"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e5639-wk-Fact-F2D586815CD053FABA749129356D0D60"
      unitRef="usd">29200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d101529877e5658-wk-Fact-F34A0D2B65625EBA8783DFFD157024C9"
      unitRef="usd">29200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e5679-wk-Fact-56878A03F07C596EA6C0EA1FAEF7AF8D"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e5698-wk-Fact-808E2815B0695918A73007D37B89E59F"
      unitRef="usd">542400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d101529877e5717-wk-Fact-A48BBC17448459BD9EC5EAB74ED619BC"
      unitRef="usd">542400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e5737-wk-Fact-1C5FFC9ECF4C535BB58980C978E1360B"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e5756-wk-Fact-D9BEDEBA8FAE53E28199D01D3298D1D1"
      unitRef="usd">389100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d101529877e5775-wk-Fact-3A50E721E3C85267B68DBF18A1B25BDE"
      unitRef="usd">389100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e6042-wk-Fact-B2618FD00F0B59A49DA7478020C06FB1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e6061-wk-Fact-A83516875A7B5AD08C6A9E2B1728B653"
      unitRef="usd">11600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d101529877e6080-wk-Fact-6DA687371D4250279E8D4249780A9A59"
      unitRef="usd">11600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e6100-wk-Fact-39294C6285D2595A986D6DFFE01D428D"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e6119-wk-Fact-DD14899F2B585BFEBC0CDBFCF21E47B9"
      unitRef="usd">17300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d101529877e6138-wk-Fact-011A83522E595928B70A8568EEE9FC68"
      unitRef="usd">17300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e6165-wk-Fact-8C9DFEAEB155584281323FE51C59B585"
      unitRef="usd">4959700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e6184-wk-Fact-A031E24CFBC251D5A964C7CF420EDB20"
      unitRef="usd">3495300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d101529877e6203-wk-Fact-57FC3BF8DA6B53A78893FAD196CDD478"
      unitRef="usd">8455000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d101529877e6223-wk-Fact-8B685FDF878C52FBA0A1B327E625E928"
      unitRef="usd">5020300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d101529877e6242-wk-Fact-DB7A56B25B415E7BA00F3080A9400CCF"
      unitRef="usd">3040800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d101529877e6262-wk-Fact-E8E82058EC25562986B774B17A9D2FFE"
      unitRef="usd">8061100000</us-gaap:Revenues>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="INF"
      id="d101529877e6278-wk-Fact-C61E43EB22CC5943ADC94704262F5FFB"
      unitRef="number">0.287</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="INF"
      id="d101529877e6282-wk-Fact-FD851A6E1E675851BFD061D688D340D8"
      unitRef="number">0.184</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="INF"
      id="d101529877e6294-wk-Fact-A72A49F9C1005FC59E5E1295A678F4DD"
      unitRef="number">0.301</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="INF"
      id="d101529877e6299-wk-Fact-4BF9A29C97E45C4EB52B9E7A010F1891"
      unitRef="number">0.170</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="3"
      id="d101529877e6314-wk-Fact-2652D87D583B5E548D209D8F99E75D20"
      unitRef="number">0.307</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="3"
      id="d101529877e6318-wk-Fact-868F694D43DB5A988013194B20313923"
      unitRef="number">0.193</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="3"
      id="d101529877e6330-wk-Fact-06567C00AE255BAF86D6DCAC34F5EF4A"
      unitRef="number">0.324</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="3"
      id="d101529877e6335-wk-Fact-DD0DA463314655248D36CB9003A7AE65"
      unitRef="number">0.180</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-6D9FD895E40E5D2C94B9B6756245BD90-0-wk-Fact-9BBAE3A3EA305CCDB7EF737D1A8A2636">&lt;div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;127.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;888.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;480.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,149.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;16.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,646.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(46.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(349.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1,510.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1,860.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(129.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(564.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(15.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(709.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;129.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;917.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;39.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,085.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d101529877e6482-wk-Fact-8D4A18B543235294BD95119660D23729"
      unitRef="usd">127800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d101529877e6501-wk-Fact-EDED2745A4E55EF88ABC9D738954C822"
      unitRef="usd">888800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d101529877e6520-wk-Fact-029B0A3DBE4351C4ACC6AA3EC03E58D4"
      unitRef="usd">34700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101529877e6540-wk-Fact-438A685C2FAD56AF9134724F56676CAC"
      unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d101529877e6555-wk-Fact-D5A32FAF0B0F587A940CD749BFC7B11D"
      unitRef="usd">480300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d101529877e6574-wk-Fact-3A58C432C96F51F8B5AFDCB90641EA1D"
      unitRef="usd">2149700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d101529877e6593-wk-Fact-599529A53E5B57C7904E672FE276F06A"
      unitRef="usd">16100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101529877e6613-wk-Fact-68A9F33ED61754EEAD6F51D9CAD27A81"
      unitRef="usd">2646100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d101529877e6633-wk-Fact-D6AC319FC4175583ACA854647F19BCAE"
      unitRef="usd">400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d101529877e6653-wk-Fact-5C9D6D9F7EC25CB0ACEC1BEBB526496D"
      unitRef="usd">46700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d101529877e6673-wk-Fact-C5570CD9005B559F9328489D66904433"
      unitRef="usd">-4600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101529877e6693-wk-Fact-511DED385AAB5DC1BA0B086A008ACD42"
      unitRef="usd">42500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d101529877e6714-wk-Fact-0ECDB2CB36AB52D98C76B44E430334AB"
      unitRef="usd">349300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d101529877e6734-wk-Fact-9955D42345DD5AF78DC234D819501CCE"
      unitRef="usd">1510000000.0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d101529877e6754-wk-Fact-5EFCEC7C44475C458F1694C6E433DC06"
      unitRef="usd">700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101529877e6775-wk-Fact-337839161C2752FDACAA22D365758851"
      unitRef="usd">1860000000.0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d101529877e6796-wk-Fact-92FEB920585455FCB7B5B84F3A85C890"
      unitRef="usd">129300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d101529877e6816-wk-Fact-C7802013E8A95037B07A33A42B405B03"
      unitRef="usd">564400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d101529877e6836-wk-Fact-BE477A46C7D55A3882BB32A4D0C85BA4"
      unitRef="usd">15400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101529877e6857-wk-Fact-8DE18F084E4B5E8AA7C941A25FC427AC"
      unitRef="usd">709100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d101529877e6883-wk-Fact-D28096BFED1753678E7D854A5FDC5CDD"
      unitRef="usd">129100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d101529877e6902-wk-Fact-DE36DF9E94245B0D99932D86DDCFF1CA"
      unitRef="usd">917400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d101529877e6921-wk-Fact-3AB2BBF12A55566FBAAB43073F619CBC"
      unitRef="usd">39300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101529877e6941-wk-Fact-B910D1665CA455B7826068B86CE5F1A6"
      unitRef="usd">1085800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-40B0449CC8A25BE49CAEC3A1C439FADB-0-wk-Fact-7AB0C86C6F9F57228C8150EB72D4BEA7">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;201.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;176.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;884.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,085.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-5"
      id="d101529877e7041-wk-Fact-8752645395D15ECEB06340FAF0BA0811"
      unitRef="usd">201600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-5"
      id="d101529877e7060-wk-Fact-676D5EB10A3F5B0C969A0EFE9CC2CA18"
      unitRef="usd">176600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d101529877e7075-wk-Fact-93E9038349A6549E86E73F0F4F359577"
      unitRef="usd">884200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d101529877e7094-wk-Fact-9790B7529BB852F99BAA6B9B78CB9C5C"
      unitRef="usd">874700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101529877e7119-wk-Fact-B910D1665CA455B7826068B86CE5F1A6"
      unitRef="usd">1085800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101529877e7138-wk-Fact-438A685C2FAD56AF9134724F56676CAC"
      unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-C2934E945E3A50979753BC5105F7D6E5-0-wk-Fact-A5FB1B58ABDA517AAE72671DB6126372">&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;393.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;358.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,161.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,066.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;202.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;528.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;378.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;595.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;511.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,689.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,445.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d101529877e7360-wk-Fact-B4B86F47BDF1540AB016AE4FFA426E0A"
      unitRef="usd">393200000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d101529877e7379-wk-Fact-EDD7FC64D769594BA686F2A1D2A5BC7D"
      unitRef="usd">358000000.0</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d101529877e7398-wk-Fact-71D19606B9155009BAAC8D2DA407F049"
      unitRef="usd">1161200000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d101529877e7418-wk-Fact-44A04E0F4FAF560DA2E675535E59D67D"
      unitRef="usd">1066600000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d101529877e7433-wk-Fact-F98145FEFE9B5AD89288DD63F6ABC6A9"
      unitRef="usd">202600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d101529877e7452-wk-Fact-28E199D3F30F5C6AB7581C161C93DEB0"
      unitRef="usd">153700000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d101529877e7471-wk-Fact-9B02CF57AFEB544E8C24E64802C076F4"
      unitRef="usd">528400000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d101529877e7491-wk-Fact-6FA55D7DE16C528C88E45FD0B02237E5"
      unitRef="usd">378700000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d101529877e7516-wk-Fact-8935D8BBEFCE5ED286B0DE4994D83C3D"
      unitRef="usd">595800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d101529877e7535-wk-Fact-084A8A14D1EB5CEC8E6948EA789D8A2A"
      unitRef="usd">511700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d101529877e7554-wk-Fact-6C7B08DD49815A12A560CB733CA3B725"
      unitRef="usd">1689600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d101529877e7574-wk-Fact-7BBDC0B573795D11894123AF71626259"
      unitRef="usd">1445300000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-496DF7A53C2B54F988A7CFE4E1A75B06-0-wk-Fact-91BC6C27CD6F544DB8797FD1409B1D45">&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;12.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;89.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;93.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;91.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;462.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;311.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;109.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;147.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;562.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;420.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101529877e7885-wk-Fact-73A4D8F8BB8B5419A251C4694C2C38D6"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101529877e7904-wk-Fact-8F32597DF04C547A903997CAFDC3B829"
      unitRef="usd">-700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101529877e7924-wk-Fact-BBAE89907F4A57E99B103B09253D17C0"
      unitRef="usd">-200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101529877e7945-wk-Fact-15BD9EAD2231570AB80EDD696AA88F4B"
      unitRef="usd">-7900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101529877e7961-wk-Fact-007F8062360750B4935397733B1696A8"
      unitRef="usd">12900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101529877e7980-wk-Fact-4FCBEA0BFDC85739AE7ACF6AA208D890"
      unitRef="usd">48100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101529877e7999-wk-Fact-80570CCC93D455EE94682B88CBB2F344"
      unitRef="usd">89900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101529877e8019-wk-Fact-100A1E9EF88E5AA082807EF6F1A109DD"
      unitRef="usd">80700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d101529877e8117-wk-Fact-902C56E9060E5FF9B0298198E8BD161E"
      unitRef="usd">3300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d101529877e8136-wk-Fact-02C92B55FBD059ACA7C3A3D7DC814983"
      unitRef="usd">7900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d101529877e8155-wk-Fact-13A197A7967D5F38BD3AE9BD4C8988F3"
      unitRef="usd">9900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d101529877e8175-wk-Fact-BE4BDBFB8A6F56EC92BF1261A9588E58"
      unitRef="usd">35800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d101529877e8195-wk-Fact-5761E083740451DFA00F565506F541EB"
      unitRef="usd">93100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d101529877e8214-wk-Fact-A1F23E4D29295EEB9B33E35F41B956B0"
      unitRef="usd">91900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d101529877e8233-wk-Fact-C3D691516939506A9B60FB15A3D7959F"
      unitRef="usd">462400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d101529877e8253-wk-Fact-50B60A0646AB5295ADE07664B861E04C"
      unitRef="usd">311600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101529877e8278-wk-Fact-DC33E683DC765E5C9A12FB403038A719"
      unitRef="usd">109600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101529877e8297-wk-Fact-F66F19EADE265DC9B1853BA2CA1992B0"
      unitRef="usd">147200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101529877e8316-wk-Fact-CEE81A8C61A050788B24277BCB2F809B"
      unitRef="usd">562000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101529877e8336-wk-Fact-0D413906F9E25B0A81CBE77DAF4D3714"
      unitRef="usd">420200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101529877e8359-wk-Fact-52263C8BD9895E598763262AE9975163"
      unitRef="usd">65600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101529877e8363-wk-Fact-EC8CFCC051075D0F8B49D175A4A2ED66"
      unitRef="usd">306900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101529877e8367-wk-Fact-2DAC540F7A8A5D51A0DF2A8E391221A2"
      unitRef="usd">36500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d101529877e8372-wk-Fact-22B9E97BBE415CEE9D40B4847DDBCC65"
      unitRef="usd">131100000</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q3_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d101529877e8379-wk-Fact-C9BE1C77D49835DAF003DF339247BCEA"
      unitRef="usd">500000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-623999EF47D450E591423751D554AA69-0-wk-Fact-3DF50D1EEF745415B4F7F35D3365F241">Inventory&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;159.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;421.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;606.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;170.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;751.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;751.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;929.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;751.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the first quarter of 2019 we sold to Bioverativ hemophilia-related inventory on hand with a cost basis totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$173.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. This transaction included the sale of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of work in process inventory. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we sold to FUJIFILM approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$41.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of raw materials that were remaining at the Hiller&#xf8;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-0C84CFE8C2BC54769812B88A1DD7724E-0-wk-Fact-9ED1C63A94995A96AF58119B533C18ED">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;159.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;421.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;606.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;170.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;751.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;751.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;929.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;751.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101504379e867-wk-Fact-1F5F40200E28588AA2FCBF16AC106042"
      unitRef="usd">159300000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101504379e886-wk-Fact-D5D7FB84C2DD5CD591483031F4A11D0F"
      unitRef="usd">196300000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101504379e901-wk-Fact-35866DFD4C3A58BBA658F07CF65E277E"
      unitRef="usd">421700000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101504379e920-wk-Fact-12A69F1BE8CB5F7CB0D00610855F4030"
      unitRef="usd">606700000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101504379e940-wk-Fact-86A82363F3B15C8C87E4DA100ECCC6F8"
      unitRef="usd">170800000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101504379e959-wk-Fact-0BB452B01D7458349EC77AE3AA9B44DB"
      unitRef="usd">133500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101504379e984-wk-Fact-AC403B171A93561E852D40EE4C010A90"
      unitRef="usd">751800000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101504379e1003-wk-Fact-492BA6EC4EA2580DB1B88690013645EE"
      unitRef="usd">936500000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101504379e1105-wk-Fact-C0E7BED0E0A95BE78B67788E90DC38BE"
      unitRef="usd">751800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101504379e1124-wk-Fact-E643FBEA510257AD9C0E842D75167864"
      unitRef="usd">929900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101504379e1139-wk-Fact-6B9FE764C5B25D7D9B1CA277A8CF3439"
      unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101504379e1158-wk-Fact-9A61F72C18CA56468209180BD8960C2D"
      unitRef="usd">6600000</us-gaap:InventoryNoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101504379e1183-wk-Fact-AC403B171A93561E852D40EE4C010A90"
      unitRef="usd">751800000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101504379e1202-wk-Fact-492BA6EC4EA2580DB1B88690013645EE"
      unitRef="usd">936500000</biib:Inventorynetcurrentandnoncurrent>
    <biib:InventorysoldtoBioverativcost
      contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_biib_BioverativMember"
      decimals="-5"
      id="d101504379e1222-wk-Fact-B43F604DFFF959C9ADFCC6E4B90A5E2B"
      unitRef="usd">173500000</biib:InventorysoldtoBioverativcost>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="FI2019Q3_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember"
      decimals="-5"
      id="d101504379e1235-wk-Fact-71E6A8218C76AB21E5A282AEE231F33B"
      unitRef="usd">14000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <biib:InventoryrawmaterialssoldtoFUJIFILM
      contextRef="I2019Q3Denmark"
      decimals="-5"
      id="d101504379e1242-wk-Fact-3EEED51EAB3E718B7FAB8288CBBDFAD2"
      unitRef="usd">41800000</biib:InventoryrawmaterialssoldtoFUJIFILM>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-D285D6F439165C71B9A95EB0F1AD89E4-0-wk-Fact-3D25F74F802F5CB197D20A41C7F45592">Intangible Assets and Goodwill&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;543.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(542.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;543.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(542.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-28&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,005.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2,764.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;240.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,005.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,734.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;270.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;954.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;954.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&#160;and&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&#160;rights&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&#160;patents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,638.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1,506.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,132.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,638.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,330.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,308.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8,206.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4,813.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,392.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,727.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,607.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,120.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization and impairment of acquired intangible assets totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$283.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$422.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$281.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$493.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization and impairments of acquired intangible assets for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects the impact of a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$215.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge related to certain IPR&amp;amp;D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis (IPF), which was discontinued during the third quarter of 2019, as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of acquired intangible assets for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects the impact of impairment charges related to certain IPR&amp;amp;D assets associated with our vixotrigine (BIIB074) program totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$189.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of acquired intangible assets, excluding impairment charges, totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$68.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$206.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$92.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$303.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The decrease in amortization of acquired intangible assets, excluding impairment charges, was primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This decrease was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$236.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of NST on June 7, 2019, we acquired IPR&amp;amp;D programs with an estimated fair value of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$700.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our acquisition of NST, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;BG00011&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF due to safety concerns. As a result, we recognized an impairment charge of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$215.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the third quarter of 2019 to reduce the fair value of the IPR&amp;amp;D intangible asset to zero. We also adjusted the value of our contingent consideration obligations related to this asset resulting in a gain of&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$61.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;in the third quarter of&#160;2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2018 we completed the Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR. As a result, we recognized an impairment charge of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the third quarter of 2018 to reduce the fair value of the IPR&amp;amp;D intangible asset to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of trigeminal neuralgia (TGN) as we awaited the outcome of ongoing interactions with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy. We reassessed the fair value of the TGN program using reduced expected lifetime revenues, higher expected clinical development costs and a lower cumulative probability of success. As a result of that assessment, we recognized an impairment charge of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$129.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the third quarter of 2018 to reduce the fair value of the TGN IPR&amp;amp;D intangible asset to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$41.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; at that date. We also adjusted the value of our contingent consideration obligations related to the TGN program to reflect the lower cumulative probabilities of success resulting in a gain of&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$89.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;in the third quarter of&#160;2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The IPR&amp;amp;D impairment charges were included in amortization of acquired intangible assets and the gain resulting from the remeasurement of our contingent consideration obligation was recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. The fair values of the intangible assets and contingent consideration obligations were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. Acquired and in-licensed rights and patents also includes our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,889.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and the net book value of the TECFIDERA asset as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our TECFIDERA license rights, please read Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long-range planning cycle was completed in the second quarter of 2019. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining three months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;65.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;255.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;215.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;215.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;210.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,706.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase in goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;112.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to Hiller&#xf8;d, Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(69.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,746.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in goodwill during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was related to our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The elimination of goodwill represents an allocation based upon the relative fair value of our Hiller&#xf8;d, Denmark manufacturing operations. In connection with the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, our remaining goodwill was reviewed for impairment, and based upon this review, no impairments were recognized. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/span&gt;&lt;/div&gt;Other includes changes related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-8F5D00B0DD6752E9BBD9724D5D8A05EB-0-wk-Fact-721A2063F127558ABD5746DCE1C18A69">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;543.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(542.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;543.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(542.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-28&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,005.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2,764.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;240.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,005.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,734.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;270.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;954.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;954.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&#160;and&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&#160;rights&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&#160;patents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,638.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1,506.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,132.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,638.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,330.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,308.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8,206.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4,813.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,392.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,727.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,607.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,120.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1132-wk-Fact-34345BAAE3115AEFBD33E989806C8EE0"
      unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1151-wk-Fact-E47033DE082D578A869F15434BAA01E4"
      unitRef="usd">542500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1172-wk-Fact-7ED35D4B8C175C10A598208C77593113"
      unitRef="usd">800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1191-wk-Fact-B3C0D4C2DBA855D7AC418C025A415CF4"
      unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1210-wk-Fact-5B6B545C01B2533E9FC4914C94AB56A3"
      unitRef="usd">542300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1231-wk-Fact-88689549E0475DDDA3B29927AE9305F6"
      unitRef="usd">1000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d101509770e1259-wk-Fact-CF403ACEFF5B5F90A14ED63BBFA30A0A"
      unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d101509770e1278-wk-Fact-E62931DB55D2512DACDD1A592E7CEAD3"
      unitRef="usd">2764600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d101509770e1299-wk-Fact-A047482676DF5F0885AFF6785B25D5F6"
      unitRef="usd">240700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d101509770e1318-wk-Fact-E84C18AEE1B350EBAE45D714F926E713"
      unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d101509770e1337-wk-Fact-5321822A791F5C458657C6E29BFB4E9A"
      unitRef="usd">2734800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d101509770e1358-wk-Fact-45EFDF2ACC4B585EA7E906A0B8140958"
      unitRef="usd">270500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e1388-wk-Fact-C00C75D2A9EC576280710969F59C97CD"
      unitRef="usd">954800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e1407-wk-Fact-79400DF27C6D5E768E0BC72A49CFDE06"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e1427-wk-Fact-C00C75D2A9EC576280710969F59C97CD"
      unitRef="usd">954800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e1446-wk-Fact-70D53D4D0D4158028DD6435D9E451955"
      unitRef="usd">476000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e1465-wk-Fact-EDA7ED89003556FDAED2B3FB2E32A0BB"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e1485-wk-Fact-70D53D4D0D4158028DD6435D9E451955"
      unitRef="usd">476000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d101509770e1518-wk-Fact-A37B20A528545064A2C56C8C78A8B929"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d101509770e1537-wk-Fact-2A67A63BA5B15EAEA9B62E6C128828A7"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d101509770e1557-wk-Fact-A37B20A528545064A2C56C8C78A8B929"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d101509770e1576-wk-Fact-2660F7F3F13B5DB3BC1821AB45972688"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d101509770e1595-wk-Fact-EB5BDBDB34415C1D90C25BDF572FC84A"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d101509770e1615-wk-Fact-2660F7F3F13B5DB3BC1821AB45972688"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1648-wk-Fact-3AC7A49E8F3652C3854ACBF43BCA3F64"
      unitRef="usd">3638700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1667-wk-Fact-2FAD57D35C275CE196141D33DBE2EBF9"
      unitRef="usd">1506600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1688-wk-Fact-3372F6D1C1D757F882AA7FA40E3B7915"
      unitRef="usd">2132100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1707-wk-Fact-0B08C52A28C757FC91BBE8FC25DDC0DE"
      unitRef="usd">3638700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1726-wk-Fact-D783F3AE93AC5F30AE9BEA661781DE14"
      unitRef="usd">1330200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d101509770e1747-wk-Fact-27E8065BE85B54D0AA05EBE5C57CE1E2"
      unitRef="usd">2308500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101509770e1782-wk-Fact-86BFE9DEC2FD567DBD41C889E2F6A3A4"
      unitRef="usd">8206100000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101509770e1801-wk-Fact-68F9B30CBAD8531B80D5079B3F7B28E1"
      unitRef="usd">4813700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101509770e1822-wk-Fact-590BC6AA99A359AE8B2D093C3E37149E"
      unitRef="usd">3392400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101509770e1841-wk-Fact-9A5FEA9159CC523DB093094C791DD61C"
      unitRef="usd">7727300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101509770e1860-wk-Fact-941A451F11BF5A408C2463F31C6FE6BC"
      unitRef="usd">4607300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101509770e1881-wk-Fact-6AEEA34F46DE51CAAAEFDC70DF10D84D"
      unitRef="usd">3120000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101509770e1909-wk-Fact-E16816F8C6345C9F843A76FE6FE7E93D"
      unitRef="usd">283900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101509770e1913-wk-Fact-12AB224A4EA35DA89408132E43CA5AB9"
      unitRef="usd">422200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101509770e1917-wk-Fact-60CBEC0AE94254A1A0FFF49B4C048842"
      unitRef="usd">281900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101509770e1922-wk-Fact-2168DD63A96A5DB78AB338B8966E624C"
      unitRef="usd">493200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e1937-wk-Fact-BE0FDD374E38CC01BE4282BA5D0AF2FB"
      unitRef="usd">215900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e1952-wk-Fact-BED16A34D5A51FF910EA82BBE98C2A83"
      unitRef="usd">189300000</us-gaap:AmortizationOfIntangibleAssets>
    <biib:Amortizationofintangibleassetsexcludingimpairment
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101509770e1959-wk-Fact-24F9C1D18A3A8A3A5DFC82C55F10FF06"
      unitRef="usd">68000000.0</biib:Amortizationofintangibleassetsexcludingimpairment>
    <biib:Amortizationofintangibleassetsexcludingimpairment
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101509770e1963-wk-Fact-995DC045F2BD4C4CE54382C590E37421"
      unitRef="usd">206300000</biib:Amortizationofintangibleassetsexcludingimpairment>
    <biib:Amortizationofintangibleassetsexcludingimpairment
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101509770e1975-wk-Fact-34C9D09C72A336F5AA8182C5AE865C96"
      unitRef="usd">92600000</biib:Amortizationofintangibleassetsexcludingimpairment>
    <biib:Amortizationofintangibleassetsexcludingimpairment
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101509770e1980-wk-Fact-6471DB02EE1E45D9116C82C5CE658BCF"
      unitRef="usd">303900000</biib:Amortizationofintangibleassetsexcludingimpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q3_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d101509770e1997-wk-Fact-DF84549E9D115BEDA8E7149F9B9B47EA"
      unitRef="usd">236600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101509770e2011-wk-Fact-CBAA3B57AABA5FB385FF1A913131541A"
      unitRef="usd">700000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e2025-wk-Fact-ABF5F11B8F71C4915AAB8311A08B86FD"
      unitRef="usd">215900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member"
      decimals="-5"
      id="d101509770e2029-wk-Fact-CD260BBA95FEDA7074308312D1B57B40"
      unitRef="usd">61200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_PLSRMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e2039-wk-Fact-2CAF8EF3164FD6B13822830DE3EC208C"
      unitRef="usd">60000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e2046-wk-Fact-0F2C8AA166B800DAA2E7830BBDE95A22"
      unitRef="usd">129300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q3_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d101509770e2050-wk-Fact-A7BE37048EAD8ADCE2CB830F8E51DE86"
      unitRef="usd">41800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember"
      decimals="-5"
      id="d101509770e2054-wk-Fact-33A49BF626AF9F65ED7F8310CEB6C4FB"
      unitRef="usd">89600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q3_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d101509770e2071-wk-Fact-737447E23DE35D9CB5A2A23A3D6BD273"
      unitRef="usd">1889600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q3_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d101509770e2079-wk-Fact-9F1626303250523A87F911EB4D30BAA9"
      unitRef="usd">45600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-0DEF8259EDC95B4388AA4B7272E84D34-0-wk-Fact-0BB1C85167FD5689B823BC1412E5783C">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining three months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;65.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;255.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;215.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;215.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;210.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101509770e2163-wk-Fact-F838795EC2F55A5ABD634299933E520E"
      unitRef="usd">65000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101509770e2178-wk-Fact-7E039C0248C954A1AD1FE4CEAEDDF1E2"
      unitRef="usd">255000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101509770e2198-wk-Fact-1A0B461ACE5C509DBEEB5742F460243A"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101509770e2218-wk-Fact-B500BBA2CEC05A39B86AC65C34BEEDA3"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101509770e2238-wk-Fact-4F35FEDB118653F088657A02C9F98D69"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101509770e2258-wk-Fact-6542DE796FDA5EEB894E090EA61EE687"
      unitRef="usd">210000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-FEFA0A947428572E948541577A5E27BF-0-wk-Fact-300288AF5EE75DD4A61E2FE7D09F8F8F">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,706.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase in goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;112.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to Hiller&#xf8;d, Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(69.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,746.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101509770e2341-wk-Fact-EDAA6B48B7F75DCC9A54B3A7C0BDDC58"
      unitRef="usd">5706400000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101509770e2356-wk-Fact-0342C28B22565AFCAD29B8AA8EFFE33F"
      unitRef="usd">112600000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101509770e2376-wk-Fact-2877ED6BF5BA52ADA1C854238A2EF7D7"
      unitRef="usd">69500000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101509770e2397-wk-Fact-8FB55A2EBA335132AE57AC9C39E8EAF3"
      unitRef="usd">-3400000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101509770e2423-wk-Fact-0C60CAE51C8B53A7ABC528A464C8294A"
      unitRef="usd">5746100000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="FI2019Q3"
      decimals="-6"
      id="d101509770e2468-wk-Fact-0B1C6011A8E75CD4A379688DA1894E9C"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-311A31172B1E59319F1A430BD739E453-0-wk-Fact-446811FD9E6E50FA9744696C7D0AFF3C">Fair Value Measurements&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,655.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,655.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,702.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,702.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;868.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;868.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;337.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;337.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;336.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;18.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;318.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;161.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;161.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;26.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;26.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,087.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;18.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,069.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;353.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;563.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,102.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,050.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;434.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairments of our assets measured and carried at fair value during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, there were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our June 2018 investment in Ionis common stock, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. For a description of our validation procedures related to prices provided by third-party pricing &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;services and our option pricing valuation model, please read Note 1, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,509.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,495.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,489.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,480.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,037.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;996.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;995.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,888.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,739.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,745.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,737.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,054.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,722.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,802.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,722.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,490.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,953.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,037.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence Pharmaceuticals Ltd., Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;499.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;523.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(57.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(87.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(66.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(91.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(20.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;412.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;412.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$196.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$265.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF resulting in a reduction of our contingent consideration obligations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$61.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to lower cumulative probabilities of success related to our vixotrigine program for the potential treatment of TGN, an increase in interest rates used to revalue our contingent consideration liabilities and the passage of time. In addition, we dosed our first patient in the Phase 2b study of BG00011 for the potential treatment of IPF in September 2018 and paid an &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$81.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment to the former shareholders of Stromedix during the fourth quarter of 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-50E3108E60C35EC2B3EA2D92A00EF310-0-wk-Fact-98DBA7AEB5F25D63B7581CB36DC48AF4">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,655.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,655.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,702.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,702.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;868.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;868.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;337.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;337.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;336.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;18.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;318.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;161.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;161.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;26.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;26.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,087.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;18.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,069.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;353.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;563.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,102.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,050.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;434.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1023-wk-Fact-DBBE4E93BCA454FCBCAC870742EC86B9"
      unitRef="usd">1655800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1042-wk-Fact-74F8055A56DB550CA018CC5A300B04E1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1061-wk-Fact-8F58B86DB67F5BA2AD19D400BB2428A5"
      unitRef="usd">1655800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1081-wk-Fact-9C5FA5B9515051568CAE51DB75ED065C"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1178-wk-Fact-37BA958C3A1A55C5B52BE2519580DA77"
      unitRef="usd">2702200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1197-wk-Fact-6BF8FA6C1FEA506BA6E65E4FBAF4D39C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1216-wk-Fact-299AB0CDF2AB591FB668155A44CE050C"
      unitRef="usd">2702200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1236-wk-Fact-55CBD3E7A2C053C7B91542A20984ADE4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1256-wk-Fact-12F116E9849C51199D1053D6A519041A"
      unitRef="usd">868200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1275-wk-Fact-8C86CA739B1650189B5D778C21008EDC"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1294-wk-Fact-0922B4A905045DED84ACAB9239E7AC45"
      unitRef="usd">868200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1314-wk-Fact-D5F544CFE10E509A89F9D64642AB3BC4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1334-wk-Fact-AEA539E7A981552BA67FCD05DF9B4DBA"
      unitRef="usd">337000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1353-wk-Fact-18590AC5A9F25A1FA8490B1347FA5D6E"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1372-wk-Fact-07D8093C7445566D8CA54A324193D727"
      unitRef="usd">337000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1392-wk-Fact-9E27CFD0125C5A8B9815C9EAE21E044A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1412-wk-Fact-9856266B2CE75C50BF9BA6A49E88F2C1"
      unitRef="usd">336700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1431-wk-Fact-600DE8986DE853FC998CC85556FFF36E"
      unitRef="usd">18500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1450-wk-Fact-8CA6C007F7995ACCA5FFFB7C5D3ACE26"
      unitRef="usd">318200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1470-wk-Fact-4C45A1A337D4592288EDFD9C6BF01BA5"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1490-wk-Fact-CA0CB4451A205380814AF4FB71CE2431"
      unitRef="usd">161700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1509-wk-Fact-9B3D80EE7D7C5CFE84A39B8C4B6AB292"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1528-wk-Fact-FA086FB1219C5B7D902C5902A9B515C5"
      unitRef="usd">161700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1548-wk-Fact-2E5C4BE87B1858A8AC73B7625B6C1E70"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1568-wk-Fact-C14C795E15EE533493C93A9CBA5A9110"
      unitRef="usd">26300000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1587-wk-Fact-CDFECED3CA5953A487286F960D355C65"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1606-wk-Fact-57987BA27D8B575AB76B9A421481DDE2"
      unitRef="usd">26300000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1626-wk-Fact-9017C465A07E505581FB0E07E2B3CEE0"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1651-wk-Fact-A5FFED0F3DA259058C00ACD05AA9EB5B"
      unitRef="usd">6087900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1670-wk-Fact-1D60B96D816951ADA3729685825F8DBF"
      unitRef="usd">18500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1689-wk-Fact-6BC2141F5D765DD7B817E96CDB4CB75C"
      unitRef="usd">6069400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1709-wk-Fact-B08B960D4E6058F58A1E09E210E9F00D"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1812-wk-Fact-3865A3EA76045585B165E3B6BF5C517E"
      unitRef="usd">9800000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1831-wk-Fact-95E011E445FA5366BDA634E92E96BF72"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1850-wk-Fact-F00D79AEF6815A1B8B780DF07864EC79"
      unitRef="usd">9800000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1870-wk-Fact-20D88B36892C5150BA3D4A8A60F12DBD"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1885-wk-Fact-942AC04AC4AD5FF38BE8576E01D16EEF"
      unitRef="usd">343500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1904-wk-Fact-FDA9FBDAA6515D7ABDAFF8FABEA4D751"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1923-wk-Fact-CEF872470A51551EBF0F6F0929F9BF5E"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1943-wk-Fact-37FC4361FDDC5848BF30192CBC417437"
      unitRef="usd">343500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1968-wk-Fact-C80F845E1D6A5B0EA9922EEE9C7023A4"
      unitRef="usd">353300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e1987-wk-Fact-917C89A7510455BB9A89FB919EFC7018"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2006-wk-Fact-A9A85DAE5397598EAB450231BFFAB1A5"
      unitRef="usd">9800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2026-wk-Fact-FFCE72358282515BB669EFA035DDBC77"
      unitRef="usd">343500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2261-wk-Fact-D0EC4D7C9BA052EA8BD20E6237672B60"
      unitRef="usd">705500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2280-wk-Fact-A6A1FB3CF6AC52FC9B273542D05F882D"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2299-wk-Fact-77680C2B0319538389814918A713909C"
      unitRef="usd">705500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2319-wk-Fact-F929ECFC3BB1528E96E3A447A4542982"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2416-wk-Fact-D3C5EA7A8BEB565A87795FB40E38E3B7"
      unitRef="usd">2459200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2435-wk-Fact-1212F702D9AD55829D1037B6F55BDF30"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2454-wk-Fact-0645F79E4F5359C19FA5BC3C18332909"
      unitRef="usd">2459200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2474-wk-Fact-AF92AB4F37275569ACF9AA50DFAF013F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2494-wk-Fact-6A3935AA5789595B8CF2AE7AB558AC1F"
      unitRef="usd">969600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2513-wk-Fact-5910CC94117B5F7197B0448C42D1DF1A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2532-wk-Fact-580CCFCA9DF2588F99842EFBB46F2915"
      unitRef="usd">969600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2552-wk-Fact-427BE0FC82675D81B515F031C1FFE301"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2572-wk-Fact-BEB2815C0C735A408F4306BF6BF06271"
      unitRef="usd">260500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2591-wk-Fact-15681AB034E1532E8904176B6A659B6E"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2610-wk-Fact-834D4A1E68805CA39723F64836475EFA"
      unitRef="usd">260500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2630-wk-Fact-1C45646B225951238DD72261EC9FE864"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2650-wk-Fact-C4FF02F86F0A5A1E88F4652456B388FE"
      unitRef="usd">615400000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2669-wk-Fact-2BA37CEF10AF5D2898235B27F769E7C1"
      unitRef="usd">51700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2688-wk-Fact-B8CAF92D58E757688A630CCFBD754ADA"
      unitRef="usd">563700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2708-wk-Fact-F7E995ED2BD958EC81E48C98ED2CFCE7"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2728-wk-Fact-FECF91BD0C4A53A7A47B43DA7F420258"
      unitRef="usd">66900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2747-wk-Fact-8F791E6C4C8956AD955F9622333E0211"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2766-wk-Fact-90E3470516FD5A90BD54FEF6F8BBA1FE"
      unitRef="usd">66900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2786-wk-Fact-61C6AB5FFB5A55019968313681096F9C"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2806-wk-Fact-CC2DABE24603568FBDE8F0EF5AF1EB39"
      unitRef="usd">25400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2825-wk-Fact-D2E37CBDD40358A1AB0321A65EB20768"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2844-wk-Fact-B461F24B46975BFAB2955EDEF501F701"
      unitRef="usd">25400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2864-wk-Fact-8142E95E46EF516DA2B218B4BCF43B49"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2889-wk-Fact-3E85CBEEC48258A187A1CF19361C328A"
      unitRef="usd">5102500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2908-wk-Fact-6BEDCE1103C85F2BBC0622CED20418D3"
      unitRef="usd">51700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2927-wk-Fact-C2F97441AFCB52B8833E931766DC1841"
      unitRef="usd">5050800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e2947-wk-Fact-002F20AC971A54F79C5D0DB6AEF72CA3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3050-wk-Fact-914B9564037556189F63F0C349D15F9C"
      unitRef="usd">24600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3069-wk-Fact-4B18FDA7C31552FBBE30175354697E5F"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3088-wk-Fact-5138C2E5A54D5CABA2D75437104E71AC"
      unitRef="usd">24600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3108-wk-Fact-697D13C8EBF659BDAFF92E5ED0FF77CF"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3123-wk-Fact-19CD2F1140065DE4B03B9E30209A19F8"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3142-wk-Fact-C9CDFD02032F5C0483303E7438578B7B"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3161-wk-Fact-72DA51BB1BC754F2BB4C5DC89EB6AC3D"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3181-wk-Fact-256CAF67851B5F82853679AE948CB003"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3206-wk-Fact-BA070C65C5B8554EB85EC11D33433029"
      unitRef="usd">434400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3225-wk-Fact-218D4C3690E15895B86E0C0E7FF9F6EC"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3244-wk-Fact-AD05EAB238475AB6ABCC0ECA51E7A1E7"
      unitRef="usd">24600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e3264-wk-Fact-B3F5D3BB2A135B05998C80E4396C4B71"
      unitRef="usd">409800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d101518089e3284-wk-Fact-83CA23BEB0955D07BFF9858757F513EF"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d101518089e3296-wk-Fact-60A34C303BC25130AD2419C9164D8BA0"
      unitRef="usd">0</us-gaap:ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-DD58FF436B4C5B2B879A13E59C008B28-0-wk-Fact-EBEAAAFF7B085EE4AEF66EBE4D14AFBC">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,509.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,495.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,489.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,480.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,037.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;996.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;995.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,888.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,739.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,745.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,737.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,054.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,722.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,802.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,722.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,490.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,953.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,037.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d101518089e3559-wk-Fact-FE042043F2EB5BA5A8DF64A243EC01BD"
      unitRef="usd">1509900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d101518089e3578-wk-Fact-9E5EF7A2EE53513589D4317EBA61E1FB"
      unitRef="usd">1495300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d101518089e3597-wk-Fact-EB913F799A9452219F75231D638BFEAC"
      unitRef="usd">1489500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d101518089e3617-wk-Fact-AF77AF747CDC5A4B9E6F029BD42B1D43"
      unitRef="usd">1480800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d101518089e3632-wk-Fact-5C5F5B2D22125316B1F96FFC6AA56268"
      unitRef="usd">1037800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d101518089e3651-wk-Fact-1C932B61350D5A9DB8E5D3DFCE6C47F9"
      unitRef="usd">996300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d101518089e3670-wk-Fact-5D8E162026845C2A911B8ED611E14538"
      unitRef="usd">1000400000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d101518089e3690-wk-Fact-94939F3C450A5FECA6DC38B806231265"
      unitRef="usd">995500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d101518089e3710-wk-Fact-891E451BC9A35236A6760582E16CAADC"
      unitRef="usd">1888800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d101518089e3729-wk-Fact-CF5D3F26B95F5F31BE6727CF246E37E7"
      unitRef="usd">1739100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d101518089e3748-wk-Fact-9E117B65C6EE5B8D8483601E840562C0"
      unitRef="usd">1745100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d101518089e3768-wk-Fact-1C4E692B04C551FA8EEB2198DE99A7E2"
      unitRef="usd">1737800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d101518089e3788-wk-Fact-196BFA741EB95C82A352A553A363F4A4"
      unitRef="usd">2054200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d101518089e3807-wk-Fact-2B0C2AE4545E54BC9497A8D1BFDA9843"
      unitRef="usd">1722800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d101518089e3826-wk-Fact-E0301F2E6A9E5D6DA34D9B9FC1532833"
      unitRef="usd">1802600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d101518089e3846-wk-Fact-9D4080C23227599BA211C36F77B5A6B0"
      unitRef="usd">1722400000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101518089e3871-wk-Fact-79688E783E635DC4809926AB442EB9A6"
      unitRef="usd">6490700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101518089e3890-wk-Fact-6B2575A08581557881448D7AEFACAFDF"
      unitRef="usd">5953500000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101518089e3909-wk-Fact-1D995634AADB5EDF87C6C18D7C2C327D"
      unitRef="usd">6037600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101518089e3929-wk-Fact-C18FD1BC4BCD5A20ADC5B4E281CBD5C5"
      unitRef="usd">5936500000</us-gaap:NotesPayable>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-90DFE05EA3825D6984B8F7216F6C4A06-0-wk-Fact-F5B02941F00258D5AD8B3076EC909F2C">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;499.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;523.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(57.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(87.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(66.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(91.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(20.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;412.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;343.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;412.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e4174-wk-Fact-792737EACD5855D8A3905684809D47E7"
      unitRef="usd">401300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e4193-wk-Fact-1D46153B21B85ED785B165AF66531CF3"
      unitRef="usd">499900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e4212-wk-Fact-19CD2F1140065DE4B03B9E30209A19F8"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e4232-wk-Fact-BE5680DF9AC05C2C844CAD2283FCBA95"
      unitRef="usd">523600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101518089e4247-wk-Fact-6A3D37E1187254C09B6AC4C5616FF447"
      unitRef="usd">57800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101518089e4267-wk-Fact-039C01D7065755E1B84538DFB48BABF7"
      unitRef="usd">87900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101518089e4287-wk-Fact-71EA0E01C5515EB8915D8014F3984813"
      unitRef="usd">66300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101518089e4308-wk-Fact-38997DD058735F02BF9DD1F00498AD0C"
      unitRef="usd">91600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101518089e4329-wk-Fact-EC24C61899E55170BD6CF5397A823C15"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101518089e4348-wk-Fact-9775B9C59FCB5743A802C11DF4DD337C"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101518089e4367-wk-Fact-D65713B9018855EB94DEC4568CB49384"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101518089e4387-wk-Fact-4F8001E784375A628E0B3B9E46AA1ED7"
      unitRef="usd">20000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e4413-wk-Fact-942AC04AC4AD5FF38BE8576E01D16EEF"
      unitRef="usd">343500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e4432-wk-Fact-AE51B9D3B1C656F485FC4846BEFC8F97"
      unitRef="usd">412000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e4451-wk-Fact-942AC04AC4AD5FF38BE8576E01D16EEF"
      unitRef="usd">343500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d101518089e4471-wk-Fact-AE51B9D3B1C656F485FC4846BEFC8F97"
      unitRef="usd">412000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101518089e4499-wk-Fact-0C4BF3A9126257ACB739E3D975A76B81"
      unitRef="usd">196000000.0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101518089e4503-wk-Fact-FDFF614CA41F5767B9AA14B62D806A98"
      unitRef="usd">265000000.0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_BG00011Member"
      decimals="-5"
      id="d101518089e4518-wk-Fact-CD260BBA95FEDA7074308312D1B57B40"
      unitRef="usd">61200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d101518089e4533-wk-Fact-DE392063FEE3FC3BC13C833F4DBF9DFC"
      unitRef="usd">81500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-ACCF45B5079555B4BEB4C2D4019EABB6-0-wk-Fact-33518BD095ED545591B6548C61DFF417">Financial Instruments&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;255.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;231.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;176.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,103.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;279.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;119.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;194.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,655.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,655.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,657.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,040.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,044.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;435.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;436.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;431.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;432.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;335.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;336.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,899.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,907.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;218.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;120.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;336.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,608.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,607.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;854.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;264.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;263.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;496.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;127.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,091.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,093.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,314.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,313.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,686.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,691.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,235.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,232.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;121.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;122.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,899.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,907.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, were approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;611.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,192.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,867.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,994.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$394.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which is included in investments and other assets in our condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investments in equity securities include shares of Ionis common stock acquired in June 2018. This investment is classified as a Level 2 marketable security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effect of the holding period restrictions on our investment in Ionis common stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The decrease in our strategic investment portfolio for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily reflects our sale of a portion of our investment in Ionis common stock for approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$382.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as well as our sale of our investment in a non-marketable equity security, partially offset by an increase in the fair value of our remaining investment in Ionis common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our June 2018 investment in Ionis common stock, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2018 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-3F163F50D263530381D7C27076BBE24A-0-wk-Fact-BA9CA8B483C155D885EABA8D24911789">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;255.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;231.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;176.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,103.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;279.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;119.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;194.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,655.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-5"
      id="d101517712e864-wk-Fact-74F3A33FF4A757F28F8A3CB2F3F002B7"
      unitRef="usd">255900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-5"
      id="d101517712e883-wk-Fact-8C7B55659D175D15AF473686D64C6731"
      unitRef="usd">231200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember"
      decimals="-5"
      id="d101517712e898-wk-Fact-6A41DAF3F5345E19AFA812DFEF9D5441"
      unitRef="usd">176900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember"
      decimals="-5"
      id="d101517712e917-wk-Fact-E84099672A6C5C0993A4940FD3D07F04"
      unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d101517712e937-wk-Fact-64F531ACF01D5057A2810B7133753F72"
      unitRef="usd">1103200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d101517712e956-wk-Fact-2BBA343CCD9E5707B893B3D8004A72E0"
      unitRef="usd">279500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-5"
      id="d101517712e976-wk-Fact-C8C34D4AD041558B934CD0366C7FD68E"
      unitRef="usd">119800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-5"
      id="d101517712e995-wk-Fact-16877A3C66245533894D2191D39B1D0A"
      unitRef="usd">194800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e1020-wk-Fact-799A91B5DE235470B756348FCD0630AF"
      unitRef="usd">1655800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e1039-wk-Fact-F14D7624488E5FCA9BBC7EAD2F0FF21D"
      unitRef="usd">705500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-7A27AF5C7E3F597FA5C38E324C6BA767-0-wk-Fact-68833170CF405C03ADE55E359F6FB09E">The following tables summarize our marketable debt and equity securities:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,655.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,657.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,040.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,044.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;435.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;436.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;431.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;432.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;335.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;336.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,899.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,907.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;218.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;120.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;336.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,608.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,607.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;854.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;264.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;263.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;496.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;127.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1285-wk-Fact-0C0B43B2B0885AD197DE321833CA8537"
      unitRef="usd">1655900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1304-wk-Fact-AFC36D941B6D5F0FA0853420AD9B39C7"
      unitRef="usd">1500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1323-wk-Fact-8E4DA25A882C51508AA31702348AAA79"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1343-wk-Fact-72D29DB503AB59A5B0C71C6A93598A34"
      unitRef="usd">1657400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1358-wk-Fact-3F37DC9732765F8BA4F85D569C1E06E4"
      unitRef="usd">1040400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1377-wk-Fact-74BAE31E128A539AA46FDFD4FF48B86F"
      unitRef="usd">4700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1396-wk-Fact-F1318701DD975343935EB5E24521D6D8"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1417-wk-Fact-7A09DD4079EF5421BAB447CD53BBF123"
      unitRef="usd">1044800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1519-wk-Fact-FEAFC06AD0C65B928E13B6D134C70CA1"
      unitRef="usd">435600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1538-wk-Fact-D34499D3D8895CAA8825B145F226B657"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1557-wk-Fact-C620D4EF87A654648EB580BE5975BC3D"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1578-wk-Fact-60DA0AF49DDF5F0C87F463AE9EFBAC88"
      unitRef="usd">436000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1598-wk-Fact-ABA36DACDE5F5A8CAE1DF0CF6B34DA8F"
      unitRef="usd">431800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1617-wk-Fact-7F0D14D3D2EA5638B4EB714F07EFCEC5"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1636-wk-Fact-BF831364DD545CE08F8925856A38A27C"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1657-wk-Fact-25CDA8D50DF3597CB4B23CB4A66A2063"
      unitRef="usd">432200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1759-wk-Fact-20504B60A2E250DD9E8E5C078D5DD23E"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1778-wk-Fact-DC14A680184F5B57BB6401AA23ABF31C"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1797-wk-Fact-661D0619D8515281883EE8DF30A25B6A"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e1817-wk-Fact-C2ECC10AD131517E855548805C7538F8"
      unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1837-wk-Fact-947D1DA9F23C5C908535CD56795B85C5"
      unitRef="usd">335700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1856-wk-Fact-ECFE37EE411D59D7B1682843131975C0"
      unitRef="usd">1600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1875-wk-Fact-35899C4D2512560DAFD3519AE9A913F6"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e1896-wk-Fact-2652EEBEA90759B68B5405DFB4EE5F77"
      unitRef="usd">336900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e1921-wk-Fact-21E0E8A8142E5E3DBF4A2429F11CB61E"
      unitRef="usd">3899500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e1940-wk-Fact-106C9EDE310F5145A5F39FF72C609BC1"
      unitRef="usd">9100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e1959-wk-Fact-9E4FC0C30586547C90172FC539166E6B"
      unitRef="usd">1200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e1980-wk-Fact-2A4B5842D5AE518C9271AF0E1DDD5274"
      unitRef="usd">3907400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d101517712e2001-wk-Fact-B186F4587D1151FC8FF2ED072E2822B5"
      unitRef="usd">218800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d101517712e2020-wk-Fact-24A1EBCBE76D5892949FFF63E9217F04"
      unitRef="usd">120700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d101517712e2039-wk-Fact-AB5455A2190955F48944313A0630381F"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d101517712e2060-wk-Fact-4CF43CEABCD858E1BD04AD0374B64B9F"
      unitRef="usd">336700000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2286-wk-Fact-DA9FD2C9D424517589E573ACCCF8D4BE"
      unitRef="usd">1608400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2305-wk-Fact-BBDF50D9825057B588DD38CF87180C24"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2324-wk-Fact-C0C7FDE656B0596CBCF197C3B2635954"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2345-wk-Fact-2BD99D4AF6945A20B6BAEEDB3F530559"
      unitRef="usd">1607500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2360-wk-Fact-2F03B4FFE9A65A9BB3A50F45AD9A1746"
      unitRef="usd">854900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2379-wk-Fact-316301EED9935592BAE82E30B20EF16E"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2398-wk-Fact-18A3DECD3CDC5F7E862B45B92C0B5333"
      unitRef="usd">3900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2419-wk-Fact-5481B76E7C265C19AB26EED753914A2F"
      unitRef="usd">851700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2521-wk-Fact-59811D26E8A85426B426C66D78F74724"
      unitRef="usd">706100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2540-wk-Fact-AE259A5B1687567487D82328D8735E51"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2559-wk-Fact-34DF829E7140565FA48ECB126D29C560"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2580-wk-Fact-BCE774B66CD85A39A5C04C171E156EBE"
      unitRef="usd">705800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2600-wk-Fact-BA960BF8BA065EC2BAD98B2AE6268137"
      unitRef="usd">264000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2619-wk-Fact-656DBC7E52855EA5BB2226591882888B"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2638-wk-Fact-FD79E103E6E05A33AC79BD7219805D64"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2659-wk-Fact-7CC4DE3C5F085B538BD3971BE702C781"
      unitRef="usd">263800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2761-wk-Fact-A8CE4214B03B5488951C7D6460B7BD29"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2780-wk-Fact-9EED7EE95E67560BA8EBBE3040CAE83B"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2799-wk-Fact-4B5A8627B5B858DF93DB02DFB5CD8932"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d101517712e2819-wk-Fact-1BBAF27BF2425F2E9540F4190BBF2112"
      unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2839-wk-Fact-878FBC03DF115C49ABEE445BA3C4F310"
      unitRef="usd">260500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2858-wk-Fact-1B671E603CDC546FB2AA1489FB966978"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2877-wk-Fact-6F1772B4D17457AEBC2B866803CA6B4F"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d101517712e2898-wk-Fact-9A9557D2A6AD528985BC7AD9481DBEA6"
      unitRef="usd">260400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e2923-wk-Fact-D20DFB3CDD5B55F684D45E1A4D612B41"
      unitRef="usd">3694000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e2942-wk-Fact-26DF51F2A8A65AF5B0F4A183E6936E1C"
      unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e2961-wk-Fact-1FBDF0CCBFC05BB09B6AF3B93C0ECD7A"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e2982-wk-Fact-4A10346547B35AF7BCD523DAE511BF86"
      unitRef="usd">3689300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d101517712e3003-wk-Fact-16003D9B21385DC6BA5BBCB3A6D5D465"
      unitRef="usd">496200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d101517712e3022-wk-Fact-C10A71651C045546802CF309A9A7445C"
      unitRef="usd">127700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d101517712e3041-wk-Fact-E477E922EDE453EF9A1C3368FE3C9657"
      unitRef="usd">8500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d101517712e3062-wk-Fact-1C46221FEACF515BBFC94F17166A3ABD"
      unitRef="usd">615400000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-6398CF9B00CF55AEBB839BE4CC39E1B4-0-wk-Fact-404DC4E418AC5952BA436F1F14A9B120">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,091.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,093.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,314.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,313.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,686.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,691.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,235.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,232.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;121.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;122.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,899.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,907.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e3304-wk-Fact-2A187C5440665A2EB694A9C8D5E2CB63"
      unitRef="usd">2091600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e3323-wk-Fact-66B83FE47E7853C0B895AAD16FA7FEA8"
      unitRef="usd">2093500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e3342-wk-Fact-CCCB35C2863D5C329C4EE002FD7EC3D7"
      unitRef="usd">2314600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e3362-wk-Fact-E94681F8C6A75892B3F4F91A19FBAEB1"
      unitRef="usd">2313400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e3377-wk-Fact-9CF98AB70DB959CDB90E8A437DDF2D3D"
      unitRef="usd">1686000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e3396-wk-Fact-DC73F31AE29D57529D0675B8A30F357B"
      unitRef="usd">1691700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e3415-wk-Fact-3B4C0A7FA4CA5180A0CC064696D1A69C"
      unitRef="usd">1235900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e3435-wk-Fact-D255A16462E353EEAF37A022218C2D5E"
      unitRef="usd">1232700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e3455-wk-Fact-30936D4F6E115BA9AA3BF24C89FC0070"
      unitRef="usd">121900000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e3474-wk-Fact-DE974DD2E78757CD9443DE0AFEF317F3"
      unitRef="usd">122200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e3493-wk-Fact-70DAE5A2D3FF50A5BEBB5AD0B714E612"
      unitRef="usd">143500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e3513-wk-Fact-035DA27FC38E5F968E1F45089BC09286"
      unitRef="usd">143200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e3538-wk-Fact-21E0E8A8142E5E3DBF4A2429F11CB61E"
      unitRef="usd">3899500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101517712e3557-wk-Fact-246ECA4FA34252B6B298F23DE9C20A17"
      unitRef="usd">3907400000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e3576-wk-Fact-D20DFB3CDD5B55F684D45E1A4D612B41"
      unitRef="usd">3694000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101517712e3596-wk-Fact-77D2F90ACC3C57428514A1146715B58B"
      unitRef="usd">3689300000</us-gaap:AvailableForSaleSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="FD2019Q3YTD"
      id="d101517712e3624-wk-Fact-9653D0C1C68A559C93362CB31A2F7160">P15M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="FD2018Q4YTD"
      id="d101517712e3628-wk-Fact-32B2F962CA2059E9BEC9064816F732BE">P12M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-EA8A1F5FBAA05454AA097354EFD2AEEA-0-wk-Fact-D875D2FB394E542AAF5B51F15CD0B483">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;611.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,192.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,867.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,994.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101517712e3848-wk-Fact-0804E7D4566B58BC9F77D28AE7232BEB"
      unitRef="usd">611800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101517712e3867-wk-Fact-DECB15CC00A45B6CA2F0497AEF8BA49A"
      unitRef="usd">1192000000.0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101517712e3886-wk-Fact-5E1D8F7CDC5D5971BFCC69B7E527C60C"
      unitRef="usd">3867600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101517712e3906-wk-Fact-F0FE9623A9FF52ED9D5ADA61948D05C3"
      unitRef="usd">7994700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101517712e3926-wk-Fact-3158E9372C71526C86CD277789BC6E2B"
      unitRef="usd">700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101517712e3945-wk-Fact-B9552088A29C57E7B3887E7814084617"
      unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101517712e3964-wk-Fact-9D95FE79271D5FD78C10515DF619BD19"
      unitRef="usd">2300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101517712e3984-wk-Fact-9412C533162651D8873CFA3F4077CD42"
      unitRef="usd">3000000.0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101517712e4004-wk-Fact-6FB885F80DFE5357A5C0B93106C0EA20"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101517712e4024-wk-Fact-DEF6AF7316A05F7C8ACEDB158135BEE8"
      unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101517712e4044-wk-Fact-62E53D30C1E75754B9C27BAB8B0937DA"
      unitRef="usd">700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101517712e4065-wk-Fact-700DD37618FC518D94AB92519677D9F8"
      unitRef="usd">10800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d101517712e4097-wk-Fact-E545C62DE0445C299609AA88BAE36E03"
      unitRef="usd">394500000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d101517712e4101-wk-Fact-9492B0525EBD514194E97DD535F7E843"
      unitRef="usd">676300000</biib:StrategicInvestmentPortfolio>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d101517712e4126-wk-Fact-82ED73A7DFE65022A371F7DA306B1AAC"
      unitRef="usd">382000000.0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-1252369334B9510F8FD8ECD9426A3A22-0-wk-Fact-9C402D14AC135609B28AB0D968D17CD4">Derivative Instruments&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,943.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,701.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;60.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;36.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;98.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;25.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;92.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,096.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,239.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$65.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$27.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect the net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$65.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to be settled over the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$59.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of these gains are expected to be settled over the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;35.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;79.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, we entered into interest rate swaps with an aggregate notional amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$675.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. The carrying value of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had remaining durations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one month&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$41.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$8.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$7.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;22.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;45.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$848.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$735.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$10.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recognized as a component of other income (expense), net for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, compared to net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and  &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be materially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;152.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;65.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember"
      id="d101529856e802-wk-Fact-0CB53547D9FD5DF4B518ADE276EBD490">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember"
      id="d101529856e806-wk-Fact-66DC20EE44385192B46A7CFB9E9639D6">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="d101529856e810-wk-Fact-0BE67837DF085CE3A0E10723487E3AF7">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d101529856e815-wk-Fact-04591DF42729556AA6FBBE368E8ACADA">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-DC31D04187BD5C5994561C8164E37DA4-0-wk-Fact-4EBC6EC4B25952E8A569C51B6CE1F953">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,943.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,701.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;60.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;36.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;98.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;25.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;92.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,096.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,239.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q3_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e941-wk-Fact-D1D8042B056457DF9D3CFA7FB8BD2EB3"
      unitRef="usd">1943700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e960-wk-Fact-F1BA9775EB155B29BFE89D077AAB1A11"
      unitRef="usd">1701400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q3_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e975-wk-Fact-9C139AF574BB5177ABDFE1190601868E"
      unitRef="usd">60900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e994-wk-Fact-57840C69919351B28F636CCC6A52D5B8"
      unitRef="usd">215300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q3_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e1014-wk-Fact-71235FF60C4B58598B2078B13E82A3F7"
      unitRef="usd">36900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e1033-wk-Fact-9669A726BD5156138BE1033028EC58AF"
      unitRef="usd">131400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q3_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e1053-wk-Fact-BB9968DA837E573C8998ECBF4B77B23F"
      unitRef="usd">29800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e1072-wk-Fact-26420E93BEC65BC8A8D59BCAE6F74DE8"
      unitRef="usd">98800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q3_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e1092-wk-Fact-35E94D9C85C75EAEBF491A6EA0BFAA55"
      unitRef="usd">25000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e1111-wk-Fact-963ABCA57FCF5D69AF07610E1C3716A4"
      unitRef="usd">92200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e1136-wk-Fact-7D2C441ED0885379B77534D587C974C8"
      unitRef="usd">2096300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e1155-wk-Fact-DDD83853FCFC5D7990C9C81FE65F2017"
      unitRef="usd">2239100000</us-gaap:DerivativeNotionalAmount>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101529856e1175-wk-Fact-17A4B938F4BE5770BB477EFCCA096948"
      unitRef="usd">-65700000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101529856e1179-wk-Fact-20C5A1050A7D5B7F8244F367A7B1800E"
      unitRef="usd">27300000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101529856e1191-wk-Fact-17A4B938F4BE5770BB477EFCCA096948"
      unitRef="usd">-65700000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember"
      id="d101529856e1196-wk-Fact-66DC20EE44385192B46A7CFB9E9639D6">P15M</us-gaap:DerivativeRemainingMaturity1>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2019Q3_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember"
      decimals="-5"
      id="d101529856e1200-wk-Fact-9A107777D64B5C888FE47F71287F0E46"
      unitRef="usd">-59800000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q3YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember"
      id="d101529856e1204-wk-Fact-3C7E52F278985F47AC9C7C8D4E6A54DC">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-B180C810201F56068D0663A03BD619F7-0-wk-Fact-97C71D95502A5E469CE47A906AE33153">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;35.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;79.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d101529856e1571-wk-Fact-CD27E87C323A558F81FF05E837C57216"
      unitRef="usd">35200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d101529856e1590-wk-Fact-FA1EC17BB43E5DBE9415A2519AFB38B5"
      unitRef="usd">-8400000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d101529856e1621-wk-Fact-F73B839B95155BDEA97DF33649C62487"
      unitRef="usd">800000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d101529856e1640-wk-Fact-EA3831132E915AAC9479DDDA958BBCDB"
      unitRef="usd">300000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d101529856e1665-wk-Fact-B5C3ACEF4D235B699F5A774AF61CA5CC"
      unitRef="usd">-800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d101529856e1685-wk-Fact-1765B3A840E35940AFBD08692564EC8E"
      unitRef="usd">-300000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d101529856e1716-wk-Fact-A5A285AEA8E456DFAE1CA40DF287B263"
      unitRef="usd">400000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d101529856e1735-wk-Fact-38BBD7C3A5625BDF988A4528B9FEB532"
      unitRef="usd">400000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d101529856e2086-wk-Fact-AAF47C5EDE3458C1ACA82A85478AB3E8"
      unitRef="usd">79800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d101529856e2105-wk-Fact-3272F850BF755076B76601589DBB8531"
      unitRef="usd">-51700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d101529856e2136-wk-Fact-B9BCF00A004D5EADA8B2E43B558A310F"
      unitRef="usd">8200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d101529856e2155-wk-Fact-13170DFBC91A5E68BB69777A8885C6A2"
      unitRef="usd">7300000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d101529856e2180-wk-Fact-4D79C0DA81B65AFBA16F49B68575D56F"
      unitRef="usd">-2000000.0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d101529856e2200-wk-Fact-1D3594444EC059E889260E0358F9D986"
      unitRef="usd">600000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d101529856e2230-wk-Fact-CA4CB9CFF43052E180843E0BDCC7EC94"
      unitRef="usd">-800000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d101529856e2250-wk-Fact-3A90B1368361500B90813F43AB77EDDE"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d101529856e2274-wk-Fact-745D0807F2EC531485CE603C650CA0F1"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e2278-wk-Fact-5A315878D52157DE8B6397AD350F70FB"
      unitRef="usd">675000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d101529856e2282-wk-Fact-745D0807F2EC531485CE603C650CA0F1"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d101529856e2286-wk-Fact-745D0807F2EC531485CE603C650CA0F1"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e2299-wk-Fact-AC69AC8A8DFE5401AB04A5DDB8C10B65"
      unitRef="usd">2100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e2303-wk-Fact-7A845FA2CB8D5BF486874BE5CE8A275F"
      unitRef="usd">14500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d101529856e2307-wk-Fact-745D0807F2EC531485CE603C650CA0F1"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d101529856e2322-wk-Fact-97B1DC30EE1451B589E24F434EE28586"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d101529856e2326-wk-Fact-57A6C7E488D15251B4859C133413AF19"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d101529856e2330-wk-Fact-41C9076F0CD05500AD40C9B1813B62B7"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101529856e2334-wk-Fact-74188DA200735AD0A97071671FA83255"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:DerivativeTermOfContract
      contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      id="d101529856e2345-wk-Fact-2F772C16994E52D7BEC927D89BFE4958">P1M</us-gaap:DerivativeTermOfContract>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e2349-wk-Fact-59EF1684015F5229A07E58FA283517B7"
      unitRef="usd">41600000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e2353-wk-Fact-786F960E4FAF5F8FA5E19F2C41B19892"
      unitRef="usd">3800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="FI2019Q3_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e2366-wk-Fact-B5FEC877BDD557FB98611AF173B7BB07"
      unitRef="usd">8800000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e2370-wk-Fact-A6D066961C6F5FB1BE607CA0ACE55CEA"
      unitRef="usd">7300000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-867CB7E7662D521D8902342FB602879A-0-wk-Fact-FEB2CA46121D5A2EB7513CB3838E3567">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;22.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;45.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e2904-wk-Fact-031FD34B96A95AF38C0B77ABA4ECA92B"
      unitRef="usd">22000000.0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e2923-wk-Fact-A4863E0AFB0D5075A6585072B01B69B1"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e2953-wk-Fact-F0293FA72F8750DF943F090C60349118"
      unitRef="usd">1400000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e2972-wk-Fact-538D64BF547D5EE9BEEA57DEA5716140"
      unitRef="usd">0</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d101529856e3002-wk-Fact-7802FC0475FD590A887FF63D17F6B9CB"
      unitRef="usd">2200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d101529856e3021-wk-Fact-EC016DAD155B57E2833BB8D6E9BB3DF4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e3543-wk-Fact-B2C540D8E99E59B9B3144D782AC142D8"
      unitRef="usd">45400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e3562-wk-Fact-47AAC987E025564C8FA3D761AFB31B41"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e3592-wk-Fact-C49547DA734E5D2AB91A65F22DD384CE"
      unitRef="usd">8100000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d101529856e3611-wk-Fact-EB1BC513F0A053F589F3B96AC31DD5B0"
      unitRef="usd">0</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d101529856e3641-wk-Fact-BC02ACCFF2275F15A30BEA911B34B359"
      unitRef="usd">6600000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d101529856e3660-wk-Fact-32B13941C1185077AAACC1FBF8EE4987"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d101529856e3686-wk-Fact-E5EF3B2E60C952E799C24A520F1130DD"
      unitRef="usd">848400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d101529856e3690-wk-Fact-98697610D2F158D696B8206FDC9666B6"
      unitRef="usd">735100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101529856e3702-wk-Fact-11DE7711E98F594F8F0336086106C752"
      unitRef="usd">10300000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101529856e3707-wk-Fact-104DEFB194C85C14A2AE0F620197DB6B"
      unitRef="usd">14200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101529856e3719-wk-Fact-92AAC1C3552B50D3A6E0FB0C94B3FF63"
      unitRef="usd">-5200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101529856e3723-wk-Fact-5A6AD6C9C1445C61B2E697323AC94AB1"
      unitRef="usd">-4800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-CC1F23C0DD915ADEA7C2F65DA64C4EBA-0-wk-Fact-E3B55C5246105BAE8441D0C6CFFB7265">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;152.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;65.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e3904-wk-Fact-5F0DF5BC7D4B5D688BF3F4508E6F84B7"
      unitRef="usd">152200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e3923-wk-Fact-F735325A93A85BA9A5D50126C558308B"
      unitRef="usd">65800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e3958-wk-Fact-BF929826D689EA27D500834DF82B4D2B"
      unitRef="usd">7500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e3977-wk-Fact-3C971F5D764DD31F3BE6834E61C30E1D"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e4012-wk-Fact-08E6365C916C572AA4439F4B570BDB58"
      unitRef="usd">1600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e4031-wk-Fact-BD89134997365CCCA2AA02181614124A"
      unitRef="usd">6900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e4122-wk-Fact-AC69AC8A8DFE5401AB04A5DDB8C10B65"
      unitRef="usd">2100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d101529856e4141-wk-Fact-7A845FA2CB8D5BF486874BE5CE8A275F"
      unitRef="usd">14500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d101529856e4232-wk-Fact-3A4DF61A252A5A18894EDFD3FC42AF2D"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d101529856e4251-wk-Fact-D04248BA74355BB8B16AC0E8276895CA"
      unitRef="usd">1100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d101529856e4286-wk-Fact-B9338614A5E45EA7B99C84EF107E594B"
      unitRef="usd">6100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d101529856e4305-wk-Fact-9899C6D2285254179AA74C2B4A4C6909"
      unitRef="usd">3200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-3A1BC886A5315D5DB290812CFEDA48A4-0-wk-Fact-8E0CAB5BFB145CBAA2C246D608702C79">Property, Plant and Equipment&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,555.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,797.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, depreciation expense totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$145.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$64.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$194.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51,000 square feet of administrative space. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to this facility. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$63.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding related to the construction of this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. This transaction included &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$631.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of property, plant and equipment, which was primarily comprised of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$312.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for buildings and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$287.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for machinery and equipment. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101518085e785-wk-Fact-DECA43AA977250CC98A44C79B06BEFF9"
      unitRef="usd">1555300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101518085e789-wk-Fact-156BF1D9B7625E97AA4A26181B93CC4D"
      unitRef="usd">1797400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101518085e816-wk-Fact-F8282C313DFF540580692E7D3564DBB2"
      unitRef="usd">45500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101518085e820-wk-Fact-34374FA1CF2D54C5AA590EE3666E919E"
      unitRef="usd">145400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101518085e824-wk-Fact-FB354661350E5450B8FA8BA04A4FA052"
      unitRef="usd">64800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101518085e828-wk-Fact-EE3542BFD4AD58F4844FA256102538E9"
      unitRef="usd">194000000.0</us-gaap:Depreciation>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2019Q3_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-8"
      id="d101518085e849-wk-Fact-906F0B80E8015C389D7721D13D72B4C6"
      unitRef="usd">1800000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-8"
      id="d101518085e853-wk-Fact-02B39D4140435845BB6EEFBD8DB7C70F"
      unitRef="usd">1600000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:OtherCommitment
      contextRef="FI2019Q3_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-5"
      id="d101518085e862-wk-Fact-3F78FC9290EA58E79E09BCB9720B862C"
      unitRef="usd">63700000</us-gaap:OtherCommitment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101518085e872-wk-Fact-5BC9A91E1ED6B4E2D01EDF3DB0889D41"
      unitRef="usd">631500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-5"
      id="d101518085e876-wk-Fact-C7079089F2365415A1DEE46F4002F0B7"
      unitRef="usd">312500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="I2019Q3Denmark_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      decimals="-5"
      id="d101518085e880-wk-Fact-F44027B7A775585BB1E8BCD1277896F4"
      unitRef="usd">287300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-88C04D4652AE5F0A9C92DE7F3746A587-0-wk-Fact-9A8E3CB3CC905A019DFDA792144CAFC6">Leases&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We lease real estate, including laboratory and office space, and certain equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our leases have remaining lease terms ranging from less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;nine years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;nine years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Our subleases do not include an option to renew as they are coterminous with our operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All of our leases qualify as operating leases. The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance sheet location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;422.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;70.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;410.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;481.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of lease costs in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:37%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;62.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(19.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other (income) expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;15.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;46.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The minimum lease payments for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining three months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;80.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;74.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;71.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;70.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;67.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;148.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;61.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;481.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;601.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(26.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(58.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(182.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;60.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;156.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;418.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term in years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;70.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 1, 2019, we completed our sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. This transaction included &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating lease assets and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating lease liabilities. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q3_srt_RangeAxis_srt_MinimumMember"
      id="d101532007e785-wk-Fact-E078D50A5B925DEDBDB14153D1B78109">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q3_srt_RangeAxis_srt_MaximumMember"
      id="d101532007e789-wk-Fact-731F4B1E48A95E13A1E02F5B3A6CDB75">P9Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q3_srt_RangeAxis_srt_MinimumMember"
      id="d101532007e793-wk-Fact-D8DCE93F5BDC56E9A4FD74C96C684188">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q3_srt_RangeAxis_srt_MaximumMember"
      id="d101532007e797-wk-Fact-0DD896FE89AC5DBE91F54D3D72444140">P6Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q3_srt_RangeAxis_srt_MinimumMember"
      id="d101532007e804-wk-Fact-E078D50A5B925DEDBDB14153D1B78109">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q3_srt_RangeAxis_srt_MaximumMember"
      id="d101532007e808-wk-Fact-731F4B1E48A95E13A1E02F5B3A6CDB75">P9Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <biib:LesseeLeaseTableTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-2367368EEDFA5CFCA9223E680F3FB5E9-0-wk-Fact-F447C98635985CCE88C5D2DB788FC006">The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance sheet location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;422.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;70.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;410.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;481.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:LesseeLeaseTableTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember"
      decimals="-5"
      id="d101532007e918-wk-Fact-4056AE589A0455BAAA742ED5E25003B4"
      unitRef="usd">422000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember"
      decimals="-5"
      id="d101532007e1010-wk-Fact-83651E4ECE335F3AB793B926252102B5"
      unitRef="usd">70600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember"
      decimals="-5"
      id="d101532007e1035-wk-Fact-F74487B0DB6D55BEA85D2F6FF49BF5C9"
      unitRef="usd">410500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1070-wk-Fact-4554B7DDB01A5621880B9264C452DFEE"
      unitRef="usd">481100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-D494D1AE78615D759397160CE8420135-0-wk-Fact-D1E2CF021190557CB369AAA32C2D16F2">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of lease costs in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:37%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;62.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(19.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other (income) expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;15.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;46.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d101532007e1229-wk-Fact-A55F7385DA3252CB881CD71F34B7E17E"
      unitRef="usd">1800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d101532007e1248-wk-Fact-BD7A78F5931A5F08899BF57AA98C823A"
      unitRef="usd">5500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d101532007e1273-wk-Fact-DD189F2DBB395985895AAC3B5257AEDB"
      unitRef="usd">21300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d101532007e1292-wk-Fact-B574C8B4397A52E4A1A1BCC48FD56A37"
      unitRef="usd">62700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d101532007e1322-wk-Fact-63518F845DA751C39D5614CC6D648CF0"
      unitRef="usd">6200000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d101532007e1342-wk-Fact-500C48257DE157C3B0C2956E3871EE6F"
      unitRef="usd">19300000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d101532007e1373-wk-Fact-52E392791F12546EB71685A31C5863E9"
      unitRef="usd">1000000.0</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d101532007e1393-wk-Fact-955C3DC2465250B7B607DB15EA785EC7"
      unitRef="usd">2900000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101532007e1429-wk-Fact-D44DFDF858FA53589482C6EB084539B2"
      unitRef="usd">15900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101532007e1448-wk-Fact-AE2AE0AB07465F67BCCEBC0E673F5A9D"
      unitRef="usd">46000000.0</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-838E892EF7555E21BBB6EEA92FF8ED91-0-wk-Fact-221C5A6FE31F536DB278E46A4FCCE96F">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The minimum lease payments for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining three months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;80.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;74.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;71.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;70.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;67.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;148.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;61.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;481.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1512-wk-Fact-10851E0259FE5DE181E7F8D8698D1FAE"
      unitRef="usd">29900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1527-wk-Fact-D961F0FC704258479FB19FFD9923804E"
      unitRef="usd">80000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1547-wk-Fact-D1A7FF46A52E5F088D39663C156EEFEC"
      unitRef="usd">74800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1567-wk-Fact-45588583F71A57B1A712D5803CC2BE69"
      unitRef="usd">71500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1587-wk-Fact-9071FB4F71935006BFDCFABB1F0FFF19"
      unitRef="usd">70200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1607-wk-Fact-840C16DAB212526B9667950DD50EAF96"
      unitRef="usd">67300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1627-wk-Fact-2CB0EE1C65E659E0AB2F273DBDA4E21D"
      unitRef="usd">148700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1652-wk-Fact-D5C150BD87D659098B432BCA8B9E3FC3"
      unitRef="usd">542400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1667-wk-Fact-C0769AFBA70559F7A8B29B58EEFB95F5"
      unitRef="usd">61300000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101532007e1692-wk-Fact-4554B7DDB01A5621880B9264C452DFEE"
      unitRef="usd">481100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-8DF3E4296906554DB35A7A788EA0709D-0-wk-Fact-566F3A54C0645B03B113F98C81B31BFA">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the prior lease accounting guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;601.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(26.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(58.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(182.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;60.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;156.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;418.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world.</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e1903-wk-Fact-55302935C24F59FBA41720DC8A54EE0C"
      unitRef="usd">87000000.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e1922-wk-Fact-A7B07601ACF855E1A65B4A1813193A76"
      unitRef="usd">80700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e1941-wk-Fact-A029C00401C85AFD9DADF455AEA16D5A"
      unitRef="usd">75900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e1961-wk-Fact-DB9174C63C515C2CA42E6BFA1BB20B8B"
      unitRef="usd">71700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e1980-wk-Fact-89959E743E025B84AF8F9BB78363313F"
      unitRef="usd">71000000.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2000-wk-Fact-7475BB6186E85FBBB0F0BF7F586372CD"
      unitRef="usd">215300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2019-wk-Fact-FF12BFE0FD8A59A1AFECB26F3FE28A72"
      unitRef="usd">601600000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2036-wk-Fact-9538B0C68BCC5CE8A85A9F274AF7F966"
      unitRef="usd">26800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2056-wk-Fact-BB1897976E86556990402A834D4B57D9"
      unitRef="usd">25600000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2076-wk-Fact-BD8EF4294ED15006B4441A4BEE61B5D9"
      unitRef="usd">23700000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2097-wk-Fact-D3574F69285154D981811D1DA24171EF"
      unitRef="usd">24000000.0</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2117-wk-Fact-235A3F0115815C6FA97D1F4C532702E8"
      unitRef="usd">24300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2137-wk-Fact-924E8BA3885653E58F9F4BC85E1A61FD"
      unitRef="usd">58400000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2158-wk-Fact-C83C3C83363E554F9C8CB9A906C7B0D8"
      unitRef="usd">182800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions>
    <biib:NetMinimumLeasePaymentsWithInOneYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2184-wk-Fact-63379C10B0655D5C9D287644877E4A0A"
      unitRef="usd">60200000</biib:NetMinimumLeasePaymentsWithInOneYear>
    <biib:NetMinimumLeasePaymentsWithInTwoYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2203-wk-Fact-65738D33067854A4B75AE596428CB9B8"
      unitRef="usd">55100000</biib:NetMinimumLeasePaymentsWithInTwoYear>
    <biib:NetMinimumLeasePaymentsWithInThreeYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2222-wk-Fact-9C959B5CD8CD5E018DF80227B4C50813"
      unitRef="usd">52200000</biib:NetMinimumLeasePaymentsWithInThreeYear>
    <biib:NetMinimumLeasePaymentsWithInFourYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2242-wk-Fact-335FA93877AB56C484D4AF6B830D8ADE"
      unitRef="usd">47700000</biib:NetMinimumLeasePaymentsWithInFourYear>
    <biib:NetMinimumLeasePaymentsWithInFiveYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2261-wk-Fact-688A24F1C36F5A46915040A8F082AD90"
      unitRef="usd">46700000</biib:NetMinimumLeasePaymentsWithInFiveYear>
    <biib:NetMinimumLeasePaymentsThereafter
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2281-wk-Fact-728F9ACF11C254ECA29E2A28EF4A94A9"
      unitRef="usd">156900000</biib:NetMinimumLeasePaymentsThereafter>
    <biib:NetMinimumLeasePayments
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101532007e2300-wk-Fact-3A154D2169805427826C9C7DFD2EEBC6"
      unitRef="usd">418800000</biib:NetMinimumLeasePayments>
    <biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-F8EB14FD365757A09511CCE5BD71530C-0-wk-Fact-9A86E6F3CDF953C2BE6205AF5FDE1DA6">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term in years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q3"
      id="d101532007e2364-wk-Fact-2A6B7CB14FE559B7AF74DBE518B126DA">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q3"
      decimals="INF"
      id="d101532007e2379-wk-Fact-92F5F5641B2756E9B260997332E7F971"
      unitRef="number">0.033</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-C68049379ED850BEB09E74EC31F78A68-0-wk-Fact-9FFD81E2538F59B7A6F6958FC567F82B">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;70.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101532007e2507-wk-Fact-862B79EF3A1E56348FB0C3C17B007550"
      unitRef="usd">23500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101532007e2526-wk-Fact-EFFEB88FD6385EEC81B96F305BE26771"
      unitRef="usd">70300000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101532007e2546-wk-Fact-045530593E2159668159B42E00E9DF22"
      unitRef="usd">4600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101532007e2565-wk-Fact-47CD428B4C44519ABA5DF203D8BDC2DC"
      unitRef="usd">17300000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <biib:DisposalGroupOperatingLeaseAssets
      contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101532007e2581-wk-Fact-BFF9DFC8BF0650B89F74DF3E2537734A"
      unitRef="usd">2200000</biib:DisposalGroupOperatingLeaseAssets>
    <biib:DisposalGroupOperatingleaseliabilities
      contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101532007e2585-wk-Fact-BAE90A15236B5B6F844343135FD39108"
      unitRef="usd">2200000</biib:DisposalGroupOperatingleaseliabilities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-1F4709E1673F566784AE4B274CE1FEF9-0-wk-Fact-F1BEB16BE1D154F4890F8249639F2ED2">Equity&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2019 Share Repurchase Program). Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. Under our 2019 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$717.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From October 1, 2019 through October 21, 2019, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$508.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under our 2019 Share Repurchase Program.  Approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remained available under our 2019 Share Repurchase Program as of October 21, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;115.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;53.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;233.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(77.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(85.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;10.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;38.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;46.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;148.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;72.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;50.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(192.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(92.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(318.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(316.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;58.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(38.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;56.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;109.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(38.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, September 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(214.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(248.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;35.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;79.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;37.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;85.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(56.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d101543163e785-wk-Fact-CE3BF3C335E853D9A150555684FFD3A0"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101543163e789-wk-Fact-4462974FA98C8ACC47E183593F50B950"
      unitRef="shares">3100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101543163e793-wk-Fact-9ECA67F8EC7D5CC79F43A0B162ADA392"
      unitRef="shares">7000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q3QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101543163e797-wk-Fact-94F6E0F5F1CF480CE20183598CA77AAF"
      unitRef="usd">717900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d101543163e801-wk-Fact-F58E7D69E4ED5ACCA7A8A4C3258663A0"
      unitRef="usd">1600000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="d101543163e817-wk-Fact-DA3853A34DEC7D159737DF3F882B6B7F"
      unitRef="shares">2300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="D2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="d101543163e821-wk-Fact-29374F4EA784B24C49CADF414D8DBE05"
      unitRef="usd">508600000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="FI2019Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d101543163e825-wk-Fact-F11D8348181357C98DF4441EF31A1846"
      unitRef="usd">2900000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-8"
      id="d101543163e832-wk-Fact-D166121B09D354B3AAD2EB054791255E"
      unitRef="usd">3500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101543163e836-wk-Fact-FA65CEDD6C6A596CB30A8730836F494C"
      unitRef="shares">8900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-8"
      id="d101543163e840-wk-Fact-DB73370AFA5F5A5FB0F6DA10BAA82DA7"
      unitRef="usd">2100000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-8"
      id="d101543163e855-wk-Fact-CAD41D4D47D357D980BFC744F3424D96"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d101543163e859-wk-Fact-3B2194995783505AB8AD186AEACB3EBE"
      unitRef="shares">10500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-8"
      id="d101543163e863-wk-Fact-551FD2EB11605154AE2A88A336BCB221"
      unitRef="usd">3000000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-66F2385BEAB5540F8F2C0ACBEAAF034F-0-wk-Fact-04386EBB607D5AF6AB1CF4F251290A71">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;115.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;53.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;233.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(77.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(85.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;10.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;38.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;46.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;148.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;72.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;50.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(192.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(92.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(318.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(316.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;58.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(38.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;56.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;109.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(38.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, September 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(214.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(248.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e1079-wk-Fact-635B12F221A55641B6BAEFE2FA779199"
      unitRef="usd">-4000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e1099-wk-Fact-092D48D2B7525F9CA8D7101FD399A6C8"
      unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e1119-wk-Fact-F7837A79320C5041A3BA69F8C0C11C70"
      unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e1138-wk-Fact-34AE5E0CC39252468413D61379EE8E4B"
      unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e1158-wk-Fact-883E3C0D1166531EB6FE74A9C3A5163F"
      unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101543163e1179-wk-Fact-2AD3B15D1D55512B9C6B95F3C78B4D85"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e1200-wk-Fact-122F895B4884534292125E856EDA3AC8"
      unitRef="usd">11600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e1219-wk-Fact-335CD73B00E05887831451E194843301"
      unitRef="usd">115800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e1238-wk-Fact-D471468B4DC15A4E80B99D7D4207E1D1"
      unitRef="usd">53500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e1258-wk-Fact-F793E8E1C37C51AEBDF33CA3406D5578"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e1277-wk-Fact-C64EE0A719E25F2993B39598E57D1A29"
      unitRef="usd">51300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101543163e1297-wk-Fact-18D13DE3565B527F850C6DEF51EBC953"
      unitRef="usd">233700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e1322-wk-Fact-08B57A371A3A5C7CBB2619E91FC06BB1"
      unitRef="usd">-1300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e1342-wk-Fact-94C875A83BF7581AB04688CB2440375B"
      unitRef="usd">-77700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e1362-wk-Fact-9C67BC4A9F1B5CB4ABF880E51F002F57"
      unitRef="usd">-6600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e1383-wk-Fact-2C2835DB46E552359E1F636FEA0FD17B"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e1402-wk-Fact-0CDE5DA95A7A521BB91114BB8195BB80"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101543163e1422-wk-Fact-7F644F30F60752C78255FA12C7265AC3"
      unitRef="usd">-85600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e1448-wk-Fact-C8334C6258795FDDBE1577E873E24892"
      unitRef="usd">10300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e1467-wk-Fact-73ECB6C0E6915CF1B1D1A34DCBC28F40"
      unitRef="usd">38100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e1486-wk-Fact-F53523D5B812595BA59B512B2E9E3D28"
      unitRef="usd">46900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e1506-wk-Fact-E2D96DD5957D54019BA84D848738031D"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e1525-wk-Fact-578384EBE6395C20A9BDBC1C543F2FED"
      unitRef="usd">51300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101543163e1545-wk-Fact-4BE449ABC68C5BBB868E2225D4530616"
      unitRef="usd">148100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e1575-wk-Fact-F4A14B1E52D25EED9649ACF032845F18"
      unitRef="usd">6300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e1594-wk-Fact-3B7F17369E6753CE8E0EDC4EC540A64A"
      unitRef="usd">72800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e1614-wk-Fact-D3699B1576FD5BB48D130397C57BD5E6"
      unitRef="usd">50400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e1633-wk-Fact-A2EDED11C2985890B99479E4C77214F2"
      unitRef="usd">-29800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e1653-wk-Fact-FF9E0C94C302564AB5469BCD2DC765CE"
      unitRef="usd">-192000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101543163e1674-wk-Fact-D19A1A49D241536C9B103A6500E3337A"
      unitRef="usd">-92300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e1864-wk-Fact-E468B46E393759DE9D6935D888D8AFA7"
      unitRef="usd">-1600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e1884-wk-Fact-333ECD5838155560AB3BA1B487B7B105"
      unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e1905-wk-Fact-55C089DB35E2577298612860FD471F60"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e1924-wk-Fact-A6F5DF0591105090A22BB9564F91B8AD"
      unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e1944-wk-Fact-5FB6F2DFBA38592B9849BF170BA50968"
      unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4"
      decimals="-5"
      id="d101543163e1965-wk-Fact-10171AA65B5858EBBD2DD843A3C0FFE9"
      unitRef="usd">-318400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e1986-wk-Fact-AF4B5D3D486157C18392BD4A56AC418C"
      unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e2005-wk-Fact-1607C892D1165369AA37D209287E057D"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e2024-wk-Fact-71A785022A7B5A68B393F778E848A58E"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e2044-wk-Fact-77410517F4325E73A7D0935FAC46A49A"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e2063-wk-Fact-55447D7198A15BE8B65D58F078C231D9"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member"
      decimals="-5"
      id="d101543163e2083-wk-Fact-746B5582208E56AC82FFC30F19A84702"
      unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e2108-wk-Fact-09F7C829E3B85067BE955E54F832A976"
      unitRef="usd">-100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e2128-wk-Fact-7D0315218B6650368D04A2F4065C6140"
      unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="0"
      id="d101543163e2148-wk-Fact-1B75927D82205839B6A4A9048D698855"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e2168-wk-Fact-D6C26711256854B8B7C7720C7631DEDE"
      unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e2188-wk-Fact-ACAA34C72E7D5ED6BD0DB6560C43E86B"
      unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate"
      decimals="-5"
      id="d101543163e2209-wk-Fact-CF2F016C0E7658B48BA40655A96561D9"
      unitRef="usd">-316900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e2235-wk-Fact-654598FC41CA5A7C92DF0E48B3B09382"
      unitRef="usd">-7900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e2255-wk-Fact-60A34CA8026456B8A76B4BC76B849F48"
      unitRef="usd">58300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e2274-wk-Fact-52307463D26455888E957E70A37589F2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e2294-wk-Fact-CEA8CB7B1DF551889ABE21911344AE9C"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e2313-wk-Fact-7D2B10C0B17C5F5ABBC1DE18DE1AF96B"
      unitRef="usd">-38800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101543163e2334-wk-Fact-BC91EE2BDFD95362A4A86405576858AC"
      unitRef="usd">11800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e2359-wk-Fact-35B884AA42E4509CAB167F6D1842BE2E"
      unitRef="usd">6100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e2378-wk-Fact-7A47F3A5B5B05AB3A24D8184D96F1AA5"
      unitRef="usd">50700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e2397-wk-Fact-B1603A059C8952F4B800C544BC9C0FAB"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e2417-wk-Fact-BEC437DFFD1350C8AEA98166C8D25633"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e2436-wk-Fact-854B33DE6AF353EE8D96CB514D019B02"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101543163e2456-wk-Fact-AF693D52806E5A598300D29D2AA9AD71"
      unitRef="usd">56800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e2481-wk-Fact-1F9CB585DA06573A9649D13DDCC298A3"
      unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e2501-wk-Fact-77C297AA58D65130A8E001050E482745"
      unitRef="usd">109000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e2520-wk-Fact-A384F0C43CC15F7F957ED958AD286768"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e2540-wk-Fact-29F8AE11800955B899CD474D91153F2D"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e2559-wk-Fact-107CDA5806A65B94A48D28F733A90A26"
      unitRef="usd">-38800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101543163e2580-wk-Fact-61FD074FCC6D59939B8BE32C48B29249"
      unitRef="usd">68600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e2610-wk-Fact-43A3A6CD371B56F8862DFDA11BDAEF1E"
      unitRef="usd">-1900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e2630-wk-Fact-93A4DD0A8DEC51C9804B6E256D71E64A"
      unitRef="usd">4500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e2650-wk-Fact-103140FC6C8A50B6B5CD973577A36E72"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d101543163e2669-wk-Fact-C14DD62B1A5E5B8CAFD61D0A0C6283DA"
      unitRef="usd">-36600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d101543163e2689-wk-Fact-143CE23DBD9B5E77820DBB0D51516429"
      unitRef="usd">-214300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q3"
      decimals="-5"
      id="d101543163e2710-wk-Fact-59C0EAD6DD2E5FDABB0786818BC7B05E"
      unitRef="usd">-248300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-3874991AEEB952EF8640040AD2308BD0-0-wk-Fact-D840189BE6E55884A78AE313B598706D">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;35.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;79.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;37.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;85.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(56.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e3061-wk-Fact-8BEFD7670409555F9640CB59A1DDDAD5"
      unitRef="usd">600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e3080-wk-Fact-77DDBEC2FF3352D392504631D620E2F1"
      unitRef="usd">-100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e3101-wk-Fact-B20E5AA5FCF8517B9FAD81076FE14931"
      unitRef="usd">1600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e3120-wk-Fact-761892AC01BA559790DAC3969D88197D"
      unitRef="usd">-7700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e3146-wk-Fact-DB8616DFC95B5B8682D8342D0D20045C"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e3166-wk-Fact-9D85D0278A0653FEA9540BCE6FACFCE9"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e3186-wk-Fact-67DEB04F037650B0A149BE90B1CFFE03"
      unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d101543163e3206-wk-Fact-B9FAF1EA9B255B5AB3EC7691008E1DD5"
      unitRef="usd">1600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3328-wk-Fact-154B0E00CF0E5A778019A18215B9F8BB"
      unitRef="usd">35200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3347-wk-Fact-3F3B25882E60546CB830130809ABC7D2"
      unitRef="usd">8400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3368-wk-Fact-61B963EA2A42509782413D0C6952F245"
      unitRef="usd">79800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3387-wk-Fact-BA40E37D5F1F540593DC23564EB1A27F"
      unitRef="usd">51700000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3418-wk-Fact-9227FF83772C50D59311281580DDFC04"
      unitRef="usd">800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3438-wk-Fact-CDC31325484955A78828C41D9FEACF8D"
      unitRef="usd">300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3459-wk-Fact-74D2840CDEFC5682B3FEB6C3A6EA14F6"
      unitRef="usd">2000000.0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3479-wk-Fact-7F3BAB48B06454F1B66864CDEF3E07C4"
      unitRef="usd">600000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3509-wk-Fact-D3BA65E6E6CD55DEA450073107787B66"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3528-wk-Fact-D9FE23793A0C5FA8907CBB11D6025006"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3548-wk-Fact-F67DE9432D9E50B69F96239AB6CDF6E0"
      unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3567-wk-Fact-9AE5BA7AF09D52DE8F2887AE21423244"
      unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3597-wk-Fact-AB422335BC6D5530A0DC89E2432C4D93"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3617-wk-Fact-7DCE4320F6735667B204AD2458806451"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3637-wk-Fact-90F39731BEDB530983A53BD175614202"
      unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d101543163e3657-wk-Fact-F8E92C9BE0995E1D934825A1645A5FEF"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e3780-wk-Fact-99058D90712A51ABB959A52124124C25"
      unitRef="usd">2200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e3799-wk-Fact-26BCCB8BBF9F5139B4A6031B835A0DF7"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e3819-wk-Fact-3B8F2ACCF3B5587A8280FC3961722B03"
      unitRef="usd">6600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e3838-wk-Fact-E8030C24F07957A980399260F10B546B"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e3868-wk-Fact-48AFA680D78C55D3AC09B20F290F3159"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e3887-wk-Fact-0BA549A4236B529FAB23C9CBD23DB478"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e3907-wk-Fact-93F401C7BDEB54F2B1037344BC2ACDB1"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d101543163e3926-wk-Fact-F837600B394C532DB0DEB38F5D4FFD60"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101543163e4053-wk-Fact-B725205ABEEA58BE818E78AFEEA230AE"
      unitRef="usd">37100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101543163e4072-wk-Fact-C7CFB9CC55E15ACFA735A4F2B4387834"
      unitRef="usd">-8700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101543163e4093-wk-Fact-6493EE6FF5685D3394B25E796C1EE325"
      unitRef="usd">85600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d101543163e4112-wk-Fact-51981C56018C5F19B969591ECE8A0D21"
      unitRef="usd">-56800000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-E5E351BDF7A45596A7E3D88A69DBC7A4-0-wk-Fact-75A7A1102D2154F4BF9DF2BE43433BC6">Earnings&#160;per Share&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,545.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,444.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,448.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,483.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;184.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;201.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;206.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;184.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;201.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;190.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-30BB3C1736B356E287B074401CBBFE33-0-wk-Fact-9CA0CBC99B975BE5AD9CB011D1D61281">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,545.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,444.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,448.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,483.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;184.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;201.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;206.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;184.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;201.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;190.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101533586e1079-wk-Fact-8BCEFCADFFDD5171A80A5930F9D729B5"
      unitRef="usd">1545900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101533586e1098-wk-Fact-A3394798436750ACA93FC560D5254E0D"
      unitRef="usd">1444400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101533586e1117-wk-Fact-FF611939A9605722A2FA20072DD911C0"
      unitRef="usd">4448800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101533586e1137-wk-Fact-71E4AC6E479B5D7B8F2CABF3359E1159"
      unitRef="usd">3483900000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101533586e1234-wk-Fact-F6CE5BEE80B6540FA43FF8EA2757EB66"
      unitRef="shares">184000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101533586e1253-wk-Fact-E9DB242D33DA5FCF80E62B38AB8B3CCC"
      unitRef="shares">201400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101533586e1272-wk-Fact-D122FB3C0DD75244A8431CFB07FAEF38"
      unitRef="shares">190300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101533586e1292-wk-Fact-A1872F8928FF5D918E5EC1A8811DC1C1"
      unitRef="shares">206600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d101533586e1394-wk-Fact-545C91A0C9A95D07ABDA3BBBD9552FC8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d101533586e1413-wk-Fact-DAC06ACAB85B50D8985F92CC7F4DE3EB"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d101533586e1432-wk-Fact-9543566ABB4856E69B37E73DFE40F500"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d101533586e1452-wk-Fact-D0939E94E36E540C828B3EDC84FB54EE"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d101533586e1472-wk-Fact-60B06648579A52399752BF84D19F7722"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d101533586e1491-wk-Fact-A440912A85E55C51B14B8F678CF94FAF"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d101533586e1510-wk-Fact-0D11369804555E75A0DFE73BECC9F6FB"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d101533586e1530-wk-Fact-53DA8026BB4B5B23A16AE2FF86D8C074"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d101533586e1550-wk-Fact-323908F7C51E5C0B8ABF71E189ECF471"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d101533586e1569-wk-Fact-6B6EEDFF745953ADB39D1492358010E0"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d101533586e1588-wk-Fact-668B22E025D25E6A8F5D8CF4D2BC24E1"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d101533586e1608-wk-Fact-136E2CB0045752068F73CEEC96DB2C16"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d101533586e1628-wk-Fact-C39C6E33ECD95D3E8430581FA7AC0C77"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d101533586e1647-wk-Fact-DF137773BA225B94AC85A022F5C47CB3"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d101533586e1666-wk-Fact-98E5A21B225D5252BACF8F1F32533579"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d101533586e1686-wk-Fact-BA76595DDA965FE3B8CC530EE56446F3"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101533586e1707-wk-Fact-C8B4136A7EB65E1D90145859BD10B5B1"
      unitRef="shares">200000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101533586e1726-wk-Fact-FBE31F4FCDF15B11935CAF33D72898AA"
      unitRef="shares">500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101533586e1745-wk-Fact-565C9C386E505E30A7B04E2D6A68288F"
      unitRef="shares">200000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101533586e1765-wk-Fact-9028B223615D51FCB60B9B58CA0F12BD"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101533586e1785-wk-Fact-93A4BEF1889A5DEBA0656CD4B052EC65"
      unitRef="shares">184200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101533586e1804-wk-Fact-3C339B177C795EFCA2E51E30FA1B6B01"
      unitRef="shares">201900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101533586e1823-wk-Fact-E79773D2EAB35D32A14B66C86F627853"
      unitRef="shares">190500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101533586e1843-wk-Fact-097BC21BCB8351D6BD7B65093FE992A9"
      unitRef="shares">207000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-BDD850B2639850D8B2ED09A7A09AF1DD-0-wk-Fact-582183C7B64E51179F0C4695C4E62C8B">Share-based Payments&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;15.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;65.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;60.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;116.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;83.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;182.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(8.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(29.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(21.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;39.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;145.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;37.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;104.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;96.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NST stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;182.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock option expense reflects the accelerated vesting of stock options previously granted to NST employees as a result of our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-C39BD9693E915261A43AD7C58AA26A8F-0-wk-Fact-A9F41029341A5745A64969DF826F5C15">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;15.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;65.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;60.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;116.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;83.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;182.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(8.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(29.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(21.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;39.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;145.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d101536639e1000-wk-Fact-ABA058359F3B5A76955AD5C4B655339A"
      unitRef="usd">15400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d101536639e1019-wk-Fact-74CA9D38F7175BEDAC11208E6EAC3ADC"
      unitRef="usd">21000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d101536639e1038-wk-Fact-143884E0BF805009A5D97F224B6F8052"
      unitRef="usd">65200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d101536639e1058-wk-Fact-673EFCB7E5E85D319CE495DC65070143"
      unitRef="usd">60500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d101536639e1073-wk-Fact-2B50999772645E229E5291EDA7AF72B1"
      unitRef="usd">34200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d101536639e1092-wk-Fact-65F3A1C5CDD35A479C04DEB0F845E1F3"
      unitRef="usd">29400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d101536639e1111-wk-Fact-D57CDB857151594E89DC7D603BE19CC5"
      unitRef="usd">116800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d101536639e1131-wk-Fact-6F70496D82D85DC78B6DC6CF2EC1D406"
      unitRef="usd">83100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101536639e1151-wk-Fact-74E16BC1DB9C51A68545C932163EA52A"
      unitRef="usd">49600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101536639e1170-wk-Fact-987AF63612A753CC8B67053776B3524B"
      unitRef="usd">50400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101536639e1189-wk-Fact-D2A3EF02E5AF5D31B3E4CC6D73CD206B"
      unitRef="usd">182000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101536639e1209-wk-Fact-B674E77FD9885D4B8825DC3A19AB4A13"
      unitRef="usd">143600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101536639e1229-wk-Fact-1F8B5DF3DDD65C42A59D8CBEAB5ACC55"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101536639e1249-wk-Fact-0459486163FC5FE88E0C4371F05FB4C9"
      unitRef="usd">3500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101536639e1269-wk-Fact-B08CB46B391C57A687231ABA0D9AEF98"
      unitRef="usd">7800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101536639e1290-wk-Fact-6B97BF69070E56B6BF5D72ADB0E54005"
      unitRef="usd">9700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101536639e1311-wk-Fact-F209147987695BC0AA500F00D653DDB6"
      unitRef="usd">47900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101536639e1330-wk-Fact-AEF85C440AA2530F8E0E1E013B6112CE"
      unitRef="usd">46900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101536639e1349-wk-Fact-8B2E2E15BAB658A08B0AFD6A401BC7AE"
      unitRef="usd">174200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101536639e1369-wk-Fact-D745268D663C5E8FADDBE423A1D47AD4"
      unitRef="usd">133900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101536639e1389-wk-Fact-E92077B62C745CFF802C66578AFAEBA0"
      unitRef="usd">8100000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101536639e1409-wk-Fact-0E0FDDCE0C89510CA268238FDBCFDC80"
      unitRef="usd">7700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101536639e1429-wk-Fact-C9587320B47E52CC895971EC5AC88C8E"
      unitRef="usd">29100000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101536639e1450-wk-Fact-18D1A95A60C95B98B8C72EB5FCCBF6AD"
      unitRef="usd">21800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d101536639e1476-wk-Fact-5AC151C5867E5A15B05FE27252A22674"
      unitRef="usd">39800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d101536639e1495-wk-Fact-6578FEE51A0A582F8F06AB4456A1D66B"
      unitRef="usd">39200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d101536639e1514-wk-Fact-87739C66D48252BD93550D991A52317B"
      unitRef="usd">145100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d101536639e1534-wk-Fact-89000F788A5D57A59F2949C219006D6E"
      unitRef="usd">112100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-25B2063DE9C553808E88FDE10FB2D5B4-0-wk-Fact-EFADBB8D785851EABA46EFF629A5D4FA">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;37.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;104.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;96.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;9.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NST stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;182.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d101536639e1763-wk-Fact-77998986CA825766801F6DD7FD25B891"
      unitRef="usd">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d101536639e1782-wk-Fact-6E1C575A18DB5CF18ECCC55E0EC86603"
      unitRef="usd">7400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d101536639e1801-wk-Fact-35212C51F5BD5022975D7F9251CDA1CD"
      unitRef="usd">24800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d101536639e1821-wk-Fact-80FC147CF5B158C79CCF9448EF1D0144"
      unitRef="usd">20600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d101536639e1836-wk-Fact-781D3C0B06DF586C9BF97ED4179F7074"
      unitRef="usd">37900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d101536639e1855-wk-Fact-0B30933B196D596C99B613757DE3D602"
      unitRef="usd">29900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d101536639e1874-wk-Fact-E9B5215F4CF5530783081A1C859B0B88"
      unitRef="usd">104400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d101536639e1894-wk-Fact-394078E62C8159349D0A1A688BE4703A"
      unitRef="usd">96600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d101536639e1914-wk-Fact-3942538699575549BCDC4DE73E2657D6"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d101536639e1933-wk-Fact-7469FB469948510983E89977ED165786"
      unitRef="usd">5800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d101536639e1952-wk-Fact-01EAFDD463E953BB9654A4CF1D454BE4"
      unitRef="usd">-300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d101536639e1973-wk-Fact-0FA867213F52583A80C5C9D2AFDC80CF"
      unitRef="usd">9400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d101536639e1993-wk-Fact-6E5BF6E7E500566FACDAD632FA66D99F"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d101536639e2012-wk-Fact-814BC632727E5CD680A5D9AF20D2ABFF"
      unitRef="usd">3000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d101536639e2031-wk-Fact-B77F75E93925519D9B3DF42E20AEA593"
      unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d101536639e2051-wk-Fact-06B27721CF4C58BD9FB2FE53BE0B0B4A"
      unitRef="usd">4200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d101536639e2071-wk-Fact-9CEAFAC279265A91A3465C5D09B9972E"
      unitRef="usd">-1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d101536639e2091-wk-Fact-CF9F90F3B6A657EE90B9E0427A35D594"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d101536639e2110-wk-Fact-9935CFACBD2C57099C6F53A878C7AE3E"
      unitRef="usd">13000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d101536639e2130-wk-Fact-17BAD4858D8B51BDB96BEFE06C7B327D"
      unitRef="usd">3400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d101536639e2150-wk-Fact-F17C663B465E53C6ABC6B0F112C3AEC6"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d101536639e2169-wk-Fact-E206A8CB76C155A2A0DFDD2C13F1CB5D"
      unitRef="usd">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d101536639e2188-wk-Fact-B131CC5B55945D809116FE1388C10D0A"
      unitRef="usd">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d101536639e2208-wk-Fact-856A7C5CDDB757ADBBE97AD9B8696BF3"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d101536639e2228-wk-Fact-FDFB1739ADA5514F839041ACB91E3D08"
      unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d101536639e2247-wk-Fact-F2636C770CF15562B0E973FBB6EB6D60"
      unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d101536639e2266-wk-Fact-35524D15DA27544FA73A9F9CB30273E6"
      unitRef="usd">9700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d101536639e2286-wk-Fact-9D9A4EE704FA55B6A71BCC39B884E800"
      unitRef="usd">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101536639e2306-wk-Fact-4B0B1A0EB02F573BB28CFAA787153B70"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101536639e2325-wk-Fact-B635FB959EF05E9F8EC03DD81F0AB1FD"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101536639e2344-wk-Fact-2D3A4507D8AE5FF8A75B4F74523BEF6F"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d101536639e2364-wk-Fact-4AD3B367C47558C8876CF5DED2B1064B"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101536639e2384-wk-Fact-74E16BC1DB9C51A68545C932163EA52A"
      unitRef="usd">49600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101536639e2403-wk-Fact-987AF63612A753CC8B67053776B3524B"
      unitRef="usd">50400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101536639e2422-wk-Fact-D2A3EF02E5AF5D31B3E4CC6D73CD206B"
      unitRef="usd">182000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101536639e2442-wk-Fact-B674E77FD9885D4B8825DC3A19AB4A13"
      unitRef="usd">143600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101536639e2463-wk-Fact-1F8B5DF3DDD65C42A59D8CBEAB5ACC55"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101536639e2483-wk-Fact-0459486163FC5FE88E0C4371F05FB4C9"
      unitRef="usd">3500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101536639e2503-wk-Fact-B08CB46B391C57A687231ABA0D9AEF98"
      unitRef="usd">7800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101536639e2524-wk-Fact-6B97BF69070E56B6BF5D72ADB0E54005"
      unitRef="usd">9700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101536639e2550-wk-Fact-F209147987695BC0AA500F00D653DDB6"
      unitRef="usd">47900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101536639e2569-wk-Fact-AEF85C440AA2530F8E0E1E013B6112CE"
      unitRef="usd">46900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101536639e2588-wk-Fact-8B2E2E15BAB658A08B0AFD6A401BC7AE"
      unitRef="usd">174200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101536639e2608-wk-Fact-D745268D663C5E8FADDBE423A1D47AD4"
      unitRef="usd">133900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-A179028EC191579A87D968DC537AA4E1-0-wk-Fact-A63B00976C9A5B469A3325B66613697F">Income Taxes&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;U.S. tax reform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss tax reform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(3.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;16.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in 2018, the decrease in our effective tax rate was primarily due to the enactment of a new taxing regime in the country and certain cantons of Switzerland, which we refer to as Swiss Tax Reform. As a result of the impact of Swiss Tax Reform, in the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded an income tax benefit of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$54.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, resulting from a remeasurement of our deferred tax assets and liabilities. In addition, in the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net benefit for the impact of the internal reorganization of certain intellectual property rights and a net benefit of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; resulting from the finalization of tax returns in various jurisdictions related to the 2018 fiscal year. We also had a higher effective tax rate in 2018 resulting from our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in 2018, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of Swiss Tax Reform. This decrease was partially offset by a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$64.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; tax expense related to the divestiture of our subsidiary that owned our Hiller&#xf8;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Although we are recognizing a loss on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, the divestiture requires us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the internal reorganization of certain intellectual property rights, as of September 30, 2019, we recorded a deferred tax asset of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$754.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a deferred tax liability of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$603.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Federal and State Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-9F3535D6213B558BBFB666590A2F64A4-0-wk-Fact-B8AD35EF9CB65FD3ADE56903FB93F5DB">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;U.S. tax reform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss tax reform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(3.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;16.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e951-wk-Fact-4A6994D6B71C5EFEB272226B4E6D2A7E"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q3QTD"
      decimals="INF"
      id="d101534516e966-wk-Fact-8BFA64FA3C705C91A74627818736C647"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e981-wk-Fact-47A31FD7D703533EBDD2399B060CCD2A"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q3YTD"
      decimals="INF"
      id="d101534516e996-wk-Fact-BA868D51D6AD565ABA1549B2B982F599"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1013-wk-Fact-B6CB4F9384EA577AB96472705A91512F"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1027-wk-Fact-E5E01A6BC9105BCF9707BC2816F773C4"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1041-wk-Fact-76DB83C47C8F58CB9DC01529C0AF7AF6"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1055-wk-Fact-E9B8E7015FE7548E915870F390A1369E"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1071-wk-Fact-318DA773A01D5B87831861612149DF46"
      unitRef="number">-0.050</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1086-wk-Fact-034B25EEB7F959B785530D12B05CA1AA"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1101-wk-Fact-6AED3382EF645E1FB16A185E36A20520"
      unitRef="number">-0.047</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1116-wk-Fact-9A35A4C8C6AD557EBF9CBCF17CB1C107"
      unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1133-wk-Fact-9272A83F67BB555DA2AFEDE761AA909E"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1148-wk-Fact-CF9EDDFB02FB5035A182092785452C33"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1163-wk-Fact-C2116C082BF85A8894F800018D209899"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1178-wk-Fact-099106EC00C8524993F8BF753568A247"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1195-wk-Fact-BE4BB4EBE26E51818ED2A6024B0595DC"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1209-wk-Fact-39EC2CB180895AE19AF5C5FAAC929740"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1223-wk-Fact-947FAB6F287C593D8F037A99625071F3"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1237-wk-Fact-4C2F2CA1C4C753B7859F143D1902D79E"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1253-wk-Fact-46DF25CE8A145732A92A2950B80FB462"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2018Q3QTD"
      decimals="INF"
      id="d101534516e1267-wk-Fact-AB82E368A87F5518AF06CF142A9C82B7"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1281-wk-Fact-3AD5BDC9C52C5435B215316C460E3DAC"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2018Q3YTD"
      decimals="INF"
      id="d101534516e1295-wk-Fact-8F964E02D8F05B978F243A79414595AA"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1311-wk-Fact-8AF7F1DBC04C5FD6ABFBF015E513B559"
      unitRef="number">-0.015</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1326-wk-Fact-F5040E734EAD50568E90CB009E329616"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1340-wk-Fact-6DE31362C9F555838103674F85C8D204"
      unitRef="number">-0.021</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1355-wk-Fact-D4F477BCC8F15EA694267CC52792C4EA"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1371-wk-Fact-8FD5955E47065BA49D62DEFCAD2AB299"
      unitRef="number">0.016</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1385-wk-Fact-91F98E5ABEC35071897E1F5CEB029A16"
      unitRef="number">0.013</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1399-wk-Fact-0C56EDA7AD1F5808BCD67B549B2103B2"
      unitRef="number">0.016</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1413-wk-Fact-2F24F38C6DE851018EACC20F3A1C635F"
      unitRef="number">0.014</biib:EffectiveTaxRateReconciliationGILTItax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1429-wk-Fact-D8D71667CF30BD58CE65DF487F096181"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1443-wk-Fact-C3A37E68E47A53D4CBA5DF48A946DFBB"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1458-wk-Fact-527D41FAC10ED8A983FEDF48CBA8EEDD"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1472-wk-Fact-C834C00E87E9BF745C73DF48EAF695D5"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1490-wk-Fact-B80F4A5B951F2CEE3D80DF49C93D5502"
      unitRef="number">-0.031</biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1505-wk-Fact-3C43984D4EC3991D5209DF49CD254F9D"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1519-wk-Fact-6F724C135CCE13217417DF49D08A25F3"
      unitRef="number">-0.010</biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1534-wk-Fact-04CCED9F0C4ACE624C77DF49D4770CE5"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1550-wk-Fact-4B41029719BC520895721907F06FD276"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1565-wk-Fact-915DF50B91CA555D86AF3146B56A93A4"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1579-wk-Fact-D50AD40AF5E35E0996237365BD3022B2"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1593-wk-Fact-038697C57FFD594F9BE27F4B479ADB25"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1609-wk-Fact-CD7D332C15D35B40A434815BEFC84607"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1624-wk-Fact-CDE90DF44FF35B4C9518B4EB5969EC63"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1639-wk-Fact-A3EF03E884C153BDB8D546527152C7B7"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1654-wk-Fact-C8719CEDE00D5818924AAB03E627ECD4"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d101534516e1671-wk-Fact-68DA5BCC5E4E57F4950C6F7B2BD5877D"
      unitRef="number">0.119</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q3QTD"
      decimals="3"
      id="d101534516e1686-wk-Fact-655A7C888E9A5EC886428E03D1A1E18B"
      unitRef="number">0.204</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d101534516e1701-wk-Fact-140A8775F21F54BC9DD63EDF285F06D8"
      unitRef="number">0.163</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d101534516e1716-wk-Fact-DCDE9D2E3DE35EBEAF4C84BD79725E49"
      unitRef="number">0.213</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="d101534516e1757-wk-Fact-D7D236741AA948C95874DF4552979A5E"
      unitRef="usd">54300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="d101534516e1770-wk-Fact-A8EB1CEFFA938331E193DF460E9B4991"
      unitRef="usd">15800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d101534516e1785-wk-Fact-DE53D21C5AE75E5C9034597BF3D7AAAC"
      unitRef="usd">64700000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2019Q3_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember"
      decimals="-5"
      id="d101534516e1795-wk-Fact-9DAC814C958E68A7266FDF440061776E"
      unitRef="usd">754200000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="FI2019Q3_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember"
      decimals="-5"
      id="d101534516e1799-wk-Fact-C2C2DE1D815220C43F65DF44423E2BA1"
      unitRef="usd">603400000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-654EFF0C4B3E5E8D8594725C1F0B11DF-0-wk-Fact-23236C586E585529A35E7B6C1336740E">Other Consolidated Financial Statement Detail&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;30.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;90.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;81.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(45.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(49.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(141.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(151.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;141.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;132.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(13.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(27.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;132.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;141.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;197.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;139.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;46.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unrealized gains (losses) recognized during the period on equity securities held as of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;141.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;150.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;140.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;884.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;259.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;222.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;224.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;188.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;147.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;444.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;125.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;677.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;609.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,429.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,861.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,370.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,389.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and included accrued income taxes totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$801.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$791.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-1C79B6F5234D50FEAFDC6B2C5605FB21-0-wk-Fact-F5AAFD9900F659B593A00AC13CFC7479">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;30.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;90.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;81.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(45.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(49.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(141.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(151.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;141.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;132.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(13.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(27.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;132.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101538747e1000-wk-Fact-AC69ED6D87DB56EB9F937E400DC25A79"
      unitRef="usd">30500000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101538747e1019-wk-Fact-232F654D865C52BD816B4BBDD2742B19"
      unitRef="usd">26000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101538747e1038-wk-Fact-317D0FA1071550369E079EAE2CCA7A44"
      unitRef="usd">90800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101538747e1058-wk-Fact-F8C14051A8275AFE8C4E902BE47B4D72"
      unitRef="usd">81400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101538747e1073-wk-Fact-BE6A17A9C60058B5BBB2C1E727E959CE"
      unitRef="usd">45800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101538747e1093-wk-Fact-1B02DE9A9A865BF7BB82747792A1338D"
      unitRef="usd">49000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101538747e1113-wk-Fact-CF7DB68D8F1052428FB71537BCAF862A"
      unitRef="usd">141400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101538747e1134-wk-Fact-12AA386232E65BB19563813890083D36"
      unitRef="usd">151200000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101538747e1155-wk-Fact-549EA97F600B511FAF77B71D21C12F33"
      unitRef="usd">-4100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101538747e1175-wk-Fact-1B3BFA171E64588DABAD643E55F66FB9"
      unitRef="usd">141100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101538747e1194-wk-Fact-58D07A5924545B3F837D6F393083D0CF"
      unitRef="usd">198900000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101538747e1214-wk-Fact-1870778514715E99A0E624A144F2FF7D"
      unitRef="usd">132000000.0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101538747e1234-wk-Fact-2DB4BEB185D05043B97FA67A703262E7"
      unitRef="usd">-4200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101538747e1254-wk-Fact-B0D41692FEFF5B26AD356976B80B246B"
      unitRef="usd">200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101538747e1273-wk-Fact-A5DBDCE0B64B50A8AC5D51A7BD4DC742"
      unitRef="usd">-4700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101538747e1294-wk-Fact-FA06420214515D18B218B780C0561FA4"
      unitRef="usd">-13800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101538747e1315-wk-Fact-D66A8A0AA9C7590B8EC6B43024565762"
      unitRef="usd">-3700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101538747e1335-wk-Fact-64F097572C235991B3664C6DE980FD1C"
      unitRef="usd">-3200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101538747e1355-wk-Fact-0A794B06EA2C5F7081196027C39E8119"
      unitRef="usd">-11000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101538747e1376-wk-Fact-F37ADCA6FBF552F9869D9048D2BAC99D"
      unitRef="usd">-8800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101538747e1402-wk-Fact-E9D12EA36B4D5C33868828CA4F85E261"
      unitRef="usd">-27300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101538747e1422-wk-Fact-2C8DF4D3F6FF5FBB8B107A909ED110C4"
      unitRef="usd">115100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101538747e1441-wk-Fact-955EC3C90AF15B78B661F5AE7D5AA578"
      unitRef="usd">132600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101538747e1461-wk-Fact-84F574B1C98951649E68D68912924040"
      unitRef="usd">39600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-EAF2CCDB7EB854B895377B94E6E58C75-0-wk-Fact-DC89261CE4CC53BE96A99D70C324C9D1">&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;141.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;197.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;139.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;46.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unrealized gains (losses) recognized during the period on equity securities held as of September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;141.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;150.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;140.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101538747e1690-wk-Fact-4F0A0E53EF0653E8BFBF1FA8974E60EC"
      unitRef="usd">-4600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101538747e1710-wk-Fact-9B0B34237D4657F584CA1C640CAC565F"
      unitRef="usd">141200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101538747e1729-wk-Fact-95D515F0048B55E381F3BF8BADAB4777"
      unitRef="usd">197300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101538747e1749-wk-Fact-20E7CF25749E58CC917B9D2C24776D46"
      unitRef="usd">139700000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101538747e1769-wk-Fact-B004330B14945A15ADE1A1036C838E15"
      unitRef="usd">-4400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101538747e1788-wk-Fact-1D694515CB5451069B7946745A629D11"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101538747e1807-wk-Fact-56AF3C182A95503C804E6A4741EA881B"
      unitRef="usd">-46800000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101538747e1827-wk-Fact-F56B0EFC65A059EC9CD1654ABA059ADD"
      unitRef="usd">500000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d101538747e1848-wk-Fact-2A998132A2EB5F2AB0BC8648B0E98380"
      unitRef="usd">-9000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d101538747e1868-wk-Fact-DA7B2270E3A55AA28CDC611D81AE4DB2"
      unitRef="usd">141200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d101538747e1887-wk-Fact-060DF082EACD59D1B9A99F90CA86211B"
      unitRef="usd">150500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d101538747e1907-wk-Fact-573D5DEE45A754718AC18B7A4832D260"
      unitRef="usd">140200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-77F0EC83DF595DFE8577AB98768C4905-0-wk-Fact-8726A81E2B8050DB8B8AA4F1C0067CF5">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;884.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;259.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;222.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;224.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;188.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;147.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;444.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;125.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;677.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;609.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,429.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,861.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d101538747e2004-wk-Fact-93E9038349A6549E86E73F0F4F359577"
      unitRef="usd">884200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d101538747e2023-wk-Fact-9790B7529BB852F99BAA6B9B78CB9C5C"
      unitRef="usd">874700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101538747e2038-wk-Fact-CFFC95FE8E8A5AA1B626B842D127F929"
      unitRef="usd">259500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101538747e2057-wk-Fact-7ED29700BF3D51FDAB4704488F8FABBB"
      unitRef="usd">320900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101538747e2077-wk-Fact-AFFBC6A9C702595BB81D4BC2EB914D92"
      unitRef="usd">222300000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101538747e2096-wk-Fact-76010EECC7325A02A135B1CFC6B17490"
      unitRef="usd">224700000</us-gaap:AccruedRoyaltiesCurrent>
    <biib:Collaborationexpensesaccrual
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101538747e2116-wk-Fact-A903322B46A45634B3E4C8BFDDED7290"
      unitRef="usd">188700000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101538747e2135-wk-Fact-55817F4886FE5A3094654C927E60D28A"
      unitRef="usd">261600000</biib:Collaborationexpensesaccrual>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101538747e2155-wk-Fact-F1BDB2B6F6745908AD67332BF552BCCC"
      unitRef="usd">147500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101538747e2174-wk-Fact-AA2E6A97539C59D8B1C886EB6579CB0D"
      unitRef="usd">444800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101538747e2194-wk-Fact-199AB922B2F4502EB81981AACC08E84B"
      unitRef="usd">49500000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101538747e2213-wk-Fact-801E712D75355E3DB04035A001F3259B"
      unitRef="usd">125200000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101538747e2233-wk-Fact-6B40452BA2825C20ADB291B3CFBB9690"
      unitRef="usd">677400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101538747e2252-wk-Fact-9649755958F75469B852C8B2232263A2"
      unitRef="usd">609300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101538747e2277-wk-Fact-C6AD992658BE523FA538C7C0C76A2090"
      unitRef="usd">2429100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101538747e2296-wk-Fact-BE16E177BEB058B89BD806D640DFC45E"
      unitRef="usd">2861200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101538747e2322-wk-Fact-3B76B476C9EC5341AA786EDA6E0726CC"
      unitRef="usd">1370900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101538747e2326-wk-Fact-54B9F535280E5673BE39CEFF072D9B0B"
      unitRef="usd">1389400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101538747e2338-wk-Fact-A152938A51CF57F294149D28EDD64EA8"
      unitRef="usd">801700000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101538747e2343-wk-Fact-45EF85BCECE25A5FA02106B4D4D6F044"
      unitRef="usd">791400000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-BC7E31AE6D6E58DEB9C29E26BA0A20C8-0-wk-Fact-4E9144A498E054759A483D2A3A25EC9D">Collaborative and Other Relationships&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and Elenbecestat Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, MISSION AD1 and MISSION AD2, designed to assess the efficacy and safety of elenbecestat in patients with mild cognitive impairment and mild AD. As a result of this decision, in the third quarter of 2019, we accrued approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$48.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to our share of the termination of various clinical trials and research and development contracts incurred under the BAN2401 and Elenbecestat Collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for early AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;168.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;305.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;176.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;84.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;152.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;88.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. On October 22, 2019, we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;of aducanumab development expense incurred and, beginning January 1, 2019, is reimbursing us for&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;of aducanumab development expense incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the termination of various clinical trials and research and development contracts net of the expected &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;170.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;204.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;93.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Skyhawk Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments as well as potential royalties on net commercial sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this agreement, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$74.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Skyhawk, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$38.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense in our condensed consolidated statements of income and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$35.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership percentage remained at approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;basis differences are amortized over their economic life. The total basis difference was approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$675 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisting of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$115 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to inventory, approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$615 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to developed technology and approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$170 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to IPR&amp;amp;D. A deferred tax liability of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$225 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years, respectively, one quarter in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized losses on our investment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$21.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$66.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These losses reflect our share of losses totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$9.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and amortization of basis differences totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$21.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$57.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;687.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$572.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$680.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net profit-sharing expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$181.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect Samsung Bioepis' &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$47.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$131.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$12.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$89.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$48.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$80.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Following the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations on August 1, 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis and our other significant collaboration arrangements, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt; Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:LossOnContractTermination
      contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e808-wk-Fact-F603D8390785954FA5B7DF4FC3E05906"
      unitRef="usd">48000000.0</us-gaap:LossOnContractTermination>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-F21BA2255B6B5D1081E0E068CCF3AB62-0-wk-Fact-80EA990B1873598B8804C9CB6BFFE5EB">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;168.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;305.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;176.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;84.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;152.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;88.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1046-wk-Fact-7B73F5DB58AF517889FEE22BE3321663"
      unitRef="usd">168700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1065-wk-Fact-934B46BE70B9570E98CA8356A42ED4B5"
      unitRef="usd">64900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1084-wk-Fact-611C1922CB775553AEBB25F630E8F6AB"
      unitRef="usd">305300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1104-wk-Fact-3644C864F3245BE58C2615E4611B5AFE"
      unitRef="usd">176000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1124-wk-Fact-AB0AB14933D655AEB7CB6965ABFF28DD"
      unitRef="usd">84300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1143-wk-Fact-015B1529CD465838B48DF9519A18770D"
      unitRef="usd">32500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1162-wk-Fact-8F26F1374421540F855D9D049C250BC7"
      unitRef="usd">152600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1182-wk-Fact-ED75C03850455951A03F6A31A56C166E"
      unitRef="usd">88000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d101543847e1205-wk-Fact-A20A9201DBA65E798200BDA5CE4810DD"
      unitRef="number">0.15</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d101543847e1209-wk-Fact-C75D5BE58E7954D29497C1EEA45BB805"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:LossOnContractTermination
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1216-wk-Fact-D6F0F74ECA5554F59E1028D87F85B0D0"
      unitRef="usd">45000000.0</us-gaap:LossOnContractTermination>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d101543847e1220-wk-Fact-C75D5BE58E7954D29497C1EEA45BB805"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-A70B00E5FFE15F628D0B87A9264FF276-0-wk-Fact-2FAEA637E15E5525B3D3C57C1F904331">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;170.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;204.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;93.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1437-wk-Fact-C45858AA40815D0D957B3CDEA86993D3"
      unitRef="usd">4700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1456-wk-Fact-387EC15DBDEC54DA90765784F4BFB660"
      unitRef="usd">64800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1475-wk-Fact-8457EA2A37BF53F38DD4C1F1A26BF747"
      unitRef="usd">170500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1495-wk-Fact-0DBEE02C8D1955FBAADFD2646430615B"
      unitRef="usd">204800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1515-wk-Fact-7629DC3CA69159E8BB2B825840670686"
      unitRef="usd">2600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1534-wk-Fact-869F1BB9F79D50C29F045335A63D97B3"
      unitRef="usd">55100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1553-wk-Fact-F821504C0EDC5226B32210F8467D382C"
      unitRef="usd">93800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1573-wk-Fact-FD94DFF7EF45538894D50CF15D1524E3"
      unitRef="usd">183600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1675-wk-Fact-B72A7ADD40045615AC11FCDE308B10EE"
      unitRef="usd">100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1694-wk-Fact-592E67D4FCFB5855A91D6A37D36B9A8D"
      unitRef="usd">12100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1713-wk-Fact-B8CBC22F72AD57D29C37DF894F9CC926"
      unitRef="usd">21300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1733-wk-Fact-D07F2679CDE957D5BF9857B3626CDA79"
      unitRef="usd">33300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1753-wk-Fact-2ACB150FBC5750C1B70DCB2B635245FE"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1772-wk-Fact-B57F6AD0986755EA9E2836A9F48BF0FC"
      unitRef="usd">5100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1791-wk-Fact-3D1A2FDC06EE5B7A9540BD306F2FAEBB"
      unitRef="usd">11700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d101543847e1811-wk-Fact-966AE8BF05495327B7C93C7BE529B4EE"
      unitRef="usd">19000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:AdditionalMilestonePayment
      contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-8"
      id="d101543847e1840-wk-Fact-443F6836C1E95321B10A41228EB42BD0"
      unitRef="usd">2000000000.0</biib:AdditionalMilestonePayment>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d101543847e1847-wk-Fact-669699FA3E4B5ADFBBCD0175083A7BF1"
      unitRef="usd">74000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d101543847e1851-wk-Fact-09D27EB3FC1F5583B66FFD1CEF40C1EF"
      unitRef="usd">38500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d101543847e1855-wk-Fact-83FE42844D2D5D6D9AD2EC92B3D55533"
      unitRef="usd">35500000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d101543847e1868-wk-Fact-97B1DC30EE1451B589E24F434EE28586"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d101543847e1872-wk-Fact-57A6C7E488D15251B4859C133413AF19"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d101543847e1876-wk-Fact-41C9076F0CD05500AD40C9B1813B62B7"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e1880-wk-Fact-74188DA200735AD0A97071671FA83255"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d101543847e1889-wk-Fact-57A6C7E488D15251B4859C133413AF19"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-6"
      id="d101543847e1902-wk-Fact-4ADB0647375A576683A472EF7E0A8666"
      unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember"
      decimals="-6"
      id="d101543847e1906-wk-Fact-D851BC4B1C335CC3B74482A13BFCF67E"
      unitRef="usd">115000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d101543847e1910-wk-Fact-3BEDE1E9E4BC51E88C84676A8C5581DD"
      unitRef="usd">615000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d101543847e1914-wk-Fact-88117E4C0E605DF2BBCD0A9D1BD20CC9"
      unitRef="usd">170000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember"
      decimals="-6"
      id="d101543847e1918-wk-Fact-75D5E2EA582B5853ADD771B13BF6AE88"
      unitRef="usd">225000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember"
      id="d101543847e1923-wk-Fact-D0B56147375C57EAB203DAD4E080DDA6">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="d101543847e1927-wk-Fact-12C935CFC7AB57C8BF3EE69A1F29D59E">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e1945-wk-Fact-5694131C618657188A5FC2186907BAC8"
      unitRef="usd">21800000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e1949-wk-Fact-676B308204A75A92841F894217824D62"
      unitRef="usd">66800000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e1953-wk-Fact-E5852F6168BE5BA58B14D3B407F5DB2D"
      unitRef="usd">800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e1958-wk-Fact-5F87E498E0D855B49F991DEAF5A9A0E7"
      unitRef="usd">-9300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e1962-wk-Fact-29FAD35FFD335207BD199E86B88BF5C1"
      unitRef="usd">-21100000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e1966-wk-Fact-07D0FCC880BE5388B970E346B41D0DAA"
      unitRef="usd">-57600000</us-gaap:AdjustmentForAmortization>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d101543847e1982-wk-Fact-614A26BF9CAA5234A94F21D03DD8B343"
      unitRef="KRW">687300000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e1986-wk-Fact-21F8693027075A7C89C073D8E7A70F10"
      unitRef="usd">572800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d101543847e1990-wk-Fact-64EA025950885D3A83542D028249601B"
      unitRef="KRW">759500000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e1995-wk-Fact-4B8BA2A26F295EA8B4A73205911DE0E9"
      unitRef="usd">680600000</us-gaap:EquityMethodInvestments>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d101543847e2008-wk-Fact-84CEB4A8EA4E59ABB78813A74FC4E419"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e2020-wk-Fact-0D1BCCD91F2A5BA397E75404BD9F30C6"
      unitRef="usd">60100000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e2024-wk-Fact-204F715EB1E05D2E8869EA3F6855ABAC"
      unitRef="usd">181600000</biib:Collaborationprofitlosssharing>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d101543847e2029-wk-Fact-84CEB4A8EA4E59ABB78813A74FC4E419"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2018Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e2033-wk-Fact-6B7A94489A0457E88CA91367EA0E88F0"
      unitRef="usd">47700000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2018Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d101543847e2037-wk-Fact-1BA41E4C34FB57CC96448CF19C880800"
      unitRef="usd">131200000</biib:Collaborationprofitlosssharing>
    <us-gaap:Revenues
      contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101543847e2055-wk-Fact-C2E0730DB89853288C1399A328D3976C"
      unitRef="usd">12900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101543847e2059-wk-Fact-4FE0583E44AC5A58B3454C36859D621D"
      unitRef="usd">89900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101543847e2063-wk-Fact-E6F4B4172899582E85224D6FDF55563A"
      unitRef="usd">48100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d101543847e2068-wk-Fact-4A63DD97BE2D507993CD98E5B245B34F"
      unitRef="usd">80700000</us-gaap:Revenues>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-9DC7D8892C215C19B8FC57EE48E08379-0-wk-Fact-81BC8636C2F75220A6F8D4BC4C459F01">Investments in Variable Interest Entities&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of our collaboration and license agreement with Neurimmune (the Neurimmune Agreement), the royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, range from the high single digits to sub-teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development costs for which we reimbursed Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$23.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$28.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read Note 20, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="FI2019Q3"
      decimals="-5"
      id="d101542224e839-wk-Fact-DBC793BD60245A08B229FEA9A0B1A6CF"
      unitRef="usd">23100000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d101542224e843-wk-Fact-15C578FB0A225420AEFF662EE7B1CF18"
      unitRef="usd">28700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-0DBE7390B6EE5959999564FD3EE012CD-0-wk-Fact-FE4CEBF7F10E5198810F9B7BB6E8BE6B">Litigation&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 Fresenius Kabi Deutschland GmbH&#160;(Fresenius Kabi)&#160;commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen commercializes in Europe, infringes the French counterpart of European Patent No. 3 148 510&#160;(the &#x2018;510 Patent), which was issued in June 2018 and expires in May 2035. No hearing on the merits has been scheduled.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of the Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#x2018;510 Patent, and against Biogen GmbH in the D&#xfc;sseldorf Regional Court relating to the German counterpart of the &#x2018;510 Patent. A hearing in the proceeding in Germany has been set for March 2020. No hearing on the merits has been scheduled.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An estimate of the possible loss or range of loss in the above matters cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the &#x2018;510 Patent. Fresenius Kabi counterclaimed for infringement, damages and injunctive relief. In July 2019 the United Kingdom Patents Court entered a consent order in which it declared that the U.K. counterpart of the '510 Patent is invalid, ordered the patent revoked and dismissed Fresenius Kabi's counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &#x2018;510 Patent. In September 2019 the parties entered an Agreement to Discontinue Proceedings wherein Fresenius Kabi declared the Dutch counterpart of the '510 Patent invalid and surrendered it in full. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the U.K. counterpart of the '667 Patent, and in August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. A hearing has been set for May 2020 in the Dutch matter and October 2020 in the U.K. matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#x2019; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case was filed under seal in January 2014 and unsealed in April 2018 after the U.S. government declined to intervene. The case alleged agreements with pharmacy benefit managers in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. In September 2019 the court dismissed the action on the U.S. government's motion.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers were defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In June 2019 the U.S. Court of Appeals for the First Circuit affirmed the judgment dismissing the complaint with prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Dismissed Shareholder Derivative Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On January 13, 2017, Mary Ann Mullaney, a Biogen shareholder, filed a complaint in the U.S. District Court for the District of Delaware asserting derivative claims on behalf of Biogen against certain of the company&#x2019;s current and former directors and officers alleging that those individuals (i) breached their fiduciary duties by failing to oversee the company&#x2019;s operations, (ii) breached their fiduciary duties and Section 14(a) of the Securities Exchange Act of 1934, as amended, and (iii) were unjustly enriched.&#160;The complaint sought unspecified damages, interest, attorneys&#x2019; fees and other costs.&#160;The parties filed a Joint Stipulation for Voluntary Dismissal and Proposed Order, which the court granted on August 6, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2017, 2018 and 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A trial date has been set in the Delaware action against Banner Life Sciences LLC for March 2020. A trial date has been set for December 2019 in the other Delaware actions and a trial date has been set for February 2020 in the West Virginia action against Mylan Pharmaceuticals Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Petition for Inter Partes Review&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 Mylan Pharmaceuticals Inc. filed a petition with the U.S. Patent Trial and Appeal Board (PTAB) seeking &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. On February 6, 2019, the PTAB instituted &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of the '514 Patent (the "Mylan IPR"). Thereafter, the PTAB &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;granted the petition of Sawai USA, Inc. and Sawai Pharmaceutical Co. Ltd. and joined them as petitioners in the Mylan IPR. A hearing has been scheduled for November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2016 the European Patent Office (EPO) revoked our European patent number 2 137 537 (the '537 Patent), which includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for March 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2018 the EPO revoked Forward Pharma&#x2019;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for June 2020. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &#x2018;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &#x2018;127 Patent) (&#x201c;Administration of agents to treat inflammation&#x201d;).  The Polish &#x2018;263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish &#x2018;263 Patent expires in February 2023. No hearing on the merits has been set in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which also concerns administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed in September 2019 and our appeal as to the German action is pending. No date for a hearing on the merits has been set in the Italian action.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We are cooperating with the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;investigation and have participated in preliminary discussions with the government regarding potential resolution of aspects of the matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also received subpoenas and other requests from the U.S. government for documents and information relating to Biogen's co-pay assistance programs. We cooperated with the investigation and have received no communication from the government in this matter since December 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$70.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="FD2019Q3YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR"
      decimals="-5"
      id="d101544328e943-wk-Fact-259FC5E41D445CB6B510A8BB339F4FF6"
      unitRef="usd">70000000.0</us-gaap:LossContingencyDamagesSoughtValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6869156720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 422.0<span></span>
</td>
<td class="nump">$ 422.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">410.5<span></span>
</td>
<td class="nump">410.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">481.1<span></span>
</td>
<td class="nump">481.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Net lease cost</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">ASC 842 - Minimum lease payments 2019 (remaining three months)</a></td>
<td class="nump">29.9<span></span>
</td>
<td class="nump">29.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">ASC 842 - Minimum lease payments, 2020</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">ASC 842 - Minimum lease payments, 2021</a></td>
<td class="nump">74.8<span></span>
</td>
<td class="nump">74.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">ASC 842 - Minimum lease payments, 2022</a></td>
<td class="nump">71.5<span></span>
</td>
<td class="nump">71.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">ASC 842 - Minimum lease payments, 2023</a></td>
<td class="nump">70.2<span></span>
</td>
<td class="nump">70.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">ASC 842 - Minimum lease payments, 2024</a></td>
<td class="nump">67.3<span></span>
</td>
<td class="nump">67.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">ASC 842 - Minimum lease payments, thereafter</a></td>
<td class="nump">148.7<span></span>
</td>
<td class="nump">148.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">ASC 842 - Minimum lease payments</a></td>
<td class="nump">542.4<span></span>
</td>
<td class="nump">542.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">$ 61.3<span></span>
</td>
<td class="nump">$ 61.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">ASC 840 - Minimum lease payments, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">ASC 840 - Minimum lease payments, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">ASC 840 - Minimum lease payments, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">ASC 840 - Minimum lease payments, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">ASC 940 - Minimum lease payments, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">ASC 840 - Minimum lease payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">ASC 840 - Minimum lease payments total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear', window );">ASC 840 - Sublease income, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears', window );">ASC 840 - Sublease income, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears', window );">ASC 840 - Sublease income, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears', window );">ASC 840 - Sublease income, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears', window );">ASC 840 - Sublease income, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter', window );">ASC 840 - Sublease income, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions', window );">ASC 840 - Sublease income total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInOneYear', window );">ASC 840 - Net minimum lease payments 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInTwoYear', window );">ASC 840 - Net minimum lease payments, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInThreeYear', window );">ASC 840 - Net minimum lease payments, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFourYear', window );">ASC 840 - Net minimum lease payments, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFiveYear', window );">ASC 840 - Net minimum lease payments, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsThereafter', window );">ASC 840 - Net minimum lease payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePayments', window );">ASC 840 - Net minimum lease payments total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 70.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease assets obtained in exchange for lease obligations</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Net lease cost</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">62.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease income</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(19.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Net lease cost</a></td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">62.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease income</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">422.0<span></span>
</td>
<td class="nump">422.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">70.6<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember', window );">Long-term operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 410.5<span></span>
</td>
<td class="nump">$ 410.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFiveYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in five year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFiveYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFourYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in four year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFourYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInThreeYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in three year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInThreeYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in two year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized for the period under subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=77891322&amp;loc=d3e41620-112719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0000875045-19-000041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-19-000041-xbrl.zip
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M*8(9Y"SV&6BV/O_Q,UW,%'QLHFOQ!V%"#X+E0PP/\%1?<9H%41M*;9'<?,@
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M+=\UU>4)XY@6<U"X:.-$F55D9$N8CY4+TORTF/XRX-#2#[_:?D1D0-M76B2
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MIYLPQ^SPL7)N=USA>OL+O]W(&SF_WOY]^LX;MX[N3'5L<2S*=#;OQ.KA/IN
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M1U#?*Y,O&7\/N#.+L!6$8(1$P;%+#O^,1URE,4QZYZW=:+E>L)(!OU]%HO_
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MOG/=&H<2O!KTX1K1 .\HSI#< [6?LZ"M!VH_-I=C>"0=9 /\"ZAT#5D]Z>'
MK0O6L.V99Z5BE5#'8(-Z!^H6*%305D;7>FE4^M^:N?:O)!,T3*--6XW236TS
MH6E*<S29\3J*@M8DF1FF4Q2F;..4&I$[)U12A,H,DI2SVSDRQP*F!F]YRPM:
MQ"6!9&;,3$796$7XF,:4S._;1+\4:.T_V!_WA_?GYYSWO,_SOL\YSWE;X65
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MN1Y>L75HRQ[C_Q2G^'\HY(>7_P502P,$%     @ DX%63XT1I]2E4P  S5\
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M^'2:FT[3W5*#C;Q(DCF=%>VT]WKQJB-B@GCD105HDZWZ *-2-VN>QEXR@G>
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M7 YZE!5#=MP+V#37^D%]1$_^ K5*,!-ASZ C.VA!-)U@!_LX_%J*!\"YH=:
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M_7[Y*I>'AY34)G=]@WU0,AUY-=4^A)_>*#""YA'#05HJ@-!OB(OP.A"C7B>
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M1%Y(F$VCKNF=^$P;143&)=J,]B[TX^2-J/]*&^EY&LUN@FEA!& #!K9Z4J5
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M6UGJCKV6&S+VC]<2AZ\)FIYKQCWZK)QZX> Y9?J,^IU/AK(\J$'JY2O#0F,
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M_KJ^O3:TN(6O3RL8FCAKD+"G#=8AM]8Q,#5'+YV5:%SOYSJ@N:W&P[":NYU
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MZJCF<2TT-N3,\]]OX\SLD[C-=[>5>&C_]OHHI:CRW$#YU6B#8CGAK?PX-*M
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MU7HWYM@!Y5XH\8$#JZ0GE%39V!UJ(9XLY*G6=Q8C*\MN@Y14]#9-GV:H4!F
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ML0( 5LB>@'0$L)&]^S][_'.1_]-KK) V 4KK5GBML%ZU8CNP4FG%*J45TE8
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M2O<&M9TF CWH']/^S;+_FF&W_K<L^W?#_F^[N,#&52MDF[=*"< #$LGNI\G
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M+*0QAV0N3 BL>H#H0.GVX+4[X$]"/->^W;N<CT^4J< ]PMD$_%K6KE-!?BM
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MGGKA$QEI89W*_/"Q5%P(!R^LA4_S'ZL+"](%J"1>U5@VOMVJ7L>QG=M>NNR
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M-=JF61-FHE=M*S&.:Y_:8 A.<33I:<@AX7JLKV@6-54AWYF&::&N!X\GYFA
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MUQ-';PA\Y Z_&;;[FQ;H>JA2:=OR\1I"1N&J5J]%_&X^K;5#^]/:>=7?;E)
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MB5/M"W\<(50M8/"_-@Q2;$/! @L9KW ?2708@IS["K.M!B..$<#R0#)\=L$
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MO?%"F60,.F9=NMBHNO0)VQU/YVR0KPVN$;@6YPHTPL=LA]OT9E:P]10JAZ7
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M_KE8[A<D)[(U_TODTX],C6S]>-V-NYJ3#JMU[PI[5/=/KH)[D-N16U5_[O>
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M)<9=Z[\[\%MU_,N_@I<Q1T^D]JM1YM+V6+1*O=,9=X.S]I=J)O@)/37#_/B
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M0_!IA,U%XTT R9 BUHB.-X+TQ#_<+)ZV/;U)K:Z9!MEKU!)I@X4 $G11S-!
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M*$:@BME5E?1@I&D9HS\,;R4;?\1A&=;O:1_$7P\@UI,M:#8 *9/@]N ]4G8
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M<=!->CB462ECZD]*- :48'6V5@.S6Q[2&8U#-F %:^?. 9=62_D<B^@ J:L
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M+2B\X2ELH"HI_E:G?SXH*T3]>AFCMX"]/KX+Z7\40UPW1+>!ILEPQC+F1C4
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M9]GOAG>5RTE6HXS^@BGU#IB313@.&NQ?#(%NF+P-/?,F9C*BC%*L7O.B8>E
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MEFOP.,E98,B4<4Q1MW["%B  +]]85)$YS\Y8QCRCI*$'W3@LF)1%/P22WA2
MC#QYWTH:OR]X$(T\^^BC18E;?S6/;(","4D0.Z:=(HWF.T"?FLK$Y>,?K:63
M;F8K/C?.#"H]$:Z"/N!",$^"+\K%. .",1"+Q=!QT(T2+6@Q<PYUDK7ASPR[
M::QZ3]<=27-#E7P98QD2G>SAEU$8]C2WG6__XC5*.G?YLJR*8SX^I=[8MO3H
MO[\9_6^-2T184&,'SGP;2GJ$S/GD4@;I[F">>Y?".FXH/_'?A=2M@R>>-8:=
MZ-DT=GKPI_KA.5GK0-+JBL&YB.)S+TVV/K9/]\$DG&;H0_F<'Q);<'K(E;X
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MY^CXVD_G2_Q^5<S_?]T^^/^GX9;?_@]02P,$%     @ DX%63Z6Q!US-%P
M]QT! !$   !B:6EB+3(P,3DP.3,P+GAS9.T]VW+;.);O_15</_54K6+)3C)Q
MJMU3\BVK+=_*5M*7ERF(A"2,*4 -D+8U7[\ >"=!D*"4$;+T2R*3YQR<"W N
M  C\\H_7E>\\0\H0P:<'HW?# P=BEW@(+TX/OCX.QH_GD\G!/W[]Z9?_&@Q^
M/WNX=BZ(&ZX@#IQS"D$ /><%!4OG-P^R)V=.R<KYC= G] P&@PC)D3]>F?>9
MN4NX @X( HIF80"O"%U=P#D(_>#T(,1_A<!'<P0]SH(/11,%@-SK - %#&[!
M"K(U<.'IP3((UI\/#U]>7M[-$%E C#SHOG/)ZO!H.#H9GAQSL;B@F'V>(30S
M@?<1?BK O\ZH_X[0!8<<'A^*US/ 8 *."<;A2HW@!?0PV*SA(0<:<"A(D9OB
M-2,5$4(V$(]9BC4';"8QDC=2E,%P-#@>)4B"JA>D*'E1/AQ&+_.@2",XPBP
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MV@ B<46\#Y-&6#B3M^T(CKY0$JY/#UYGU$>?40!7!T[ Y3D]P 3C</79(RN
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MY^:#@JB86.($P8JHD* >PURR!!D65<21$"([#''="EG!@W[\78$=<X%)@H(
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M19B@R 4L]68)$#5VCM0_'_/JPGOV[?0]IQ:?KN,BVE*H$\]COQ<LO(Y@D/J
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MS&--,Q0#)H8%(U7D(NUN6(%"+3DLBL&'^G[5\R0&UZ5%RSCUQ8QU5;H#8S_
MC&--,\0#H!A@58R6.V8T"K#8.K#KA(!MM/[6?YZLV;K,:!FG 0?C;3TQ*5NC
M2%-[>*S="+T#+\J,9K#HIGLOE(+-'3XQ1*4E5L*NKJ6N7\#_/&FW3;>ILZ!:
M6S^-HVGY[Z/9*C^2'NZGBW45^/<PG7U*;)V^,F4B9IA1XQ#F! 5CX0^+-)AK
MZ>K%^FO6>=)E3V5/7\!=8K[@992JP$9JL$4I@YV$<Z&,3968,69"D!2649O
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M0CP\:ORH<6V!4&6HT81YZRU6@=D=FMP/\>RY)3G6B&L[#:L?.WHVU8Z.1LN
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M'5W%Y#_8+K.<A2"TMX19KQ!2VF$?L4GUM#6N%BC3S7QW@UT\FL'CZP%?I\&
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M#=M[5&#Z:;1C' 8ZUA9=ZP6A.OKJ3L:@+_?4)NOV(7/RWC8[XN<^T"JSAE-
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M.D0K!<,. -GN7XHU*/+5\3UKY]J_6X/R$A.3B)!8:F1#0,C:Z+QC:#M#8?C
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MFMT",U^MYU=-1?YJ^V1!C69<42N]CM[*$ WQH%L+(HVSHGWV]<%B+'J7>1_
MC+[*A[^^P;I8V&(!X->E1SS0(VD9M#621:RHE 9CI@/,CW.BA%9V@G6F!CY]
M[H3/B,Z*GZV@//B;F^)J_?[FU;^O=U6<_KPDC/2,"F0EF.)!4*D"J;#VQ+;?
M*(9?-'KESACHC<:L%^<WJ^T-YSKJO-HA.9B%TU(*AIQ0W BM?34[ICK$L@R6
M!WH@;O0!SQF$7YW;S8M3&/"R5Z(,T\@]6.',:L>)#['RF4CK0ON\1(.E:QZ<
M!ATQ&B%*\TE<X2C!F>O9XG8.W_/P@IC%]6]E>?WG_&[8C'PUWUL?O#G*#<?Y
MNG@[_UY<OQSEVP;1E$VZI^A@ZR&11BN5H3A01-&6=99XX4*C/#[#S/[Q=F/-
M1)JGX3OVD,2I\<9$CG'TA@C'/0\[)+ U=LP[2K5AE_V*]6 BOI[Q&C<<\V.Q
M*N ;O\X6U]?%]^*N_):?-<NCKPO&/-(M<8T5\Y)KHCC"'H,1R*HI(V4G&XHY
MA%3+P7!K?7Q6,XSZF+RC'9.(,6K& Z<HW_&CEE%5S4 &R:?I$^]7. TEW@FQ
M2Y3]I/S?4Q9Y3Z*VOR&$,*X_#G_6*)D0M3+121,91C N0LAN9!PCV;[&[3#1
MDSU"7?:$26MI?7C[Z6.]J!Y;I%Q4!%-FP1:&2<B Y>YL'<9DL)B0*VE(.;4&
MI+60/O_VKEY&^P8I1JNQ<-$*[ZAAV"B!JQ'1$-N+J'>/SI B:HO'6"Z<5ZZ>
M'LLI_7J/A)W!W%(G16 64T_R3'?STQ2WUWE'2_'7N\[;+V3GI$3^N"R.QS >
M[9N,1,$ASY546%"29RVK.3O*)AXTTEF2#9C1!UY_#ZY,2J&>+D5ZVOO?S6^_
MKE?KV;)> WC1+ 7I%8I<8"<09CQZI^)>?31JS%(#[=,QM$6\[ V8\4(%=F"_
MOA':'[_/_JM<NCO0C(X&CI[TI.0=%\$[!OLJ15@2[.5>0;**74!VO<$4B&&A
MG BU'N?0Z+I$BZ>EB 5'7CCAE;/"P,O*U/Z]Q29,6_D8C 6GL:U'9/_-O J?
M2:HRETRX<Q%MFW9IM:K<"69Q[1_="0TN=C?HGZPU/"A/ 0#KC*8LQFH;X9*(
M"68F'E3"/[&I?PS'XL_GY>RZR%>+<GC!]H<,R/$4YK7]4I1,48808HI0%"Q,
MN#KDY9&Q]C5X!@R\&X\O?6(W6MQ^+QKZ"4])$9&@HD3"6"RE04[C_?M"M6M_
M(_#TR*RI:>?#P3@!.IVH&YWXI"1XQ,1AB[#ERGHC/7[TBFA'IZV1#R+YYNSJ
M$=%_,VV2&O@E$NQ7UKP%H593IZ771/M(D'150 1'2DPP)?%@TFVE=9^&7VM7
M]?O-^NW\*M_+N?XP6Q_/17ZH?9(XF!@HPQHS1H)E3NY]M :LV^EISD/+NT^\
MQKNGL.5A<?VYN/JZ*._*VQ\?M\[XX[<?ZWLF*SUS6&(K-9:*!Z(HK^8K>!C3
M9ST1?@R#7.N5X,WBI(7@0/.D"!$,(ZVD]D1) 0;"WK8,5K;/=C'8O911UH%^
MX&JY#*R6ZR=+ /ST\O6'7^4LZ->;J_7[Y4-5AD,I=@\U32H$J1C12B E\U4;
M%_=Q53K2]A>=^<F"GXK9VQ-6(TC]L1I'<;B.36W[)*6-L)4Q(Q4&,E,,JO5N
M3J#$2#--^[2[B'Z6=6_@_!J"GY2Y.!%Y][1GFW^\?Q?^;_U&_;1-DE8YKK(!
MP93)";RH]]6X/"(3RE;6$[YE/TBT#P/^L9I]6<YW,SD2$?Q*VQ29!;U <X-M
M4+#?F%PH;3?.@#N\7;W;50-(K =$VDNNN+J9 U*S(T)[WBP1JR.P"2.+$)AX
M3EA7K2/:2MO^#>O=SAE"7IW &'*[^YB+N]:HM/N_3QKGJKY1(RE(U$Q:SFEU
MSY,PU?YBBSA9@%/28]L"-+A0#[Z>+UHDI#A7TA,N-=%<*RYH-6N/I?/355!;
M8/]2<ITPN!P93D[7'$]TXXGL=X#O?G-?*[1G;9)0$0LK# T\(&.TMZBZ& =_
M\ F%X;1&O>QG[H/*;?;7<;D];9.HCDP''7G -EKAHF1F/W9MVK]N@RB?G>76
M8>[C'=X]W]#?%>OPURZ#<Y5DQ7Q9K9>SJ_JD=<T?DQ!0%L40O*;$2!*5M7L&
M2\S:>_;.<93WMG-"CP&Q.W]LP1^KXF9S]W9^4Y<"IDGWA&20.&C-,/*(4T6#
M?MSO))W@;99A!-LXAJ U=AV.?&IC!VNY<-H#$K<:\9BCFZU#RL(:3%PU(QZG
MY,88A0V#HG?^563UV[)<M8RGW';-M<V4%,SI""LQCL#_73D*2W$4HOWJ,6"6
MP[.N'JUPF\BMDI]PJM5<3GM4(I8R3["RV$F$I:<QL H11E'[?)D#)DH<@4D#
MXSC:&C2;+_\QN]N WC_+M6]R!-5_S-=?_UB47U;%\GOV=[U9?-NL5Q^+JW)Q
M-;^;;Y/$?LP5O7,Q$CM;S5?[6GJ_@7S>PGOT4!4EPQ)FRP4TJUW,QAI#\L8:
MXY'S5/  6X*BNT3I((.@<?N\2:>?L4^)RU,5P 0V8L"[W38,'9-@WC@+2H?W
M@5.P@BG9O_(@H/9NF]-=X9.B6Y^HG<MQL%473MMXFSP@>18$=5R10&6@'C17
MAJK94]&!,_*B.3,(>A-87\S5U>9^<S=;%]?FOERNY_\ZEA'_](<EA2G6BFBE
M642,.F^#K%!!)K:/)5<7S:G!D9R24[.C,S,%%ZDAQ EL(_;1,^'V,U?(M%^7
M]$5S: #LQF+-4V*_OWDYD1J^U'=,FEC."&S=)!?--LQ20:K9&BS:5PD]QTV&
M[N[N7M%J'^GV9!0E8%N-8IMV<%54E)W??P-;X"'+]>LNRY,?E%BT) @IK4*
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M.V0!N00W]_@(7@+SFC@1>GE^<H+I( *E,@2'@Q*,5M@)UB5C/KD$#_DY,+P
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M[3WS-YFAM\MBM?IM6:[JG,<UO9+P3A,;I==8.AVC)EI5\X05?$+W?49@0']
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M4O@2/!B=P!CKQ/^8G^/5=BE7+@(=5L1\6\N1H(!_C@6%/<PRH@XOX<2=''W
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MVO(0/1_5E=IHYQ^<!J<ATCI* 5:V]7+^90-POE\<3F5QL&T2"E$KN5%,,RY
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M==,0C0'X3]<M#F)B8.'BG<V<%AHR7B @(>%Y3D3!.IM8:>KU]&*0I<0RDKB
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MS92?HCPL%GPF.7F&DAXM&4+@-(1DD =]%8.#V'"5D.=K.'7;10%P :DA>4$
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M0#DNFE %UWD)<X A*D6G1D8"NCLBTLMYF@""$;K)7L@A+ %6U,[#BBG$<EU
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M@:4 1@MH#&<D-R7,E3*2E+I45IH]Y3#0R&CWJBZR#MEN=1>Z ?!ET7>MGI#
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M+/?#"2!?+?*W7TJ$2JQRI0J.,5(<-)E:D282YL*"&5FG;CJX7:K;TR'S\9K
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M6I:ZX';?C@Q3G338;;W3U:+A*"!1RA*1$RHD;I+GYE!0KBD VA08I#XZ1C\
M#)Z?6'&82B=H"+]I];QM,&!2;8#O!+F!_I(:MW\\;$9-T%9A\^EYVRS";)JD
M[;RG4F\:'2;2=$TSK6DTH9\G)M'4S'I/H0V$!H^=LQ]#,?7J 1)"0%[P F$"
M!:0:&YG#3@<0UNX%F@+M0T.+HF2Z)$7SYDDPQIN[RYPP"@13J=_EXA_L7W]V
MVD2ATV9,\CTGS#/Q/F2J;.6UE=MF4_*,T+; H\R1,1LF<'8\4P/%F!>C-I3_
MA.C.G,M4F* =)C8)IO#PU/27C,VP(Z$WAR2+'!<R9UP;4A@%"@38_AQ#ZH*$
M'PL=;*C<\!Q*RI4Q=N8N.,",YISBLI1YJ57B">S1^<6 ++[!)(8<!J7ASV\B
M"J)NA..?-PZ)9H>R.<5CH  O>H^"0EEQ59U6_-[-OC<G3L^<@U\*J$E!E":<
MX9*7!&NZ6T08K0J#+K]4JX^UJ_Z\:"T7U.0"& PAUD!SAKB07 NM%%-<^HRC
M8V#.PVF[3KC;(KS(KIO['U\:D'XR-)A5-SD:DTX_6=KR^*[C\=E[-./*TPM<
M]<A4+):G(5?1O*G3],5P^;JT7VKNY2#,C0&%H1A@T(VJYA5HN%9=EHH:C 11
M*%<8X9P3#%$!R@(#KK5?O?,8PG0U6ZV^-]=)!XK3RYSY*U%4L@;(SOGTQ5%,
MG(F:GG*X0^^1"4__PS92>RVZ%)@5S,ZO$"G )-8EE8>N3FCI)P^GK,@2,"AA
MSK7=%.:-=Q)2A8PA'$%JO.Z&!2E%NR-8'"Z#A:]B@HD,V4RE87#09FH2ZY83
M+#EOJ_QYG8;:#/:B=UL5RHJK!OVUKN=?%S<W?#E_O=S8/K:P>L?7ZVJS/G2D
M_1WCO+F,@ 6CV)04*FA4R=L!Q?-2Y&7N.*#\C,I<8RID;A@H,<P+@:$PR@!,
M94&P-.F&68>S?6-Z0)IMH1Z-M+-=M/=BLF<HIFF1:0S01+[58_3I!(/Y*(&<
M!H93^S]6&"LL -E1W(UF1;3R6V=X&M< &(E*38#2.-> $FQR2 IC?U=;=I(O
M/YZ.YV:4=U[X+4!B$Q]11M,PGDQ'SY;0QX_,H5+JWRI_("T-<"Y$3$,Y]"CO
MM;/T]EK6MW?5<MT>Z?Y2W<PVU;S)R+E^_WFVJC[.UM6\RQ"TEWBN"B@Y+R7&
M0DN=4T;+[B3'*KU'8:E!*.R6AV$&<PPU-@I29)0FJF!<%IJCA"&.%M2K%E67
MRROCJY7]D6I[ '2F)=,P0ONV,^.TU#2$8"QGG]::&H_CZ$(ACD$=I034H,@1
MS(VD2/!"LK($G5*412D\XST#T7"I:9G+G&. ,,H9*PC!6#5)$8J"E>DCR,\(
MAV>FQN0-$EFZ1VB)R-I]MF7:0$YCR/? UOJ#Z?=0;T,%/ K+K@HN9^O/S?_K
M?[]??)G=M'/&<O[3;/5[M6D. -Y75TT*X$5UA 1QQ$C!D;8"T;Q]Y0)MC\8Y
MH#S7TD^U0Q!P H0N!62DY%@9PTK0'-<SHB'E"M/D2FT6R]GR:C&[.7[3[2?5
M29AWD^=S4^XGR0W2BZSY9W8$^*+=4A\P9P?09Q3I &9[A#EE.TU#C)-Z6(_7
MZ_U$5]RO%\MJO;;3P$<K)&W)[D. M,PI5%01:20F)*<YVMV#9)"8O' <X[TV
MBKPPG!4Z!X)@29BU5G #2X&H #SE^JJ#E1WC.MN.N(^DGG$9A=MI#, XKM0)
M^M[@(?5<O(Q""6F1Y]80D5ISP(J\&UPYXTYE #U-<B,(*)C=9D.$-2XX9@7@
MA "B,57::ZP%7-SF5U;NUHNV#?P6*+$H#=:KU&P.5ZYI!/#=J//3LR'<3U;9
M!CGULL8-Y\Q5[?A5FYEWL?STKKY97"V.DJ$A5B*"FKJJ#$&[8U1<[4_82%ZZ
MGK#U6. B1T0J#K0L,<6%*(BUP3"B2I"\2%CUZ  JZU"=;>EPFJ">@1:!U6D,
MKAB.U-%[G&?!H<6GY>)Z<35;;I[:/CIB*U&I3<GL;IM+.Y^55.%N0&F0 Z^*
M0FXFN2:YH1@6"F*<(TTYLBLEDDO#A3#_'WOOVMO&<JP+_Y4!#G"0 '+>OE_.
M^=37; ->RWYM)\'!^B#0TLCBCL112,IK.;_^= \Y)"6+U/1,SW <G+V#1#>S
MJY[J?JJZJ[O*)E73[%(&\/'^?K;\'@O8K?8"%[/]ZGO8BIS81B@3X.T8[ Q8
M)QXU'V#[(K.=K\5/*^A.\%QF[*?!>;F5>MZ%9PC,TINOA;$?[Q_K(^GWZ]MR
M&8^JE^5MN5C-OY5O%U?5??FN6OW0VTMXXZU'V#*&*?66$K.I(@XME;!5"?Y<
MLH3X!S%)J8&,4.NH%,X@J!@ \62%#5V*_[#^YX$"1:U!\42%8J-#\:>HQ9^[
M]F0;R&(M679"QDJDWZYVFE 'MDZ8G^+MD:PY$4(?2]NC_=;&0+FM"_A87MW-
M5JO:!<7=[/O'=2L!GQ>XQY X); /0@J)B"?(-KPB-4BJA9!))$T<%)2Z,+RD
M#!!IG.7:,FT1,('K!G8(S[4HJL=U>]))\PIC&;&=<YB@_=)\1#_3G=U1Y,'_
MA+\8V<#3<!MC*UV==5&E.9$/R^JA7*Z_?[B+VYC%=<RU/L3+$;NS'$VTXI!!
M!Y5'EDG',:MW]]PK0UW;R\&O#P2\9<@13I4%U!.IK?%.*6R=-E;Q 2/+1K:+
MHI:NOJBPD^]L!Y:O(G9BG>=#>QI+.*,^U5#S,M/">RDIX15'%&!B# O_QR$E
M"C=K$$J-4V*TI($1-\1B+RVED$+$% = .H^M@,89R@:.Q$XNS+1 *R_>/3EO
M:*ASTM\D,J8I2':AQ3X&F3A#]E*M+5GVQR^!-Z_*\GKE P*?9G=E?2-L'>^!
M?0]1U;?9_*ZNEE,MXR_W-\0N%6<A;N%,& "\!%B$_5)SZX&'75(BA7:2@3M%
M&4'.28)I0$)[3PB*96*,<50F/0_OQJ:UV$6</<7]1N*8N(@+?A5$34P/#6:*
MUNQZ=BLD$^V! :)8VSNQ&ZGC1K4NE[$7]J+8*?+FIEJ^B58:G7F[H'R:A >U
MVV3X>%@M?Z3F$5!-J1>T'^3Y\!_+V=W\W^7U7V?SQ:4PBJ(05'OI,!'<8A=D
MV+(!Q"PI79\P+ !A8(*TEU+2\!^M%!+((0V,98 E/3'O=,:XD:7X&H1)?3.6
M$=QV5'LF7-/8M05U7A0[W*.PXU<=:@?B"?(<P!+3X,LA%'NA7-$@V.5EQ9A
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M3CG5'/!-C3DZ:'"40+JBD=(JH[I15^OYM_GZ^\?R+M8/6U<.,2"#V];J5T0
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M-2+^N3YYJZ4L]F)>%/[O;WY].WH\W0*]T^%N3OBGP8*YE?HQ6,R/6;?3I\W
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M6'].#R,;X8H@78LG;),U\?@!XY!FG5*<^.(,^:G/9UZVW$A!8<]I,PVG,R5
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M)322$4FA-$3!SHJ%+.K*;NRW\XO/X173ZP.J;@NQ\K]W-+KJVWT-J-U^5IQ
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M1V1[GG$*<\/YLD]#DCKU^2'6G> 9(HFG\&3%MEHNJS;3W)UUVU<^P251$%B
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MZ/.(O'B$7AQC3ZJ@F*V=DL/3T9MHB,"T?^N,%9*&T!L7C [:8-.8 ;)[^78
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M8M.UN%<S_27TN)^'<9H\ )OANOQA=\JI>WM/KF[,XQ&G[EZ3DL1R@SP I:5
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M%\NFO*FKUY_FR^KQ5=S/S>_.F#!^!:UAB9CCDC(NM8!22V!(Z4S8N?]XJU(
MARF$P#E-$.<2$(R4C[2E)=;AW O=#F@S'1Z@_GQ;KW_>>+!';TD7?[1X Q?!
M&=@/FTPO0WS<5#L<YUFT*IC",V(V?#-,0^TR^%7G[L!1CSZMOS5OEU2F^K)]
MM+<O$=F%O1IRBJ5J,HNFR3J6S4FA9J12J 0F8369P^UIYBPT3A+)F?<3*,60
M5<;#0,B'05$Q<=K;(!W*XL;#+#:/X_.M&L.Y&#ZOA9>A-DX#'SEM\!UKWN$!
M[_AS',.0&_5NU,@DI[X?]48'/IW!"GU#ZFT>3AT-&93#"1P8&=:?.E=OZS\K
M^ 7I4].RV6H20%EF%0>$4(9$-[*HH8'/GD>9)- Y8+B? -LYT IGK2EQB15J
M[F%&55@;>&YH$BK70\T/\5RG3Q%921YJEO @,\P4\33WGRRRTMUWOCA#>Z8Y
MXSD=D=-&,IO3G3G270J8/'KR%31__%)[:5TUW?#4I&6PX=*41E$  8)404B[
M889*:R-FCK>-:6.M7SL1J7%)&':J.8PI)6(<:PA,5*&EI#GC$6*_M<0 O ;,
M$N,2&C<_'#$YS IB $HC9H1QJ4V;"\YVUKYSP)L$G%+_X9B;@.X/Z$R=I7?U
MU/H7<XPRT')N";8.8D>;.N"/496CH*?<O["'*2*<&[_Z,88H"!0DI5\+44,,
M09)&528=4/'35@C#,)PH_%FI'4+[CS@=2O_CR>TY!60EN?<LD&<U$,)#S&20
MS.%$YX-T?]Z:$GHR%5;"MUYO[^9WE5S=[!YQVVRJK9I?_Z.Z.34W48E5LPO(
M"254E0Q:J[I!)GDI(^:(!.N62<@I<5A*1BS7RDF"*;"E1AAB'56,)FG&Z# _
MOK96S!O8Q9<6=[^%0X[F")A0+MP.<=/+H0$\VF+_S&3; #O  ZTW<K1$3"WB
MR[9(8IGBZ*'1=W**I^G45)61\ E,7#F]J\?IMD-/:B]F5ZHA!J4QE#>7/[BQ
MG!R&KRZ1&GI>>P& MP<$<&FXU01@H 1PW)1^=N?<:1A5@2CWU):V0LK4,$/-
M<%E;)-LDUW/#)5.;##W796V;GM-=5!N-,N6%+M#R4O]7F?C2'8R>^WIR&7JV
MUO[7PV+[X]%L-]<Z3AB0! IBE> .E8P=1JTK@]X,>,.$@2545 GJOTH,$HI2
M"X"45C!$O>7,IV9_FZ__46V;4WA%U0(\FK3B#LBF4GA^,AJ1O;@)9P?HR1'7
MBUPX>9V8,P=:>S(YC=.K?9VH!^U=PY_C_W6QJMYMJ_O-3&I '/=2QQ0TC&/+
M2]V-'\-54,VO-,O ^J5%J:E%L/2"J_T*W2#%E9=9"1#/71[GV8&-J]<.F/_1
MH"U:N!F.\T<T0IB(78[_.&T;C/J+G>H_L'A&"/.TQC3T,9-O"2?\4QD,5=/G
MEI\>"I+7?J'RL)QOJYM?UO5F\_?5NIHO%__M?SE?K%3ENW/U>?ZG5WI9$FI5
M$Y%0ZTJ)L.L&.)$XZGKP,(@ M-PB2I$6D'C"));2RX]"RA,H2.Y+ABVVXN$
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M%/7X0\*,M:LXVF&+T+]>Q 7,/&-Q%C>_/*6KWPS2B\&(>6(L)M-F@W1&PZ:
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MQ(!/)NCR@SX=>CU !PD?_/O7+W[ \LOGQ799S32BUOAEM(68,@+\_SXF[K0
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M>H@RU:PQ DC!B9^<%)' <H@X,@0@_PM#54XAZ) V2O $8K$/Q"^6IXOC\-Q
MS]0:$QG@N;Q[/K"SLA@ZH-N#JZ^8_;7>;+I5_X>F"F6]DMOM>O'E8=OJ3+W;
M6SJ@\]!@B:TS"$KCA%1,P-U Q\ Z)N)"L<%0^5C524JYL(18AP6&%BAJD?8A
M"8?Y3R=TI[B/=6"W^_)O<1'9:.T4)LA3;* XH=ZUS*L*_5/CQ=^NBM]WN]O>
ME>9EOM:9XMB;YBC>SI^+B?I [7!&[,=NZ6E, J-[75]V? TW:<CO\\6RP>+J
M]:?YLMH74%]4&WGSOQXVVV;&.Z23";>  %@*)JFTP!B@>*=&V"\CAYLUHF!A
MY&-52"76W!#D9;*$SECN8U8OF$3@[-/&WU?K:K>]6]S-%ZM-\=/2^U!M_E9X
M"=H<H!?SSJOBMO8+?>]7T)F<"S=J_RGF8JTY^!SSB/RJ.'CULV_-GW>M^>C/
M53&_W?K/_?_MO6N/&SF6)OQ]?T4 +[#;#;A[>;_L @OPVFW 5?:67;.7PD)0
M9D;:FLJ4/)+259Y?OV1((<EVIC(8088B%V\/IMOE2IO/>4[P.8>'A^2'L9NM
M<CFB9Y IXNOI1YDR9B>$F8*\YX@SMEXOOLSC7=6;__X0M/+VZV+Y46W^6=]\
MK \A<B8H$<(  C"4(0PRZB$ZI+O&=KI5.A\::I730GGIG::4<(D0=<02;P04
MW)2^0?)L5+F>;SY5MW>K/ZI/#>@R@223UX9'D/$=ECUTG)A0'6VHYIOJGWL/
M'A<PTXD8G8CO&2KR.G7Z,2*SO0G!H033.:+"N_@;31M:\U/Q1?9UO5VLFT+;
M?F_S79AHC\4P0$D$YXAVWB@A <.J51T:\*>UCY1"":F3D@*B%<.4A7BK)17Q
M71C+E4.J6S8[I)_D;!3YO+.LNMH94:U.CLB5B"=%_3T\RES<T=EBSU]V1OVU
MBF;%V'.[6(8O8&]#%8UH%RB_U-??M(!.?0TSP$D]X]08G\7TH]<H+"3$M/&\
MDB/2A559O?BXW#W2<_WUPSH BV_W- 8T_W2WZ\C^$:SBTL2+2!BP#FC%'<#V
MD%X[G=@V4PAD?%B$4Z2D@)Q:&F"%7 +%%]@90YR5/VS3@JZV1YS5_  T7PPK
MZ<GA(6PB+LR^>MK;51W<?&)9TZAS8MLW$6R*BZK^3NH9P4;X*J8?P,8@(2%^
MC>:3D7H+9DS$?2MAL&,",B6( H<RD '&I1S,&8J% HP5]]I9B"B0*E EC!6(
M>,BQY+;P29W=@>S5D]T$NT787R]W(GL@O^4VH#M[;OIZD]7:O!O.B2QW59!'
M !V+2Q@Z:XD$"F$36XQ/EN\0 9VB#N?&8=H+*H6"+.3TT @E,'?< BPT0LB7
M/J-G'IOM\^^Z4/1B];%>QA3G[VEYZ2""NR678W&;EB%V;OQYO.%G7'$]0^$9
MX<Q!_#1$,8LEJ_R?938Q^U92?PZLQ$O=5G?A;_O8O,I;;[8SC!QP45H!0-):
M8'"8C?OYJ*6!:?7IH6BXTQ0#0[SB@%*MI7,X"#\A@%&H?/DZ]*/"N$N#?M#'
MY3<VA!_>&3%@D[.X,P>+ZWA>'%> O[6D:DV9C")WX;V?:F?UZ.25/:^UW=6_
M ,L9(L3KYF:?>.7@8TGX$R@)@4(S19"EDACG2 AH!Y%1DF5*D7MA<\8;Q[V-
M&"G'2$H@'/4>1WR&)!W1R9169XL 99PU.")<W$^%(L3!KB>[]*<>,_IXIE\,
M*?H-3#ZFE+6^>XP9P0M=8XZ?+];_,K][J.UB<QVRYX<PULF!;A "&B&.<*P(
M(UH :'8'N@D WJNTK<+S8QF+I!%"6RTDI1@*":3 1I*P%"-.)Y58>^WX17A5
M@Z_ZJ9Y'=,UM56EA82"?W41^/"+3)/N$P1-DU6\7.^5^EJ@S"IJ'X&GH829;
M5B4^P9Y:I3:;>KM1RYLWB_G5XJ[I2M]/V9NWRU]BIWJ\!#_\0-#2=?N/\<#\
MICDF'_ I#I45RD,#$0J9/.7-/)3(:H,[O6B5'Y4UVE/!+$8.TB#T&C!%,0XJ
M0;!Q..G>WQ[]X<?9&U;=C2W-1OB)-:TNWL1>OX-!S4^=FM1<=['97W'1\<62
M"_@X46LGY=Z^NOSJG-N><UA9B1[*;Q<Y'\V'$Y/^\>Q^*DR,S'QR2-%?#[_\
MYZ)>QPOFO[Z)U\NK/Q>;&8CW7J&0>G/,L'(6860/6N*U[!4OS@\IO(.0JEA6
M$M0H+A62E"-JB +:JM)OI9ZD<@=P.\50_U+]%A'V%?:!3">J]G@D]TZ5D_DM
MJ\-G&>LBLGDHGYB"9C+J*7G,R5FR]IVN=G^$85?QM9L9TE8P:(U43&E.C;$<
MM!,3"2!Z26"GD0TUTGD85LS>!ZM%[$HSTAM#);3 E7Z!ZS1Y.L7[JGIT#O^V
M0]U7'?/X(E$D1W=#3JU\CN^R:MF%NBZBF=4%$]/.O+8]):$%&$Q6TM?+SP_;
M32/<</_NBC:("44I%D2%7$9X$A+9_5PE /8MH3XRDA42: \AU)!3RK$4#C,/
M@K'((:IE\0+J?W]8Q:LMWZT7U_4FOD&BKN,1T>JG^?KW6$WX2P.W@G_MJ8U]
MV$U4PL*T]E^V[X"]JO84)C\#G5GV?N2IB\@-8'=BDC;$DJ<$;# [0^0*[4=4
MW"-H/$8&.P,U$Y+YP_I+2S!<KMJ1O&+6*.VMP9):A13"$C&M* <.0V"*R]7[
MQ<=E<TIUN:UV)X;>7FWJ]9=FUW@'N)4LE$&R.C/<7[)*4)M+LM"$) OUDJQ4
M=J<K6<F6=)"L?NP,D2S</O;HN! Z3"BK**-,(V8/A7[%+1DN6>U(<3]+ .@
MA)Y""R5"D@ $D&!.05M^B_I4LGY=KIZ2*YQ!KCJSVU^N2M":2Z[PA.0*]Y*K
M5':G*U?)EG20JW[L]-A6:#8^FD?1FE*>)$(*(:%C(=I+;97 M)U.W!/6<R?A
MNU$\HT8(AKTA87%$K,)88T2##@/BG$H[KIA>,FO05 V<H7L%J?0E;P\49"Y-
MBQ)(*[T!\"TGW6K^/7F<F.KTM^/IROX@9GKVQCRRM=KLI9XF#8T:AG\=*%K<
M+9JSX:=@]Q4S 0A'W)B@C4!A*)RCAUJS4Y0,:)7)!Q*CL(12+BB "5F*XMJ#
MH!  >(XY!#CIJHEAFZ577ZN3B3RH]V5$'_9JA9FF^P:([F5W$C*3VKT=9GP_
M3DST+T;#^6:92_FE^W&E]>?5>KZM;7VU/5X/O$^LL3*>08,$PEYKHPAFKM4<
M@7WB+5/GQ[)>.,X!IU83"A!7(+Z1 HG5"B(BRS_!=H!7W01\)U>TIYXI&L1H
M-Q4?C\HT*3YR&(&=W(Q^H97X69[.J&L>?J<AD9EL^>%D3#Z&NHK5K^\_K!L]
M_:J6-_]8A5F^C#O%;=$2B_ 12.A]R(;BFE(?N\XP<8F;M.?'$N$O-?&U3!G/
M@@@KH5!A-> E#"M8@&%QL3HBZBU4 ]GL)E3CT9@F5+^^KUI@31?*"9^74:JS
M1)U1JCP$3T.I,MFR*O$)IBE5D[WI^?7O]<TC*8#DR#*L(0\:B0AQ6K8SBP&6
MN-5Q=B0)(9->60<-!8XH+DG('SD2&#+*:'&5^FFUWGZ<?ZR;*;:[^6S>+-:N
M&L"]I6L0O=V$:RQ>>RQU_[9G[^+9U1F.SBA6#F:GH5=9+%GE_^[&/Y'W9K&L
M7V_K^\T,!<W4+M9'%?5&RJ"AAP6.#^G?V*?RCL@,HYXHY;FRAC*BI$':!ZW'
MP!G Q8L[F1<MJQK3+G \+\'AO>J2$_)U_]WHT=P\V4-]!X]TKV2.Y/EI1) +
MV5[@@%]?#XP9I0Y/:DJKA5/ "B:=L]QHXN&AX]B+O@V2.: 9Z*7!'$A*"?7,
M!VGU(8MUDA$KH$]2KG[M20_W]_.P*E[=[G+UG7[=G>A70!XGQDTUWU:W4>Z^
M1./'CT'=W3E>""KBQPM'H N]BYS3'87#3[+7_]^)/NFF%P@^/?E/JN8<SR,=
M;TLYC.L Y0X8'I9C1BG!$<6'!DLND>Y1TSD[GE26 @G"Q,&:,N@5QU*&" N,
M-'%WJ7B4V$'\+SW*-L-X3"C>C$9@CQ+.MP=/C_@N)K;/,O9<02<+V].0Q8SV
M/%;<R<A4YUW^^>93T,WX/^[?'A8A7_OF@.41QPPBKI60L;L 020X8)+M)B"V
M5&.4N./?>5Q'I2,,(:,EHQ0[S2@R!$'AL =LA%)UQ%C51Y")F_[Y".[8 ' 1
M9A.; 2*E,:EL?G$"\PGQ&[DUH"N#Y]H$LGMA&@I8P*[OVP<*,=<YI7OR9?1O
M^QEF1%A!(512.*^\=0PCT\Y7B[E+J6=W'E0[+BS0(9LUGE*$E.:&"(H-A#0V
M4Q0N5>_.>C=GDKJV0I5)2CKR=2XWR4WY-"9H?K.^SU3*\-9U>KY>?JEW[YL]
MJ@G&0@A#=D1#CB0X@<AZV4Y*"$#255[/#,4HEXX#!S@A%!.KC)$*<<0I=0B1
MTE=XG4S%F)QLO_;>,Q]*:;>\9$0VTY*1$V"32#_.$W5&T3(Q/ T=RV7,JLA7
MF+A#\>W;C29>_QV6=,V:[S$45$ #N0ZIC>4&<T@Y/V06!*8NM5)'=XX2B3S#
M"C J&%0>A*Q*" BH=]R6[V"T]3JD?<W=,M=[L*E';7(3WG&;X(),)^X$?/\^
M;HMUOS$P"2%,I/-<);^08Z8AE<6L^[X>7Y3%Y\3T:K&XFL47VO>ELM7:UK=U
M@'(3GV*HEYOF>,QC.$28QUH: CF*A6,;D/!V=AN!:#<Y'3"^5!1HABW +(01
M)I01V#!J2'R%#I2_N2NB;K=L;U?KL'3; 6\>FVV1=U/8@EXXK['3H#]-91O>
M]QNM 7#5(JY.(2<J[5C>N%E=/\0TJ?D;)NZ5;["F[88W#0J;,#F:=P(_U=75
M//S0=5UM/M7UMKJ)!Y9BO\/=73N!PC\].G^JS^$/;IY^H?6[$!F9:P(?D!@T
M8:\WEX\$OO)^N6SH&\&^U5A?>*8=YQGS/ Q"X]ONB(95#$4AXNZG- ^_DVFG
M>88!$Q)C(SS45 $A(?28Z;!:8HK $8YC-L^E9]I??IZU@?O*6>G*N)\\D4WD
M/IO'G2F=1GJ>P8ZNF\6)S'35G).VF[,[U%1HH0B.E\)I *05\+"*9L)WS+,3
M!PV)BZ5("H( "7-72 \]]UIJ8"EGGA57HQ.<B4TON6CMIE 7X#--KDX 3JT'
MIAMW9[0L,_G3$+;<1JV*?K!92K:;%M371PL>B"G$I29<64^9]," =J8JEGP9
M>!\(ADL>(?"PM*-82Q'4PWOKH$:<(>Q>;O%V(/6#*KCC<9ZIC!LONFPA3R(!
M[$-L>D$WCY^FH:YE3>Q6VLW)9U?EU0^;Q;+>;,+R^FJQ;%;7$<YB^;%>;L.O
M-HM ?//;!W A!GA#E;8&H'CD53EN8#O[!4Q[O:;/^-P[YY&0PG%(-:/2ZI"I
M<6(<<(3XI!NY>[0"'/%%S3T"K%97=XN/S2]'[L_I0>*9V5[2)=.8[$4M7(WW
M@>=<5\Z(I[%,;35V0",:Q@/N4)I1#,VVL1"48S4Y\R(8(S&T'D%*L=$&,J0I
M(1 X&A0E:0(?4)6L: WE+L>B,2MMB9E/^'*7UXOY77LV[?;P&\^O(Z>T>.R]
M:.Q,_C04+I<Q28O$1(ZZZM;[ZT_US<-=_?;6-9UW/]7;3ZN;D]:BW9NFTL7G
MBRRB&D,&/+'<8J!A4$W"'8-)64G'(<-D]UAH*ZFEE"BH!.&<"Z\D,\C*TCV)
M+<JX2;;#6>V 5B=(^[T<G8OS;KIW ;K3]"\/TT7TKAMW9W0O,_G3T+_<1JV*
M?K 3N9U<"HT#0DDX"PE,T&W#:#N;B1)BT&T,^6!J$3A$CGGB-<4PK(B5%I81
MK9F%'.OB1;?__Y[K2[AS&L)R>1K&NN<ZS2\I!TJ6P8''R]2$A1H()*Q"2-J0
M)EII]ZHCJ$(Z]0S)MW^[LE@B* '%DM&0EVKE%$2&0!LEC95^[[@%]#7]C$@B
M2]TRK;($I255)U@N=&_B#VR<T;_^S$U#N ;@?^10QQ F.K4>MVU?V_F?[95'
M7]O;%RV&!D,/"05*VS@6V$\%J3#@703CN3&4EL(:XK !B$KLE; <6TB=U81;
M5;K$?&A=#= .5SYUU)#!])U7DC&92].3QTE[7EKRLI?0R3L2B_WZ=?NRV:WQ
M]FG3GVJOS4#6!)IH<UBQROL)92[&O3G</PC#2M=I"HGU% *JK7!MRJ)"]@*S
M%N2.PQJ'G#6Q^&X192%I11B$>>II2%OCZ>AI%.7>]+TT-J<#,E7GRG!?I$+7
MA?;+E.G>=+BAM8 GII&<EC LM637E[NNROGXL&__6 :-^;3X_*X.'W8(TA_K
MF0<,<J6<DUI9@[!%AZJZ!IJ:M#I<]W%U?+>5 (H0"JHAH"3$.4@\18JYP$GQ
MPMH12YS&F^W\][I:+*OP6W$^W\__7-P_W(\[;SNS=V;:YO? -&9M ;M6I;_=
M''/6+FY#UE4'CG2]_:.NEV:^7G^-5V+>KQZ66[6\^749J+^+O[7[&V8!![!,
ML( ,0\890!*V4YIX8%)RH6R@)+0:,>.<@(PJX*7QC'#N+9#QN>;2#WT&8.OM
MXM_WO5.WU55SR^W-P8[$1M;Q?-4M;9JDF]*2JJ<2J5?5T8QJ;T?5&E+M+&DZ
M18ZV[).R*8AWN@N2M;V@EZ<L_27-[A09BO/>J7:Y^YOO&VR+ [9&WH[J-C]1
MO\_U>K&ZF2D(N7<J9)X"(:& L^J0]TFI.@6)00"0%B+DNMP8Q2D&4#.OO25:
M,(JQHTD)8(^ L)>;'>[J"/R'R%"=8J]VX!/*>\7\TZ%R.@77] H"+]<K"179
M*7BG7[FVC)>Z%7-[LO94I;>T$R90!BYNXFK$CSJU >!Z=5^_66TV/G#R1"WF
MYWK[]M8NOBQNZN7-YNW:+C;;]>+JH3E;,2,@1&I(65CN*0@@P)B[_8PW$I*D
MJV SP*$ (";B21PF*9%<*ZPET]QS8HEG25?8]XB:$?OQ*9@PI]_/[S</\=60
MQ:K^'.;^OZX600?BGNT%+E<<RN[9'?G17#>-I'M,@W_8\Q^9ZZQR,@.$6,&L
M<T$N@HIA[+EL%8,9Q&;+^N-\6]]\R"P<,ZH$E-Y*3%PPVF$EF*<>,D:0@9YW
MZZZ1.VWX 6-GB7C[L*XVG^;KIJSZO3Q\G"^6F^HO=\&2>O/7">K#4 GH[(07
M-,N[V]1G(B<RUODRI9M_?=B-X%?KT^K?3%H2UMU48:8M- @Z0=JN"F,0=3WF
MY].# 4\<A 8+I2@E7HA@%$,(&!I&5:S;%4&#YV3FZN< ;KN5,POSV>_*I1,8
M(]^P]!0;9\1J.(/3$*@,=GQ_PU(F9H9MZVQF3CJ,I'#  J0DU29>G+^?*EYJ
M-'R7)BQ>>)!1+8'!1E,@B60  V"M=-2&+"7IQI^>#<G[RL#BAZ5"C@V7#BP.
MV3_)2V">[9"13_NGITE#J9R&[@RVHM,60BHKG78$POSZ6"^;%'QU>[WZ'&Q;
M-966]>IVL=VLUKOL>P:Q=$AQ1Z5'5#*JPY"'=0IGI/,.0-<!!:,(48N(@8 *
M"Y66$AH J,<&65*Z=K&#>5R;7*_^=H!:[;&&#ZO:H4TH)F<CO$-)_Q)<IPG7
M]&E.J-%?@NY^-?E,M'<KPG>DY:FB>VY6)U!DSV[2JN!7F); OEOO^[[?;U?7
MO[^;K]^NWV_C0K0Y"?BN7K^/P&9(AU4?1%"$I1^EE&,C[.Y:$B<\P8EW%'<<
M5#N.&2'*.RDH4UR':"J-@IYBQA1+Z@'NUT78XJPV$>BKZO.\U]/HN4CNENY>
M@-VT('*D]?V.UH QJM<.Y?[6EX"S:H".FQ)W(^],AIR9_6DDS+F-6A7]8A-?
MTEW=WZ^6YT>VX3\2&>Q=$%^F.:%&MC.32I'81]UE1. 44@0J(S6/;V1* ZC&
MU#-G!5/8%M>^'<B!PI>%VVZJ-S:I:9*W9W-Z>M>!MC-BEY/T:2A=5HN^?R$W
M.UO=2@;[>P/?!AWXLJC_>+>Z6UQ__5#_N=7!\M]GBD-#+134<(BUH=J;PSN1
M7G.?\,S2<T-!"K!4Q!MK%44*2Q',1=XIHJ%%:07^7JK6 DM9F0ZEK\O"?T3>
M$A?\>V15"ZWZ;0>NBNBJ!E[*@>C!;*:L[T=DM>_1Z,WU>G$5'S):5JN6X?V+
M1O&1HOGR:]/^WJSO/^^O]QS\6-$SQ#RYLL_$YQ16]+E,617XWA+O78[;O6]O
MU?5U;$Q?+#_NAOU^<(,@$EQYX G'L69&XB7[^ZN6 4A\Y*/CH/'%0.V,1%Q+
MJ@ 4G"J,-):6.<DM+Z[W#<XXH3Z''VJG9UH.FXO?;FGL!8A-# @MHT>((:'=
MA824T%#F^NI.[)U):#/3/XV<-K=1W]]+78*S[JOWY28,=--,[.^'Q$ 2AZ1B
M!G@,-;':B</C$D+IU&7[F:&0"I9 H*V7ABJN%!8> \]-$'GD4/G'E[]!E[I*
M'\)AU^7Y2.2EKLM/8$U'Q\ZQ=78YGH'D:6A6'E-^6(!GXZ>K/OVZB?=$;+:+
M^[#6W\Q,2/2D<88:)8RPL=1U>!/,,6S3%.F[OQQHRHU#-$BLH]9(I35!@E&M
MM+=^A.M, YZ8&=0MHC092J6JF_ 4Y"A-:O;D'*!,1VV^I>B,OO3D<AJ*TA?\
M*LOWE%"OVUV_&E;])W?D_[.^N_&K]?OY7?V];C&H->0>.L8)XLQJJ0X!VF#:
M_:QOXK@<0:FA],AP0[&0&CFF-%)6L3"Z*G[GP^Y5YU@<N3OBK3X%P,U;Z9L
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M2[&A81U(DYKW>@C2 4["JG8 7QWJ!^-0E:9!#::J 54=4%4[6.,0E[#R'X?
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MU-Q(O3[A!VAONT!KZG@SZ+UD#EN'O"?(":04;@5$  934MB!2!R&+F1_GIO
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M?ZDW;Q;+^O6VOM_,M% 86.Q!"%B,>JLDP:V^8(637A<L!E)X8RAQ"D*M*-9
M<^DD4-0K9A$NWN3W@P8=#4N4HWBKR=' ZK=H8M78.'!!,=[WT"_>3/)3&!B)
M1OT*1HE3N;R4$,%&_S"F&=O&I^&9J'<AOW1^C_RI@\DSBCGRP@-&!61.,*KP
MH5:B1=JIX*='06%Y%X*Z$\ !JIQ4"#A(H1/<<PYXZ0WKLR?]1W[7^BF.SHC
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M^Y,Q:'P/=(U!A_$[!,5?EZNK3;W^$G&]7GY^V(9_'?P1_E2SOW"B78 **8W
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M@@(:FYW]<50VPIZPSD9XN90VR4,O4&O3[!NBMCV8+*&W/DR&F;<("&P)TP1
M;QP#@AR*(*;;;7/%!I^"VN)R:MO- ?G%-COWHVAM1#U=J8WH,BEMDGM>GM"F
MF3= 9WOP6$1F%U_J&<1 ,6<,A5X8;!3':'^&09"0<>??M$L9? HR2PK*;"<'
M%)#9W-R/([,!]81E-J#+);,I[GF!,IMDWA"93><QM\RJVR!+!RQ&!R0("D,
M=HJS(/NVQ6+BJ^H%M#8-P<4%-UXJ5,\CYC*RF^B0O-I;SA>E!;CQR-1E^!MZ
M,VAQ/W>]+$'N:6-/51[":&YIGA%%C9)>4.,)U]I+RMHN"X($<BF'TK(-FB3
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M;#^MUHM_KV]4TZ$)9TQ0!:0B2E(#)?6&&-Z.#JV125E-IC%+YSG-1#KBK/9
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MS74_G+HKU\D--CND#T54,!YJ[P#[ZC36L??3ZKZ8SK^_'P\F\ZA%IQN<^R>
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MNK"PV/.3K@LI]<)']%3OT,"! GIQ2Y;B.5/^?KE15BDQ.??)/8QJ[<4^VJ1
MNB+?^VEQ/RA'JTZNX\T.IAS85RU80ZUUUBH.+3/"8"PVTXP+EQ-K(?ZBWE;J
M-2B/WL0YNL4C5[\5\]MJ]&;R):[R"UC_"GBL$V+&/#8F+C?2:TL!D-H*8+ 2
M$"!/?+VD!FT'/.X0</T@QGT-! >TQT);22U-&0:4()QSX95D!EGY5V!B#FMV
M!B8V*)*NML!-/B+]?;%@FO%@=NCUV)UU I"2>F$A4!Y1Z71<=!G3%""+!'=9
MFU\/:=>TX*MV8.Z<2LN=][=BD#(.C*Y2@I^'Z;2<W.C!K)S]/JD^SXKIEX3-
MF\G]PSSE_XES<EPN1/YTL >C#MOZRJ!%E!!R+$Y\33&4FJOT0"71FEG(<:>!
M95T$^33 M5WL/:]HNHN;_1)AKJ9EC7BS%V6#LE@B* '%DE'KD59.060(M"FW
M/;L0%Z/^4.-%<&V>0+HBV<JP+D:?BN'MI!I7-]\_+-+7'Z3<@9K!4@(]1LH)
M@*@!0GG ,1%0.4A8QT&-?T("-BN>[M:\]]-J6,QFV\]^:JR#->H'KXT31FD/
M&*2<>05IG)J:Q]V(1HT]QY3IX<5L[ZC9AI!.ONQ8I]J;#V+A9:J][_O=.W?7
M"$I+80UQV,1));%7PG)L(756$VXOS:FN-\1J5BRO*]:;" L$%1#H: HJ"31C
M,#U$2R0WF'MP6=MLR_9Q$Q!??ORV0D(XPRV"PE//E8*0>FV]3&_:.'=A*5(R
M.9$9OWT<UN=V>,^.W[9Q>T8$(&@-E5 +)@2Q2$EL*8]3^+*8U1H7CHS?/@KT
M-N/J#JWN+S\MBG>#NWTQG3E-!A^'[XTFVB-**30"60>(<HXS8#'(.4/IH9W0
MTM[:L13:Y.>N;NX-_MQ?*5#(&';(0PT893R.2R5/5$"M@\9WF\ZXW=BP;DA0
MM83\Z2D,!G>SAV@*E=6LO"O'@ZFZF1;[=\M:]0)-+TABY*G0<=WV0!K/B+08
M.AT% W*B"GO&G*8$6;4';U>:U\%%^FV-0,+ZC03CD+.&(>HMBM@JC3"PRGD:
MP3'07]B)1LOF96NXGQZ$M;4?5U\G$>K;\OXQHD(7U]6T>/1-?O\P'=X.9L43
M-7770M;D=X1T5"V%(LIR0S&+<U%Y*Z+"ZBCP %_(=MDF8:I^B*:K!;/V$/>L
ME[7;"!I Z F@""%-H8"2$.<@\10IYJ*$NCR-Z^*2OT6"M@U^9Q[!SY^PW('4
M/N_@FDT$[)15 %-CI*&"*ZD%T!8S+PWP#.8X2[U&@S6??"TA?][%SY;748[%
M9!B7]?G7HIB8P73ZO9S<J+OT/J":C'Z?1)F/TT?+%HY>&X__BB"AU8@9YP1D
M5 &_T+<Y]Q9(IZ#-"=-^C9IF6PMGZY+)U$7O%OTM-_W]G*X01YM.#^ZJZ7SE
MEWM?3,MJVQ.Y.<T%I(6("'-C%*<80,V\]I9HP2C&CN9LX3V,=^Q&PVQ;"MVY
MIZ3$!2F^UT<D=R#VKIA?7=OR2SDJ)J/9U=2F%.3EYX?%4?Y>WY7<Q@,% #'A
M;8IIIT1RK;"63'//B26>Y>S_/0R;[& -[5PFO6)R+ED#55$+]U9BXN+8'5:"
M>>HA8P1%U'G.!4K]H$FYY..DN$FY'S[]:6AY)/J=^2V,_O-AV4-?3=63E7^?
MA\*N.@%XXB T6"A%*?%"Q+$QA$!4P@E0+,?]I7YLY 4RK"G$SVOI[%O!=LT:
MLHA&D,!@HRF01#*  ;!6.FH)J?>TX0Y&R3_E'MH,T">;%7H1+#N[C7!4U\/J
M/D)0+13-:75=SF?5=!R7T6(;4XZI'J)BBA"UB!@(J+!0:2FA 2#YJB*;]R >
M^%/QID783R;1#V_$+ON0.I#Z%^WD7=S97RNXY'6C8>RG,32]H$"LB#8VP89S
M*556B,Z?\#*C4;2[2U;RI9@\;%U^GA<)0@HM4NX?0A1U4,;!0*J@L1QS3EG6
MDX=_UMN%$\'M35*'Q87T7\D;]H?A8PXX=1QC)1G5GBK$M(9$&*GB;D%K'2W7
M]?9YN+L;3+]7UVH8918Y^V&3<O#'U.4_K%8+*6X>4M_I$=1 VX$8[J3V'"OC
M4@IM#=(3>%C'GR@"]1)9O)X+]([Y4YU76J?[J.WLZV,&]D8)6ZO9()*+LX($
MD(BRD%Q9J1P5WFM-!-0Y[N ]C&WI)5?;$%1GFV?<!">S8O0(9C'2@W&$KOAX
M6Q3SV>^3P<.HC)^>;?_<"/")4-]7LX6738WML4[UX"WEUAN?'GA2!#F@:,H:
M*0QF!-MZ+Z&U=!2XB!NL,<X?"P8"O(L4]]XZRG74\R  JQ$)%"W +O>P3O3@
M1L7\_*0O!]O.#HT7G30I9?UD7ILPS\H':32CA%FGE2"4"L8=W8S-\!QGUE[R
MYE31;F5('IB=1:8-9BF<//V3;,8O@_%B=YROO1P6\<I[B%.K?@!.0>XM8R[N
M<E9Y1)Q9CYU0UND[H]T1Z60&/(]':P'CSA:B+X-RG)0?7TT_QHY_3*'N<2$N
M9K;X/'_\;875OB7JN):"2,YDSB@)A# <0<L]7N%AHD61<R_10V6X6<:UBW5G
MW!L.DXO6[$,Q+,I%.H5WQ;P&T?94"PQ9P!72S%DNO,$.0+X>*3<V)XCH:(_1
MU[>2-0CMZ0E,'HHTS,%D7L9&P?SQ,=;[:74S'6R-!*I9,QA$""-4*B.-9)92
MK39C\()U&O[S>NC1#KK=N08M4Y=]CUS>ZP'T6"Q@(ZA2%C*N!7;84TWE>B2,
MHIRPG*.=)E\/3QJ LBM2/,E_?7C'>5DX:":HX=!%>+AE49-#< V-$<[FW'4>
M[9GX^@B2#>A9[/2Z]GD  *2'P*045!*CL45FI>IS(I3,N9,X_FV%:CX8OR)J
MY"#9-Z,II?=OS&YZ;"Q0&'=8KE)&.4T]!HI:N4:%"'F1IE/^J4_;.'<6@#>M
M[HOI_/O[\6 1WY+.'!:)!O?K-_NJ!809%R+.62$4M'$EQI:N1PHQL)=I-F5S
MJD%,.U-\8H>CB"8W;XO!K%BD4+VZ_GVVS'FX3P?:5R]H3:@C!D'I'(D($NS<
M>JQ*H1QOP1X&NS7$GB8A[<Z8F@\F-V5<1I<@1**[;\/QPR@.X]>J&GTMQ^,]
M+*I3/3B#L27<<TD=Y/&G.(_6(Y?6YI"IQ\97-IU:P+8K5M5@SF8$W$L6;4KN
M+,-48$4<]>L1  9S3//ZEM<F0F+^&IAQ(G9=27^=Z?;3X-MRP&]7^6Z3-E;,
M:VG1M=L(0I-H23"-%96 88<IL&L,.(8YJDX/'[YKB$%MP7N&XYY:=-I:/D O
M#*,:.\XI-U@(;L!Z;%[5\[MLZN&Z5[0Q-0%FMP<^!T]Z G$*&JT41TPY)6T<
MQD:YMXAW&U75T1%/0XX71V+7E>2?K&C1DOLXKX9_W%;C*)'50X,UO'3J-A&,
M<D@K&@U$)*F$+-J':+-(*MKI <ZK=_AJ"?4S\*Z^/]CN2L%:)3UG.,XKHCF,
M:ZO;')E2I#I-H]D%MYH7_VY^Y6'=%:/>5?-B]G[P/1UV'KZZV%(Z"&<-L10!
M+3T6U&C(V6)<48/3+.M!F1X&530AX*II4+LB2]3HCR#+EM*!("@49]  !Z4$
MV$*],2H%5#D&>2\WLQ;HD@]KUSY;M1FSO4) 4BA@D?;0&H\LD-*H]>@T1CDN
M[[V\<&B!-(T@VZD!_A*$0R;XRQJ!(QCA88![(*V*%@3$9#4^@;#L]*KAE3*G
M&6C/IR ?I1B'%#+-HKVJ*3$&<F$E7U^D"*U(SH'?\0GP6C?56Z!+-J:=,:6:
MW'PJIG?I0G\?1YX4"\X*H36PW"&DXOH(2'J"9CD2I4VG,9F782Z=CNX9+AR>
MGF,?><^PM6K00 JI?)Q06! MG9$0KD>,>9;O5]\5FW;XU##BY_&S6/?\>[W;
MAT-U0UR\H7<(2F2\(11@SM9'J"(N[Q?VC$7K'&L:\'-IU?7OMK9/)>S37-(4
M0H QX081M-G6(<AZ@J>7GA?M$ZLIK,^@;-?3L@.E*4T\9AY3"*S7W*BUO2F9
MD3F7HL?GZ.U2O6[]M/E(:#L+2:[N[LKY^I5'4TW2PEE,AOLILZ=6@(AZXCR+
M.S@F($Z):%6LQQE-DQP=_&B7C(M8=IH#NRM2O03AS63EN_8^)6N-0ITODU O
M,K54:2&-PXJ@QZ[<O)E$):28U;DY:_:+@G(<4RX08P)#$-5/#=$&38ESSC%[
MZ1+2.G7/*I_SL?TDYFY&J:W3%C!A*&%11<68ZLV<9H)?W)WON4ARD*LG2J2[
MT)&5)!<]/Y0[9$OI &540J0RT#CCHD4$B%][;4G$_<5E"FE"Q"^"1G)A[5+3
MJR:UN/*\: ",<!#55L^I]!!C$W];C4A)FO540B_/55L@2B:FG5T)/[ZB."A'
M;R9F<%]&,VS?G?#V&D$Q[22GFGM,*#-1,]U$3$7U07?ZW-LKY4PST';H3?!P
M][!(S;@X*8F,CU*Z+2:S\DOQ^"C(XD&:3X-O^]T,CFDI( Z=UE1YP2WE% CA
M-WAHS7..Z7MYB]P&U5J%O"L*?BCF@W)2C-Q@.HFZX>S)J&QQ70[+?2KYX<H!
MXSB[G%:>.V4DBZNTP>M18X O[DBU!:(UCG)GOG738C![F'ZOI4&]+!R0@\P2
M)CWF$'(G)/1KP+0'..=<[(10M\5C0*^-.]FHGN](X*BC@&"I2(?%FE)&C$+0
M2[0^*]8ISJ++,]3VC^%;8$HVIETQY;=R4DT71Q[+8XP]/'E>-%@AC2-&"$0A
MEEAXI-9.I9HHE'-O_$JLLK,<%&7*X74=PK=^^![B5L^TI 3":,<XB!G=:)(:
M"YQSMG#\L^!G6.MZ<MC9@>SZ$OQ7[RY\:]7@*0%(2N/3\SM.,\[-&G"=TFEF
ML+6'H:)=7I W@?<CP_KR>,/[!<ZWQ;P</IZB7>1+#I8JK: 7$M&X#"@=M3/'
MH.9<.&N9T75F1A<7)5$B5]/%B$8+$^)],?V87O*K?7>RJX&@XV+,"%'>24&9
MXAHR)DW$),X+IK+RT?;T.J5)6NR]6&D(\S/<M9Q MQJU4P)ZI$A*::<YI=A)
M ZC&U#-G!5,X)PZBI[I_BUQK'O!S;D1/H%INHIL/^K#_G.@M4:-^L)((XS"V
M7 G$G;=)\H@K!YWAB-4*=&YY_(NGJ>H,=%$P$(P=P90Y0)10CBJ&Q7I$T+E.
M=Y0.WF!M5LHO3)X,:+OSZ:AF]\5P\:+FJ+I?OJCVKOBZ"@]-YMFTFL0?AZN7
MU;Z5^_PT3VDN1%S3NR886*:$EQ$AI]?($)B5/K3/I#N2%B^3A[:-=,=1X2G1
MX$/<46*/?RON/A?3_1>V6ZL$3 #DSB%DD(8(:2DL68_0@JS\?CWD4KLDV!XQ
MGHMY]ZR*,VXR&DQ'L]_OD[X2RS, CZ#8GOH! LJI)%$M(QY(RCTP:#5V"YG.
M>K6\?WS+I\!.3C4'<B\(!ED>P=;U ^?20\JME!IP0)529#/VB$E.@$P?L[5W
M2K 30>[L0B79@1^*^X?I\'8P*]XO'\HYH('MKA2@-)Y!X&QZ$L'2N/K#]<)O
M#<07EOB_(3VK,3S/RQI;W0W*R=&\65:+)E":"-H"$4>'+:54;D:JD<IQ)>GA
M+M>$R&NQZ"1T#_-HQ]-H*GVTO2,[]ZIZ%8/' AHE'!/,*TN,I&R].CMML_(Q
MO1I^'"O,JD6$LS@B3N7(WHK!42$!)Y8)RQ!34A/GUR.PT.7XS/9Q]VF%(TTB
MG,41=BI']E8,L:<J=A1;"'S\'X%,JO4(#/*=/B3S6CG2),+=N0ZM=+7ET6OR
M!:\F-8X;]]8+#&K-%5#Q_YD&<<&D!*_'RC$#%\:FAO3=!B'MBC[/NGI0U]U:
M/BC,+0; 8 YXQ"UBYC?+IV!9:;7[J,0T(^>J>63/$\YZ\+AF6_& F=!&>XHA
MX) Q+^/85B/SG+A. UK;YTRF=/<Z7)P$Z!G<*P[RY$79H!@"EGNB-**2<@<T
M7^^YWEA7RU'I]6B^S9(D%\TSA[$>/@3>5R\@@1V4"A-@(%,(,8WE>JS4NDY#
M6E\;<YI$MD<1K76N%>JU$9(A(*P7U*$4J&*88>M3;P]4UD.P/4P#V#"[6D+Y
M7(&K!VFUO4(@BL&X2R///-<&>RS42E'T &F8L[<=GQ[YE7&H$4C/$HUZD"U;
M2@?@+:+ *,, $-1R@Y!8CXMKG7, >'RJOU=&E7P\N^+)]L"=@X395RV@:()B
M*#Q#T?04<:1QKUZ/- *8L\CT\-'%9IG3(+"=&>8+F X;Y$^*!<.L(9S'A=*!
MA8,3MG8]$D6STO0?G4GOM5$D \C.#XC?Q@WS3?RQUJGPIG"0$!%CB<2*$!Z5
M+N UV^RIQN?$M_=0U6WZ*/A4'/^*//XQ>M5SQ;CP,MJ71C&)#<(;S4YAV:FS
MX'TQ+:L4NC%M]Q'J'!*U$T-\G!0Z==N9O9G-'HK1/B8^*1:D\BD6R$6]3PLE
MG2!BY13@89SOW>1C^#'#R_M72*O3(7TMZ5V\=X:A:"!@#+W02@@(UJ-" N80
MY>ASQ(M8>(Y$]#4D=\%:.TXA38&&RF,OXK@>F=_M:> KY$@FGIV9Y\7\,;G>
M/GO\:;G L/94(F0I-YQISJU0Z[%PHW->=.WA*5^#K,B!\2R4R%24CVXK3A,(
M)1&660S3(43$!:XQ 0!VDZ7N'''E#9.K!; [C$&]+N<'%J3'0M&>%9 "RBU)
MSQ\+RC#<C$)!FA/CU\/CP 8)<S*&73&A3B;8K:;>\@AK#WTR6P["&>$%PTHQ
M#2 U2**U78 TX3F<Z^'Y8H.<ZQ;X/A$UDXT!0 RT]I9XK:/"H"V%9CUR:+*2
M3!^?^>O2*'<DNB<[R_^X$9>KC;B<#-.%7C$JEO]6J<>[W.:/:"( JHS%A .V
M<#:($X>L-4PD),LYYX;@(DG3,L3GLOSMJL\^8F;+V7)AC0*=[=(-_[$\WCCB
MQ.#4KPB.8 DI189P[)V4C&FZ1M"[K#2RL/XY^(_GEI]> U?/+(FSN)HLDF*I
MX?]]**<IZU2ZNI[?5ON.R.M4C\N_ XRR%.WMHU8AM2!K_1<1;K/>O#KU[/Q5
M<; %E,_"K^7I_[KO=6GU8ZT09XYTG@%$/29 >4:P7H]36I;CH +K'[!?"INR
MP#T+B3X4\Q^9K^Y2UHFZ;-I1/1"/@27:H_0:A85,:KV^J<2:F:Q%JOZ9_*70
MJAF4.[WR>XSB'*G):#4 ^S!--][+*Y+%5#ET&5BSF>",AX :PU-B;4DH,9!O
MD  L)]P UC_G?\5\:Q'M3GFWO Q_VN?%#O]L.I4'G16.;2O=D#@!/)2$>062
MX](&>$QYWD;:0R?AIJG7(M9GYM]RSC1$P#V-Q5E)F&1"**<IC2:0--"O49&9
MQNEEWRZT#G8O*+CXX]4BU>+,?2NFPW)V.@6W-A8$IPX*KC#S! !/$#;K(V^,
MN<LZQ+OLRX;6P>[#+MP0 W>W%2+D4AD3K?>4)52RE#UFA0FAB&?MPO6O'EZ[
M'M@BY)W%HXX7PBV6,T@/%HG?[^Z+R6PA5_<M_;@OO7B]!@+EDJ2,:M!1Y*(F
MG"S[]>@9$CE.(.@RKRU:!?A\;JU7.R["#M0(5,>5VT%H. *<>XXI71\T$F&R
M<K>@'B;B:-6W]11$_XKT>.9H)21#!@)"!:!2.RO6J=@\@7F)S-#1.3^6WK1N
MTO;SJWT+]#A."*_%EY]YX 2!TM,4 .P-H' -*G' Y?CBHA.=^5\UM8X$]#6X
M\B-(J++".\VD)<3HN/&O1X1IUN4F.M&7_Q51)!/./@>,6<HHM]8)@#P RMC(
M]]5(XO9N<]*5H5,/^-^_-GYD(/K(C3.^TC6[NC:#V:T?5U\?GXW\L9_G>:EK
MTZOC'NAZ42THAQ!W40:: ![% :,&:SU4TGCEM:CEK-M:K$7J[OMI]26*;*2_
M_QZE]&9R%1?)07JD0*6W7):ODQ[&X/C&@B(0,HJC'J2$]4@S#-0&&:@ZS7'9
M\2M^&31Y&7?1+NY]#;PP#A$+N8>("4JHPPB9]2B@$3FJ9R_9TZ:@=X=F'(=R
M9T>!H_]\F,T7^\>GZD,1[:UA.2Y^"$'Z5#6WMK7Q=<$C"3V/<YTR1["S0!*V
M1M8 EI-_H9=OF';(WQ[(JZN98(LHZ6&Y8$#\>5PLJ#!)[D33>?E?B\_W,+M.
M]> )MXICA[A6S@"OB/>/8O YKS[U<J4]+WVJUB74%3<_1)''[[J-O;7%EV)<
MW2=,WTPB;,-B[S9_H&;P6DD"F5#4&B<)8E!L=B7'23>Y1KI[AZQ/?&Q6-)V>
M3[RXD#IT4O&B0E#4)4\EQJ2.9K9*:3;T>G169EWM''W<^:=;"AN125>,\X-R
MNKAB_VWA:[2P^_Y9SF]_GU2?9\7T2[HL>#.Y?YC/UK NU_CXV\,TW=+'@9:S
MM^7@<_S+_/NO@W*2T%[>/22$UXE:]Y"XLSX$(63*VZB)T5QCR"V4<&,F,)NS
M(!]]QONGFQ=]%7-74^T1\Q1S]F8RBL".'@;C\?>/Y<VDO"Z'@\G\,3]E.;N/
M]!A=75]-_U&,1[Z:?AR,"_=M=:D7_Y[N[\K)0RRSE%8UF6T+!]?%=35=A?/N
M#['N20^#U-X")GW<I+D$P LIT5I^4F?E_.NO2WVOYNKK9$)WUNR20)M^KER&
M=#$IKLM]1S0':@8I.*#$N*@K0",TP@QMY,4,S+ELZJ$K?Z\HWZQH.MQ4%F',
MZW#FN LN;N@_IDUS 8S_\J[<O^;7:"#$><>PQ0ABD7(<0^ (68\>(9&36*.'
M'OZ](F8K$CJ/TK/L^#*2\,WD2['">)%@Q*8MIIB,9E?3'^+Q:^LKIS0>(CC
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MW\?N__CMM=._S=838Q9;O:F^_#(JRN6<B#\\GPKQH[#XPCU;_XLR(6K%!E@
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MC1G(O#%,&9J,&&Y87-L8T4QJF_4.+;K0L\5&D&SYPB(B&0=9?BGL8#Y8=?C
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M_:Y*0AR,E].HUNKZ8Y6 J=' .PV]5Y(ASR&RUAO&';=QAN40JH<I/-I>"+/
M/=G0VO[PT]772<3SMKQ_Y/-2%5>C4;GLYON'Z?!V,"L^30>3V6"8/MQE>#7Y
M'4$1K"E 4@E%B4>: /]X-L>S#+$>QK:V8(:=41I=+7*UA[AGU:O=1D!82FX
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M"8QWT1('7 0;V5H..@;^S\'!A5DJITI^A(>['J<SO5[_I9OSW4==YD0"I4&
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MV^&_0XNC&"+3V6VY2OE:S5?R7*Q_]:ZZJF=7TYOIW=HZC$M'WY"93"&8LM5
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M':!YNM2KJX]3Q'AR0."//Y:9,PF92(DC!!TI+YW?Z"_CE&NSLD?D3?0AZU9
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M2M[F5?=H4>UUGU;=4+AQ:BPWO\ILG]]7":ON'P*7DS*GQY*\/R>_VM<G,<[
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MD**V?RA 44^ LODZ_?;I!50\_F7*XD^4,J +-D_8^'RH"I:55^%4T#K*,X)
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M$SIM/Y]*#0^KW9T26B:D\TB"4Z A7Q\2O3(@=!8[&*^U%WHZ7_;1O]:Q46N
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MXW<JS3%L?8JV<E)(LLBV!*XZZ1);\Q0D^9B3*\A(1^N84D=&.MJS,)MXU!8
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MTB H"YHI&3K^*[?,63,_B*<Z1)-T9G08I*?VZ-DD!QUX] [T-<:W3J+P";\
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M.B")([E7<3'&JQN:("F6*JH&)S &K[(6;0D&9VJ<KO"\_-:]SJ3[)16N/JL
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M5]#F)J-M-LUKJ\RL#GVO37TV0T @&0?I:C^[VBHDD\BU0^3"@ZZRCN>EJHQ
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MPG\>TT5MU W"1UQ3JI/@]HRB"-1/^"[XP\_4LY>,LM/24XSA]M HO,=?BK\
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M/*C_>+V]4V^&(JO":KD"_J-92>%MG2Y"LUV8LL7566W+2X=U\<)3O-M&^!P
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M(^ <&&Z1%QA:8Y36@UN'!C-7XG5,NL^HZHGK!JG?;DB$HAYP%FG0>P<*'#/
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M1=/)?-NYL6-!^8U/0%9F^E-FMB_=7HP$>A%; Y9.Z\HCV:A)U32^)I1DE M
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MF2#^-A>\O![#O,N"ETSZ'9 ^H[4ZKZAFQ@<LI=+@O-&( [>.&03$6]X:!_2
MH+C9XY:\V()QWM_,M$S[F?9W@/8;<TRII509+(05"M*8+^(!>XJ"QH8;M"[M
M/P'-79OG6ZWCRJ#=!=#N,U-SV4AT54)01[PV%!PE&C/#N94\<"(DT%Z8NE,#
M?1A9_QGTNP#Z7<+VVFB6-9J1$L82;*R1%+#CQ@G# 2D:O%)$MP:B=,+4'9KH
M8KM!L9<UT?]2&:AWKU?_-BXGGI3RA]N4.X+^_%/C^D[+-#FZIROLZQJ>?O[S
MM;VZ:SLNRU%Q>CJ[C%_X.8J4T72V+!?)2[.\*!=EE"/%]=DX.7:BJ(G<LE@]
MJL89%>GE\_&TF)Z.BTF\G/C"9;SBQ=O68F_OP=>+;Z_US;=O3H^W KX2#-6_
M%_/;[[Z* OF'C_.R^-</Q7F\TA^+R>_%YT6\@K]<S&\6651LL-!2"6FC^N8U
M!@12"NFD1I9R0QAHEOZF^.+NK+=DN5IQ\;SEIF^IGOV^^I&/LTG4ET87\T07
M?UH@R[P01*HH_H$S)T%2I *P:&VFA75RR^^_AK^>5"["V?G()EZ+)^EN2XJ6
M7'[H2#T-3Z2S0T1J_1^?0B'.[EN@.7SW-W\T.CRR;T?ZR(V.?S7'A^Y0?SCT
MQQU)B"VOR+X[<O[HV+M1?'3\[N=#IT_BD^.3^)]?_-')\>A=B&_]\OZ#_WO\
MW.$_?5K]NU_\;B[WNSN!>)"RPN-O3*)2M/A^_=74OZB>JB.H!U7SIXG,QJ>_
MT,!15*^KFSU.HG[UO/EUTZ0K3KY0TC%:J>0KY_YI.9G<O%O52:;G\3)/;Y_?
ML\J3\67DFZ/R]]&'V671LEU^'Y\M+WY4ZJU$T4P6\.=;+3+NU*2X6I0_WC[X
MZ6M]\<U=U.7.8,'\S<-!F=5/L?@3MQ_Z^CW\C;>^]5[G;^W[C[UH<>G#=HGL
M2A;)]6UP\20;O#V*LE,3O"6>.[TC]XCC,)LG175T$K67<O1+_,#%8E0I!CZ*
ML+/1<7D5==)H1(\H.MAS;TT^*>FD'$4^V^"@9(DSS&J9K1VI+UW[]QRPY$K?
M<PGSZ,GH0<(,YH#<?R1D/A(O*2PVF\*=)<G0C\V>2(J]J+QOS'CMLS5V-W2S
M3INY)TB:7>O3V%Y:1VT:GW#/AI7#(0$)62I9]ZR5QJ:D+!>"<X %UA)I4!0%
MY011II5L&<__877\?YXM%FOVT=XL.^, &/28>_6$P[$5M.3<C2$(S '*Q7XD
MX:X*O#5%'$:H[L>H*55,*,DH%X"TU8H&"QPY(, \:DT->$S&W=>->T,9QQCK
ML?SS'AF71=F^B+*L^V7=[S[!2!I-, +'6%&E%4<@"-$D:(*0(,XIC"W:0/EK
MM:?=2#"R*!CEV_[FWV7E+TO,K/SMG,1;6\:Q6L8)[)FVW$<%T( 31@9BM0F4
M@O(80RNK>0WEKQL91P^8I-LU< <IRO;";?AN&>_**&6NSLN+<KH8_U;>N!%S
M?\[<[N_5M_O+>YD!^QK6MS> '0XI?_$;5:N1'FGZU^F\C+_]O^79Z%,QGBY&
MWTVB%E@NOA]%+7-1GE['NS@N%Z/BMV(\J>)^4<$;+:*V=S":ELM4#+ L_GAN
M(>(>%A??*.Z8UN6(@FOP#F.&I0,3A E*TS0^QRI*P+>Z^E4JEFUJ6+4>KV_W
M*\SFQW&WCN^V4I_]O^O%,A4"1<7_W?E)\4>?02WT%G>I[^=ZXA>D@,=@O$MH
MO<7G=X\"%,0=0)D&Q3''C'F7'BG,M1)*!D48972; 'U:1&81[VA\[1&D=MG$
MIWV&GW,8^C96O\_(S@3] /Y%C7^+ I(X>*D9@ "A%?*:&X2HI-JC+1-T-TXY
MW''/SLS0 \;Q+L%U?896-4(E#Q8, LVY!87C_RFKE12@L25!M1(?^F7H)R!T
M'8;&G<8'=Y^AL\G>-ME/B\7%*(F>T45Y]JE<9"N]"R6 X-I*I]AX8;@V!*5Y
M&E)J8,BZ8()3"*'P%!'CXB7^5BSC:XM_7,?UGZ<>'WKQ]VKKMF&>@\KV>6;_
M >)T;632AGE. 9#%EFE!@ NA#-%2^VBE(X=$:#7>[ .9G65*0J?F>,;? /"W
MSP0*O(:I!!8D:,4=AV"<LD@%*D1 P6*I]98(M*.<%ID)=&\ O$LX71N9HD8F
M\I@3I %AS$ 2*X$XB;QCG"/MVMFQ/1%H5XXMU6E[S)PNMETS]V\MVW9:5:+&
M U6Y7FX,W,S)&W.R:B"?>$C!9H^B$LV)EX)BIC0WC$A'<"MG]"1>X"*-VYY-
M:V=8F,VK7-+;':JP?@OU]_'"9V=1/LS+8E&Z<O7?/FU;@KL=2Y&I.5/S5JF9
M8J@K^J31@6&L9;!)=39:2BLQYYQYH5"K\7R/ -W<Q/W?<CX[*Q87:<\EP>2G
MUT#/&86931-8*:L3N0*2 A2F4AD@06EI@_(N1.TZ/F8M"[=?-NVH0(UW6[F1
MV73 .-XEN*X-4*@!RH!$+&I-)9% '5(2!V,M&"(BL>)6#Y!^V71#@+Y*-MU3
M8_>;,=VKY%N)__U83LOS\7(T^QBOLCJ,.;K;"76+6C)()KEV/@A/&'A%%;7*
MHD") "XU\4]Q@;U?[9N>GE6?>C];+.?E<CROIC"8U6:^G\3%])"2O5[&9Z?U
MYIG1,Z-O-_,KHK/V8''C-($0L+? -=864620M20^0DZ\'' ["PGG#.V,[TS?
M+2G <"T%L,->4M :N "/N,02,^8<(I2Q()\46^Z<OCM/!^UTEF.F[P'#>Y=0
MO#9N*6VXMY% 6AK,! 5LA,:>(R0%)YP)Z9Z4NM4Y>W>,VVYI/%OJV[74[?5\
M7DY//X^6M4]H5-R=I$Y'LF[0TFT7!,2&- ^UN C2& B"<X$-2!SM="*Q#5@J
MQJ)<>5*B2IC-R[CHVWVM7'VK2X@2Y%['WS82LX7:;I?,S/X#9O^MCOX9BG8@
MZG:V 2-/'*?657EIV#CE/75&<"I!J"?9]IW"O3/37O8XEWU G<\RJ#/5KX-]
M57<S!$T1JTP"GLHYD;8!/*9.<<6#;K?KWR;5=Q-9!]QM!7:F^E<L%78)_&O[
M\0'7>*?!6(T8"818L"F+AA-+"%9,8 CPHES?L2. ;K?A\^X[_(?C<NAQX2>S
M93$9S1YLG[I*#?B^R]!_UD0>E$R4-'+D04:K0PM!%2@1M"<:!Z55\/&U\*3>
M$G=I0K-Y)8 :@[5.9N^+**Z6O8X:XN@MSSI'UCEZTSEVNILZ0*V/$ ]2LV"\
M#@P8DIHPSC'&2*:I.DSVC_KNAN_0[1H:@VR^GH'_0L0_2(FPH58@4)U*;#QC
M2AO+I05CC.32$T+ ,:"(8[X5K:"CBEG6<3%[GD"SKY+CU0B(M46"JD4"Q\$A
MP8*UW(%25!EI/"6624,48:UBVEY4AFY$ I?;M1,&"?R]<#O8^UP-3Q[XG/,5
M'Q<5'->B H372"MBI(CZ K?&D/BVMXH:X05OE1O<(R6VD8V #P3B.=UP;^A]
MET"X-NR(NH.=LTXH",QI1\!PK[BS5&@/ H)@[4;.3X-=E]-R0;P5KR%;,*.K
M)^X;I-:\(3&RNLLJ6 7.^F"40,!4D ;)$*C@&!/'"'LV,78UMA74E@KCAZD;
M9UP_;ZV#A._:@.4U8"U3()RWDG *$:LI@]]0QAP/W)EV@YHG4VI7,T@!2!_)
M=@/#Y?[:K*OP>,MTC9N=3M5\-HF_\"E^>%G.R\6RTP;I.8[^H*20M?+MJ1*
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MH?:?9#DZ?6(BR7-9=IM#OX?%PH^:RM#PGRE-F!<D&!00:.-ED/'_A8K:M02
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M Q*P^NRV-/=],3X[G-I5O6DV<;.LS;(VR]KMR-H'Q[[<"5O"ZV;&WFE."$:
MTO\)21VR@&C\3H($;LUG'9*PK4NYJP'SMEF@'*]J=ED^3?"N-64&2+?-E#L=
M)K4;Z-UDUE26[EFZ9^F^CB;-:DV:,VDLU<%1&@! :^>M,?&S $Q2:+MUAR/<
M;XOY_4W=?&?^"LP/L"3=3@O)BO2K$+7[&RMZ7&7DN![ S6W4%[4QUGBP$K0-
M.IKI% '!5,BVRMAUL.BVC4+WX:*.IPAEW2X+G*S;9=VN.S$L:S$LD-7*<RW
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MK!..5G#0?1A]< +N=P(H;JK9:8D4U3E1GEB.<FX()4IQ@W3!'1-KZ<[/= *
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MF2 GF,E3!C@%. 4XM0.<D@@U+*I@W+&<*D\\MTPH7'B*E='2.4$9:RE. <H
MRKPZRH!W?H2"@XUYG(UA8&/ QD#YM1V47X-4$C!<0%M@]%LJ^/Y1%=V4(G&(
M^P(1J91AO&#2YE0B(;U5''GGZ>OOG]QF^&Y'Y==@C0&\:O"K=I)#KS!=8)7
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M;&>5LH$  HZ6K:RF>K5RCO9F^6?'3EK 4NVCI;H385]UL:6MI[ =VKRL"UP
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M<)D@ML!EC@/!)8A(3#3/';/:6Y+GENB\P/(QBT2;,78;'BL]D4*<"O!8 =
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MY.?[RB=:RI=E9H#,@,R S >+S \",T>LJ:2! \4EB$A,-,\=L]I;DN>6Z+S
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M'4G'9@^F8S\M[?IC6;D?II-+6V4;_2UZ=_9Z-H]6_O2'Z=782:D\YU19#E2
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M1-?+]_,X+;G?Y2X:;UU1^7V>A(,=>%[]+FSP75GD/1CKOH\OK^7^C.]@UO)
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M+;B/$NDFTET\CRH2F"6*2/(MD422;XET#X]T5\NW(R@^^>%OGR?CC_U>IXY
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M/]H9:X>_AIU>==FWWOBF(K!?;_*RR-!5&->D^ST2FOXI6,P09C]<7/Z?CQ"
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M\HR+ "_4"R0H9EPJ)XDP&H"EV-^=1)9==)H<JT&4*ARDY(HC3Z[ :*'LI5:
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MD]GNIH=HRUC$"U5_?:LU\G+0BW"DRFQPG=GBJL+:#,.C+*"VR+X[Z6?A#KT
ME.43WMCZ;)YKSNAKK.M50)MBN,T)FZ;3'T[*GCQ=S/&_PJ"] Q>Y=6G<D'YO
M722J&'HOA;4)[/?R\6).]S7'H)(R)65*RO3H\6+J[E6'"I,V':BCY//N<"]%
M\7_SWKCXJ#5/9C"\&PSST9KG?=<6W7>@IN]]?&DMW\_XTEJ^G_%]F+7\& RC
MSS8_:7U]=S;,UVS [?$VVKH;9T@TM$"1]=0B(RU!)+Q/A7248V6,\<(2O0G6
M"?$WLAX]T,S/>WB3UBD+CQ@0K9ZDV-O2L$-'WX0^AX\^&#0$B5I;3X&5 E%
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M!J!)G@6C";"5&D$LJ#5,1P(>H[%BEMJ D>MCX8/$V2OW%J;ONTHIFFNWMG]
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M$R/&*A]U/5GSJ^F:%[_7[U9)N_(XK'-6$>94^;N -5^K7%Z=S:\O$YL95MG
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MJ7+RT>:6K166PB-)<*++/W0+G*@\]A3UUL4YUF2L/-1*<DZ=AI1J)+5W0EK
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MY5$6)BO$[-WR)DY0>,SPV> R',U_M+CKA@^&JW>*8$4&=T=Q$V!\':2UND6
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M(.4][+5\F91VWZ?]E@\2U*BKJ^&XZ&23HX1SD<V>S,6AKW4*:?;#[K\JI"$
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MMU'+GZIN6M/76[GV@Z9T]=]1"KK]<5Y/5?6QO!+(4FEG&*<86^<H=U@QX+V
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M><M7^F68'C7%7[=_6EZ+"Y,VN9#W;,^@=7I,$(Q)89 SW $8KR4X$G@(3)D
M=BF>]9$](ZIR]V7;1F7_3(*?Y'YXQP[:W\(6PC!Z( 6[*6/H,\1MG_:8_4/2
MLU1R/J-H'M^K>0OG=ZMB-Y=089^/6-MT)6XV:>W<;$5]0&, S CG#,(:.,%2
MHG0^8Y8!<<$O-3AX9+/=6C,D)IMM-;ZYC.Q$:]K4"_!N,8<-"QI$(;'#\61U
MCH%CBCFLO9 <@Q.@J!(13:V7+%X^TL-:9AWVQ 9$,%8(0%A#N=):4V*)PSR0
M^TD"#29_;+DLV1KI#.7%1:KX/KR8$X?4YFV\(J^AKMF1?M>K"F+="TC,Z09W
MTPTP0B]+,,!H988!?2+FGXK&,PR:SUEX\<U:%?R0"6X>7\X4V%JFP$T#O+.J
M7]VOPZJK7$4]?-5:[DX.P2[-'5DVLVS.9?,D94(_7S1S5E[.RGOQ;,WJU!:W
MA6J+7W)BWAY VF9F@5?&NT<R]%J^Q3YCJELKK*V9H=8+XT$X@^[G4R5K3DOP
M?H>S\+D<EYU1][(*I#LOOY7]856?LB4SL>\'Z1Q.M\^A$834Y2DU0!!4@M.4
M +%&2FR=P($R(SP6*[PUR1#_:*?PQ_HE/!A(=Z.P>G#N:G7ULWC8Q@(B'NJ"
M]99"ZEXLXQGD#MG;G9W9%3RR.FO6.*&%#* HUA!2XYD4,2:T5M)*0O6F\/C/
M5L(C-!LMMH=^[^PYVGOJ?UKVX]>_OB^^EH.HC/WJ"'"W$6Q+)J6U4<6'&S5,
MQ$)!;H=33R=G#%6I]J14H+6E!N(UM7=F5]1X+M!_GXESU6%L49CGFT!S4<,$
M/]"()[/DM\&2,PBL 0*J;D)H0# K#:-*:"">:9R:I%LF@P.NZ5)OMVT1P%V#
M "</=%)]2R!P$,;@TYMB];,(O9;PGDP&\S[0AGW@IU4; 27U1L I8!DD Z<%
M8$M5Q'_,K.6.,VG#4AN0>SW7[F'\C6)^CH?YP;3<3Z+(C\@NMHAES7F)I.W6
M#+=1D$JFGP<..VRA"39"D6S&*SB/0<33)[)$ ?=4"NP]#UN G;934ZQV<SY]
M:[B3#9QO@]-^2G6!BI]FE/XO-S6#WA>#\D##&W*YA"8VG07+)Q!/%1$*!TR
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M _4@@PK,6%D%ON.PY,7<" IVX-,$V6S)X(P"&07>. J K,L"2VII_(?R" '
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M'L*\;2_W7>/W'>CK3.(.V1V.JR#DG>#!RKUQH5&[8H%[%"!@&SDHLCX518R
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M@Q55/5C587JHGB'A-,KJ^7 :M?5%[8L/KVCRJED\D*K**[<=46\[@6G,#/9
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M/!1\VR<86QNX5)TZ1KBQUDAC@@J J3),<T2QD10T<D'D_(Y]!J[L87[C\'3
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M>$<L TT'QX\1$XOI.9^_9WG,4AJ$_PPZK?CGBS&RIG_ &JB J]/M7$"+#="
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M*<!7*[V/EG@PRC[]M1Q)$H82=Y,63-N<V"Q(S2:CA&][>/3I#; )V39ALW+
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M:-DP@VV.;R]A8UV@D!5MT$HP82FT3%G*J-(*4B(UTE(@3^5RL9UMT8:7@.+
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M4<"AWR@$5HM%K9%]-Q;U(ROR(>GKVAJ*JZ-7Q""/C(*&F.#OQKPTZ2'!%DJ
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M+..Z: 03O%:-:K-X-6[4-A;O(ROF(>G?NAI'9KJH((^(Q\(PZP0-WQ%.&8.
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M?.Q9EX^2%2Y?$F:W&_Y8</UJ%(926R,ZW SZ=X7ZW@7D&<7_E! 2\:<=U;X
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M-@4-Q&KM<M!@PP%APY,(OX^EB]Z;N^QEU:\-B0T64XS"D%O@%00\=C7&@>4
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M*K(NRIU=I7_LR$&M,UK5.*B-D=YKC5_;2--*Q36P!#*)O/.>:L24Q91)SK0
M&A&VU*G^;2I>F[L*:M7LA@[O@:8=M=&=2:!2U&IK'-",: J44(9:"A77EEC#
MR5(6Y)N-[BM(]'I&=[D_06-T&Z/[P8WNRSH^$Y'R"C""0/"6*:06"HW"_[D
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M:_H83Q&,U57UVN?]7FO+QI0T>YV-+=U'55Q7^8*K6IV( M!QB&PPIK%/B=6
M $P5 -!C1&6-RE>/X82(UIHDV1C.;<KCB@."K[>2NSPI<UA6%.%*D9DF@ 2'
M5"&!J$% !9]50HV-UUJRY<V88FF6CUMNVQ-EG-=;RWY3Z6BLZQY8UVV<5MI[
MZTM1E0G,2'!CJ:3"<TJ8C/G 1NB@V @QK);R%5ZMM/48709DO6D++RS[01EE
M<7!6^:H_3+M)^N01\KTIFG)T)\&: E3K0>A,RI=ARDJ)&!7:482]"E\RW ##
MF4+@"=ZSR]3H$X+D*6P*3ATS(7H'[-Q#B&P*3FU&&&=2[K2#S$'.M=,@()Z0
MV@K +"/ >D.HVQSM:DHK.!&LJ4C:%)AZ?8&I0E*3+_WXP-G@+ID1VO7K%LT.
M>=<EF<H!=*<#Z%8#2!ZR099,AE$S?/S[2_@1?,DI?F#-F2:<&>D,Q00JQ05S
M5C$'.&++N0R+^+&#[15X@OFJ4RV3TCL+4%+;;!;^S_NM487QE&CI*:9( $<9
MQ]IA:9SW886LU& I)/^J-:HI"G^"A5P1Q]O^&I7E7NJ^[K364$GB%CN#[+F,
M30K?C!\>%@\O:K_-22P3<Q^+[GW/NH\GQ5@ZO59WU,[:TVA">*-_ER7#](\
M>\,8:(@GG-Y-K69.TRI(D<1"46@\Y1Y) HFT2#@;Z)-3XHG3"F?%@*[B>'8
M?@+ %6G0'QOZ2+6)$1BL%U0;9QRBBGH%$ 3!8%EBF0>$O'&-Z@$_+N$[0-^\
M]ITNT\(R(;0L%%&PI+_^1UI,=DZ]YT9#:YW7%'H6#(J2$'GNJ?$(H;!4?TY?
M2Z^@F*=3J#8ZA2H"2;F DJVBBY"?EG"W_.]F-4AGLK"_9VH0'O=;=A?$R';R
M5K>?CP;/%R'5ACL,E0N^F*/".BT-D@XQK8!"P(B9(J3$24B((E(X0 FG,I8+
MMDAAA:@STGX:Y_8&P5;#5]\'+M8PG1M85;8U*4XKQRSAV\Y]ON18+!9UG96N
M388/WS8J].DC^3JNDZ>=Q/1/3Y(OP_9I/?[-HD)N990!M!&F*T;YZ:]:G2,"
M8"%AKIOUK@,KR8?I,)D[W_#&L<XX[[OT[?Z6);=IU)ZD-7=*+?TVR J42!XZ
MP]MD85V3'XHW?@P\*/E'O],;=A^#O0GPW;\O9BD8K:!MK4Y1_3L9SU_@5<E=
MO]</H-.+NS1!9Z[[[<=D>!NF<I@.OF6Q,-_=8[??B?56AFEXB/ 4W])AEI><
M+)N9_).B!'!XW&ZXOG')#]=IGDU_WNIFZ??(S[+>OQ[OLA\#>[OM7'>&_4'X
MW4-_/)[[0;\]:@V35KAXIQWO4Y0)+'KN]8=A\&$ R7"0I<-B)@(_5S;Y(7Z\
MGDC\>+HJ=/IZ;7\GV3CKS?04C.8E>/OEB(O92WN]_JC7"M0XSD@D$7F4G" 2
M19W%$A*+S[YU^]=A)G^]C4N$PXR&>0U+^LO9Y>79Q7F8U'(BJ]?H)%PO-EZ+
M%^\'WRC/\KRX5'9STVFEK<?B!WEZDPT?X[K,2D:1QQKF/XN%'@OI#<./,ODM
M\*-H*3IW]VEG4"QIO$KQJ;*GB0KB%[G(J#LL2TQW\NFP3N)5XP.$=P?MY)^C
M=# ,LQ*^%B?FI)B9L:.0W@>Y^B,PJF&@,[LGGP2+0#X%J/P#SP"V DO !964
M>$4UMYYX@X.9EH M$H98J?^B2"2/%[_*!G?CW/(G>^E-:VU=/=['6N<5R2@J
M<<7#8'\OA*:VHEM$K&BYMW5O8E)5-,AD?S1(\MMTD$VJD0^K>8IO?4\'G?XH
M#TC4Z<78[UCJ"XF+14G30>NV>#'&S;OQ>:=BSO/H;4:RWPXSU<Y*2%H/<S:T
MN>\.-E=KCS )T]B/V/V]$_WS$HP*/0^/TK\?CD'H9;N4!O!/@UREUR?%<D:+
M]'G> $ULU-1"% 8B+%ZX<+0%:GJ)Y**X\X^EI7KED_1[A1A-'V*8CE:8RAAO
M_4'%SZ_"Y^/[G28!IB]:PWX$Z;5\IS+VOB@=RZ6.7R"F6Y0% A8&4OQ[.YA<
M_#[]EGV^#G;Y]\_I37C4G]+N0_J81V_O=C >Y7J//B[BG+[ML5=7<$YN!Q'A
M_BT'ACC.D9 (<,J(%51@(#TEADLE)*]EZIZH(ETTF8BR%>$\6L3IS*[E%S]7
M 'L[/!RV:,K;JX:BSRY^=N?)V;D)IOK<)I>_Z<LS>Z:^GKG+]4%OGT9T?G'E
M+DN*>'61F(MSZ\XOG8U_75Y\.;/J*KSP9^?JW)RI+\GE57CC%W=^=:##_6'4
M2T?M3C"@)Y7+O-AN8#*B.9RJP4U';W/3\49N^FYR#P(-XV,SF/T1C4H>P]6!
M1"Q9I\+T!*I:2$(1TX[L.NEE#T^Z?Q.'J#!B<V1ET8Q-J4]E5^<,Y+P15Y,[
M! M6/GOP#I)>?Y@\9L/%<<S;O+>&%=Z)X?@PD_%QXA""4>_T2GI;3%JOL/WK
M\9^3Y#YXM\&3"@:PG9P'1S6)'DC-;'=5(&3-@%OM\>$QW8[5 &(.1$'!;P+7
M[D7!2^(,%9*45YLVG7)"8V0\"?-^ET#P^;\/6&ZB!M8^L<- 4,IE[(7QU^\M
M!08[O,T#V,05:78V%S%[&_N8>7"=2Q_S+AW\G@V+$%B9!CWKO*[O3B8/ 94[
M=S&8$?W7TV0I?K[^AD11$^9R%"XV>.S?J+CATQD^CFN+#OO!W (9GF;\8'./
M\7*O-(^@5@A1JIFF%@(!'7" "6,\5IJAV5YIP"DI@8:"8RJ%%@(0(TWXH?>.
M.OWV7FGOA!0JR<O9C59XUE2_300Z><Q.*+NMY:_HM?;2U,QE?ZYJM[8\53.W
M>_'7>]&L#0+PMO9LD'UZ^@A'>0]"/TQ_MH][L[4[SWV I/"I\/)].B6W\PY>
M$^)V5?"L7THV5+BUKJ!$<WW@CO/X0",I<Y)R'DS6!H+2=+7\Z%TM-SL*\,XM
M+YNFEDU3RV616-6WLA&)+=7.:I#D6,3F2)!BQV[4?AXV+<L<K KP3--&KA\+
M0CF_J[,0_DG;WV/GO$ENVVPT:#:?ZKV[XQYRV8,W5#4XD,(%9;H9!&2F>X;F
MV%.KJ5">0BZ$],XAI!W&"#*&Y^+!KI3<B>!>/P;)G)/:IY/.\L'P[[^6*9P7
M@\ML\+W3RF;RS>;#R67FV>X3U2!KRO\?O!6N'^SVTJXT[6U7 !NC,\V[B29,
M.PZTI!PX*8P2F#)%D+-$TS<#FS@@8&.DU@9]^UGLH,&VIKC55EG>7F+CAA10
M5)6O&80&2H2,YIQ2BI73&E'/,'#",Z7KH(#_>RA(B0'=36_$!D,_#(;N(50V
M_' 5Z@7/MZI!PP@Q@A&/$:':46$0@]21@(::*N_JX(<'@WJ0LQ5'M#X:07S7
MM(X=JK[N]+]EO?^35V?>G@H7/I%X=A,3]<K,W">/OU51S$F^;SN^;L]G_L[D
M^X;'*,NRO#>U/5+V>E@$%:*93DL:* V)Q-@R2@,]Y48SR:C2WB-A[2JHG@IQ
M/&S8Z55RV+\II?# 0Y6"-"V\&R:ZKHH?*-G<>SXY4S0JO*MC;2]C":,""TV$
M]9)"J:#@'-0&4H<4=L2HUAY5#18=$!8U]&L_L&Q#^L6J:JW"(^8AYH2@\#GP
M@E(K+2#2( JTX372K\-QF"FJM7%UP[\^ N8U_&O'_$M4*.4LIP9@00&)K8R@
M M@SA:&BS$#&5L;S-N1?!X-28E7AI0/D7WM?QOZ=BQZ^7+CA,$_3_S:MI_7R
M"$_F"]X]=+K=H+R?[P?]NUAU8:;.15E^*AEDW^)9Y%B*L!TK5-UTADE^W^T,
M)X4WNK%D0U&XL/>M'P]GSX8_YTIG'&BQ@K->\DL1VRW+XI4S$0N*A.G(/L<R
MOYV;3BS?,!H6[<C#Q*3=Q[R3%W,]4SBP_5SE0/>+^_JS*Y?F_&?ULYNO%YA]
M3[NC6*SKF8J!,XNW5"]P4M_K-%%%;93),Q:_2[JQ5.4@::?#\%##Y"9(0[Q1
M>,#)X\7 ]6@2[8ZQZU%W.#Y-'R\?G\I;=9+DM_V'8J"Q &9X<S+,\?#RX:C]
MF-R%>\0B*//S=S_H% >]BT%E\8;Q5=9KW\<Z+?EI<E%5!4/H9*9*X<KZC>$!
MPF?WW;0H6'8_&N2C&+3_-NJFPWZ\3:QI&&:U* <S/W7QP7\[O3Q0>9V<O+L/
M'_?C3 3"_.UV+,.3@O/%Q!6=+F*EZK">G7AD/$Y%/-Z]>-B^U<]G"_BMS,2>
M5-592,&>K9PS\_>*/9(?3Y.%1U=!)+K)^(FG YE4T)\92[GZ@ZQS=QW6.988
M+,J>SK/:';,N!*HL.X6 DN%1K5:,.BX% D!;18TC H*%T/ROV2 >34B_9?V;
M@"FC,./59!4K,9C6EXCCGF=?)?E"F[.HL#[%&Q61.COW4R85BTX]Z_ M$:D_
M;:MT9;FZ\R+V[ &"@!,!OH,]Z_6BG?JO\)N(,' ")0$-)R(4/]\+&9)5[SQ.
M;;$#'^2'$HLDD=Q YQ2A6@M :Y2AV3C#^\@1V6,Y6BP8<S#U2,]*RW;3&>3#
MY7*_Z6*IX.<+("\8]HJW3*K"EL55HB(5-UU)CO:JOC!$L#KP$5M8>$Z<4912
MXJET$"!A!8\M+X!=ZE3YN@+#\'T*#--W+C!<?TWA7C85UJBF!4%]+ZQ&H,'J
M;6/U(M.;L,QGR.KH%=[QP4+[Y3-%TF)R4Y'B5/AN 6CO^X-)'><X+7D0Q6?<
M_-*3BG&"ZRPI4/Q?I3:O#!N4'#Y.S>J:D.M&*9IZD'74@SS<<MFP*9?=E,MN
MRF4WY;+K*Y>-WU8NFWRJMS9H905?6194<: !<-1[!ZEGP2L!6G E$2/>(\YF
MRH(BKYQBF(<O.DH1U=AB0P,5]1(0C)?:CQU,C//)LJ!E1'SMBK$O4Y&F5&A3
M*O3M'QW[S9I2H4=; +(I%=I(2E,JM"D5VA3X.SI8:TJ%-J5"FU*A#9(TI4*;
M4J%UEPI]/EGCO4]O[>/,O??1KKVLB;+9N2^">;773ZB@0BD"!*066$FYQL8Z
M)9B4V.ZH-&@5R%PX17%6G-"XG&P@?NFWBOL4OYQ\Y^LXT4+UVK;2I?&SOM>I
M#+*;&J/[68/E"&Q[_6"\AYC;%)A:"9^T2K3#@CL3@%-;9RBQ2@+.*!?$$^TU
M8V W!4@_'GPR<BH^?*FJ!B8;SMIPUC5!EU?G402AW"FD,->>8H^%M<1 #Q5B
MVG.RLE9!_;5,/Q[H0@YJ+>72L-:/#\=[B+H-:UT)H+("4&"U<P 98:&DU&NE
M;, ]1AC!@$'Z]F+0:]5/^'@ BL QT-;CK;#ZPA&[IJ;JAV31AT64*:QPGC,D
MK<%&,0FI=$)KI 6B@@#& 1-LIS55/R#<-]7!&D+<5 =[5UI+<55"6C#IH=;2
M<VDI,$AZ0"C&5#%L)=<K][*V5IWUX\$=I:?P(Q0::V"MX81'Q@EI5<+:"P0I
M( 8X:RA"3&.$(/"",&ZQ0&:GA5X_'DA*7&\$H"&%'P ]&U*X8U+(9_#.2F*]
MY\Z3 (-"A%>!&WI(+:2(N#I)X3'B'12X5B_X.*.:BP W/OE*5YZC_9"I[?LR
M'\W2?_1A']%0&^5NEOZ(E/M8-B:7CI \5S+DV;+'3?2HB1Z]Z$VQF=0[S9'B
MREH" *$,4F4@],8Z#(2&P+V]H>[VMQ(OLVZ8L6\_9[ULD':#,Z7:=YU>)Q^6
M5?/&#YV_ET,%:@VR-_&C)G[4Q(]>&S]BLMI4I!(YQBWQQFLJ*%426J8PMYAI
MJ<3*EH][=L)CSQ$/HF9?\5B1K6&&^X&,FS%##JLXNQ9&&X1\((B6<HND"1CI
MA21>&B/1RERS/3N4L><XB6#3#;P!T(8:OBLUY+B"/ NX1XS+X/_* 'E4>REB
M^02&F+&*RP,X1K'GD(=QK9!WG)N+^W)DXOG"QC-')_)2*$^2;Z58%K])YP2S
M.471,-NM,MN9C#FDC(84>&THI\! S8$U&FF&*2+4U]9T^/A"G__*PCC3_#9R
M)H$@^DM#;QMZV]#;]Z2WO&JVKBGW3%D@!>.4.B4=$I@IZ8G0'OC:,H6//@#:
MG*LX6GQK6.)^X..&+%'"JA*8A0IY:P!SCFJN)"5 6PR8CVUL],J:"OMYKF+/
MT1+"W916;'#T@'"TX8F[Y8D"5L@G&5,N4D)*),6(:VXD-EP[BJ0FJW."]O.$
MQ;XCGUS1 ?D B6(1#?UST;MK\GXMUY[K;U=C^ULD7Y6XNDEG\_@X<3G+ON*Q
M&WG1*7BF2:WZGXMS]_^=)%?_>ZGTU[/B2U?.^#/KOJH8!OVO-#Y/^*,55CLM
MPJC#&&/-9Z[7CK+<N1X-LWSQ@B<S5XL_^/6+^_GKF?W?>,6S7KN3%N_VBW:R
M*N^DGW]-6YV;,+PRF)N?)-D?L;=KC.J:H-+I0C/7UZ_&>/8AV^;L5\0/7Z?C
M#^-%)SUUBW?FJ]M/6NK.U/>QL;U\T++'9 8&\LTFX,7FA*N[Z]6777R;%6V7
MJW&$)7Z<=.XM<HCO^[$5:VSM&] J*;M^QVX]63[L]\+'Z6/YN[(?\[AO<MJZ
M[63?ISVO)U(Z;9T>YS% =%#>HFGP;,FD<,&R#6R8XB1-[L.#]]OQ(GGX4MP@
M> Q+D6\H<&Q1WL0.Y(UB@3!=(6^?_GKY^^-M^O![$M9AD-YGHX#<0;F"^7KK
M^-Y)GLXB-/5&L=ME=%\BP!7]*(J]GF$_K.?<-F@A!T\6S\I+>Q\P;=KA,C*(
MY.E)2WX8?_9C<C\:Y*,T_"3<]2$\^^TX(?XN#+43KEFT">\6(O4MFUSR_^3Q
MK\LK]3499JW;7EB_;X_)?3<=1DM=WCU>YEL_R&%LYSF&@HB#G5ZO_[W<K\J#
M!>\F=_W >D9!DH>#+!V62A)5Z#Y\J7A17*Z7C0;Q-H5:A.O%7N)A-*4&QNO^
M<EE,S.4OZC3Y6S9M;QYF[;[?RSM156[&7<D6NXM6JEOI6N=?XP;G-^$KQ2F!
M,(=Q0L(%1]UBG^XF6*'P02=?L5AA02- !"[3CYHZ78O1?5(L[[ XKA O?A^,
MV1^!RPRS[F/=[= GS/7?7Z2NI.HP2PCV3&!FH(O4%6H(%($(":<)TG:^?+=J
M3]K"_S*!NE]+I%L@JV>EF[X.01S/U:S8OD@7Q90NRA?*4RVSQ>2Z[*FVP!IK
M6X/(%M+I/*VR"6D0\D"SXW\K61ST'],@:$'DPH+ULN&L(2BVC4^3@P6_(!J]
MLO?Q!"PZ,_!U4JI/.[*^H#%!STI[-S&3[Z<E58\0QB23TBOLB*;*>JV-!9!3
M(+#BVL,Y+?FM'$-PGA:U)/\E#/.J/].I^'OX:##L16E?$>>"<5=@2SJTKLO%
MR2HENMNR$@78' _J),I ::O>31)HY>H#:1%W&GL#/:4":\:\M] X3T# 4#^1
MA/&J_?1LR8*]770L5I3!WOJB/Z31X+9BR==V4OQ=>P'1XE+O)T<S%=RQ=P0)
M0BRRU#(KE47.2*2QI91BO"A'OPZR^[33'@M.D*;"!U-Y<''SE<87OKL,T7V0
MH?MRWEZ0I6"N@P-7DL].#"%\#[@]MM93GS\M)OL%H;M.NVFO%=CN;9:-?STA
MIV.I+1XK$M.*R0??,?#"[YWPS)N:^?T/&ERF=_DH$&G=Z6?WG;>&!O;$5?VO
M?O#@DO\)CQ(# &K":0Z6JOGL>C!Q5-$*1_4?Q7B_C\>[Z()6*_PE^FXQ(I;'
M(&<GOXTN5'C,R':'CR?)@C"<1(,_ULJ30 9[HYL &,4MILF2@;CW\TX863J(
MVA*CW_EIN<42'>Q1H-@Q1%X\]!^1.1>1EZ"I_?L"C4=A$@?%&T\-(CQ#L!*#
MZ&R6/WP(Q"P\^GV,M\06DM$I#O.Y\/"E:[@3U^Y%"\-$M2G!-;0& ^<@H5!3
M(1TBGF#B'!)TL?3Q/T=A77[)AK?]]MD4_2XF$_#K=/PZ"Y"?58[@KZ, JF'"
MKL* \O*I5I@C$7S!N&MQV;K-VL'[O[A9?</E=[/L/#SEC,4JYUY/96&J<TN&
M*]BCXHW*=J&IZ?J,GL]'63)<?]HFU=T/V9E)?*)<,<,=$2+6" O20P25!F),
M(%8>RD5VLK;X/!$GV /9P.O*!I&G<G?B<1H#>N-D\ONQKB7#2MD*PA,#>-UL
MG#M^WO]>C+9$PX"?)\&K[L<P<YB6F%/^$&,1G:W1X)?EK&H>1Z")_>(\".XT
MI0 H&[PHJ:& P;%"FB^QX+$??=57K2 .@VRUJ"PRXG+OE$QR['8J:?_]]6\;
MQ:XXE:OX\[:C5Y?]4;#D_QTP/ESQ(2S?#^_F+8DJ2LE)>&D5 H!CJBQ0D@,.
M&8=>"8PH_0!RLG&?0,Y6E!_<MI_U8Q&A6>1[IXG*MQ*RN\SNA\6$E7P/@Y-D
MMJEZ;?<Y>9KW#;*[-)#WX+T-]\1>"]G8Z_VSUV]UW]_)]_M;5H1-OO7">X42
M3,^OQ5!%N0U6Z'8_Z$2Q\Q7C+-TBYA&@(/ZBBIJL<I)*]RM>+"L$([DK)*/8
M%6NU^J->L<L6-TK^&1S0X'06&RF#0=S73AYNL][B@Q27*MS)Y#HK8WO?TR!%
MU]WL9!PP[N0SQ^H"3QK?N8CP%+_X(7"B_,<R/%A*Z$FQ^1(OG_ZQ07SQ-+&C
M8N,S* H]B?><F\MXNRR/>2)9%@-4Q>YK&.1C_,GWM#LJOE5.9J?8%ZHFM2!N
M^2B/X:JL/5VMPK&N]IO*.YPF9^5\W70&^7 ZH^':DPWH0?3,!\.%"\T][,(*
M_I^Y2<OR'T\F>Y_7V;>T-_] =_W!<+JI6B7D7*=Y6)-VY^8F&V2]UO(&:WR
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MKCCP$!R83&S<0H*C=_"*?MS!5M;34B"K="U&G *(2@J$H!8K@2E!%B"!B&0
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M*=+G.$[SCK=[\-R5:0<K#1X*Y[PT5]S>3)B&U!$[&5"9]T"9O6U^:LP<,RR
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MGQZNLKQ5EG?1=_1)97D_+LM[!ZJG\3S5L[E5.K DY?;(+GF_/=#5T,,S91]
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M&IR,C.-QJZ6/^H/C84,' /Q@/@:V!$?+ >X!7W2>%.S>6F5J3DSQ(S[T1RN
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M>!1"K'D1)UEOGB"9#?3B\L]?SA9"SM3\Y8K/7]XC-ID+-T0R QW'B84K2('
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MY56&MPTEI6R0*&7EX'3RXF6-,O'6<<L.,?2,S< *LF91"@B(3S!(N#4_X<;
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M[>:PQ!!9PJ>/;IUR-,PL]2>Z((>^VD&QDJ-)FGUB_70X*C$NN9]^.JRJ$/O
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MO)I</9Z]%*X3A,$Q-YXB3ZMD^9+3K[?>4ZK&XL@>PM4(CENZFGUOEJ2_&5I
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MY%KR29*M:?9Y:%8#U:%"KJA5&6F&U=!?F"T34(//,+IQ@P)09'S$1QLC97A
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MD=EN=[)I[3D[,]Z:Z$",^/3JZK3=:C7D/WI$?/3O=NO>X,2C0PCMDS)#"*8
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M\\2JB;M$R"V&^K$G5&KO7V:7>K6'[[N\[16R7\[N'LP6[ ](C)&6&,62*"=
MLJHM?E(@,91 F3U,CNTE:%Z)G+G4895:SM1RYON2,T5H?GMD(FX'GLL@UNWN
M)5^@J.HX^4GW8M0Y&PW'YR?#?KLU'O7'W=[)^'30[0_.+]K[Q\DSG&>8O8Z=
M@UW'CL5H!L/VZ*3(C8C>PP@EB.L['R9@S;O&#?9A/C\^E0W7KZGA^MAJK58E
M1OL@Z+7B':D&\_W $,)Z :%UI.9J(."?%R<:]=IZB!&_.7 7H*.2W<S:+"8L
M9M O_!!7*$#9P;Y9F2$HM4!"W$Y$ /]*+-Q#8TR:GQ RD)_.Z#Y+/<U2 M-
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MT]/SR^'HY*33;HV&9]UV%>N)$*%F/)VB5,$3OTY0@D>SBMA#E)&GX!FDBAW
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M?,C/(@655%=S8Z4R+Q0W2&BO(8X+ BRY5Z)FT)#@>,,E@HQ)?/GLY#S3NRT
M<C@\+VKW92."<@H4M:L,LUZI&%%MNO:&854HAV:6(2K3 C;3WT@]8L:TCYXB
MJ;4 G/!IL G/C8ORRG)BONALQT<Z^YY;-T*NQ?[TM<V0'N27WLINT#:J?A)5
MOTZB^HZ3J)ZXHD>Z$F;89AI-2TJ,L",1#W$_L^<Z1M&*>2:H8L!*N%T.IW"P
M<\=#1-N<LV4F\TU)#XDR4Z T)R\TP9![PU9Y#X]F,QS0^X*Y2N1+N7$9K%+Q
M'E7B)X,\QK:U$C:S(1Z3P1MOZPBY/]JO>>%K5<RS]508OG%,CL3K4,PQ2(U.
M,JGE%BBUMM KH&49Z;/QF:2^FG7F>$ YDE)5,5%(82-49*0"MI?[ASRYN7GI
M:13=-UL#1J$+^BCH@(C3M#7G3XVAT?]C8@%\I:A$$YO;4SA()N.3FS)%D^,_
M8H>98")9I+;Z;#*SGF\EF:AZL]R&R#VVMK)ZE_ZY"?XSD;$/*\!=^+>=DV+C
ME$M--L[I>OID=5($ZG5;+#@OL,V*1H%-L>GSS%D9U8=\J#@T@.LLUBMT_,M$
ML!FEK#KMUH^:!/;P#6\TL;.C#.XTPKQ;;!JRQ "XQ!J@\DX9,,%ZH.Q$[):>
MF]FLFP2Y"7W4&?:L0G<\I3>=4<M\E 7(9G:CDM]F&7\Y+_2.6D!QCK<,ME)V
MJ?(NFTM$R<'V8K):FMY7\A<F5)<HF6*>F:*!EL;2]TQYRJK AU0FOMWSM72[
M4.B7I JF!*?D(3;9-%YL)S+8=3U4&\75,7(17'L[$;;FYZMZ&1B-=VLK<^%Z
M'GM"\'(?M%J*<$D$22\Q:;@)UFU1)I 4$D0M&T1G&(SM BH-??RYU;/WL'M7
MNKTKZ6.BVMH8TC/'3/6J]G226CJ';>2HQA\;/$=6A>63#?)A6MD'A3+,,HU0
M=!"3/M;-CX  T2<AG7'7(,!2^.FI%XH5JVU9)M0;-4<_DDY$C@R2F4591+O<
MK85Z*5TJW8[@7@^KB0-2'&P5RN0\=CR7YAS%K#CRCI;@'*W5AI>N-CQ PN=J
M5;*"O-_*R_&3WB/$^,/D]W>>XY8Y*<,O]E==7FOVZY5*;OZ$^U'MC%=+"J,%
M#5:C%QK#D"QA++*&ZZ,KS.,%/,C 85;C>;YUV4N,<HDU0/+[QF*J-/^L(BHU
MXYQ<-@T7+-DE%<IL#KQTN>2>SS$5]#?DTM(%057E\N 7;LQE,UQ'Q_5Y.;[5
M;K5D+?LJ]%!3E;Q/WXU">Z<66,\KL.XLM$K*EB'[Z&$'>X] H^K2^X199Y 7
M9NW1-F&F^Z7M0;KY*ZB34*UKRKA/E@SDEGIVNT95  /[>$L)4'!Q."U0(35-
M\"NZTC,W<2N:%/8Y5*CM6-$(Y@:JYDOO*_D6/(09I#(DE-JX&]G]Q[[93%"V
M3K^KZD7AN&.;+N)%RH6L,B3PE<=Z<#I+*N[6D7 SE&ZHR>W @43)]6F/H:<"
MIO2*S1E7+X8?^>WJ],.G8X8NED]I6\#WYCK;S4HF!CM=U%SLN=5NS:2.MS"I
M(VVYPLATS&\EX])?R(:;!A-->FLG&ST*3II#7M-2-;E]K7K=1\GX/LK*OVH
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MR"4*--@MP6'RHP1*E;&SLF!!3>>/!3J(V(O"V @4.39:']4I:(7RG@).679
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M7804LPD5J NJ3DDBEJO$^E V[=1SP*;S8D,OF]L+V\KKY19MNZ;U+=U^2\%
M6F&[SVFB.TM*%0[I)G*YQP**/1#RLJR1NNO*U#42*JKM"1LW,IG,EJ/ZC5*2
MY3-QMM_N[/%O]Y@N/#+T-O(7-/7:"D@V_"=#6!CXH;0:\04$(IPC)6<HCY3B
M <8WB%\H-]6::5/IHK+H'#B;8AEV*LHR#'CN,U#T\;#<&_3L)30!=8F NM%N
MDST*">K!#3#@-)U&*1L$64A< \6-\+):*BL&IZ.2+G:=\;@+4)2G('-4;$%O
MZD^&8<L=4F>JC [51M%LO1P-\Y7RK"=G2<BP=JSP%0/K+4H#(V,YZY"_DZ8
MI1/(X><>56I&E*ZK+!?= BOC/$1G)%N2!I87_9I>-$V72E;L,#?VL#/J@,N]
M 1<,$& KX&.DUXU0@7%M:Y]R)B*6#W#E0!1AT=*_Q"JS3N<K&S_\*<(J9M=N
M/;O<^"8*[Y(%V_8VM/CN;=RQ:TB:&SN7!R)_P %EO/PZH7-KU!,ESJU,0Z(
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M4\D9'RQBYU05F[TI<E&N\*F<DX!!]K@#WX?]!E4,Y=L'-!_CTD&+7!SEKE5
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M+](L *@0JH3/1"Z&V^"\CAWD^+<F1W_!8UFTC))W'C:B)?%%59]VX]C3$"A
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M"UQSQGP_Z@* =41G,Z*0H:.IY_L#T40JT1DE>#.W2PEQT!,67D$(A2M!X'4
M=]1D8 C<:"Z]CMYY4X+]BESC;?AZXD720[="0RS2Q)6C!D&N<\B0L0A'+'40
MD4[7)RJ/2$L(S/F#2(Q#<F&,,,8K:TX(/G/]G5#O$-XP5#EMG<"MAK:6^AJ?
M&@#$DRI,CCLJC<LV9"!@>X!\>%HTE:_$$Y^!0RVM'#4*!9QR>HE0.0 =:;#A
M<&QM(P:Y[:9EN0,;.U3KAX#YBA?(8-E,XXN"['$_4Y=7< HIS0;:O6&978N
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M_KQ]WN!7:IV.UZIQZ3%AEC4?,V+Z"5BL:0_]O".G:'<#A5@OOVIP-J'IF_8
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M\J<] ?G_^C]_'A?)^C__MXVZZT7VG_\#4$L#!!0    ( ).!5D\YUZ%_ZP,
M -LC   6    8FEI8BTR,#$Y.3,P>&5X,3 Q+FAT;>U:46_;-A!^3G[%55F&
M%J@LR4F36%8,M':P=6BR(O 0[)$23Q81BA0H.H[WZT?25N8D'H:B=I8F,F!;
MY)&\^X[?G4\RDS>CWX?C/[^>0:%+#E__^/3E\Q \/PBN#H9!,!J/X-?Q^1<X
M[(01C!41-=-,"L*#X.S" Z_0NHJ#8#:;=68'':DFP?@RL$L=!ES*&CM44V^P
MF]BNP>Y.4B"AYGLG>>/[,)+9M$2A(5-(-%*8UDQ,X(IB?0T1^/[=R*&LYHI-
M"@W=,.K!E537[(8T(S33' =GMP5+F4Z"1=,H"Y;:DE32.=1ZSO'4RZ70?DY*
MQN?QF)58PP7.X%*61/2=K&9_81R%E>Y;PRF[&20$!"G-W#I+(]K+<YIWH^-#
MTB5I>)02DF>]WN$1(2>1-T@"8MYN5O/1:.9,H%^@A1%'W7#_L;K$]JPSE(D"
M%=-K9J3*J+/=C=85W4[VGU94A%+C=C^56LLRCHZJV[[&6^T3SB8B=FY?51Q]
MLZEVAEN18B85L02*IX*BLK:8M98[!U'8B>Z#^0Z[,T,L5-]ON&O.%GI3R:E9
MXD(*_ZRLN)PCPH@IS+14AJ-EA:)V\#:&@F.^ >=[@W&!D$O.Y<Q&&*N!0#TM
M2Z+F('/01JI0$V.<JJ$B<Y)R!"U!&*38(*5+I#5@GILK=H/P&Q%3NTCTWD1F
M-XP;X"N0&X062APV\)C9?[%HK_I$2%42?N<5+2O+]%N+63NC,N1\*3WU0L^U
MZXID3?O;HWS&J"[B7M3I1F'OX/C#?C^5RI#3SXR_2%5CW%P\VAAKE8DQ3<$,
M,5:(4Z]K4X"F]D/=29=&+32='._WFT$/9='!/[(U"]R@TBPC?&G#@C.-N0V#
MJENH)6<4]D+WZJ<DNYXH:2+.0I(JWB.8=?&P?V]GNL;+JVY?;2^77NUR:<'U
M+-6[1=8H7T@7P_]5[/;YD="[QZ.-1\6:R+YL@N!!3KV_5Z]Z&Z1!GYL\$A>,
MFA#>Q(_8SWO14=A?X_*-A<"/Y>(MY/^/PN1I#I\D410:EF^!Y#^LHS=5+GB#
MGZ+NA_=&5\OG[?/Y+E_#6R;  K35EZU<UA+^7?SJ*?\"TO?)<_?Q%OC^V93+
MYN["ULPP+ @S5;)H*G?'\5=/[.WD\N,G3N6OD=L?IR9MV]OGDFEM[C,=OUL^
M;X7/!V'+YVWS>?5!$!!!X9P(,D'WI'.$-\AEY:Y;QK>,?RF,5Y5]L(OPBZTO
M!1$9MO1NZ?U"Z/VP0#G',D4%;Z6IOI4IP4TI[BC^KN7X=AZHM$7X,RQ:VBAH
MH^"YN/F)"IF6\L^)\H'[1_C1N8>G/6[Q^*#%_W7F8R<)[#F7P6[B#N ,_@90
M2P,$%     @ DX%63^ 7!0YY"   \S8  !8   !B:6EB+3(P,3DY,S!X97@S
M,3$N:'1M[5MM;]LV$/[<_@K.Q884L"._)&WFN 'BEZX&NF1(W77[2$N4180B
M59*RX_WZW5%2+,=.8Z]>VJ0)D,3BV]U1]]P]1\F=G_KGO='??PQ(9&-!_OC8
M?3_LD4K-\SZU>I[7'_7)N]'O[\G!?KU!1II*PRU7D@K/&YQ52"6R-FE[WFPV
MVY^U]I6>>*,+#Y<Z\(12ANT'-JB</.]@T\GS9YV(T0#^/^O\5*N1OO+3F$E+
M?,VH90%)#9<3\BE@YI(T2*UV/;*GDKGFD\B29KWQ*_FD]"6?TF*$Y5:PD\%5
MQ,?<=KSL$H1YN;3.6 5S8NQ<L#>54$E;"VG,Q;P]XC$SY(S-R(6*J3QV?8;_
MP]J->F*/4?& 3T\ZE$@:PUS3/7K=:S7[C=?-@_YAOW'0A9_6X5'_M-OOM[JO
MNI63CD?AU\TJ_A22!9>L%C$TH]UHUG]>%=?!EG6*<ADQS>V:&6,-XK"YD%J2
M[?KNU,*R*UNC@D]DVVUQ64CSRVJ]!8>XA 7);\I&W"==I2ZK!IRD9D#=\.9*
M[G*6B1XK$<#2^4TCK<9^8]F.+ZF<T"  3ZE9E>#*5V4;?' HIN_5B-[@8C1\
M.^R=CH;G9^3\+>F]&P[>DL%?@]['T?#/ 31![^ "X'7QX>/IV8B,SC<W]MO:
M]F'0<U:UZDVT;/1N0#Z<7G1/SP8?:N=_O1_\34Y[(^QIUNO-K[B#FV-A"YNR
ME895\COW(R;(GRJ5U!IEJL1GVO)P3FQ$;?O[U'L5VY:.!0/5A<CU>%.I5]RU
M2:A?7&\0Z,BJ, O";%!,GO' 1NV#([ 08YH-L#/_X+FA2\.GN)L^%;F?PNY4
MM@I]Q;8*%MIV/1.ZLWUL[-^(D)DUM^M^O)WR._55$M$I(YI-.9M!1H19AGQ.
MJ0;<BSFT)TI;HD+2Y6K")!E*?_]XC7GN'GG.7S9S:+?S[GX_>?1W[]'-!^31
M76K CY4D\9Q<2C43+)BP:N;8N3L'"FZE5, #83*%M:F<DU1:G3)0 9BA(XG@
M])3$<*4Y%22D/C1IHF)@#U9EXU8&2.8S8ZB>XY"87C*06UK30%L RH!(X=@E
MR, !/M? 3&&8A.F@2< TF8&U$3$I_EG,GS'-\D70@)@; 9P36>R,VP@,- GS
MG8*X;@*JJ0#,A#L$FS*>E[?A"<8_&HQ;CP'&C(1< E 0<PM@5 '#,!RZ=:F?
MRU!I0"A4D/#9%VD :X(2)114 ;@<4UT"V$'88S@08H'K'%+FAF@('8$K3:LX
M(A4P ,"L '%.G''Z^-1$)!1J9@JD:S;AQL)F6$*Q,=,;M*R6 &L*95:T?<+L
MCX;9@P>$V=&2@__RXJC9>'UL<E3F!1"F*A6&'"[WS$OG_4-"-7,X ]QP=!+
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MGUK?&%_]ZBUZ,+!]'$=&AUL?&:V-(EN8XU#-@;Y)VZ[M/ K]YV,E]V@S*,)
M=9%6,,N5H;C(, BF+:CO2DEXK1V%LM J;:[9IFN )>.86\O8%W+X6 &?Q?Z
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M/>MX^/VOD^<=]\6TDW\!4$L#!!0    ( ).!5D^W/%^RE @  . Y   6
M8FEI8BTR,#$Y.3,P>&5X,S$R+FAT;>U;;5/;2!+^G/R*6:=VBU39R"^P(<:A
MROAEXZL<I(CW<OMQ+(VL*48:[<S(QO?KKWLDV0(;L"M>@L%4 =:\=?>HG^ZG
M1W+KE^YE9_C7UQX)3"C(US_/OPPZI%1QG.^-CN-TAUWR>?CO+^3HL%HC0T4C
MS0V7$16.T[LHD5)@3-QTG.ET>CAM'$HU=H97#BYUY @I-3OTC%<Z>]O"IK.W
M;UH!HQ[\?]/ZI5(A7>DF(8L,<16CAGDDT3P:D^\>T]>D1BJ5^<B.C&>*CP-#
MZM7:1_)=JFL^H?D(PXU@9[V;@(^X:3GI)0AS,FFMD?1F1)N98)]*OHQ,Q:<A
M%[/FD(=,DPLV)5<RI-&I[=/\?ZQ9J\;F%!7W^.2L14E$0YBK>^?]XW:U76^W
MV[WCCR?5D_YQM][XT.\>]QO=[H=NZ:SE4/BUL_(_N63!(U8)&)K1K-6KORZ+
M:V'+*D5Y%##%S8H9(P7BL#F76I!M^Q[5PK ;4Z&"CZ.FW>*BD/K#:O7!(:YA
M0?*'- %WR;F4UV4-3E+1H*Y_=R5[.4U%CZ3P8.GLII%&[;!^VXZ'5(ZIYX&G
M5(R,<>6;H@TN.!133VI$IW<U'/0'G?9P<'E!+OND\WG0ZY/^X*)]T1FTOT 3
M]/:N %Y7W_YL7PS)\')]8W^N;=]Z'6M5HUI'RX:?>^1;^^J\?='[5KG\[Y?>
M7Z3=&6)/O5K]D3NX/A8VL"E=:5 F_V*^K]B,= ])A\9,"%DF+E.&^S-B FJ:
MSU/S970;.A(,5!<BT^-3J5JRUSJF;GZ]1J@CR\(,"#->/GG*/1,TCT[ 0HQJ
MQL/.[(-CA]X:/L'==*G(/!5VI[11\,NW53#?-*NIT*WM8^WP3HQ,K;E?]]/-
ME-^JMY* 3AA1;,+9%'(BS-+D[X0J0+Z807LLE2'2)^=<CEE$!I%[>+K"/'N/
M'.LOZSFTW7E[O_<>_>P]NKY#'GU.-?BQC$@X(]>1G KFC5DY=>S,G3T)MS*2
MP 1A,H6U:30C2614PD %X(:6)H+34Q+"E>)4$)^ZT*2(#($_&)F.6QH0,9=I
M3=4,AX3TFH'<PIH:VCQ0!D0*RR]!!@YPN0)N"L,BF Z:>$R1*5@;$)W@G\7\
M*5,L6P0-"+D6P#J1QTZY"<! '3/7*HCKQJ":],!,N$.P*:-9<1OV,'YM,&Z\
M!!@SXO,(@(*86P"C#!B&X="M"OT\\J4"A$(-"9]=D7BP)BA10$$9@,LQU<6
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M>H]TYUQR2_W>HXYE:A9W'W>R8LK=?P%02P,$%     @ DX%63Z0RP]*CO@
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M;;"N5%F8Z,PLCS%@'7V[$R10'VNY WG"S/TBJ_:G#%WE99$<3)'5$*NUN=:
M+1HT.=O:; SCLA7S  Z6(1M8A)V 7"^X$BAV=$C&NR%>XF&_U<($ T<L(]&
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MGB]/L&J7M/E.(%=\;%6TD,G !]%RVC/F(;SVLYX-CWL=DYQA>*<IX:%843F
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M+WRX\(G"9PI?+'R]<%WA.X4?%FXH_*)PR\;&QMZ-K8V3-D[=.&/C[ UH ]W
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MVM&W7VR74GNW50D@3NI34G99B#/^?D9:L<C9L=3:6BLMHSSA/DWC,[;%(K\
MREI2(7IC6G=)W49F1)_7MQUJZLZGU,$U3FSV%&NB/P,X1/*?J8%G'57=Y!+7
M<JIAD4DTDYA!A7//"WJYWD&UW!:1=YOS"YYNIJE[VX<5;]A:X)]T5SO4*QZF
MN#XY)J=LOPY*K;=9HCI]49S-U[] .]1XRSHGU.5/[FI1!BL6=[UWG<@7&2R^
MU#N$#)O(RD -3F3BU?7=N4QMOV*N$/40]Z'?J4%TWX'"\CVP9+SZ'0?VTNP/
M:JAF(^E8/XTNRGP/';2&PB08G[=%--LHJ=5-F&.F)UI<8TA^$8%OTZX4)MFT
M0_IE]X,5IX>Z4Y8W^M8G\SY=+;US!K+(OY45ZKQY3I$:'M<^WH[)$6A8R;(U
M"LP?BTL&_UVRJ^@R=W7T6J1BKJO[$[/$,@<O0MUDN:VZ0<(01A'IX/2D]J:?
M>6&H"(47.B,0V?;)O4E]T;E"$7BN\F+'=;'5D4;'X!KM!K_-YG'47S7E5AB[
M49D]MXKK#34-\8X1K[+N&'QX(2?R_BSRI[L6NB!4C\(.':T*41G#XG(:O1B
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MV"A^%?-L8=")HFP1_9N^TZ+' /@P )&LN I6_<P"'_)]A%_IQ?""F%P-1=\
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M!8+/ESN$:O[@ZQY)NG-(E8(\&".$K]8P *X, ">0!3I"OQGI\1M99$L:TF(
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M,QS9DS.@7S^!//O.U?7+"8_#8]#:ESM/4SS.!$5<E;N6" F;KTW?1I=#?S(
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M8331]RW^R,WM2+K./S RD8LF!NP_GJ?&N3( "3"R.1LMC;ES[+#>C_:PW^A
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MAE[36P6*=GKPNO>_)RT9X8S?_R0/Y;WU=-NO^[46)O4VL.ULOE>O9#G%%X?
M B/H9TC</1WVEX:W#S6Y3.R^3=O>/A/<*'^</5VJSCT0*)IQK"6]%&/]I*4\
MTL"W8?X5H;D>:N-<&@S9#+!]O[GJNJ42@34LJ$\O<ERK:+P]GY[#PD2CX)#
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M]*A(SQ\NH)^2',]6//LN[^C1<X81Q>;GO2VL&0H5Q'+FV7\[V]+C,$%HL'2
M^/\R3L +L^VH9-[E=&2A>T:^W:DZY:O^I7V? W:_?:^%)Z[\::/A>@"'E<&U
M6]2TI+SA$4N)P8VKEQV)#ZO"=DE;E;;L+YM*^7K-!=5YS9<%V>8>UA=Q"JX9
M>1!]M3P!% -E\I1HMLC1RF+A,\#8NY](U(84*HD>'-DL%%?Y0(B@@S+=0,F
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M8CEIK[W_/A>D*H%]'13W(Y8[T%MPPE_HA=L2V%OF\L9\V1X[59C+?]$\.$S
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MW55)M'URBQ'%P2G_NB'37J%=6*UP9?]3FQS:G YRL>S/W<;5-$QL3E;66)V
M-()/??@6%Z\?1]YR_7;G]W2W,25K$RN5.7?-'C?NBJZVTOOW"REHSC\_)A;O
M-E[K!,GO$##Q5]^MJUDW1!H@XAVB5K$:Q[>QQ51WEW2C#A#6]Z"#L;$,W3J
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ME:)ZP$QOP>C#PBTH^^DD;^;8ZNG/N5X#ET^K,(W*WKLZ?7J5][5 W,FME69
MNP260%2GUX/<>+&\:/]J:1UEN'":[Q,Y_HV["9,DLO4'D1S&@=>0'^I!F 16
MJUYY34!.YJJ$IQWOY,US5E7L>E#:4UI9R>_!^?2P5?0[7ZW8;G3 )I0)OJ@=
M43W1EJ8A5(?JRJ"5UC$K0 +C8%*R='5 Q&QY*)\FBS_(EOJL#J1< RM* M/
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MTS&;^=^3;AXLGD!Y[BZ9_SSW^X,T.2QE1:HC/D#+BRT0B4=),JL\[1/:YFL
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MIQ/TF^IT.MA\:Z.OD]5NHO&W6ETU:>U[S9W.](IH )%MNKMJ3IECYKAPPBU
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MNBZ!*1-< 1*9R;OA2SA.$5Y-%%#CB;JB2V >K0+OQV["D&FU:9&\A'A!L*^
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MM!(@6Z_@_OL0W;]>ZDGK3*4J/']NZN#'?UD]=2<XS?CC,"/KPTKS*@FSLC&
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M*H'FN??]R@"V03EUQ2LGT-1.=BQ;D)I)YD>YV(%>:26S#%WP $T@G>*"A<*
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MQ,3H&WWZ/ST!8<'K%7>]*%W.%9X4)U8RKQ\ Y]Q(@\BZ[ 6--<266>B&)SF
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M*TE*T)'Q#I(.I ]F&M"0:1+NV+"TH#S <ORGHFB,>*L/EFD%X]Q!_7?"?"6
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M<71DHS:>FPGK=!.](\C<K_VE1$.YZ:HXM)_^]5EB\'G.;EZ[&  "J2KQ-\2
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M:(5MED7%+E>0Y>_DL]O]H<=%XV05LQ!9SNA3SFS".->'U-.:K<=O2]C:8U_
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M72MX]BIY8&%Y,4 41<2 WLQQ"1960ED[J9IFN)N78>NJ</Y (AHE.#9**&K
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MR>7E'K%$KM]_+OY&*J&Y+B _UO,@B9W:8A&/F5+&PQF,/S9+C(<$^&ZZWD3
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M>6R$F*T(,;_?7_(.N0/&EAO;\<P56H*')2/@.BG%*YTWL6U1P;;K]A_)OW.
M]Y\YP& CL!S4VFA-]%;3^(CW&;Q)F[Y8@'@O_EGE%QSDZV+[+&8UR[8QU-M#
M:9\]F$/]E^?M_TUTU&\ K%8?&=GBO$XPL"@2J2-U].1UU35/<X:N(3=ESLM&
M<K@%_1+*,)MZSM)-B^GA':8=Q\(;F>,1\_%$AD)S7>L\+#67RLY ORH'1:"3
M0HJF->/QH9JG"ZBE_7?AU\U4<S.:A E=I1PAJR)^^4A )(DR3[P3/425R=+T
M+9)^?=2E?/*=_XKB3UZU-B03>B7][CT(,*]H=2I<MN/I7K\/G@_#?STR<EE5
MBRAJR;\MV*>ZA=H4/A]<L\:X8(]%$WZF=/Q@E\X":A%9:\=T1VUK)R,.%T0R
M7'6@L\(?97!M]^< 1+8O%#^?&1,/9&4I;'9TN"IZK6\N^K1A?!X2"[@Z2N9$
MR . 14I[P9<S)AP2E-BF<VV)H?&2O)0AV +"-GTK?6GRH-JSS MT'XQ>&7@'
M\SYIVB/,1.&FHK0'GI@+_2,FJ?AYZ[EOQPJ(+JCH7&ZR]C,RJCRD25Q+@V_'
MKD:]O30SA"#$[L:_G''OVA)/5'R![K\.G?Q-!-D )%/FC\,*^;3DO/V@ T45
M!@=#4M]N74TRR3D3W*:,5F"OS-Q9(NH)+7<SY&;()Y:\Q[VO"[;/XR0 =M?E
M/?(=VJ+GYK_J[-JEO7E\11E;Y\W<]SKXVFGL[(L%E-+Q(F68.)6S@))'+*#$
M5:BDK4MMNLYM7-2 &FE#BKD/1N\S@JX6<?F])?\\,OQC[RN:U/[+WQ]WQ9^C
M%O *U14-XO71A[/>G;8P'RL VFA>J,_MB@ ^>S7<)F>,9\NCT7UN<2QP(SPC
MYUD! W+OU_;[Q7CG^]3?B#4XOK?]\ZC)XU<2O0)!LF)*?^2#F.0YR4I3A>P]
MD/OBQ21 S?HCY.7%QXT\RG=B?V+9=)UM&N*5H)S_F+'] BL4%C+YDLYG"QV;
M#?<FS_9BO9!T//X[#=$?V4X?CY\9F=IM\,\+][9+Z_+X:#/P1TTN=[MZ*[0D
M?TFE FL)6,_N@[3YNS1I.88#+*>)E$Z^':N\/2HTO,3AG5WP+46Z">KG'VMG
MC,_KZ=[$[GV&;=]98E"VXRM%<M(*=&&;%RI['6K-Y>L?G=WQCEG\NW&+$^8^
M^?Z1S@)*^%F=;;=_V]\8AY5"W_!%#6;_L^L2XBG*T>]T'?[\D=47C_E99WX?
M& 'WS<VJ5Z-;"RQA1$*P=9H4KA7L(2 :J-%A+.#K3TW2E3,8]F4Q&-6%)RFI
M.",@+D1)3@<M%-FG+VJ7#W/(J;%,W9?%/C*TR6B0[MNA[+!'/%$\:37H#XME
M6(F'*D'Y%ZDQP9;7')U%-JM2+Y+WQ6*(ER7T9^C%;^#D)H*SN(;=_QM XZ\;
M4Z75P$J6FO3*D5:C]NK);6_:SKE[6TIO#"B/J*LJA;=*Q]A(97SLT4R28 Y!
M89F@7_'KX064,==Z;&!-+]Y6:>,)S2;51J_J=Y=5^4X=>@Q]*$%G-^+D0C1P
MI_GD[/>\KK70;,9YGQ_:]BD->@:V0L]>J2.*1ZR_>C3^8 %U4GKI-DU@07 *
M!-?""12E?W##2\_&.+W4Z7*UN^91^5^]BT==Y@8<GAC#>=]W?LC;WX7W6>,I
MQV@L/1WOO/PA<== _Z5U2EZ*UI$,(++2PD-K-PU3L9V35 P[99J]%&8UG0/N
M\#G15]F-$:61ALHM*@?G0*CGZ0/O4F!?I(L3,_5&2_S^_,0XVYK>^CIE1@GV
MKA8#5\_O@^M5AS1IX!XV/*MPG\Q1:(B!) E.WM:$I@]8*HEM=S0DGU=.Y6IC
M6BFPR@MRSHB:7D MAYF""YD;6JP.RJ;XB?ZS_!/X77K]>-=!'P_!D;4BFK\Z
M<1"[5$V"J V#.*OAW(%U$"/C5 \_N//TNX:TU]_7>*=OZ;$X\>A)34.6@Z!F
M9>6>&'UZ]AGX.1$?3ON9-DZ3">F/U9LZD>91F-9#6\%LZ1GXEMZ,[7M\.%P2
MES'A^+1F1^TOI@.3H[)IC*(HA!S^R;O(N\RA(Z=\-#Y6Y!-6(6TZM\AYG*@,
M:"-:TDZ2Z#0CJLWD#<%L+].HD5A.?DDI"CQ"Z3FB [,4T:AP:_NN"?RW9V-E
ME$2R0&L%<6_($W_$+N_0FC$.=;,#^$F[5HT;E_4XY14.Q^/2'$-L^%2,R/&E
M#E^RY-:QHN$@T\QC$27A<UL8)1+!B=((%_];QPQ_R<TO'>DYPX\(#0U;O+TN
MM]-]L;''ZDC6#Y>6PW&J9"6N!;U:*R(C%GF\5R;-H&Z$<3)<.L^ 2U#[*YVO
M-J+U4@+:"#;=5*,QHBZX2R9,*S#M;@PK@MG?=8I4Q$P7(0/O[<!.G9RY,V'?
M9,I)+"T\5DR2VSZ=O](8IJA_ADVEU= OQ1+I9%,0=T)N9:K25Y1*/Y]IDN.6
MC?9R0E37N';0R5_>_4J3,5;U]XTZ7PNBN(2V$?\6$Q-ZH3X^ZNW[[.=Z[_*N
M4O%4\6WA> ZQC6V@/J$<>"I?0"7/X5KS74,X,)&E%7)(2;YY4*@"U\K30>2D
M5MA&,@ TIQLI\JGD!901N KZ::R79ZC5'4X^U)TK;<-!//?N6 L0ER C]F%7
MCG"_5CZ!_=BPGGP9U)-:"@@]E7E7%/6=56PYG#UHT8B59^Z1&?8.BX?KYG*K
M'P+DEO:*UZ>ZOB*O*,EPQ9WV:WQ";<-6JZIE4VGQQ!9F6L%_P>S[X&:HE#XH
M1"- 74"MH%I%S(K@!/YOHI$@IX[D0>9R@-1D!%QX,9SY&KMDI,#T9\@W+[XR
MM@0XUWK&FEOTM;F)S=K+B^.3F[!7PW4^;FOY\@H@>A&(]"=)*=X/P:!7:G<E
M6R9L0Z, ]&!'23'H6M?I:$4,@A]!-%4H#Z(WD^F$-9QZY:GKD;>G&-Q-4L#[
M&7<C?.NLPCLX&@,7\05$(\0[!;X%:+ZJJ;Y@.0WIW59'8JVY&/ HTI24%0(\
M&2U+;6-W"W%4BA:I@=,"*JO  O+(!BVB*L)OMV7@$Z&=#PEH0,@?P/5.,\W>
M @22?N3MR6K96(C]P5?X8_?=*H,$A>%<YB"SSTVU%[X8IZ!(EX$H.*[46[G!
MC0L-M2Q]+YJ,I1 MASDW;^^KSR5L%->VOR61>E<>O!=^-B,6$SBY-OF ..K>
M;?L$>X"E8J;REA!,P%6=T2 18CTCF$/6.?<C?1Z,0D",=]J+D+  2OAF6FUL
MY;AG.<7E>E]0X$@G.;(^+N^;B)X+\>#6MC!*].*CUOE?UA^':!,1"I*$**L7
M2%,D8<TT(X]8&5%23AQO/V;*BBKTQCXC96V?(V=Q-R"HPDX_B4XQH]J([6 _
MF?!*/#F]T3:&4!&=H.#IJ4V\#>W:/7KPB16]K4RK2>I.]=>]O$%6O#"-2,%)
M]G[ 7J95X_@X:[7#JYF7T;*ZDB(X1D"T/$5UCI!\N.\0(#MO%I0R8$G3&W9A
M)$W,V$_L%7IT11G4;Y?<7>5#P4UT-,BP!D#!IV8)/?V\%2Z0"WFDTS,;;>+*
M^P4(P?"^C@YQ?)V0SG?73!]UZ]$;?>2&YB'-_N3QB3"_6F%>[%=X>B9AF=I6
M^3:OI<JU%8L&-\GM<5E'C,6-NLK]TD,BA\F#;=05(H>9UR$X?H'M9IW1(/_\
M:'FTD4<HQ5ZWUO*7SRDLW]9+A*/PIBK0#;XX[P<LH%21W=P-L$+AD71^ZA)W
M$<PO 6[(#T"U4PQ0ATV1&N-I@ZY,PS'"6HB1BK>-K@(26GNLS4@K87<GS1:?
M.%\NU)L=FAS<X^B:3VCCWZV?\(R9]P6_@K<6V$'2-N]%F[$UO)29_)B_T.B<
MJ 74E=-44[6GYC[5.KS !':6C0PAUC6%YB9V)*-@[GP3UU:9.DN?05 \&N_+
MQ SC"L=ZI^2)V\:D*>1%W!7J):+871B9'I^G#R]I/\S-/-A[9[<X%Z.A^=4C
MQC!X@A;P)"$_]#"G^M&!\<UAW>PIZ];F'>,/?C-]5&R#4>2-"Z$-JIOB&@>L
MHHQ/-%1_)VK<ED@H*1P9L+NJDK]HULK&3R0\F:B*CEJ7>Y[YG?AAU;LG@=DE
M[[.KWK-OQ"Z.V:@WY#'!5 ZI,N&="E[V$:?.6E)FCV5<L\9,MN+I/!%P?<;5
MA1[R()P\R^5A22A%Z>P&:Q0AWORYAV4RFLDHY^T;KNFK&GVAF=JUVPZ:$*8X
M,9+]![8K6\OD^ICHOI+U2:39N]3E[]"O8J;(NR3:7Z75L:4-T"?!,H@LFQY8
M#_NQABW1?*0DD@'JZX,]C4XE@&_@)-XV*N)^Y/Y)E:QQ0VQ<0H(LN&H_Y;70
MD(S\PN-<$M]/='W4&.[6!4/GSZKWP7G0!ME23;'6ZDVD94?^/'XT1NT)5T %
MXOD5MG ;%"_UZ*IA8($?^'X]!1V[,*U'K,4S&ZGK0$*768#H%!L?.#B&,QB;
M]98AYF:4A.[O[@!XS=;FRB]??D&:0J!WCTCM)\.M'G'FF*6K7:OZ!;1B2A"A
M1#^8/,+)N2DKXCQNN"RQ3U^ONS[[RL]-]] OI*MA,U5ZM0;I,7]DZ\-3J@JX
MES7*-*T19@U\!7<.3J7=YET^STR[#M!EDS?NJ?>(&IUDP2$'91T5<GW2TA'G
M =L&:%^>7E!R@-(Y93IQZ]3!)_4]6W!;R#F:G[@;P3.B\XP^NIR<0<##B$FN
M$D[$*@_*Z4G<=>IOE-/6BQM%CHE;T;KJ6)A>"O-EH4!"D]9"B4NM(F#>@)M?
M.1JZ^7*ZU&ZRL2^^I53FE![0XEU(J9S[5 %O:[XMS "_55@%\"6^A7*F;FD#
M-F5FOF%C:3>(+]A072=6[^;X*'0<KH]M][]0QTE/9]0T1:\^=^+[Y4IA*O%Q
MP'@_1&R1E&5I5X-FD-[EQD.5I;6&';RB\+,>]YLBY#Z!L5*CD;F0]^UOV@M'
MXB=KKHUR.G(*\UU]NF;T$X(K7P=^J*T+O^2 Y-7,Q+SGP.P'B RV9LOZU#Z#
M)'H0FJ]Q;J$N90A<R'R<T;#ET-5)[GI@4E\_A.3V5.G_2"XT@.G\[4%VF96C
MG<,NOO6#^5M5<Y(%U'>\[NGV!=1+G!EX7E.&]X%TM,N$E$%#DGRV19@N-4>,
MU0'"9G4X5/;L-3O)6@\Q?PDA^H.S_#MC['1.7!;5>43B\4RJC^!(SLQ6[RP#
M%'PM+65FRCB22X0XL)TK8P5 $W MNXB'";;@-LBY%:T[AD43U@,7V@54PU[!
MM1Y'*_=)137/,E;SL.*D70+FCFO5S^3 UX<W7I7I..XYCK8X'[U,Q#M&ZS?;
M!R>4@IO$!!2XHQ9.1.J&M=TK_!;'"#NQVO7!VY'XT_2+L;+>)YS;L_R1BT7A
M<Z>SXTZP0OI&9H-\BEVB!,5U1YN?66T8SU8Z_P +YIW4%G#F0_B*6'!DO=+L
M<DVI\DA]A&Q>NCR381X11:#+QX*%:')_1/6(2UV./ KGWSG3L$\T7>G>4Z/9
M,SV!\Q$7B%Z@610S?@$&T=[D:4-,,W?5JVF& 1S*YYS(S;P').P6GZI)7+6O
M<[IO92])-)UO[YLFX?N*'T2QK@Z(7G0,8"A Z('";..]V??_7S_T_'^Y+?3_
M'5!+ P04    " "3@59/M]G@6V>$  #LC0  #P   &-O<W1O9G-A;&5S+FIP
M9^R[>5136=CN&41%1(R #((0E4G&E#(IQ$2E !$!0049HU+()* "1820*/,@
MI!R *A"B3 $Q1(6 ,B1" I12R!P$A$Q:3 (Y"N$49.C4[5ZW^WY]N[]>?5?W
M6KU6A[7_.)R=<_:[][O?Y_?L!=)/4@YDSUEG5V>(G!P$(B?[@4BG((ZRJ_^Q
MS[\/^1]]AIST'41EAYRAW EYN4.0+2IR\BIR4B8$)AOGMO^Y ^1_^<AMD=^Z
M;;O"#L6=2K(.U#V0+7+R\ENVRF_;MG6K[&Z*[#YDJ\HVU8-'3FU7\[JJ<.C6
MWJ/W'CS;H7_Z5:>Z]Y# P.K:[53%G1J:6ONT#8V,#YN86MO8VAT[;N_XLY.S
MRQG7LQ<N7O+QO>SG'_)+Z/6P\(C(N/B$7Q,Q=Y+2TC,RL[)S<A\^>EQ85/S[
M'R45E575-:3:NN>O&YNHS2UOWK9V,9C=/;U_OO\P/#(ZQAK_-#')Y?&_?/U[
M=FY^ ?C^8W5-N [^L_%O7'(0^?\:^G\W+A597%NV;I7?JO!O7');$O_MH+)U
MV\$CVU5/>2E<O:5VZ.B]'7M//WCVJE-1W\I;H'[M]M!.#0-KKB'P;VC_);+_
M:X&E_M^*[+\&]K_&-0G9)2\G6SQY%0@*(I$<KLB%_#_9?L#ST2IX[GF1'D@&
M B,4F##!"XD.Y@</*MS3(>FW'Q<=#-X[)O(4/[2!OF:GI"^@)]#7-(G7VC9-
MB .;-KW%7^@,O *=4R'9P<+MGQ Y@=V\E8GO42@5?]T+#%O4:V,F/5L*:=XV
M7?#H*<;-"< SZZ406 #&F-.<5X>Q[>7V_,$C*@5ABGU+W3N&K-N4\:YO60FZ
M1GS?H1L)\#:<I0CQ&GPKJ.>AN\AN7JW#UE)(#AXJBA!(-B^]RMVW$C^%TL:$
M713TLYZ%*?=N(%I\SD<^#)SJ1BW_4F+@BCL]]H/.I$RH251_E^Q;0.^6F&%*
M.5+(?8D>U@P(>_>^W9=+WP5:!>%5L*; &N'>DLBW:GINQF#$<G41IN)8A[47
M$+/;#_*2T582E8XHSQ*')7UFR>YGM>&^!_3H',])?2Z<*85H8&8[Z5"1:P)O
MZ0*7:;]_!DX?%-GQ\E:4(E9XL8J8"[TS.DV-0)6]%<8M:+3]%(>@ Z*[2RR+
MGT;9EU?78?"7F\8LR,'#/Q?2#@I0(O4P#CVW:25+SW(<H0ZX<*40!EL/:R)^
MBC2>B9PQ!V.!XXBK7#?XQ"9OY2Y2"U.^>!F\4PUNET*"T?*.5_EW$!$4[#DQ
M.QU[L')N76-CC/>YH2)^H!$)D0P@H>(R:[0F)JI3TS\-$\<,/B1H>%43D?C5
M$*D[@MTGB.+:=;K+GV[IV-:P=BQ:9"?(^[FM1 KQ2J2_I=$Z5.T>O[SWP_:>
M%+)U5;#\X!FFKZL1>QZP?,;M#^-0EGP%\ET:9.[2SDDII).]FQZ)EBU.;ROU
MQ<9]*SN10>M JLV2AH3-V"!_+7^R442HG?)?9*W[%_P^V5PAM]I<N.DE4F%)
M3.B=2\;=+;X2RZ#(V:Z7,U.8"SU',;O7>YJ#U?00=,'V/X SX3 !.<$SVQ^?
MV@(^ET+>M2;F+F,OA#T[=2<%691WM=:"DB>Z*GZ&"F=#<,/!NT$4US,=M0WK
MQH'N$]F"Q4 PHZ=DO8>HAXGK^75&"X0G"O+<P0S29XR..ZC)BU9>VVR30O**
M8((,!K1@RF-T*3[YK4W?TI;D6HOQ(C!$%C\?=!*T"=-0>O'9(N-D',+S.=;I
M\AH\#:5(06"(JHA3G'2!+;W>$7C^@U&,5S-OAR?&Q(I.A7!/V/F\>C.<L(3V
M?M4,6)=O*X)M[5PS+J#MF$?:@Y4<=JZO_TQE")[#3L?K2%3](WYM%C[T"XZ@
MZU!1Z4GE]?6>UG1ZP>;/^/22&_[Q*OC*0",R=AQMK3$J]P//@((FT&^S?&(Z
M;B?X!V5!<D" J^81%' #P?IO!'$8!5XFM;:O%C=<$@%3ENTER/MHCED4)<_?
M+EN$#FL Y1DT2Q!?LVBOU\:;5EUT2KULXWKE%?XBJIG^;6(WB7_"S@M,,\J
MWFTBP!;U#@#0;-%!/@&*,7S$M=\.DFO"]1 LA$T89T 3\XA[GQ9*8$*5,)Z!
MK'8GKKOWP*5A:M!173<G5G2\%&(]A+]"5P@?1V^+"0'&<XRED P+P8C0'8RJ
M=K+\HS*==0/_"UL5T\@LUQY=VR4O3![8^QELP"34DH\HYUZ><B6IZ)_ B,=%
MJF["^-$U5#YK@TS(,A(0>MSM^%C54Z&".,Y8,;-?[8+X*75Q11VS_'V1'R]1
MIH/W>/T.;H!&W?,@T.[4>(..9\OPF@-="<.E'0#]3Z!<7D$V?W#Q/2M9;,TF
MNDID\)Z.<7*-(/.Y-5H#3.ZA*0%$1JPVQM?[D<N(R"DBEH>6QYX>1%CQEI03
MX-"%UIBVJH':N<& R%:GM0X)T>8O\Z\(/WHL=.+YS/#??&\ E6_M4(MP$HPP
M;"<5LFG*V%#!2AZUS)%O6]DP)X4H+B..<Z9CW]GJF0$:!  :(&"U/0,O! PU
M1?5;76 U3>6;6*J"W5N+\&'X"9TN- 0A!RAU:1L.9*YV^/)PE8FU()&)WR%1
MQ]J)B44S88(Q>H;U8KZ""QA0,3\?]CPB*>7M:'3"4H@7L+UQ>UMBPJVK=TCA
M0Q'!L&%:!.@J2^PW H4NBNH<#4[@;1N30K+C.P*$=^BT]B':/JRM "XR=-NT
M!>MYL;*EK\?TMQM63\R E-Y@$Y@:]9CDD.@DL$U8^0*3YM68=6&$,WBEW-T$
M<L*,[R+:B^? &:BTR17F@%)0%'$/M0V>*3$#\VHP>N.==-75Y$TWM")(]P83
M:B]CS[<CY4:_@+"C(J=!T2G./FBW.XJ1J()A,' &@ZK#T2Z,#:9&<"6P+GSV
MB&/7[3DAA71I4^Y-70;Q0-@%X%<B(,]#!!]R4Q/@!CQ82%T,O'/&< SK8/3@
M9BL[0^0$&/.RTD0Z/-W J*2CH-&)R &F[Q![;G"A,8*VC0\#C;?G\93->,A[
M3[$W@/&T)D)^:UBWIS+V>M-(^PFN\CEPH*L<"6X"><),P?(?(7'U?I_=N-$N
MG<C#()=/5PY8M(_JAV>W:]:[A]9.3"ZR-E#9J[&-M(-8%0%>)ABJ\R6]^0?M
M/V;%"OIX*UWDV"[-6_KA,X:"WAX'0M9W3(&RQT7,RI[N6(Y9LD,\]>&)H85B
M[\8JH?#U884^FK(4DGH/LWW=+8^)5B5;#V39&[064;A-+UO> KWY[2'&N41A
M$T#Z5L:)MIUBS.B",<+U9HD]D)CQS?N=W\*/Q5^U)6\U[B'3+-)5, 4_AF/Q
M,?2)4L\A['%*$,@.RAUA:B"/C%%DDPS/O;V(DQO"Z6(:\%NP)\<E/X%)L&WO
M&[":@O5[HHCH!"Y>(XJN+JLD.^;]]1I#:Z>"IRLB2NZSRG4% Q+%%BXJ*U@#
M#.*^Q\%%CD!^+\/"D?MW1;D!X$[(6D:X\-H&LNC4ZQV;EZ;08/GRQ\EAAPYT
M(*#19I>UMG16*=RP[;4+*]WM^>?^P%DF&C3T[*1DT\R*>^Q[JI\N:O=0>=#[
MWS%%L3"L%G@*N&W2K@.4\NVR:;8+]M ,<XD1&,><C$U#.'+I*F ]>K@)O>_R
MIT@E/%=\33C0':PSOFS1I$3>(3]/F$P65J,:8]YN(KOC.&]$GEQX'DKS1KL<
M(-]MS$QSDI4F+\Z2RYG63&B.!:DYOZZ7EV+?VS,NV3E(G;:A0J$UQ=Q^O ^
M%U9W81*:RMS^LD:!AXWO#?1X3H9P9_,1=@E<X@[1'@#>N;(5BP2"LXQSD =
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M%@@UOE^[/K]#TQ-,"Q573.ZFE1\:7"-F^M>'JSKQ4\R85@O:QIF6\13=SII
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MC3^+N%M-:R&HLB5C7AB#'.():.:BPHB35LP-RK='+Z+PKP=2D7!,T::0.(;
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MS<OSC:/)Y4D?E;>7AT^I_=GI>M'/[7!.V5TOHZ_?WT/?WGH#N1*..R(@YLB
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MSE+IJDA8H\--<)\0K8(NCR&AFVIYH(E'WKB,!B*XH4^G\W6XL]@/?1Q6 ZH
M:#DI+5^PB8]I !U2SX'8E^O.@R@6Z-[+QE#8<:DT 5H[=*FLB%:L.\<Z1N+;
M2>]B4OB (XANPT"'JSA;X$H)M#86D-5N6GUWZ9/]PW#9/UD'X]*O*97=2JL>
MN'1.>;^FZGT44M:MR>MZX@@J\\_G%W+OFMMDVR_P5%LE2WN[3?_IO= :FMW?
M?/IYT34N=6M5\*3+;J;K+X-[LE==I"F?>R2^MO$R[ YYJ>UO.;G,RJF'G0-_
M(Z->*_G"^U"KJD;2)O8;*@)7GZ"V$+MY<-0N_&%[""EH]>-:DSN,:,Y/"$:
M5RMXF/\U!5S%T6M*CR&MQY]K0UFSBG".2()#E2._-8I3M!4P][:\6K2^L=><
MURI/YGK HG2%.5T":UR&3<1\\366<]/'2;:OY]T4/B\-JS1OJN.2[#<]?#2[
M&H]S[MM]6N7='[5]W[8UU=63XUM^>0$.AHL71E[<HV)[+1*0V+Z+#85:;G4#
M]85.HV;S4F?,\XSOKT7#;O>^FU:?"<X(\5_5>.SCG9JVI[CQFGNG*@27[SVU
MW69VZC73L&K':Z^(.TZE6QX\+:B-K8TX'\V/LFTR..#1=F'C[H!C#D4GV&<?
M>S\X$_WBBYZG\3;]UR;W2ZM[6S]ZRS3H<-)[+:=EV$OE")D5-A?;%/QM&NSL
M8!D2%:"?HHM03'P)U+R-RFY"Z##V@#I_]4I,:.PSXXB<]].^\#E=((D[MA%4
M2"&< PJ<!PG7]#_@4/J]"[PTJT;47BAI/'R#9$-"]11Q2[-T+20&ASO'42G%
MN#S9)B:X*>YKP_9L@]84:5GR7:%A8=1CW='O$S>W'FKDFJ:M6GOZX\L_)'7+
M,/AZ0"C5Y&E$=DNR?*TVI;Q:AAT9#TJ<'$A<. UON N0-2Y I\Y=^=9X*LO4
MT?7/)S4;G<+<:2C':M^!Z:XKKRQBUQ<6>'M%?/U)5<<?)H,+>]_R#J3"#9S,
M:>[)S^XM5>^I6G>R_!< ^=93S8UU?5P:XLV+R%V!YM)D$@ZK(>O/GG#FI:'7
MQ"#)5'6"E3@4BI?/LGHT)G5L*[#(P:["1TPH7+=5!<3CY.3Y^7Z4:5ASS @$
M/_A^]S?S4'.,"JG]0'!D&23F+#'EIEX1R?DE-/HZ#_^(%#W,/ (%FU*O2X)I
M;&"5DS3?UD, )U/7H_;C,=PQ/6@$)(U;<7CKPIKZ9-TB4?-DFCDV4;;F!72M
M&+ICNX\69@)$M><W99/;@P:96O@C>)N38#3"7[[X.P@'Y*/4P@DXM@R[23DZ
M\Z?\FQ+X4/W8W,U91_F0:@/CLT +QV[?,LS(,/O]I(+,+N[R-9$%3]ZSQ2ST
ME M:8O)&PIHQZ082*":R+3PR==ZM=TCV<!\6N73]IT07D4C4ET3TY8E20'_L
MRF@;N(9LD+=>$BY0M6KG:=@>'(=K0)CQ2Q0^[Z,?&ZLD4:PB1/4R[*K#]N#;
MB#OQW?S FSA0F8U>UT R>!,4--%EK=]Z5/3&'C1L0.3*VI9AM20.*PFA^91.
MP/"QF7=)\&C2QVY'R(<4(78DN$+GP$R?'@*V&**Q\\M3Y.GZXR/A2]_NM&J)
M J!G9PG7HJ=+K 3I#-NE^B5TV_-YS+J0V?&YX_" 91@Y XJE0@W,+>/C\NSA
M4'+9X02IQUINX^$;_G.A1<L76IS5\9M4:'[Z;X=^C6$*1&:<D;-GJ#SD [%?
MEF%N@:2D;PA06V+;)]MK[;L,ZU\;/LA;6#'YB_J0!63CXV77\[UE,#\2V"Q@
M;IF*,Z4EVMI'XLI"!W]VGE6).AR\^@J7V -[;<W5=574=5=3-%"LCA]'<D>0
M.4R= 0;F#']6J&9?AOL9@@Q-2,"1=O?:TT*';[QP##^7KKFW.9%C%&2F9WEQ
M[K1".&@E.X+6(@TE+L.FCV\ -ODD=@1]#%8_75-?J.*%,'E[QC?W]G8^\O'
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M#<3ANC[S.9NWXC799=3"IBZQ!>/$M0*KB[PO3[Z/M#9.[O\4V3_$1:BP/A,
MGC3A$VEZS6A""[89CZEVN&?%$K5&2 ^]X:QWLR>6_Y\EMBM/!^_7G7X013G>
MVV,/(_[Q[_4<5]%-0L1&R?XXN?8T]3PWP$@P#.?>YW1HYT5G*\GZ)-DZ3_WZ
M#-IO*'#\LVNW)H$JAX)/*W8C-V4HGMAD<GW*1W_76_@9<>PT%YXYALCY&#&9
M);'N^5AT3;B@H!+3K5'A9L?^="SSNOX;GY5KS[8=/(N9*M)I,-Q9_KD7>X(;
M-NP<EN#S2R%'D;FZ^E8XH]NL)VP9EHXJQ'3J1PQ;^;Z0EL<LPVX8LXEJS^IZ
M" =(CS],#PNSJPE6X#FN^ZE#36\$E!7X<W[O36U-)N!KP_8<:PXOU4-G?!V\
MV,4L$YB&33C7]UFHJHT5E8D/21R JV6/\7Z=6#6"IFP_"\AC(]7QWH< 3(Y%
MJQ^FA^$ Q@IR<@%J.P).W#';3$L-SSW6?WZP(30&(F#Y!08.1T%DBL1T(K,;
M/N44[6(9'MMCP?KXFA<(58:#-B? ;LZTH'>"[ E,WA":S8]ZMP?J@%_N%E?,
M6&.RYLT'ZI6[+HV-'&T9N!1C9_.2_A2=J!,0BJPV+\C>*PA8]X.H)LTM!Q:3
M&1[CW5H$?Z@0U'<% [[F"IR[< % $QNC!GU'IUNKL4J@O"-0#9IB:S1>:!4X
M1+A6,M.\]N^ED\PMN2>![P5!9W"//D#$$;8(F )E$UT%8PPO(Y^S>WK9_:)[
M"J[K@UQ-%!7[;L7H>2)>N/^\[7[["9]G[BX[[<YOVK2[2$\[1VM7SBYRW5MI
MP_'C)M@_*UWKSU<8[[*,V>&K47![,YF[E;;S--0M^AN<O&&K"U["R5'5%Y&!
MVBR1^Z[DI[98G12)=V2YQ JC" TYO+=U_GUE:<],X/;Z)O"V9>S2T:K'(:(Q
ME<:>F*HXC.Y4GAYAN*R)O)VDY2/N[D2G[97H0\&@@F"3M37^!D'Y?(QRIDW!
MQ_G9C=$?%EH,3-R'%@I:E%6Q[N2# +<@-DI 5:_.+)G5^SQL1GGL%^+K55+I
M$H1#WH/>B ):0?(-V_#Q:909P;FW 9OA.]K8 'IW-HYI0EB2 +NI_'Y92+[9
MC4=F!15X;:PBWNHO8(S*[S)456.W-6OG;556G0WXQ,-4SD1]$LG^@$R>XKN=
MDIS!3@XOK6B;V(Z28O:HF7(0@),'D6E$)2B5JL&P 0-5D8Z MV@OOKK;K;ZW
M/G1>N5*?1\Y;TLZ-,. EE_9_CXC9&9M]/"YU+ZK7->;/JM-/7,M7<%-B/39.
M_WR,*?(T.EJ^QC,JVVDOW8F^M7#GSH&)!U=\3KZY4'S4?/I<R>[7=W9=HZ%,
M5+_5=GAZQ.P46T<'I]'NOX'K72D)W.A_%#%\>&2G1QD54)Y0P>K96@E,XP87
MV_2D9#(CB,17QN@1S/L71IU?&N[)<^DS+QAU6F17"*K0SN#1!TO;2RHP_-:P
MSE.-]]=6E?O[3_L6E='\';8B^B*^=2W#MBKST=+T.(SLQC;2?BR<N*'I!ET2
M+%#NBN?(+$$J)]SOT*!MQ 1<8[I9^WY"U2@^F"T:TP;F(Z?&X,#ORDX[FM]T
MG$&MKTD;K:N"]\\/_["E\H>O+MS%]F"^C3X:Z0*,^"=O=5=V&.&MG)";?+DU
M81D<IV/:8*#]IK^"5VB:GX"M.&KRDZ)5YB?U?WTNO4+I7LK]5R<CHQ<H-1W6
M5R*39XZ:]HD([[.=7JL^%\=)F,.T;TP%J2>80]JM>L"CW38']7KOY-6\P2N\
MB[>?>)0<Z!QY4KW!0 5=3S:U3VG?N=L"226-%R_#?OQ!0"W#:@1R#':K<F?=
MHPQ/"LRJQN&9)*6%:ZBM8:*B]>_#76LJ)0< 1$>X#I_.P3EZLTG:W\T806?X
MF/73.BA]:)*&&VS4NWJ#!NDMGM31F W<E,?V164F")!I>D%=] 43,8YP8-!6
M'NIK??$7G6,C<8*1S,H[ PWB$KV1QJ3'A_2,*OS]';Y>>YNTZ%1[,?A-^%;O
MKQ?*Q'OP]%/,]Q9VV/8Q]0$+I-+,OAG91E9_1'3\"$]MILDWX5U>5$5(K+?E
M#Y<R'J9\+,#G3<QYX.U[IX/AK[0</@.3NI>O8ML_^!>83Y@9_A/E=.J%=Q'B
MSZ[+]RZZ[$B(\:;MY,\(0ET'0I_WT[IU%(UU#'VN>-*(?YPG'$2K@[\:=5+J
MLH1F%7GOV5R\[=HM54JY13X8^#:5(W\NN%]^_&F7M7O6A'!G_+$H_BSQ++Z.
MH_<9H67K&0-X"+ 9,B/HY\L?DO-#Q&U32[2<,ZU0J,I=DJHD. '@B2*!2?8V
M9H F"3$=:$Y]V>2LDQ*=#.:EF <@_%@071"?'<6U'-/O)^ X) V&)S\;S5^@
MMB_#,@V1$)G?G4%51JE F1/&60W(S+M#.FBX!5I?KJ$1?#]JFG:@Z<#(J7IH
M.TM]GJ4!"=EQ7:EYH4&E>.TW[&P!1@F/>N,'/"B?7/C:*3*IZ[.5VS+%Z@*
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MS3](]M!\(:_X%N=*Y1>2/>%!M(,*Y."6&B:SMH5JG\/UJ[29'?$CWQK[\?5
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MA6@***3/\Z CA#T)XPG[.O7(Z>$-<SIN@"@WM-CE:4""5IDDF $:OZ2J27#
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M?3!VO!#NR)*V00OO4HI/:RW#M.[;('X!+T3T;D0ZNH[TDIYE: J@<YC;)29
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M_@0[RMY1!:,D#G%UOX24  @#6X<NFI4]8U"\@#M?,DY55166E555I5)5:0%
M]SBRK3LI:L8;JX(R""&JO1BHGT,?:7E1DQ#E]IS"SC_R<S1$IME+ [4KJYSY
MPM533596.M96-R3[EQR2Y@O2BQ+0AQMO&]'_D<;O/G'BKL90!BW5G>3)/F-R
MLG#7G5TGG34.-=@?TO0X^4E&#VP(.Y%EO"LJH_I-5?0OW*A-;-] ^"*$^78
M+/&#%L5HB,Q1!N-?8C=)8OF83&J] _OW9C/XHSP'E'H+ Z!T\#9-D53'A/;
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MJ4R_<-\WJTRPLF.)E/E4LD'^ >Q+G%6[):8V+K@.K$II7ST.-"A_48I?LKO
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ME,=F*=GZ51\4*)K9.CZ:WFZWSQD\6EP\AM,[T[SDW49JH'^; )6&;>CK"('
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M-B<N?IR3[YJ3OLZ<N>=!NMS4=P7WBG;46QY*.\_[=6MK1.L;T?S$\V\_7-T
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M13)7(C]US9:5TPU$"BZ"_H(ST)%%=+V1/2K[FJ5835@/+R?#'A;,Q!!=B)F
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M.G*HB'*M#=@-FWN#&6T9219N+;.).NJPS)FQV62+!]D"IE+@$WA@K")7;!-
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M&I-?/8TPH=(7=1^S$X4@-6'>R"7\5G#I>_N=Z(8:2'VAHF I.Z!PPG5;Y;N
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MQU9E_I$9TH;X87"=(3Y,<[.'^86(.Y?E" ]<@LP%U&BB#MV,(\DCC'=;J4=
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M.)J+^,M1[CP=Z^N?QS3C&3/FO/)ZL^I&TO&H@S8J;O/;8AJ6""F87C" ,R/
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MZ=4JM:>7_BQV]A>4RY<W_P-02P,$%     @ DX%63VV6Z?QI@P  [Y   !<
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MN@)D'@TR9HO5QHJ!\62"<VDHAY8HU>AYR_C0)93*W)E&9JIU&Z93WW2TT:'
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M$([2<;Y6/;.:CXV]#A%@<;'S1]9<1:?7J0U,;6C!%=I;AF?R[3JYY%RF&M(
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M^XIOH91%) G,=!OQ+7PYC<F1BG/?'+X24> CM:G_D?;[+S\];Z+\^[5Q>7C
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MGVL*[[8/*-8:-==9_^9:]Y=B=)U?WY%:SG5"::/?G.T+B]W:-[I$T%*%[H/
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M[V\EW*,VE'\%C5D51$1Y#R:Q'RA6\EI3)J5A0=..&MZ^&)J] ^YK&L&WY=5
MR2ART.QWTI6V[]R;=08)5+-'\WBRD-Q!W4S98)?.,!/9 !R1Q[TA>$H-#3_7
MR3E&.)J[;G;Y.:4#0:J<+$_W7;(Y8EFCG#+^*FJ]M'SS!8[X#?JG&Q^A0 @9
M0!I"ILN9H#R+F8U2$ZL24) $!LK[#5]U# 9ZVSGH^2,U[_ KRY% ,RL>GH4T
MA6[R]+0[\A@'\]KUS09%[D!KIYW.>,HCZ&4(P.I>P1EEQ?-5ML[H9/7<FY;
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M///J_ (V(L;;Q>94I'+&^K*IRLG)-=\1_ACGAVO,X$]NO>5X!VG[^8.]8/&
MZ59<(Q3XB&5_.;,A(JHFH'/[UOD?YI]^>6>6+>.%$.TBJ2M$H'8Z_D++OIS1
M+H$ICWP9]7;?])O,3,J'[M^C_D[!91(W)9G@,IB*EZ=.>$1$;10"!R_<&^ZR
MLD?L^1)\SO"6\@E-M%@[)&F[@-N3K_33S-NR%++K6JU'9XK&>LL^^.L^!11W
M1(C>W9$U6K_5&.NR[PUGY?K7SI-CS-'GGA]6/L;]_-82FGTXY*6A?^E?P=<2
MB@*3T.4N/O7H06Z0-R9%?/"^G@2FAS1\'*S0S76%_&#R,*U,!*OIG>O'Z^\.
MO;W6+V#.&U>'<_K9#C76'/SM!HI2F-WJIKM/IV9BQVIJPU4#5*O"QNH24L8X
MW[Y_GS<XGY44J'!4(_?9$ZOCC6LJ582(Y\.+"6COX7%VD4$$\O7G65,]71Z7
MW9US)I=C=']B,N"#"ZZ,91JDYAX;H]16]^U>K$(2O!N=@=E.#P)SNE0$./6I
M[8*D[=%'U%YCQT\,F&68;HZ>_M!K\^9-FOERN?%J\-?9Y*)#NQJ;$Z?X3*5K
M.SWR/7L$0K.F7"\W]<T"4_[[RLIWTT.8EZS3T2&'U^R]DBI?GRE7.!=^_'O%
MOG;H]"'0S8B_U6('/\C-X8WE/2)+,;GKF,:>8_<?S\_Y=!\K,M)X>;9$)[ID
MRVC%8=-NC9%*Q!CMW0^V+R6-L1U-JGD7IA/Y<E.M==^52<_A!>N)CR-FUG/[
M/M)/("+F/X;B!-]KV>FE<G5]RO/@ ?CY\2_E7V/!E1ZNZNZ7T$V!C$7Y37Z6
MD4,K>L<';&S^HP+T!6>Z3FP:K634+/?(^119M[:8W(1+BN$EL055%RQJB<#_
MG22"#ETJE[^T_[)ZYIZ=AK.GR77W'AB3V:,5J<4S?E-9-@KI!Y)_K3QFZ9'_
MV9WYG%^TI_V:MWO2VSINV#/HP;[7#T(/G7L<D/.1=BSN^MNSE<9PK/OK0C>3
M8^Y6D>GL?S^9QT>((K[C:RS>@I# ?CZJ]>+:3E>CC=FD1;5!%.!*DL#Z-OK7
MN[LZ]L\K%NAFSG]G] 0=*7H3R?U\<S5YY6'KQ\GFUY,I;]=9H1MG_Z\ZO7?<
M+*6D)(QSD^K5I,V)6'_X<C RO^=\L[9M_;&0(=Q=8;SY:7/Q%>J-[*P(_+,W
MU:4R-2?WR?Z< ZA?)P"?SAH^2@E/6RX"G?!KG?;,KZ]X\_*L01$2ZGI$"!@@
MJA'?$$W:H.22&>0.P*QNKL@,I4$TP:_.S4M@VT2!_+4]?(<,?^]UND/Q*4'W
MYR^K&X=HS(;%/@=/K;RQ#>+78XOG9V_4!#V=R/A3+3""=/GK0LC-S=?T^JHS
M+S<_#-B!C/[-XNO%+Y]7(R.8[B\G*5<O%0Z7PFP>G ]\<%[YE]\V]]-V#6TN
M\7[__-&E5L6-9TY>;NK\Y=69-V^T'YGU[#!&%-_2?6X[SVDEM39$B)Y3ANY7
M_A5\E'/])8RW2G%:+/W7;^B_]#NKZ8_$90!* *U\ZX9$P65A/O;]+*[RI-:H
MHR5VBPNP!!XT8^Q_D6[05^7;*Y<1?F2D,GC P <OU/*)'5<E4H;WIA\NN;>C
MQ/72 YW#>^Z>$]ZS\ZS-SE1HL;]7FZE0=Z]ZLZ'/?R/O3<.:RKIUT2@B*$*4
MODU45%1 2ND4 E$I1*00L:$54HI()U((2("0J BA$2@;H 0ATH,T42&@$!)(
M A$I#7T3A'0JTLE:*F$5A'#CM\^/?<[=^]R]G_/<'_>Y/V9^)&NN9XRYYASC
M?=\YUTC#GT&6-[:,*.>[ESIMVZ]R*CKLA.GI',=N]W,%]\J/UR3AWU,LWRF4
M/9I^&SWU'>?-Q.)-WKQXO<=0+97AI*']ML@0?L1Q@'SJ5+G.A;)R[<O!^]-L
M7H62'Y1=$.V/*3U%04\A!0MW<+Z@7&>+4PI.+20RACQQT2DRW$*U.PR19U#[
MXNWRT&3QUHF*L>G,3Q_LEN^;W$@-:%"=[ G?0FIIL69&Z#N6AGCX;X?&1?,.
M9YI>4#+<6P8L%M:%W/?S=UC/WM6+HFUI&WR@^<=)WYJ5FK07G_W<=M5_;J(A
M)-NA!*#)#Q^Q 7MSQ+& E7\O/ZO<Y-IWYY3+O=/B[(-77_;-390G&.S_4%Y8
MXVKLJ&UV?SIG43^ K2K4/XTX;&*Z7]MDUY5I%ZUDAF?G8,V%8T,/<TYZGM^A
MI:%]KA1-R+E0LP\=M!D-%XRD'!3H(_;'%=DT&9NSW^^G_J(]=U/+K/SXW<JY
M'=KNU2FY^VL?E=ODO%!?[;0^?F^'AD>%87>!X'S_"VN,FM3$+^+W0+E.C_C@
MG!/V1RW\X+^M'/IS?>[+%8O*W.^HKJ!#E0P[Q905MS2\D;_Y'XB(=+Q]:LGO
MDO0FF\4GV%T/O$M#-AWF-<HCJAUQ4>_,X0UIU6Y2ZK=>+M?GT>\/^HQ-32N&
MG;[T&+Z-+=J<$\13G4J/")_<><$W?&9ROFEI\!L1V@U\]J,'#UBV]KX>M43J
M0;/NOQKIY5O00)-I_7LPY9WR-S&/7IQ+]Z(IX';=*R; L->_5!JM''\SXQ^P
MU>DQ6GPO[[CPLG. A=#9Y>&>U:F8>(HZ(>QJ;K,XUWZ"]CJU6?I$]\T-BZ\O
M<75VEE(. ^/BBPGL?_-]U%X59]RT>3L4SM_[%OW7/93A4QV-[Z\.WV\4)W;<
MVC_^4E&[2_ZZ+]:,H7EJ-DB 4>::W-,9'C_>_]0S4-LC4J-DX^^;8$_^5%G7
M&3WHH=8EVD]0TTJK3OQG=HAT7CI(.I^5'G?=[\1DS[JD\O"V(MU[-KYS'=$#
M_;,U.[,F%9U_Z=CRZSTU_>"[V<<OG'!J/O50CO<=+7)QC&H:;PVGS;<6INVJ
M?> <MRF+-Y@O^0=:7%%GBK*UO* :0=UPCJ!B).97A,7 ];Z!T\U:*IP88:(N
M5[Z#=NT@K2^G;GY1J5KUJW'&$1^ LPQWC!\[D/#XBG;SO1[C%=V7E?LO&.Y]
M]BB4X7NB;E]"SI'=(<S']MYE(^>EA+3#F-U"ZOJ>AMJ=K#/)7A[EAYW[66>J
M-Y+W:PA"!L1_RA:E5LC PWL/^\A'(%^@F4%0I.X+$J WC?UC!5Y.=#CSQ' F
M?K+L2W7DL]"\S353?JZ-^W<F-S?>#FAL2-<+#K@7;ZGN69C*\NP<J4GKO%"-
MV>9_H]J'XGUDL/J([=NS#X>:H6N-3B^2.@0W)*9;-#<GFQQ04SJE_@L4_\OY
MZ;/EI_?_<M=0_8&SF<?7\? F=7?'R]')_^FVFN=#W WHG0 ^MB(@I.%-H&G+
M$*JMH**W+K"AMY9/&[:T\^VTW]U'-1#4(=W2OWUW'=C^:ACG)C1 GO)S\AV*
MCH"'[ 1FBG8.-X:K<,X,F<+LKJ9#M5)NB^(F00YT!(S'9+Z4N+9!;@KM>K&0
M>Z2HF^I:+CG4+ST4VIPF?$7;A^YX! SG ".^?1*'ZMDEI!J_^3EUZ$?V)O]C
M"IDQX=;,YHMU/(FZ+W]*8C@M7)7K(&GA? 5(%9S= 'X?+GSDA]OF8  ^QNF(
MG=P'YMTAD^T/!+<LI5M$J"H',1&&4"2(@&MCSPF^9HL65*$P%T K57*L*J34
M4<IJ'6ZWEY8\UK__=YK)Z9=..XE9O_[^YDN[1G3@;F^#DU=DGR<#=VT-^;$.
MBA7)4K!7DOB/-5BCJ[0?LSQ(4@Q;4J7_)YGBS#I']?^SAD'C!PD;8\RX"OS8
M>U+5Z9:OI!("PV,2Z7IVQ&_@^B)A$Y;-S/=,:TP,DZ'M+9+8BNG\E.S:20D:
M*A:LVIX%%++"&\,QIP<K 7HJY63)@QFC@M-MRQO389(LZ-P*#.<,[;;/ \T$
MEKSV[)1)&Z"YTTP+.]Z!7H^290&=:7J#=3+52/;[\'U^=GJ14M^&LTQAX<85
M]N0>8"&%9AIJLT3$F9=#\9PNF_6^/A+[0]B,3NFND5T9TDU3H!-C<AM4R8_8
M@/,$+/()\X' =T_ <]Y7B-R*-6=M"YT5NFEC6X5+:=+M$AEQ*IN>-'S='[WJ
MQ,IWZUK0PIJ= HCW#EQOY*CX!ONO RU:Q&V))5#V"3!V-EQ]G<.I 9-&/W.W
MOA^CFB.G^VO#+<:5K@1=:7[YHCFKOU\^Q.]C8 I7NV3+U_<=U@=-G&O1.ECK
MD^#PO6C3T.^=5E:N,>'8(("0A0H!5KR^U^GD[T+L !!T05M<^,476E;&U4K&
MG9OS;GXOV9]5GPZ3$BA((@()>$KTD2MV(?'VI:*>GC .M-MHWC#&@F8"E8+F
M[/P[I^B-2XR3ZWUF)@^#$:DQ+GKA#\PM<S(_M16\5_W$#WOD[+2 %BOG221A
M&,@]3(;N&LB=F/]DCR1C-2EP#8;6'9&J^_P4/$R^2#M>KL%(F;)^FTUE\RTW
MAN((N[P&^WV,P.FBK,&2->EKL!X;]/-K]"F1K LC R.#*87A[D>UZ:-6F.]@
M'4'@2%Z#?7N?/:=G]@\T3 =*1F3S.<CW_)F-9O^S6:4K&WND>$NR9*_LQE+O
MX2'U_S_94S\V>BS@<]PA_^[/\Q/B=TYG!@\VW$31FR]^B//^$!OG:RV(_<I]
MU?H_[Y?\1PUO ,G,]=B^^@0]KT9HS)-2C!BZJRPRD_X?/_3_^-CN?[-YMA,:
MT?/&8':']!#T[JE$&UA@9I[FB -721*[%0?<F6;H%NYT##+5@[9_T-[(I01W
M -#XFD0HYT*&/@5,S$9<^+,)W'%0GIC5F.#G>18HNDM3+M++C/+HITG(>30K
M?#=)17H$NK/ LI&V@7#&$F(WL!UR ZUZVOU-[/6>0ZW O5!N;A-)V7[[B>7K
MY5'6Q*?T$9R+V/0<(P^O!E847A)RM(*YL>GST1CUL/A$O@(-:]Z9[Y2-,A00
M]+[ 4?E:]U"VQ5#EB0<S&RFO$XU8/A<J&BK:.AMRP^*X7<L;\S=>OOR(>N7!
MZPJHN6M2!5#Y,V8-I@^1F?[*O<,SD]T4DL8LUXUH41R'_3LWE^@^'&%R+?G=
M@*$I=2/!ZJ;'-L.<[=&:34U-5L-B#P_ QYM[3(-25UY[<'S<U_>8;J=\&W7;
M?L<M6W]-4_^E*T/?O:1D_[-;.G$!054.XH05E[!1ZYI_M&X"'YAMYB\DU?V_
M?BA[4-=\0[SS%OHO G= #*W^2;BZ !U SGT"9X4C;/3F:9)BZ1KL3K $"T6B
M,R4[PH3P#%V_RDR)T\I)G.UPHYL*SP&0!;;AXDMQ5=-X@^&(WQ]\>ZODKO%P
MTP%5YW!1P3P)2B5(%1?78$X$+:DVAINT!GN2@W_G'1)_/7^7GSWC;?NI8W]Z
M^XQS-VV^M^]/7[;V#058TTG]+1?FX(2_UV"9,+SQ&HSEL 8#G,C+MA =8$@'
MD9*/56NP5.(:C)^-^1$+$@3)JU7H?[H]YT\HT#\3NN[]U[JB_X.NCW=>SQP,
M,KFG\'=\SO;8Q:?PSN@U6%*J[/*LEQ'?UF#77+QQKQ$Z./)M3.-<T?D^T=]W
M_$CR>F^+3'L^,_>,!7QH[8O=0I?N1/X4P A]O,XU6(J6^.D:;&HWYBF] <E8
M@VGCS O$R00M;]\Q,Q:2FR <8?&VZ"6>&%Z#S>.W@9>QEZ)=QCK+7B:F"Z,J
M_/[)3WS?4Q.>,76"=GEJ!O7_^J#\?Z5KM8S**FQ;@W48!(Q]QH_FOHA[8'(P
MCKZ>'C)*'7MR,$N1RKF3\9FSW>E@!V+ZBN*G;7>LT*& W1K,7&KY;6'^($#O
M0JJ2Z4$ZDMV!$0E()ID;*R"Q>!IZF<>'66.0$],'G5F[&#8J_^%%P6QJT/"/
MQ2S&J'/,X1SNWM%?/QU%VQ.$.]9@D"%GU4""@2X10N'2&^<)_W<[:\3Y%MS4
MRB/GS^ OQ\'DWL<M#SS_EQ46ZR!9S-X&E[F H']9$*[!F$HK9PC?'Y3^Q[.'
MHHU8@SU>@^G^\K_O3FZD7X%#>TES,2OQZ&S1ZB/[7RH[@Z"+J$.X:*UVM#IN
MVVH**F#U]1I,46 D=+J#TK<TFT="3I9/" &%#G.D /3U%3.N*6X-1OD?AKYB
MDX7.TNC_<AR/GG5^'=EJB'BM/55I=X2,@!81)6LP)9RS:5Z7-FW]F#<A< 9O
M!%5=P]G&Q@D(\M/Q;5G%HCW]UZD7C8"NI-I0FE[38+2K>:?/9![9&_*9=7>-
ML5"^_*UK^-T:S!*G("1PX6S_7R 7P)I%UY&:2VP@/S"L$]VXE$E3D[C\1-20
MB_@OD,@@W=5%MK>ZI?BK@;988CLF !!7"B-4L4M".JO.RB"A/=Z351<D@#-Y
M&[VQW_J5?41"><H7A;FK3F3_HA^/=;I.1#X)>A(OJC?^9LZ?8F.X3D)36597
M2V+;[X3R*MA\>H9/7A<2)DN63 0"L'I8(<O._&&J&M @ODWOMS<+]=]=)%RU
MX"EBFY IDPK0;;[;)JSY28!":93N&:JG9&(P_1@F=P^Q V>Q6D(/WK0&"YV0
MNPCZTT$KM[$EH=F\+]C*)R;9&_5$ ;0E<0R83928!XHFM-J1FZBF -FU?QZ/
MQNH)L^Z#<@R;A11*1,;DH3$^4FV6H(SR38P0^ODR"=OP>E#H&SEQ5_I1!UC[
MQZV*]D_O)4']O?\.L2>B.=^>;GCS_I#Y/1%*-&(0>73[@W4;LIXBG$;ZZ4?L
M]_E+KCQ?K43IE$NLH 4100?+]H2*^7:>++2\!68S]BR/3V(0QJ[:VKH04JU)
MFF:\XT.6H[@HX<@ RBD.(+.:$39]*(R0A)S15<D4F"D@DZ7*4$ZDOP$@)U*8
MWR14(H]I=>:2=(- NBS8AB_<)NB@8H0<!2R=&8^@ #R^6S;.6"!C#0W,95(R
MZJ"@@""'?<OIP&Q!.9&1MZ5HH*E<U$U!JLTLDU,B*,H8%_!&:,OPTW4K.G]N
M=-9>?,.N]"_$EI/9F4I"SWFU6GPWIF&XIE[R*\04"JKPO01=W*:5XY)3D(.,
MYKJ!:[ + #P)%;=R# IB<+-O293*L![+<@;L--0.OA):=TQB#J2\%F7"V[?-
M-!?I#&RPXG+2+;)?HB]QTB9M(3*@+P-S6P.'%Q8+E83-[&RB36PJRA6>8BIQ
M%9(WXWZ!.*)L&!;-PN\E=K@[\!?!\#48$86N[)2M8^C$SB1'^WV-PS[O^UE:
M+YI@R]+TO4_7_S<:W )J!B($06S2!A[N,-3#1RI)7( ]Y57!\92ENY* LO%9
M'X/WU8+"RQP6PF P\'F+1RHO./XKZ5+MM/7133]6S[[MEPZ)7C>E_/H]S&UT
M0>S7 $5:,]0A-6!8)"AG9UP!/Q8I#>(L@VJ""<#C=T&(0G2:J&G(<;:C[D/(
MBT(;T9GFW'U?+::_SAF%F"Q$['BU?#8=]D^L$#GGOF(D\03A*2A/4(VOP(1K
M8HD=-E;W!0L*H?F5*>&N[&0+NXVV51;A9LRP:^'\WKG&6=_9'F,OBS?A9^WL
M9Q)1<H&&1Q/>68MC('@ISK45XI1)D%!$)<ZS+7_YZY10F934:$O0:)/6A-OE
MDI\=>&&0/^%0,ZMI;3X:NLQ2UJQY-GI*[)/Y::A&.[OA?]$2-JQ71-WYQ:G*
MPOTH\A!G14?:8XW4K)?:=@/&@K>2WP=1?F70DCN4II)DT)RVB-8-]KE96/IE
M<N_@HE+(99O<UHH0W1,YY=ZAUMV141L+*KV]##-<@B_Y9TMU".)87U+:R'.)
M%A0>D@@6,=W[I?MF-!%J_='S3FP?_(O(W9_)04*]5?M)[K=ORKYG\L//G;_G
MICU(B?L\M$#KJ^[9/9[0IK[N6RR1< D]NL# ;QZ1ZD,)XNN00SFDQ5J>S!.&
MAS%RI2H#OK^V@GO28ZSZJ0X&]Z8M;MK,W\M_3S;1I16*71VO#L7LR^QQ3HSN
M7S46D+9@HSKPR#ZJD<! X01 3T'95OI,Z\*).+L*[^ 61$:Y%^NY=TC+Z8>5
MQ\(O57KY'*_1H)27;3NV)533PMWWT?^3"%! )"/:Z/9%$_'@4:5_^VIBNO7Z
MXL3 =4&K_5_O":=@,>KNJ_'_1T*#W*Y(7=1=\PTG;FSS_I!\EK5_K\G?1QE5
M&UZTPQ[(XW0)_&+2YMN!: 49<KM6<^@)GHULW+>A>O])PW9H?V3.)>:6K2=W
MTA;+VI<D'&BD.E=X*!\QOG+.M/.J_B1G--'7/ LS]SINM1)MA<D23_8#GYI?
MBG$/Z&ATZ^?/ZN:G)MDKUK\P^$<2*YN6W_NA")36RKE_CD2.F@5V]YS+EPYP
MHSH3TLT*OI6*[\HR>B&$:<=LL-\'L=LQBO20P[@PP1I,/DR+IM$"I:V82<*!
MH-O7J$?!\J+[!"%=#9O$L++9DU,\RO,[%I>XIYQP*3Q&?WV[_S'+#ZZ8[D^5
M\RLKU[R@>7M#QY4SN !2Y\$9MM>^1.'JJ07&PXG<+<-Y:/BG1]".'_LN.%*+
MD!G',DZ['+K4E#YY(4N II,T(1=FD2U 3Z5J"%=WRN* !G@UK1J*8L4C2C(M
M4\@E8591(<M%A;':T5?O?'TO]+HR.KV3R%.__Z9J%B+*".Q&&4%\:R6U<\7/
M"K6ZPIW:G:L3FZ4:A<-U E9C/@MY,%J)K.W[Q1U;'[Z=_G7/X^O%(T'/)^1F
M=W[B+M.?4O>(9&SW<- ZTAFABGZ-@UK&(Z/3]>9PA[3 3,:)I$J3ED>?;C%J
M36>B7/MK3A^^YE#W+I5%#E!D P1UK%JGBB'[2LZW ]O+?>')]XK/YJIMPQ"+
MDUAO&P/U&66&F:P>U4%39-CI&ZPSY^N<5"9\'A#<<3]!53X6V47:3-/'TCN1
M"NC0#:!1&G6;H"X"@Y'']R -4+[\A?DZAU--!1<B-D.DDT#FUSPR%+?PCOEE
MN9Z4$!<2^WLORO.<I!_IB ;.+"3OW_2OF74#MNOVBAZ^MPPP;T<H=-O?BB&_
M:G15<P8F,\N@A&,#\]&9\&,#)A;A>J>>I_IZ3>>?S@M13BFL]/9EI\[/F]3.
M"YJ:DF$GB].VG9 /_3U!&B0) W&G@SH6(P^G-Q[&F)>>*(^G[.W+5CUW*F??
MX(U*5Z/[@R''->^<CHH/VQ?Z:66CW@$A%XNSL_G@G#M<=SIS[X6: \BJ3QZU
M^QB6^ZWU9[9=CSK[L'%[0?R)?8W%S8^OUPE>.>9;O$HY<M\HC5^H&3SLZ'TI
MQ^-DX)EV9_5TLEZ*TYFWCOA#$@+(25^#!=&Y(R(G5A@Y@]>HD(';!GP7WX2B
MP)[CT [K3E.T ^2= "*%:#9<'Z?3V!\S9@24STTB(<SU/[&7O_L\2,B816X*
M$=NPTZ7LQ,B(7>?PO2-JM3A+*$%HX((9DA'##5BWBX,23SX3F&4MM;")/]I.
M$[9AY>LI+B. _ZN1X89,3T:_WVS^.U:^\C=.A?.!FBK;\8.M)$*WK=^8-\8Q
M8>PF+6_QQ>)^L6?LS2'N2.)\7=L!_&^AZ&:%>4N!#-?[  K9UV2.<#;ACJP6
MT>#2 ?^]J\4' D!X=KT$+4P,$$S=HE^-2$?#9=9L@KJI&HGUV+-<I@.T4!YL
M?P!874C!.59-+ZG-<LLIV1E%L^U6-Y9(B@39/=/16K0#.'LH4);59Y!;J&Y\
M.C?V)(!DZ2E&FZE#8:X@YPZ.L**%PT,\@=<XD[3M1YTUVV9K/^Z8P-1X/N19
MR'+X^]*XIUZAD8Z5OCS_+YJ8"%]I-Z_!E$R4F I\";<PBI> J3L4S-:P(HV^
M<X*EE!,%Q3.3)OT'HN$:O%&NS"WM85&GS>X/RTYI/NY[P8WY0K:7[WBP,,N.
MLT[ZGK .KU612U*AJ> L 2?Q@<K NI ( 6'C%Q^3)I_W!0+Z5LB&Z9F2H'?X
MJG2H$2!EH%P%-8DGG!'?3)7\AZ++GWA-OI/;04)(!WA-/%;$+>EAJ+H$2A <
M>"R*4,99 >PYUHX6RB#J4A74S,)LI8?R,A '(3M^YF8V [$5(*59[@$6[BY&
MJ/AB2SNY]225:O*,KNM;+(%AKS.,<XC3\XZ4ZL@6YAV<TVM[_5Z)+^!*-15R
MD,T9>"3N0 :K%YH2?$380>\$Z'0Z' 77>.*O Q$%=4IL?QT@+PVE!P8QT:K7
MYG''BL>QS),#*#40/_R9>7: NJ,2RO!:U0&-&*04_X/$KIN3)A"!SU/SE3CV
M6F1OAL0\?V#R84V'R$P9BP_W%QWOI;K*KY:S?(8?EKJ19Z.F;UI/V[7=7:Z3
M#%>K-Q]JO12,@>$5L0&GH,1BB" P8A;JG83<A;X+NCC+@1\+&[]H-DW*@UG5
MI5 2<[DR V=RWXLLMDY;=-7J+#(:L$1O]?YK,?$$A^7SP7,D3^X<U1R&]YQ&
M Q?@:;3=LG&7) KH8S4^!8P\,3B#WAR!\JS$N4.)%1=9Z!!RB@RL%A1#[*[)
M_5!<&+\.<Q$L(H$:^.TA>9A-%#>]:<0V7:MJ 5JU.R[.((O\+"&<.#\E<M7S
M@0KYG%3[=<") B$A":^P^G)Q06=F&9E!2</MJ KE-6BE$*Y&(+"$%<TIW[X?
M$R<X3F!L$CVXQQ/<-%2R@B%:$C:'NERR>E'NBGAJ_[9I-4\VWXSMPKKL#2F0
M%I _[@\E58^&V5L/;P<44BX-4L\]FY8YBPL/)-1-.E74+BV=@3A._1+_P)SN
M@DXK3=K.5]\IJ6=_>(.$N9$5>ZSD TD?IP;Y"D5QP@D'=EX0"[\1^/SRNB2H
M!AO*[&AI3JMWE9)L+X;95-[]T6;.]"F<*R\?M+"S9_]&->?Z^'9J*TR-,$G0
M/B0+F8I4OPQ,DE90V-S9#H_\HAR^791_8Y_4T-?;"QK^+H[LI=E-0D68M/SF
M.R92Q6D2?#[&%<\4C Y0LA&^T"?3J358<G9L)5/PY6J_\31G]+OX,9C''L?H
M3*/54+N?2NR@9($Q?!WTT!W87=?<:6K,BM^8!&JY#E^W>$-Y9RO$,'D*/F&Y
M5C93*;AS@D0]V1=^L6ST%JFAFZ NX#PP2:Y(S!*=)(Y?HP?!;^G&9L[1=H]*
M-"&_$%#AM Q9W+V&"U*XC;-&IH6C+(.>(C?[?.D-%9U>N7;38U+C*D#=NYN'
M3"F4V+]4-ICLIN U)<J0-7"\QW. !L>9 G"FDG+\-[W5JP/M1>I].+.(ZHM<
MMHF5:ZQF=E!P@V-EAT43-_P%\LJ :=F#<;<[PPK!;Q2>_9\IMM9_NX['5LR)
M_@W.11U5*4E'D__]6UNWCGW<ZH3*BM='O@$2_Z.CX__;MDZGJ>;@AF3YU#,N
M^EOXZ[J-GNL_;">3W.8-!'^<7(/=A8OB.@P-^6363A650W"QM6%OEN)'S][H
MO_Z'3@+[Y[M4UY:YX19*'F0]. K#J4/)#]Q@<.C!HM'M!0QB#/]!<TJ<27_P
M<79*H-&5@4RJC6[L-_LXO!.4KWT7]5-T5_QF)LX6YX@IEFQBX/-MB777'!^B
MU@?K'ER^(/0[L.(#2"EE(?&=;.*BLIL+;6#>LL?K[,RL<]&WB?D!=\J=$,-T
MEQJW7]Y=VQUA&N0U,91SJGGJ=UFP"\=>,6 *.1ER2:].61AL_4W?@.%N1J+^
M5K_ASL4%5=@_$^]@B5Z$X(4MZX\!6NRMQ[8G >>$VMN3[BA*N_A)'0:9.U9+
M)0?6H8';DC]$ _Q*ELD:;#J_34:-8\0YQ5^6KU;6N)%#=6\^#@Q(J+MXO*G9
MAO*NCOJ'2]6'\<Y=]QVCL'T%&7?3J'0;Y\WR9S5B_DT5LX"]^>"J>K+D5]6N
M>HV^TOL.5;\;:&]T.O/'V_9#S_<?W9XNP:P^184+"6.S8@HT!.X7"3GSZX2<
MC3C;U4)[?5Q4+VW3!]Q%720CXR>%WT8[#(GX0TTD<NTD@H9 0KYA6Q Z;2,^
M'O0!W.Z*Z65V^HA;6TOS@R/T$..,(:D^#CVR:)K@.8)3$]B%G0/=DK*9'#5,
MJ!393S$F;84VR?# ,.#_>O=\[1J,2]-(:(OP?O7P*%U+]^*#F9:,MAJ]GNQ?
MY+ZYN:\VK\%"Z%ND RU3MZAQ6G-+ K>4-5@#NV.!&\M:@S4:_&W#SOY*M1.V
MA?TK[V/2_6$C$F.1G,#.!0/@;*X209Y++\I/T$I6QE:Z/\\-CSW?] +$-4O7
MO<RF0L=6KN+.0ZU@;#MRB^RB1(>?Y7?55MR"I?+@ZCU=9!KJ8"5VJ@.]%7V9
MGLW3HQIOH>F JXUXR]Z4^T+XIND3,Z8>/+?6P?H?!F@/W_ ]>N-MZSE?PPAC
MY\3!C3]+DU&-PP$EO@2A!YRH(8?A57N%4)S@?+\$78.M.=722SU7%9(;\-NW
MWUM ^[2$F#)LEFMMS+S5U9=#R9^>G\P+:Z<WT-LC4C:5LX%9/H]I)E>?5NT=
M9N,,D._@T,5V*2\JL;$LQ+870W6?!FI-/_J=YC!H)J!URCQE_>=_Y?S&G+^\
M>!>/\Y$VN%]7:ZAA G*F% 5@B#@]?@&=B)%KS+[;DMWYSJ43<6C0 IYJ(Z'K
ML#,">TWMX=!-9=4UF".H4ESF WE?&OA1&';A)0UZ*&P[(6J?U)&^&8J^VS8D
MQ0W0(WA9(T7JC7])- %$G?#GVW6*]" >5TV03&:NP;0ADE C*QG($XUDD*F6
M,3)05I%1B8WZ#?3,Q(4 2ZX-B+TO@"E&3?CQ)9'&$_O= Q+Y@, H@5Y/IM./
M4@QD">1U^MO]W!%6E5@ >^B@48?F?(@ C@A#J/=9(K6P5X?*7O_E^Z5H1^O+
MO/,#E[/"QJ?K^H<_'PRS7)0,TWYK'HFP5HM8V8O_.[=("\R^$XX.XB59T;9"
M2<^\9XNL@*%F)D91UGW?</1L=<2/-D_?@>+^L]R5,_T14_EK,*?67#3:B9[O
M.[%O[FOY@ZLP:$4<LEJ%MY5$K58]=&X9Q*L[ 492'2?FI-40%?UTFK1M!^B?
M#=*8(G97Q%W$D88[2VRI"J"0-E<7G7A.4/Z>*'3;A!UAZ"JDXHR>>5G=CZD@
MA/G,Q&=*8SLYT%YTFE1/$C,H42K'JAT'\Y@)!$W),<A9*^/'84G\Y3Z:,804
M7P-Y\UN6W=(DOL^P"8Z 2=XGE'RBP [3@5!N!?VKBSL30\@\[#.#T[SSP-7"
MI2XBH,>O3(DQ6Q>&T(/<@._,93)C0NDBP&86.CD 6<2R2:P1$V^T5[JS%V4>
M63GFVUWVA?NQCQU5$])4FYN?+#2='SP[";=O6$2/T<6$85QXC<1YB+899SPH
MW3X[K1N&MZ0#R)3K,L#P#QXYB-M#)M2[5C25QAAC?3T&498FWSY8?(?P,ZZZ
M<;L&[OAN5VBWUUZEXFUGK0EP/'*&L$FJ^H6G@;?TPO?8&T&Q?_"V2CPC@26F
MO_YJJ10AP4.WHRJA%?>''>)ERE0ZSB!BQ1Q:.35@BK+*J( 6O$"S)(L5WS;8
M'DH,@GP+?0V)_%E)X\[-2?R _Y&^>JDI[G@#]!B$=S2U:-Y.C*MS>#9;M'/U
M)=4;0+;[!.:6/\6&^F'. Y4I= KJR/6E9;?D SB'!('?MO+GO0N6W8*7!0MN
M6_&<-9@<SK.$)R/5=$6\WBQ7I5+ D8,<SO0M1FS\HK4<PTN6ZO!"N97,PHUA
MO@4Z.\.-V^.+VNI"[>$-FW<"$^*:*K^0]?T)KR>6%6GJN(-)[5J$S9>@.'XJ
M39LW&KI\88'9"-2GH."QY;-+L7G<R<=1 K?GA9O#;3VH@V;U,4HZ)KK#,PFM
M:;O3\CUWR7T_.R#=K ;:NB4)Y$GW[+>.0D%GH6)PZN)J_@X:Z%J933/XQ][,
M%!!Y D&=K:3UV!7'?ND.;!A_^'4)MN8B<)5BE-[8JAQ[')J(!)H%JX7#S>62
M<WT2]["W6-F=(T&D8"1E'A=>+U$#1M)Q=J"A*]0="$0XRZ@>1QW[L!. V#)Z
M[<!'CN5^8PO][U="Z+,)=GJ^0_B]V%C_5WD=+V9;UF I9HV) 1U:-GLH0CM/
MQWW+SF4_R\TU#"<)*,#-3,!%X%\@<.RE1&Q9@S&.A/#1RITE34GDV?B(-,OY
M_7X6(;S ?(X?J))=-MO"==&CU=6&Y-\LKW*.3+@4@D*Q;ZW! A;&..VZZ R+
M F0R0F'D*G2[$IO]*T0D8VLZI*K#.$=0Z2CHEH$[)G+U9$J/#*DD7Y_<UX?Q
M 0^4>+H-"5M2O#1[_3-:"ZZ\WHY4>K="P/=9YY^_J8MN=U,)H1G+0K@LA''I
M0J/T>IH1O1.9K.O?*N",X:0<W3(;TETJ4DA0(##>]#T4>CP&6Z:.-P](@DI]
M)B%S%EZOE?Z8ZBGX7ME-OHG8*9N01(C(P%L_] 31#"@:?OL[=GT/2ZHU=-TI
MRS)"2W)LR&P-=K5[#1:,;81OP68S[56'I2I?[.W-Q_UPJ &I"NXTF'<+%R%T
MN$[:BCI(J ENH2?_,-N:."&S9Y;O=M?"Q4P9\N4O,3'P8)M8(BI$H&1JZ"2+
M]3]6%%$'083H5RJ47%Q'H=P+YD9D1:"L!2MTK?&3!CCGF)+I6-T.:G[7A"B=
M+8Z"%"J@V5,0J1*G!?D%@%K'^Z[A;$NQ0AD6U6T&/1Z7A,3OQX;]-G"-\J9Q
M:-!TOI&GLAT0%ZE&[LZZPRGA=JOD[<J]M^X?-I\.[76:5Q9A4O)SVX)6+$(U
M$;NH;=".ZN"\):D6].Y2Z2CD)))QSSJ,U\/3P$8ZGZ BN0B-U.-V$SL.LFN9
M0-#Q(5-)8AGT8+Q3NBV%XPRP[YE$9_>C;V$TPNVM)$A B[7B344;0N1?M6P>
M^6NU@0;BC,I9;N+\YPRAJ^XP1ALZUTX[D.('9]E<K2[%C&(K.VA:X)Z<JE&_
MZ?C/R14SN;$>W=WC^#?HEQ12DN08(.V1^;\[D)^M/JMIOP.$)YM(M2&;D>-#
ME/F][Z,3KWX_W=QOV)SH]NO*;R*'ME^S$I5W/[#;,><^X3LN,1<0E"&SH_VH
M??Q5N1- <XJ%DK;%.SB39M _U^BGYC00GA=.27E<'O+<UVMTK)UNXB'N=51=
M?[-JUX-UK?]]M?1*%.<T_$77'X3U\-Y_M_FS?<>M_<<4BC=LQ=^-=/EWDKCJ
MQD-'N]LY45_LW#;^UXLO;&HW*MJ(U4'?TG\X?_$8.'%K%^$2Q,YVVQRFO0;K
M#YW_4G_1%15XVNV9L/I2W;MYNPH-8=Q"3T^89W%W3PA&^/FS[XT9A(/(3<\)
MG1SS9BYZ#:8YO>1ZF:$W%FT0X)HU)GD#&O+^*O4]L]$IOW][MU*K+++!);LF
M=TVLP0Q56D<JQ;3BV0%DR*KQ5Z1J<(_0 'ZNST=0I^7>9/7YTV4UBR.!X<(]
M6.;]9CT7LC]%2 >>UGTG0:>NFS]9@[W9<X .&6!RP$IE\'K(7Y?" K]CWYX'
M(LMM'AF[]P3H%DTV/C'0?36UKR?7_6%58TA5A)Z*F-+XG=?L=H$ !50#L9DE
M1,:R?FQ+;$:,4OF 4&VR\VF8[KW80^O;W^8Q=#2G?>_]]O+PM41A?#0=*!PE
M]"IUH:%386A)IN^D0=\(<WG/XY(ZIM^!@C"#JE?!+%>KOR6?MW_=^F2U=TZA
M[MH(+Q RF<F2DSM1'T"L],B%*Y\JVWU+_#+Y5'1(5V3.A>S(FKUO36TRG%N[
M@WL;I20)'#,;?>[UA><G^"K:&I?N/SE4=,R@XR-"&>\=1F]L9K]3$_\)50(8
MP:?L),FE9UBVN A$,SD;>D!SW^'&[,TR],2YC>:32 T$]F,/;9QQV>1L/*6B
M5437FBV981S*._,!^T!T+OW[FX85)6FEIXJ]CL06HX;4-;M-W87RYWY:2BM@
MB9C+7B.<5 I:,9@$IQC\,<,8G^=Q1Z3R (\H,8BKBN.%O@+>IY5]>?"6&Y-<
M1R4<;1KQ')K_ WT(MV\-)K\=S,Z@PNMQ6 H4R+<SXG-DT36Y2 $D9$F,GTE<
MBLPRX]EIN,B572$D2JU/+&-U9_AZ#K/(N'$@VC7*";B:5\$QK:>+7%[A@H2%
M=M%A\ VR#(#-6L9S95S 4[)'J@(A>'#:>G^<'Y0D1-YU?0HE,7FJ*(Q0%KG=
M[MH?QBFO5ML;8^,6,X^/,W.75Q?2<+MKI'\OYSY.#+^DKQN;1344^LEUQ>L7
MZ=C<Y9Y^N"3.6['#*?:AG 48[2]KL(TTK1"\"6"=5(='R()\+D(.Z*Q_+7!;
M/SK=;&.9?1=E]\RAPO3K?4&/ 4*\XORR;^YJRML!%_J@Q7CPY1=TZIVH#D(#
MKSV;J-GBERUS/HF@)%$++,&^)"""AXO4 *,4G%UX.79XBME"OKL']"]4>5CA
MXQ0DW CDOJ[%>L=X:9CM!";+XXH=3.+/+P0?19N,2#=G@R=&VOV1(+X&0#H5
MK8@4F&:W$%:0;3'6W >LS+8T-3P'L<%*-TBYU@MW=,#"3:&^N6X4&X6A9W3%
MVV*57/*\042.B;]2N/EOX(8F[J>1@?CF>23(["(]1[-YF?Y:P".DHO2PQ!Z
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M(7"(8,^ZL^@66T>,J%T"<W;JO'30/!NS >O>/J)67<4KLC#&.OKV-=J,$M5
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M8N=^3'.N0S)4\ Z[P]*1I_2LS!<TMV%4JKG4]2Q94J6Q+,HVT.L@ROXEL+K
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MBP"%1G$V-;&^4Z#O2-[HR$*K!!EC":U[ U?NR"$V=*%&GY'6+1FX'\VC:TB
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M0_(WU$%.Z$U&?P-[ZBEN'F3O212F?!<!S[#G%OW(/Y+'_PG)I?B#A#^E#XN
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M8"7&T/=<VN:.B*L'Z7%AV9Y;JY!_NBA@4VDKZ-D\SB/I=AF649+YK<0V8OP
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MU'F^J]6P6#!_&[T1GS]]%KY9#*^6 P%8I</GA3=1(33"<2DWD;"U<&))=WE
M\*6RX'I7-1J0=:$1TJ<V6#U\6+.>;P(^BAVP#:RL>A$2\\T$O:6/L D,X]LU
MNRD=JF]2KES<%RZQ S/^:,R5 QXQS+<,1I.6W<-7=W[NO2,'5BV <_>?XSM:
MJ@DG(<OG_,X@'FW6&U1JT:7R9U4Y<J"9J\$,Q2H6I[VAMF+YKK6=Q+BA*]YV
M5E?&92U3O^4_6<XFEX[X3@\N^=[[FU-7L&*A[I'80Z(Y*-O!;)XU:ZWWEEGZ
MAXZWO!H;P9]JVX/76&JK"] V1#'!U8^AH\%(D!KMGNI+BJ^'7\J!=PTQZ7.$
M4T'/#]Z,0V=GG"^UH&5(SDN?8X*Y +$W0 /&\-T3,<H$5QYBDV0OG ,%L-IR
ME]HHAOBHMAMC&V&K&####4XJ^8(W<(/U!.'JB^)&.9"1C0236(A[(R?Z9Z_'
MOK7MF%T96VHQE U?5.0OA)W 1E$"QO!ZJL0LEHAR?TEP.KMHE8!92T/A*5JH
M@[Q$<"^S_##T\B<KAZ2]BVX5$X&3'+S(=[3SJGK3&SV+]:RJ@VSRE;.1JYH7
MS>XQUDRB[>%"'C?=VW>L\"*)QTTD&<BT?$-NU(D>^ 2$, UJ,8FW\LO+W6V8
MS'OB/TB)N5=\KVN2"L^94@E#6!O=_A4_22P$O ,Q,RZD)!)5X<>T*=EO(+%8
M0%8A=@48O0&C\"J"Y-K2CE)B;VX(4EVQEX#WX3SS,%J&KUVJ!!M4"2NQ&)8P
MZ<6TO6&C8%1KVBG^K*W+GU6DTY@ZYLRP1HG0T<X#3C!-0MRN(2.G#7^#$*F2
MK4(R F^2Q;=?#5-?!!NB!E&V0;PN/7P6_RXCD,Q&J.'=SPW2G?ANGEUG>FO]
M]VQQ=1H,ORX';'I(?S)5@H>PRA$7H:$T,SF09 'VB=S@L&(GR\>%B8-72)>X
M6OAJ=KY^_^(Z)5%LE\X7N!(?74K=K9Y^=L2E1-/($2\=DFBYBJ[W+V(R!Y>I
MY!13D-SF9B<D:!T,!*-X SGL3NU3TF>UT_,;\',_IH779>I,^(Z@T\$5TBU[
MZ0_;'1RJ-'"O[UUT8*KA^8S?8%]'C',5(/[))[7-IW#U:IB:H0'KFX:H+\#D
MES9873BVC:$&45@X?;RW9Y9SG\0I!"? *A$.=:.L!;/JT5:(J8:(QJ*NTHEN
MO] &I\4F&<7VXZYO*!\F#C'\<JSWN] 3PF3:.)2BG, ^UEZ.2BI#G1 (SF?4
M/CTLW%M8.2$'ULZA]O-&<>_V&II#NF0(X0<.-CZ'3_GUU(1U6I\:K!G)W&&I
M!;>NRB8%D88-6K  :@6DUJ)OTI6\T.0M(!;&E,(4-FF-; /!3DK)'@L"!YA)
M-M.9*LZP7\'D9-#+D%MQ;_O#HV<O>D"KJU<WQD1'GK]9$MP3$H#L983 +HK"
M?@.JM-"T)AA69('R@!Q(O=[D)[K)9-![&)L(>T$KB8FK>"]<+L IEKX<WTDW
M*1X>@VGM 3N0VK7[9-LD!R!E46$%/L&C.N54'Z_[SWRW'8"CN=!9HD/B6;$P
M"9QY=I>:?QAE?6VC5;+,',YX@3<<:F9J+<2*7;%K8:8G'%UZEG"2CE[1_Q5&
M[I$X=4L.\C8A6MTPK!A-/(M%-.[6Z@UW9BVS=0,*H271\RR>7:O[L!QHT:?=
M&3D+DZ"@4] -"J0D0 5L<]4&B5TG!M%;\%;-8R8#! ?3^U<;N$D2)\A,D)(@
M,1!L.1=V:P]LZAC:Q?;NX4YT3U6',)2%2-AL=89 W5R OO.,< 4:2J@A9S8$
MM;JK$R[7]-$=^>K'X:Z6?#0LAC)$R>#<XXM1Y3Y?7/GASLWH[3!?R%3WF[8/
MZ[1*I>N5NP66#G.F!Y<QJ0NX:L96@B9(4A"&UF1N>^96^T\I.+!#,-]"Q;7H
M11H%CYF [6T.Y)0?^'OJ)T[CY]>WXGCFL0[7:Q\X]DSE>%87B42OMZMT,-3E
M0/P=_.HEUPPV5HMJTY5B;]R03>/7O*I_"[5GTB^:I5-$-5#)S%->^-X1UM@6
M.$*T5">SAV*29CS?^4S]G+ZA+WNK>P>=8)&HB;_WLQ='BF .Y[GW$/;3_&&N
M?WH?6Q>]>X"FF&2K]&O3Q!4]Q"WX2M)*PH$AV>_P+:3R^TJ"'KAT1Q(2'LTG
MZ88Q-RB09,VDKV%U8.E(P&A!2.[=P?PM8)=L;3T?DQ*@"_OSWQ.M)(>AS':6
MQ6'^]X)\8\B-G#*'<A8T=J4P:R\WB<^,8.'\N4^<7H<F[#E(M]$N97'VF%JP
M2>-KY\%$UY=?.L^-L[&PB7LS+95AGM-FWU;\;%J_K5: N/L#GXU#$C;"!Z%K
M.^@&4)[0+I6Q=\H>D;1+9@I'L3FX!-1A/E,3+L?VUF WG?T<JD;B2R^(NEH#
M#(;F+&K4J&N4)LF<6%$QICKBK1C=&L5[(W'G6V5@]*[05T!*K6;L!"<%-'GP
M9IV/-B0CTBQ*ZC++V@5Q]NUM0S+5[MI1VUH$XD4.OY/D!9%$Q2WXZ)JGKA]M
M,/!VLSM=;>Z<B_SQ3)1=-)^R1K(>LFJ>7T5 0P$I9FGHWV"FD);),.J"L <A
MO60%]1:VH-6;H-,-E 1")!C5CM9-[CN<U6IWJS]@$^2<&C&[H&[ 6HI"QL*S
MB@UH)_R>]0(?PQX:XD3<N<AW3S=4I[CV_EE]M+*&G([4J,6D>/_SP-4@+EWX
M1U6_]^F>HCJW[E"O&P\>J6D]^D5S4U30C4GT)L-U0Q(CJ+R=$]2*2#'4@Y4"
M%>HH39]!YI.U0KT-]\$6)<2>7.\T.DF8N4<T-M;7YDMN-\!P,@2-A).OPC)U
MFF2U4AH_T_W0P-;:QEI@L4C*8 :ZU"+40P:96G-66#8'<9ONL64VYP[:R']"
M9@#* 383B6_G>R<NXE)]^PVUXJSXF15R0)NN)&"F-'1)=KG2UKGRL9M"K/&D
MUMW!RW<T$6N[,;PRRNI%BU-'\MB&RC"3AU$)\)-]#BN?1EO";E# 4*M]X/@,
M":+PQUM(NMQA";I/AN3"9%_PS$!)IBU&#\YH$]VO)(."$99^\AW!]_JA\,6P
M."-JK6(>8F#3OF:2-L$8;00/_A *NA*(FX(-?X<LBP/YD[5/7=DR%>ESV1Y9
MK\P(ZK_O,SS).7ZKA,S8*@F'7/IK8K>@VP]VUY0K"N)0=?(^GQ/4G!GSDH,T
MB0NC"2X6F$N56F6;I*_I._CARA);_H@?>54(J6Z<C5A#\(6+"OWJ+E'8\T4$
M)U!67HX_Y';BTZ#?%@.V"FOY"2=W4C?FQ^U8.9#"#*$D*'3?TV@PCZ4OJQ8@
MM7W<MF1^HA; !NVY%%9I]%N47C'AB+M:?6L>1MT-?(>OHBM73C LL>N0NIGA
M"Q:>GWXXF/T\'H),(X4BXO.UX.>!(,D7\O]*M'G+ "]G$7:A3(2.02UC&P=E
MQM@MUORN%'J4<!3)6I*M!I&ILM^F5NR2:#_#L]B^EC1!6 9UKX5E[XU!F_.E
M>&0BYKR;00MI,\-0$E@/9]XRX(]E\#/W?NIPAN-XB#5P/?LJ/HBO13"L!BGW
M%/CH=[P/=5'(3>S\DPGF^4GV0WGXQ,^$0PFN S,H#\/,Y\&,+:\SVIB@.SF1
ML5M:6B@M^9[1P@7_"LTWAL\(,1O\\"F\I1:R(3Y[NI6B_+R/2E]+XM'2#&W!
M3U5"9'+V:]\)HF$*.]M0_]&+!@J+<[F:[ZJ@-?B>_T7?@=L.%@8R517QCFF.
M1JT@W$%@^<+&PH!EGY(1OJC IO96=5-N:^Z)+&AE!Q]-1;(*R_![AF6FH<O8
M5G6_0W!,*3Z6OXS/P2K@-0VUF__^>D\93':J;Q(2+.2 LBYL5NH$:<RWBF26
MX*/Z1/0NB2L<6_AY1.((5PEPNE/Y&V$7/C)IS!1.@*Q:B4J]C,WDC1(;D!8?
M@=X>HN^<68O8.#'HZYPX9]RK4591W)5Z?=KZ?I1B^+/@E?RU\!G^/K09?LBM
M'ZVNP!%<$@$AR%.W8P6=[J-[5Q"[,<IR(,1*%2^+=9UVD)I.*50X<SU1!0Z\
MV%TY:]I#.%P8,+5,K"SLNO?'3])F4O-.E!)D"$E\A,PMDS(4?+\<+A&TO160
MM"7.L &(%9Q(BBHA1/0R-(?QPA-@UVU4%'\VAD74[*_)ZTH(T&7 <0('TJS#
M[$J]?AO*!C]8#IQH:KSW56D2HR,;P:K-H*T(%O!^WO-8X2RNG:)O0TO@S#&+
M)P-V);S+U^V/QMYA8.")^':!/=[K)[\K@W JA$]>.Z%GGW+'AJ+[HNE\(;[C
MQ!!NE:9?GHOLH\IOR).(<>R:">:KP0P^+=U0#\*F$$W@K*-P$(^;&2(^C(_A
M=98DTPU44FKFT^U(:U$N8 Q;3W=9^B(GA.J'/WRZ6^(<(U"S6GVV./^IPE5M
M^()U>W$.L4X!=^$J<[S?@06 >!JH\7 "=/X[C7!0L=HK[=Q!50<_7$:#7G-S
M'*3 L:;!6J%C6#MQ'7Q3,*(#G:G]MM2B4%!<;<9F1V8Z0P=V$)RIK<C7:8)F
MBZ7%U.3G<<4A^HGVH_EOK9*CNSK\*",C DH+-EFV!L2UA*LX=2_$NF\D#O@2
MRQ5,1#%D;);$P2XQ-,)&S-I%YAJ\"F^HG<11$PS-O$=DRK3P!9AT7WK6Z%AH
M;DXK;D4(5YWXFT+1HS68:-6F011&NG[4UP_KYQX4BU,?+>[?X_>%\Z5ULVAI
M_?',S:_.'=Q)/W5XI[7Q_6/DS:G'&EX_,+>EV_&7^F9L<KH74GH7WEYYT6<S
MV'<EEW4BSRTZRSV[Y9]F4=C^7<9.L3LL"M)FMQP>J;EB?0!Y+W^']#4IV(TD
M<!IB*:S!$-\ND1Y)([B"B&97TNUE;/(X1&NE(3B2<U(RT5 2-,#8,T'\#:L;
MXC6VLY>A L^WYA8OLD4!6GG-8UO!@#ME(9Q/547XY)\GWO02H^$0Q<RODI:B
M,+RNSXKZKF,8@69M%G[>TK_EP&7,%CQ9H)(6S8U':V(,B=L);E!=/<\]C:3Q
MM9^.@Q3];\UET@AF_JNY++1I$^S#8]YE*-1+4KU ?3L\TN*[I:F3F4P_+!8_
MEZ#!F.1%19'@2XYT4RU0AX7^-R6N D>?NT/>]1PV0Q^D)%[.WU3Y[6G-]$T)
MAH=3'3X7PCE?W1=AW+N5D=OK=L@OKZSV MB>\EOL_O/=UX.+^^87U;U:CM8T
MKOGZNG_Q\M-%MR.=PGJO6F9__M2W6K7/ZV*\J:BV*9_CE6>5("R;6:<W&XOC
M8S;AJX] .<V-L3?1VJ3F/Q0&+<R]GZ@Y/71M8B_SE=WL!CF@*CX"CCV/PD&'
MV/C;A M@2JJ-J[O.U#9U+=*JJ5L6@X7\FGZ*U^ZS4(/S[".HFF^5+ML72MPX
M1+""$DX.8((IG(AI9^FC>8O%SL-"?;S#'])'E0P'A>TFZD.:T+GZNOP5?9)(
MGM2!+QCY+'' K?W"@;_]V;MX5')ME\W3PTMY8J-CNW\YN_5]O*PFOI#\82AH
M>-''*^Z$>OX)KMG)QUYA$U7?QHX5N#YZ].[/JDG[2]Z%'AGNK\DG=2G#@F4'
M5_R\,OFIB%*E5I09I$L)E@-'Q;__=7!<)@<Z?A)O 0H,-1"'$0>8^D;P37Z<
MG1]L&Q@ME /WL.OH&D23"I(J/7)#<J80.3PD2H3;A:.Z7<T8)5(P\Z[OEN+Y
MY&BKI !=4DH#+0,55QB6VY4L.>W=*M/THQKZ'V8;#BG*R7H099B__DVU>[IL
M,XAK[33B4^ZA7'@8#8*3](7,3/;14#W^_?EL<VZZX?I!PHH7U'HVYF[ RJ%=
MU]>@MO(S_<[<X[K5#UH:?I]N&1S;ZA\@!Q:UN@[WU'P]6F'S=.^'[?-SM7_<
MZVWIY=CTTX@]HLZ#6AL]O);G9[U-IZ #;]_8:?_J9>:93MIN01X;D+V7EK_X
M''JHY8?Z$39V>"1 S4%\H6ULN?M<Z_8Z^NWJC1$\S2].;WY=JSQQ +,JFI;N
MRZ@OA;/:?BH@N^2%;'"9U#K_^66'R ?V$7;IA3$1=*R %L]=+]$66X<2C:H'
M9:N#.:TIB82#YX6SSFQLS6ELC2E5H=_;TRPDZI5X;_84I^TQ#HQM6>)X*PBD
M'9G&5++%#M,$.#9R@ZQ;A%S'6!LL&C/N(T1!K'<4S06*!BW9 J4M]*$;"9OT
MW.&$0&D!1X.1OZU[D9+L6QZLY22,,V=;3^F;)5M>IVUI?G'.1VID^>A%9ZGO
M5/59GXZRSZS(\,#2]^&K<D392\E&,<I485M$.*_Q]P,1SY-/W^.Q-!^?*Q!J
M=;R3K>^C.V 2J83]A;3DB(A%/S%5(TPMMG//G-AO<![E4C[FSPDH9MO%V&<S
M2P.F]:J_%+T^%^IM'7"TTR'G&:*9NPK/?,?Y7LV+1>@1 AI THP19"2L9X_\
M0]\1)3X^I5_$5:,1'$"C9E>PG#_>ALWP-6./NOO#_D$0KM6+LH%H,XE1J46D
M(2^!,F8)K'V@OZ &.E%=#N]E7;:ZY]PRIJO0DU?A+B%R-KP"]MQ/"B9IA=C;
M):&W$DZ S-LJK<AAF9WT98U5$E)?MK.R;MDJ$[T5J4W8V2/3P:IQ-X36!VCF
ML.W^@EO$;OWTZ+CSU!#NFULX%G?%Q/(965(1;-5RZW+&RX[-R_GW2_"X/ZIZ
M%S<5:.[RY$Z*ZM8/C[EL3-8T^-)L_BS=HNAF2"WAH$)MOV/L>I,\WVJH#I:D
MSE%G]5O4GI)8N9:UD>H9'>--3TY-W;"[UA[ZD[A([1G4S5E*4OMY )E&-(;&
M[]501LS<NNEV0A6HI&TV2-0#VC8QFOA<SM;:N#U6P]9LWX!'%7@*?V^QV.+L
M]$__":-W%-6(:(Q6*,-D0+9E!%:=F[(P$"JT5(2BC ),7H.) ;/B<-F7,90T
M7V:+O]C,6,D YXH1*35RX(Z]',A$*0DLC%KL3>1 NHU[AAS0-X5#RLX%!YA!
MF%8+1%O MCCS@[7]M?MV,;0DQM #O.O9O@N-$#?5]/7@+HFUWE2_O>5]'$E:
MOCJGY'"9--["7'S(W/SL/+/ZM[\Z5S\5U:1%H)O7%76HY^2)SA:9_I&&_5[<
MV%.3)RZ/G1ZU=F]LJDD6< ;GICYP!-\Y8V#+T%6_+AM/UU5V;KB(B MIO0X)
MJTP#HW1B#V V1.-&,D3/0&R2%2J\ BO9/C1#B.3/C^R7F)_78\UKAH@P:[?^
M2TA7D"J2M7TR$WR7YVNHLW,\4V+Q0F()C0ZQ*>F^%D\I26@6\C8.ZS14,VH_
M[L' G""V,5 #=/\"XA??]@PT>H*XO]<&P[&</]8CVPL[+70BFV^1DFWFA[5%
M(8V-D%EB^&)G6-O8NNZ%483/6TBCNLRV6%;,*Q2DVDH]8VWNC9^N<N_9T+O0
M_T/TV<?J87V9II]K].[*XNV4DV<_L/=:++QSQ6L'-SQ<:[GJGK7'2'"#8W;^
M\IG\1R6^D^0("X,3]54U\<U4KX%=V9^'6U7]#**KTQW.W&9?T/TGF[]J9RF
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M&AQ@#O> K!:,%NHP.,1>#DJNZ7"_/68TN$#93$M![09'V(,4K>M':OKI.^+
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MSD$KFUD'EGX,JY&L,T7<VC"PL*\FUJ&O<A(97A4GOBSK$AEN[B4<X2R1K>1
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M_3NZ78!<UO E\>Z3?H4X?Y8<E@,'.]PE6@H<MS GI@/OQ,A4TL1^Q?CBG>3
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M"K;=%R"US_F&)9RMC2,=>-70;1P;CN[KZ%T8]1QA9P<8/0@[3?'+.=,WYF!
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MY?;5OU;\>-6'/^\7W/<,_.-^P8TC:MOO'?CG^]ZM+?MVMAYZM?/H;UH1 <1
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M+8F["":-H/\2BS*,Y7'3"$@A5QEO=A0LYB;:<C<0CD,I+)R.Q&,@FK02KO>
MDEY4"SK\8YQ[B8:?1WWK;[_H?5'+& R27MCBZ'#KNBP_?P!.$LXGE;1B:UZ4
M4WU@!)MT$29#73Q,FRG\GB9K0^HODC@(/DUBY(51FZ/*#/%Z0AO?:_C#+(:&
M&)/RK2>B-L[]9(^%3#=8M@M^S*?&-N=;-L1YSBV)%M:MBR-1W$M*ZK8K02HR
M57<YL$.12;R.'!@>E/4CE]LQZ\-$/S"+D7+@#7-Y#8V-@7=@)$59LC6*D@CR
M$Y\D36^6'*2-_",'!MIE CDPL>TVTDGGY(K_K&'W$(</U,^T0XG;=[DG]:TX
M>($DB"Q> +1(*[!N0^-=D@U>-V>9/ JR=K.HKS,<1=(0!H_7Y_K=%.+@8RA[
M.V<;RP=MGXT#MYQ8NZEY&R,K(<1>@FUY>/JM?X3Q/Y,[;#\63%W^^VR4;71L
M@*BAB1K]]B<=>\:#?\*T0OBQ[*HL\DRKP_Z=-XG;"&7#'%'MS&S38_A2=V>6
M^'$#Y5>@&4U<DW^<^[,-)UXTDP/:V'@<;5H\(C-;7AK#_;H7.E8BH^Q@CBPK
MW*G*XKS$,)0K>8R=O,!7S<;.@L.DCS9TID+"TOC?24_EP#0!,[&2!'LR?SG3
M%FJE<S\4WC_?FL0MP\"YJ,?,\;O<I2EWF2ES%:E^40&BB&DNC!I@_MI#GI62
M9 G+2S*$+4YVO$16>EJ!2#")_Q_!D?]7D:6_*Y;N0F$)FYDVTM.'5NZ!FC9%
MR8$-VM>_K Z#^3+ND&)],#02[Z>7'/CZ02J3 PF$:(MC8H4^G%7:,E=<.E9$
M4D'M@HKGGM_$IXZW1ZAM.]>ULU"S.7!%*N]))/8)_)9UJAD?V;JOY&ZFD[-*
M4E;\,\$W0H>2093]Z[K7N*#7SA/H#="NW8S?P+8-?WYS&VR[8/1INJQTQ++M
MF(319@>'0Q:26ED9RD<.;/OW+XDS2A5R8+)NBMFIA5GT( UM9R[X#BW[P]4R
M)Y*F'/BLHNC8%SY RC4F317(@4H/TD0MK0NM .H6(6WY%XNR?.)&'+,W Y9H
MRX$ 6"$?C_WCW..T07J;M#U)Q^, \AD%/,;\==1YIDD.7*Q/Q2SZX;\SFXS%
M&;(IA5S$-N,D6C29IZ;8BO1Y5H"0>HWMI\V[H!6%W,#\QQLD]^;)7 D9LO?G
M,#+JSRAQT$2G'#"^$2,' M&*(CFS?]_4]@+F8_<)L"!]._!OJW@:%Q-\JT7Z
MM/)G<:C13-F%AKPOWS]$BJ[WY8==8H94?[/(.G>@/C"IT6W]7_\T]&<N^4W$
M-=[J5N%CD]  )@F]'59&O$.JS?;1W<'Q,X;;>IB\)X9*X, C,B<0G'O3YP=3
MF2%AY7) /0"/'\US=#U;WUWK0K>JF,SI]?,)[2HNBL$V)"SG?YXC?8I=I+65
M+7"5?66?L1O-(.<D!N"#3_& I3RUV6UR0$":>0J1A>WLS@O#!#WP \MU4&(.
M+0_*@3] 7/PN65_)^Q>P>TNVE_VG/)#LT6LR6.L8 $7W%84@7Q>"4[?6Q6!H
M97,WGR'8R/\N*# 1"E%?G#JO\"__NI<-NZ[56"ARP(I/('>?V1)/FXD5BJ)7
M.EV7"E:3(SU/W?AF<)O&V;C0B>UPATM+Q!ERX/=.ZVY2GRHP45J)G!6-8]$;
M#!U?H<W\3:)%X!Q7$3XB<RW-S\W_RN1&6;?^X=#MR[>FCG!GCOS2[SX1=&KC
M-XD5I/=NS"XN%+-:$@QZ9QB#7PZ1UK?SG\:^6Q9/G+3^TF8ZZ'V4WA1NN4T4
M$_*=FX%?\OV2.1SO?]NPV>EF%I[&ZN!GD/3K6ZTT: F5$G(UGDJ3&*-L(T7E
MM:_J?@_[?K[HN*75XRN\W6.O<F>3*F)+MME/F5;WA_,>3)&TZ7M!]L].FP9B
MUF:/P_J;C+-=##<<%69N>/KUQND_E(?CXP^HN#I%WC+Y .<<>SU$<!1F.,8X
M]3_7L[]!*W1^%IKK+VVTWI[?<?*5GF[,U6PO#POZCS8?G\.!1_69P[E,Z3K%
MQ/.JC\L!H<X*IM.?I,NA"E6S6X'F\9W6"B'L/>X]ZR$.Q,^+8J7/T4H$O;X%
M.9#2H]!O&RP%8?/ZDDM0"\&L6W+*9(X,F?#@6#"#W0N;^8'A2ZV.UF? @)2H
MT@G9[L&%XOZ+$/..!%,P^?.]('9>!W]4::$W75+8PPR?3PN#$@1!*71_,]8L
MAC\43S\C/H3W;F$8=*,-">$,N!/2.PUK/X>S_- &8$YFM/NZ$#E0/9^&-L9G
M' /OU0OZX2"^]-92ZU]XF\.$[./AT:X=:&=G10X9>)$K>37>]50?6A6?(PAJ
M1ZR4&$'<=Q;F?&?V+XD_[^UO<#.DUR('$#92-<%X6EZS6VR17:)*Q@PJK!1/
M:\D-',VY1]_Q#-^+5(-QS@,+?FL6;R,^OS17^+K;3%U)-+2#: E[MX.3:'VX
M##03J$H<H;G[O!QR )A?:UG"0Z@0/,&4=+I>)'6RX<9;#;* I@3_//BTQC':
MN)^.$?B%DUB]4PT#E7EAM%!;TF7<7:XFT;X9>@;W-2]AUT3CDD@&MN2D09E.
MTP!]MV#T9DT8+D51_W12P11C5U.W10GXB2)H[$"D>K12)] ;!U%NSR9B=,M+
M?/"%;/55R\7_J R=^:6@ &4_.?#PIJR?*SJA@,/^$M:CI2#1986&/:R@;'A7
M'P9N)1+E0//I*]%K,#P*IG97CCY[*)*<LONR[NNJ.V<5N.G-+[@&MKS^LS3P
MW?FE^J"=RG'>*Q5^&=?,%)VYNB2C@D$?(^LE]^F*;[HTJ-"(+S]Z2$PP7-Q2
MWJ_<\/TR,8G._=@7)O6_U]%#=/Y%T/%P^EU5IC#OO#'2KWU6'&W9/T-)S$74
M+1G1?&E)IOXC7D B,VNV^04X/J2 +^@6XO[DM5T2\O W2\UNR<N.=TC2_@_I
MDOHVYB];NL*R_[G/7>K[30YDRX%'P\M!"90?47AG&:L*NUS1CAS@9F"^>D-(
MZ>UHBG3OJ/>O F?92ZOE;WJR#%\YX"('="8;7L)![,#%7Z.D5[95]6('MW-9
MQ:-)^]<'J;)W*\VOJ/]M\]"O5__E4Q+G"8K$TEY!KD_VRX&B<=)05[\T8]))
M0ERK.$=P_O75:*(@7?8.\_"00BDBNMUA$ZRDR$@4H)# (VSD,I4>A1U[$-<J
M!Z))?]%XA;*U%QXHQJ&L+,T9W.^K@K8;JMI6X+ =J4&XTIETWV?/AXK'@0XQ
M$4K7$K!CZ*=A-Z]01=0CKM)IPTY17=V85W?,Q9F>%])?F[A/&X]\N30..T^Z
MR0$3AI-B,2J1<L#KUUMI]8*"\Q\X.,B!UQ0%Z[U\\J2W(-W\UT,9^3^>AQVZ
MNG;Z]@G'R$5!]DNN,VHPYNK(,?"+:SCJJMOF^RSC4RYJ19Y%KSE<9^UV(_,*
M<M"-U ^;J)4Z&\\I\=2X'/&9!NES5"08/]*&>4VY70 J).<:O!9)37(:_GZ=
M<I>QJP;23>*[W;+2Q,>\:SA3D>T%X9/H3C<+\$8N;YE-C(%:"]U3+[?LF9IR
MV]:^8$S<XNY^42*-F_YI[@;.MW<J87LM:BV\16+HQ-L7 1QL9RBG?F83"60%
MQ*&G-EVN9T -$@R8D[H-_%[^52WV%_,URE9H5.)JDZUO4;SL5T$J6K[4D+@<
MG<BI+:Y-+K-X6M.0F?EH>LKKAG?O(7),2%CI^Z 2%Q(N?/^#C3CCOIF *1N?
MW-XO;], C#:35R0'?CQPA[>Z2Y_B9@_*@8HH:#4SHONRR>:?&S=O1C;8:]]&
M/#>.PJ92_M,?"2E,EBXFE)R(7$4X?)Z/08;F#F17Q3[GA-5!(6.;!Z+Q!NX-
M#4VODSA3;9NVNKBU/;U&5;/[^V7IU_!HLT;+#NO-(UJO;EY6TR:W[CM6H##M
M_32?OJ2WXS.3;9Z124/6QSXL/\%+VE<\XH^9[VX[#^X+W-<7#9UY?NC!D]'G
M>IY%A88A-C.TF*!+71_BL.]\10H447:'S%()1F!)*]%Z0.+WO"M&$.XL0#2'
MD6$7B1Z_Z:+K$,&B5/(';"WV";'O#]"J _<^?O$YY$;#_\+:>T8UM47MPK$B
M(D2E28V*]&8!40CD*"("0@2D2,M!1 @14 &)$!*E]QQ%X A"E-ZCTA0A$4(1
M$>E$0" )(AVRE;(/:5_.>]]OC/M]]WWON#_NCYV,/9*1G3G7G,]\GK7F7ENV
ME:SP/6![M32R!H/?5U?+1F:C3=-(C_#[V=/1. 46(N$^5PW, "(W[R=LAH*!
M13A4+>"RK%O*U0&"X_FZH&,796\_W(@I;O312X'M]PAG"S2V;ALEK#8C 5D6
M*5KU/<@L7Y"AB&+K2$K@._#7$,VX<4&=>Y;::LXD@+;-I$2_-L2XI;694'7$
M85C4Y7ME^UI/YJZ]_N?89?S7(!LQ5/UM6A_GS[,;MM0@U&.Q>P5NI\!'>LVV
M&+](9H\YF]Y1LH2JI3;E]"";!@+C'I,<&EI:&O*G.C'G9M,7_3W<ZW)#O#XS
M*#K91OH2<]"G(<4F?YZ"/BW6^.U4JNV(JRU5^%RD5+ROY,?36KP-:_6(1V/?
MV^*^?=?3@&]AO7:5]J7G^+^GXJS,7*V\SD18- A5L3;E(->42%,V> -,=Q)C
MQQO;A5KI)C1]6KF>9WF#O;9, G:U3OT[@P=+(NV@^IE*?B1)KR!N"N'Y,A<U
M$RR&M6D#0,2,>NM#N(5,',L$)H7[ P@J!/1L*NUG/G"&M_Q#]1.SIE]GTXAC
M0QTPJ)GV4KXZNX742DKFPT'G*1$@J#$LDJ.")M7'Q9>6X_:^ PR<791E &1[
MH,AFZ, ,VR69(HZ>.C8,]V69JELVL^?[@T(%D,/?4J8IV9L?0*_QX7QY3Q'6
M&V"W\ZG%M_,S3%2J[3;ZZ2==UO 8GE;WK>>\NVOP[O@I3.&F1E'DZS\5-[)7
M1MB2#J.RM 8CY?--]'P6JSO4"8QBN6[ ZL=%TT8*Q_HP4G]]=W\HF<1\[O-4
M)O[2$Z>_ROZ^&RYM:WWMTYD;G5*9Z,_GM'ZE:G2?OUSWXL]A]+ER0_OZO85J
M18.*[VKC"UC%^;Y/A"2CU4;.XKRSG=;U@A=K6F_N)V<:O!A"GYNRI\(XTEC"
M,D675P[W8Q!% U!0/@1G#I*9NN$, 21V PG!(,0H]*A2[G&V71S@V)6C3N,1
M+K%'R<Q@">Q0EQLN^H@^]WQ!'PMV<-Y,'?CR@)Z%UZD?-=2G8&9XA,TI$,;4
MSG77%P)J6R23\V'I L$ON()K!B@U9S^PO6?XLKFQ]X/H2F]O?0?U16K/W 6=
M&],*.]8;H^&^K[@7V=D)7 RSO$;/ ":)SMINR#0<J1HU.CSF$7WS8;6>M%_C
M?:F?FDZ>D<G,KA]R4R[QA:E?[C<_@(HFDFI?);5[5PR]<BO5*>ZVJRHH_^J<
M.EFHQAM[8'+RQD_D\YM:S)-R66*RR:^0XZ.T_G:'<K=,DS;XAN9EN[M$ P99
MH_BAWB+/^8_%>R@Y_!#L36D"%3U]$'3@=,"D*5I83.NHS#8E!=C%3$@P3),/
MWL5%LDOJ&:1$_+YA QN.T!<YDWW1&TJ6UF!:U<(X/84/\\0&MV_W)6RB9;,%
MD,"A9NT:$)4L9&$Q7 M@FD:$@"+7V+ 40ZHH*L#,Z-UKRH?^U8ZB+6<,L\5A
M-K#T0;HMN[K=_HODKJW$ZGQMUEK,M"Q%"YQHY1OE<&9DA<ER$,OZNH]^A3WZ
M'!"YS.Y\@[F]W1BOLUQ/D!C'-)F@\_6&R6N&NC:V&5>RKS?\95B=_P3MHU?.
MTC6Y]I:CF$WSZ#K/7%2T1)[ZR&1G OH'RIW2PIU?9&EZ>UK77A]5SCSR^7>F
M6^:K(UT6$>E2<[\>4A-=%0O-R+3?/4 F</UDS^'%H<P]=D5><C<SM4Z&*474
M%^]ERM\M5)NM>3:C21[$](T%*06S[%)F@F6X_F#+#.P %M&UO=6!A.#TZ!O0
M/=2XYD/"@+D(A"=(5)9@H[M:G0F'-G15:!%^:=Q+<"@3<1!+=V*OQ=8$5\^^
M?9NO)-+60($!*V)\T3XVU6Z(ZS#>U0Z%@3&=QO7TN'KH/IQYBB6(8) /<PU'
M<7( U JL+L1^H+F%TTAQ4P?97F]F)I$LD81F$Q9,61C(0GWM7 U(AYHB_@#\
M)G#:FRW[EYC:A%0!1,Z0N N'H/13C'%N9EJ ?CN' ,%LY=048S %W_K*Y\>5
M9NOD[7)WG_'L"RSV#"CR6 RG'YQ<?"NJ$H,<8L2K&%63TREJ*&R^[NDNUE:[
MQ4"H_F$LC39U8J2*<@8]WB(LLR+Q]7DVELC$K=)6MB5[K-[4\5)F/?'@O!4+
M(8J., _(NN9)"/)?T>&7J+1=I1TH6IP[3WCW)ATS=O,E4U'JA:KFY6KC^_BI
M>W=IET\]F],TSS=X5O.P#N[PD:7H!"]4_LXO><7YKC,\FWKMF8^<0[F#]K<V
M.VR25>?)U%N,Q7-C_$=<."]WU4S1)KA\ 27'5UM45J/CCX,9K(1._4.+H],2
MJWK\<UBB.WB+>L @1?_(&(T1&65"RY=GZSTI H\OM;K!:.[!>U53J=!F0Y]*
M3TR$)SU9%V?1Q_\*JU5/Y>\$::S2Y'H!9!S)LNST-]/#IA,4L=E_ .1HOA@8
M8M< S'Z-89!%>UA16DM,*FUMWV(_H4.7H0N]XBG_D[]D>8">DU2/62C,@7TA
M*G'=P']*L/2/9HK]? -PO$U?&4V1>J+^!A@V.\NNDR<EADVD23";S[# T!X$
M:+6>LM?=!]<J/V,WZN+<7_0^K^HPLX;K+!1.*32WJ-Z^.#,]\)_"?FY@&7C&
M93C03-L5VUXT.MI(]($FA[:S1S,$D'US2>1IZV'R<21T$N-U^.FX&$]+6P!9
M"53V:YK*CGF>AV9X'UC3#H;)?<W%'"RT/IE=VX*^?^/WB$,A<G'M8+'#*"[]
M3-89P$^O5/'67,9/JS]]]UVWZO]9,7=DF#?L,9RMJ[[BMQ%WH5.AQE>#//4B
MIO\GU13!J"3\(B+&<_G=PZCM9^#]!J$8($T?A <#DDQ42AA!":R\ 025^@'[
M?]O64T97G1=_3K4*64-/45VR1;KI:]V.WO;6D_=.#"IROU410*TF.00C7P"I
ME_*Y?0N,"CSR6TUFX"E?ASV^0[5'VMV_^UQDEJ][J-IMW^LG<*M6&:/,-4DP
M7*U]I-BK =6I:'JY.@#^^=DLK_1Q.3;20O3^.#JRVZ2T?RND:CPKDDF)RKU6
M[!"G0]COE_G*NE&[<@\O+S6N='GVW!00//DL,V=TCBTLUE%==Y?WK9__"GW5
M*J+TL&3GOD]'B=<NB,Q;[J5Z4>\@=[O/\P^ >V8"SS#V$OU*_%-"F!/01SG"
MXI';MP^<8CTDXPV6Y EQZR085W6T!C732+.5Y$CT.0&J/_]>8MG\K="6K],$
M[*DG=:2Y!W^FUI%IHM54##4E*YRR<Q0GRZ;;@4\*,7B-#!I_[W#S&29Y#U=_
M>(,DXB^\1E)HCTF@WL35?KA*B<?2_85-H\W/.8;IY:;YV=+=%"PS@R?;_8XJ
MEM,EP:^9U_IV9["%_^9R(S7K]I&KNVB.]C_R D;PC=95?G90<2,-FBA*3F:Q
MBRN ]+Y#2F8V+4U4\+LDLZX)(.'55K]NNQZP,[P9<%[S8IH\RJG:SK[<,#$Z
M)5\K_M#X"XK^@:+7!XH*I>\>.9RZU[I!=/SC_>N,Q]U2- .MBA4#+6)>NF^J
MRDR9BVY]XMQ1R528.:J. @,Q+Y?X9L J"<A@(N/@1TA0O"GN#_;6<F/1-YQR
M__(*_^A\!+0-FI:OQA9 :"LJM$V9?!AJ?!=-AJXL"YYAD26L:@+&0< EN=G&
MNQ %UOP<8DGSTOI2\U0\,F:R/_9>G')A/\@ M)DBB<(0U)OHH-8*%?':;J[+
M$$41IS*"/XHE=8QGIW+%9>,-21 W,+O=2XYMNXS? <S%XS09'/)!,,)S]Y*Q
MYY=MSZ^%5?<'9Y*E_=QRVAQ3R_Y4-@Y332G7,;S2K*<..^(-G,.)8^GVK=ZG
M] ^=ZXA4#$247Y2>V*RL(.]U+MSOY)ORXI6[XFO[4D7=<ZSR[IMWO\DA#R60
MTU[.G_<YA25XB]I6?#-.D3L_X"Q4)2=IVN*?/W^^<"PS1D_DQ.KN&HB(^KDC
MYQ=0_0BNPN?/TW4B*WN%GT_OQ>DX/8MWAK'SSWU^?>+07Y<OP*.U?QFU9<,D
M\6I<%"$U7QD\58*99F>"M9TY-7G,O#/,VR06-&'3:-LEO@B0J64*(*)8N<L)
M3.01; HS.X:LT^Q8!(J:T>]5>BR,.Y=6^<M74PK#I*?7 P60W=7]==4FFR]&
M-U:,;/,[@^7X'21H?5K0E@>(*<+) '-)82LF,PGI=0K34B!'2,82;B(E0 6'
MX>HZCA@,^MT_9'H,.]'69)<Q8Y*R8&CK?BT>F@)4&MO0^,=[M :+*F=.OS"U
M3L[2=,E2D+0YU39<>3' P$?$#N%2O6\TTRT,<SVV)4LF=)Y5X<VGMG[/1Q+/
M19XN=:A\%=M;.113&1>JDD0;[@$.%GOE9MZPM?.:>C9KY5AN]TP=ADF*LWX7
M@"5."2#2#-"G_8\7T&5='_5^PNW)6W2VB_XRA]VPM'FVGW\:ZQ L#79U'<2<
M%4#8)&PV#:_)#BHLX!IF5G%-E"N9"&6<5F8@+K(8&TFCCK-[A?[[F:%7;;I9
M7HZ6'9RP8)K>;]-%<(8 /VXR7T4 >2TA#+F2B0H!!(X50-#49%MVI"UXY@1%
M.H/V(%[[1E@C.S@^(2U,?Y\:Z>58%WO."0@UOF6\LA5MC8V\FK[ZV08H7W1S
MJF^,#U-RF*,Y.[MYP!*CY-EC#<>S#S=7-/OS4.>9UN"&\89&9\-.@W?1A@OO
M!DLUG3-^II1:AQV[,'PM,R+LE;(KOV<]L7W6-:+91'$PM8+GH\G*.:*^7VK)
M+NNL(W/K<D6FVY.T(Y6&#E6:7]^6S,H;:GRU=@CNFDX@27!W(-ILB/%N72G<
M"\P^9:Y\?_/#D"IP"#E4%^AH/[J*"P:@;1&9*Z2$]3&R"GLJ*8(BT= RL"[6
MZ^(V$KKD_JBIH3($_[M+!/42!P?568@8BA$0ZDR5KKO!5\ B6G-*$_$ZBTVD
M!,G6" &D W80S#:O'3$3!5%,7B<1H]I9 M<M6]JFQVXD\H]Z+!D] <_8 T;)
M=;IB;?+/_.QH'WC%AIZ8&V!8&9C-M/R89HD$O4N\YO,5^T/[XN4?$$MZF/_<
M:4;Q2,Q K_-K88EAB -H_%$@JYA5&766]>U[3<-?GA?*)FS$Z[+^"2?4$=+7
MX-)"O&F%,J?C9#:I8@:3QEW"-$G4,5-8V/328;=LQ!?Z5O:R\A .Q&O&'I0S
MHQLV8I'34MC*:_WD>J3DNY-+3[W&55N:82/3SBPY[[M''D:B@A,ZAJK=%70^
MG\RTAGFT7P]=;(N7%Y.T]T;WOW*0/G;@!/Z],4"[61Q=>A'U93_%7-'.Y&!+
M]AMR;)[\.</LK_=*W1?_]M<<RKMS:?8B5-JA!6LGF:^'NIXFZD(SEW5H-G5A
M6;:18J8.L:%M:RG;T.CFL K0KT-8>6\P_H%+PCJG]V"G[0&)QWY,6Y@[&U]?
M!4XPZ=&KRV:'<%8CY+ ;/E30HG*AZ6MY.-K'</69KL%$9.7[9OJ,7S1> >LR
MXYE 0^P?#Z!(U[)YT[%P)<#,,Z2S']O6=05\?+8X.!@XKJO0GH$-;UL2,H^M
MZ-N4;%K\)@<I%E(!!KN-XCZM?Z@\=_,3G>J/A&'2F,,)5\%@ICM4 G?I#=BH
MG,30CZ<<87O%D''60_F2Z!FHS$*$P:$.EM+%?3<C%3":^=,7AT(G)AUZ+@\:
M?*JWF39)12:9J7JZ=^8??8J 3H(I76X\<G(8XN"BLL)@F&Z()2!-3G/IZG)A
MQ[\B[*&!;JN_47M-[:L.%8Z$GE?KUY\A7<UQ15W]H/>U+%+^[^9+%=>+D0IV
M)V_DFQ6??>.Z&$*SKM-N>EWNN",VC%Y?OG\$\SF4V6<M57XQ"\NEJ5>OH)G^
M&H[ECGL<G!"UKZ__S%?8<XY5:'T]*M/Z;A=KYD)3Z-SES'V7[\^6&V?ZN6S0
M-XU >P9J+W]: 'G+;V'G=]'&28_KUHBDPV8PE)!6PY29X(A8P"CJ /Y8@)G"
MH"''E:(,RD#%%R.H\<MZS1:EBSFJ?<E<==:Y@A%= \\(M(%V/6),_O^=:F3!
M^*)TH+(3=8@:K#_F_L>(#ER,V;L3D>*E#Q1O)K&7A+03)!1C*&>'*5+@DFTS
MD)!XAVL:N#NBIGD\LL_G=GMKT?QH=DX<):8(;1]@U(/89)/N$291/[1!TH)<
M0I<W-C=^_K:TM(>%F4Q)2V'[S5-.JB)Y?H=3JA/;&QV*+1],OO?>]\XQUN$Q
M+VT=W_[G&P^3=FFV%"]+&6?C/#RJ'"]S**?[EW^WPZL$ZSSC@&[M]W;W?[[X
M\3W!WD*:NX[?_)_O0%7;&_(X_WG7N?5>7:EK(LPYKE3#]1C^_@O"ZJ/UI#W.
M<L638Q=]//G&]VP>$8Y/27QE=2+X>3RK[&*-9W)![0$2J#'[0Y:DB#NE8Q9Q
M%/1^1=ZV+9Y\]ESY&&!SR_SA@<-OO>,5CUV\_RK)>1?FOUGE_EW)%\L#?%B6
MCZD8TDY__B$@GOP2G<'OFSI,S?I*6_:ZFOT6G&'I'/9H'-=9A7W!!KY,>\T\
MV_GNVGWDBO).1L!MY:/7:(-YYVQGS[_XI^*\!N=U<>D'.9,/"Z6][JA/N. N
MAQY0IN%XE9:=V)F>PAY;B\^_\BZ16C0JU2F-O\RJB1U>AYIY^=Z#AF19_Z&E
MT0--B(0[Z^_ACB_!ALY5;0V_-^RMI-!/O5VQS?:,GH<_6W+6O%H.MFV'C\D=
MXMK<S+*T:O8M& ,_,)')7!<A-BN?;AFB*&,;6[U4A^\T(ZLPLN/!23@+_?;I
MY;S[F[8FMO4CV;3M6_@3 X=_V_??"#98LE*M&U@IR/HLC?R9P9?7GHDG_"@!
MB4<)P]K'K):(RU]6)J=+UB+N\0KPYP%24K[:7 GA[3]FTX#.U@J*3FP;KW9)
M^5+8G43^FYYC>SETYKEW<1S94OP<\_B\@WUN6>$>M,NU2GL[J^E_;+&Y%L:'
M;X39W3$\L.?(_ NU7UQ;N*W\NT0;656W4KBTD2;U04JF,:Z\DG"ENAJ[4P"Y
M%+QS49Y,PP9N0 _X#X)9$[1\72 [%BX23/97UJ>3FTUE8PS?<XU8''>DB@4]
MB"STA46A10'&[040H*SX/J$CRT72XV%"AZDY#6\&/F;!CJ"WI])\"[ 9G0TY
MI\<:-Y]%U#=DH(OFLV3-#-^_H=3G%0ZLN2E4?O+Z?>T]71ZX[7FY'TEYB-A)
M8 K-GX.Q:^&V'X;DO>X)P^C+((%F@;O_%<&\C<T^SR"TD\\+"XF?VV(K>"^Y
ME>6;4OS\M],+3$=39L57V0X;,:W!M//>L_NHFSHG-+OUL Z%\@YY5\I^_68U
M7VICL8&VX1Y5>?O,O2UY\M=RM^ON'2J4NYY^S-HJ*D1:ZPE59]$Y\TKGX>#<
M+03+K+%T*?\<?3749R<VJ).WKK]O8CPMZT$^E,UI>,+\6U=E//=8E-KHU.9%
M^Q/YOWZM_KH;%'3[-O^1 .)K>OOSQ.9]T.A >5DV<J<_X^_0J)NL,X]//\UP
M_]9S(.6ONP.?/EL>_>L"F=%"\">E'Z.'M_<=YLU^4K&9>T+GJS[_27U/!-7/
MUE> *9ORO.SZWOO;44CG8?Y!K-?:->K[7US.A^<JI"_Y*,WCQ$B&S)B\_DMI
M,&%0-F'IUHMCM(%,-R=-\_/%\:7=6D_+1N"-4H6:[QVC SMEG]7?SPBL#L+W
M,LX2+(U9S=O7BMWRK&YMW).<2SM'VWJ>+O[YY+5R(VDY6XW.;F'JW"+_LN1*
M+\T81?,5<*J@53GX#!NG&X9(EAT/*W_+7GVE$_]3?P\F_,X)F];2.&+W95KE
M!UG&L1UC!"G<,0%D#XQ-?%P7Z'.1O4IF3;@KN8H>_(Z5M*,V#03W3CT/UR,S
M)WJ64E+2))W>&5NDGO$<LY([+A;Y:=#4H0M)K>-I"2 Q\=0?C_A] LBFAR&,
MYTS1),^Z6+$;D^IY)NT1E 3F9,B-P69826L52'88K*N<X$#%T49&F]N^E.(:
M3S>:CK%OZGC<9$N!AV>S_?,3.E>2-7^DK#1+,+]D&[*IFI4Y;8;'X%TG[:1G
M+9B3KK?KCR74:3L^BRJJ,+X;_2'DQ3.'(!QY!N[/TIG3!K0-BC.'0^<.[-TY
M6"A/F1[KT2XTWLK4>I)]O+1/<_Z9M^QYG!&JIEIHM008.B49TYJ"@<L;U@\&
MR RYX]3[J^L_&88VU-?RIU+:[WGHO<WAC(^YN_=4Z7YK>:KQ"&WT=*/:B"OU
M@>;XI5;)Q3/1ZE[95,#H*%4,KH\I!4NV7-X$&CFU /EYN^]] RE+#F^>NF/>
MA\WK[Y!$PC7%9]OI^F"/3$9%;S%JZ?5"Q+-QY<PP;Y\*S#WTUM/Y<=_5LFP'
M] .WK&I%\=)O7@'VWZ:Z2]V\/&CW"$J9/[*>?,EJW&LJ'MZ6K\5^NQ#,(HEA
M2331FAMJI05&23B3:FQ46/59Y[2;PP8A5:XWQ)T[+^=(I_]&&IU=';I8>>S,
M)=C&7*NBSERWCJ'<]3RWE8L8,<W/U5<<\]4&,F6^+SINAE0];7XYHXF^3=4@
MR@&7_IQ3M'4=BC/6_"HFN>]RYOG/4K(&&(VRRP7E^SU5U,^U]5K!JK?)7"G]
MC_)M-M+#X\-GYVS>#%3I&JS%N\ED8I@\!)*.8)Z(@^M*Y&_.T%S.8"[;K)@[
M#,I/.(Z<R)\U5.@I6SUQ,5]=B!UQH&3'9I)/M1>8.*%DYWG_EZD^\VO2*R4?
M5/[W\5Z6TL-UO[=1(9Y/)V=C%]V2<FZYIS0D6NJN_,C@(U#H\?3GA+#B@(@H
M?F[%-\]N[ZCB11D79^.\S/73#\^X3J&W[ID_1$=*33=E#;+VK1[/WG*X]!97
M/PB6,NGM^KO,?>[-$"#8N=:[ ?=M)7(1J7 E%DK,O*PW6/'^=XO2'O)"1&CX
MX$2'CD.?4N55=M>)^U<JTJL"X$HTJ0KO9VB'N!OGA]O<7%V'G[W0Y+C]'6GO
M\*S83FK2RO'#O52/O$*98B!<TJDT*:AJSDKK;@?EZJ7R3JW[FW?)'+K4LUE[
MQS3;XO,:&]3-?Q5F.DACK"4*(#OP1Y?,%% '#3.)'3SSJR^FL.$.Z<AZ_6@N
M+/2B;@[J%5*+=>9]L?/D7SZ[,(CR?]>YZU-,J*!ZWXK5 <TRD> $^S_[B@)&
M!XA@1?-9,W1-E7?<Y2N<51'\HYD9)&C4P[=%LN9X+_3>"" 5$\S>J);_:D6=
M:]CN&H%%PA:8"^>-0]]M)?A(W'Y1O?&]FM-[(O=#I.H\P?_'N>2_R3OG$JL_
M+SHQ4G\YSGJ\H0[_%L^<S!KWW":U%6)K.VS,'AO@U0$I2=#2+DJV+?MLT\]R
MOS!FFA+94&QSD&L:[A>V9S2EM'ZULGS2M";/L!FIRQOSU3ZCZY'1Q3?.GW:K
M_P 0DPV/X,Q?=3#S_#@HU$A8>3#.1.)]"9@9>N9>I>?4]PM%E)8B=$[1ILP@
M+3 DW%>L3_&1,55- (FB3@7_1-?S$WGN4+W+['7W%(>4T)??;U5$^JIB%U3=
M-JYG512&()\W$';J7#ZFEAG1;76N6RO#VCYT1%W.S:W42NM!N%>OAGOV15YG
M=:67N&'01J#;2B@&NV+@^V'$4*QX(/!8IE\\_;*L[&GQXZ,*<>Z)@74#F-U&
M^VL[Y*TKF%O&7VLCRSP#Z$VCM9&5*$L=E_'Z57+Y5 !] 'GGSEPRY_K[INQK
MS<F1IX4GBS]=?]:IC3I%ALPZ!TH7E-JZ]4>_?>944.<8X.@>J*FJJ5>MMG%L
M.'?J_I0^*[(-_CIR[4CCD9;!0%VY^TJ6]HWIH]I1PK?D3FY PRGW1=G7%CX5
ML<FG*KYU'%A0RBI3:8Q&K)@XQ0L@/='[^ -OCV0B" 3&(^/9D;X5:8Y%P/@L
M_TWE]!1.B5WHN6A$K@1CKG]X @^;K<K.?DKP#Y ]4/[6X.E/2VWY*O]6E7%J
M7SWA#P&$'8S@OI!=$15 ;F':IK?S3?&>,QY'F_5F1,LZ;!:/.'TI>%^M,Z'W
M+'.4\MN*LJ*VYK-.%5%79Z%$+3[;(5#M9EY^F"[MKDZ]"2_-NKJ!LYD9B'*B
MU-)X).C7'E!><6O>>&#N(EWJ7HFGY-/QN[L>19"\>PDYR__9!"> S(NA%L)9
M??](<RT%D#^5_ 00VT8GOO\385RG\-];"" %HU3);2'"B*53E^8D" OGQS@B
M_[;)2?_;)I?R^U/"_Z=)#L:VD7. @AKZRU3MI/WDM/KEQ%=9#R76$I2-+C1H
M'+9"_?3.2YQPT?GF=!/1G")^<9SGOKST %Y,)(R'<C@PBL0D*;"A\3=^87)V
M;:R3]R$;T3K]?[FQ[C^/7<"N_X; _RKEBP%]*\_9H \"2,^78(0A !3.AD5U
M^F_6_+40#"J</X:"?I5 ,%]PE;X)(/T<0(\:N6U$Z/Y"$T"^Y1H*((/^I'C>
M,>J/R9N(Y<!, 61A+']7$4ZE'X?D2*"-O&1 HR*H\K?I&]@NS_= Z6/*T06O
MTT [<D]R8S)%$N?-WJR-9$:Y7P'$2TJ+P.#+;%BB#LZPM*5U%&=2-!X@@!RJ
M#N79+56Q7=J(<0BI9;X2IFF+1D[ PT;@)@"*Q4^:08CZDT3,CN.TA7RFG(D:
MV^J$'>8>XIB"V;3:@' O;9"#X*KFBPS?&N;:%P2<!#=7=8T)>S!&\3-=.9Z\
M[-DYKOJ4D0 2>Q1G('S]T$YBDQ,2W3MB6@D3;H_8GP %-S&52@'$)XG?M4D]
M9@Z=?*@=BJB3.526$1JT1)7"JX$%2[2M*37P"2#2'CYU&/N#7;S:,D.0PLCF
M'\F1;7RJ39287)2O[NA,"E/,RGJJ._5<M[H_TMWY=U)#3 ^_M[SM^?#HV9-]
M ?;8U"ZC3F] :I'E>4=5A[9_WK'P2"\%ZY#KA+XH[7^==KU4U$8RK5"3B?JE
M:J;Q^2C[:9:579W_GZ>K]%2@#OE*#AU.'V_Z>!7?L#[E\;3R",<X/73)L=VQ
M_%P7-*:B, D5 7YHFY(:P$.7$'5^,7@%G![P]<-#!C4>PU2"7@=WA3$F#A4&
MD*3-U+!&7:1#7$^.:0>+*(,]*V[)<6^;@H+WF'U2H,NU]VQ\<3&VP/2VM@TL
M4??>0Y%$K@7XT)>!&B_L-$8^YA\20-K03/T#2QD!XFRA>N+Z"N/Z 'A_PTQ^
MP<P(Z(H+L_$\O#GM!>B26CTM74:#PI!B5E4-I6%%V/.A HADW>;A@/M(AC80
MSOH,4I")FH -ZR)VVQVVW(V[FV\"N&$IMF=Z7 FUJ/;*2G'?NH'#)S"EN=-O
MM JD']^XGNH.4P2GK[I+#<'1+)YA*%4*.1-U$LW7H-])SYMQKW1=#FKVN3G:
M%(M$LWHJC]Q\VP2<$%>N#4'+NWWWZH8<HC\02?CM<>+-Z?*_S0_)@W=\]PWE
M>5Q5L3M2]J=/_*L(K52ITWWE+JX1WP)<4?Z_K_I:N^)VO^I&)2CD^_Y=YEUX
M8/>\=;R*B)?3,1NHN@,6/:.:5,6KK3YO<WI[4M8K_7B-^EA5HXA=C8I\<:_Y
M/'F\D.9U>$@-E&/U[7'%HD.)B81]DFY40#V6*U+&/3[0',@*%.OBGV)WOB>[
MXV C)[*"(6*7AM;[H*=>/ZF#R?45]LTHR>FZ.#37QG#@PJ2_3>B.YG<+"?=E
MN*80YU:UP=. >@K<:280S;TP@Y $4SJV>>T/1H>6\)IT0^3!Q=_NX_J9Z#O;
M6>3PA]C :A\U$W?OD]&38CJ'.N4>\W\3&,\38*^-EDET_I6N.!-) 41GU70/
M?M?ZDU;Z1RRA[=M5B_"D2IO$Q1"GC)]!9UI_.FD._;Q6+!HI'Q*G''#]Y+#J
M\IJY:$S! M.?O[(>T3'0=8]^F%5F[QKAA(V USU]ZQ!_1KO4X4%(I>I*Q<6P
MG$KW0S>,L\C)':-.IPP)9Q$,)OF?HXA: 827+2X$<R=R,@;XO7D"H"?4D:,)
M<LW:K+7D?"60P$S\879\.$P<RO)+,9/AHM@A 5X:H%7!)+;R2FW#H&&?*,ZK
MGUS7<FIEO4^DNP"CK&+KCAR!2YX8W_L8.+UF'_P- 9[S(SU"U/+/"""J-/ME
MPGP.6#I.S2"8?S]\855TCY5R;+G6E=;Q*_-7R,5L]Q/%)- T@Z'M4IZ0W M\
MRW1^YJ/U)$OA7![&,N=[S;W4ET4Y7AL5;?4B+E"7.?C-KUJW\#H_ORU>1[-4
M>9G1M"8G58TV^_9;ZYI>'HT_[3,<[J$;>R+N%]]P)-NLA]@!:ZVG.-K84F8V
MC9P<08FI0;LE+/>Q=&7;\/I@9 $8BJV<\22GPBW+L1.=.?GU48"8X\!:J(U)
M>5W@3E,'SN6,*^ ]]A#-#.;I@AS.]:#_R-EJKT:QPF,LHYL5F+ T 03*U\1N
MHE(HI\ 6,C=DA _G*@#*J53IL.F=4_X1T=QS#8!E:I@AVRBV+D^U7JR'D.BE
M4\ON+)Y!)2*^R6?'AQ(.-,;C9(,1/ZO51%YR*S<^L3.UPA9'MED=CM5IG3Y+
M]E]>'[GJ4M?.8A_Q$',L3TC?6VPMMCA8[0AU&BY-S'O8U#U<G%!I\ZO\GJWU
M,_00UC(^3U%9<M?E&L^T=F9+/DPTK7WF.-/N0V=;7OA&XD!I8LDKAUB-"PX!
MTJ>D%GDDCM6\?0"L'M8YG>2,-P:1E>#MX.125OKSRG&N/9N:/ /H)\ O ,9?
MVP9GKC:R:PI9NBZ>(W^B%;P H_AJ)D$6/245SVD/09^Y>%QR 3^<DQ C9),!
M7IK#,,8LJ4,\?,8ER3!P?Q\CO*-/FNO<O[$6E\,G52VYD9-QM_E' 432R_Z-
MVT!49YI(K'K^=*N7WLCZ!P'DX#B6^+')MB:N^&\S6.&)C1._D*P(4OF:Y]]!
ML$R1C/<^%58_AC69:&.#N83-;Q&A)X>=C-^X)@WEE.L@3(/1^\L[<<]DE.TW
MW\Z0\R]7] [?O3[8N]0G:>^<![=\0W9HB:@IUK2![G\2.H/*(M;FJ14K!WQM
MOK5 7J+RQ7\)(!F.X'L!Q$^LBK#8 (:@@@FMS@+(K#*AWHB744;=T&3/XLP%
MD+W_O,!_)L@:"R#=;4M*20)(3B![;I R)020ZA="X6"*"+CCQ[<:]A3*CN>E
MM/P":BQ6R%?DA(R"0)O>SLTD3>!."2!JLOQEW&\!Y-KO7: !@3*]9O3;8#R$
MMRF /*0^+Z%O'U/*+N 2&=<*DC4?N:Q#A=<5?KF[%=]/VKS<K"N E,_0?P/_
ML8#7U[6RBW-1F? C#>LNE!^O@*5?T_("R(]1(('WB(G8P&232K#G!1!UHUC"
M\K\H5/'E'L_U?W\CQ'H3X UCIX!$,O=16'X7_W&CUPC?_\W_((%"+'FIBU=9
M1_)EE0CTKXI"*A-2NZE?+ N ZOP6 ,;/_(M8D*S-@?#M_V/_E L(1B;AUU_$
ML4A^5_!!H7.!7D*$U98L;X1_D1H]_?_O>^7^V_>J6+#!J1P^-#%%C<4_F_[E
M_@.U:<T40#:"<TD3B,O!_ZC44CF: &*[O+OKWUG?SP3+?_GFGO_I@.WA3U#9
M2%2L -)XB[K'$ G#6?)>X@^!M$T<D)T$#V,WLM27)X&;OQEK[0CQI2D==A%?
MC*Y:!P3E%@7D9#:[4)2:FH9^R$!][O[9U/2XQFMT\><4ZBLRD< .LES^ (2[
M-0+Z'<$3LOS]*8!VNW/$'7G=D@\SY(G(#C.-D96Z2$Q*Y8= K>EKHW#5L! 9
MTIZ1E94O9Y..1I]?7?6]!#6(H[[<UBX43^E@5%2 <&<544^+#N<V>F5"1:%V
MB,7U8@UDEK/'0$M>_57:H7C:S06.HI=RO%;*TXSBQ$*[%G6-)3GC,!\-(]G:
M@*57W'%"NQ[U-8&G".-*"<?G\-)U >2GVA,J@Q[\[0]-E<T887@FLH6J(J-I
MQ 3*.8S9OEK0 ML0ULSYJ#P"DPZ;%4"0W">MO,=/"/T9&@((+4BLA__BH<H_
M6J P9/;^X'=2_Z4U2'_\4=Y+1/#(6]"<8^'%U6<_&:(&3+H-/F"W(_90]H';
M*I6?I@Z_DQTG;6ZUPP[N;18-$G_TNN'7WQ,/!WE"C7"PB=\J@*S?);#M85R;
M:D<!Y.\<?OIR:)[^U6P'DMW0'1WUT;!=%8N_;]R8<.NI" CT\RUM*"SK#I8*
MCL+?,5@Q^S3E:4!7&^S\^JWGAUNK8H04H>K?M#1?7A) )-X)(/K;B;\N_*<9
M:P+(\>^R&0((2?D*/U"$*[_"V;?K"4?(TULO75",1F!:'(]N"R"?,E#F6!1_
MGR=[[2-?>8"KPJ""&HU<&<DV+VGV1JKQ[1@F68+0>I%R;'Y;)J5D8N[3Z\'U
M#U#H!3\?OWVW#[F[=RC:1U_4D.:D6-QG_;[:!]LWU'7;E1MXSB9?"L!^L5,[
M2-(FPKW=BF;D[C<JW\JH#=@,XIWS:-1KM7-L]045%>>4K?K$8FG,.0U/LQO6
M:>>L[9L=9P,KBU9"V$B6,,4!MOJ,3%ZIOP B(X $44%M6#M/W9(:Y6(U!(_B
M/,32.QX8WR[9?/N-4NB-J0*]5A7<Z6_S(R^_CW-P##1XG?7KAZ_9A?_&]T_G
M*VE^YSLEGOG_^=NC1_2BGIW!W6]<I_WV][,-<DJMJXZ^*%ZS*IMLF/AP)_6R
M8^;-Q2:PJE:_??1I<N:=RV+B7E7/'.SMBMT<<NWMK34_G*BJ0^0BP3CZIA"R
M"O\CZ@00EF< B=M.[]WVXRKD<A2F\*/\,Z"*?I< ,L'&GOF#]X(OS[5_$\JK
M# L;[4N&WP!<6-,Q&_;WR@AM:CUZ?QL$[YZGWJJ52?KAF3O6/";>>9S?L&0:
MFJ9I>*-^>"AT?;3&@!.E%N5YISK[.LFF]GU32]U0R?#NB[_<Q=Q[EB8J(XV>
M5[]\W]R4K_'4/2EO2P!Q!1/X"6-TOM(]/FKCT(]4PNO3N@BFI,90,&C;^I P
M1#Q!.$<"Q,C+, '$4D0 V2/$R?:F$<0_287\8V$\H57S# &$48  L]U*!9!3
MACS5 <OMKG;$NME7*GN)**PEI?PKB->G];</^\+ P/_QF_@#.&'1B"'P1;BP
M07TX@IV["0C]4\L]W5^O9+619RZ4<"LK,X3]"^'CS5D-HZ<#LA\8&\7KZLY1
M(TU,3"R;GIY]7KT2R-1SD'*:!(*Y!PN99"+W?"76I LE'%!0!YK*525/B.F&
MT)0U_J.M\B+=0/SF%UOIC_7#Z]7FM-HQKXDD1GRP&DM.Y??-M,W5/RQ7G:3G
MD++)Y4G;LU?MCF.I:'FJ6U[ TW:.JP'39>*S';DN)M7#KZ]75FK(5H5RY(XA
M'#&BR9PW%UN>M5D<*+0[1_ U&"[G2$LCQ[JMK:_-SCX--!CR^XT6QMH'?)L(
M>>7_T'M>Q/_%?0S^QT_4>:MG!&;C'B$XV<&?<'-P?PH=>)?J@]B%L^)E-JL7
MX/L1C?\,\D_C@@$$;?J(PMKX!Z?W32CH JPVO(N4/)I6^!6N<O#U,(*I"08S
M9W,6"MY#BY4N]WQVQ*K'S$/_ZSA=CPPO7FC<DO>=W"3Y/ POF.HIF]\R<L[:
M,I)W?G4V+ZK(-JJDUR!8-^Y'DW-I.?JMIQO\3'?I]-08/'Y\E:6I;\]_ T!Y
MT-IJQ"+F7V/*B"=@W^1D>:*GB=RSC&;J0M?3_S9'"KCGA":&$6X38YK2BRNY
M)WA"_LXHIQXP#+S9J7O&99B[AW,/K&UKW,[/"[ZW^4E'?[4N6'3<-LQ/?"KH
M9N/S*8TY-:=K/W+XC\NJ*N<>CFH]8X,O9@S:KY4]"[A&_OOFDGU91NK3/./,
M8M%BC4XK:[VOFJLU&$OUSR='O%'03-]W$<,3H4OV'[W13B7?'[K'68<6GFM4
MZ'C7?3;7W8C0845@)..5WB6[_CO%G$-HO?TSVO]'O+^O\"P-9_M4\V:F_/GC
M3Q0N:BT</Z-2N5/.-?HD1CAX_V'KD5V;T?_:^@@"(= \ U[L^+B+KY'_Z*[V
MMDW!Z[;;-])1*V:OB)V,*+)Z_7:^'D5AG&,6A$0O:YF3,G(\7M!G?V96?UEK
MT-;_Z/-"V6A73*>QQU0WZ_7P*>6^O(Z^,8X_,N-YF^+WAI^S:6NW"&?_ZP0F
MYQ(PPO]C9+1Y#E3@&.!\P5H&>7S7)I<@C95M#<_9C&V:7G&O##"VIT9OMDEQ
MPIZ"UE^^7YC];BV/J+-\>GUU]TY$]?C7D;HT;:^AFO6TD*M#&VEJ?,G@J)*
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M:F;;BV0N/7!1,PZ\&I_)3#+,@,7G"'6@EB/U*7< ]R.A<"E4#!"<W#6O<M.
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MMJ!/(6"4C^RM!5MRQY)/_B1_[;=##X\EW_EK_L%EE&O%_\]9Z/HO4$L#!!0
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M?* =BP6=C)O#5""O(]WXRR6TP*ZF''/(F*='[\ E8G7 G.>EM)3FK/R<XOS
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MBQZ?("F@3&TT0GUESQ33Z2H%?I?Q;=QS(6Y1A8@J6Y'0 VP#B9^H:Q%W3@K
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MG%6G+;F;<U[$7#-YQT92EF=5U5(=F7,CNH O60(-T -9,Y(8,RDP6U7\@9Q
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M2X'4P7^O]4,)W+%5^4SA"EDV&LAP@(UA=FL>E@*-RE34^M^!P0<KBY_-MZ7
M%1T!$IP.'^3828&]SJ92 ##CPN^#>O;*L.._YHG*3,7F"0_X-*,6=YU:MVPJ
M_M*Z=LM=OSEL]9M66YU7<N:6\,;M=<(;W5ES2J(?WVZ^2!!3%T&RQ"2&\Z<4
M0'_V&)(DA^(D!TJL:N?(=R$](:OH8?Y_BUWFAL0?>SBFPP3%-Z<F]%_7&,YE
M5WT(R/>JW?27^NO"3V#,JXUN2BV \FJ-W<9KW9.&ZI!_[!(6&V3SFQ4R*G^2
MQ5U,2M3G^[ >$^+_V:Z>?[:IM-9T\=;!_ZKW.C&=<[<@8,3OS=:@K<AT _5M
MJ?C:7V_K+D@!,_=+[Z=K]K2-ICUB_\T&72+N7^(%0U:YFF3Q^7$C"]S/6K(1
M\*])@5.?Q2J,$0>TC+@@(XE]6L#BE@=7E/Z'L6RO'EXI>*Y->!'C?+]\3_O>
M^SFQ:T<+[/:P96ZB1#2DST? ?RQ&M*2ZBS:]Z)U]PE@W;N.0/)>$M_UU9%./
MSJ*W,UW9K.9Z)54E<-?*S_80,P79R7Q(\5D!/BHHI0WR3G<7=&N>*D=V2&YQ
M+H,+K>05S',SBLBE(2I=96GC^!VNEB53!W[+#" EHILD+"0 BAD2+DQ]%[-C
M=^F3VRVT?6"+%D]<;%BGK@\L5K@R,Y<GHVP51K>/<O\L56G29_T ?8]H..4W
MS#B5?=CT@^"-GP><),:\=1 VE$+[9UH\,Y/-D>WA\T&^;:LB<-?#9U8TB0V#
MAT69B<C9VNLA@2SP#UJZZ$\L9HA^G%_B>S(ZZEC_QOZ."<S%Z;G;_Q?5UWO/
M0VM^>[<R)">D"\:]6-1W6RI]Z5KY=>6AT4+#%Y-I<\@4L@^^!N&:9")T3 JD
M]]"W03YL*&/T8#V8TAYIW#RCTC0J2/%1AV::.^DTZ]$[^4)#A59B15I5 +&9
MG,B2P]N)2Q4<<GCBH$J&]M-[QR!J#/[D63Q5[.SNR>V_0GQPK*D6]Y=Z>^$+
M/85R/87!;/(-5KE.E? N8S?,X,W3X#@Q.Y&I5-7UUF@O%#&-"2F%!2T,@HWQ
M-"YD%+>Z23C,U>T4V_EZ932QUN+/B.I8*3,0LUENEJ0F*XN*-;$?H0MQU$V/
M8CL6/__]5O7?9$)%9'H*WCJW0R6'7?)F?($49-B\+]3\I;ZNA?X+786/%@:%
MA,<4*.-O]GQGK4<O&[7:!*_"022/62G [MS?0$[Y]LY!]</7OY[T^P\5KSV*
M32X@L]Y^';R5P:S[<U-XD-UD!.D7NR54Q^(J=\ROEPG*2GIYWC].V0D[HDF?
M_%_.$>^R7TD!\=;/Y%FS5^@460I81LI(W+V ]5[6SPTM1D;+<$59MU$PNW.<
M"*O+2+WGG^9#O+N$@F^6YQ99?\DNJ?O)&MW<8/>%LU+@>][0HF?698D C&86
M%+QC@N4_XN@ 08:45W&2U' W]^JLU/SZN=26"+<(EY+!!;7JL4=)#9-Y$:YO
MAC[_86R4T1]!J%K0Y;&_JR/;92)ZC_F!,O7,-#4$<4YO/;.==@2+U=I&U=0[
M,Q <X.B6[W3'9[#4OB,P=2RCUG/LBY?3(BJ+WYU/;IY(7+8$'EWYXL/OG_4^
M'$QSZ+_R$ZY:YEIG+JCS60I<'WAL.GO9I.;+*Y-+OUV,MOG6WE5 7J^M\O[Y
M&L(EXB1_#->8>'7Y):,;'FZ1U 1+R>:NO4]ZIGX-,R/P^:]Y]I4]<0T9OG[G
MC'3<[D3^ZI9TGD*YL#YEJAIL_'WXN\OW+7&ZABNT2MU1A@RG5W M%B]_0*7
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MLK,QR_TJQXE: +NWH*:5'H1U$RP,PV"BIL' 1#1&>"D2+ LD_ 2I9BS6C,X
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M+MFE&V_HQ[5MINSLPZN206P+82=]H1'6YA$6.^X]J=$Z5YR$1[&E<[ PKTD
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MLNI,9XLC LH#X:KQT0O8(>^)<5*L!99%E1?AJ]-J:O'M,HN;+-E]K&%;'XZ
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MZ937]WA/?V\8?,,/AH@QR*EG%%5.^)RU:-6J5LFM<!@^C#/?/J:>/?VK#:Z
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M0<Y>OG^L'J)@OJ5/.#2CUE.9;\:4!PE;<;%$/RRX?:F@G&_/?<J]\2X"-1?
M<QE)>-:'/YB/,VVN6_?$1(3SQT[V\O>PL!L#AL/R;]RLN/)C(.Q@DD.)Q9[(
M+<]P59!TU;, #<(#B=E6$2^\PU7_MUK.-*BIK,WC0404A2 B*)A$10&%D%;
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M-<R&(>"+?S?/\;]33Y5;G.Z!$OVEAIB_5$]T*NH^LH/VEQJ23X.<^5^T$XW
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M*$J+*%6"BT&^8"R-JBGM1&MBK)CZ%%LX62FU'E-$[6!K2@T1&\AMOAR4 8=
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M[#7NZV:F-/_LRN=919/TTBUE>-B%8BL#]@\;R8"5NQE(!/T?3["+#X9VG6*
M=^!(:5RMLW1-* Z>1O_](?!_4L._LG=VVOFM9,5<KOANC5S-N-:&_DM#UC_<
MAR)#0^N>YA89J )^_VHO"E+\W\A4L%0^XS82DFC@,=H/%U-D;9'T7<V\?'#Z
M]\)QA)K;,J"4OM0B SH= ?N4+?>7_:OR I_,_K81SI'6Z\B P[]4S/S#":8I
M3JYAVN$RX.R?/!EP=$K-EGGB!T.]QG,.]^[.W5I&L33L+I+RTU\-9D;"JO(&
MM4=*F[3E8N'3)]":D0$*[$][Y?;K_2:^#'#U^5>#\YCXAF6-'*Z'<6 !#[WN
M*P5=3OXVU;2XH;:>JMVI+6#.H7<(1U8;W_U:-1UPM*:[ZE6%<=^<I-WZX$"X
MJX$BO@\3UJ[DRZZIZ2;9G7R)-H"=< 8PWALLR]L(!<:KE9,T?R5G-"[.\1+J
M3^3[#?D-\3^$^.QFDC9,J;:7?WZXSJYZ[M&#AR$1S3%FI[OGW/0698![K;10
M_0=S%#7$%GJEL\^YH>;3U*6OLF/RB0MZ@72JJ>FT3KD_LAP\F4$***S22YN>
M+KJFSP/)<L3G+K;FCEZ5&DSIV=]]/*Z39<KU2:B[_,O@I7LELZRM2^RY-LPU
M&5!)XG:@$$,=0WMXS+21H YG">8+A*\?];!T*3_#I5"BH*:YW+<UDKJU:W8U
MW_?._(+0X 9AU6QJFCYG,8OK6I,]N=C&B8I,H%RBX/J0;4MQEZ1JY!UO>$VX
MJH[6=B/AGS6#,3+@IKWY^PD9H-R-3]I:2,8Y@H:W"^ "0:Z8(Q$G7 D:,03[
MXXIX@I?F%#N2, 9S/"7F&$TSQ+PX9'X R;J)&[W#?MJ1QC*$O1IKQ3?J7<(?
MD_U1B1%NT K*&>8$:P]DF ,NB+06>*LL9<"Z-D&;& 6'S'3X0L_9(MO4.B)*
M-3ASQ+ :8B?] FXWU$1_('PHF:J5L@4#(THE;1!I/J-JJ8)B#?XR@58(IR?4
M]M^53VDTT6+"IH/[@F4*6PA.WBR_3[[BWS\MMO0<O2>?AYK(@?KN>MO"( _^
M(*\X.-/?NG]VZ/5 D]?\@!ZC.G':(T:"8UZK(BF1=_&%IC<IGB*Y6ME$)LVV
MI?DL./=0M$ >CZ$O-: 8]".D8O[$HC]S>_;;["+Z=%A'8I[F'7UO"E&H$GJ\
M_/.CZP*\]F2V5S49/\I+1#9"!"&JI4[5\_3+?BQME!:/1FWN)LV85UC*C46@
M8 U_[24$%_A XZ+5'NDP#3+E6B_6$29U6H73]S,QQLF4C@SI#EJ3)2Y0/*C"
MJ5V'A.>T\#7LM[P_A6SJP;I K=^][-7@>-&P]>@8]Y"]$3F"TY*)5LUJREN6
MV3WF$1KHGFO)5)I@%KXG9_F] #]F[V9>42M4"!^F$< IL>*LG;M3S'OJ0?J$
MZXFR:?-9B2M1__C.(>\A#I&D>]5D9Q-)CZ.L:W+5).-<4"G+ZRI:/_?#ZX +
M?_P]=AWW;#>HLCA]^)3C\F-N&P]]NAM[,/YCV66CMHW*1:OU;)\VYU>N7;6\
MRNN=-:Y*[:E^6^1YB2VU2Z\HON#%3AG0[$L4X%?X.)L\^445,5S1S]HT@=,Q
MK5YEN'\=Q5;O88IZZ.SK3[>/2J19Q3Y3>J'II>?G;P<^'O0=&5(9TI_>]77_
ME77M:VM[PFV)=D[-HT;7K7*7"JL_5UU_\#)VZVW14117GI2WXI"'&=)5GG*^
M]I4<I4UM0/8SA^3@T<?[2PW'-['7RH#1AS+@VQT\O!&_E$N:WB\#RJY *]DD
MN<Y[H26I,N!^"A#S[Y'GKPP-VB<'R'J)C)'^WN0W_/?'_NXT&;!I^Y2T92]=
M^J!_0^1?V<OH/Y>]AJ6*M%=7_&3 $T>V-+,ZAJ!(>^U]A_;>C;!TD*L:BL'W
MH=U/6QAKU/ZYBV.T=?:\TT_?><LOL(S0Z^K)<G))R9;(I3WS) Y))H3ZT7C5
MO*5?<V2 8S4U@KE_%OV&?1#R1*<W'7_5C]*_V51R^VU#?K.P5-#G[ISUVQ6)
MWJTOG\:R,%8_KA82_9)F:(+S9+$T@2B6S,G3\*O?:<UO(/[2F@'^PJ1<Y6^;
M)>:SC:7#';CQ</E/"-KT94 ;DO71=C&F;7'BQT*@')!5S'BT60L"C5^*EAXL
MD&I[I<M[_P)+!K#_:N%I.TW:I3'&K$V['!@_I\F SU+7&97_Y_)*6(E'Q?1A
MSSP(7DQHB P_'WYEUVG?UP;W73PNSIQ3;K4]=SGQX"\G>C\[_;9::RZ-X@BV
M29T[Y+EE8)@GO>4W,%0MH<?#]?X6FWG'6\\^W5-[NWU;3]J1$U$ODEM5E*[?
MN7'^Y)4[*;]_ZO5\]MNE@8OR\?":^$73PQ'X6TE\,$928KC;?.<9! >C'/*<
MU)S]1Q+CX$XE(;J%MH9<U$JKIJ5>-)?BIO2J[-?"WT&)'YC&C+=$#\:UI((#
M+8:;^G 7ZN1Z%\0RS6JT7SE@KT(F>L,TL$@PEDS9.<I7Y<,)=CJGGBT]Q 8+
M.U(ZR<&%O0^AR&GA[)AIQL D^=.:ZYT;?@.LX P1*>4RK#-? %=7D"-;]?CQ
M6#NB!(^LA2-%]/C=C"I6CH"=3,5"M/0J.:[K.;)O2@VI[4PPX'1E'V)>_(%<
MZB0)"Q4M67-I&EA; 4,;OF/@>CC'J7NZ&C_TRV\6<POB]]#M\>B;>@ B9YW8
MK(.!\O]T6I/*)N]'-1C)26K/J-NE\8S-N !VDNJW2MZV:^\'1ULCC7;%/DQ
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MP.?TF7<C0?GT0SU6[2&NH;O?"<?\^LYTAME%<BW&!]T+4(EA;H%^&>X].V3
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M3@;:8-=!9Z<6O'+Z$L>261/R$] AF2OI7XVFIT;.I%$KWNO3&P>W@R>YI@V
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M2?8TY9P#X-.)P)0$J[QS)9>2]*0C"KK8V?O$*^ G#\#R(_SE_N7@&=()R",
M<M*VZ2 J2:U574J$=QKJ]XTE51G!CW(K06;JM!5\S8@IYX&9\H]KRJU)07Y$
M:"==KK,X*N)+1D7*.SM*V>9_4TMGVRY.ITW2-L:[ZZ]O[M_?9BFT^&BRCY7
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MB[&#Z)^-"_\^(%?L3R:] C/N A6>D+W$CV1!#3&*/=(55-N'\I;B8RVN+)P
MOJ?=S&_*@U*JZ@,,SBTI6R&9Q W&+AYF0;O;_)=A;R&2M-C@]#+L+K$X\,"
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MX4ZDY%%829E?X>=VW4S+ORUN3%[Y+FA!VU+X-<LP70OJU7(FV:$"F%N&37L
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MLC 3Y*=@#F)6"-7M%CZ[U^&6DO8$Y^DGBBQ.AR1-&9"JYFOA5=*?6>YB=\&
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M$-? T((W $>2NR<I:N"['!#%/0JU-E="K2?!F*+R$&&T=9H-Y"KR(9:9PYK
MK_XM1:I5N39H W^HU+WKZM 6RH='U['!SR ]1H-87>]P/8B]$0$4<.E&D?0!
MTX.=!5W6- B/3+>.(_+R+),::VH_+/R<9TQ=%DQ8#?N70]PC/?G=WCP^X%I
M"I!M#;] M$YW9U*70*T\NZS7;5$M!C,)Q3UL_6%2)8^]HYME5AAV$FL$(M,C
MB4LG\M2 YA+12^LZJ:MGM]6,FJ,8M5K@3"SW%P34#\&6CE?N^6UC_*BXO[1_
MQ\='_ST?GX"_R][@OE[F*"C5_HD<,6')\)Y=6Z_20=V.\-WZZ/K*/P5N-4[X
M6#%3]_#0!KPTESCM*$>418#+.<1-<H0W:C%-CGB8"CLIJEG!DF_=<,($G"22
MPU21/6_G&2B86GJ:^@4MN[E5:?8O*/&/6+.LIW09ZQNK9*63SCW6BR6>5NGZ
M_1^VK3JQQGVGY]HGZW??6XL_@9Z9NMKJ-C-GW^J!;>['M.:T3OX2;F$Q\J'T
M,S[B$LA=>3'0_ZM=^N\%>]<K))7IE#-X=H28#E-!!0NZIN""VS4GY8@U++\B
M3CIK [B[G2=0D2."B?TUQ[JLJ.JR=]64[8JF#;F;N#;#*\&HQM^*<L0'+"'<
M'\<??P#V&&].#-N+-84R1#.\Q6GO&<)[NMBD4HQZSY5<!@D\=+(6E-&<9PKY
MY$OKFBDVO5=OE$-UO)^"!^[/]94\;0\A/@Z97V@;RLN(+IOH#%X(O/\LD7^T
MMJK;_.KB^<1!!D%AF)^_?4_V[*+=Y 2E6-'3!WHYR6STN&4(#FG2)=LRF9DY
M$%A>73P2;G<\%J?IOS\;F[O=IG#5!/J'\ ,E/1<O?AE]"V0U$-X7BV8IFM50
ME!#7SQ<-TX5XE#OHRC7 7[>B)AFK=UDQDJ] FW@$#=?;/W1C')8E/"(EHI="
M-3SLNJ3C![N^.IB=>%6E]<NZYGVX35]DYN1PR BXB%OA 6HW#7!:Z#3<4NQJ
MJ$943+M*'<2=D#Z^BC0,L^484%:0[4#;!(LOF#/">GM1RY2HC!S1BS6W36 ;
MDB\!%;DCZ(0\K:I>:YSV@7D/H(OK AJT@G42>F]X%;U_WH4%<=%-_DA)/MCW
M0(SO;R0.(+F^0;QQV<HQ3B4G'C[SN-]7-K2_:\2E[^1@4]Y.8+ZI\K&340W/
MO=ZT:41TOB2"^ A2\^YAXOH=4*\)+U!)53/ZXW8J\=0@"VTWB-;"L[ \",PW
M2FV/@/T"3)),V]#,?D\XV:/6/:?$)_()XVAKQ.4=G9N_5G91$U'/<R -@>@"
M'2E'G(^" L-*C6+XHA&((/(C&0M.AUUCVO48ZX9M>N1<RF31U$)3SM7,:+,\
M+G56;D- \\[0(!C40@7PC&4D&A>GR0SW&E&;P"([V%O=BT,%ZBQ+,!.Y:DR.
MJ/*"3:!.$7U)*'9SSP69\21AS05S*^1:!0M30=UM%S#;0'R+W6%C<T"]Z;X<
MD0+OR62W+JX@.X&<M$$)#<BLM^65*G0D>1O46TC"B<[G@UFG.EE.8 "?.\!H
MH"6P[4"]!')<>7"-WN=O?@#]#ME';+_5 G8L#979=%[UJS?=!Y9/439V,:R&
M<$,F '6*'AD6&7A91.S__/G=XNL8[\:ZR9!9?&*$WS"\LX,Q8^VO+6KZ@ SM
M^$!"NO9:6[AZ=L&H[;BDJL7%Q<%6!SO#G))/U/U0V!D@JW%@6=8-RNI^& /,
M)V(<EA8? 9*X3S"6A6.^6YA#'VJT<CQ4N&;+$G/5V^9XW]Z"O@=J]"(\K&Y_
M>SOUVJA:X5+7U[O+6&CJ;&:HS#_C"WJQ%$Z@'K/[2PVO@YCX!U3]$^@=^S\;
M]+Y1IZ\]%51&-14&GO02/7[[;%6QS&0@Z*BC"KAF-H%D.NWX:(*R 5(!;9T[
MRWT7C_=@L,]\!C;_Q.MNE187OWGF=GGST?SWM_OO'0C8]:MP-7(T^A%S?_MF
MFU*#B]'&!PM.=5FU'ORZ\^A)JWV_3ZENO_YL_?6PK]]<H!DPC>M+X(6CFO/6
M@VMF>#.:I'917XK(+!:I3+900,60_6&0D8)=0MK$P]I!^F*!1@"WB)36R$:]
M@LJ+6A^3SHJCU98);F,TQ=35H9:#G/3I4LE/L"KT8NU=X>)#IW.H:2.]]?$_
MN<*':^-_8YAT**R1&4K==>3E573_?,-"8 UOO#"KI?K:0- MSU9>IT?8V1 3
M>ER0A%'94K"F>_J+EU/5'8%;DI?EY&J?EJ>GVZZ]1JW T WA$Y_(UL!P.7B1
MWRS3AIZ7A@3LZ=I!]EO$0F?%)CFB(;S(B)X&(XM;P=W=K]FF0-9M\K;+3R9C
M*'6QY:0HD2]IHNFB.;Q+;&'0BN\F\&ID<\)RK\-0%F#OVF>!\1F941GT'\M.
M*"H=B:UC++/EI2^??SWPI>0AU#SOU5?.LBTC&2QZ5?:2S2H&0WV;[XK&JXS\
MCK@QC;3ZNM1:76OFO:4)%IN!7D:\0(A.&N16^_:VI%B8'Y8L^2S@164V-B_R
M=DVV,A@IG!KB+%![/K_,IGH@,__QT^!YOK?!\9!S==6"Y\.EY^;5SP)G#SS3
M"T#$BPX#[W?<.!LL1ZB'%_=\*8=75>MF_ZJ[FG3%,#WLY /S\/(S&^8,R]X>
MN+Y5Y7="Y6WCC?70B4>DXB8%EQ%O;P'A2M(BM[BEA:M'V0@(;I ]EA6.WB#;
MQD:+:&JD(XU?YS [:Z_5E[69_&R21.#/^=MLR\%WEYV@GJ4*<YXWTS79FW7N
M6)DVV+D<<DG&P\?5&[8K;1I@8Y]+\V0FXYDV=N?IPI +L]+=S:V'N\O*9ZI.
M34]52>WZ# W5S$@*?&O/(@8%$9=5:7Z<2MQ\^M?S[ 7I3:P1J;N!@@&G9U)F
M]U:5^@E4QS.K7[R)/+,GDS37?']$+23JTL3)W8813TO&UN9M59Z=\98C?@HH
ME","]#@+[M;4'6_F]:2]LOV<)[E_O8V!B/RW?4WG_VS%R\ARQ#GZ]ST"Q:(U
MZJ'.Z?-+%U8%Q(_A[B,L_FJ#-(D >(Y]ROJ';3\89--E.^VSB)]^\&/JC[](
M[\C6:R=_5C>\>-3+?(7_(/_S"<; @6[K*\E4T4;Z%P;<./O\_;75/\2I*#_\
M5WU[I35U86VQ0HZ<?R!'-&^5_:[PD&,_TN6(9=E!<L3:\H6MRLJ+EHJ1R4^E
MPKHA=/A'VE0;09:X38X ?(JH8.K?+.S_N;V8I4%)9TJ<A6T4M[E7%W]T7Q\P
M5"7%;MBZ>$ Y)'/KR0,?XW]>#P84GS;EM7_7)+LI)E]9CCA4_D197#U!*?[>
MY5GC-8=[=^_O:"TAQ.O.>QN\>U9=T_[#9.%@Y6^9?7P39]N7JB<_&1U5_G;Q
M6(;@(<. <072DR,VM$7(&FP$"X1]QJ*GX[4ONZV7D)WV+FD&?KI:;WYS6=7C
M^,4;/=2D&-FY[G\CG7FPK-K[KLW^-V&7;A^_?@FH7:>E^F[M2'S[V2Z. 5\2
M %U=XSH(^W10?S_)[98UZ"@!UFOF^?#N>2Y#8<# ()GZ!=SW8ZY_?F$?:DDG
M(8[*19/MY C%<.I2A7U<.>*^SE^\I"0BO+A]I771";:XH]]6Q2B?V&!ZJN"7
M9JK(@.^V<:]C^@LEPB_KEILO%YHM*#]CLJJUXAC'8J5B'#JNO+SF?I7-5-P#
M;0I<$35ZL;-&?R_<HE!UR@U8+:A22-<,R:)LNB='N/=4C%:[M^U_%W8^VBKN
M4/^M3M>BQB_LTU_V^1Q-6AEQW5%Z<!W"X2^_G/K_P-+^N11*ZRJTQ4%P,EOQ
MD0PE.:+P9(\2Z!>)\X+'M_F5+-!'W?Z^?&.S7G.^:X31)2NJ%9IA 1B81]^@
M?EW'QTUIARNNFE6:K>?#L:>I_!6<63_OT:=_V\N<W3XI<ZC 3=X2+%B4?NO]
MYTW,*)0Z]6,L()!2%!D7+;Y=_)%M"H7)$9L$B7+$Y%>JU';8>_!O&X=_#B7H
MQG_8SY2>I2=;+T:C%E[*$1\(TJ7>8M1_N1N\#_F??4GXYS'I'>*O "UE!PA:
M5/YU1?ZEH0BHO)9>(KOZ<WF/%/_M\=\WA>M;A00XR;I]<>D@=3R.%/ZG04,L
M!/R'\3BQL"92CC#FH^8:B5+=WN\3_RRE[&F)G*\.$%'&4:3;'?<I[CE!&[:6
M(^[.<*ESWW&RG!FSZ;_^HSMXWW^EJ<Q Y']=;0]5.O_C!/PMO/\T(E\F;T$*
M3-J(3L%-OJ:.GV B*&:48:P5]$E(O/DBE+,$;>V!\[,K;(481X$ A:%:3?;K
M9FT)*CI]*#NID:%*=NVY@+$6QQU!Z[2*6G%Z!YZ'+GS.$+8Y>?9<-=*5S.\>
M('FGR:S(YVJ?XXRM9@P5OHASOCV1HX*Q&"$DLRT@-X7>;A7=\GA*<F^AZUFU
MW^$'V$,>(&,_.-/DCEX#[><V+.S(%1,2L!I]9/-:<P/4;>W&&%FE>(75T#;*
M+-0*.(F\IY6$@PP$F0 $W!\AK&J_DO7,3["BG&F!.I:\EG\"^%Q_9DLU4]1V
MHCP@#AOGY,Q^\:JVZ\O,U;KB[,:OXN$C8;[23,6BQ*T>@F)F3D!HX5Z<2+>S
MBJ ^5JWK&_DY[2$CD6Q9\B$L8"W07"E*1Q[MQEB.(-6ALSYU=;WPWH?0H"MH
M<C]_(BNJ-C$G)#PZ+M;ZM4IV&$%+9@ZY2VA0?3&II1FG846\N8":NB'FW*&H
MU&1Q:X?R$D1(Z ![L]O#=E!%7)/^Y7#>AIZIHJZNB4F>+R[QPNPTDHO5[CYK
M<&A29O:JOA=_C]),,&#C2/P6 ^)--B9$ 9(PFD$JED0"+4VE>"3Y$A0.C+Y>
M2$J!?\"X%HP;XT"]J6^VC7%8,W\OH5[2&5 O2<SNI&P_[0>?!SZUI\F,/TP,
MZ.8N+V4<$AP1R-[*$4J1^%0^W9")6S(T0=">6ULQ'8G4G$"MEID'](<:!.1?
MXD?)4!P@L)U6"%%C1>Z+-;%U<L3R(=(1@NKPT)LM;7U)5E_MF7$XR4%I3E6Y
M7A/6J%NF-79MP?7VK 6ZL59:-TFQ9;W,:O0U>54,9;D"%-K3":P9JP^S23AM
M2^BZVN;+;PQ8U8.Q%S6QGC&#NC[>41TYBLRKHJ?CUE[$. IG4K]!C7ZTI:1V
MR2R8-16&>UTI0JXLRLHGX5Q !H^6D(U/FX*]C;/T:'0Q.ZL,=D@2\],H0V+[
M=E5_LGU?I,.2]D:["[XNN6(;Z0U(*RK,MUOSYM58+]IA@7(J-(&[B5(50;E1
M8#8Z28:BB>/FAB3%D>)/_@=.8VN>!G="Q.,@)L96<@-@,FXS\>K.>HF1>,.!
M8!O9KAZ6M0%$60QXV3GO8_M>L$2.^+BW@OK>9%#!+V/*X[$,2*( N@IMZE@U
MH_W$&#;^N_?8B7\/P+>Z&\*(%FV]3?6%Y55:IT\/#9]V# H)"U\:;CYO&Y7E
MZ106$D9<B>';>ELZA8<O<<-\;5EU<4+)>HU8CU/5/O6I",8",TWI[B."AGI[
M45(:<X4578V\GP-EB QQRZ$T[U3#P0=5Z9MXM@9E,9%?&,NJ<Y^<_A"R\_>!
M=&;]_3:>Y#E7^S<[,WHZ=7E9.;PL*@Z,$,4EU#0=M+A(6=O^A+P/R*2C>.YA
M(Q>JO;$JM@/UST$/YLAPOU-81(':;SMV$,O"-]S]P@@_\XMR=W"%'3J9COR"
M(48#;Y%&T YBBMVUS-K/^<!7])HQ+=)$BPM)=#_2KUW5Y.'PANIG7R^&%X<]
MJ/J8:A^6X_=*W^)B>5%6A"?_JH=!G ;_5-_57)/))H-V>%.>?G7/G)D%=I1'
MV2!KX_3=B1=!.T83P\-\_0T/]5I'=57Q:MD>9AZ<GH!E+RI?YNU$>OP'@EH#
MXK@!Y$A1&;7]HQRQ0&0QJO^:VH$9V<K3W0Q8ARI3/=4'NEIQ)>728HFK51O1
MD-IL!.]3KPU,%&6HO4K<$/?[$G)=#7K:*@J[X3T=W-K%5I#Z[]=&.Z@]RSEZ
MG/_:3R-:%O')U#'-0JI0,JJ@2:NX8AYN5K6+ \1&*!C!8/#1]5W8;C%J86D(
M 7)X)4=\4D>%@$CI$BL&;/Q!T7MB]=C#5?@J*$EVP\!;AKQ(_>[D.D!6N/1]
MZ69RA$H-#LXOK]VJK#V-W:#X/)?[<D3\(%UVM%-"7RU'=&PZI-"GT^URQ-:P
MBZD(WO_^>SGMS?.9*P8(R;JC'MWYU_N5S)]-?/MP*$WRBX:G2N=TG]-/RU>!
MUU?8W]D9M_\E/H7^=2.4(6.IR.[['55I"O\;81=>+)Z@YF[Y^Q;"E$)./&;3
M?/H\TLN9W;D[/ARLL7WALWU]_>;=F&O>A>^KE?;?O1W!RC-K-OO 7B9'_!9Q
M6HYXYE$CR^I087_X %T??*=QMU#I8VN&M"[B]?O^3;+-FWZR6W5[X0[S>Q H
M:% ,"U8#FF^(&M8%7=/+6*X%_:?\27X-!C.)\-X1"U]5IE3OV!E1N'>S,]G8
M>GIOF?:I[JL,713D0O:X7,1(8,YEN?5]$67,9?][_=!SY:&QB\K7A\@F!7?S
M7Q.TIF7J9",^>RM)69(%*(PU'C6979R$\0%4A')$(R.14Q50G@]QA!\H&J!Q
M*9@DHB=X\>QZ+KN62TM?R[2A>&&<FALH*<P/J74BC7(I:P&OHO(G5PF:GZ#[
M8F(BVQBR!7,D$5!;J<*5CM :UL+ZBX<IG6PM:6X1]*I"P2'+IV7K26,D)Y'N
MKUC=4Q/L-;@JA=6+CSS1A_%V>-+)UH&-P>+D.4:RP>& G: ="<_-Y#!^5PZZ
M-)214?=Y\\*]_C?S5@FKOQYS>ZV_':G\<+SCFH[2]P>B]@3.Z@(PB3N3](*\
M"TQ/2H7U%5.V DI?])JD&G^9-;,4AOL)6U(CZ:F^LUY^\(%7/2:]UH1U4+>H
M_0[&;''O)$>]N(:H%7)R&,5A]0G3&BC&G=:QK504<TB; -U8U"6')4G.28N8
M5$.2GQB?A(FH"+7!57+28?\15 )G92" ;"$@PX;U^>57U>JC#@+4- ;&7XQ:
MU29&KQS+:!6GGSU8VT&T=J]W=>PVSW\FW3;P:NA&7=$E2]KAN<=;D_2=]ZS5
M/WK)064=,A0Q*3-HLX1J&K\-#&;FN6'&RHFWJS56#?CS;IJQ&BY;/P;-[N?I
MUD1OR#5>L<;G%&.@^LK$[F@ZL;**V2PPFZKY.CSS;GH1;E5#F5W4N]B] _YU
M:L"6' ;P9:X,=3F"_]<X]*0XSS X\.7+NS_>5'V<'7):M"EU\VZW37EOD\M^
MC]VZ&=CNZ_).0_% YK<0&J]CP^F2'$!,*.ZGZ).I/?".YMW#=ETR5>CS-R[E
M>/*Z #^?-%4XI&2\#IF=77%7*'7RR$/LL*@HOGFP,&/,P?3$,[Y5/<ZGJ\+S
MFT?OA7*FFMIC'\T=%N@-[FG1]TT.%CIN]MQT(7//Q\/3=S6Y6^%S4-,3\K%Z
MZ5,F9Q5R@-&8O;-#9D72(P#H1"OZ;916^9S%<J)N&+72UUU$,("M .(M5&,?
M#DB$MP.N33GJ:J+Y--A#;*0GEC 6713%'B*VQR]5Q[:<8DI+ G201_9NOAO?
MD?&FQ:,EXW:>!X*RX;]U:.+/)N.H\MA_\B\OS/ZDA:,B&\F'%;)=CT>?$^)F
MGPY<QYK]'8',_N:U_CY'?[+6 88!GP"TS"E[5'HSG#/+OH[-JI4C:&&T!9&M
M+"T4GOO;5@LEP9_:PFR17LJ1(YR9E!B&XRSJ[77=?QQ2T1@1,6 :Q5#A9-[(
M$;.":,(%;YX<\6?K]<_[MB[-W7DN&BZ6=^^01G&'(]Q]8CZV+T\OQ1MU][MI
M/'CB;O3QRCC@4-H29%GXUJ/4=4>6]NNW6WRLMSY^EOZ3PX3#B[>/E;_JG88R
MRF$;:3[%&FIIP&Z&"D2TF]4<IEXC.HFPMBH=W8*K+*);\)MFDF."&MLU6DH@
M)^%H,BX(J0D[]2FTJ+.X/:G/>%N/*<07"8Q)U<CI=BW8'I#"UWP]^"G4LXZ_
MM?._TX]PGW_9^YFSI(J:*M# ;I1U$M0I6T*QIH#S*.\JJ,(5(,<IFZFW!<#!
M=EV(O6?:[PBP./B>E-@BDA6#=PC3W9$E0_[CQBM!AZ**'=92+S? / ;C-7[-
M1L N*.ZX._A\T[K++8>OC44_1/X+)_ X"OK[%^CY/SUK<XFNC?OH#)I*24CI
M]NJ*+R^1J5Y.1"%*VP/SW'%5#&FW.^8Y5PO)'%S%>O'")7[SJDJE>\NO.&\[
MM.MVX;:MS=O>>F8<VI7J?27CFMOFG/"Z+:7J-5CTW^OLO,VK1PIDX(VZ3E _
M6Q3'*("BUU3R.451ZKDH!7(/1,D16[Q-)8G*LOA+=.B8NQR1\0U>W.WP&)>'
M@K3D")SU?/;/)PE_ON28]-4C:D>0JX+RJW/EB#?'J<$_X,9L5\@1"3J<[SA<
M>R4R!#F:)%O*:6^+^USX)TO\?70QXH!B3-[1%#01;B]'W"L=EBF%ZNIE2UB9
M41+;B]D.E7:^PP,?:K?UV"1>O1FB?SQ/>>=*/&(T]>792Y%!:[V:SDP<\759
M77Y$D?KTUA*;H8JIS#>2LU[QUSS3B.<>Y\#M3RHX(P,CLI<><L2C 8Z#]Q\G
MR CYW@1P6N%Q3YO($9WAA+S2/\X95-Q+^#>Y]O(OE1[ANS%L*T<0%+YZG/V5
M_?Z?SX25!KR>/QEULO/#!Q^'IBI@RZ='@]:]I1[:S34VK='$J&#^:LL59_Q*
M_7(BMF_-&PY.XTF"-ZVG':-]NWU4Y6/O:"IV2\VT?@EDZP*EC-3K<65*X#R7
MLT(P+D>LEEG(WN#4*^#P)6,!2'8/^82(EOB5TFJ\ ?Q<)R*LP4<]:=#(#QLA
MK!@B%3?IYIE5 C$0P:.Z:PM3>@[5LQ!#5RQT L,:Z*;\-M!+:YXQ@$]TP'C@
MTGB>'90BFDGVK;@_@NY_U]H2L)?)[K(BJH]Y9PZX-GGXB>.J2XK+),:&+^PV
M5'?H'0%RN_6OIF_Z\<U20002E'K\=\^?_3^ TL^" 4AYT9;LNW0),M%[_77%
MDDIA9_6LBR>X>;=QF#-P#K6)OJCK+4<<6? GXU-BH(B6-].R0A O*]G58H*3
MMBC0[X=?Z%)+R^_@55H$Y0N.1?V4'4.7A-1IRZ);Y A*MZ)+AA7$!(.X=%6K
MM9%ML7AP1WU4R?"'<1D*J(F_&L1G>8GM)\W4RH,\DPYU_RZY5JJ;\>B4(,RN
M4%) /7LF\$SPIR_JO+[J;SULB"\T0^J2;0',-R@5IP-[9H)DW*,/)'>>79R$
MMBPO05P?74&.6EY\]MSP\L7# 6J@[H/B4Y,*3.F=<R!ZU#WOGIU\8C[#",<U
M&>Q=3DQI]&P1?2WSOV 42,LU=S;'%!\YVKHU[O_B[;VCFNJ^O=]801%"1XI$
MI=>H5#$0%0$! 0$!!2$B(DV,*$C D"@M=!1$'D&(2*\1:0*12'\0D=Z%D$0%
MJ0EU REO?,ZY[SB_4\9X[QCWOG_DCSU&LLM::\[Y^>XUYXP7Q)%A5:+O?/K-
MO&/*-=(CM]-O"G'E4MA453%/,1T+:VA6L7)M1D%] >MDVN3DU./@^+K2>S;;
MLQ#6K@U;,9%KQ# :!T3B0EO;: HW8L[2NQCBE;F*.%K7NHW _ X'A-/A@&(V
MFX0:B(#?.R"]9>+*SFALH)59FVZZO>\#W0@_?\/H<@(8#(\H0UN)H R0(M"X
MRCP)- SHIA!B)<1U)^['TA "W14HB 6 IYRFV8!=YCPZ$/PZW9DNAFJ=1C*Z
M&4WO$:8-]4WO8\MU<MZAPD=W+W98E@LKS]Z-*WFPB;0$VXO9:Q".&$II^PT5
M_2Z]F(5!WIT@G4DK_F9?B/0Q%0Q2[1"T.#]WS;QK,,5<<:K6!MGM/^#T^/+&
MOS[?W"A3),@!(X<V4XW) ^0N=SDX*+%5=>?/RSP))'3Y@>,-%$MITOA#/MDR
M#':^GP?5U:99;_K<>WK"*%:@C.B7>Z/F%X$23Q*Z$+I%M\EOJ$TN\EOUEFMV
M=%.UG]G%BW92W5GIB'($W6IE6YDL1%J\/ #?D/-E/9ECI5/?R^H"03)N4M=#
M1CJH#-&7U)=9JJ\UO7/5-&ZM^UY-5Z?Y6:C.LPO,#QGK?BXV::_O*BWU_FW#
MK)UR_LIZ^M_%^PC$WR<JB6G/3IYSP1WWD)?7_''D^9F+S\^$CE);V,/9AR=(
M#&M4W=NY!J5"5F0IZRJ5+*2O]DSA:;)$@ #?R5?>E6<^J]\\K87*CT %Q0:R
M"3@"\C;C>I FQF7W^BK9!1,?V^E^"ATOYB8:5JBG9)#ZZ\?/7W7JGO0UTZWE
M,!,3]"<N/MR8(>Q(P%PX(/0<GODAERU5U8Q8UT35L;?[X=N>B&,<D,BAF4Z6
MS!$NE!RXBV4V_VI:2]]%JG!=_3P\R(9MO%.U2AK2=NHFT[EWS 'E/&HG;7WC
M3EJW*IQ2"A/C@"[.QF-7LD0XH%?7L&TMJ-,<D-D^KJ]NOH'G@$Z%$(CPVE7\
MCD#NUC4.Z >\%*[&JOH#P*3_",!JJ[DS-DM@"D*"Z4K7BU[4A@M-3,U/9'T7
MM G5SO&7-LOU33<IV#5<K_)7N?]%U[3SB:;I5!NF-.F\4<T64:7CC4;G41E3
MSY:0$8ESGRD!#S]33^M?'TU0N4TQC3YY3;Y2U+LWZVI;7W&0A*SSB^I,*\WO
MNE#^A,@2]Y*.:CE-<PO8B-V'U/A?YE,J2C4UW[F^;"?B[?_CU53Y2F.6_"LT
M[Y[A+9_)"#EB:P5[I^_A<[/S /%AKU:D\0?EVRDWI ^)WE\L\2HJB#X7XQGN
M21;M)]HIW@@V.RD:]"7-O?YZ0O%^KW"P]AX@UIT*P1F0EXRI2"EC"CX2+JQA
M),>\15>*(6I1(0G8#[-+R&+T+;IE>P$ ;^4Q[F/Z$)@G4EN:I >J,WL.&KHT
M/[:UHDSQM3AMU6TU9*U'_UJ[&K_)#%S_L2E7OWC^K"'+1F?M)KG*M70>,H>7
M(GE_TFKI<'C!%')G!#M(F9^_EHF"V82XAS L;:J/GU&H?<T0_J)\$JDY=OY%
MR\D="?.!Q6HKJ$W_^E@&/]SR0^W@8D[(\OUL-9?+=KQ"RTC%CXT?@Y)TP(9?
MUVY>&4_QN?/B]=@^!I1]V/7,)'?&S4@S4:EGK$X6_MDK3'E%MPPXW?LGQQ=S
MV=WI!=W:Q3>K2'+R<%[RQ/6-W5LQ_-'$4W&G OFORT84[2KQ3) D_B<DNT_;
MUYW\;$OB/7ON[1$D<%F#--OJRKV>0#E7X;_$MESPYX",I%;8O$%(]J7RK^ +
MVX=/&?+\4-X'9@OS(;?IHUBZ<2EV50%"?^Z"[8UNY(#"CW$MXH7:HWU]F(L)
M?[X/:N6 (L,GV6@=,E-PGLR,-6/*BY/7*!7<>\(Y<E>NQ??/ZY#GN7]^\$^>
M\7$N%>'YN5RUWZ".JQ_^9.(?J&,"?B3@Q#!I6[CNGQOX\Y.W1^#_=^X888 9
MR6B30%01VKV%>YT2\^@#14\2(;9USVPV:_]Z)+\VV2GJD53Q^<GH$" ;L2JV
MAEP*!;$RV>HSX&UQISJ6R7H#@.?BXX_OC"W6"S07G4NN!'1Q<2^@@P,:4^12
MP96O[)MP'W)4PU;[2K1!>B0:GH<V8/#3IA5F^IH4G/U.^Z2GM.\V^I6+M&<?
MJX]WY:[J]<Z4&TM!+-T1UG+U=HV&\+4JJ7#$Y ,##J@5,<%G&;^)'6!J!-#)
M5!D(#\R\".AT8D#;D#%D(9AA.2K";@BFQC!K?HX*[>!M@C#-2)F7Z<NQM"G%
M43,&/)9I60R4.@XR=?CK8FAX!V+#2,'N(?8NEDC^.NC'O-,<<-<KO/M4O4%^
M>)LG<,7:,S[?3.BB?\-XQ8&?8X4&U7Y72T:'O1R%?K[Q5'+4K"XI4]SC#E>-
M5LSSZ4C+4;[HH/@R]=.\<8I30$!HQ\*3QGFR@I%-G/0F@G$L.6YEA:E0 N@U
M#UHR]*C@=E=IFF$Z4]Z T#&UAWV\E=ICND)):\HJNE$812#R%0"D]M'0N/*M
MF#M]-1"!L?'QFZC#$#$\8/'6JP4Z/MI!VK^,OE"!UJ=O-1,.('KI:Q;T",#2
ME.'4;H5H)HG W N Y,M#)P \K?L3UI0]0D_*SY\K['!LL$Z<V35TW^!2TU$W
ML+"?Q.,,S%]]834FP8XTMER;N]JM )W?MT]]S-#W/5JBXV[;*F'#[^Q D[GI
MX"!SQ3!OWCI1]4O@PYUAI=@OQ3.G'V6%N'2,OI114%#N,C'77E(0__$RQ<?<
MM3:U(8)87&1>#SGA3:[R7\%AE)R!")/X9MT)33RCKITLJ<$^:=@9)P_T![P#
M>J\R=.O+T"+U,1/8%E@3B#@*LR]2^#[;%BQUI4DZ:9J7>0@23[,1:]U-X]K.
M;V)2)U6B32]%>KP5I73YO/IB!2'O /IB6W6LGTQ%G!GCXV'K\_+A:FM?2*;8
MF<P9"'=E?-#B@$1-7XRR.W0)@VB^WD<R6]P%RC__R^'3IYN:4,GH0MO"7F7U
M7-UB%6N[EUFS=@\S(V64+]JE5^9:65BX1=LX!U6A]Q4MTU1,C&HW'63+IY97
M/._4?'"".]:XAHY7]USBXP]6[*!C_^9QW)?I8R8_\10N@OAJ%S;, 05B3R"&
MHBMX-MUR/W,#/M]T*SOL+N&G?9N;?!\30F$9MTTK#(E8]JT_\;ZO(ST;OKS8
MEOI]\KIS^X&L2 FGK=&ZB:B?V5F%/B/B=4X[2;DA/NX>_H937T^1ELE6$PYJ
M-.*IG(M9%L,+9O'*_?D6PL6.Y<XU*&?1WW:%^V<-TI246P3C'KZ92+#WEQNG
M_OC^X4>J/\M3/FW2GS)@KN&"O/3JUY+86D_GT@4Z_@IPG20!,P^@KO#,\3_.
M0&[RQ#'YJ/Z0S@^^JR9B$SZ/9?E?M6]HW'4O^*+S>H-?K(;_<.>E< [(8:C&
M3\U5S=%/EM2)E8*)T%=N#*W;""K%W<^G3^/\J'CI>3<I>G8YU0I,&8V"$G0L
MI2$BP*[#X(O</FV_KFHK7ZIXM(:EK962Z3#3.*A@$O7$NGXX%4BZJ=5VJN+]
M0-<C_9$TM)NX((KK XB$9]E2V:II*@\?.J:I_O7]F&ZQ!7KX-,KYP:]LQ02O
M5;A317[WHJ_;:F*];(6FJOFY&^/?^*RKXA#"I-)^-R\OAD>K5'*\%_T5O@"8
MO.J"%/:5/53/R$\.UUD@1S] S5H,9CH,$26AR?ZW,LV37=_7F$7/.SG0UPT:
M]*+Q;?O:]^V*%P&C-,0SYKY2Q&\I*JID:9W_8&=[MO80\2Q% ]'F#&DE')I/
M-T@KR*0B8Z0*LA.R90>@"-.1^R=/FQ3[GO8Q,"JG\O7HCK8V!'TK^\M8[IOJ
M;15WGY]_C5/]*)2X_(OZH4GE5PS-.[(,*G$:V[X.;Y0'!S;4A@I-#SOX7A1.
M,RU-B>.BFYC\2]?O+N9PTPE+8H9+=?)'TIW?K\B;L< -+?D!]=!?[]HU**^H
M=R'TA(7<K0<M!/5(+_F3*:):0E'RV NZ!I%.+3::? #L[>O=Q_@0CT;4O1"L
M;_0)1=TL]@W_UZYCW[68+/;? +P:VY(@=BMHRNQ(644".%IG\8R!N+E0M.0Q
MR1=#T::>Q_%SYN=!M_9\9CNP$UF'L3^F O2P&Y/<L%PB"YD+(Q_B@#Y2X8N:
MB)V[,=6V)M@[$+O_CVJ<_E]HS%GXQ(0(?'&6X7;\8CHWPLD+\S"MJENSSRZQ
M84[]:6NC2]PXJ;C&E93M[1S08$&6PY%43:I/*TXK]$R;YUEF;LK=P!/.%;)!
M'Y@CEOL2\P^O*UG72%YK=2KF'<ZU$_.I+;0.>&/OIB1R6Y6B_PC>WN>K\WY<
MT\?MY9MK+WUM/X\6'Z3)T^3S12=2?!8'G<S6@ F79>2TV5:RU\;.(/8#F1UJ
MM@T'1B;_>5FH1F#+2\]Q=>LE-V[ C\6+;V.':%TLMAD#PKQT7_T/8T. "URK
M^WD0NLF][][+'!!W9*3@__L\PZ+8MHBPHQS07'P/B:%%)4-WWH3 27_#J7(!
M7BR>JUP]>(0[JLJG__>E1^=P3)'LKG+V">:EA_/-1+&\"M%3S;(G[BZ'"B'V
MC\[I,44ZV18\;=!=D4 ""R[U.DR N)^^#$U$V4>MJ8,%?XBW_?RKX;MMVU_S
MU_R<_/;9V;=X:!D SET4A@,UU_DE]<U0BEW"G:;!UB8]JGIOXL,C![4D3 ND
M1>+*#_<E@?FL[1(>7"^)51G,E^P8C'2ER4^5K?M#2O]3(JL)HR"*&\%/5*!"
MI[M;0E]F=&2_LBI K5@TC1"EBS]OB0^X_FZ2'PSLCG>U<(5>K4YZ<E93^[<S
MET$RO(/\U)YT9_*656!+R_\U(Z[NWS/B."!#3&;0O'L5A"] VSGQ)GQGU.UE
M1D.BA<Y'QWS=D1Z5]G.&Q\JP9HQ[;[S2S9&0LJ[00IP? PY;)STE5Q]\MJL*
MM,ZP,]UG6!YMLK!!TX@"E#$"Z.(J3SXFI-^S?_'ML),)HS>&*4E=$4*]@@@"
MX1W^C]=:'CL_CJ?T'*C1BSA?+Q@_=M]0@B;1G!P+ESPY,FL Q6$@\W QMLPT
M4Q\H9,4R\!U:/B,3=R9P<?YEJ6U2BJ_IJZU60+M[#@K;MO.2+9$TLD!QK!0H
M+Y[''&48E9<!AW\N22QFJ %LS'$ONZ\*&9W@=+O.[C.==RL^*7N\^QG;J<YC
M4&RSL)SH;5><YOE7QD."=;GO1R(_S.U,K9J0B[2]V.J*M$/OQ,-!^\W4XJ\O
M!Q_BJSZ-&F98IZGX9CX*?_DF[]=/1B'79.].>37#!:LMIPY"P1/>SA+MO:),
MTW@J.AO*"!IM8QE_-M(@,C2KBM \0S#%P(\P'7ATW@C14CTX] U;#G\QTV*P
MK*81>:B9]CDC_PWWD7G05D!5_E3^-)X"/[B %<6(%+;:)#BYB0&-M.ZP@_H9
M".$;D4/HLY!G[^)I!Y,I2^"VADS4V:1<>BF"/3@4! 4#!-LA)L_CP#E,_[O*
MFR%XK#=ES>=;U+U.?M,T550)V27+;+%TJ+W8*LS_HCDMWTSV/;/T@)E89&LW
M."K7<G*  +]9WBN5V/Y-Q=GF]2?I5TT;&;,_\1KUHKD21]M=X3DDC^[K][#>
MB(A:W>E;M95#A94UPN]#3,K3(W5*+=VUBAQ"T#$>:ZX.#C^^?RGAM64=^>?E
M/2F;/ YA6\,I9BQ<$(1EJC//CORG[A5!)E^LMW"3#;B4]SU?4Z_CK.[R9 @8
M7#NY/+Y)5&+38CB@]_78WQDG^TW$6$EAE_^OYTT1LDF^Y&T]?!QV4Q/*SM*>
MWQ%O"F658G],8[@G&_M(V@D<+!VCK&Q#?F W];OA&[K/UH@(#D@>SQ7ZX_ W
M'-!\HR#F\+]E):;]DV"5QGJ*S3[Q)W4-\99,MX%L*T,$28M6 Z1UIM_:+](%
MTDPV?/6JT0GL6&8^]C<PVL489:;<(+,B^CF@H:^G=WBBL*L/4![LUM.0'4+'
M?_$82)-S3A%;9AYS:CO/_RDP+.* _KW"L =TE(\]_\]K_7#8A1UU;%N7C6HY
MFUC!SP'9CQC@U2B%;9 )R&3O <7E*F;J/-[AAI9CK=)DF$>H4?<6OE]6,R!X
MIQP6#A_G@-QVUA_IL3<VD)X;/IZ_.:"ONG+X+*<562?9NL'GS>OP%[D\?6S3
MAAVU-3R0/\@!Y9)E\6O^9"[,_B)N[+)7N"A*U< .<8WH3#9^0W.#"?MF_.<7
M"1#C;:F%N5RV2B#W1K<Z"YF3P3^QVP1###>J<D Q-1R0'9CY)10[U#A*7S-\
MLFFV'\,=F,-G>+F!8SEW"#M427!:/_E/TAE3A)4&_T'!2&#'D'\*G?Q<"=/M
M_Z26+,@<6,=@S6X2Q%J0\? 1#FCI#1I(7EB08W_>(=6VNC\D%;.<=CT,-HD$
MU4UN:-YI5]O%>BU*5,T6[Y*C9,S953]"HK7FL7:;DC57H%4[G2,A]:>N2WU#
MLUMP&E,8-S>G^RYK1GX*[^+4EFV&+OZG.FMP&_C_]XT7],8N5XYW$9G<*U1R
MU_CO0J>^FO\:]=TZP5CN5;FGK.RXP0$55X.SN)??E@?P["[F+!=SQR*V<P$.
MB,'UN$(4-;#@=P"ST&[01"KK>HOR.A]_D\X!1:EO:#B2+89T%HIJ(&) P6;G
MQ7XY*XC%D,*')*_&H8UR$XWJ1(DK30T?GT_>15\&UL+H RV]-T<P0JAQ[:/K
M+*Z6;GLX;R0'A+Q#I5O6C]10WNI%,55FNF"61;XD,9A_3H]";6XY$-SL=.;B
MCF-.OE[T!E9XOJ&\X/ECK#<T:H<#XCY,]$YO. Q.==UW'F^/T%SN[C#B&3 Z
M@9)K>QQ]7>9WM@I]^=UF>@??#7<K2\NA0 TG:U+UD/^ 6MI08'=CH]:/Z9.L
M-!U^%\KF"_JK7JILE-(S[2F0]ZO@)D7 ZIT?0A #F;8L\\VHV8HS.@ T=+8Y
MPYFJK(!V5A*>$O\D'BXZSM2OI(]&GZ3G]?CEED=U;FB>N='2=GM$6$S!;+[:
M3=@6Q3N8I')VK<6W,<WY>?&[8MM='2OEEBPUB^NI@)<F3H HZZH>9B'4%H85
MDFD1N5$V;[EW&.)EE]EB*NIS+7]E5]7'8?-#FD6:GV7*4;D!F V#.LF-/<?I
MN 286 D*VUJ7T1E7[0*7[J62#B)N&J#TFJ?E&1V5-+7>Z)V[A<&T+"W*M09X
M9,U"F!Y58;@XW-]N^LLT!W1Q8$DG2Y4]O]("3=Q';<LHCF].=Y.I_C 0Z']_
M^B?S$7VK0^+!A8I2&P\*!R3MG2TP&J3AP?43\H-?I6IFPV'F?EH7"K]??K%0
M9U"17NX3&BQ)(XQW8&.GS\0[,&;C8*=+ .=))X;8]S._L?S:*V#T;2*],!9V
MEKO*CKBBY4>:H#X-7)?DC8;BK!G9[U)_=U'XPEP0EH9G#!\O4S?YLFYOPGG1
M>QCX\,J2.9(@C,^/NL+/E.]G'T8;#"\V"33G^XAG"PTPK2@LC+\'U1'G0;.%
M)C-=0@X^K=7MM!E&*U ^'=RR'PU:4C.5F)8;?NMY:%9-_/OO:Z_X'4N5.S.A
M#I[F@[G=ASYV.9_&UP:>E2^Q=HQ6+7/OOJIJ3^FZ)7?4*>=(Q_5[,$\=F?&^
M**R_2W:YCH[:MVN?XMIW+QN(4D)FBKZ4I$D0"C #!K+%#.L5RAM9B:8+/@SH
M#<!,L8BM2L]$9<$0.:@PIN63TBFF0M(2,:P0#<VTN600W,[7'=B/O$T<J GP
MD(C>"#OG@M]T8A_B1B6%?50)5FR#4QVS,[D<(]^Z"VT%MTM#(%R.-:9$)U\!
MZDN9B!J&,A BA7Y"S'0D#FLB**\^,<IA5^6',<*M7D7.P$W AZC VT!7Q.4
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M_\1(L?LX(%"3EJN?(YS72!]]'"@-H]148X5N,/6 US/X8Z[>*EB-K^+0<A?
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M+_LSUSKF^/.Q,[7='%""4S3:%EC;/<,497@]1?,S$%2)5C@(J*)B<G739\+
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M/3UZPU+U:Y)8C+[">?T5A%(G8M7<ZS%7IX3"=UY'P\_3"6QK\!'LV%VNW'
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M8M3$]%DQQ=B8(*8@W8DIFDZM?4UOI15&WF>KL?MEU5@YZ" :(>H#VE!7 G^
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M GC&77"S+5,'$5'!&/@ 1@[H=@%PCY!OT29#Y>M0'.[S1%A2(L5&P$_(>^)
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MPAB/V&;C2%;L;PYH_K$^NVX'CNW2R.3BFW$,!S1\]YJ&J"WB)9X8]9\;[\1
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M-TJ1=O]&XQ,3G:-%S,L8?E0X/$%\6J^/R4-?:4XN1%]EX-JLG*A&$;1DL9L
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MW@XI=#_$%?I.=P9_&#3>K@2:$]6EK!=R>V#)I.,(;U**F_ $4^L%J$;GPDW
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ME2G<KS35]KU?;MY7X&.45(G\/)ZU4*&A_EP+OSH^\M.,25(@>4HY]^H=V<^
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MCB=^!N^C^09>^N:0N$.@?)BD$5,@DI"JX:HD,DXJ_AXH=WSRK7[]8"DO<CO
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MQX+PZGOK%Y+H&FXTN$A@%"M>/8L)<XBC][).-$<5'0<+@9AKP)_#:'JRS"
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MFL(L2[/<IT3SB\UOD*GE=$#X7GU AW%*R,4;O=C1/3G<)Y0T' E,=[/^ LE
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M/R"S(0DW]3CW,^;PIWQC@CW#G@UY6K$KLWV?<[^B.$Y_ZM )[<8TTD,VA.'
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M^O+UZ5KG6&HA@5@6$"QTS?K);AKB?"@]__]>#/MWQ8 '6'9,"RF#BGP]7U4
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M"(HU=!8T%0SXIU'P,M)R@GI>?C[1^\?&=0N_% T23$YFNA>'8P>N0#%NJO\
M,G#-K$[B345.-UXPD$POE([-N$36<[K^SV#^_[M1_Z"U>-+4>N PK^8?2%_.
M2N;JDH,49J5I*E,U#D5A*JHA_BE@LB.C$[8TZ:0O(&KD;-%U6S]CV;=:P9LY
MMXYUW L=1EDO#0:_/\=#NS(5G*,=]O!.3?ZK<\F$O0N(I )%P>MVTUV^-+F.
M3.^UU8O=+=6F*AWU?&260=8+B(OS"X@F*R$;,OU=22&']G-4_5OTS7^F-$FB
M1XYF7C%:=?$7;Y4<?'0/J['U->?$RWZVM5_9R^C1\@8RI35K+??0?J=2'ZTA
M'W$CC2^QA,K;?Z'6@78GLZZ:43;C;[<?S-;77F=XTM>!P-EL4I'ZY-+2PS6G
MO_W)\BWZ7,6Z\' !<?CW8T^O(3K0+A<SJB?.BNPX)!E.$^(.>]?G>U7$8Y0"
MB9DH^DWEF3?9NT)?)W=[?:E/O;DQU?.AXP/EP7.%3:S5\X\6$/^JI6<!T6\
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M$4MHBH0VM[=E.)G&.Z*#@*_#K2Z7<^;6DX?W <^&B'4UX4P4;*VD]7\33]>
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M;X2[H8=ME&V+Q7WX>;Q,&QO Y3Z4D"<F'0;3*M)*$RXD[#:QTGJ1OQF8R-_
M;/5DA;,4>9%;76\H^<3G'YUXR])LW]:D^><=--(\GN:5/6$:\'.%K5_'UT6W
MPW; 65"FPA[:/-.VAW&GX?*CIR-8G:]<JPCSK9"4U1FCY*7GAJ5?QR_!MN&7
MP]9 U2<WMU[>^;S.VRHTD%QASX_#_RZ-J<V; &7!^X/Q'3P@3+#'^S@>_+R
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M>ZH_/JALR3ME'I-:,FRZZH_?=^VTSLYAX9ULD>,"8K6'W-OG^^%N#E%AGSX
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M5_/81,ON?]%E\_^Y-M[\)U!+ P04    " "3@59/@MM(S;N<   CJ   $@
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MY"7Y0#>LPVKVD"WM9GI<%T:YK.*)Q=$[#M$+-Q8DD\])G^,N32$H7915$$Z
MOT-8@G$&Y(@6JEK]1OCT:S"_#LQIK3<$GS+BL:J#\/INROK .2.5;LI2*.-
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M"3C29E@K29&-DU<8!;%'.B>,RRLEOCG1ULVR@NAMH3?G%O*?7[]>&!11_IW
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MA]D#&@_-<2;L#^MS:1BW$(&9]WNRAV P@$U\3E?C0Q'-O!U :PSSW*L/A=?
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MB@) M-63\5+Z26XNT"M[1[P9L>31%TH2B>KDHWR@L]*D)SS$)RS$@GW$QX/
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MPN:Y"0V)&WP8\@:<FPFK,"$@SJ>[DAZ'TPEGW,NV@(PE.V&[;C*!""(;L>N
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M)(,]=PB=R&H234:IXL/+>_\7VMX[J*GM[1^-#5"$"(@("%$14"FQ4 0".8J
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MJ' +#F&S"ZC(2<R6:6$G'U[<>V+EQ:\)NPP7URA53V?!&'ZC$UGY-/#^T\
MSRZ]C5L+;(SC-^J_/15L^'T5]][9"8_[6C8V#V^G8"5:+0(/C\^L)GZ^+^T^
MI1WJ-7T&YB*S:L/XM5R_"6OV8T#Q0CSO^#/V'I_B@4=XHW_Z[0+K\2IN>H-K
M&)L0K:>WN\[9ZKT9<+=U"Z[PC.>O">H8^$V8*ODC^1 4G@NYMZK*LW/ F)B5
MK]=7,?)6/(G"&MK%(9WJ::]*X<>!ZND1Q<//LPE&ZH$'/9(34@EQMQCC;Q#[
MRPC:"]\A/^#UT47=A:M/;86G<;I&98?CK78+CWS>93G?7/>WQ$?OL^6S!&ER
M).<"4IZH< 14CB12U#KNU.WYU,Z[^X^S9ORI6](:I=J,D^W>Q'1'\3B6N<Q%
M^[;QDR<3?;9/25@&-MY\SA]LWX39P,50*-Z7_D=G<HV[[KPP3QELM>^X5G3#
M*.UXDO%?7U05$#&76+VOIKMLI!)S-":T+.WLP]IHC4[_H5G+50<IOHA'QK;]
MGZU!\U9L=E[9)3^S??3T#B7FF>MT[ Q9HA:4!U,.)D5_,11/W#UX%LR8<]PF
MW+,4B5-N="X33PD/'A]%QF#U'L9);,)&*'(K/3NO2%SXU?BYNB3QF"(U=!C7
MO<PWF8AS*(QCW6D/2+V*M[B8YL?:[\,,-;WP]Y=2']19[:KC]B'.SRKBS7P6
M'"=NRR6Y?<JE?7^?K/OLO;_W+X-#/N_SCF17A#I?K/B5RG9Z6_H+48R6LD/M
MY&8S?DBKQ&W"TOK#=GTC&[V SO64\V/F&V0V8;IA,47EM$85S043'D7"]ZDO
M8B=]-R0K7KW5U+%C$R;/=Y^PQ9X_;5/K1](!UEJQ=DGO8<P6.'77Z0/:D(.[
M,J^\E9+\E$CN6VO#(8)*]XW9.@\I])O)\ ]^0NGU5HU\92BML2(H//KK;WNO
MWDPV.=?\Z&W;!W2?(FVG0PYWHC #])'P%JE\ESM/_&[^578X\E(KM_PHCZB%
MY"4>>%:^4;>2JCC]ZQGN5&>@]Y_G11R!C"+6Z44-SG[49M[A7QVER$N?Z #&
M#"X:WS,^@ZVT+K&H??+\P-V+@7OO7K2RE]5[''%.[# =+RCA^[TD^HR+MX?C
MR_?[DE5!D2_$R;>\PF)X 896[*E!]?X\FS/5"5:,VD'O 562>J4KBZUQ2]N<
M(M]7UXP0G\UW:5O?A+41XF1-#F=2E$B.8-80S21[*Z75B!N^"9,DAC*-_OY#
M[[XMZWC!UJ)6<&U^ 9BZ#%F#FBTT. D.]+2$T1)1,CP,W)68@=SMMP]T]?#$
M?KP^DIQ;/C*SAF4,O]&4KH_ZV\,V\/;,\;_/S_(8*N.:W&SSCBORSR<;;5BN
MZXHXA3O=)HAY"(?\^,/UVMO0(7&9.):-/@M419\N?IQKF76QIK@GZIAS\479
M1XD^.BA5W2NAF4#ZWO%3_(0C+6S1/(5'M1B!8H;*&38R<7^#3K[V;L&[J>(/
M"^-*G//\^EZ<B<\_'NRM:&2M0TEG0*Z</8SI") AW*=Z1)B1_[O!38O.2I./
M)R0Y8=-USV4PN.0=77NVMO>K_WKJ8O$]E7K(L?6NMDP/Q915O*OS2'*%5BRS
MX9U'-XM/IHP_Y2C6_:( 568*.R6/Q_)IRCLES0R.)D+W0GV^-.S=ZGYWH=N2
M8D/Q0@S/L7!5&*942 OY**@0S;<**8-^K+'2L#'1-'MA]XFO?L9FT6E;;9W[
MVMUJMC?UECWAUEG_<>?J]B\6>O:;L-<T.T8>O+>#A<L5^C#-%$':KBF2HTL<
MA%.TVO+,^\R\ZBE7;0V#RR=3O3SICI$%Q7UY_<4*'D8ZN6K\'^N'H9,3M.U0
MY\,>XEKTNP0M[GJH6$1T2<(_52@#K5T5KB^T#T473/?]$WCZV:PM5M8I(R&A
M,3=GY6MX3#/UEZ+^_[T9)[W]P'CQR/W:_;)O+E_1@ED['YWFNN^V[P5KGM&\
MH6/7_(J(D<[QBT@#O=[&-H\?!0=PV+)[<NT=CRQW=ABUX_E!_VDS[S6E1'SH
M>8_(Y5*G+)PJ*VK[N2>P5M_/>^2-TJU^C6Y)GO&TG/*=N"]^U:@D6/#GEM\/
M>']_W$;JOYJE%JO'H])+"\=*\P+'=&EJ7_7?O/JJQ@@/SZ^\_]>K_%'W*SI5
M,B9G3R2VC^C%Y$P34:HQ<PM_(!+$V\C' ,,.C!3_S) 017QJZV,-XIC*R#U$
M=Q:MCA-%0%GABXC1[-;Z04[,RE),&J+*\<O7CUK^/["??5T\U3XMH7Q>T;.*
M6PRB_'A:5C6"(L3 QMHF#&V7^JO$B\M()"L(<LVTOKK/H&OVQ8SW["=Y XRX
M( ;D,+9/D"+2DX^P8TG(*))D[FS]5.)-*":\G'23SBXGZ&6=8_.<&PHI5VMS
M\EQG<$"4[^IZ5%;7PM2,RR8,5V8:P;"#YKI@Y(.4%NM-V/<C-. <;<.8,Q*Y
M"7.=XDF1XTF_-V9CS#=A;[=29H('R<&BM/Y_]9<D\3C:CXO7*?/(;9NP8IEM
MK)*?)<)=WN-416ACG!(91-T&85C9)P=UR,=FZI.ZL[A)"I?8R-)EB*_#RPQI
MRNBW?<0CECKP)B640BQB;?3LTZ0.1RXC%T)XC(3L[8),^FGBW'A!X;A LGU,
M',*#V]I[H9CV,(T<7H*MI!T0\K#1FA>ZM(S;-=Q4$Q/;:*NSF%KH-V)+C:M1
MAN\:T5D9JRJ5NFYZ"B&--T-N6!#K5A\#F[#84I07-Y.3G*'90MC*A_6;:?*M
M!LB2T[2J'2NM_L[8NM@5D8[],N<';E@-D<Q+/7PYTM4F*AAS ,/\:+MOR;V2
MAFM,<([P9-OTCXZ3E"=('UM[9" DJ[%\9^HD<7%OM\_S:Z?^Z9''24:U#>5$
MI\*]XDK/R9;8R3OKAR-O?'=PC+0[F9"8#WJJ 98*K.0=O-MB'5Z!BK?A<953
M:;R3GR\&S?).5'_WC*+@+;-P7[M) TZA/MY^!C6C0(Q0L6XU>A/V2@&\MPF3
MFHIG_'+!?8II1@\W< WY1S=ACRE !DD9^)O($,ISHAA<35O*N89:MMP585?B
MK%;)Z!?;W8#_X?&ZD5=I^_.M[Y;%6VI50A\G>A3&YCA5+DR1^*5K-0(>C 45
M7KD" G(;(4174V1FUUT>\N4 /(NFP*=N]QTSZ%O![68DD.ZI9A;XU=LNQ?'1
M92/3&2IU"<C,/QJ&;@58I+<_)0^@JVDQRV+LE9EJ*3L33"Q%@7*S2Q.7P/14
M[><K3J!522= GS9.3 :U;8ZQ>Z8.2V/A3<TQ0RBM<4:L$C62KR9RSP^/ ,DT
M<%OK_:>:\2N(G5CJ+ 5!SR1K"@X10V).^8=Z2C)#;[QONL4[0Y?E):NUW%3,
M*(EJ_UXBGO#,.R81F,W7MG!U7*W,*#GKE'7&,? Y7S!>V"O^D*3<]?/%Z,;%
M0F7M">W\] A,W _M3)F8%F/7>M?RTFNYQX-_X3L=@_(6E/N?I:[XC*&!+L;6
M+68XIJG2\,XC9[U*B'68FG-VF!3O:SP3_(5M!ZJT]UB^^?[BT?P_Y">0^8::
ML$>I)UJW;(FL/*I77.K1O(M(Z[B JJZI"/Z@>KS%Z,G[N427YY"F9S_)EFLJ
M[M87G+FT9\3V^JV\H6"/0XTF;SC^&?)='3$U:^S&,ZMAX1"!=0**L1X,()WE
M,J_=U%/QEQ2HZ^3$=^LC OB[145I_%/8+KDD.-R/_[7&I,BB+M#VMB>KL52-
M2_=?K2CN8P429"X_>J%RM*2W_"]]12NG9R_S52ZG?!+&I</N'$BE;0."R[)?
M()^T?:6$G=G.'ZMO\ACF99L)J!0?4W3+V,'&6HAPNVKT\W,U'1Y%Q3A:SF(0
M$__6<N<$6[P6WFF[8<#?_>L!%.H;\R]5M"RT:+1GE?@-(U_2<9CV_(BEB^66
M)Y$PJUD"B_%+!F6[";LZL0G+S2F/?9O??/-X?G.(9..KM"U_:7P?NWRWQ5"7
M9[!XY5L(L9B'B1TXW;C]CO!@8+<J\GBAYFZT0J"8JC3.O:W,1\DH\?#W&^FG
M[9RM/3NWD]#C1]L_/H1,G)>Z6G\=J+5W_[AU[&OC1A4K9GX)2#](N0[EIO3P
M/2B)'CWHGY=,UMD_V,4D ^A1??)+-4 A>?=UX;(EA2L#ZCUHUYV4(#$+C.Y<
M.C;FEA Q>=U:7["7B%O]"]1\3.&^;33?L$8^0,ES:<-++(;4Z+E^E,SKKW,*
M)XA>(G6XBZ_/ZY)C&M/B47_4JY0G"M6)M#;L2EI4@0K2$N#$;,+J^&?S($>;
MZ!]CG7RKU\&TBK4.C#+?'RAO"^^)4ST$103RJ#&,:O3O)D(NJY3=-1NV&*9P
M/U 0(QX53)/V"UFOR:XIU2VEY+@2'VW"S@_P\<C/;U >(2\YQ!C;OOGJM7UW
MR,SEV^LWB5'+P5<(\?]4O@B)#R)F']"1,-.8>#.YIS/;3:20<#II:CNR6ZLZ
M''ONS"G-H$X5 .]PX3)*_Q(A_%9P=#JG557?@1M[[22$AF_"!CNGY(K-5+E_
MOK[;1:G)3;645)@_:>1RO'D3=O/C9R-C/L>]U-NN;Y66C@;L>H9_6H/L./JQ
M4;X+$)(T?VN9LQORGSKO]9I_%@J='+N"3W_[M>C]IQ6X5.?K@+H+/<-EW@W)
MGU-0@>V+W10G-#>)X;.TKL GB*8@<T)S$V88#(:T,$8QJ[%05?%,MNJ^RAX>
M19&H>1E\/1VY2@:E'U[C?C4TARJX&(DY)=I\*8\A PE_GA,TD/1]QFT=/<#'
M(D\7C<#4I=MBMD/-'WT*B"/,YN*5I7GFAKD'_Y[M_8C[&ZT9SB7X?"C,]'3S
M^JDO/<55TUCG3!]0K4,<&UI6_17#K.])7OFLMPF3\%VW$.:;Q8PWX'81R]T:
MLQ%Q]=O[2-1DA/72?OZ?X#;TQ)>Z.&(=LY&!L#J:KRK#I>PY\]3-V?4'OVI;
MJEV9TAG*?!@.R,&)XQ#8P&;[Q)(!EDUVY9U2W&PC<MV0>(_+WN%]1?.O&P>0
M[5!C?<$UXQ?6V0#Y_$_4W?;)_8D19UQ6/_WC7_,X6F/_1=3G^K3<<SN/JL]S
M9Q!P]'7",/LRF!QW+93;HV):PTJ_[D2="&G_Z'/8U&SQ\JAI(6N_KAJS/>^O
M[^>:Y:_;_X5X+3(08^C*.L$NA@P#/$3QI0C#1!D0]=L]APOK.929LG4ZNXRQ
M&W45]%%\,J&9 *)9VI<O3-;D*/V5?)IG_#-Q'QPVH&;\_EG>J_QC-JDFG@[W
M&[.$FS#A(60493F *%[P!<'\B*<,-'0BJ.@]C-\AVH#)===\1"&JUS36OE)/
M^1UB^I9Y'?6 _J_\L]D\3-;GR"-E3GM>1EW>EBA:.0,!C3&-$^EN54(BC?^5
M_07];YLO)'MPCH=K0\9D(P59"Z1#^= >HJ2H'A%D)=)I*+T<2EN[W A>]*.C
MFMA!4!!R*W2[5=+#N'LE^D5&=^$$=0_>95^]=W[E--8E2M_4_'**VZ=-V-$N
MO@]80#)_<>VM4)>8>O%DU[TS?3'K&ZSEXM:]%9>_^+5H#UH>L]RU=Z;-W;?M
MB O_'&[78#K?W!,V8@*$2*]2!39EJQYCV87?$?R]F%52'TF21XVJ%:$$2F4B
M?%3'JE5XY/W07_ZT/>1#OT+2UA?R#.)OUW29L^[.A)=F]0R7YE?'CPO7+^0%
MR\)[/+2X#-:VUWZ/<##B "M8!77A"! 2^\_-T^$PRFER>M6U<^:+ORY^,U0L
MGS9GH6L&6P2E9#A_+X!)("MUC$MR#O#_A&Q 3_??V_-]4(\S5/>2) TJM'D8
MMF9+5V%DL%^G5\>VU/<UFN9 ?Z\O60UH@,C$QIOT;;T6-;][ D[2T@15%#PF
MGK85%1S 71*[XB_C6X]KYLCRW0=O\XT FS9:M<:KL2-]C:Y!*LI,QKXW?"1O
M$[:[<\.,I#RD-UV&[&CONF\4-#=<S5&2""X50\1D/#.>6A5].:,ZG(6 D\RX
M..DJ-/PHV.[SX..]8Y@$*(;ZD[KP8F0_?_1TAT-I\F4B19]U_+,_\:^K12T3
M%;;7 (CL9V_;E\-/Y2$^(1\3IY+OD4\V!R;9R;3># ;TIX$AVU;%6W<;&V9=
M#^R3#@+&.O2;'>Q93DP;>9=T<0OCS_'ICB$O-F'F07-2://(>:PJK7 ZS?I'
M?G:<ET_NR/&BD=>U];<,:L=WP&!JL-U;FK>62KO*=6H^#=6<Q6@P4+<I_K18
M,Q502.7B8F6)IULR-)/TI0S;E0B)WOV65>,]TJ3#??I+,F-S&76/&ZU?S=8G
M,O;I450@66;+72*:I]^>POV*L!CB7Y[("G>J36C]G1O6?J^$,<>V%RO?N7/6
M4OKQ@3WV+5>GS^XX<%JK>/?^1SLW82=.?KYU62F>KDL>*4-FY++"K9V)T>]#
M"X\OH/W4#2:TNAT<J ;5WR\&HYL.V>W-L4LZ8YFU_^CKH)?/_/J3TQ(/*5L>
MTW([DO[4+___]/R;^>1_.5;S/>+WEB/:3&CDCX O,R+1\OJ(^/5L1B[_5#6@
M$*<!/2PFNO&O(>("^ >U5?0'/E&9T[JD^^OY"PF=A=A1R&P,)^.ISZWL&[AR
M1:O\&_I1(8284)Y#QAN+#!$.3N[$UG64;YW%*3%N<B0@1Z=!_A8@DVEV0$"C
MZT(AXTLL)-43]HE_.G#\5S!"B>\^T(@L(WE^0AW+(Z8W9TNIRD+G.7OT"?*S
MPKV@9KR:H-OZ2-S0A;RGQ_8L6E\/B3]_K??I^>/3S"JMK29*64OEWXCY3X5"
MZZN=C]R097EI6YF[KZ9.^CQ^V^PEIS$.,VJCH*]6*43F8I\6.M]N\'=(UAP^
M=^+IH]M92"][*]E\B8'\^,FI?(<LA?UW+4N-9U?[V0QWG,\WLD-+.*\$^9G!
M*V\1$=R0T+2_\=I$.&(DH9U6A7AX*PBA.J.*0E1ZQH$=&%MEYOH.P6J6"N=Q
MXP41\S1Z&*0 Z:UAJ\4YQ!D2FH?<[C>FW#L4L&O:ER]= 7":R4@0T8Z4(_]C
M;,57VX1MD3>3@.Z-LQ_Q]0$F%N \)+EOV!'?06LMGL<&2#)<CLQG(D8HOUHN
M8DY;X#(J%*3:]4[4 =(-7(XBWK@Z;"FAFB!WG/SAN?>A@8]:VLGJJ7\F.[M9
M\M2?V,@<R25EWKC3C>H\P0S_WH<)U*I.N7+%5JWPV0];5.6'WBT/Y:S5JJK_
MN*-VY.6!'6U!CMT^%R\7VB7FBLKN79RAVT79X-?<63O]@]/D'Y^8EEE&[X\Y
M!E=<EKM;+G^>L5)HX;U&-K/J1%?J,LK\S7:!9G$\TUWNMI3SH.U0*6])_L_Z
M;R'9IZ&$B<RO>!9BSV*CM5A3KF^7UX2'&B[*T;U/[V0QT84YICK(E^,RX/X.
MGZ?_3E@W_Z\GMUAN7U>70B+B90P;S%A7%LY_L1NXDE7T[G)GLV+Y[7\_YCYW
M)\D[=D+[=7U!\?%WG9CA8J.BNICB+C^]S,FG]VJ>4@VU'>+/"1GE<XO_ZQ G
MZ7\?XOS7BZT16TQ[IK=H MO7=V%+(OSK:EWNWU:[T5#[KC;XN>J%Y[J'B*[6
M!^XV+RFZ'.K5B,JZ6Z)]R[Q(?"KJ]P6R)!=<-2ZY\5@YD<9;>T@ZQN7$D:5Z
M2? \HN:J 90"2C:KG@)T<W,@AU4/C O$-7RX8BO+L6\"I:;BEBGR_L;W\_-\
M/<7?UKSU3IN8KPL33$U_$!;6FFS"LL-7RO^10J[JT5KK)U.1(GEZ$SU<$( Y
M-W"KQE:!Y\+7I22MZSF'C%CP%<(\WVS")-4!0IRFPOVJ%GF>KSG/>R6Q2Z(N
MG15X)*IC)NVY:HYTUK5]I<'XB-<=/K<R4A>2GM4')WU=;WWT8[('D['FD-'>
M%TX]91-N5*-RSMW7[=#3U9G>PG]M PW_FQWP94<1'B4:(P0/Y$3K55;RLT&X
MR^W OR@MYRGC,=B!#\#TNM6"VX9-;>GKOTM%7E1]:IX"BHWUKDA.;1WJO'T;
M'7C[]LU8C.'BJ[%-F$[$&IB ^Q0<<<^*=I%=K7)N?_7Y:.L _:[#-Y+M0^\*
MW2O'QLW:G4<%0V)T.5:8?@E U\C:=5G+B?A&[E+^3J=,&YE](XERJ4\'&_P&
MX&ET79(*% ZR6](9</)1/^/:AO$%VWRELH1\(KN#OL,#.S*%H?>5ZW6Y7X)"
M>=2=_NME<91"?Y?:C/28%:ES4^<&>']1?/W82*D&YI0"3I1G\U-%,QG23][P
MC3-9SF35WL5&_=LD#"C.8\01:F@[128#R\_>!7:7EA%%K'D9RAR_$)PYVG2N
M0T3"2R0<5^64>^9?05W[NKLG)X<(N<)^OTT8>ATGE%HN%]KF+AC0?HKR>!,V
MSOE]FWU$2"Z,Z9ZQ/)%O;I OT=E]HA"C;'?RQ5.[P,3#S[R/]-VUMBZ\N1!D
M$A8QMS[W:]7G*90RKM"*5+#B?0/AD6W\; ,P/9I^&!_RA)C2'F97@I]@B!,]
MF2UD!3#D<7"I'*O^9@4PY=&+TBD8]:T-H4DC^>KU0[9GR_HF(WRPF?;9\(<(
M\8!J'3GF/HXTWR2 RY$B*KM#!.["OA&3Z2 !O(6N/JB7=8]E[)DBBQ.K;!Q:
M*16W'%S!R%H<!+U7"PO=_164?HZ%5MEPL,1,ILMZ;<W+86(ZTR5L*KK?,H5E
M;,&(K;:N49%"6?D$%A$C5MS/,TZ[:8AD9TAX?O7LH]61$;^7ND\JE!A^U9LP
MF@"Y"1-;=]F$:7QZ.SR2>/WMK\I$[!UJ9?O=MJ+CUNVHV@2G!5N]%"=!FV^)
MFLNOVVE#F["' C4M)EFY%Z66,S.F#$S25--?S=CWJ*1FV(8$_<T.23=.6AGL
M6LP)#"F:-4[.+QX;F\TH*R[V]/3'EA6'AQ;-&H88UCEVBXKNWQS\-TKU"*5'
MF+X)BXS0VH2EX&>HD71MH.P)%U_BX<@2*O<O*KLW/K]:#XHE[4Z2''$]_$&^
MO-(^P_#2UYW.*B6+*,-6+[_ \_CK=][5!Z:)*W<Y-^WZY/#BZ['PP>,6GG<#
MZNY_U[R_N(B<H\RM+YL:\G#\V&R-3=C;P$U8[R<VZSRWZL&=82;L[SOWHAU;
M'!/W$-74FB("P&WM="D&X!-[:[[1G1M>4CR_ZRQ!/#;(3R/UGUZ5BE=C3[L>
MV(E?M24]OAVP$SVSCG/<A)W\7_$WM*%4D3)9XYHQK3Q\BW<0[[ME%+;"87U2
MY\?[<Z<N.OL--PP75B$L:I=>SWE-4G>2.]&[^,=X#%5B[1068H"RA+A-F#<A
M5G7_[]YB+(2"4 6JG/BSOUJ@]@=]B*Q*'%.Q:66'".7[]$K1-D#^0)IZM:26
MZ]->TC>WCK-<W'#">/J#-"$"1CP^REW)K@ ?34RDQU9S8%?0C_2H\M#8W/EZ
M8*&;QA-HMO;.8"GQ0I6NO#';;7Q=]L(27VI2HDPL43U**KQN)  ])4*B35@+
M_7>/B)K4$BB=B=UN8*@T%4?2SVTIG@O3C*X>KD'*^*8]X4 QK(S'QIB8:A.K
M#,'Y];+WKZ^<+?1S/IEBNC)?,=I,5=N"R_H[.=3DYZ4NG-ZUG9I6"G[G=ITL
MW/=>>T#MXWY-H.W(F]0G(9P>"FUR:>U7MDP.N9,CCC*5J:W Q"D8&'B*@4@F
M1FPF@]..B",?[A/N)<JU*^E0H_E67$;D?>.IV*4<R">@F'C/MI]O7!_]2*Q!
M9&__9C/7-<H+?.]HO#!5%@E.<:$JA&2Q/;4 ^N-U4_ZZH^]01G!9+IF^_],M
MGPH@^7D1=3?1M3L()WT%'Q;R "7E5?9E)JW7NGB4:'7.&E6UH]\S[$1]E=IA
MT;P<_"$QI/="9DYDO*HC"OJ%E&4&7WD&Q\^\&'3Z[Q=_!YUV*VYKO>@4^-0A
M\85[@IWNK&WQQ8W.SH;WUE6><TN>N&_TJ<DP="OC%Z+1=!/F06 LLR-P>#83
M+;42H(D!RV)"*6]\:^__RYIX\_V[H>J_N+%F6:%*Z??"HZ347L.=KYJP164)
MO"6)U*AY^6,&D-=+^67,( "U46&*J@;RTT,YFIDN3Y/\'?,U%2*;U=45VW7:
MJOO\L#.E_3(_ZO[KZ3W<89*O( NE (XMM2IDGP!CVCEPQ-8YXY XDB$>J)HP
M3#13F!D:.]Y;-M7TB>\>ZL5]?CW& 32(U!EL]1VI&7\R'U#X].OUIZ>V"MQ
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M%11?C/@,H@HQ[P[432@\YMOS:/(0DE6O!C';LW4$934<.6+5A#PUEK0KJ/S
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MB[;]1/(X"_*@"/@Y-1@JRJ9@CB&7+\@R4Q2*;%(5HV7!G8>.7H%'@?S=T.4
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M^B9V+>SHMH_!M$<(<93Y1*D"C]P U#4K=; (4M-5T+T_P.Y\KLJNM;8,L\A
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M+;3'545N="6BTN4]?+NZK9C=?M(H:I)Q!_\(6N':KU+,HE!C+F_.S,0N^]C
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MWANR\CUQP NWR)WJNW;08J71Y'Y3. Q@H7GW,)O%C#F1X2DFNY-BRH[\$4T
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MZ9J]-R.H/]3ZP$%[,9M>RVNMV4 ^U@QY"'":4V-;P?WT&^KW8\HG"M: W\J
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M4TMO8=&\#!;H;?#4,3WP*R]I9K[*X0RC#[F#D-!G/4=F&H'V#_6SAZ].C6F
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M]3-/R,<!5CPYL'J*LJMW>U_5=[Z4Y7&;7L.*Z%TR3G[5#J-L5GBE6+:OV^C
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ML6MXQ./BW5U/)RL?N9A;QZ3_U??7RGUL[;=ZLWL/FOVI))GS)76U+G6V8RZ
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M L=244Z A3AQGD.AACCT,:Z5CYOH@0^RC ??3E'8G4#CX0%SC!$$/PHTWLG
M-;&X7C?J@I2TH]K/L!;?L$.HX9A[L)>A@XLV<@-(E_(\DJ+.0%)*A"$0Y0@0
M6]5>*Q$:0EUR!Q%6G9>HE!-JD5)3;_,Y)EM,5D'7G@1'^C<:HF\R3&RQZW&]
M'TJ'/5T;:H-^W]U<].;?\BN9RS"T$NY4IM'_&#+CEBICIW9-RZY#%5&KNV^4
M ()*W)>1W1([[P,U;T2G-J]\OT=WSEYE3OZ)8H/=KQ@\C*BE<(LP\DPO)1MU
M^WN;,&=5Y(N-OG/HC_<?_F=3YG^6!?S',7+MQA-U?.96TI'[O\ZM]Q!U;=-X
MD.O]P6[L_-X-5S4[KL+FZ;S(_WMOTQ7*'E0<*;1X8J:XN&9VH5MUHJA"$JQ;
MUW60+%"Q=[AY<72FI:Y8D=@R^<^#_^QGZBX=F?B,BT]?E62%7/M/-C[@Z/0D
M]OVK1&5'Q%+^>*SZ?RU0J,PB?Q1'J].GX$"#1"Q_?7Y@;LV]=\U1JNQ 27:N
M7=R!BR=_E;=?O:)BMK#B9;]5K*;%IS'M&Z9H&\TNDQ%QPS*L.@,UAEM\TWZ@
MPT"^<ND^Y8N4K+3RG^).;HX>9#L"Z!+*P<SNV'''^Y1"F/7_GI3O;KOWK*NY
M-G=S][%LG>YWF>8^7-,']P^873DIC=D6O$DW=ML9C:/E.Q[#"TJ7'BBT/,P.
MKY0?XY.<3=_=A[3=(#%(<X6N?K=BGFO$JN!"G.N +F8^3--XX\>VP8/$:SKY
M0>T?RL:=;8[QZX(=.X[V6D79ME@>JVM\R:^;5"-665VZ5&5ZU#K*VOKW(ZFC
M@M%-O3O.I>OME[H>.?%X?8LKC+R%\E\W4/#_G@ZE?*DG$A2=1>G+L'+5#$NS
M_VT58VX9EE.U]-QQ!>7;1_*6!7(]7<G$&_^&^.(/7S%R2VO]Z15[LS6(CR\D
MWU59A;CB'OH;0G4)]Z1[;&/92HL-&U7+QVYAUWJ!<&Z3_U2T"U6"27,Q:P$<
MTJK]WS(U>N6K)5AJ$RMI-LK7YTU3/9]A!!J]S;/7(+D!+(YEL.=[_Y9F4)9^
MH[J^J9%:7;^]&Z5Y(SKTTL&GQ-=0D"RE7ZX))DNF1FEADBDU4=DMH03149;5
MWBA:AID0@S!0N211K2-D=VW^^]9X17/E1/QTV_2Z4?;J][^-&MX/<C*:2N"<
MOG)$99[\U6SK@[M__=V>://(]]7>1^"@<\TD5CMBGFG!Y),"@ 8^!ZWWTV6[
M_ #X92 _+RD&+@ABYS%W0X_RA4ERA"33B;)>?ADJ$T?!0WILX2O&1ZUZZ^G:
M4 AF8T13;E85PSYP43AN.%"4W]Z>!ZIV,'<MW4>M5D8^.-24F"#1HXL)5(<0
MR\'9HW(+,=TP,OYW<"!/C,T(I";9TC0]\&(OBLGG@ !BF3O@S>V[ H4'@X^N
MYQ"CCN47)5_\S:759YW/VBWWDC8>'.OSGW58M*9T,N1;EV$U9D>5D_8"_:N_
M+!X,3YN;\I5BJ+%NX%<>E:0":K,7X$ETYHXN')KCQZ^GI8YJ@:>;'T/,H-B@
MUN=$ L>Q_MV0@)A%:X^_G%F!"Z1D!M@9$:=$BA>L,"8ZG';[@*KB2)99C>(+
ME=^= ?N'IUB/J)A80+.78=09G&%#Q3-OY-W=IKG!ECY,_K;<K>(J/X[/^]!H
M@OD]JE^T4>UVP.BR:*T\3REEPG;AK".Q0VD261K+L%_O6$J_*"J6*R'X^I5H
MI89][3#7'&0;LI[+T _)JL1):6FAB)<> H<"SHEHAM D9W1;?:9_WY0<H4_]
M^AH83/WY@Q$5'5JU# N;#)3=>P%5E;X!]--,FWI19N$5D89A6<7"T=MOWO3$
M%!+.G+?D9V0YSCW1O5Z\OO;VY9'AN@NY]$2T35&IMMKIX[%7/L777F=,G"@Y
MX!1@_G6'?:^'>4$/KD8U4[%N@J+A@@P@'0-Y7%::8E=/3*+C!6 ^V2[8K9^.
M<G@1@M 9#FE5>I-TO8$!H68=9A6F%&(%I4$V'J#N_<[81)1^?/T@U95Y2Q>S
M6@Y#K+?CI9&W0P? (,DTNXO2+H0KC.2.O;M_,DU)!Z%[940C5P@?7='PIRT!
M3CH*\M)BHGQV_K"[V'LI9NKTIP#H>-NZ+4"C+,:PJ&KUMS&JP@ZGV $N#2;-
M(M=-+N3FX:N)Q>SP]MQ\5E+9JQP_(*I?ED<79J]!IKMSB')5>'I,EWMK+E8+
MVR8$,B="]M5&&8X,?)2\#VCZV$MV<I4LQ4F$J2Z;(3C'Q'% H>LM^G/+76M*
M&]F@E[P%G3F-PI0&OQ<M)83T^7 OD:PK(!N.P+[D>>1W7%1E9)-W%XL:=#*Y
ML_FOI5 -VCYZ@!>9@/?-7PQFXAOQ%<RLJ@)XN=CJ*? Z7*?RZ;A/M.?WX8=M
M TW'!T8LFMR]T*EDVT[P*]G6??$(,55]+\H&><L,T  N[&LB&E)T!%!;E [I
M-XI1MH:Q=WW!T08H[3LY<@C^JB'/3"4ZY!_E"&)E-4/\=O/Y95@&G6-&*Y/E
M(3P!3(I0>S?9%#*9[S#,3IHCK!8()D9WO6QX67"V&Q6]O;Z,>'PB08VE24PX
M 1QI2BEJ?#81F)5:$?;$.J,SH=*CM$Z0V,*M?E+2=0/SEJ4/SV0<(QE7D]!*
M1,G6'"&:#$HN)I<2F=@-(V?Q(6N:!B3 E_R4-@@;/(@6&X ;<RI'SIR!DEN+
MMMKG?WRXO3C2+.=$1.RI7@'W_,.I=(YE,TO8W_^]8GXNWC1$==44R41S* "K
M[CJT.P,8?C_8C'Z,@"R852\FE+,&%1Q=,=%45!6-X'C]'4KSZR/$[I3>)N+9
M]]>&YB\DI/ML^?G3U%^3&G>E^:]T6;9@4N'-DO"6,O^S_<LP4ZSC=;0A-VW>
M3&G[FSFVZBX**7[T:\W^OWE]\1GS%,'XF(P U;8NP^[A$A +Z[^7\06O'I0<
M.'#<YU'1KP>/GBT$=S8,SUP:O[WU^"X=\:9#NWINFQ9OJGZWUV/;EWO_)RT\
MW/8_L?*_Y&-4S)2R7%FB1XA?)\EFRJASS\)C?-TR[*];+2X/5!:D%<NPOY$^
MRS"ZFG!I6SXK[\+_DYQ1>:UD8LL*2C>2<EMI2"J+^0.LO%-FYW^Y3,R;)-U$
MN&YW?R[G&I@4S^C ZGPNQ&=_.'EO KWW-X0;N1/]*YJUGO+#Z?DR;,*&[C^[
MJ46UF[)+06)=N ^?,@;*5-&@<]]Q58OL#7@.X*QJM[2&?G#P\<1:10RL[K]D
M@Y&-*:U>5:*F?S,0**UJ6]ZD;T_%"!IE14*=Y*OVPD_3DI75[HG5+]B?U_.5
MO[GY:>@3Z2+PQ=[^I>"(4+T.9[A?P]3 " ONR]L2>_Y%!<T5$5BB#+<6R[ '
M]RFMR@>=I$3"ET)I:78URJ\WK))' J,J:/#2[''AW!YBT4WT?O>;I(VH2*&6
M:K)\#XHLT(+"&)&VUGN(C\?5K@QZE11>^R$4H"]J.6UUH3R*@LL2/&. AJ?R
M(EV T61?+NYDV(G_D3M58RH_3P:N;L\J.SN>S^U(H_^,#28G^GJ\;LC#]&T?
MF/-ZWX+QN_]S]"*K;W<XX\V^LT=[C7]"K;Q2Y]KLZ@,=9;;Q1>RD1/B3V<?P
M_331=)L3?4, <?N8.([=G*V*:Z27?U?H%;22C7,.U?1]6X4I'_K.*RM(2#S^
MU<.KRVU;T.2G]"291+*BQQA/IV+A]"S>,$E5U%QS0[2(I39&?X;\#Q49T6"?
MA,SR,%%Z5<E+?#B0DEMF-F$?8K1G&18Z)&P43%5*7JN9RIQK/\4ZLQQ]UGY)
M4BW7"8Y3L$J9P!ZYG3A;'7)R?P5,WR:AGQ*QO_$_L,[UH)Q+AB($?A5GCPWJ
M[SL<6L9>W=05>V4Z.O;*R>K=/XW'WN0&%#Y:AAW^]Z3BK:<C9)Y25R[OMFT^
M4);7&NCUWNJ/"M3=T\=JM?MR.EU*633NJC]^^_OO+]=&64_H0WB%]Y@8OI1N
MB%$D;X.1_NU5[=Z8+B?Q//N[U:6H*O.<#O^UTZO.&>0H-*O\&FJ,W41E)B\L
M_QE;>HH.SR)(B^I%'N=!3$I=HAH[;[[103N2J=(P@(H5#;^1VTFZ=J'UY:8@
M-[?F:>2H(4@=GJO2FEC57W"JQ[;*E]WDD%%95<+@5\]Z$Q9V*,?='Y1.)RA.
MV5)?>8IBPWKR;]VJG7J45R,MU'1KY9^;RU:/*%+GDRU([E#]LTCR9J!^- =\
M-XR%"L.E:;'T#8W<DY7>ZJS;,8O3:88CL@+GN]2-=.NL[%2Y$TI/%H^494U
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M,M*?B*A%_^@151UN1YN0?/&5I,M@&;MPI42O K!\V^3 864P[:',50)AF]H
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M*&U+%NR3F;AOH,F3<#+*+=9IQ!?37==B(O@Y$\C@UTUZ=7D.CWFOE D&Y-$
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MT .A<^60KW@P50UBB;ZQP.3 QA:HIHP-3&E[0L6/(3[[*=\-],^4[U%HT8Z
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M64@DMG%N]*D@CCK[G'"Q;JG%CI!NF-L2%6[-_=K5\E#(3E.8A01%Y-_.;:0
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M)]+"_Z(L&@4H X1+S3(LJ5 YD^]%K%R +>4R*!):NG UPT:*,, >? XE^S!
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MQ!+[3(YY#HFX'/'?H/R6QSHB=G(Q<^BFKIL:.^#M-*.4( YYQD2N,A8<I#J
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M_6)&E>/_1^;[7[2/S&_^"U!+ P04    " "3@59/I/1])4)9  ":8P  !P
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M"W7(2. @4@.X6"8N9FB.U:GH$TS=6%V/C9<8P2F%)#UV$T-E(6K%B:  ,\[
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M\H_>*)H@ [SS> !\=":(C[%20[#X?KWOUS%)E,[K=8*C;?<MK@<7C^EYW>B
MM);:U,$+XWO'C19.3DD.E>.F8CG+)J7SU?^E9(IK@FH36DJ/U&*"J'\%QT7$
M8E[Y^+\_,6IYL?;G53XNTRH_K\4%?BPOIA.%][)4_/TSA#O++[6-<KY&Y]V:
MIV9<[7C-#/UPW';?_VTW]>]M%7SG/V !+8A)50OD"$T'5Y#%__ITN)&"5,^_
M?B003T:X_7X1@NNO(A$KZF2^3C2/I/;W'<^!CQ0DG9U^Q]S/69I^"EFZBZL
M'C 1F=X,K($OBLQJ(AGW&K;Z0S)V<*9@9BO1/-@/3.!S[E0Q5 =%YG!^_J=
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M.^@#H6;U4[<64[[O2#\NSK'5GM!V3[]1C[B1I-$]V7Q+9ID#;TT]3>0 OQ(
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M<,M$]Z@[5PQ1 3?\(JYYM1PE?@5]Z_MC/'U<?0E.N,N'#:RX,E;SU_&:9?\
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MI20CXL:[189G]<KLB"HC 9H@(7X0M*-%#A@2R8(#;0:2D^-^YTK$Q1''L@X
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M#0<'GM:!WK75T%[6)>1=][8Q/96?_!7J%B)$T<^A4_O)X62=""?'%/16HC?
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MP(L[,^^>)3^LVM=1:OD17F3W</"X<Y:$8VVVB>(R0B1 GM?!90R#0,([+MY
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M*?2^O*XQRGD5TT+4/7:M2@!JQ3Z<K-\(&)06G*P<$YE=6$0_2-YE\"[(X^%
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M5',-_DA H#0A-TGWS[JD>07H>T@;8-^97U;+INQMYEN^&(&?;)FGYC]CTVO
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MJ81<$1*54ZY&#>@!@@3.*FI@D%:,;&%+"@@18HR.5:YD8$LK8H6(+5]RV)
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MV=O)S]5+VA;N]!]?IL4:%KH@)5_4V0.8,W"52P&Y+3% @-^GV:(JKI<@"SK
M,\O/4.98IFPR<V508F";3>KBS ?LUB^D[H?+(69>WBEOHAB1TPQYHLS0-]_\
MGQW^?UO4Y>'_ E!+ P04    " "3@59/?FWF4<""  #CC   $    '1A>'!R
M;W9I<VEO;BYJ<&?<NWE44]N[+;@1%04A()V $!45%34JG=(D*@(B8@0/("!$
M1840(2H@04*B(KV8(R@H*%%I(B)$I8G214@ E8/TH""$)"K2!/96"%M(\W)^
MK]ZM][O-N[?JC:HQJI*Q_EC9*XOUK36_;\ZYV9%_DH\ FH><79T!)24 4%*\
M ?D@X*CH_>^]_I[D?W<.)?E;0&N94J"2@[+2.F"1EI*REI*<"R 5ZUSRWP<
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M[#S[*C[//+;W:=ZTGK5@)WLWK"6ERY"2_2 E)8(_9/$'_/#IT+C)1DB_$9>
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M>_5_'(CGZA$A\_Q,^WDAJW2;:1 AN&B9O?#IK&A6U'<5\Q S$$)V 7$B'T'
M=IDBERG;H8VED)%[-QE5Y@KIBW>!+2WMRRGM]?90, >AW?9( D#89/*Q$<S
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M*I0U$O_N\Q05N)^3M[0'K>P[SEXITR>?[Z\]MH"&M2AV$PA&&-P+F7G QY[
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M^<[9W8V6W90/#XQ.O$P74EPVB%8'.'_]XE\=L)V-:6^/Q;\4SW&PO[7L+>3
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M>;RA'K@>%GW5^EY"&S9E3!'J$Z:05?!F09[[^A>[W=L*]LD"M:0P0Y>V,2.
ME%*K'F^%:QLS!#KJ@P+*OD4.W7]3V[#]2MLP+SV+5#S=8#567!C(\Z'>FUR
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M;"9<X*)N"_[=G42Q%B#'H$BET'OM[00;\!_^=B+"?UE)-JX7GP=8J.!WS'N
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ME?"X2P/H?5"/YR!JCY!JMZT\U%?L)U&)$L4WBDG*^')A4,_#L!!Y6Y")2;)
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M6^J ?A$8/.FQ-=]]3!Q;$\8Y<7?GRY9!3(!R$V_C36=7E-R3Y.+LA^"'Q+\
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MDPE9RX=[V[*62:I85,^;E&@EAZ!R:2/?*IYA6%CWF%+35UX[>]$$U22#=/O
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M!+'>I0D62LN+FBK1HOQH?W2T=."&[OL;8S]V]2M14??5\TS,W+<]A/9@,A"
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M\P1,1N4AM/ ZDQZ"5(^S)DYMCJ&BS&JO5<(":?TT?A!E(MTC=AD4^Q" CN-
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M5LL@6U<:9) \.6(A.$:],.!<%[2/I)/8Z.H*!M^8LM(T]@H0PAC0C6CIC@Z
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M%]L,K!,&B9CK_N^8#'O.=*;M$C1P+GF%G+VL)(-D9*V9CPFY"R3A/3YR45%
MRC&Q <G =1EDBLQ I8>92AYT^@!/8&DFCJW"1FXW37?.L+:A8<)->!S!45PW
M@QJ%A,RM^H<S]@(C,\]G,\.1ZFJ#HN&?$S*(AOR0".\#>E"@%T(&L;:00;+F
M)96(&4N>C7@/25YL>B*$4/'PL)3PV1CQ%6'T108YQW)8/?19SM.' *)$<9H
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MUDI@,^0,4O4H>TD4E@<UCJRF.QGIC&F,/LZ_#&6C.E QU!WP=L;=G]-R_,M
M0"<JQ:H;+1V.DH)RF; 2(,]\%JWD/FE6*"8,2XKQEAI\]&$0D]RF \G;UJ>W
MNA>S.+V*\%[4'N_Q10.CX(S$9W>CM/[[Y/@"(:0^"WK@36DWI02YY=N,!)^%
MPJ1.>7NVRVA192'<;?^6[)>3+^_&+>^.=!W>1-1)=CU&!Z+O%2(@>D21>H(>
M5<HM*$?Y*/!%_D&0BP<RW?@0UP3_!C88#*]V\8RT)D;)L;J4%<9T?II<\3RC
MH1>EI$W<KZ-3^/7O3"&L0IK3: "#&<]'_OPO@;'F)?0HJHP=0N7@S)I>;VJG
MGNB:7K4$"8(L]Q6X K0"A#(WBC%%^(9K"%KX\'ULZ9+7^&?/[DH/H4R?OX3Y
MXX5:.>WUVNBCW'6\T3-&;93-NQ_VMI7FNI(4'/%JK6+^[2OGKR7@;_LWO4S
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M"D*:#:";<L;=0PX.M"$+7*YWGZP:B'&R.BYM*7-^-7Z7VA?GO6^/%/TIJOK
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MKWQ;Q3-^J/OX/T+G'. 7H*1 LH[.-YKA,Q94WOYO4V#P4V_X8&#R;97?]4@
MW[1T4,)J6?CEVZ7^N+E34+-V(598PX?MHL0Y%.A0!(NQ#8JT C)C_OV'&].
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MK6C.(]]<6\ .SE;+CN!*R@;E^.S-]YGEM02?F>F.:9-:H.[D>_IS*,FFVFT
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MHLK<PWD86_!4F[I"YIL4 .X,/OB$*BU&GNQ+N/MRF+6\2FG =N"TI$VVG*'
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M>?5?BT2V$,U%J-?@6Z"*B^VH=G9O'K"4P%)(<!$.@(1G:U.W+T:,8[3P@6>
MWN&B0*7N-533N=/!61?&.S$+E_/UG8A'AY9H#,JH*J3R)[1]%KL%,L$73$I@
M#R!=@@D_\-V'5B\.;3-HX4=2)NSEKV3>GQ=YE7R9GM!GF2_/(93M*P@V #FY
M=1<W&FL!*;>%N.7;SNLQ\K<4E0=Y[=2E3;J-Z7&0# E, S_53H.+G"*Y\YX<
MALV."22M3V3-35M4Q"URPQ3PGMT3VO5U_!(;"[RSWV#KD<E,;1#;F6^>]RS$
MIK"T D\Z7S]D5NT_<"R'N@O B-0#)VFI]8M)NN8C*'6^(T<"H[-U"<;B9VBC
MB> )4S",?PAUD>.,'!5R%^^AM^$+Y\Z#=TK!#1*8/U;6_B+O#@I'(9P2L^,)
MNXJG5S76AKB?:YY',.O0,(B)AHN?6F(U\2'MFCYQ^'"&_VZ@IO8%+NJ; 5J'
M1=@.A'"LVUUDCS:UR=6L' P560-IQUKR)3#W*-I;*K5-Q?K1J_M+!^Y+8.N7
M@86'1?B>CCK":;YY$:<W<)(R[P7(=FA4<^8WC4E@[>PMM&"L-#C=S0TOUQY8
M6(OTFYFQ5O,:$)N^5OVM\,E:;F;YN,_<\*I/QI]CC<]EEAMSA.XBY6'(F-8^
M;]39Y 69^P5/=;R:&,=[=NW';UGM:O17U471@ V/^2>"$$!UI%NR#RFV":R4
MP-XU1Z4N$#P#BX[<B4'GIETL-Z.DB2Z*BS!!;!AQP'\+B.&XQ6/D",Z3\.VB
M V >WY_>E;_:1=;%AW?=GM@&(J. -!<PH>PS7ML%U.2&*JT(6R2PM%P$D$"'
M9XR[#LY'1+^UZIE?%UUN-I(+!DC]YX$.0(L@#J,;D2PRBB:BW"H)#N=7D'$8
M!0H*3U9!'9F,!P[0JNSYE4OT/)*J:2LRZGJ8Z$@ Q\[Z7.V;@<AYK$=M(]^R
M4"X7L;Y]Q2B#NG$&;0,63[)3O7PFB@-(D^QXDC:DXH.[W2C(\O;'T;0;,/%W
M"ZNJW"QIM SA,5)\_C6?"&52\07#:L((UE)C4&:)1(>#QO ?4SQR/'$3^)@R
M"^T$B*7<3'DBTU_O#1".E^<F-I3WE!,'\G$()6DMP3Z$3IJ$4-)\K)-%V, :
M4)9.-0=)+^9L=%NX7U3F'&+/6SG]7DLZ@VFD_1C=4L:SLW8'XPP3X/?J,Q%S
MNCOY\&31+EXF'&^0S;'9 %:_"-)%#:.L B>9FOALS@/JE4P&7!'O=F&XU8'C
MXL$\.]#@MU_'V6$X-$("L^PG_4Z3#QK!RET/X(^D&$E@"68 2^ "AI0ZF#\N
MCA^^1KK,5L'7,0JU!E<VRPJBF6J?P1I\9'GU/J74\^-.9<IZ=GCQB$C%61 Q
MN())'UZKSDPR!#*[7*QY!)4C5X#PR:$\1J^JI_A9P]RB.G[AYQPO E*B@?>Y
MO;;.?(V*2C_0^LA(C;9;T\"*+4T1SZ'N!'WL,(ZU,.$2A]2UF,36K*<I!_MO
M;1NI?@$D5EIB-<#H+JHBGTP/T\)[>60[LD0.N# N5I9PM ]EP9U7BD3"9YNO
MMY0PRZ?[?(.;'5;:(++5WZ;?4-ZT,/AHY<3 =YX''Y-N:5N.<@!8] -C\LE4
M)<(58#&MX:D][T!QS;0$IK" .C3Y)>S= 5T3OD8F'^X+#+<4@9Z^_?4AO1:>
MP_7CZ<;F*F#G^EQ2(&E4NP,+0\GP%3NT#)B)RVU>7&)Q5#E(9I V0NH$:S$Y
M=R(0&*(E6,ZERSN"OL]G9@(K<7=CW@Z&1LX'N/,WU&UHB8J\>?%.65 _SA\Q
M0,6!3M+$?@/(=U!4IJG(3*[<D 26'-'F*[A#H[;V4[<3#@!(D8&S\ !8Q0V3
MAKX*W]MJ4#HZ 5*Z_8T1J@T'H=VBPWPY0?%+?)Q[79(G:[+O]T(78YB="<]1
MI$::1-(Q<6.+#*:B7PAY:T,+,A$R =->X'5'VFDJR]%"9ZP"2/, (\O/$TZW
MHF4&OX*(_2*'/M&1R>WP3A<,/4H93Z<3]?M4!D(=Z6L,#?]B_JJ@*'O2NM-M
M5 +KT*+<'S\/DOB!GOS;9+XL%^6_VUD5(#)=A]$Z>&3[A,$0P=;PX8UF=H+(
M@6_$38H3:7-U+H3<W0\:V@4S&5[][.F^V3H<58Z' (TVI'&53+CH^\\(U_@C
M<?69Z<V!G6Y*A*OUK%8[CM(ID-E1B :%_#1!(K#P.""\RONS,R?4L1V]!^3P
M:$J^<S8AO<CD5LTJEROEHV-SPVN8Y.6P.NHN@C) DA*&RDQ^=_HNFX])84 /
M=[&C.JQ#\Z9>T(0!T-UEFYGT$Y^AY'H&O[BU,VS2)-HVHB'+KG\VSZ.N1"!X
MO4>^AZHD@<7>QV]8=4YC8%6J+9E)-OK-N11._:NFM_SN]-8 HU2RH)Y?]N/I
M9.B!<?J$#GA=L-H(V?"C$GYXO/.>79J[K06]U;B/CC.+5\9G+ V$D:[31@O<
M^@F'*'X@VR^5Q=! [QNB2#<9F7IKCBC33]3!UY#6$0Z/0+^!=Q%R'VH(FL#J
M?1$N-))#T@BAJ4N19..,CV[=E?)Q_R_/<?D/A@MU ":DT,3!)/EK@'Z<#T2D
MR)Z?WDTWL^=\?UZHSW?)3%I .7);F$FTAJMMPK/C6+!PX>/8@&T;]@)?H\4Z
M:67^I&*00<MKQ^%XY\K/O1>F&%C0P*V=DDPUR>NRZ2I]-J?5U<"%/_B)SPU#
M$+:!1_BWC%NU^04\ZV3J@5D;>((I9 B&,\;"XE#V')HR6(4=J,=N/_\I6)'$
M$5\2,#O]M4<6S.H5JS?*SF2.10M*,777WPK1G>&3;T1N'&0:1O-:JPQ?MM.(
M$><@A2;WR7G'$\V)\!2SLL;TBFYNC$UWUPBTJ:_ABU4#'/XBC]-+.L<G"4H[
M\)'U3YW_ML2 >XSN,[O<Q@(X4^DHZT@.>:-H*Q_9OKB>@.;[)QFEH'>"-!XE
MG:K'Y&./\#43I=1;W(%6:N.?:2;'$6X"X=UHC426?7:G]=U!_^U\Q^3K\\M*
MVO35<$0T."\M0&O>]^P7^"C&R,C8]?L!'+=4726R\\#O=2=JZC-3$5L:,$E>
M[[.<M6-2><=J![W.])<TNO0%G[N=E:.HDO.+XB+-H-LSZ.VZFT=$>ORJ[K'
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MM2P7HRZTV3 M<'$;B!'DLQ:N+8>-OL>1-C8P-8@?5YM?U G/XB;V-#7S8Z3
M)7("ICKNIC<CDR+#MH(%7;JV<3S7-Z'H<7$<U0R'WB!^((%=82;>9F^A[@'#
MNC5\7/, ;4= \P%57G01M,<5@:MT"4Q1=(4/=^U;N<AE)JX= KKO[006X\PM
M[_-Z+8X/BM1+@CUF"K4;F_-\WKP>T(>)31KY6Q*B7P9/Z-8-1U2U11]I&* T
MM*F,N]>]&5I.LXN:YQUK&5Q^'Q@]CQX_;^-?8EFQ,,])<[>) 5[?Z2WMSDMZ
M29 VZYS%39V\ZNAN-+R?H'ZP+HC@5P62C[((R+VS%F;4P@"^TD+1A@SN&F=
M<7]3B=^I.;4-3MN,15Z@["0BG;@5I M]0]B-V'<Z)'N U(D<I0C"AHG6!'=I
MU\Y.H6E:296$JB4E50*K7[\VDD! %!$0H&^1Z,A(JW492.J\ZWB?]8ZJ%2+,
ME"7L -AQ$9EJGT)L2.DK(8^FT-MQ%*,?#X6R(6M8.BE9ZS9%:/YI0HJDF(ZP
M-$0M=EZ3B]P0U.2_%[S5;)F7+=HS@%(H(3C4#:)V/1\W3)?"!M?ZGDB5AY6=
MF:N1<E8A)9+SGG 9V@F \HLQP]4OO'%16E^^%P>$%(]]^E#Q>;;)^C: :UR+
M^$V[(FR*EG^L/O$ODRLA*>;?'IOQ[FTO/)NLJ4:PX)*5\"/V+)';I 2V=9JX
M%YBH5NTMG8.TAY;GHXX-%CE=OO_MU5!]04$O6J"?;[P;9U9SQ2'WD-[5+0^*
M?RY.-F;?G(1_JNM@UXUT4V+)ZNA=LV.(>\MDW3FT>B.H'L[+W Q&=>CN X7<
M G8BI)U&/\>:U=TXLL*\=]> EA!)41') "_:>' -,+!]0HT5\07NR"=X! 5X
MKR!!H\!XU%D.8A/4)\_0.E E)DLA90SAPQ])HNZ<0RA8849G>=RVFA: Q4DH
MK.*.D^YI=99F% /-/<XC$3'V[7N:#MA<EKJ%1"%C^#:S[R9 ZISG$ QSS-C:
M?/ZM=NV3J.Y?4&&]]2;&UA+9V#NR&251LA44>J\F+_"!)1S<Z]K&R50AX$9:
MPSGL;>.?178 .@48X9(2K3 ;\9J>*H23+2R4#+] <'7(,AW3V6PWDC#>(:VE
MEZ*SP);:ZKG5FV0%,+,3K0>4T2FJ'XIQDX@WC^6+F&'= ]FWIJYSR*<>+,N7
M^<<CBN3;B'>@+MK6!C/-4^*JE^C?H#X,\+H4C!2ZXRGV:#2_\2W';TNW2]\"
MI$78.L1C63ZUZ7!&P$';]N:H%)%?^7E\P.&4[UH17HW#^8G5-7--7LU=94O(
M;DPR25ED)G3"6Y\#3?C,TT/SU)V$$R ;Z,"J@YF\%?(#ZHYILOHU]$914".P
M^ ZC3.S1TDQZ68]=C\=PK!GP#?BP;N)>D%7672DZV<<#/E8'\E9&4&9<EY"S
MK,,87)2YPN<W,)5;O\E,NZ%D/PW$PG?&[C]^A+ES,L,VKGW92L2?P6I2[1P#
M*:#C.\@0G'J!#S@M?BJ!!;HELS7#J 80"[,1%<A7663<G9K7G*0H@,-+DYF=
M[GPC!G8+6FL64^_6,<Y,T<)VH/!3G)$X@A=EVL=NM9VM(#I ,NG,CFD0FHN"
M1A9$)L*S>$\??BZ%HZ/=@=5$79QDCGX/R\"J+<.U",<'JB/8H^QW;!44CH-5
M!EF0"D+3C=MFS\%F1"*T)X+[ON!;N,B45G7.^/9EQ'9\HHM;QUUJ3M$]8E$_
M-@?[*BHE$JL 3A-T^.?JHOFRC EC\1-HNPB'3<['S.?Q*8(6H&TBOZD6[_IC
M=D#DVV*#O=] T9QK3E]-(5B\%!UB+2\JB)SZYJW>ST?,VR!AOC$M*^?N;=KS
M_+\-].\@2^A#V \J\\D"+U"=9PO7_ +V"*C@?5YFHA17:UHQI;B\L0U/*00,
M&%I-\!A>0 7&1%?/Y.6[YB&3ZDVJ_&QB3%Q':FJL[E17OWC=4(];G%S#;WWW
MV_1AO>GC(7QY:).;!&:L+Q7Z:A+8Z# TB%CKQFP-$?S$K-R4P-[0UC8^D^]W
M4(.Y_XOAM9T/[\Z'TQ$;\''=A48A0WT$J\O(E0.L>5UHV;<@V2QI=%[O\AUV
M[YO,K^?DKW^?CQL=^9O4B!45:'8AA.HL"<Q-R^_N6]TM&0%/O_XBZCT]W7WU
M+7$+K2XKW2T@M;._R#/+Q>DX(3O/],GE1R_'HG6O1CZHROOZJQ$=&T>)[;GY
MJ7GO\ULO9CG 4#!K*O7FK224YGZ/M. 9J[??2 #?;;3=:1VO&[9\$/";1*EV
M:Q[F'3JXHK]JI48&3B^.5GKOS/7BE[P>:_D0:EJX\6V6\QW]E,F'DU%OS511
M^S\HUE]Q=M#K8A3_AHFK'A2[+9509DLGD];7D]%1E6YBJ0[[)H&=Q@RWC8J8
M$IARY@-,GM$_/]I!V!7M;^ :>[4,TC43'B(QF1DD(+U5 OM:Z0;B*3]X$U/=
M1CL>@/L!7M/Z+U$[$.X/)VARTV52;,+$DLBV4ALBC 3VVR]BS"<2(X '__9!
M @,2:7GBX[^(Z";QM 26E I]/-@]AKIY_P$<M$?^MH\E.W]^V_RR;FQ;WB1M
MWAZHXW7550?YR^0QD*0B7.Y:&S@<L7WY3^*'2/RU@*"KN;CU []X4P]@1PF,
MPAS1J-=,GDA5%3J)92P*E2/"Q"?RJ=ATE"'G0ES"T@.VC.D0%[#<,U@TSW\4
M[/&]$*ET_ *0H?*DY.W>D\-/0DWL(MUF#MHS%@P_@MG&?]56F9Z_$'JW?LYF
MV\G!V9]T)9_*KT]J(_4TF2>MKZOT-[2\%9Y8>%AE^_KY[MRHVYLJ*Q4M+%36
M59;K9QV&J;C*$<"ULA]-UAE6\)2L.0E,]@5?0.'L02E4@%U^4>^6\$FG@2MM
M\Q/%\$3S%1Q2=X%WU'=<V)+Y8]0@Q.O.9R?M9\>PMX9I7Y4K29^D'9@$YF1(
M^3IZ*2V8.(M\0_[YP;8<\X7RD7 0$"IV__;1(.7OVNW1/0;W'JAOMK.!A@(T
MS#[TC)U)0AH-Y9E1>C\NAIB(5Y-W1*9,?OBVC_YM>1][;%_77\2QUFDALM)Y
M0U:FP:&E</%5K[;JOZJCR;3&?VY73SX=.Y##M=.DD^ 2V&6$ F[B-]:R&-%Y
M V]+IVT@Z!.<GL_D?W_,M751]<NC#_M$--<\R/^8689M?'QWR;NA\^7^7T=/
M](\,SS<@1WV8W=8TU6HIMT'CW..E >+'Y7AH8I'3JGN QCIVDV$YQ]8X]H&K
M6"6CMN^XZ=3@Y2;E[AU$__?]7K_*?TKYL="=Q)8J23 ?]88V]0B[.HN!#&DN
M$EBR3"ZIWS%3FFF;I9F&7($*R4])C!M_TZ:/Q$J_G)6F,/PK)('IK3GV%XO_
M:+7E,%5!6_J4X$:?R(#GFR:D;0.QCMB$L< D@E=49=?NP856YZ)/)5K^;>'E
MC/512[/#>5D3Q]==L$P^,"36.RU^),*$3!;H*)X6DR-",(E9P:J$0_4#UZG:
M,XT3,GGG6&'+H1YN<KZCEEM!#Q=GQZ%(E[WBY?6LL267P; ?UT\U-N7M<Q8-
M_KI)8NZA+0Z21"ZZ%[!+?R&%*P@)3-51='AS'92*(D%;+TI@OTB4Y64,]^!5
M[/+.=A(GDH1<2_I)(CT46XFLLP4W@*??H#0@BQ1+W#&(\JMB5@7?=:.7 1KI
M=[@Q=\]_RY_RI+X":*-7AU?N[/8N+11\-ZD:3K\2E1?TQ\@;KZ48H;;C-G$9
M>NO#';^GDSS;E9_I0<;8K5LV7LB !T-_:#Y;@W_#9N*3VM\0%7I?W;F.T/%%
M;#[GMSFB<KAXT_[XLA1&7\3@Q4-E:J]F+_2^^)S?D$6;;97O; #IIIT\_C:;
M\\:<VJ7VRHC@C_57MEU\U2 N?L394(!/TCV3?]+XR\2'H.>IH.K"T=0]S];]
M'P:< 0>-,:*2;&BCIY1+?86G27,[1$<HXV_>_^3-K6K60M,"RC]SKOWVF=1^
M C.9X.ZF%GZ,W1 U;].[H[SF08 X$T7:K?)RT].:2MY.SB/=(:$C(A%E^ZU,
MY&3)?$/[.05_)H%=NF?]TTZ:%)#:Y6C(460"AY0SMTA@?:JG)+!W!S%@*H:S
M#5@4RU@R1;)QTB1[IO1W)NF]!):P75<">RB!;9+V ?$!=)HTL!A@"QS:G0D>
M1TGA[K"+A00&DTI.[A[9<#WV3PSGN"/M*ZGCE03VGPT6_]<+PCZ_7Q5E@NX/
M%W\A@)>8_V;NOUSOGO7^_V_6C]T'C09BZC2[=&D_3<HN8;[O*UU+79/]K]?[
M11%T]-7[8D:+N>+.%SD7PVSP?IM<U%\:[U9^.>.XAV-M_'Y'A?QV'05Y-L?M
MUUY\"-3]"P.]O-&=T(GXZ7(3+DZQP(J/U)!LS?Z=G@Z#4<#B6?!A34\);F3M
M>&8H;G.43TU3S>>VQL>EXY_]'"\&#23KY2]\C_YR%&\Z'QJZ,\M;_V$)R7SC
ME8=A.*F#*R$]WHOFK4Z3+KJ?9^\FIA?[!?OO2:]GJ\UJ^>64KBSA2=ZL:PTZ
MN^J3 P8CWF,X>L-A]7ZR0GO/6A;B=(9XP6R>UEKV^/<]@X6Z-89/0MP3MI\I
M73QY\VSQ(<_5 (WQK_&5?^UKK>@_V>"PR>,!F^^ HFT_EV.S#*P8'']9>?2I
MBY["R>P'@8M.)7DHWLG]M]-/,C^Q;E4^T?RSW^_C4T#H-XA2KA(=5L$)_'7[
M5T+U3N10%@Q3(8&?QYJ.34C;@2X3[Z_-K'K?EJH]D2UM_#3<XLZ&!N?QSL()
M39#\KIA^5S>%NY'@RPE3GH%VTH9>6@[UPU,NMCP*BOT2J63_8V(W,'%OL;0S
M,E+W25/?]N)L#^<"JPV^MK5R+XDJ9W,V#GN6\]5_RXW?Z[J/,5"TP^6D:L7&
MDT_V=L7G."I\1.:X_K7\O1@IEWJFK;[B(&NM=9_3Q]/QI8D5WAR._]9'CZ9<
MSSZ?J3BZ_\)'.R-Y\RVT4[3)/Y,0*I 1Z5-:L< (NFJX3$DP!"]2CG!&(X<'
M4>B17&A;+;]M*IXW: Y/,VW5K+C0'G:%&YVV@37B)MQ<%74EQNR)3?U8[XN'
M,8$O_6;^F%G:GKT !PT3$G(D, 8IY17;Q_=+%W5#_U^E#*?]50CE)Z^3-JMG
M]"F:*\AN[U;GZ^I?"KJ$5TSYLJFVLL*=SBI((_X8QLB9!#>X[O>(S^$<;-CS
MH?.S$ E_M0*(PNC!#8<\(TV&*[:$A&C&=E9-?\G/NOG(KU3!:+O^4.;HEZ#,
M'^F>%%$<18CXM5PP1LLN%59 7-+T.EIE6P#=7]?%R/-*?\0[NBNM7>/&Y:L?
M;W9_:.\F%I=_I^6(;3J$9UM>LR)Z3*H=W:E9BKXFBMOTFUM;F_^42YT8FU#'
M7<T_?O",@_Y/5[5]B'PQXFNQ?9J!8?$VIN&C4L.LU-.]OJ$M^EE>H2T&T>1G
MX-<G53?J+STIW1.H['YRO@E5H9\UU/@EZ^3\V,C;<ZG+!=(J1JC4,U4G\.C5
M#I\'6BN)A6.=@_M[ N3B??8[Z;2$F-5\^3(>Y%RB^%:E6^BTHM9@DZ)UXP\V
MD?N\#G3B'X!"+TV,M&LM?9ZV2?^86>G3(]=6^MFF\VF9(&'X84C(G?"PFU6S
MC6MW7([Z63ND>;3Y*H0NHN)"PT--V30)#/>M9E.9($,^ZPS'QP+_MTU:J7NI
M:V5V15B@^X<]KJ*ZT#V-HV!XSY*<D?R]KJ7*[!+.RBG[K"H7:X_LU#(2SL5P
M2C'\B.'7+)?"*(?0'DX;$0[W!E_'($['T6TR*FX^GQG[.KRH\;0\N/%V1734
ME0!4 7'$K+JN) ^^[L-F@];'!K[W^I4RMXAL^=UIU\PC,4KX ,_A:Z&!^4,+
M9@Z5"HNA/R2P>G-+\0&3JH+H]$"/IE>=/]:NIF\I*K</[F>:O2ZIU1S#MYKM
MO57MJ9I4=E)=QWBHPO^1<<?+RYR]MRJ,]QQ_GG_C1JB3TZV&F,T7$QF#3W L
M^DB%QXWT$YYEQTMF79\\+]5Z&'_IVYZ##0:63RY@K>8K?K!K::(G[ Z$$#Y+
M6DL%8VG%WP[)4HX,*H]/T J8GP0;S4FXL/@;3+7P=L.V\KS4,]Z[_X KS@V8
M?[UQ]MZ5<S+WO\H^2(7232W;;%W@ D5M7\Q!HP)!D ?2HN=+'?&==>C$>#CK
M9K</=)X_!YU\4@4QU$@K 7^2!PH52!\./9; /OUL@JI^LJ3$2J%GCL;^![?N
M-1Z:4,@]=$K%TF/OJ?(L2]?W[5>4WV_?T<4XZ"AWOOR<G-/Z=2X]S+];=^@Z
MRO>M(8)]1#?!'#Z3DQ</F5P =X9@&LI26_V*1&?2VOU18-(+8I]/7J(IP>"R
M%7ETL7T)/^(&.I2!62/M-A__0.^&6(@M(J,2O#VD;O8'_T1_:^3+Z34BI33(
M)DQD@'BE=:6AM[#@(BZZW*W*WV=T?-PON.GTJ/33:^NQARZD\+ R7^\9X+/_
MB?2;EK</W,[%F3YH;&P$-G(.PQF+_UHA2.EMJ!N22L7IW;2M4O%:(H']S'(#
M=[F)GX;-'Y' 7H;S-]#"]"0P+X0P30)[E@J+47,_+/>O!J%;>$4"^U!+D(JP
M6C_,,K]TA)6SA)C/D\ ,._E)4&>$!,;JRO.7\@SI@R<=*\!(^YJ5@$24N92G
MLT*223^<\B6P6:5P('LR+].2E.1_J(&_I1:3=NWW$X5R@R*="GI(N7?Q(HY+
M':B9+'#C&V83[^]L'@C;O-NXN&%PY\/"H6<%+$OV&,(YUM=I2P&7!L>-::99
M,55G($W@:7=BM25R^UB(P.;8W;Q$:/<QTWJA14!Y<+[?1&E%S<-B_^FL3J[+
MW1XW8"@^MNL7VO-ZV2SIJ0'I%A<DF79S]P;L.Q/HT>:C5GY@EIEK.=-5C]#7
MOAE?YJ9\KB#+ZT69S:.8G."<O6X@4Z'PZD%3.Y2Y5CVNO\RG%%_JBOI8ZG@\
MZLF 1U;Z2;47V;?)^KAA0?U%UT=V'Z#?9E;)<)']Y#A;!G]+L8JIB+?N:-Y0
M7.K&C<9;"L,4P<0I;'1/E7:FFLOO3=D3$_[!U-#"0E7W$:2Y>>2?UT,?7_)W
M]N,;)1*<:_#NR/D&(7PC&-7NKPT\KF=AZK2]'0<B<%^'S'_D_CS'VO<2W[7J
M,6P4DN3MPSS]]*G#;$G Q_*:RD/GX/"]=45:@U/G(BN;5E*'#IEX%271/U9;
M^42J[8TVM;+:[A!=<]:LU,F(Z;N_TRM]S[D<XZY'>P92!6JX)?<B?^INM4J;
MTW%/K3U:/Q<;_GJ$>R&!16FT-<]QK\?=+,$&![B,.&:N8!/R21U^1QXTGP=B
M<;?SK^=QQLDJ8^J8\;!*-A[K6,_:D&[U^KQ/L,>7.<6*S[OB7#-_8$'#74P&
M+65JY%WS(0FL)Z5J:?^_,2?YI\>_,R=I]M@0WW_7Y W07(:+[WN05:BMP'?U
M_!J_[],>SV*WQ]23EL_?XEC^/SS#O ^P/]W88DY%9AP,';YY?=L3U]KXB\Q#
MD_Q;%><(%>%GJ\R"7>9,''#;.I&C=B'0$:TR<1Q% EO."H;.$U0KNXM LOU0
MZ5"-I?[K7$>;-FI**/?XZZ7ZN2J_)9"X</[WX?H9:K_ Q?=4(/M.R6>L_3J7
M&WUTHQ6[:M)[O3,2V*M("0S*<L%^^$L\*('=Q"S+8 OP\JY6KUHO'B?)87^D
M>JY>Q-PN-1U36=W;47HHNEK88/SQ2>,3 PUI>1[F4TO*N6]<7Z)ML&-#>HNN
MZ!6;MZ=XBYZ/]CJ>:9L-C^>U&FTW,! P'T"[":8%_F!2,7A]\9U@M="8);(U
MP9=Y )G)5NR$*3]@*@49>3 @KB.*C\^X*>A5=,?6L\N2%@C[)PQ8U0L[^\RN
MGAT*^(:RXC(3?-P8;PEA%ZM!8K<#2^2X60J4S8NQ*-_(\O.??&=L+EA#AJ"=
M5?IP2>$V_I:J"H<J=$( A?F"EE"423_J7%!@JYE(_[;71)!_P2R^.*DB,<-V
M_TU*(M[G9\X%RRD?E>($>N,W3P7TN8J+QD>S$HJ.FE<6;]P[=$<"VU7%^+.R
M868D%X[T*$X^GZ^<;GHLX&1PX^YF)WMU.?U9;O#'ER5/YGI&_WKY8GK@QJK.
M40GL. VTWI!VDZ]]JFU8"C7;CG!=$'2;^_STB8HR,)C=,:*E0TY\WI)-)P&9
MOK.W1_*0-\VJ7Y3I/NARKGJS^#=K/YK9(;9_AY;CGZUIB.&1%.<.3.CP==X_
M7,&LQW_\+EX^SVL*$GD"60O;AI;=MK&++XRU&Z6$UF^/2#_>XSAHD/OSKP,A
MI*=!-;./K6S>7#NG<O[ORT&79B\9^5@.;S#_E*-^\#C6X_J^U >/+M/PXI(O
M3H.$UM8;O5($2>PT-50Y^ZH> $J-6R_G /-O/MY<&_-X5)"YG\@]'5NF15RU
M9I%KIZ2R3@D#Y'U0279+7@G8^#1G2AFQ&4QF&$7(Z-[4[;=XMO'GXA69$^IB
M'<J19<1?M">(3VS(-8P#%R>M8,0.A"/8_I_+B".BJE]EW=4'BXW]7F^R790V
M1#NZP]<TVY&_C"PP0ETO*2,0?<S4W+%)B+K_ /=='[?83/+FQG(KV7YF.4^_
M\#HC;7S&+URH/W".Y>]_\M71)<MSN;FS2Y\_O]]:VM:Z9X!IH>]>95N^$_%H
MK+>Q*EKH*W*2ZJ[QPR"Y:.*"Z#SH'#79LIB$>4UKIZF F&[J)L#U(<>9MC&$
MNA=\S(,G3AB#Q96SD!S_>C%/T26P,[=Y(;-$9%?;W! FXU+J$A+SDKG&L+E[
M>WE&;&=7Q5?L9BNZI=)P+EX^=?\\W]G-1_#([T@/7/C96/$#M-6L5-0@Z%CP
M^$NBYA=?$0I =@75?P62D@@Z A*\Y_F7X+7"HN>^(M-^D3??@NZS&H?RBU@K
M_;(X/[UMVYH$AB:[N5T[+<^%B]3(D,<__RHPEL#JJL7EF)4,XLZ1^:^D69ZT
MJ$G+RM@D"0SP:)>>COU# FO?=&R#53:D11,\^7[VZF$RT$W%+!'/7+XT<4X<
M=T-;L/#KEHD@UI+OF$NF]A&EA=ZCY-Q'8@W!(B*\,'6=B*5Q*0G3M*0<:M#_
MGP_[Y(\XA M1[A*873U"R*\@_?33_D]'L BU_U^84/\7&N#7?[8RTH-H_$BY
MR6&/^O+\&[A/?>G-Y^+*0">CP4@%A_G6<Z\DL.M!_%]93,N?CEJ+#T];Z!'^
M+MZF/])W(_\6MT;+W=6%O^%4EE/C^-\W/NCGC(=.9WF%'<-?\!C@%.X.+2]]
M^'W@NHO^HQO;$L?#CDG;A.GF:9+=_+_WS'O#,L@;HJQ%?G"Y%<R2IBYMI2L;
MTJ2TD]?VZBI*X_=& N-907$O=<U[Q'FJKR6P/'4"[>WW3 ZFYG>I:D)*YR2H
MD7YA,,PZ.Y_4GV30G[:!-%V.1TI@&Z09\:!? E,<F62*U>'_W!O\3.+GD\YT
M2F!]YD;2'#K[$YK*A_\+0_^=X\#%_V9(+$W#V',$>R O';V'<.XU@'A ,.,J
M'>WA"%(BH\-PD58S30W9C._;OC\T&Y-/UST]O2-7#GCV>S96EINAK;I%ANO$
MA/OO.W_!XE:.UL-4MWWM)F]/&ALLFK$]%U '.B^6=:-L-UZZL?2H]NRO@$V#
MWPRAHK3;[@\*KD_X"2U6G7TDL#^.5TA@O\])8&+]?%IVSG\T?*%!^(>6,6>_
MO^GST&=9:3P4/3TL=_;UDUR#&D%ES?Z_[\+<@J%C(SQXQZ5R$N<J7G/!$,,M
M&V@.W2;=7O))4=WTJFOIR0O>/V8&*WH\]6GZ!K;ACE8G115C@MMOU]PR5G">
M51W00*E-5-F3\<*;Z>(?E8+OP8*YT.;"3(<[3)$Y(IZ][(GZ9T?1V5)):DGJ
MX( N$IB#Q3L:Z#F#$65CI6'Q8I#Z[$@B5<\>(34((JT-:T.Q>TB3GT@__4GD
MJW>MU*<PP!NB*JG_%("$U-;<)##]?X*9Q+$6JS'726 <MW_$L@OB/]E!-R3^
MHY(1X &$*(\\-4H.@[JDL\))&TD_,-+-FC7A;H(R\_[M/N'?1C^\^!8<J$GH
M(=(::+7CL3<$WQU:3&XX^-+4K&%<>W3ALIL"F'%'Q<37EXR^ZHM_D7WM\M:M
M;VW/5JV%L+K*9:7-I%W<5\>OXD3;1]U*M+^%QP:F,(:]!3>7KG\\CLDFQ)1Y
MD-6^[2T]Q I+FOY@W'4Z%-6]W^NDDZV?5;3/6D3@L@1V?\5XD-/:SWJRUZ!P
MV*7CI!/FAZAV=+3%-N)NOJ6[ U&#./"_/>N@GDVIF8>?Q]8U3$14'XO),?7R
MC'XRZHK^F!_>>RUO_@"A]'5(LL:/5TVXYRK;-7T>4N=BX$UA/C"1"5#V3AXH
MZT3 BD!93DQS5 JT8[:8X6,M4HU[1]1Z72L\1=49T0HAJ3?-FT62.%5,N'9=
M8$6(QII&A77"RM/]:\XA9M[+]1ESJZ=)GN,ZS%],8@,XA"Z8K,*.*_+60WN
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M',I2.4'%7E6[6&O;%,Z9O_WOXM$,]W!W%^%GM:?1V6[.\CR'/C'$"V<@ACQ
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M,G_I94E!R3]]8N3"L'6AG,W\5"I]@W PR[UHUKDHZ$?3BW[]'!UG<(>S^Y'
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MTLQW9M[BHM+5K)L*Z,R5RSU<0SI!= "C?N'9$+49OM>0\//0BD3D0%L,P'8
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M!49QI]EV!4?B4O,OWD]4@")!,_ZYI6DSWE@&#HIU!H-JL9H@@X/:A<%SU<&
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M84N/(+S4G?553:MW/0T .5T0(4\$5OD)9M9]99A"5L?^?"]OXXC:%4?GS0P
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MI"9\UUFZ8MOQQ^ -N+ZK'S]V4/6<FN[X37P(.W.]R*^F4>''0RP-D-G0 RF
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MUCT\7>J65W^^<_P!'%S7,+434')]-JE^P!!Z*GEG8-'L+L4I$]@D*G(?.U3
M^K@&S8?G*>BMM?ELX.;T[C2(X>>AC.*FJ,JJ5!8+8:N=<[@^BJ?'A6G#KQ-*
M?VZ]8$UI;P469NY&DAR,$JB)<FGA&!BH&BQ@6KQ<H):5?R.5&6."C]^)-X[
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M%"(]ZY,R1Y+W1_;,[<J4\>OV5DUY&I_\^C9%,),9B]53MO?](X\& QIQ9-V
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M?\L65X5Q/VXJ-(A^A%Y*#Q*;"K<8/<C;.-:\'7\4'LP&#R"[NBFM;KU0,9,
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M+FIP9U!+ 0(4 Q0    ( ).!5D^-$:?4I5,  ,U?   ;              "
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M+3(P,3DP.3,P7V1E9BYX;6Q02P$"% ,4    " "3@59/=(B:NIA1 0 %%1
M%0              @ 'N(0( 8FEI8BTR,#$Y,#DS,%]L86(N>&UL4$L! A0#
M%     @ DX%63YGJO>C[S   N.8) !4              ( !N7,# &)I:6(M
M,C Q.3 Y,S!?<')E+GAM;%!+ 0(4 Q0    ( ).!5D\CY1<-.>8# +>K.0 4
M              "  >= ! !B:6EB+3(P,3DY,S!X,3!Q+FAT;5!+ 0(4 Q0
M   ( ).!5D\YUZ%_ZP,  -LC   6              "  5(G" !B:6EB+3(P
M,3DY,S!X97@Q,#$N:'1M4$L! A0#%     @ DX%63^ 7!0YY"   \S8  !8
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M;FQO9V]A,#4N:G!G4$L! A0#%     @ DX%63[<0>%M?B@  LI(   \
M         ( !O $) &)I;W-I;6EL87)S+FIP9U!+ 0(4 Q0    ( ).!5D\!
MT0S*0E,   A=   5              "  4B,"0!C;VQL86)P<F]F:71S:&%R
M92YJ<&=02P$"% ,4    " "3@59/M]G@6V>$  #LC0  #P
M@ &]WPD 8V]S=&]F<V%L97,N:G!G4$L! A0#%     @ DX%63W &>4II2
M\U   !@              ( !460* &5Q=6ET>6QO<W-O9FEN=F5S=&5E+FIP
M9U!+ 0(4 Q0    ( ).!5D]MENG\:8,  .^0   7              "  ?"L
M"@!F:6YA;F-I86QH:6=H;&EG:'1S+FIP9U!+ 0(4 Q0    ( ).!5D\P7LX;
M_U<  /-A   :              "  8XP"P!G86EN;&]S<V9V8V]N=&-O;G-I
M9&5R+FIP9U!+ 0(4 Q0    ( ).!5D_Y64(9BXX  +Z6   .
M  "  <6("P!I;G1E<F9E<F]N+FIP9U!+ 0(4 Q0    ( ).!5D^S4*!H1$8
M %]0   5              "  7P7# !L;W-S;VYD:79E<W1I='5R92YJ<&=0
M2P$"% ,4    " "3@59/MK!3&Q93   -7   $@              @ 'S70P
M;W1H97)I;F-O;65E>' N:G!G4$L! A0#%     @ DX%63Y.'_KRV=P  9X(
M !$              ( !.;$, &]T:&5R<F5V96YU97,N:G!G4$L! A0#%
M  @ DX%63ZA8D5LV%0$ TBL!  8              ( !'BD- ')D+FIP9U!+
M 0(4 Q0    ( ).!5D^"VTC-NYP  ".H   2              "  7@^#@!R
M9'!E<F-E;G1O9G)E=BYJ<&=02P$"% ,4    " "3@59/ZO/,[7./  #XEP
M&@              @ %CVPX <F5S97)V97-F;W)D:7-A;F1A;&QO=RYJ<&=0
M2P$"% ,4    " "3@59/I/1])4)9  ":8P  !P              @ $.:P\
M<V=A+FIP9U!+ 0(4 Q0    ( ).!5D_.LD+3=X@  +Z0   ,
M  "  77$#P!S<&EN<F%Z82YJ<&=02P$"% ,4    " "3@59/?FWF4<""  #C
MC   $               @ $631  =&%X<')O=FES:6]N+FIP9U!+ 0(4 Q0
M   ( ).!5D\HFV-JJY8  #>@   -              "  030$ !T96-F:61E
M<F$N:G!G4$L! A0#%     @ DX%63WYUYR$-D   3)@   L
H ( !VF81 '1Y<V%B<FDN:G!G4$L%!@     @ "  #P@  !#W$0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855087888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text">Other Consolidated Financial Statement Detail<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>90.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>81.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(45.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(49.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(141.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(151.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>141.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>198.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>132.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(13.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(11.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(27.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>115.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>132.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>141.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>197.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>139.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>46.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>141.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>150.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>140.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>884.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>259.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>320.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>222.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>224.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>188.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>147.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>444.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>125.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>677.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>609.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,429.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,861.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,370.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,389.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and included accrued income taxes totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$801.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$791.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6742687792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy, Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock', window );">Assets and liabilities held for sale</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$463.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$526.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on the composition of our investment portfolio and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative and Hedging</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities Held For Sale [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855119984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>842.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,122.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>842.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>247.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,090.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>360.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>530.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>421.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>168.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>590.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>263.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>483.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>253.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>217.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>470.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,465.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>694.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,160.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,516.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>656.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,172.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>236.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>310.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>547.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>223.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>243.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>467.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>115.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>115.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>123.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>123.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>183.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>183.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>134.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>134.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,702.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,192.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,894.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,740.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,039.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,780.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,429.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>841.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,271.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,396.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>766.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,163.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,067.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>518.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,585.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>528.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,765.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>772.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>647.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,419.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>768.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>631.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,399.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>71.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>71.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,269.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,078.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,347.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,402.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,997.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,400.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>690.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>863.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,553.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>617.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>636.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,254.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>360.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>360.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>359.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>359.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>132.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>132.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>389.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>389.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,959.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,495.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8,455.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,020.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,040.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8,061.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>28.7%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.4%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.1%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.7%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>19.3%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.4%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>127.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>888.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>480.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,149.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,646.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(46.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(42.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(349.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1,510.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1,860.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(129.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(564.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(15.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(709.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>129.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>917.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>39.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,085.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>201.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>176.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>884.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,085.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>393.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>358.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,161.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,066.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>202.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>153.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>528.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>378.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>595.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>511.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,689.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,445.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>48.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>89.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>80.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>93.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>91.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>462.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>311.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>109.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>147.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>562.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>420.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$65.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$306.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$36.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$131.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we will license certain of our manufacturing-related intellectual property to the customer. We will be eligible to receive </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in a series of three payments. The first payment is due upon a regulatory achievement related to the customer&#8217;s product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We do not expect to recognize any amounts related to this arrangement in 2019 as we do not expect the regulatory achievement to occur until 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc., please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our manufacturing and supply agreement with Bioverativ, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841951136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>255.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>231.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>176.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,103.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>119.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>194.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,655.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,655.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,657.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,040.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,044.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>435.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>436.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>431.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>432.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>335.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>336.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,899.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,907.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>218.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>120.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>336.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,608.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,607.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>854.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>851.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>706.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>263.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>496.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>127.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated<br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,091.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,093.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,314.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,313.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,686.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,691.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,235.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,232.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>121.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>122.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,899.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,907.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>611.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,192.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,867.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,994.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$394.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which is included in investments and other assets in our condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in equity securities include shares of Ionis common stock acquired in June 2018. This investment is classified as a Level 2 marketable security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effect of the holding period restrictions on our investment in Ionis common stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in our strategic investment portfolio for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflects our sale of a portion of our investment in Ionis common stock for approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$382.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as our sale of our investment in a non-marketable equity security, partially offset by an increase in the fair value of our remaining investment in Ionis common stock.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our June 2018 investment in Ionis common stock, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855090384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2019 Share Repurchase Program). Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. Under our 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$717.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.6 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From October 1, 2019 through October 21, 2019, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$508.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2019 Share Repurchase Program.  Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.9 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our 2019 Share Repurchase Program as of October 21, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.1 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>115.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>53.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>233.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(77.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(85.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>46.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>148.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>72.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>50.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(29.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(192.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(92.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(318.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(316.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>58.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(38.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>56.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>109.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(38.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>68.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(214.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(248.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:26%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>79.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(51.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>37.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>85.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(56.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6852430944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>115.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>53.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>233.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(77.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(85.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>46.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>148.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>72.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>50.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(29.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(192.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(92.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(318.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(316.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>58.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(38.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>56.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>109.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(38.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>68.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(214.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(248.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:26%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>79.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(51.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>37.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>85.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(56.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855037376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,655.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,655.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,702.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,702.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>868.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>868.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>337.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>337.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>336.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>318.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>161.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>161.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,087.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,069.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>353.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>563.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,102.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,050.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>434.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,509.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,495.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,489.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,480.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,037.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>996.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,000.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>995.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,888.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,739.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,745.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,737.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,054.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,722.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,802.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,722.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,490.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,953.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,037.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>499.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>523.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(57.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(87.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(66.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(91.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(20.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>412.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>343.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>412.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6852493632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventorysoldtoBioverativcost', window );">Inventory sold to Bioverativ, cost</a></td>
<td class="nump">$ 173.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventorysoldtoBioverativcost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory sold to Bioverativ, cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventorysoldtoBioverativcost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6874374480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 3,907.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,689.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,655.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">336.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">161.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">26.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,087.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,102.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">343.5<span></span>
</td>
<td class="nump">$ 401.3<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">$ 412.0<span></span>
</td>
<td class="nump">$ 499.9<span></span>
</td>
<td class="nump">$ 523.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">353.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,702.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,459.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">868.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">969.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">337.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,655.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">318.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">161.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">26.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,069.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,050.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,702.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,459.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">868.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">969.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">337.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">343.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">343.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6634883984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 211.3<span></span>
</td>
<td class="nump">$ 369.8<span></span>
</td>
<td class="nump">$ 881.9<span></span>
</td>
<td class="nump">$ 956.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred tax asset recorded on transfer of intellectual property</a></td>
<td class="nump">754.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred tax liability recorded on transfer of intellectual property</a></td>
<td class="nump">$ 603.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841971824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy, Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Assets and Liabilities Held For Sale</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$463.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$526.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on the composition of our investment portfolio and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative and Hedging</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6667931024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_BR', window );">Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="nump">$ 70.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6864121296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,343.9<span></span>
</td>
<td class="nump">$ 1,224.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,093.5<span></span>
</td>
<td class="nump">2,313.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,933.5<span></span>
</td>
<td class="nump">1,958.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">582.3<span></span>
</td>
<td class="nump">526.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">751.8<span></span>
</td>
<td class="nump">929.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">743.2<span></span>
</td>
<td class="nump">687.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,448.2<span></span>
</td>
<td class="nump">7,640.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">1,813.9<span></span>
</td>
<td class="nump">1,375.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,138.1<span></span>
</td>
<td class="nump">3,601.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">422.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,392.4<span></span>
</td>
<td class="nump">3,120.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,746.1<span></span>
</td>
<td class="nump">5,706.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax asset</a></td>
<td class="nump">3,284.5<span></span>
</td>
<td class="nump">2,153.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,238.8<span></span>
</td>
<td class="nump">1,690.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">27,484.0<span></span>
</td>
<td class="nump">25,288.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">1,495.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">125.6<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">382.2<span></span>
</td>
<td class="nump">370.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,429.1<span></span>
</td>
<td class="nump">2,861.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,432.2<span></span>
</td>
<td class="nump">3,295.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">4,458.2<span></span>
</td>
<td class="nump">5,936.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">2,820.4<span></span>
</td>
<td class="nump">1,636.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">410.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,370.9<span></span>
</td>
<td class="nump">1,389.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,492.2<span></span>
</td>
<td class="nump">12,257.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(92.3)<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">17,065.2<span></span>
</td>
<td class="nump">16,257.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">13,995.9<span></span>
</td>
<td class="nump">13,039.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">13,991.8<span></span>
</td>
<td class="nump">13,031.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 27,484.0<span></span>
</td>
<td class="nump">$ 25,288.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31958-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6855167904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 1,444.4<span></span>
</td>
<td class="nump">$ 4,448.8<span></span>
</td>
<td class="nump">$ 3,483.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">201.4<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">206.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
<td class="nump">190.5<span></span>
</td>
<td class="nump">207.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6853730464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingleaseliabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisposalGroupOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisposalGroupOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisposalGroupOperatingleaseliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisposalGroupOperatingleaseliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6670535728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 1,370.9<span></span>
</td>
<td class="nump">$ 1,389.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">$ 801.7<span></span>
</td>
<td class="nump">$ 791.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
